[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZNM-Dm9_Tk3R_LTfKX0foK2ZZbadTSqqvRwnIh-zBUo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"AstraZeneca",[4,6],"AstraZeneca Turkey",3436,false,485,789,315385226,409,864,[15,18,21,24,27,30,32,35],{"name":16,"count":17},"Asthma",251,{"name":19,"count":20},"Healthy",151,{"name":22,"count":23},"Type 2 Diabetes Mellitus",122,{"name":25,"count":26},"Breast Cancer",113,{"name":28,"count":29},"Chronic Obstructive Pulmonary Disease",95,{"name":31,"count":29},"Type 2 Diabetes",{"name":33,"count":34},"Schizophrenia",71,{"name":36,"count":37},"Healthy Volunteers",62,[39,44,49,54,59,64,69,74,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT00463814","AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies","2008-06-17","AZD6244",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT00777582","Phase I Comparative Bioavailability Study","2009-02-06","AZD2281",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT00099437","Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","2009-02-27","Fulvestrant",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT00750841","Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours","2009-07-30","cediranib",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT01081951","Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer","2011-10-10","olaparib",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT01933932","Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","2016-06-07","Selumetinib",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT01874353","Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","2016-09-19","Olaparib 300mg",{"nctId":75,"briefTitle":76,"date":77,"intervention":73},"NCT01844986","Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","2018-05-17",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT02453282","Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","2018-10-04","MEDI4736",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT03091192","Savolitinib vs. Sunitinib in MET-driven PRCC.","2019-08-18","Savolitinib",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,450,962,1107,1334,1541,1906,1988,2043,2870,2892,2915,2939,2957,2980,3006,3782,4184,4443,4710,4862,4990,5075,5177,5354,5534,5625,5711,5838,5992,6050,6265,6355,6609,6748,6813,6859,7016,7123,7208,7254,7322,7585,7727,7796,7840,7878,7942,7981,8015,8049,8083,8208,8258,8348,8424,8458,8492,8522,8552,8582,8612,8642,8672,8720,8758,8796,8830,8865,8891,8935,8966,8992,9023,9049,9155,9201,9239,9283,9318,9349,9371,9393,9415,9443,9465,9487,9509,9531,9553,9575,9597,9629,9651,9673,9695,9717,9753,9775,9797,9819,9841,10036,10094,10122,10228,10262,10306,10338,10364,10386,10410,10443,10477,10504,10522,10540,10558,10576,10594,10612,10630,10648,10666,10684,10702,10720,10744,10768,10786,10804,10822,10840,10858,10876,10894,10912,10930,10956,10974,10992,11010,11034,11052,11070,11088,11106,11124,11142,11160,11184,11202,11220,11238,11256,11280,11298,11316,11341,11359,11377,11395,11413,11437,11455,11473,11491,11509,11535,11553,11571,11589,11607,11625,11643,11661,11679,11697,11715,11733,11751,11769,11787,11805,11823,11841,11859,11877,11895,11913,11931,11949,11967,11990,12008,12026,12044,12062,12080,12217,12313,12361,12395,12435,12467,12493,12531,13060,13144,13224,13283,13324,13350,13372,13405,13436,13458,13480,13502,13533,13555,13807,13840,13876,13898,13956,14012,14050,14081,14112,14134,14160,14178,14196,14221,14239,14257,14275,14299,14317,14340,14365,14388,14406,14424,14442,14470,14488,14506,14524,14542,14565,14583,14601,14619,14643,14661,14679,14702,14720,14738,14762,14780,14798,14821,14839,14857,14875,14893,14911,14929,14947,14970,14988,15006,15024,15047,15065,15088,15111,15136,15154,15172,15196,15214,15232,15250,15268,15295,15313,15331,15349,15367,15385,15403,15421,15439,15457,15475,15493,15511,15535,15553,15650,15679,15705,15739,15761,15871,15975,16005,16078,16154,16208,16249,16283,16404,16460,16495,16521,16543,16565,16587,16609,16627,16645,16667,16685,16703,16726,16749,16767,16790,16808,16833,16856,16882,16900,16918,16936,16959,16981,17013,17031,17049,17067,17085,17103,17121,17139,17172,17190,17208,17226,17244,17262,17280,17298,17316,17334,17358,17376,17394,17412,17430,17448,17476,17498,17523,17541,17565,17583,17601,17625,17643,17666,17684,17702,17726,17744,17771,17797,17815,17842,17860,17878,17896,17914,17932,17950,17975,17993,18011,18029,18047,18070,18088,18106,18124,18170,18210,18238,18516,18546,18568,18589,18607,18629,18653,18675,18953,19169,19396,19565,19663,19739,19828,19907,19955,20005,20064,20122,20175,20222,20268,20311,20354,20404,20438,20470,20513,20563,20599,20637,20672,20698,20739,20765,20802,20836,20861,20893,20918,20948,20977,20999,21024,21046,21073,21098,21126,21150,21172,21197,21215,21233,21251,21272,21290,21313,21331,21353,21371,21393,21415,21436,21454,21472,21494,21515,21537,21555,21577,21595,21613,21631,21653,21671,21689,21707,21725,21743,21761,21779,21797,21815,21838,21859,21881,21899,21921,21939,21965,21983,22001,22024,22048,22072,22090,22113,22136,22154,22177,22195,22218,22236,22257,22279,22302,22323,22345,22366,22384,22405,22428,22446,22464,22490,22508,22526,22547,22565,22583,22601,22623,22646,22667,22689,22716,22734,22752,22770,22788,22927,23045,23135,23219,23296,23390,23470,23540,23625,23704,23778,23847,23908,23981,24025,24090,24145,24201,24253,24308,24350,24384,24426,24463,24497,24543,24589,24633,24670,24703,24753,24801,24850,24885,24934,24969,25007,25051,25077,25103,25136,25162,25199,25225,25251,25300,25326,25352,25378,25404,25430,25461,25494,25526,25568,25604,25626,25658,25683,25705,25727,25749,25779,25804,25834,25856,25882,25904,25935,25957,25989,26019,26044,26069,26101,26123,26153,26195,26225,26252,26274,26304,26326,26352,26387,26409,26443,26465,26487,26509,26531,26568,26590,26619,26641,26666,26698,26725,26762,26793,26815,26847,26869,26898,26928,26958,26982,27005,27023,27045,27063,27081,27102,27120,27138,27156,27174,27192,27216,27239,27257,27275,27299,27317,27335,27359,27377,27395,27413,27431,27449,27477,27495,27513,27536,27554,27572,27594,27612,27635,27653,27671,27689,27707,27725,27747,27765,27786,27804,27825,27847,27865,27888,27906,27924,27942,27960,27984,28002,28020,28043,28061,28079,28097,28115,28133,28151,28174,28192,28214,28232,28250,28272,28290,28318,28336,28354,28372,28390,28408,28426,28444,28462,28480,28498,28520,28538,28560,28578,28599,28617,28639,28657,28675,28693,28711,28729,28755,28773,28795,28813,28831,28849,28874,28892,28916,28934,28956,28974,28992,29010,29028,29050,29068,29086,29112,29130,29153,29171,29197,29215,29233,29256,29274,29292,29310,29328,29349,29367,29389,29407,29425,29443,29461,29479,29497,29518,29536,29559,29581,29599,29617,29635,29658,29676,29694,29717,29739,29762,29780,29803,29821,29839,29857,29879,29897,29915,29933,29951,29984,30002,30020,30038,30056,30074,30092,30110,30128,30146,30164,30182,30200,30218,30244,30262,30280,30298,30323,30347,30365,30387,30411,30433,30455,30478,30500,30526,30544,30562,30583,30601,30619,30637,30655,30677,30698,30716,30734,30752,30773,30791,30812,30835,30853,30871,30896,30914,30937,30955,30979,30997,31020,31038,31060,31078,31096,31118,31136,31154,31172,31190,31208,31358,31472,31565,31651,31736,31825,31917,32004,32084,32162,32241,32305,32374,32444,32503,32580,32624,32672,32728,32786,32847,32904,32954,33011,33049,33099,33148,33191,33233,33278,33320,33370,33424,33464,33510,33557,33603,33652,33691,33730,33770,33818,33861,33908,33947,33987,34020,34064,34094,34134,34171,34206,34240,34270,34305,34343,34365,34394,34416,34447,34472,34500,34526,34556,34588,34621,34645,34674,34702,34733,34761,34783,34810,34845,34871,34893,34922,34944,34966,34988,35006,35028,35046,35068,35086,35111,35129,35151,35173,35191,35209,35234,35256,35274,35292,35310,35328,35346,35370,35388,35406,35431,35449,35467,35490,35508,35530,35554,35572,35590,35608,35626,35644,35662,35680,35704,35722,35745,35763,35781,35799,35822,35840,35858,35880,35898,35916,35934,35957,35975,35997,36015,36033,36051,36069,36087,36112,36130,36148,36170,36194,36212,36230,36248,36266,36284,36302,36324,36342,36367,36385,36403,36421,36443,36461,36484,36507,36525,36543,36570,36588,36606,36624,36642,36660,36678,36696,36714,36741,36759,36777,36799,36817,36840,36858,36886,36904,36922,36940,36958,36976,36997,37015,37033,37051,37069,37090,37113,37131,37152,37173,37198,37216,37234,37252,37277,37295,37313,37337,37355,37377,37399,37424,37442,37460,37481,37499,37517,37539,37560,37582,37600,37622,37645,37670,37688,37706,37728,37746,37764,37782,37806,37824,37842,37860,37882,37900,37922,37943,37961,37983,38010,38028,38046,38064,38082,38100,38118,38136,38159,38181,38202,38220,38238,38256,38274,38292,38315,38333,38351,38369,38391,38412,38436,38454,38477,38498,38519,38537,38555,38577,38599,38617,38642,38660,38685,38703,38721,38742,38764,38782,38805,38823,38848,38866,38884,38912,38930,38948,38966,38984,39002,39020,39041,39059,39077,39095,39113,39131,39152,39180,39198,39216,39234,39252,39270,39291,39314,39332,39350,39376,39394,39412,39437,39455,39478,39496,39517,39539,39557,39581,39599,39617,39635,39715,39793,39847,39920,39966,40016,40071,40124,40162,40207,40248,40293,40339,40373,40420,40460,40500,40533,40575,40622,40659,40694,40724,40765,40805,40831,40857,40883,40918,40952,40987,41032,41064,41103,41133,41159,41188,41222,41258,41304,41339,41366,41393,41417,41441,41463,41494,41529,41556,41578,41605,41627,41649,41671,41693,41721,41743,41765,41793,41820,41852,41889,41923,41945,41967,41996,42023,42048,42078,42100,42130,42161,42193,42215,42245,42267,42295,42317,42348,42370,42392,42421,42453,42477,42507,42541,42566,42584,42602,42625,42643,42661,42679,42697,42715,42733,42751,42776,42794,42812,42834,42852,42875,42893,42911,42932,42953,42977,42995,43016,43041,43059,43077,43104,43122,43140,43158,43176,43194,43219,43237,43255,43273,43291,43309,43327,43349,43371,43389,43407,43432,43450,43468,43486,43509,43527,43545,43568,43586,43604,43622,43649,43667,43685,43703,43721,43742,43760,43778,43801,43825,43843,43861,43879,43897,43915,43933,43951,43969,43987,44008,44029,44047,44077,44095,44113,44131,44152,44176,44194,44216,44234,44257,44275,44296,44314,44332,44354,44385,44403,44421,44439,44457,44475,44499,44517,44535,44553,44574,44595,44613,44631,44649,44667,44685,44703,44727,44745,44763,44781,44803,44821,44839,44857,44875,44900,44918,44936,44954,44972,44993,45011,45029,45047,45065,45083,45101,45123,45141,45159,45182,45207,45225,45243,45261,45283,45301,45324,45342,45360,45378,45396,45414,45437,45460,45478,45496,45517,45538,45556,45577,45595,45613,45631,45655,45673,45691,45709,45733,45751,45769,45787,45805,45823,45841,45859,45887,45905,45923,45941,45959,45980,45998,46019,46037,46062,46080,46098,46116,46143,46161,46179,46197,46215,46233,46251,46274,46292,46310,46328,46346,46364,46382,46400,46418,46436,46454,46472,46490,46511,46535,46553,46571,46589,46607,46631,46649,46667,46689,46711,46729,46756,46774,46792,46810,46834,46852,46870,46893,46911,46932,46950,46968,46986,47004,47022,47045,47063,47081,47104,47122,47140,47164,47182,47204,47222,47243,47265,47297,47315,47333,47351,47369,47387,47405,47423,47441,47459,47485,47503,47521,47546,47564,47582,47600,47618,47639,47664,47682,47705,47723,47746,47764,47782,47806,47824,47850,47868,47886,47904,47922,47940,47958,47976,47994,48017,48035,48053,48071,48094,48118,48143,48161,48183,48201,48224,48248,48266,48289,48307,48325,48346,48370,48388,48406,48424,48447,48465,48483,48509,48527,48545,48563,48581,48599,48621,48639,48664,48682,48700,48718,48744,48762,48780,48802,48824,48848,48866,48887,48905,48928,48946,48969,48990,49008,49029,49047,49065,49091,49109,49127,49145,49163,49181,49202,49220,49238,49256,49274,49295,49315,49333,49354,49378,49396,49414,49432,49457,49475,49493,49511,49529,49555,49573,49591,49609,49631,49649,49667,49685,49708,49726,49747,49765,49790,49808,49826,49844,49871,49892,49910,49928,49946,49964,49986,50008,50026,50044,50066,50088,50109,50127,50145,50163,50185,50206,50228,50250,50268,50286,50308,50326,50347,50371,50389,50407,50425,50443,50461,50479,50497,50515,50533,50556,50574,50602,50620,50638,50656,50674,50692,50710,50734,50752,50770,50788,50811,50829,50847,50865,50883,50906,50924,50942,50969,50987,51005,51027,51045,51066,51092,51110,51134,51155,51179,51197,51215,51233,51258,51276,51294,51312,51333,51354,51377,51395,51416,51434,51452,51470,51488,51511,51533,51551,51569,51592,51615,51633,51651,51672,51696,51714,51732,51750,51772,51790,51808,51830,51848,51869,51890,51908,51926,51944,51962,51980,51998,52016,52034,52052,52074,52092,52114,52139,52157,52180,52198,52219,52244,52262,52290,52308,52326,52344,52362,52380,52401,52426,52444,52462,52484,52506,52524,52547,52565,52586,52604,52633,52651,52669,52687,52705,52723,52741,52759,52781,52799,52823,52841,52864,52895,52913,52931,52949,52967,52985,53003,53021,53039,53062,53080,53104,53125,53143,53161,53179,53201,53219,53240,53258,53276,53300,53318,53336,53354,53372,53390,53408,53426,53451,53469,53487,53505,53523,53545,53567,53591,53609,53627,53648,53669,53692,53710,53732,53755,54123,54358,54586,54789,54912,55023,55137,55224,55302,55372,55435,55500,55556,55614,55668,55714,55748,55806,55840,55871,55897,55919,55948,55978,56008,56035,56057,56081,56104,56127,56149,56170,56192,56216,56234,56256,56278,56296,56314,56332,56357,56375,56393,56417,56435,56457,56479,56497,56515,56533,56556,56574,56601,56619,56637,56655,56673,56691,56709,56727,56745,56767,56789,56812,56836,56854,56876,56898],{"intervention":97,"totalTrials":98,"cells":99},"Trastuzumab deruxtecan",25,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":123,"PHASE3":270,"PHASE4":371,"NA":382},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":122,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT04556773","A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","ACTIVE_NOT_RECRUITING",[90],"2023-08-16","2026-06-16","2020-12-17",138,[115],"Metastatic Breast Cancer",[97,117,118,119,120,53,121],"Durvalumab","Paclitaxel","Capivasertib","Anastrozole","Capecitabine",1,{"trials":124,"activeCount":269,"soonestReadout":185},[125,136,148,164,181,192,203,214,228,240,253],{"nctId":126,"briefTitle":127,"status":108,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":135},"NCT05246514","A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC",[91],"2024-11-04","2026-06-30","2022-07-13",72,[134],"HER2-mutant Non-Small Cell Lung Cancer",[97],{"nctId":137,"briefTitle":138,"status":108,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":145},"NCT04538742","A Phase 1b\u002F2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer",[90,91],"2025-01-31","2030-01-31","2020-12-28",245,[115],[97,117,118,146,147],"Pertuzumab","Tucatinib",{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","RECRUITING",[90,91],"2027-10-13","2022-06-24",695,[157],"Advanced Solid Malignancies",[159,160,161,162,163],"AZD9574","Temozolomide","[11C]AZ1419 3391","Trastuzumab Deruxtecan","Datopotamab Deruxtecan",{"nctId":165,"briefTitle":166,"status":151,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NCT04379596","Ph1b\u002F2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)",[91],"2027-06-01","2020-06-03",450,[172],"Gastric Cancer",[174,121,117,175,176,97,177,178,179,180],"Fluorouracil","Oxaliplatin","Trastuzumab","Cisplatin","Pembrolizumab","Volrustomig","Rilvegostomig",{"nctId":182,"briefTitle":183,"status":108,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},"NCT04639219","A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations",[91],"2023-01-25","2026-07-14","2020-12-30",102,[190],"Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast",[97],{"nctId":193,"briefTitle":194,"status":195,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":29,"conditions":200,"interventions":202},"NCT04989816","Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens","COMPLETED",[91],"2023-06-16","2024-02-28","2021-08-20",[201],"Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",[162],{"nctId":204,"briefTitle":205,"status":108,"phases":206,"primaryCompletion":207,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":213},"NCT04482309","A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors",[91],"2027-03-23","2020-08-18",477,[211,212],"Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer","Part 2: HER2 Expressing\u002FAmplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer",[97],{"nctId":215,"briefTitle":216,"status":151,"phases":217,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":224},"NCT07069712","A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma",[91],"2027-01-28","2028-09-06","2025-07-17",100,[223],"Gastroesophageal Adenocarcinoma",[225,180,162,121,226,227],"AZD0901","5-Fluorouracil","FLOT Chemotherapy",{"nctId":229,"briefTitle":230,"status":108,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":238},"NCT06271837","A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors",[91],"2025-11-28","2027-02-10","2024-02-22",127,[237],"Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)",[97,239],"Bevacizumab",{"nctId":241,"briefTitle":242,"status":108,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT03742102","A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer",[90,91],"2024-11-29","2027-02-26","2018-12-21",243,[249],"Triple Negative Breast Neoplasms",[117,119,251,118,97,252],"Oleclumab","Datopotamab deruxtecan",{"nctId":254,"briefTitle":255,"status":108,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},"NCT03334617","Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1\u002FPD-L1 Containing Therapy",[91],"2024-09-13","2026-09-11","2017-12-18",528,[262],"Non-Small Cell Lung Cancer",[117,264,265,266,267,251,97,268],"Danvatirsen","Ceralasertib","Vistusertib","Olaparib","Cediranib",10,{"trials":271,"activeCount":370,"soonestReadout":315},[272,284,297,311,321,333,346,358],{"nctId":273,"briefTitle":274,"status":151,"phases":275,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},"NCT06467357","Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer",[92],"2028-06-12","2029-05-16","2024-08-12",620,[281],"Biliary Tract Cancer",[283,177,117,97,180],"Gemcitabine",{"nctId":285,"briefTitle":286,"status":151,"phases":287,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":295},"NCT06764875","A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer",[92],"2029-04-27","2030-12-09","2025-03-01",840,[293,294],"HER2-positive Gastric Cancer","Gastroesophageal Junction Adenocarcinoma",[180,97,176,178,296,121,177,175],"5-fluorouracil",{"nctId":298,"briefTitle":299,"status":108,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":308},"NCT05113251","Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",[92],"2025-03-12","2027-04-30","2021-10-25",927,[306,25,307],"Breast Neoplasms","HER2-positive Early Breast Cancer",[162,118,176,146,309,310],"Doxorubicin","cyclophosphamide",{"nctId":312,"briefTitle":313,"status":108,"phases":314,"primaryCompletion":315,"completion":316,"start":317,"enrollment":318,"conditions":319,"interventions":320},"NCT04739761","A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer",[92],"2024-02-08","2027-05-26","2021-06-22",506,[25],[162],{"nctId":322,"briefTitle":323,"status":108,"phases":324,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":331},"NCT04494425","Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer",[92],"2024-03-18","2026-06-19","2020-07-24",866,[330],"Advanced or Metastatic Breast Cancer",[97,121,118,332],"Nab-Paclitaxel",{"nctId":334,"briefTitle":335,"status":108,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT05048797","A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced\u002FMetastatic Non-Small Cell Lung Cancer With HER2 Mutations",[92],"2026-04-30","2027-07-30","2021-10-28",454,[342],"Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[162,177,344,178,345],"Carboplatin","Pemetrexed",{"nctId":347,"briefTitle":348,"status":108,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT04784715","Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)",[92],"2026-07-06","2029-12-30","2021-04-26",1157,[355],"Breast Cancer; HER2-positive; Metastatic",[97,357,146,176],"Taxane",{"nctId":359,"briefTitle":360,"status":151,"phases":361,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT06989112","DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+\u002F2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer",[92],"2029-01-19","2031-02-19","2025-03-27",600,[367],"Endometrial Cancer",[97,180,178,344,118,369],"Docetaxel",8,{"trials":372,"activeCount":122,"soonestReadout":377},[373],{"nctId":374,"briefTitle":375,"status":151,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":221,"conditions":379,"interventions":381},"NCT06429761","Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients",[93],"2026-10-31","2025-01-02",[380],"BREAST CANCER",[97],{"trials":383,"activeCount":447,"soonestReadout":388},[384,394,428,440],{"nctId":385,"briefTitle":386,"status":151,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":392},"NCT06727227","Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer",[],"2027-10-31","2025-01-29",135,[25],[393],"trastuzumab deruxtecan",{"nctId":395,"briefTitle":396,"status":151,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":221,"conditions":400,"interventions":427},"NCT07124000","DESTINY-PANTUMOUR04",[],"2028-03-30","2025-09-18",[401,402,403,404,367,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer",[97],{"nctId":429,"briefTitle":430,"status":195,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":439},"NCT06386263","HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada",[],"2025-07-07","2024-04-22",22,[436,115,437,438],"Unresectable Breast Cancer","HER2-low Expressing Breast Cancer","HER2-positive Breast Cancer",[97],{"nctId":441,"briefTitle":442,"status":443,"phases":444,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":449},"NCT06231693","Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil","TERMINATED",[],"2024-03-26","2023-12-04",2,[25],[97],{"intervention":267,"totalTrials":451,"cells":452},46,{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":594,"PHASE3":724,"PHASE4":903,"NA":935},{"trials":454,"activeCount":102},[],{"trials":456,"activeCount":122,"soonestReadout":562},[457,470,480,489,500,513,525,538,548,558,572,582],{"nctId":458,"briefTitle":459,"status":195,"phases":460,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":467},"NCT02093351","To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer",[90],"2015-04-30","2019-04-29","2014-09-01",79,[466],"Solid Tumours",[267,468,120,469],"Tamoxifen","Letrozole",{"nctId":471,"briefTitle":472,"status":195,"phases":473,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":479},"NCT01921140","To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours",[90],"2014-04-08","2022-03-15","2013-09-24",60,[466],[267],{"nctId":481,"briefTitle":482,"status":195,"phases":483,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":488},"NCT04236414","Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours",[90],"2025-02-04","2020-01-14",16,[466],[267],{"nctId":490,"briefTitle":491,"status":195,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":497,"interventions":499},"NCT02430311","The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.",[90],"2016-07-27","2017-04-28","2015-06-10",36,[498],"Advanced Solid Tumours",[267,118,267],{"nctId":501,"briefTitle":502,"status":195,"phases":503,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":511},"NCT03205176","AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas",[90],"2021-03-01","2021-04-08","2017-06-30",49,[509,510,414,25,415,416],"Malignant Solid Tumors","Lymphoma",[512,267],"AZD5153",{"nctId":514,"briefTitle":515,"status":443,"phases":516,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":522},"NCT02561832","A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer",[90],"2016-09-30","2017-02-01","2015-11-06",15,[25],[267,344,523,524],"Anthracycline","Cyclophosphamide",{"nctId":526,"briefTitle":527,"status":195,"phases":528,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":534},"NCT02588105","Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer",[90],"2019-09-13","2022-07-26","2015-11-10",84,[498],[535,267,536,174,537],"AZD0156","irinotecan","Folinic Acid",{"nctId":539,"briefTitle":540,"status":195,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":547},"NCT03022409","A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).",[90],"2021-01-20","2017-09-18",21,[546],"Head and Neck Squamous Cell Carcinoma",[265,267],{"nctId":549,"briefTitle":550,"status":195,"phases":551,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":557},"NCT01813474","Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies",[90],"2016-08-31","2013-03-25",23,[556,157],"Cancer",[63],{"nctId":559,"briefTitle":560,"status":108,"phases":561,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":568},"NCT02546661","Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w\u002F Muscle Invasive Bladder Cancer",[90],"2020-03-18","2026-01-30","2016-12-28",117,[567],"Muscle Invasive Bladder Cancer",[569,82,267,570,266,571,68],"AZD4547","AZD1775","AZD9150",{"nctId":573,"briefTitle":574,"status":195,"phases":575,"primaryCompletion":576,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT01851265","D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours",[90],"2013-10-18","2017-06-06","2013-07-04",32,[466],[267],{"nctId":583,"briefTitle":584,"status":195,"phases":585,"primaryCompletion":586,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":593},"NCT02511795","AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors",[90],"2019-04-25","2019-10-16","2015-08-06",128,[591,592],"Refractory Solid Tumours","Relapsed Small Cell Lung Cancer (SCLC)",[570,267],{"trials":595,"activeCount":723,"soonestReadout":62},[596,610,621,630,642,655,666,674,683,693,697,712],{"nctId":597,"briefTitle":598,"status":108,"phases":599,"primaryCompletion":600,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":609},"NCT02734004","A Phase I\u002FII Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.",[90,91],"2021-09-17","2026-09-17","2016-03-17",264,[605,606,607,608],"Ovarian","Breast","SCLC","Gastric Cancers",[267,82,239],{"nctId":611,"briefTitle":612,"status":195,"phases":613,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":619},"NCT01063517","Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients",[91],"2012-05-11","2023-06-29","2010-02-02",124,[172],[63,620],"paclitaxel",{"nctId":622,"briefTitle":623,"status":624,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":102,"conditions":628,"interventions":629},"NCT04239014","A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.","WITHDRAWN",[91],"2021-01-25","2020-08-07",[414],[267,265],{"nctId":631,"briefTitle":632,"status":195,"phases":633,"primaryCompletion":634,"completion":278,"start":635,"enrollment":636,"conditions":637,"interventions":641},"NCT01078662","Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats",[91],"2012-07-31","2010-02-21",298,[605,606,638,639,640],"Prostate","Pancreatic","Advanced Tumours",[63],{"nctId":643,"briefTitle":644,"status":195,"phases":645,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":652},"NCT01972217","Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.",[91],"2017-09-22","2023-08-24","2014-04-01",158,[651],"Metastatic Castration-resistant Prostate Cancer",[267,653,654],"Abiraterone","Prednisone or prednisolone",{"nctId":656,"briefTitle":657,"status":108,"phases":658,"primaryCompletion":659,"completion":660,"start":661,"enrollment":662,"conditions":663,"interventions":665},"NCT03459846","A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)",[91],"2020-10-15","2026-12-31","2018-03-16",154,[664],"Urinary Bladder Neoplasms",[117,267],{"nctId":60,"briefTitle":61,"status":108,"phases":667,"primaryCompletion":62,"completion":660,"start":668,"enrollment":669,"conditions":670,"interventions":671},[91],"2010-02-04",162,[414],[63,620,672,620,673],"carboplatin","Drug: carboplatin",{"nctId":675,"briefTitle":676,"status":195,"phases":677,"primaryCompletion":52,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":682},"NCT00494234","Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer",[91],"2022-12-21","2007-06-15",54,[306],[267],{"nctId":684,"briefTitle":685,"status":195,"phases":686,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":692},"NCT00912743","Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status",[91],"2012-03","2009-05",33,[691],"Colorectal Cancer",[63],{"nctId":254,"briefTitle":255,"status":108,"phases":694,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":695,"interventions":696},[91],[262],[117,264,265,266,267,251,97,268],{"nctId":698,"briefTitle":699,"status":108,"phases":700,"primaryCompletion":701,"completion":702,"start":246,"enrollment":703,"conditions":704,"interventions":706},"NCT03775486","Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)",[91],"2021-01-11","2026-09-27",401,[705],"Non-small Cell Lung Cancer NSCLC",[117,267,707,708,709,710,711],"Nab-paclitaxel+carboplatin","Gemcitabine+carboplatin","Pemetrexed+carboplatin","Gemcitabine+cisplatin","Pemetrexed+cisplatin",{"nctId":713,"briefTitle":714,"status":195,"phases":715,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},"NCT02983799","Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status",[91],"2020-12-03","2016-12-22",272,[720],"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity",[722],"OLAPARIB",5,{"trials":725,"activeCount":370,"soonestReadout":792},[726,737,748,757,767,776,788,798,810,824,835,845,856,866,878,889],{"nctId":727,"briefTitle":728,"status":195,"phases":729,"primaryCompletion":730,"completion":731,"start":732,"enrollment":662,"conditions":733,"interventions":736},"NCT02184195","Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy",[92],"2019-01-15","2023-01-27","2014-12-16",[734,735],"Germline BRCA1\u002F2 Mutations and","Metastatic Adenocarcinoma of the Pancreas",[267,267],{"nctId":738,"briefTitle":739,"status":108,"phases":740,"primaryCompletion":741,"completion":742,"start":743,"enrollment":744,"conditions":745,"interventions":746},"NCT05171816","Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)",[92],"2024-01-22","2026-04-28","2021-06-24",110,[651],[63,747],"abiraterone acetate",{"nctId":749,"briefTitle":750,"status":108,"phases":751,"primaryCompletion":752,"completion":752,"start":753,"enrollment":754,"conditions":755,"interventions":756},"NCT04421963","Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib",[92],"2027-04-06","2020-08-04",185,[414,25],[267],{"nctId":758,"briefTitle":759,"status":108,"phases":760,"primaryCompletion":761,"completion":762,"start":763,"enrollment":764,"conditions":765,"interventions":766},"NCT04884360","D9319C00001- 1L OC Mono Global RCT",[92],"2026-07-27","2027-07-27","2021-05-31",366,[414],[267],{"nctId":768,"briefTitle":769,"status":624,"phases":770,"primaryCompletion":771,"completion":771,"start":772,"enrollment":102,"conditions":773,"interventions":775},"NCT02392676","Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations",[92],"2019-06","2016-07",[774],"Platinum Sensitive Relapsed Ovarian Cancer",[722],{"nctId":777,"briefTitle":778,"status":108,"phases":779,"primaryCompletion":780,"completion":398,"start":781,"enrollment":782,"conditions":783,"interventions":785},"NCT03737643","Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients",[92],"2025-03-28","2019-01-04",1407,[784],"Advanced Ovarian Cancer",[239,117,267,786,787],"Durvalumab placebo","Carboplatin+Paclitaxel",{"nctId":789,"briefTitle":790,"status":108,"phases":791,"primaryCompletion":792,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":797},"NCT02032823","Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer",[92],"2020-03-27","2029-05-28","2014-04-22",1837,[25],[267],{"nctId":799,"briefTitle":800,"status":108,"phases":801,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":807},"NCT06112379","A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant\u002FAdjuvant Treatment of Triple-Negative or Hormone Receptor-low\u002FHER2-negative Breast Cancer",[92],"2028-11-20","2032-09-23","2023-11-14",1902,[25],[808,117,178,309,809,524,118,344,121,267],"Dato-DXd","Epirubicin",{"nctId":811,"briefTitle":812,"status":195,"phases":813,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":822},"NCT02000622","Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1\u002F2 Mutations.",[92],"2016-12-09","2025-12-23","2014-03-27",302,[819,820,821],"Breast Cancer Metastatic","BRCA 1 Gene Mutation","BRCA 2 Gene Mutation",[267,823],"Physician's choice chemotherapy",{"nctId":825,"briefTitle":826,"status":195,"phases":827,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":834},"NCT03402841","Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients",[92],"2020-10-02","2022-03-10","2018-01-30",279,[833],"Non-Germline BRCA Mutated Ovarian Cancer",[267],{"nctId":836,"briefTitle":837,"status":195,"phases":838,"primaryCompletion":839,"completion":840,"start":841,"enrollment":842,"conditions":843,"interventions":844},"NCT01924533","Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.",[92],"2016-04-04","2023-03-27","2013-09-03",525,[172],[267,118],{"nctId":846,"briefTitle":847,"status":195,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":854},"NCT02282020","Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments",[92],"2018-10-10","2022-07-19","2015-02-06",266,[720],[722,855],"Single agent chemotherapy",{"nctId":857,"briefTitle":858,"status":108,"phases":859,"primaryCompletion":860,"completion":861,"start":862,"enrollment":863,"conditions":864,"interventions":865},"NCT03732820","Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer",[92],"2021-07-30","2027-02-05","2018-10-31",895,[651],[63,747],{"nctId":867,"briefTitle":868,"status":195,"phases":869,"primaryCompletion":870,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":877},"NCT03286842","To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.",[92],"2021-10-08","2018-01-17",256,[874,875,876],"HER2-ve Metastatic Breast Cancer","Germline BRCA1\u002F2 Mutations","Somatic BRCA1\u002F2 Mutations",[267],{"nctId":879,"briefTitle":880,"status":195,"phases":881,"primaryCompletion":882,"completion":883,"start":884,"enrollment":885,"conditions":886,"interventions":887},"NCT02987543","Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)",[92],"2019-06-04","2023-02-15","2017-02-06",387,[651],[63,888,747,747,888],"enzalutamide",{"nctId":890,"briefTitle":891,"status":108,"phases":892,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT04269200","Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer",[92],"2024-07-08","2027-04-01","2020-05-05",805,[898],"Endometrial Neoplasms",[63,900,901,902,344,118],"durvalumab","durvalumab placebo","olaparib placebo",{"trials":904,"activeCount":122,"soonestReadout":909},[905,915,926],{"nctId":906,"briefTitle":907,"status":108,"phases":908,"primaryCompletion":909,"completion":660,"start":910,"enrollment":911,"conditions":912,"interventions":913},"NCT05457257","Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1\u002F2 Mutations",[93],"2024-10-22","2022-07-29",43,[651],[63,888,747,914],"Prednisone",{"nctId":916,"briefTitle":917,"status":195,"phases":918,"primaryCompletion":919,"completion":920,"start":921,"enrollment":922,"conditions":923,"interventions":925},"NCT02476968","To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer",[93],"2020-04-17","2021-12-17","2015-09-28",181,[924],"BRCA or HRR+ Mutated Ovarian Cancer Patients",[267],{"nctId":927,"briefTitle":928,"status":195,"phases":929,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":934},"NCT04330040","Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer",[93],"2022-09-30","2020-05-25",202,[414,25],[267],{"trials":936,"activeCount":102},[937,947,955],{"nctId":938,"briefTitle":939,"status":195,"phases":940,"primaryCompletion":941,"completion":941,"start":942,"enrollment":943,"conditions":944,"interventions":946},"NCT04532645","Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK",[],"2024-09-27","2021-01-07",342,[945],"Ovary Cancer",[267],{"nctId":948,"briefTitle":949,"status":950,"phases":951,"conditions":952,"interventions":954},"NCT03063710","Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan","NO_LONGER_AVAILABLE",[],[953],"PSR Ovarian Cancer With a BRCA Mutation",[63],{"nctId":956,"briefTitle":957,"status":958,"phases":959,"conditions":960,"interventions":961},"NCT03079687","Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.","APPROVED_FOR_MARKETING",[],[414],[267],{"intervention":252,"totalTrials":963,"cells":964},13,{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":982,"PHASE3":1040,"PHASE4":1092,"NA":1105},{"trials":966,"activeCount":102},[],{"trials":968,"activeCount":122,"soonestReadout":973},[969],{"nctId":970,"briefTitle":971,"status":108,"phases":972,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":978},"NCT04612751","Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer",[90],"2026-05-04","2021-02-02",155,[977],"Advanced or Metastatic NSCLC",[252,117,344,979,980,981],"AZD2936","MEDI5752","AZD7789",{"trials":983,"activeCount":1039,"soonestReadout":988},[984,995,999,1003,1018,1028],{"nctId":985,"briefTitle":986,"status":108,"phases":987,"primaryCompletion":988,"completion":130,"start":989,"enrollment":990,"conditions":991,"interventions":994},"NCT05460273","A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)",[90,91],"2023-11-07","2022-07-11",119,[992,993],"Carcinoma, Non-Small-Cell Lung","Triple Negative Breast Cancer",[163],{"nctId":149,"briefTitle":150,"status":151,"phases":996,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":997,"interventions":998},[90,91],[157],[159,160,161,162,163],{"nctId":241,"briefTitle":242,"status":108,"phases":1000,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":1001,"interventions":1002},[90,91],[249],[117,119,251,118,97,252],{"nctId":1004,"briefTitle":1005,"status":108,"phases":1006,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1011},"NCT03944772","Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)",[91],"2025-05-06","2019-06-25",247,[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],"Osimertinib","Gefitinib","Necitumumab","Alectinib","Selpercatinib","Etoposide",{"nctId":1019,"briefTitle":1020,"status":151,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":340,"conditions":1024,"interventions":1026},"NCT05489211","Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)",[91],"2027-10-01","2022-09-06",[367,172,651,414,691,1025,281],"Urothelial Cancer",[252,121,226,179,344,239,180,1027,177],"Prednisone\u002F prednisolone",{"nctId":1029,"briefTitle":1030,"status":151,"phases":1031,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT06130553","A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced\u002FMetastatic Solid Tumors",[90,91],"2028-12-04","2024-01-18",334,[1036],"Advanced Solid Tumors That Are MTAP Deficient",[1038,252],"AZD3470",6,{"trials":1041,"activeCount":723,"soonestReadout":1046},[1042,1053,1062,1072,1082],{"nctId":1043,"briefTitle":1044,"status":108,"phases":1045,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":98,"conditions":1048,"interventions":1050},"NCT06564844","A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features",[92],"2027-06-30","2024-10-15",[1049],"Non-small Cell Lung Cancer",[163,180,344,177,1017,345,1051,1052],"Vinorelbine","UFT",{"nctId":1054,"briefTitle":1055,"status":151,"phases":1056,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":1059,"conditions":1060,"interventions":1061},"NCT06357533","Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations",[92],"2029-12-28","2024-04-11",675,[262],[163,180,178],{"nctId":1063,"briefTitle":1064,"status":151,"phases":1065,"primaryCompletion":1066,"completion":1067,"start":1068,"enrollment":1069,"conditions":1070,"interventions":1071},"NCT06350097","Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer",[92],"2028-03-21","2031-08-29","2024-04-29",582,[1049],[1012,163],{"nctId":1073,"briefTitle":1074,"status":151,"phases":1075,"primaryCompletion":1076,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1081},"NCT07291037","Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations",[92],"2029-01-29","2025-10-31",400,[1080],"Non-small Cell Lung Cancer (NSCLC)",[252,369],{"nctId":1083,"briefTitle":1084,"status":108,"phases":1085,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1091},"NCT05687266","Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations",[92],"2027-11-01","2022-12-29",1350,[1090],"NSCLC",[252,117,344,178,177,345,118],{"trials":1093,"activeCount":122,"soonestReadout":1099},[1094],{"nctId":1095,"briefTitle":1096,"status":1097,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":221,"conditions":1101,"interventions":1103},"NCT07357597","An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.","NOT_YET_RECRUITING",[93],"2027-10-09","2026-02-27",[1102],"Stomatitis",[1104,163],"Dexamethasone mouthwash",{"trials":1106,"activeCount":102},[],{"intervention":1108,"totalTrials":554,"cells":1109},"Anifrolumab",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1142,"PHASE3":1164,"PHASE4":1264,"NA":1274},{"trials":1111,"activeCount":102},[],{"trials":1113,"activeCount":102},[1114,1124,1133],{"nctId":1115,"briefTitle":1116,"status":195,"phases":1117,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":1120,"conditions":1121,"interventions":1123},"NCT05339100","Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab",[90],"2023-04-13","2022-03-22",180,[1122],"Healthy Participants Study",[1108],{"nctId":1125,"briefTitle":1126,"status":195,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1132},"NCT06662123","Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants",[90],"2025-01-10","2024-10-21",24,[36],[1108],{"nctId":1134,"briefTitle":1135,"status":195,"phases":1136,"primaryCompletion":1137,"completion":1137,"start":1138,"enrollment":520,"conditions":1139,"interventions":1141},"NCT05001698","Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)",[90],"2022-06-02","2021-07-27",[1140],"Systemic Lupus Erythematosus",[1108],{"trials":1143,"activeCount":102},[1144,1155],{"nctId":1145,"briefTitle":1146,"status":195,"phases":1147,"primaryCompletion":1148,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1154},"NCT02547922","Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis",[91],"2019-11-26","2021-01-18","2015-11-04",147,[1153],"Lupus Nephritis",[1108],{"nctId":1156,"briefTitle":1157,"status":195,"phases":1158,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":496,"conditions":1162,"interventions":1163},"NCT02962960","A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations",[91],"2018-01-22","2018-12-17","2017-02-14",[1140],[1108],{"trials":1165,"activeCount":1039,"soonestReadout":1257},[1166,1177,1186,1196,1204,1213,1222,1232,1241,1253],{"nctId":1167,"briefTitle":1168,"status":151,"phases":1169,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":1173,"conditions":1174,"interventions":1176},"NCT06455449","A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)",[92],"2027-05-14","2028-08-04","2024-06-20",240,[1175],"Polymyositis, Dermatomyositis",[1108,1108],{"nctId":1178,"briefTitle":1179,"status":108,"phases":1180,"primaryCompletion":245,"completion":1181,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1185},"NCT05138133","Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis",[92],"2028-12-05","2022-02-15",359,[1153],[1108],{"nctId":1187,"briefTitle":1188,"status":195,"phases":1189,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1195},"NCT02794285","Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus",[92],"2021-12-21","2016-06-30",559,[1194],"Active Systemic Lupus Erythematosus",[1108],{"nctId":1197,"briefTitle":1198,"status":151,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":143,"conditions":1202,"interventions":1203},"NCT07430306","A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus",[92],"2029-01-26","2026-04-13",[1140],[1108],{"nctId":1205,"briefTitle":1206,"status":195,"phases":1207,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":1211,"interventions":1212},"NCT02446912","Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",[92],"2018-07-17","2015-06-09",460,[1194],[1108],{"nctId":1214,"briefTitle":1215,"status":195,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1220,"interventions":1221},"NCT02446899","Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",[92],"2018-09-27","2015-07-09",373,[1194],[1108],{"nctId":1223,"briefTitle":1224,"status":195,"phases":1225,"primaryCompletion":1226,"completion":1227,"start":1228,"enrollment":1229,"conditions":1230,"interventions":1231},"NCT04931563","Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)",[92],"2025-04-07","2025-06-10","2021-09-13",277,[1194],[1108],{"nctId":1233,"briefTitle":1234,"status":151,"phases":1235,"primaryCompletion":1236,"completion":1237,"start":1238,"enrollment":221,"conditions":1239,"interventions":1240},"NCT05835310","An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants",[92],"2028-10-05","2030-01-09","2024-03-14",[1140],[1108],{"nctId":1242,"briefTitle":1243,"status":108,"phases":1244,"primaryCompletion":1245,"completion":1246,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1252},"NCT05925803","Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)",[92],"2027-01-06","2028-04-05","2023-11-08",314,[1250,1251],"Systemic Sclerosis","Scleroderma",[1108,1108],{"nctId":1254,"briefTitle":1255,"status":108,"phases":1256,"primaryCompletion":1257,"completion":1258,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1263},"NCT06015737","A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and\u002For Subacute Cutaneous Lupus Erythematosus",[92],"2026-12-11","2027-08-11","2024-06-29",306,[1262],"Cutaneous Lupus Erythematosus",[1108],{"trials":1265,"activeCount":122,"soonestReadout":1270},[1266],{"nctId":1267,"briefTitle":1268,"status":151,"phases":1269,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":486,"conditions":1272,"interventions":1273},"NCT06594068","Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users",[93],"2027-08-31","2026-01-16",[1140],[1108],{"trials":1275,"activeCount":1039,"soonestReadout":1280},[1276,1285,1294,1303,1312,1321,1328],{"nctId":1277,"briefTitle":1278,"status":151,"phases":1279,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":221,"conditions":1282,"interventions":1284},"NCT06673043","Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus",[],"2028-06-30","2025-02-28",[1283],"Lupus Erythematosus, Systemic",[1108],{"nctId":1286,"briefTitle":1287,"status":1097,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1293},"NCT07431775","Saphnelo Use in Females of Child-bearing Potential",[],"2032-03-31","2026-10-01",26000000,[1140],[1108],{"nctId":1295,"briefTitle":1296,"status":151,"phases":1297,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1302},"NCT06659029","Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users",[],"2031-04-15","2025-07-01",442,[1140],[1108],{"nctId":1304,"briefTitle":1305,"status":151,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1310,"interventions":1311},"NCT07000110","Anifrolumab Malignancy and Serious Infections Study",[],"2031-11-30","2026-01-26",3195,[1140],[1108],{"nctId":1313,"briefTitle":1314,"status":151,"phases":1315,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1318,"conditions":1319,"interventions":1320},"NCT07330245","Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.",[],"2028-09-30","2025-12-31",218,[1283],[1108],{"nctId":1322,"briefTitle":1323,"status":151,"phases":1324,"primaryCompletion":1298,"completion":1298,"start":1325,"enrollment":1173,"conditions":1326,"interventions":1327},"NCT06795893","The Anifrolumab PRIM Program",[],"2025-11-07",[1140],[1108],{"nctId":1329,"briefTitle":1330,"status":950,"phases":1331,"conditions":1332,"interventions":1333},"NCT04750057","Anifrolumab Early Access Program",[],[1140],[1108],{"intervention":1335,"totalTrials":1336,"cells":1337},"Acalabrutinib",18,{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1365,"PHASE3":1469,"PHASE4":1502,"NA":1522},{"trials":1339,"activeCount":102},[],{"trials":1341,"activeCount":122,"soonestReadout":1357},[1342,1353],{"nctId":1343,"briefTitle":1344,"status":195,"phases":1345,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":1348,"conditions":1349,"interventions":1351},"NCT04489797","A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants",[90],"2020-08-28","2020-07-20",35,[1350],"Infectious Disease",[1335,1352],"Rabeprazole",{"nctId":1354,"briefTitle":1355,"status":108,"phases":1356,"primaryCompletion":1357,"completion":1317,"start":1358,"enrollment":1348,"conditions":1359,"interventions":1363},"NCT03198650","A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies",[90],"2022-10-27","2017-06-27",[1360,1361,1362],"Part1: Advanced B-cell Malignancies","Part2: r\u002FrCLL and r\u002FrMCL","Part3: Untreated CLL",[1335,1364],"Obinutuzumab",{"trials":1366,"activeCount":723,"soonestReadout":1425},[1367,1379,1389,1400,1412,1421,1434,1441,1453],{"nctId":1368,"briefTitle":1369,"status":108,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":1373,"conditions":1374,"interventions":1376},"NCT05951959","A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma",[91],"2028-10-31","2023-12-13",108,[1375],"Mantle Cell Lymphoma (MCL)",[1335,1377,1378],"Venetoclax","Rituximab",{"nctId":1380,"briefTitle":1381,"status":195,"phases":1382,"primaryCompletion":1383,"completion":1383,"start":1384,"enrollment":1385,"conditions":1386,"interventions":1388},"NCT04346199","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.",[91],"2020-11-17","2020-06-12",177,[1387],"COVID-19",[1335],{"nctId":1390,"briefTitle":1391,"status":1097,"phases":1392,"primaryCompletion":1393,"completion":1394,"start":563,"enrollment":1395,"conditions":1396,"interventions":1399},"NCT07024706","Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab",[91],"2029-05-01","2029-05-15",80,[1397,1398],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)",[1335,1377],{"nctId":1401,"briefTitle":1402,"status":624,"phases":1403,"primaryCompletion":1404,"completion":1405,"start":1406,"enrollment":102,"conditions":1407,"interventions":1410},"NCT06839872","A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2028-07-28","2030-07-29","2025-06-30",[1408,1409],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",[1411,1335],"Pirtobrutinib",{"nctId":1413,"briefTitle":1414,"status":151,"phases":1415,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1395,"conditions":1418,"interventions":1420},"NCT05952024","Study of Acalabrutinib and Rituximab in Untreated Elderly and\u002For Frail Patients With DLBCL",[91],"2029-04-22","2024-07-16",[1419],"Diffuse Large B-Cell Lymphoma",[1335,1378],{"nctId":1422,"briefTitle":1423,"status":108,"phases":1424,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1433},"NCT03932331","Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies",[90,91],"2022-12-22","2026-06-24","2020-04-29",105,[1430,1431,1432],"Phase I: Relapsed or Refractory B-cell Malignancies","Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma","Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia",[1335],{"nctId":1435,"briefTitle":1381,"status":195,"phases":1436,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":37,"conditions":1439,"interventions":1440},"NCT04380688",[91],"2020-11-16","2020-06-13",[1387],[1335],{"nctId":1442,"briefTitle":1443,"status":195,"phases":1444,"primaryCompletion":1445,"completion":1446,"start":1447,"enrollment":1448,"conditions":1449,"interventions":1451},"NCT04630756","AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer",[90,91],"2023-09-08","2025-02-27","2021-02-17",40,[1450],"Advanced Haematological Malignancies",[1452,1335],"AZD4573",{"nctId":1454,"briefTitle":1455,"status":151,"phases":1456,"primaryCompletion":1457,"completion":1458,"start":1459,"enrollment":1460,"conditions":1461,"interventions":1466},"NCT06564038","A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies",[90,91],"2028-02-28","2029-06-11","2025-01-30",408,[1462,1409,1463,1464,1465],"Chronic Lymphocytic Leukaemia","Mantle-cell Lymphoma","Large B-cell Lymphoma","B-cell Non-Hodgkin Lymphoma",[1467,914,1378,524,1468,309,1335],"Surovatamig","Vincristine",{"trials":1470,"activeCount":447,"soonestReadout":1484},[1471,1480,1491],{"nctId":1472,"briefTitle":1473,"status":195,"phases":1474,"primaryCompletion":1475,"completion":1475,"start":1476,"enrollment":1477,"conditions":1478,"interventions":1479},"NCT04008706","Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients",[92],"2025-11-04","2019-09-17",552,[1408],[1335],{"nctId":1481,"briefTitle":1482,"status":108,"phases":1483,"primaryCompletion":1484,"completion":1485,"start":1486,"enrollment":975,"conditions":1487,"interventions":1489},"NCT04075292","Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia",[92],"2024-01-03","2027-01-01","2020-01-20",[1488],"Untreated Chronic Lymphocytic Leukemia",[1335,1378,1490],"Chlorambucil",{"nctId":1492,"briefTitle":1493,"status":108,"phases":1494,"primaryCompletion":1495,"completion":1496,"start":1497,"enrollment":1498,"conditions":1499,"interventions":1501},"NCT05057494","A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[92],"2027-07-15","2029-04-10","2022-09-12",607,[1500],"Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[1335,1377,1364],{"trials":1503,"activeCount":122,"soonestReadout":1518},[1504,1514],{"nctId":1505,"briefTitle":1506,"status":195,"phases":1507,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1513},"NCT04930536","Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma",[93],"2023-05-02","2021-07-14",103,[1512],"Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma",[1335],{"nctId":1515,"briefTitle":1516,"status":151,"phases":1517,"primaryCompletion":1518,"completion":1518,"start":484,"enrollment":477,"conditions":1519,"interventions":1521},"NCT06651970","Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure",[93],"2030-08-16",[1462,1520],"Heart Failure",[1335],{"trials":1523,"activeCount":447,"soonestReadout":894},[1524,1533],{"nctId":1525,"briefTitle":1526,"status":151,"phases":1527,"primaryCompletion":894,"completion":894,"start":1528,"enrollment":1529,"conditions":1530,"interventions":1532},"NCT05557695","Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom",[],"2022-10-17",350,[1531],"Chronic Lymphocytic Leukemia, CLL",[1335],{"nctId":1534,"briefTitle":1535,"status":108,"phases":1536,"primaryCompletion":302,"completion":302,"start":1537,"enrollment":20,"conditions":1538,"interventions":1539},"NCT06205498","Acalabrutinib Real World Italian obSErvational Study -ARISE",[],"2023-08-08",[1408],[1540],"acalabrutinib",{"intervention":1542,"totalTrials":1543,"cells":1544},"Benralizumab",37,{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1566,"PHASE3":1590,"PHASE4":1856,"NA":1886},{"trials":1546,"activeCount":102},[],{"trials":1548,"activeCount":102},[1549,1558],{"nctId":1550,"briefTitle":1551,"status":195,"phases":1552,"primaryCompletion":1553,"completion":1553,"start":1554,"enrollment":496,"conditions":1555,"interventions":1557},"NCT03928262","Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects",[90],"2019-08-12","2019-04-02",[1556],"Healthy Subjects",[1542],{"nctId":1559,"briefTitle":1560,"status":195,"phases":1561,"primaryCompletion":1562,"completion":1562,"start":1563,"enrollment":1120,"conditions":1564,"interventions":1565},"NCT02968914","Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers",[90],"2017-07-13","2017-01-04",[16,28],[1542,1542],{"trials":1567,"activeCount":102},[1568,1579],{"nctId":1569,"briefTitle":1570,"status":443,"phases":1571,"primaryCompletion":1572,"completion":1573,"start":1574,"enrollment":1575,"conditions":1576,"interventions":1578},"NCT04605094","Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis",[91],"2022-04-25","2022-09-13","2020-11-12",194,[1577],"Atopic Dermatitis",[1542],{"nctId":1580,"briefTitle":1581,"status":443,"phases":1582,"primaryCompletion":1583,"completion":1584,"start":1585,"enrollment":1586,"conditions":1587,"interventions":1589},"NCT04612725","A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)",[91],"2022-10-13","2023-03-28","2020-10-27",159,[1588],"Chronic Spontaneous Urticaria",[1542],{"trials":1591,"activeCount":1855,"soonestReadout":1839},[1592,1603,1611,1621,1631,1643,1652,1660,1670,1678,1688,1696,1705,1714,1723,1731,1741,1751,1762,1771,1780,1790,1799,1809,1818,1826,1835,1847],{"nctId":1593,"briefTitle":1594,"status":443,"phases":1595,"primaryCompletion":1596,"completion":1597,"start":1598,"enrollment":1599,"conditions":1600,"interventions":1602},"NCT04543409","A Study of Benralizumab in Patients With Eosinophilic Esophagitis",[92],"2022-09-19","2023-02-06","2020-09-22",211,[1601],"Eosinophilic Esophagitis",[1542],{"nctId":1604,"briefTitle":1605,"status":195,"phases":1606,"primaryCompletion":1607,"completion":1607,"start":1608,"enrollment":669,"conditions":1609,"interventions":1610},"NCT02417961","Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home",[92],"2016-03-14","2015-04-27",[16],[1542],{"nctId":1612,"briefTitle":1613,"status":443,"phases":1614,"primaryCompletion":1615,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1620},"NCT04612790","A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.",[92],"2023-10-26","2021-03-31",67,[1619],"Bullous Pemphigoid",[1542],{"nctId":1622,"briefTitle":1623,"status":195,"phases":1624,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1510,"conditions":1627,"interventions":1628},"NCT02814643","Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma",[92],"2017-01-24","2016-07-01",[16],[1542,1629,1630],"Benralizumab Placebo","Seasonal influenza virus vaccine",{"nctId":1632,"briefTitle":1633,"status":151,"phases":1634,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":1639,"interventions":1642},"NCT06512883","A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases",[92],"2028-02-21","2029-05-14","2025-04-17",14,[1640,1641],"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","Hypereosinophilia Syndrome (HES)",[1542],{"nctId":1644,"briefTitle":1645,"status":108,"phases":1646,"primaryCompletion":1647,"completion":1647,"start":198,"enrollment":1648,"conditions":1649,"interventions":1651},"NCT06465485","STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma",[92],"2026-05-29",504,[1650],"Severe Eosinophilic Asthma",[1542],{"nctId":1653,"briefTitle":1654,"status":195,"phases":1655,"primaryCompletion":1656,"completion":1656,"start":1657,"enrollment":1599,"conditions":1658,"interventions":1659},"NCT02322775","Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma",[92],"2015-10-07","2015-02-02",[16],[1542],{"nctId":1661,"briefTitle":1662,"status":108,"phases":1663,"primaryCompletion":1664,"completion":1665,"start":1347,"enrollment":1666,"conditions":1667,"interventions":1669},"NCT04191304","A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)",[92],"2025-05-07","2027-02-28",134,[1668],"Hypereosinophilic Syndrome",[1542],{"nctId":1671,"briefTitle":1672,"status":195,"phases":1673,"primaryCompletion":1674,"completion":1674,"start":1191,"enrollment":1675,"conditions":1676,"interventions":1677},"NCT02808819","A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist",[92],"2020-06-18",447,[16],[1542,1542],{"nctId":1679,"briefTitle":1680,"status":151,"phases":1681,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1687},"NCT05692180","A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)",[92],"2030-05-05","2032-05-16","2023-04-05",200,[16],[1542],{"nctId":1689,"briefTitle":1690,"status":443,"phases":1691,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":963,"conditions":1694,"interventions":1695},"NCT01947946","Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma",[92],"2014-07","2013-11",[16],[1542],{"nctId":1697,"briefTitle":1698,"status":195,"phases":1699,"primaryCompletion":1700,"completion":1700,"start":1701,"enrollment":1702,"conditions":1703,"interventions":1704},"NCT01914757","Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist",[92],"2016-03","2013-08",2508,[16],[1542],{"nctId":1706,"briefTitle":1707,"status":195,"phases":1708,"primaryCompletion":1497,"completion":1497,"start":1709,"enrollment":1710,"conditions":1711,"interventions":1713},"NCT04305405","PK\u002FPD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma",[92],"2019-11-21",30,[1712],"Severe Uncontrolled Asthma",[1542],{"nctId":1715,"briefTitle":1716,"status":1097,"phases":1717,"primaryCompletion":1057,"completion":1057,"start":1718,"enrollment":1719,"conditions":1720,"interventions":1722},"NCT07444567","Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment",[92],"2026-05-25",230,[16,1640,1721],"Hypereosinophilic Syndrome (HES)",[1542],{"nctId":1724,"briefTitle":1725,"status":195,"phases":1726,"primaryCompletion":1727,"completion":1727,"start":1728,"enrollment":451,"conditions":1729,"interventions":1730},"NCT02821416","Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics",[92],"2019-10-22","2016-10-11",[16],[1542],{"nctId":1732,"briefTitle":1733,"status":151,"phases":1734,"primaryCompletion":1735,"completion":1735,"start":780,"enrollment":1078,"conditions":1736,"interventions":1738},"NCT06750289","Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment",[92],"2028-11-03",[1737],"Eosinophilic Asthma",[1739,1740],"ICS-LABA","benralizumab",{"nctId":1742,"briefTitle":1743,"status":195,"phases":1744,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1750},"NCT03557307","Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma",[92],"2021-04-16","2022-03-24","2018-08-01",598,[16],[1542],{"nctId":1752,"briefTitle":1753,"status":443,"phases":1754,"primaryCompletion":1755,"completion":1755,"start":1756,"enrollment":1757,"conditions":1758,"interventions":1761},"NCT05251909","Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and\u002For Gastroenteritis (The HUDSON GI Study)",[92],"2024-02-13","2022-01-18",12,[1759,1760],"Eosinophilic Gastritis","Eosinophilic Gastroenteritis",[1542],{"nctId":1763,"briefTitle":1764,"status":443,"phases":1765,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":221,"conditions":1768,"interventions":1770},"NCT05006573","Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis",[92],"2024-04-16","2021-07-21",[1769],"Non-cystic Fibrosis Bronchiectasis",[1542],{"nctId":1772,"briefTitle":1773,"status":195,"phases":1774,"primaryCompletion":1775,"completion":1775,"start":1776,"enrollment":1777,"conditions":1778,"interventions":1779},"NCT02918071","Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home",[92],"2017-08-21","2016-11-10",121,[16],[1542],{"nctId":1781,"briefTitle":1782,"status":195,"phases":1783,"primaryCompletion":1784,"completion":1785,"start":1786,"enrollment":1787,"conditions":1788,"interventions":1789},"NCT02258542","A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA",[92],"2017-10-18","2018-07-02","2014-11-19",2133,[16],[1542,1542],{"nctId":1791,"briefTitle":1792,"status":195,"phases":1793,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":1796,"conditions":1797,"interventions":1798},"NCT04053634","Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations",[92],"2025-07-28","2019-08-26",689,[28],[1542],{"nctId":1800,"briefTitle":1801,"status":195,"phases":1802,"primaryCompletion":1803,"completion":1804,"start":1805,"enrollment":1806,"conditions":1807,"interventions":1808},"NCT03170271","A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.",[92],"2019-09-25","2020-10-21","2017-07-07",660,[16],[1542],{"nctId":1810,"briefTitle":1811,"status":195,"phases":1812,"primaryCompletion":1813,"completion":1813,"start":1814,"enrollment":1815,"conditions":1816,"interventions":1817},"NCT01928771","Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma",[92],"2016-04-05","2013-09-19",2681,[16],[1542],{"nctId":1819,"briefTitle":1820,"status":195,"phases":1821,"primaryCompletion":1822,"completion":1822,"start":1823,"enrollment":155,"conditions":1824,"interventions":1825},"NCT03186209","Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)",[92],"2023-01-30","2017-09-07",[16],[1542],{"nctId":1827,"briefTitle":1828,"status":195,"phases":1829,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1832,"conditions":1833,"interventions":1834},"NCT02075255","Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy",[92],"2016-08-08","2014-04-28",220,[16],[1542,1542],{"nctId":1836,"briefTitle":1837,"status":108,"phases":1838,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1842,"conditions":1843,"interventions":1845},"NCT04157348","Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.",[92],"2023-08-10","2026-11-30","2019-10-29",140,[1844],"Eosinophilic Granulomatous Vasculitis",[1542,1846],"Mepolizumab",{"nctId":1848,"briefTitle":1849,"status":195,"phases":1850,"primaryCompletion":1747,"completion":1747,"start":1851,"enrollment":1852,"conditions":1853,"interventions":1854},"NCT02869438","A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation",[92],"2016-11-09",233,[16],[1542],7,{"trials":1857,"activeCount":122,"soonestReadout":1881},[1858,1867,1877],{"nctId":1859,"briefTitle":1860,"status":195,"phases":1861,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":1864,"conditions":1865,"interventions":1866},"NCT05552508","BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging",[93],"2024-07-19","2022-10-11",45,[16],[1542],{"nctId":1868,"briefTitle":1869,"status":195,"phases":1870,"primaryCompletion":1871,"completion":1871,"start":1872,"enrollment":1873,"conditions":1874,"interventions":1876},"NCT05384938","FAsenra Safety Trial in India",[93],"2023-07-01","2021-11-19",139,[1875],"In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India",[1542],{"nctId":1878,"briefTitle":1879,"status":108,"phases":1880,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1883,"conditions":1884,"interventions":1885},"NCT03953300","Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics",[93],"2026-10-19","2019-10-08",75,[16],[1542],{"trials":1887,"activeCount":122,"soonestReadout":1892},[1888,1897],{"nctId":1889,"briefTitle":1890,"status":151,"phases":1891,"primaryCompletion":1892,"completion":1892,"start":1893,"enrollment":1894,"conditions":1895,"interventions":1896},"NCT07214753","A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy",[],"2028-12-31","2025-12-20",335,[1650],[1740],{"nctId":1898,"briefTitle":1899,"status":195,"phases":1900,"primaryCompletion":1901,"completion":1901,"start":1902,"enrollment":1903,"conditions":1904,"interventions":1905},"NCT05932849","Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma Centres",[],"2022-02-28","2021-10-05",276,[16],[1542],{"intervention":747,"totalTrials":370,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1928,"PHASE3":1942,"PHASE4":1980,"NA":1986},{"trials":1909,"activeCount":102},[],{"trials":1911,"activeCount":102},[1912],{"nctId":1913,"briefTitle":1914,"status":195,"phases":1915,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":1920,"interventions":1924},"NCT02740985","A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies",[90],"2020-12-31","2023-03-31","2016-06-17",313,[157,1921,1922,1923],"Non-Small Cell Lung Cancer (NSCLC)","Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","Colorectal Carcinoma (CRC)",[1925,117,1926,1927,251,369],"AZD4635","Abiraterone Acetate","Enzalutamide",{"trials":1929,"activeCount":122,"soonestReadout":1934},[1930],{"nctId":1931,"briefTitle":1932,"status":108,"phases":1933,"primaryCompletion":1934,"completion":1934,"start":1137,"enrollment":1935,"conditions":1936,"interventions":1938},"NCT05367440","Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer",[90,91],"2031-04-11",174,[1937],"Metastatic Prostate Cancer",[1939,1927,1926,1940,1941],"AZD5305","Darolutamide","Apalutamide",{"trials":1943,"activeCount":1979,"soonestReadout":860},[1944,1948,1960,1971,1975],{"nctId":738,"briefTitle":739,"status":108,"phases":1945,"primaryCompletion":741,"completion":742,"start":743,"enrollment":744,"conditions":1946,"interventions":1947},[92],[651],[63,747],{"nctId":1949,"briefTitle":1950,"status":108,"phases":1951,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1958},"NCT06120491","Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents",[92],"2027-09-30","2031-04-30","2023-11-21",1889,[1957],"Metastatic Castration-Sensitive Prostate Cancer",[1959,1926,1940,1927],"Saruparib",{"nctId":1961,"briefTitle":1962,"status":108,"phases":1963,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":1967,"conditions":1968,"interventions":1970},"NCT04493853","Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency",[92],"2024-10-07","2027-03-31","2020-07-13",1012,[1969],"Hormone-Sensitive Prostate Cancer",[119,1926],{"nctId":857,"briefTitle":858,"status":108,"phases":1972,"primaryCompletion":860,"completion":861,"start":862,"enrollment":863,"conditions":1973,"interventions":1974},[92],[651],[63,747],{"nctId":879,"briefTitle":880,"status":195,"phases":1976,"primaryCompletion":882,"completion":883,"start":884,"enrollment":885,"conditions":1977,"interventions":1978},[92],[651],[63,888,747,747,888],4,{"trials":1981,"activeCount":122,"soonestReadout":909},[1982],{"nctId":906,"briefTitle":907,"status":108,"phases":1983,"primaryCompletion":909,"completion":660,"start":910,"enrollment":911,"conditions":1984,"interventions":1985},[93],[651],[63,888,747,914],{"trials":1987,"activeCount":102},[],{"intervention":1927,"totalTrials":1855,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":2006,"PHASE3":2012,"PHASE4":2035,"NA":2041},{"trials":1991,"activeCount":102},[],{"trials":1993,"activeCount":102},[1994,1998],{"nctId":1913,"briefTitle":1914,"status":195,"phases":1995,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":1996,"interventions":1997},[90],[157,1921,1922,1923],[1925,117,1926,1927,251,369],{"nctId":1999,"briefTitle":2000,"status":195,"phases":2001,"primaryCompletion":317,"completion":317,"start":2002,"enrollment":2003,"conditions":2004,"interventions":2005},"NCT04087174","A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer",[90],"2019-08-05",27,[416],[119,1927,653],{"trials":2007,"activeCount":122,"soonestReadout":1934},[2008],{"nctId":1931,"briefTitle":1932,"status":108,"phases":2009,"primaryCompletion":1934,"completion":1934,"start":1137,"enrollment":1935,"conditions":2010,"interventions":2011},[90,91],[1937],[1939,1927,1926,1940,1941],{"trials":2013,"activeCount":447,"soonestReadout":1952},[2014,2018,2022],{"nctId":1949,"briefTitle":1950,"status":108,"phases":2015,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":1955,"conditions":2016,"interventions":2017},[92],[1957],[1959,1926,1940,1927],{"nctId":879,"briefTitle":880,"status":195,"phases":2019,"primaryCompletion":882,"completion":883,"start":884,"enrollment":885,"conditions":2020,"interventions":2021},[92],[651],[63,888,747,747,888],{"nctId":2023,"briefTitle":2024,"status":151,"phases":2025,"primaryCompletion":2026,"completion":2027,"start":973,"enrollment":2028,"conditions":2029,"interventions":2030},"NCT07611110","AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)",[92],"2029-02-13","2029-12-20",670,[651],[2031,2032,653,1927,1941,1940,2033,2034],"AZD2265","Cabazitaxel","Rezvilutamide","Radium-223",{"trials":2036,"activeCount":122,"soonestReadout":909},[2037],{"nctId":906,"briefTitle":907,"status":108,"phases":2038,"primaryCompletion":909,"completion":660,"start":910,"enrollment":911,"conditions":2039,"interventions":2040},[93],[651],[63,888,747,914],{"trials":2042,"activeCount":102},[],{"intervention":2044,"totalTrials":2045,"cells":2046},"Dapagliflozin",90,{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2282,"PHASE3":2390,"PHASE4":2775,"NA":2858},{"trials":2048,"activeCount":102},[],{"trials":2050,"activeCount":102},[2051,2063,2073,2082,2091,2100,2109,2117,2127,2139,2147,2156,2164,2175,2183,2191,2199,2208,2216,2226,2232,2238,2247,2256,2263,2273],{"nctId":2052,"briefTitle":2053,"status":195,"phases":2054,"primaryCompletion":2055,"completion":2056,"start":2057,"enrollment":520,"conditions":2058,"interventions":2060},"NCT01002807","Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State",[90],"2009-12","2010-01","2009-11",[2059],"Type 2 Diabetes Mellitus (T2DM)",[2044,2061,2062],"Metformin XR","Glucophage",{"nctId":2064,"briefTitle":2065,"status":195,"phases":2066,"primaryCompletion":2067,"completion":2067,"start":2068,"enrollment":2069,"conditions":2070,"interventions":2071},"NCT00930865","Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects",[90],"2009-09","2009-07",42,[22],[2072,2044],"Bumetanide",{"nctId":2074,"briefTitle":2075,"status":195,"phases":2076,"primaryCompletion":688,"completion":688,"start":2077,"enrollment":1336,"conditions":2078,"interventions":2079},"NCT00842556","Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects",[90],"2009-03",[22],[2044,2080,2081],"Glimepiride","Sitagliptin",{"nctId":2083,"briefTitle":2084,"status":195,"phases":2085,"primaryCompletion":2086,"completion":2086,"start":2087,"enrollment":1448,"conditions":2088,"interventions":2090},"NCT00554450","Renal Impairment in Type 2 Diabetic Subjects",[90],"2008-10","2006-03",[2089],"Diabetes Mellitus, Type 2",[2044],{"nctId":2092,"briefTitle":2093,"status":195,"phases":2094,"primaryCompletion":2077,"completion":2077,"start":2095,"enrollment":1130,"conditions":2096,"interventions":2097},"NCT00839683","Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects",[90],"2009-02",[22],[2098,2044,2098,2099],"simvastatin","valsartan",{"nctId":2101,"briefTitle":2102,"status":195,"phases":2103,"primaryCompletion":2104,"completion":2104,"start":2105,"enrollment":2069,"conditions":2106,"interventions":2107},"NCT01662999","Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants",[90],"2012-11","2012-08",[22],[2108,2044],"Saxagliptin",{"nctId":2110,"briefTitle":2111,"status":195,"phases":2112,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":486,"conditions":2115,"interventions":2116},"NCT01072578","A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose",[90],"2010-04","2010-02",[36],[2044,2044],{"nctId":2118,"briefTitle":2119,"status":195,"phases":2120,"primaryCompletion":2121,"completion":2121,"start":2122,"enrollment":451,"conditions":2123,"interventions":2125},"NCT05266404","Phase 1 Bioequivalence Study of Dapagliflozin\u002FSitagliptin FDC vs Loose Combination of Single Components",[90],"2022-05-31","2022-03-21",[2124],"Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)",[2126,2081,2044],"Dapagliflozin\u002Fsitagliptin FDC",{"nctId":2128,"briefTitle":2129,"status":195,"phases":2130,"primaryCompletion":2131,"completion":2131,"start":2132,"enrollment":2003,"conditions":2133,"interventions":2135},"NCT04991571","Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants",[90],"2021-10-22","2021-07-29",[2134],"Chronic Kidney Disease",[2136,2044,2137,2138],"Zibotentan","Zibotentan\u002FDapagliflozin - Formulation 1","Zibotentan\u002FDapagliflozin - Formulation 2",{"nctId":2140,"briefTitle":2141,"status":195,"phases":2142,"primaryCompletion":2143,"completion":2143,"start":2144,"enrollment":1130,"conditions":2145,"interventions":2146},"NCT01165268","Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)",[90],"2010-12","2010-08",[22],[2044],{"nctId":2148,"briefTitle":2149,"status":443,"phases":2150,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":122,"conditions":2153,"interventions":2155},"NCT00726505","Renal Mechanism of Action\u002FSplay vs. TmG",[90],"2009-08","2009-06",[2154],"Diabetes, NOS",[2044],{"nctId":2157,"briefTitle":2158,"status":195,"phases":2159,"primaryCompletion":463,"completion":463,"start":2160,"enrollment":2161,"conditions":2162,"interventions":2163},"NCT01525238","PK Study of Dapagliflozin in Pediatric Subjects With T2DM",[90],"2012-07-01",53,[22],[2044,2044,2044],{"nctId":2165,"briefTitle":2166,"status":195,"phases":2167,"primaryCompletion":2168,"completion":2168,"start":2169,"enrollment":1336,"conditions":2170,"interventions":2172},"NCT00546741","Drug Interaction With Metformin",[90],"2008-02","2007-11",[2171],"Healthy Male and Female Subjects",[2044,2173,2174],"Metformin","Dapagliflozin + Metformin",{"nctId":2176,"briefTitle":2177,"status":195,"phases":2178,"primaryCompletion":2179,"completion":2179,"start":2180,"enrollment":496,"conditions":2181,"interventions":2182},"NCT02223065","Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State",[90],"2014-12","2014-09",[22],[2108,2044],{"nctId":2184,"briefTitle":2185,"status":195,"phases":2186,"primaryCompletion":2113,"completion":2113,"start":2056,"enrollment":2187,"conditions":2188,"interventions":2189},"NCT01055691","A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets",[90],120,[36],[2190,2044,2173,2190,2044,2173],"Dapagliflozin\u002FMetformin",{"nctId":2192,"briefTitle":2193,"status":195,"phases":2194,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1710,"conditions":2195,"interventions":2196},"NCT00904176","Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects",[90],[22],[2044,2197,2198],"Warfarin","Digoxin",{"nctId":2200,"briefTitle":2201,"status":195,"phases":2202,"primaryCompletion":2203,"completion":2203,"start":2204,"enrollment":132,"conditions":2205,"interventions":2206},"NCT02060201","Bioequivalence\u002FFood Effect - Saxa\u002FDapa Dual Fixed Dose Combination (FDC)",[90],"2014-05","2014-02",[22],[2108,2044,2207],"Saxagliptin\u002FDapagliflozin FDC",{"nctId":2209,"briefTitle":2210,"status":443,"phases":2211,"primaryCompletion":2113,"completion":2113,"start":2212,"enrollment":1638,"conditions":2213,"interventions":2214},"NCT01068756","Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects",[90],"2010-03",[22],[2044,2215],"Rifampin",{"nctId":2217,"briefTitle":2218,"status":195,"phases":2219,"primaryCompletion":2220,"completion":2220,"start":2221,"enrollment":2222,"conditions":2223,"interventions":2224},"NCT00562250","Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects",[90],"2008-08","2008-05",11,[2089],[2044,2080,2225],"Dapagliflozin + Glimepiride",{"nctId":2227,"briefTitle":2228,"status":195,"phases":2229,"primaryCompletion":2221,"completion":2221,"start":2169,"enrollment":496,"conditions":2230,"interventions":2231},"NCT00538174","Phase I Multiple-Ascending Dose (Japan)",[90],[2089],[2044],{"nctId":2233,"briefTitle":2234,"status":195,"phases":2235,"primaryCompletion":2151,"completion":2151,"start":2068,"enrollment":1855,"conditions":2236,"interventions":2237},"NCT00908271","Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects",[90],[22],[2044],{"nctId":2239,"briefTitle":2240,"status":195,"phases":2241,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":1348,"conditions":2244,"interventions":2245},"NCT01135446","Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects",[90],"2010-06","2010-05",[31],[2246,2246,2246,2246,2246,2246],"dapagliflozin",{"nctId":2248,"briefTitle":2249,"status":195,"phases":2250,"completion":2251,"start":2252,"enrollment":496,"conditions":2253,"interventions":2254},"NCT00688493","Effects of Single Oral Dose Dapagliflozin QT Study",[90],"2008-04","2007-07",[19],[2044,2044,2255],"Moxifloxacin",{"nctId":2257,"briefTitle":2258,"status":195,"phases":2259,"primaryCompletion":2113,"completion":2113,"start":2056,"enrollment":2260,"conditions":2261,"interventions":2262},"NCT01055652","Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients",[90],28,[22],[2044],{"nctId":2264,"briefTitle":2265,"status":195,"phases":2266,"primaryCompletion":2267,"completion":2267,"start":2268,"enrollment":1448,"conditions":2269,"interventions":2270},"NCT02722239","An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions",[90],"2016-05-05","2016-03-30",[2089],[2271,2272,2044],"Xigduo XR","Metformin ER",{"nctId":2274,"briefTitle":2275,"status":443,"phases":2276,"primaryCompletion":2277,"completion":2277,"start":941,"enrollment":370,"conditions":2278,"interventions":2280},"NCT06639087","A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment",[90],"2025-05-29",[2279,1520],"Renal Impairment",[2281,2044],"AZD5462",{"trials":2283,"activeCount":122,"soonestReadout":2288},[2284,2294,2305,2316,2324,2334,2345,2354,2361,2371,2380],{"nctId":2285,"briefTitle":2286,"status":151,"phases":2287,"primaryCompletion":2288,"completion":2288,"start":1664,"enrollment":2289,"conditions":2290,"interventions":2292},"NCT06942910","A Study to Investigate the Effects of Zibotentan\u002FDapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria",[91],"2026-07-31",224,[2291],"Chronic Kidney Disease With High Proteinuria",[2293,2044],"Zibotentan\u002FDapagliflozin",{"nctId":2295,"briefTitle":2296,"status":195,"phases":2297,"primaryCompletion":2298,"completion":2298,"start":2299,"enrollment":2300,"conditions":2301,"interventions":2303},"NCT02279407","A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients",[91],"2015-12","2015-01",223,[2302],"T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)",[2304,2044],"Omega-3 carboxylic acids",{"nctId":2306,"briefTitle":2307,"status":195,"phases":2308,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":496,"conditions":2311,"interventions":2313},"NCT03316131","A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA",[91],"2018-07-19","2017-10-25",[2312],"Asymptomatic Hyperuricemia",[2314,2315,2044],"Verinurad","Febuxostat",{"nctId":2317,"briefTitle":2318,"status":195,"phases":2319,"primaryCompletion":2144,"completion":2144,"start":2320,"enrollment":2321,"conditions":2322,"interventions":2323},"NCT00831779","Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes",[91],"2009-04",116,[22],[2044],{"nctId":2325,"briefTitle":2326,"status":195,"phases":2327,"primaryCompletion":2328,"completion":2328,"start":2329,"enrollment":2330,"conditions":2331,"interventions":2332},"NCT00263276","A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus",[91],"2007-02","2005-12",389,[31],[2246,2246,2246,2246,2246,2333],"metformin",{"nctId":2335,"briefTitle":2336,"status":195,"phases":2337,"primaryCompletion":2338,"completion":2338,"start":2339,"enrollment":2340,"conditions":2341,"interventions":2343},"NCT04170543","A Phase 2b Diabetic Kidney Disease Study",[91],"2023-05-16","2019-11-18",609,[2342],"Diabetic Kidney Disease",[2344,2044],"MEDI3506",{"nctId":2346,"briefTitle":2347,"status":195,"phases":2348,"primaryCompletion":2349,"completion":2349,"start":2350,"enrollment":662,"conditions":2351,"interventions":2352},"NCT00976495","Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes",[91],"2010-11","2009-10",[22],[2044,2353],"Hydrochlorothiazide",{"nctId":2355,"briefTitle":2356,"status":195,"phases":2357,"primaryCompletion":2243,"completion":2243,"start":2151,"enrollment":2358,"conditions":2359,"interventions":2360},"NCT00972244","Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients",[91],417,[22],[2044],{"nctId":2362,"briefTitle":2363,"status":195,"phases":2364,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":2367,"conditions":2368,"interventions":2370},"NCT01498185","BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes",[91],"2012-10","2012-02",171,[2369],"Type 1 Diabetes Mellitus",[2044],{"nctId":2372,"briefTitle":2373,"status":195,"phases":2374,"primaryCompletion":2375,"completion":2375,"start":2376,"enrollment":2377,"conditions":2378,"interventions":2379},"NCT04724837","Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)",[91],"2023-06-01","2021-04-28",542,[2134],[2136,2044],{"nctId":2381,"briefTitle":2382,"status":195,"phases":2383,"primaryCompletion":2384,"completion":2384,"start":2385,"enrollment":2386,"conditions":2387,"interventions":2388},"NCT04595370","Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease",[91],"2023-09-22","2021-01-26",153,[1520,2134],[2389,2044],"AZD9977",{"trials":2391,"activeCount":122,"soonestReadout":2764},[2392,2401,2410,2419,2428,2439,2449,2459,2466,2476,2485,2493,2503,2512,2520,2528,2538,2546,2556,2566,2575,2585,2593,2601,2611,2623,2635,2643,2654,2663,2671,2678,2687,2694,2701,2708,2716,2725,2732,2741,2751,2760,2768],{"nctId":2393,"briefTitle":2394,"status":195,"phases":2395,"primaryCompletion":2396,"completion":2396,"start":2397,"enrollment":2398,"conditions":2399,"interventions":2400},"NCT02284893","Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone",[92],"2016-09-20","2014-09-09",461,[31],[2108,2044,2081],{"nctId":2402,"briefTitle":2403,"status":195,"phases":2404,"primaryCompletion":2405,"completion":2405,"start":2406,"enrollment":2407,"conditions":2408,"interventions":2409},"NCT01137474","A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker",[92],"2013-02","2010-07",2996,[31],[2044],{"nctId":2411,"briefTitle":2412,"status":195,"phases":2413,"primaryCompletion":2414,"completion":2243,"start":2415,"enrollment":2416,"conditions":2417,"interventions":2418},"NCT00528879","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone",[92],"2008-11","2007-09",915,[31],[2044,2173],{"nctId":2420,"briefTitle":2421,"status":195,"phases":2422,"primaryCompletion":2423,"completion":2423,"start":2424,"enrollment":2425,"conditions":2426,"interventions":2427},"NCT00736879","Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes",[92],"2009-12-29","2008-09-22",497,[22],[2044],{"nctId":2429,"briefTitle":2430,"status":195,"phases":2431,"primaryCompletion":2432,"completion":2432,"start":2433,"enrollment":2434,"conditions":2435,"interventions":2438},"NCT01294436","Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus",[92],"2012-09","2011-02",728,[2436,2437],"Type2 Diabetes","High Blood Sugar",[2044],{"nctId":2440,"briefTitle":2441,"status":195,"phases":2442,"primaryCompletion":2443,"completion":2443,"start":2242,"enrollment":2444,"conditions":2445,"interventions":2446},"NCT01095666","A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone",[92],"2013-03",1484,[31],[2044,2044,2173,2447,2448],"Dapagliflozin Placebo","Pioglitazone",{"nctId":2450,"briefTitle":2451,"status":195,"phases":2452,"primaryCompletion":2453,"completion":2454,"start":2455,"enrollment":2456,"conditions":2457,"interventions":2458},"NCT02460978","Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes",[92],"2017-09-02","2018-04-18","2015-07-08",815,[2369],[2044],{"nctId":2460,"briefTitle":2461,"status":195,"phases":2462,"primaryCompletion":687,"completion":687,"start":2433,"enrollment":2463,"conditions":2464,"interventions":2465},"NCT01294423","Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus",[92],261,[31,2437],[2044,2044],{"nctId":2467,"briefTitle":2468,"status":195,"phases":2469,"primaryCompletion":2470,"completion":2299,"start":2471,"enrollment":2472,"conditions":2473,"interventions":2474},"NCT01619059","Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes",[92],"2014-06","2012-06",315,[31],[2108,2044,2475],"Metformin IR",{"nctId":2477,"briefTitle":2478,"status":195,"phases":2479,"primaryCompletion":2480,"completion":2480,"start":2481,"enrollment":2482,"conditions":2483,"interventions":2484},"NCT01606007","Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes",[92],"2014-01","2012-07",1282,[31],[2108,2061,2044],{"nctId":2486,"briefTitle":2487,"status":195,"phases":2488,"primaryCompletion":2405,"completion":2405,"start":2489,"enrollment":2490,"conditions":2491,"interventions":2492},"NCT01195662","A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication",[92],"2010-10",2245,[31],[2044],{"nctId":2494,"briefTitle":2495,"status":195,"phases":2496,"primaryCompletion":2057,"completion":2243,"start":2251,"enrollment":2497,"conditions":2498,"interventions":2499},"NCT00680745","Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients",[92],597,[31],[2246,2080,2500,2501,2502],"metformin hydrochloride","pioglitazone hydrochloride","Rosiglitazone",{"nctId":2504,"briefTitle":2505,"status":195,"phases":2506,"primaryCompletion":2056,"completion":2242,"start":2507,"enrollment":2508,"conditions":2509,"interventions":2510},"NCT00683878","Add-on to Thiazolidinedione (TZD) Failures",[92],"2008-07",972,[31],[2044,2044,2511],"Thiazolidinedione",{"nctId":2513,"briefTitle":2514,"status":195,"phases":2515,"primaryCompletion":688,"completion":2516,"start":2251,"enrollment":2517,"conditions":2518,"interventions":2519},"NCT00673231","Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",[92],"2011-01",1240,[31],[2044,2044,2044,2044,2044],{"nctId":2521,"briefTitle":2522,"status":195,"phases":2523,"primaryCompletion":2151,"completion":2151,"start":2524,"enrollment":2525,"conditions":2526,"interventions":2527},"NCT00643851","An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets",[92],"2008-06",994,[31],[2044,2061],{"nctId":2529,"briefTitle":2530,"status":195,"phases":2531,"primaryCompletion":2532,"completion":2532,"start":2533,"enrollment":2534,"conditions":2535,"interventions":2537},"NCT04564742","Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.",[92],"2023-07-05","2020-12-22",4017,[2536,1520],"Acute Myocardial Infarction",[2044],{"nctId":2539,"briefTitle":2540,"status":195,"phases":2541,"primaryCompletion":2055,"completion":2542,"start":2524,"enrollment":2543,"conditions":2544,"interventions":2545},"NCT00663260","Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment",[91,92],"2011-06",631,[2089],[2044,2044],{"nctId":2547,"briefTitle":2548,"status":195,"phases":2549,"primaryCompletion":2550,"completion":2550,"start":2551,"enrollment":2552,"conditions":2553,"interventions":2555},"NCT03036124","Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure",[92],"2019-07-17","2017-02-08",4744,[2554],"Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)",[2044],{"nctId":2557,"briefTitle":2558,"status":195,"phases":2559,"primaryCompletion":2560,"completion":2561,"start":2432,"enrollment":2562,"conditions":2563,"interventions":2564},"NCT01646320","Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes",[92],"2014-08","2015-02",320,[31],[2044,2108,2565],"Metformin immediate release",{"nctId":2567,"briefTitle":2568,"status":195,"phases":2569,"primaryCompletion":2570,"completion":2571,"start":2350,"enrollment":2572,"conditions":2573,"interventions":2574},"NCT00984867","Dapagliflozin DPPIV Inhibitor add-on Study",[92],"2011-03","2011-09",833,[31],[2044],{"nctId":2576,"briefTitle":2577,"status":195,"phases":2578,"primaryCompletion":2055,"completion":2579,"start":2580,"enrollment":2581,"conditions":2582,"interventions":2583},"NCT00660907","Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients",[92],"2013-01","2008-03",1217,[31],[2246,2584,2500],"glipizide",{"nctId":2586,"briefTitle":2587,"status":195,"phases":2588,"primaryCompletion":2242,"completion":2589,"start":2095,"enrollment":2590,"conditions":2591,"interventions":2592},"NCT00855166","Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes",[92],"2011-12",182,[22],[2044,2173,2081],{"nctId":2594,"briefTitle":2595,"status":195,"phases":2596,"primaryCompletion":1384,"completion":1384,"start":2597,"enrollment":2598,"conditions":2599,"interventions":2600},"NCT03036150","A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease",[92],"2017-02-02",4304,[2134],[2044],{"nctId":2602,"briefTitle":2603,"status":195,"phases":2604,"primaryCompletion":2605,"completion":2605,"start":2606,"enrollment":2607,"conditions":2608,"interventions":2610},"NCT03619213","Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.",[92],"2022-03-27","2018-08-27",6263,[2609],"Heart Failure With Preserved Ejection Fraction",[2044],{"nctId":2612,"briefTitle":2613,"status":195,"phases":2614,"primaryCompletion":2615,"completion":2616,"start":2114,"enrollment":2617,"conditions":2618,"interventions":2622},"NCT01031680","Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",[92],"2011-05","2012-12",922,[22,2619,2620,2621],"Cardiovascular Disease","Hypertension","Inadequate Glycaemic Control",[2044],{"nctId":2624,"briefTitle":2625,"status":195,"phases":2626,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":155,"conditions":2630,"interventions":2632},"NCT02229396","Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo",[92],"2016-04-26","2017-12-28","2014-09-04",[2631],"Diabetes Mellitus",[2633,2634,2044],"Exantide with Dapagliflozin","Exentide",{"nctId":2636,"briefTitle":2637,"status":195,"phases":2638,"primaryCompletion":2580,"completion":2580,"start":2639,"enrollment":2640,"conditions":2641,"interventions":2642},"NCT00357370","A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes",[91,92],"2006-10",163,[31],[2044],{"nctId":2644,"briefTitle":2645,"status":195,"phases":2646,"primaryCompletion":2647,"completion":2648,"start":2649,"enrollment":2650,"conditions":2651,"interventions":2653},"NCT02419612","A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",[92],"2017-08-29","2019-09-18","2015-08-14",444,[2652],"Diabetes",[2108,2044,2080],{"nctId":2655,"briefTitle":2656,"status":195,"phases":2657,"primaryCompletion":2658,"completion":2658,"start":2659,"enrollment":1919,"conditions":2660,"interventions":2662},"NCT03877237","DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction",[92],"2020-03-07","2019-04-09",[2661],"Heart Failure With Reduced Ejection Fraction (HFrEF)",[2044],{"nctId":2664,"briefTitle":2665,"status":195,"phases":2666,"primaryCompletion":2667,"completion":2667,"start":2668,"enrollment":209,"conditions":2669,"interventions":2670},"NCT02096705","Phase III Insulin Add-On Asia Regional Program - ST",[92],"2016-01-28","2014-03-31",[2652],[2044,2447],{"nctId":2672,"briefTitle":2673,"status":195,"phases":2674,"primaryCompletion":2675,"completion":2675,"start":2349,"enrollment":1078,"conditions":2676,"interventions":2677},"NCT01217892","Evaluation of Dapagliflozin Taken Twice-daily",[92],"2011-08",[31],[2246,2246,2246,2333],{"nctId":2679,"briefTitle":2680,"status":195,"phases":2681,"primaryCompletion":2682,"completion":2682,"start":2683,"enrollment":2684,"conditions":2685,"interventions":2686},"NCT02681094","A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",[92],"2017-07-15","2016-02-26",905,[22,2621],[2044,2108],{"nctId":2688,"briefTitle":2689,"status":195,"phases":2690,"primaryCompletion":2243,"completion":2243,"start":2320,"enrollment":2691,"conditions":2692,"interventions":2693},"NCT00859898","Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes",[92],1093,[22],[2044,2061,2061],{"nctId":2695,"briefTitle":2451,"status":195,"phases":2696,"primaryCompletion":1563,"completion":2697,"start":2698,"enrollment":2572,"conditions":2699,"interventions":2700},"NCT02268214",[92],"2017-08-25","2014-11-11",[2369],[2044],{"nctId":2702,"briefTitle":2703,"status":195,"phases":2704,"primaryCompletion":687,"completion":687,"start":2242,"enrollment":2705,"conditions":2706,"interventions":2707},"NCT01095653","A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise",[92],1179,[31],[2044,2044,2173,2447],{"nctId":2709,"briefTitle":2710,"status":195,"phases":2711,"primaryCompletion":2712,"completion":1484,"start":2713,"enrollment":872,"conditions":2714,"interventions":2715},"NCT03199053","Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old",[92],"2023-02-01","2017-10-11",[2089],[2044,2108],{"nctId":2717,"briefTitle":2718,"status":195,"phases":2719,"primaryCompletion":2720,"completion":2720,"start":2721,"enrollment":1648,"conditions":2722,"interventions":2724},"NCT03877224","DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction",[92],"2020-07-09","2019-04-04",[2723],"Heart Failure With Preserved Ejection Fraction (HFpEF)",[2044],{"nctId":2726,"briefTitle":2727,"status":195,"phases":2728,"primaryCompletion":2615,"completion":2616,"start":2212,"enrollment":2729,"conditions":2730,"interventions":2731},"NCT01042977","Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease",[92],964,[22,2619,2621],[2044],{"nctId":2733,"briefTitle":2734,"status":195,"phases":2735,"primaryCompletion":2579,"completion":1701,"start":2736,"enrollment":2737,"conditions":2738,"interventions":2740},"NCT01392677","Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea",[92],"2011-10",311,[22,2739,2621],"High HbA1c Level",[2246],{"nctId":2742,"briefTitle":2743,"status":2744,"phases":2745,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":2748,"conditions":2749,"interventions":2750},"NCT01257412","Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone","SUSPENDED",[92],"2013-06","2012-01",375,[31],[2044,2044],{"nctId":2752,"briefTitle":2753,"status":195,"phases":2754,"primaryCompletion":2755,"completion":2755,"start":2756,"enrollment":132,"conditions":2757,"interventions":2758},"NCT02725593","Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years",[92],"2020-04-06","2016-06-22",[31],[2044,2759],"Dapagliflozin placebo",{"nctId":2761,"briefTitle":2762,"status":108,"phases":2763,"primaryCompletion":2764,"completion":2764,"start":988,"enrollment":2765,"conditions":2766,"interventions":2767},"NCT06087835","Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan\u002FDapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)",[92],"2027-02-18",1835,[2291],[2293,2044],{"nctId":2769,"briefTitle":2770,"status":195,"phases":2771,"primaryCompletion":2095,"completion":2406,"start":2415,"enrollment":2772,"conditions":2773,"interventions":2774},"NCT00528372","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise",[92],1067,[31],[2044,2759,2173],{"trials":2776,"activeCount":122,"soonestReadout":2835},[2777,2786,2796,2805,2814,2821,2831,2840,2849],{"nctId":2778,"briefTitle":2779,"status":195,"phases":2780,"primaryCompletion":2781,"completion":2781,"start":2782,"enrollment":2783,"conditions":2784,"interventions":2785},"NCT02426541","Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus",[93],"2016-04-28","2015-03-23",55,[22],[2044],{"nctId":2787,"briefTitle":2788,"status":443,"phases":2789,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":2792,"conditions":2793,"interventions":2794},"NCT03344341","A Phase IV Study in Drug-Naive Patients With T2DM in China",[93],"2019-05-24","2017-12-15",304,[22],[2044,2795],"Acarbose",{"nctId":2797,"briefTitle":2798,"status":195,"phases":2799,"primaryCompletion":2800,"completion":2800,"start":2801,"enrollment":2161,"conditions":2802,"interventions":2804},"NCT03387683","A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients",[93],"2019-03-19","2018-02-28",[2803],"Diabetes Mellitus Type 2",[2246],{"nctId":2806,"briefTitle":2807,"status":195,"phases":2808,"primaryCompletion":2809,"completion":2809,"start":2810,"enrollment":2811,"conditions":2812,"interventions":2813},"NCT02564926","Foxiga Korea Local Phase 4 Study",[93],"2018-01-15","2016-01-05",125,[2089],[2044,2080],{"nctId":2815,"briefTitle":2816,"status":624,"phases":2817,"primaryCompletion":2818,"completion":2818,"start":772,"enrollment":102,"conditions":2819,"interventions":2820},"NCT02719132","Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice",[93],"2017-11",[2803],[2044,2173],{"nctId":2822,"briefTitle":2823,"status":195,"phases":2824,"primaryCompletion":2825,"completion":2825,"start":2826,"enrollment":2827,"conditions":2828,"interventions":2830},"NCT03338855","Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.",[93],"2019-11-04","2018-03-05",26,[2089,2829],"Skeletal Muscle Insulin Sensitivity",[2044],{"nctId":2832,"briefTitle":2833,"status":108,"phases":2834,"primaryCompletion":2835,"completion":2835,"start":2836,"enrollment":2837,"conditions":2838,"interventions":2839},"NCT06610526","A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease",[93],"2027-05-31","2024-08-23",731,[2134],[2044],{"nctId":2841,"briefTitle":2842,"status":443,"phases":2843,"primaryCompletion":2844,"completion":2844,"start":2845,"enrollment":1130,"conditions":2846,"interventions":2848},"NCT03152084","The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.",[93],"2020-03-20","2017-07-12",[2089,2847],"Kidney Function Tests",[2044],{"nctId":2850,"briefTitle":2851,"status":195,"phases":2852,"primaryCompletion":2853,"completion":2853,"start":2854,"enrollment":2855,"conditions":2856,"interventions":2857},"NCT02471404","Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea",[93],"2017-03-13","2015-09-21",939,[22,2621],[2044,2108,2080],{"trials":2859,"activeCount":102},[2860],{"nctId":2861,"briefTitle":2862,"status":195,"phases":2863,"primaryCompletion":2864,"completion":2864,"start":2865,"enrollment":2866,"conditions":2867,"interventions":2869},"NCT05250011","Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice",[],"2024-04-15","2022-04-19",252,[2868],"Heart Failure, Reduced Ejection Fraction",[2044],{"intervention":914,"totalTrials":447,"cells":2871},{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2876,"PHASE3":2882,"PHASE4":2884,"NA":2890},{"trials":2873,"activeCount":102},[],{"trials":2875,"activeCount":102},[],{"trials":2877,"activeCount":122,"soonestReadout":1457},[2878],{"nctId":1454,"briefTitle":1455,"status":151,"phases":2879,"primaryCompletion":1457,"completion":1458,"start":1459,"enrollment":1460,"conditions":2880,"interventions":2881},[90,91],[1462,1409,1463,1464,1465],[1467,914,1378,524,1468,309,1335],{"trials":2883,"activeCount":102},[],{"trials":2885,"activeCount":122,"soonestReadout":909},[2886],{"nctId":906,"briefTitle":907,"status":108,"phases":2887,"primaryCompletion":909,"completion":660,"start":910,"enrollment":911,"conditions":2888,"interventions":2889},[93],[651],[63,888,747,914],{"trials":2891,"activeCount":102},[],{"intervention":2893,"totalTrials":122,"cells":2894},"Albuterol and budesonide inhalation aerosol",{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2901,"PHASE4":2903,"NA":2913},{"trials":2896,"activeCount":102},[],{"trials":2898,"activeCount":102},[],{"trials":2900,"activeCount":102},[],{"trials":2902,"activeCount":102},[],{"trials":2904,"activeCount":122,"soonestReadout":1965},[2905],{"nctId":2906,"briefTitle":2907,"status":108,"phases":2908,"primaryCompletion":1965,"completion":1965,"start":2909,"enrollment":2910,"conditions":2911,"interventions":2912},"NCT06422689","Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care",[93],"2024-05-10",1511,[16],[2893],{"trials":2914,"activeCount":102},[],{"intervention":2916,"totalTrials":122,"cells":2917},"Budesonide\u002FGlycopyrronium\u002FFormoterol Fumarate",{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2924,"PHASE4":2926,"NA":2937},{"trials":2919,"activeCount":102},[],{"trials":2921,"activeCount":102},[],{"trials":2923,"activeCount":102},[],{"trials":2925,"activeCount":102},[],{"trials":2927,"activeCount":122,"soonestReadout":2835},[2928],{"nctId":2929,"briefTitle":2930,"status":151,"phases":2931,"primaryCompletion":2835,"completion":2835,"start":2932,"enrollment":2933,"conditions":2934,"interventions":2936},"NCT07073950","A Study to Investigate the Effect of Budesonide\u002FGlycopyrronium\u002FFormoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation",[93],"2025-11-24",56,[28,2935],"Hyperinflation",[2916],{"trials":2938,"activeCount":102},[],{"intervention":1104,"totalTrials":122,"cells":2940},{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2945,"PHASE3":2947,"PHASE4":2949,"NA":2955},{"trials":2942,"activeCount":102},[],{"trials":2944,"activeCount":102},[],{"trials":2946,"activeCount":102},[],{"trials":2948,"activeCount":102},[],{"trials":2950,"activeCount":122,"soonestReadout":1099},[2951],{"nctId":1095,"briefTitle":1096,"status":1097,"phases":2952,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":221,"conditions":2953,"interventions":2954},[93],[1102],[1104,163],{"trials":2956,"activeCount":102},[],{"intervention":2958,"totalTrials":122,"cells":2959},"Osimertinib+cisplatin or carboplatin + pemetrexed Edit",{"EARLY_PHASE1":2960,"PHASE1":2962,"PHASE2":2964,"PHASE3":2966,"PHASE4":2968,"NA":2978},{"trials":2961,"activeCount":102},[],{"trials":2963,"activeCount":102},[],{"trials":2965,"activeCount":102},[],{"trials":2967,"activeCount":102},[],{"trials":2969,"activeCount":122,"soonestReadout":2974},[2970],{"nctId":2971,"briefTitle":2972,"status":151,"phases":2973,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":221,"conditions":2976,"interventions":2977},"NCT07279935","Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.",[93],"2030-05-18","2026-05-26",[1049],[2958],{"trials":2979,"activeCount":102},[],{"intervention":2981,"totalTrials":122,"cells":2982},"Breztri Aerosphere",{"EARLY_PHASE1":2983,"PHASE1":2985,"PHASE2":2987,"PHASE3":2989,"PHASE4":2991,"NA":3004},{"trials":2984,"activeCount":102},[],{"trials":2986,"activeCount":102},[],{"trials":2988,"activeCount":102},[],{"trials":2990,"activeCount":102},[],{"trials":2992,"activeCount":122,"soonestReadout":2997},[2993],{"nctId":2994,"briefTitle":2995,"status":151,"phases":2996,"primaryCompletion":2997,"completion":2998,"start":2999,"enrollment":3000,"conditions":3001,"interventions":3003},"NCT06531798","Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease",[93],"2026-10-30","2027-12-30","2025-12-19",150,[3002],"Moderate to Severe COPD",[2981],{"trials":3005,"activeCount":102},[],{"intervention":117,"totalTrials":3007,"cells":3008},85,{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3138,"PHASE3":3312,"PHASE4":3718,"NA":3739},{"trials":3010,"activeCount":102},[],{"trials":3012,"activeCount":723,"soonestReadout":3122},[3013,3017,3041,3049,3059,3063,3067,3075,3086,3098,3109,3118,3129],{"nctId":970,"briefTitle":971,"status":108,"phases":3014,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":3015,"interventions":3016},[90],[977],[252,117,344,979,980,981],{"nctId":3018,"briefTitle":3019,"status":195,"phases":3020,"primaryCompletion":3021,"completion":3021,"start":2781,"enrollment":579,"conditions":3022,"interventions":3032},"NCT02658214","Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors",[90],"2019-11-14",[3023,3024,3025,249,3026,3027,3028,3029,3030,3031],"Small Cell Lung Carcinoma","Carcinoma, Squamous Cell of Head and Neck","Stomach Neoplasms","Ovarian Neoplasms","Fallopian Tube Neoplasms","Peritoneal Neoplasms","Esophagogastric Junction Neoplasms","Carcinoma, Pancreatic Ductal","Esophageal Squamous Cell Carcinoma",[3033,3034,3035,3036,3037,900,3038,3039,3040],"paclitaxel + carboplatin","carboplatin + etoposide","gemcitabine + carboplatin","nab-paclitaxel (paclitaxel-albumin) + carboplatin","oxaliplatin + 5-fluorouracil","tremelimumab","nab-paclitaxel (paclitaxel-albumin) + gemcitabine","cisplatin + 5-fluorouracil",{"nctId":3042,"briefTitle":3043,"status":151,"phases":3044,"primaryCompletion":1046,"completion":1046,"start":3045,"enrollment":2792,"conditions":3046,"interventions":3047},"NCT04686305","Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC",[90],"2021-03-09",[342],[3048,117,177,344,345,179,180],"T-DXd",{"nctId":3050,"briefTitle":3051,"status":443,"phases":3052,"primaryCompletion":3053,"completion":3053,"start":3054,"enrollment":1448,"conditions":3055,"interventions":3057},"NCT04613492","A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors",[90],"2024-05-31","2020-12-02",[3056],"Solid Tumors",[3058,117],"MEDI9253",{"nctId":106,"briefTitle":107,"status":108,"phases":3060,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":3061,"interventions":3062},[90],[115],[97,117,118,119,120,53,121],{"nctId":1913,"briefTitle":1914,"status":195,"phases":3064,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":3065,"interventions":3066},[90],[157,1921,1922,1923],[1925,117,1926,1927,251,369],{"nctId":3068,"briefTitle":3069,"status":443,"phases":3070,"primaryCompletion":3071,"completion":3071,"start":3072,"enrollment":1336,"conditions":3073,"interventions":3074},"NCT04870112","A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer",[90],"2023-08-30","2021-06-28",[262,420],[117,177,344,1017],{"nctId":3076,"briefTitle":3077,"status":195,"phases":3078,"primaryCompletion":3079,"completion":3080,"start":3081,"enrollment":2827,"conditions":3082,"interventions":3084},"NCT02978482","A Phase 1\u002F2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies",[90],"2018-01-28","2020-11-26","2016-12-01",[3083],"Advanced Malignancy",[900,3085],"tremelimumab + durvalumab",{"nctId":3087,"briefTitle":3088,"status":195,"phases":3089,"primaryCompletion":3090,"completion":3091,"start":3092,"enrollment":3093,"conditions":3094,"interventions":3095},"NCT03421353","AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer",[90],"2020-01-17","2024-03-28","2018-02-07",76,[498],[571,117,177,3096,344,283,3097],"5-Flourouracil","Nab-paclitaxel",{"nctId":3099,"briefTitle":3100,"status":195,"phases":3101,"primaryCompletion":1964,"completion":1964,"start":208,"enrollment":477,"conditions":3102,"interventions":3107},"NCT04504669","First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours",[90],[3103,3104,249,3105,420,3106,410,404,498],"Clear Cell Renal Cell Cancer","Non-Small-Cell Lung Cancer","Squamous Cell Cancer of Head and Neck","Gastroesophageal Cancer",[3108,117],"AZD8701",{"nctId":3110,"briefTitle":3111,"status":108,"phases":3112,"primaryCompletion":3113,"completion":3114,"start":3115,"enrollment":1638,"conditions":3116,"interventions":3117},"NCT05514132","A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours",[90],"2023-10-20","2026-03-31","2022-09-23",[498],[265,117],{"nctId":3119,"briefTitle":3120,"status":108,"phases":3121,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":3126,"interventions":3128},"NCT03819465","A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC",[90],"2023-05-23","2026-07-01","2018-12-27",175,[3127],"Metastatic Non-Small Cell Lung Cancer (NSCLC)",[117,264,251,980,345,344,283,177,3097,979],{"nctId":3130,"briefTitle":3131,"status":195,"phases":3132,"primaryCompletion":1916,"completion":3133,"start":3134,"enrollment":1428,"conditions":3135,"interventions":3136},"NCT03509012","Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors",[90],"2025-01-08","2018-05-02",[3024,992,3023],[117,3137,177,177,344,344,1017,1017,118,345,177,177],"Tremelimumab",{"trials":3139,"activeCount":1336,"soonestReadout":659},[3140,3149,3153,3157,3166,3176,3184,3193,3202,3213,3223,3237,3241,3253,3257,3266,3274,3283,3292,3296,3304,3308],{"nctId":3141,"briefTitle":3142,"status":195,"phases":3143,"primaryCompletion":3144,"completion":3145,"start":753,"enrollment":1710,"conditions":3146,"interventions":3148},"NCT04495179","A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.",[91],"2021-11-01","2022-08-08",[3147],"Progressive Metastatic Castrate-Resistant Prostate Cancer",[1925,117,2032],{"nctId":137,"briefTitle":138,"status":108,"phases":3150,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":3151,"interventions":3152},[90,91],[115],[97,117,118,146,147],{"nctId":165,"briefTitle":166,"status":151,"phases":3154,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":3155,"interventions":3156},[91],[172],[174,121,117,175,176,97,177,178,179,180],{"nctId":3158,"briefTitle":3159,"status":108,"phases":3160,"primaryCompletion":3161,"completion":3162,"start":3163,"enrollment":1575,"conditions":3164,"interventions":3165},"NCT05061134","A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition",[91],"2024-04-12","2026-11-02","2022-08-11",[410],[265,117],{"nctId":3167,"briefTitle":3168,"status":108,"phases":3169,"primaryCompletion":3170,"completion":3170,"start":3171,"enrollment":3172,"conditions":3173,"interventions":3175},"NCT05374603","Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC",[91],"2027-01-18","2022-11-15",47,[3174],"Lung Cancer",[87,117],{"nctId":3177,"briefTitle":3178,"status":108,"phases":3179,"primaryCompletion":3123,"completion":3123,"start":1755,"enrollment":3180,"conditions":3181,"interventions":3183},"NCT06040099","A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE",[91],58,[3182],"Hepatocellular Carcinoma (HCC)",[117,239],{"nctId":3185,"briefTitle":3186,"status":108,"phases":3187,"primaryCompletion":3188,"completion":1485,"start":3189,"enrollment":3190,"conditions":3191,"interventions":3192},"NCT05941897","A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy",[91],"2024-07-29","2023-06-21",39,[977],[265,117],{"nctId":3194,"briefTitle":3195,"status":195,"phases":3196,"primaryCompletion":3197,"completion":3198,"start":3199,"enrollment":565,"conditions":3200,"interventions":3201},"NCT03693300","A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer",[91],"2022-12-13","2023-04-21","2019-04-16",[1080],[117],{"nctId":3203,"briefTitle":3204,"status":195,"phases":3205,"primaryCompletion":3206,"completion":3207,"start":3208,"enrollment":3209,"conditions":3210,"interventions":3212},"NCT04089553","An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer",[91],"2021-06-16","2023-04-11","2019-08-29",59,[416,3211],"Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[1925,251,117],{"nctId":3214,"briefTitle":3215,"status":108,"phases":3216,"primaryCompletion":1840,"completion":1892,"start":3217,"enrollment":3218,"conditions":3219,"interventions":3221},"NCT07081633","Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma",[91],"2025-08-05",114,[3220],"Hepatocellular Carcinoma",[117,3137,3222],"Lenvatinib",{"nctId":3224,"briefTitle":3225,"status":151,"phases":3226,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":3230,"interventions":3231},"NCT05061550","Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer",[91],"2030-05-28","2022-04-14",630,[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],"Monalizumab","AZD0171","Pemetrexed\u002FCisplatin","Pemetrexed\u002FCarboplatin","Carboplatin\u002FPaclitaxel",{"nctId":241,"briefTitle":242,"status":108,"phases":3238,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":3239,"interventions":3240},[90,91],[249],[117,119,251,118,97,252],{"nctId":3242,"briefTitle":3243,"status":108,"phases":3244,"primaryCompletion":3245,"completion":3246,"start":3247,"enrollment":3248,"conditions":3249,"interventions":3251},"NCT04745689","Study of AZD2811 + Durvalumab in ES-SCLC",[91],"2022-06-18","2026-12-01","2021-02-23",31,[3250],"Small-Cell Lung Cancer",[117,3252,344,177,1017],"AZD2811",{"nctId":656,"briefTitle":657,"status":108,"phases":3254,"primaryCompletion":659,"completion":660,"start":661,"enrollment":662,"conditions":3255,"interventions":3256},[91],[664],[117,267],{"nctId":3258,"briefTitle":3259,"status":108,"phases":3260,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":221,"conditions":3264,"interventions":3265},"NCT06008093","A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and\u002For Co-mutations in STK11, KEAP1, or KRAS",[91],"2026-12-08","2027-12-23","2024-04-04",[992],[117,3137,345,178,344,177],{"nctId":3267,"briefTitle":3268,"status":195,"phases":3269,"primaryCompletion":3270,"completion":3271,"start":3080,"enrollment":188,"conditions":3272,"interventions":3273},"NCT04249362","Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy",[91],"2023-03-30","2024-11-25",[1049],[117],{"nctId":3275,"briefTitle":3276,"status":108,"phases":3277,"primaryCompletion":1964,"completion":130,"start":3278,"enrollment":3279,"conditions":3280,"interventions":3282},"NCT04999969","Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours",[91],"2021-12-10",126,[3281],"Locally Advanced or Metastatic Solid Tumours",[3233,117,283,3097],{"nctId":3284,"briefTitle":3285,"status":108,"phases":3286,"primaryCompletion":3287,"completion":3288,"start":234,"enrollment":3289,"conditions":3290,"interventions":3291},"NCT05925530","Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)",[91],"2026-01-12","2027-08-27",142,[1049],[117],{"nctId":254,"briefTitle":255,"status":108,"phases":3293,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":3294,"interventions":3295},[91],[262],[117,264,265,266,267,251,97,268],{"nctId":3297,"briefTitle":3298,"status":108,"phases":3299,"primaryCompletion":973,"completion":3300,"start":3301,"enrollment":1710,"conditions":3302,"interventions":3303},"NCT06606847","A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)",[91],"2027-03-30","2024-09-24",[262],[251,117],{"nctId":1004,"briefTitle":1005,"status":108,"phases":3305,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":3306,"interventions":3307},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"nctId":698,"briefTitle":699,"status":108,"phases":3309,"primaryCompletion":701,"completion":702,"start":246,"enrollment":703,"conditions":3310,"interventions":3311},[91],[705],[117,267,707,708,709,710,711],{"trials":3313,"activeCount":3717,"soonestReadout":3428},[3314,3318,3329,3343,3357,3368,3377,3387,3396,3408,3412,3424,3434,3446,3450,3460,3470,3479,3490,3500,3510,3519,3527,3535,3544,3555,3565,3577,3587,3595,3599,3606,3616,3620,3630,3640,3648,3658,3668,3679,3689,3698,3710],{"nctId":273,"briefTitle":274,"status":151,"phases":3315,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":3316,"interventions":3317},[92],[281],[283,177,117,97,180],{"nctId":3319,"briefTitle":3320,"status":108,"phases":3321,"primaryCompletion":3322,"completion":3323,"start":3324,"enrollment":3325,"conditions":3326,"interventions":3328},"NCT05883644","Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)",[92],"2026-03-30","2026-09-30","2023-06-27",111,[3327],"Advanced Hepatocellular Carcinoma",[117,3137],{"nctId":3330,"briefTitle":3331,"status":108,"phases":3332,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":3336,"conditions":3337,"interventions":3338},"NCT03519971","Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer",[92],"2023-09-07","2025-12-01","2018-03-29",328,[262],[117,3339,3340,3341,3342],"Cisplatin\u002F Etoposide","Carboplatin\u002F Paclitaxel","Pemetrexed\u002F Cisplatin","Pemetrexed\u002F Carboplatin",{"nctId":3344,"briefTitle":3345,"status":108,"phases":3346,"primaryCompletion":1357,"completion":130,"start":3347,"enrollment":3348,"conditions":3349,"interventions":3351},"NCT03003962","Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)",[92],"2017-01-02",669,[3350],"Non Small Cell Lung Carcinoma NSCLC",[117,3352,3353,3354,3355,3356],"Paclitaxel + carboplatin","Gemcitabine + cisplatin","Gemcitabine + carboplatin","Pemetrexed + cisplatin","Pemetrexed + carboplatin",{"nctId":3358,"briefTitle":3359,"status":108,"phases":3360,"primaryCompletion":3361,"completion":3362,"start":3363,"enrollment":3364,"conditions":3365,"interventions":3367},"NCT05450692","A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy",[92],"2025-10-06","2027-12-31","2022-09-15",594,[3366],"Advanced or Metastatic Non-Small Cell Lung Cancer",[265,117,369],{"nctId":3369,"briefTitle":3370,"status":151,"phases":3371,"primaryCompletion":3372,"completion":3372,"start":3373,"enrollment":3374,"conditions":3375,"interventions":3376},"NCT05557838","Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma",[92],"2025-03-31","2023-02-22",210,[3220],[117,3137],{"nctId":3378,"briefTitle":3379,"status":195,"phases":3380,"primaryCompletion":3381,"completion":3382,"start":3383,"enrollment":1710,"conditions":3384,"interventions":3386},"NCT04642469","Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.",[92],"2023-05-31","2024-01-15","2020-11-30",[3385],"Carcinoma, Non- Small Cell Lung",[117],{"nctId":3388,"briefTitle":3389,"status":108,"phases":3390,"primaryCompletion":130,"completion":3391,"start":3392,"enrollment":3393,"conditions":3394,"interventions":3395},"NCT05221840","A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer",[92],"2030-07-02","2022-02-07",1051,[262],[117,251,3232],{"nctId":3397,"briefTitle":3398,"status":108,"phases":3399,"primaryCompletion":3400,"completion":601,"start":110,"enrollment":3289,"conditions":3401,"interventions":3402},"NCT05771480","Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)",[92],"2025-10-02",[281],[117,3403,3353,3404,3354,3405,3406,3407],"Gemcitabine monotherapy","Gemcitabine + oxaliplatin","Gemcitabine + cisplatin + S-1","Gemcitabine + S-1","Gemcitabine + cisplatin + albumin-bound paclitaxel",{"nctId":777,"briefTitle":778,"status":108,"phases":3409,"primaryCompletion":780,"completion":398,"start":781,"enrollment":782,"conditions":3410,"interventions":3411},[92],[784],[239,117,267,786,787],{"nctId":3413,"briefTitle":3414,"status":108,"phases":3415,"primaryCompletion":3416,"completion":3417,"start":3418,"enrollment":3419,"conditions":3420,"interventions":3422},"NCT03528694","Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer",[92],"2025-04-03","2028-10-03","2018-05-14",1018,[3421],"Non-muscle-invasive Bladder Cancer",[117,3423],"Bacillus Calmette-Guerin",{"nctId":3425,"briefTitle":3426,"status":108,"phases":3427,"primaryCompletion":3428,"completion":660,"start":3429,"enrollment":3430,"conditions":3431,"interventions":3433},"NCT03043872","Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)",[92],"2020-01-27","2017-03-27",987,[3432],"Small Cell Lung Carcinoma Extensive Disease",[117,3137,344,177,1017],{"nctId":3435,"briefTitle":3436,"status":108,"phases":3437,"primaryCompletion":3438,"completion":3439,"start":1383,"enrollment":3440,"conditions":3441,"interventions":3444},"NCT04592913","Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer",[92],"2024-12-20","2027-09-27",957,[3442,3443],"Gastrointestinal Neoplasms","Esophagogastric Junction",[117,3445],"FLOT chemotherapy",{"nctId":799,"briefTitle":800,"status":108,"phases":3447,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":3448,"interventions":3449},[92],[25],[808,117,178,309,809,524,118,344,121,267],{"nctId":3451,"briefTitle":3452,"status":108,"phases":3453,"primaryCompletion":3454,"completion":1965,"start":3455,"enrollment":221,"conditions":3456,"interventions":3458},"NCT05943106","BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants",[92],"2025-06-16","2023-08-11",[3457],"Non-Muscle- Invasive Bladder Cancer",[117,3459],"BCG",{"nctId":3461,"briefTitle":3462,"status":195,"phases":3463,"primaryCompletion":3464,"completion":378,"start":3465,"enrollment":3466,"conditions":3467,"interventions":3469},"NCT04774380","Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer",[92],"2023-06-12","2021-11-11",152,[3468],"Extensive-stage Small Cell Lung Cancer",[117,177,344,1017],{"nctId":3471,"briefTitle":3472,"status":151,"phases":3473,"primaryCompletion":3474,"completion":3474,"start":3475,"enrollment":3476,"conditions":3477,"interventions":3478},"NCT06992609","Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.",[92],"2029-06-30","2025-09-15",70,[3023],[117],{"nctId":3480,"briefTitle":3481,"status":108,"phases":3482,"primaryCompletion":1317,"completion":3483,"start":339,"enrollment":3484,"conditions":3485,"interventions":3487},"NCT05043090","Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC",[92],"2027-02-01",148,[3486],"Papillary Renal Cell Carcinoma",[3488,900,3489],"savolitinib","sunitinib",{"nctId":3491,"briefTitle":3492,"status":108,"phases":3493,"primaryCompletion":3494,"completion":3495,"start":3199,"enrollment":3496,"conditions":3497,"interventions":3499},"NCT03875235","Durvalumab or Placebo in Combination With Gemcitabine\u002FCisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)",[92],"2021-08-11","2027-05-16",810,[3498],"Biliary Tract Neoplasms",[117],{"nctId":3501,"briefTitle":3502,"status":108,"phases":3503,"primaryCompletion":3504,"completion":3505,"start":3506,"enrollment":3507,"conditions":3508,"interventions":3509},"NCT05629585","A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)",[92],"2027-09-20","2030-01-30","2022-11-28",1174,[25],[808,117,121,178],{"nctId":3511,"briefTitle":3512,"status":195,"phases":3513,"primaryCompletion":3514,"completion":3514,"start":3515,"enrollment":2321,"conditions":3516,"interventions":3518},"NCT05924880","A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)",[92],"2025-02-07","2023-07-21",[3517],"Biliary Tract Cancers",[900],{"nctId":3520,"briefTitle":3521,"status":3522,"phases":3523,"primaryCompletion":660,"completion":660,"start":2865,"enrollment":3524,"conditions":3525,"interventions":3526},"NCT05303532","Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab","ENROLLING_BY_INVITATION",[92],214,[556],[117],{"nctId":3528,"briefTitle":3529,"status":108,"phases":3530,"primaryCompletion":3382,"completion":3531,"start":1217,"enrollment":3532,"conditions":3533,"interventions":3534},"NCT03703297","Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy",[92],"2026-10-23",730,[420],[117,3137],{"nctId":3536,"briefTitle":3537,"status":108,"phases":3538,"primaryCompletion":3539,"completion":245,"start":3540,"enrollment":3541,"conditions":3542,"interventions":3543},"NCT03706690","A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients",[92],"2024-06-23","2018-11-27",407,[992],[117],{"nctId":3545,"briefTitle":3546,"status":195,"phases":3547,"primaryCompletion":3548,"completion":3549,"start":3550,"enrollment":3551,"conditions":3552,"interventions":3554},"NCT03830866","Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)",[92],"2022-01-20","2023-07-03","2019-02-15",770,[3553],"Locally Advanced Cervical Cancer",[117,177,344],{"nctId":3556,"briefTitle":3557,"status":108,"phases":3558,"primaryCompletion":3559,"completion":3560,"start":3561,"enrollment":3562,"conditions":3563,"interventions":3564},"NCT03778957","A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma",[92],"2023-09-11","2026-08-31","2018-11-30",724,[3220],[117,239],{"nctId":3566,"briefTitle":3567,"status":108,"phases":3568,"primaryCompletion":3569,"completion":168,"start":1217,"enrollment":3570,"conditions":3571,"interventions":3574},"NCT03682068","Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer",[92],"2026-06-01",1246,[3572,3573],"Unresectable Locally Advanced Urothelial Cancer","Metastatic Urothelial Cancer",[117,3137,3575,3576],"Cisplatin + Gemcitabine","Carboplatin + Gemcitabine",{"nctId":3578,"briefTitle":3579,"status":151,"phases":3580,"primaryCompletion":1371,"completion":1371,"start":3581,"enrollment":3000,"conditions":3582,"interventions":3586},"NCT06960577","Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine\u002FCisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)",[92],"2025-05-15",[664,3583,3584,3585,309,177,283],"Immune Checkpoint Inhibitors","Methotrexate","Vinblastine",[117,3584,3585,309,177,117,283,177],{"nctId":3588,"briefTitle":3589,"status":108,"phases":3590,"primaryCompletion":1068,"completion":130,"start":3591,"enrollment":3592,"conditions":3593,"interventions":3594},"NCT03732677","Durvalumab+ Gemcitabine\u002FCisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC",[92],"2018-11-16",1063,[567],[117,177,283],{"nctId":890,"briefTitle":891,"status":108,"phases":3596,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":3597,"interventions":3598},[92],[898],[63,900,901,902,344,118],{"nctId":3600,"briefTitle":3601,"status":108,"phases":3602,"primaryCompletion":1647,"completion":2835,"start":462,"enrollment":3603,"conditions":3604,"interventions":3605},"NCT03847428","Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment",[92],908,[3220],[117,239],{"nctId":3607,"briefTitle":3608,"status":108,"phases":3609,"primaryCompletion":3610,"completion":3611,"start":3612,"enrollment":3613,"conditions":3614,"interventions":3615},"NCT03800134","A Study of Neoadjuvant\u002FAdjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer",[92],"2022-11-10","2028-09-11","2018-12-06",825,[262],[117,344,177,345,118,283],{"nctId":1083,"briefTitle":1084,"status":108,"phases":3617,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":1088,"conditions":3618,"interventions":3619},[92],[1090],[252,117,344,178,177,345,118],{"nctId":3621,"briefTitle":3622,"status":108,"phases":3623,"primaryCompletion":3624,"completion":3625,"start":2713,"enrollment":3626,"conditions":3627,"interventions":3628},"NCT03298451","Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma",[92],"2021-08-27","2026-08-27",1324,[3220],[117,3137,3137,3629,117,117],"Sorafenib",{"nctId":3631,"briefTitle":3632,"status":108,"phases":3633,"primaryCompletion":1046,"completion":1046,"start":3634,"enrollment":3635,"conditions":3636,"interventions":3637},"NCT04550260","Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC",[92],"2020-10-19",640,[3031],[117,3638,3639],"cisplatin + fluorouracil","cisplatin + capecitabine",{"nctId":3641,"briefTitle":3642,"status":195,"phases":3643,"primaryCompletion":3189,"completion":3189,"start":3644,"enrollment":3645,"conditions":3646,"interventions":3647},"NCT04712903","Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer",[92],"2020-12-16",101,[3432],[117,177,1017,344],{"nctId":3649,"briefTitle":3650,"status":151,"phases":3651,"primaryCompletion":3652,"completion":3652,"start":3653,"enrollment":3654,"conditions":3655,"interventions":3656},"NCT07221253","A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)",[92],"2029-07-04","2025-12-04",1100,[281],[180,117,3657],"Gemcitabine\u002FCisplatin",{"nctId":3659,"briefTitle":3660,"status":108,"phases":3661,"primaryCompletion":337,"completion":3662,"start":3663,"enrollment":3664,"conditions":3665,"interventions":3666},"NCT04960709","Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin",[92],"2028-09-08","2021-08-05",712,[567],[117,3137,3667],"Enfortumab Vedotin",{"nctId":3669,"briefTitle":3670,"status":151,"phases":3671,"primaryCompletion":3672,"completion":3673,"start":3674,"enrollment":3675,"conditions":3676,"interventions":3677},"NCT05211895","A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC",[92],"2028-07-12","2030-10-01","2022-02-18",860,[262],[117,3678],"Domvanalimab",{"nctId":3680,"briefTitle":3681,"status":151,"phases":3682,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":3686,"conditions":3687,"interventions":3688},"NCT06103864","A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer",[92],"2027-07-28","2030-09-30","2023-11-23",625,[25],[808,117,118,3097,283,344,178],{"nctId":3690,"briefTitle":3691,"status":108,"phases":3692,"primaryCompletion":3693,"completion":245,"start":3694,"enrollment":3695,"conditions":3696,"interventions":3697},"NCT05301842","Evaluate Durvalumab and Tremelimumab +\u002F- Lenvatinib in Combination With TACE in Patients With Locoregional HCC",[92],"2026-02-23","2022-03-28",760,[3220],[3137,117,3222],{"nctId":3699,"briefTitle":3700,"status":108,"phases":3701,"primaryCompletion":3702,"completion":3703,"start":3704,"enrollment":3705,"conditions":3706,"interventions":3708},"NCT03164616","Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).",[92],"2021-03-12","2027-11-15","2017-06-01",1186,[3707],"Non Small Cell Lung Cancer NSCLC",[117,3137,3709,3353,3354,3356,3355],"Abraxane + carboplatin",{"nctId":3711,"briefTitle":3712,"status":108,"phases":3713,"primaryCompletion":1371,"completion":1371,"start":3714,"enrollment":3562,"conditions":3715,"interventions":3716},"NCT03833154","Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients\u002F Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation",[92],"2019-03-06",[992],[117],38,{"trials":3719,"activeCount":102},[3720,3730],{"nctId":3721,"briefTitle":3722,"status":195,"phases":3723,"primaryCompletion":3724,"completion":3725,"start":3726,"enrollment":2640,"conditions":3727,"interventions":3729},"NCT04078152","Durvalumab Long-Term Safety and Efficacy Study",[93],"2022-10-31","2024-10-31","2019-09-05",[3728],"Solid Tumor",[117],{"nctId":3731,"briefTitle":3732,"status":195,"phases":3733,"primaryCompletion":3734,"completion":3734,"start":3735,"enrollment":221,"conditions":3736,"interventions":3738},"NCT04416633","Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC",[93],"2023-10-27","2021-11-30",[3737],"Unresectable Non-small Cell Lung Cancer (NSCLC)",[117],{"trials":3740,"activeCount":122,"soonestReadout":3745},[3741,3750,3759,3767,3775],{"nctId":3742,"briefTitle":3743,"status":108,"phases":3744,"primaryCompletion":3745,"completion":3745,"start":3746,"enrollment":3747,"conditions":3748,"interventions":3749},"NCT05683977","A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.",[],"2027-03-01","2022-11-14",254,[3023],[900],{"nctId":3751,"briefTitle":3752,"status":195,"phases":3753,"primaryCompletion":3754,"completion":3754,"start":743,"enrollment":3755,"conditions":3756,"interventions":3758},"NCT04667312","Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom",[],"2022-09-28",115,[3757],"Non-Small Cell Lung Cancer NSCLC",[117],{"nctId":3760,"briefTitle":3761,"status":195,"phases":3762,"primaryCompletion":3763,"completion":3763,"start":1872,"enrollment":3764,"conditions":3765,"interventions":3766},"NCT05933044","RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada",[],"2022-08-31",662,[1049],[117],{"nctId":3768,"briefTitle":3769,"status":195,"phases":3770,"primaryCompletion":3771,"completion":3771,"start":3772,"enrollment":34,"conditions":3773,"interventions":3774},"NCT06826677","REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER",[],"2025-01-23","2024-07-30",[3023],[117],{"nctId":3776,"briefTitle":3777,"status":958,"phases":3778,"conditions":3779,"interventions":3781},"NCT05345678","Himalaya Early Access Program",[],[3780],"Unresectable Hepatocellular Carcinoma",[117,3137],{"intervention":344,"totalTrials":680,"cells":3783},{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3888,"PHASE3":4010,"PHASE4":4180,"NA":4182},{"trials":3785,"activeCount":102},[],{"trials":3787,"activeCount":3887,"soonestReadout":3122},[3788,3792,3805,3815,3819,3823,3831,3835,3844,3848,3858,3867,3879,3883],{"nctId":970,"briefTitle":971,"status":108,"phases":3789,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":3790,"interventions":3791},[90],[977],[252,117,344,979,980,981],{"nctId":3793,"briefTitle":3794,"status":195,"phases":3795,"primaryCompletion":3796,"completion":3796,"start":3797,"enrollment":2783,"conditions":3798,"interventions":3800},"NCT01809210","Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer",[90],"2016-01-04","2013-04-04",[3799],"Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV",[3801,3802,3803,672,3804],"selumetinib","gemcitabine","cisplatin","pemetrexed",{"nctId":3806,"briefTitle":3807,"status":195,"phases":3808,"completion":3809,"start":3810,"enrollment":3811,"conditions":3812,"interventions":3814},"NCT00252798","ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer",[90],"2005-10","2002-07",44,[3813],"Non Small Cell Lung Carcinoma",[1013,344,118],{"nctId":3042,"briefTitle":3043,"status":151,"phases":3816,"primaryCompletion":1046,"completion":1046,"start":3045,"enrollment":2792,"conditions":3817,"interventions":3818},[90],[342],[3048,117,177,344,345,179,180],{"nctId":514,"briefTitle":515,"status":443,"phases":3820,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":3821,"interventions":3822},[90],[25],[267,344,523,524],{"nctId":3824,"briefTitle":3825,"status":443,"phases":3826,"primaryCompletion":3827,"completion":3827,"start":2415,"enrollment":1039,"conditions":3828,"interventions":3829},"NCT00539331","Phase I\u002FII Study of AZD2171 in Combination With Paclitaxel\u002FCarboplatin in Japanese Non-Small Cell Lung Cancer Patients",[90],"2008-09",[992],[3830,118,344],"AZD2171",{"nctId":3068,"briefTitle":3069,"status":443,"phases":3832,"primaryCompletion":3071,"completion":3071,"start":3072,"enrollment":1336,"conditions":3833,"interventions":3834},[90],[262,420],[117,177,344,1017],{"nctId":3836,"briefTitle":3837,"status":195,"phases":3838,"primaryCompletion":2056,"completion":2212,"start":3839,"enrollment":3484,"conditions":3840,"interventions":3842},"NCT00496028","Phase I Study in Patients With Solid Tumours",[90],"2007-03",[3841],"Neoplasms",[3843,344,118],"AZD0530",{"nctId":3087,"briefTitle":3088,"status":195,"phases":3845,"primaryCompletion":3090,"completion":3091,"start":3092,"enrollment":3093,"conditions":3846,"interventions":3847},[90],[498],[571,117,177,3096,344,283,3097],{"nctId":3849,"briefTitle":3850,"status":195,"phases":3851,"primaryCompletion":3852,"completion":3853,"start":3854,"enrollment":3855,"conditions":3856,"interventions":3857},"NCT02341456","Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours",[90],"2016-12-14","2018-07-09","2015-01-16",19,[498],[570,118,672],{"nctId":3859,"briefTitle":3860,"status":624,"phases":3861,"primaryCompletion":3862,"completion":2570,"start":2056,"enrollment":2003,"conditions":3863,"interventions":3866},"NCT01000896","Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel",[90],"2010-09",[556,3864,3865],"Non Small Cell Lung Cancer","Epithelial Ovarian Cancer",[3843,344,620],{"nctId":3868,"briefTitle":3869,"status":195,"phases":3870,"primaryCompletion":3871,"completion":1058,"start":3872,"enrollment":3873,"conditions":3874,"interventions":3876},"NCT00516724","Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and\u002For Paclitaxel",[90],"2013-01-04","2007-06-22",189,[3875,784,344,118],"Triple Negative Metastatic Breast Cancer",[3877,344,3877,118,3877,3878],"KU-0059436","Paclitaxel + Carboplatin",{"nctId":3119,"briefTitle":3120,"status":108,"phases":3880,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":3881,"interventions":3882},[90],[3127],[117,264,251,980,345,344,283,177,3097,979],{"nctId":3130,"briefTitle":3131,"status":195,"phases":3884,"primaryCompletion":1916,"completion":3133,"start":3134,"enrollment":1428,"conditions":3885,"interventions":3886},[90],[3024,992,3023],[117,3137,177,177,344,344,1017,1017,118,345,177,177],3,{"trials":3889,"activeCount":2222,"soonestReadout":62},[3890,3898,3904,3916,3926,3935,3950,3954,3967,3971,3975,3979,3986,3993,3997,4001],{"nctId":3891,"briefTitle":3892,"status":443,"phases":3893,"primaryCompletion":2542,"completion":2542,"start":2152,"enrollment":2187,"conditions":3894,"interventions":3896},"NCT00929162","ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer",[91],[3895],"Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy",[3897,118,344],"ZD4054 Zibotentan",{"nctId":3899,"briefTitle":3900,"status":195,"phases":3901,"primaryCompletion":2151,"completion":2747,"start":2251,"enrollment":1599,"conditions":3902,"interventions":3903},"NCT00610714","AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer",[91],[3026,414],[3843,344,118],{"nctId":3905,"briefTitle":3906,"status":195,"phases":3907,"primaryCompletion":3908,"completion":3909,"start":3910,"enrollment":29,"conditions":3911,"interventions":3913},"NCT02272790","Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[91],"2018-12-13","2023-03-08","2015-01-30",[3912],"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation",[3914,118,344,283,3915],"Adavosertib","PLD",{"nctId":3917,"briefTitle":3918,"status":151,"phases":3919,"primaryCompletion":3920,"completion":3920,"start":3921,"enrollment":318,"conditions":3922,"interventions":3924},"NCT05797168","Phase I\u002FIIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors",[90,91],"2028-01-06","2023-06-05",[414,3923,367],"Lung Adenocarcinoma",[3925,1959,239,344,159],"AZD5335",{"nctId":3927,"briefTitle":3928,"status":151,"phases":3929,"primaryCompletion":3930,"completion":3930,"start":2932,"enrollment":3466,"conditions":3931,"interventions":3933},"NCT06996782","A Platform Study in Non-Small Cell Lung Cancer (NSCLC)",[90,91],"2029-02-23",[3932],"Advanced or Metastatic Non-small Cell Lung Cancer",[180,177,344,345,118,3097,3934],"Ramucirumab",{"nctId":3936,"briefTitle":3937,"status":151,"phases":3938,"primaryCompletion":3939,"completion":3939,"start":3940,"enrollment":3941,"conditions":3942,"interventions":3948},"NCT06535607","Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced\u002FMetastatic Solid Tumors",[91],"2028-11-30","2024-08-22",257,[3943,3944,3945,3946,3947],"Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)","Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)","Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)","Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)","Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)",[179,177,344,118,3949],"5-FU",{"nctId":3224,"briefTitle":3225,"status":151,"phases":3951,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":3952,"interventions":3953},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"nctId":3955,"briefTitle":3956,"status":108,"phases":3957,"primaryCompletion":3958,"completion":3958,"start":1574,"enrollment":3959,"conditions":3960,"interventions":3964},"NCT04644068","Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",[90,91],"2027-05-28",702,[414,25,415,416,3961,1049,691,403,172,3962,404,367,3963],"Additional Indications Below for Module 4 and 5","Biliary Cancer","Small Cell Lung Cancer Only in Module 5",[1939,118,344,3965,808,3966],"T- Dxd","Camizestrant",{"nctId":3242,"briefTitle":3243,"status":108,"phases":3968,"primaryCompletion":3245,"completion":3246,"start":3247,"enrollment":3248,"conditions":3969,"interventions":3970},[91],[3250],[117,3252,344,177,1017],{"nctId":60,"briefTitle":61,"status":108,"phases":3972,"primaryCompletion":62,"completion":660,"start":668,"enrollment":669,"conditions":3973,"interventions":3974},[91],[414],[63,620,672,620,673],{"nctId":3258,"briefTitle":3259,"status":108,"phases":3976,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":221,"conditions":3977,"interventions":3978},[91],[992],[117,3137,345,178,344,177],{"nctId":3980,"briefTitle":3981,"status":151,"phases":3982,"primaryCompletion":338,"completion":338,"start":3983,"enrollment":1120,"conditions":3984,"interventions":3985},"NCT06448754","Volrustomig Priming Regimens Exploratory Phase II Platform Study",[91],"2024-08-27",[1049],[179,344,345,3934,118],{"nctId":3987,"briefTitle":3988,"status":195,"phases":3989,"completion":2524,"start":3990,"enrollment":3717,"conditions":3991,"interventions":3992},"NCT00264498","Phase II Iressa & Carbo\u002FGem in NSCLC",[91],"2004-10",[992],[1013,283,344],{"nctId":1004,"briefTitle":1005,"status":108,"phases":3994,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":3995,"interventions":3996},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"nctId":1019,"briefTitle":1020,"status":151,"phases":3998,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":340,"conditions":3999,"interventions":4000},[91],[367,172,651,414,691,1025,281],[252,121,226,179,344,239,180,1027,177],{"nctId":4002,"briefTitle":4003,"status":443,"phases":4004,"primaryCompletion":4005,"completion":4005,"start":4006,"enrollment":434,"conditions":4007,"interventions":4009},"NCT02087241","Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer",[91],"2015-06","2014-03",[4008],"Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer",[570,3804,672],{"trials":4011,"activeCount":1336,"soonestReadout":3428},[4012,4020,4031,4040,4049,4061,4065,4073,4080,4084,4088,4092,4102,4115,4119,4123,4127,4131,4135,4145,4156,4160,4164,4168],{"nctId":4013,"briefTitle":4014,"status":108,"phases":4015,"primaryCompletion":3428,"completion":660,"start":4016,"enrollment":4017,"conditions":4018,"interventions":4019},"NCT02516241","Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer",[92],"2015-11-02",1126,[1025],[82,3137,177,344,283],{"nctId":4021,"briefTitle":4022,"status":108,"phases":4023,"primaryCompletion":4024,"completion":4025,"start":4026,"enrollment":4027,"conditions":4028,"interventions":4030},"NCT05984277","A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.",[92],"2028-04-24","2029-03-23","2023-10-24",1200,[4029],"Metastatic Non-small Cell Lung Cancer",[179,178,344,118,345],{"nctId":4032,"briefTitle":4033,"status":4034,"phases":4035,"start":4036,"conditions":4037,"interventions":4038},"NCT00006049","ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer","UNKNOWN",[92],"2000-05",[3174],[672,4039,620],"gefitinib",{"nctId":4041,"briefTitle":4042,"status":151,"phases":4043,"primaryCompletion":3323,"completion":4044,"start":4045,"enrollment":4046,"conditions":4047,"interventions":4048},"NCT06417814","A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[92],"2028-09-27","2024-10-04",744,[4029],[808,1012,345,344,177],{"nctId":4050,"briefTitle":4051,"status":108,"phases":4052,"primaryCompletion":4053,"completion":4054,"start":4055,"enrollment":4056,"conditions":4057,"interventions":4060},"NCT05261399","Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment",[92],"2026-06-18","2026-11-23","2022-08-03",345,[4058,4059],"Carcinoma","Non-Small-Cell Lung",[87,1012,345,177,344],{"nctId":1043,"briefTitle":1044,"status":108,"phases":4062,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":98,"conditions":4063,"interventions":4064},[92],[1049],[163,180,344,177,1017,345,1051,1052],{"nctId":4066,"briefTitle":4067,"status":108,"phases":4068,"primaryCompletion":1047,"completion":4069,"start":3644,"enrollment":4070,"conditions":4071,"interventions":4072},"NCT04351555","A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer",[92],"2029-06-13",358,[262],[1012,177,344,345],{"nctId":4074,"briefTitle":4075,"status":195,"phases":4076,"primaryCompletion":2251,"completion":2242,"start":2087,"enrollment":4077,"conditions":4078,"interventions":4079},"NCT00322452","First Line IRESSA™ Versus Carboplatin\u002FPaclitaxel in Asia",[92],1329,[262],[1013,344,118],{"nctId":3425,"briefTitle":3426,"status":108,"phases":4081,"primaryCompletion":3428,"completion":660,"start":3429,"enrollment":3430,"conditions":4082,"interventions":4083},[92],[3432],[117,3137,344,177,1017],{"nctId":799,"briefTitle":800,"status":108,"phases":4085,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":4086,"interventions":4087},[92],[25],[808,117,178,309,809,524,118,344,121,267],{"nctId":3461,"briefTitle":3462,"status":195,"phases":4089,"primaryCompletion":3464,"completion":378,"start":3465,"enrollment":3466,"conditions":4090,"interventions":4091},[92],[3468],[117,177,344,1017],{"nctId":4093,"briefTitle":4094,"status":151,"phases":4095,"primaryCompletion":4096,"completion":4097,"start":4098,"enrollment":4099,"conditions":4100,"interventions":4101},"NCT06692738","A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)",[92],"2029-02-05","2029-10-08","2024-11-18",880,[1049],[180,178,344,118,3097],{"nctId":4103,"briefTitle":4104,"status":195,"phases":4105,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":4110,"interventions":4112},"NCT02551159","Phase III Open Label Study of MEDI 4736 With\u002FWithout Tremelimumab Versus Standard of Care (SOC) in Recurrent\u002FMetastatic Head and Neck Cancer",[92],"2020-07-06","2021-05-21","2015-10-15",823,[4111],"Squamous Cell Carcinoma of the Head and Neck",[82,3137,4113,4114,296,177,344],"MEDI4736+Tremelimumab","Cetuximab",{"nctId":3545,"briefTitle":3546,"status":195,"phases":4116,"primaryCompletion":3548,"completion":3549,"start":3550,"enrollment":3551,"conditions":4117,"interventions":4118},[92],[3553],[117,177,344],{"nctId":890,"briefTitle":891,"status":108,"phases":4120,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":4121,"interventions":4122},[92],[898],[63,900,901,902,344,118],{"nctId":3607,"briefTitle":3608,"status":108,"phases":4124,"primaryCompletion":3610,"completion":3611,"start":3612,"enrollment":3613,"conditions":4125,"interventions":4126},[92],[262],[117,344,177,345,118,283],{"nctId":1083,"briefTitle":1084,"status":108,"phases":4128,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":1088,"conditions":4129,"interventions":4130},[92],[1090],[252,117,344,178,177,345,118],{"nctId":3641,"briefTitle":3642,"status":195,"phases":4132,"primaryCompletion":3189,"completion":3189,"start":3644,"enrollment":3645,"conditions":4133,"interventions":4134},[92],[3432],[117,177,1017,344],{"nctId":4136,"briefTitle":4137,"status":108,"phases":4138,"primaryCompletion":4139,"completion":660,"start":4140,"enrollment":4141,"conditions":4142,"interventions":4143},"NCT05374512","A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1\u002FPD-L1 Inhibitor Therapy (TROPION-Breast02)",[92],"2025-08-25","2022-05-16",644,[25],[808,118,3097,344,121,4144],"Eribulin mesylate",{"nctId":4146,"briefTitle":4147,"status":151,"phases":4148,"primaryCompletion":4149,"completion":4150,"start":4151,"enrollment":4152,"conditions":4153,"interventions":4155},"NCT06627647","A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC",[92],"2029-05-10","2030-03-25","2024-11-27",878,[4154],"Non-squamous Non-small Cell Lung Cancer",[180,178,344,177,345],{"nctId":334,"briefTitle":335,"status":108,"phases":4157,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":4158,"interventions":4159},[92],[342],[162,177,344,178,345],{"nctId":359,"briefTitle":360,"status":151,"phases":4161,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":4162,"interventions":4163},[92],[367],[97,180,178,344,118,369],{"nctId":3680,"briefTitle":3681,"status":151,"phases":4165,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":3686,"conditions":4166,"interventions":4167},[92],[25],[808,117,118,3097,283,344,178],{"nctId":4169,"briefTitle":4170,"status":151,"phases":4171,"primaryCompletion":4172,"completion":4173,"start":4174,"enrollment":3613,"conditions":4175,"interventions":4177},"NCT06097728","MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma",[92],"2027-11-19","2028-11-16","2023-11-09",[4176],"Unresectable Pleural Mesothelioma",[179,345,344,177,4178,4179],"Nivolumab","Ipilimumab",{"trials":4181,"activeCount":102},[],{"trials":4183,"activeCount":102},[],{"intervention":177,"totalTrials":451,"cells":4185},{"EARLY_PHASE1":4186,"PHASE1":4188,"PHASE2":4246,"PHASE3":4344,"PHASE4":4439,"NA":4441},{"trials":4187,"activeCount":102},[],{"trials":4189,"activeCount":447,"soonestReadout":3122},[4190,4196,4200,4208,4219,4223,4227,4234,4238,4242],{"nctId":4191,"briefTitle":4192,"status":195,"phases":4193,"primaryCompletion":2151,"completion":2366,"start":2168,"enrollment":37,"conditions":4194,"interventions":4195},"NCT00621361","Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients",[90],[3174],[3830,1017,177],{"nctId":3793,"briefTitle":3794,"status":195,"phases":4197,"primaryCompletion":3796,"completion":3796,"start":3797,"enrollment":2783,"conditions":4198,"interventions":4199},[90],[3799],[3801,3802,3803,672,3804],{"nctId":4201,"briefTitle":4202,"status":443,"phases":4203,"primaryCompletion":2560,"completion":2560,"start":4204,"enrollment":1039,"conditions":4205,"interventions":4207},"NCT01949870","Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study",[90],"2013-10",[4206],"Inoperable Locally Advanced or Metastatic Biliary Tract Cancer",[177,283,68],{"nctId":4209,"briefTitle":4210,"status":195,"phases":4211,"primaryCompletion":4212,"completion":4213,"start":4214,"enrollment":4215,"conditions":4216,"interventions":4218},"NCT00782574","Phase I AZD2281\u002FCisplatin in Advanced Solid Tumour Patients",[90],"2012-02-01","2023-12-07","2008-11-12",57,[4217],"Advanced Solid Tumors",[48,177],{"nctId":3042,"briefTitle":3043,"status":151,"phases":4220,"primaryCompletion":1046,"completion":1046,"start":3045,"enrollment":2792,"conditions":4221,"interventions":4222},[90],[342],[3048,117,177,344,345,179,180],{"nctId":3068,"briefTitle":3069,"status":443,"phases":4224,"primaryCompletion":3071,"completion":3071,"start":3072,"enrollment":1336,"conditions":4225,"interventions":4226},[90],[262,420],[117,177,344,1017],{"nctId":4228,"briefTitle":4229,"status":195,"phases":4230,"primaryCompletion":2056,"completion":2570,"start":2151,"enrollment":1638,"conditions":4231,"interventions":4232},"NCT00960349","Study of Cediranib Plus Cisplatin Plus Capecitabine\u002FS-1 in Japanese Gastric Cancer Patients",[90],[172],[268,177,4233,177,121],"S-1",{"nctId":3087,"briefTitle":3088,"status":195,"phases":4235,"primaryCompletion":3090,"completion":3091,"start":3092,"enrollment":3093,"conditions":4236,"interventions":4237},[90],[498],[571,117,177,3096,344,283,3097],{"nctId":3119,"briefTitle":3120,"status":108,"phases":4239,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":4240,"interventions":4241},[90],[3127],[117,264,251,980,345,344,283,177,3097,979],{"nctId":3130,"briefTitle":3131,"status":195,"phases":4243,"primaryCompletion":1916,"completion":3133,"start":3134,"enrollment":1428,"conditions":4244,"interventions":4245},[90],[3024,992,3023],[117,3137,177,177,344,344,1017,1017,118,345,177,177],{"trials":4247,"activeCount":4343,"soonestReadout":3245},[4248,4252,4260,4268,4272,4276,4280,4289,4293,4302,4313,4323,4327,4335,4339],{"nctId":165,"briefTitle":166,"status":151,"phases":4249,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":4250,"interventions":4251},[91],[172],[174,121,117,175,176,97,177,178,179,180],{"nctId":4253,"briefTitle":4254,"status":195,"phases":4255,"completion":2087,"start":4256,"enrollment":1448,"conditions":4257,"interventions":4259},"NCT00239304","Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer",[90,91],"2003-06",[4258],"Head and Neck Neoplasms",[1013,177],{"nctId":4261,"briefTitle":4262,"status":195,"phases":4263,"completion":2524,"start":4264,"enrollment":2289,"conditions":4265,"interventions":4267},"NCT00229723","IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III\u002FIV Non-Metastatic Head and Neck Squamous Cell Carcinoma",[91],"2004-11",[4266],"Neoplasms, Squamous Cell",[4039,3803,1013],{"nctId":3927,"briefTitle":3928,"status":151,"phases":4269,"primaryCompletion":3930,"completion":3930,"start":2932,"enrollment":3466,"conditions":4270,"interventions":4271},[90,91],[3932],[180,177,344,345,118,3097,3934],{"nctId":3936,"briefTitle":3937,"status":151,"phases":4273,"primaryCompletion":3939,"completion":3939,"start":3940,"enrollment":3941,"conditions":4274,"interventions":4275},[91],[3943,3944,3945,3946,3947],[179,177,344,118,3949],{"nctId":3224,"briefTitle":3225,"status":151,"phases":4277,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":4278,"interventions":4279},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"nctId":4281,"briefTitle":4282,"status":195,"phases":4283,"completion":4284,"start":4285,"enrollment":4286,"conditions":4287,"interventions":4288},"NCT00333294","Phase II Iressa + Irradiation Followed by Chemo in NSCLC",[91],"2006-01","2004-09",50,[262],[1013,177,1051],{"nctId":3242,"briefTitle":3243,"status":108,"phases":4290,"primaryCompletion":3245,"completion":3246,"start":3247,"enrollment":3248,"conditions":4291,"interventions":4292},[91],[3250],[117,3252,344,177,1017],{"nctId":4294,"briefTitle":4295,"status":195,"phases":4296,"primaryCompletion":4297,"completion":4298,"start":4299,"enrollment":2811,"conditions":4300,"interventions":4301},"NCT00246974","Phase II Gemcitabine + Cisplatin +\u002F- Iressa Bladder CCT",[91],"2007-10","2007-12","2003-05",[403],[283,177,1013],{"nctId":4303,"briefTitle":4304,"status":195,"phases":4305,"completion":2252,"start":4306,"enrollment":4307,"conditions":4308,"interventions":4311},"NCT00255476","The IRESSA Novel Head and Neck Chemotherapy Evaluation Study",[91],"2004-02",64,[4309,4310],"Squamous Cell Cancer","Cancer of Head and Neck",[4039,3803,4312],"5-flourouracil",{"nctId":4314,"briefTitle":4315,"status":151,"phases":4316,"primaryCompletion":4317,"completion":4318,"start":4319,"enrollment":4320,"conditions":4321,"interventions":4322},"NCT05775159","Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer",[91],"2026-10-27","2027-10-28","2023-04-24",294,[3220,281],[179,239,3222,180,283,177],{"nctId":3258,"briefTitle":3259,"status":108,"phases":4324,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":221,"conditions":4325,"interventions":4326},[91],[992],[117,3137,345,178,344,177],{"nctId":4328,"briefTitle":4329,"status":195,"phases":4330,"primaryCompletion":2087,"completion":2087,"start":4331,"enrollment":496,"conditions":4332,"interventions":4333},"NCT00242762","ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer",[91],"2003-07",[408],[4334,369,177],"ZD1839",{"nctId":1004,"briefTitle":1005,"status":108,"phases":4336,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":4337,"interventions":4338},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"nctId":1019,"briefTitle":1020,"status":151,"phases":4340,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":340,"conditions":4341,"interventions":4342},[91],[367,172,651,414,691,1025,281],[252,121,226,179,344,239,180,1027,177],9,{"trials":4345,"activeCount":520,"soonestReadout":3428},[4346,4350,4354,4358,4362,4366,4370,4374,4384,4388,4395,4399,4403,4407,4411,4415,4419,4423,4427,4431,4435],{"nctId":273,"briefTitle":274,"status":151,"phases":4347,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":4348,"interventions":4349},[92],[281],[283,177,117,97,180],{"nctId":4013,"briefTitle":4014,"status":108,"phases":4351,"primaryCompletion":3428,"completion":660,"start":4016,"enrollment":4017,"conditions":4352,"interventions":4353},[92],[1025],[82,3137,177,344,283],{"nctId":285,"briefTitle":286,"status":151,"phases":4355,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":4356,"interventions":4357},[92],[293,294],[180,97,176,178,296,121,177,175],{"nctId":4041,"briefTitle":4042,"status":151,"phases":4359,"primaryCompletion":3323,"completion":4044,"start":4045,"enrollment":4046,"conditions":4360,"interventions":4361},[92],[4029],[808,1012,345,344,177],{"nctId":4050,"briefTitle":4051,"status":108,"phases":4363,"primaryCompletion":4053,"completion":4054,"start":4055,"enrollment":4056,"conditions":4364,"interventions":4365},[92],[4058,4059],[87,1012,345,177,344],{"nctId":1043,"briefTitle":1044,"status":108,"phases":4367,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":98,"conditions":4368,"interventions":4369},[92],[1049],[163,180,344,177,1017,345,1051,1052],{"nctId":4066,"briefTitle":4067,"status":108,"phases":4371,"primaryCompletion":1047,"completion":4069,"start":3644,"enrollment":4070,"conditions":4372,"interventions":4373},[92],[262],[1012,177,344,345],{"nctId":4375,"briefTitle":4376,"status":195,"phases":4377,"primaryCompletion":4378,"completion":4379,"start":4380,"enrollment":4381,"conditions":4382,"interventions":4383},"NCT01544179","A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone",[92],"2014-05-05","2019-11-20","2012-03-15",265,[262],[1013,345,177],{"nctId":3425,"briefTitle":3426,"status":108,"phases":4385,"primaryCompletion":3428,"completion":660,"start":3429,"enrollment":3430,"conditions":4386,"interventions":4387},[92],[3432],[117,3137,344,177,1017],{"nctId":4389,"briefTitle":4390,"status":4034,"phases":4391,"start":4036,"conditions":4392,"interventions":4393},"NCT00006048","ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer",[92],[3174],[3803,4039,4394],"gemcitabine hydrochloride",{"nctId":3461,"briefTitle":3462,"status":195,"phases":4396,"primaryCompletion":3464,"completion":378,"start":3465,"enrollment":3466,"conditions":4397,"interventions":4398},[92],[3468],[117,177,344,1017],{"nctId":4103,"briefTitle":4104,"status":195,"phases":4400,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":4401,"interventions":4402},[92],[4111],[82,3137,4113,4114,296,177,344],{"nctId":3545,"briefTitle":3546,"status":195,"phases":4404,"primaryCompletion":3548,"completion":3549,"start":3550,"enrollment":3551,"conditions":4405,"interventions":4406},[92],[3553],[117,177,344],{"nctId":3578,"briefTitle":3579,"status":151,"phases":4408,"primaryCompletion":1371,"completion":1371,"start":3581,"enrollment":3000,"conditions":4409,"interventions":4410},[92],[664,3583,3584,3585,309,177,283],[117,3584,3585,309,177,117,283,177],{"nctId":3588,"briefTitle":3589,"status":108,"phases":4412,"primaryCompletion":1068,"completion":130,"start":3591,"enrollment":3592,"conditions":4413,"interventions":4414},[92],[567],[117,177,283],{"nctId":3607,"briefTitle":3608,"status":108,"phases":4416,"primaryCompletion":3610,"completion":3611,"start":3612,"enrollment":3613,"conditions":4417,"interventions":4418},[92],[262],[117,344,177,345,118,283],{"nctId":1083,"briefTitle":1084,"status":108,"phases":4420,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":1088,"conditions":4421,"interventions":4422},[92],[1090],[252,117,344,178,177,345,118],{"nctId":3641,"briefTitle":3642,"status":195,"phases":4424,"primaryCompletion":3189,"completion":3189,"start":3644,"enrollment":3645,"conditions":4425,"interventions":4426},[92],[3432],[117,177,1017,344],{"nctId":4146,"briefTitle":4147,"status":151,"phases":4428,"primaryCompletion":4149,"completion":4150,"start":4151,"enrollment":4152,"conditions":4429,"interventions":4430},[92],[4154],[180,178,344,177,345],{"nctId":334,"briefTitle":335,"status":108,"phases":4432,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":4433,"interventions":4434},[92],[342],[162,177,344,178,345],{"nctId":4169,"briefTitle":4170,"status":151,"phases":4436,"primaryCompletion":4172,"completion":4173,"start":4174,"enrollment":3613,"conditions":4437,"interventions":4438},[92],[4176],[179,345,344,177,4178,4179],{"trials":4440,"activeCount":102},[],{"trials":4442,"activeCount":102},[],{"intervention":118,"totalTrials":451,"cells":4444},{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4522,"PHASE3":4601,"PHASE4":4706,"NA":4708},{"trials":4446,"activeCount":102},[],{"trials":4448,"activeCount":122,"soonestReadout":110},[4449,4460,4469,4473,4477,4481,4485,4492,4502,4506,4510,4514,4518],{"nctId":4450,"briefTitle":4451,"status":195,"phases":4452,"primaryCompletion":4453,"completion":4454,"start":2667,"enrollment":1979,"conditions":4455,"interventions":4457},"NCT02640755","Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase",[90],"2016-12-21","2017-07-06",[4456],"Solid Malignancies",[4458,4459,53,118],"[14C]AZD2014","Multiple dose AZD2014",{"nctId":4461,"briefTitle":4462,"status":195,"phases":4463,"primaryCompletion":4464,"completion":4465,"start":4466,"enrollment":3855,"conditions":4467,"interventions":4468},"NCT00707707","Phase I\u002FII Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer",[90],"2009-11-09","2018-02-19","2008-09-15",[25,993,115],[48,118],{"nctId":3806,"briefTitle":3807,"status":195,"phases":4470,"completion":3809,"start":3810,"enrollment":3811,"conditions":4471,"interventions":4472},[90],[3813],[1013,344,118],{"nctId":490,"briefTitle":491,"status":195,"phases":4474,"primaryCompletion":493,"completion":494,"start":495,"enrollment":496,"conditions":4475,"interventions":4476},[90],[498],[267,118,267],{"nctId":106,"briefTitle":107,"status":108,"phases":4478,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":4479,"interventions":4480},[90],[115],[97,117,118,119,120,53,121],{"nctId":3824,"briefTitle":3825,"status":443,"phases":4482,"primaryCompletion":3827,"completion":3827,"start":2415,"enrollment":1039,"conditions":4483,"interventions":4484},[90],[992],[3830,118,344],{"nctId":4486,"briefTitle":4487,"status":195,"phases":4488,"primaryCompletion":910,"completion":910,"start":4489,"enrollment":486,"conditions":4490,"interventions":4491},"NCT04742036","Capivasertib China PK Study",[90],"2021-02-22",[498],[119,118],{"nctId":4493,"briefTitle":4494,"status":195,"phases":4495,"primaryCompletion":4496,"completion":4496,"start":2350,"enrollment":4497,"conditions":4498,"interventions":4500},"NCT01003158","Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.",[90],"2012-04",17,[3841,4499,25],"Metastatic Cancer",[4501,118],"AZD8931",{"nctId":3836,"briefTitle":3837,"status":195,"phases":4503,"primaryCompletion":2056,"completion":2212,"start":3839,"enrollment":3484,"conditions":4504,"interventions":4505},[90],[3841],[3843,344,118],{"nctId":3849,"briefTitle":3850,"status":195,"phases":4507,"primaryCompletion":3852,"completion":3853,"start":3854,"enrollment":3855,"conditions":4508,"interventions":4509},[90],[498],[570,118,672],{"nctId":3859,"briefTitle":3860,"status":624,"phases":4511,"primaryCompletion":3862,"completion":2570,"start":2056,"enrollment":2003,"conditions":4512,"interventions":4513},[90],[556,3864,3865],[3843,344,620],{"nctId":3868,"briefTitle":3869,"status":195,"phases":4515,"primaryCompletion":3871,"completion":1058,"start":3872,"enrollment":3873,"conditions":4516,"interventions":4517},[90],[3875,784,344,118],[3877,344,3877,118,3877,3878],{"nctId":3130,"briefTitle":3131,"status":195,"phases":4519,"primaryCompletion":1916,"completion":3133,"start":3134,"enrollment":1428,"conditions":4520,"interventions":4521},[90],[3024,992,3023],[117,3137,177,177,344,344,1017,1017,118,345,177,177],{"trials":4523,"activeCount":1855,"soonestReadout":62},[4524,4528,4532,4542,4549,4553,4557,4561,4568,4572,4576,4585,4589,4593,4597],{"nctId":137,"briefTitle":138,"status":108,"phases":4525,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":4526,"interventions":4527},[90,91],[115],[97,117,118,146,147],{"nctId":3891,"briefTitle":3892,"status":443,"phases":4529,"primaryCompletion":2542,"completion":2542,"start":2152,"enrollment":2187,"conditions":4530,"interventions":4531},[91],[3895],[3897,118,344],{"nctId":4533,"briefTitle":4534,"status":443,"phases":4535,"primaryCompletion":4536,"completion":4536,"start":4537,"enrollment":2222,"conditions":4538,"interventions":4540},"NCT02403895","AZD2014 and Weekly Paclitaxel in Squamous NSCLC",[91],"2016-12-29","2015-04-15",[4539],"Squamous Non Small Cell Lung Cancer",[4541,620],"Open-label AZD2014",{"nctId":4543,"briefTitle":4544,"status":195,"phases":4545,"primaryCompletion":4496,"completion":2561,"start":2152,"enrollment":4546,"conditions":4547,"interventions":4548},"NCT00900627","Phase I\u002FII AZD8931\u002FPaclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)",[90,91],330,[3841,306,25],[4501,118],{"nctId":611,"briefTitle":612,"status":195,"phases":4550,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":4551,"interventions":4552},[91],[172],[63,620],{"nctId":3899,"briefTitle":3900,"status":195,"phases":4554,"primaryCompletion":2151,"completion":2747,"start":2251,"enrollment":1599,"conditions":4555,"interventions":4556},[91],[3026,414],[3843,344,118],{"nctId":3905,"briefTitle":3906,"status":195,"phases":4558,"primaryCompletion":3908,"completion":3909,"start":3910,"enrollment":29,"conditions":4559,"interventions":4560},[91],[3912],[3914,118,344,283,3915],{"nctId":4562,"briefTitle":4563,"status":443,"phases":4564,"primaryCompletion":2443,"completion":2443,"start":4496,"enrollment":3190,"conditions":4565,"interventions":4567},"NCT01579578","Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer",[91],[4566],"Metastatic, Gastric or Gastro-oesophageal Junction, Cancer",[4501,118],{"nctId":3927,"briefTitle":3928,"status":151,"phases":4569,"primaryCompletion":3930,"completion":3930,"start":2932,"enrollment":3466,"conditions":4570,"interventions":4571},[90,91],[3932],[180,177,344,345,118,3097,3934],{"nctId":3936,"briefTitle":3937,"status":151,"phases":4573,"primaryCompletion":3939,"completion":3939,"start":3940,"enrollment":3941,"conditions":4574,"interventions":4575},[91],[3943,3944,3945,3946,3947],[179,177,344,118,3949],{"nctId":4577,"briefTitle":4578,"status":443,"phases":4579,"primaryCompletion":1701,"completion":2561,"start":4580,"enrollment":4581,"conditions":4582,"interventions":4584},"NCT01457846","Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer",[91],"2011-11",960,[4583,172],"Gastro-oesophageal Junction Cancer",[569,620],{"nctId":3955,"briefTitle":3956,"status":108,"phases":4586,"primaryCompletion":3958,"completion":3958,"start":1574,"enrollment":3959,"conditions":4587,"interventions":4588},[90,91],[414,25,415,416,3961,1049,691,403,172,3962,404,367,3963],[1939,118,344,3965,808,3966],{"nctId":241,"briefTitle":242,"status":108,"phases":4590,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":4591,"interventions":4592},[90,91],[249],[117,119,251,118,97,252],{"nctId":60,"briefTitle":61,"status":108,"phases":4594,"primaryCompletion":62,"completion":660,"start":668,"enrollment":669,"conditions":4595,"interventions":4596},[91],[414],[63,620,672,620,673],{"nctId":3980,"briefTitle":3981,"status":151,"phases":4598,"primaryCompletion":338,"completion":338,"start":3983,"enrollment":1120,"conditions":4599,"interventions":4600},[91],[1049],[179,344,345,3934,118],{"trials":4602,"activeCount":520,"soonestReadout":3610},[4603,4618,4630,4634,4638,4642,4646,4654,4658,4662,4666,4670,4674,4686,4690,4694,4698,4702],{"nctId":4604,"briefTitle":4605,"status":108,"phases":4606,"primaryCompletion":4607,"completion":4608,"start":4609,"enrollment":4610,"conditions":4611,"interventions":4613},"NCT06346392","AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2",[92],"2026-06-15","2026-10-14","2024-03-04",592,[172,4612],"Gastroesophageal Junction Cancer",[225,225,4614,118,369,4615,4616,4617],"Ramucirumab+ paclitaxel","Irinotecan","TAS-102","Apatinib",{"nctId":4619,"briefTitle":4620,"status":151,"phases":4621,"primaryCompletion":4622,"completion":4623,"start":4624,"enrollment":4625,"conditions":4626,"interventions":4628},"NCT07044336","Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)",[92],"2028-01-20","2029-07-17","2025-08-01",700,[367,4627],"Malignant Solid Tumour",[4629,309,118],"Puxitatug Samrotecan",{"nctId":4021,"briefTitle":4022,"status":108,"phases":4631,"primaryCompletion":4024,"completion":4025,"start":4026,"enrollment":4027,"conditions":4632,"interventions":4633},[92],[4029],[179,178,344,118,345],{"nctId":298,"briefTitle":299,"status":108,"phases":4635,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":4636,"interventions":4637},[92],[306,25,307],[162,118,176,146,309,310],{"nctId":4032,"briefTitle":4033,"status":4034,"phases":4639,"start":4036,"conditions":4640,"interventions":4641},[92],[3174],[672,4039,620],{"nctId":4074,"briefTitle":4075,"status":195,"phases":4643,"primaryCompletion":2251,"completion":2242,"start":2087,"enrollment":4077,"conditions":4644,"interventions":4645},[92],[262],[1013,344,118],{"nctId":4647,"briefTitle":4648,"status":108,"phases":4649,"primaryCompletion":4650,"completion":4650,"start":1008,"enrollment":4651,"conditions":4652,"interventions":4653},"NCT03997123","Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC",[92],"2026-03-16",923,[249],[119,118],{"nctId":799,"briefTitle":800,"status":108,"phases":4655,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":4656,"interventions":4657},[92],[25],[808,117,178,309,809,524,118,344,121,267],{"nctId":836,"briefTitle":837,"status":195,"phases":4659,"primaryCompletion":839,"completion":840,"start":841,"enrollment":842,"conditions":4660,"interventions":4661},[92],[172],[267,118],{"nctId":4093,"briefTitle":4094,"status":151,"phases":4663,"primaryCompletion":4096,"completion":4097,"start":4098,"enrollment":4099,"conditions":4664,"interventions":4665},[92],[1049],[180,178,344,118,3097],{"nctId":890,"briefTitle":891,"status":108,"phases":4667,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":4668,"interventions":4669},[92],[898],[63,900,901,902,344,118],{"nctId":3607,"briefTitle":3608,"status":108,"phases":4671,"primaryCompletion":3610,"completion":3611,"start":3612,"enrollment":3613,"conditions":4672,"interventions":4673},[92],[262],[117,344,177,345,118,283],{"nctId":4675,"briefTitle":4676,"status":151,"phases":4677,"primaryCompletion":4678,"completion":4679,"start":4680,"enrollment":3654,"conditions":4681,"interventions":4682},"NCT07218809","AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer",[92],"2028-11-17","2030-05-27","2025-12-29",[3865],[3925,4683,118,4684,4685],"Mirvetuximab Soravtansine","Pegylated liposomal Doxorubicin","Topotecan",{"nctId":322,"briefTitle":323,"status":108,"phases":4687,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":4688,"interventions":4689},[92],[330],[97,121,118,332],{"nctId":1083,"briefTitle":1084,"status":108,"phases":4691,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":1088,"conditions":4692,"interventions":4693},[92],[1090],[252,117,344,178,177,345,118],{"nctId":4136,"briefTitle":4137,"status":108,"phases":4695,"primaryCompletion":4139,"completion":660,"start":4140,"enrollment":4141,"conditions":4696,"interventions":4697},[92],[25],[808,118,3097,344,121,4144],{"nctId":359,"briefTitle":360,"status":151,"phases":4699,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":4700,"interventions":4701},[92],[367],[97,180,178,344,118,369],{"nctId":3680,"briefTitle":3681,"status":151,"phases":4703,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":3686,"conditions":4704,"interventions":4705},[92],[25],[808,117,118,3097,283,344,178],{"trials":4707,"activeCount":102},[],{"trials":4709,"activeCount":102},[],{"intervention":180,"totalTrials":434,"cells":4711},{"EARLY_PHASE1":4712,"PHASE1":4714,"PHASE2":4720,"PHASE3":4780,"PHASE4":4858,"NA":4860},{"trials":4713,"activeCount":102},[],{"trials":4715,"activeCount":122,"soonestReadout":1046},[4716],{"nctId":3042,"briefTitle":3043,"status":151,"phases":4717,"primaryCompletion":1046,"completion":1046,"start":3045,"enrollment":2792,"conditions":4718,"interventions":4719},[90],[342],[3048,117,177,344,345,179,180],{"trials":4721,"activeCount":4343,"soonestReadout":4317},[4722,4726,4735,4739,4743,4747,4751,4765,4776],{"nctId":165,"briefTitle":166,"status":151,"phases":4723,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":4724,"interventions":4725},[91],[172],[174,121,117,175,176,97,177,178,179,180],{"nctId":4727,"briefTitle":4728,"status":151,"phases":4729,"primaryCompletion":4730,"completion":4730,"start":4731,"enrollment":4732,"conditions":4733,"interventions":4734},"NCT07098338","A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)",[91],"2029-04-06","2025-08-07",278,[262],[180,3934,808],{"nctId":3927,"briefTitle":3928,"status":151,"phases":4736,"primaryCompletion":3930,"completion":3930,"start":2932,"enrollment":3466,"conditions":4737,"interventions":4738},[90,91],[3932],[180,177,344,345,118,3097,3934],{"nctId":215,"briefTitle":216,"status":151,"phases":4740,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":4741,"interventions":4742},[91],[223],[225,180,162,121,226,227],{"nctId":3224,"briefTitle":3225,"status":151,"phases":4744,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":4745,"interventions":4746},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"nctId":4314,"briefTitle":4315,"status":151,"phases":4748,"primaryCompletion":4317,"completion":4318,"start":4319,"enrollment":4320,"conditions":4749,"interventions":4750},[91],[3220,281],[179,239,3222,180,283,177],{"nctId":4752,"briefTitle":4753,"status":151,"phases":4754,"primaryCompletion":4755,"completion":4755,"start":4756,"enrollment":477,"conditions":4757,"interventions":4762},"NCT07115043","A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors",[90,91],"2029-10-02","2025-07-29",[410,1049,4758,417,4759,993,546,4760,4761],"Squamous Cell Carcinoma (Skin)","Merkel Cell Carcinoma","Gastric Cancer\u002FGastroesophageal Junction Cancer","High Grade Serous Ovarian Carcinoma",[4763,4764],"AZD6750","rilvegostomig",{"nctId":4766,"briefTitle":4767,"status":151,"phases":4768,"primaryCompletion":4769,"completion":4770,"start":4771,"enrollment":2640,"conditions":4772,"interventions":4773},"NCT05702229","Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",[91],"2027-11-30","2029-05-31","2023-01-16",[172],[180,179,4774,4775,225,226,121],"FOLFOX","XELOX",{"nctId":1019,"briefTitle":1020,"status":151,"phases":4777,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":340,"conditions":4778,"interventions":4779},[91],[367,172,651,414,691,1025,281],[252,121,226,179,344,239,180,1027,177],{"trials":4781,"activeCount":1757,"soonestReadout":1046},[4782,4786,4796,4800,4811,4815,4819,4823,4827,4831,4844,4854],{"nctId":273,"briefTitle":274,"status":151,"phases":4783,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":4784,"interventions":4785},[92],[281],[283,177,117,97,180],{"nctId":4787,"briefTitle":4788,"status":151,"phases":4789,"primaryCompletion":4790,"completion":4791,"start":1007,"enrollment":4792,"conditions":4793,"interventions":4794},"NCT06921785","Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma",[92],"2029-03-16","2030-03-15",1220,[3220],[3137,180,239,4795],"Atezolizumab",{"nctId":285,"briefTitle":286,"status":151,"phases":4797,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":4798,"interventions":4799},[92],[293,294],[180,97,176,178,296,121,177,175],{"nctId":4801,"briefTitle":4802,"status":151,"phases":4803,"primaryCompletion":4804,"completion":4805,"start":4806,"enrollment":4807,"conditions":4808,"interventions":4810},"NCT06868277","A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer",[92],"2030-01-17","2030-12-02","2025-04-10",830,[4809],"Carcinoma, Non-Small Cell Lung",[180,178],{"nctId":1043,"briefTitle":1044,"status":108,"phases":4812,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":98,"conditions":4813,"interventions":4814},[92],[1049],[163,180,344,177,1017,345,1051,1052],{"nctId":1054,"briefTitle":1055,"status":151,"phases":4816,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":1059,"conditions":4817,"interventions":4818},[92],[262],[163,180,178],{"nctId":4093,"briefTitle":4094,"status":151,"phases":4820,"primaryCompletion":4096,"completion":4097,"start":4098,"enrollment":4099,"conditions":4821,"interventions":4822},[92],[1049],[180,178,344,118,3097],{"nctId":4146,"briefTitle":4147,"status":151,"phases":4824,"primaryCompletion":4149,"completion":4150,"start":4151,"enrollment":4152,"conditions":4825,"interventions":4826},[92],[4154],[180,178,344,177,345],{"nctId":3649,"briefTitle":3650,"status":151,"phases":4828,"primaryCompletion":3652,"completion":3652,"start":3653,"enrollment":3654,"conditions":4829,"interventions":4830},[92],[281],[180,117,3657],{"nctId":4832,"briefTitle":4833,"status":151,"phases":4834,"primaryCompletion":4835,"completion":4836,"start":4837,"enrollment":4838,"conditions":4839,"interventions":4840},"NCT07431281","Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2",[92],"2029-08-16","2031-10-27","2026-02-03",2130,[172,294,405],[4841,180,4178,121,226,175,4842,4843],"Sonesitatug vedotin","Zolbetuximab","Leucovorin",{"nctId":4845,"briefTitle":4846,"status":108,"phases":4847,"primaryCompletion":4848,"completion":4849,"start":446,"enrollment":4850,"conditions":4851,"interventions":4852},"NCT06109779","Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)",[92],"2029-01-02","2030-05-03",757,[281],[180,121,3657,4853],"S-1 [Tegafur\u002FOteracil\u002Fgimeracil]",{"nctId":359,"briefTitle":360,"status":151,"phases":4855,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":4856,"interventions":4857},[92],[367],[97,180,178,344,118,369],{"trials":4859,"activeCount":102},[],{"trials":4861,"activeCount":102},[],{"intervention":345,"totalTrials":1130,"cells":4863},{"EARLY_PHASE1":4864,"PHASE1":4866,"PHASE2":4901,"PHASE3":4940,"PHASE4":4986,"NA":4988},{"trials":4865,"activeCount":102},[],{"trials":4867,"activeCount":447,"soonestReadout":3122},[4868,4872,4881,4885,4893,4897],{"nctId":3793,"briefTitle":3794,"status":195,"phases":4869,"primaryCompletion":3796,"completion":3796,"start":3797,"enrollment":2783,"conditions":4870,"interventions":4871},[90],[3799],[3801,3802,3803,672,3804],{"nctId":4873,"briefTitle":4874,"status":195,"phases":4875,"primaryCompletion":2169,"completion":2542,"start":4876,"enrollment":4877,"conditions":4878,"interventions":4880},"NCT00502567","A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors",[90],"2005-01",104,[4879],"Advanced Solid Tumor",[3830,4774,345,4615,369],{"nctId":3042,"briefTitle":3043,"status":151,"phases":4882,"primaryCompletion":1046,"completion":1046,"start":3045,"enrollment":2792,"conditions":4883,"interventions":4884},[90],[342],[3048,117,177,344,345,179,180],{"nctId":4886,"briefTitle":4887,"status":443,"phases":4888,"primaryCompletion":2077,"completion":2077,"start":2220,"enrollment":1883,"conditions":4889,"interventions":4891},"NCT00733031","Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918",[90],[4890,3056,157],"Cancer,",[4892,3802,3804],"AZD6918",{"nctId":3119,"briefTitle":3120,"status":108,"phases":4894,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":4895,"interventions":4896},[90],[3127],[117,264,251,980,345,344,283,177,3097,979],{"nctId":3130,"briefTitle":3131,"status":195,"phases":4898,"primaryCompletion":1916,"completion":3133,"start":3134,"enrollment":1428,"conditions":4899,"interventions":4900},[90],[3024,992,3023],[117,3137,177,177,344,344,1017,1017,118,345,177,177],{"trials":4902,"activeCount":1979,"soonestReadout":1007},[4903,4907,4911,4920,4924,4932,4936],{"nctId":3927,"briefTitle":3928,"status":151,"phases":4904,"primaryCompletion":3930,"completion":3930,"start":2932,"enrollment":3466,"conditions":4905,"interventions":4906},[90,91],[3932],[180,177,344,345,118,3097,3934],{"nctId":3258,"briefTitle":3259,"status":108,"phases":4908,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":221,"conditions":4909,"interventions":4910},[91],[992],[117,3137,345,178,344,177],{"nctId":4912,"briefTitle":4913,"status":195,"phases":4914,"primaryCompletion":2252,"completion":4915,"start":4916,"enrollment":4917,"conditions":4918,"interventions":4919},"NCT00372788","AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen",[91],"2008-12","2006-08",88,[1049],[43,345],{"nctId":3980,"briefTitle":3981,"status":151,"phases":4921,"primaryCompletion":338,"completion":338,"start":3983,"enrollment":1120,"conditions":4922,"interventions":4923},[91],[1049],[179,344,345,3934,118],{"nctId":4925,"briefTitle":4926,"status":195,"phases":4927,"primaryCompletion":2056,"completion":2056,"start":2220,"enrollment":4928,"conditions":4929,"interventions":4930},"NCT00745875","ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study",[91],66,[3864,3174],[4931,345],"ZD4054",{"nctId":1004,"briefTitle":1005,"status":108,"phases":4933,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":4934,"interventions":4935},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"nctId":4002,"briefTitle":4003,"status":443,"phases":4937,"primaryCompletion":4005,"completion":4005,"start":4006,"enrollment":434,"conditions":4938,"interventions":4939},[91],[4008],[570,3804,672],{"trials":4941,"activeCount":269,"soonestReadout":3610},[4942,4946,4950,4954,4958,4962,4966,4970,4974,4978,4982],{"nctId":4021,"briefTitle":4022,"status":108,"phases":4943,"primaryCompletion":4024,"completion":4025,"start":4026,"enrollment":4027,"conditions":4944,"interventions":4945},[92],[4029],[179,178,344,118,345],{"nctId":4041,"briefTitle":4042,"status":151,"phases":4947,"primaryCompletion":3323,"completion":4044,"start":4045,"enrollment":4046,"conditions":4948,"interventions":4949},[92],[4029],[808,1012,345,344,177],{"nctId":4050,"briefTitle":4051,"status":108,"phases":4951,"primaryCompletion":4053,"completion":4054,"start":4055,"enrollment":4056,"conditions":4952,"interventions":4953},[92],[4058,4059],[87,1012,345,177,344],{"nctId":1043,"briefTitle":1044,"status":108,"phases":4955,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":98,"conditions":4956,"interventions":4957},[92],[1049],[163,180,344,177,1017,345,1051,1052],{"nctId":4066,"briefTitle":4067,"status":108,"phases":4959,"primaryCompletion":1047,"completion":4069,"start":3644,"enrollment":4070,"conditions":4960,"interventions":4961},[92],[262],[1012,177,344,345],{"nctId":4375,"briefTitle":4376,"status":195,"phases":4963,"primaryCompletion":4378,"completion":4379,"start":4380,"enrollment":4381,"conditions":4964,"interventions":4965},[92],[262],[1013,345,177],{"nctId":3607,"briefTitle":3608,"status":108,"phases":4967,"primaryCompletion":3610,"completion":3611,"start":3612,"enrollment":3613,"conditions":4968,"interventions":4969},[92],[262],[117,344,177,345,118,283],{"nctId":1083,"briefTitle":1084,"status":108,"phases":4971,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":1088,"conditions":4972,"interventions":4973},[92],[1090],[252,117,344,178,177,345,118],{"nctId":4146,"briefTitle":4147,"status":151,"phases":4975,"primaryCompletion":4149,"completion":4150,"start":4151,"enrollment":4152,"conditions":4976,"interventions":4977},[92],[4154],[180,178,344,177,345],{"nctId":334,"briefTitle":335,"status":108,"phases":4979,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":4980,"interventions":4981},[92],[342],[162,177,344,178,345],{"nctId":4169,"briefTitle":4170,"status":151,"phases":4983,"primaryCompletion":4172,"completion":4173,"start":4174,"enrollment":3613,"conditions":4984,"interventions":4985},[92],[4176],[179,345,344,177,4178,4179],{"trials":4987,"activeCount":102},[],{"trials":4989,"activeCount":102},[],{"intervention":178,"totalTrials":520,"cells":4991},{"EARLY_PHASE1":4992,"PHASE1":4994,"PHASE2":4996,"PHASE3":5021,"PHASE4":5071,"NA":5073},{"trials":4993,"activeCount":102},[],{"trials":4995,"activeCount":102},[],{"trials":4997,"activeCount":3887,"soonestReadout":3261},[4998,5013,5017],{"nctId":4999,"briefTitle":5000,"status":151,"phases":5001,"primaryCompletion":5002,"completion":5002,"start":5003,"enrollment":5004,"conditions":5005,"interventions":5012},"NCT06137144","AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.",[90,91],"2029-04-30","2024-01-23",161,[510,5006,5007,5008,5009,5010,5011],"Non-Hodgkin Lymphoma","Hodgkin Lymphoma","Peripheral T-cell Lymphoma (PTCL)","PTCL-NOS","ALCL","AITL",[1038,178],{"nctId":165,"briefTitle":166,"status":151,"phases":5014,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":5015,"interventions":5016},[91],[172],[174,121,117,175,176,97,177,178,179,180],{"nctId":3258,"briefTitle":3259,"status":108,"phases":5018,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":221,"conditions":5019,"interventions":5020},[91],[992],[117,3137,345,178,344,177],{"trials":5022,"activeCount":1757,"soonestReadout":337},[5023,5027,5031,5035,5039,5043,5047,5051,5055,5059,5063,5067],{"nctId":285,"briefTitle":286,"status":151,"phases":5024,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":5025,"interventions":5026},[92],[293,294],[180,97,176,178,296,121,177,175],{"nctId":4021,"briefTitle":4022,"status":108,"phases":5028,"primaryCompletion":4024,"completion":4025,"start":4026,"enrollment":4027,"conditions":5029,"interventions":5030},[92],[4029],[179,178,344,118,345],{"nctId":4801,"briefTitle":4802,"status":151,"phases":5032,"primaryCompletion":4804,"completion":4805,"start":4806,"enrollment":4807,"conditions":5033,"interventions":5034},[92],[4809],[180,178],{"nctId":799,"briefTitle":800,"status":108,"phases":5036,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":5037,"interventions":5038},[92],[25],[808,117,178,309,809,524,118,344,121,267],{"nctId":1054,"briefTitle":1055,"status":151,"phases":5040,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":1059,"conditions":5041,"interventions":5042},[92],[262],[163,180,178],{"nctId":3501,"briefTitle":3502,"status":108,"phases":5044,"primaryCompletion":3504,"completion":3505,"start":3506,"enrollment":3507,"conditions":5045,"interventions":5046},[92],[25],[808,117,121,178],{"nctId":4093,"briefTitle":4094,"status":151,"phases":5048,"primaryCompletion":4096,"completion":4097,"start":4098,"enrollment":4099,"conditions":5049,"interventions":5050},[92],[1049],[180,178,344,118,3097],{"nctId":1083,"briefTitle":1084,"status":108,"phases":5052,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":1088,"conditions":5053,"interventions":5054},[92],[1090],[252,117,344,178,177,345,118],{"nctId":4146,"briefTitle":4147,"status":151,"phases":5056,"primaryCompletion":4149,"completion":4150,"start":4151,"enrollment":4152,"conditions":5057,"interventions":5058},[92],[4154],[180,178,344,177,345],{"nctId":334,"briefTitle":335,"status":108,"phases":5060,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":5061,"interventions":5062},[92],[342],[162,177,344,178,345],{"nctId":359,"briefTitle":360,"status":151,"phases":5064,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":5065,"interventions":5066},[92],[367],[97,180,178,344,118,369],{"nctId":3680,"briefTitle":3681,"status":151,"phases":5068,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":3686,"conditions":5069,"interventions":5070},[92],[25],[808,117,118,3097,283,344,178],{"trials":5072,"activeCount":102},[],{"trials":5074,"activeCount":102},[],{"intervention":179,"totalTrials":520,"cells":5076},{"EARLY_PHASE1":5077,"PHASE1":5079,"PHASE2":5085,"PHASE3":5132,"PHASE4":5173,"NA":5175},{"trials":5078,"activeCount":102},[],{"trials":5080,"activeCount":122,"soonestReadout":1046},[5081],{"nctId":3042,"briefTitle":3043,"status":151,"phases":5082,"primaryCompletion":1046,"completion":1046,"start":3045,"enrollment":2792,"conditions":5083,"interventions":5084},[90],[342],[3048,117,177,344,345,179,180],{"trials":5086,"activeCount":4343,"soonestReadout":4317},[5087,5095,5099,5103,5107,5111,5115,5124,5128],{"nctId":5088,"briefTitle":5089,"status":108,"phases":5090,"primaryCompletion":5091,"completion":5092,"start":3372,"enrollment":1543,"conditions":5093,"interventions":5094},"NCT06943833","A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)",[91],"2028-03-13","2029-03-13",[3553],[179],{"nctId":165,"briefTitle":166,"status":151,"phases":5096,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":5097,"interventions":5098},[91],[172],[174,121,117,175,176,97,177,178,179,180],{"nctId":3936,"briefTitle":3937,"status":151,"phases":5100,"primaryCompletion":3939,"completion":3939,"start":3940,"enrollment":3941,"conditions":5101,"interventions":5102},[91],[3943,3944,3945,3946,3947],[179,177,344,118,3949],{"nctId":3224,"briefTitle":3225,"status":151,"phases":5104,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":5105,"interventions":5106},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"nctId":4314,"briefTitle":4315,"status":151,"phases":5108,"primaryCompletion":4317,"completion":4318,"start":4319,"enrollment":4320,"conditions":5109,"interventions":5110},[91],[3220,281],[179,239,3222,180,283,177],{"nctId":3980,"briefTitle":3981,"status":151,"phases":5112,"primaryCompletion":338,"completion":338,"start":3983,"enrollment":1120,"conditions":5113,"interventions":5114},[91],[1049],[179,344,345,3934,118],{"nctId":5116,"briefTitle":5117,"status":151,"phases":5118,"primaryCompletion":2835,"completion":5119,"start":301,"enrollment":2187,"conditions":5120,"interventions":5122},"NCT06792695","A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer",[91],"2028-06-07",[5121],"Metastatic Colorectal Cancer",[179,5123,239],"FOLFIRI",{"nctId":4766,"briefTitle":4767,"status":151,"phases":5125,"primaryCompletion":4769,"completion":4770,"start":4771,"enrollment":2640,"conditions":5126,"interventions":5127},[91],[172],[180,179,4774,4775,225,226,121],{"nctId":1019,"briefTitle":1020,"status":151,"phases":5129,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":340,"conditions":5130,"interventions":5131},[91],[367,172,651,414,691,1025,281],[252,121,226,179,344,239,180,1027,177],{"trials":5133,"activeCount":723,"soonestReadout":4172},[5134,5138,5150,5158,5169],{"nctId":4021,"briefTitle":4022,"status":108,"phases":5135,"primaryCompletion":4024,"completion":4025,"start":4026,"enrollment":4027,"conditions":5136,"interventions":5137},[92],[4029],[179,178,344,118,345],{"nctId":5139,"briefTitle":5140,"status":151,"phases":5141,"primaryCompletion":5142,"completion":5143,"start":5144,"enrollment":5145,"conditions":5146,"interventions":5148},"NCT06129864","A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy",[92],"2028-04-18","2030-09-12","2023-12-14",1145,[5147],"Locally Advanced Head and Neck Squamous Cell Carcinoma",[5149],"volrustomig",{"nctId":5151,"briefTitle":5152,"status":151,"phases":5153,"primaryCompletion":5154,"completion":3684,"start":2384,"enrollment":5155,"conditions":5156,"interventions":5157},"NCT06079671","Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)",[92],"2027-11-26",800,[3553],[179],{"nctId":5159,"briefTitle":5160,"status":108,"phases":5161,"primaryCompletion":5162,"completion":5163,"start":1794,"enrollment":5164,"conditions":5165,"interventions":5167},"NCT07000149","A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC",[92],"2030-02-21","2032-07-29",1116,[5166],"Advanced Clear Cell Renal Cell Carcinoma",[179,5168,4178,4179],"Casdatifan",{"nctId":4169,"briefTitle":4170,"status":151,"phases":5170,"primaryCompletion":4172,"completion":4173,"start":4174,"enrollment":3613,"conditions":5171,"interventions":5172},[92],[4176],[179,345,344,177,4178,4179],{"trials":5174,"activeCount":102},[],{"trials":5176,"activeCount":102},[],{"intervention":3137,"totalTrials":2827,"cells":5178},{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5232,"PHASE3":5274,"PHASE4":5346,"NA":5348},{"trials":5180,"activeCount":102},[],{"trials":5182,"activeCount":122,"soonestReadout":5202},[5183,5194,5198,5207,5217,5228],{"nctId":5184,"briefTitle":5185,"status":195,"phases":5186,"primaryCompletion":5187,"completion":5187,"start":5188,"enrollment":5189,"conditions":5190,"interventions":5193},"NCT02141347","Ph1 to Assess Safety, Tolerability of Tremelimumab\u002F Tremelimumab+MEDI4736 in Japanese Solid Malignancies\u002F Mesothelioma",[90],"2017-01-27","2014-05-22",65,[5191,5192],"Part A and B: Advanced Solid Malignancies","Part C: Malignant Mesothelioma",[3137,82],{"nctId":3018,"briefTitle":3019,"status":195,"phases":5195,"primaryCompletion":3021,"completion":3021,"start":2781,"enrollment":579,"conditions":5196,"interventions":5197},[90],[3023,3024,3025,249,3026,3027,3028,3029,3030,3031],[3033,3034,3035,3036,3037,900,3038,3039,3040],{"nctId":5199,"briefTitle":5200,"status":151,"phases":5201,"primaryCompletion":5202,"completion":5202,"start":3114,"enrollment":1448,"conditions":5203,"interventions":5204},"NCT07391670","A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab",[90],"2027-08-30",[466],[5205,5206,3137],"SC durvalumab + rHu","IV durvalumab",{"nctId":5208,"briefTitle":5209,"status":195,"phases":5210,"primaryCompletion":5211,"completion":5212,"start":5213,"enrollment":5214,"conditions":5215,"interventions":5216},"NCT01938612","A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours",[90],"2018-03-01","2020-11-25","2013-09-12",269,[4217],[82,3038],{"nctId":5218,"briefTitle":5219,"status":195,"phases":5220,"primaryCompletion":5221,"completion":5222,"start":5223,"enrollment":3180,"conditions":5224,"interventions":5227},"NCT02586987","A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours",[90],"2018-07-25","2019-09-20","2015-12-28",[3174,410,5225,3106,25,5226,691,281],"Head and Neck Carcinoma","Pancreatic Adenocarcinoma",[68,82,3137],{"nctId":3130,"briefTitle":3131,"status":195,"phases":5229,"primaryCompletion":1916,"completion":3133,"start":3134,"enrollment":1428,"conditions":5230,"interventions":5231},[90],[3024,992,3023],[117,3137,177,177,344,344,1017,1017,118,345,177,177],{"trials":5233,"activeCount":447,"soonestReadout":1840},[5234,5244,5248,5259,5263],{"nctId":5235,"briefTitle":5236,"status":195,"phases":5237,"primaryCompletion":5238,"completion":4106,"start":4537,"enrollment":5239,"conditions":5240,"interventions":5242},"NCT02319044","Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w\u002F Tremelimumab Squamous Cell Carcinoma of the Head and Neck",[91],"2016-09-26",267,[5241],"Recurrent\u002FMetastatic Squamous Cell Carcinoma of Head & Neck",[82,3137,5243],"MEDI4736 + Tremelimumab",{"nctId":3214,"briefTitle":3215,"status":108,"phases":5245,"primaryCompletion":1840,"completion":1892,"start":3217,"enrollment":3218,"conditions":5246,"interventions":5247},[91],[3220],[117,3137,3222],{"nctId":5249,"briefTitle":5250,"status":195,"phases":5251,"primaryCompletion":5252,"completion":5252,"start":5253,"enrollment":579,"conditions":5254,"interventions":5256},"NCT02179671","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",[91],"2016-06-11","2014-07-25",[5255],"Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)",[1013,5257,5258,3137],"AZD9291","Selumetinib+Docetaxel",{"nctId":3258,"briefTitle":3259,"status":108,"phases":5260,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":221,"conditions":5261,"interventions":5262},[91],[992],[117,3137,345,178,344,177],{"nctId":5264,"briefTitle":5265,"status":195,"phases":5266,"primaryCompletion":5267,"completion":5268,"start":588,"enrollment":5269,"conditions":5270,"interventions":5272},"NCT02499328","Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck",[90,91],"2020-02-28","2025-10-08",340,[5271],"Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck",[571,82,5273,3038],"AZD5069",{"trials":5275,"activeCount":1757,"soonestReadout":81},[5276,5280,5284,5288,5292,5296,5308,5318,5322,5326,5330,5334,5338,5342],{"nctId":3319,"briefTitle":3320,"status":108,"phases":5277,"primaryCompletion":3322,"completion":3323,"start":3324,"enrollment":3325,"conditions":5278,"interventions":5279},[92],[3327],[117,3137],{"nctId":4787,"briefTitle":4788,"status":151,"phases":5281,"primaryCompletion":4790,"completion":4791,"start":1007,"enrollment":4792,"conditions":5282,"interventions":5283},[92],[3220],[3137,180,239,4795],{"nctId":4013,"briefTitle":4014,"status":108,"phases":5285,"primaryCompletion":3428,"completion":660,"start":4016,"enrollment":4017,"conditions":5286,"interventions":5287},[92],[1025],[82,3137,177,344,283],{"nctId":3369,"briefTitle":3370,"status":151,"phases":5289,"primaryCompletion":3372,"completion":3372,"start":3373,"enrollment":3374,"conditions":5290,"interventions":5291},[92],[3220],[117,3137],{"nctId":3425,"briefTitle":3426,"status":108,"phases":5293,"primaryCompletion":3428,"completion":660,"start":3429,"enrollment":3430,"conditions":5294,"interventions":5295},[92],[3432],[117,3137,344,177,1017],{"nctId":79,"briefTitle":80,"status":108,"phases":5297,"primaryCompletion":81,"completion":660,"start":5298,"enrollment":5299,"conditions":5300,"interventions":5302},[92],"2015-07-21",1118,[5301],"Non-Small-Cell Lung Carcinoma NSCLC",[82,5303,3878,5304,5305,5306,5307,3137],"MEDI4736 (Durvalumab)+Tremelimumab","Gemcitabine + Cisplatin","Gemcitabine + Carboplatin","Pemetrexed + Cisplatin","Pemetrexed + Carboplatin",{"nctId":5309,"briefTitle":5310,"status":195,"phases":5311,"primaryCompletion":5312,"completion":3071,"start":5313,"enrollment":2497,"conditions":5314,"interventions":5316},"NCT02352948","A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",[92],"2018-02-09","2015-01-13",[5315],"Non - Small Cell Lung Cancer NSCLC",[82,1051,283,5317,82,3038],"Erlotinib",{"nctId":4103,"briefTitle":4104,"status":195,"phases":5319,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":5320,"interventions":5321},[92],[4111],[82,3137,4113,4114,296,177,344],{"nctId":3528,"briefTitle":3529,"status":108,"phases":5323,"primaryCompletion":3382,"completion":3531,"start":1217,"enrollment":3532,"conditions":5324,"interventions":5325},[92],[420],[117,3137],{"nctId":3566,"briefTitle":3567,"status":108,"phases":5327,"primaryCompletion":3569,"completion":168,"start":1217,"enrollment":3570,"conditions":5328,"interventions":5329},[92],[3572,3573],[117,3137,3575,3576],{"nctId":3621,"briefTitle":3622,"status":108,"phases":5331,"primaryCompletion":3624,"completion":3625,"start":2713,"enrollment":3626,"conditions":5332,"interventions":5333},[92],[3220],[117,3137,3137,3629,117,117],{"nctId":3659,"briefTitle":3660,"status":108,"phases":5335,"primaryCompletion":337,"completion":3662,"start":3663,"enrollment":3664,"conditions":5336,"interventions":5337},[92],[567],[117,3137,3667],{"nctId":3690,"briefTitle":3691,"status":108,"phases":5339,"primaryCompletion":3693,"completion":245,"start":3694,"enrollment":3695,"conditions":5340,"interventions":5341},[92],[3220],[3137,117,3222],{"nctId":3699,"briefTitle":3700,"status":108,"phases":5343,"primaryCompletion":3702,"completion":3703,"start":3704,"enrollment":3705,"conditions":5344,"interventions":5345},[92],[3707],[117,3137,3709,3353,3354,3356,3355],{"trials":5347,"activeCount":102},[],{"trials":5349,"activeCount":102},[5350],{"nctId":3776,"briefTitle":3777,"status":958,"phases":5351,"conditions":5352,"interventions":5353},[],[3780],[117,3137],{"intervention":1012,"totalTrials":544,"cells":5355},{"EARLY_PHASE1":5356,"PHASE1":5358,"PHASE2":5381,"PHASE3":5448,"PHASE4":5494,"NA":5505},{"trials":5357,"activeCount":102},[],{"trials":5359,"activeCount":122,"soonestReadout":5364},[5360,5371],{"nctId":5361,"briefTitle":5362,"status":151,"phases":5363,"primaryCompletion":5364,"completion":5364,"start":678,"enrollment":5365,"conditions":5366,"interventions":5369},"NCT05647122","First in Human Study of AZD9592 in Solid Tumors",[90],"2028-08-02",403,[498,5367,4258,5368],"Carcinoma Non-small Cell Lung","Colorectal Neoplasms",[5370,1012,226,4843,239],"AZD9592",{"nctId":5372,"briefTitle":5373,"status":195,"phases":5374,"primaryCompletion":5375,"completion":5376,"start":5377,"enrollment":1979,"conditions":5378,"interventions":5379},"NCT03463525","Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases",[90],"2020-03-19","2020-10-05","2018-10-24",[1049],[1012,5380],"[11C]osimertinib",{"trials":5382,"activeCount":1039,"soonestReadout":2836},[5383,5392,5403,5412,5420,5428,5436,5444],{"nctId":5384,"briefTitle":5385,"status":108,"phases":5386,"primaryCompletion":2836,"completion":660,"start":5387,"enrollment":5388,"conditions":5389,"interventions":5390},"NCT03778229","Osimertinib Plus Savolitinib in EGFRm+\u002FMET+ NSCLC Following Prior Osimertinib",[91],"2019-01-09",367,[4058],[5391,3488],"osimertinib",{"nctId":5393,"briefTitle":5394,"status":108,"phases":5395,"primaryCompletion":5396,"completion":5397,"start":5398,"enrollment":3093,"conditions":5399,"interventions":5400},"NCT06194448","To Evaluate the Efficacy\u002FSafety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations",[91],"2026-07-07","2027-07-07","2024-04-21",[3174],[1012,5401,5402],"Cisplatin or Carboplatin; Pemetrexed or Paclitaxel","Radiation",{"nctId":5404,"briefTitle":5405,"status":195,"phases":5406,"primaryCompletion":5407,"completion":5407,"start":5408,"enrollment":662,"conditions":5409,"interventions":5411},"NCT03239340","A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib",[91],"2023-09-19","2018-05-30",[5410],"EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[1012],{"nctId":5413,"briefTitle":5414,"status":443,"phases":5415,"primaryCompletion":5416,"completion":5416,"start":5417,"enrollment":1979,"conditions":5418,"interventions":5419},"NCT05215951","Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC",[91],"2023-03-09","2022-01-19",[3174],[5391],{"nctId":5421,"briefTitle":5422,"status":108,"phases":5423,"primaryCompletion":3474,"completion":3474,"start":5424,"enrollment":5425,"conditions":5426,"interventions":5427},"NCT05546866","Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm",[91],"2023-02-09",51,[1049],[1012],{"nctId":5429,"briefTitle":5430,"status":151,"phases":5431,"primaryCompletion":5432,"completion":5432,"start":5433,"enrollment":477,"conditions":5434,"interventions":5435},"NCT07295821","Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study",[91],"2029-05-30","2026-04-01",[3174],[1012],{"nctId":5437,"briefTitle":5438,"status":108,"phases":5439,"primaryCompletion":1022,"completion":1022,"start":5440,"enrollment":477,"conditions":5441,"interventions":5442},"NCT05801029","A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations",[91],"2023-07-18",[1921],[1012,5443],"Amivantamab",{"nctId":1004,"briefTitle":1005,"status":108,"phases":5445,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":5446,"interventions":5447},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"trials":5449,"activeCount":1855,"soonestReadout":5466},[5450,5454,5458,5462,5472,5482,5486],{"nctId":4041,"briefTitle":4042,"status":151,"phases":5451,"primaryCompletion":3323,"completion":4044,"start":4045,"enrollment":4046,"conditions":5452,"interventions":5453},[92],[4029],[808,1012,345,344,177],{"nctId":4050,"briefTitle":4051,"status":108,"phases":5455,"primaryCompletion":4053,"completion":4054,"start":4055,"enrollment":4056,"conditions":5456,"interventions":5457},[92],[4058,4059],[87,1012,345,177,344],{"nctId":4066,"briefTitle":4067,"status":108,"phases":5459,"primaryCompletion":1047,"completion":4069,"start":3644,"enrollment":4070,"conditions":5460,"interventions":5461},[92],[262],[1012,177,344,345],{"nctId":5463,"briefTitle":5464,"status":108,"phases":5465,"primaryCompletion":5466,"completion":5467,"start":5468,"enrollment":5469,"conditions":5470,"interventions":5471},"NCT04035486","A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)",[92],"2023-04-03","2026-12-22","2019-07-02",587,[262],[1012,3235,3234],{"nctId":5473,"briefTitle":5474,"status":108,"phases":5475,"primaryCompletion":5476,"completion":5477,"start":5478,"enrollment":5479,"conditions":5480,"interventions":5481},"NCT05120349","A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection",[92],"2027-08-02","2032-11-01","2022-02-21",390,[262],[1012],{"nctId":1063,"briefTitle":1064,"status":151,"phases":5483,"primaryCompletion":1066,"completion":1067,"start":1068,"enrollment":1069,"conditions":5484,"interventions":5485},[92],[1049],[1012,163],{"nctId":5487,"briefTitle":5488,"status":108,"phases":5489,"primaryCompletion":5490,"completion":5490,"start":5491,"enrollment":1543,"conditions":5492,"interventions":5493},"NCT05629234","Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)",[92],"2027-02-22","2023-05-08",[556],[1012],{"trials":5495,"activeCount":102},[5496],{"nctId":5497,"briefTitle":5498,"status":195,"phases":5499,"primaryCompletion":5500,"completion":5500,"start":5501,"enrollment":477,"conditions":5502,"interventions":5504},"NCT03853551","Osimertinib Study in Indian Patients",[93],"2020-04-15","2019-04-18",[5503],"Non Small Cell Lung Cancer (NSCLC)",[1012],{"trials":5506,"activeCount":122,"soonestReadout":5520},[5507,5516,5525],{"nctId":5508,"briefTitle":5509,"status":195,"phases":5510,"primaryCompletion":5511,"completion":5511,"start":5512,"enrollment":3172,"conditions":5513,"interventions":5515},"NCT03133234","Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC",[],"2017-09-13","2017-05-23",[5514],"T790M Positive NSCLC Patients",[5391],{"nctId":5517,"briefTitle":5518,"status":108,"phases":5519,"primaryCompletion":5520,"completion":5520,"start":5521,"enrollment":5522,"conditions":5523,"interventions":5524},"NCT05103605","Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations",[],"2026-01-15","2021-05-12",274,[3864],[1012],{"nctId":5526,"briefTitle":5527,"status":195,"phases":5528,"primaryCompletion":5529,"completion":5529,"start":5530,"enrollment":5531,"conditions":5532,"interventions":5533},"NCT03219970","Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.",[],"2020-10-28","2017-09-05",156,[1049],[1012],{"intervention":121,"totalTrials":486,"cells":5535},{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5548,"PHASE3":5581,"PHASE4":5621,"NA":5623},{"trials":5537,"activeCount":102},[],{"trials":5539,"activeCount":122,"soonestReadout":110},[5540,5544],{"nctId":106,"briefTitle":107,"status":108,"phases":5541,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":5542,"interventions":5543},[90],[115],[97,117,118,119,120,53,121],{"nctId":4228,"briefTitle":4229,"status":195,"phases":5545,"primaryCompletion":2056,"completion":2570,"start":2151,"enrollment":1638,"conditions":5546,"interventions":5547},[90],[172],[268,177,4233,177,121],{"trials":5549,"activeCount":1979,"soonestReadout":218},[5550,5554,5558,5566,5570,5574],{"nctId":165,"briefTitle":166,"status":151,"phases":5551,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":5552,"interventions":5553},[91],[172],[174,121,117,175,176,97,177,178,179,180],{"nctId":215,"briefTitle":216,"status":151,"phases":5555,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":5556,"interventions":5557},[91],[223],[225,180,162,121,226,227],{"nctId":5559,"briefTitle":5560,"status":195,"phases":5561,"primaryCompletion":5562,"completion":2507,"start":5563,"enrollment":4307,"conditions":5564,"interventions":5565},"NCT00514761","Phase II Efficacy Study of AZD6244 in Colorectal Cancer",[91],"2007-06","2006-09",[5121],[43,121],{"nctId":4766,"briefTitle":4767,"status":151,"phases":5567,"primaryCompletion":4769,"completion":4770,"start":4771,"enrollment":2640,"conditions":5568,"interventions":5569},[91],[172],[180,179,4774,4775,225,226,121],{"nctId":1019,"briefTitle":1020,"status":151,"phases":5571,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":340,"conditions":5572,"interventions":5573},[91],[367,172,651,414,691,1025,281],[252,121,226,179,344,239,180,1027,177],{"nctId":5575,"briefTitle":5576,"status":195,"phases":5577,"primaryCompletion":2251,"completion":2086,"start":4916,"enrollment":3476,"conditions":5578,"interventions":5579},"NCT00372944","AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy",[91],[415],[43,5580],"capecitabine",{"trials":5582,"activeCount":370,"soonestReadout":325},[5583,5587,5591,5595,5599,5603,5607,5611],{"nctId":285,"briefTitle":286,"status":151,"phases":5584,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":5585,"interventions":5586},[92],[293,294],[180,97,176,178,296,121,177,175],{"nctId":799,"briefTitle":800,"status":108,"phases":5588,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":5589,"interventions":5590},[92],[25],[808,117,178,309,809,524,118,344,121,267],{"nctId":3501,"briefTitle":3502,"status":108,"phases":5592,"primaryCompletion":3504,"completion":3505,"start":3506,"enrollment":3507,"conditions":5593,"interventions":5594},[92],[25],[808,117,121,178],{"nctId":322,"briefTitle":323,"status":108,"phases":5596,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":5597,"interventions":5598},[92],[330],[97,121,118,332],{"nctId":4136,"briefTitle":4137,"status":108,"phases":5600,"primaryCompletion":4139,"completion":660,"start":4140,"enrollment":4141,"conditions":5601,"interventions":5602},[92],[25],[808,118,3097,344,121,4144],{"nctId":4832,"briefTitle":4833,"status":151,"phases":5604,"primaryCompletion":4835,"completion":4836,"start":4837,"enrollment":4838,"conditions":5605,"interventions":5606},[92],[172,294,405],[4841,180,4178,121,226,175,4842,4843],{"nctId":4845,"briefTitle":4846,"status":108,"phases":5608,"primaryCompletion":4848,"completion":4849,"start":446,"enrollment":4850,"conditions":5609,"interventions":5610},[92],[281],[180,121,3657,4853],{"nctId":5612,"briefTitle":5613,"status":108,"phases":5614,"primaryCompletion":5615,"completion":2288,"start":5616,"enrollment":5617,"conditions":5618,"interventions":5619},"NCT05104866","A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)",[92],"2024-07-24","2021-10-18",732,[25],[808,121,283,5620,1051],"Eribulin",{"trials":5622,"activeCount":102},[],{"trials":5624,"activeCount":102},[],{"intervention":239,"totalTrials":520,"cells":5626},{"EARLY_PHASE1":5627,"PHASE1":5629,"PHASE2":5642,"PHASE3":5679,"PHASE4":5707,"NA":5709},{"trials":5628,"activeCount":102},[],{"trials":5630,"activeCount":122,"soonestReadout":5364},[5631,5638],{"nctId":5632,"briefTitle":5633,"status":195,"phases":5634,"primaryCompletion":2077,"completion":2057,"start":2524,"enrollment":1336,"conditions":5635,"interventions":5637},"NCT00710268","Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours",[90],[5636],"Neoplasm Metastasis",[48,239],{"nctId":5361,"briefTitle":5362,"status":151,"phases":5639,"primaryCompletion":5364,"completion":5364,"start":678,"enrollment":5365,"conditions":5640,"interventions":5641},[90],[498,5367,4258,5368],[5370,1012,226,4843,239],{"trials":5643,"activeCount":1855,"soonestReadout":600},[5644,5648,5655,5659,5663,5667,5671,5675],{"nctId":597,"briefTitle":598,"status":108,"phases":5645,"primaryCompletion":600,"completion":601,"start":602,"enrollment":603,"conditions":5646,"interventions":5647},[90,91],[605,606,607,608],[267,82,239],{"nctId":5649,"briefTitle":5650,"status":195,"phases":5651,"primaryCompletion":2169,"completion":2350,"start":4284,"enrollment":5652,"conditions":5653,"interventions":5654},"NCT00278889","Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)",[91],215,[691],[3830,296,4843,175,239],{"nctId":3177,"briefTitle":3178,"status":108,"phases":5656,"primaryCompletion":3123,"completion":3123,"start":1755,"enrollment":3180,"conditions":5657,"interventions":5658},[91],[3182],[117,239],{"nctId":3917,"briefTitle":3918,"status":151,"phases":5660,"primaryCompletion":3920,"completion":3920,"start":3921,"enrollment":318,"conditions":5661,"interventions":5662},[90,91],[414,3923,367],[3925,1959,239,344,159],{"nctId":229,"briefTitle":230,"status":108,"phases":5664,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":5665,"interventions":5666},[91],[237],[97,239],{"nctId":4314,"briefTitle":4315,"status":151,"phases":5668,"primaryCompletion":4317,"completion":4318,"start":4319,"enrollment":4320,"conditions":5669,"interventions":5670},[91],[3220,281],[179,239,3222,180,283,177],{"nctId":5116,"briefTitle":5117,"status":151,"phases":5672,"primaryCompletion":2835,"completion":5119,"start":301,"enrollment":2187,"conditions":5673,"interventions":5674},[91],[5121],[179,5123,239],{"nctId":1019,"briefTitle":1020,"status":151,"phases":5676,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":340,"conditions":5677,"interventions":5678},[91],[367,172,651,414,691,1025,281],[252,121,226,179,344,239,180,1027,177],{"trials":5680,"activeCount":1979,"soonestReadout":3559},[5681,5685,5689,5693,5697],{"nctId":4787,"briefTitle":4788,"status":151,"phases":5682,"primaryCompletion":4790,"completion":4791,"start":1007,"enrollment":4792,"conditions":5683,"interventions":5684},[92],[3220],[3137,180,239,4795],{"nctId":777,"briefTitle":778,"status":108,"phases":5686,"primaryCompletion":780,"completion":398,"start":781,"enrollment":782,"conditions":5687,"interventions":5688},[92],[784],[239,117,267,786,787],{"nctId":3556,"briefTitle":3557,"status":108,"phases":5690,"primaryCompletion":3559,"completion":3560,"start":3561,"enrollment":3562,"conditions":5691,"interventions":5692},[92],[3220],[117,239],{"nctId":3600,"briefTitle":3601,"status":108,"phases":5694,"primaryCompletion":1647,"completion":2835,"start":462,"enrollment":3603,"conditions":5695,"interventions":5696},[92],[3220],[117,239],{"nctId":5698,"briefTitle":5699,"status":195,"phases":5700,"primaryCompletion":5701,"completion":5702,"start":5703,"enrollment":5704,"conditions":5705,"interventions":5706},"NCT00384176","First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX",[91,92],"2009-11-15","2015-08-19","2006-08-30",1814,[691],[268,239,296,4843,175],{"trials":5708,"activeCount":102},[],{"trials":5710,"activeCount":102},[],{"intervention":283,"totalTrials":554,"cells":5712},{"EARLY_PHASE1":5713,"PHASE1":5715,"PHASE2":5760,"PHASE3":5800,"PHASE4":5834,"NA":5836},{"trials":5714,"activeCount":102},[],{"trials":5716,"activeCount":122,"soonestReadout":3122},[5717,5721,5730,5734,5738,5746,5750,5756],{"nctId":3793,"briefTitle":3794,"status":195,"phases":5718,"primaryCompletion":3796,"completion":3796,"start":3797,"enrollment":2783,"conditions":5719,"interventions":5720},[90],[3799],[3801,3802,3803,672,3804],{"nctId":5722,"briefTitle":5723,"status":195,"phases":5724,"primaryCompletion":2736,"completion":2481,"start":5725,"enrollment":5726,"conditions":5727,"interventions":5729},"NCT00515866","Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer",[90],"2007-08",68,[5728],"Pancreatic Neoplasms",[3877,283],{"nctId":4201,"briefTitle":4202,"status":443,"phases":5731,"primaryCompletion":2560,"completion":2560,"start":4204,"enrollment":1039,"conditions":5732,"interventions":5733},[90],[4206],[177,283,68],{"nctId":4886,"briefTitle":4887,"status":443,"phases":5735,"primaryCompletion":2077,"completion":2077,"start":2220,"enrollment":1883,"conditions":5736,"interventions":5737},[90],[4890,3056,157],[4892,3802,3804],{"nctId":5739,"briefTitle":5740,"status":195,"phases":5741,"primaryCompletion":2243,"completion":2243,"start":5742,"enrollment":2069,"conditions":5743,"interventions":5744},"NCT00413686","Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies",[90],"2006-12",[3056],[5745,283],"AZD7762",{"nctId":3087,"briefTitle":3088,"status":195,"phases":5747,"primaryCompletion":3090,"completion":3091,"start":3092,"enrollment":3093,"conditions":5748,"interventions":5749},[90],[498],[571,117,177,3096,344,283,3097],{"nctId":5751,"briefTitle":5752,"status":443,"phases":5753,"primaryCompletion":2433,"completion":2433,"start":2068,"enrollment":1130,"conditions":5754,"interventions":5755},"NCT00937664","Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine",[90],[556,3056,157],[5745,3802],{"nctId":3119,"briefTitle":3120,"status":108,"phases":5757,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":5758,"interventions":5759},[90],[3127],[117,264,251,980,345,344,283,177,3097,979],{"trials":5761,"activeCount":3887,"soonestReadout":1964},[5762,5766,5776,5780,5784,5788,5792],{"nctId":3905,"briefTitle":3906,"status":195,"phases":5763,"primaryCompletion":3908,"completion":3909,"start":3910,"enrollment":29,"conditions":5764,"interventions":5765},[91],[3912],[3914,118,344,283,3915],{"nctId":5767,"briefTitle":5768,"status":151,"phases":5769,"primaryCompletion":5770,"completion":1952,"start":1372,"enrollment":2289,"conditions":5771,"interventions":5773},"NCT06219941","AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2",[91],"2026-08-11",[172,4612,281,5772],"Pancreatic Ductal Adenocarcinoma",[225,226,4843,5774,4615,5775,283],"l-leucovorin","Nanoliposomal Irinotecan",{"nctId":4294,"briefTitle":4295,"status":195,"phases":5777,"primaryCompletion":4297,"completion":4298,"start":4299,"enrollment":2811,"conditions":5778,"interventions":5779},[91],[403],[283,177,1013],{"nctId":4314,"briefTitle":4315,"status":151,"phases":5781,"primaryCompletion":4317,"completion":4318,"start":4319,"enrollment":4320,"conditions":5782,"interventions":5783},[91],[3220,281],[179,239,3222,180,283,177],{"nctId":3275,"briefTitle":3276,"status":108,"phases":5785,"primaryCompletion":1964,"completion":130,"start":3278,"enrollment":3279,"conditions":5786,"interventions":5787},[91],[3281],[3233,117,283,3097],{"nctId":3987,"briefTitle":3988,"status":195,"phases":5789,"completion":2524,"start":3990,"enrollment":3717,"conditions":5790,"interventions":5791},[91],[992],[1013,283,344],{"nctId":5793,"briefTitle":5794,"status":195,"phases":5795,"completion":5796,"start":5797,"enrollment":1864,"conditions":5798,"interventions":5799},"NCT00234416","IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer",[90,91],"2005-03","2002-08",[415],[1013,283],{"trials":5801,"activeCount":1855,"soonestReadout":3428},[5802,5806,5810,5814,5818,5822,5826,5830],{"nctId":273,"briefTitle":274,"status":151,"phases":5803,"primaryCompletion":276,"completion":277,"start":278,"enrollment":279,"conditions":5804,"interventions":5805},[92],[281],[283,177,117,97,180],{"nctId":4013,"briefTitle":4014,"status":108,"phases":5807,"primaryCompletion":3428,"completion":660,"start":4016,"enrollment":4017,"conditions":5808,"interventions":5809},[92],[1025],[82,3137,177,344,283],{"nctId":5309,"briefTitle":5310,"status":195,"phases":5811,"primaryCompletion":5312,"completion":3071,"start":5313,"enrollment":2497,"conditions":5812,"interventions":5813},[92],[5315],[82,1051,283,5317,82,3038],{"nctId":3578,"briefTitle":3579,"status":151,"phases":5815,"primaryCompletion":1371,"completion":1371,"start":3581,"enrollment":3000,"conditions":5816,"interventions":5817},[92],[664,3583,3584,3585,309,177,283],[117,3584,3585,309,177,117,283,177],{"nctId":3588,"briefTitle":3589,"status":108,"phases":5819,"primaryCompletion":1068,"completion":130,"start":3591,"enrollment":3592,"conditions":5820,"interventions":5821},[92],[567],[117,177,283],{"nctId":3607,"briefTitle":3608,"status":108,"phases":5823,"primaryCompletion":3610,"completion":3611,"start":3612,"enrollment":3613,"conditions":5824,"interventions":5825},[92],[262],[117,344,177,345,118,283],{"nctId":3680,"briefTitle":3681,"status":151,"phases":5827,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":3686,"conditions":5828,"interventions":5829},[92],[25],[808,117,118,3097,283,344,178],{"nctId":5612,"briefTitle":5613,"status":108,"phases":5831,"primaryCompletion":5615,"completion":2288,"start":5616,"enrollment":5617,"conditions":5832,"interventions":5833},[92],[25],[808,121,283,5620,1051],{"trials":5835,"activeCount":102},[],{"trials":5837,"activeCount":102},[],{"intervention":119,"totalTrials":1336,"cells":5839},{"EARLY_PHASE1":5840,"PHASE1":5842,"PHASE2":5912,"PHASE3":5928,"PHASE4":5988,"NA":5990},{"trials":5841,"activeCount":102},[],{"trials":5843,"activeCount":3887,"soonestReadout":110},[5844,5854,5858,5862,5871,5880,5888,5892,5902],{"nctId":5845,"briefTitle":5846,"status":151,"phases":5847,"primaryCompletion":5848,"completion":5848,"start":5849,"enrollment":2069,"conditions":5850,"interventions":5852},"NCT07241065","A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants",[90],"2026-06-17","2026-03-19",[5851],"Healthy Participants",[5853,119],"Dextromethorphan",{"nctId":106,"briefTitle":107,"status":108,"phases":5855,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":5856,"interventions":5857},[90],[115],[97,117,118,119,120,53,121],{"nctId":4486,"briefTitle":4487,"status":195,"phases":5859,"primaryCompletion":910,"completion":910,"start":4489,"enrollment":486,"conditions":5860,"interventions":5861},[90],[498],[119,118],{"nctId":5863,"briefTitle":5864,"status":195,"phases":5865,"primaryCompletion":1597,"completion":883,"start":5866,"enrollment":544,"conditions":5867,"interventions":5869},"NCT04958226","A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours",[90],"2021-10-15",[5868],"Solid Tumour",[119,5870],"Midazolam",{"nctId":5872,"briefTitle":5873,"status":151,"phases":5874,"primaryCompletion":2288,"completion":2288,"start":5875,"enrollment":5876,"conditions":5877,"interventions":5879},"NCT07343960","A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment",[90],"2026-01-06",20,[5878],"Moderate Hepatic Impairment",[119],{"nctId":5881,"briefTitle":5882,"status":195,"phases":5883,"primaryCompletion":5884,"completion":5884,"start":1794,"enrollment":5876,"conditions":5885,"interventions":5886},"NCT07088913","A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants",[90],"2026-02-20",[5851],[119,5887],"Rosuvastatin",{"nctId":1999,"briefTitle":2000,"status":195,"phases":5889,"primaryCompletion":317,"completion":317,"start":2002,"enrollment":2003,"conditions":5890,"interventions":5891},[90],[416],[119,1927,653],{"nctId":5893,"briefTitle":5894,"status":195,"phases":5895,"primaryCompletion":5896,"completion":5896,"start":5897,"enrollment":5898,"conditions":5899,"interventions":5901},"NCT04944771","Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants",[90],"2022-05-04","2021-07-26",48,[5900],"Solid and Hematological Malignancies",[119,1352],{"nctId":5903,"briefTitle":5904,"status":195,"phases":5905,"primaryCompletion":5906,"completion":5906,"start":5907,"enrollment":2222,"conditions":5908,"interventions":5910},"NCT04712396","A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body",[90],"2021-03-25","2021-02-01",[5909],"Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)",[119,5911],"Itraconazole",{"trials":5913,"activeCount":122,"soonestReadout":244},[5914,5924],{"nctId":5915,"briefTitle":5916,"status":195,"phases":5917,"primaryCompletion":5918,"completion":5919,"start":5920,"enrollment":1710,"conditions":5921,"interventions":5923},"NCT05008055","Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",[91],"2023-08-22","2024-10-25","2021-11-03",[5922],"Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",[119],{"nctId":241,"briefTitle":242,"status":108,"phases":5925,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":5926,"interventions":5927},[90,91],[249],[117,119,251,118,97,252],{"trials":5929,"activeCount":1855,"soonestReadout":5954},[5930,5941,5950,5961,5965,5969,5980],{"nctId":5931,"briefTitle":5932,"status":108,"phases":5933,"primaryCompletion":5934,"completion":5934,"start":5935,"enrollment":5936,"conditions":5937,"interventions":5938},"NCT05348577","Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)",[92],"2026-03-04","2022-03-25",1035,[416],[5939,5940],"capivasertib","docetaxel",{"nctId":5942,"briefTitle":5943,"status":108,"phases":5944,"primaryCompletion":377,"completion":5945,"start":5946,"enrollment":5947,"conditions":5948,"interventions":5949},"NCT06635447","Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+\u002FHER2- Breast Cancer in Chinese Patients",[92],"2027-01-10","2024-09-26",258,[25],[119,53],{"nctId":5951,"briefTitle":5952,"status":108,"phases":5953,"primaryCompletion":5954,"completion":5955,"start":5956,"enrollment":5957,"conditions":5958,"interventions":5960},"NCT04305496","Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+\u002FHER2- Breast Cancer",[92],"2023-05-09","2026-06-22","2020-04-16",818,[5959],"Locally Advanced (Inoperable) or Metastatic Breast Cancer",[53,119],{"nctId":1961,"briefTitle":1962,"status":108,"phases":5962,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":1967,"conditions":5963,"interventions":5964},[92],[1969],[119,1926],{"nctId":4647,"briefTitle":4648,"status":108,"phases":5966,"primaryCompletion":4650,"completion":4650,"start":1008,"enrollment":4651,"conditions":5967,"interventions":5968},[92],[249],[119,118],{"nctId":5970,"briefTitle":5971,"status":151,"phases":5972,"primaryCompletion":1086,"completion":5973,"start":5974,"enrollment":863,"conditions":5975,"interventions":5976},"NCT04862663","Capivasertib + CDK4\u002F6i + Fulvestrant for Advanced\u002FMetastatic HR+\u002FHER2- Breast Cancer (CAPItello-292)",[92],"2029-08-14","2021-05-10",[5959],[119,53,5977,5978,5979],"Palbociclib","Ribociclib","Abemaciclib",{"nctId":5981,"briefTitle":5982,"status":108,"phases":5983,"primaryCompletion":3362,"completion":3362,"start":5984,"enrollment":3645,"conditions":5985,"interventions":5987},"NCT06764186","A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed\u002FProgressed on ET and CDK4\u002F6 Inhibitor Reflecting Real World Clinical Practice in Spain",[92],"2025-01-07",[5986],"Locally Advanced or Metastatic Breast Cancer",[53,119],{"trials":5989,"activeCount":102},[],{"trials":5991,"activeCount":102},[],{"intervention":808,"totalTrials":269,"cells":5993},{"EARLY_PHASE1":5994,"PHASE1":5996,"PHASE2":5998,"PHASE3":6012,"PHASE4":6046,"NA":6048},{"trials":5995,"activeCount":102},[],{"trials":5997,"activeCount":102},[],{"trials":5999,"activeCount":3887,"soonestReadout":3958},[6000,6004,6008],{"nctId":4727,"briefTitle":4728,"status":151,"phases":6001,"primaryCompletion":4730,"completion":4730,"start":4731,"enrollment":4732,"conditions":6002,"interventions":6003},[91],[262],[180,3934,808],{"nctId":3224,"briefTitle":3225,"status":151,"phases":6005,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":6006,"interventions":6007},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"nctId":3955,"briefTitle":3956,"status":108,"phases":6009,"primaryCompletion":3958,"completion":3958,"start":1574,"enrollment":3959,"conditions":6010,"interventions":6011},[90,91],[414,25,415,416,3961,1049,691,403,172,3962,404,367,3963],[1939,118,344,3965,808,3966],{"trials":6013,"activeCount":1855,"soonestReadout":5615},[6014,6022,6026,6030,6034,6038,6042],{"nctId":6015,"briefTitle":6016,"status":151,"phases":6017,"primaryCompletion":6018,"completion":6018,"start":6019,"enrollment":221,"conditions":6020,"interventions":6021},"NCT07205822","A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer",[92],"2028-02-02","2025-10-30",[25],[808],{"nctId":4041,"briefTitle":4042,"status":151,"phases":6023,"primaryCompletion":3323,"completion":4044,"start":4045,"enrollment":4046,"conditions":6024,"interventions":6025},[92],[4029],[808,1012,345,344,177],{"nctId":799,"briefTitle":800,"status":108,"phases":6027,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":6028,"interventions":6029},[92],[25],[808,117,178,309,809,524,118,344,121,267],{"nctId":3501,"briefTitle":3502,"status":108,"phases":6031,"primaryCompletion":3504,"completion":3505,"start":3506,"enrollment":3507,"conditions":6032,"interventions":6033},[92],[25],[808,117,121,178],{"nctId":4136,"briefTitle":4137,"status":108,"phases":6035,"primaryCompletion":4139,"completion":660,"start":4140,"enrollment":4141,"conditions":6036,"interventions":6037},[92],[25],[808,118,3097,344,121,4144],{"nctId":3680,"briefTitle":3681,"status":151,"phases":6039,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":3686,"conditions":6040,"interventions":6041},[92],[25],[808,117,118,3097,283,344,178],{"nctId":5612,"briefTitle":5613,"status":108,"phases":6043,"primaryCompletion":5615,"completion":2288,"start":5616,"enrollment":5617,"conditions":6044,"interventions":6045},[92],[25],[808,121,283,5620,1051],{"trials":6047,"activeCount":102},[],{"trials":6049,"activeCount":102},[],{"intervention":6051,"totalTrials":434,"cells":6052},"Tezepelumab",{"EARLY_PHASE1":6053,"PHASE1":6055,"PHASE2":6072,"PHASE3":6100,"PHASE4":6227,"NA":6238},{"trials":6054,"activeCount":102},[],{"trials":6056,"activeCount":102},[6057,6064],{"nctId":6058,"briefTitle":6059,"status":195,"phases":6060,"primaryCompletion":6061,"completion":6061,"start":3247,"enrollment":1336,"conditions":6062,"interventions":6063},"NCT04673630","Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma",[90],"2022-09-27",[16],[6051],{"nctId":6065,"briefTitle":6066,"status":195,"phases":6067,"primaryCompletion":6068,"completion":6068,"start":6069,"enrollment":2472,"conditions":6070,"interventions":6071},"NCT03989544","A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects",[90],"2019-12-30","2019-06-19",[16],[6051],{"trials":6073,"activeCount":102},[6074,6085],{"nctId":6075,"briefTitle":6076,"status":195,"phases":6077,"primaryCompletion":6078,"completion":6079,"start":6080,"enrollment":6081,"conditions":6082,"interventions":6084},"NCT04039113","Tezepelumab COPD Exacerbation Study",[91],"2023-11-10","2024-01-31","2019-07-30",337,[6083],"Chronic Obstructive Pulmonary Disease (COPD)",[6051],{"nctId":6086,"briefTitle":6087,"status":195,"phases":6088,"primaryCompletion":1437,"completion":1437,"start":6089,"enrollment":2321,"conditions":6090,"interventions":6099},"NCT03688074","Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)",[91],"2018-11-02",[16,6091,6092,6093,6094,6095,6096,6097,6098],"Bronchial Diseases","Respiratory Tract Diseases","Lung Diseases, Obstructive","Lung Diseases","Respiratory Hypersensitivity","Hypersensitivity, Immediate","Hypersensitivity","Immune System Diseases",[6051],{"trials":6101,"activeCount":370,"soonestReadout":186},[6102,6109,6119,6128,6137,6146,6155,6165,6174,6181,6194,6202,6212,6220],{"nctId":6103,"briefTitle":6104,"status":108,"phases":6105,"primaryCompletion":186,"completion":207,"start":3610,"enrollment":6106,"conditions":6107,"interventions":6108},"NCT05583227","Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis",[92],368,[1601],[6051,6051],{"nctId":6110,"briefTitle":6111,"status":151,"phases":6112,"primaryCompletion":6113,"completion":6114,"start":6115,"enrollment":1078,"conditions":6116,"interventions":6118},"NCT07363642","Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab",[92],"2027-08-07","2029-03-31","2026-01-28",[6117],"Severe Asthma",[6051],{"nctId":6120,"briefTitle":6121,"status":151,"phases":6122,"primaryCompletion":5092,"completion":6123,"start":6124,"enrollment":6125,"conditions":6126,"interventions":6127},"NCT06883305","A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)",[92],"2029-06-05","2025-03-18",990,[6083],[6051],{"nctId":6129,"briefTitle":6130,"status":195,"phases":6131,"primaryCompletion":6132,"completion":6132,"start":6133,"enrollment":6134,"conditions":6135,"interventions":6136},"NCT05274815","Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma",[92],"2024-09-09","2022-05-17",305,[16],[6051],{"nctId":6138,"briefTitle":6139,"status":195,"phases":6140,"primaryCompletion":6141,"completion":6141,"start":6142,"enrollment":6143,"conditions":6144,"interventions":6145},"NCT03968978","Tezepelumab Home Use Study",[92],"2020-06-05","2019-05-21",216,[16],[6051,6051],{"nctId":6147,"briefTitle":6148,"status":195,"phases":6149,"primaryCompletion":2122,"completion":6150,"start":6151,"enrollment":3476,"conditions":6152,"interventions":6154},"NCT05062759","Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma",[92],"2022-07-18","2021-08-23",[6153],"Moderate to Severe Asthma",[6051],{"nctId":6156,"briefTitle":6157,"status":151,"phases":6158,"primaryCompletion":6159,"completion":6160,"start":6161,"enrollment":1719,"conditions":6162,"interventions":6164},"NCT07520162","A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab",[92],"2028-03-01","2028-03-07","2026-04-24",[6163],"Chronic Rhinosinusitis With Nasal Polyps",[6051],{"nctId":6166,"briefTitle":6167,"status":151,"phases":6168,"primaryCompletion":6169,"completion":6170,"start":647,"enrollment":6171,"conditions":6172,"interventions":6173},"NCT06023589","A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to \u003C 12 Years Old With Severe Asthma",[92],"2028-05-31","2030-08-23",231,[16],[6051],{"nctId":6175,"briefTitle":6176,"status":151,"phases":6177,"primaryCompletion":5092,"completion":6123,"start":6178,"enrollment":6125,"conditions":6179,"interventions":6180},"NCT06878261","A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)",[92],"2025-03-25",[6083],[6051],{"nctId":6182,"briefTitle":6183,"status":108,"phases":6184,"primaryCompletion":6185,"completion":6185,"start":6186,"enrollment":6187,"conditions":6188,"interventions":6189},"NCT06473779","Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.",[92],"2027-06-25","2024-09-30",326,[6117],[6051,6190,6191,6192,6193],"Budesonide\u002Fformoterol","Albuterol\u002Fbudesonide","Mannitol","Salbutamol",{"nctId":6195,"briefTitle":6196,"status":443,"phases":6197,"primaryCompletion":6198,"completion":6198,"start":6199,"enrollment":2811,"conditions":6200,"interventions":6201},"NCT05398263","Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma",[92],"2025-03-24","2022-08-09",[16],[6051],{"nctId":6203,"briefTitle":6204,"status":195,"phases":6205,"primaryCompletion":6206,"completion":6207,"start":6208,"enrollment":6209,"conditions":6210,"interventions":6211},"NCT03706079","Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma",[92],"2021-10-26","2022-05-18","2019-01-07",951,[16],[6051],{"nctId":6213,"briefTitle":6214,"status":151,"phases":6215,"primaryCompletion":6216,"completion":6216,"start":6217,"enrollment":1120,"conditions":6218,"interventions":6219},"NCT06706817","A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab",[92],"2027-01-13","2024-12-03",[6163],[6051],{"nctId":6221,"briefTitle":6222,"status":195,"phases":6223,"primaryCompletion":6224,"completion":6224,"start":2826,"enrollment":3000,"conditions":6225,"interventions":6226},"NCT03406078","Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma",[92],"2020-09-25",[16],[6051],{"trials":6228,"activeCount":102},[6229],{"nctId":6230,"briefTitle":6231,"status":195,"phases":6232,"primaryCompletion":6233,"completion":6233,"start":6234,"enrollment":6235,"conditions":6236,"interventions":6237},"NCT05329194","Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States",[93],"2025-10-01","2022-04-29",287,[16],[6051],{"trials":6239,"activeCount":447,"soonestReadout":6244},[6240,6248,6256],{"nctId":6241,"briefTitle":6242,"status":108,"phases":6243,"primaryCompletion":6244,"completion":6244,"start":6245,"enrollment":2472,"conditions":6246,"interventions":6247},"NCT06948396","Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy",[],"2027-05-30","2025-06-25",[16],[6051],{"nctId":6249,"briefTitle":6250,"status":195,"phases":6251,"primaryCompletion":6252,"completion":6252,"start":433,"enrollment":6253,"conditions":6254,"interventions":6255},"NCT06455462","Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres",[],"2025-11-25",352,[6117],[6051],{"nctId":6257,"briefTitle":6258,"status":151,"phases":6259,"primaryCompletion":4770,"completion":4770,"start":3475,"enrollment":6260,"conditions":6261,"interventions":6264},"NCT06951867","Tezspire Cardiac Events PASS",[],16640,[6262,6263],"Cardiovascular Events","MACE",[6051],{"intervention":1959,"totalTrials":4343,"cells":6266},{"EARLY_PHASE1":6267,"PHASE1":6269,"PHASE2":6299,"PHASE3":6322,"PHASE4":6351,"NA":6353},{"trials":6268,"activeCount":102},[],{"trials":6270,"activeCount":3887,"soonestReadout":4837},[6271,6280,6288],{"nctId":6272,"briefTitle":6273,"status":108,"phases":6274,"primaryCompletion":4837,"completion":337,"start":6178,"enrollment":6275,"conditions":6276,"interventions":6277},"NCT06899061","Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib",[90],41,[157],[1959,2198,6278,6279,5887,1352],"Furosemide","Metformin Hydrochloride",{"nctId":6281,"briefTitle":6282,"status":151,"phases":6283,"primaryCompletion":6284,"completion":6284,"start":6285,"enrollment":2187,"conditions":6286,"interventions":6287},"NCT05938270","A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.",[90],"2026-08-17","2023-09-21",[416],[1959,1940],{"nctId":6289,"briefTitle":6290,"status":151,"phases":6291,"primaryCompletion":6292,"completion":6292,"start":6293,"enrollment":370,"conditions":6294,"interventions":6296},"NCT06713369","AZD5305 hADME in Patients With Advanced Solid Malignancies",[90],"2026-10-02","2025-04-02",[6295],"Locally Advanced or Metastatic Solid Tumor",[1959,6297,6298],"[14C]-AZD5305 microtracer","[14C]-AZD5305",{"trials":6300,"activeCount":447,"soonestReadout":3920},[6301,6305,6313],{"nctId":3917,"briefTitle":3918,"status":151,"phases":6302,"primaryCompletion":3920,"completion":3920,"start":3921,"enrollment":318,"conditions":6303,"interventions":6304},[90,91],[414,3923,367],[3925,1959,239,344,159],{"nctId":6306,"briefTitle":6307,"status":624,"phases":6308,"primaryCompletion":2999,"completion":2999,"start":6309,"enrollment":102,"conditions":6310,"interventions":6312},"NCT07060365","A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced\u002FRecurrent Ovarian Cancer",[90,91],"2025-09-02",[6311],"Advanced\u002FRecurrent Ovarian Cancer",[1959],{"nctId":6314,"briefTitle":6315,"status":151,"phases":6316,"primaryCompletion":6317,"completion":6317,"start":6318,"enrollment":1120,"conditions":6319,"interventions":6320},"NCT07446855","Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced\u002FMetastatic Homologous Recombination Deficient Solid Tumours",[90,91],"2030-03-29","2026-03-17",[466],[6321,1959],"AZD4956",{"trials":6323,"activeCount":3887,"soonestReadout":1952},[6324,6328,6339],{"nctId":1949,"briefTitle":1950,"status":108,"phases":6325,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":1955,"conditions":6326,"interventions":6327},[92],[1957],[1959,1926,1940,1927],{"nctId":6329,"briefTitle":6330,"status":151,"phases":6331,"primaryCompletion":6332,"completion":6333,"start":6334,"enrollment":4625,"conditions":6335,"interventions":6336},"NCT06952803","A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT\u002FADT in Men With High-risk Prostate Cancer With a BRCA Mutation",[92],"2033-03-31","2036-04-30","2025-08-06",[416],[1959,6337,6338],"Abiraterone + Prednisolone\u002FPrednisone","Androgen Deprivation Therapy",{"nctId":6340,"briefTitle":6341,"status":151,"phases":6342,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":6346,"conditions":6347,"interventions":6349},"NCT06380751","Saruparib (AZD5305) Plus Camizestrant Compared With CDK4\u002F6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+\u002F ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",[92],"2029-03-30","2030-10-18","2024-08-01",500,[6348],"Advanced Breast Cancer",[1959,3966,5979,5978,5977,53,469,120,6350],"Exemestane",{"trials":6352,"activeCount":102},[],{"trials":6354,"activeCount":102},[],{"intervention":53,"totalTrials":579,"cells":6356},{"EARLY_PHASE1":6357,"PHASE1":6359,"PHASE2":6398,"PHASE3":6503,"PHASE4":6588,"NA":6601},{"trials":6358,"activeCount":102},[],{"trials":6360,"activeCount":122,"soonestReadout":110},[6361,6365,6373,6383,6394],{"nctId":4450,"briefTitle":4451,"status":195,"phases":6362,"primaryCompletion":4453,"completion":4454,"start":2667,"enrollment":1979,"conditions":6363,"interventions":6364},[90],[4456],[4458,4459,53,118],{"nctId":6366,"briefTitle":6367,"status":195,"phases":6368,"primaryCompletion":6369,"completion":2242,"start":6370,"enrollment":5876,"conditions":6371,"interventions":6372},"NCT00328120","Faslodex 500mg Multiple Dose Tolerability Study in BC Patients",[90],"2006-04","2004-04",[6348],[53],{"nctId":6374,"briefTitle":6375,"status":195,"phases":6376,"primaryCompletion":6377,"completion":3685,"start":6378,"enrollment":680,"conditions":6379,"interventions":6381},"NCT02599714","Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer",[90],"2018-03-30","2015-12-07",[6380],"Advanced and Metastatic Breast Cancer",[6382,5977,53],"AZD2014",{"nctId":6384,"briefTitle":6385,"status":195,"phases":6386,"primaryCompletion":6387,"completion":6388,"start":6389,"enrollment":6390,"conditions":6391,"interventions":6393},"NCT01597388","AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer",[90],"2016-08-04","2026-01-13","2012-05-08",99,[6392],"Advanced Metastatic Breast Cancer",[6382,53],{"nctId":106,"briefTitle":107,"status":108,"phases":6395,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":6396,"interventions":6397},[90],[115],[97,117,118,119,120,53,121],{"trials":6399,"activeCount":122,"soonestReadout":6426},[6400,6412,6422,6432,6441,6449,6457,6464,6471,6478,6489,6495],{"nctId":6401,"briefTitle":6402,"status":195,"phases":6403,"primaryCompletion":6404,"completion":6405,"start":6406,"enrollment":6407,"conditions":6408,"interventions":6409},"NCT00274469","A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer",[91],"2008-01-10","2017-01-13","2006-02-06",205,[115],[6410,6411],"fulvestrant","anastrozole",{"nctId":6413,"briefTitle":6414,"status":195,"phases":6415,"primaryCompletion":6416,"completion":6417,"start":6418,"enrollment":6419,"conditions":6420,"interventions":6421},"NCT00313170","A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg",[91],"2008-06-13","2019-03-13","2006-05-30",144,[6348,115],[53],{"nctId":6423,"briefTitle":6424,"status":108,"phases":6425,"primaryCompletion":6426,"completion":6318,"start":6427,"enrollment":1173,"conditions":6428,"interventions":6430},"NCT04214288","A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer",[91],"2022-08-30","2020-04-22",[6429],"Advanced ER-Positive HER2-Negative Breast Cancer",[6431,53],"AZD9833",{"nctId":6433,"briefTitle":6434,"status":195,"phases":6435,"primaryCompletion":2180,"completion":6436,"start":2143,"enrollment":235,"conditions":6437,"interventions":6440},"NCT01202591","Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients",[90,91],"2014-10",[6438,6439],"FGFR Inhibition, Pharmacokinetics, Biomarkers","ER+ Breast Cancer",[569,6350,53],{"nctId":6442,"briefTitle":6443,"status":195,"phases":6444,"completion":2252,"start":6445,"enrollment":6446,"conditions":6447,"interventions":6448},"NCT00093002","Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer",[91],"2004-06",179,[25],[53],{"nctId":6450,"briefTitle":6451,"status":195,"phases":6452,"start":6453,"enrollment":6454,"conditions":6455,"interventions":6456},"NCT00272740","SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer",[91],"2000-03",93,[306],[53],{"nctId":6458,"briefTitle":6459,"status":195,"phases":6460,"primaryCompletion":2086,"completion":2086,"start":6370,"enrollment":2187,"conditions":6461,"interventions":6462},"NCT00259090","Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer",[91],[25],[53,6463],"Anastrazole",{"nctId":6465,"briefTitle":6466,"status":195,"phases":6467,"primaryCompletion":4915,"completion":6468,"start":3839,"enrollment":1883,"conditions":6469,"interventions":6470},"NCT00454805","AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.",[91],"2016-04",[6348],[3830,53],{"nctId":6472,"briefTitle":6473,"status":195,"phases":6474,"primaryCompletion":2580,"completion":2366,"start":2087,"enrollment":6475,"conditions":6476,"interventions":6477},"NCT00305448","A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg",[91],143,[6348,115],[53,53],{"nctId":6479,"briefTitle":6480,"status":195,"phases":6481,"primaryCompletion":6482,"completion":6483,"start":6484,"enrollment":1710,"conditions":6485,"interventions":6488},"NCT00278915","Faslodex in McCune-Albright Syndrome",[91],"2009-12-08","2023-07-20","2006-01-31",[6486,6487],"Puberty, Precocious","McCune-Albright Syndrome",[53],{"nctId":6490,"briefTitle":6491,"status":195,"phases":6492,"primaryCompletion":2086,"completion":2086,"start":6369,"enrollment":963,"conditions":6493,"interventions":6494},"NCT00357110","Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer",[91],[25],[53,120],{"nctId":6496,"briefTitle":6497,"status":195,"phases":6498,"primaryCompletion":2516,"completion":2516,"start":6499,"enrollment":1348,"conditions":6500,"interventions":6502},"NCT00334295","Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.",[91],"2002-12",[6501],"Endometrial Carcinoma",[53],{"trials":6504,"activeCount":1039,"soonestReadout":52},[6505,6513,6521,6525,6529,6535,6543,6547,6551,6558,6568,6576,6584],{"nctId":6506,"briefTitle":6507,"status":195,"phases":6508,"primaryCompletion":3839,"completion":2747,"start":6509,"enrollment":5425,"conditions":6510,"interventions":6512},"NCT00241449","A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer",[92],"1998-11",[25,6511],"Metastasis",[53,468],{"nctId":6514,"briefTitle":6515,"status":195,"phases":6516,"completion":2415,"start":6517,"enrollment":6518,"conditions":6519,"interventions":6520},"NCT00327769","Faslodex Advanced Breast Cancer Local Chinese Study",[92],"2005-11",234,[6348],[53,120],{"nctId":5942,"briefTitle":5943,"status":108,"phases":6522,"primaryCompletion":377,"completion":5945,"start":5946,"enrollment":5947,"conditions":6523,"interventions":6524},[92],[25],[119,53],{"nctId":5951,"briefTitle":5952,"status":108,"phases":6526,"primaryCompletion":5954,"completion":5955,"start":5956,"enrollment":5957,"conditions":6527,"interventions":6528},[92],[5959],[53,119],{"nctId":50,"briefTitle":51,"status":108,"phases":6530,"primaryCompletion":52,"completion":660,"start":6531,"enrollment":6532,"conditions":6533,"interventions":6534},[92],"2005-02-13",736,[25],[53],{"nctId":6536,"briefTitle":6537,"status":195,"phases":6538,"completion":4285,"start":6539,"enrollment":6540,"conditions":6541,"interventions":6542},"NCT00635713","Second Line Breast Cancer Trial",[92],"1997-05",588,[6348],[53,120,53],{"nctId":5970,"briefTitle":5971,"status":151,"phases":6544,"primaryCompletion":1086,"completion":5973,"start":5974,"enrollment":863,"conditions":6545,"interventions":6546},[92],[5959],[119,53,5977,5978,5979],{"nctId":5981,"briefTitle":5982,"status":108,"phases":6548,"primaryCompletion":3362,"completion":3362,"start":5984,"enrollment":3645,"conditions":6549,"interventions":6550},[92],[5986],[53,119],{"nctId":6552,"briefTitle":6553,"status":195,"phases":6554,"primaryCompletion":4006,"completion":4006,"start":2570,"enrollment":6555,"conditions":6556,"interventions":6557},"NCT01300351","Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women",[92],249,[25],[53],{"nctId":6559,"briefTitle":6560,"status":195,"phases":6561,"primaryCompletion":6562,"completion":2180,"start":6563,"enrollment":6564,"conditions":6565,"interventions":6567},"NCT00065325","The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer",[92],"2006-06","2003-08",694,[6566,115],"Locally Advanced Breast Cancer",[53,6350],{"nctId":6569,"briefTitle":6570,"status":195,"phases":6571,"primaryCompletion":2320,"completion":2366,"start":6572,"enrollment":6573,"conditions":6574,"interventions":6575},"NCT00256698","Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy",[92],"2004-01",514,[25],[53,120],{"nctId":6577,"briefTitle":6578,"status":195,"phases":6579,"primaryCompletion":2542,"completion":2542,"start":4915,"enrollment":98,"conditions":6580,"interventions":6582},"NCT00944918","Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)",[92],[6581],"Progression-free Survival",[6410,6411,6583],"exemestane",{"nctId":6340,"briefTitle":6341,"status":151,"phases":6585,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":6346,"conditions":6586,"interventions":6587},[92],[6348],[1959,3966,5979,5978,5977,53,469,120,6350],{"trials":6589,"activeCount":102},[6590],{"nctId":6591,"briefTitle":6592,"status":195,"phases":6593,"primaryCompletion":6594,"completion":6595,"start":6596,"enrollment":6597,"conditions":6598,"interventions":6600},"NCT02447328","A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",[93],"2016-05-06","2020-09-16","2015-05-29",83,[6599,115],"Locally Advanced or",[53],{"trials":6602,"activeCount":102},[6603],{"nctId":6604,"briefTitle":6605,"status":195,"phases":6606,"primaryCompletion":2320,"completion":2320,"start":2221,"enrollment":1685,"conditions":6607,"interventions":6608},"NCT00660803","Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer",[],[25],[53],{"intervention":369,"totalTrials":3855,"cells":6610},{"EARLY_PHASE1":6611,"PHASE1":6613,"PHASE2":6644,"PHASE3":6683,"PHASE4":6738,"NA":6746},{"trials":6612,"activeCount":102},[],{"trials":6614,"activeCount":102},[6615,6619,6623,6638],{"nctId":4873,"briefTitle":4874,"status":195,"phases":6616,"primaryCompletion":2169,"completion":2542,"start":4876,"enrollment":4877,"conditions":6617,"interventions":6618},[90],[4879],[3830,4774,345,4615,369],{"nctId":1913,"briefTitle":1914,"status":195,"phases":6620,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":6621,"interventions":6622},[90],[157,1921,1922,1923],[1925,117,1926,1927,251,369],{"nctId":6624,"briefTitle":6625,"status":195,"phases":6626,"primaryCompletion":6627,"completion":6628,"start":6629,"enrollment":1842,"conditions":6630,"interventions":6635},"NCT00600496","A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)",[90],"2010-08-20","2025-12-18","2007-12-14",[25,306,6631,6632,6633,3174,410,6634],"Colon Cancer","Colonic Cancer","Colon Neoplasms","Kidney Cancer",[43,6636,5317,369,6637],"Dacarbazine","Temsirolimus",{"nctId":6639,"briefTitle":6640,"status":195,"phases":6641,"primaryCompletion":2580,"completion":2077,"start":2087,"enrollment":3811,"conditions":6642,"interventions":6643},"NCT00314782","Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC",[90],[416],[4931,369],{"trials":6645,"activeCount":122,"soonestReadout":6668},[6646,6655,6664,6673,6679],{"nctId":6647,"briefTitle":6648,"status":195,"phases":6649,"completion":6650,"start":6651,"enrollment":6652,"conditions":6653,"interventions":6654},"NCT00247481","ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer",[91],"2005-06","2002-09",77,[25],[1013,369],{"nctId":6656,"briefTitle":6657,"status":195,"phases":6658,"primaryCompletion":6659,"completion":6660,"start":6661,"enrollment":4917,"conditions":6662,"interventions":6663},"NCT00890825","AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients",[91],"2011-05-11","2016-11-02","2009-04-20",[3864],[43,5940],{"nctId":6665,"briefTitle":6666,"status":1097,"phases":6667,"primaryCompletion":6668,"completion":6668,"start":6669,"enrollment":3466,"conditions":6670,"interventions":6671},"NCT07590934","Phase Ib\u002FII Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer",[90,91],"2029-09-05","2026-05-14",[1937],[2031,159,369,6672],"AZD2287",{"nctId":6674,"briefTitle":6675,"status":195,"phases":6676,"completion":6562,"start":4256,"enrollment":4928,"conditions":6677,"interventions":6678},"NCT00319618","Combination Weekly Taxotere™ With Iressa™ \u002FPlacebo in Metastatic Breast Cancer",[91],[115],[1013,369],{"nctId":4328,"briefTitle":4329,"status":195,"phases":6680,"primaryCompletion":2087,"completion":2087,"start":4331,"enrollment":496,"conditions":6681,"interventions":6682},[91],[408],[4334,369,177],{"trials":6684,"activeCount":1039,"soonestReadout":67},[6685,6689,6697,6701,6705,6714,6722,6726,6730],{"nctId":4604,"briefTitle":4605,"status":108,"phases":6686,"primaryCompletion":4607,"completion":4608,"start":4609,"enrollment":4610,"conditions":6687,"interventions":6688},[92],[172,4612],[225,225,4614,118,369,4615,4616,4617],{"nctId":6690,"briefTitle":6691,"status":195,"phases":6692,"primaryCompletion":3839,"completion":4297,"start":4306,"enrollment":6693,"conditions":6694,"interventions":6696},"NCT00076388","Iressa Versus Docetaxel (Taxotere)",[92],1440,[6695],"Non-Small-Cell Lung Carcinoma",[1013,369],{"nctId":5931,"briefTitle":5932,"status":108,"phases":6698,"primaryCompletion":5934,"completion":5934,"start":5935,"enrollment":5936,"conditions":6699,"interventions":6700},[92],[416],[5939,5940],{"nctId":3358,"briefTitle":3359,"status":108,"phases":6702,"primaryCompletion":3361,"completion":3362,"start":3363,"enrollment":3364,"conditions":6703,"interventions":6704},[92],[3366],[265,117,369],{"nctId":6706,"briefTitle":6707,"status":195,"phases":6708,"primaryCompletion":2615,"completion":6709,"start":6710,"enrollment":6711,"conditions":6712,"interventions":6713},"NCT00617669","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer",[92],"2011-07","2008-01",1494,[416],[369,4931],{"nctId":6715,"briefTitle":6716,"status":195,"phases":6717,"primaryCompletion":6718,"completion":2095,"start":6719,"enrollment":2640,"conditions":6720,"interventions":6721},"NCT00478049","Iressa as Second Line Therapy in Advanced NSCLC-Asia",[92],"2007-05","2005-09",[1090],[1013,369],{"nctId":1073,"briefTitle":1074,"status":151,"phases":6723,"primaryCompletion":1076,"completion":1076,"start":1077,"enrollment":1078,"conditions":6724,"interventions":6725},[92],[1080],[252,369],{"nctId":359,"briefTitle":360,"status":151,"phases":6727,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":6728,"interventions":6729},[92],[367],[97,180,178,344,118,369],{"nctId":65,"briefTitle":66,"status":108,"phases":6731,"primaryCompletion":67,"completion":1317,"start":6732,"enrollment":6733,"conditions":6734,"interventions":6736},[92],"2013-09-25",510,[6735],"Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV",[68,369,6737],"Pegylated G-CSF",{"trials":6739,"activeCount":102},[6740],{"nctId":6741,"briefTitle":6742,"status":443,"phases":6743,"primaryCompletion":2151,"completion":2151,"start":4297,"enrollment":1638,"conditions":6744,"interventions":6745},"NCT00536107","Study to Assess Safety\u002FTolerability\u002FEfficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[93],[992],[1013,369],{"trials":6747,"activeCount":102},[],{"intervention":226,"totalTrials":2222,"cells":6749},{"EARLY_PHASE1":6750,"PHASE1":6752,"PHASE2":6758,"PHASE3":6791,"PHASE4":6809,"NA":6811},{"trials":6751,"activeCount":102},[],{"trials":6753,"activeCount":122,"soonestReadout":5364},[6754],{"nctId":5361,"briefTitle":5362,"status":151,"phases":6755,"primaryCompletion":5364,"completion":5364,"start":678,"enrollment":5365,"conditions":6756,"interventions":6757},[90],[498,5367,4258,5368],[5370,1012,226,4843,239],{"trials":6759,"activeCount":1979,"soonestReadout":5770},[6760,6764,6768,6772,6776,6787],{"nctId":5649,"briefTitle":5650,"status":195,"phases":6761,"primaryCompletion":2169,"completion":2350,"start":4284,"enrollment":5652,"conditions":6762,"interventions":6763},[91],[691],[3830,296,4843,175,239],{"nctId":5767,"briefTitle":5768,"status":151,"phases":6765,"primaryCompletion":5770,"completion":1952,"start":1372,"enrollment":2289,"conditions":6766,"interventions":6767},[91],[172,4612,281,5772],[225,226,4843,5774,4615,5775,283],{"nctId":215,"briefTitle":216,"status":151,"phases":6769,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":6770,"interventions":6771},[91],[223],[225,180,162,121,226,227],{"nctId":4766,"briefTitle":4767,"status":151,"phases":6773,"primaryCompletion":4769,"completion":4770,"start":4771,"enrollment":2640,"conditions":6774,"interventions":6775},[91],[172],[180,179,4774,4775,225,226,121],{"nctId":6777,"briefTitle":6778,"status":443,"phases":6779,"primaryCompletion":4306,"completion":4306,"start":6780,"enrollment":1120,"conditions":6781,"interventions":6783},"NCT00065117","Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.",[91],"2003-09",[5368,6782],"Metastases, Neoplasm",[6784,296,6785,6786],"ZD6126","leucovorin","oxaliplatin",{"nctId":1019,"briefTitle":1020,"status":151,"phases":6788,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":340,"conditions":6789,"interventions":6790},[91],[367,172,651,414,691,1025,281],[252,121,226,179,344,239,180,1027,177],{"trials":6792,"activeCount":447,"soonestReadout":288},[6793,6797,6801,6805],{"nctId":285,"briefTitle":286,"status":151,"phases":6794,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":6795,"interventions":6796},[92],[293,294],[180,97,176,178,296,121,177,175],{"nctId":4103,"briefTitle":4104,"status":195,"phases":6798,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":6799,"interventions":6800},[92],[4111],[82,3137,4113,4114,296,177,344],{"nctId":5698,"briefTitle":5699,"status":195,"phases":6802,"primaryCompletion":5701,"completion":5702,"start":5703,"enrollment":5704,"conditions":6803,"interventions":6804},[91,92],[691],[268,239,296,4843,175],{"nctId":4832,"briefTitle":4833,"status":151,"phases":6806,"primaryCompletion":4835,"completion":4836,"start":4837,"enrollment":4838,"conditions":6807,"interventions":6808},[92],[172,294,405],[4841,180,4178,121,226,175,4842,4843],{"trials":6810,"activeCount":102},[],{"trials":6812,"activeCount":102},[],{"intervention":3097,"totalTrials":370,"cells":6814},{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6827,"PHASE3":6837,"PHASE4":6855,"NA":6857},{"trials":6816,"activeCount":102},[],{"trials":6818,"activeCount":122,"soonestReadout":3122},[6819,6823],{"nctId":3087,"briefTitle":3088,"status":195,"phases":6820,"primaryCompletion":3090,"completion":3091,"start":3092,"enrollment":3093,"conditions":6821,"interventions":6822},[90],[498],[571,117,177,3096,344,283,3097],{"nctId":3119,"briefTitle":3120,"status":108,"phases":6824,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":6825,"interventions":6826},[90],[3127],[117,264,251,980,345,344,283,177,3097,979],{"trials":6828,"activeCount":447,"soonestReadout":1964},[6829,6833],{"nctId":3927,"briefTitle":3928,"status":151,"phases":6830,"primaryCompletion":3930,"completion":3930,"start":2932,"enrollment":3466,"conditions":6831,"interventions":6832},[90,91],[3932],[180,177,344,345,118,3097,3934],{"nctId":3275,"briefTitle":3276,"status":108,"phases":6834,"primaryCompletion":1964,"completion":130,"start":3278,"enrollment":3279,"conditions":6835,"interventions":6836},[91],[3281],[3233,117,283,3097],{"trials":6838,"activeCount":1979,"soonestReadout":325},[6839,6843,6847,6851],{"nctId":4093,"briefTitle":4094,"status":151,"phases":6840,"primaryCompletion":4096,"completion":4097,"start":4098,"enrollment":4099,"conditions":6841,"interventions":6842},[92],[1049],[180,178,344,118,3097],{"nctId":322,"briefTitle":323,"status":108,"phases":6844,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":6845,"interventions":6846},[92],[330],[97,121,118,332],{"nctId":4136,"briefTitle":4137,"status":108,"phases":6848,"primaryCompletion":4139,"completion":660,"start":4140,"enrollment":4141,"conditions":6849,"interventions":6850},[92],[25],[808,118,3097,344,121,4144],{"nctId":3680,"briefTitle":3681,"status":151,"phases":6852,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":3686,"conditions":6853,"interventions":6854},[92],[25],[808,117,118,3097,283,344,178],{"trials":6856,"activeCount":102},[],{"trials":6858,"activeCount":102},[],{"intervention":6860,"totalTrials":486,"cells":6861},"AZD0780",{"EARLY_PHASE1":6862,"PHASE1":6864,"PHASE2":6946,"PHASE3":6973,"PHASE4":7012,"NA":7014},{"trials":6863,"activeCount":102},[],{"trials":6865,"activeCount":122,"soonestReadout":3569},[6866,6877,6885,6896,6907,6916,6924,6931,6938],{"nctId":6867,"briefTitle":6868,"status":195,"phases":6869,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":3209,"conditions":6872,"interventions":6874},"NCT06671405","An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions",[90],"2025-02-17","2024-09-25",[6873],"Dyslipidaemia",[6860,5911,6875,5870,6876],"Carbamazepine","Ethinyl estradiol\u002Flevonorgestrel",{"nctId":6878,"briefTitle":6879,"status":195,"phases":6880,"primaryCompletion":6881,"completion":6881,"start":6882,"enrollment":1710,"conditions":6883,"interventions":6884},"NCT06592482","A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780",[90],"2024-12-01","2024-08-02",[2279],[6860],{"nctId":6886,"briefTitle":6887,"status":195,"phases":6888,"primaryCompletion":6889,"completion":6889,"start":6890,"enrollment":370,"conditions":6891,"interventions":6893},"NCT05817461","An ADME Study of [14C]AZD0780 in Healthy Male Subjects",[90],"2023-06-06","2023-04-19",[6892],"Cardiovascular Diseases",[6860,6894,6895],"[14C]AZD0780 Solution for","[14C]AZD0780 Oral Solution",{"nctId":6897,"briefTitle":6898,"status":195,"phases":6899,"primaryCompletion":6900,"completion":6900,"start":3438,"enrollment":6901,"conditions":6902,"interventions":6904},"NCT06742853","A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.",[90],"2025-10-29",81,[6903],"Dyslipidemia",[6860,6905,5887,6906],"Ezetimibe","Bempedoic Acid",{"nctId":6908,"briefTitle":6909,"status":195,"phases":6910,"primaryCompletion":6911,"completion":6911,"start":6912,"enrollment":486,"conditions":6913,"interventions":6915},"NCT06576765","Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780",[90],"2024-11-08","2024-08-08",[6914],"Hepatic Impairment",[6860],{"nctId":6917,"briefTitle":6918,"status":195,"phases":6919,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":1638,"conditions":6922,"interventions":6923},"NCT07216131","A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years",[90],"2025-12-30","2025-11-10",[5851],[6860,2173],{"nctId":6925,"briefTitle":6926,"status":108,"phases":6927,"primaryCompletion":3569,"completion":3569,"start":6928,"enrollment":1448,"conditions":6929,"interventions":6930},"NCT07423598","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels",[90],"2026-02-24",[5851],[6860],{"nctId":6932,"briefTitle":6933,"status":195,"phases":6934,"primaryCompletion":6935,"completion":6935,"start":5416,"enrollment":486,"conditions":6936,"interventions":6937},"NCT05787002","A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.",[90],"2023-05-15",[6903],[6860,5887],{"nctId":6939,"briefTitle":6940,"status":195,"phases":6941,"primaryCompletion":6942,"completion":6942,"start":6207,"enrollment":6943,"conditions":6944,"interventions":6945},"NCT05384262","A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects",[90],"2024-06-14",183,[6903],[6860,6860,6860,5887],{"trials":6947,"activeCount":122,"soonestReadout":3323},[6948,6955,6963],{"nctId":6949,"briefTitle":6950,"status":151,"phases":6951,"primaryCompletion":3323,"completion":3323,"start":6952,"enrollment":3093,"conditions":6953,"interventions":6954},"NCT07218900","A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia",[91],"2025-11-13",[6873],[6860,5887],{"nctId":6956,"briefTitle":6957,"status":195,"phases":6958,"primaryCompletion":6186,"completion":6186,"start":6959,"enrollment":6960,"conditions":6961,"interventions":6962},"NCT06173570","A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia",[91],"2024-01-19",428,[6903],[6860],{"nctId":6964,"briefTitle":6965,"status":195,"phases":6966,"primaryCompletion":6967,"completion":6968,"start":6969,"enrollment":932,"conditions":6970,"interventions":6972},"NCT06692764","A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure",[91],"2025-04-18","2025-05-02","2024-10-30",[6971],"Atherosclerotic Cardiovascular Disease",[6860],{"trials":6974,"activeCount":1979,"soonestReadout":6989},[6975,6985,6994,7003],{"nctId":6976,"briefTitle":6977,"status":108,"phases":6978,"primaryCompletion":5490,"completion":5490,"start":6979,"enrollment":6980,"conditions":6981,"interventions":6982},"NCT06834932","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia",[91,92],"2024-12-06",432,[6873],[6983,6984,6860],"Rosuvastatin Dose 1","Rosuvastatin dose 2",{"nctId":6986,"briefTitle":6987,"status":108,"phases":6988,"primaryCompletion":6989,"completion":6989,"start":1227,"enrollment":6990,"conditions":6991,"interventions":6993},"NCT07000136","A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH",[92],"2027-01-04",473,[6992],"Heterozygous Familial Hypercholesterolaemia",[6860],{"nctId":6995,"briefTitle":6996,"status":108,"phases":6997,"primaryCompletion":6998,"completion":6998,"start":6999,"enrollment":7000,"conditions":7001,"interventions":7002},"NCT07000123","A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event",[92],"2027-01-11","2025-05-28",3103,[2619],[6860],{"nctId":7004,"briefTitle":7005,"status":151,"phases":7006,"primaryCompletion":7007,"completion":7007,"start":7008,"enrollment":7009,"conditions":7010,"interventions":7011},"NCT07000357","A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event",[92],"2029-10-26","2025-06-04",15100,[2619],[6860],{"trials":7013,"activeCount":102},[],{"trials":7015,"activeCount":102},[],{"intervention":87,"totalTrials":963,"cells":7017},{"EARLY_PHASE1":7018,"PHASE1":7020,"PHASE2":7082,"PHASE3":7096,"PHASE4":7119,"NA":7121},{"trials":7019,"activeCount":102},[],{"trials":7021,"activeCount":102},[7022,7031,7039,7047,7056,7065,7074],{"nctId":7023,"briefTitle":7024,"status":195,"phases":7025,"primaryCompletion":7026,"completion":7026,"start":7027,"enrollment":1039,"conditions":7028,"interventions":7030},"NCT05768360","A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects",[90],"2023-06-24","2023-04-25",[7029],"Healthy Male Subjects",[87,2198,6279,5887,6278],{"nctId":7032,"briefTitle":7033,"status":195,"phases":7034,"primaryCompletion":7035,"completion":7035,"start":7036,"enrollment":486,"conditions":7037,"interventions":7038},"NCT04121910","A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole",[90],"2020-01-12","2019-11-07",[5868],[87,5911],{"nctId":7040,"briefTitle":7041,"status":195,"phases":7042,"primaryCompletion":7043,"completion":7043,"start":3161,"enrollment":1855,"conditions":7044,"interventions":7045},"NCT06348355","A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers",[90],"2024-06-24",[36],[7046,87],"[11C]savolitinib",{"nctId":7048,"briefTitle":7049,"status":195,"phases":7050,"primaryCompletion":7051,"completion":7051,"start":7052,"enrollment":1448,"conditions":7053,"interventions":7054},"NCT04118842","A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin",[90],"2020-02-26","2019-10-17",[3056],[87,7055],"Rifampicin",{"nctId":7057,"briefTitle":7058,"status":195,"phases":7059,"primaryCompletion":7060,"completion":7060,"start":7061,"enrollment":486,"conditions":7062,"interventions":7063},"NCT04179071","A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine",[90],"2020-03-11","2019-12-13",[466],[87,7064],"Famotidine",{"nctId":7066,"briefTitle":7067,"status":195,"phases":7068,"primaryCompletion":7069,"completion":7069,"start":7070,"enrollment":486,"conditions":7071,"interventions":7072},"NCT05888207","A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects",[90],"2023-08-17","2023-06-02",[7029],[87,7073],"Fluvoxamine",{"nctId":7075,"briefTitle":7076,"status":195,"phases":7077,"primaryCompletion":7078,"completion":7078,"start":7079,"enrollment":1638,"conditions":7080,"interventions":7081},"NCT04187456","A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body",[90],"2020-03-06","2019-12-27",[3056],[87,5870],{"trials":7083,"activeCount":3887,"soonestReadout":2836},[7084,7088,7092],{"nctId":5384,"briefTitle":5385,"status":108,"phases":7085,"primaryCompletion":2836,"completion":660,"start":5387,"enrollment":5388,"conditions":7086,"interventions":7087},[91],[4058],[5391,3488],{"nctId":3167,"briefTitle":3168,"status":108,"phases":7089,"primaryCompletion":3170,"completion":3170,"start":3171,"enrollment":3172,"conditions":7090,"interventions":7091},[91],[3174],[87,117],{"nctId":1004,"briefTitle":1005,"status":108,"phases":7093,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":7094,"interventions":7095},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"trials":7097,"activeCount":3887,"soonestReadout":86},[7098,7111,7115],{"nctId":84,"briefTitle":85,"status":108,"phases":7099,"primaryCompletion":86,"completion":660,"start":7100,"enrollment":477,"conditions":7101,"interventions":7109},[92],"2017-07-25",[4058,7102,7103,7104,7105,7106,7107,7108],"Carcinoma, Renal Cell","Kidney Neoplasms","Urologic Neoplasms","Kidney Diseases","Neoplasms by Site","Enzyme Inhibitors","Protein Kinase Inhibitors",[87,7110],"Sunitinib",{"nctId":4050,"briefTitle":4051,"status":108,"phases":7112,"primaryCompletion":4053,"completion":4054,"start":4055,"enrollment":4056,"conditions":7113,"interventions":7114},[92],[4058,4059],[87,1012,345,177,344],{"nctId":3480,"briefTitle":3481,"status":108,"phases":7116,"primaryCompletion":1317,"completion":3483,"start":339,"enrollment":3484,"conditions":7117,"interventions":7118},[92],[3486],[3488,900,3489],{"trials":7120,"activeCount":102},[],{"trials":7122,"activeCount":102},[],{"intervention":3966,"totalTrials":4343,"cells":7124},{"EARLY_PHASE1":7125,"PHASE1":7127,"PHASE2":7151,"PHASE3":7178,"PHASE4":7204,"NA":7206},{"trials":7126,"activeCount":102},[],{"trials":7128,"activeCount":102},[7129,7137,7144],{"nctId":7130,"briefTitle":7131,"status":195,"phases":7132,"primaryCompletion":7133,"completion":7133,"start":7134,"enrollment":1638,"conditions":7135,"interventions":7136},"NCT05551897","A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole",[90],"2022-12-28","2022-10-04",[1556],[3966,5911],{"nctId":7138,"briefTitle":7139,"status":195,"phases":7140,"primaryCompletion":234,"completion":234,"start":7141,"enrollment":434,"conditions":7142,"interventions":7143},"NCT05790304","Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects",[90],"2023-02-20",[6914],[3966],{"nctId":7145,"briefTitle":7146,"status":195,"phases":7147,"primaryCompletion":7148,"completion":7148,"start":3983,"enrollment":1448,"conditions":7149,"interventions":7150},"NCT06547164","A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants",[90],"2025-08-20",[5851],[5870,3966,6875],{"trials":7152,"activeCount":3887,"soonestReadout":3958},[7153,7165,7174],{"nctId":7154,"briefTitle":7155,"status":151,"phases":7156,"primaryCompletion":7157,"completion":7157,"start":7158,"enrollment":7159,"conditions":7160,"interventions":7163},"NCT06188520","A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors",[90,91],"2027-08-04","2023-12-05",564,[7161,7162],"ER+ HER2- Advanced Breast Cancer","High-grade Serous Ovarian Cancer (HGSOC)",[7164,3966,5978,5977,5979],"AZD8421",{"nctId":7166,"briefTitle":7167,"status":151,"phases":7168,"primaryCompletion":7169,"completion":7169,"start":7170,"enrollment":1130,"conditions":7171,"interventions":7172},"NCT07427394","Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer",[91],"2027-12-03","2026-05-06",[6348],[3966,7173],"Atirmociclib",{"nctId":3955,"briefTitle":3956,"status":108,"phases":7175,"primaryCompletion":3958,"completion":3958,"start":1574,"enrollment":3959,"conditions":7176,"interventions":7177},[90,91],[414,25,415,416,3961,1049,691,403,172,3962,404,367,3963],[1939,118,344,3965,808,3966],{"trials":7179,"activeCount":3887,"soonestReadout":7184},[7180,7190,7200],{"nctId":7181,"briefTitle":7182,"status":151,"phases":7183,"primaryCompletion":7184,"completion":7185,"start":1917,"enrollment":7186,"conditions":7187,"interventions":7189},"NCT05774951","A Study of Camizestrant in ER+\u002FHER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy",[92],"2027-04-20","2036-05-29",4300,[7188],"Breast Cancer, Early Breast Cancer",[3966,468,120,469,6350],{"nctId":7191,"briefTitle":7192,"status":151,"phases":7193,"primaryCompletion":7194,"completion":7195,"start":7196,"enrollment":7197,"conditions":7198,"interventions":7199},"NCT05952557","An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+\u002FHER2- Early Breast Cancer (CAMBRIA-2)",[92],"2030-03-04","2037-05-06","2023-10-05",5500,[7188],[3966,468,120,469,6350,5979],{"nctId":6340,"briefTitle":6341,"status":151,"phases":7201,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":6346,"conditions":7202,"interventions":7203},[92],[6348],[1959,3966,5979,5978,5977,53,469,120,6350],{"trials":7205,"activeCount":102},[],{"trials":7207,"activeCount":102},[],{"intervention":251,"totalTrials":370,"cells":7209},{"EARLY_PHASE1":7210,"PHASE1":7212,"PHASE2":7222,"PHASE3":7244,"PHASE4":7250,"NA":7252},{"trials":7211,"activeCount":102},[],{"trials":7213,"activeCount":122,"soonestReadout":3122},[7214,7218],{"nctId":1913,"briefTitle":1914,"status":195,"phases":7215,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":7216,"interventions":7217},[90],[157,1921,1922,1923],[1925,117,1926,1927,251,369],{"nctId":3119,"briefTitle":3120,"status":108,"phases":7219,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":7220,"interventions":7221},[90],[3127],[117,264,251,980,345,344,283,177,3097,979],{"trials":7223,"activeCount":1979,"soonestReadout":257},[7224,7228,7232,7236,7240],{"nctId":3203,"briefTitle":3204,"status":195,"phases":7225,"primaryCompletion":3206,"completion":3207,"start":3208,"enrollment":3209,"conditions":7226,"interventions":7227},[91],[416,3211],[1925,251,117],{"nctId":3224,"briefTitle":3225,"status":151,"phases":7229,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":7230,"interventions":7231},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"nctId":241,"briefTitle":242,"status":108,"phases":7233,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":7234,"interventions":7235},[90,91],[249],[117,119,251,118,97,252],{"nctId":254,"briefTitle":255,"status":108,"phases":7237,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":7238,"interventions":7239},[91],[262],[117,264,265,266,267,251,97,268],{"nctId":3297,"briefTitle":3298,"status":108,"phases":7241,"primaryCompletion":973,"completion":3300,"start":3301,"enrollment":1710,"conditions":7242,"interventions":7243},[91],[262],[251,117],{"trials":7245,"activeCount":122,"soonestReadout":130},[7246],{"nctId":3388,"briefTitle":3389,"status":108,"phases":7247,"primaryCompletion":130,"completion":3391,"start":3392,"enrollment":3393,"conditions":7248,"interventions":7249},[92],[262],[117,251,3232],{"trials":7251,"activeCount":102},[],{"trials":7253,"activeCount":102},[],{"intervention":1467,"totalTrials":1039,"cells":7255},{"EARLY_PHASE1":7256,"PHASE1":7258,"PHASE2":7269,"PHASE3":7294,"PHASE4":7318,"NA":7320},{"trials":7257,"activeCount":102},[],{"trials":7259,"activeCount":122,"soonestReadout":7264},[7260],{"nctId":7261,"briefTitle":7262,"status":151,"phases":7263,"primaryCompletion":7264,"completion":7264,"start":7265,"enrollment":5898,"conditions":7266,"interventions":7268},"NCT07201558","Study Evaluating Safety, Tolerability, PK\u002FPD of Surovatamig in Adult RA or SLE Participants",[90],"2028-06-27","2025-12-02",[7267,1140],"Rheumatoid Arthritis",[1467],{"trials":7270,"activeCount":3887,"soonestReadout":7275},[7271,7281,7290],{"nctId":7272,"briefTitle":7273,"status":151,"phases":7274,"primaryCompletion":7275,"completion":7276,"start":4151,"enrollment":1173,"conditions":7277,"interventions":7280},"NCT06526793","Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed\u002FRefractory (R\u002FR) B-cell NHL",[91],"2027-03-10","2029-06-14",[1465,7278,7279],"Follicular Lymphoma (FL)","Large B-Cell Lymphoma (LBCL)",[1467],{"nctId":7282,"briefTitle":7283,"status":151,"phases":7284,"primaryCompletion":4024,"completion":7285,"start":7286,"enrollment":911,"conditions":7287,"interventions":7289},"NCT07571746","A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease",[91],"2029-10-15","2026-03-28",[7288],"Primary Membranous Nephropathy",[1467],{"nctId":1454,"briefTitle":1455,"status":151,"phases":7291,"primaryCompletion":1457,"completion":1458,"start":1459,"enrollment":1460,"conditions":7292,"interventions":7293},[90,91],[1462,1409,1463,1464,1465],[1467,914,1378,524,1468,309,1335],{"trials":7295,"activeCount":447,"soonestReadout":1067},[7296,7306],{"nctId":7297,"briefTitle":7298,"status":151,"phases":7299,"primaryCompletion":1067,"completion":7300,"start":7301,"enrollment":7302,"conditions":7303,"interventions":7305},"NCT07509151","Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)",[92],"2032-04-05","2026-05-05",420,[7304],"Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV",[1467],{"nctId":7307,"briefTitle":7308,"status":151,"phases":7309,"primaryCompletion":7310,"completion":7310,"start":7311,"enrollment":3419,"conditions":7312,"interventions":7314},"NCT06549595","A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients",[92],"2031-11-26","2024-08-07",[7313],"Untreated Follicular Lymphoma",[1467,7315,7316,7317],"R-CHOP","R-CVP","BR",{"trials":7319,"activeCount":102},[],{"trials":7321,"activeCount":102},[],{"intervention":120,"totalTrials":496,"cells":7323},{"EARLY_PHASE1":7324,"PHASE1":7326,"PHASE2":7336,"PHASE3":7386,"PHASE4":7517,"NA":7548},{"trials":7325,"activeCount":102},[],{"trials":7327,"activeCount":122,"soonestReadout":110},[7328,7332],{"nctId":458,"briefTitle":459,"status":195,"phases":7329,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":7330,"interventions":7331},[90],[466],[267,468,120,469],{"nctId":106,"briefTitle":107,"status":108,"phases":7333,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":7334,"interventions":7335},[90],[115],[97,117,118,119,120,53,121],{"trials":7337,"activeCount":102},[7338,7346,7350,7357,7364,7368,7376],{"nctId":7339,"briefTitle":7340,"status":195,"phases":7341,"primaryCompletion":7342,"completion":7342,"start":6650,"enrollment":1348,"conditions":7343,"interventions":7345},"NCT00241436","Open Label Arimidex in Gynecomastia",[91],"2006-11",[7344],"Gynecomastia",[120],{"nctId":6401,"briefTitle":6402,"status":195,"phases":7347,"primaryCompletion":6404,"completion":6405,"start":6406,"enrollment":6407,"conditions":7348,"interventions":7349},[91],[115],[6410,6411],{"nctId":7351,"briefTitle":7352,"status":195,"phases":7353,"primaryCompletion":7354,"completion":7354,"start":6572,"enrollment":1935,"conditions":7355,"interventions":7356},"NCT00077025","Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and\u002For Progesterone Receptor Metastatic Breast Cancer",[91],"2013-05",[25],[1013,120],{"nctId":7358,"briefTitle":7359,"status":443,"phases":7360,"primaryCompletion":2579,"completion":2579,"start":2242,"enrollment":7361,"conditions":7362,"interventions":7363},"NCT01151215","Study of Anastrozole +\u002F- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer",[91],482,[3841,306,25],[4501,6411],{"nctId":6490,"briefTitle":6491,"status":195,"phases":7365,"primaryCompletion":2086,"completion":2086,"start":6369,"enrollment":963,"conditions":7366,"interventions":7367},[91],[25],[53,120],{"nctId":7369,"briefTitle":7370,"status":195,"phases":7371,"completion":4285,"start":7372,"enrollment":7373,"conditions":7374,"interventions":7375},"NCT00287534","Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.",[91],"1996-11",1059,[25],[120,468],{"nctId":7377,"briefTitle":7378,"status":195,"phases":7379,"primaryCompletion":7380,"completion":7381,"start":7382,"enrollment":1638,"conditions":7383,"interventions":7384},"NCT00094328","Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]",[91],"2008-05-22","2017-12-06","2004-11-22",[6486],[7385,120],"Bicalutamide",{"trials":7387,"activeCount":723,"soonestReadout":1406},[7388,7397,7401,7405,7409,7422,7426,7435,7443,7452,7460,7471,7479,7483,7490,7499,7503,7507],{"nctId":7389,"briefTitle":7390,"status":195,"phases":7391,"completion":6370,"start":7392,"enrollment":7393,"conditions":7394,"interventions":7396},"NCT00784680","ATAC - Quality of Life Sub-Protocol",[92],"1998-04",308,[7395],"Quality of Life",[120,468],{"nctId":7181,"briefTitle":7182,"status":151,"phases":7398,"primaryCompletion":7184,"completion":7185,"start":1917,"enrollment":7186,"conditions":7399,"interventions":7400},[92],[7188],[3966,468,120,469,6350],{"nctId":7191,"briefTitle":7192,"status":151,"phases":7402,"primaryCompletion":7194,"completion":7195,"start":7196,"enrollment":7197,"conditions":7403,"interventions":7404},[92],[7188],[3966,468,120,469,6350,5979],{"nctId":6514,"briefTitle":6515,"status":195,"phases":7406,"completion":2415,"start":6517,"enrollment":6518,"conditions":7407,"interventions":7408},[92],[6348],[53,120],{"nctId":7410,"briefTitle":7411,"status":108,"phases":7412,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":7415,"interventions":7417},"NCT04964934","Phase III Study to Assess AZD9833+ CDK4\u002F6 Inhibitor in HR+\u002FHER2-MBC With Detectable ESR1m Before Progression (SERENA-6)",[92],"2028-09-01","2021-06-30",[7416],"ER-Positive HER2-Negative Breast Cancer",[6431,7418,120,7419,469,7420,5977,5979,7421,5978],"AZD9833 Placebo","Anastrozole placebo","Letrozole placebo","Luteinizing hormone-releasing hormone (LHRH) agonist",{"nctId":6536,"briefTitle":6537,"status":195,"phases":7423,"completion":4285,"start":6539,"enrollment":6540,"conditions":7424,"interventions":7425},[92],[6348],[53,120,53],{"nctId":7427,"briefTitle":7428,"status":195,"phases":7429,"completion":7430,"start":7431,"enrollment":7432,"conditions":7433,"interventions":7434},"NCT00784862","ATAC - Pharmacokinetics (PK) Sub-Protocol",[92],"1999-03","1998-06",9358,[25],[120,468],{"nctId":7436,"briefTitle":7437,"status":195,"phases":7438,"primaryCompletion":5796,"completion":7439,"start":7431,"enrollment":7393,"conditions":7440,"interventions":7442},"NCT00784940","ATAC - Bone Density Sub-Protocol",[92],"2007-04",[7441],"Bone Density",[120,468],{"nctId":7444,"briefTitle":7445,"status":195,"phases":7446,"primaryCompletion":7447,"completion":7448,"start":7449,"conditions":7450,"interventions":7451},"NCT00637182","Gynecomastia Extension Study",[92],"2002-06","2002-10","2001-01",[7344],[120],{"nctId":7453,"briefTitle":7454,"status":195,"phases":7455,"primaryCompletion":506,"completion":506,"start":7456,"enrollment":7457,"conditions":7458,"interventions":7459},"NCT00295620","Secondary Adjuvant Long Term Study With Arimidex",[92],"2004-03-01",3484,[25],[120],{"nctId":7461,"briefTitle":7462,"status":108,"phases":7463,"primaryCompletion":7464,"completion":7465,"start":7466,"enrollment":7467,"conditions":7468,"interventions":7469},"NCT04711252","A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease",[92],"2026-08-24","2029-02-01","2021-01-28",1370,[7416],[6431,120,7419,7470,5977,7421],"AZD9833 placebo",{"nctId":7472,"briefTitle":7473,"status":195,"phases":7474,"start":7475,"enrollment":7476,"conditions":7477,"interventions":7478},"NCT00300508","3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer",[92],"1996-01",856,[306],[120],{"nctId":6569,"briefTitle":6570,"status":195,"phases":7480,"primaryCompletion":2320,"completion":2366,"start":6572,"enrollment":6573,"conditions":7481,"interventions":7482},[92],[25],[53,120],{"nctId":7484,"briefTitle":7485,"status":195,"phases":7486,"primaryCompletion":2152,"completion":2152,"start":7475,"enrollment":7487,"conditions":7488,"interventions":7489},"NCT00291759","ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.",[92],3858,[25],[468,120],{"nctId":7491,"briefTitle":7492,"status":195,"phases":7493,"completion":7494,"start":7495,"enrollment":7496,"conditions":7497,"interventions":7498},"NCT00286117","ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years",[92],"2006-05","1998-03",448,[25],[120,468],{"nctId":6577,"briefTitle":6578,"status":195,"phases":7500,"primaryCompletion":2542,"completion":2542,"start":4915,"enrollment":98,"conditions":7501,"interventions":7502},[92],[6581],[6410,6411,6583],{"nctId":6340,"briefTitle":6341,"status":151,"phases":7504,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":6346,"conditions":7505,"interventions":7506},[92],[6348],[1959,3966,5979,5978,5977,53,469,120,6350],{"nctId":7508,"briefTitle":7509,"status":195,"phases":7510,"completion":2329,"start":7511,"enrollment":7512,"conditions":7513,"interventions":7514},"NCT00814125","ATAC - Endometrial Sub-Protocol",[92],"1997-06",285,[25],[120,468,7515,7516],"Nolvadex placebo","Arimidex placebo",{"trials":7518,"activeCount":102},[7519,7526,7532,7540],{"nctId":7520,"briefTitle":7521,"status":195,"phases":7522,"primaryCompletion":2589,"completion":2589,"start":2415,"enrollment":7523,"conditions":7524,"interventions":7525},"NCT00537771","Liver Safety Under Upfront Arimidex vs Tamoxifen",[93],384,[25],[120,468],{"nctId":7527,"briefTitle":7528,"status":195,"phases":7529,"primaryCompletion":2169,"completion":2169,"start":6650,"conditions":7530,"interventions":7531},"NCT00544986","A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer",[93],[25],[120],{"nctId":7533,"briefTitle":7534,"status":195,"phases":7535,"primaryCompletion":4297,"completion":4297,"start":6370,"enrollment":7536,"conditions":7537,"interventions":7538},"NCT00082277","Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer",[93],237,[25],[120,7539],"Risedronate Sodium",{"nctId":7541,"briefTitle":7542,"status":195,"phases":7543,"primaryCompletion":7544,"completion":7544,"start":6562,"enrollment":3218,"conditions":7545,"interventions":7547},"NCT00323479","Arthralgia During Anastrozole Therapy for Breast Cancer",[93],"2009-01",[7546],"Early Breast Cancer",[120],{"trials":7549,"activeCount":102},[7550,7558,7564,7570,7577],{"nctId":7551,"briefTitle":7552,"status":195,"phases":7553,"completion":3839,"start":7554,"enrollment":7555,"conditions":7556,"interventions":7557},"NCT00638391","Ax-003\u002FArimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer",[],"2005-05",1600,[25],[120],{"nctId":7559,"briefTitle":7560,"status":195,"phases":7561,"start":5742,"enrollment":1685,"conditions":7562,"interventions":7563},"NCT00562458","Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer",[],[6348],[6411],{"nctId":7565,"briefTitle":7566,"status":195,"phases":7567,"primaryCompletion":2055,"completion":2143,"start":2152,"enrollment":4877,"conditions":7568,"interventions":7569},"NCT00936442","Arimidex Therapy Compliance Electronic Monitoring System",[],[25],[120],{"nctId":7571,"briefTitle":7572,"status":443,"phases":7573,"primaryCompletion":2433,"completion":2433,"start":2639,"enrollment":7574,"conditions":7575,"interventions":7576},"NCT00555867","Patient's Anastrozole Compliance to Therapy Programme",[],4923,[25],[120],{"nctId":7578,"briefTitle":7579,"status":195,"phases":7580,"completion":2055,"start":2168,"enrollment":3000,"conditions":7581,"interventions":7584},"NCT00660244","Breast Cancer Tumor Care Observational Programme",[],[7582,7583],"Post Menopausal","Arthralgia",[6411],{"intervention":68,"totalTrials":3855,"cells":7586},{"EARLY_PHASE1":7587,"PHASE1":7589,"PHASE2":7675,"PHASE3":7690,"PHASE4":7716,"NA":7718},{"trials":7588,"activeCount":102},[],{"trials":7590,"activeCount":3887,"soonestReadout":562},[7591,7597,7601,7610,7614,7623,7629,7636,7643,7651,7655,7659,7668],{"nctId":7592,"briefTitle":7593,"status":195,"phases":7594,"primaryCompletion":2204,"completion":2204,"start":1693,"enrollment":3190,"conditions":7595,"interventions":7596},"NCT01974349","To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers",[90],[466],[3801],{"nctId":3793,"briefTitle":3794,"status":195,"phases":7598,"primaryCompletion":3796,"completion":3796,"start":3797,"enrollment":2783,"conditions":7599,"interventions":7600},[90],[3799],[3801,3802,3803,672,3804],{"nctId":7602,"briefTitle":7603,"status":195,"phases":7604,"primaryCompletion":3206,"completion":7605,"start":7606,"enrollment":1757,"conditions":7607,"interventions":7609},"NCT04495127","Selumetinib Paediatric NF1 Japan Study",[90],"2023-03-24","2020-08-31",[7608],"Neurofibromatosis Type 1",[68],{"nctId":4201,"briefTitle":4202,"status":443,"phases":7611,"primaryCompletion":2560,"completion":2560,"start":4204,"enrollment":1039,"conditions":7612,"interventions":7613},[90],[4206],[177,283,68],{"nctId":7615,"briefTitle":7616,"status":195,"phases":7617,"primaryCompletion":2470,"completion":2470,"start":7618,"enrollment":2827,"conditions":7619,"interventions":7620},"NCT02093728","To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers",[90],"2014-04",[466],[3801,7621,7621,3801,3801,7622,7622,3801],"itraconazole","fluconazole",{"nctId":7624,"briefTitle":7625,"status":195,"phases":7626,"primaryCompletion":1692,"completion":1692,"start":4006,"enrollment":1130,"conditions":7627,"interventions":7628},"NCT02063204","To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects",[90],[466],[3801],{"nctId":7630,"briefTitle":7631,"status":195,"phases":7632,"primaryCompletion":2203,"completion":2203,"start":4204,"enrollment":565,"conditions":7633,"interventions":7635},"NCT01960374","Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK",[90],[7634],"Healthy Volunteers Pharmacokinetic Study",[68],{"nctId":7637,"briefTitle":7638,"status":195,"phases":7639,"primaryCompletion":7618,"completion":7618,"start":2204,"enrollment":1130,"conditions":7640,"interventions":7641},"NCT02046850","To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers",[90],[466],[3801,7642,3801,7642],"rifampicin",{"nctId":7644,"briefTitle":7645,"status":108,"phases":7646,"primaryCompletion":7647,"completion":7648,"start":1767,"enrollment":1130,"conditions":7649,"interventions":7650},"NCT05101148","Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas",[90],"2022-04-06","2028-04-28",[7608],[68],{"nctId":5218,"briefTitle":5219,"status":195,"phases":7652,"primaryCompletion":5221,"completion":5222,"start":5223,"enrollment":3180,"conditions":7653,"interventions":7654},[90],[3174,410,5225,3106,25,5226,691,281],[68,82,3137],{"nctId":559,"briefTitle":560,"status":108,"phases":7656,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":7657,"interventions":7658},[90],[567],[569,82,267,570,266,571,68],{"nctId":7660,"briefTitle":7661,"status":108,"phases":7662,"primaryCompletion":7663,"completion":3560,"start":3644,"enrollment":579,"conditions":7664,"interventions":7667},"NCT04590235","A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)",[90],"2022-08-16",[7665,7666],"Neurofibromatosis 1","Neurofibroma Plexiform",[68],{"nctId":7669,"briefTitle":7670,"status":195,"phases":7671,"primaryCompletion":2560,"completion":2560,"start":4006,"enrollment":680,"conditions":7672,"interventions":7673},"NCT02056392","To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers",[90],[466],[68,2255,7674],"selumetinib placebo",{"trials":7676,"activeCount":122,"soonestReadout":1007},[7677,7686],{"nctId":7678,"briefTitle":7679,"status":624,"phases":7680,"primaryCompletion":130,"completion":130,"start":7681,"enrollment":102,"conditions":7682,"interventions":7685},"NCT05825365","Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study",[91],"2023-08-31",[7608,7683,7684],"Plexiform Neurofibromas","Post-operative",[68],{"nctId":1004,"briefTitle":1005,"status":108,"phases":7687,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":7688,"interventions":7689},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"trials":7691,"activeCount":447,"soonestReadout":67},[7692,7702,7712],{"nctId":7693,"briefTitle":7694,"status":108,"phases":7695,"primaryCompletion":7696,"completion":7697,"start":1872,"enrollment":7698,"conditions":7699,"interventions":7701},"NCT04924608","Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas",[92],"2024-08-05","2029-02-15",145,[7665,7700],"Plexiform Neurofibroma (PN)",[68],{"nctId":7703,"briefTitle":7704,"status":443,"phases":7705,"primaryCompletion":7706,"completion":3714,"start":7707,"enrollment":1852,"conditions":7708,"interventions":7710},"NCT01843062","Comparing Complete Remission After Treatment With Selumetinib\u002FPlacebo in Patient With Differentiated Thyroid Cancer",[92],"2018-05-18","2013-08-27",[7709],"Differentiated Thyroid Cancer",[68,7711],"Radioactive Iodine Therapy",{"nctId":65,"briefTitle":66,"status":108,"phases":7713,"primaryCompletion":67,"completion":1317,"start":6732,"enrollment":6733,"conditions":7714,"interventions":7715},[92],[6735],[68,369,6737],{"trials":7717,"activeCount":102},[],{"trials":7719,"activeCount":102},[7720],{"nctId":7721,"briefTitle":7722,"status":958,"phases":7723,"conditions":7724,"interventions":7726},"NCT03259633","An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1",[],[7725],"NF type1 With Inoperable Plexiform Neurofibromas",[68],{"intervention":265,"totalTrials":269,"cells":7728},{"EARLY_PHASE1":7729,"PHASE1":7731,"PHASE2":7760,"PHASE3":7786,"PHASE4":7792,"NA":7794},{"trials":7730,"activeCount":102},[],{"trials":7732,"activeCount":122,"soonestReadout":3113},[7733,7744,7748,7752],{"nctId":7734,"briefTitle":7735,"status":443,"phases":7736,"primaryCompletion":7737,"completion":6628,"start":7738,"enrollment":122,"conditions":7739,"interventions":7740},"NCT06929260","A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z",[90],"2025-10-15","2025-05-21",[498],[265,7741,7742,7743],"Drug X","Drug Y","Drug Z",{"nctId":539,"briefTitle":540,"status":195,"phases":7745,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":7746,"interventions":7747},[90],[546],[265,267],{"nctId":3110,"briefTitle":3111,"status":108,"phases":7749,"primaryCompletion":3113,"completion":3114,"start":3115,"enrollment":1638,"conditions":7750,"interventions":7751},[90],[498],[265,117],{"nctId":7753,"briefTitle":7754,"status":195,"phases":7755,"primaryCompletion":7069,"completion":7756,"start":7757,"enrollment":1757,"conditions":7758,"interventions":7759},"NCT05469919","An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies",[90],"2024-03-12","2022-06-09",[157],[265],{"trials":7761,"activeCount":3887,"soonestReadout":3161},[7762,7766,7770,7774,7782],{"nctId":622,"briefTitle":623,"status":624,"phases":7763,"primaryCompletion":626,"completion":626,"start":627,"enrollment":102,"conditions":7764,"interventions":7765},[91],[414],[267,265],{"nctId":3158,"briefTitle":3159,"status":108,"phases":7767,"primaryCompletion":3161,"completion":3162,"start":3163,"enrollment":1575,"conditions":7768,"interventions":7769},[91],[410],[265,117],{"nctId":3185,"briefTitle":3186,"status":108,"phases":7771,"primaryCompletion":3188,"completion":1485,"start":3189,"enrollment":3190,"conditions":7772,"interventions":7773},[91],[977],[265,117],{"nctId":7775,"briefTitle":7776,"status":195,"phases":7777,"primaryCompletion":7778,"completion":7778,"start":7779,"enrollment":680,"conditions":7780,"interventions":7781},"NCT04564027","A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer",[91],"2025-02-18","2020-12-01",[498],[265],{"nctId":254,"briefTitle":255,"status":108,"phases":7783,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":7784,"interventions":7785},[91],[262],[117,264,265,266,267,251,97,268],{"trials":7787,"activeCount":122,"soonestReadout":3361},[7788],{"nctId":3358,"briefTitle":3359,"status":108,"phases":7789,"primaryCompletion":3361,"completion":3362,"start":3363,"enrollment":3364,"conditions":7790,"interventions":7791},[92],[3366],[265,117,369],{"trials":7793,"activeCount":102},[],{"trials":7795,"activeCount":102},[],{"intervention":3354,"totalTrials":1039,"cells":7797},{"EARLY_PHASE1":7798,"PHASE1":7800,"PHASE2":7806,"PHASE3":7808,"PHASE4":7836,"NA":7838},{"trials":7799,"activeCount":102},[],{"trials":7801,"activeCount":102},[7802],{"nctId":3018,"briefTitle":3019,"status":195,"phases":7803,"primaryCompletion":3021,"completion":3021,"start":2781,"enrollment":579,"conditions":7804,"interventions":7805},[90],[3023,3024,3025,249,3026,3027,3028,3029,3030,3031],[3033,3034,3035,3036,3037,900,3038,3039,3040],{"trials":7807,"activeCount":102},[],{"trials":7809,"activeCount":723,"soonestReadout":81},[7810,7814,7818,7828,7832],{"nctId":3344,"briefTitle":3345,"status":108,"phases":7811,"primaryCompletion":1357,"completion":130,"start":3347,"enrollment":3348,"conditions":7812,"interventions":7813},[92],[3350],[117,3352,3353,3354,3355,3356],{"nctId":3397,"briefTitle":3398,"status":108,"phases":7815,"primaryCompletion":3400,"completion":601,"start":110,"enrollment":3289,"conditions":7816,"interventions":7817},[92],[281],[117,3403,3353,3404,3354,3405,3406,3407],{"nctId":7819,"briefTitle":7820,"status":108,"phases":7821,"primaryCompletion":7822,"completion":660,"start":7823,"enrollment":7824,"conditions":7825,"interventions":7826},"NCT02542293","Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)",[92],"2020-09-21","2015-11-03",953,[3350],[7827,3352,3353,3354,3355,3356],"Durvalumab +Tremelimumab",{"nctId":79,"briefTitle":80,"status":108,"phases":7829,"primaryCompletion":81,"completion":660,"start":5298,"enrollment":5299,"conditions":7830,"interventions":7831},[92],[5301],[82,5303,3878,5304,5305,5306,5307,3137],{"nctId":3699,"briefTitle":3700,"status":108,"phases":7833,"primaryCompletion":3702,"completion":3703,"start":3704,"enrollment":3705,"conditions":7834,"interventions":7835},[92],[3707],[117,3137,3709,3353,3354,3356,3355],{"trials":7837,"activeCount":102},[],{"trials":7839,"activeCount":102},[],{"intervention":5977,"totalTrials":1039,"cells":7841},{"EARLY_PHASE1":7842,"PHASE1":7844,"PHASE2":7850,"PHASE3":7856,"PHASE4":7874,"NA":7876},{"trials":7843,"activeCount":102},[],{"trials":7845,"activeCount":102},[7846],{"nctId":6374,"briefTitle":6375,"status":195,"phases":7847,"primaryCompletion":6377,"completion":3685,"start":6378,"enrollment":680,"conditions":7848,"interventions":7849},[90],[6380],[6382,5977,53],{"trials":7851,"activeCount":122,"soonestReadout":7157},[7852],{"nctId":7154,"briefTitle":7155,"status":151,"phases":7853,"primaryCompletion":7157,"completion":7157,"start":7158,"enrollment":7159,"conditions":7854,"interventions":7855},[90,91],[7161,7162],[7164,3966,5978,5977,5979],{"trials":7857,"activeCount":1979,"soonestReadout":1406},[7858,7862,7866,7870],{"nctId":7410,"briefTitle":7411,"status":108,"phases":7859,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":7860,"interventions":7861},[92],[7416],[6431,7418,120,7419,469,7420,5977,5979,7421,5978],{"nctId":5970,"briefTitle":5971,"status":151,"phases":7863,"primaryCompletion":1086,"completion":5973,"start":5974,"enrollment":863,"conditions":7864,"interventions":7865},[92],[5959],[119,53,5977,5978,5979],{"nctId":7461,"briefTitle":7462,"status":108,"phases":7867,"primaryCompletion":7464,"completion":7465,"start":7466,"enrollment":7467,"conditions":7868,"interventions":7869},[92],[7416],[6431,120,7419,7470,5977,7421],{"nctId":6340,"briefTitle":6341,"status":151,"phases":7871,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":6346,"conditions":7872,"interventions":7873},[92],[6348],[1959,3966,5979,5978,5977,53,469,120,6350],{"trials":7875,"activeCount":102},[],{"trials":7877,"activeCount":102},[],{"intervention":7879,"totalTrials":723,"cells":7880},"AZD0120",{"EARLY_PHASE1":7881,"PHASE1":7883,"PHASE2":7903,"PHASE3":7921,"PHASE4":7938,"NA":7940},{"trials":7882,"activeCount":102},[],{"trials":7884,"activeCount":447,"soonestReadout":7898},[7885,7894],{"nctId":7886,"briefTitle":7887,"status":151,"phases":7888,"primaryCompletion":7889,"completion":7889,"start":7890,"enrollment":1448,"conditions":7891,"interventions":7893},"NCT07073547","A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)",[90],"2028-05-26","2025-07-31",[7892],"Multiple Myeloma",[7879],{"nctId":7895,"briefTitle":7896,"status":151,"phases":7897,"primaryCompletion":7898,"completion":7898,"start":7899,"enrollment":2003,"conditions":7900,"interventions":7902},"NCT07295847","A Study of AZD0120 in Autoimmune Diseases",[90],"2028-02-22","2026-01-09",[1250,7901,7267],"Idiopathic Inflammatory Myopathies",[7879],{"trials":7904,"activeCount":447,"soonestReadout":1270},[7905,7913],{"nctId":7906,"briefTitle":7907,"status":151,"phases":7908,"primaryCompletion":1393,"completion":1393,"start":7909,"enrollment":3000,"conditions":7910,"interventions":7911},"NCT06897930","A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE",[90,91],"2025-04-21",[1283],[7879,524,7912],"Fludarabine",{"nctId":7914,"briefTitle":7915,"status":151,"phases":7916,"primaryCompletion":1270,"completion":7917,"start":6483,"enrollment":2590,"conditions":7918,"interventions":7920},"NCT05850234","AZD0120 in Relapsed\u002FRefractory Multiple Myeloma (DURGA-1)",[90,91],"2028-11-14",[7919],"Relapsed\u002FRefractory Multiple Myeloma",[7879],{"trials":7922,"activeCount":122,"soonestReadout":7927},[7923],{"nctId":7924,"briefTitle":7925,"status":151,"phases":7926,"primaryCompletion":7927,"completion":7928,"start":3693,"enrollment":7929,"conditions":7930,"interventions":7932},"NCT07391657","A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)",[92],"2028-06-14","2030-08-12",508,[7931],"Relapsed Refractory Multiple Myeloma",[7879,7933,7934,7935,7936,7937],"Daratumumab","Carfilzomib","Dexamethasone","Bortezomib","Pomalidomide",{"trials":7939,"activeCount":102},[],{"trials":7941,"activeCount":102},[],{"intervention":225,"totalTrials":723,"cells":7943},{"EARLY_PHASE1":7944,"PHASE1":7946,"PHASE2":7948,"PHASE3":7971,"PHASE4":7977,"NA":7979},{"trials":7945,"activeCount":102},[],{"trials":7947,"activeCount":102},[],{"trials":7949,"activeCount":1979,"soonestReadout":5770},[7950,7954,7958,7967],{"nctId":5767,"briefTitle":5768,"status":151,"phases":7951,"primaryCompletion":5770,"completion":1952,"start":1372,"enrollment":2289,"conditions":7952,"interventions":7953},[91],[172,4612,281,5772],[225,226,4843,5774,4615,5775,283],{"nctId":215,"briefTitle":216,"status":151,"phases":7955,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":7956,"interventions":7957},[91],[223],[225,180,162,121,226,227],{"nctId":7959,"briefTitle":7960,"status":108,"phases":7961,"primaryCompletion":7962,"completion":7963,"start":7964,"enrollment":689,"conditions":7965,"interventions":7966},"NCT07143604","A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2",[91],"2026-09-28","2027-09-28","2025-08-29",[172,4612],[225],{"nctId":4766,"briefTitle":4767,"status":151,"phases":7968,"primaryCompletion":4769,"completion":4770,"start":4771,"enrollment":2640,"conditions":7969,"interventions":7970},[91],[172],[180,179,4774,4775,225,226,121],{"trials":7972,"activeCount":122,"soonestReadout":4607},[7973],{"nctId":4604,"briefTitle":4605,"status":108,"phases":7974,"primaryCompletion":4607,"completion":4608,"start":4609,"enrollment":4610,"conditions":7975,"interventions":7976},[92],[172,4612],[225,225,4614,118,369,4615,4616,4617],{"trials":7978,"activeCount":102},[],{"trials":7980,"activeCount":102},[],{"intervention":309,"totalTrials":723,"cells":7982},{"EARLY_PHASE1":7983,"PHASE1":7985,"PHASE2":7987,"PHASE3":7993,"PHASE4":8011,"NA":8013},{"trials":7984,"activeCount":102},[],{"trials":7986,"activeCount":102},[],{"trials":7988,"activeCount":122,"soonestReadout":1457},[7989],{"nctId":1454,"briefTitle":1455,"status":151,"phases":7990,"primaryCompletion":1457,"completion":1458,"start":1459,"enrollment":1460,"conditions":7991,"interventions":7992},[90,91],[1462,1409,1463,1464,1465],[1467,914,1378,524,1468,309,1335],{"trials":7994,"activeCount":1979,"soonestReadout":301},[7995,7999,8003,8007],{"nctId":4619,"briefTitle":4620,"status":151,"phases":7996,"primaryCompletion":4622,"completion":4623,"start":4624,"enrollment":4625,"conditions":7997,"interventions":7998},[92],[367,4627],[4629,309,118],{"nctId":298,"briefTitle":299,"status":108,"phases":8000,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":8001,"interventions":8002},[92],[306,25,307],[162,118,176,146,309,310],{"nctId":799,"briefTitle":800,"status":108,"phases":8004,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":8005,"interventions":8006},[92],[25],[808,117,178,309,809,524,118,344,121,267],{"nctId":3578,"briefTitle":3579,"status":151,"phases":8008,"primaryCompletion":1371,"completion":1371,"start":3581,"enrollment":3000,"conditions":8009,"interventions":8010},[92],[664,3583,3584,3585,309,177,283],[117,3584,3585,309,177,117,283,177],{"trials":8012,"activeCount":102},[],{"trials":8014,"activeCount":102},[],{"intervention":3353,"totalTrials":723,"cells":8016},{"EARLY_PHASE1":8017,"PHASE1":8019,"PHASE2":8021,"PHASE3":8023,"PHASE4":8045,"NA":8047},{"trials":8018,"activeCount":102},[],{"trials":8020,"activeCount":102},[],{"trials":8022,"activeCount":102},[],{"trials":8024,"activeCount":723,"soonestReadout":81},[8025,8029,8033,8037,8041],{"nctId":3344,"briefTitle":3345,"status":108,"phases":8026,"primaryCompletion":1357,"completion":130,"start":3347,"enrollment":3348,"conditions":8027,"interventions":8028},[92],[3350],[117,3352,3353,3354,3355,3356],{"nctId":3397,"briefTitle":3398,"status":108,"phases":8030,"primaryCompletion":3400,"completion":601,"start":110,"enrollment":3289,"conditions":8031,"interventions":8032},[92],[281],[117,3403,3353,3404,3354,3405,3406,3407],{"nctId":7819,"briefTitle":7820,"status":108,"phases":8034,"primaryCompletion":7822,"completion":660,"start":7823,"enrollment":7824,"conditions":8035,"interventions":8036},[92],[3350],[7827,3352,3353,3354,3355,3356],{"nctId":79,"briefTitle":80,"status":108,"phases":8038,"primaryCompletion":81,"completion":660,"start":5298,"enrollment":5299,"conditions":8039,"interventions":8040},[92],[5301],[82,5303,3878,5304,5305,5306,5307,3137],{"nctId":3699,"briefTitle":3700,"status":108,"phases":8042,"primaryCompletion":3702,"completion":3703,"start":3704,"enrollment":3705,"conditions":8043,"interventions":8044},[92],[3707],[117,3137,3709,3353,3354,3356,3355],{"trials":8046,"activeCount":102},[],{"trials":8048,"activeCount":102},[],{"intervention":5979,"totalTrials":723,"cells":8050},{"EARLY_PHASE1":8051,"PHASE1":8053,"PHASE2":8055,"PHASE3":8061,"PHASE4":8079,"NA":8081},{"trials":8052,"activeCount":102},[],{"trials":8054,"activeCount":102},[],{"trials":8056,"activeCount":122,"soonestReadout":7157},[8057],{"nctId":7154,"briefTitle":7155,"status":151,"phases":8058,"primaryCompletion":7157,"completion":7157,"start":7158,"enrollment":7159,"conditions":8059,"interventions":8060},[90,91],[7161,7162],[7164,3966,5978,5977,5979],{"trials":8062,"activeCount":1979,"soonestReadout":1406},[8063,8067,8071,8075],{"nctId":7191,"briefTitle":7192,"status":151,"phases":8064,"primaryCompletion":7194,"completion":7195,"start":7196,"enrollment":7197,"conditions":8065,"interventions":8066},[92],[7188],[3966,468,120,469,6350,5979],{"nctId":7410,"briefTitle":7411,"status":108,"phases":8068,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":8069,"interventions":8070},[92],[7416],[6431,7418,120,7419,469,7420,5977,5979,7421,5978],{"nctId":5970,"briefTitle":5971,"status":151,"phases":8072,"primaryCompletion":1086,"completion":5973,"start":5974,"enrollment":863,"conditions":8073,"interventions":8074},[92],[5959],[119,53,5977,5978,5979],{"nctId":6340,"briefTitle":6341,"status":151,"phases":8076,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":6346,"conditions":8077,"interventions":8078},[92],[6348],[1959,3966,5979,5978,5977,53,469,120,6350],{"trials":8080,"activeCount":102},[],{"trials":8082,"activeCount":102},[],{"intervention":82,"totalTrials":1336,"cells":8084},{"EARLY_PHASE1":8085,"PHASE1":8087,"PHASE2":8113,"PHASE3":8146,"PHASE4":8204,"NA":8206},{"trials":8086,"activeCount":102},[],{"trials":8088,"activeCount":122,"soonestReadout":562},[8089,8093,8097,8101,8105],{"nctId":5184,"briefTitle":5185,"status":195,"phases":8090,"primaryCompletion":5187,"completion":5187,"start":5188,"enrollment":5189,"conditions":8091,"interventions":8092},[90],[5191,5192],[3137,82],{"nctId":5208,"briefTitle":5209,"status":195,"phases":8094,"primaryCompletion":5211,"completion":5212,"start":5213,"enrollment":5214,"conditions":8095,"interventions":8096},[90],[4217],[82,3038],{"nctId":5218,"briefTitle":5219,"status":195,"phases":8098,"primaryCompletion":5221,"completion":5222,"start":5223,"enrollment":3180,"conditions":8099,"interventions":8100},[90],[3174,410,5225,3106,25,5226,691,281],[68,82,3137],{"nctId":559,"briefTitle":560,"status":108,"phases":8102,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":8103,"interventions":8104},[90],[567],[569,82,267,570,266,571,68],{"nctId":8106,"briefTitle":8107,"status":195,"phases":8108,"primaryCompletion":8109,"completion":8110,"start":5223,"enrollment":2933,"conditions":8111,"interventions":8112},"NCT02617277","Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours",[90],"2019-04-22","2026-02-17",[498],[570,82],{"trials":8114,"activeCount":122,"soonestReadout":600},[8115,8125,8129,8133,8142],{"nctId":8116,"briefTitle":8117,"status":195,"phases":8118,"primaryCompletion":8119,"completion":8120,"start":8121,"enrollment":8122,"conditions":8123,"interventions":8124},"NCT02087423","A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",[91],"2016-06-03","2025-03-26","2014-02-25",446,[262],[82],{"nctId":597,"briefTitle":598,"status":108,"phases":8126,"primaryCompletion":600,"completion":601,"start":602,"enrollment":603,"conditions":8127,"interventions":8128},[90,91],[605,606,607,608],[267,82,239],{"nctId":5235,"briefTitle":5236,"status":195,"phases":8130,"primaryCompletion":5238,"completion":4106,"start":4537,"enrollment":5239,"conditions":8131,"interventions":8132},[91],[5241],[82,3137,5243],{"nctId":8134,"briefTitle":8135,"status":195,"phases":8136,"primaryCompletion":5238,"completion":4106,"start":8137,"enrollment":8138,"conditions":8139,"interventions":8141},"NCT02207530","Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[91],"2014-10-23",112,[8140],"Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck",[82],{"nctId":5264,"briefTitle":5265,"status":195,"phases":8143,"primaryCompletion":5267,"completion":5268,"start":588,"enrollment":5269,"conditions":8144,"interventions":8145},[90,91],[5271],[571,82,5273,3038],{"trials":8147,"activeCount":447,"soonestReadout":81},[8148,8152,8161,8165,8169,8180,8189,8193],{"nctId":4013,"briefTitle":4014,"status":108,"phases":8149,"primaryCompletion":3428,"completion":660,"start":4016,"enrollment":4017,"conditions":8150,"interventions":8151},[92],[1025],[82,3137,177,344,283],{"nctId":8153,"briefTitle":8154,"status":195,"phases":8155,"primaryCompletion":8156,"completion":647,"start":8157,"enrollment":8158,"conditions":8159,"interventions":8160},"NCT02125461","A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer",[92],"2017-02-13","2014-05-07",713,[262],[82],{"nctId":79,"briefTitle":80,"status":108,"phases":8162,"primaryCompletion":81,"completion":660,"start":5298,"enrollment":5299,"conditions":8163,"interventions":8164},[92],[5301],[82,5303,3878,5304,5305,5306,5307,3137],{"nctId":5309,"briefTitle":5310,"status":195,"phases":8166,"primaryCompletion":5312,"completion":3071,"start":5313,"enrollment":2497,"conditions":8167,"interventions":8168},[92],[5315],[82,1051,283,5317,82,3038],{"nctId":8170,"briefTitle":8171,"status":195,"phases":8172,"primaryCompletion":8173,"completion":8174,"start":8175,"enrollment":6532,"conditions":8176,"interventions":8178},"NCT02369874","Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer",[92],"2018-09-10","2020-11-13","2015-09-09",[8177],"Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN",[82,5243,8179],"Standard of Care",{"nctId":8181,"briefTitle":8182,"status":195,"phases":8183,"primaryCompletion":1775,"completion":3189,"start":8184,"enrollment":8185,"conditions":8186,"interventions":8188},"NCT02454933","Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours",[92],"2015-07-15",29,[8187],"Locally Advanced or Metastatic EGFR T790M+ NSCLC",[5257,82],{"nctId":4103,"briefTitle":4104,"status":195,"phases":8190,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":8191,"interventions":8192},[92],[4111],[82,3137,4113,4114,296,177,344],{"nctId":8194,"briefTitle":8195,"status":195,"phases":8196,"primaryCompletion":8197,"completion":8198,"start":8199,"enrollment":8200,"conditions":8201,"interventions":8202},"NCT03084471","An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.",[92],"2020-03-31","2022-12-16","2017-06-05",867,[157],[82,8203],"MEDI4736 (Durvalumab) + Tremelimumab",{"trials":8205,"activeCount":102},[],{"trials":8207,"activeCount":102},[],{"intervention":1017,"totalTrials":4343,"cells":8209},{"EARLY_PHASE1":8210,"PHASE1":8212,"PHASE2":8226,"PHASE3":8236,"PHASE4":8254,"NA":8256},{"trials":8211,"activeCount":102},[],{"trials":8213,"activeCount":102},[8214,8218,8222],{"nctId":4191,"briefTitle":4192,"status":195,"phases":8215,"primaryCompletion":2151,"completion":2366,"start":2168,"enrollment":37,"conditions":8216,"interventions":8217},[90],[3174],[3830,1017,177],{"nctId":3068,"briefTitle":3069,"status":443,"phases":8219,"primaryCompletion":3071,"completion":3071,"start":3072,"enrollment":1336,"conditions":8220,"interventions":8221},[90],[262,420],[117,177,344,1017],{"nctId":3130,"briefTitle":3131,"status":195,"phases":8223,"primaryCompletion":1916,"completion":3133,"start":3134,"enrollment":1428,"conditions":8224,"interventions":8225},[90],[3024,992,3023],[117,3137,177,177,344,344,1017,1017,118,345,177,177],{"trials":8227,"activeCount":447,"soonestReadout":3245},[8228,8232],{"nctId":3242,"briefTitle":3243,"status":108,"phases":8229,"primaryCompletion":3245,"completion":3246,"start":3247,"enrollment":3248,"conditions":8230,"interventions":8231},[91],[3250],[117,3252,344,177,1017],{"nctId":1004,"briefTitle":1005,"status":108,"phases":8233,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":8234,"interventions":8235},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"trials":8237,"activeCount":447,"soonestReadout":3428},[8238,8242,8246,8250],{"nctId":1043,"briefTitle":1044,"status":108,"phases":8239,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":98,"conditions":8240,"interventions":8241},[92],[1049],[163,180,344,177,1017,345,1051,1052],{"nctId":3425,"briefTitle":3426,"status":108,"phases":8243,"primaryCompletion":3428,"completion":660,"start":3429,"enrollment":3430,"conditions":8244,"interventions":8245},[92],[3432],[117,3137,344,177,1017],{"nctId":3461,"briefTitle":3462,"status":195,"phases":8247,"primaryCompletion":3464,"completion":378,"start":3465,"enrollment":3466,"conditions":8248,"interventions":8249},[92],[3468],[117,177,344,1017],{"nctId":3641,"briefTitle":3642,"status":195,"phases":8251,"primaryCompletion":3189,"completion":3189,"start":3644,"enrollment":3645,"conditions":8252,"interventions":8253},[92],[3432],[117,177,1017,344],{"trials":8255,"activeCount":102},[],{"trials":8257,"activeCount":102},[],{"intervention":8259,"totalTrials":4343,"cells":8260},"Tozorakimab",{"EARLY_PHASE1":8261,"PHASE1":8263,"PHASE2":8278,"PHASE3":8308,"PHASE4":8344,"NA":8346},{"trials":8262,"activeCount":102},[],{"trials":8264,"activeCount":102},[8265,8272],{"nctId":8266,"briefTitle":8267,"status":195,"phases":8268,"primaryCompletion":6132,"completion":6132,"start":8269,"enrollment":451,"conditions":8270,"interventions":8271},"NCT06304961","A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers",[90],"2024-04-08",[5851],[8259],{"nctId":8273,"briefTitle":8274,"status":195,"phases":8275,"primaryCompletion":6252,"completion":6252,"start":1226,"enrollment":3747,"conditions":8276,"interventions":8277},"NCT06908577","An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab",[90],[5851],[8259],{"trials":8279,"activeCount":447,"soonestReadout":337},[8280,8288,8297],{"nctId":8281,"briefTitle":8282,"status":108,"phases":8283,"primaryCompletion":337,"completion":337,"start":8284,"enrollment":8285,"conditions":8286,"interventions":8287},"NCT06897748","A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils",[91],"2025-04-12",98,[6083],[8259],{"nctId":8289,"briefTitle":8290,"status":151,"phases":8291,"primaryCompletion":8292,"completion":8293,"start":8120,"enrollment":8294,"conditions":8295,"interventions":8296},"NCT06932263","Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids",[91],"2027-06-24","2028-03-16",540,[16],[8259],{"nctId":8298,"briefTitle":8299,"status":195,"phases":8300,"primaryCompletion":8301,"completion":8302,"start":8303,"enrollment":8304,"conditions":8305,"interventions":8307},"NCT04631016","A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis",[91],"2023-05-30","2023-11-13","2020-12-14",137,[6083,8306],"Chronic Bronchitis",[8259],{"trials":8309,"activeCount":447,"soonestReadout":8314},[8310,8319,8328,8336],{"nctId":8311,"briefTitle":8312,"status":108,"phases":8313,"primaryCompletion":8314,"completion":8315,"start":2384,"enrollment":8316,"conditions":8317,"interventions":8318},"NCT06040086","Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations",[92],"2026-03-06","2026-05-22",1454,[6083],[8259],{"nctId":8320,"briefTitle":8321,"status":195,"phases":8322,"primaryCompletion":8323,"completion":8324,"start":3392,"enrollment":8325,"conditions":8326,"interventions":8327},"NCT05158387","Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.",[92],"2026-01-19","2026-03-22",1172,[6083],[8259,8259],{"nctId":8329,"briefTitle":8330,"status":151,"phases":8331,"primaryCompletion":326,"completion":326,"start":3197,"enrollment":8332,"conditions":8333,"interventions":8335},"NCT05624450","Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen",[92],2870,[8334],"Viral Lung Infection and Acute Respiratory Failure",[8259],{"nctId":8337,"briefTitle":8312,"status":195,"phases":8338,"primaryCompletion":8323,"completion":8339,"start":8340,"enrollment":8341,"conditions":8342,"interventions":8343},"NCT05166889",[92],"2026-03-11","2022-01-03",1132,[6083],[8259,8259],{"trials":8345,"activeCount":102},[],{"trials":8347,"activeCount":102},[],{"intervention":6431,"totalTrials":370,"cells":8349},{"EARLY_PHASE1":8350,"PHASE1":8352,"PHASE2":8395,"PHASE3":8410,"PHASE4":8420,"NA":8422},{"trials":8351,"activeCount":102},[],{"trials":8353,"activeCount":122,"soonestReadout":8378},[8354,8364,8374,8387],{"nctId":8355,"briefTitle":8356,"status":195,"phases":8357,"primaryCompletion":3197,"completion":3197,"start":8358,"enrollment":3209,"conditions":8359,"interventions":8360},"NCT05438303","Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers",[90],"2022-06-13",[36],[6431,5870,8361,8362,8363],"Omeprazole","Dabigatran Etexilate","Celecoxib",{"nctId":8365,"briefTitle":8366,"status":195,"phases":8367,"primaryCompletion":3333,"completion":3333,"start":8368,"enrollment":2260,"conditions":8369,"interventions":8371},"NCT04818632","AZD9833 China PK Study",[90],"2021-11-12",[8370],"ER+, HER2-, Metastatic Breast Cancer",[6431,6431,8372,8373],"AZD9833 with palbociclib","AZD9833 with everolimus",{"nctId":8375,"briefTitle":8376,"status":108,"phases":8377,"primaryCompletion":8378,"completion":8292,"start":8379,"enrollment":8380,"conditions":8381,"interventions":8382},"NCT03616587","Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.",[90],"2024-09-16","2018-10-11",396,[7161],[6431,6431,8372,8372,8373,8373,8383,8383,8384,8384,8385,8385,8386,8386],"AZD9833 with abemaciclib","AZD9833 with capivasertib","AZD9833 with ribociclib","AZD9833 with anastrozole",{"nctId":8388,"briefTitle":8389,"status":195,"phases":8390,"primaryCompletion":910,"completion":8391,"start":8392,"enrollment":269,"conditions":8393,"interventions":8394},"NCT04541433","A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer",[90],"2025-06-23","2020-09-29",[7161],[6431],{"trials":8396,"activeCount":122,"soonestReadout":6426},[8397,8401],{"nctId":6423,"briefTitle":6424,"status":108,"phases":8398,"primaryCompletion":6426,"completion":6318,"start":6427,"enrollment":1173,"conditions":8399,"interventions":8400},[91],[6429],[6431,53],{"nctId":8402,"briefTitle":8403,"status":195,"phases":8404,"primaryCompletion":8405,"completion":8405,"start":8406,"enrollment":390,"conditions":8407,"interventions":8409},"NCT04588298","A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer",[91],"2023-06-19","2020-11-02",[8408],"HER2-negative Breast Cancer",[6431],{"trials":8411,"activeCount":447,"soonestReadout":1406},[8412,8416],{"nctId":7410,"briefTitle":7411,"status":108,"phases":8413,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":8414,"interventions":8415},[92],[7416],[6431,7418,120,7419,469,7420,5977,5979,7421,5978],{"nctId":7461,"briefTitle":7462,"status":108,"phases":8417,"primaryCompletion":7464,"completion":7465,"start":7466,"enrollment":7467,"conditions":8418,"interventions":8419},[92],[7416],[6431,120,7419,7470,5977,7421],{"trials":8421,"activeCount":102},[],{"trials":8423,"activeCount":102},[],{"intervention":469,"totalTrials":723,"cells":8425},{"EARLY_PHASE1":8426,"PHASE1":8428,"PHASE2":8434,"PHASE3":8436,"PHASE4":8454,"NA":8456},{"trials":8427,"activeCount":102},[],{"trials":8429,"activeCount":102},[8430],{"nctId":458,"briefTitle":459,"status":195,"phases":8431,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":8432,"interventions":8433},[90],[466],[267,468,120,469],{"trials":8435,"activeCount":102},[],{"trials":8437,"activeCount":1979,"soonestReadout":1406},[8438,8442,8446,8450],{"nctId":7181,"briefTitle":7182,"status":151,"phases":8439,"primaryCompletion":7184,"completion":7185,"start":1917,"enrollment":7186,"conditions":8440,"interventions":8441},[92],[7188],[3966,468,120,469,6350],{"nctId":7191,"briefTitle":7192,"status":151,"phases":8443,"primaryCompletion":7194,"completion":7195,"start":7196,"enrollment":7197,"conditions":8444,"interventions":8445},[92],[7188],[3966,468,120,469,6350,5979],{"nctId":7410,"briefTitle":7411,"status":108,"phases":8447,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":8448,"interventions":8449},[92],[7416],[6431,7418,120,7419,469,7420,5977,5979,7421,5978],{"nctId":6340,"briefTitle":6341,"status":151,"phases":8451,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":6346,"conditions":8452,"interventions":8453},[92],[6348],[1959,3966,5979,5978,5977,53,469,120,6350],{"trials":8455,"activeCount":102},[],{"trials":8457,"activeCount":102},[],{"intervention":524,"totalTrials":723,"cells":8459},{"EARLY_PHASE1":8460,"PHASE1":8462,"PHASE2":8468,"PHASE3":8478,"PHASE4":8488,"NA":8490},{"trials":8461,"activeCount":102},[],{"trials":8463,"activeCount":102},[8464],{"nctId":514,"briefTitle":515,"status":443,"phases":8465,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":8466,"interventions":8467},[90],[25],[267,344,523,524],{"trials":8469,"activeCount":447,"soonestReadout":1457},[8470,8474],{"nctId":7906,"briefTitle":7907,"status":151,"phases":8471,"primaryCompletion":1393,"completion":1393,"start":7909,"enrollment":3000,"conditions":8472,"interventions":8473},[90,91],[1283],[7879,524,7912],{"nctId":1454,"briefTitle":1455,"status":151,"phases":8475,"primaryCompletion":1457,"completion":1458,"start":1459,"enrollment":1460,"conditions":8476,"interventions":8477},[90,91],[1462,1409,1463,1464,1465],[1467,914,1378,524,1468,309,1335],{"trials":8479,"activeCount":447,"soonestReadout":301},[8480,8484],{"nctId":298,"briefTitle":299,"status":108,"phases":8481,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":8482,"interventions":8483},[92],[306,25,307],[162,118,176,146,309,310],{"nctId":799,"briefTitle":800,"status":108,"phases":8485,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":8486,"interventions":8487},[92],[25],[808,117,178,309,809,524,118,344,121,267],{"trials":8489,"activeCount":102},[],{"trials":8491,"activeCount":102},[],{"intervention":1378,"totalTrials":1979,"cells":8493},{"EARLY_PHASE1":8494,"PHASE1":8496,"PHASE2":8498,"PHASE3":8512,"PHASE4":8518,"NA":8520},{"trials":8495,"activeCount":102},[],{"trials":8497,"activeCount":102},[],{"trials":8499,"activeCount":3887,"soonestReadout":1457},[8500,8504,8508],{"nctId":1368,"briefTitle":1369,"status":108,"phases":8501,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":1373,"conditions":8502,"interventions":8503},[91],[1375],[1335,1377,1378],{"nctId":1413,"briefTitle":1414,"status":151,"phases":8505,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1395,"conditions":8506,"interventions":8507},[91],[1419],[1335,1378],{"nctId":1454,"briefTitle":1455,"status":151,"phases":8509,"primaryCompletion":1457,"completion":1458,"start":1459,"enrollment":1460,"conditions":8510,"interventions":8511},[90,91],[1462,1409,1463,1464,1465],[1467,914,1378,524,1468,309,1335],{"trials":8513,"activeCount":122,"soonestReadout":1484},[8514],{"nctId":1481,"briefTitle":1482,"status":108,"phases":8515,"primaryCompletion":1484,"completion":1485,"start":1486,"enrollment":975,"conditions":8516,"interventions":8517},[92],[1488],[1335,1378,1490],{"trials":8519,"activeCount":102},[],{"trials":8521,"activeCount":102},[],{"intervention":176,"totalTrials":1979,"cells":8523},{"EARLY_PHASE1":8524,"PHASE1":8526,"PHASE2":8528,"PHASE3":8534,"PHASE4":8548,"NA":8550},{"trials":8525,"activeCount":102},[],{"trials":8527,"activeCount":102},[],{"trials":8529,"activeCount":122,"soonestReadout":168},[8530],{"nctId":165,"briefTitle":166,"status":151,"phases":8531,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":8532,"interventions":8533},[91],[172],[174,121,117,175,176,97,177,178,179,180],{"trials":8535,"activeCount":3887,"soonestReadout":301},[8536,8540,8544],{"nctId":285,"briefTitle":286,"status":151,"phases":8537,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":8538,"interventions":8539},[92],[293,294],[180,97,176,178,296,121,177,175],{"nctId":298,"briefTitle":299,"status":108,"phases":8541,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":8542,"interventions":8543},[92],[306,25,307],[162,118,176,146,309,310],{"nctId":347,"briefTitle":348,"status":108,"phases":8545,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":8546,"interventions":8547},[92],[355],[97,357,146,176],{"trials":8549,"activeCount":102},[],{"trials":8551,"activeCount":102},[],{"intervention":3355,"totalTrials":1979,"cells":8553},{"EARLY_PHASE1":8554,"PHASE1":8556,"PHASE2":8558,"PHASE3":8560,"PHASE4":8578,"NA":8580},{"trials":8555,"activeCount":102},[],{"trials":8557,"activeCount":102},[],{"trials":8559,"activeCount":102},[],{"trials":8561,"activeCount":1979,"soonestReadout":81},[8562,8566,8570,8574],{"nctId":3344,"briefTitle":3345,"status":108,"phases":8563,"primaryCompletion":1357,"completion":130,"start":3347,"enrollment":3348,"conditions":8564,"interventions":8565},[92],[3350],[117,3352,3353,3354,3355,3356],{"nctId":7819,"briefTitle":7820,"status":108,"phases":8567,"primaryCompletion":7822,"completion":660,"start":7823,"enrollment":7824,"conditions":8568,"interventions":8569},[92],[3350],[7827,3352,3353,3354,3355,3356],{"nctId":79,"briefTitle":80,"status":108,"phases":8571,"primaryCompletion":81,"completion":660,"start":5298,"enrollment":5299,"conditions":8572,"interventions":8573},[92],[5301],[82,5303,3878,5304,5305,5306,5307,3137],{"nctId":3699,"briefTitle":3700,"status":108,"phases":8575,"primaryCompletion":3702,"completion":3703,"start":3704,"enrollment":3705,"conditions":8576,"interventions":8577},[92],[3707],[117,3137,3709,3353,3354,3356,3355],{"trials":8579,"activeCount":102},[],{"trials":8581,"activeCount":102},[],{"intervention":3356,"totalTrials":1979,"cells":8583},{"EARLY_PHASE1":8584,"PHASE1":8586,"PHASE2":8588,"PHASE3":8590,"PHASE4":8608,"NA":8610},{"trials":8585,"activeCount":102},[],{"trials":8587,"activeCount":102},[],{"trials":8589,"activeCount":102},[],{"trials":8591,"activeCount":1979,"soonestReadout":81},[8592,8596,8600,8604],{"nctId":3344,"briefTitle":3345,"status":108,"phases":8593,"primaryCompletion":1357,"completion":130,"start":3347,"enrollment":3348,"conditions":8594,"interventions":8595},[92],[3350],[117,3352,3353,3354,3355,3356],{"nctId":7819,"briefTitle":7820,"status":108,"phases":8597,"primaryCompletion":7822,"completion":660,"start":7823,"enrollment":7824,"conditions":8598,"interventions":8599},[92],[3350],[7827,3352,3353,3354,3355,3356],{"nctId":79,"briefTitle":80,"status":108,"phases":8601,"primaryCompletion":81,"completion":660,"start":5298,"enrollment":5299,"conditions":8602,"interventions":8603},[92],[5301],[82,5303,3878,5304,5305,5306,5307,3137],{"nctId":3699,"briefTitle":3700,"status":108,"phases":8605,"primaryCompletion":3702,"completion":3703,"start":3704,"enrollment":3705,"conditions":8606,"interventions":8607},[92],[3707],[117,3137,3709,3353,3354,3356,3355],{"trials":8609,"activeCount":102},[],{"trials":8611,"activeCount":102},[],{"intervention":5978,"totalTrials":1979,"cells":8613},{"EARLY_PHASE1":8614,"PHASE1":8616,"PHASE2":8618,"PHASE3":8624,"PHASE4":8638,"NA":8640},{"trials":8615,"activeCount":102},[],{"trials":8617,"activeCount":102},[],{"trials":8619,"activeCount":122,"soonestReadout":7157},[8620],{"nctId":7154,"briefTitle":7155,"status":151,"phases":8621,"primaryCompletion":7157,"completion":7157,"start":7158,"enrollment":7159,"conditions":8622,"interventions":8623},[90,91],[7161,7162],[7164,3966,5978,5977,5979],{"trials":8625,"activeCount":3887,"soonestReadout":1406},[8626,8630,8634],{"nctId":7410,"briefTitle":7411,"status":108,"phases":8627,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":8628,"interventions":8629},[92],[7416],[6431,7418,120,7419,469,7420,5977,5979,7421,5978],{"nctId":5970,"briefTitle":5971,"status":151,"phases":8631,"primaryCompletion":1086,"completion":5973,"start":5974,"enrollment":863,"conditions":8632,"interventions":8633},[92],[5959],[119,53,5977,5978,5979],{"nctId":6340,"briefTitle":6341,"status":151,"phases":8635,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":6346,"conditions":8636,"interventions":8637},[92],[6348],[1959,3966,5979,5978,5977,53,469,120,6350],{"trials":8639,"activeCount":102},[],{"trials":8641,"activeCount":102},[],{"intervention":1940,"totalTrials":1979,"cells":8643},{"EARLY_PHASE1":8644,"PHASE1":8646,"PHASE2":8652,"PHASE3":8658,"PHASE4":8668,"NA":8670},{"trials":8645,"activeCount":102},[],{"trials":8647,"activeCount":122,"soonestReadout":6284},[8648],{"nctId":6281,"briefTitle":6282,"status":151,"phases":8649,"primaryCompletion":6284,"completion":6284,"start":6285,"enrollment":2187,"conditions":8650,"interventions":8651},[90],[416],[1959,1940],{"trials":8653,"activeCount":122,"soonestReadout":1934},[8654],{"nctId":1931,"briefTitle":1932,"status":108,"phases":8655,"primaryCompletion":1934,"completion":1934,"start":1137,"enrollment":1935,"conditions":8656,"interventions":8657},[90,91],[1937],[1939,1927,1926,1940,1941],{"trials":8659,"activeCount":447,"soonestReadout":1952},[8660,8664],{"nctId":1949,"briefTitle":1950,"status":108,"phases":8661,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":1955,"conditions":8662,"interventions":8663},[92],[1957],[1959,1926,1940,1927],{"nctId":2023,"briefTitle":2024,"status":151,"phases":8665,"primaryCompletion":2026,"completion":2027,"start":973,"enrollment":2028,"conditions":8666,"interventions":8667},[92],[651],[2031,2032,653,1927,1941,1940,2033,2034],{"trials":8669,"activeCount":102},[],{"trials":8671,"activeCount":102},[],{"intervention":4843,"totalTrials":1855,"cells":8673},{"EARLY_PHASE1":8674,"PHASE1":8676,"PHASE2":8682,"PHASE3":8706,"PHASE4":8716,"NA":8718},{"trials":8675,"activeCount":102},[],{"trials":8677,"activeCount":122,"soonestReadout":5364},[8678],{"nctId":5361,"briefTitle":5362,"status":151,"phases":8679,"primaryCompletion":5364,"completion":5364,"start":678,"enrollment":5365,"conditions":8680,"interventions":8681},[90],[498,5367,4258,5368],[5370,1012,226,4843,239],{"trials":8683,"activeCount":122,"soonestReadout":5770},[8684,8688,8698,8702],{"nctId":5649,"briefTitle":5650,"status":195,"phases":8685,"primaryCompletion":2169,"completion":2350,"start":4284,"enrollment":5652,"conditions":8686,"interventions":8687},[91],[691],[3830,296,4843,175,239],{"nctId":8689,"briefTitle":8690,"status":624,"phases":8691,"primaryCompletion":4284,"completion":4284,"start":8692,"enrollment":8693,"conditions":8694,"interventions":8695},"NCT00233623","Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer",[91],"2004-07",190,[5121],[8696,4615,8697,4843],"Iressa","5Fluorouracil",{"nctId":5767,"briefTitle":5768,"status":151,"phases":8699,"primaryCompletion":5770,"completion":1952,"start":1372,"enrollment":2289,"conditions":8700,"interventions":8701},[91],[172,4612,281,5772],[225,226,4843,5774,4615,5775,283],{"nctId":6777,"briefTitle":6778,"status":443,"phases":8703,"primaryCompletion":4306,"completion":4306,"start":6780,"enrollment":1120,"conditions":8704,"interventions":8705},[91],[5368,6782],[6784,296,6785,6786],{"trials":8707,"activeCount":122,"soonestReadout":4835},[8708,8712],{"nctId":5698,"briefTitle":5699,"status":195,"phases":8709,"primaryCompletion":5701,"completion":5702,"start":5703,"enrollment":5704,"conditions":8710,"interventions":8711},[91,92],[691],[268,239,296,4843,175],{"nctId":4832,"briefTitle":4833,"status":151,"phases":8713,"primaryCompletion":4835,"completion":4836,"start":4837,"enrollment":4838,"conditions":8714,"interventions":8715},[92],[172,294,405],[4841,180,4178,121,226,175,4842,4843],{"trials":8717,"activeCount":102},[],{"trials":8719,"activeCount":102},[],{"intervention":175,"totalTrials":1039,"cells":8721},{"EARLY_PHASE1":8722,"PHASE1":8724,"PHASE2":8726,"PHASE3":8740,"PHASE4":8754,"NA":8756},{"trials":8723,"activeCount":102},[],{"trials":8725,"activeCount":102},[],{"trials":8727,"activeCount":122,"soonestReadout":168},[8728,8732,8736],{"nctId":165,"briefTitle":166,"status":151,"phases":8729,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":8730,"interventions":8731},[91],[172],[174,121,117,175,176,97,177,178,179,180],{"nctId":5649,"briefTitle":5650,"status":195,"phases":8733,"primaryCompletion":2169,"completion":2350,"start":4284,"enrollment":5652,"conditions":8734,"interventions":8735},[91],[691],[3830,296,4843,175,239],{"nctId":6777,"briefTitle":6778,"status":443,"phases":8737,"primaryCompletion":4306,"completion":4306,"start":6780,"enrollment":1120,"conditions":8738,"interventions":8739},[91],[5368,6782],[6784,296,6785,6786],{"trials":8741,"activeCount":447,"soonestReadout":288},[8742,8746,8750],{"nctId":285,"briefTitle":286,"status":151,"phases":8743,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":8744,"interventions":8745},[92],[293,294],[180,97,176,178,296,121,177,175],{"nctId":5698,"briefTitle":5699,"status":195,"phases":8747,"primaryCompletion":5701,"completion":5702,"start":5703,"enrollment":5704,"conditions":8748,"interventions":8749},[91,92],[691],[268,239,296,4843,175],{"nctId":4832,"briefTitle":4833,"status":151,"phases":8751,"primaryCompletion":4835,"completion":4836,"start":4837,"enrollment":4838,"conditions":8752,"interventions":8753},[92],[172,294,405],[4841,180,4178,121,226,175,4842,4843],{"trials":8755,"activeCount":102},[],{"trials":8757,"activeCount":102},[],{"intervention":6350,"totalTrials":1039,"cells":8759},{"EARLY_PHASE1":8760,"PHASE1":8762,"PHASE2":8764,"PHASE3":8770,"PHASE4":8792,"NA":8794},{"trials":8761,"activeCount":102},[],{"trials":8763,"activeCount":102},[],{"trials":8765,"activeCount":102},[8766],{"nctId":6433,"briefTitle":6434,"status":195,"phases":8767,"primaryCompletion":2180,"completion":6436,"start":2143,"enrollment":235,"conditions":8768,"interventions":8769},[90,91],[6438,6439],[569,6350,53],{"trials":8771,"activeCount":3887,"soonestReadout":7184},[8772,8776,8780,8784,8788],{"nctId":7181,"briefTitle":7182,"status":151,"phases":8773,"primaryCompletion":7184,"completion":7185,"start":1917,"enrollment":7186,"conditions":8774,"interventions":8775},[92],[7188],[3966,468,120,469,6350],{"nctId":7191,"briefTitle":7192,"status":151,"phases":8777,"primaryCompletion":7194,"completion":7195,"start":7196,"enrollment":7197,"conditions":8778,"interventions":8779},[92],[7188],[3966,468,120,469,6350,5979],{"nctId":6559,"briefTitle":6560,"status":195,"phases":8781,"primaryCompletion":6562,"completion":2180,"start":6563,"enrollment":6564,"conditions":8782,"interventions":8783},[92],[6566,115],[53,6350],{"nctId":6577,"briefTitle":6578,"status":195,"phases":8785,"primaryCompletion":2542,"completion":2542,"start":4915,"enrollment":98,"conditions":8786,"interventions":8787},[92],[6581],[6410,6411,6583],{"nctId":6340,"briefTitle":6341,"status":151,"phases":8789,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":6346,"conditions":8790,"interventions":8791},[92],[6348],[1959,3966,5979,5978,5977,53,469,120,6350],{"trials":8793,"activeCount":102},[],{"trials":8795,"activeCount":102},[],{"intervention":3352,"totalTrials":723,"cells":8797},{"EARLY_PHASE1":8798,"PHASE1":8800,"PHASE2":8810,"PHASE3":8812,"PHASE4":8826,"NA":8828},{"trials":8799,"activeCount":102},[],{"trials":8801,"activeCount":102},[8802,8806],{"nctId":3018,"briefTitle":3019,"status":195,"phases":8803,"primaryCompletion":3021,"completion":3021,"start":2781,"enrollment":579,"conditions":8804,"interventions":8805},[90],[3023,3024,3025,249,3026,3027,3028,3029,3030,3031],[3033,3034,3035,3036,3037,900,3038,3039,3040],{"nctId":3868,"briefTitle":3869,"status":195,"phases":8807,"primaryCompletion":3871,"completion":1058,"start":3872,"enrollment":3873,"conditions":8808,"interventions":8809},[90],[3875,784,344,118],[3877,344,3877,118,3877,3878],{"trials":8811,"activeCount":102},[],{"trials":8813,"activeCount":3887,"soonestReadout":81},[8814,8818,8822],{"nctId":3344,"briefTitle":3345,"status":108,"phases":8815,"primaryCompletion":1357,"completion":130,"start":3347,"enrollment":3348,"conditions":8816,"interventions":8817},[92],[3350],[117,3352,3353,3354,3355,3356],{"nctId":7819,"briefTitle":7820,"status":108,"phases":8819,"primaryCompletion":7822,"completion":660,"start":7823,"enrollment":7824,"conditions":8820,"interventions":8821},[92],[3350],[7827,3352,3353,3354,3355,3356],{"nctId":79,"briefTitle":80,"status":108,"phases":8823,"primaryCompletion":81,"completion":660,"start":5298,"enrollment":5299,"conditions":8824,"interventions":8825},[92],[5301],[82,5303,3878,5304,5305,5306,5307,3137],{"trials":8827,"activeCount":102},[],{"trials":8829,"activeCount":102},[],{"intervention":1377,"totalTrials":1979,"cells":8831},{"EARLY_PHASE1":8832,"PHASE1":8834,"PHASE2":8845,"PHASE3":8855,"PHASE4":8861,"NA":8863},{"trials":8833,"activeCount":102},[],{"trials":8835,"activeCount":102},[8836],{"nctId":8837,"briefTitle":8838,"status":443,"phases":8839,"primaryCompletion":5906,"completion":5906,"start":8840,"enrollment":4286,"conditions":8841,"interventions":8843},"NCT03217838","Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.",[90],"2017-07-31",[8842],"Acute Myeloid Leukaemia",[3252,8844,1377],"Azacitidine",{"trials":8846,"activeCount":447,"soonestReadout":1371},[8847,8851],{"nctId":1368,"briefTitle":1369,"status":108,"phases":8848,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":1373,"conditions":8849,"interventions":8850},[91],[1375],[1335,1377,1378],{"nctId":1390,"briefTitle":1391,"status":1097,"phases":8852,"primaryCompletion":1393,"completion":1394,"start":563,"enrollment":1395,"conditions":8853,"interventions":8854},[91],[1397,1398],[1335,1377],{"trials":8856,"activeCount":122,"soonestReadout":1495},[8857],{"nctId":1492,"briefTitle":1493,"status":108,"phases":8858,"primaryCompletion":1495,"completion":1496,"start":1497,"enrollment":1498,"conditions":8859,"interventions":8860},[92],[1500],[1335,1377,1364],{"trials":8862,"activeCount":102},[],{"trials":8864,"activeCount":102},[],{"intervention":146,"totalTrials":3887,"cells":8866},{"EARLY_PHASE1":8867,"PHASE1":8869,"PHASE2":8871,"PHASE3":8877,"PHASE4":8887,"NA":8889},{"trials":8868,"activeCount":102},[],{"trials":8870,"activeCount":102},[],{"trials":8872,"activeCount":122,"soonestReadout":140},[8873],{"nctId":137,"briefTitle":138,"status":108,"phases":8874,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":8875,"interventions":8876},[90,91],[115],[97,117,118,146,147],{"trials":8878,"activeCount":447,"soonestReadout":301},[8879,8883],{"nctId":298,"briefTitle":299,"status":108,"phases":8880,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":8881,"interventions":8882},[92],[306,25,307],[162,118,176,146,309,310],{"nctId":347,"briefTitle":348,"status":108,"phases":8884,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":8885,"interventions":8886},[92],[355],[97,357,146,176],{"trials":8888,"activeCount":102},[],{"trials":8890,"activeCount":102},[],{"intervention":8892,"totalTrials":3887,"cells":8893},"Baxdrostat\u002Fdapagliflozin",{"EARLY_PHASE1":8894,"PHASE1":8896,"PHASE2":8898,"PHASE3":8910,"PHASE4":8931,"NA":8933},{"trials":8895,"activeCount":102},[],{"trials":8897,"activeCount":102},[],{"trials":8899,"activeCount":122,"soonestReadout":8904},[8900],{"nctId":8901,"briefTitle":8902,"status":151,"phases":8903,"primaryCompletion":8904,"completion":8904,"start":8905,"enrollment":1318,"conditions":8906,"interventions":8908},"NCT07222917","A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.",[91],"2027-05-24","2025-12-05",[8907],"Chronic Kidney Disease and Hypertension",[8892,8909],"Baxdrostat\u002FPlacebo",{"trials":8911,"activeCount":447,"soonestReadout":8925},[8912,8921],{"nctId":8913,"briefTitle":8914,"status":151,"phases":8915,"primaryCompletion":8916,"completion":8916,"start":8917,"enrollment":8918,"conditions":8919,"interventions":8920},"NCT06742723","A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure",[92],"2029-12-18","2025-03-03",5000,[8907],[8892],{"nctId":8922,"briefTitle":8923,"status":108,"phases":8924,"primaryCompletion":8925,"completion":8925,"start":8926,"enrollment":8927,"conditions":8928,"interventions":8929},"NCT06268873","A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.",[92],"2028-02-24","2024-03-29",2554,[8907],[8892,8930],"Dapagliflozin in combination with placebo",{"trials":8932,"activeCount":102},[],{"trials":8934,"activeCount":102},[],{"intervention":3232,"totalTrials":3887,"cells":8936},{"EARLY_PHASE1":8937,"PHASE1":8939,"PHASE2":8941,"PHASE3":8947,"PHASE4":8962,"NA":8964},{"trials":8938,"activeCount":102},[],{"trials":8940,"activeCount":102},[],{"trials":8942,"activeCount":122,"soonestReadout":3227},[8943],{"nctId":3224,"briefTitle":3225,"status":151,"phases":8944,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":8945,"interventions":8946},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"trials":8948,"activeCount":447,"soonestReadout":8953},[8949,8958],{"nctId":8950,"briefTitle":8951,"status":108,"phases":8952,"primaryCompletion":8953,"completion":8954,"start":828,"enrollment":8955,"conditions":8956,"interventions":8957},"NCT04590963","Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer",[92],"2022-05-11","2026-09-24",370,[4111],[3232,4114],{"nctId":3388,"briefTitle":3389,"status":108,"phases":8959,"primaryCompletion":130,"completion":3391,"start":3392,"enrollment":3393,"conditions":8960,"interventions":8961},[92],[262],[117,251,3232],{"trials":8963,"activeCount":102},[],{"trials":8965,"activeCount":102},[],{"intervention":4178,"totalTrials":3887,"cells":8967},{"EARLY_PHASE1":8968,"PHASE1":8970,"PHASE2":8972,"PHASE3":8974,"PHASE4":8988,"NA":8990},{"trials":8969,"activeCount":102},[],{"trials":8971,"activeCount":102},[],{"trials":8973,"activeCount":102},[],{"trials":8975,"activeCount":3887,"soonestReadout":4172},[8976,8980,8984],{"nctId":5159,"briefTitle":5160,"status":108,"phases":8977,"primaryCompletion":5162,"completion":5163,"start":1794,"enrollment":5164,"conditions":8978,"interventions":8979},[92],[5166],[179,5168,4178,4179],{"nctId":4832,"briefTitle":4833,"status":151,"phases":8981,"primaryCompletion":4835,"completion":4836,"start":4837,"enrollment":4838,"conditions":8982,"interventions":8983},[92],[172,294,405],[4841,180,4178,121,226,175,4842,4843],{"nctId":4169,"briefTitle":4170,"status":151,"phases":8985,"primaryCompletion":4172,"completion":4173,"start":4174,"enrollment":3613,"conditions":8986,"interventions":8987},[92],[4176],[179,345,344,177,4178,4179],{"trials":8989,"activeCount":102},[],{"trials":8991,"activeCount":102},[],{"intervention":3925,"totalTrials":3887,"cells":8993},{"EARLY_PHASE1":8994,"PHASE1":8996,"PHASE2":9007,"PHASE3":9013,"PHASE4":9019,"NA":9021},{"trials":8995,"activeCount":102},[],{"trials":8997,"activeCount":122,"soonestReadout":9002},[8998],{"nctId":8999,"briefTitle":9000,"status":151,"phases":9001,"primaryCompletion":9002,"completion":9002,"start":1308,"enrollment":1130,"conditions":9003,"interventions":9006},"NCT07402915","Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[90],"2027-10-15",[9004,414,9005],"Fallopian Tube Cancer","Primary Peritoneal",[3925,5911],{"trials":9008,"activeCount":122,"soonestReadout":3920},[9009],{"nctId":3917,"briefTitle":3918,"status":151,"phases":9010,"primaryCompletion":3920,"completion":3920,"start":3921,"enrollment":318,"conditions":9011,"interventions":9012},[90,91],[414,3923,367],[3925,1959,239,344,159],{"trials":9014,"activeCount":122,"soonestReadout":4678},[9015],{"nctId":4675,"briefTitle":4676,"status":151,"phases":9016,"primaryCompletion":4678,"completion":4679,"start":4680,"enrollment":3654,"conditions":9017,"interventions":9018},[92],[3865],[3925,4683,118,4684,4685],{"trials":9020,"activeCount":102},[],{"trials":9022,"activeCount":102},[],{"intervention":3222,"totalTrials":3887,"cells":9024},{"EARLY_PHASE1":9025,"PHASE1":9027,"PHASE2":9029,"PHASE3":9039,"PHASE4":9045,"NA":9047},{"trials":9026,"activeCount":102},[],{"trials":9028,"activeCount":102},[],{"trials":9030,"activeCount":447,"soonestReadout":4317},[9031,9035],{"nctId":3214,"briefTitle":3215,"status":108,"phases":9032,"primaryCompletion":1840,"completion":1892,"start":3217,"enrollment":3218,"conditions":9033,"interventions":9034},[91],[3220],[117,3137,3222],{"nctId":4314,"briefTitle":4315,"status":151,"phases":9036,"primaryCompletion":4317,"completion":4318,"start":4319,"enrollment":4320,"conditions":9037,"interventions":9038},[91],[3220,281],[179,239,3222,180,283,177],{"trials":9040,"activeCount":122,"soonestReadout":3693},[9041],{"nctId":3690,"briefTitle":3691,"status":108,"phases":9042,"primaryCompletion":3693,"completion":245,"start":3694,"enrollment":3695,"conditions":9043,"interventions":9044},[92],[3220],[3137,117,3222],{"trials":9046,"activeCount":102},[],{"trials":9048,"activeCount":102},[],{"intervention":468,"totalTrials":4497,"cells":9050},{"EARLY_PHASE1":9051,"PHASE1":9053,"PHASE2":9059,"PHASE3":9083,"PHASE4":9147,"NA":9153},{"trials":9052,"activeCount":102},[],{"trials":9054,"activeCount":102},[9055],{"nctId":458,"briefTitle":459,"status":195,"phases":9056,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":9057,"interventions":9058},[90],[466],[267,468,120,469],{"trials":9060,"activeCount":102},[9061,9071,9079],{"nctId":9062,"briefTitle":9063,"status":195,"phases":9064,"primaryCompletion":6650,"completion":9065,"start":9066,"conditions":9067,"interventions":9069},"NCT00637871","Casodex - Nolvadex Combination",[91],"2005-08","2002-11",[9068,416],"Gynaecomastia",[9070,468],"Casodex",{"nctId":9072,"briefTitle":9073,"status":195,"phases":9074,"primaryCompletion":5742,"completion":4005,"start":9075,"enrollment":9076,"conditions":9077,"interventions":9078},"NCT00229697","Phase II Metastatic ER+\u002FPgR+ Nolvadex +\u002F- Iressa Study",[91],"2003-10",317,[306],[1013,468],{"nctId":7369,"briefTitle":7370,"status":195,"phases":9080,"completion":4285,"start":7372,"enrollment":7373,"conditions":9081,"interventions":9082},[91],[25],[120,468],{"trials":9084,"activeCount":447,"soonestReadout":7184},[9085,9096,9100,9104,9108,9112,9116,9120,9127,9135,9139,9143],{"nctId":9086,"briefTitle":9087,"status":195,"phases":9088,"primaryCompletion":9089,"completion":2113,"start":9090,"enrollment":7432,"conditions":9091,"interventions":9092},"NCT00849030","ATAC - Arimidex, Tamoxifen Alone or in Combination",[92],"2001-06","1996-07",[25],[9093,468,9094,9095],"Anastozole","Anastozole (Arimidex) placebo","Tamoxifen (Nolvadex) placebo",{"nctId":7389,"briefTitle":7390,"status":195,"phases":9097,"completion":6370,"start":7392,"enrollment":7393,"conditions":9098,"interventions":9099},[92],[7395],[120,468],{"nctId":6506,"briefTitle":6507,"status":195,"phases":9101,"primaryCompletion":3839,"completion":2747,"start":6509,"enrollment":5425,"conditions":9102,"interventions":9103},[92],[25,6511],[53,468],{"nctId":7181,"briefTitle":7182,"status":151,"phases":9105,"primaryCompletion":7184,"completion":7185,"start":1917,"enrollment":7186,"conditions":9106,"interventions":9107},[92],[7188],[3966,468,120,469,6350],{"nctId":7191,"briefTitle":7192,"status":151,"phases":9109,"primaryCompletion":7194,"completion":7195,"start":7196,"enrollment":7197,"conditions":9110,"interventions":9111},[92],[7188],[3966,468,120,469,6350,5979],{"nctId":7427,"briefTitle":7428,"status":195,"phases":9113,"completion":7430,"start":7431,"enrollment":7432,"conditions":9114,"interventions":9115},[92],[25],[120,468],{"nctId":7436,"briefTitle":7437,"status":195,"phases":9117,"primaryCompletion":5796,"completion":7439,"start":7431,"enrollment":7393,"conditions":9118,"interventions":9119},[92],[7441],[120,468],{"nctId":9121,"briefTitle":9122,"status":195,"phases":9123,"primaryCompletion":4297,"completion":4297,"start":9124,"enrollment":1120,"conditions":9125,"interventions":9126},"NCT00233610","Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer",[92],"2003-12",[416],[7385,468],{"nctId":9128,"briefTitle":9129,"status":195,"phases":9130,"primaryCompletion":2057,"completion":2143,"start":4297,"enrollment":9131,"conditions":9132,"interventions":9133},"NCT00605267","Arimidex\u002FTamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment",[92],197,[25],[468,6463,9134],"Goserelin acetate",{"nctId":7484,"briefTitle":7485,"status":195,"phases":9136,"primaryCompletion":2152,"completion":2152,"start":7475,"enrollment":7487,"conditions":9137,"interventions":9138},[92],[25],[468,120],{"nctId":7491,"briefTitle":7492,"status":195,"phases":9140,"completion":7494,"start":7495,"enrollment":7496,"conditions":9141,"interventions":9142},[92],[25],[120,468],{"nctId":7508,"briefTitle":7509,"status":195,"phases":9144,"completion":2329,"start":7511,"enrollment":7512,"conditions":9145,"interventions":9146},[92],[25],[120,468,7515,7516],{"trials":9148,"activeCount":102},[9149],{"nctId":7520,"briefTitle":7521,"status":195,"phases":9150,"primaryCompletion":2589,"completion":2589,"start":2415,"enrollment":7523,"conditions":9151,"interventions":9152},[93],[25],[120,468],{"trials":9154,"activeCount":102},[],{"intervention":4615,"totalTrials":1855,"cells":9156},{"EARLY_PHASE1":9157,"PHASE1":9159,"PHASE2":9175,"PHASE3":9191,"PHASE4":9197,"NA":9199},{"trials":9158,"activeCount":102},[],{"trials":9160,"activeCount":102},[9161,9165,9171],{"nctId":4873,"briefTitle":4874,"status":195,"phases":9162,"primaryCompletion":2169,"completion":2542,"start":4876,"enrollment":4877,"conditions":9163,"interventions":9164},[90],[4879],[3830,4774,345,4615,369],{"nctId":9166,"briefTitle":9167,"status":443,"phases":9168,"primaryCompletion":2516,"completion":2516,"start":6718,"enrollment":477,"conditions":9169,"interventions":9170},"NCT00473616","Phase I Single Ascending Dose\u002FMultiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan",[90],[4217,556,157],[5745,4615],{"nctId":526,"briefTitle":527,"status":195,"phases":9172,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":9173,"interventions":9174},[90],[498],[535,267,536,174,537],{"trials":9176,"activeCount":122,"soonestReadout":5770},[9177,9181,9185],{"nctId":8689,"briefTitle":8690,"status":624,"phases":9178,"primaryCompletion":4284,"completion":4284,"start":8692,"enrollment":8693,"conditions":9179,"interventions":9180},[91],[5121],[8696,4615,8697,4843],{"nctId":5767,"briefTitle":5768,"status":151,"phases":9182,"primaryCompletion":5770,"completion":1952,"start":1372,"enrollment":2289,"conditions":9183,"interventions":9184},[91],[172,4612,281,5772],[225,226,4843,5774,4615,5775,283],{"nctId":9186,"briefTitle":9187,"status":195,"phases":9188,"primaryCompletion":2481,"completion":2481,"start":2113,"enrollment":579,"conditions":9189,"interventions":9190},"NCT01116271","Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec",[91],[691],[43,4615],{"trials":9192,"activeCount":122,"soonestReadout":4607},[9193],{"nctId":4604,"briefTitle":4605,"status":108,"phases":9194,"primaryCompletion":4607,"completion":4608,"start":4609,"enrollment":4610,"conditions":9195,"interventions":9196},[92],[172,4612],[225,225,4614,118,369,4615,4616,4617],{"trials":9198,"activeCount":102},[],{"trials":9200,"activeCount":102},[],{"intervention":1051,"totalTrials":723,"cells":9202},{"EARLY_PHASE1":9203,"PHASE1":9205,"PHASE2":9207,"PHASE3":9221,"PHASE4":9235,"NA":9237},{"trials":9204,"activeCount":102},[],{"trials":9206,"activeCount":102},[],{"trials":9208,"activeCount":102},[9209,9217],{"nctId":9210,"briefTitle":9211,"status":195,"phases":9212,"completion":9213,"start":8692,"enrollment":9214,"conditions":9215,"interventions":9216},"NCT00256711","Phase II Iressa Versus Vinorelbine (INVITE)",[91],"2006-02",192,[6695],[1013,1051],{"nctId":4281,"briefTitle":4282,"status":195,"phases":9218,"completion":4284,"start":4285,"enrollment":4286,"conditions":9219,"interventions":9220},[91],[262],[1013,177,1051],{"trials":9222,"activeCount":447,"soonestReadout":5615},[9223,9227,9231],{"nctId":1043,"briefTitle":1044,"status":108,"phases":9224,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":98,"conditions":9225,"interventions":9226},[92],[1049],[163,180,344,177,1017,345,1051,1052],{"nctId":5309,"briefTitle":5310,"status":195,"phases":9228,"primaryCompletion":5312,"completion":3071,"start":5313,"enrollment":2497,"conditions":9229,"interventions":9230},[92],[5315],[82,1051,283,5317,82,3038],{"nctId":5612,"briefTitle":5613,"status":108,"phases":9232,"primaryCompletion":5615,"completion":2288,"start":5616,"enrollment":5617,"conditions":9233,"interventions":9234},[92],[25],[808,121,283,5620,1051],{"trials":9236,"activeCount":102},[],{"trials":9238,"activeCount":102},[],{"intervention":73,"totalTrials":3887,"cells":9240},{"EARLY_PHASE1":9241,"PHASE1":9243,"PHASE2":9245,"PHASE3":9247,"PHASE4":9279,"NA":9281},{"trials":9242,"activeCount":102},[],{"trials":9244,"activeCount":102},[],{"trials":9246,"activeCount":102},[],{"trials":9248,"activeCount":447,"soonestReadout":72},[9249,9261,9270],{"nctId":75,"briefTitle":76,"status":108,"phases":9250,"primaryCompletion":77,"completion":9251,"start":9252,"enrollment":170,"conditions":9253,"interventions":9260},[92],"2028-08-29","2013-08-26",[9254,784,9255,9256,9257,9258,9259],"Newly Diagnosed","FIGO Stage III-IV","BRCA Mutation","Complete Response","Partial Response","First Line Platinum Chemotherapy",[73],{"nctId":70,"briefTitle":71,"status":108,"phases":9262,"primaryCompletion":72,"completion":1317,"start":841,"enrollment":9263,"conditions":9264,"interventions":9269},[92],327,[9265,9266,9267,9268],"Platinum Sensitive","BRCA Mutated","Relapsed Ovarian Cancer","Following Complete or Partial Response to Platinum Based Chemotherapy",[73],{"nctId":9271,"briefTitle":9272,"status":195,"phases":9273,"primaryCompletion":9274,"completion":9274,"start":9275,"enrollment":9276,"conditions":9277,"interventions":9278},"NCT03534453","Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy",[92],"2025-01-27","2018-05-29",229,[9267,9268,9265],[73],{"trials":9280,"activeCount":102},[],{"trials":9282,"activeCount":102},[],{"intervention":9284,"totalTrials":447,"cells":9285},"Laroprovstat",{"EARLY_PHASE1":9286,"PHASE1":9288,"PHASE2":9299,"PHASE3":9301,"PHASE4":9314,"NA":9316},{"trials":9287,"activeCount":102},[],{"trials":9289,"activeCount":122,"soonestReadout":9294},[9290],{"nctId":9291,"briefTitle":9292,"status":151,"phases":9293,"primaryCompletion":9294,"completion":9294,"start":9295,"enrollment":579,"conditions":9296,"interventions":9297},"NCT07513571","A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults",[90],"2026-07-09","2026-04-10",[5851],[9298,9284],"AZD4954",{"trials":9300,"activeCount":102},[],{"trials":9302,"activeCount":122,"soonestReadout":338},[9303],{"nctId":9304,"briefTitle":9305,"status":1097,"phases":9306,"primaryCompletion":338,"completion":338,"start":6284,"enrollment":365,"conditions":9307,"interventions":9309},"NCT07619131","A Phase III Study to Assess the Effect of FDC Laroprovstat\u002FRosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.",[92],[9308],"Hypercholesterolaemia",[9284,9310,9311,9312,9313],"Rosuvastatin 1","Rosuvastatin 2","Laroprovstat\u002FRosuvastatin 1","Laroprovstat\u002FRosuvastatin 2",{"trials":9315,"activeCount":102},[],{"trials":9317,"activeCount":102},[],{"intervention":9310,"totalTrials":447,"cells":9319},{"EARLY_PHASE1":9320,"PHASE1":9322,"PHASE2":9324,"PHASE3":9326,"PHASE4":9345,"NA":9347},{"trials":9321,"activeCount":102},[],{"trials":9323,"activeCount":102},[],{"trials":9325,"activeCount":102},[],{"trials":9327,"activeCount":447,"soonestReadout":3958},[9328,9332],{"nctId":9304,"briefTitle":9305,"status":1097,"phases":9329,"primaryCompletion":338,"completion":338,"start":6284,"enrollment":365,"conditions":9330,"interventions":9331},[92],[9308],[9284,9310,9311,9312,9313],{"nctId":9333,"briefTitle":9334,"status":1097,"phases":9335,"primaryCompletion":3958,"completion":3958,"start":9336,"enrollment":1685,"conditions":9337,"interventions":9338},"NCT07619118","A Phase III Study to Assess the Effect of FDC Laroprovstat\u002FRosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia",[92],"2026-09-15",[9308],[9339,9340,9341,9342,9310,9311,9343,9344],"laroprovstat\u002Frosuvastatin 1","laroprovstat\u002Frosuvastatin 2","laroprovstat\u002Frosuvastatin 3","laroprovstat\u002Frosuvastatin 4","Rosuvastatin 3","Rosuvastatin 4",{"trials":9346,"activeCount":102},[],{"trials":9348,"activeCount":102},[],{"intervention":9311,"totalTrials":447,"cells":9350},{"EARLY_PHASE1":9351,"PHASE1":9353,"PHASE2":9355,"PHASE3":9357,"PHASE4":9367,"NA":9369},{"trials":9352,"activeCount":102},[],{"trials":9354,"activeCount":102},[],{"trials":9356,"activeCount":102},[],{"trials":9358,"activeCount":447,"soonestReadout":3958},[9359,9363],{"nctId":9304,"briefTitle":9305,"status":1097,"phases":9360,"primaryCompletion":338,"completion":338,"start":6284,"enrollment":365,"conditions":9361,"interventions":9362},[92],[9308],[9284,9310,9311,9312,9313],{"nctId":9333,"briefTitle":9334,"status":1097,"phases":9364,"primaryCompletion":3958,"completion":3958,"start":9336,"enrollment":1685,"conditions":9365,"interventions":9366},[92],[9308],[9339,9340,9341,9342,9310,9311,9343,9344],{"trials":9368,"activeCount":102},[],{"trials":9370,"activeCount":102},[],{"intervention":9312,"totalTrials":447,"cells":9372},{"EARLY_PHASE1":9373,"PHASE1":9375,"PHASE2":9377,"PHASE3":9379,"PHASE4":9389,"NA":9391},{"trials":9374,"activeCount":102},[],{"trials":9376,"activeCount":102},[],{"trials":9378,"activeCount":102},[],{"trials":9380,"activeCount":447,"soonestReadout":3958},[9381,9385],{"nctId":9304,"briefTitle":9305,"status":1097,"phases":9382,"primaryCompletion":338,"completion":338,"start":6284,"enrollment":365,"conditions":9383,"interventions":9384},[92],[9308],[9284,9310,9311,9312,9313],{"nctId":9333,"briefTitle":9334,"status":1097,"phases":9386,"primaryCompletion":3958,"completion":3958,"start":9336,"enrollment":1685,"conditions":9387,"interventions":9388},[92],[9308],[9339,9340,9341,9342,9310,9311,9343,9344],{"trials":9390,"activeCount":102},[],{"trials":9392,"activeCount":102},[],{"intervention":9313,"totalTrials":447,"cells":9394},{"EARLY_PHASE1":9395,"PHASE1":9397,"PHASE2":9399,"PHASE3":9401,"PHASE4":9411,"NA":9413},{"trials":9396,"activeCount":102},[],{"trials":9398,"activeCount":102},[],{"trials":9400,"activeCount":102},[],{"trials":9402,"activeCount":447,"soonestReadout":3958},[9403,9407],{"nctId":9304,"briefTitle":9305,"status":1097,"phases":9404,"primaryCompletion":338,"completion":338,"start":6284,"enrollment":365,"conditions":9405,"interventions":9406},[92],[9308],[9284,9310,9311,9312,9313],{"nctId":9333,"briefTitle":9334,"status":1097,"phases":9408,"primaryCompletion":3958,"completion":3958,"start":9336,"enrollment":1685,"conditions":9409,"interventions":9410},[92],[9308],[9339,9340,9341,9342,9310,9311,9343,9344],{"trials":9412,"activeCount":102},[],{"trials":9414,"activeCount":102},[],{"intervention":7937,"totalTrials":447,"cells":9416},{"EARLY_PHASE1":9417,"PHASE1":9419,"PHASE2":9421,"PHASE3":9433,"PHASE4":9439,"NA":9441},{"trials":9418,"activeCount":102},[],{"trials":9420,"activeCount":102},[],{"trials":9422,"activeCount":122,"soonestReadout":9427},[9423],{"nctId":9424,"briefTitle":9425,"status":151,"phases":9426,"primaryCompletion":9427,"completion":9427,"start":7158,"enrollment":9428,"conditions":9429,"interventions":9430},"NCT06106945","AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma",[90,91],"2027-08-16",226,[7892],[9431,9432,7937,7935],"AZD0305","Elranatamab",{"trials":9434,"activeCount":122,"soonestReadout":7927},[9435],{"nctId":7924,"briefTitle":7925,"status":151,"phases":9436,"primaryCompletion":7927,"completion":7928,"start":3693,"enrollment":7929,"conditions":9437,"interventions":9438},[92],[7931],[7879,7933,7934,7935,7936,7937],{"trials":9440,"activeCount":102},[],{"trials":9442,"activeCount":102},[],{"intervention":7935,"totalTrials":447,"cells":9444},{"EARLY_PHASE1":9445,"PHASE1":9447,"PHASE2":9449,"PHASE3":9455,"PHASE4":9461,"NA":9463},{"trials":9446,"activeCount":102},[],{"trials":9448,"activeCount":102},[],{"trials":9450,"activeCount":122,"soonestReadout":9427},[9451],{"nctId":9424,"briefTitle":9425,"status":151,"phases":9452,"primaryCompletion":9427,"completion":9427,"start":7158,"enrollment":9428,"conditions":9453,"interventions":9454},[90,91],[7892],[9431,9432,7937,7935],{"trials":9456,"activeCount":122,"soonestReadout":7927},[9457],{"nctId":7924,"briefTitle":7925,"status":151,"phases":9458,"primaryCompletion":7927,"completion":7928,"start":3693,"enrollment":7929,"conditions":9459,"interventions":9460},[92],[7931],[7879,7933,7934,7935,7936,7937],{"trials":9462,"activeCount":102},[],{"trials":9464,"activeCount":102},[],{"intervention":7110,"totalTrials":447,"cells":9466},{"EARLY_PHASE1":9467,"PHASE1":9469,"PHASE2":9471,"PHASE3":9473,"PHASE4":9483,"NA":9485},{"trials":9468,"activeCount":102},[],{"trials":9470,"activeCount":102},[],{"trials":9472,"activeCount":102},[],{"trials":9474,"activeCount":447,"soonestReadout":86},[9475,9479],{"nctId":84,"briefTitle":85,"status":108,"phases":9476,"primaryCompletion":86,"completion":660,"start":7100,"enrollment":477,"conditions":9477,"interventions":9478},[92],[4058,7102,7103,7104,7105,7106,7107,7108],[87,7110],{"nctId":3480,"briefTitle":3481,"status":108,"phases":9480,"primaryCompletion":1317,"completion":3483,"start":339,"enrollment":3484,"conditions":9481,"interventions":9482},[92],[3486],[3488,900,3489],{"trials":9484,"activeCount":102},[],{"trials":9486,"activeCount":102},[],{"intervention":2293,"totalTrials":447,"cells":9488},{"EARLY_PHASE1":9489,"PHASE1":9491,"PHASE2":9493,"PHASE3":9499,"PHASE4":9505,"NA":9507},{"trials":9490,"activeCount":102},[],{"trials":9492,"activeCount":102},[],{"trials":9494,"activeCount":122,"soonestReadout":2288},[9495],{"nctId":2285,"briefTitle":2286,"status":151,"phases":9496,"primaryCompletion":2288,"completion":2288,"start":1664,"enrollment":2289,"conditions":9497,"interventions":9498},[91],[2291],[2293,2044],{"trials":9500,"activeCount":122,"soonestReadout":2764},[9501],{"nctId":2761,"briefTitle":2762,"status":108,"phases":9502,"primaryCompletion":2764,"completion":2764,"start":988,"enrollment":2765,"conditions":9503,"interventions":9504},[92],[2291],[2293,2044],{"trials":9506,"activeCount":102},[],{"trials":9508,"activeCount":102},[],{"intervention":7418,"totalTrials":447,"cells":9510},{"EARLY_PHASE1":9511,"PHASE1":9513,"PHASE2":9515,"PHASE3":9517,"PHASE4":9527,"NA":9529},{"trials":9512,"activeCount":102},[],{"trials":9514,"activeCount":102},[],{"trials":9516,"activeCount":102},[],{"trials":9518,"activeCount":447,"soonestReadout":1406},[9519,9523],{"nctId":7410,"briefTitle":7411,"status":108,"phases":9520,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":9521,"interventions":9522},[92],[7416],[6431,7418,120,7419,469,7420,5977,5979,7421,5978],{"nctId":7461,"briefTitle":7462,"status":108,"phases":9524,"primaryCompletion":7464,"completion":7465,"start":7466,"enrollment":7467,"conditions":9525,"interventions":9526},[92],[7416],[6431,120,7419,7470,5977,7421],{"trials":9528,"activeCount":102},[],{"trials":9530,"activeCount":102},[],{"intervention":7419,"totalTrials":447,"cells":9532},{"EARLY_PHASE1":9533,"PHASE1":9535,"PHASE2":9537,"PHASE3":9539,"PHASE4":9549,"NA":9551},{"trials":9534,"activeCount":102},[],{"trials":9536,"activeCount":102},[],{"trials":9538,"activeCount":102},[],{"trials":9540,"activeCount":447,"soonestReadout":1406},[9541,9545],{"nctId":7410,"briefTitle":7411,"status":108,"phases":9542,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":9543,"interventions":9544},[92],[7416],[6431,7418,120,7419,469,7420,5977,5979,7421,5978],{"nctId":7461,"briefTitle":7462,"status":108,"phases":9546,"primaryCompletion":7464,"completion":7465,"start":7466,"enrollment":7467,"conditions":9547,"interventions":9548},[92],[7416],[6431,120,7419,7470,5977,7421],{"trials":9550,"activeCount":102},[],{"trials":9552,"activeCount":102},[],{"intervention":7421,"totalTrials":447,"cells":9554},{"EARLY_PHASE1":9555,"PHASE1":9557,"PHASE2":9559,"PHASE3":9561,"PHASE4":9571,"NA":9573},{"trials":9556,"activeCount":102},[],{"trials":9558,"activeCount":102},[],{"trials":9560,"activeCount":102},[],{"trials":9562,"activeCount":447,"soonestReadout":1406},[9563,9567],{"nctId":7410,"briefTitle":7411,"status":108,"phases":9564,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":9565,"interventions":9566},[92],[7416],[6431,7418,120,7419,469,7420,5977,5979,7421,5978],{"nctId":7461,"briefTitle":7462,"status":108,"phases":9568,"primaryCompletion":7464,"completion":7465,"start":7466,"enrollment":7467,"conditions":9569,"interventions":9570},[92],[7416],[6431,120,7419,7470,5977,7421],{"trials":9572,"activeCount":102},[],{"trials":9574,"activeCount":102},[],{"intervention":786,"totalTrials":447,"cells":9576},{"EARLY_PHASE1":9577,"PHASE1":9579,"PHASE2":9581,"PHASE3":9583,"PHASE4":9593,"NA":9595},{"trials":9578,"activeCount":102},[],{"trials":9580,"activeCount":102},[],{"trials":9582,"activeCount":102},[],{"trials":9584,"activeCount":447,"soonestReadout":893},[9585,9589],{"nctId":777,"briefTitle":778,"status":108,"phases":9586,"primaryCompletion":780,"completion":398,"start":781,"enrollment":782,"conditions":9587,"interventions":9588},[92],[784],[239,117,267,786,787],{"nctId":890,"briefTitle":891,"status":108,"phases":9590,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":9591,"interventions":9592},[92],[898],[63,900,901,902,344,118],{"trials":9594,"activeCount":102},[],{"trials":9596,"activeCount":102},[],{"intervention":9598,"totalTrials":447,"cells":9599},"Eplontersen",{"EARLY_PHASE1":9600,"PHASE1":9602,"PHASE2":9604,"PHASE3":9614,"PHASE4":9625,"NA":9627},{"trials":9601,"activeCount":102},[],{"trials":9603,"activeCount":102},[],{"trials":9605,"activeCount":122,"soonestReadout":3930},[9606],{"nctId":9607,"briefTitle":9608,"status":1097,"phases":9609,"primaryCompletion":3930,"completion":3930,"start":130,"enrollment":6187,"conditions":9610,"interventions":9612},"NCT07608354","A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM.",[91],[9611],"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",[9598,9613],"ALXN2220",{"trials":9615,"activeCount":122,"soonestReadout":6669},[9616],{"nctId":9617,"briefTitle":9618,"status":108,"phases":9619,"primaryCompletion":6669,"completion":9620,"start":9621,"enrollment":4307,"conditions":9622,"interventions":9624},"NCT06194825","EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy",[92],"2027-01-05","2023-12-01",[9623],"Transthyretin Amyloid Cardiomyopathy",[9598],{"trials":9626,"activeCount":102},[],{"trials":9628,"activeCount":102},[],{"intervention":3445,"totalTrials":447,"cells":9630},{"EARLY_PHASE1":9631,"PHASE1":9633,"PHASE2":9635,"PHASE3":9641,"PHASE4":9647,"NA":9649},{"trials":9632,"activeCount":102},[],{"trials":9634,"activeCount":102},[],{"trials":9636,"activeCount":122,"soonestReadout":218},[9637],{"nctId":215,"briefTitle":216,"status":151,"phases":9638,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":9639,"interventions":9640},[91],[223],[225,180,162,121,226,227],{"trials":9642,"activeCount":122,"soonestReadout":3438},[9643],{"nctId":3435,"briefTitle":3436,"status":108,"phases":9644,"primaryCompletion":3438,"completion":3439,"start":1383,"enrollment":3440,"conditions":9645,"interventions":9646},[92],[3442,3443],[117,3445],{"trials":9648,"activeCount":102},[],{"trials":9650,"activeCount":102},[],{"intervention":4179,"totalTrials":447,"cells":9652},{"EARLY_PHASE1":9653,"PHASE1":9655,"PHASE2":9657,"PHASE3":9659,"PHASE4":9669,"NA":9671},{"trials":9654,"activeCount":102},[],{"trials":9656,"activeCount":102},[],{"trials":9658,"activeCount":102},[],{"trials":9660,"activeCount":447,"soonestReadout":4172},[9661,9665],{"nctId":5159,"briefTitle":5160,"status":108,"phases":9662,"primaryCompletion":5162,"completion":5163,"start":1794,"enrollment":5164,"conditions":9663,"interventions":9664},[92],[5166],[179,5168,4178,4179],{"nctId":4169,"briefTitle":4170,"status":151,"phases":9666,"primaryCompletion":4172,"completion":4173,"start":4174,"enrollment":3613,"conditions":9667,"interventions":9668},[92],[4176],[179,345,344,177,4178,4179],{"trials":9670,"activeCount":102},[],{"trials":9672,"activeCount":102},[],{"intervention":3235,"totalTrials":447,"cells":9674},{"EARLY_PHASE1":9675,"PHASE1":9677,"PHASE2":9679,"PHASE3":9685,"PHASE4":9691,"NA":9693},{"trials":9676,"activeCount":102},[],{"trials":9678,"activeCount":102},[],{"trials":9680,"activeCount":122,"soonestReadout":3227},[9681],{"nctId":3224,"briefTitle":3225,"status":151,"phases":9682,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":9683,"interventions":9684},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"trials":9686,"activeCount":122,"soonestReadout":5466},[9687],{"nctId":5463,"briefTitle":5464,"status":108,"phases":9688,"primaryCompletion":5466,"completion":5467,"start":5468,"enrollment":5469,"conditions":9689,"interventions":9690},[92],[262],[1012,3235,3234],{"trials":9692,"activeCount":102},[],{"trials":9694,"activeCount":102},[],{"intervention":3234,"totalTrials":447,"cells":9696},{"EARLY_PHASE1":9697,"PHASE1":9699,"PHASE2":9701,"PHASE3":9707,"PHASE4":9713,"NA":9715},{"trials":9698,"activeCount":102},[],{"trials":9700,"activeCount":102},[],{"trials":9702,"activeCount":122,"soonestReadout":3227},[9703],{"nctId":3224,"briefTitle":3225,"status":151,"phases":9704,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":9705,"interventions":9706},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"trials":9708,"activeCount":122,"soonestReadout":5466},[9709],{"nctId":5463,"briefTitle":5464,"status":108,"phases":9710,"primaryCompletion":5466,"completion":5467,"start":5468,"enrollment":5469,"conditions":9711,"interventions":9712},[92],[262],[1012,3235,3234],{"trials":9714,"activeCount":102},[],{"trials":9716,"activeCount":102},[],{"intervention":9718,"totalTrials":447,"cells":9719},"AZD0486",{"EARLY_PHASE1":9720,"PHASE1":9722,"PHASE2":9724,"PHASE3":9737,"PHASE4":9749,"NA":9751},{"trials":9721,"activeCount":102},[],{"trials":9723,"activeCount":102},[],{"trials":9725,"activeCount":122,"soonestReadout":9730},[9726],{"nctId":9727,"briefTitle":9728,"status":151,"phases":9729,"primaryCompletion":9730,"completion":9731,"start":9732,"enrollment":9733,"conditions":9734,"interventions":9736},"NCT06137118","AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia",[90,91],"2026-11-13","2027-06-29","2023-12-29",236,[9735],"B-cell Acute Lymphoblastic Leukemia (B-ALL)",[9718],{"trials":9738,"activeCount":122,"soonestReadout":9743},[9739],{"nctId":9740,"briefTitle":9741,"status":151,"phases":9742,"primaryCompletion":9743,"completion":9744,"start":9745,"enrollment":7302,"conditions":9746,"interventions":9747},"NCT07215585","AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL",[92],"2030-06-10","2033-07-28","2025-11-11",[1464],[9718,9748],"R-mini-CHOP",{"trials":9750,"activeCount":102},[],{"trials":9752,"activeCount":102},[],{"intervention":1941,"totalTrials":447,"cells":9754},{"EARLY_PHASE1":9755,"PHASE1":9757,"PHASE2":9759,"PHASE3":9765,"PHASE4":9771,"NA":9773},{"trials":9756,"activeCount":102},[],{"trials":9758,"activeCount":102},[],{"trials":9760,"activeCount":122,"soonestReadout":1934},[9761],{"nctId":1931,"briefTitle":1932,"status":108,"phases":9762,"primaryCompletion":1934,"completion":1934,"start":1137,"enrollment":1935,"conditions":9763,"interventions":9764},[90,91],[1937],[1939,1927,1926,1940,1941],{"trials":9766,"activeCount":122,"soonestReadout":2026},[9767],{"nctId":2023,"briefTitle":2024,"status":151,"phases":9768,"primaryCompletion":2026,"completion":2027,"start":973,"enrollment":2028,"conditions":9769,"interventions":9770},[92],[651],[2031,2032,653,1927,1941,1940,2033,2034],{"trials":9772,"activeCount":102},[],{"trials":9774,"activeCount":102},[],{"intervention":1364,"totalTrials":447,"cells":9776},{"EARLY_PHASE1":9777,"PHASE1":9779,"PHASE2":9785,"PHASE3":9787,"PHASE4":9793,"NA":9795},{"trials":9778,"activeCount":102},[],{"trials":9780,"activeCount":122,"soonestReadout":1357},[9781],{"nctId":1354,"briefTitle":1355,"status":108,"phases":9782,"primaryCompletion":1357,"completion":1317,"start":1358,"enrollment":1348,"conditions":9783,"interventions":9784},[90],[1360,1361,1362],[1335,1364],{"trials":9786,"activeCount":102},[],{"trials":9788,"activeCount":122,"soonestReadout":1495},[9789],{"nctId":1492,"briefTitle":1493,"status":108,"phases":9790,"primaryCompletion":1495,"completion":1496,"start":1497,"enrollment":1498,"conditions":9791,"interventions":9792},[92],[1500],[1335,1377,1364],{"trials":9794,"activeCount":102},[],{"trials":9796,"activeCount":102},[],{"intervention":2031,"totalTrials":447,"cells":9798},{"EARLY_PHASE1":9799,"PHASE1":9801,"PHASE2":9803,"PHASE3":9809,"PHASE4":9815,"NA":9817},{"trials":9800,"activeCount":102},[],{"trials":9802,"activeCount":102},[],{"trials":9804,"activeCount":122,"soonestReadout":6668},[9805],{"nctId":6665,"briefTitle":6666,"status":1097,"phases":9806,"primaryCompletion":6668,"completion":6668,"start":6669,"enrollment":3466,"conditions":9807,"interventions":9808},[90,91],[1937],[2031,159,369,6672],{"trials":9810,"activeCount":122,"soonestReadout":2026},[9811],{"nctId":2023,"briefTitle":2024,"status":151,"phases":9812,"primaryCompletion":2026,"completion":2027,"start":973,"enrollment":2028,"conditions":9813,"interventions":9814},[92],[651],[2031,2032,653,1927,1941,1940,2033,2034],{"trials":9816,"activeCount":102},[],{"trials":9818,"activeCount":102},[],{"intervention":3657,"totalTrials":447,"cells":9820},{"EARLY_PHASE1":9821,"PHASE1":9823,"PHASE2":9825,"PHASE3":9827,"PHASE4":9837,"NA":9839},{"trials":9822,"activeCount":102},[],{"trials":9824,"activeCount":102},[],{"trials":9826,"activeCount":102},[],{"trials":9828,"activeCount":447,"soonestReadout":4848},[9829,9833],{"nctId":3649,"briefTitle":3650,"status":151,"phases":9830,"primaryCompletion":3652,"completion":3652,"start":3653,"enrollment":3654,"conditions":9831,"interventions":9832},[92],[281],[180,117,3657],{"nctId":4845,"briefTitle":4846,"status":108,"phases":9834,"primaryCompletion":4848,"completion":4849,"start":446,"enrollment":4850,"conditions":9835,"interventions":9836},[92],[281],[180,121,3657,4853],{"trials":9838,"activeCount":102},[],{"trials":9840,"activeCount":102},[],{"intervention":9842,"totalTrials":98,"cells":9843},"budesonide\u002Fformoterol",{"EARLY_PHASE1":9844,"PHASE1":9846,"PHASE2":9848,"PHASE3":9867,"PHASE4":10017,"NA":10034},{"trials":9845,"activeCount":102},[],{"trials":9847,"activeCount":102},[],{"trials":9849,"activeCount":102},[9850,9859],{"nctId":9851,"briefTitle":9852,"status":195,"phases":9853,"primaryCompletion":2406,"completion":2406,"start":2067,"enrollment":4928,"conditions":9854,"interventions":9856},"NCT00989833","Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients",[91],[9855],"Exercise Induced Asthma",[9857,9858,9842],"budesonide","terbutaline",{"nctId":9860,"briefTitle":9861,"status":195,"phases":9862,"completion":4299,"start":7448,"enrollment":3125,"conditions":9863,"interventions":9865},"NCT00658255","Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler",[91],[9864],"Stable Asthma",[9842,9866],"formoterol",{"trials":9868,"activeCount":122,"soonestReadout":6185},[9869,9875,9883,9890,9897,9905,9913,9919,9926,9933,9940,9949,9953,9959,9966,9974,9982,9990,9997,10005,10011],{"nctId":9870,"briefTitle":9871,"status":195,"phases":9872,"completion":6572,"start":3810,"enrollment":170,"conditions":9873,"interventions":9874},"NCT00652002","Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160\u002F4.5",[92],[16],[9842,9857,9866],{"nctId":9876,"briefTitle":9877,"status":195,"phases":9878,"primaryCompletion":2570,"completion":2570,"start":2056,"enrollment":9879,"conditions":9880,"interventions":9881},"NCT01069289","Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients",[92],1293,[28],[6190,9882],"Formoterol",{"nctId":9884,"briefTitle":9885,"status":195,"phases":9886,"completion":5742,"start":6719,"enrollment":9887,"conditions":9888,"interventions":9889},"NCT00319306","Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy",[92],550,[16],[6190],{"nctId":9891,"briefTitle":9892,"status":195,"phases":9893,"primaryCompletion":5742,"completion":5562,"start":6517,"enrollment":2187,"conditions":9894,"interventions":9895},"NCT00255255","Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160\u002F4.5 µg Twice Daily) in Japanese Patients With Asthma",[92],[16],[9896],"Budesonide\u002FFormoterol",{"nctId":9898,"briefTitle":9899,"status":195,"phases":9900,"completion":4876,"start":9901,"enrollment":4027,"conditions":9902,"interventions":9903},"NCT00646594","Atlantis Symbicort",[92],"2003-11",[16],[9842,9904],"fluticasone\u002Fsalmeterol",{"nctId":9906,"briefTitle":9907,"status":195,"phases":9908,"completion":6780,"start":9909,"enrollment":5898,"conditions":9910,"interventions":9911},"NCT00646620","Symbicort Onset of Action 1",[92],"2003-04",[16],[9842,9904,9912],"albuterol",{"nctId":9914,"briefTitle":9915,"status":195,"phases":9916,"completion":6780,"start":5797,"enrollment":170,"conditions":9917,"interventions":9918},"NCT00651651","Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80\u002F4.5",[92],[16],[9842,9857,9866],{"nctId":9920,"briefTitle":9921,"status":195,"phases":9922,"completion":2169,"start":5563,"enrollment":2472,"conditions":9923,"interventions":9924},"NCT00421122","Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD",[92],[28],[9842,9857,9925],"terbutaline sulfate",{"nctId":9927,"briefTitle":9928,"status":195,"phases":9929,"completion":6563,"start":9930,"enrollment":5898,"conditions":9931,"interventions":9932},"NCT00646009","Symbicort Onset of Action 2",[92],"2003-03",[16],[9842,9904,9912],{"nctId":9934,"briefTitle":9935,"status":195,"phases":9936,"completion":2252,"start":6719,"enrollment":2187,"conditions":9937,"interventions":9938},"NCT00259779","Comparison Between Symbicort® and Prednisolone in COPD",[92],[28],[9842,9939],"Prednisolone",{"nctId":9941,"briefTitle":9942,"status":195,"phases":9943,"completion":9944,"start":9075,"enrollment":9945,"conditions":9946,"interventions":9948},"NCT00646516","Gemini Symbicort pMDI",[92],"2005-02",615,[9947],"Mild or Moderate Asthma",[9842],{"nctId":6182,"briefTitle":6183,"status":108,"phases":9950,"primaryCompletion":6185,"completion":6185,"start":6186,"enrollment":6187,"conditions":9951,"interventions":9952},[92],[6117],[6051,6190,6191,6192,6193],{"nctId":9954,"briefTitle":9955,"status":195,"phases":9956,"completion":6718,"start":7494,"enrollment":365,"conditions":9957,"interventions":9958},"NCT00326053","Prevention of Asthma Relapse After Discharge From Emergency",[92],[16],[6190],{"nctId":9960,"briefTitle":9961,"status":195,"phases":9962,"completion":9963,"start":9909,"enrollment":8294,"conditions":9964,"interventions":9965},"NCT00646321","Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT",[92],"2004-08",[16],[9842,9857],{"nctId":9967,"briefTitle":9968,"status":195,"phases":9969,"completion":7342,"start":3809,"enrollment":5269,"conditions":9970,"interventions":9971},"NCT00252785","Efficacy & Safety of Symbicort® TURBUHALER® 160\u002F4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients",[92],[16],[9896,9972,9973],"Budesonide","Theophylline",{"nctId":9975,"briefTitle":9976,"status":195,"phases":9977,"completion":6445,"start":9909,"enrollment":9978,"conditions":9979,"interventions":9980},"NCT00652392","Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM",[92],750,[16],[9842,9981],"budesonide and placebo",{"nctId":9983,"briefTitle":9984,"status":195,"phases":9985,"completion":4916,"start":9986,"enrollment":9987,"conditions":9988,"interventions":9989},"NCT00290264","SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma",[92],"2004-12",1000,[16],[6190],{"nctId":9991,"briefTitle":9992,"status":195,"phases":9993,"completion":9075,"start":3810,"enrollment":9994,"conditions":9995,"interventions":9996},"NCT00651547","Symbicort in Asthmatic Children - SEEDLING",[92],405,[16],[9842,9857,9866],{"nctId":9998,"briefTitle":9999,"status":195,"phases":10000,"completion":4876,"start":6563,"enrollment":10001,"conditions":10002,"interventions":10003},"NCT00651768","Titratable Dosing in Moderate to Severe Asthmatics",[92],570,[16],[9842,10004],"Symbicort pMDI + budesonide HFA pMDI",{"nctId":10006,"briefTitle":10007,"status":195,"phases":10008,"completion":7494,"start":3990,"enrollment":486,"conditions":10009,"interventions":10010},"NCT00288379","SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma",[92],[16],[9866,9842],{"nctId":10012,"briefTitle":10013,"status":195,"phases":10014,"completion":9075,"start":3810,"enrollment":3125,"conditions":10015,"interventions":10016},"NCT00646529","Long-Term Safety of Symbicort in Asthmatic Children - SAPLING",[92],[16],[9842,9857],{"trials":10018,"activeCount":102},[10019,10027],{"nctId":10020,"briefTitle":10021,"status":195,"phases":10022,"primaryCompletion":2746,"completion":2746,"start":6709,"enrollment":10023,"conditions":10024,"interventions":10025},"NCT01397890","Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)",[93],793,[6083],[6190,10026],"Tiotropium",{"nctId":10028,"briefTitle":10029,"status":195,"phases":10030,"completion":4915,"start":3839,"enrollment":10031,"conditions":10032,"interventions":10033},"NCT00463866","Local Phase 4 Pan-European SMART Study",[93],8424,[16],[6190],{"trials":10035,"activeCount":102},[],{"intervention":6193,"totalTrials":723,"cells":10037},{"EARLY_PHASE1":10038,"PHASE1":10040,"PHASE2":10042,"PHASE3":10057,"PHASE4":10081,"NA":10092},{"trials":10039,"activeCount":102},[],{"trials":10041,"activeCount":102},[],{"trials":10043,"activeCount":102},[10044],{"nctId":10045,"briefTitle":10046,"status":195,"phases":10047,"primaryCompletion":10048,"completion":10048,"start":10049,"enrollment":680,"conditions":10050,"interventions":10053},"NCT02479412","A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma",[91],"2016-02-08","2015-06-25",[16,10051,10052],"Efficacy","Safety",[10054,10055,10056,6193],"800 μg AZD7594 once daily","250 µg AZD7594 once daily","58 µg AZD7594 once daily",{"trials":10058,"activeCount":122,"soonestReadout":6185},[10059,10069,10077],{"nctId":10060,"briefTitle":10061,"status":195,"phases":10062,"primaryCompletion":10063,"completion":10063,"start":2570,"enrollment":10064,"conditions":10065,"interventions":10067},"NCT01313494","A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:",[92],"2012-05",626,[10066],"COPD",[10068,6193],"Roflumilast",{"nctId":10070,"briefTitle":10071,"status":195,"phases":10072,"primaryCompletion":5725,"completion":2220,"start":5563,"enrollment":10073,"conditions":10074,"interventions":10075},"NCT00384189","A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma",[92],1080,[16],[10076,6193],"Ciclesonide",{"nctId":6182,"briefTitle":6183,"status":108,"phases":10078,"primaryCompletion":6185,"completion":6185,"start":6186,"enrollment":6187,"conditions":10079,"interventions":10080},[92],[6117],[6051,6190,6191,6192,6193],{"trials":10082,"activeCount":102},[10083],{"nctId":10084,"briefTitle":10085,"status":195,"phases":10086,"completion":6517,"start":6370,"enrollment":5876,"conditions":10087,"interventions":10088},"NCT00272753","Effect of Budesonide \u002F Formoterol Combination in Repeated AMP Provocations",[93],[16],[10089,10090,10091],"budesonide\u002Fformoterol Turbuhaler","formoterol Turbuhaler","salbutamol",{"trials":10093,"activeCount":102},[],{"intervention":10095,"totalTrials":447,"cells":10096},"Albuterol\u002FBudesonide",{"EARLY_PHASE1":10097,"PHASE1":10099,"PHASE2":10101,"PHASE3":10103,"PHASE4":10109,"NA":10120},{"trials":10098,"activeCount":102},[],{"trials":10100,"activeCount":102},[],{"trials":10102,"activeCount":102},[],{"trials":10104,"activeCount":122,"soonestReadout":6185},[10105],{"nctId":6182,"briefTitle":6183,"status":108,"phases":10106,"primaryCompletion":6185,"completion":6185,"start":6186,"enrollment":6187,"conditions":10107,"interventions":10108},[92],[6117],[6051,6190,6191,6192,6193],{"trials":10110,"activeCount":102},[10111],{"nctId":10112,"briefTitle":10113,"status":195,"phases":10114,"primaryCompletion":6928,"completion":6928,"start":10115,"enrollment":3645,"conditions":10116,"interventions":10118},"NCT06563102","Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma",[93],"2024-09-11",[10117],"Mild Asthma",[10095,10119],"Albuterol",{"trials":10121,"activeCount":102},[],{"intervention":10123,"totalTrials":2222,"cells":10124},"Baxdrostat",{"EARLY_PHASE1":10125,"PHASE1":10127,"PHASE2":10178,"PHASE3":10189,"PHASE4":10224,"NA":10226},{"trials":10126,"activeCount":102},[],{"trials":10128,"activeCount":102},[10129,10136,10144,10153,10161,10169],{"nctId":10130,"briefTitle":10131,"status":195,"phases":10132,"primaryCompletion":10133,"completion":10133,"start":1766,"enrollment":1638,"conditions":10134,"interventions":10135},"NCT06357520","A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants",[90],"2024-06-17",[5851],[10123,5911],{"nctId":10137,"briefTitle":10138,"status":195,"phases":10139,"primaryCompletion":10140,"completion":10140,"start":10141,"enrollment":2260,"conditions":10142,"interventions":10143},"NCT06194032","A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants",[90],"2024-05-13","2024-02-29",[5851],[10123,2255],{"nctId":10145,"briefTitle":10146,"status":195,"phases":10147,"primaryCompletion":10148,"completion":10148,"start":10149,"enrollment":5876,"conditions":10150,"interventions":10151},"NCT05961397","Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment",[90],"2022-04-15","2021-08-10",[2620],[10152],"baxdrostat",{"nctId":10154,"briefTitle":10155,"status":195,"phases":10156,"primaryCompletion":10157,"completion":10157,"start":10158,"enrollment":6275,"conditions":10159,"interventions":10160},"NCT05966324","Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population",[90],"2022-09-20","2022-07-05",[2620],[10152],{"nctId":10162,"briefTitle":10163,"status":195,"phases":10164,"primaryCompletion":10165,"completion":10165,"start":10166,"enrollment":370,"conditions":10167,"interventions":10168},"NCT05961384","Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat",[90],"2022-01-15","2021-11-18",[2620],[10152],{"nctId":10170,"briefTitle":10171,"status":195,"phases":10172,"primaryCompletion":10173,"completion":10173,"start":10174,"enrollment":434,"conditions":10175,"interventions":10176},"NCT06657105","A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential",[90],"2025-02-03","2024-11-01",[5851],[10177,10123],"EE\u002FLNG",{"trials":10179,"activeCount":102},[10180],{"nctId":10181,"briefTitle":10182,"status":195,"phases":10183,"primaryCompletion":10184,"completion":10184,"start":10185,"enrollment":5898,"conditions":10186,"interventions":10188},"NCT06336356","A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension",[91],"2024-12-04","2024-06-10",[10187],"Uncontrolled Hypertension",[10123],{"trials":10190,"activeCount":122,"soonestReadout":10195},[10191,10200,10208,10216],{"nctId":10192,"briefTitle":10193,"status":151,"phases":10194,"primaryCompletion":10195,"completion":10195,"start":4731,"enrollment":10196,"conditions":10197,"interventions":10199},"NCT07007793","A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism",[92],"2028-02-18",250,[10198],"Primary Hyperaldosteronism",[10123],{"nctId":10201,"briefTitle":10202,"status":195,"phases":10203,"primaryCompletion":2932,"completion":10204,"start":8269,"enrollment":6187,"conditions":10205,"interventions":10207},"NCT06344104","A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension",[92],"2026-04-03",[10187,10206],"Resistant Hypertension",[10123],{"nctId":10209,"briefTitle":10202,"status":195,"phases":10210,"primaryCompletion":7738,"completion":10211,"start":10212,"enrollment":10213,"conditions":10214,"interventions":10215},"NCT06034743",[92],"2025-10-10","2023-11-22",796,[10187,10206],[10123],{"nctId":10217,"briefTitle":10218,"status":195,"phases":10219,"primaryCompletion":10220,"completion":10220,"start":10221,"enrollment":1318,"conditions":10222,"interventions":10223},"NCT06168409","A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension",[92],"2025-08-17","2024-03-01",[10206],[10123],{"trials":10225,"activeCount":102},[],{"trials":10227,"activeCount":102},[],{"intervention":4114,"totalTrials":3887,"cells":10229},{"EARLY_PHASE1":10230,"PHASE1":10232,"PHASE2":10246,"PHASE3":10248,"PHASE4":10258,"NA":10260},{"trials":10231,"activeCount":102},[],{"trials":10233,"activeCount":102},[10234],{"nctId":10235,"briefTitle":10236,"status":443,"phases":10237,"primaryCompletion":10238,"completion":10239,"start":10240,"enrollment":4497,"conditions":10241,"interventions":10244},"NCT06599502","A Phase I\u002FIIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation",[90],"2025-10-20","2026-01-29","2024-10-18",[498,1921,10242,10243],"Pancreatic Ductal Adenocarcinoma (PDAC)","Colorectal Cancer (CRC)",[10245,4114],"AZD0022",{"trials":10247,"activeCount":102},[],{"trials":10249,"activeCount":122,"soonestReadout":8953},[10250,10254],{"nctId":8950,"briefTitle":8951,"status":108,"phases":10251,"primaryCompletion":8953,"completion":8954,"start":828,"enrollment":8955,"conditions":10252,"interventions":10253},[92],[4111],[3232,4114],{"nctId":4103,"briefTitle":4104,"status":195,"phases":10255,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":10256,"interventions":10257},[92],[4111],[82,3137,4113,4114,296,177,344],{"trials":10259,"activeCount":102},[],{"trials":10261,"activeCount":102},[],{"intervention":10263,"totalTrials":3887,"cells":10264},"BGF MDI 320\u002F14.4\u002F9.6 μg",{"EARLY_PHASE1":10265,"PHASE1":10267,"PHASE2":10269,"PHASE3":10271,"PHASE4":10302,"NA":10304},{"trials":10266,"activeCount":102},[],{"trials":10268,"activeCount":102},[],{"trials":10270,"activeCount":102},[],{"trials":10272,"activeCount":122,"soonestReadout":7169},[10273,10285,10293],{"nctId":10274,"briefTitle":10275,"status":195,"phases":10276,"primaryCompletion":10277,"completion":10277,"start":10278,"enrollment":10279,"conditions":10280,"interventions":10281},"NCT04609878","Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)",[92],"2025-03-21","2020-12-15",2274,[16],[10282,10263,10283,10284],"BGF MDI 320\u002F28.8\u002F9.6 μg","BFF MDI 320\u002F9.6 μg","BFF pMDI 320\u002F9 μg",{"nctId":10286,"briefTitle":10287,"status":195,"phases":10288,"primaryCompletion":10289,"completion":10289,"start":504,"enrollment":10290,"conditions":10291,"interventions":10292},"NCT04609904","Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)",[92],"2025-03-20",2187,[16],[10282,10263,10283,10284],{"nctId":10294,"briefTitle":10295,"status":151,"phases":10296,"primaryCompletion":7169,"completion":7169,"start":10297,"enrollment":8918,"conditions":10298,"interventions":10300},"NCT06283966","A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease",[92],"2024-02-21",[10299],"COPD (Chronic Obstructive Pulmonary Disease)",[10263,10301],"GFF MDI 14.4\u002F9.6 μg",{"trials":10303,"activeCount":102},[],{"trials":10305,"activeCount":102},[],{"intervention":3584,"totalTrials":3887,"cells":10307},{"EARLY_PHASE1":10308,"PHASE1":10310,"PHASE2":10319,"PHASE3":10321,"PHASE4":10334,"NA":10336},{"trials":10309,"activeCount":102},[],{"trials":10311,"activeCount":102},[10312],{"nctId":10313,"briefTitle":10314,"status":624,"phases":10315,"completion":2067,"start":688,"enrollment":1757,"conditions":10316,"interventions":10317},"NCT00920608","A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients",[90],[7267],[10318,3584],"AZD9056",{"trials":10320,"activeCount":102},[],{"trials":10322,"activeCount":122,"soonestReadout":1371},[10323,10330],{"nctId":10324,"briefTitle":10325,"status":195,"phases":10326,"primaryCompletion":2415,"completion":2415,"start":9901,"enrollment":209,"conditions":10327,"interventions":10328},"NCT00206219","Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)",[92],[4111],[1013,10329],"methotrexate",{"nctId":3578,"briefTitle":3579,"status":151,"phases":10331,"primaryCompletion":1371,"completion":1371,"start":3581,"enrollment":3000,"conditions":10332,"interventions":10333},[92],[664,3583,3584,3585,309,177,283],[117,3584,3585,309,177,117,283,177],{"trials":10335,"activeCount":102},[],{"trials":10337,"activeCount":102},[],{"intervention":653,"totalTrials":3887,"cells":10339},{"EARLY_PHASE1":10340,"PHASE1":10342,"PHASE2":10348,"PHASE3":10354,"PHASE4":10360,"NA":10362},{"trials":10341,"activeCount":102},[],{"trials":10343,"activeCount":102},[10344],{"nctId":1999,"briefTitle":2000,"status":195,"phases":10345,"primaryCompletion":317,"completion":317,"start":2002,"enrollment":2003,"conditions":10346,"interventions":10347},[90],[416],[119,1927,653],{"trials":10349,"activeCount":102},[10350],{"nctId":643,"briefTitle":644,"status":195,"phases":10351,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":10352,"interventions":10353},[91],[651],[267,653,654],{"trials":10355,"activeCount":122,"soonestReadout":2026},[10356],{"nctId":2023,"briefTitle":2024,"status":151,"phases":10357,"primaryCompletion":2026,"completion":2027,"start":973,"enrollment":2028,"conditions":10358,"interventions":10359},[92],[651],[2031,2032,653,1927,1941,1940,2033,2034],{"trials":10361,"activeCount":102},[],{"trials":10363,"activeCount":102},[],{"intervention":2032,"totalTrials":447,"cells":10365},{"EARLY_PHASE1":10366,"PHASE1":10368,"PHASE2":10370,"PHASE3":10376,"PHASE4":10382,"NA":10384},{"trials":10367,"activeCount":102},[],{"trials":10369,"activeCount":102},[],{"trials":10371,"activeCount":102},[10372],{"nctId":3141,"briefTitle":3142,"status":195,"phases":10373,"primaryCompletion":3144,"completion":3145,"start":753,"enrollment":1710,"conditions":10374,"interventions":10375},[91],[3147],[1925,117,2032],{"trials":10377,"activeCount":122,"soonestReadout":2026},[10378],{"nctId":2023,"briefTitle":2024,"status":151,"phases":10379,"primaryCompletion":2026,"completion":2027,"start":973,"enrollment":2028,"conditions":10380,"interventions":10381},[92],[651],[2031,2032,653,1927,1941,1940,2033,2034],{"trials":10383,"activeCount":102},[],{"trials":10385,"activeCount":102},[],{"intervention":4685,"totalTrials":447,"cells":10387},{"EARLY_PHASE1":10388,"PHASE1":10390,"PHASE2":10398,"PHASE3":10400,"PHASE4":10406,"NA":10408},{"trials":10389,"activeCount":102},[],{"trials":10391,"activeCount":102},[10392],{"nctId":10393,"briefTitle":10394,"status":195,"phases":10395,"primaryCompletion":2077,"completion":2057,"start":2252,"enrollment":5898,"conditions":10396,"interventions":10397},"NCT00516438","Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan",[90],[509],[3877,4685],{"trials":10399,"activeCount":102},[],{"trials":10401,"activeCount":122,"soonestReadout":4678},[10402],{"nctId":4675,"briefTitle":4676,"status":151,"phases":10403,"primaryCompletion":4678,"completion":4679,"start":4680,"enrollment":3654,"conditions":10404,"interventions":10405},[92],[3865],[3925,4683,118,4684,4685],{"trials":10407,"activeCount":102},[],{"trials":10409,"activeCount":102},[],{"intervention":10411,"totalTrials":447,"cells":10412},"AS MDI",{"EARLY_PHASE1":10413,"PHASE1":10415,"PHASE2":10417,"PHASE3":10428,"PHASE4":10439,"NA":10441},{"trials":10414,"activeCount":102},[],{"trials":10416,"activeCount":102},[],{"trials":10418,"activeCount":102},[10419],{"nctId":10420,"briefTitle":10421,"status":195,"phases":10422,"primaryCompletion":10423,"completion":10423,"start":10424,"enrollment":451,"conditions":10425,"interventions":10426},"NCT03371459","Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma",[91],"2018-03-26","2017-12-29",[16],[10411,10427],"Proventil",{"trials":10429,"activeCount":122,"soonestReadout":153},[10430],{"nctId":10431,"briefTitle":10432,"status":151,"phases":10433,"primaryCompletion":153,"completion":153,"start":10434,"enrollment":10435,"conditions":10436,"interventions":10437},"NCT06307665","Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to \u003C 18 Years of Age With Asthma",[92],"2024-05-20",440,[16],[10438,10411],"BDA MDI",{"trials":10440,"activeCount":102},[],{"trials":10442,"activeCount":102},[],{"intervention":10444,"totalTrials":447,"cells":10445},"Medi-546",{"EARLY_PHASE1":10446,"PHASE1":10448,"PHASE2":10450,"PHASE3":10462,"PHASE4":10473,"NA":10475},{"trials":10447,"activeCount":102},[],{"trials":10449,"activeCount":102},[],{"trials":10451,"activeCount":102},[10452],{"nctId":10453,"briefTitle":10454,"status":195,"phases":10455,"primaryCompletion":10456,"completion":10457,"start":10458,"enrollment":4497,"conditions":10459,"interventions":10460},"NCT01559090","Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.",[91],"2014-08-19","2017-02-21","2012-04-20",[1140],[10461,10461,10461],"MEDI-546",{"trials":10463,"activeCount":122,"soonestReadout":10468},[10464],{"nctId":10465,"briefTitle":10466,"status":108,"phases":10467,"primaryCompletion":10468,"completion":10469,"start":10470,"enrollment":5388,"conditions":10471,"interventions":10472},"NCT04877691","Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus",[92],"2025-08-22","2026-11-06","2021-06-08",[1140],[10444],{"trials":10474,"activeCount":102},[],{"trials":10476,"activeCount":102},[],{"intervention":10478,"totalTrials":122,"cells":10479},"AZD9291 80 mg\u002F40 mg",{"EARLY_PHASE1":10480,"PHASE1":10482,"PHASE2":10484,"PHASE3":10486,"PHASE4":10500,"NA":10502},{"trials":10481,"activeCount":102},[],{"trials":10483,"activeCount":102},[],{"trials":10485,"activeCount":102},[],{"trials":10487,"activeCount":122,"soonestReadout":10492},[10488],{"nctId":10489,"briefTitle":10490,"status":108,"phases":10491,"primaryCompletion":10492,"completion":10493,"start":10494,"enrollment":10495,"conditions":10496,"interventions":10498},"NCT02511106","AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.",[92],"2022-04-11","2029-01-31","2015-10-21",682,[10497],"Stage IB-IIIA Non-small Cell Lung Carcinoma",[10478,10499],"Open-label AZD9291 80 mg\u002F40 mg",{"trials":10501,"activeCount":102},[],{"trials":10503,"activeCount":102},[],{"intervention":10499,"totalTrials":122,"cells":10505},{"EARLY_PHASE1":10506,"PHASE1":10508,"PHASE2":10510,"PHASE3":10512,"PHASE4":10518,"NA":10520},{"trials":10507,"activeCount":102},[],{"trials":10509,"activeCount":102},[],{"trials":10511,"activeCount":102},[],{"trials":10513,"activeCount":122,"soonestReadout":10492},[10514],{"nctId":10489,"briefTitle":10490,"status":108,"phases":10515,"primaryCompletion":10492,"completion":10493,"start":10494,"enrollment":10495,"conditions":10516,"interventions":10517},[92],[10497],[10478,10499],{"trials":10519,"activeCount":102},[],{"trials":10521,"activeCount":102},[],{"intervention":3339,"totalTrials":122,"cells":10523},{"EARLY_PHASE1":10524,"PHASE1":10526,"PHASE2":10528,"PHASE3":10530,"PHASE4":10536,"NA":10538},{"trials":10525,"activeCount":102},[],{"trials":10527,"activeCount":102},[],{"trials":10529,"activeCount":102},[],{"trials":10531,"activeCount":122,"soonestReadout":3333},[10532],{"nctId":3330,"briefTitle":3331,"status":108,"phases":10533,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":3336,"conditions":10534,"interventions":10535},[92],[262],[117,3339,3340,3341,3342],{"trials":10537,"activeCount":102},[],{"trials":10539,"activeCount":102},[],{"intervention":3340,"totalTrials":122,"cells":10541},{"EARLY_PHASE1":10542,"PHASE1":10544,"PHASE2":10546,"PHASE3":10548,"PHASE4":10554,"NA":10556},{"trials":10543,"activeCount":102},[],{"trials":10545,"activeCount":102},[],{"trials":10547,"activeCount":102},[],{"trials":10549,"activeCount":122,"soonestReadout":3333},[10550],{"nctId":3330,"briefTitle":3331,"status":108,"phases":10551,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":3336,"conditions":10552,"interventions":10553},[92],[262],[117,3339,3340,3341,3342],{"trials":10555,"activeCount":102},[],{"trials":10557,"activeCount":102},[],{"intervention":3341,"totalTrials":122,"cells":10559},{"EARLY_PHASE1":10560,"PHASE1":10562,"PHASE2":10564,"PHASE3":10566,"PHASE4":10572,"NA":10574},{"trials":10561,"activeCount":102},[],{"trials":10563,"activeCount":102},[],{"trials":10565,"activeCount":102},[],{"trials":10567,"activeCount":122,"soonestReadout":3333},[10568],{"nctId":3330,"briefTitle":3331,"status":108,"phases":10569,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":3336,"conditions":10570,"interventions":10571},[92],[262],[117,3339,3340,3341,3342],{"trials":10573,"activeCount":102},[],{"trials":10575,"activeCount":102},[],{"intervention":3342,"totalTrials":122,"cells":10577},{"EARLY_PHASE1":10578,"PHASE1":10580,"PHASE2":10582,"PHASE3":10584,"PHASE4":10590,"NA":10592},{"trials":10579,"activeCount":102},[],{"trials":10581,"activeCount":102},[],{"trials":10583,"activeCount":102},[],{"trials":10585,"activeCount":122,"soonestReadout":3333},[10586],{"nctId":3330,"briefTitle":3331,"status":108,"phases":10587,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":3336,"conditions":10588,"interventions":10589},[92],[262],[117,3339,3340,3341,3342],{"trials":10591,"activeCount":102},[],{"trials":10593,"activeCount":102},[],{"intervention":4614,"totalTrials":122,"cells":10595},{"EARLY_PHASE1":10596,"PHASE1":10598,"PHASE2":10600,"PHASE3":10602,"PHASE4":10608,"NA":10610},{"trials":10597,"activeCount":102},[],{"trials":10599,"activeCount":102},[],{"trials":10601,"activeCount":102},[],{"trials":10603,"activeCount":122,"soonestReadout":4607},[10604],{"nctId":4604,"briefTitle":4605,"status":108,"phases":10605,"primaryCompletion":4607,"completion":4608,"start":4609,"enrollment":4610,"conditions":10606,"interventions":10607},[92],[172,4612],[225,225,4614,118,369,4615,4616,4617],{"trials":10609,"activeCount":102},[],{"trials":10611,"activeCount":102},[],{"intervention":4616,"totalTrials":122,"cells":10613},{"EARLY_PHASE1":10614,"PHASE1":10616,"PHASE2":10618,"PHASE3":10620,"PHASE4":10626,"NA":10628},{"trials":10615,"activeCount":102},[],{"trials":10617,"activeCount":102},[],{"trials":10619,"activeCount":102},[],{"trials":10621,"activeCount":122,"soonestReadout":4607},[10622],{"nctId":4604,"briefTitle":4605,"status":108,"phases":10623,"primaryCompletion":4607,"completion":4608,"start":4609,"enrollment":4610,"conditions":10624,"interventions":10625},[92],[172,4612],[225,225,4614,118,369,4615,4616,4617],{"trials":10627,"activeCount":102},[],{"trials":10629,"activeCount":102},[],{"intervention":4617,"totalTrials":122,"cells":10631},{"EARLY_PHASE1":10632,"PHASE1":10634,"PHASE2":10636,"PHASE3":10638,"PHASE4":10644,"NA":10646},{"trials":10633,"activeCount":102},[],{"trials":10635,"activeCount":102},[],{"trials":10637,"activeCount":102},[],{"trials":10639,"activeCount":122,"soonestReadout":4607},[10640],{"nctId":4604,"briefTitle":4605,"status":108,"phases":10641,"primaryCompletion":4607,"completion":4608,"start":4609,"enrollment":4610,"conditions":10642,"interventions":10643},[92],[172,4612],[225,225,4614,118,369,4615,4616,4617],{"trials":10645,"activeCount":102},[],{"trials":10647,"activeCount":102},[],{"intervention":4795,"totalTrials":122,"cells":10649},{"EARLY_PHASE1":10650,"PHASE1":10652,"PHASE2":10654,"PHASE3":10656,"PHASE4":10662,"NA":10664},{"trials":10651,"activeCount":102},[],{"trials":10653,"activeCount":102},[],{"trials":10655,"activeCount":102},[],{"trials":10657,"activeCount":122,"soonestReadout":4790},[10658],{"nctId":4787,"briefTitle":4788,"status":151,"phases":10659,"primaryCompletion":4790,"completion":4791,"start":1007,"enrollment":4792,"conditions":10660,"interventions":10661},[92],[3220],[3137,180,239,4795],{"trials":10663,"activeCount":102},[],{"trials":10665,"activeCount":102},[],{"intervention":6983,"totalTrials":122,"cells":10667},{"EARLY_PHASE1":10668,"PHASE1":10670,"PHASE2":10672,"PHASE3":10674,"PHASE4":10680,"NA":10682},{"trials":10669,"activeCount":102},[],{"trials":10671,"activeCount":102},[],{"trials":10673,"activeCount":102},[],{"trials":10675,"activeCount":122,"soonestReadout":5490},[10676],{"nctId":6976,"briefTitle":6977,"status":108,"phases":10677,"primaryCompletion":5490,"completion":5490,"start":6979,"enrollment":6980,"conditions":10678,"interventions":10679},[91,92],[6873],[6983,6984,6860],{"trials":10681,"activeCount":102},[],{"trials":10683,"activeCount":102},[],{"intervention":6984,"totalTrials":122,"cells":10685},{"EARLY_PHASE1":10686,"PHASE1":10688,"PHASE2":10690,"PHASE3":10692,"PHASE4":10698,"NA":10700},{"trials":10687,"activeCount":102},[],{"trials":10689,"activeCount":102},[],{"trials":10691,"activeCount":102},[],{"trials":10693,"activeCount":122,"soonestReadout":5490},[10694],{"nctId":6976,"briefTitle":6977,"status":108,"phases":10695,"primaryCompletion":5490,"completion":5490,"start":6979,"enrollment":6980,"conditions":10696,"interventions":10697},[91,92],[6873],[6983,6984,6860],{"trials":10699,"activeCount":102},[],{"trials":10701,"activeCount":102},[],{"intervention":4629,"totalTrials":122,"cells":10703},{"EARLY_PHASE1":10704,"PHASE1":10706,"PHASE2":10708,"PHASE3":10710,"PHASE4":10716,"NA":10718},{"trials":10705,"activeCount":102},[],{"trials":10707,"activeCount":102},[],{"trials":10709,"activeCount":102},[],{"trials":10711,"activeCount":122,"soonestReadout":4622},[10712],{"nctId":4619,"briefTitle":4620,"status":151,"phases":10713,"primaryCompletion":4622,"completion":4623,"start":4624,"enrollment":4625,"conditions":10714,"interventions":10715},[92],[367,4627],[4629,309,118],{"trials":10717,"activeCount":102},[],{"trials":10719,"activeCount":102},[],{"intervention":10721,"totalTrials":122,"cells":10722},"Osimertinib 80mg\u002F40mg",{"EARLY_PHASE1":10723,"PHASE1":10725,"PHASE2":10727,"PHASE3":10729,"PHASE4":10740,"NA":10742},{"trials":10724,"activeCount":102},[],{"trials":10726,"activeCount":102},[],{"trials":10728,"activeCount":102},[],{"trials":10730,"activeCount":122,"soonestReadout":10735},[10731],{"nctId":10732,"briefTitle":10733,"status":108,"phases":10734,"primaryCompletion":10735,"completion":10736,"start":2309,"enrollment":6143,"conditions":10737,"interventions":10739},"NCT03521154","A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)",[92],"2024-01-05","2027-10-29",[10738],"Non Small Cell Lung Cancer (Stage III)",[10721],{"trials":10741,"activeCount":102},[],{"trials":10743,"activeCount":102},[],{"intervention":10745,"totalTrials":122,"cells":10746},"Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level",{"EARLY_PHASE1":10747,"PHASE1":10749,"PHASE2":10751,"PHASE3":10753,"PHASE4":10764,"NA":10766},{"trials":10748,"activeCount":102},[],{"trials":10750,"activeCount":102},[],{"trials":10752,"activeCount":102},[],{"trials":10754,"activeCount":122,"soonestReadout":5162},[10755],{"nctId":10756,"briefTitle":10757,"status":151,"phases":10758,"primaryCompletion":5162,"completion":5162,"start":1554,"enrollment":1842,"conditions":10759,"interventions":10761},"NCT03813407","An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia",[92],[10760],"Hyperkalaemia",[10745,10762,10762,10762,10763],"Sodium Zirconium Cyclosilicate","Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase",{"trials":10765,"activeCount":102},[],{"trials":10767,"activeCount":102},[],{"intervention":10763,"totalTrials":122,"cells":10769},{"EARLY_PHASE1":10770,"PHASE1":10772,"PHASE2":10774,"PHASE3":10776,"PHASE4":10782,"NA":10784},{"trials":10771,"activeCount":102},[],{"trials":10773,"activeCount":102},[],{"trials":10775,"activeCount":102},[],{"trials":10777,"activeCount":122,"soonestReadout":5162},[10778],{"nctId":10756,"briefTitle":10757,"status":151,"phases":10779,"primaryCompletion":5162,"completion":5162,"start":1554,"enrollment":1842,"conditions":10780,"interventions":10781},[92],[10760],[10745,10762,10762,10762,10763],{"trials":10783,"activeCount":102},[],{"trials":10785,"activeCount":102},[],{"intervention":10438,"totalTrials":122,"cells":10787},{"EARLY_PHASE1":10788,"PHASE1":10790,"PHASE2":10792,"PHASE3":10794,"PHASE4":10800,"NA":10802},{"trials":10789,"activeCount":102},[],{"trials":10791,"activeCount":102},[],{"trials":10793,"activeCount":102},[],{"trials":10795,"activeCount":122,"soonestReadout":153},[10796],{"nctId":10431,"briefTitle":10432,"status":151,"phases":10797,"primaryCompletion":153,"completion":153,"start":10434,"enrollment":10435,"conditions":10798,"interventions":10799},[92],[16],[10438,10411],{"trials":10801,"activeCount":102},[],{"trials":10803,"activeCount":102},[],{"intervention":7420,"totalTrials":122,"cells":10805},{"EARLY_PHASE1":10806,"PHASE1":10808,"PHASE2":10810,"PHASE3":10812,"PHASE4":10818,"NA":10820},{"trials":10807,"activeCount":102},[],{"trials":10809,"activeCount":102},[],{"trials":10811,"activeCount":102},[],{"trials":10813,"activeCount":122,"soonestReadout":1406},[10814],{"nctId":7410,"briefTitle":7411,"status":108,"phases":10815,"primaryCompletion":1406,"completion":7413,"start":7414,"enrollment":2472,"conditions":10816,"interventions":10817},[92],[7416],[6431,7418,120,7419,469,7420,5977,5979,7421,5978],{"trials":10819,"activeCount":102},[],{"trials":10821,"activeCount":102},[],{"intervention":1052,"totalTrials":122,"cells":10823},{"EARLY_PHASE1":10824,"PHASE1":10826,"PHASE2":10828,"PHASE3":10830,"PHASE4":10836,"NA":10838},{"trials":10825,"activeCount":102},[],{"trials":10827,"activeCount":102},[],{"trials":10829,"activeCount":102},[],{"trials":10831,"activeCount":122,"soonestReadout":1046},[10832],{"nctId":1043,"briefTitle":1044,"status":108,"phases":10833,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":98,"conditions":10834,"interventions":10835},[92],[1049],[163,180,344,177,1017,345,1051,1052],{"trials":10837,"activeCount":102},[],{"trials":10839,"activeCount":102},[],{"intervention":3403,"totalTrials":122,"cells":10841},{"EARLY_PHASE1":10842,"PHASE1":10844,"PHASE2":10846,"PHASE3":10848,"PHASE4":10854,"NA":10856},{"trials":10843,"activeCount":102},[],{"trials":10845,"activeCount":102},[],{"trials":10847,"activeCount":102},[],{"trials":10849,"activeCount":122,"soonestReadout":3400},[10850],{"nctId":3397,"briefTitle":3398,"status":108,"phases":10851,"primaryCompletion":3400,"completion":601,"start":110,"enrollment":3289,"conditions":10852,"interventions":10853},[92],[281],[117,3403,3353,3404,3354,3405,3406,3407],{"trials":10855,"activeCount":102},[],{"trials":10857,"activeCount":102},[],{"intervention":3404,"totalTrials":122,"cells":10859},{"EARLY_PHASE1":10860,"PHASE1":10862,"PHASE2":10864,"PHASE3":10866,"PHASE4":10872,"NA":10874},{"trials":10861,"activeCount":102},[],{"trials":10863,"activeCount":102},[],{"trials":10865,"activeCount":102},[],{"trials":10867,"activeCount":122,"soonestReadout":3400},[10868],{"nctId":3397,"briefTitle":3398,"status":108,"phases":10869,"primaryCompletion":3400,"completion":601,"start":110,"enrollment":3289,"conditions":10870,"interventions":10871},[92],[281],[117,3403,3353,3404,3354,3405,3406,3407],{"trials":10873,"activeCount":102},[],{"trials":10875,"activeCount":102},[],{"intervention":3405,"totalTrials":122,"cells":10877},{"EARLY_PHASE1":10878,"PHASE1":10880,"PHASE2":10882,"PHASE3":10884,"PHASE4":10890,"NA":10892},{"trials":10879,"activeCount":102},[],{"trials":10881,"activeCount":102},[],{"trials":10883,"activeCount":102},[],{"trials":10885,"activeCount":122,"soonestReadout":3400},[10886],{"nctId":3397,"briefTitle":3398,"status":108,"phases":10887,"primaryCompletion":3400,"completion":601,"start":110,"enrollment":3289,"conditions":10888,"interventions":10889},[92],[281],[117,3403,3353,3404,3354,3405,3406,3407],{"trials":10891,"activeCount":102},[],{"trials":10893,"activeCount":102},[],{"intervention":3406,"totalTrials":122,"cells":10895},{"EARLY_PHASE1":10896,"PHASE1":10898,"PHASE2":10900,"PHASE3":10902,"PHASE4":10908,"NA":10910},{"trials":10897,"activeCount":102},[],{"trials":10899,"activeCount":102},[],{"trials":10901,"activeCount":102},[],{"trials":10903,"activeCount":122,"soonestReadout":3400},[10904],{"nctId":3397,"briefTitle":3398,"status":108,"phases":10905,"primaryCompletion":3400,"completion":601,"start":110,"enrollment":3289,"conditions":10906,"interventions":10907},[92],[281],[117,3403,3353,3404,3354,3405,3406,3407],{"trials":10909,"activeCount":102},[],{"trials":10911,"activeCount":102},[],{"intervention":3407,"totalTrials":122,"cells":10913},{"EARLY_PHASE1":10914,"PHASE1":10916,"PHASE2":10918,"PHASE3":10920,"PHASE4":10926,"NA":10928},{"trials":10915,"activeCount":102},[],{"trials":10917,"activeCount":102},[],{"trials":10919,"activeCount":102},[],{"trials":10921,"activeCount":122,"soonestReadout":3400},[10922],{"nctId":3397,"briefTitle":3398,"status":108,"phases":10923,"primaryCompletion":3400,"completion":601,"start":110,"enrollment":3289,"conditions":10924,"interventions":10925},[92],[281],[117,3403,3353,3404,3354,3405,3406,3407],{"trials":10927,"activeCount":102},[],{"trials":10929,"activeCount":102},[],{"intervention":10931,"totalTrials":122,"cells":10932},"Nexium 20mg",{"EARLY_PHASE1":10933,"PHASE1":10935,"PHASE2":10937,"PHASE3":10939,"PHASE4":10952,"NA":10954},{"trials":10934,"activeCount":102},[],{"trials":10936,"activeCount":102},[],{"trials":10938,"activeCount":102},[],{"trials":10940,"activeCount":122,"soonestReadout":10945},[10941],{"nctId":10942,"briefTitle":10943,"status":108,"phases":10944,"primaryCompletion":10945,"completion":10946,"start":10947,"enrollment":2161,"conditions":10948,"interventions":10950},"NCT05267613","Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.",[92],"2026-08-14","2026-08-19","2022-07-01",[10949],"Erosive Esophagitis",[10931,10951],"Nexium 10mg",{"trials":10953,"activeCount":102},[],{"trials":10955,"activeCount":102},[],{"intervention":10951,"totalTrials":122,"cells":10957},{"EARLY_PHASE1":10958,"PHASE1":10960,"PHASE2":10962,"PHASE3":10964,"PHASE4":10970,"NA":10972},{"trials":10959,"activeCount":102},[],{"trials":10961,"activeCount":102},[],{"trials":10963,"activeCount":102},[],{"trials":10965,"activeCount":122,"soonestReadout":10945},[10966],{"nctId":10942,"briefTitle":10943,"status":108,"phases":10967,"primaryCompletion":10945,"completion":10946,"start":10947,"enrollment":2161,"conditions":10968,"interventions":10969},[92],[10949],[10931,10951],{"trials":10971,"activeCount":102},[],{"trials":10973,"activeCount":102},[],{"intervention":787,"totalTrials":122,"cells":10975},{"EARLY_PHASE1":10976,"PHASE1":10978,"PHASE2":10980,"PHASE3":10982,"PHASE4":10988,"NA":10990},{"trials":10977,"activeCount":102},[],{"trials":10979,"activeCount":102},[],{"trials":10981,"activeCount":102},[],{"trials":10983,"activeCount":122,"soonestReadout":780},[10984],{"nctId":777,"briefTitle":778,"status":108,"phases":10985,"primaryCompletion":780,"completion":398,"start":781,"enrollment":782,"conditions":10986,"interventions":10987},[92],[784],[239,117,267,786,787],{"trials":10989,"activeCount":102},[],{"trials":10991,"activeCount":102},[],{"intervention":3423,"totalTrials":122,"cells":10993},{"EARLY_PHASE1":10994,"PHASE1":10996,"PHASE2":10998,"PHASE3":11000,"PHASE4":11006,"NA":11008},{"trials":10995,"activeCount":102},[],{"trials":10997,"activeCount":102},[],{"trials":10999,"activeCount":102},[],{"trials":11001,"activeCount":122,"soonestReadout":3416},[11002],{"nctId":3413,"briefTitle":3414,"status":108,"phases":11003,"primaryCompletion":3416,"completion":3417,"start":3418,"enrollment":3419,"conditions":11004,"interventions":11005},[92],[3421],[117,3423],{"trials":11007,"activeCount":102},[],{"trials":11009,"activeCount":102},[],{"intervention":11011,"totalTrials":122,"cells":11012},"Baxdrostat and dapagliflozin",{"EARLY_PHASE1":11013,"PHASE1":11015,"PHASE2":11017,"PHASE3":11019,"PHASE4":11030,"NA":11032},{"trials":11014,"activeCount":102},[],{"trials":11016,"activeCount":102},[],{"trials":11018,"activeCount":102},[],{"trials":11020,"activeCount":122,"soonestReadout":11025},[11021],{"nctId":11022,"briefTitle":11023,"status":151,"phases":11024,"primaryCompletion":11025,"completion":11025,"start":11026,"enrollment":11027,"conditions":11028,"interventions":11029},"NCT06677060","Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin",[92],"2029-12-17","2025-03-14",11300,[1520],[11011],{"trials":11031,"activeCount":102},[],{"trials":11033,"activeCount":102},[],{"intervention":5168,"totalTrials":122,"cells":11035},{"EARLY_PHASE1":11036,"PHASE1":11038,"PHASE2":11040,"PHASE3":11042,"PHASE4":11048,"NA":11050},{"trials":11037,"activeCount":102},[],{"trials":11039,"activeCount":102},[],{"trials":11041,"activeCount":102},[],{"trials":11043,"activeCount":122,"soonestReadout":5162},[11044],{"nctId":5159,"briefTitle":5160,"status":108,"phases":11045,"primaryCompletion":5162,"completion":5163,"start":1794,"enrollment":5164,"conditions":11046,"interventions":11047},[92],[5166],[179,5168,4178,4179],{"trials":11049,"activeCount":102},[],{"trials":11051,"activeCount":102},[],{"intervention":809,"totalTrials":122,"cells":11053},{"EARLY_PHASE1":11054,"PHASE1":11056,"PHASE2":11058,"PHASE3":11060,"PHASE4":11066,"NA":11068},{"trials":11055,"activeCount":102},[],{"trials":11057,"activeCount":102},[],{"trials":11059,"activeCount":102},[],{"trials":11061,"activeCount":122,"soonestReadout":802},[11062],{"nctId":799,"briefTitle":800,"status":108,"phases":11063,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":11064,"interventions":11065},[92],[25],[808,117,178,309,809,524,118,344,121,267],{"trials":11067,"activeCount":102},[],{"trials":11069,"activeCount":102},[],{"intervention":7933,"totalTrials":122,"cells":11071},{"EARLY_PHASE1":11072,"PHASE1":11074,"PHASE2":11076,"PHASE3":11078,"PHASE4":11084,"NA":11086},{"trials":11073,"activeCount":102},[],{"trials":11075,"activeCount":102},[],{"trials":11077,"activeCount":102},[],{"trials":11079,"activeCount":122,"soonestReadout":7927},[11080],{"nctId":7924,"briefTitle":7925,"status":151,"phases":11081,"primaryCompletion":7927,"completion":7928,"start":3693,"enrollment":7929,"conditions":11082,"interventions":11083},[92],[7931],[7879,7933,7934,7935,7936,7937],{"trials":11085,"activeCount":102},[],{"trials":11087,"activeCount":102},[],{"intervention":7934,"totalTrials":122,"cells":11089},{"EARLY_PHASE1":11090,"PHASE1":11092,"PHASE2":11094,"PHASE3":11096,"PHASE4":11102,"NA":11104},{"trials":11091,"activeCount":102},[],{"trials":11093,"activeCount":102},[],{"trials":11095,"activeCount":102},[],{"trials":11097,"activeCount":122,"soonestReadout":7927},[11098],{"nctId":7924,"briefTitle":7925,"status":151,"phases":11099,"primaryCompletion":7927,"completion":7928,"start":3693,"enrollment":7929,"conditions":11100,"interventions":11101},[92],[7931],[7879,7933,7934,7935,7936,7937],{"trials":11103,"activeCount":102},[],{"trials":11105,"activeCount":102},[],{"intervention":7936,"totalTrials":122,"cells":11107},{"EARLY_PHASE1":11108,"PHASE1":11110,"PHASE2":11112,"PHASE3":11114,"PHASE4":11120,"NA":11122},{"trials":11109,"activeCount":102},[],{"trials":11111,"activeCount":102},[],{"trials":11113,"activeCount":102},[],{"trials":11115,"activeCount":122,"soonestReadout":7927},[11116],{"nctId":7924,"briefTitle":7925,"status":151,"phases":11117,"primaryCompletion":7927,"completion":7928,"start":3693,"enrollment":7929,"conditions":11118,"interventions":11119},[92],[7931],[7879,7933,7934,7935,7936,7937],{"trials":11121,"activeCount":102},[],{"trials":11123,"activeCount":102},[],{"intervention":1490,"totalTrials":122,"cells":11125},{"EARLY_PHASE1":11126,"PHASE1":11128,"PHASE2":11130,"PHASE3":11132,"PHASE4":11138,"NA":11140},{"trials":11127,"activeCount":102},[],{"trials":11129,"activeCount":102},[],{"trials":11131,"activeCount":102},[],{"trials":11133,"activeCount":122,"soonestReadout":1484},[11134],{"nctId":1481,"briefTitle":1482,"status":108,"phases":11135,"primaryCompletion":1484,"completion":1485,"start":1486,"enrollment":975,"conditions":11136,"interventions":11137},[92],[1488],[1335,1378,1490],{"trials":11139,"activeCount":102},[],{"trials":11141,"activeCount":102},[],{"intervention":3459,"totalTrials":122,"cells":11143},{"EARLY_PHASE1":11144,"PHASE1":11146,"PHASE2":11148,"PHASE3":11150,"PHASE4":11156,"NA":11158},{"trials":11145,"activeCount":102},[],{"trials":11147,"activeCount":102},[],{"trials":11149,"activeCount":102},[],{"trials":11151,"activeCount":122,"soonestReadout":3454},[11152],{"nctId":3451,"briefTitle":3452,"status":108,"phases":11153,"primaryCompletion":3454,"completion":1965,"start":3455,"enrollment":221,"conditions":11154,"interventions":11155},[92],[3457],[117,3459],{"trials":11157,"activeCount":102},[],{"trials":11159,"activeCount":102},[],{"intervention":11161,"totalTrials":122,"cells":11162},"Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin",{"EARLY_PHASE1":11163,"PHASE1":11165,"PHASE2":11167,"PHASE3":11169,"PHASE4":11180,"NA":11182},{"trials":11164,"activeCount":102},[],{"trials":11166,"activeCount":102},[],{"trials":11168,"activeCount":102},[],{"trials":11170,"activeCount":122,"soonestReadout":11175},[11171],{"nctId":11172,"briefTitle":11173,"status":108,"phases":11174,"primaryCompletion":11175,"completion":11176,"start":11177,"enrollment":8285,"conditions":11178,"interventions":11179},"NCT04765059","A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)",[92],"2024-10-28","2027-06-02","2021-09-12",[1049],[11161],{"trials":11181,"activeCount":102},[],{"trials":11183,"activeCount":102},[],{"intervention":7827,"totalTrials":122,"cells":11185},{"EARLY_PHASE1":11186,"PHASE1":11188,"PHASE2":11190,"PHASE3":11192,"PHASE4":11198,"NA":11200},{"trials":11187,"activeCount":102},[],{"trials":11189,"activeCount":102},[],{"trials":11191,"activeCount":102},[],{"trials":11193,"activeCount":122,"soonestReadout":7822},[11194],{"nctId":7819,"briefTitle":7820,"status":108,"phases":11195,"primaryCompletion":7822,"completion":660,"start":7823,"enrollment":7824,"conditions":11196,"interventions":11197},[92],[3350],[7827,3352,3353,3354,3355,3356],{"trials":11199,"activeCount":102},[],{"trials":11201,"activeCount":102},[],{"intervention":5303,"totalTrials":122,"cells":11203},{"EARLY_PHASE1":11204,"PHASE1":11206,"PHASE2":11208,"PHASE3":11210,"PHASE4":11216,"NA":11218},{"trials":11205,"activeCount":102},[],{"trials":11207,"activeCount":102},[],{"trials":11209,"activeCount":102},[],{"trials":11211,"activeCount":122,"soonestReadout":81},[11212],{"nctId":79,"briefTitle":80,"status":108,"phases":11213,"primaryCompletion":81,"completion":660,"start":5298,"enrollment":5299,"conditions":11214,"interventions":11215},[92],[5301],[82,5303,3878,5304,5305,5306,5307,3137],{"trials":11217,"activeCount":102},[],{"trials":11219,"activeCount":102},[],{"intervention":1739,"totalTrials":122,"cells":11221},{"EARLY_PHASE1":11222,"PHASE1":11224,"PHASE2":11226,"PHASE3":11228,"PHASE4":11234,"NA":11236},{"trials":11223,"activeCount":102},[],{"trials":11225,"activeCount":102},[],{"trials":11227,"activeCount":102},[],{"trials":11229,"activeCount":122,"soonestReadout":1735},[11230],{"nctId":1732,"briefTitle":1733,"status":151,"phases":11231,"primaryCompletion":1735,"completion":1735,"start":780,"enrollment":1078,"conditions":11232,"interventions":11233},[92],[1737],[1739,1740],{"trials":11235,"activeCount":102},[],{"trials":11237,"activeCount":102},[],{"intervention":8930,"totalTrials":122,"cells":11239},{"EARLY_PHASE1":11240,"PHASE1":11242,"PHASE2":11244,"PHASE3":11246,"PHASE4":11252,"NA":11254},{"trials":11241,"activeCount":102},[],{"trials":11243,"activeCount":102},[],{"trials":11245,"activeCount":102},[],{"trials":11247,"activeCount":122,"soonestReadout":8925},[11248],{"nctId":8922,"briefTitle":8923,"status":108,"phases":11249,"primaryCompletion":8925,"completion":8925,"start":8926,"enrollment":8927,"conditions":11250,"interventions":11251},[92],[8907],[8892,8930],{"trials":11253,"activeCount":102},[],{"trials":11255,"activeCount":102},[],{"intervention":11257,"totalTrials":122,"cells":11258},"Tozorakimab Dose Regimen 1",{"EARLY_PHASE1":11259,"PHASE1":11261,"PHASE2":11263,"PHASE3":11265,"PHASE4":11276,"NA":11278},{"trials":11260,"activeCount":102},[],{"trials":11262,"activeCount":102},[],{"trials":11264,"activeCount":102},[],{"trials":11266,"activeCount":122,"soonestReadout":11271},[11267],{"nctId":11268,"briefTitle":11269,"status":151,"phases":11270,"primaryCompletion":11271,"completion":11271,"start":7301,"enrollment":11272,"conditions":11273,"interventions":11274},"NCT07566195","Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations",[92],"2028-12-29",82,[28,10066],[11257,11275],"Tozorakimab Dose Regimen 2",{"trials":11277,"activeCount":102},[],{"trials":11279,"activeCount":102},[],{"intervention":11275,"totalTrials":122,"cells":11281},{"EARLY_PHASE1":11282,"PHASE1":11284,"PHASE2":11286,"PHASE3":11288,"PHASE4":11294,"NA":11296},{"trials":11283,"activeCount":102},[],{"trials":11285,"activeCount":102},[],{"trials":11287,"activeCount":102},[],{"trials":11289,"activeCount":122,"soonestReadout":11271},[11290],{"nctId":11268,"briefTitle":11269,"status":151,"phases":11291,"primaryCompletion":11271,"completion":11271,"start":7301,"enrollment":11272,"conditions":11292,"interventions":11293},[92],[28,10066],[11257,11275],{"trials":11295,"activeCount":102},[],{"trials":11297,"activeCount":102},[],{"intervention":6192,"totalTrials":122,"cells":11299},{"EARLY_PHASE1":11300,"PHASE1":11302,"PHASE2":11304,"PHASE3":11306,"PHASE4":11312,"NA":11314},{"trials":11301,"activeCount":102},[],{"trials":11303,"activeCount":102},[],{"trials":11305,"activeCount":102},[],{"trials":11307,"activeCount":122,"soonestReadout":6185},[11308],{"nctId":6182,"briefTitle":6183,"status":108,"phases":11309,"primaryCompletion":6185,"completion":6185,"start":6186,"enrollment":6187,"conditions":11310,"interventions":11311},[92],[6117],[6051,6190,6191,6192,6193],{"trials":11313,"activeCount":102},[],{"trials":11315,"activeCount":102},[],{"intervention":11317,"totalTrials":122,"cells":11318},"BDA MDI HFO 160\u002F180 μg",{"EARLY_PHASE1":11319,"PHASE1":11321,"PHASE2":11323,"PHASE3":11325,"PHASE4":11337,"NA":11339},{"trials":11320,"activeCount":102},[],{"trials":11322,"activeCount":102},[],{"trials":11324,"activeCount":102},[],{"trials":11326,"activeCount":122,"soonestReadout":11331},[11327],{"nctId":11328,"briefTitle":11329,"status":108,"phases":11330,"primaryCompletion":11331,"completion":11331,"start":11332,"enrollment":11333,"conditions":11334,"interventions":11335},"NCT06502366","A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma",[92],"2026-03-03","2024-07-22",422,[16],[11317,11336],"BDA MDI HFA 160\u002F180 μg",{"trials":11338,"activeCount":102},[],{"trials":11340,"activeCount":102},[],{"intervention":11336,"totalTrials":122,"cells":11342},{"EARLY_PHASE1":11343,"PHASE1":11345,"PHASE2":11347,"PHASE3":11349,"PHASE4":11355,"NA":11357},{"trials":11344,"activeCount":102},[],{"trials":11346,"activeCount":102},[],{"trials":11348,"activeCount":102},[],{"trials":11350,"activeCount":122,"soonestReadout":11331},[11351],{"nctId":11328,"briefTitle":11329,"status":108,"phases":11352,"primaryCompletion":11331,"completion":11331,"start":11332,"enrollment":11333,"conditions":11353,"interventions":11354},[92],[16],[11317,11336],{"trials":11356,"activeCount":102},[],{"trials":11358,"activeCount":102},[],{"intervention":7315,"totalTrials":122,"cells":11360},{"EARLY_PHASE1":11361,"PHASE1":11363,"PHASE2":11365,"PHASE3":11367,"PHASE4":11373,"NA":11375},{"trials":11362,"activeCount":102},[],{"trials":11364,"activeCount":102},[],{"trials":11366,"activeCount":102},[],{"trials":11368,"activeCount":122,"soonestReadout":7310},[11369],{"nctId":7307,"briefTitle":7308,"status":151,"phases":11370,"primaryCompletion":7310,"completion":7310,"start":7311,"enrollment":3419,"conditions":11371,"interventions":11372},[92],[7313],[1467,7315,7316,7317],{"trials":11374,"activeCount":102},[],{"trials":11376,"activeCount":102},[],{"intervention":7316,"totalTrials":122,"cells":11378},{"EARLY_PHASE1":11379,"PHASE1":11381,"PHASE2":11383,"PHASE3":11385,"PHASE4":11391,"NA":11393},{"trials":11380,"activeCount":102},[],{"trials":11382,"activeCount":102},[],{"trials":11384,"activeCount":102},[],{"trials":11386,"activeCount":122,"soonestReadout":7310},[11387],{"nctId":7307,"briefTitle":7308,"status":151,"phases":11388,"primaryCompletion":7310,"completion":7310,"start":7311,"enrollment":3419,"conditions":11389,"interventions":11390},[92],[7313],[1467,7315,7316,7317],{"trials":11392,"activeCount":102},[],{"trials":11394,"activeCount":102},[],{"intervention":7317,"totalTrials":122,"cells":11396},{"EARLY_PHASE1":11397,"PHASE1":11399,"PHASE2":11401,"PHASE3":11403,"PHASE4":11409,"NA":11411},{"trials":11398,"activeCount":102},[],{"trials":11400,"activeCount":102},[],{"trials":11402,"activeCount":102},[],{"trials":11404,"activeCount":122,"soonestReadout":7310},[11405],{"nctId":7307,"briefTitle":7308,"status":151,"phases":11406,"primaryCompletion":7310,"completion":7310,"start":7311,"enrollment":3419,"conditions":11407,"interventions":11408},[92],[7313],[1467,7315,7316,7317],{"trials":11410,"activeCount":102},[],{"trials":11412,"activeCount":102},[],{"intervention":11414,"totalTrials":122,"cells":11415},"Durvalumab + Chemotherapy phase",{"EARLY_PHASE1":11416,"PHASE1":11418,"PHASE2":11420,"PHASE3":11422,"PHASE4":11433,"NA":11435},{"trials":11417,"activeCount":102},[],{"trials":11419,"activeCount":102},[],{"trials":11421,"activeCount":102},[],{"trials":11423,"activeCount":122,"soonestReadout":3939},[11424],{"nctId":11425,"briefTitle":11426,"status":108,"phases":11427,"primaryCompletion":3939,"completion":3939,"start":11428,"enrollment":1864,"conditions":11429,"interventions":11431},"NCT06746116","A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain",[92],"2024-12-30",[11430],"Advanced or Recurrent Endometrial Cancer",[11414,11432],"Durvalumab + Olaparib phase",{"trials":11434,"activeCount":102},[],{"trials":11436,"activeCount":102},[],{"intervention":11432,"totalTrials":122,"cells":11438},{"EARLY_PHASE1":11439,"PHASE1":11441,"PHASE2":11443,"PHASE3":11445,"PHASE4":11451,"NA":11453},{"trials":11440,"activeCount":102},[],{"trials":11442,"activeCount":102},[],{"trials":11444,"activeCount":102},[],{"trials":11446,"activeCount":122,"soonestReadout":3939},[11447],{"nctId":11425,"briefTitle":11426,"status":108,"phases":11448,"primaryCompletion":3939,"completion":3939,"start":11428,"enrollment":1864,"conditions":11449,"interventions":11450},[92],[11430],[11414,11432],{"trials":11452,"activeCount":102},[],{"trials":11454,"activeCount":102},[],{"intervention":3575,"totalTrials":122,"cells":11456},{"EARLY_PHASE1":11457,"PHASE1":11459,"PHASE2":11461,"PHASE3":11463,"PHASE4":11469,"NA":11471},{"trials":11458,"activeCount":102},[],{"trials":11460,"activeCount":102},[],{"trials":11462,"activeCount":102},[],{"trials":11464,"activeCount":122,"soonestReadout":3569},[11465],{"nctId":3566,"briefTitle":3567,"status":108,"phases":11466,"primaryCompletion":3569,"completion":168,"start":1217,"enrollment":3570,"conditions":11467,"interventions":11468},[92],[3572,3573],[117,3137,3575,3576],{"trials":11470,"activeCount":102},[],{"trials":11472,"activeCount":102},[],{"intervention":3576,"totalTrials":122,"cells":11474},{"EARLY_PHASE1":11475,"PHASE1":11477,"PHASE2":11479,"PHASE3":11481,"PHASE4":11487,"NA":11489},{"trials":11476,"activeCount":102},[],{"trials":11478,"activeCount":102},[],{"trials":11480,"activeCount":102},[],{"trials":11482,"activeCount":122,"soonestReadout":3569},[11483],{"nctId":3566,"briefTitle":3567,"status":108,"phases":11484,"primaryCompletion":3569,"completion":168,"start":1217,"enrollment":3570,"conditions":11485,"interventions":11486},[92],[3572,3573],[117,3137,3575,3576],{"trials":11488,"activeCount":102},[],{"trials":11490,"activeCount":102},[],{"intervention":3585,"totalTrials":122,"cells":11492},{"EARLY_PHASE1":11493,"PHASE1":11495,"PHASE2":11497,"PHASE3":11499,"PHASE4":11505,"NA":11507},{"trials":11494,"activeCount":102},[],{"trials":11496,"activeCount":102},[],{"trials":11498,"activeCount":102},[],{"trials":11500,"activeCount":122,"soonestReadout":1371},[11501],{"nctId":3578,"briefTitle":3579,"status":151,"phases":11502,"primaryCompletion":1371,"completion":1371,"start":3581,"enrollment":3000,"conditions":11503,"interventions":11504},[92],[664,3583,3584,3585,309,177,283],[117,3584,3585,309,177,117,283,177],{"trials":11506,"activeCount":102},[],{"trials":11508,"activeCount":102},[],{"intervention":11510,"totalTrials":122,"cells":11511},"Tozorakimab 1",{"EARLY_PHASE1":11512,"PHASE1":11514,"PHASE2":11516,"PHASE3":11518,"PHASE4":11531,"NA":11533},{"trials":11513,"activeCount":102},[],{"trials":11515,"activeCount":102},[],{"trials":11517,"activeCount":102},[],{"trials":11519,"activeCount":122,"soonestReadout":11524},[11520],{"nctId":11521,"briefTitle":11522,"status":108,"phases":11523,"primaryCompletion":11524,"completion":11525,"start":11526,"enrollment":11527,"conditions":11528,"interventions":11529},"NCT05742802","Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).",[92],"2026-02-26","2026-05-28","2023-03-06",1713,[6083],[11510,11530],"Tozorakimab 2",{"trials":11532,"activeCount":102},[],{"trials":11534,"activeCount":102},[],{"intervention":11530,"totalTrials":122,"cells":11536},{"EARLY_PHASE1":11537,"PHASE1":11539,"PHASE2":11541,"PHASE3":11543,"PHASE4":11549,"NA":11551},{"trials":11538,"activeCount":102},[],{"trials":11540,"activeCount":102},[],{"trials":11542,"activeCount":102},[],{"trials":11544,"activeCount":122,"soonestReadout":11524},[11545],{"nctId":11521,"briefTitle":11522,"status":108,"phases":11546,"primaryCompletion":11524,"completion":11525,"start":11526,"enrollment":11527,"conditions":11547,"interventions":11548},[92],[6083],[11510,11530],{"trials":11550,"activeCount":102},[],{"trials":11552,"activeCount":102},[],{"intervention":902,"totalTrials":122,"cells":11554},{"EARLY_PHASE1":11555,"PHASE1":11557,"PHASE2":11559,"PHASE3":11561,"PHASE4":11567,"NA":11569},{"trials":11556,"activeCount":102},[],{"trials":11558,"activeCount":102},[],{"trials":11560,"activeCount":102},[],{"trials":11562,"activeCount":122,"soonestReadout":893},[11563],{"nctId":890,"briefTitle":891,"status":108,"phases":11564,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":11565,"interventions":11566},[92],[898],[63,900,901,902,344,118],{"trials":11568,"activeCount":102},[],{"trials":11570,"activeCount":102},[],{"intervention":4683,"totalTrials":122,"cells":11572},{"EARLY_PHASE1":11573,"PHASE1":11575,"PHASE2":11577,"PHASE3":11579,"PHASE4":11585,"NA":11587},{"trials":11574,"activeCount":102},[],{"trials":11576,"activeCount":102},[],{"trials":11578,"activeCount":102},[],{"trials":11580,"activeCount":122,"soonestReadout":4678},[11581],{"nctId":4675,"briefTitle":4676,"status":151,"phases":11582,"primaryCompletion":4678,"completion":4679,"start":4680,"enrollment":3654,"conditions":11583,"interventions":11584},[92],[3865],[3925,4683,118,4684,4685],{"trials":11586,"activeCount":102},[],{"trials":11588,"activeCount":102},[],{"intervention":4684,"totalTrials":122,"cells":11590},{"EARLY_PHASE1":11591,"PHASE1":11593,"PHASE2":11595,"PHASE3":11597,"PHASE4":11603,"NA":11605},{"trials":11592,"activeCount":102},[],{"trials":11594,"activeCount":102},[],{"trials":11596,"activeCount":102},[],{"trials":11598,"activeCount":122,"soonestReadout":4678},[11599],{"nctId":4675,"briefTitle":4676,"status":151,"phases":11600,"primaryCompletion":4678,"completion":4679,"start":4680,"enrollment":3654,"conditions":11601,"interventions":11602},[92],[3865],[3925,4683,118,4684,4685],{"trials":11604,"activeCount":102},[],{"trials":11606,"activeCount":102},[],{"intervention":2033,"totalTrials":122,"cells":11608},{"EARLY_PHASE1":11609,"PHASE1":11611,"PHASE2":11613,"PHASE3":11615,"PHASE4":11621,"NA":11623},{"trials":11610,"activeCount":102},[],{"trials":11612,"activeCount":102},[],{"trials":11614,"activeCount":102},[],{"trials":11616,"activeCount":122,"soonestReadout":2026},[11617],{"nctId":2023,"briefTitle":2024,"status":151,"phases":11618,"primaryCompletion":2026,"completion":2027,"start":973,"enrollment":2028,"conditions":11619,"interventions":11620},[92],[651],[2031,2032,653,1927,1941,1940,2033,2034],{"trials":11622,"activeCount":102},[],{"trials":11624,"activeCount":102},[],{"intervention":2034,"totalTrials":122,"cells":11626},{"EARLY_PHASE1":11627,"PHASE1":11629,"PHASE2":11631,"PHASE3":11633,"PHASE4":11639,"NA":11641},{"trials":11628,"activeCount":102},[],{"trials":11630,"activeCount":102},[],{"trials":11632,"activeCount":102},[],{"trials":11634,"activeCount":122,"soonestReadout":2026},[11635],{"nctId":2023,"briefTitle":2024,"status":151,"phases":11636,"primaryCompletion":2026,"completion":2027,"start":973,"enrollment":2028,"conditions":11637,"interventions":11638},[92],[651],[2031,2032,653,1927,1941,1940,2033,2034],{"trials":11640,"activeCount":102},[],{"trials":11642,"activeCount":102},[],{"intervention":3629,"totalTrials":122,"cells":11644},{"EARLY_PHASE1":11645,"PHASE1":11647,"PHASE2":11649,"PHASE3":11651,"PHASE4":11657,"NA":11659},{"trials":11646,"activeCount":102},[],{"trials":11648,"activeCount":102},[],{"trials":11650,"activeCount":102},[],{"trials":11652,"activeCount":122,"soonestReadout":3624},[11653],{"nctId":3621,"briefTitle":3622,"status":108,"phases":11654,"primaryCompletion":3624,"completion":3625,"start":2713,"enrollment":3626,"conditions":11655,"interventions":11656},[92],[3220],[117,3137,3137,3629,117,117],{"trials":11658,"activeCount":102},[],{"trials":11660,"activeCount":102},[],{"intervention":3638,"totalTrials":122,"cells":11662},{"EARLY_PHASE1":11663,"PHASE1":11665,"PHASE2":11667,"PHASE3":11669,"PHASE4":11675,"NA":11677},{"trials":11664,"activeCount":102},[],{"trials":11666,"activeCount":102},[],{"trials":11668,"activeCount":102},[],{"trials":11670,"activeCount":122,"soonestReadout":1046},[11671],{"nctId":3631,"briefTitle":3632,"status":108,"phases":11672,"primaryCompletion":1046,"completion":1046,"start":3634,"enrollment":3635,"conditions":11673,"interventions":11674},[92],[3031],[117,3638,3639],{"trials":11676,"activeCount":102},[],{"trials":11678,"activeCount":102},[],{"intervention":3639,"totalTrials":122,"cells":11680},{"EARLY_PHASE1":11681,"PHASE1":11683,"PHASE2":11685,"PHASE3":11687,"PHASE4":11693,"NA":11695},{"trials":11682,"activeCount":102},[],{"trials":11684,"activeCount":102},[],{"trials":11686,"activeCount":102},[],{"trials":11688,"activeCount":122,"soonestReadout":1046},[11689],{"nctId":3631,"briefTitle":3632,"status":108,"phases":11690,"primaryCompletion":1046,"completion":1046,"start":3634,"enrollment":3635,"conditions":11691,"interventions":11692},[92],[3031],[117,3638,3639],{"trials":11694,"activeCount":102},[],{"trials":11696,"activeCount":102},[],{"intervention":4144,"totalTrials":122,"cells":11698},{"EARLY_PHASE1":11699,"PHASE1":11701,"PHASE2":11703,"PHASE3":11705,"PHASE4":11711,"NA":11713},{"trials":11700,"activeCount":102},[],{"trials":11702,"activeCount":102},[],{"trials":11704,"activeCount":102},[],{"trials":11706,"activeCount":122,"soonestReadout":4139},[11707],{"nctId":4136,"briefTitle":4137,"status":108,"phases":11708,"primaryCompletion":4139,"completion":660,"start":4140,"enrollment":4141,"conditions":11709,"interventions":11710},[92],[25],[808,118,3097,344,121,4144],{"trials":11712,"activeCount":102},[],{"trials":11714,"activeCount":102},[],{"intervention":1846,"totalTrials":122,"cells":11716},{"EARLY_PHASE1":11717,"PHASE1":11719,"PHASE2":11721,"PHASE3":11723,"PHASE4":11729,"NA":11731},{"trials":11718,"activeCount":102},[],{"trials":11720,"activeCount":102},[],{"trials":11722,"activeCount":102},[],{"trials":11724,"activeCount":122,"soonestReadout":1839},[11725],{"nctId":1836,"briefTitle":1837,"status":108,"phases":11726,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1842,"conditions":11727,"interventions":11728},[92],[1844],[1542,1846],{"trials":11730,"activeCount":102},[],{"trials":11732,"activeCount":102},[],{"intervention":3667,"totalTrials":122,"cells":11734},{"EARLY_PHASE1":11735,"PHASE1":11737,"PHASE2":11739,"PHASE3":11741,"PHASE4":11747,"NA":11749},{"trials":11736,"activeCount":102},[],{"trials":11738,"activeCount":102},[],{"trials":11740,"activeCount":102},[],{"trials":11742,"activeCount":122,"soonestReadout":337},[11743],{"nctId":3659,"briefTitle":3660,"status":108,"phases":11744,"primaryCompletion":337,"completion":3662,"start":3663,"enrollment":3664,"conditions":11745,"interventions":11746},[92],[567],[117,3137,3667],{"trials":11748,"activeCount":102},[],{"trials":11750,"activeCount":102},[],{"intervention":4841,"totalTrials":122,"cells":11752},{"EARLY_PHASE1":11753,"PHASE1":11755,"PHASE2":11757,"PHASE3":11759,"PHASE4":11765,"NA":11767},{"trials":11754,"activeCount":102},[],{"trials":11756,"activeCount":102},[],{"trials":11758,"activeCount":102},[],{"trials":11760,"activeCount":122,"soonestReadout":4835},[11761],{"nctId":4832,"briefTitle":4833,"status":151,"phases":11762,"primaryCompletion":4835,"completion":4836,"start":4837,"enrollment":4838,"conditions":11763,"interventions":11764},[92],[172,294,405],[4841,180,4178,121,226,175,4842,4843],{"trials":11766,"activeCount":102},[],{"trials":11768,"activeCount":102},[],{"intervention":4842,"totalTrials":122,"cells":11770},{"EARLY_PHASE1":11771,"PHASE1":11773,"PHASE2":11775,"PHASE3":11777,"PHASE4":11783,"NA":11785},{"trials":11772,"activeCount":102},[],{"trials":11774,"activeCount":102},[],{"trials":11776,"activeCount":102},[],{"trials":11778,"activeCount":122,"soonestReadout":4835},[11779],{"nctId":4832,"briefTitle":4833,"status":151,"phases":11780,"primaryCompletion":4835,"completion":4836,"start":4837,"enrollment":4838,"conditions":11781,"interventions":11782},[92],[172,294,405],[4841,180,4178,121,226,175,4842,4843],{"trials":11784,"activeCount":102},[],{"trials":11786,"activeCount":102},[],{"intervention":9748,"totalTrials":122,"cells":11788},{"EARLY_PHASE1":11789,"PHASE1":11791,"PHASE2":11793,"PHASE3":11795,"PHASE4":11801,"NA":11803},{"trials":11790,"activeCount":102},[],{"trials":11792,"activeCount":102},[],{"trials":11794,"activeCount":102},[],{"trials":11796,"activeCount":122,"soonestReadout":9743},[11797],{"nctId":9740,"briefTitle":9741,"status":151,"phases":11798,"primaryCompletion":9743,"completion":9744,"start":9745,"enrollment":7302,"conditions":11799,"interventions":11800},[92],[1464],[9718,9748],{"trials":11802,"activeCount":102},[],{"trials":11804,"activeCount":102},[],{"intervention":6337,"totalTrials":122,"cells":11806},{"EARLY_PHASE1":11807,"PHASE1":11809,"PHASE2":11811,"PHASE3":11813,"PHASE4":11819,"NA":11821},{"trials":11808,"activeCount":102},[],{"trials":11810,"activeCount":102},[],{"trials":11812,"activeCount":102},[],{"trials":11814,"activeCount":122,"soonestReadout":6332},[11815],{"nctId":6329,"briefTitle":6330,"status":151,"phases":11816,"primaryCompletion":6332,"completion":6333,"start":6334,"enrollment":4625,"conditions":11817,"interventions":11818},[92],[416],[1959,6337,6338],{"trials":11820,"activeCount":102},[],{"trials":11822,"activeCount":102},[],{"intervention":6338,"totalTrials":122,"cells":11824},{"EARLY_PHASE1":11825,"PHASE1":11827,"PHASE2":11829,"PHASE3":11831,"PHASE4":11837,"NA":11839},{"trials":11826,"activeCount":102},[],{"trials":11828,"activeCount":102},[],{"trials":11830,"activeCount":102},[],{"trials":11832,"activeCount":122,"soonestReadout":6332},[11833],{"nctId":6329,"briefTitle":6330,"status":151,"phases":11834,"primaryCompletion":6332,"completion":6333,"start":6334,"enrollment":4625,"conditions":11835,"interventions":11836},[92],[416],[1959,6337,6338],{"trials":11838,"activeCount":102},[],{"trials":11840,"activeCount":102},[],{"intervention":4853,"totalTrials":122,"cells":11842},{"EARLY_PHASE1":11843,"PHASE1":11845,"PHASE2":11847,"PHASE3":11849,"PHASE4":11855,"NA":11857},{"trials":11844,"activeCount":102},[],{"trials":11846,"activeCount":102},[],{"trials":11848,"activeCount":102},[],{"trials":11850,"activeCount":122,"soonestReadout":4848},[11851],{"nctId":4845,"briefTitle":4846,"status":108,"phases":11852,"primaryCompletion":4848,"completion":4849,"start":446,"enrollment":4850,"conditions":11853,"interventions":11854},[92],[281],[180,121,3657,4853],{"trials":11856,"activeCount":102},[],{"trials":11858,"activeCount":102},[],{"intervention":9341,"totalTrials":122,"cells":11860},{"EARLY_PHASE1":11861,"PHASE1":11863,"PHASE2":11865,"PHASE3":11867,"PHASE4":11873,"NA":11875},{"trials":11862,"activeCount":102},[],{"trials":11864,"activeCount":102},[],{"trials":11866,"activeCount":102},[],{"trials":11868,"activeCount":122,"soonestReadout":3958},[11869],{"nctId":9333,"briefTitle":9334,"status":1097,"phases":11870,"primaryCompletion":3958,"completion":3958,"start":9336,"enrollment":1685,"conditions":11871,"interventions":11872},[92],[9308],[9339,9340,9341,9342,9310,9311,9343,9344],{"trials":11874,"activeCount":102},[],{"trials":11876,"activeCount":102},[],{"intervention":9342,"totalTrials":122,"cells":11878},{"EARLY_PHASE1":11879,"PHASE1":11881,"PHASE2":11883,"PHASE3":11885,"PHASE4":11891,"NA":11893},{"trials":11880,"activeCount":102},[],{"trials":11882,"activeCount":102},[],{"trials":11884,"activeCount":102},[],{"trials":11886,"activeCount":122,"soonestReadout":3958},[11887],{"nctId":9333,"briefTitle":9334,"status":1097,"phases":11888,"primaryCompletion":3958,"completion":3958,"start":9336,"enrollment":1685,"conditions":11889,"interventions":11890},[92],[9308],[9339,9340,9341,9342,9310,9311,9343,9344],{"trials":11892,"activeCount":102},[],{"trials":11894,"activeCount":102},[],{"intervention":9343,"totalTrials":122,"cells":11896},{"EARLY_PHASE1":11897,"PHASE1":11899,"PHASE2":11901,"PHASE3":11903,"PHASE4":11909,"NA":11911},{"trials":11898,"activeCount":102},[],{"trials":11900,"activeCount":102},[],{"trials":11902,"activeCount":102},[],{"trials":11904,"activeCount":122,"soonestReadout":3958},[11905],{"nctId":9333,"briefTitle":9334,"status":1097,"phases":11906,"primaryCompletion":3958,"completion":3958,"start":9336,"enrollment":1685,"conditions":11907,"interventions":11908},[92],[9308],[9339,9340,9341,9342,9310,9311,9343,9344],{"trials":11910,"activeCount":102},[],{"trials":11912,"activeCount":102},[],{"intervention":9344,"totalTrials":122,"cells":11914},{"EARLY_PHASE1":11915,"PHASE1":11917,"PHASE2":11919,"PHASE3":11921,"PHASE4":11927,"NA":11929},{"trials":11916,"activeCount":102},[],{"trials":11918,"activeCount":102},[],{"trials":11920,"activeCount":102},[],{"trials":11922,"activeCount":122,"soonestReadout":3958},[11923],{"nctId":9333,"briefTitle":9334,"status":1097,"phases":11924,"primaryCompletion":3958,"completion":3958,"start":9336,"enrollment":1685,"conditions":11925,"interventions":11926},[92],[9308],[9339,9340,9341,9342,9310,9311,9343,9344],{"trials":11928,"activeCount":102},[],{"trials":11930,"activeCount":102},[],{"intervention":3678,"totalTrials":122,"cells":11932},{"EARLY_PHASE1":11933,"PHASE1":11935,"PHASE2":11937,"PHASE3":11939,"PHASE4":11945,"NA":11947},{"trials":11934,"activeCount":102},[],{"trials":11936,"activeCount":102},[],{"trials":11938,"activeCount":102},[],{"trials":11940,"activeCount":122,"soonestReadout":3672},[11941],{"nctId":3669,"briefTitle":3670,"status":151,"phases":11942,"primaryCompletion":3672,"completion":3673,"start":3674,"enrollment":3675,"conditions":11943,"interventions":11944},[92],[262],[117,3678],{"trials":11946,"activeCount":102},[],{"trials":11948,"activeCount":102},[],{"intervention":357,"totalTrials":122,"cells":11950},{"EARLY_PHASE1":11951,"PHASE1":11953,"PHASE2":11955,"PHASE3":11957,"PHASE4":11963,"NA":11965},{"trials":11952,"activeCount":102},[],{"trials":11954,"activeCount":102},[],{"trials":11956,"activeCount":102},[],{"trials":11958,"activeCount":122,"soonestReadout":350},[11959],{"nctId":347,"briefTitle":348,"status":108,"phases":11960,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":11961,"interventions":11962},[92],[355],[97,357,146,176],{"trials":11964,"activeCount":102},[],{"trials":11966,"activeCount":102},[],{"intervention":11968,"totalTrials":122,"cells":11969},"Budesonide\u002FAlbuterol metered dose inhaler, MDI",{"EARLY_PHASE1":11970,"PHASE1":11972,"PHASE2":11974,"PHASE3":11976,"PHASE4":11986,"NA":11988},{"trials":11971,"activeCount":102},[],{"trials":11973,"activeCount":102},[],{"trials":11975,"activeCount":102},[],{"trials":11977,"activeCount":122,"soonestReadout":2997},[11978],{"nctId":11979,"briefTitle":11980,"status":151,"phases":11981,"primaryCompletion":2997,"completion":2997,"start":10133,"enrollment":11982,"conditions":11983,"interventions":11984},"NCT06471257","A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma",[92],790,[16],[11968,11985],"Albuterol sulfate metered dose inhaler, MDI",{"trials":11987,"activeCount":102},[],{"trials":11989,"activeCount":102},[],{"intervention":11985,"totalTrials":122,"cells":11991},{"EARLY_PHASE1":11992,"PHASE1":11994,"PHASE2":11996,"PHASE3":11998,"PHASE4":12004,"NA":12006},{"trials":11993,"activeCount":102},[],{"trials":11995,"activeCount":102},[],{"trials":11997,"activeCount":102},[],{"trials":11999,"activeCount":122,"soonestReadout":2997},[12000],{"nctId":11979,"briefTitle":11980,"status":151,"phases":12001,"primaryCompletion":2997,"completion":2997,"start":10133,"enrollment":11982,"conditions":12002,"interventions":12003},[92],[16],[11968,11985],{"trials":12005,"activeCount":102},[],{"trials":12007,"activeCount":102},[],{"intervention":10301,"totalTrials":122,"cells":12009},{"EARLY_PHASE1":12010,"PHASE1":12012,"PHASE2":12014,"PHASE3":12016,"PHASE4":12022,"NA":12024},{"trials":12011,"activeCount":102},[],{"trials":12013,"activeCount":102},[],{"trials":12015,"activeCount":102},[],{"trials":12017,"activeCount":122,"soonestReadout":7169},[12018],{"nctId":10294,"briefTitle":10295,"status":151,"phases":12019,"primaryCompletion":7169,"completion":7169,"start":10297,"enrollment":8918,"conditions":12020,"interventions":12021},[92],[10299],[10263,10301],{"trials":12023,"activeCount":102},[],{"trials":12025,"activeCount":102},[],{"intervention":3709,"totalTrials":122,"cells":12027},{"EARLY_PHASE1":12028,"PHASE1":12030,"PHASE2":12032,"PHASE3":12034,"PHASE4":12040,"NA":12042},{"trials":12029,"activeCount":102},[],{"trials":12031,"activeCount":102},[],{"trials":12033,"activeCount":102},[],{"trials":12035,"activeCount":122,"soonestReadout":3702},[12036],{"nctId":3699,"briefTitle":3700,"status":108,"phases":12037,"primaryCompletion":3702,"completion":3703,"start":3704,"enrollment":3705,"conditions":12038,"interventions":12039},[92],[3707],[117,3137,3709,3353,3354,3356,3355],{"trials":12041,"activeCount":102},[],{"trials":12043,"activeCount":102},[],{"intervention":6737,"totalTrials":122,"cells":12045},{"EARLY_PHASE1":12046,"PHASE1":12048,"PHASE2":12050,"PHASE3":12052,"PHASE4":12058,"NA":12060},{"trials":12047,"activeCount":102},[],{"trials":12049,"activeCount":102},[],{"trials":12051,"activeCount":102},[],{"trials":12053,"activeCount":122,"soonestReadout":67},[12054],{"nctId":65,"briefTitle":66,"status":108,"phases":12055,"primaryCompletion":67,"completion":1317,"start":6732,"enrollment":6733,"conditions":12056,"interventions":12057},[92],[6735],[68,369,6737],{"trials":12059,"activeCount":102},[],{"trials":12061,"activeCount":102},[],{"intervention":5620,"totalTrials":122,"cells":12063},{"EARLY_PHASE1":12064,"PHASE1":12066,"PHASE2":12068,"PHASE3":12070,"PHASE4":12076,"NA":12078},{"trials":12065,"activeCount":102},[],{"trials":12067,"activeCount":102},[],{"trials":12069,"activeCount":102},[],{"trials":12071,"activeCount":122,"soonestReadout":5615},[12072],{"nctId":5612,"briefTitle":5613,"status":108,"phases":12073,"primaryCompletion":5615,"completion":2288,"start":5616,"enrollment":5617,"conditions":12074,"interventions":12075},[92],[25],[808,121,283,5620,1051],{"trials":12077,"activeCount":102},[],{"trials":12079,"activeCount":102},[],{"intervention":10762,"totalTrials":1638,"cells":12081},{"EARLY_PHASE1":12082,"PHASE1":12084,"PHASE2":12105,"PHASE3":12124,"PHASE4":12178,"NA":12206},{"trials":12083,"activeCount":102},[],{"trials":12085,"activeCount":102},[12086,12095],{"nctId":12087,"briefTitle":12088,"status":195,"phases":12089,"primaryCompletion":12090,"completion":12090,"start":12091,"enrollment":434,"conditions":12092,"interventions":12094},"NCT03283267","A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)",[90],"2017-11-23","2017-10-24",[12093],"Hyperkalemia",[10762],{"nctId":12096,"briefTitle":12097,"status":195,"phases":12098,"primaryCompletion":12099,"completion":12099,"start":12100,"enrollment":37,"conditions":12101,"interventions":12102},"NCT04788641","Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects",[90],"2021-09-16","2021-03-30",[10760],[12103,12104,10762],"Tacrolimus","Cyclosporin",{"trials":12106,"activeCount":102},[12107,12115],{"nctId":12108,"briefTitle":12109,"status":443,"phases":12110,"primaryCompletion":12111,"completion":12111,"start":12112,"enrollment":2590,"conditions":12113,"interventions":12114},"NCT03532009","Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure",[91],"2020-05-22","2018-06-26",[1520],[10762],{"nctId":12116,"briefTitle":12117,"status":195,"phases":12118,"primaryCompletion":246,"completion":246,"start":12119,"enrollment":3476,"conditions":12120,"interventions":12121},"NCT03337477","A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8",[91],"2018-02-13",[12093],[10762,12122,12123,12122,12123],"Insulin","Glucose",{"trials":12125,"activeCount":122,"soonestReadout":5162},[12126,12130,12136,12146,12155,12165],{"nctId":10756,"briefTitle":10757,"status":151,"phases":12127,"primaryCompletion":5162,"completion":5162,"start":1554,"enrollment":1842,"conditions":12128,"interventions":12129},[92],[10760],[10745,10762,10762,10762,10763],{"nctId":12131,"briefTitle":12132,"status":195,"phases":12133,"primaryCompletion":8340,"completion":8340,"start":1437,"enrollment":1666,"conditions":12134,"interventions":12135},"NCT04217590","Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects",[92],[12093],[10762],{"nctId":12137,"briefTitle":12138,"status":443,"phases":12139,"primaryCompletion":12140,"completion":12140,"start":12141,"enrollment":3190,"conditions":12142,"interventions":12144},"NCT04727528","Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease",[92],"2022-09-14","2021-03-22",[10760,12143,2134],"Metabolic Acidosis",[12145],"Sodium zirconium cyclosilicate",{"nctId":12147,"briefTitle":12148,"status":195,"phases":12149,"primaryCompletion":12150,"completion":12150,"start":12151,"enrollment":12152,"conditions":12153,"interventions":12154},"NCT03303521","A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.",[92],"2018-11-07","2017-12-14",196,[12093],[10762],{"nctId":12156,"briefTitle":12157,"status":443,"phases":12158,"primaryCompletion":12159,"completion":12159,"start":12160,"enrollment":12161,"conditions":12162,"interventions":12163},"NCT04847232","Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)",[92],"2024-03-07","2021-04-30",2690,[12093],[10762,12164],"SZC Placebo",{"nctId":12166,"briefTitle":12167,"status":443,"phases":12168,"primaryCompletion":12169,"completion":12169,"start":12170,"enrollment":12171,"conditions":12172,"interventions":12174},"NCT05056727","A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia",[92],"2024-02-07","2021-09-30",1112,[12173,12093],"Renal Insufficiency, Chronic",[10762,12175,12176,12177],"Lisinopril","Valsartan","Irbesartan",{"trials":12179,"activeCount":102},[12180,12189,12198],{"nctId":12181,"briefTitle":12182,"status":195,"phases":12183,"primaryCompletion":12184,"completion":12184,"start":12185,"enrollment":764,"conditions":12186,"interventions":12188},"NCT04676646","Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone",[93],"2024-07-15","2021-03-08",[10760,12187],"Heart Failure With Reduced Ejection Fraction",[12145],{"nctId":12190,"briefTitle":12191,"status":195,"phases":12192,"primaryCompletion":12193,"completion":12193,"start":1746,"enrollment":12194,"conditions":12195,"interventions":12196},"NCT05347693","Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study",[93],"2024-12-10",186,[10760,2134],[10762,12197],"Local standard of care",{"nctId":12199,"briefTitle":12200,"status":443,"phases":12201,"primaryCompletion":12202,"completion":12202,"start":12203,"enrollment":3887,"conditions":12204,"interventions":12205},"NCT04997161","Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia",[93],"2021-11-17","2021-08-17",[10760],[10762],{"trials":12207,"activeCount":102},[12208],{"nctId":12209,"briefTitle":12210,"status":195,"phases":12211,"primaryCompletion":12212,"completion":12212,"start":12213,"enrollment":2811,"conditions":12214,"interventions":12215},"NCT06185660","A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece",[],"2025-01-03","2024-02-09",[10760],[12216],"sodium zirconium cyclosilicate",{"intervention":12218,"totalTrials":4343,"cells":12219},"AZD6234",{"EARLY_PHASE1":12220,"PHASE1":12222,"PHASE2":12264,"PHASE3":12307,"PHASE4":12309,"NA":12311},{"trials":12221,"activeCount":102},[],{"trials":12223,"activeCount":447,"soonestReadout":12260},[12224,12231,12239,12248,12256],{"nctId":12225,"briefTitle":12226,"status":195,"phases":12227,"primaryCompletion":4837,"completion":12228,"start":8302,"enrollment":4877,"conditions":12229,"interventions":12230},"NCT06132841","A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese",[90],"2026-03-07",[5851],[12218],{"nctId":12232,"briefTitle":12233,"status":195,"phases":12234,"primaryCompletion":12235,"completion":12235,"start":12236,"enrollment":1130,"conditions":12237,"interventions":12238},"NCT06845813","Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234",[90],"2025-09-30","2025-02-24",[2279],[12218],{"nctId":12240,"briefTitle":12241,"status":151,"phases":12242,"primaryCompletion":12243,"completion":12243,"start":12244,"enrollment":2260,"conditions":12245,"interventions":12246},"NCT07546760","A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234",[90],"2027-02-04","2026-03-20",[6914],[12218,12247],"AZD9550",{"nctId":12249,"briefTitle":12250,"status":195,"phases":12251,"primaryCompletion":12252,"completion":12252,"start":10157,"enrollment":680,"conditions":12253,"interventions":12254},"NCT05511025","Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese",[90],"2023-12-19",[5851],[12218,12255],"Acetaminophen",{"nctId":12257,"briefTitle":12258,"status":151,"phases":12259,"primaryCompletion":12260,"completion":12260,"start":7008,"enrollment":4286,"conditions":12261,"interventions":12262},"NCT07013643","A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol\u002FLevonorgestrel in Healthy Female Participants Living With Overweight or Obesity",[90],"2026-12-25",[5851],[12218,12263,12255,12247],"Ethinyl estradiol\u002FLevonorgestrel",{"trials":12265,"activeCount":3887,"soonestReadout":1718},[12266,12277,12288,12295],{"nctId":12267,"briefTitle":12268,"status":108,"phases":12269,"primaryCompletion":12270,"completion":12270,"start":301,"enrollment":12271,"conditions":12272,"interventions":12276},"NCT06851858","Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist",[91],"2026-05-27",69,[12273,12274,12275],"Endocrinology","Diabetes, Type II","Obesity",[12218],{"nctId":12278,"briefTitle":12279,"status":195,"phases":12280,"primaryCompletion":12281,"completion":12282,"start":12283,"enrollment":12284,"conditions":12285,"interventions":12287},"NCT06595238","A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity",[91],"2025-08-08","2025-12-03","2024-10-01",262,[12286],"Obesity or Overweight",[12218],{"nctId":12289,"briefTitle":12290,"status":108,"phases":12291,"primaryCompletion":1718,"completion":1718,"start":7778,"enrollment":12292,"conditions":12293,"interventions":12294},"NCT06862791","A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone",[91],377,[12286],[12247,12218],{"nctId":12296,"briefTitle":12297,"status":151,"phases":12298,"primaryCompletion":12299,"completion":12299,"start":12300,"enrollment":12301,"conditions":12302,"interventions":12304},"NCT07017179","This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity \u002F Overweight",[91],"2026-08-06","2025-05-20",871,[12303],"Obesity\u002FOverweight",[12218,12247,12305,12306],"Plocebo","AZD6234 in combination with AZD9550",{"trials":12308,"activeCount":102},[],{"trials":12310,"activeCount":102},[],{"trials":12312,"activeCount":102},[],{"intervention":12247,"totalTrials":1039,"cells":12314},{"EARLY_PHASE1":12315,"PHASE1":12317,"PHASE2":12334,"PHASE3":12355,"PHASE4":12357,"NA":12359},{"trials":12316,"activeCount":102},[],{"trials":12318,"activeCount":447,"soonestReadout":12260},[12319,12323,12330],{"nctId":12240,"briefTitle":12241,"status":151,"phases":12320,"primaryCompletion":12243,"completion":12243,"start":12244,"enrollment":2260,"conditions":12321,"interventions":12322},[90],[6914],[12218,12247],{"nctId":12324,"briefTitle":12325,"status":195,"phases":12326,"primaryCompletion":8302,"completion":8302,"start":1508,"enrollment":5898,"conditions":12327,"interventions":12329},"NCT05848440","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants",[90],[12328],"Non-alcoholic Steatohepatitis",[12247,12247],{"nctId":12257,"briefTitle":12258,"status":151,"phases":12331,"primaryCompletion":12260,"completion":12260,"start":7008,"enrollment":4286,"conditions":12332,"interventions":12333},[90],[5851],[12218,12263,12255,12247],{"trials":12335,"activeCount":3887,"soonestReadout":1718},[12336,12347,12351],{"nctId":12337,"briefTitle":12338,"status":151,"phases":12339,"primaryCompletion":12340,"completion":12340,"start":12341,"enrollment":12342,"conditions":12343,"interventions":12345},"NCT06151964","A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight",[90,91],"2027-01-29","2023-09-29",160,[12344],"Overweight and Obesity",[12247,12346],"AZD9550 and AZD6234",{"nctId":12289,"briefTitle":12290,"status":108,"phases":12348,"primaryCompletion":1718,"completion":1718,"start":7778,"enrollment":12292,"conditions":12349,"interventions":12350},[91],[12286],[12247,12218],{"nctId":12296,"briefTitle":12297,"status":151,"phases":12352,"primaryCompletion":12299,"completion":12299,"start":12300,"enrollment":12301,"conditions":12353,"interventions":12354},[91],[12303],[12218,12247,12305,12306],{"trials":12356,"activeCount":102},[],{"trials":12358,"activeCount":102},[],{"trials":12360,"activeCount":102},[],{"intervention":159,"totalTrials":1979,"cells":12362},{"EARLY_PHASE1":12363,"PHASE1":12365,"PHASE2":12367,"PHASE3":12389,"PHASE4":12391,"NA":12393},{"trials":12364,"activeCount":102},[],{"trials":12366,"activeCount":102},[],{"trials":12368,"activeCount":1979,"soonestReadout":153},[12369,12373,12381,12385],{"nctId":149,"briefTitle":150,"status":151,"phases":12370,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":12371,"interventions":12372},[90,91],[157],[159,160,161,162,163],{"nctId":12374,"briefTitle":12375,"status":151,"phases":12376,"primaryCompletion":12377,"completion":12377,"start":6233,"enrollment":1385,"conditions":12378,"interventions":12379},"NCT07181161","Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer",[90,91],"2029-01-18",[1937],[12380,159],"AZD0516",{"nctId":3917,"briefTitle":3918,"status":151,"phases":12382,"primaryCompletion":3920,"completion":3920,"start":3921,"enrollment":318,"conditions":12383,"interventions":12384},[90,91],[414,3923,367],[3925,1959,239,344,159],{"nctId":6665,"briefTitle":6666,"status":1097,"phases":12386,"primaryCompletion":6668,"completion":6668,"start":6669,"enrollment":3466,"conditions":12387,"interventions":12388},[90,91],[1937],[2031,159,369,6672],{"trials":12390,"activeCount":102},[],{"trials":12392,"activeCount":102},[],{"trials":12394,"activeCount":102},[],{"intervention":1939,"totalTrials":1979,"cells":12396},{"EARLY_PHASE1":12397,"PHASE1":12399,"PHASE2":12410,"PHASE3":12429,"PHASE4":12431,"NA":12433},{"trials":12398,"activeCount":102},[],{"trials":12400,"activeCount":102},[12401],{"nctId":12402,"briefTitle":12403,"status":195,"phases":12404,"primaryCompletion":12405,"completion":12406,"start":12407,"enrollment":486,"conditions":12408,"interventions":12409},"NCT05573724","Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies",[90],"2023-04-17","2024-05-17","2022-11-07",[157],[1939,5911],{"trials":12411,"activeCount":3887,"soonestReadout":3958},[12412,12416,12420],{"nctId":3955,"briefTitle":3956,"status":108,"phases":12413,"primaryCompletion":3958,"completion":3958,"start":1574,"enrollment":3959,"conditions":12414,"interventions":12415},[90,91],[414,25,415,416,3961,1049,691,403,172,3962,404,367,3963],[1939,118,344,3965,808,3966],{"nctId":1931,"briefTitle":1932,"status":108,"phases":12417,"primaryCompletion":1934,"completion":1934,"start":1137,"enrollment":1935,"conditions":12418,"interventions":12419},[90,91],[1937],[1939,1927,1926,1940,1941],{"nctId":12421,"briefTitle":12422,"status":151,"phases":12423,"primaryCompletion":1200,"completion":1200,"start":12424,"enrollment":12425,"conditions":12426,"interventions":12427},"NCT07336446","A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs",[90,91],"2026-01-27",300,[416],[12428,1939],"AZD9750",{"trials":12430,"activeCount":102},[],{"trials":12432,"activeCount":102},[],{"trials":12434,"activeCount":102},[],{"intervention":979,"totalTrials":3887,"cells":12436},{"EARLY_PHASE1":12437,"PHASE1":12439,"PHASE2":12449,"PHASE3":12461,"PHASE4":12463,"NA":12465},{"trials":12438,"activeCount":102},[],{"trials":12440,"activeCount":447,"soonestReadout":3122},[12441,12445],{"nctId":970,"briefTitle":971,"status":108,"phases":12442,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":12443,"interventions":12444},[90],[977],[252,117,344,979,980,981],{"nctId":3119,"briefTitle":3120,"status":108,"phases":12446,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":12447,"interventions":12448},[90],[3127],[117,264,251,980,345,344,283,177,3097,979],{"trials":12450,"activeCount":122,"soonestReadout":12455},[12451],{"nctId":12452,"briefTitle":12453,"status":108,"phases":12454,"primaryCompletion":12455,"completion":12456,"start":12457,"enrollment":12458,"conditions":12459,"interventions":12460},"NCT04995523","A Study of AZD2936 Anti-TIGIT\u002FAnti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC",[90,91],"2026-08-28","2028-06-01","2021-09-14",212,[6695],[979],{"trials":12462,"activeCount":102},[],{"trials":12464,"activeCount":102},[],{"trials":12466,"activeCount":102},[],{"intervention":3934,"totalTrials":3887,"cells":12468},{"EARLY_PHASE1":12469,"PHASE1":12471,"PHASE2":12473,"PHASE3":12487,"PHASE4":12489,"NA":12491},{"trials":12470,"activeCount":102},[],{"trials":12472,"activeCount":102},[],{"trials":12474,"activeCount":3887,"soonestReadout":338},[12475,12479,12483],{"nctId":4727,"briefTitle":4728,"status":151,"phases":12476,"primaryCompletion":4730,"completion":4730,"start":4731,"enrollment":4732,"conditions":12477,"interventions":12478},[91],[262],[180,3934,808],{"nctId":3927,"briefTitle":3928,"status":151,"phases":12480,"primaryCompletion":3930,"completion":3930,"start":2932,"enrollment":3466,"conditions":12481,"interventions":12482},[90,91],[3932],[180,177,344,345,118,3097,3934],{"nctId":3980,"briefTitle":3981,"status":151,"phases":12484,"primaryCompletion":338,"completion":338,"start":3983,"enrollment":1120,"conditions":12485,"interventions":12486},[91],[1049],[179,344,345,3934,118],{"trials":12488,"activeCount":102},[],{"trials":12490,"activeCount":102},[],{"trials":12492,"activeCount":102},[],{"intervention":6672,"totalTrials":3887,"cells":12494},{"EARLY_PHASE1":12495,"PHASE1":12497,"PHASE2":12511,"PHASE3":12525,"PHASE4":12527,"NA":12529},{"trials":12496,"activeCount":102},[],{"trials":12498,"activeCount":122,"soonestReadout":12503},[12499],{"nctId":12500,"briefTitle":12501,"status":151,"phases":12502,"primaryCompletion":12503,"completion":12503,"start":12504,"enrollment":12505,"conditions":12506,"interventions":12508},"NCT06879041","A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer",[90],"2029-04-16","2025-03-10",136,[12507],"Metastatic Castration-Resistant Prostate Cancer",[6672,12509,12510],"AZD2275","AZD2284",{"trials":12512,"activeCount":447,"soonestReadout":12517},[12513,12521],{"nctId":12514,"briefTitle":12515,"status":151,"phases":12516,"primaryCompletion":12517,"completion":12517,"start":7756,"enrollment":477,"conditions":12518,"interventions":12519},"NCT06267729","Study of AZD0754 in Participants With Metastatic Prostate Cancer",[90,91],"2026-11-24",[1937],[12520,6672],"AZD0754",{"nctId":6665,"briefTitle":6666,"status":1097,"phases":12522,"primaryCompletion":6668,"completion":6668,"start":6669,"enrollment":3466,"conditions":12523,"interventions":12524},[90,91],[1937],[2031,159,369,6672],{"trials":12526,"activeCount":102},[],{"trials":12528,"activeCount":102},[],{"trials":12530,"activeCount":102},[],{"intervention":5887,"totalTrials":12271,"cells":12532},{"EARLY_PHASE1":12533,"PHASE1":12552,"PHASE2":12688,"PHASE3":12708,"PHASE4":12972,"NA":13041},{"trials":12534,"activeCount":102},[12535,12543],{"nctId":12536,"briefTitle":12537,"status":195,"phases":12538,"completion":688,"start":2086,"enrollment":1395,"conditions":12539,"interventions":12542},"NCT00783042","Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements",[89],[12540,12541],"Atherosclerosis","Inflammatory Activity in Coronary Arteries",[5887],{"nctId":12544,"briefTitle":12545,"status":195,"phases":12546,"completion":2152,"start":4298,"enrollment":12547,"conditions":12548,"interventions":12550},"NCT00689416","Effects of Crestor on Inflammation of Atherosclerotic Plaques",[89],74,[12540,12549],"Inflammatory Activity in Carotid Arteries",[12551],"rosuvastatin",{"trials":12553,"activeCount":447,"soonestReadout":4837},[12554,12558,12568,12578,12590,12598,12605,12609,12617,12621,12628,12632,12641,12650,12656,12663,12667,12671,12682],{"nctId":7023,"briefTitle":7024,"status":195,"phases":12555,"primaryCompletion":7026,"completion":7026,"start":7027,"enrollment":1039,"conditions":12556,"interventions":12557},[90],[7029],[87,2198,6279,5887,6278],{"nctId":12559,"briefTitle":12560,"status":195,"phases":12561,"primaryCompletion":2220,"start":2221,"enrollment":4307,"conditions":12562,"interventions":12565},"NCT00681395","Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium",[90],[12563,12564],"Adverse Events","Pharmacokinetic",[12566,12567,5887],"ABT-143","ABT-335",{"nctId":12569,"briefTitle":12570,"status":195,"phases":12571,"primaryCompletion":12572,"completion":12573,"start":12574,"enrollment":3811,"conditions":12575,"interventions":12576},"NCT02317016","Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",[90],"2015-07-11","2018-05-22","2015-03-10",[3864],[12577,5887],"AZD9291 tablet dosing",{"nctId":12579,"briefTitle":12580,"status":195,"phases":12581,"primaryCompletion":12582,"completion":12582,"start":1007,"enrollment":507,"conditions":12583,"interventions":12584},"NCT06948747","A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants",[90],"2025-10-03",[5851],[12585,5887,12586,12587,12588,12589],"AZD5004","Erythromycin","Atorvastatin","Simvastatin","Repaglinide",{"nctId":12591,"briefTitle":12592,"status":195,"phases":12593,"primaryCompletion":12594,"completion":12594,"start":1637,"enrollment":1757,"conditions":12595,"interventions":12596},"NCT06925854","A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants",[90],"2025-06-12",[19],[12597,5887],"AZD4144",{"nctId":12599,"briefTitle":12600,"status":195,"phases":12601,"primaryCompletion":2579,"completion":2579,"start":2104,"enrollment":2069,"conditions":12602,"interventions":12603},"NCT01725230","Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib",[90],[7267],[12604,5887,12588],"Fostamatinib",{"nctId":6272,"briefTitle":6273,"status":108,"phases":12606,"primaryCompletion":4837,"completion":337,"start":6178,"enrollment":6275,"conditions":12607,"interventions":12608},[90],[157],[1959,2198,6278,6279,5887,1352],{"nctId":12610,"briefTitle":12611,"status":195,"phases":12612,"primaryCompletion":12613,"completion":12613,"start":7696,"enrollment":2260,"conditions":12614,"interventions":12615},"NCT06554821","A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants",[90],"2024-10-08",[5851],[5887,12616],"Ticagrelor",{"nctId":6897,"briefTitle":6898,"status":195,"phases":12618,"primaryCompletion":6900,"completion":6900,"start":3438,"enrollment":6901,"conditions":12619,"interventions":12620},[90],[6903],[6860,6905,5887,6906],{"nctId":12622,"briefTitle":12623,"status":195,"phases":12624,"primaryCompletion":1497,"completion":1497,"start":12625,"enrollment":579,"conditions":12626,"interventions":12627},"NCT05395117","A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin",[90],"2022-06-30",[5851],[2281,5870,5887,2198],{"nctId":5881,"briefTitle":5882,"status":195,"phases":12629,"primaryCompletion":5884,"completion":5884,"start":1794,"enrollment":5876,"conditions":12630,"interventions":12631},[90],[5851],[119,5887],{"nctId":12633,"briefTitle":12634,"status":195,"phases":12635,"primaryCompletion":12636,"completion":12636,"start":12637,"enrollment":2069,"conditions":12638,"interventions":12639},"NCT03019549","A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin",[90],"2017-05-22","2017-01-12",[19],[12640,5887],"Lanabecestat",{"nctId":12642,"briefTitle":12643,"status":151,"phases":12644,"primaryCompletion":12645,"completion":12645,"start":12646,"enrollment":1448,"conditions":12647,"interventions":12648},"NCT07534592","A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants",[90],"2026-09-18","2026-04-16",[5851],[12649,12587,5887],"Elecoglipron",{"nctId":12651,"briefTitle":12652,"status":195,"phases":12653,"primaryCompletion":7544,"start":4915,"enrollment":2045,"conditions":12654,"interventions":12655},"NCT00808678","Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium",[90],[19],[12566,12567,12551],{"nctId":12657,"briefTitle":12658,"status":195,"phases":12659,"primaryCompletion":2086,"completion":2086,"start":6710,"enrollment":1543,"conditions":12660,"interventions":12662},"NCT00585143","Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly",[90],[12661],"Dyslipidemia, Renal Insufficiency",[12567,5887],{"nctId":6932,"briefTitle":6933,"status":195,"phases":12664,"primaryCompletion":6935,"completion":6935,"start":5416,"enrollment":486,"conditions":12665,"interventions":12666},[90],[6903],[6860,5887],{"nctId":6939,"briefTitle":6940,"status":195,"phases":12668,"primaryCompletion":6942,"completion":6942,"start":6207,"enrollment":6943,"conditions":12669,"interventions":12670},[90],[6903],[6860,6860,6860,5887],{"nctId":12672,"briefTitle":12673,"status":195,"phases":12674,"primaryCompletion":12675,"completion":12675,"start":12676,"enrollment":1757,"conditions":12677,"interventions":12679},"NCT02963116","A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet",[90],"2017-03-01","2016-12-20",[12678],"High Risk Coronary Artery Disease",[12680,12681,5887],"AZD5718 IR","AZD5718 oral suspension",{"nctId":12683,"briefTitle":12684,"status":195,"phases":12685,"primaryCompletion":2414,"start":2414,"enrollment":2045,"conditions":12686,"interventions":12687},"NCT00826358","Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5\u002F45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg",[90],[19],[12566,12567,12551],{"trials":12689,"activeCount":122,"soonestReadout":3323},[12690,12697,12701],{"nctId":12691,"briefTitle":12692,"status":195,"phases":12693,"primaryCompletion":2152,"completion":2152,"start":9213,"enrollment":7536,"conditions":12694,"interventions":12696},"NCT00296400","Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease",[91],[12695],"Hyperlipidemia",[5887,12587],{"nctId":6949,"briefTitle":6950,"status":151,"phases":12698,"primaryCompletion":3323,"completion":3323,"start":6952,"enrollment":3093,"conditions":12699,"interventions":12700},[91],[6873],[6860,5887],{"nctId":12702,"briefTitle":12703,"status":195,"phases":12704,"primaryCompletion":2077,"completion":2077,"start":9213,"enrollment":12705,"conditions":12706,"interventions":12707},"NCT00296374","Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease",[91],353,[2631],[5887,5887,12587],{"trials":12709,"activeCount":102},[12710,12717,12727,12736,12744,12753,12762,12770,12778,12784,12791,12798,12805,12812,12820,12827,12836,12842,12849,12856,12864,12871,12879,12887,12895,12901,12910,12917,12926,12933,12942,12950,12959,12966],{"nctId":12711,"briefTitle":12712,"status":195,"phases":12713,"completion":6370,"start":6651,"enrollment":1300,"conditions":12714,"interventions":12716},"NCT00654446","IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin",[92],[12715],"Fredrickson Type IIa & Type IIb Dyslipidaemia",[5887,12588],{"nctId":12718,"briefTitle":12719,"status":195,"phases":12720,"primaryCompletion":12721,"completion":12721,"start":2524,"enrollment":12722,"conditions":12723,"interventions":12725},"NCT00680017","30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease",[92],"2011-04",280,[6903,12724],"Kidney Disease",[12726,5887],"ABT-335 plus rosuvastatin",{"nctId":12728,"briefTitle":12729,"status":195,"phases":12730,"completion":6499,"start":12731,"enrollment":12722,"conditions":12732,"interventions":12735},"NCT00657527","Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease",[92],"2001-12",[12733,12734],"Myocardial Ischaemia","Coronary Artery Disease",[5887],{"nctId":12737,"briefTitle":12738,"status":195,"phases":12739,"completion":9944,"start":12740,"enrollment":12741,"conditions":12742,"interventions":12743},"NCT00654303","OLE Study to Evaluate Safety \u002F Efficacy of ZD4522",[92],"1999-08",3500,[9308],[5887],{"nctId":12745,"briefTitle":12746,"status":195,"phases":12747,"primaryCompletion":12748,"completion":12748,"start":12749,"enrollment":12750,"conditions":12751,"interventions":12752},"NCT02546323","A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis",[92],"2019-01-29","2015-09-17",543,[12540],[5887],{"nctId":12754,"briefTitle":12755,"status":195,"phases":12756,"completion":4306,"start":12757,"enrollment":12758,"conditions":12759,"interventions":12761},"NCT00379249","Rosuvastatin ORBITAL Germany",[92],"2002-02",8000,[12760],"Hypercholesterolemia",[5887],{"nctId":12763,"briefTitle":12764,"status":195,"phases":12765,"primaryCompletion":2328,"completion":2328,"start":9944,"enrollment":1710,"conditions":12766,"interventions":12768},"NCT00214604","Type III Dysbetalipoproteinemia",[92],[12767],"Hyperlipoproteinemia Type III",[5887,12551,12769],"pravastatin",{"nctId":12771,"briefTitle":12772,"status":195,"phases":12773,"primaryCompletion":2542,"completion":2542,"start":6710,"enrollment":12774,"conditions":12775,"interventions":12777},"NCT00620542","CRESTOR Athero Imaging Head to Head IVUS Study",[92],2333,[12776],"Coronary Atherosclerosis",[5887,12587],{"nctId":12779,"briefTitle":12780,"status":195,"phases":12781,"completion":9963,"start":9901,"enrollment":9987,"conditions":12782,"interventions":12783},"NCT00329173","PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.",[92],[9308],[5887,12587],{"nctId":12785,"briefTitle":12786,"status":195,"phases":12787,"completion":6650,"start":6445,"conditions":12788,"interventions":12790},"NCT00653445","Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg",[92],[12760,12789,12540],"Coronary Heart Disease",[5887,6905],{"nctId":12792,"briefTitle":12793,"status":195,"phases":12794,"completion":4285,"start":7447,"enrollment":12795,"conditions":12796,"interventions":12797},"NCT00654173","Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)",[92],4444,[12760],[5887,12588,12587],{"nctId":12799,"briefTitle":12800,"status":195,"phases":12801,"completion":5796,"start":7448,"enrollment":12802,"conditions":12803,"interventions":12804},"NCT00654225","Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)",[92],2340,[12760,6873],[5887,12587],{"nctId":12806,"briefTitle":12807,"status":195,"phases":12808,"primaryCompletion":2068,"completion":2068,"start":2221,"enrollment":12809,"conditions":12810,"interventions":12811},"NCT00683618","Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia",[92],934,[12760],[5887,12587],{"nctId":12813,"briefTitle":12814,"status":195,"phases":12815,"primaryCompletion":9944,"completion":9944,"start":4256,"enrollment":12816,"conditions":12817,"interventions":12819},"NCT00239330","Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy",[92],824,[12818],"Hypercholesteremia",[5887,12587],{"nctId":12821,"briefTitle":12822,"status":195,"phases":12823,"primaryCompletion":2329,"completion":2328,"start":4256,"enrollment":12824,"conditions":12825,"interventions":12826},"NCT00241488","DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia",[92],1362,[12760],[5887],{"nctId":12828,"briefTitle":12829,"status":195,"phases":12830,"completion":3990,"start":12831,"enrollment":12832,"conditions":12833,"interventions":12834},"NCT00654537","STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges",[92],"2001-04",5625,[12760],[5887,12587,12835,12588],"Pravastatin",{"nctId":12837,"briefTitle":12838,"status":195,"phases":12839,"completion":4285,"start":9909,"conditions":12840,"interventions":12841},"NCT00653588","Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks",[92],[12760,12789],[5887,12587],{"nctId":12843,"briefTitle":12844,"status":195,"phases":12845,"primaryCompletion":2086,"completion":2086,"start":12846,"enrollment":269,"conditions":12847,"interventions":12848},"NCT00240279","The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study",[92],"2003-01",[12760],[5887],{"nctId":12850,"briefTitle":12851,"status":195,"phases":12852,"primaryCompletion":3827,"completion":3827,"start":5725,"enrollment":12853,"conditions":12854,"interventions":12855},"NCT00525824","12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe",[92],1743,[12760,12789,12540],[5887,6905,12588],{"nctId":12857,"briefTitle":12858,"status":195,"phases":12859,"completion":9963,"start":12860,"enrollment":1685,"conditions":12861,"interventions":12863},"NCT00654394","Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects",[92],"2000-01",[12862,12760],"Carotid Artery Stenosis",[5887],{"nctId":12865,"briefTitle":12866,"status":195,"phases":12867,"completion":7494,"start":6370,"enrollment":520,"conditions":12868,"interventions":12870},"NCT00240305","A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome",[92],[12869,6903],"Metabolic Syndrome",[5887],{"nctId":12872,"briefTitle":12873,"status":195,"phases":12874,"primaryCompletion":3827,"completion":3827,"start":9066,"enrollment":12875,"conditions":12876,"interventions":12878},"NCT00800800","Effects of Rosuvastatin on Aortic Stenosis Progression",[92],378,[12877],"Aortic Stenosis",[5887],{"nctId":12880,"briefTitle":12881,"status":195,"phases":12882,"completion":9944,"start":12883,"enrollment":12884,"conditions":12885,"interventions":12886},"NCT00654485","COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects",[92],"2002-05",940,[12869],[5887,12587],{"nctId":12888,"briefTitle":12889,"status":195,"phases":12890,"completion":4285,"start":12891,"enrollment":12892,"conditions":12893,"interventions":12894},"NCT00654407","Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia",[92],"2001-11",4875,[12760],[5887,12587,12588],{"nctId":12896,"briefTitle":12897,"status":195,"phases":12898,"primaryCompletion":4264,"completion":9986,"start":6563,"enrollment":520,"conditions":12899,"interventions":12900},"NCT00240266","Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)",[92],[12869,6903],[5887],{"nctId":12902,"briefTitle":12903,"status":195,"phases":12904,"primaryCompletion":2507,"completion":2507,"start":12905,"enrollment":12906,"conditions":12907,"interventions":12909},"NCT00355615","PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin",[92],"2006-07",173,[12908],"Familial Hypercholesterolemia",[5887],{"nctId":12911,"briefTitle":12912,"status":195,"phases":12913,"completion":4264,"start":12757,"enrollment":12914,"conditions":12915,"interventions":12916},"NCT00654602","48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety",[92],1500,[6873],[5887],{"nctId":12918,"briefTitle":12919,"status":624,"phases":12920,"primaryCompletion":2443,"completion":2443,"start":2433,"enrollment":12921,"conditions":12922,"interventions":12925},"NCT01164540","Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis",[92],3000,[12923,12924],"Venous Thrombosis","Pulmonary Embolism",[5887],{"nctId":12927,"briefTitle":12928,"status":195,"phases":12929,"completion":2252,"start":4306,"enrollment":1448,"conditions":12930,"interventions":12932},"NCT00228514","Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study",[92],[5887,1520,12931],"Positron Emission Tomography (PET)",[5887],{"nctId":12934,"briefTitle":12935,"status":195,"phases":12936,"completion":12937,"start":12938,"enrollment":12939,"conditions":12940,"interventions":12941},"NCT00653744","Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)",[92],"2004-03","2002-03",1700,[12760,6873],[5887,12587],{"nctId":12943,"briefTitle":12944,"status":195,"phases":12945,"completion":4297,"start":4284,"enrollment":12946,"conditions":12947,"interventions":12949},"NCT00296387","Effects in The ApoB\u002FApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome",[92],1160,[12948],"Acute Coronary Syndrome",[5887,12587],{"nctId":12951,"briefTitle":12952,"status":443,"phases":12953,"primaryCompletion":3827,"completion":3827,"start":12954,"enrollment":12955,"conditions":12956,"interventions":12958},"NCT00239681","JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events",[92],"2003-02",17802,[12957],"Elevated High-sensitivity C-Reactive Protein (hsCRP)",[5887],{"nctId":12960,"briefTitle":12961,"status":195,"phases":12962,"start":12954,"enrollment":12342,"conditions":12963,"interventions":12965},"NCT00240292","Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines",[92],[12964],"Heart Failure, Congestive",[5887],{"nctId":12967,"briefTitle":12968,"status":195,"phases":12969,"completion":9944,"start":4299,"enrollment":12921,"conditions":12970,"interventions":12971},"NCT00653965","Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)",[92],[12760,6873],[5887,12587],{"trials":12973,"activeCount":102},[12974,12982,12988,12996,13003,13010,13017,13027,13034],{"nctId":12975,"briefTitle":12976,"status":624,"phases":12977,"start":12757,"enrollment":12978,"conditions":12979,"interventions":12981},"NCT00396240","ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals",[93],1294,[12980],"Primary Hypercholesterolaemia",[5887],{"nctId":12983,"briefTitle":12984,"status":195,"phases":12985,"primaryCompletion":2151,"completion":2151,"start":2221,"enrollment":1748,"conditions":12986,"interventions":12987},"NCT00747149","A Diabetes Study to Treat A Population Previously Not at Target",[93],[31],[5887],{"nctId":12989,"briefTitle":12990,"status":195,"phases":12991,"primaryCompletion":2086,"completion":2086,"start":4297,"enrollment":12992,"conditions":12993,"interventions":12995},"NCT00631189","Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients",[93],668,[12994],"Type IIa and IIb Hypercholesterolaemia",[5887,12835,12587],{"nctId":12997,"briefTitle":12998,"status":443,"phases":12999,"primaryCompletion":2168,"completion":2168,"start":5742,"enrollment":2783,"conditions":13000,"interventions":13001},"NCT00427960","Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg",[93],[9308],[12551,13002],"atorvastatin",{"nctId":13004,"briefTitle":13005,"status":195,"phases":13006,"primaryCompletion":2212,"completion":2212,"start":4915,"enrollment":13007,"conditions":13008,"interventions":13009},"NCT00815659","Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome",[93],97,[12869],[12551],{"nctId":13011,"briefTitle":13012,"status":195,"phases":13013,"completion":13014,"start":9065,"enrollment":8955,"conditions":13015,"interventions":13016},"NCT00335699","Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome",[93],"2007-01",[12760],[5887],{"nctId":13018,"briefTitle":13019,"status":195,"phases":13020,"primaryCompletion":2095,"completion":2095,"start":13014,"enrollment":1034,"conditions":13021,"interventions":13026},"NCT00473655","Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients",[93],[13022,13023,13024,13025,12695],"Hypertriglyceridemia","Hyperlipoproteinemia Type IV","Hyperlipoproteinemia Type V","Hyperlipoproteinemia Type IIb",[12551],{"nctId":13028,"briefTitle":13029,"status":195,"phases":13030,"primaryCompletion":2524,"completion":2524,"start":5563,"enrollment":5947,"conditions":13031,"interventions":13033},"NCT00395486","ROMEO (Rosuvastatin in Metabolic syndrOme)",[93],[13032],"Metabolic Syndrome X",[5887,12587],{"nctId":13035,"briefTitle":13036,"status":195,"phases":13037,"primaryCompletion":2086,"completion":2086,"start":3809,"enrollment":3524,"conditions":13038,"interventions":13039},"NCT00329160","Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease",[93],[12818],[5887,13040],"HMG CoA inhibitor",{"trials":13042,"activeCount":102},[13043,13052],{"nctId":13044,"briefTitle":13045,"status":195,"phases":13046,"completion":13047,"start":4299,"conditions":13048,"interventions":13051},"NCT00660764","Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)",[],"2005-04",[12760,12789,13049,13050,2652],"Peripheral Vascular Disease","Cerebrovascular Accident",[5887],{"nctId":13053,"briefTitle":13054,"status":624,"phases":13055,"primaryCompletion":13056,"completion":13056,"start":13056,"enrollment":102,"conditions":13057,"interventions":13059},"NCT02561845","Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in PCI Patients",[],"2015-10",[13058],"PCI Patients",[12551],{"intervention":268,"totalTrials":2222,"cells":13061},{"EARLY_PHASE1":13062,"PHASE1":13064,"PHASE2":13096,"PHASE3":13117,"PHASE4":13140,"NA":13142},{"trials":13063,"activeCount":102},[],{"trials":13065,"activeCount":122,"soonestReadout":57},[13066,13072,13078,13082,13087],{"nctId":13067,"briefTitle":13068,"status":195,"phases":13069,"primaryCompletion":2243,"completion":12721,"start":2067,"enrollment":5876,"conditions":13070,"interventions":13071},"NCT00981721","A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies",[90],[157],[58],{"nctId":13073,"briefTitle":13074,"status":195,"phases":13075,"primaryCompletion":2320,"completion":2516,"start":2220,"enrollment":451,"conditions":13076,"interventions":13077},"NCT00750425","Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours",[90],[4217],[58],{"nctId":4228,"briefTitle":4229,"status":195,"phases":13079,"primaryCompletion":2056,"completion":2570,"start":2151,"enrollment":1638,"conditions":13080,"interventions":13081},[90],[172],[268,177,4233,177,121],{"nctId":55,"briefTitle":56,"status":108,"phases":13083,"primaryCompletion":57,"completion":660,"start":13084,"enrollment":4307,"conditions":13085,"interventions":13086},[90],"2008-09-09",[3056],[58],{"nctId":13088,"briefTitle":13089,"status":195,"phases":13090,"primaryCompletion":4915,"completion":4915,"start":2415,"enrollment":5876,"conditions":13091,"interventions":13094},"NCT00503204","Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour",[90],[13092,13093],"Recurrent Glioblastoma","Brain Tumor",[268,13095],"Lomustine",{"trials":13097,"activeCount":122,"soonestReadout":257},[13098,13106,13113],{"nctId":13099,"briefTitle":13100,"status":195,"phases":13101,"primaryCompletion":2580,"completion":13102,"start":13014,"enrollment":1428,"conditions":13103,"interventions":13104},"NCT00423332","Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma",[91],"2016-10",[417],[268,13105],"Cediranib Placebo",{"nctId":13107,"briefTitle":13108,"status":195,"phases":13109,"primaryCompletion":6710,"completion":3827,"start":6562,"enrollment":477,"conditions":13110,"interventions":13111},"NCT00306891","Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)",[91],[556],[268,13112],"Cediranib 30 - 90 mg",{"nctId":254,"briefTitle":255,"status":108,"phases":13114,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":13115,"interventions":13116},[91],[262],[117,264,265,266,267,251,97,268],{"trials":13118,"activeCount":102},[13119,13127,13136],{"nctId":13120,"briefTitle":13121,"status":195,"phases":13122,"primaryCompletion":2212,"completion":13123,"start":7342,"enrollment":13124,"conditions":13125,"interventions":13126},"NCT00399035","Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer",[92],"2016-08",1254,[5121],[268,4774,4775,13105],{"nctId":13128,"briefTitle":13129,"status":195,"phases":13130,"primaryCompletion":2113,"completion":13131,"start":2086,"enrollment":13132,"conditions":13133,"interventions":13134},"NCT00777153","Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma",[92],"2016-09",423,[13092],[268,268,13135],"Lomustine Chemotherapy",{"nctId":5698,"briefTitle":5699,"status":195,"phases":13137,"primaryCompletion":5701,"completion":5702,"start":5703,"enrollment":5704,"conditions":13138,"interventions":13139},[91,92],[691],[268,239,296,4843,175],{"trials":13141,"activeCount":102},[],{"trials":13143,"activeCount":102},[],{"intervention":13145,"totalTrials":370,"cells":13146},"AZD2389",{"EARLY_PHASE1":13147,"PHASE1":13149,"PHASE2":13203,"PHASE3":13218,"PHASE4":13220,"NA":13222},{"trials":13148,"activeCount":102},[],{"trials":13150,"activeCount":122,"soonestReadout":13197},[13151,13161,13169,13176,13185,13193],{"nctId":13152,"briefTitle":13153,"status":195,"phases":13154,"primaryCompletion":13155,"completion":13155,"start":13156,"enrollment":486,"conditions":13157,"interventions":13159},"NCT06974565","A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine",[90],"2025-07-18","2025-05-12",[13158,5851],"Advanced Chronic Liver Disease",[13145,13160],"Quinidine",{"nctId":13162,"briefTitle":13163,"status":195,"phases":13164,"primaryCompletion":13165,"completion":13165,"start":13166,"enrollment":486,"conditions":13167,"interventions":13168},"NCT06846528","A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants",[90],"2025-04-23","2025-02-26",[5851],[13145,5911],{"nctId":13170,"briefTitle":13171,"status":195,"phases":13172,"primaryCompletion":13173,"completion":13173,"start":484,"enrollment":1348,"conditions":13174,"interventions":13175},"NCT06812780","A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389",[90],"2025-09-04",[6914],[13145],{"nctId":13177,"briefTitle":13178,"status":195,"phases":13179,"primaryCompletion":13155,"completion":13155,"start":13180,"enrollment":486,"conditions":13181,"interventions":13182},"NCT06973005","A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants",[90],"2025-05-08",[13158,5851],[13145,5870,13183,13184],"Caffeine","Bupropion",{"nctId":13186,"briefTitle":13187,"status":195,"phases":13188,"primaryCompletion":13189,"completion":13189,"start":13190,"enrollment":2187,"conditions":13191,"interventions":13192},"NCT06138795","A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants",[90],"2025-08-24","2023-11-20",[5851],[13145],{"nctId":13194,"briefTitle":13195,"status":151,"phases":13196,"primaryCompletion":13197,"completion":13197,"start":13198,"enrollment":1757,"conditions":13199,"interventions":13202},"NCT07069725","The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.",[90],"2026-07-13","2025-05-26",[13200,13201],"Liver Fibrosis","Hepatic Cirrhosis",[13145],{"trials":13204,"activeCount":122,"soonestReadout":5397},[13205,13212],{"nctId":13206,"briefTitle":13207,"status":151,"phases":13208,"primaryCompletion":5397,"completion":5397,"start":13209,"enrollment":4877,"conditions":13210,"interventions":13211},"NCT07610837","Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis",[91],"2026-05-07",[13200,13201],[13145],{"nctId":13213,"briefTitle":13214,"status":195,"phases":13215,"primaryCompletion":1794,"completion":1794,"start":6979,"enrollment":1448,"conditions":13216,"interventions":13217},"NCT06750276","A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.",[91],[13200,13201],[13145],{"trials":13219,"activeCount":102},[],{"trials":13221,"activeCount":102},[],{"trials":13223,"activeCount":102},[],{"intervention":13225,"totalTrials":723,"cells":13226},"AZD7798",{"EARLY_PHASE1":13227,"PHASE1":13229,"PHASE2":13258,"PHASE3":13277,"PHASE4":13279,"NA":13281},{"trials":13228,"activeCount":102},[],{"trials":13230,"activeCount":102},[13231,13240,13249],{"nctId":13232,"briefTitle":13233,"status":195,"phases":13234,"primaryCompletion":12613,"completion":12613,"start":13235,"enrollment":963,"conditions":13236,"interventions":13238},"NCT06053424","Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease",[90],"2023-09-25",[13237],"Crohn's Disease",[13225,13239],"[11C]AZ14132516",{"nctId":13241,"briefTitle":13242,"status":195,"phases":13243,"primaryCompletion":13244,"completion":4151,"start":13245,"enrollment":8138,"conditions":13246,"interventions":13248},"NCT05452304","AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease",[90],"2024-11-14","2022-07-12",[1556,13247],"Crohns Disease",[13225],{"nctId":13250,"briefTitle":13251,"status":195,"phases":13252,"primaryCompletion":13253,"completion":13253,"start":13254,"enrollment":4343,"conditions":13255,"interventions":13257},"NCT06432764","Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.",[90],"2026-03-27","2024-10-16",[13256],"Crohn Disease",[13225,13239],{"trials":13259,"activeCount":447,"soonestReadout":337},[13260,13268],{"nctId":13261,"briefTitle":13262,"status":108,"phases":13263,"primaryCompletion":337,"completion":1170,"start":13264,"enrollment":2187,"conditions":13265,"interventions":13267},"NCT06450197","Phase IIa Study Evaluating AZD7798 in Crohn's Disease",[91],"2024-08-28",[13266],"Moderate to Severe Crohn's Disease",[13225],{"nctId":13269,"briefTitle":13270,"status":108,"phases":13271,"primaryCompletion":13272,"completion":13273,"start":13274,"enrollment":1130,"conditions":13275,"interventions":13276},"NCT06681324","Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy",[91],"2026-08-20","2027-09-03","2024-12-11",[13237],[13225],{"trials":13278,"activeCount":102},[],{"trials":13280,"activeCount":102},[],{"trials":13282,"activeCount":102},[],{"intervention":13284,"totalTrials":3887,"cells":13285},"AZD0292",{"EARLY_PHASE1":13286,"PHASE1":13288,"PHASE2":13306,"PHASE3":13318,"PHASE4":13320,"NA":13322},{"trials":13287,"activeCount":102},[],{"trials":13289,"activeCount":122,"soonestReadout":13302},[13290,13298],{"nctId":13291,"briefTitle":13292,"status":195,"phases":13293,"primaryCompletion":13294,"completion":13294,"start":13295,"enrollment":579,"conditions":13296,"interventions":13297},"NCT06311760","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants",[90],"2025-02-20","2024-04-09",[1122],[13284],{"nctId":13299,"briefTitle":13300,"status":108,"phases":13301,"primaryCompletion":13302,"completion":13302,"start":13303,"enrollment":1336,"conditions":13304,"interventions":13305},"NCT07222254","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants",[90],"2026-07-20","2025-12-12",[5851],[13284],{"trials":13307,"activeCount":122,"soonestReadout":13312},[13308],{"nctId":13309,"briefTitle":13310,"status":151,"phases":13311,"primaryCompletion":13312,"completion":7927,"start":13313,"enrollment":13314,"conditions":13315,"interventions":13317},"NCT07088926","A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization",[91],"2027-12-09","2025-11-06",435,[13316],"Bronchiectasis With Pseudomonas Aeruginosa Colonization",[13284],{"trials":13319,"activeCount":102},[],{"trials":13321,"activeCount":102},[],{"trials":13323,"activeCount":102},[],{"intervention":981,"totalTrials":447,"cells":13325},{"EARLY_PHASE1":13326,"PHASE1":13328,"PHASE2":13334,"PHASE3":13344,"PHASE4":13346,"NA":13348},{"trials":13327,"activeCount":102},[],{"trials":13329,"activeCount":122,"soonestReadout":973},[13330],{"nctId":970,"briefTitle":971,"status":108,"phases":13331,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":13332,"interventions":13333},[90],[977],[252,117,344,979,980,981],{"trials":13335,"activeCount":122,"soonestReadout":10184},[13336],{"nctId":13337,"briefTitle":13338,"status":108,"phases":13339,"primaryCompletion":10184,"completion":13340,"start":13341,"enrollment":12505,"conditions":13342,"interventions":13343},"NCT04931654","A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer",[90,91],"2026-08-12","2021-09-28",[992,172,4612],[981],{"trials":13345,"activeCount":102},[],{"trials":13347,"activeCount":102},[],{"trials":13349,"activeCount":102},[],{"intervention":1038,"totalTrials":447,"cells":13351},{"EARLY_PHASE1":13352,"PHASE1":13354,"PHASE2":13356,"PHASE3":13366,"PHASE4":13368,"NA":13370},{"trials":13353,"activeCount":102},[],{"trials":13355,"activeCount":102},[],{"trials":13357,"activeCount":447,"soonestReadout":1032},[13358,13362],{"nctId":4999,"briefTitle":5000,"status":151,"phases":13359,"primaryCompletion":5002,"completion":5002,"start":5003,"enrollment":5004,"conditions":13360,"interventions":13361},[90,91],[510,5006,5007,5008,5009,5010,5011],[1038,178],{"nctId":1029,"briefTitle":1030,"status":151,"phases":13363,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":13364,"interventions":13365},[90,91],[1036],[1038,252],{"trials":13367,"activeCount":102},[],{"trials":13369,"activeCount":102},[],{"trials":13371,"activeCount":102},[],{"intervention":13373,"totalTrials":447,"cells":13374},"AZD5492",{"EARLY_PHASE1":13375,"PHASE1":13377,"PHASE2":13388,"PHASE3":13399,"PHASE4":13401,"NA":13403},{"trials":13376,"activeCount":102},[],{"trials":13378,"activeCount":122,"soonestReadout":13383},[13379],{"nctId":13380,"briefTitle":13381,"status":151,"phases":13382,"primaryCompletion":13383,"completion":13384,"start":13385,"enrollment":132,"conditions":13386,"interventions":13387},"NCT06916806","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.",[90],"2027-05-05","2027-09-15","2025-05-01",[1140,7901,7267],[13373],{"trials":13389,"activeCount":122,"soonestReadout":13394},[13390],{"nctId":13391,"briefTitle":13392,"status":151,"phases":13393,"primaryCompletion":13394,"completion":13394,"start":13395,"enrollment":1935,"conditions":13396,"interventions":13398},"NCT06542250","A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R\u002FR B-Cell Malignancies.",[90,91],"2028-02-14","2024-09-18",[13397],"B-cell Malignancies",[13373],{"trials":13400,"activeCount":102},[],{"trials":13402,"activeCount":102},[],{"trials":13404,"activeCount":102},[],{"intervention":13406,"totalTrials":447,"cells":13407},"AZD7760",{"EARLY_PHASE1":13408,"PHASE1":13410,"PHASE2":13420,"PHASE3":13430,"PHASE4":13432,"NA":13434},{"trials":13409,"activeCount":102},[],{"trials":13411,"activeCount":122,"soonestReadout":13416},[13412],{"nctId":13413,"briefTitle":13414,"status":1097,"phases":13415,"primaryCompletion":13416,"completion":13416,"start":1426,"enrollment":1336,"conditions":13417,"interventions":13419},"NCT07612813","A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults",[90],"2027-09-24",[13418],"Staphylococcus Aureus Bloodstream Infection",[13406],{"trials":13421,"activeCount":122,"soonestReadout":1840},[13422],{"nctId":13423,"briefTitle":13424,"status":151,"phases":13425,"primaryCompletion":1840,"completion":13426,"start":11428,"enrollment":6171,"conditions":13427,"interventions":13429},"NCT06749457","A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)",[90,91],"2027-09-09",[13428],"Staphylococcus Aureus",[13406],{"trials":13431,"activeCount":102},[],{"trials":13433,"activeCount":102},[],{"trials":13435,"activeCount":102},[],{"intervention":3233,"totalTrials":447,"cells":13437},{"EARLY_PHASE1":13438,"PHASE1":13440,"PHASE2":13442,"PHASE3":13452,"PHASE4":13454,"NA":13456},{"trials":13439,"activeCount":102},[],{"trials":13441,"activeCount":102},[],{"trials":13443,"activeCount":447,"soonestReadout":1964},[13444,13448],{"nctId":3224,"briefTitle":3225,"status":151,"phases":13445,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":13446,"interventions":13447},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"nctId":3275,"briefTitle":3276,"status":108,"phases":13449,"primaryCompletion":1964,"completion":130,"start":3278,"enrollment":3279,"conditions":13450,"interventions":13451},[91],[3281],[3233,117,283,3097],{"trials":13453,"activeCount":102},[],{"trials":13455,"activeCount":102},[],{"trials":13457,"activeCount":102},[],{"intervention":266,"totalTrials":447,"cells":13459},{"EARLY_PHASE1":13460,"PHASE1":13462,"PHASE2":13468,"PHASE3":13474,"PHASE4":13476,"NA":13478},{"trials":13461,"activeCount":102},[],{"trials":13463,"activeCount":122,"soonestReadout":562},[13464],{"nctId":559,"briefTitle":560,"status":108,"phases":13465,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":13466,"interventions":13467},[90],[567],[569,82,267,570,266,571,68],{"trials":13469,"activeCount":122,"soonestReadout":257},[13470],{"nctId":254,"briefTitle":255,"status":108,"phases":13471,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":13472,"interventions":13473},[91],[262],[117,264,265,266,267,251,97,268],{"trials":13475,"activeCount":102},[],{"trials":13477,"activeCount":102},[],{"trials":13479,"activeCount":102},[],{"intervention":264,"totalTrials":447,"cells":13481},{"EARLY_PHASE1":13482,"PHASE1":13484,"PHASE2":13490,"PHASE3":13496,"PHASE4":13498,"NA":13500},{"trials":13483,"activeCount":102},[],{"trials":13485,"activeCount":122,"soonestReadout":3122},[13486],{"nctId":3119,"briefTitle":3120,"status":108,"phases":13487,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":13488,"interventions":13489},[90],[3127],[117,264,251,980,345,344,283,177,3097,979],{"trials":13491,"activeCount":122,"soonestReadout":257},[13492],{"nctId":254,"briefTitle":255,"status":108,"phases":13493,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":13494,"interventions":13495},[91],[262],[117,264,265,266,267,251,97,268],{"trials":13497,"activeCount":102},[],{"trials":13499,"activeCount":102},[],{"trials":13501,"activeCount":102},[],{"intervention":13503,"totalTrials":447,"cells":13504},"AZD5851",{"EARLY_PHASE1":13505,"PHASE1":13507,"PHASE2":13509,"PHASE3":13519,"PHASE4":13521,"NA":13523},{"trials":13506,"activeCount":102},[],{"trials":13508,"activeCount":102},[],{"trials":13510,"activeCount":122,"soonestReadout":13515},[13511],{"nctId":13512,"briefTitle":13513,"status":108,"phases":13514,"primaryCompletion":13515,"completion":13515,"start":5144,"enrollment":13516,"conditions":13517,"interventions":13518},"NCT06084884","A Phase I\u002FII Study to Evaluate AZD5851 in GPC3+ Advanced\u002FRecurrent Hepatocellular Carcinoma",[90,91],"2027-12-13",94,[3220],[13503],{"trials":13520,"activeCount":102},[],{"trials":13522,"activeCount":102},[],{"trials":13524,"activeCount":122,"soonestReadout":13529},[13525],{"nctId":13526,"briefTitle":13527,"status":1097,"phases":13528,"primaryCompletion":13529,"completion":13529,"start":13530,"enrollment":4307,"conditions":13531,"interventions":13532},"NCT06194461","LTFU for All Cell and Gene Therapy Studies",[],"2041-11-29","2025-09-17",[3220,416],[13503,12520],{"intervention":12520,"totalTrials":447,"cells":13534},{"EARLY_PHASE1":13535,"PHASE1":13537,"PHASE2":13539,"PHASE3":13545,"PHASE4":13547,"NA":13549},{"trials":13536,"activeCount":102},[],{"trials":13538,"activeCount":102},[],{"trials":13540,"activeCount":122,"soonestReadout":12517},[13541],{"nctId":12514,"briefTitle":12515,"status":151,"phases":13542,"primaryCompletion":12517,"completion":12517,"start":7756,"enrollment":477,"conditions":13543,"interventions":13544},[90,91],[1937],[12520,6672],{"trials":13546,"activeCount":102},[],{"trials":13548,"activeCount":102},[],{"trials":13550,"activeCount":122,"soonestReadout":13529},[13551],{"nctId":13526,"briefTitle":13527,"status":1097,"phases":13552,"primaryCompletion":13529,"completion":13529,"start":13530,"enrollment":4307,"conditions":13553,"interventions":13554},[],[3220,416],[13503,12520],{"intervention":1013,"totalTrials":1864,"cells":13556},{"EARLY_PHASE1":13557,"PHASE1":13559,"PHASE2":13587,"PHASE3":13720,"PHASE4":13777,"NA":13805},{"trials":13558,"activeCount":102},[],{"trials":13560,"activeCount":102},[13561,13565,13571,13579],{"nctId":3806,"briefTitle":3807,"status":195,"phases":13562,"completion":3809,"start":3810,"enrollment":3811,"conditions":13563,"interventions":13564},[90],[3813],[1013,344,118],{"nctId":13566,"briefTitle":13567,"status":195,"phases":13568,"primaryCompletion":2350,"completion":2350,"start":4306,"enrollment":1710,"conditions":13569,"interventions":13570},"NCT00681967","Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer",[90],[408],[1013,1013],{"nctId":13572,"briefTitle":13573,"status":195,"phases":13574,"completion":6562,"start":13575,"enrollment":496,"conditions":13576,"interventions":13578},"NCT00255489","A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer",[90],"2004-05",[13577],"Non-small-cell Lung Cancer",[1013],{"nctId":13580,"briefTitle":13581,"status":195,"phases":13582,"completion":6710,"start":13583,"enrollment":4928,"conditions":13584,"interventions":13586},"NCT00127829","Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic",[90],"2005-07",[13585],"Tumors",[1013],{"trials":13588,"activeCount":122,"soonestReadout":1007},[13589,13595,13601,13605,13609,13613,13619,13625,13631,13635,13639,13645,13649,13656,13662,13666,13672,13679,13685,13692,13696,13700,13704,13708,13712,13716],{"nctId":13590,"briefTitle":13591,"status":195,"phases":13592,"completion":6517,"start":6572,"enrollment":754,"conditions":13593,"interventions":13594},"NCT00255463","Phase II Neoadjuvant ER+\u002FPgR + Arimidex +\u002F- Iressa Study",[91],[25],[6463,1013],{"nctId":13596,"briefTitle":13597,"status":195,"phases":13598,"completion":2675,"start":12846,"enrollment":1395,"conditions":13599,"interventions":13600},"NCT00265070","Trial of Iressa in Prostate Cancer Patients",[91],[416],[1013],{"nctId":9210,"briefTitle":9211,"status":195,"phases":13602,"completion":9213,"start":8692,"enrollment":9214,"conditions":13603,"interventions":13604},[91],[6695],[1013,1051],{"nctId":7351,"briefTitle":7352,"status":195,"phases":13606,"primaryCompletion":7354,"completion":7354,"start":6572,"enrollment":1935,"conditions":13607,"interventions":13608},[91],[25],[1013,120],{"nctId":6647,"briefTitle":6648,"status":195,"phases":13610,"completion":6650,"start":6651,"enrollment":6652,"conditions":13611,"interventions":13612},[91],[25],[1013,369],{"nctId":13614,"briefTitle":13615,"status":195,"phases":13616,"completion":2329,"start":6445,"enrollment":477,"conditions":13617,"interventions":13618},"NCT00228488","Effect of Iressa With\u002FWithout Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma",[91],[408],[1013],{"nctId":13620,"briefTitle":13621,"status":195,"phases":13622,"completion":9944,"start":4331,"enrollment":5189,"conditions":13623,"interventions":13624},"NCT00637026","Ph II Early BC Pre-Surgical Biologic Study",[91],[25],[1013],{"nctId":13626,"briefTitle":13627,"status":195,"phases":13628,"primaryCompletion":6718,"completion":6718,"start":3990,"enrollment":12342,"conditions":13629,"interventions":13630},"NCT00239343","Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer",[91],[25],[4039],{"nctId":4253,"briefTitle":4254,"status":195,"phases":13632,"completion":2087,"start":4256,"enrollment":1448,"conditions":13633,"interventions":13634},[90,91],[4258],[1013,177],{"nctId":4261,"briefTitle":4262,"status":195,"phases":13636,"completion":2524,"start":4264,"enrollment":2289,"conditions":13637,"interventions":13638},[91],[4266],[4039,3803,1013],{"nctId":13640,"briefTitle":13641,"status":195,"phases":13642,"completion":3809,"start":9124,"enrollment":1710,"conditions":13643,"interventions":13644},"NCT00241475","Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy",[91],[416],[1013],{"nctId":9072,"briefTitle":9073,"status":195,"phases":13646,"primaryCompletion":5742,"completion":4005,"start":9075,"enrollment":9076,"conditions":13647,"interventions":13648},[91],[306],[1013,468],{"nctId":13650,"briefTitle":13651,"status":195,"phases":13652,"primaryCompletion":4298,"completion":4298,"start":2087,"enrollment":451,"conditions":13653,"interventions":13655},"NCT00344773","First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation",[91],[13654],"Pulmonary Cancer",[1013],{"nctId":13657,"briefTitle":13658,"status":624,"phases":13659,"start":4306,"enrollment":477,"conditions":13660,"interventions":13661},"NCT00252811","A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer",[91],[25],[1013],{"nctId":4281,"briefTitle":4282,"status":195,"phases":13663,"completion":4284,"start":4285,"enrollment":4286,"conditions":13664,"interventions":13665},[91],[262],[1013,177,1051],{"nctId":13667,"briefTitle":13668,"status":195,"phases":13669,"completion":3809,"start":12831,"enrollment":680,"conditions":13670,"interventions":13671},"NCT00632723","IRESSA™ (Gefitinib) in Breast Cancer Patients",[91],[25],[4039],{"nctId":13673,"briefTitle":13674,"status":195,"phases":13675,"completion":12954,"start":13676,"enrollment":221,"conditions":13677,"interventions":13678},"NCT00635856","Open Label Trial to Assess Iressa in Prostate Cancer Patients",[91],"2001-05",[416],[1013],{"nctId":13680,"briefTitle":13681,"status":195,"phases":13682,"completion":3839,"start":4285,"enrollment":2933,"conditions":13683,"interventions":13684},"NCT00298688","A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer",[91],[420],[1013],{"nctId":13686,"briefTitle":13687,"status":195,"phases":13688,"completion":2087,"start":12954,"enrollment":496,"conditions":13689,"interventions":13691},"NCT00238797","A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme",[91],[13690],"Glioblastoma",[1013],{"nctId":4294,"briefTitle":4295,"status":195,"phases":13693,"primaryCompletion":4297,"completion":4298,"start":4299,"enrollment":2811,"conditions":13694,"interventions":13695},[91],[403],[283,177,1013],{"nctId":5249,"briefTitle":5250,"status":195,"phases":13697,"primaryCompletion":5252,"completion":5252,"start":5253,"enrollment":579,"conditions":13698,"interventions":13699},[91],[5255],[1013,5257,5258,3137],{"nctId":4303,"briefTitle":4304,"status":195,"phases":13701,"completion":2252,"start":4306,"enrollment":4307,"conditions":13702,"interventions":13703},[91],[4309,4310],[4039,3803,4312],{"nctId":6674,"briefTitle":6675,"status":195,"phases":13705,"completion":6562,"start":4256,"enrollment":4928,"conditions":13706,"interventions":13707},[91],[115],[1013,369],{"nctId":3987,"briefTitle":3988,"status":195,"phases":13709,"completion":2524,"start":3990,"enrollment":3717,"conditions":13710,"interventions":13711},[91],[992],[1013,283,344],{"nctId":1004,"briefTitle":1005,"status":108,"phases":13713,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":13714,"interventions":13715},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"nctId":5793,"briefTitle":5794,"status":195,"phases":13717,"completion":5796,"start":5797,"enrollment":1864,"conditions":13718,"interventions":13719},[90,91],[415],[1013,283],{"trials":13721,"activeCount":102},[13722,13726,13730,13736,13740,13744,13748,13752,13759,13763,13770],{"nctId":6690,"briefTitle":6691,"status":195,"phases":13723,"primaryCompletion":3839,"completion":4297,"start":4306,"enrollment":6693,"conditions":13724,"interventions":13725},[92],[6695],[1013,369],{"nctId":4032,"briefTitle":4033,"status":4034,"phases":13727,"start":4036,"conditions":13728,"interventions":13729},[92],[3174],[672,4039,620],{"nctId":13731,"briefTitle":13732,"status":195,"phases":13733,"primaryCompletion":2328,"completion":6468,"start":4285,"enrollment":6143,"conditions":13734,"interventions":13735},"NCT00259064","Iressa v BSC (Best Supportive Care) in First Line NSCLC",[91,92],[1090],[1013],{"nctId":4074,"briefTitle":4075,"status":195,"phases":13737,"primaryCompletion":2251,"completion":2242,"start":2087,"enrollment":4077,"conditions":13738,"interventions":13739},[92],[262],[1013,344,118],{"nctId":4375,"briefTitle":4376,"status":195,"phases":13741,"primaryCompletion":4378,"completion":4379,"start":4380,"enrollment":4381,"conditions":13742,"interventions":13743},[92],[262],[1013,345,177],{"nctId":6715,"briefTitle":6716,"status":195,"phases":13745,"primaryCompletion":6718,"completion":2095,"start":6719,"enrollment":2640,"conditions":13746,"interventions":13747},[92],[1090],[1013,369],{"nctId":4389,"briefTitle":4390,"status":4034,"phases":13749,"start":4036,"conditions":13750,"interventions":13751},[92],[3174],[3803,4039,4394],{"nctId":13753,"briefTitle":13754,"status":195,"phases":13755,"primaryCompletion":13756,"completion":13756,"start":4876,"enrollment":1638,"conditions":13757,"interventions":13758},"NCT00357734","Iressa Follow-up Trial",[92],"2015-05",[3174,25],[1013],{"nctId":10324,"briefTitle":10325,"status":195,"phases":13760,"primaryCompletion":2415,"completion":2415,"start":9901,"enrollment":209,"conditions":13761,"interventions":13762},[92],[4111],[1013,10329],{"nctId":13764,"briefTitle":13765,"status":195,"phases":13766,"completion":13047,"start":4331,"enrollment":13767,"conditions":13768,"interventions":13769},"NCT00242801","Iressa vs Best Supportive Care - 2nd\u002F3rd Line Survival Study",[92],1692,[1090],[1013],{"nctId":13771,"briefTitle":13772,"status":195,"phases":13773,"completion":9075,"start":13774,"enrollment":221,"conditions":13775,"interventions":13776},"NCT00635973","Open-Label Extension of Other SZ1839 (Iressa) Trials",[92],"2000-02",[556],[1013],{"trials":13778,"activeCount":102},[13779,13783,13792,13798],{"nctId":6741,"briefTitle":6742,"status":443,"phases":13780,"primaryCompletion":2151,"completion":2151,"start":4297,"enrollment":1638,"conditions":13781,"interventions":13782},[93],[992],[1013,369],{"nctId":13784,"briefTitle":13785,"status":195,"phases":13786,"primaryCompletion":2105,"completion":13787,"start":3862,"enrollment":13788,"conditions":13789,"interventions":13791},"NCT01203917","Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC",[93],"2016-06",1060,[13790],"Caucasian Patients With EGFR Mutation Positive Advanced NSCLC",[1013],{"nctId":13793,"briefTitle":13794,"status":195,"phases":13795,"primaryCompletion":7544,"completion":7544,"start":13014,"enrollment":5531,"conditions":13796,"interventions":13797},"NCT00608868","SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients",[93],[3813],[1013],{"nctId":13799,"briefTitle":13800,"status":195,"phases":13801,"primaryCompletion":2516,"completion":2433,"start":3827,"enrollment":13802,"conditions":13803,"interventions":13804},"NCT00770588","Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB\u002FIV) Non Small Cell Lung Cancer (NSCLC)",[93],296,[1080],[1013],{"trials":13806,"activeCount":102},[],{"intervention":4774,"totalTrials":1979,"cells":13808},{"EARLY_PHASE1":13809,"PHASE1":13811,"PHASE2":13817,"PHASE3":13830,"PHASE4":13836,"NA":13838},{"trials":13810,"activeCount":102},[],{"trials":13812,"activeCount":102},[13813],{"nctId":4873,"briefTitle":4874,"status":195,"phases":13814,"primaryCompletion":2169,"completion":2542,"start":4876,"enrollment":4877,"conditions":13815,"interventions":13816},[90],[4879],[3830,4774,345,4615,369],{"trials":13818,"activeCount":122,"soonestReadout":4769},[13819,13826],{"nctId":13820,"briefTitle":13821,"status":195,"phases":13822,"primaryCompletion":2350,"completion":2105,"start":5562,"enrollment":13823,"conditions":13824,"interventions":13825},"NCT00494221","A Phase I\u002FII Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX",[90,91],172,[5121],[3830,4774],{"nctId":4766,"briefTitle":4767,"status":151,"phases":13827,"primaryCompletion":4769,"completion":4770,"start":4771,"enrollment":2640,"conditions":13828,"interventions":13829},[91],[172],[180,179,4774,4775,225,226,121],{"trials":13831,"activeCount":102},[13832],{"nctId":13120,"briefTitle":13121,"status":195,"phases":13833,"primaryCompletion":2212,"completion":13123,"start":7342,"enrollment":13124,"conditions":13834,"interventions":13835},[92],[5121],[268,4774,4775,13105],{"trials":13837,"activeCount":102},[],{"trials":13839,"activeCount":102},[],{"intervention":160,"totalTrials":3887,"cells":13841},{"EARLY_PHASE1":13842,"PHASE1":13844,"PHASE2":13846,"PHASE3":13860,"PHASE4":13872,"NA":13874},{"trials":13843,"activeCount":102},[],{"trials":13845,"activeCount":102},[],{"trials":13847,"activeCount":122,"soonestReadout":153},[13848,13852],{"nctId":149,"briefTitle":150,"status":151,"phases":13849,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":13850,"interventions":13851},[90,91],[157],[159,160,161,162,163],{"nctId":13853,"briefTitle":13854,"status":195,"phases":13855,"primaryCompletion":2415,"completion":13856,"start":12905,"enrollment":13857,"conditions":13858,"interventions":13859},"NCT00338130","Randomised Study to Compare the Efficacy of AZD6244 vs TMZ",[91],"2013-07",239,[410],[43,160],{"trials":13861,"activeCount":102},[13862],{"nctId":13863,"briefTitle":13864,"status":195,"phases":13865,"primaryCompletion":2144,"completion":2144,"start":2087,"enrollment":13866,"conditions":13867,"interventions":13868},"NCT00257205","CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy",[92],655,[410],[13869,13870,13871],"dacarbazine","CP-675,206","temozolomide",{"trials":13873,"activeCount":102},[],{"trials":13875,"activeCount":102},[],{"intervention":4775,"totalTrials":447,"cells":13877},{"EARLY_PHASE1":13878,"PHASE1":13880,"PHASE2":13882,"PHASE3":13888,"PHASE4":13894,"NA":13896},{"trials":13879,"activeCount":102},[],{"trials":13881,"activeCount":102},[],{"trials":13883,"activeCount":122,"soonestReadout":4769},[13884],{"nctId":4766,"briefTitle":4767,"status":151,"phases":13885,"primaryCompletion":4769,"completion":4770,"start":4771,"enrollment":2640,"conditions":13886,"interventions":13887},[91],[172],[180,179,4774,4775,225,226,121],{"trials":13889,"activeCount":102},[13890],{"nctId":13120,"briefTitle":13121,"status":195,"phases":13891,"primaryCompletion":2212,"completion":13123,"start":7342,"enrollment":13124,"conditions":13892,"interventions":13893},[92],[5121],[268,4774,4775,13105],{"trials":13895,"activeCount":102},[],{"trials":13897,"activeCount":102},[],{"intervention":12597,"totalTrials":1039,"cells":13899},{"EARLY_PHASE1":13900,"PHASE1":13902,"PHASE2":13938,"PHASE3":13950,"PHASE4":13952,"NA":13954},{"trials":13901,"activeCount":102},[],{"trials":13903,"activeCount":102},[13904,13911,13919,13923,13930],{"nctId":13905,"briefTitle":13906,"status":195,"phases":13907,"primaryCompletion":13908,"completion":13908,"start":13165,"enrollment":579,"conditions":13909,"interventions":13910},"NCT06948006","A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants",[90],"2025-06-27",[5851],[12597,8361],{"nctId":13912,"briefTitle":13913,"status":195,"phases":13914,"primaryCompletion":13915,"completion":13915,"start":13916,"enrollment":8185,"conditions":13917,"interventions":13918},"NCT06675175","A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.",[90],"2025-10-27","2024-12-09",[2134,6971],[12597],{"nctId":12591,"briefTitle":12592,"status":195,"phases":13920,"primaryCompletion":12594,"completion":12594,"start":1637,"enrollment":1757,"conditions":13921,"interventions":13922},[90],[19],[12597,5887],{"nctId":13924,"briefTitle":13925,"status":195,"phases":13926,"primaryCompletion":13165,"completion":13165,"start":4098,"enrollment":6275,"conditions":13927,"interventions":13929},"NCT06693765","A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants",[90],[2279,13928,5851],"End-stage Kidney Disease",[12597],{"nctId":13931,"briefTitle":13932,"status":195,"phases":13933,"primaryCompletion":13934,"completion":13934,"start":13935,"enrollment":2260,"conditions":13936,"interventions":13937},"NCT06942923","A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity",[90],"2025-09-29","2025-04-22",[5851],[12597],{"trials":13939,"activeCount":122,"soonestReadout":13944},[13940],{"nctId":13941,"briefTitle":13942,"status":151,"phases":13943,"primaryCompletion":13944,"completion":13944,"start":13945,"enrollment":617,"conditions":13946,"interventions":13949},"NCT07215702","A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.",[91],"2027-02-11","2026-02-10",[13947,13948],"Sepsis","Acute Kidney Injury",[12597],{"trials":13951,"activeCount":102},[],{"trials":13953,"activeCount":102},[],{"trials":13955,"activeCount":102},[],{"intervention":13957,"totalTrials":723,"cells":13958},"AZD6793",{"EARLY_PHASE1":13959,"PHASE1":13961,"PHASE2":13997,"PHASE3":14006,"PHASE4":14008,"NA":14010},{"trials":13960,"activeCount":102},[],{"trials":13962,"activeCount":102},[13963,13972,13980,13988],{"nctId":13964,"briefTitle":13965,"status":195,"phases":13966,"primaryCompletion":13967,"completion":13967,"start":13968,"enrollment":6454,"conditions":13969,"interventions":13971},"NCT05662033","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.",[90],"2024-10-29","2022-12-05",[13970],"Inflammatory Diseases",[13957],{"nctId":13973,"briefTitle":13974,"status":195,"phases":13975,"primaryCompletion":13976,"completion":13976,"start":13977,"enrollment":3190,"conditions":13978,"interventions":13979},"NCT06368440","A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants",[90],"2024-12-23","2024-05-15",[5851],[13957,13957],{"nctId":13981,"briefTitle":13982,"status":2744,"phases":13983,"primaryCompletion":4053,"completion":4053,"start":13984,"enrollment":2260,"conditions":13985,"interventions":13986},"NCT07433062","A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus",[90],"2026-01-14",[22],[13957,13987],"AZD6793 Placebo",{"nctId":13989,"briefTitle":13990,"status":195,"phases":13991,"primaryCompletion":13992,"completion":13992,"start":13993,"enrollment":4497,"conditions":13994,"interventions":13995},"NCT06494644","A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.",[90],"2024-10-05","2024-07-23",[5851],[13957,5911,13996],"AZD6793+ Itraconazole",{"trials":13998,"activeCount":122,"soonestReadout":14003},[13999],{"nctId":14000,"briefTitle":14001,"status":151,"phases":14002,"primaryCompletion":14003,"completion":14003,"start":13908,"enrollment":12946,"conditions":14004,"interventions":14005},"NCT07082738","A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",[91],"2027-11-05",[6083],[13957],{"trials":14007,"activeCount":102},[],{"trials":14009,"activeCount":102},[],{"trials":14011,"activeCount":102},[],{"intervention":14013,"totalTrials":3887,"cells":14014},"AZD5148",{"EARLY_PHASE1":14015,"PHASE1":14017,"PHASE2":14034,"PHASE3":14044,"PHASE4":14046,"NA":14048},{"trials":14016,"activeCount":102},[],{"trials":14018,"activeCount":102},[14019,14026],{"nctId":14020,"briefTitle":14021,"status":195,"phases":14022,"primaryCompletion":14023,"completion":14023,"start":7043,"enrollment":532,"conditions":14024,"interventions":14025},"NCT06469151","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults",[90],"2025-10-22",[5851],[14013],{"nctId":14027,"briefTitle":14028,"status":195,"phases":14029,"primaryCompletion":14030,"completion":14030,"start":3725,"enrollment":486,"conditions":14031,"interventions":14033},"NCT06639997","Safety and Tolerability of AZD5148 in Japanese Participants",[90],"2025-12-25",[14032],"Clostridioides Difficile Infection",[14013],{"trials":14035,"activeCount":122,"soonestReadout":7184},[14036],{"nctId":14037,"briefTitle":14038,"status":151,"phases":14039,"primaryCompletion":7184,"completion":14040,"start":14041,"enrollment":1719,"conditions":14042,"interventions":14043},"NCT07285213","Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody",[91],"2028-01-18","2025-12-10",[14032],[14013],{"trials":14045,"activeCount":102},[],{"trials":14047,"activeCount":102},[],{"trials":14049,"activeCount":102},[],{"intervention":3252,"totalTrials":3887,"cells":14051},{"EARLY_PHASE1":14052,"PHASE1":14054,"PHASE2":14069,"PHASE3":14075,"PHASE4":14077,"NA":14079},{"trials":14053,"activeCount":102},[],{"trials":14055,"activeCount":102},[14056,14065],{"nctId":14057,"briefTitle":14058,"status":195,"phases":14059,"primaryCompletion":14060,"completion":14061,"start":14062,"enrollment":132,"conditions":14063,"interventions":14064},"NCT02579226","A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.",[90],"2020-02-07","2020-04-03","2015-10-28",[498],[3252],{"nctId":8837,"briefTitle":8838,"status":443,"phases":14066,"primaryCompletion":5906,"completion":5906,"start":8840,"enrollment":4286,"conditions":14067,"interventions":14068},[90],[8842],[3252,8844,1377],{"trials":14070,"activeCount":122,"soonestReadout":3245},[14071],{"nctId":3242,"briefTitle":3243,"status":108,"phases":14072,"primaryCompletion":3245,"completion":3246,"start":3247,"enrollment":3248,"conditions":14073,"interventions":14074},[91],[3250],[117,3252,344,177,1017],{"trials":14076,"activeCount":102},[],{"trials":14078,"activeCount":102},[],{"trials":14080,"activeCount":102},[],{"intervention":14082,"totalTrials":447,"cells":14083},"AZD1163",{"EARLY_PHASE1":14084,"PHASE1":14086,"PHASE2":14095,"PHASE3":14106,"PHASE4":14108,"NA":14110},{"trials":14085,"activeCount":102},[],{"trials":14087,"activeCount":102},[14088],{"nctId":14089,"briefTitle":14090,"status":195,"phases":14091,"primaryCompletion":6388,"completion":6388,"start":14092,"enrollment":1373,"conditions":14093,"interventions":14094},"NCT06103877","A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers",[90],"2023-11-01",[36],[14082],{"trials":14096,"activeCount":122,"soonestReadout":14101},[14097],{"nctId":14098,"briefTitle":14099,"status":151,"phases":14100,"primaryCompletion":14101,"completion":14102,"start":14103,"enrollment":2562,"conditions":14104,"interventions":14105},"NCT07276581","A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis",[91],"2027-11-12","2028-08-18","2025-12-15",[7267],[14082],{"trials":14107,"activeCount":102},[],{"trials":14109,"activeCount":102},[],{"trials":14111,"activeCount":102},[],{"intervention":174,"totalTrials":447,"cells":14113},{"EARLY_PHASE1":14114,"PHASE1":14116,"PHASE2":14122,"PHASE3":14128,"PHASE4":14130,"NA":14132},{"trials":14115,"activeCount":102},[],{"trials":14117,"activeCount":102},[14118],{"nctId":526,"briefTitle":527,"status":195,"phases":14119,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":14120,"interventions":14121},[90],[498],[535,267,536,174,537],{"trials":14123,"activeCount":122,"soonestReadout":168},[14124],{"nctId":165,"briefTitle":166,"status":151,"phases":14125,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":14126,"interventions":14127},[91],[172],[174,121,117,175,176,97,177,178,179,180],{"trials":14129,"activeCount":102},[],{"trials":14131,"activeCount":102},[],{"trials":14133,"activeCount":102},[],{"intervention":14135,"totalTrials":122,"cells":14136},"Acalabrutinib + R-CHOP standard of care",{"EARLY_PHASE1":14137,"PHASE1":14139,"PHASE2":14141,"PHASE3":14154,"PHASE4":14156,"NA":14158},{"trials":14138,"activeCount":102},[],{"trials":14140,"activeCount":102},[],{"trials":14142,"activeCount":122,"soonestReadout":14147},[14143],{"nctId":14144,"briefTitle":14145,"status":151,"phases":14146,"primaryCompletion":14147,"completion":14148,"start":14149,"enrollment":2783,"conditions":14150,"interventions":14151},"NCT07029737","A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain",[91],"2027-06-15","2028-12-15","2025-09-05",[1463],[14135,14152,14153],"Acalabrutinib combination with Rituximab","Acalabrutinib monotherapy",{"trials":14155,"activeCount":102},[],{"trials":14157,"activeCount":102},[],{"trials":14159,"activeCount":102},[],{"intervention":14152,"totalTrials":122,"cells":14161},{"EARLY_PHASE1":14162,"PHASE1":14164,"PHASE2":14166,"PHASE3":14172,"PHASE4":14174,"NA":14176},{"trials":14163,"activeCount":102},[],{"trials":14165,"activeCount":102},[],{"trials":14167,"activeCount":122,"soonestReadout":14147},[14168],{"nctId":14144,"briefTitle":14145,"status":151,"phases":14169,"primaryCompletion":14147,"completion":14148,"start":14149,"enrollment":2783,"conditions":14170,"interventions":14171},[91],[1463],[14135,14152,14153],{"trials":14173,"activeCount":102},[],{"trials":14175,"activeCount":102},[],{"trials":14177,"activeCount":102},[],{"intervention":14153,"totalTrials":122,"cells":14179},{"EARLY_PHASE1":14180,"PHASE1":14182,"PHASE2":14184,"PHASE3":14190,"PHASE4":14192,"NA":14194},{"trials":14181,"activeCount":102},[],{"trials":14183,"activeCount":102},[],{"trials":14185,"activeCount":122,"soonestReadout":14147},[14186],{"nctId":14144,"briefTitle":14145,"status":151,"phases":14187,"primaryCompletion":14147,"completion":14148,"start":14149,"enrollment":2783,"conditions":14188,"interventions":14189},[91],[1463],[14135,14152,14153],{"trials":14191,"activeCount":102},[],{"trials":14193,"activeCount":102},[],{"trials":14195,"activeCount":102},[],{"intervention":14197,"totalTrials":122,"cells":14198},"AZD2373-Arm 1",{"EARLY_PHASE1":14199,"PHASE1":14201,"PHASE2":14203,"PHASE3":14215,"PHASE4":14217,"NA":14219},{"trials":14200,"activeCount":102},[],{"trials":14202,"activeCount":102},[],{"trials":14204,"activeCount":122,"soonestReadout":5202},[14205],{"nctId":14206,"briefTitle":14207,"status":151,"phases":14208,"primaryCompletion":5202,"completion":5202,"start":14209,"enrollment":14210,"conditions":14211,"interventions":14213},"NCT06824987","Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease",[91],"2025-03-05",96,[14212],"APOL1-Mediated Kidney Disease",[14197,14214],"AZD2373-Arm 2",{"trials":14216,"activeCount":102},[],{"trials":14218,"activeCount":102},[],{"trials":14220,"activeCount":102},[],{"intervention":14214,"totalTrials":122,"cells":14222},{"EARLY_PHASE1":14223,"PHASE1":14225,"PHASE2":14227,"PHASE3":14233,"PHASE4":14235,"NA":14237},{"trials":14224,"activeCount":102},[],{"trials":14226,"activeCount":102},[],{"trials":14228,"activeCount":122,"soonestReadout":5202},[14229],{"nctId":14206,"briefTitle":14207,"status":151,"phases":14230,"primaryCompletion":5202,"completion":5202,"start":14209,"enrollment":14210,"conditions":14231,"interventions":14232},[91],[14212],[14197,14214],{"trials":14234,"activeCount":102},[],{"trials":14236,"activeCount":102},[],{"trials":14238,"activeCount":102},[],{"intervention":147,"totalTrials":122,"cells":14240},{"EARLY_PHASE1":14241,"PHASE1":14243,"PHASE2":14245,"PHASE3":14251,"PHASE4":14253,"NA":14255},{"trials":14242,"activeCount":102},[],{"trials":14244,"activeCount":102},[],{"trials":14246,"activeCount":122,"soonestReadout":140},[14247],{"nctId":137,"briefTitle":138,"status":108,"phases":14248,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":14249,"interventions":14250},[90,91],[115],[97,117,118,146,147],{"trials":14252,"activeCount":102},[],{"trials":14254,"activeCount":102},[],{"trials":14256,"activeCount":102},[],{"intervention":12346,"totalTrials":122,"cells":14258},{"EARLY_PHASE1":14259,"PHASE1":14261,"PHASE2":14263,"PHASE3":14269,"PHASE4":14271,"NA":14273},{"trials":14260,"activeCount":102},[],{"trials":14262,"activeCount":102},[],{"trials":14264,"activeCount":122,"soonestReadout":12340},[14265],{"nctId":12337,"briefTitle":12338,"status":151,"phases":14266,"primaryCompletion":12340,"completion":12340,"start":12341,"enrollment":12342,"conditions":14267,"interventions":14268},[90,91],[12344],[12247,12346],{"trials":14270,"activeCount":102},[],{"trials":14272,"activeCount":102},[],{"trials":14274,"activeCount":102},[],{"intervention":14276,"totalTrials":122,"cells":14277},"Osimertinib 80 mg\u002F40 mg",{"EARLY_PHASE1":14278,"PHASE1":14280,"PHASE2":14282,"PHASE3":14293,"PHASE4":14295,"NA":14297},{"trials":14279,"activeCount":102},[],{"trials":14281,"activeCount":102},[],{"trials":14283,"activeCount":122,"soonestReadout":14288},[14284],{"nctId":14285,"briefTitle":14286,"status":108,"phases":14287,"primaryCompletion":14288,"completion":14288,"start":11526,"enrollment":14289,"conditions":14290,"interventions":14292},"NCT05526755","A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)",[91],"2029-11-22",188,[14291],"Stage II-IIIB Non-small Cell Lung Carcinoma",[14276],{"trials":14294,"activeCount":102},[],{"trials":14296,"activeCount":102},[],{"trials":14298,"activeCount":102},[],{"intervention":161,"totalTrials":122,"cells":14300},{"EARLY_PHASE1":14301,"PHASE1":14303,"PHASE2":14305,"PHASE3":14311,"PHASE4":14313,"NA":14315},{"trials":14302,"activeCount":102},[],{"trials":14304,"activeCount":102},[],{"trials":14306,"activeCount":122,"soonestReadout":153},[14307],{"nctId":149,"briefTitle":150,"status":151,"phases":14308,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":14309,"interventions":14310},[90,91],[157],[159,160,161,162,163],{"trials":14312,"activeCount":102},[],{"trials":14314,"activeCount":102},[],{"trials":14316,"activeCount":102},[],{"intervention":14318,"totalTrials":122,"cells":14319},"AZD4360",{"EARLY_PHASE1":14320,"PHASE1":14322,"PHASE2":14324,"PHASE3":14334,"PHASE4":14336,"NA":14338},{"trials":14321,"activeCount":102},[],{"trials":14323,"activeCount":102},[],{"trials":14325,"activeCount":122,"soonestReadout":1965},[14326],{"nctId":14327,"briefTitle":14328,"status":151,"phases":14329,"primaryCompletion":1965,"completion":14330,"start":14331,"enrollment":565,"conditions":14332,"interventions":14333},"NCT06921928","Study for AZD4360 in Participants With Advanced Solid Tumours",[90,91],"2027-12-16","2025-04-29",[172,4612,281,5772],[14318],{"trials":14335,"activeCount":102},[],{"trials":14337,"activeCount":102},[],{"trials":14339,"activeCount":102},[],{"intervention":14341,"totalTrials":122,"cells":14342},"AZD5863",{"EARLY_PHASE1":14343,"PHASE1":14345,"PHASE2":14347,"PHASE3":14359,"PHASE4":14361,"NA":14363},{"trials":14344,"activeCount":102},[],{"trials":14346,"activeCount":102},[],{"trials":14348,"activeCount":122,"soonestReadout":14353},[14349],{"nctId":14350,"briefTitle":14351,"status":151,"phases":14352,"primaryCompletion":14353,"completion":14353,"start":14354,"enrollment":12722,"conditions":14355,"interventions":14358},"NCT06005493","Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors",[90,91],"2027-07-16","2023-07-11",[172,14356,5772,14357],"Gastro-esophageal Junction Cancer","Esophageal Adenocarcinoma",[14341],{"trials":14360,"activeCount":102},[],{"trials":14362,"activeCount":102},[],{"trials":14364,"activeCount":102},[],{"intervention":14366,"totalTrials":122,"cells":14367},"AZD4512",{"EARLY_PHASE1":14368,"PHASE1":14370,"PHASE2":14372,"PHASE3":14382,"PHASE4":14384,"NA":14386},{"trials":14369,"activeCount":102},[],{"trials":14371,"activeCount":102},[],{"trials":14373,"activeCount":122,"soonestReadout":6159},[14374],{"nctId":14375,"briefTitle":14376,"status":151,"phases":14377,"primaryCompletion":6159,"completion":6159,"start":14378,"enrollment":14379,"conditions":14380,"interventions":14381},"NCT07123454","A Phase I\u002FII Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma",[90,91],"2025-09-24",91,[1465],[14366],{"trials":14383,"activeCount":102},[],{"trials":14385,"activeCount":102},[],{"trials":14387,"activeCount":102},[],{"intervention":9431,"totalTrials":122,"cells":14389},{"EARLY_PHASE1":14390,"PHASE1":14392,"PHASE2":14394,"PHASE3":14400,"PHASE4":14402,"NA":14404},{"trials":14391,"activeCount":102},[],{"trials":14393,"activeCount":102},[],{"trials":14395,"activeCount":122,"soonestReadout":9427},[14396],{"nctId":9424,"briefTitle":9425,"status":151,"phases":14397,"primaryCompletion":9427,"completion":9427,"start":7158,"enrollment":9428,"conditions":14398,"interventions":14399},[90,91],[7892],[9431,9432,7937,7935],{"trials":14401,"activeCount":102},[],{"trials":14403,"activeCount":102},[],{"trials":14405,"activeCount":102},[],{"intervention":9432,"totalTrials":122,"cells":14407},{"EARLY_PHASE1":14408,"PHASE1":14410,"PHASE2":14412,"PHASE3":14418,"PHASE4":14420,"NA":14422},{"trials":14409,"activeCount":102},[],{"trials":14411,"activeCount":102},[],{"trials":14413,"activeCount":122,"soonestReadout":9427},[14414],{"nctId":9424,"briefTitle":9425,"status":151,"phases":14415,"primaryCompletion":9427,"completion":9427,"start":7158,"enrollment":9428,"conditions":14416,"interventions":14417},[90,91],[7892],[9431,9432,7937,7935],{"trials":14419,"activeCount":102},[],{"trials":14421,"activeCount":102},[],{"trials":14423,"activeCount":102},[],{"intervention":8909,"totalTrials":122,"cells":14425},{"EARLY_PHASE1":14426,"PHASE1":14428,"PHASE2":14430,"PHASE3":14436,"PHASE4":14438,"NA":14440},{"trials":14427,"activeCount":102},[],{"trials":14429,"activeCount":102},[],{"trials":14431,"activeCount":122,"soonestReadout":8904},[14432],{"nctId":8901,"briefTitle":8902,"status":151,"phases":14433,"primaryCompletion":8904,"completion":8904,"start":8905,"enrollment":1318,"conditions":14434,"interventions":14435},[91],[8907],[8892,8909],{"trials":14437,"activeCount":102},[],{"trials":14439,"activeCount":102},[],{"trials":14441,"activeCount":102},[],{"intervention":14443,"totalTrials":122,"cells":14444},"AZD8205",{"EARLY_PHASE1":14445,"PHASE1":14447,"PHASE2":14449,"PHASE3":14464,"PHASE4":14466,"NA":14468},{"trials":14446,"activeCount":102},[],{"trials":14448,"activeCount":102},[],{"trials":14450,"activeCount":122,"soonestReadout":14455},[14451],{"nctId":14452,"briefTitle":14453,"status":151,"phases":14454,"primaryCompletion":14455,"completion":14455,"start":5616,"enrollment":1210,"conditions":14456,"interventions":14459},"NCT05123482","A Phase I\u002FIIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced\u002FMetastatic Solid Malignancies",[90,91],"2027-09-29",[25,14457,414,367,14458],"Biliary Tract Carcinoma","Squamous Non-Small Cell Lung Cancer",[14443,14460,14461,14461,14462,14463],"AZD8205 and AZD2936","AZD8205 and AZD5305","AZD8205 in combination with AZD9574","AZD8205 in combination with AZD9574 plus rilvegostomig",{"trials":14465,"activeCount":102},[],{"trials":14467,"activeCount":102},[],{"trials":14469,"activeCount":102},[],{"intervention":14460,"totalTrials":122,"cells":14471},{"EARLY_PHASE1":14472,"PHASE1":14474,"PHASE2":14476,"PHASE3":14482,"PHASE4":14484,"NA":14486},{"trials":14473,"activeCount":102},[],{"trials":14475,"activeCount":102},[],{"trials":14477,"activeCount":122,"soonestReadout":14455},[14478],{"nctId":14452,"briefTitle":14453,"status":151,"phases":14479,"primaryCompletion":14455,"completion":14455,"start":5616,"enrollment":1210,"conditions":14480,"interventions":14481},[90,91],[25,14457,414,367,14458],[14443,14460,14461,14461,14462,14463],{"trials":14483,"activeCount":102},[],{"trials":14485,"activeCount":102},[],{"trials":14487,"activeCount":102},[],{"intervention":14461,"totalTrials":122,"cells":14489},{"EARLY_PHASE1":14490,"PHASE1":14492,"PHASE2":14494,"PHASE3":14500,"PHASE4":14502,"NA":14504},{"trials":14491,"activeCount":102},[],{"trials":14493,"activeCount":102},[],{"trials":14495,"activeCount":122,"soonestReadout":14455},[14496],{"nctId":14452,"briefTitle":14453,"status":151,"phases":14497,"primaryCompletion":14455,"completion":14455,"start":5616,"enrollment":1210,"conditions":14498,"interventions":14499},[90,91],[25,14457,414,367,14458],[14443,14460,14461,14461,14462,14463],{"trials":14501,"activeCount":102},[],{"trials":14503,"activeCount":102},[],{"trials":14505,"activeCount":102},[],{"intervention":14462,"totalTrials":122,"cells":14507},{"EARLY_PHASE1":14508,"PHASE1":14510,"PHASE2":14512,"PHASE3":14518,"PHASE4":14520,"NA":14522},{"trials":14509,"activeCount":102},[],{"trials":14511,"activeCount":102},[],{"trials":14513,"activeCount":122,"soonestReadout":14455},[14514],{"nctId":14452,"briefTitle":14453,"status":151,"phases":14515,"primaryCompletion":14455,"completion":14455,"start":5616,"enrollment":1210,"conditions":14516,"interventions":14517},[90,91],[25,14457,414,367,14458],[14443,14460,14461,14461,14462,14463],{"trials":14519,"activeCount":102},[],{"trials":14521,"activeCount":102},[],{"trials":14523,"activeCount":102},[],{"intervention":14463,"totalTrials":122,"cells":14525},{"EARLY_PHASE1":14526,"PHASE1":14528,"PHASE2":14530,"PHASE3":14536,"PHASE4":14538,"NA":14540},{"trials":14527,"activeCount":102},[],{"trials":14529,"activeCount":102},[],{"trials":14531,"activeCount":122,"soonestReadout":14455},[14532],{"nctId":14452,"briefTitle":14453,"status":151,"phases":14533,"primaryCompletion":14455,"completion":14455,"start":5616,"enrollment":1210,"conditions":14534,"interventions":14535},[90,91],[25,14457,414,367,14458],[14443,14460,14461,14461,14462,14463],{"trials":14537,"activeCount":102},[],{"trials":14539,"activeCount":102},[],{"trials":14541,"activeCount":102},[],{"intervention":14543,"totalTrials":122,"cells":14544},"Neoadjuvant Olaparib monotherapy group",{"EARLY_PHASE1":14545,"PHASE1":14547,"PHASE2":14549,"PHASE3":14559,"PHASE4":14561,"NA":14563},{"trials":14546,"activeCount":102},[],{"trials":14548,"activeCount":102},[],{"trials":14550,"activeCount":122,"soonestReadout":14555},[14551],{"nctId":14552,"briefTitle":14553,"status":108,"phases":14554,"primaryCompletion":14555,"completion":660,"start":12407,"enrollment":4286,"conditions":14556,"interventions":14557},"NCT05498155","Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer",[91],"2024-11-20",[25],[14543,14558],"Neoadjuvant combination therapy with olaparib plus durvalumab",{"trials":14560,"activeCount":102},[],{"trials":14562,"activeCount":102},[],{"trials":14564,"activeCount":102},[],{"intervention":14558,"totalTrials":122,"cells":14566},{"EARLY_PHASE1":14567,"PHASE1":14569,"PHASE2":14571,"PHASE3":14577,"PHASE4":14579,"NA":14581},{"trials":14568,"activeCount":102},[],{"trials":14570,"activeCount":102},[],{"trials":14572,"activeCount":122,"soonestReadout":14555},[14573],{"nctId":14552,"briefTitle":14553,"status":108,"phases":14574,"primaryCompletion":14555,"completion":660,"start":12407,"enrollment":4286,"conditions":14575,"interventions":14576},[91],[25],[14543,14558],{"trials":14578,"activeCount":102},[],{"trials":14580,"activeCount":102},[],{"trials":14582,"activeCount":102},[],{"intervention":5401,"totalTrials":122,"cells":14584},{"EARLY_PHASE1":14585,"PHASE1":14587,"PHASE2":14589,"PHASE3":14595,"PHASE4":14597,"NA":14599},{"trials":14586,"activeCount":102},[],{"trials":14588,"activeCount":102},[],{"trials":14590,"activeCount":122,"soonestReadout":5396},[14591],{"nctId":5393,"briefTitle":5394,"status":108,"phases":14592,"primaryCompletion":5396,"completion":5397,"start":5398,"enrollment":3093,"conditions":14593,"interventions":14594},[91],[3174],[1012,5401,5402],{"trials":14596,"activeCount":102},[],{"trials":14598,"activeCount":102},[],{"trials":14600,"activeCount":102},[],{"intervention":5402,"totalTrials":122,"cells":14602},{"EARLY_PHASE1":14603,"PHASE1":14605,"PHASE2":14607,"PHASE3":14613,"PHASE4":14615,"NA":14617},{"trials":14604,"activeCount":102},[],{"trials":14606,"activeCount":102},[],{"trials":14608,"activeCount":122,"soonestReadout":5396},[14609],{"nctId":5393,"briefTitle":5394,"status":108,"phases":14610,"primaryCompletion":5396,"completion":5397,"start":5398,"enrollment":3093,"conditions":14611,"interventions":14612},[91],[3174],[1012,5401,5402],{"trials":14614,"activeCount":102},[],{"trials":14616,"activeCount":102},[],{"trials":14618,"activeCount":102},[],{"intervention":14620,"totalTrials":122,"cells":14621},"AZD4117",{"EARLY_PHASE1":14622,"PHASE1":14624,"PHASE2":14626,"PHASE3":14637,"PHASE4":14639,"NA":14641},{"trials":14623,"activeCount":102},[],{"trials":14625,"activeCount":102},[],{"trials":14627,"activeCount":122,"soonestReadout":6115},[14628],{"nctId":14629,"briefTitle":14630,"status":108,"phases":14631,"primaryCompletion":6115,"completion":14632,"start":13173,"enrollment":9994,"conditions":14633,"interventions":14635},"NCT07128615","A Phase I\u002FII Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)",[90,91],"2026-12-29",[14634],"Influenza A",[14620,14636],"AZD5315",{"trials":14638,"activeCount":102},[],{"trials":14640,"activeCount":102},[],{"trials":14642,"activeCount":102},[],{"intervention":14636,"totalTrials":122,"cells":14644},{"EARLY_PHASE1":14645,"PHASE1":14647,"PHASE2":14649,"PHASE3":14655,"PHASE4":14657,"NA":14659},{"trials":14646,"activeCount":102},[],{"trials":14648,"activeCount":102},[],{"trials":14650,"activeCount":122,"soonestReadout":6115},[14651],{"nctId":14629,"briefTitle":14630,"status":108,"phases":14652,"primaryCompletion":6115,"completion":14632,"start":13173,"enrollment":9994,"conditions":14653,"interventions":14654},[90,91],[14634],[14620,14636],{"trials":14656,"activeCount":102},[],{"trials":14658,"activeCount":102},[],{"trials":14660,"activeCount":102},[],{"intervention":7912,"totalTrials":122,"cells":14662},{"EARLY_PHASE1":14663,"PHASE1":14665,"PHASE2":14667,"PHASE3":14673,"PHASE4":14675,"NA":14677},{"trials":14664,"activeCount":102},[],{"trials":14666,"activeCount":102},[],{"trials":14668,"activeCount":122,"soonestReadout":1393},[14669],{"nctId":7906,"briefTitle":7907,"status":151,"phases":14670,"primaryCompletion":1393,"completion":1393,"start":7909,"enrollment":3000,"conditions":14671,"interventions":14672},[90,91],[1283],[7879,524,7912],{"trials":14674,"activeCount":102},[],{"trials":14676,"activeCount":102},[],{"trials":14678,"activeCount":102},[],{"intervention":14680,"totalTrials":122,"cells":14681},"AZD6621",{"EARLY_PHASE1":14682,"PHASE1":14684,"PHASE2":14686,"PHASE3":14696,"PHASE4":14698,"NA":14700},{"trials":14683,"activeCount":102},[],{"trials":14685,"activeCount":102},[],{"trials":14687,"activeCount":122,"soonestReadout":14692},[14688],{"nctId":14689,"briefTitle":14690,"status":151,"phases":14691,"primaryCompletion":14692,"completion":14692,"start":12235,"enrollment":14693,"conditions":14694,"interventions":14695},"NCT07192614","A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer",[90,91],"2029-03-29",52,[416],[14680],{"trials":14697,"activeCount":102},[],{"trials":14699,"activeCount":102},[],{"trials":14701,"activeCount":102},[],{"intervention":12380,"totalTrials":122,"cells":14703},{"EARLY_PHASE1":14704,"PHASE1":14706,"PHASE2":14708,"PHASE3":14714,"PHASE4":14716,"NA":14718},{"trials":14705,"activeCount":102},[],{"trials":14707,"activeCount":102},[],{"trials":14709,"activeCount":122,"soonestReadout":12377},[14710],{"nctId":12374,"briefTitle":12375,"status":151,"phases":14711,"primaryCompletion":12377,"completion":12377,"start":6233,"enrollment":1385,"conditions":14712,"interventions":14713},[90,91],[1937],[12380,159],{"trials":14715,"activeCount":102},[],{"trials":14717,"activeCount":102},[],{"trials":14719,"activeCount":102},[],{"intervention":9613,"totalTrials":122,"cells":14721},{"EARLY_PHASE1":14722,"PHASE1":14724,"PHASE2":14726,"PHASE3":14732,"PHASE4":14734,"NA":14736},{"trials":14723,"activeCount":102},[],{"trials":14725,"activeCount":102},[],{"trials":14727,"activeCount":122,"soonestReadout":3930},[14728],{"nctId":9607,"briefTitle":9608,"status":1097,"phases":14729,"primaryCompletion":3930,"completion":3930,"start":130,"enrollment":6187,"conditions":14730,"interventions":14731},[91],[9611],[9598,9613],{"trials":14733,"activeCount":102},[],{"trials":14735,"activeCount":102},[],{"trials":14737,"activeCount":102},[],{"intervention":14739,"totalTrials":122,"cells":14740},"AZD3632",{"EARLY_PHASE1":14741,"PHASE1":14743,"PHASE2":14745,"PHASE3":14756,"PHASE4":14758,"NA":14760},{"trials":14742,"activeCount":102},[],{"trials":14744,"activeCount":102},[],{"trials":14746,"activeCount":122,"soonestReadout":7697},[14747],{"nctId":14748,"briefTitle":14749,"status":151,"phases":14750,"primaryCompletion":7697,"completion":7697,"start":7899,"enrollment":532,"conditions":14751,"interventions":14754},"NCT07155226","Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression",[90,91],[14752,8842,14753],"Acute Lymphoblastic Leukaemia","Higher-risk Myelodysplastic Syndromes",[14739,14755],"Posaconazole",{"trials":14757,"activeCount":102},[],{"trials":14759,"activeCount":102},[],{"trials":14761,"activeCount":102},[],{"intervention":14755,"totalTrials":122,"cells":14763},{"EARLY_PHASE1":14764,"PHASE1":14766,"PHASE2":14768,"PHASE3":14774,"PHASE4":14776,"NA":14778},{"trials":14765,"activeCount":102},[],{"trials":14767,"activeCount":102},[],{"trials":14769,"activeCount":122,"soonestReadout":7697},[14770],{"nctId":14748,"briefTitle":14749,"status":151,"phases":14771,"primaryCompletion":7697,"completion":7697,"start":7899,"enrollment":532,"conditions":14772,"interventions":14773},[90,91],[14752,8842,14753],[14739,14755],{"trials":14775,"activeCount":102},[],{"trials":14777,"activeCount":102},[],{"trials":14779,"activeCount":102},[],{"intervention":7164,"totalTrials":122,"cells":14781},{"EARLY_PHASE1":14782,"PHASE1":14784,"PHASE2":14786,"PHASE3":14792,"PHASE4":14794,"NA":14796},{"trials":14783,"activeCount":102},[],{"trials":14785,"activeCount":102},[],{"trials":14787,"activeCount":122,"soonestReadout":7157},[14788],{"nctId":7154,"briefTitle":7155,"status":151,"phases":14789,"primaryCompletion":7157,"completion":7157,"start":7158,"enrollment":7159,"conditions":14790,"interventions":14791},[90,91],[7161,7162],[7164,3966,5978,5977,5979],{"trials":14793,"activeCount":102},[],{"trials":14795,"activeCount":102},[],{"trials":14797,"activeCount":102},[],{"intervention":14799,"totalTrials":122,"cells":14800},"Selumetinib granule formulation",{"EARLY_PHASE1":14801,"PHASE1":14803,"PHASE2":14805,"PHASE3":14815,"PHASE4":14817,"NA":14819},{"trials":14802,"activeCount":102},[],{"trials":14804,"activeCount":102},[],{"trials":14806,"activeCount":122,"soonestReadout":4769},[14807],{"nctId":14808,"briefTitle":14809,"status":108,"phases":14810,"primaryCompletion":4769,"completion":7648,"start":14811,"enrollment":496,"conditions":14812,"interventions":14813},"NCT05309668","Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to \u003C7 Years With NF1-related Symptomatic, Inoperable PN",[90,91],"2022-01-21",[7608],[14799,14814],"Selumetinib capsule formulation",{"trials":14816,"activeCount":102},[],{"trials":14818,"activeCount":102},[],{"trials":14820,"activeCount":102},[],{"intervention":14814,"totalTrials":122,"cells":14822},{"EARLY_PHASE1":14823,"PHASE1":14825,"PHASE2":14827,"PHASE3":14833,"PHASE4":14835,"NA":14837},{"trials":14824,"activeCount":102},[],{"trials":14826,"activeCount":102},[],{"trials":14828,"activeCount":122,"soonestReadout":4769},[14829],{"nctId":14808,"briefTitle":14809,"status":108,"phases":14830,"primaryCompletion":4769,"completion":7648,"start":14811,"enrollment":496,"conditions":14831,"interventions":14832},[90,91],[7608],[14799,14814],{"trials":14834,"activeCount":102},[],{"trials":14836,"activeCount":102},[],{"trials":14838,"activeCount":102},[],{"intervention":12305,"totalTrials":122,"cells":14840},{"EARLY_PHASE1":14841,"PHASE1":14843,"PHASE2":14845,"PHASE3":14851,"PHASE4":14853,"NA":14855},{"trials":14842,"activeCount":102},[],{"trials":14844,"activeCount":102},[],{"trials":14846,"activeCount":122,"soonestReadout":12299},[14847],{"nctId":12296,"briefTitle":12297,"status":151,"phases":14848,"primaryCompletion":12299,"completion":12299,"start":12300,"enrollment":12301,"conditions":14849,"interventions":14850},[91],[12303],[12218,12247,12305,12306],{"trials":14852,"activeCount":102},[],{"trials":14854,"activeCount":102},[],{"trials":14856,"activeCount":102},[],{"intervention":12306,"totalTrials":122,"cells":14858},{"EARLY_PHASE1":14859,"PHASE1":14861,"PHASE2":14863,"PHASE3":14869,"PHASE4":14871,"NA":14873},{"trials":14860,"activeCount":102},[],{"trials":14862,"activeCount":102},[],{"trials":14864,"activeCount":122,"soonestReadout":12299},[14865],{"nctId":12296,"briefTitle":12297,"status":151,"phases":14866,"primaryCompletion":12299,"completion":12299,"start":12300,"enrollment":12301,"conditions":14867,"interventions":14868},[91],[12303],[12218,12247,12305,12306],{"trials":14870,"activeCount":102},[],{"trials":14872,"activeCount":102},[],{"trials":14874,"activeCount":102},[],{"intervention":5774,"totalTrials":122,"cells":14876},{"EARLY_PHASE1":14877,"PHASE1":14879,"PHASE2":14881,"PHASE3":14887,"PHASE4":14889,"NA":14891},{"trials":14878,"activeCount":102},[],{"trials":14880,"activeCount":102},[],{"trials":14882,"activeCount":122,"soonestReadout":5770},[14883],{"nctId":5767,"briefTitle":5768,"status":151,"phases":14884,"primaryCompletion":5770,"completion":1952,"start":1372,"enrollment":2289,"conditions":14885,"interventions":14886},[91],[172,4612,281,5772],[225,226,4843,5774,4615,5775,283],{"trials":14888,"activeCount":102},[],{"trials":14890,"activeCount":102},[],{"trials":14892,"activeCount":102},[],{"intervention":5775,"totalTrials":122,"cells":14894},{"EARLY_PHASE1":14895,"PHASE1":14897,"PHASE2":14899,"PHASE3":14905,"PHASE4":14907,"NA":14909},{"trials":14896,"activeCount":102},[],{"trials":14898,"activeCount":102},[],{"trials":14900,"activeCount":122,"soonestReadout":5770},[14901],{"nctId":5767,"briefTitle":5768,"status":151,"phases":14902,"primaryCompletion":5770,"completion":1952,"start":1372,"enrollment":2289,"conditions":14903,"interventions":14904},[91],[172,4612,281,5772],[225,226,4843,5774,4615,5775,283],{"trials":14906,"activeCount":102},[],{"trials":14908,"activeCount":102},[],{"trials":14910,"activeCount":102},[],{"intervention":3949,"totalTrials":122,"cells":14912},{"EARLY_PHASE1":14913,"PHASE1":14915,"PHASE2":14917,"PHASE3":14923,"PHASE4":14925,"NA":14927},{"trials":14914,"activeCount":102},[],{"trials":14916,"activeCount":102},[],{"trials":14918,"activeCount":122,"soonestReadout":3939},[14919],{"nctId":3936,"briefTitle":3937,"status":151,"phases":14920,"primaryCompletion":3939,"completion":3939,"start":3940,"enrollment":3941,"conditions":14921,"interventions":14922},[91],[3943,3944,3945,3946,3947],[179,177,344,118,3949],{"trials":14924,"activeCount":102},[],{"trials":14926,"activeCount":102},[],{"trials":14928,"activeCount":102},[],{"intervention":7173,"totalTrials":122,"cells":14930},{"EARLY_PHASE1":14931,"PHASE1":14933,"PHASE2":14935,"PHASE3":14941,"PHASE4":14943,"NA":14945},{"trials":14932,"activeCount":102},[],{"trials":14934,"activeCount":102},[],{"trials":14936,"activeCount":122,"soonestReadout":7169},[14937],{"nctId":7166,"briefTitle":7167,"status":151,"phases":14938,"primaryCompletion":7169,"completion":7169,"start":7170,"enrollment":1130,"conditions":14939,"interventions":14940},[91],[6348],[3966,7173],{"trials":14942,"activeCount":102},[],{"trials":14944,"activeCount":102},[],{"trials":14946,"activeCount":102},[],{"intervention":14948,"totalTrials":122,"cells":14949},"AZD4512 monotherapy",{"EARLY_PHASE1":14950,"PHASE1":14952,"PHASE2":14954,"PHASE3":14964,"PHASE4":14966,"NA":14968},{"trials":14951,"activeCount":102},[],{"trials":14953,"activeCount":102},[],{"trials":14955,"activeCount":122,"soonestReadout":7648},[14956],{"nctId":14957,"briefTitle":14958,"status":151,"phases":14959,"primaryCompletion":7648,"completion":14960,"start":14961,"enrollment":6597,"conditions":14962,"interventions":14963},"NCT07109219","Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia",[90,91],"2028-07-03","2025-11-12",[9735],[14948],{"trials":14965,"activeCount":102},[],{"trials":14967,"activeCount":102},[],{"trials":14969,"activeCount":102},[],{"intervention":3236,"totalTrials":122,"cells":14971},{"EARLY_PHASE1":14972,"PHASE1":14974,"PHASE2":14976,"PHASE3":14982,"PHASE4":14984,"NA":14986},{"trials":14973,"activeCount":102},[],{"trials":14975,"activeCount":102},[],{"trials":14977,"activeCount":122,"soonestReadout":3227},[14978],{"nctId":3224,"briefTitle":3225,"status":151,"phases":14979,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":3229,"conditions":14980,"interventions":14981},[91],[1049],[117,251,3232,808,3233,344,177,3234,3235,3236,179,180],{"trials":14983,"activeCount":102},[],{"trials":14985,"activeCount":102},[],{"trials":14987,"activeCount":102},[],{"intervention":3965,"totalTrials":122,"cells":14989},{"EARLY_PHASE1":14990,"PHASE1":14992,"PHASE2":14994,"PHASE3":15000,"PHASE4":15002,"NA":15004},{"trials":14991,"activeCount":102},[],{"trials":14993,"activeCount":102},[],{"trials":14995,"activeCount":122,"soonestReadout":3958},[14996],{"nctId":3955,"briefTitle":3956,"status":108,"phases":14997,"primaryCompletion":3958,"completion":3958,"start":1574,"enrollment":3959,"conditions":14998,"interventions":14999},[90,91],[414,25,415,416,3961,1049,691,403,172,3962,404,367,3963],[1939,118,344,3965,808,3966],{"trials":15001,"activeCount":102},[],{"trials":15003,"activeCount":102},[],{"trials":15005,"activeCount":102},[],{"intervention":673,"totalTrials":122,"cells":15007},{"EARLY_PHASE1":15008,"PHASE1":15010,"PHASE2":15012,"PHASE3":15018,"PHASE4":15020,"NA":15022},{"trials":15009,"activeCount":102},[],{"trials":15011,"activeCount":102},[],{"trials":15013,"activeCount":122,"soonestReadout":62},[15014],{"nctId":60,"briefTitle":61,"status":108,"phases":15015,"primaryCompletion":62,"completion":660,"start":668,"enrollment":669,"conditions":15016,"interventions":15017},[91],[414],[63,620,672,620,673],{"trials":15019,"activeCount":102},[],{"trials":15021,"activeCount":102},[],{"trials":15023,"activeCount":102},[],{"intervention":15025,"totalTrials":122,"cells":15026},"Osimertinib + Savolitinib",{"EARLY_PHASE1":15027,"PHASE1":15029,"PHASE2":15031,"PHASE3":15041,"PHASE4":15043,"NA":15045},{"trials":15028,"activeCount":102},[],{"trials":15030,"activeCount":102},[],{"trials":15032,"activeCount":122,"soonestReadout":678},[15033],{"nctId":15034,"briefTitle":15035,"status":108,"phases":15036,"primaryCompletion":678,"completion":3322,"start":15037,"enrollment":1710,"conditions":15038,"interventions":15039},"NCT04606771","A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC",[91],"2020-09-28",[262],[15025,15040],"Savolitinib + Placebo",{"trials":15042,"activeCount":102},[],{"trials":15044,"activeCount":102},[],{"trials":15046,"activeCount":102},[],{"intervention":15040,"totalTrials":122,"cells":15048},{"EARLY_PHASE1":15049,"PHASE1":15051,"PHASE2":15053,"PHASE3":15059,"PHASE4":15061,"NA":15063},{"trials":15050,"activeCount":102},[],{"trials":15052,"activeCount":102},[],{"trials":15054,"activeCount":122,"soonestReadout":678},[15055],{"nctId":15034,"briefTitle":15035,"status":108,"phases":15056,"primaryCompletion":678,"completion":3322,"start":15037,"enrollment":1710,"conditions":15057,"interventions":15058},[91],[262],[15025,15040],{"trials":15060,"activeCount":102},[],{"trials":15062,"activeCount":102},[],{"trials":15064,"activeCount":102},[],{"intervention":15066,"totalTrials":122,"cells":15067},"AZD8359",{"EARLY_PHASE1":15068,"PHASE1":15070,"PHASE2":15072,"PHASE3":15082,"PHASE4":15084,"NA":15086},{"trials":15069,"activeCount":102},[],{"trials":15071,"activeCount":102},[],{"trials":15073,"activeCount":122,"soonestReadout":15078},[15074],{"nctId":15075,"briefTitle":15076,"status":151,"phases":15077,"primaryCompletion":15078,"completion":15078,"start":15079,"enrollment":2069,"conditions":15080,"interventions":15081},"NCT07529717","First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer",[90,91],"2027-11-17","2026-05-18",[1937],[15066,15066,15066,15066],{"trials":15083,"activeCount":102},[],{"trials":15085,"activeCount":102},[],{"trials":15087,"activeCount":102},[],{"intervention":15089,"totalTrials":122,"cells":15090},"AZD9829",{"EARLY_PHASE1":15091,"PHASE1":15093,"PHASE2":15095,"PHASE3":15105,"PHASE4":15107,"NA":15109},{"trials":15092,"activeCount":102},[],{"trials":15094,"activeCount":102},[],{"trials":15096,"activeCount":122,"soonestReadout":1077},[15097],{"nctId":15098,"briefTitle":15099,"status":108,"phases":15100,"primaryCompletion":1077,"completion":15101,"start":6079,"enrollment":2933,"conditions":15102,"interventions":15104},"NCT06179511","Study of AZD9829 in CD123+ Hematological Malignancies",[90,91],"2026-03-23",[15103],"Hematological Malignancies",[15089,15089],{"trials":15106,"activeCount":102},[],{"trials":15108,"activeCount":102},[],{"trials":15110,"activeCount":102},[],{"intervention":15112,"totalTrials":122,"cells":15113},"Durvalumab \u002F Tremelimumab Combination Therapy",{"EARLY_PHASE1":15114,"PHASE1":15116,"PHASE2":15118,"PHASE3":15130,"PHASE4":15132,"NA":15134},{"trials":15115,"activeCount":102},[],{"trials":15117,"activeCount":102},[],{"trials":15119,"activeCount":122,"soonestReadout":15124},[15120],{"nctId":15121,"briefTitle":15122,"status":108,"phases":15123,"primaryCompletion":15124,"completion":660,"start":15125,"enrollment":4286,"conditions":15126,"interventions":15129},"NCT03837899","Durvalumab and Tremelimumab for Pediatric Malignancies",[90,91],"2023-02-28","2019-03-07",[15127,15128,15103],"Pediatric Cancer","Solid Tumor Pediatric",[15112],{"trials":15131,"activeCount":102},[],{"trials":15133,"activeCount":102},[],{"trials":15135,"activeCount":102},[],{"intervention":4763,"totalTrials":122,"cells":15137},{"EARLY_PHASE1":15138,"PHASE1":15140,"PHASE2":15142,"PHASE3":15148,"PHASE4":15150,"NA":15152},{"trials":15139,"activeCount":102},[],{"trials":15141,"activeCount":102},[],{"trials":15143,"activeCount":122,"soonestReadout":4755},[15144],{"nctId":4752,"briefTitle":4753,"status":151,"phases":15145,"primaryCompletion":4755,"completion":4755,"start":4756,"enrollment":477,"conditions":15146,"interventions":15147},[90,91],[410,1049,4758,417,4759,993,546,4760,4761],[4763,4764],{"trials":15149,"activeCount":102},[],{"trials":15151,"activeCount":102},[],{"trials":15153,"activeCount":102},[],{"intervention":6321,"totalTrials":122,"cells":15155},{"EARLY_PHASE1":15156,"PHASE1":15158,"PHASE2":15160,"PHASE3":15166,"PHASE4":15168,"NA":15170},{"trials":15157,"activeCount":102},[],{"trials":15159,"activeCount":102},[],{"trials":15161,"activeCount":122,"soonestReadout":6317},[15162],{"nctId":6314,"briefTitle":6315,"status":151,"phases":15163,"primaryCompletion":6317,"completion":6317,"start":6318,"enrollment":1120,"conditions":15164,"interventions":15165},[90,91],[466],[6321,1959],{"trials":15167,"activeCount":102},[],{"trials":15169,"activeCount":102},[],{"trials":15171,"activeCount":102},[],{"intervention":15173,"totalTrials":122,"cells":15174},"GP MDI",{"EARLY_PHASE1":15175,"PHASE1":15177,"PHASE2":15179,"PHASE3":15190,"PHASE4":15192,"NA":15194},{"trials":15176,"activeCount":102},[],{"trials":15178,"activeCount":102},[],{"trials":15180,"activeCount":122,"soonestReadout":15185},[15181],{"nctId":15182,"briefTitle":15183,"status":151,"phases":15184,"primaryCompletion":15185,"completion":15185,"start":15186,"enrollment":12271,"conditions":15187,"interventions":15188},"NCT07525375","A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma",[91],"2029-05-23","2026-04-14",[16],[15173,15189],"BFF MDI",{"trials":15191,"activeCount":102},[],{"trials":15193,"activeCount":102},[],{"trials":15195,"activeCount":102},[],{"intervention":15189,"totalTrials":122,"cells":15197},{"EARLY_PHASE1":15198,"PHASE1":15200,"PHASE2":15202,"PHASE3":15208,"PHASE4":15210,"NA":15212},{"trials":15199,"activeCount":102},[],{"trials":15201,"activeCount":102},[],{"trials":15203,"activeCount":122,"soonestReadout":15185},[15204],{"nctId":15182,"briefTitle":15183,"status":151,"phases":15205,"primaryCompletion":15185,"completion":15185,"start":15186,"enrollment":12271,"conditions":15206,"interventions":15207},[91],[16],[15173,15189],{"trials":15209,"activeCount":102},[],{"trials":15211,"activeCount":102},[],{"trials":15213,"activeCount":102},[],{"intervention":5123,"totalTrials":122,"cells":15215},{"EARLY_PHASE1":15216,"PHASE1":15218,"PHASE2":15220,"PHASE3":15226,"PHASE4":15228,"NA":15230},{"trials":15217,"activeCount":102},[],{"trials":15219,"activeCount":102},[],{"trials":15221,"activeCount":122,"soonestReadout":2835},[15222],{"nctId":5116,"briefTitle":5117,"status":151,"phases":15223,"primaryCompletion":2835,"completion":5119,"start":301,"enrollment":2187,"conditions":15224,"interventions":15225},[91],[5121],[179,5123,239],{"trials":15227,"activeCount":102},[],{"trials":15229,"activeCount":102},[],{"trials":15231,"activeCount":102},[],{"intervention":5443,"totalTrials":122,"cells":15233},{"EARLY_PHASE1":15234,"PHASE1":15236,"PHASE2":15238,"PHASE3":15244,"PHASE4":15246,"NA":15248},{"trials":15235,"activeCount":102},[],{"trials":15237,"activeCount":102},[],{"trials":15239,"activeCount":122,"soonestReadout":1022},[15240],{"nctId":5437,"briefTitle":5438,"status":108,"phases":15241,"primaryCompletion":1022,"completion":1022,"start":5440,"enrollment":477,"conditions":15242,"interventions":15243},[91],[1921],[1012,5443],{"trials":15245,"activeCount":102},[],{"trials":15247,"activeCount":102},[],{"trials":15249,"activeCount":102},[],{"intervention":12428,"totalTrials":122,"cells":15251},{"EARLY_PHASE1":15252,"PHASE1":15254,"PHASE2":15256,"PHASE3":15262,"PHASE4":15264,"NA":15266},{"trials":15253,"activeCount":102},[],{"trials":15255,"activeCount":102},[],{"trials":15257,"activeCount":122,"soonestReadout":1200},[15258],{"nctId":12421,"briefTitle":12422,"status":151,"phases":15259,"primaryCompletion":1200,"completion":1200,"start":12424,"enrollment":12425,"conditions":15260,"interventions":15261},[90,91],[416],[12428,1939],{"trials":15263,"activeCount":102},[],{"trials":15265,"activeCount":102},[],{"trials":15267,"activeCount":102},[],{"intervention":15269,"totalTrials":122,"cells":15270},"Olaparib Continuous (28-Day cycle) 300 mg BD.",{"EARLY_PHASE1":15271,"PHASE1":15273,"PHASE2":15275,"PHASE3":15289,"PHASE4":15291,"NA":15293},{"trials":15272,"activeCount":102},[],{"trials":15274,"activeCount":102},[],{"trials":15276,"activeCount":122,"soonestReadout":8174},[15277],{"nctId":15278,"briefTitle":15279,"status":108,"phases":15280,"primaryCompletion":8174,"completion":15281,"start":15282,"enrollment":15283,"conditions":15284,"interventions":15286},"NCT03330847","To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.",[91],"2026-09-04","2018-03-07",273,[15285],"Metastatic Triple Negative Breast Cancer",[15269,15287,15288],"Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).","Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).",{"trials":15290,"activeCount":102},[],{"trials":15292,"activeCount":102},[],{"trials":15294,"activeCount":102},[],{"intervention":15287,"totalTrials":122,"cells":15296},{"EARLY_PHASE1":15297,"PHASE1":15299,"PHASE2":15301,"PHASE3":15307,"PHASE4":15309,"NA":15311},{"trials":15298,"activeCount":102},[],{"trials":15300,"activeCount":102},[],{"trials":15302,"activeCount":122,"soonestReadout":8174},[15303],{"nctId":15278,"briefTitle":15279,"status":108,"phases":15304,"primaryCompletion":8174,"completion":15281,"start":15282,"enrollment":15283,"conditions":15305,"interventions":15306},[91],[15285],[15269,15287,15288],{"trials":15308,"activeCount":102},[],{"trials":15310,"activeCount":102},[],{"trials":15312,"activeCount":102},[],{"intervention":15288,"totalTrials":122,"cells":15314},{"EARLY_PHASE1":15315,"PHASE1":15317,"PHASE2":15319,"PHASE3":15325,"PHASE4":15327,"NA":15329},{"trials":15316,"activeCount":102},[],{"trials":15318,"activeCount":102},[],{"trials":15320,"activeCount":122,"soonestReadout":8174},[15321],{"nctId":15278,"briefTitle":15279,"status":108,"phases":15322,"primaryCompletion":8174,"completion":15281,"start":15282,"enrollment":15283,"conditions":15323,"interventions":15324},[91],[15285],[15269,15287,15288],{"trials":15326,"activeCount":102},[],{"trials":15328,"activeCount":102},[],{"trials":15330,"activeCount":102},[],{"intervention":1014,"totalTrials":122,"cells":15332},{"EARLY_PHASE1":15333,"PHASE1":15335,"PHASE2":15337,"PHASE3":15343,"PHASE4":15345,"NA":15347},{"trials":15334,"activeCount":102},[],{"trials":15336,"activeCount":102},[],{"trials":15338,"activeCount":122,"soonestReadout":1007},[15339],{"nctId":1004,"briefTitle":1005,"status":108,"phases":15340,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":15341,"interventions":15342},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"trials":15344,"activeCount":102},[],{"trials":15346,"activeCount":102},[],{"trials":15348,"activeCount":102},[],{"intervention":1015,"totalTrials":122,"cells":15350},{"EARLY_PHASE1":15351,"PHASE1":15353,"PHASE2":15355,"PHASE3":15361,"PHASE4":15363,"NA":15365},{"trials":15352,"activeCount":102},[],{"trials":15354,"activeCount":102},[],{"trials":15356,"activeCount":122,"soonestReadout":1007},[15357],{"nctId":1004,"briefTitle":1005,"status":108,"phases":15358,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":15359,"interventions":15360},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"trials":15362,"activeCount":102},[],{"trials":15364,"activeCount":102},[],{"trials":15366,"activeCount":102},[],{"intervention":1016,"totalTrials":122,"cells":15368},{"EARLY_PHASE1":15369,"PHASE1":15371,"PHASE2":15373,"PHASE3":15379,"PHASE4":15381,"NA":15383},{"trials":15370,"activeCount":102},[],{"trials":15372,"activeCount":102},[],{"trials":15374,"activeCount":122,"soonestReadout":1007},[15375],{"nctId":1004,"briefTitle":1005,"status":108,"phases":15376,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":15377,"interventions":15378},[91],[262],[1012,87,1013,1014,117,344,345,1015,1016,68,1017,177,252],{"trials":15380,"activeCount":102},[],{"trials":15382,"activeCount":102},[],{"trials":15384,"activeCount":102},[],{"intervention":1027,"totalTrials":122,"cells":15386},{"EARLY_PHASE1":15387,"PHASE1":15389,"PHASE2":15391,"PHASE3":15397,"PHASE4":15399,"NA":15401},{"trials":15388,"activeCount":102},[],{"trials":15390,"activeCount":102},[],{"trials":15392,"activeCount":122,"soonestReadout":1022},[15393],{"nctId":1019,"briefTitle":1020,"status":151,"phases":15394,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":340,"conditions":15395,"interventions":15396},[91],[367,172,651,414,691,1025,281],[252,121,226,179,344,239,180,1027,177],{"trials":15398,"activeCount":102},[],{"trials":15400,"activeCount":102},[],{"trials":15402,"activeCount":102},[],{"intervention":707,"totalTrials":122,"cells":15404},{"EARLY_PHASE1":15405,"PHASE1":15407,"PHASE2":15409,"PHASE3":15415,"PHASE4":15417,"NA":15419},{"trials":15406,"activeCount":102},[],{"trials":15408,"activeCount":102},[],{"trials":15410,"activeCount":122,"soonestReadout":701},[15411],{"nctId":698,"briefTitle":699,"status":108,"phases":15412,"primaryCompletion":701,"completion":702,"start":246,"enrollment":703,"conditions":15413,"interventions":15414},[91],[705],[117,267,707,708,709,710,711],{"trials":15416,"activeCount":102},[],{"trials":15418,"activeCount":102},[],{"trials":15420,"activeCount":102},[],{"intervention":708,"totalTrials":122,"cells":15422},{"EARLY_PHASE1":15423,"PHASE1":15425,"PHASE2":15427,"PHASE3":15433,"PHASE4":15435,"NA":15437},{"trials":15424,"activeCount":102},[],{"trials":15426,"activeCount":102},[],{"trials":15428,"activeCount":122,"soonestReadout":701},[15429],{"nctId":698,"briefTitle":699,"status":108,"phases":15430,"primaryCompletion":701,"completion":702,"start":246,"enrollment":703,"conditions":15431,"interventions":15432},[91],[705],[117,267,707,708,709,710,711],{"trials":15434,"activeCount":102},[],{"trials":15436,"activeCount":102},[],{"trials":15438,"activeCount":102},[],{"intervention":709,"totalTrials":122,"cells":15440},{"EARLY_PHASE1":15441,"PHASE1":15443,"PHASE2":15445,"PHASE3":15451,"PHASE4":15453,"NA":15455},{"trials":15442,"activeCount":102},[],{"trials":15444,"activeCount":102},[],{"trials":15446,"activeCount":122,"soonestReadout":701},[15447],{"nctId":698,"briefTitle":699,"status":108,"phases":15448,"primaryCompletion":701,"completion":702,"start":246,"enrollment":703,"conditions":15449,"interventions":15450},[91],[705],[117,267,707,708,709,710,711],{"trials":15452,"activeCount":102},[],{"trials":15454,"activeCount":102},[],{"trials":15456,"activeCount":102},[],{"intervention":710,"totalTrials":122,"cells":15458},{"EARLY_PHASE1":15459,"PHASE1":15461,"PHASE2":15463,"PHASE3":15469,"PHASE4":15471,"NA":15473},{"trials":15460,"activeCount":102},[],{"trials":15462,"activeCount":102},[],{"trials":15464,"activeCount":122,"soonestReadout":701},[15465],{"nctId":698,"briefTitle":699,"status":108,"phases":15466,"primaryCompletion":701,"completion":702,"start":246,"enrollment":703,"conditions":15467,"interventions":15468},[91],[705],[117,267,707,708,709,710,711],{"trials":15470,"activeCount":102},[],{"trials":15472,"activeCount":102},[],{"trials":15474,"activeCount":102},[],{"intervention":711,"totalTrials":122,"cells":15476},{"EARLY_PHASE1":15477,"PHASE1":15479,"PHASE2":15481,"PHASE3":15487,"PHASE4":15489,"NA":15491},{"trials":15478,"activeCount":102},[],{"trials":15480,"activeCount":102},[],{"trials":15482,"activeCount":122,"soonestReadout":701},[15483],{"nctId":698,"briefTitle":699,"status":108,"phases":15484,"primaryCompletion":701,"completion":702,"start":246,"enrollment":703,"conditions":15485,"interventions":15486},[91],[705],[117,267,707,708,709,710,711],{"trials":15488,"activeCount":102},[],{"trials":15490,"activeCount":102},[],{"trials":15492,"activeCount":102},[],{"intervention":1468,"totalTrials":122,"cells":15494},{"EARLY_PHASE1":15495,"PHASE1":15497,"PHASE2":15499,"PHASE3":15505,"PHASE4":15507,"NA":15509},{"trials":15496,"activeCount":102},[],{"trials":15498,"activeCount":102},[],{"trials":15500,"activeCount":122,"soonestReadout":1457},[15501],{"nctId":1454,"briefTitle":1455,"status":151,"phases":15502,"primaryCompletion":1457,"completion":1458,"start":1459,"enrollment":1460,"conditions":15503,"interventions":15504},[90,91],[1462,1409,1463,1464,1465],[1467,914,1378,524,1468,309,1335],{"trials":15506,"activeCount":102},[],{"trials":15508,"activeCount":102},[],{"trials":15510,"activeCount":102},[],{"intervention":15512,"totalTrials":122,"cells":15513},"AZD9793 Intravenous (IV) monotherapy",{"EARLY_PHASE1":15514,"PHASE1":15516,"PHASE2":15518,"PHASE3":15529,"PHASE4":15531,"NA":15533},{"trials":15515,"activeCount":102},[],{"trials":15517,"activeCount":102},[],{"trials":15519,"activeCount":122,"soonestReadout":15524},[15520],{"nctId":15521,"briefTitle":15522,"status":151,"phases":15523,"primaryCompletion":15524,"completion":15525,"start":364,"enrollment":2792,"conditions":15526,"interventions":15527},"NCT06795022","First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours",[90,91],"2028-02-25","2028-07-25",[3220],[15512,15528],"AZD9793 Subcutaneous (SC) monotherapy",{"trials":15530,"activeCount":102},[],{"trials":15532,"activeCount":102},[],{"trials":15534,"activeCount":102},[],{"intervention":15528,"totalTrials":122,"cells":15536},{"EARLY_PHASE1":15537,"PHASE1":15539,"PHASE2":15541,"PHASE3":15547,"PHASE4":15549,"NA":15551},{"trials":15538,"activeCount":102},[],{"trials":15540,"activeCount":102},[],{"trials":15542,"activeCount":122,"soonestReadout":15524},[15543],{"nctId":15521,"briefTitle":15522,"status":151,"phases":15544,"primaryCompletion":15524,"completion":15525,"start":364,"enrollment":2792,"conditions":15545,"interventions":15546},[90,91],[3220],[15512,15528],{"trials":15548,"activeCount":102},[],{"trials":15550,"activeCount":102},[],{"trials":15552,"activeCount":102},[],{"intervention":12585,"totalTrials":2222,"cells":15554},{"EARLY_PHASE1":15555,"PHASE1":15557,"PHASE2":15626,"PHASE3":15644,"PHASE4":15646,"NA":15648},{"trials":15556,"activeCount":102},[],{"trials":15558,"activeCount":447,"soonestReadout":15581},[15559,15565,15569,15577,15585,15593,15600,15609,15618],{"nctId":15560,"briefTitle":15561,"status":195,"phases":15562,"primaryCompletion":6115,"completion":6115,"start":6999,"enrollment":5425,"conditions":15563,"interventions":15564},"NCT06942936","A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants",[90],[5851],[12585,5911,10177],{"nctId":12579,"briefTitle":12580,"status":195,"phases":15566,"primaryCompletion":12582,"completion":12582,"start":1007,"enrollment":507,"conditions":15567,"interventions":15568},[90],[5851],[12585,5887,12586,12587,12588,12589],{"nctId":15570,"briefTitle":15571,"status":195,"phases":15572,"primaryCompletion":15573,"completion":15573,"start":15574,"enrollment":3248,"conditions":15575,"interventions":15576},"NCT06555822","A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants",[90],"2025-03-06","2024-08-15",[5851],[12585],{"nctId":15578,"briefTitle":15579,"status":108,"phases":15580,"primaryCompletion":15581,"completion":15581,"start":15582,"enrollment":5189,"conditions":15583,"interventions":15584},"NCT07455825","A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years",[90],"2026-06-03","2026-03-05",[5851],[12585],{"nctId":15586,"briefTitle":15587,"status":195,"phases":15588,"primaryCompletion":15589,"completion":15589,"start":15590,"enrollment":486,"conditions":15591,"interventions":15592},"NCT06742762","A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004",[90],"2025-04-20","2024-12-17",[2279],[12585],{"nctId":15594,"briefTitle":15595,"status":195,"phases":15596,"primaryCompletion":3400,"completion":3400,"start":15597,"enrollment":689,"conditions":15598,"interventions":15599},"NCT06813781","Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004",[90],"2024-12-19",[6914],[12585],{"nctId":15601,"briefTitle":15602,"status":195,"phases":15603,"primaryCompletion":15604,"completion":15605,"start":15606,"enrollment":486,"conditions":15607,"interventions":15608},"NCT06996886","A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations",[90],"2025-07-15","2025-07-25","2025-05-22",[5851],[12585],{"nctId":15610,"briefTitle":15611,"status":108,"phases":15612,"primaryCompletion":15613,"completion":15613,"start":15614,"enrollment":579,"conditions":15615,"interventions":15616},"NCT07444424","A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants",[90],"2026-07-02","2026-03-13",[5851],[12585,15617,2448],"Mitiglinide",{"nctId":15619,"briefTitle":15620,"status":195,"phases":15621,"primaryCompletion":15622,"completion":15622,"start":15623,"enrollment":1348,"conditions":15624,"interventions":15625},"NCT06703658","A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus",[90],"2025-03-13","2024-11-02",[5851,31],[12585,12585],{"trials":15627,"activeCount":102},[15628,15636],{"nctId":15629,"briefTitle":15630,"status":195,"phases":15631,"primaryCompletion":2999,"completion":2999,"start":12613,"enrollment":15632,"conditions":15633,"interventions":15634},"NCT06579105","Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.",[91],406,[2089],[12585,15635],"Semaglutide",{"nctId":15637,"briefTitle":15638,"status":195,"phases":15639,"primaryCompletion":15640,"completion":15640,"start":12613,"enrollment":15641,"conditions":15642,"interventions":15643},"NCT06579092","Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity",[91],"2025-11-21",310,[12286],[12585],{"trials":15645,"activeCount":102},[],{"trials":15647,"activeCount":102},[],{"trials":15649,"activeCount":102},[],{"intervention":980,"totalTrials":3887,"cells":15651},{"EARLY_PHASE1":15652,"PHASE1":15654,"PHASE2":15671,"PHASE3":15673,"PHASE4":15675,"NA":15677},{"trials":15653,"activeCount":102},[],{"trials":15655,"activeCount":447,"soonestReadout":3122},[15656,15660,15667],{"nctId":970,"briefTitle":971,"status":108,"phases":15657,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":15658,"interventions":15659},[90],[977],[252,117,344,979,980,981],{"nctId":15661,"briefTitle":15662,"status":195,"phases":15663,"primaryCompletion":1537,"completion":4756,"start":15664,"enrollment":1039,"conditions":15665,"interventions":15666},"NCT05685472","MEDI5752 in Japanese Patients With Advanced Solid Tumors.",[90],"2022-12-08",[4217],[980],{"nctId":3119,"briefTitle":3120,"status":108,"phases":15668,"primaryCompletion":3122,"completion":3123,"start":3124,"enrollment":3125,"conditions":15669,"interventions":15670},[90],[3127],[117,264,251,980,345,344,283,177,3097,979],{"trials":15672,"activeCount":102},[],{"trials":15674,"activeCount":102},[],{"trials":15676,"activeCount":102},[],{"trials":15678,"activeCount":102},[],{"intervention":9298,"totalTrials":447,"cells":15680},{"EARLY_PHASE1":15681,"PHASE1":15683,"PHASE2":15697,"PHASE3":15699,"PHASE4":15701,"NA":15703},{"trials":15682,"activeCount":102},[],{"trials":15684,"activeCount":447,"soonestReadout":9294},[15685,15689],{"nctId":9291,"briefTitle":9292,"status":151,"phases":15686,"primaryCompletion":9294,"completion":9294,"start":9295,"enrollment":579,"conditions":15687,"interventions":15688},[90],[5851],[9298,9284],{"nctId":15690,"briefTitle":15691,"status":151,"phases":15692,"primaryCompletion":15693,"completion":15693,"start":15694,"enrollment":12505,"conditions":15695,"interventions":15696},"NCT06980428","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia",[90],"2026-12-04","2025-05-27",[5851,6903],[9298],{"trials":15698,"activeCount":102},[],{"trials":15700,"activeCount":102},[],{"trials":15702,"activeCount":102},[],{"trials":15704,"activeCount":102},[],{"intervention":15706,"totalTrials":447,"cells":15707},"FPI-2053",{"EARLY_PHASE1":15708,"PHASE1":15710,"PHASE2":15731,"PHASE3":15733,"PHASE4":15735,"NA":15737},{"trials":15709,"activeCount":102},[],{"trials":15711,"activeCount":447,"soonestReadout":15727},[15712,15723],{"nctId":15713,"briefTitle":15714,"status":151,"phases":15715,"primaryCompletion":15716,"completion":15716,"start":15717,"enrollment":3476,"conditions":15718,"interventions":15720},"NCT06147037","A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours",[90],"2028-05-12","2024-07-31",[4879,15719,546,1049,5772,172,417],"Metastatic Colorectal Carcinoma",[15706,15721,15722],"[111In]-FPI-2107","[225Ac]-FPI-2068",{"nctId":15724,"briefTitle":15725,"status":151,"phases":15726,"primaryCompletion":15727,"completion":15727,"start":1100,"enrollment":1757,"conditions":15728,"interventions":15730},"NCT07500987","Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC",[90],"2026-07-21",[15729],"EGFR Mutation-positive NSCLC",[15721,15706],{"trials":15732,"activeCount":102},[],{"trials":15734,"activeCount":102},[],{"trials":15736,"activeCount":102},[],{"trials":15738,"activeCount":102},[],{"intervention":15721,"totalTrials":447,"cells":15740},{"EARLY_PHASE1":15741,"PHASE1":15743,"PHASE2":15753,"PHASE3":15755,"PHASE4":15757,"NA":15759},{"trials":15742,"activeCount":102},[],{"trials":15744,"activeCount":447,"soonestReadout":15727},[15745,15749],{"nctId":15713,"briefTitle":15714,"status":151,"phases":15746,"primaryCompletion":15716,"completion":15716,"start":15717,"enrollment":3476,"conditions":15747,"interventions":15748},[90],[4879,15719,546,1049,5772,172,417],[15706,15721,15722],{"nctId":15724,"briefTitle":15725,"status":151,"phases":15750,"primaryCompletion":15727,"completion":15727,"start":1100,"enrollment":1757,"conditions":15751,"interventions":15752},[90],[15729],[15721,15706],{"trials":15754,"activeCount":102},[],{"trials":15756,"activeCount":102},[],{"trials":15758,"activeCount":102},[],{"trials":15760,"activeCount":102},[],{"intervention":12587,"totalTrials":434,"cells":15762},{"EARLY_PHASE1":15763,"PHASE1":15765,"PHASE2":15783,"PHASE3":15793,"PHASE4":15855,"NA":15869},{"trials":15764,"activeCount":102},[],{"trials":15766,"activeCount":122,"soonestReadout":12645},[15767,15771,15779],{"nctId":12579,"briefTitle":12580,"status":195,"phases":15768,"primaryCompletion":12582,"completion":12582,"start":1007,"enrollment":507,"conditions":15769,"interventions":15770},[90],[5851],[12585,5887,12586,12587,12588,12589],{"nctId":15772,"briefTitle":15773,"status":195,"phases":15774,"primaryCompletion":2220,"completion":2220,"start":2507,"enrollment":1757,"conditions":15775,"interventions":15777},"NCT00722956","Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin",[90],[36,15776],"Pharmacokinetics",[15778,13002],"AZD5672",{"nctId":12642,"briefTitle":12643,"status":151,"phases":15780,"primaryCompletion":12645,"completion":12645,"start":12646,"enrollment":1448,"conditions":15781,"interventions":15782},[90],[5851],[12649,12587,5887],{"trials":15784,"activeCount":102},[15785,15789],{"nctId":12691,"briefTitle":12692,"status":195,"phases":15786,"primaryCompletion":2152,"completion":2152,"start":9213,"enrollment":7536,"conditions":15787,"interventions":15788},[91],[12695],[5887,12587],{"nctId":12702,"briefTitle":12703,"status":195,"phases":15790,"primaryCompletion":2077,"completion":2077,"start":9213,"enrollment":12705,"conditions":15791,"interventions":15792},[91],[2631],[5887,5887,12587],{"trials":15794,"activeCount":102},[15795,15799,15803,15807,15811,15815,15823,15827,15831,15835,15839,15843,15847,15851],{"nctId":12771,"briefTitle":12772,"status":195,"phases":15796,"primaryCompletion":2542,"completion":2542,"start":6710,"enrollment":12774,"conditions":15797,"interventions":15798},[92],[12776],[5887,12587],{"nctId":12779,"briefTitle":12780,"status":195,"phases":15800,"completion":9963,"start":9901,"enrollment":9987,"conditions":15801,"interventions":15802},[92],[9308],[5887,12587],{"nctId":12792,"briefTitle":12793,"status":195,"phases":15804,"completion":4285,"start":7447,"enrollment":12795,"conditions":15805,"interventions":15806},[92],[12760],[5887,12588,12587],{"nctId":12799,"briefTitle":12800,"status":195,"phases":15808,"completion":5796,"start":7448,"enrollment":12802,"conditions":15809,"interventions":15810},[92],[12760,6873],[5887,12587],{"nctId":12806,"briefTitle":12807,"status":195,"phases":15812,"primaryCompletion":2068,"completion":2068,"start":2221,"enrollment":12809,"conditions":15813,"interventions":15814},[92],[12760],[5887,12587],{"nctId":15816,"briefTitle":15817,"status":195,"phases":15818,"primaryCompletion":5725,"completion":5725,"start":9124,"enrollment":3613,"conditions":15819,"interventions":15821},"NCT00214630","LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes",[92],[15820],"Acute Coronary Syndromes",[15822,13002],"rosuvastatin calcium",{"nctId":12813,"briefTitle":12814,"status":195,"phases":15824,"primaryCompletion":9944,"completion":9944,"start":4256,"enrollment":12816,"conditions":15825,"interventions":15826},[92],[12818],[5887,12587],{"nctId":12828,"briefTitle":12829,"status":195,"phases":15828,"completion":3990,"start":12831,"enrollment":12832,"conditions":15829,"interventions":15830},[92],[12760],[5887,12587,12835,12588],{"nctId":12837,"briefTitle":12838,"status":195,"phases":15832,"completion":4285,"start":9909,"conditions":15833,"interventions":15834},[92],[12760,12789],[5887,12587],{"nctId":12880,"briefTitle":12881,"status":195,"phases":15836,"completion":9944,"start":12883,"enrollment":12884,"conditions":15837,"interventions":15838},[92],[12869],[5887,12587],{"nctId":12888,"briefTitle":12889,"status":195,"phases":15840,"completion":4285,"start":12891,"enrollment":12892,"conditions":15841,"interventions":15842},[92],[12760],[5887,12587,12588],{"nctId":12934,"briefTitle":12935,"status":195,"phases":15844,"completion":12937,"start":12938,"enrollment":12939,"conditions":15845,"interventions":15846},[92],[12760,6873],[5887,12587],{"nctId":12943,"briefTitle":12944,"status":195,"phases":15848,"completion":4297,"start":4284,"enrollment":12946,"conditions":15849,"interventions":15850},[92],[12948],[5887,12587],{"nctId":12967,"briefTitle":12968,"status":195,"phases":15852,"completion":9944,"start":4299,"enrollment":12921,"conditions":15853,"interventions":15854},[92],[12760,6873],[5887,12587],{"trials":15856,"activeCount":102},[15857,15861,15865],{"nctId":12989,"briefTitle":12990,"status":195,"phases":15858,"primaryCompletion":2086,"completion":2086,"start":4297,"enrollment":12992,"conditions":15859,"interventions":15860},[93],[12994],[5887,12835,12587],{"nctId":12997,"briefTitle":12998,"status":443,"phases":15862,"primaryCompletion":2168,"completion":2168,"start":5742,"enrollment":2783,"conditions":15863,"interventions":15864},[93],[9308],[12551,13002],{"nctId":13028,"briefTitle":13029,"status":195,"phases":15866,"primaryCompletion":2524,"completion":2524,"start":5563,"enrollment":5947,"conditions":15867,"interventions":15868},[93],[13032],[5887,12587],{"trials":15870,"activeCount":102},[],{"intervention":2448,"totalTrials":963,"cells":15872},{"EARLY_PHASE1":15873,"PHASE1":15875,"PHASE2":15898,"PHASE3":15921,"PHASE4":15971,"NA":15973},{"trials":15874,"activeCount":102},[],{"trials":15876,"activeCount":122,"soonestReadout":15613},[15877,15884,15894],{"nctId":15878,"briefTitle":15879,"status":195,"phases":15880,"primaryCompletion":2243,"completion":2243,"start":2114,"enrollment":2260,"conditions":15881,"interventions":15882},"NCT01082120","Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus",[90],[22],[15883,2448],"AZD1656",{"nctId":15885,"briefTitle":15886,"status":195,"phases":15887,"primaryCompletion":2615,"completion":2615,"start":2570,"enrollment":520,"conditions":15888,"interventions":15891},"NCT01309854","Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects",[90],[7267,36,15776,2448,15889,15890],"Drug-drug Interaction","Amount of Pioglitazone in Blood",[15892,15893],"fostamatinib","pioglitazone",{"nctId":15610,"briefTitle":15611,"status":108,"phases":15895,"primaryCompletion":15613,"completion":15613,"start":15614,"enrollment":579,"conditions":15896,"interventions":15897},[90],[5851],[12585,15617,2448],{"trials":15899,"activeCount":102},[15900,15907,15915],{"nctId":15901,"briefTitle":15902,"status":443,"phases":15903,"primaryCompletion":2180,"completion":2180,"start":2746,"enrollment":5876,"conditions":15904,"interventions":15906},"NCT01703260","Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis",[91],[15905],"Nonalcoholic Steatohapatitis",[10068,2448],{"nctId":15908,"briefTitle":15909,"status":195,"phases":15910,"completion":4256,"start":15911,"enrollment":6346,"conditions":15912,"interventions":15913},"NCT00280865","GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes",[91],"2002-04",[31],[15914,2448],"Tesaglitazar",{"nctId":15916,"briefTitle":15917,"status":443,"phases":15918,"primaryCompletion":6562,"completion":6562,"start":4285,"enrollment":221,"conditions":15919,"interventions":15920},"NCT00229684","ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)",[91],[2089],[15914,15893],{"trials":15922,"activeCount":102},[15923,15927,15936,15942,15950,15958,15965],{"nctId":2440,"briefTitle":2441,"status":195,"phases":15924,"primaryCompletion":2443,"completion":2443,"start":2242,"enrollment":2444,"conditions":15925,"interventions":15926},[92],[31],[2044,2044,2173,2447,2448],{"nctId":15928,"briefTitle":15929,"status":195,"phases":15930,"primaryCompletion":2406,"completion":2516,"start":2414,"enrollment":15931,"conditions":15932,"interventions":15933},"NCT00676338","Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",[92],820,[22],[15934,2333,15935,15893],"exenatide once weekly","sitagliptin",{"nctId":15937,"briefTitle":15938,"status":195,"phases":15939,"primaryCompletion":2095,"completion":2068,"start":6710,"enrollment":6573,"conditions":15940,"interventions":15941},"NCT00637273","A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",[92],[22],[15934,15935,15893],{"nctId":15943,"briefTitle":15944,"status":195,"phases":15945,"primaryCompletion":4297,"completion":2086,"start":2087,"enrollment":15946,"conditions":15947,"interventions":15948},"NCT00295633","A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone",[92],565,[2089],[2108,2108,15893,15949,2333],"rosiglitazone",{"nctId":15951,"briefTitle":15952,"status":195,"phases":15953,"primaryCompletion":2639,"completion":2114,"start":9065,"enrollment":15954,"conditions":15955,"interventions":15956},"NCT00121667","Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone",[92],1462,[2089],[15957,15957,15957,2448],"Saxagliptin + Metformin",{"nctId":15959,"briefTitle":15960,"status":195,"phases":15961,"primaryCompletion":2169,"completion":4915,"start":7494,"enrollment":15962,"conditions":15963,"interventions":15964},"NCT00327015","A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",[92],1306,[2652],[2108,2108,2173,15893],{"nctId":15966,"briefTitle":15967,"status":443,"phases":15968,"primaryCompletion":5742,"completion":5742,"start":5796,"enrollment":3654,"conditions":15969,"interventions":15970},"NCT00226330","GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus",[92],[2089],[15914,2448],{"trials":15972,"activeCount":102},[],{"trials":15974,"activeCount":102},[],{"intervention":6279,"totalTrials":1979,"cells":15976},{"EARLY_PHASE1":15977,"PHASE1":15979,"PHASE2":15989,"PHASE3":15991,"PHASE4":16001,"NA":16003},{"trials":15978,"activeCount":102},[],{"trials":15980,"activeCount":122,"soonestReadout":4837},[15981,15985],{"nctId":7023,"briefTitle":7024,"status":195,"phases":15982,"primaryCompletion":7026,"completion":7026,"start":7027,"enrollment":1039,"conditions":15983,"interventions":15984},[90],[7029],[87,2198,6279,5887,6278],{"nctId":6272,"briefTitle":6273,"status":108,"phases":15986,"primaryCompletion":4837,"completion":337,"start":6178,"enrollment":6275,"conditions":15987,"interventions":15988},[90],[157],[1959,2198,6278,6279,5887,1352],{"trials":15990,"activeCount":102},[],{"trials":15992,"activeCount":102},[15993,15997],{"nctId":2494,"briefTitle":2495,"status":195,"phases":15994,"primaryCompletion":2057,"completion":2243,"start":2251,"enrollment":2497,"conditions":15995,"interventions":15996},[92],[31],[2246,2080,2500,2501,2502],{"nctId":2576,"briefTitle":2577,"status":195,"phases":15998,"primaryCompletion":2055,"completion":2579,"start":2580,"enrollment":2581,"conditions":15999,"interventions":16000},[92],[31],[2246,2584,2500],{"trials":16002,"activeCount":102},[],{"trials":16004,"activeCount":102},[],{"intervention":43,"totalTrials":2222,"cells":16006},{"EARLY_PHASE1":16007,"PHASE1":16009,"PHASE2":16038,"PHASE3":16072,"PHASE4":16074,"NA":16076},{"trials":16008,"activeCount":102},[],{"trials":16010,"activeCount":122,"soonestReadout":42},[16011,16018,16025,16029],{"nctId":16012,"briefTitle":16013,"status":195,"phases":16014,"primaryCompletion":2320,"completion":2242,"start":2507,"enrollment":1710,"conditions":16015,"interventions":16017},"NCT00710515","Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies",[90],[410,16016],"Malignant Melanoma",[43],{"nctId":40,"briefTitle":41,"status":108,"phases":16019,"primaryCompletion":42,"completion":16020,"start":16021,"enrollment":3180,"conditions":16022,"interventions":16024},[90],"2027-03-26","2007-03-08",[16023,556],"Tumor",[43],{"nctId":6624,"briefTitle":6625,"status":195,"phases":16026,"primaryCompletion":6627,"completion":6628,"start":6629,"enrollment":1842,"conditions":16027,"interventions":16028},[90],[25,306,6631,6632,6633,3174,410,6634],[43,6636,5317,369,6637],{"nctId":16030,"briefTitle":16031,"status":195,"phases":16032,"primaryCompletion":16033,"completion":13756,"start":2471,"enrollment":689,"conditions":16034,"interventions":16037},"NCT01605916","Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer",[90],"2015-04",[16035,16036,262,157],"Neoplasms,","Metastatic Cancer,",[43],{"trials":16039,"activeCount":102},[16040,16048,16052,16056,16060,16064,16068],{"nctId":16041,"briefTitle":16042,"status":195,"phases":16043,"primaryCompletion":4580,"completion":16044,"start":2068,"enrollment":16045,"conditions":16046,"interventions":16047},"NCT00936221","Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients",[91],"2014-11",385,[410],[43,6636],{"nctId":5559,"briefTitle":5560,"status":195,"phases":16049,"primaryCompletion":5562,"completion":2507,"start":5563,"enrollment":4307,"conditions":16050,"interventions":16051},[91],[5121],[43,121],{"nctId":6656,"briefTitle":6657,"status":195,"phases":16053,"primaryCompletion":6659,"completion":6660,"start":6661,"enrollment":4917,"conditions":16054,"interventions":16055},[91],[3864],[43,5940],{"nctId":13853,"briefTitle":13854,"status":195,"phases":16057,"primaryCompletion":2415,"completion":13856,"start":12905,"enrollment":13857,"conditions":16058,"interventions":16059},[91],[410],[43,160],{"nctId":4912,"briefTitle":4913,"status":195,"phases":16061,"primaryCompletion":2252,"completion":4915,"start":4916,"enrollment":4917,"conditions":16062,"interventions":16063},[91],[1049],[43,345],{"nctId":9186,"briefTitle":9187,"status":195,"phases":16065,"primaryCompletion":2481,"completion":2481,"start":2113,"enrollment":579,"conditions":16066,"interventions":16067},[91],[691],[43,4615],{"nctId":5575,"briefTitle":5576,"status":195,"phases":16069,"primaryCompletion":2251,"completion":2086,"start":4916,"enrollment":3476,"conditions":16070,"interventions":16071},[91],[415],[43,5580],{"trials":16073,"activeCount":102},[],{"trials":16075,"activeCount":102},[],{"trials":16077,"activeCount":102},[],{"intervention":48,"totalTrials":4343,"cells":16079},{"EARLY_PHASE1":16080,"PHASE1":16082,"PHASE2":16117,"PHASE3":16148,"PHASE4":16150,"NA":16152},{"trials":16081,"activeCount":102},[],{"trials":16083,"activeCount":122,"soonestReadout":47},[16084,16088,16094,16098,16102,16112],{"nctId":5632,"briefTitle":5633,"status":195,"phases":16085,"primaryCompletion":2077,"completion":2057,"start":2524,"enrollment":1336,"conditions":16086,"interventions":16087},[90],[5636],[48,239],{"nctId":16089,"briefTitle":16090,"status":195,"phases":16091,"primaryCompletion":2086,"completion":2086,"start":2251,"enrollment":1039,"conditions":16092,"interventions":16093},"NCT00633269","Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours",[90],[5636],[48],{"nctId":4461,"briefTitle":4462,"status":195,"phases":16095,"primaryCompletion":4464,"completion":4465,"start":4466,"enrollment":3855,"conditions":16096,"interventions":16097},[90],[25,993,115],[48,118],{"nctId":4209,"briefTitle":4210,"status":195,"phases":16099,"primaryCompletion":4212,"completion":4213,"start":4214,"enrollment":4215,"conditions":16100,"interventions":16101},[90],[4217],[48,177],{"nctId":16103,"briefTitle":16104,"status":443,"phases":16105,"primaryCompletion":16106,"completion":16107,"start":16108,"enrollment":3811,"conditions":16109,"interventions":16110},"NCT00819221","AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours",[90],"2011-11-30","2021-12-22","2009-01-05",[3056],[48,16111],"liposomal doxorubicin",{"nctId":45,"briefTitle":46,"status":108,"phases":16113,"primaryCompletion":47,"completion":1965,"start":16114,"enrollment":9131,"conditions":16115,"interventions":16116},[90],"2008-10-27",[3056],[48],{"trials":16118,"activeCount":102},[16119,16128,16138],{"nctId":16120,"briefTitle":16121,"status":195,"phases":16122,"primaryCompletion":16123,"completion":16124,"start":16125,"enrollment":4381,"conditions":16126,"interventions":16127},"NCT00753545","Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer",[91],"2010-06-30","2023-10-12","2008-08-28",[414],[48],{"nctId":16129,"briefTitle":16130,"status":195,"phases":16131,"primaryCompletion":16132,"completion":16133,"start":16134,"enrollment":13007,"conditions":16135,"interventions":16136},"NCT00628251","Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer",[91],"2009-09-15","2018-09-19","2008-07-30",[3026],[48,16137,48],"Liposomal Doxorubicin",{"nctId":16139,"briefTitle":16140,"status":195,"phases":16141,"primaryCompletion":16142,"completion":16143,"start":16144,"enrollment":6390,"conditions":16145,"interventions":16147},"NCT00679783","Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status\u002F Triple Neg Breast Cancer",[91],"2010-03-26","2022-07-20","2008-07-08",[16146,25],"Ovarian Carcinoma",[48],{"trials":16149,"activeCount":102},[],{"trials":16151,"activeCount":102},[],{"trials":16153,"activeCount":102},[],{"intervention":570,"totalTrials":1855,"cells":16155},{"EARLY_PHASE1":16156,"PHASE1":16158,"PHASE2":16186,"PHASE3":16202,"PHASE4":16204,"NA":16206},{"trials":16157,"activeCount":102},[],{"trials":16159,"activeCount":122,"soonestReadout":562},[16160,16170,16174,16178,16182],{"nctId":16161,"briefTitle":16162,"status":195,"phases":16163,"primaryCompletion":16164,"completion":16164,"start":16165,"enrollment":37,"conditions":16166,"interventions":16169},"NCT02610075","Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.",[90],"2018-04-26","2015-12-01",[16167,16168,414],"Locally Advanced Solid Tumours","Metastatic Solid Tumours",[570],{"nctId":3849,"briefTitle":3850,"status":195,"phases":16171,"primaryCompletion":3852,"completion":3853,"start":3854,"enrollment":3855,"conditions":16172,"interventions":16173},[90],[498],[570,118,672],{"nctId":559,"briefTitle":560,"status":108,"phases":16175,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":16176,"interventions":16177},[90],[567],[569,82,267,570,266,571,68],{"nctId":8106,"briefTitle":8107,"status":195,"phases":16179,"primaryCompletion":8109,"completion":8110,"start":5223,"enrollment":2933,"conditions":16180,"interventions":16181},[90],[498],[570,82],{"nctId":583,"briefTitle":584,"status":195,"phases":16183,"primaryCompletion":586,"completion":587,"start":588,"enrollment":589,"conditions":16184,"interventions":16185},[90],[591,592],[570,267],{"trials":16187,"activeCount":102},[16188,16198],{"nctId":16189,"briefTitle":16190,"status":443,"phases":16191,"primaryCompletion":13756,"completion":13756,"start":4006,"enrollment":5898,"conditions":16192,"interventions":16194},"NCT02087176","A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer",[91],[16193],"Previously Treated Non Small Cell Lung Cancer",[570,16195,16196,16197],"AZD1775 Placebo","Antimitotic Agent","pegfiligrastim",{"nctId":4002,"briefTitle":4003,"status":443,"phases":16199,"primaryCompletion":4005,"completion":4005,"start":4006,"enrollment":434,"conditions":16200,"interventions":16201},[91],[4008],[570,3804,672],{"trials":16203,"activeCount":102},[],{"trials":16205,"activeCount":102},[],{"trials":16207,"activeCount":102},[],{"intervention":569,"totalTrials":723,"cells":16209},{"EARLY_PHASE1":16210,"PHASE1":16212,"PHASE2":16233,"PHASE3":16243,"PHASE4":16245,"NA":16247},{"trials":16211,"activeCount":102},[],{"trials":16213,"activeCount":122,"soonestReadout":562},[16214,16223,16227],{"nctId":16215,"briefTitle":16216,"status":443,"phases":16217,"primaryCompletion":16218,"completion":16219,"start":16220,"enrollment":29,"conditions":16221,"interventions":16222},"NCT00979134","Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours",[90],"2014-02-12","2015-03-05","2009-10-21",[556,157],[569,569,569],{"nctId":559,"briefTitle":560,"status":108,"phases":16224,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":16225,"interventions":16226},[90],[567],[569,82,267,570,266,571,68],{"nctId":16228,"briefTitle":16229,"status":195,"phases":16230,"primaryCompletion":2746,"completion":2746,"start":2349,"enrollment":1448,"conditions":16231,"interventions":16232},"NCT01213160","Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient",[90],[556,157],[569],{"trials":16234,"activeCount":102},[16235,16239],{"nctId":6433,"briefTitle":6434,"status":195,"phases":16236,"primaryCompletion":2180,"completion":6436,"start":2143,"enrollment":235,"conditions":16237,"interventions":16238},[90,91],[6438,6439],[569,6350,53],{"nctId":4577,"briefTitle":4578,"status":443,"phases":16240,"primaryCompletion":1701,"completion":2561,"start":4580,"enrollment":4581,"conditions":16241,"interventions":16242},[91],[4583,172],[569,620],{"trials":16244,"activeCount":102},[],{"trials":16246,"activeCount":102},[],{"trials":16248,"activeCount":102},[],{"intervention":571,"totalTrials":1979,"cells":16250},{"EARLY_PHASE1":16251,"PHASE1":16253,"PHASE2":16271,"PHASE3":16277,"PHASE4":16279,"NA":16281},{"trials":16252,"activeCount":102},[],{"trials":16254,"activeCount":122,"soonestReadout":562},[16255,16259,16263],{"nctId":3087,"briefTitle":3088,"status":195,"phases":16256,"primaryCompletion":3090,"completion":3091,"start":3092,"enrollment":3093,"conditions":16257,"interventions":16258},[90],[498],[571,117,177,3096,344,283,3097],{"nctId":559,"briefTitle":560,"status":108,"phases":16260,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":16261,"interventions":16262},[90],[567],[569,82,267,570,266,571,68],{"nctId":16264,"briefTitle":16265,"status":195,"phases":16266,"primaryCompletion":2561,"completion":2561,"start":7354,"enrollment":3180,"conditions":16267,"interventions":16270},"NCT01839604","A Phase I\u002FIb Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced\u002FMetastatic Hepatocellular Carcinoma",[90],[16268,16269],"Advanced Adult Hepatocellular Carcinoma","Hepatocellular Carcinoma Metastatic",[571],{"trials":16272,"activeCount":102},[16273],{"nctId":5264,"briefTitle":5265,"status":195,"phases":16274,"primaryCompletion":5267,"completion":5268,"start":588,"enrollment":5269,"conditions":16275,"interventions":16276},[90,91],[5271],[571,82,5273,3038],{"trials":16278,"activeCount":102},[],{"trials":16280,"activeCount":102},[],{"trials":16282,"activeCount":102},[],{"intervention":5911,"totalTrials":1336,"cells":16284},{"EARLY_PHASE1":16285,"PHASE1":16287,"PHASE2":16396,"PHASE3":16398,"PHASE4":16400,"NA":16402},{"trials":16286,"activeCount":102},[],{"trials":16288,"activeCount":122,"soonestReadout":9002},[16289,16293,16297,16301,16305,16312,16316,16320,16327,16331,16339,16343,16347,16358,16366,16370,16381,16385],{"nctId":10130,"briefTitle":10131,"status":195,"phases":16290,"primaryCompletion":10133,"completion":10133,"start":1766,"enrollment":1638,"conditions":16291,"interventions":16292},[90],[5851],[10123,5911],{"nctId":15560,"briefTitle":15561,"status":195,"phases":16294,"primaryCompletion":6115,"completion":6115,"start":6999,"enrollment":5425,"conditions":16295,"interventions":16296},[90],[5851],[12585,5911,10177],{"nctId":12402,"briefTitle":12403,"status":195,"phases":16298,"primaryCompletion":12405,"completion":12406,"start":12407,"enrollment":486,"conditions":16299,"interventions":16300},[90],[157],[1939,5911],{"nctId":6867,"briefTitle":6868,"status":195,"phases":16302,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":3209,"conditions":16303,"interventions":16304},[90],[6873],[6860,5911,6875,5870,6876],{"nctId":16306,"briefTitle":16307,"status":443,"phases":16308,"primaryCompletion":16309,"completion":16309,"start":3072,"enrollment":723,"conditions":16310,"interventions":16311},"NCT04959266","A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib",[90],"2022-06-01",[498],[3914,5911,7055,8361],{"nctId":7130,"briefTitle":7131,"status":195,"phases":16313,"primaryCompletion":7133,"completion":7133,"start":7134,"enrollment":1638,"conditions":16314,"interventions":16315},[90],[1556],[3966,5911],{"nctId":7032,"briefTitle":7033,"status":195,"phases":16317,"primaryCompletion":7035,"completion":7035,"start":7036,"enrollment":486,"conditions":16318,"interventions":16319},[90],[5868],[87,5911],{"nctId":16321,"briefTitle":16322,"status":195,"phases":16323,"primaryCompletion":7618,"completion":13131,"start":4204,"enrollment":3007,"conditions":16324,"interventions":16325},"NCT01900028","To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours",[90],[466],[16326,5911],"Olaparib tablet dosing",{"nctId":7615,"briefTitle":7616,"status":195,"phases":16328,"primaryCompletion":2470,"completion":2470,"start":7618,"enrollment":2827,"conditions":16329,"interventions":16330},[90],[466],[3801,7621,7621,3801,3801,7622,7622,3801],{"nctId":16332,"briefTitle":16333,"status":195,"phases":16334,"primaryCompletion":16335,"completion":16335,"start":3674,"enrollment":544,"conditions":16336,"interventions":16337},"NCT05236543","A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole",[90],"2022-08-12",[36],[16338,5911],"AZD4831",{"nctId":8999,"briefTitle":9000,"status":151,"phases":16340,"primaryCompletion":9002,"completion":9002,"start":1308,"enrollment":1130,"conditions":16341,"interventions":16342},[90],[9004,414,9005],[3925,5911],{"nctId":13162,"briefTitle":13163,"status":195,"phases":16344,"primaryCompletion":13165,"completion":13165,"start":13166,"enrollment":486,"conditions":16345,"interventions":16346},[90],[5851],[13145,5911],{"nctId":16348,"briefTitle":16349,"status":195,"phases":16350,"primaryCompletion":16351,"completion":16352,"start":16353,"enrollment":3190,"conditions":16354,"interventions":16357},"NCT02157883","Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)",[90],"2015-04-03","2023-05-17","2014-11-06",[16355,16356],"Advanced Non Small Cell Lung Cancer","Advanced (Inoperable) Non Small Cell Lung Cancer",[5257,5911],{"nctId":16359,"briefTitle":16360,"status":195,"phases":16361,"primaryCompletion":16362,"completion":16362,"start":16363,"enrollment":1638,"conditions":16364,"interventions":16365},"NCT03843060","A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers",[90],"2019-04-01","2019-02-22",[2723],[2389,5911],{"nctId":13989,"briefTitle":13990,"status":195,"phases":16367,"primaryCompletion":13992,"completion":13992,"start":13993,"enrollment":4497,"conditions":16368,"interventions":16369},[90],[5851],[13957,5911,13996],{"nctId":16371,"briefTitle":16372,"status":195,"phases":16373,"primaryCompletion":16374,"completion":16374,"start":16375,"enrollment":520,"conditions":16376,"interventions":16377},"NCT02653872","A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects",[90],"2016-04-13","2016-01-22",[1556],[16378,16379,5911,16380],"AZD7986","Verapamil","Diltiazem",{"nctId":5903,"briefTitle":5904,"status":195,"phases":16382,"primaryCompletion":5906,"completion":5906,"start":5907,"enrollment":2222,"conditions":16383,"interventions":16384},[90],[5909],[119,5911],{"nctId":16386,"briefTitle":16387,"status":443,"phases":16388,"primaryCompletion":15717,"completion":15717,"start":10140,"enrollment":520,"conditions":16389,"interventions":16391},"NCT06406400","Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).",[90],[16390],"Opioid Use Disorder",[16392,5911,16393,16394,16395],"AZD4041","Buprenorphine","Buprenorphine \u002F Naloxone","Hydromorphone",{"trials":16397,"activeCount":102},[],{"trials":16399,"activeCount":102},[],{"trials":16401,"activeCount":102},[],{"trials":16403,"activeCount":102},[],{"intervention":2198,"totalTrials":370,"cells":16405},{"EARLY_PHASE1":16406,"PHASE1":16408,"PHASE2":16452,"PHASE3":16454,"PHASE4":16456,"NA":16458},{"trials":16407,"activeCount":102},[],{"trials":16409,"activeCount":122,"soonestReadout":4837},[16410,16414,16420,16426,16430,16434,16438,16444],{"nctId":7023,"briefTitle":7024,"status":195,"phases":16411,"primaryCompletion":7026,"completion":7026,"start":7027,"enrollment":1039,"conditions":16412,"interventions":16413},[90],[7029],[87,2198,6279,5887,6278],{"nctId":16415,"briefTitle":16416,"status":195,"phases":16417,"primaryCompletion":2571,"completion":2571,"start":2542,"enrollment":544,"conditions":16418,"interventions":16419},"NCT01355354","Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects",[90],[36,7267],[2198,12604],{"nctId":16421,"briefTitle":16422,"status":195,"phases":16423,"primaryCompletion":2143,"completion":2143,"start":2242,"enrollment":5876,"conditions":16424,"interventions":16425},"NCT01103622","Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients",[90],[22],[15883,2198],{"nctId":2192,"briefTitle":2193,"status":195,"phases":16427,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1710,"conditions":16428,"interventions":16429},[90],[22],[2044,2197,2198],{"nctId":6272,"briefTitle":6273,"status":108,"phases":16431,"primaryCompletion":4837,"completion":337,"start":6178,"enrollment":6275,"conditions":16432,"interventions":16433},[90],[157],[1959,2198,6278,6279,5887,1352],{"nctId":12622,"briefTitle":12623,"status":195,"phases":16435,"primaryCompletion":1497,"completion":1497,"start":12625,"enrollment":579,"conditions":16436,"interventions":16437},[90],[5851],[2281,5870,5887,2198],{"nctId":16439,"briefTitle":16440,"status":195,"phases":16441,"primaryCompletion":4915,"completion":4915,"start":2507,"enrollment":1130,"conditions":16442,"interventions":16443},"NCT00723424","Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin",[90],[36,15776],[15778,2198],{"nctId":16445,"briefTitle":16446,"status":195,"phases":16447,"primaryCompletion":2414,"completion":2414,"start":2220,"enrollment":1336,"conditions":16448,"interventions":16450},"NCT00712465","An Interaction Study With Digoxin and AZD1305",[90],[16449],"Atrial Fibrillation",[16451,2198],"AZD1305",{"trials":16453,"activeCount":102},[],{"trials":16455,"activeCount":102},[],{"trials":16457,"activeCount":102},[],{"trials":16459,"activeCount":102},[],{"intervention":12255,"totalTrials":3887,"cells":16461},{"EARLY_PHASE1":16462,"PHASE1":16464,"PHASE2":16487,"PHASE3":16489,"PHASE4":16491,"NA":16493},{"trials":16463,"activeCount":102},[],{"trials":16465,"activeCount":122,"soonestReadout":12260},[16466,16479,16483],{"nctId":16467,"briefTitle":16468,"status":195,"phases":16469,"primaryCompletion":16470,"completion":16470,"start":16471,"enrollment":1130,"conditions":16472,"interventions":16474},"NCT03649165","A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants",[90],"2018-10-21","2018-09-05",[16473,5851],"Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)",[16475,16476,16477,16478,12255],"Treatment A","Treatment B","Treatment C","Treatment D",{"nctId":12249,"briefTitle":12250,"status":195,"phases":16480,"primaryCompletion":12252,"completion":12252,"start":10157,"enrollment":680,"conditions":16481,"interventions":16482},[90],[5851],[12218,12255],{"nctId":12257,"briefTitle":12258,"status":151,"phases":16484,"primaryCompletion":12260,"completion":12260,"start":7008,"enrollment":4286,"conditions":16485,"interventions":16486},[90],[5851],[12218,12263,12255,12247],{"trials":16488,"activeCount":102},[],{"trials":16490,"activeCount":102},[],{"trials":16492,"activeCount":102},[],{"trials":16494,"activeCount":102},[],{"intervention":1352,"totalTrials":3887,"cells":16496},{"EARLY_PHASE1":16497,"PHASE1":16499,"PHASE2":16513,"PHASE3":16515,"PHASE4":16517,"NA":16519},{"trials":16498,"activeCount":102},[],{"trials":16500,"activeCount":122,"soonestReadout":4837},[16501,16505,16509],{"nctId":6272,"briefTitle":6273,"status":108,"phases":16502,"primaryCompletion":4837,"completion":337,"start":6178,"enrollment":6275,"conditions":16503,"interventions":16504},[90],[157],[1959,2198,6278,6279,5887,1352],{"nctId":1343,"briefTitle":1344,"status":195,"phases":16506,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":1348,"conditions":16507,"interventions":16508},[90],[1350],[1335,1352],{"nctId":5893,"briefTitle":5894,"status":195,"phases":16510,"primaryCompletion":5896,"completion":5896,"start":5897,"enrollment":5898,"conditions":16511,"interventions":16512},[90],[5900],[119,1352],{"trials":16514,"activeCount":102},[],{"trials":16516,"activeCount":102},[],{"trials":16518,"activeCount":102},[],{"trials":16520,"activeCount":102},[],{"intervention":6278,"totalTrials":447,"cells":16522},{"EARLY_PHASE1":16523,"PHASE1":16525,"PHASE2":16535,"PHASE3":16537,"PHASE4":16539,"NA":16541},{"trials":16524,"activeCount":102},[],{"trials":16526,"activeCount":122,"soonestReadout":4837},[16527,16531],{"nctId":7023,"briefTitle":7024,"status":195,"phases":16528,"primaryCompletion":7026,"completion":7026,"start":7027,"enrollment":1039,"conditions":16529,"interventions":16530},[90],[7029],[87,2198,6279,5887,6278],{"nctId":6272,"briefTitle":6273,"status":108,"phases":16532,"primaryCompletion":4837,"completion":337,"start":6178,"enrollment":6275,"conditions":16533,"interventions":16534},[90],[157],[1959,2198,6278,6279,5887,1352],{"trials":16536,"activeCount":102},[],{"trials":16538,"activeCount":102},[],{"trials":16540,"activeCount":102},[],{"trials":16542,"activeCount":102},[],{"intervention":8372,"totalTrials":447,"cells":16544},{"EARLY_PHASE1":16545,"PHASE1":16547,"PHASE2":16557,"PHASE3":16559,"PHASE4":16561,"NA":16563},{"trials":16546,"activeCount":102},[],{"trials":16548,"activeCount":122,"soonestReadout":8378},[16549,16553],{"nctId":8365,"briefTitle":8366,"status":195,"phases":16550,"primaryCompletion":3333,"completion":3333,"start":8368,"enrollment":2260,"conditions":16551,"interventions":16552},[90],[8370],[6431,6431,8372,8373],{"nctId":8375,"briefTitle":8376,"status":108,"phases":16554,"primaryCompletion":8378,"completion":8292,"start":8379,"enrollment":8380,"conditions":16555,"interventions":16556},[90],[7161],[6431,6431,8372,8372,8373,8373,8383,8383,8384,8384,8385,8385,8386,8386],{"trials":16558,"activeCount":102},[],{"trials":16560,"activeCount":102},[],{"trials":16562,"activeCount":102},[],{"trials":16564,"activeCount":102},[],{"intervention":8373,"totalTrials":447,"cells":16566},{"EARLY_PHASE1":16567,"PHASE1":16569,"PHASE2":16579,"PHASE3":16581,"PHASE4":16583,"NA":16585},{"trials":16568,"activeCount":102},[],{"trials":16570,"activeCount":122,"soonestReadout":8378},[16571,16575],{"nctId":8365,"briefTitle":8366,"status":195,"phases":16572,"primaryCompletion":3333,"completion":3333,"start":8368,"enrollment":2260,"conditions":16573,"interventions":16574},[90],[8370],[6431,6431,8372,8373],{"nctId":8375,"briefTitle":8376,"status":108,"phases":16576,"primaryCompletion":8378,"completion":8292,"start":8379,"enrollment":8380,"conditions":16577,"interventions":16578},[90],[7161],[6431,6431,8372,8372,8373,8373,8383,8383,8384,8384,8385,8385,8386,8386],{"trials":16580,"activeCount":102},[],{"trials":16582,"activeCount":102},[],{"trials":16584,"activeCount":102},[],{"trials":16586,"activeCount":102},[],{"intervention":6876,"totalTrials":447,"cells":16588},{"EARLY_PHASE1":16589,"PHASE1":16591,"PHASE2":16601,"PHASE3":16603,"PHASE4":16605,"NA":16607},{"trials":16590,"activeCount":102},[],{"trials":16592,"activeCount":122,"soonestReadout":12260},[16593,16597],{"nctId":6867,"briefTitle":6868,"status":195,"phases":16594,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":3209,"conditions":16595,"interventions":16596},[90],[6873],[6860,5911,6875,5870,6876],{"nctId":12257,"briefTitle":12258,"status":151,"phases":16598,"primaryCompletion":12260,"completion":12260,"start":7008,"enrollment":4286,"conditions":16599,"interventions":16600},[90],[5851],[12218,12263,12255,12247],{"trials":16602,"activeCount":102},[],{"trials":16604,"activeCount":102},[],{"trials":16606,"activeCount":102},[],{"trials":16608,"activeCount":102},[],{"intervention":5370,"totalTrials":122,"cells":16610},{"EARLY_PHASE1":16611,"PHASE1":16613,"PHASE2":16619,"PHASE3":16621,"PHASE4":16623,"NA":16625},{"trials":16612,"activeCount":102},[],{"trials":16614,"activeCount":122,"soonestReadout":5364},[16615],{"nctId":5361,"briefTitle":5362,"status":151,"phases":16616,"primaryCompletion":5364,"completion":5364,"start":678,"enrollment":5365,"conditions":16617,"interventions":16618},[90],[498,5367,4258,5368],[5370,1012,226,4843,239],{"trials":16620,"activeCount":102},[],{"trials":16622,"activeCount":102},[],{"trials":16624,"activeCount":102},[],{"trials":16626,"activeCount":102},[],{"intervention":5853,"totalTrials":122,"cells":16628},{"EARLY_PHASE1":16629,"PHASE1":16631,"PHASE2":16637,"PHASE3":16639,"PHASE4":16641,"NA":16643},{"trials":16630,"activeCount":102},[],{"trials":16632,"activeCount":122,"soonestReadout":5848},[16633],{"nctId":5845,"briefTitle":5846,"status":151,"phases":16634,"primaryCompletion":5848,"completion":5848,"start":5849,"enrollment":2069,"conditions":16635,"interventions":16636},[90],[5851],[5853,119],{"trials":16638,"activeCount":102},[],{"trials":16640,"activeCount":102},[],{"trials":16642,"activeCount":102},[],{"trials":16644,"activeCount":102},[],{"intervention":16646,"totalTrials":122,"cells":16647},"Budesonide\u002Fformoterol fumarate Aerosphere",{"EARLY_PHASE1":16648,"PHASE1":16650,"PHASE2":16659,"PHASE3":16661,"PHASE4":16663,"NA":16665},{"trials":16649,"activeCount":102},[],{"trials":16651,"activeCount":122,"soonestReadout":3531},[16652],{"nctId":16653,"briefTitle":16654,"status":108,"phases":16655,"primaryCompletion":3531,"completion":3531,"start":15582,"enrollment":520,"conditions":16656,"interventions":16657},"NCT07433569","A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma",[90],[16],[16646,16658],"Budesonide\u002Fformoterol fumarate pMDI",{"trials":16660,"activeCount":102},[],{"trials":16662,"activeCount":102},[],{"trials":16664,"activeCount":102},[],{"trials":16666,"activeCount":102},[],{"intervention":16658,"totalTrials":122,"cells":16668},{"EARLY_PHASE1":16669,"PHASE1":16671,"PHASE2":16677,"PHASE3":16679,"PHASE4":16681,"NA":16683},{"trials":16670,"activeCount":102},[],{"trials":16672,"activeCount":122,"soonestReadout":3531},[16673],{"nctId":16653,"briefTitle":16654,"status":108,"phases":16674,"primaryCompletion":3531,"completion":3531,"start":15582,"enrollment":520,"conditions":16675,"interventions":16676},[90],[16],[16646,16658],{"trials":16678,"activeCount":102},[],{"trials":16680,"activeCount":102},[],{"trials":16682,"activeCount":102},[],{"trials":16684,"activeCount":102},[],{"intervention":15722,"totalTrials":122,"cells":16686},{"EARLY_PHASE1":16687,"PHASE1":16689,"PHASE2":16695,"PHASE3":16697,"PHASE4":16699,"NA":16701},{"trials":16688,"activeCount":102},[],{"trials":16690,"activeCount":122,"soonestReadout":15716},[16691],{"nctId":15713,"briefTitle":15714,"status":151,"phases":16692,"primaryCompletion":15716,"completion":15716,"start":15717,"enrollment":3476,"conditions":16693,"interventions":16694},[90],[4879,15719,546,1049,5772,172,417],[15706,15721,15722],{"trials":16696,"activeCount":102},[],{"trials":16698,"activeCount":102},[],{"trials":16700,"activeCount":102},[],{"trials":16702,"activeCount":102},[],{"intervention":16704,"totalTrials":122,"cells":16705},"AZD1613",{"EARLY_PHASE1":16706,"PHASE1":16708,"PHASE2":16718,"PHASE3":16720,"PHASE4":16722,"NA":16724},{"trials":16707,"activeCount":102},[],{"trials":16709,"activeCount":122,"soonestReadout":16714},[16710],{"nctId":16711,"briefTitle":16712,"status":151,"phases":16713,"primaryCompletion":16714,"completion":16714,"start":16715,"enrollment":12505,"conditions":16716,"interventions":16717},"NCT06995820","A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.",[90],"2026-09-23","2025-06-06",[19],[16704],{"trials":16719,"activeCount":102},[],{"trials":16721,"activeCount":102},[],{"trials":16723,"activeCount":102},[],{"trials":16725,"activeCount":102},[],{"intervention":16727,"totalTrials":122,"cells":16728},"[14C]AZD4144 Solution for",{"EARLY_PHASE1":16729,"PHASE1":16731,"PHASE2":16741,"PHASE3":16743,"PHASE4":16745,"NA":16747},{"trials":16730,"activeCount":102},[],{"trials":16732,"activeCount":122,"soonestReadout":11525},[16733],{"nctId":16734,"briefTitle":16735,"status":108,"phases":16736,"primaryCompletion":11525,"completion":11525,"start":16737,"enrollment":370,"conditions":16738,"interventions":16739},"NCT07518459","A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144",[90],"2026-02-11",[5851],[16727,16740],"[14C]AZD4144 Oral Solution",{"trials":16742,"activeCount":102},[],{"trials":16744,"activeCount":102},[],{"trials":16746,"activeCount":102},[],{"trials":16748,"activeCount":102},[],{"intervention":16740,"totalTrials":122,"cells":16750},{"EARLY_PHASE1":16751,"PHASE1":16753,"PHASE2":16759,"PHASE3":16761,"PHASE4":16763,"NA":16765},{"trials":16752,"activeCount":102},[],{"trials":16754,"activeCount":122,"soonestReadout":11525},[16755],{"nctId":16734,"briefTitle":16735,"status":108,"phases":16756,"primaryCompletion":11525,"completion":11525,"start":16737,"enrollment":370,"conditions":16757,"interventions":16758},[90],[5851],[16727,16740],{"trials":16760,"activeCount":102},[],{"trials":16762,"activeCount":102},[],{"trials":16764,"activeCount":102},[],{"trials":16766,"activeCount":102},[],{"intervention":16768,"totalTrials":122,"cells":16769},"AZD4063",{"EARLY_PHASE1":16770,"PHASE1":16772,"PHASE2":16782,"PHASE3":16784,"PHASE4":16786,"NA":16788},{"trials":16771,"activeCount":102},[],{"trials":16773,"activeCount":122,"soonestReadout":16778},[16774],{"nctId":16775,"briefTitle":16776,"status":151,"phases":16777,"primaryCompletion":16778,"completion":16778,"start":3334,"enrollment":3248,"conditions":16779,"interventions":16781},"NCT07241104","A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy",[90],"2027-11-22",[16780],"Dilated Cardiomyopathy",[16768],{"trials":16783,"activeCount":102},[],{"trials":16785,"activeCount":102},[],{"trials":16787,"activeCount":102},[],{"trials":16789,"activeCount":102},[],{"intervention":3048,"totalTrials":122,"cells":16791},{"EARLY_PHASE1":16792,"PHASE1":16794,"PHASE2":16800,"PHASE3":16802,"PHASE4":16804,"NA":16806},{"trials":16793,"activeCount":102},[],{"trials":16795,"activeCount":122,"soonestReadout":1046},[16796],{"nctId":3042,"briefTitle":3043,"status":151,"phases":16797,"primaryCompletion":1046,"completion":1046,"start":3045,"enrollment":2792,"conditions":16798,"interventions":16799},[90],[342],[3048,117,177,344,345,179,180],{"trials":16801,"activeCount":102},[],{"trials":16803,"activeCount":102},[],{"trials":16805,"activeCount":102},[],{"trials":16807,"activeCount":102},[],{"intervention":16809,"totalTrials":122,"cells":16810},"Autologous, engineered T Cells targeting TP53 R175H",{"EARLY_PHASE1":16811,"PHASE1":16813,"PHASE2":16825,"PHASE3":16827,"PHASE4":16829,"NA":16831},{"trials":16812,"activeCount":102},[],{"trials":16814,"activeCount":122,"soonestReadout":16819},[16815],{"nctId":16816,"briefTitle":16817,"status":151,"phases":16818,"primaryCompletion":16819,"completion":16819,"start":16820,"enrollment":1864,"conditions":16821,"interventions":16824},"NCT05877599","A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and\u002For Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",[90],"2029-07-31","2023-07-12",[1049,546,16822,5226,25,16823,414],"Colorectal Carcinoma","Other Solid Tumors",[16809],{"trials":16826,"activeCount":102},[],{"trials":16828,"activeCount":102},[],{"trials":16830,"activeCount":102},[],{"trials":16832,"activeCount":102},[],{"intervention":16834,"totalTrials":122,"cells":16835},"AZD1705",{"EARLY_PHASE1":16836,"PHASE1":16838,"PHASE2":16848,"PHASE3":16850,"PHASE4":16852,"NA":16854},{"trials":16837,"activeCount":102},[],{"trials":16839,"activeCount":122,"soonestReadout":3334},[16840],{"nctId":16841,"briefTitle":16842,"status":108,"phases":16843,"primaryCompletion":3334,"completion":3560,"start":16844,"enrollment":8285,"conditions":16845,"interventions":16847},"NCT06238466","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia",[90],"2024-01-16",[16846],"Cardiovascular",[16834],{"trials":16849,"activeCount":102},[],{"trials":16851,"activeCount":102},[],{"trials":16853,"activeCount":102},[],{"trials":16855,"activeCount":102},[],{"intervention":16857,"totalTrials":122,"cells":16858},"IV Rilvegostomig",{"EARLY_PHASE1":16859,"PHASE1":16861,"PHASE2":16874,"PHASE3":16876,"PHASE4":16878,"NA":16880},{"trials":16860,"activeCount":102},[],{"trials":16862,"activeCount":122,"soonestReadout":16867},[16863],{"nctId":16864,"briefTitle":16865,"status":151,"phases":16866,"primaryCompletion":16867,"completion":16868,"start":6252,"enrollment":1448,"conditions":16869,"interventions":16870},"NCT07161414","A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy",[90],"2027-07-19","2029-07-24",[4217],[16857,16871,16872,16873],"Recombinant Human Hyaluronidase","SC Rilvegostomig","SC rilvegostomig + rHu",{"trials":16875,"activeCount":102},[],{"trials":16877,"activeCount":102},[],{"trials":16879,"activeCount":102},[],{"trials":16881,"activeCount":102},[],{"intervention":16871,"totalTrials":122,"cells":16883},{"EARLY_PHASE1":16884,"PHASE1":16886,"PHASE2":16892,"PHASE3":16894,"PHASE4":16896,"NA":16898},{"trials":16885,"activeCount":102},[],{"trials":16887,"activeCount":122,"soonestReadout":16867},[16888],{"nctId":16864,"briefTitle":16865,"status":151,"phases":16889,"primaryCompletion":16867,"completion":16868,"start":6252,"enrollment":1448,"conditions":16890,"interventions":16891},[90],[4217],[16857,16871,16872,16873],{"trials":16893,"activeCount":102},[],{"trials":16895,"activeCount":102},[],{"trials":16897,"activeCount":102},[],{"trials":16899,"activeCount":102},[],{"intervention":16872,"totalTrials":122,"cells":16901},{"EARLY_PHASE1":16902,"PHASE1":16904,"PHASE2":16910,"PHASE3":16912,"PHASE4":16914,"NA":16916},{"trials":16903,"activeCount":102},[],{"trials":16905,"activeCount":122,"soonestReadout":16867},[16906],{"nctId":16864,"briefTitle":16865,"status":151,"phases":16907,"primaryCompletion":16867,"completion":16868,"start":6252,"enrollment":1448,"conditions":16908,"interventions":16909},[90],[4217],[16857,16871,16872,16873],{"trials":16911,"activeCount":102},[],{"trials":16913,"activeCount":102},[],{"trials":16915,"activeCount":102},[],{"trials":16917,"activeCount":102},[],{"intervention":16873,"totalTrials":122,"cells":16919},{"EARLY_PHASE1":16920,"PHASE1":16922,"PHASE2":16928,"PHASE3":16930,"PHASE4":16932,"NA":16934},{"trials":16921,"activeCount":102},[],{"trials":16923,"activeCount":122,"soonestReadout":16867},[16924],{"nctId":16864,"briefTitle":16865,"status":151,"phases":16925,"primaryCompletion":16867,"completion":16868,"start":6252,"enrollment":1448,"conditions":16926,"interventions":16927},[90],[4217],[16857,16871,16872,16873],{"trials":16929,"activeCount":102},[],{"trials":16931,"activeCount":102},[],{"trials":16933,"activeCount":102},[],{"trials":16935,"activeCount":102},[],{"intervention":16937,"totalTrials":122,"cells":16938},"AZD3974",{"EARLY_PHASE1":16939,"PHASE1":16941,"PHASE2":16951,"PHASE3":16953,"PHASE4":16955,"NA":16957},{"trials":16940,"activeCount":102},[],{"trials":16942,"activeCount":122,"soonestReadout":16947},[16943],{"nctId":16944,"briefTitle":16945,"status":151,"phases":16946,"primaryCompletion":16947,"completion":16947,"start":14041,"enrollment":16948,"conditions":16949,"interventions":16950},"NCT07290283","A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants",[90],"2026-10-21",176,[5851],[16937],{"trials":16952,"activeCount":102},[],{"trials":16954,"activeCount":102},[],{"trials":16956,"activeCount":102},[],{"trials":16958,"activeCount":102},[],{"intervention":16960,"totalTrials":122,"cells":16961},"AZD4916",{"EARLY_PHASE1":16962,"PHASE1":16964,"PHASE2":16973,"PHASE3":16975,"PHASE4":16977,"NA":16979},{"trials":16963,"activeCount":102},[],{"trials":16965,"activeCount":122,"soonestReadout":8954},[16966],{"nctId":16967,"briefTitle":16968,"status":1097,"phases":16969,"primaryCompletion":8954,"completion":8954,"start":13908,"enrollment":16970,"conditions":16971,"interventions":16972},"NCT06951880","A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers",[90],178,[5851],[16960],{"trials":16974,"activeCount":102},[],{"trials":16976,"activeCount":102},[],{"trials":16978,"activeCount":102},[],{"trials":16980,"activeCount":102},[],{"intervention":16982,"totalTrials":122,"cells":16983},"Administration of ceralasertib",{"EARLY_PHASE1":16984,"PHASE1":16986,"PHASE2":17005,"PHASE3":17007,"PHASE4":17009,"NA":17011},{"trials":16985,"activeCount":102},[],{"trials":16987,"activeCount":122,"soonestReadout":16992},[16988],{"nctId":16989,"briefTitle":16990,"status":108,"phases":16991,"primaryCompletion":16992,"completion":130,"start":16993,"enrollment":16994,"conditions":16995,"interventions":16997},"NCT02264678","Ascending Doses of Ceralasertib in Combination With Chemotherapy and\u002For Novel Anti Cancer Agents",[90],"2025-03-04","2014-10-31",354,[16996],"Adv Solid Malig - H&N SCC, ATM Pro \u002F Def NSCLC, Gastric, Breast and Ovarian Cancer",[16982,16998,16999,17000,17001,17002,17003,17004],"Administration of ceralasertib in combination with olaparib","Administation of ceralasertib in combination with durvalumab","Administration of ceralasertib monotherapy","Administration of ceralasertib and olaparib","Administration of ceralasertib and durvalumab","Administration of ceralasertib in combination with AZD5305","Administration of ceralasertib in combination with carboplatin",{"trials":17006,"activeCount":102},[],{"trials":17008,"activeCount":102},[],{"trials":17010,"activeCount":102},[],{"trials":17012,"activeCount":102},[],{"intervention":16998,"totalTrials":122,"cells":17014},{"EARLY_PHASE1":17015,"PHASE1":17017,"PHASE2":17023,"PHASE3":17025,"PHASE4":17027,"NA":17029},{"trials":17016,"activeCount":102},[],{"trials":17018,"activeCount":122,"soonestReadout":16992},[17019],{"nctId":16989,"briefTitle":16990,"status":108,"phases":17020,"primaryCompletion":16992,"completion":130,"start":16993,"enrollment":16994,"conditions":17021,"interventions":17022},[90],[16996],[16982,16998,16999,17000,17001,17002,17003,17004],{"trials":17024,"activeCount":102},[],{"trials":17026,"activeCount":102},[],{"trials":17028,"activeCount":102},[],{"trials":17030,"activeCount":102},[],{"intervention":16999,"totalTrials":122,"cells":17032},{"EARLY_PHASE1":17033,"PHASE1":17035,"PHASE2":17041,"PHASE3":17043,"PHASE4":17045,"NA":17047},{"trials":17034,"activeCount":102},[],{"trials":17036,"activeCount":122,"soonestReadout":16992},[17037],{"nctId":16989,"briefTitle":16990,"status":108,"phases":17038,"primaryCompletion":16992,"completion":130,"start":16993,"enrollment":16994,"conditions":17039,"interventions":17040},[90],[16996],[16982,16998,16999,17000,17001,17002,17003,17004],{"trials":17042,"activeCount":102},[],{"trials":17044,"activeCount":102},[],{"trials":17046,"activeCount":102},[],{"trials":17048,"activeCount":102},[],{"intervention":17000,"totalTrials":122,"cells":17050},{"EARLY_PHASE1":17051,"PHASE1":17053,"PHASE2":17059,"PHASE3":17061,"PHASE4":17063,"NA":17065},{"trials":17052,"activeCount":102},[],{"trials":17054,"activeCount":122,"soonestReadout":16992},[17055],{"nctId":16989,"briefTitle":16990,"status":108,"phases":17056,"primaryCompletion":16992,"completion":130,"start":16993,"enrollment":16994,"conditions":17057,"interventions":17058},[90],[16996],[16982,16998,16999,17000,17001,17002,17003,17004],{"trials":17060,"activeCount":102},[],{"trials":17062,"activeCount":102},[],{"trials":17064,"activeCount":102},[],{"trials":17066,"activeCount":102},[],{"intervention":17001,"totalTrials":122,"cells":17068},{"EARLY_PHASE1":17069,"PHASE1":17071,"PHASE2":17077,"PHASE3":17079,"PHASE4":17081,"NA":17083},{"trials":17070,"activeCount":102},[],{"trials":17072,"activeCount":122,"soonestReadout":16992},[17073],{"nctId":16989,"briefTitle":16990,"status":108,"phases":17074,"primaryCompletion":16992,"completion":130,"start":16993,"enrollment":16994,"conditions":17075,"interventions":17076},[90],[16996],[16982,16998,16999,17000,17001,17002,17003,17004],{"trials":17078,"activeCount":102},[],{"trials":17080,"activeCount":102},[],{"trials":17082,"activeCount":102},[],{"trials":17084,"activeCount":102},[],{"intervention":17002,"totalTrials":122,"cells":17086},{"EARLY_PHASE1":17087,"PHASE1":17089,"PHASE2":17095,"PHASE3":17097,"PHASE4":17099,"NA":17101},{"trials":17088,"activeCount":102},[],{"trials":17090,"activeCount":122,"soonestReadout":16992},[17091],{"nctId":16989,"briefTitle":16990,"status":108,"phases":17092,"primaryCompletion":16992,"completion":130,"start":16993,"enrollment":16994,"conditions":17093,"interventions":17094},[90],[16996],[16982,16998,16999,17000,17001,17002,17003,17004],{"trials":17096,"activeCount":102},[],{"trials":17098,"activeCount":102},[],{"trials":17100,"activeCount":102},[],{"trials":17102,"activeCount":102},[],{"intervention":17003,"totalTrials":122,"cells":17104},{"EARLY_PHASE1":17105,"PHASE1":17107,"PHASE2":17113,"PHASE3":17115,"PHASE4":17117,"NA":17119},{"trials":17106,"activeCount":102},[],{"trials":17108,"activeCount":122,"soonestReadout":16992},[17109],{"nctId":16989,"briefTitle":16990,"status":108,"phases":17110,"primaryCompletion":16992,"completion":130,"start":16993,"enrollment":16994,"conditions":17111,"interventions":17112},[90],[16996],[16982,16998,16999,17000,17001,17002,17003,17004],{"trials":17114,"activeCount":102},[],{"trials":17116,"activeCount":102},[],{"trials":17118,"activeCount":102},[],{"trials":17120,"activeCount":102},[],{"intervention":17004,"totalTrials":122,"cells":17122},{"EARLY_PHASE1":17123,"PHASE1":17125,"PHASE2":17131,"PHASE3":17133,"PHASE4":17135,"NA":17137},{"trials":17124,"activeCount":102},[],{"trials":17126,"activeCount":122,"soonestReadout":16992},[17127],{"nctId":16989,"briefTitle":16990,"status":108,"phases":17128,"primaryCompletion":16992,"completion":130,"start":16993,"enrollment":16994,"conditions":17129,"interventions":17130},[90],[16996],[16982,16998,16999,17000,17001,17002,17003,17004],{"trials":17132,"activeCount":102},[],{"trials":17134,"activeCount":102},[],{"trials":17136,"activeCount":102},[],{"trials":17138,"activeCount":102},[],{"intervention":17140,"totalTrials":122,"cells":17141},"Part A - AZD9291 in combination with AZD6094",{"EARLY_PHASE1":17142,"PHASE1":17144,"PHASE2":17164,"PHASE3":17166,"PHASE4":17168,"NA":17170},{"trials":17143,"activeCount":102},[],{"trials":17145,"activeCount":122,"soonestReadout":17150},[17146],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17149,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17153,"interventions":17154},"NCT02143466","AZD9291 in Combination With Ascending Doses of Novel Therapeutics",[90],"2020-03-04","2014-08-05",344,[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],"Part A - AZD9291 in combination with continuous selumetinib","Part A - AZD9291 in combination with intermittent selumetinib","Part A - AZD9291 in combination with MEDI4736","Part B - AZD9291 in combination with AZD6094","Part B - AZD9291 in combination with selumetinib","Part B - AZD9291 in combination with MEDI4736","Part C - AZD6094 monotherapy","Part C - AZD9291 in combination with AZD6094","Part D - AZD9291 in combination with AZD6094",{"trials":17165,"activeCount":102},[],{"trials":17167,"activeCount":102},[],{"trials":17169,"activeCount":102},[],{"trials":17171,"activeCount":102},[],{"intervention":17155,"totalTrials":122,"cells":17173},{"EARLY_PHASE1":17174,"PHASE1":17176,"PHASE2":17182,"PHASE3":17184,"PHASE4":17186,"NA":17188},{"trials":17175,"activeCount":102},[],{"trials":17177,"activeCount":122,"soonestReadout":17150},[17178],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17179,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17180,"interventions":17181},[90],[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],{"trials":17183,"activeCount":102},[],{"trials":17185,"activeCount":102},[],{"trials":17187,"activeCount":102},[],{"trials":17189,"activeCount":102},[],{"intervention":17156,"totalTrials":122,"cells":17191},{"EARLY_PHASE1":17192,"PHASE1":17194,"PHASE2":17200,"PHASE3":17202,"PHASE4":17204,"NA":17206},{"trials":17193,"activeCount":102},[],{"trials":17195,"activeCount":122,"soonestReadout":17150},[17196],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17197,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17198,"interventions":17199},[90],[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],{"trials":17201,"activeCount":102},[],{"trials":17203,"activeCount":102},[],{"trials":17205,"activeCount":102},[],{"trials":17207,"activeCount":102},[],{"intervention":17157,"totalTrials":122,"cells":17209},{"EARLY_PHASE1":17210,"PHASE1":17212,"PHASE2":17218,"PHASE3":17220,"PHASE4":17222,"NA":17224},{"trials":17211,"activeCount":102},[],{"trials":17213,"activeCount":122,"soonestReadout":17150},[17214],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17215,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17216,"interventions":17217},[90],[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],{"trials":17219,"activeCount":102},[],{"trials":17221,"activeCount":102},[],{"trials":17223,"activeCount":102},[],{"trials":17225,"activeCount":102},[],{"intervention":17158,"totalTrials":122,"cells":17227},{"EARLY_PHASE1":17228,"PHASE1":17230,"PHASE2":17236,"PHASE3":17238,"PHASE4":17240,"NA":17242},{"trials":17229,"activeCount":102},[],{"trials":17231,"activeCount":122,"soonestReadout":17150},[17232],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17233,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17234,"interventions":17235},[90],[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],{"trials":17237,"activeCount":102},[],{"trials":17239,"activeCount":102},[],{"trials":17241,"activeCount":102},[],{"trials":17243,"activeCount":102},[],{"intervention":17159,"totalTrials":122,"cells":17245},{"EARLY_PHASE1":17246,"PHASE1":17248,"PHASE2":17254,"PHASE3":17256,"PHASE4":17258,"NA":17260},{"trials":17247,"activeCount":102},[],{"trials":17249,"activeCount":122,"soonestReadout":17150},[17250],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17251,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17252,"interventions":17253},[90],[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],{"trials":17255,"activeCount":102},[],{"trials":17257,"activeCount":102},[],{"trials":17259,"activeCount":102},[],{"trials":17261,"activeCount":102},[],{"intervention":17160,"totalTrials":122,"cells":17263},{"EARLY_PHASE1":17264,"PHASE1":17266,"PHASE2":17272,"PHASE3":17274,"PHASE4":17276,"NA":17278},{"trials":17265,"activeCount":102},[],{"trials":17267,"activeCount":122,"soonestReadout":17150},[17268],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17269,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17270,"interventions":17271},[90],[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],{"trials":17273,"activeCount":102},[],{"trials":17275,"activeCount":102},[],{"trials":17277,"activeCount":102},[],{"trials":17279,"activeCount":102},[],{"intervention":17161,"totalTrials":122,"cells":17281},{"EARLY_PHASE1":17282,"PHASE1":17284,"PHASE2":17290,"PHASE3":17292,"PHASE4":17294,"NA":17296},{"trials":17283,"activeCount":102},[],{"trials":17285,"activeCount":122,"soonestReadout":17150},[17286],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17287,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17288,"interventions":17289},[90],[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],{"trials":17291,"activeCount":102},[],{"trials":17293,"activeCount":102},[],{"trials":17295,"activeCount":102},[],{"trials":17297,"activeCount":102},[],{"intervention":17162,"totalTrials":122,"cells":17299},{"EARLY_PHASE1":17300,"PHASE1":17302,"PHASE2":17308,"PHASE3":17310,"PHASE4":17312,"NA":17314},{"trials":17301,"activeCount":102},[],{"trials":17303,"activeCount":122,"soonestReadout":17150},[17304],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17305,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17306,"interventions":17307},[90],[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],{"trials":17309,"activeCount":102},[],{"trials":17311,"activeCount":102},[],{"trials":17313,"activeCount":102},[],{"trials":17315,"activeCount":102},[],{"intervention":17163,"totalTrials":122,"cells":17317},{"EARLY_PHASE1":17318,"PHASE1":17320,"PHASE2":17326,"PHASE3":17328,"PHASE4":17330,"NA":17332},{"trials":17319,"activeCount":102},[],{"trials":17321,"activeCount":122,"soonestReadout":17150},[17322],{"nctId":17147,"briefTitle":17148,"status":108,"phases":17323,"primaryCompletion":17150,"completion":660,"start":17151,"enrollment":17152,"conditions":17324,"interventions":17325},[90],[16355],[17140,17155,17155,17156,17157,17158,17159,17160,17161,17162,17163],{"trials":17327,"activeCount":102},[],{"trials":17329,"activeCount":102},[],{"trials":17331,"activeCount":102},[],{"trials":17333,"activeCount":102},[],{"intervention":17335,"totalTrials":122,"cells":17336},"AZD1613 - Part A",{"EARLY_PHASE1":17337,"PHASE1":17339,"PHASE2":17350,"PHASE3":17352,"PHASE4":17354,"NA":17356},{"trials":17338,"activeCount":102},[],{"trials":17340,"activeCount":122,"soonestReadout":17345},[17341],{"nctId":17342,"briefTitle":17343,"status":151,"phases":17344,"primaryCompletion":17345,"completion":17345,"start":6921,"enrollment":1448,"conditions":17346,"interventions":17348},"NCT07228364","Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease",[90],"2027-01-26",[17347],"Autosomal Dominant Polycystic Kidney Disease",[17335,17349],"AZD1613 - Part B",{"trials":17351,"activeCount":102},[],{"trials":17353,"activeCount":102},[],{"trials":17355,"activeCount":102},[],{"trials":17357,"activeCount":102},[],{"intervention":17349,"totalTrials":122,"cells":17359},{"EARLY_PHASE1":17360,"PHASE1":17362,"PHASE2":17368,"PHASE3":17370,"PHASE4":17372,"NA":17374},{"trials":17361,"activeCount":102},[],{"trials":17363,"activeCount":122,"soonestReadout":17345},[17364],{"nctId":17342,"briefTitle":17343,"status":151,"phases":17365,"primaryCompletion":17345,"completion":17345,"start":6921,"enrollment":1448,"conditions":17366,"interventions":17367},[90],[17347],[17335,17349],{"trials":17369,"activeCount":102},[],{"trials":17371,"activeCount":102},[],{"trials":17373,"activeCount":102},[],{"trials":17375,"activeCount":102},[],{"intervention":8383,"totalTrials":122,"cells":17377},{"EARLY_PHASE1":17378,"PHASE1":17380,"PHASE2":17386,"PHASE3":17388,"PHASE4":17390,"NA":17392},{"trials":17379,"activeCount":102},[],{"trials":17381,"activeCount":122,"soonestReadout":8378},[17382],{"nctId":8375,"briefTitle":8376,"status":108,"phases":17383,"primaryCompletion":8378,"completion":8292,"start":8379,"enrollment":8380,"conditions":17384,"interventions":17385},[90],[7161],[6431,6431,8372,8372,8373,8373,8383,8383,8384,8384,8385,8385,8386,8386],{"trials":17387,"activeCount":102},[],{"trials":17389,"activeCount":102},[],{"trials":17391,"activeCount":102},[],{"trials":17393,"activeCount":102},[],{"intervention":8384,"totalTrials":122,"cells":17395},{"EARLY_PHASE1":17396,"PHASE1":17398,"PHASE2":17404,"PHASE3":17406,"PHASE4":17408,"NA":17410},{"trials":17397,"activeCount":102},[],{"trials":17399,"activeCount":122,"soonestReadout":8378},[17400],{"nctId":8375,"briefTitle":8376,"status":108,"phases":17401,"primaryCompletion":8378,"completion":8292,"start":8379,"enrollment":8380,"conditions":17402,"interventions":17403},[90],[7161],[6431,6431,8372,8372,8373,8373,8383,8383,8384,8384,8385,8385,8386,8386],{"trials":17405,"activeCount":102},[],{"trials":17407,"activeCount":102},[],{"trials":17409,"activeCount":102},[],{"trials":17411,"activeCount":102},[],{"intervention":8385,"totalTrials":122,"cells":17413},{"EARLY_PHASE1":17414,"PHASE1":17416,"PHASE2":17422,"PHASE3":17424,"PHASE4":17426,"NA":17428},{"trials":17415,"activeCount":102},[],{"trials":17417,"activeCount":122,"soonestReadout":8378},[17418],{"nctId":8375,"briefTitle":8376,"status":108,"phases":17419,"primaryCompletion":8378,"completion":8292,"start":8379,"enrollment":8380,"conditions":17420,"interventions":17421},[90],[7161],[6431,6431,8372,8372,8373,8373,8383,8383,8384,8384,8385,8385,8386,8386],{"trials":17423,"activeCount":102},[],{"trials":17425,"activeCount":102},[],{"trials":17427,"activeCount":102},[],{"trials":17429,"activeCount":102},[],{"intervention":8386,"totalTrials":122,"cells":17431},{"EARLY_PHASE1":17432,"PHASE1":17434,"PHASE2":17440,"PHASE3":17442,"PHASE4":17444,"NA":17446},{"trials":17433,"activeCount":102},[],{"trials":17435,"activeCount":122,"soonestReadout":8378},[17436],{"nctId":8375,"briefTitle":8376,"status":108,"phases":17437,"primaryCompletion":8378,"completion":8292,"start":8379,"enrollment":8380,"conditions":17438,"interventions":17439},[90],[7161],[6431,6431,8372,8372,8373,8373,8383,8383,8384,8384,8385,8385,8386,8386],{"trials":17441,"activeCount":102},[],{"trials":17443,"activeCount":102},[],{"trials":17445,"activeCount":102},[],{"trials":17447,"activeCount":102},[],{"intervention":17449,"totalTrials":122,"cells":17450},"AZD0486 IV",{"EARLY_PHASE1":17451,"PHASE1":17453,"PHASE2":17468,"PHASE3":17470,"PHASE4":17472,"NA":17474},{"trials":17452,"activeCount":102},[],{"trials":17454,"activeCount":122,"soonestReadout":17459},[17455],{"nctId":17456,"briefTitle":17457,"status":151,"phases":17458,"primaryCompletion":17459,"completion":17459,"start":17460,"enrollment":17461,"conditions":17462,"interventions":17467},"NCT04594642","A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma",[90],"2028-04-19","2021-03-02",227,[17463,17464,17465,17466],"B-cell Non Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Follicular Lymphoma",[17449],{"trials":17469,"activeCount":102},[],{"trials":17471,"activeCount":102},[],{"trials":17473,"activeCount":102},[],{"trials":17475,"activeCount":102},[],{"intervention":17477,"totalTrials":122,"cells":17478},"AZD4248",{"EARLY_PHASE1":17479,"PHASE1":17481,"PHASE2":17490,"PHASE3":17492,"PHASE4":17494,"NA":17496},{"trials":17480,"activeCount":102},[],{"trials":17482,"activeCount":122,"soonestReadout":4053},[17483],{"nctId":17484,"briefTitle":17485,"status":151,"phases":17486,"primaryCompletion":4053,"completion":4053,"start":17487,"enrollment":617,"conditions":17488,"interventions":17489},"NCT07024823","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort",[90],"2025-06-09",[2134],[17477,17477],{"trials":17491,"activeCount":102},[],{"trials":17493,"activeCount":102},[],{"trials":17495,"activeCount":102},[],{"trials":17497,"activeCount":102},[],{"intervention":17499,"totalTrials":122,"cells":17500},"AZD0120 - Regimen 1",{"EARLY_PHASE1":17501,"PHASE1":17503,"PHASE2":17515,"PHASE3":17517,"PHASE4":17519,"NA":17521},{"trials":17502,"activeCount":102},[],{"trials":17504,"activeCount":122,"soonestReadout":17509},[17505],{"nctId":17506,"briefTitle":17507,"status":151,"phases":17508,"primaryCompletion":17509,"completion":17509,"start":17510,"enrollment":1130,"conditions":17511,"interventions":17513},"NCT07224373","An Open-label Study of AZD0120 in Adults With Multiple Sclerosis",[90],"2028-12-07","2025-12-09",[17512],"Multiple Sclerosis",[17499,17514],"AZD0120 - Regimen 2",{"trials":17516,"activeCount":102},[],{"trials":17518,"activeCount":102},[],{"trials":17520,"activeCount":102},[],{"trials":17522,"activeCount":102},[],{"intervention":17514,"totalTrials":122,"cells":17524},{"EARLY_PHASE1":17525,"PHASE1":17527,"PHASE2":17533,"PHASE3":17535,"PHASE4":17537,"NA":17539},{"trials":17526,"activeCount":102},[],{"trials":17528,"activeCount":122,"soonestReadout":17509},[17529],{"nctId":17506,"briefTitle":17507,"status":151,"phases":17530,"primaryCompletion":17509,"completion":17509,"start":17510,"enrollment":1130,"conditions":17531,"interventions":17532},[90],[17512],[17499,17514],{"trials":17534,"activeCount":102},[],{"trials":17536,"activeCount":102},[],{"trials":17538,"activeCount":102},[],{"trials":17540,"activeCount":102},[],{"intervention":17542,"totalTrials":122,"cells":17543},"AZD6234 Formulation 1",{"EARLY_PHASE1":17544,"PHASE1":17546,"PHASE2":17557,"PHASE3":17559,"PHASE4":17561,"NA":17563},{"trials":17545,"activeCount":102},[],{"trials":17547,"activeCount":122,"soonestReadout":17552},[17548],{"nctId":17549,"briefTitle":17550,"status":151,"phases":17551,"primaryCompletion":17552,"completion":894,"start":9745,"enrollment":544,"conditions":17553,"interventions":17554},"NCT07220954","A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234",[90],"2026-09-09",[5851],[17542,17555,17555,17556],"AZD6234 Formulation 2","AZD6234 Formulation 3",{"trials":17558,"activeCount":102},[],{"trials":17560,"activeCount":102},[],{"trials":17562,"activeCount":102},[],{"trials":17564,"activeCount":102},[],{"intervention":17555,"totalTrials":122,"cells":17566},{"EARLY_PHASE1":17567,"PHASE1":17569,"PHASE2":17575,"PHASE3":17577,"PHASE4":17579,"NA":17581},{"trials":17568,"activeCount":102},[],{"trials":17570,"activeCount":122,"soonestReadout":17552},[17571],{"nctId":17549,"briefTitle":17550,"status":151,"phases":17572,"primaryCompletion":17552,"completion":894,"start":9745,"enrollment":544,"conditions":17573,"interventions":17574},[90],[5851],[17542,17555,17555,17556],{"trials":17576,"activeCount":102},[],{"trials":17578,"activeCount":102},[],{"trials":17580,"activeCount":102},[],{"trials":17582,"activeCount":102},[],{"intervention":17556,"totalTrials":122,"cells":17584},{"EARLY_PHASE1":17585,"PHASE1":17587,"PHASE2":17593,"PHASE3":17595,"PHASE4":17597,"NA":17599},{"trials":17586,"activeCount":102},[],{"trials":17588,"activeCount":122,"soonestReadout":17552},[17589],{"nctId":17549,"briefTitle":17550,"status":151,"phases":17590,"primaryCompletion":17552,"completion":894,"start":9745,"enrollment":544,"conditions":17591,"interventions":17592},[90],[5851],[17542,17555,17555,17556],{"trials":17594,"activeCount":102},[],{"trials":17596,"activeCount":102},[],{"trials":17598,"activeCount":102},[],{"trials":17600,"activeCount":102},[],{"intervention":17602,"totalTrials":122,"cells":17603},"[14C] AZD6738",{"EARLY_PHASE1":17604,"PHASE1":17606,"PHASE2":17617,"PHASE3":17619,"PHASE4":17621,"NA":17623},{"trials":17605,"activeCount":102},[],{"trials":17607,"activeCount":122,"soonestReadout":12281},[17608],{"nctId":17609,"briefTitle":17610,"status":1097,"phases":17611,"primaryCompletion":12281,"completion":12281,"start":17612,"enrollment":370,"conditions":17613,"interventions":17615},"NCT06754761","Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib",[90],"2025-01-17",[17614],"Neoplasm",[17602,17616],"AZD6738 \u002F ceralasertib",{"trials":17618,"activeCount":102},[],{"trials":17620,"activeCount":102},[],{"trials":17622,"activeCount":102},[],{"trials":17624,"activeCount":102},[],{"intervention":17616,"totalTrials":122,"cells":17626},{"EARLY_PHASE1":17627,"PHASE1":17629,"PHASE2":17635,"PHASE3":17637,"PHASE4":17639,"NA":17641},{"trials":17628,"activeCount":102},[],{"trials":17630,"activeCount":122,"soonestReadout":12281},[17631],{"nctId":17609,"briefTitle":17610,"status":1097,"phases":17632,"primaryCompletion":12281,"completion":12281,"start":17612,"enrollment":370,"conditions":17633,"interventions":17634},[90],[17614],[17602,17616],{"trials":17636,"activeCount":102},[],{"trials":17638,"activeCount":102},[],{"trials":17640,"activeCount":102},[],{"trials":17642,"activeCount":102},[],{"intervention":17644,"totalTrials":122,"cells":17645},"Opemalirsen",{"EARLY_PHASE1":17646,"PHASE1":17648,"PHASE2":17658,"PHASE3":17660,"PHASE4":17662,"NA":17664},{"trials":17647,"activeCount":102},[],{"trials":17649,"activeCount":122,"soonestReadout":4607},[17650],{"nctId":17651,"briefTitle":17652,"status":108,"phases":17653,"primaryCompletion":4607,"completion":4607,"start":17654,"enrollment":17655,"conditions":17656,"interventions":17657},"NCT07154901","Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)",[90],"2025-08-18",34,[2279],[17644],{"trials":17659,"activeCount":102},[],{"trials":17661,"activeCount":102},[],{"trials":17663,"activeCount":102},[],{"trials":17665,"activeCount":102},[],{"intervention":5205,"totalTrials":122,"cells":17667},{"EARLY_PHASE1":17668,"PHASE1":17670,"PHASE2":17676,"PHASE3":17678,"PHASE4":17680,"NA":17682},{"trials":17669,"activeCount":102},[],{"trials":17671,"activeCount":122,"soonestReadout":5202},[17672],{"nctId":5199,"briefTitle":5200,"status":151,"phases":17673,"primaryCompletion":5202,"completion":5202,"start":3114,"enrollment":1448,"conditions":17674,"interventions":17675},[90],[466],[5205,5206,3137],{"trials":17677,"activeCount":102},[],{"trials":17679,"activeCount":102},[],{"trials":17681,"activeCount":102},[],{"trials":17683,"activeCount":102},[],{"intervention":5206,"totalTrials":122,"cells":17685},{"EARLY_PHASE1":17686,"PHASE1":17688,"PHASE2":17694,"PHASE3":17696,"PHASE4":17698,"NA":17700},{"trials":17687,"activeCount":102},[],{"trials":17689,"activeCount":122,"soonestReadout":5202},[17690],{"nctId":5199,"briefTitle":5200,"status":151,"phases":17691,"primaryCompletion":5202,"completion":5202,"start":3114,"enrollment":1448,"conditions":17692,"interventions":17693},[90],[466],[5205,5206,3137],{"trials":17695,"activeCount":102},[],{"trials":17697,"activeCount":102},[],{"trials":17699,"activeCount":102},[],{"trials":17701,"activeCount":102},[],{"intervention":17703,"totalTrials":122,"cells":17704},"AZD2962",{"EARLY_PHASE1":17705,"PHASE1":17707,"PHASE2":17718,"PHASE3":17720,"PHASE4":17722,"NA":17724},{"trials":17706,"activeCount":102},[],{"trials":17708,"activeCount":122,"soonestReadout":17713},[17709],{"nctId":17710,"briefTitle":17711,"status":151,"phases":17712,"primaryCompletion":17713,"completion":17713,"start":17714,"enrollment":132,"conditions":17715,"interventions":17717},"NCT07064122","A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)",[90],"2028-10-20","2025-11-03",[17716],"Haematologic Neoplasms",[17703],{"trials":17719,"activeCount":102},[],{"trials":17721,"activeCount":102},[],{"trials":17723,"activeCount":102},[],{"trials":17725,"activeCount":102},[],{"intervention":12649,"totalTrials":122,"cells":17727},{"EARLY_PHASE1":17728,"PHASE1":17730,"PHASE2":17736,"PHASE3":17738,"PHASE4":17740,"NA":17742},{"trials":17729,"activeCount":102},[],{"trials":17731,"activeCount":122,"soonestReadout":12645},[17732],{"nctId":12642,"briefTitle":12643,"status":151,"phases":17733,"primaryCompletion":12645,"completion":12645,"start":12646,"enrollment":1448,"conditions":17734,"interventions":17735},[90],[5851],[12649,12587,5887],{"trials":17737,"activeCount":102},[],{"trials":17739,"activeCount":102},[],{"trials":17741,"activeCount":102},[],{"trials":17743,"activeCount":102},[],{"intervention":17745,"totalTrials":122,"cells":17746},"AZD1390",{"EARLY_PHASE1":17747,"PHASE1":17749,"PHASE2":17763,"PHASE3":17765,"PHASE4":17767,"NA":17769},{"trials":17748,"activeCount":102},[],{"trials":17750,"activeCount":122,"soonestReadout":17755},[17751],{"nctId":17752,"briefTitle":17753,"status":151,"phases":17754,"primaryCompletion":17755,"completion":17755,"start":17756,"enrollment":1120,"conditions":17757,"interventions":17762},"NCT03423628","A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer",[90],"2026-09-16","2018-04-02",[17758,17759,17760,17761],"Recurrent Glioblastoma Multiforme","Primary Glioblastoma Multiforme","Brain Neoplasms, Malignant","Leptomeningeal Disease (LMD)",[17745,17745,17745],{"trials":17764,"activeCount":102},[],{"trials":17766,"activeCount":102},[],{"trials":17768,"activeCount":102},[],{"trials":17770,"activeCount":102},[],{"intervention":17772,"totalTrials":122,"cells":17773},"NT-112: Autologous, engineered T Cells targeting KRAS G12D",{"EARLY_PHASE1":17774,"PHASE1":17776,"PHASE2":17789,"PHASE3":17791,"PHASE4":17793,"NA":17795},{"trials":17775,"activeCount":102},[],{"trials":17777,"activeCount":122,"soonestReadout":5202},[17778],{"nctId":17779,"briefTitle":17780,"status":151,"phases":17781,"primaryCompletion":5202,"completion":17782,"start":17783,"enrollment":1373,"conditions":17784,"interventions":17787},"NCT06218914","Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and\u002For Metastatic Solid Tumors",[90],"2043-11-18","2024-03-22",[1049,16822,5772,367,17785,17786],"Solid Tumor, Adult","KRAS G12D",[17772,17788],"AZD0240: Autologous, engineered T Cells targeting KRAS G12D",{"trials":17790,"activeCount":102},[],{"trials":17792,"activeCount":102},[],{"trials":17794,"activeCount":102},[],{"trials":17796,"activeCount":102},[],{"intervention":17788,"totalTrials":122,"cells":17798},{"EARLY_PHASE1":17799,"PHASE1":17801,"PHASE2":17807,"PHASE3":17809,"PHASE4":17811,"NA":17813},{"trials":17800,"activeCount":102},[],{"trials":17802,"activeCount":122,"soonestReadout":5202},[17803],{"nctId":17779,"briefTitle":17780,"status":151,"phases":17804,"primaryCompletion":5202,"completion":17782,"start":17783,"enrollment":1373,"conditions":17805,"interventions":17806},[90],[1049,16822,5772,367,17785,17786],[17772,17788],{"trials":17808,"activeCount":102},[],{"trials":17810,"activeCount":102},[],{"trials":17812,"activeCount":102},[],{"trials":17814,"activeCount":102},[],{"intervention":17816,"totalTrials":122,"cells":17817},"Laroprovstat Dose X\u002FRosuvastatin Dose 1 FCDP test formulation 1",{"EARLY_PHASE1":17818,"PHASE1":17820,"PHASE2":17834,"PHASE3":17836,"PHASE4":17838,"NA":17840},{"trials":17819,"activeCount":102},[],{"trials":17821,"activeCount":122,"soonestReadout":1647},[17822],{"nctId":17823,"briefTitle":17824,"status":108,"phases":17825,"primaryCompletion":1647,"completion":1647,"start":4650,"enrollment":3811,"conditions":17826,"interventions":17827},"NCT07316608","A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat\u002FRosuvastatin vs Their Single Therapy Products in Healthy Adults",[90],[5851],[17816,17828,17829,17830,17831,17832,17833],"Laroprovstat Dose X\u002FRosuvastatin Dose 2 FCDP test formulation 1","Laroprovstat Dose X\u002FRosuvastatin Dose 1 FCDP test formulation 2","Laroprovstat Dose X\u002FRosuvastatin Dose 2 FCDP test formulation 2","Laroprovstat Dose X STP","Rosuvastatin Dose 1 STP","Rosuvastatin Dose 2 STP",{"trials":17835,"activeCount":102},[],{"trials":17837,"activeCount":102},[],{"trials":17839,"activeCount":102},[],{"trials":17841,"activeCount":102},[],{"intervention":17828,"totalTrials":122,"cells":17843},{"EARLY_PHASE1":17844,"PHASE1":17846,"PHASE2":17852,"PHASE3":17854,"PHASE4":17856,"NA":17858},{"trials":17845,"activeCount":102},[],{"trials":17847,"activeCount":122,"soonestReadout":1647},[17848],{"nctId":17823,"briefTitle":17824,"status":108,"phases":17849,"primaryCompletion":1647,"completion":1647,"start":4650,"enrollment":3811,"conditions":17850,"interventions":17851},[90],[5851],[17816,17828,17829,17830,17831,17832,17833],{"trials":17853,"activeCount":102},[],{"trials":17855,"activeCount":102},[],{"trials":17857,"activeCount":102},[],{"trials":17859,"activeCount":102},[],{"intervention":17829,"totalTrials":122,"cells":17861},{"EARLY_PHASE1":17862,"PHASE1":17864,"PHASE2":17870,"PHASE3":17872,"PHASE4":17874,"NA":17876},{"trials":17863,"activeCount":102},[],{"trials":17865,"activeCount":122,"soonestReadout":1647},[17866],{"nctId":17823,"briefTitle":17824,"status":108,"phases":17867,"primaryCompletion":1647,"completion":1647,"start":4650,"enrollment":3811,"conditions":17868,"interventions":17869},[90],[5851],[17816,17828,17829,17830,17831,17832,17833],{"trials":17871,"activeCount":102},[],{"trials":17873,"activeCount":102},[],{"trials":17875,"activeCount":102},[],{"trials":17877,"activeCount":102},[],{"intervention":17830,"totalTrials":122,"cells":17879},{"EARLY_PHASE1":17880,"PHASE1":17882,"PHASE2":17888,"PHASE3":17890,"PHASE4":17892,"NA":17894},{"trials":17881,"activeCount":102},[],{"trials":17883,"activeCount":122,"soonestReadout":1647},[17884],{"nctId":17823,"briefTitle":17824,"status":108,"phases":17885,"primaryCompletion":1647,"completion":1647,"start":4650,"enrollment":3811,"conditions":17886,"interventions":17887},[90],[5851],[17816,17828,17829,17830,17831,17832,17833],{"trials":17889,"activeCount":102},[],{"trials":17891,"activeCount":102},[],{"trials":17893,"activeCount":102},[],{"trials":17895,"activeCount":102},[],{"intervention":17831,"totalTrials":122,"cells":17897},{"EARLY_PHASE1":17898,"PHASE1":17900,"PHASE2":17906,"PHASE3":17908,"PHASE4":17910,"NA":17912},{"trials":17899,"activeCount":102},[],{"trials":17901,"activeCount":122,"soonestReadout":1647},[17902],{"nctId":17823,"briefTitle":17824,"status":108,"phases":17903,"primaryCompletion":1647,"completion":1647,"start":4650,"enrollment":3811,"conditions":17904,"interventions":17905},[90],[5851],[17816,17828,17829,17830,17831,17832,17833],{"trials":17907,"activeCount":102},[],{"trials":17909,"activeCount":102},[],{"trials":17911,"activeCount":102},[],{"trials":17913,"activeCount":102},[],{"intervention":17832,"totalTrials":122,"cells":17915},{"EARLY_PHASE1":17916,"PHASE1":17918,"PHASE2":17924,"PHASE3":17926,"PHASE4":17928,"NA":17930},{"trials":17917,"activeCount":102},[],{"trials":17919,"activeCount":122,"soonestReadout":1647},[17920],{"nctId":17823,"briefTitle":17824,"status":108,"phases":17921,"primaryCompletion":1647,"completion":1647,"start":4650,"enrollment":3811,"conditions":17922,"interventions":17923},[90],[5851],[17816,17828,17829,17830,17831,17832,17833],{"trials":17925,"activeCount":102},[],{"trials":17927,"activeCount":102},[],{"trials":17929,"activeCount":102},[],{"trials":17931,"activeCount":102},[],{"intervention":17833,"totalTrials":122,"cells":17933},{"EARLY_PHASE1":17934,"PHASE1":17936,"PHASE2":17942,"PHASE3":17944,"PHASE4":17946,"NA":17948},{"trials":17935,"activeCount":102},[],{"trials":17937,"activeCount":122,"soonestReadout":1647},[17938],{"nctId":17823,"briefTitle":17824,"status":108,"phases":17939,"primaryCompletion":1647,"completion":1647,"start":4650,"enrollment":3811,"conditions":17940,"interventions":17941},[90],[5851],[17816,17828,17829,17830,17831,17832,17833],{"trials":17943,"activeCount":102},[],{"trials":17945,"activeCount":102},[],{"trials":17947,"activeCount":102},[],{"trials":17949,"activeCount":102},[],{"intervention":17951,"totalTrials":122,"cells":17952},"Rivaroxaban",{"EARLY_PHASE1":17953,"PHASE1":17955,"PHASE2":17967,"PHASE3":17969,"PHASE4":17971,"NA":17973},{"trials":17954,"activeCount":102},[],{"trials":17956,"activeCount":122,"soonestReadout":17961},[17957],{"nctId":17958,"briefTitle":17959,"status":108,"phases":17960,"primaryCompletion":17961,"completion":17961,"start":8323,"enrollment":6446,"conditions":17962,"interventions":17963},"NCT07312851","A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants",[90],"2026-06-11",[5851],[17964,17951,17965,17966],"Andexanet alfa","Apixaban","Enoxaparin",{"trials":17968,"activeCount":102},[],{"trials":17970,"activeCount":102},[],{"trials":17972,"activeCount":102},[],{"trials":17974,"activeCount":102},[],{"intervention":17965,"totalTrials":122,"cells":17976},{"EARLY_PHASE1":17977,"PHASE1":17979,"PHASE2":17985,"PHASE3":17987,"PHASE4":17989,"NA":17991},{"trials":17978,"activeCount":102},[],{"trials":17980,"activeCount":122,"soonestReadout":17961},[17981],{"nctId":17958,"briefTitle":17959,"status":108,"phases":17982,"primaryCompletion":17961,"completion":17961,"start":8323,"enrollment":6446,"conditions":17983,"interventions":17984},[90],[5851],[17964,17951,17965,17966],{"trials":17986,"activeCount":102},[],{"trials":17988,"activeCount":102},[],{"trials":17990,"activeCount":102},[],{"trials":17992,"activeCount":102},[],{"intervention":17966,"totalTrials":122,"cells":17994},{"EARLY_PHASE1":17995,"PHASE1":17997,"PHASE2":18003,"PHASE3":18005,"PHASE4":18007,"NA":18009},{"trials":17996,"activeCount":102},[],{"trials":17998,"activeCount":122,"soonestReadout":17961},[17999],{"nctId":17958,"briefTitle":17959,"status":108,"phases":18000,"primaryCompletion":17961,"completion":17961,"start":8323,"enrollment":6446,"conditions":18001,"interventions":18002},[90],[5851],[17964,17951,17965,17966],{"trials":18004,"activeCount":102},[],{"trials":18006,"activeCount":102},[],{"trials":18008,"activeCount":102},[],{"trials":18010,"activeCount":102},[],{"intervention":6297,"totalTrials":122,"cells":18012},{"EARLY_PHASE1":18013,"PHASE1":18015,"PHASE2":18021,"PHASE3":18023,"PHASE4":18025,"NA":18027},{"trials":18014,"activeCount":102},[],{"trials":18016,"activeCount":122,"soonestReadout":6292},[18017],{"nctId":6289,"briefTitle":6290,"status":151,"phases":18018,"primaryCompletion":6292,"completion":6292,"start":6293,"enrollment":370,"conditions":18019,"interventions":18020},[90],[6295],[1959,6297,6298],{"trials":18022,"activeCount":102},[],{"trials":18024,"activeCount":102},[],{"trials":18026,"activeCount":102},[],{"trials":18028,"activeCount":102},[],{"intervention":6298,"totalTrials":122,"cells":18030},{"EARLY_PHASE1":18031,"PHASE1":18033,"PHASE2":18039,"PHASE3":18041,"PHASE4":18043,"NA":18045},{"trials":18032,"activeCount":102},[],{"trials":18034,"activeCount":122,"soonestReadout":6292},[18035],{"nctId":6289,"briefTitle":6290,"status":151,"phases":18036,"primaryCompletion":6292,"completion":6292,"start":6293,"enrollment":370,"conditions":18037,"interventions":18038},[90],[6295],[1959,6297,6298],{"trials":18040,"activeCount":102},[],{"trials":18042,"activeCount":102},[],{"trials":18044,"activeCount":102},[],{"trials":18046,"activeCount":102},[],{"intervention":18048,"totalTrials":122,"cells":18049},"AZD1043",{"EARLY_PHASE1":18050,"PHASE1":18052,"PHASE2":18062,"PHASE3":18064,"PHASE4":18066,"NA":18068},{"trials":18051,"activeCount":102},[],{"trials":18053,"activeCount":122,"soonestReadout":18058},[18054],{"nctId":18055,"briefTitle":18056,"status":151,"phases":18057,"primaryCompletion":18058,"completion":18059,"start":3322,"enrollment":4877,"conditions":18060,"interventions":18061},"NCT07511205","A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and\u002For Obesity.",[90],"2027-03-15","2027-10-21",[5851,12275],[18048],{"trials":18063,"activeCount":102},[],{"trials":18065,"activeCount":102},[],{"trials":18067,"activeCount":102},[],{"trials":18069,"activeCount":102},[],{"intervention":15617,"totalTrials":122,"cells":18071},{"EARLY_PHASE1":18072,"PHASE1":18074,"PHASE2":18080,"PHASE3":18082,"PHASE4":18084,"NA":18086},{"trials":18073,"activeCount":102},[],{"trials":18075,"activeCount":122,"soonestReadout":15613},[18076],{"nctId":15610,"briefTitle":15611,"status":108,"phases":18077,"primaryCompletion":15613,"completion":15613,"start":15614,"enrollment":579,"conditions":18078,"interventions":18079},[90],[5851],[12585,15617,2448],{"trials":18081,"activeCount":102},[],{"trials":18083,"activeCount":102},[],{"trials":18085,"activeCount":102},[],{"trials":18087,"activeCount":102},[],{"intervention":12509,"totalTrials":122,"cells":18089},{"EARLY_PHASE1":18090,"PHASE1":18092,"PHASE2":18098,"PHASE3":18100,"PHASE4":18102,"NA":18104},{"trials":18091,"activeCount":102},[],{"trials":18093,"activeCount":122,"soonestReadout":12503},[18094],{"nctId":12500,"briefTitle":12501,"status":151,"phases":18095,"primaryCompletion":12503,"completion":12503,"start":12504,"enrollment":12505,"conditions":18096,"interventions":18097},[90],[12507],[6672,12509,12510],{"trials":18099,"activeCount":102},[],{"trials":18101,"activeCount":102},[],{"trials":18103,"activeCount":102},[],{"trials":18105,"activeCount":102},[],{"intervention":12510,"totalTrials":122,"cells":18107},{"EARLY_PHASE1":18108,"PHASE1":18110,"PHASE2":18116,"PHASE3":18118,"PHASE4":18120,"NA":18122},{"trials":18109,"activeCount":102},[],{"trials":18111,"activeCount":122,"soonestReadout":12503},[18112],{"nctId":12500,"briefTitle":12501,"status":151,"phases":18113,"primaryCompletion":12503,"completion":12503,"start":12504,"enrollment":12505,"conditions":18114,"interventions":18115},[90],[12507],[6672,12509,12510],{"trials":18117,"activeCount":102},[],{"trials":18119,"activeCount":102},[],{"trials":18121,"activeCount":102},[],{"trials":18123,"activeCount":102},[],{"intervention":17964,"totalTrials":1979,"cells":18125},{"EARLY_PHASE1":18126,"PHASE1":18128,"PHASE2":18134,"PHASE3":18136,"PHASE4":18147,"NA":18149},{"trials":18127,"activeCount":102},[],{"trials":18129,"activeCount":122,"soonestReadout":17961},[18130],{"nctId":17958,"briefTitle":17959,"status":108,"phases":18131,"primaryCompletion":17961,"completion":17961,"start":8323,"enrollment":6446,"conditions":18132,"interventions":18133},[90],[5851],[17964,17951,17965,17966],{"trials":18135,"activeCount":102},[],{"trials":18137,"activeCount":102},[18138],{"nctId":18139,"briefTitle":18140,"status":624,"phases":18141,"primaryCompletion":9620,"completion":18142,"start":6882,"enrollment":102,"conditions":18143,"interventions":18145},"NCT05926349","A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure",[92],"2027-09-07",[18144],"Urgent Surgery",[17964,18146],"Usual Care",{"trials":18148,"activeCount":102},[],{"trials":18150,"activeCount":102},[18151,18161],{"nctId":18152,"briefTitle":18153,"status":195,"phases":18154,"primaryCompletion":18155,"completion":18155,"start":3363,"enrollment":18156,"conditions":18157,"interventions":18159},"NCT05548777","Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed",[],"2022-12-20",5480,[18158],"Anticoagulant-related Major Bleed",[17964,18160],"4F-PCC",{"nctId":18162,"briefTitle":18163,"status":195,"phases":18164,"primaryCompletion":6252,"completion":6252,"start":18165,"enrollment":18166,"conditions":18167,"interventions":18169},"NCT05898412","Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya",[],"2023-10-06",217,[18168],"Hemorrhage",[17964],{"intervention":18171,"totalTrials":3887,"cells":18172},"Ravulizumab",{"EARLY_PHASE1":18173,"PHASE1":18175,"PHASE2":18177,"PHASE3":18179,"PHASE4":18181,"NA":18183},{"trials":18174,"activeCount":102},[],{"trials":18176,"activeCount":102},[],{"trials":18178,"activeCount":102},[],{"trials":18180,"activeCount":102},[],{"trials":18182,"activeCount":102},[],{"trials":18184,"activeCount":3887,"soonestReadout":18189},[18185,18194,18202],{"nctId":18186,"briefTitle":18187,"status":108,"phases":18188,"primaryCompletion":18189,"completion":18189,"start":18190,"enrollment":4307,"conditions":18191,"interventions":18193},"NCT06633536","Real-life Treatment Outcomes of Ravulizumab in PNH",[],"2028-08-01","2025-02-06",[18192],"Paroxysmal Nocturnal Haemoglobinuria",[18171],{"nctId":18195,"briefTitle":18196,"status":151,"phases":18197,"primaryCompletion":18198,"completion":18198,"start":3581,"enrollment":4286,"conditions":18199,"interventions":18201},"NCT06909253","Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis",[],"2029-12-31",[18200],"Myasthenia Gravis, Generalized",[18171],{"nctId":18203,"briefTitle":18204,"status":1097,"phases":18205,"primaryCompletion":18206,"completion":18206,"start":5433,"enrollment":1395,"conditions":18207,"interventions":18209},"NCT07399730","Ravulizumab Outcomes in Polish Patients With aHUS",[],"2030-12-31",[18208],"Atypical Hemolytic Uremic Syndrome",[18171],{"intervention":18211,"totalTrials":447,"cells":18212},"Non interventional study",{"EARLY_PHASE1":18213,"PHASE1":18215,"PHASE2":18217,"PHASE3":18219,"PHASE4":18221,"NA":18223},{"trials":18214,"activeCount":102},[],{"trials":18216,"activeCount":102},[],{"trials":18218,"activeCount":102},[],{"trials":18220,"activeCount":102},[],{"trials":18222,"activeCount":102},[],{"trials":18224,"activeCount":447,"soonestReadout":18235},[18225,18231],{"nctId":18226,"briefTitle":18227,"status":108,"phases":18228,"primaryCompletion":1316,"completion":1316,"start":1372,"enrollment":10196,"conditions":18229,"interventions":18230},"NCT06170671","REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania",[],[1408],[18211],{"nctId":18232,"briefTitle":18233,"status":108,"phases":18234,"primaryCompletion":18235,"completion":18235,"start":1573,"enrollment":1529,"conditions":18236,"interventions":18237},"NCT05437250","National Acalabrutinib Observational Study",[],"2026-11-15",[1408],[18211],{"intervention":18239,"totalTrials":3717,"cells":18240},"exenatide",{"EARLY_PHASE1":18241,"PHASE1":18243,"PHASE2":18265,"PHASE3":18297,"PHASE4":18459,"NA":18473},{"trials":18242,"activeCount":102},[],{"trials":18244,"activeCount":102},[18245,18251,18259],{"nctId":18246,"briefTitle":18247,"status":195,"phases":18248,"primaryCompletion":2507,"completion":2507,"start":2251,"enrollment":3476,"conditions":18249,"interventions":18250},"NCT00672399","Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects",[90],[1556],[18239,2255],{"nctId":18252,"briefTitle":18253,"status":195,"phases":18254,"primaryCompletion":2104,"completion":2104,"start":2481,"enrollment":1448,"conditions":18255,"interventions":18256},"NCT01664624","Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes",[90],[31],[10068,18257,18258],"Alogliptin","Exenatide",{"nctId":18260,"briefTitle":18261,"status":195,"phases":18262,"primaryCompletion":12721,"completion":2615,"start":2433,"enrollment":13516,"conditions":18263,"interventions":18264},"NCT01297062","A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects",[90],[1556],[18258,2255],{"trials":18266,"activeCount":102},[18267,18273,18279,18285,18291],{"nctId":18268,"briefTitle":18269,"status":443,"phases":18270,"primaryCompletion":2747,"completion":2747,"start":2220,"enrollment":1395,"conditions":18271,"interventions":18272},"NCT00701935","Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin",[91],[2631],[18239],{"nctId":18274,"briefTitle":18275,"status":195,"phases":18276,"primaryCompletion":9065,"completion":9065,"start":4306,"enrollment":507,"conditions":18277,"interventions":18278},"NCT00099333","Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents",[91],[22],[18239,12122],{"nctId":18280,"briefTitle":18281,"status":195,"phases":18282,"primaryCompletion":5562,"completion":5562,"start":3809,"enrollment":1710,"conditions":18283,"interventions":18284},"NCT00241423","Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes",[91],[22],[18239],{"nctId":18286,"briefTitle":18287,"status":195,"phases":18288,"primaryCompletion":2168,"completion":2168,"start":5562,"enrollment":2640,"conditions":18289,"interventions":18290},"NCT00500370","A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients",[91],[12275],[18239],{"nctId":18292,"briefTitle":18293,"status":195,"phases":18294,"primaryCompletion":6718,"completion":6718,"start":5563,"enrollment":2386,"conditions":18295,"interventions":18296},"NCT00382239","A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes",[91],[22],[18239,18239,18239],{"trials":18298,"activeCount":102},[18299,18306,18312,18318,18324,18331,18337,18344,18350,18357,18365,18371,18377,18386,18393,18401,18407,18415,18421,18429,18436,18442,18451],{"nctId":18300,"briefTitle":18301,"status":195,"phases":18302,"primaryCompletion":2055,"completion":2055,"start":4285,"enrollment":12271,"conditions":18303,"interventions":18304},"NCT00097500","Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes",[92],[22],[18239,18305,2173],"Insulin glargine",{"nctId":18307,"briefTitle":18308,"status":195,"phases":18309,"primaryCompletion":2056,"completion":2056,"start":2086,"enrollment":2463,"conditions":18310,"interventions":18311},"NCT00765817","Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus",[92],[31],[18239],{"nctId":18313,"briefTitle":18314,"status":195,"phases":18315,"primaryCompletion":2251,"completion":2251,"start":5725,"enrollment":3180,"conditions":18316,"interventions":18317},"NCT00516048","An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes",[92],[22],[18239],{"nctId":18319,"briefTitle":18320,"status":195,"phases":18321,"primaryCompletion":9065,"completion":9065,"start":13575,"enrollment":2590,"conditions":18322,"interventions":18323},"NCT00099320","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin",[92],[22],[18239],{"nctId":18325,"briefTitle":18326,"status":195,"phases":18327,"primaryCompletion":7439,"completion":7439,"start":4284,"enrollment":18328,"conditions":18329,"interventions":18330},"NCT00324363","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin",[92],466,[22],[18239],{"nctId":18332,"briefTitle":18333,"status":195,"phases":18334,"primaryCompletion":2068,"completion":2057,"start":2086,"enrollment":1666,"conditions":18335,"interventions":18336},"NCT00753896","Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin",[92],[31],[18239],{"nctId":18338,"briefTitle":18339,"status":195,"phases":18340,"primaryCompletion":5563,"completion":5563,"start":9066,"enrollment":18341,"conditions":18342,"interventions":18343},"NCT00111540","Study to Examine the Effect on Glucose Control and Safety\u002FTolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes",[92],456,[2089],[18239],{"nctId":18345,"briefTitle":18346,"status":195,"phases":18347,"primaryCompletion":2415,"completion":2415,"start":5563,"enrollment":1852,"conditions":18348,"interventions":18349},"NCT00381342","Safety and Efficacy of Exenatide as Monotherapy",[92],[22],[18239,18239],{"nctId":18351,"briefTitle":18352,"status":195,"phases":18353,"primaryCompletion":2507,"completion":2507,"start":4256,"enrollment":18354,"conditions":18355,"interventions":18356},"NCT00082381","Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin",[92],551,[2089],[18258,18305],{"nctId":18358,"briefTitle":18359,"status":195,"phases":18360,"primaryCompletion":2570,"completion":2570,"start":5563,"enrollment":18361,"conditions":18362,"interventions":18363},"NCT00359762","Exenatide Versus Glimepiride in Patients With Type 2 Diabetes",[92],1029,[22],[18239,18364],"glimepiride",{"nctId":18366,"briefTitle":18367,"status":195,"phases":18368,"primaryCompletion":2251,"completion":2251,"start":2415,"enrollment":680,"conditions":18369,"interventions":18370},"NCT00516074","A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes",[92],[22],[18239],{"nctId":18372,"briefTitle":18373,"status":195,"phases":18374,"primaryCompletion":2252,"completion":2252,"start":5563,"enrollment":12292,"conditions":18375,"interventions":18376},"NCT00359879","Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes",[92],[31],[18239,18239],{"nctId":18378,"briefTitle":18379,"status":195,"phases":18380,"primaryCompletion":2105,"completion":2105,"start":2067,"enrollment":18381,"conditions":18382,"interventions":18383},"NCT00960661","A Trial Comparing Two Therapies: Basal Insulin\u002FGlargine, Exenatide and Metformin Therapy (BET) or Basal Insulin\u002FGlargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes",[92],1036,[22],[18239,18384,2173,18385],"insulin lispro","Insulin\u002F Glargine",{"nctId":18387,"briefTitle":18388,"status":195,"phases":18389,"primaryCompletion":2507,"completion":2507,"start":9124,"enrollment":18390,"conditions":18391,"interventions":18392},"NCT01876849","An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus",[92],275,[22],[18239],{"nctId":18394,"briefTitle":18395,"status":195,"phases":18396,"primaryCompletion":2507,"completion":2560,"start":6369,"enrollment":18397,"conditions":18398,"interventions":18399},"NCT00308139","Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)",[92],303,[22],[18400,18239],"exenatide, long acting release",{"nctId":18402,"briefTitle":18403,"status":195,"phases":18404,"primaryCompletion":2414,"completion":2414,"start":6710,"enrollment":922,"conditions":18405,"interventions":18406},"NCT00577824","Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)",[92],[31],[18239,18239],{"nctId":18408,"briefTitle":18409,"status":195,"phases":18410,"primaryCompletion":5501,"completion":18411,"start":18412,"enrollment":23,"conditions":18413,"interventions":18414},"NCT00658021","Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes",[92],"2020-04-01","2008-05-30",[31],[18258,18258],{"nctId":18416,"briefTitle":18417,"status":195,"phases":18418,"primaryCompletion":2168,"completion":2168,"start":5563,"enrollment":12152,"conditions":18419,"interventions":18420},"NCT00375492","Effect on Weight Loss of Exenatide Versus Placebo",[92],[22],[18239],{"nctId":18422,"briefTitle":18423,"status":195,"phases":18424,"primaryCompletion":2507,"completion":2507,"start":9901,"enrollment":18425,"conditions":18426,"interventions":18427},"NCT00082407","Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin",[92],505,[2089],[18239,18428],"biphasic insulin aspart",{"nctId":18430,"briefTitle":18431,"status":195,"phases":18432,"primaryCompletion":2068,"completion":2068,"start":6710,"enrollment":18433,"conditions":18434,"interventions":18435},"NCT00603239","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin",[92],165,[22],[18239],{"nctId":18437,"briefTitle":18438,"status":195,"phases":18439,"primaryCompletion":2507,"completion":2507,"start":3809,"enrollment":8304,"conditions":18440,"interventions":18441},"NCT00135330","An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus",[92],[2089],[18239,15949],{"nctId":18443,"briefTitle":18444,"status":195,"phases":18445,"primaryCompletion":18446,"completion":18446,"start":18447,"enrollment":18448,"conditions":18449,"interventions":18450},"NCT02229383","Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus",[92],"2016-08-29","2014-09-06",464,[2631],[18258],{"nctId":18452,"briefTitle":18453,"status":195,"phases":18454,"primaryCompletion":2251,"completion":2251,"start":6562,"enrollment":18455,"conditions":18456,"interventions":18457},"NCT00360334","A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients",[92],235,[31],[18239,18458],"insulin glargine",{"trials":18460,"activeCount":102},[18461,18467],{"nctId":18462,"briefTitle":18463,"status":195,"phases":18464,"primaryCompletion":2415,"completion":2415,"start":6718,"enrollment":188,"conditions":18465,"interventions":18466},"NCT00477581","A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus",[93],[22],[18239,15935],{"nctId":18468,"briefTitle":18469,"status":195,"phases":18470,"primaryCompletion":2350,"completion":2350,"start":2220,"enrollment":6597,"conditions":18471,"interventions":18472},"NCT00729326","Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione",[93],[22],[18239,15935],{"trials":18474,"activeCount":122,"soonestReadout":1290},[18475,18482,18490,18498,18508],{"nctId":18476,"briefTitle":18477,"status":195,"phases":18478,"primaryCompletion":4006,"completion":4006,"start":2095,"enrollment":18479,"conditions":18480,"interventions":18481},"NCT02090673","Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea",[],1711,[2803],[18258],{"nctId":18483,"briefTitle":18484,"status":195,"phases":18485,"primaryCompletion":10063,"completion":10063,"start":2113,"enrollment":18486,"conditions":18487,"interventions":18488},"NCT01060059","Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes",[],888,[22],[18239,18489],"basal insulin",{"nctId":18491,"briefTitle":18492,"status":151,"phases":18493,"primaryCompletion":1290,"completion":1290,"start":6186,"enrollment":18494,"conditions":18495,"interventions":18496},"NCT05663515","A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs",[],24000,[415],[18258,18497],"Non-GLP-1 RA based glucose lowering drugs",{"nctId":18499,"briefTitle":18500,"status":195,"phases":18501,"primaryCompletion":2580,"completion":2580,"start":4285,"enrollment":18502,"conditions":18503,"interventions":18506},"NCT01077323","A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents",[],363766,[18504,18505],"Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)","Healthy Subjects (Treated With no Diabetes Therapies)",[18239,18507],"Other antidiabetic therapies",{"nctId":18509,"briefTitle":18510,"status":195,"phases":18511,"primaryCompletion":2589,"completion":2589,"start":6710,"enrollment":18512,"conditions":18513,"interventions":18514},"NCT00635492","CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy",[],2515,[22],[18239,18515],"any human insulin or analog insulin(s) given in any regimen by subcutaneous",{"intervention":18517,"totalTrials":122,"cells":18518},"Treatment of transthyretin (ATTR) amyloidosis in observational study setting",{"EARLY_PHASE1":18519,"PHASE1":18521,"PHASE2":18523,"PHASE3":18525,"PHASE4":18527,"NA":18529},{"trials":18520,"activeCount":102},[],{"trials":18522,"activeCount":102},[],{"trials":18524,"activeCount":102},[],{"trials":18526,"activeCount":102},[],{"trials":18528,"activeCount":102},[],{"trials":18530,"activeCount":122,"soonestReadout":18535},[18531],{"nctId":18532,"briefTitle":18533,"status":151,"phases":18534,"primaryCompletion":18535,"completion":18535,"start":18536,"enrollment":18537,"conditions":18538,"interventions":18545},"NCT06465810","Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis",[],"2031-12-29","2024-06-25",1850,[18539,18540,18541,18542,18543,18544],"Transthyretin Amyloidosis","ATTR-CM","ATTRv-PN","ATTR","ATTR-Mixed","hATTR",[18517],{"intervention":18547,"totalTrials":122,"cells":18548},"Budenoside\u002FGlycopyrronium\u002FFormoterol",{"EARLY_PHASE1":18549,"PHASE1":18551,"PHASE2":18553,"PHASE3":18555,"PHASE4":18557,"NA":18559},{"trials":18550,"activeCount":102},[],{"trials":18552,"activeCount":102},[],{"trials":18554,"activeCount":102},[],{"trials":18556,"activeCount":102},[],{"trials":18558,"activeCount":102},[],{"trials":18560,"activeCount":122,"soonestReadout":2288},[18561],{"nctId":18562,"briefTitle":18563,"status":108,"phases":18564,"primaryCompletion":2288,"completion":2288,"start":18565,"enrollment":3466,"conditions":18566,"interventions":18567},"NCT06511193","Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside\u002FGlycopyrronium\u002FFormoterol [BGF]",[],"2024-09-17",[6083],[18547],{"intervention":18569,"totalTrials":122,"cells":18570},"STRIDE",{"EARLY_PHASE1":18571,"PHASE1":18573,"PHASE2":18575,"PHASE3":18577,"PHASE4":18579,"NA":18581},{"trials":18572,"activeCount":102},[],{"trials":18574,"activeCount":102},[],{"trials":18576,"activeCount":102},[],{"trials":18578,"activeCount":102},[],{"trials":18580,"activeCount":102},[],{"trials":18582,"activeCount":122,"soonestReadout":1371},[18583],{"nctId":18584,"briefTitle":18585,"status":151,"phases":18586,"primaryCompletion":1371,"completion":1371,"start":12646,"enrollment":1685,"conditions":18587,"interventions":18588},"NCT07607769","MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.",[],[3220],[18569],{"intervention":18497,"totalTrials":122,"cells":18590},{"EARLY_PHASE1":18591,"PHASE1":18593,"PHASE2":18595,"PHASE3":18597,"PHASE4":18599,"NA":18601},{"trials":18592,"activeCount":102},[],{"trials":18594,"activeCount":102},[],{"trials":18596,"activeCount":102},[],{"trials":18598,"activeCount":102},[],{"trials":18600,"activeCount":102},[],{"trials":18602,"activeCount":122,"soonestReadout":1290},[18603],{"nctId":18491,"briefTitle":18492,"status":151,"phases":18604,"primaryCompletion":1290,"completion":1290,"start":6186,"enrollment":18494,"conditions":18605,"interventions":18606},[],[415],[18258,18497],{"intervention":18608,"totalTrials":122,"cells":18609},"Palivizumab 15 mg\u002Fkg",{"EARLY_PHASE1":18610,"PHASE1":18612,"PHASE2":18614,"PHASE3":18616,"PHASE4":18618,"NA":18620},{"trials":18611,"activeCount":102},[],{"trials":18613,"activeCount":102},[],{"trials":18615,"activeCount":102},[],{"trials":18617,"activeCount":102},[],{"trials":18619,"activeCount":102},[],{"trials":18621,"activeCount":122,"soonestReadout":1665},[18622],{"nctId":18623,"briefTitle":18624,"status":151,"phases":18625,"primaryCompletion":1665,"completion":1665,"start":14041,"enrollment":113,"conditions":18626,"interventions":18628},"NCT06851806","Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease",[94],[18627],"Respiratory Syncytial Virus (RSV)",[18608],{"intervention":18630,"totalTrials":122,"cells":18631},"Budesonide\u002Fglycopyrrolate\u002Fformoterol fumarate",{"EARLY_PHASE1":18632,"PHASE1":18634,"PHASE2":18636,"PHASE3":18638,"PHASE4":18640,"NA":18642},{"trials":18633,"activeCount":102},[],{"trials":18635,"activeCount":102},[],{"trials":18637,"activeCount":102},[],{"trials":18639,"activeCount":102},[],{"trials":18641,"activeCount":102},[],{"trials":18643,"activeCount":122,"soonestReadout":18648},[18644],{"nctId":18645,"briefTitle":18646,"status":151,"phases":18647,"primaryCompletion":18648,"completion":18648,"start":1637,"enrollment":18649,"conditions":18650,"interventions":18652},"NCT06712563","Pooled Analysis of Single-arm Studies of Budesonide\u002FGlycopyrronium\u002FFormoterol (BGF) in Routine Care Setting",[],"2026-12-14",2000,[18651],"Pulmonary Disease, Chronic Obstructive",[18630],{"intervention":18654,"totalTrials":122,"cells":18655},"TDxd",{"EARLY_PHASE1":18656,"PHASE1":18658,"PHASE2":18660,"PHASE3":18662,"PHASE4":18664,"NA":18666},{"trials":18657,"activeCount":102},[],{"trials":18659,"activeCount":102},[],{"trials":18661,"activeCount":102},[],{"trials":18663,"activeCount":102},[],{"trials":18665,"activeCount":102},[],{"trials":18667,"activeCount":122,"soonestReadout":3474},[18668],{"nctId":18669,"briefTitle":18670,"status":1097,"phases":18671,"primaryCompletion":3474,"completion":3474,"start":130,"enrollment":18672,"conditions":18673,"interventions":18674},"NCT07597993","BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy",[],109,[25],[18654],{"intervention":18676,"totalTrials":496,"cells":18677},"Quetiapine fumarate",{"EARLY_PHASE1":18678,"PHASE1":18680,"PHASE2":18690,"PHASE3":18706,"PHASE4":18898,"NA":18951},{"trials":18679,"activeCount":102},[],{"trials":18681,"activeCount":102},[18682],{"nctId":18683,"briefTitle":18684,"status":195,"phases":18685,"primaryCompletion":2220,"completion":2220,"start":2507,"enrollment":18686,"conditions":18687,"interventions":18688},"NCT00702676","Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison",[90],63,[36],[18689,18689],"Quetiapine Fumarate",{"trials":18691,"activeCount":102},[18692,18699],{"nctId":18693,"briefTitle":18694,"status":195,"phases":18695,"primaryCompletion":2169,"completion":2169,"start":2087,"conditions":18696,"interventions":18698},"NCT00733668","Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder",[91],[18697],"Major Depressive Disorder",[18676],{"nctId":18700,"briefTitle":18701,"status":195,"phases":18702,"completion":5562,"start":6445,"enrollment":1448,"conditions":18703,"interventions":18705},"NCT00254748","Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients",[91],[18704],"Borderline Personality Disorder",[18676],{"trials":18707,"activeCount":102},[18708,18717,18726,18737,18745,18751,18758,18766,18773,18781,18787,18794,18801,18807,18813,18821,18828,18835,18841,18848,18855,18861,18870,18877,18885,18892],{"nctId":18709,"briefTitle":18710,"status":195,"phases":18711,"primaryCompletion":4298,"completion":4298,"start":9963,"enrollment":18712,"conditions":18713,"interventions":18715},"NCT00227305","Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder",[92],381,[33,18714],"Bipolar I Disorder",[18716],"quetiapine fumarate",{"nctId":18718,"briefTitle":18719,"status":195,"phases":18720,"completion":2639,"start":6370,"enrollment":18721,"conditions":18722,"interventions":18723},"NCT00107731","Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder",[92],710,[18714],[18716,18724,18725],"lithium","divalproex",{"nctId":18727,"briefTitle":18728,"status":195,"phases":18729,"completion":6718,"start":7554,"enrollment":18730,"conditions":18731,"interventions":18735},"NCT00119652","Seroquel in Bipolar Depression Versus SSRI",[92],676,[18732,18733,18734],"Bipolar Disorder","Bipolar Depression","Depression",[18716,18736],"paroxetine",{"nctId":18738,"briefTitle":18739,"status":195,"phases":18740,"completion":2415,"start":6369,"enrollment":5155,"conditions":18741,"interventions":18743},"NCT00329446","Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder",[92],[18742],"Generalized Anxiety Disorder",[18689,18744],"Escitalopram oxylate",{"nctId":18746,"briefTitle":18747,"status":195,"phases":18748,"completion":2252,"start":6369,"enrollment":170,"conditions":18749,"interventions":18750},"NCT00326105","Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders",[92],[18697],[18676],{"nctId":18752,"briefTitle":18753,"status":195,"phases":18754,"completion":9065,"start":6445,"enrollment":18755,"conditions":18756,"interventions":18757},"NCT00083954","Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression",[92],530,[18732],[18689],{"nctId":18759,"briefTitle":18760,"status":195,"phases":18761,"primaryCompletion":2415,"completion":2220,"start":9986,"enrollment":2045,"conditions":18762,"interventions":18764},"NCT00306540","Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder",[92],[18763],"Post-Traumatic Stress Disorder",[18689,18765],"quetiapine fumarate placebo",{"nctId":18767,"briefTitle":18768,"status":195,"phases":18769,"completion":6718,"start":9065,"enrollment":18770,"conditions":18771,"interventions":18772},"NCT00206141","Seroquel in Bipolar Depression Versus Lithium",[92],672,[18732,18733,18734],[18689],{"nctId":18774,"briefTitle":18775,"status":195,"phases":18776,"primaryCompletion":2406,"completion":2406,"start":2320,"enrollment":18777,"conditions":18778,"interventions":18779},"NCT00882518","Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients",[92],388,[33],[18689,18780],"Chlorpromazine",{"nctId":18782,"briefTitle":18783,"status":195,"phases":18784,"completion":6369,"start":9963,"enrollment":1448,"conditions":18785,"interventions":18786},"NCT00304473","Fast Titration in the Treatment of Schizophrenia, Taiwan",[92],[33],[18676],{"nctId":18788,"briefTitle":18789,"status":195,"phases":18790,"completion":6719,"start":6445,"enrollment":18791,"conditions":18792,"interventions":18793},"NCT00085891","Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia",[92],535,[33],[18689],{"nctId":18795,"briefTitle":18796,"status":195,"phases":18797,"completion":12846,"start":12891,"enrollment":1864,"conditions":18798,"interventions":18799},"NCT00305422","Effect of Quetiapine on Negative Symptoms and Cognition",[92],[33],[18676,18800],"Risperidone",{"nctId":18802,"briefTitle":18803,"status":195,"phases":18804,"completion":5562,"start":4285,"enrollment":6555,"conditions":18805,"interventions":18806},"NCT00090324","Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia",[92],[33],[18716],{"nctId":18808,"briefTitle":18809,"status":195,"phases":18810,"completion":12905,"start":8692,"enrollment":1832,"conditions":18811,"interventions":18812},"NCT00090311","Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania",[92],[18732],[18716],{"nctId":18814,"briefTitle":18815,"status":195,"phases":18816,"completion":6562,"start":9065,"enrollment":3000,"conditions":18817,"interventions":18819},"NCT00448578","Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients",[92],[18818,18732],"Mania",[18689,18820],"Lithium",{"nctId":18822,"briefTitle":18823,"status":195,"phases":18824,"completion":6718,"start":7494,"enrollment":5155,"conditions":18825,"interventions":18826},"NCT00322595","Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder",[92],[18742],[18676,18827],"Paroxetine",{"nctId":18829,"briefTitle":18830,"status":195,"phases":18831,"primaryCompletion":4284,"completion":4284,"start":4331,"enrollment":3000,"conditions":18832,"interventions":18834},"NCT00449397","Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis",[92],[18833],"Psychosis",[18689],{"nctId":18836,"briefTitle":18837,"status":195,"phases":18838,"completion":6718,"start":6369,"enrollment":365,"conditions":18839,"interventions":18840},"NCT00320268","Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder",[92],[18697],[18676],{"nctId":18842,"briefTitle":18843,"status":195,"phases":18844,"completion":5725,"start":6369,"enrollment":18845,"conditions":18846,"interventions":18847},"NCT00329264","Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder",[92],876,[18742],[18676],{"nctId":18849,"briefTitle":18850,"status":195,"phases":18851,"completion":6718,"start":6369,"enrollment":365,"conditions":18852,"interventions":18853},"NCT00321490","Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder",[92],[18697],[18676,18854],"Duloxetine",{"nctId":18856,"briefTitle":18857,"status":443,"phases":18858,"primaryCompletion":2243,"completion":2243,"start":2095,"enrollment":2260,"conditions":18859,"interventions":18860},"NCT00852631","Seroquel XR in Adults With Schizophrenia",[92],[33],[18676],{"nctId":18862,"briefTitle":18863,"status":195,"phases":18864,"primaryCompletion":9901,"completion":9901,"start":6651,"enrollment":18865,"conditions":18866,"interventions":18869},"NCT00621647","Seroquel- Agitation Associated With Dementia",[92],333,[18867,18868],"Alzheimer's Disease","Vascular Dementia",[18689,18689],{"nctId":18871,"briefTitle":18872,"status":195,"phases":18873,"completion":2252,"start":5796,"enrollment":18874,"conditions":18875,"interventions":18876},"NCT00314184","Quetiapine Fumarate Bipolar Maintenance Monotherapy",[92],1255,[18732],[18716],{"nctId":18878,"briefTitle":18879,"status":195,"phases":18880,"completion":2087,"start":15911,"enrollment":3811,"conditions":18881,"interventions":18883},"NCT00254735","Quetiapine Augmentation in Severe Obsessive Compulsive Disorder",[92],[18882],"Obsessive Compulsive Disorder",[18716,18884],"SSRI\u002FClomipramine",{"nctId":18886,"briefTitle":18887,"status":195,"phases":18888,"completion":7439,"start":4284,"enrollment":1529,"conditions":18889,"interventions":18891},"NCT00114686","Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder",[92],[18714,18890],"Alcohol Dependence",[18676,18724,18725],{"nctId":18893,"briefTitle":18894,"status":195,"phases":18895,"completion":6718,"start":6369,"enrollment":15641,"conditions":18896,"interventions":18897},"NCT00326144","Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders",[92],[18697],[18676],{"trials":18899,"activeCount":102},[18900,18908,18914,18921,18928,18937,18944],{"nctId":18901,"briefTitle":18902,"status":195,"phases":18903,"primaryCompletion":2068,"completion":2068,"start":2251,"enrollment":18904,"conditions":18905,"interventions":18907},"NCT00672490","Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder",[93],376,[18906],"Acute Mania in Bipolar Disorder",[18689,18820],{"nctId":18909,"briefTitle":18910,"status":195,"phases":18911,"primaryCompletion":2415,"completion":2415,"start":5742,"enrollment":2187,"conditions":18912,"interventions":18913},"NCT00428350","Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic",[93],[33],[18689],{"nctId":18915,"briefTitle":18916,"status":443,"phases":18917,"primaryCompletion":2570,"completion":2570,"start":2242,"enrollment":579,"conditions":18918,"interventions":18920},"NCT01128114","Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy",[93],[18919],"Acute Bipolar Mania",[18676],{"nctId":18922,"briefTitle":18923,"status":443,"phases":18924,"primaryCompletion":6562,"completion":6562,"start":13583,"enrollment":4497,"conditions":18925,"interventions":18926},"NCT00139074","Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients",[93],[18732],[18676,18927],"sodium valproate",{"nctId":18929,"briefTitle":18930,"status":195,"phases":18931,"primaryCompletion":2086,"completion":2086,"start":6780,"enrollment":18932,"conditions":18933,"interventions":18935},"NCT00206102","A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder",[93],1098,[33,18934],"Schizoaffective Disorder",[18716,18936],"risperidone",{"nctId":18938,"briefTitle":18939,"status":443,"phases":18940,"primaryCompletion":2365,"completion":2365,"start":2143,"enrollment":18941,"conditions":18942,"interventions":18943},"NCT01254721","A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study",[93],131,[18919],[18676,18724],{"nctId":18945,"briefTitle":18946,"status":195,"phases":18947,"primaryCompletion":4298,"completion":4298,"start":6719,"enrollment":3007,"conditions":18948,"interventions":18949},"NCT00255515","Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia",[93],[33],[18676,18950],"conventional treatment for schizophrenia",{"trials":18952,"activeCount":102},[],{"intervention":2173,"totalTrials":17655,"cells":18954},{"EARLY_PHASE1":18955,"PHASE1":18957,"PHASE2":19002,"PHASE3":19014,"PHASE4":19146,"NA":19167},{"trials":18956,"activeCount":102},[],{"trials":18958,"activeCount":102},[18959,18967,18976,18980,18984,18990,18994],{"nctId":18960,"briefTitle":18961,"status":195,"phases":18962,"primaryCompletion":2212,"completion":2212,"start":2114,"enrollment":1130,"conditions":18963,"interventions":18964},"NCT01068743","Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin\u002F850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered",[90],[22],[18965,2333,18966],"saxagliptin","saxagliptin + metformin",{"nctId":18968,"briefTitle":18969,"status":195,"phases":18970,"primaryCompletion":4580,"completion":4580,"start":2542,"enrollment":8138,"conditions":18971,"interventions":18972},"NCT01365091","Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin\u002FMetformin-Brazil",[90],[22],[18973,2108,18974,18975,2173],"Saxagliptin\u002Fmetformin fixed-dose combination","Metformin extended-release","Saxagliptin\u002FMetformin FDC",{"nctId":2165,"briefTitle":2166,"status":195,"phases":18977,"primaryCompletion":2168,"completion":2168,"start":2169,"enrollment":1336,"conditions":18978,"interventions":18979},[90],[2171],[2044,2173,2174],{"nctId":2184,"briefTitle":2185,"status":195,"phases":18981,"primaryCompletion":2113,"completion":2113,"start":2056,"enrollment":2187,"conditions":18982,"interventions":18983},[90],[36],[2190,2044,2173,2190,2044,2173],{"nctId":18985,"briefTitle":18986,"status":195,"phases":18987,"primaryCompletion":2113,"completion":2113,"start":2114,"enrollment":2260,"conditions":18988,"interventions":18989},"NCT01068730","Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects",[90],[22],[2333,2333,2333,2333],{"nctId":6917,"briefTitle":6918,"status":195,"phases":18991,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":1638,"conditions":18992,"interventions":18993},[90],[5851],[6860,2173],{"nctId":18995,"briefTitle":18996,"status":195,"phases":18997,"primaryCompletion":18998,"completion":18998,"start":5529,"enrollment":2003,"conditions":18999,"interventions":19000},"NCT05526690","Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects",[90],"2020-12-12",[2620],[2173,19001],"CIN-107",{"trials":19003,"activeCount":102},[19004,19008],{"nctId":2325,"briefTitle":2326,"status":195,"phases":19005,"primaryCompletion":2328,"completion":2328,"start":2329,"enrollment":2330,"conditions":19006,"interventions":19007},[91],[31],[2246,2246,2246,2246,2246,2333],{"nctId":19009,"briefTitle":19010,"status":443,"phases":19011,"completion":12905,"start":9065,"enrollment":1428,"conditions":19012,"interventions":19013},"NCT00263965","ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity",[91],[31],[15914,2173],{"trials":19015,"activeCount":102},[19016,19020,19027,19031,19039,19043,19056,19060,19066,19073,19077,19081,19089,19093,19099,19105,19109,19121,19128,19132,19136,19142],{"nctId":18300,"briefTitle":18301,"status":195,"phases":19017,"primaryCompletion":2055,"completion":2055,"start":4285,"enrollment":12271,"conditions":19018,"interventions":19019},[92],[22],[18239,18305,2173],{"nctId":19021,"briefTitle":19022,"status":443,"phases":19023,"completion":2087,"start":8692,"enrollment":19024,"conditions":19025,"interventions":19026},"NCT00251953","GALLANT 8 Tesaglitazar Add-on to Metformin",[92],555,[31],[15914,2173],{"nctId":2411,"briefTitle":2412,"status":195,"phases":19028,"primaryCompletion":2414,"completion":2243,"start":2415,"enrollment":2416,"conditions":19029,"interventions":19030},[92],[31],[2044,2173],{"nctId":19032,"briefTitle":19033,"status":195,"phases":19034,"primaryCompletion":2415,"completion":3827,"start":6369,"enrollment":19035,"conditions":19036,"interventions":19037},"NCT00313313","A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas",[92],768,[2652],[2108,2108,19038,19038,2173],"Glyburide",{"nctId":2440,"briefTitle":2441,"status":195,"phases":19040,"primaryCompletion":2443,"completion":2443,"start":2242,"enrollment":2444,"conditions":19041,"interventions":19042},[92],[31],[2044,2044,2173,2447,2448],{"nctId":19044,"briefTitle":19045,"status":195,"phases":19046,"primaryCompletion":19047,"completion":19048,"start":19049,"enrollment":19050,"conditions":19051,"interventions":19052},"NCT02551874","A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",[92],"2017-05-08","2017-11-10","2015-10-20",650,[22],[19053,19054,19055,2173],"Saxagliptin, Onglyza","Dapagliflozin, Farxiga","Glargine insulin",{"nctId":15928,"briefTitle":15929,"status":195,"phases":19057,"primaryCompletion":2406,"completion":2516,"start":2414,"enrollment":15931,"conditions":19058,"interventions":19059},[92],[22],[15934,2333,15935,15893],{"nctId":19061,"briefTitle":19062,"status":195,"phases":19063,"primaryCompletion":2067,"completion":2067,"start":2524,"enrollment":10001,"conditions":19064,"interventions":19065},"NCT00661362","Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes",[92],[31],[2108,2173],{"nctId":19067,"briefTitle":19068,"status":195,"phases":19069,"primaryCompletion":2169,"completion":2414,"start":6562,"enrollment":19070,"conditions":19071,"interventions":19072},"NCT00316082","Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",[92],365,[2652],[2108,2108,2108,2108,2333],{"nctId":2586,"briefTitle":2587,"status":195,"phases":19074,"primaryCompletion":2242,"completion":2589,"start":2095,"enrollment":2590,"conditions":19075,"interventions":19076},[92],[22],[2044,2173,2081],{"nctId":15943,"briefTitle":15944,"status":195,"phases":19078,"primaryCompletion":4297,"completion":2086,"start":2087,"enrollment":15946,"conditions":19079,"interventions":19080},[92],[2089],[2108,2108,15893,15949,2333],{"nctId":19082,"briefTitle":19083,"status":195,"phases":19084,"primaryCompletion":2151,"completion":2144,"start":4298,"enrollment":19085,"conditions":19086,"interventions":19087},"NCT00575588","52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period",[92],891,[31],[2173,19088,2108],"Sulphonylurea",{"nctId":18378,"briefTitle":18379,"status":195,"phases":19090,"primaryCompletion":2105,"completion":2105,"start":2067,"enrollment":18381,"conditions":19091,"interventions":19092},[92],[22],[18239,18384,2173,18385],{"nctId":19094,"briefTitle":19095,"status":195,"phases":19096,"primaryCompletion":4916,"completion":2114,"start":13583,"enrollment":5936,"conditions":19097,"interventions":19098},"NCT00121641","Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",[92],[2089],[2108,2108,2108,2173,2108,2173],{"nctId":19100,"briefTitle":19101,"status":195,"phases":19102,"primaryCompletion":6710,"completion":2055,"start":5563,"enrollment":5531,"conditions":19103,"interventions":19104},"NCT00374907","A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",[92],[31],[2108,2173,2173],{"nctId":2672,"briefTitle":2673,"status":195,"phases":19106,"primaryCompletion":2675,"completion":2675,"start":2349,"enrollment":1078,"conditions":19107,"interventions":19108},[92],[31],[2246,2246,2246,2333],{"nctId":19110,"briefTitle":19111,"status":443,"phases":19112,"primaryCompletion":753,"completion":753,"start":19113,"enrollment":6275,"conditions":19114,"interventions":19115},"NCT03608358","Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin\u002FSaxagliptin",[92],"2019-02-27",[22],[19116,19117,19118,19119,19120,2173],"Dapagliflozin 10 mg","Dapagliflozin 5 mg","Dapagliflozin 10 mg placebo to match","Dapagliflozin 5 mg placebo to match","Saxagliptin 5 mg",{"nctId":19122,"briefTitle":19123,"status":443,"phases":19124,"completion":5742,"start":5796,"enrollment":9987,"conditions":19125,"interventions":19126},"NCT00261352","GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate",[92],[31],[15914,2173,19127],"Fenofibrate",{"nctId":15959,"briefTitle":15960,"status":195,"phases":19129,"primaryCompletion":2169,"completion":4915,"start":7494,"enrollment":15962,"conditions":19130,"interventions":19131},[92],[2652],[2108,2108,2173,15893],{"nctId":2702,"briefTitle":2703,"status":195,"phases":19133,"primaryCompletion":687,"completion":687,"start":2242,"enrollment":2705,"conditions":19134,"interventions":19135},[92],[31],[2044,2044,2173,2447],{"nctId":19137,"briefTitle":19138,"status":195,"phases":19139,"primaryCompletion":6468,"completion":6468,"start":2542,"enrollment":2827,"conditions":19140,"interventions":19141},"NCT01204775","Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",[92],[31],[2108,2475,2173],{"nctId":2769,"briefTitle":2770,"status":195,"phases":19143,"primaryCompletion":2095,"completion":2406,"start":2415,"enrollment":2772,"conditions":19144,"interventions":19145},[92],[31],[2044,2759,2173],{"trials":19147,"activeCount":102},[19148,19155,19163],{"nctId":19149,"briefTitle":19150,"status":195,"phases":19151,"completion":2143,"start":2350,"enrollment":19152,"conditions":19153,"interventions":19154},"NCT01006590","Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes",[93],286,[22],[2108,2173],{"nctId":19156,"briefTitle":19157,"status":195,"phases":19158,"primaryCompletion":13056,"completion":13056,"start":13756,"enrollment":9428,"conditions":19159,"interventions":19161},"NCT02429258","Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin",[93],[19160],"Type II Diabetes",[19162,2173,12122],"Farxiga",{"nctId":2815,"briefTitle":2816,"status":624,"phases":19164,"primaryCompletion":2818,"completion":2818,"start":772,"enrollment":102,"conditions":19165,"interventions":19166},[93],[2803],[2044,2173],{"trials":19168,"activeCount":102},[],{"intervention":12616,"totalTrials":2827,"cells":19170},{"EARLY_PHASE1":19171,"PHASE1":19173,"PHASE2":19230,"PHASE3":19274,"PHASE4":19329,"NA":19394},{"trials":19172,"activeCount":102},[],{"trials":19174,"activeCount":102},[19175,19183,19191,19199,19208,19212,19221],{"nctId":19176,"briefTitle":19177,"status":195,"phases":19178,"primaryCompletion":687,"completion":687,"start":2615,"enrollment":434,"conditions":19179,"interventions":19181},"NCT01350921","Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers",[90],[19180],"Drug Drug Interaction",[12616,19182],"Venlaflaxin",{"nctId":19184,"briefTitle":19185,"status":195,"phases":19186,"primaryCompletion":2471,"completion":2471,"start":2747,"enrollment":5876,"conditions":19187,"interventions":19188},"NCT01504906","Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor",[90],[19],[19189,19190],"cyclosporine","ticagrelor",{"nctId":19192,"briefTitle":19193,"status":195,"phases":19194,"primaryCompletion":5417,"completion":5417,"start":659,"enrollment":1510,"conditions":19195,"interventions":19196},"NCT04588727","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects",[90],[2619],[19197,12616,19198],"AZD3366","acetylsalicylic acid",{"nctId":19200,"briefTitle":19201,"status":195,"phases":19202,"primaryCompletion":19203,"completion":19203,"start":19204,"enrollment":544,"conditions":19205,"interventions":19207},"NCT03492931","PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)",[90],"2019-05-07","2018-03-28",[19206],"Sickle Cell Disease",[12616],{"nctId":12610,"briefTitle":12611,"status":195,"phases":19209,"primaryCompletion":12613,"completion":12613,"start":7696,"enrollment":2260,"conditions":19210,"interventions":19211},[90],[5851],[5887,12616],{"nctId":19213,"briefTitle":19214,"status":195,"phases":19215,"primaryCompletion":19216,"completion":19216,"start":19217,"enrollment":2003,"conditions":19218,"interventions":19220},"NCT02022748","Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects",[90],"2016-05-09","2013-12-29",[19219],"Kidney Failure, Chronic",[19190,19190,19190],{"nctId":19222,"briefTitle":19223,"status":195,"phases":19224,"primaryCompletion":7618,"completion":7618,"start":2616,"enrollment":5947,"conditions":19225,"interventions":19227},"NCT01744288","Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets",[90],[19226],"Inhibition on Platelet Aggregation",[12616,19228,19229],"Clopidogrel","ASA",{"trials":19231,"activeCount":102},[19232,19241,19249,19259,19266],{"nctId":19233,"briefTitle":19234,"status":195,"phases":19235,"primaryCompletion":2077,"completion":2077,"start":4297,"enrollment":19236,"conditions":19237,"interventions":19238},"NCT00528411","A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin",[91],123,[12734],[12616,19239,19240],"Clopidogrel (over encapsulated)","Aspirin",{"nctId":19242,"briefTitle":19243,"status":195,"phases":19244,"primaryCompletion":19245,"completion":19245,"start":1218,"enrollment":19246,"conditions":19247,"interventions":19248},"NCT02482298","A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease",[91],"2016-11-16",87,[19206],[12616],{"nctId":19250,"briefTitle":19251,"status":443,"phases":19252,"primaryCompletion":19253,"completion":19253,"start":19254,"enrollment":1448,"conditions":19255,"interventions":19257},"NCT02227368","Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR",[91],"2016-05-23","2014-10-20",[19256],"Peripheral Artery Disease (PAD)",[12616,19258],"Comparator",{"nctId":19260,"briefTitle":19261,"status":195,"phases":19262,"primaryCompletion":2077,"completion":2077,"start":2221,"enrollment":8285,"conditions":19263,"interventions":19265},"NCT00642811","A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders",[91],[19264],"Stable Coronary Artery Disease",[12616,19228,19240],{"nctId":19267,"briefTitle":19268,"status":195,"phases":19269,"primaryCompletion":2570,"completion":2570,"start":2113,"enrollment":19270,"conditions":19271,"interventions":19272},"NCT01118325","An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease",[91],146,[19264],[19190,19273],"clopidogrel",{"trials":19275,"activeCount":102},[19276,19285,19295,19304,19313,19320],{"nctId":19277,"briefTitle":19278,"status":195,"phases":19279,"primaryCompletion":7061,"completion":7061,"start":1159,"enrollment":19280,"conditions":19281,"interventions":19284},"NCT03354429","THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death",[92],11016,[19282,19283],"Acute Ischaemic Stroke","Transient Ischaemic Attack",[12616],{"nctId":19286,"briefTitle":19287,"status":195,"phases":19288,"primaryCompletion":19289,"completion":19289,"start":19290,"enrollment":19291,"conditions":19292,"interventions":19293},"NCT01994720","[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]",[92],"2016-03-02","2014-01-07",13307,[19282,19283],[19190,19294],"Acetylsalicylic acid",{"nctId":19296,"briefTitle":19297,"status":195,"phases":19298,"primaryCompletion":2481,"completion":2481,"start":2433,"enrollment":19299,"conditions":19300,"interventions":19302},"NCT01294462","Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian\u002FJapanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)",[92],801,[12948,19301],"Percutaneous Coronary Intervention",[12616,19228,19303],"Acetylsalicylic acid ASA",{"nctId":19305,"briefTitle":19306,"status":195,"phases":19307,"primaryCompletion":5238,"completion":5238,"start":19308,"enrollment":19309,"conditions":19310,"interventions":19312},"NCT01732822","A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease",[92],"2012-12-04",13885,[19311],"Peripheral Artery Disease",[12616,19228],{"nctId":19314,"briefTitle":19315,"status":195,"phases":19316,"primaryCompletion":2077,"completion":2077,"start":2639,"enrollment":19317,"conditions":19318,"interventions":19319},"NCT00391872","A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome",[92],18624,[12948],[12616,19228],{"nctId":19321,"briefTitle":19322,"status":443,"phases":19323,"primaryCompletion":19324,"completion":19324,"start":19325,"enrollment":19326,"conditions":19327,"interventions":19328},"NCT03615924","Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease",[92],"2020-08-13","2018-09-26",193,[19206],[12616],{"trials":19330,"activeCount":102},[19331,19340,19346,19353,19360,19367,19374,19383],{"nctId":19332,"briefTitle":19333,"status":195,"phases":19334,"primaryCompletion":19335,"completion":19335,"start":19336,"enrollment":19337,"conditions":19338,"interventions":19339},"NCT01870921","Brilinta DaYu Study",[93],"2015-09-30","2013-06-26",2004,[12948],[12616],{"nctId":19341,"briefTitle":19342,"status":195,"phases":19343,"primaryCompletion":7354,"completion":7354,"start":4496,"enrollment":2161,"conditions":19344,"interventions":19345},"NCT01523366","A Pharmacodynamic Study With Ticagrelor in Hispanic Patients",[93],[19264],[12616,19228],{"nctId":19347,"briefTitle":19348,"status":443,"phases":19349,"primaryCompletion":16033,"completion":16033,"start":2180,"enrollment":17655,"conditions":19350,"interventions":19352},"NCT02052635","Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.",[93],[19351],"Non-ST Elevation Acute Coronary Syndrome",[19190,19273],{"nctId":19354,"briefTitle":19355,"status":195,"phases":19356,"primaryCompletion":4006,"completion":4006,"start":7354,"enrollment":477,"conditions":19357,"interventions":19359},"NCT01864005","A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS",[93],[19358],"Non-ST or ST Elevation Acute Coronary Syndromes",[12616,19228],{"nctId":19361,"briefTitle":19362,"status":195,"phases":19363,"primaryCompletion":19364,"completion":19364,"start":687,"enrollment":4286,"conditions":19365,"interventions":19366},"NCT01523392","A Pharmacodynamic Study With Ticagrelor in African American Patients",[93],"2013-09",[19264],[12616,19228],{"nctId":19368,"briefTitle":19369,"status":195,"phases":19370,"primaryCompletion":2470,"completion":2470,"start":2481,"enrollment":19371,"conditions":19372,"interventions":19373},"NCT01603082","Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients",[93],343,[12948],[12616,19228],{"nctId":19375,"briefTitle":19376,"status":195,"phases":19377,"primaryCompletion":1693,"completion":1693,"start":2571,"enrollment":19378,"conditions":19379,"interventions":19382},"NCT01347580","A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)",[93],1875,[19380,19381],"Myocardial Infarction","Segment Elevation Myocardial Infarction (STEMI)",[12616],{"nctId":19384,"briefTitle":19385,"status":624,"phases":19386,"primaryCompletion":19387,"completion":19387,"start":2179,"enrollment":102,"conditions":19388,"interventions":19393},"NCT02121288","Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients",[93],"2016-02",[19311,19389,19390,19391,19392],"Vascular Disease","Arterial Occlusion Disease","Intermittent Claudication","Ankle Brachial Index (0.9 or Less)",[12616,19273],{"trials":19395,"activeCount":102},[],{"intervention":9857,"totalTrials":98,"cells":19397},{"EARLY_PHASE1":19398,"PHASE1":19400,"PHASE2":19402,"PHASE3":19436,"PHASE4":19530,"NA":19563},{"trials":19399,"activeCount":102},[],{"trials":19401,"activeCount":102},[],{"trials":19403,"activeCount":102},[19404,19408,19415,19422,19429],{"nctId":9851,"briefTitle":9852,"status":195,"phases":19405,"primaryCompletion":2406,"completion":2406,"start":2067,"enrollment":4928,"conditions":19406,"interventions":19407},[91],[9855],[9857,9858,9842],{"nctId":19409,"briefTitle":19410,"status":195,"phases":19411,"primaryCompletion":7554,"completion":7554,"start":6370,"enrollment":19050,"conditions":19412,"interventions":19414},"NCT00641693","Assess the Efficacy and Safety of Rhinocort Aqua",[91],[19413],"Allergic Rhinitis",[9972,9972,9972],{"nctId":19416,"briefTitle":19417,"status":195,"phases":19418,"primaryCompletion":5797,"completion":5797,"start":15911,"enrollment":1685,"conditions":19419,"interventions":19421},"NCT00641979","New Nasal Applicator \u002F New Formulation - User Study",[91],[19420],"Seasonal Allergic Rhinitis",[9857],{"nctId":19423,"briefTitle":19424,"status":195,"phases":19425,"primaryCompletion":19426,"completion":19426,"start":2406,"enrollment":2792,"conditions":19427,"interventions":19428},"NCT01136382","A 6-week Study in Asthmatic Children Aged 6 to \u003C12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo",[91],"2013-04",[16],[9857],{"nctId":19430,"briefTitle":19431,"status":195,"phases":19432,"primaryCompletion":19426,"completion":19426,"start":4496,"enrollment":12705,"conditions":19433,"interventions":19434},"NCT01555099","Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol",[91],[6083],[19435,9972],"AZD5423",{"trials":19437,"activeCount":102},[19438,19442,19449,19456,19462,19466,19470,19477,19484,19491,19495,19502,19506,19510,19514,19522],{"nctId":9870,"briefTitle":9871,"status":195,"phases":19439,"completion":6572,"start":3810,"enrollment":170,"conditions":19440,"interventions":19441},[92],[16],[9842,9857,9866],{"nctId":19443,"briefTitle":19444,"status":195,"phases":19445,"primaryCompletion":9986,"completion":9986,"start":9909,"enrollment":19446,"conditions":19447,"interventions":19448},"NCT00642122","Adults With Moderate to Severe Asthma",[92],900,[16],[9972,9972,9972,9972,9972],{"nctId":19450,"briefTitle":19451,"status":195,"phases":19452,"completion":4297,"start":2639,"enrollment":1173,"conditions":19453,"interventions":19454},"NCT00504062","Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma",[92],[16],[9857,19455],"fluticasone",{"nctId":19457,"briefTitle":19458,"status":195,"phases":19459,"primaryCompletion":3990,"completion":3990,"start":3810,"enrollment":842,"conditions":19460,"interventions":19461},"NCT00642187","New Version Pulmicort Turbuhaler USA Adults",[92],[16],[9857],{"nctId":9914,"briefTitle":9915,"status":195,"phases":19463,"completion":6780,"start":5797,"enrollment":170,"conditions":19464,"interventions":19465},[92],[16],[9842,9857,9866],{"nctId":9920,"briefTitle":9921,"status":195,"phases":19467,"completion":2169,"start":5563,"enrollment":2472,"conditions":19468,"interventions":19469},[92],[28],[9842,9857,9925],{"nctId":19471,"briefTitle":19472,"status":195,"phases":19473,"primaryCompletion":4285,"completion":4285,"start":9066,"enrollment":19474,"conditions":19475,"interventions":19476},"NCT00642161","New Version Pulmicort Turbuhaler USA Children",[92],430,[16],[9857],{"nctId":19478,"briefTitle":19479,"status":195,"phases":19480,"primaryCompletion":4331,"completion":4331,"start":9909,"enrollment":9978,"conditions":19481,"interventions":19482},"NCT00641680","Rhinocort Aqua Versus Placebo and Fluticasone Propionate",[92],[19420],[9972,19483],"Fluticasone propionate",{"nctId":19485,"briefTitle":19486,"status":195,"phases":19487,"primaryCompletion":2151,"completion":2151,"start":2095,"enrollment":1373,"conditions":19488,"interventions":19489},"NCT00855959","Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients",[92],[16],[9972,19490],"Pulmicort Turbuhaler",{"nctId":9960,"briefTitle":9961,"status":195,"phases":19492,"completion":9963,"start":9909,"enrollment":8294,"conditions":19493,"interventions":19494},[92],[16],[9842,9857],{"nctId":19496,"briefTitle":19497,"status":195,"phases":19498,"primaryCompletion":2105,"completion":2105,"start":4580,"enrollment":3524,"conditions":19499,"interventions":19500},"NCT01360021","New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day",[92],[16],[19501,19501,9972],"Symbicort",{"nctId":9967,"briefTitle":9968,"status":195,"phases":19503,"completion":7342,"start":3809,"enrollment":5269,"conditions":19504,"interventions":19505},[92],[16],[9896,9972,9973],{"nctId":9991,"briefTitle":9992,"status":195,"phases":19507,"completion":9075,"start":3810,"enrollment":9994,"conditions":19508,"interventions":19509},[92],[16],[9842,9857,9866],{"nctId":10012,"briefTitle":10013,"status":195,"phases":19511,"completion":9075,"start":3810,"enrollment":3125,"conditions":19512,"interventions":19513},[92],[16],[9842,9857],{"nctId":19515,"briefTitle":19516,"status":195,"phases":19517,"completion":6718,"start":6370,"enrollment":19518,"conditions":19519,"interventions":19520},"NCT00259766","SHARE - Symbicort and Health Economics in a Real Life Evaluation",[92],1970,[16],[9972,9882,19521],"Terbutaline",{"nctId":19523,"briefTitle":19524,"status":195,"phases":19525,"primaryCompletion":2086,"completion":2086,"start":5742,"enrollment":19526,"conditions":19527,"interventions":19528},"NCT00509028","Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma",[92],241,[16],[9972,19529],"Conventional Asthma Therapy",{"trials":19531,"activeCount":102},[19532,19540,19547,19555],{"nctId":19533,"briefTitle":19534,"status":195,"phases":19535,"primaryCompletion":9075,"completion":9075,"start":19536,"enrollment":10196,"conditions":19537,"interventions":19538},"NCT00641446","Varicella Vaccination With Pulmicort",[93],"2001-10",[16],[9857,19539],"varicella zoster virus",{"nctId":19541,"briefTitle":19542,"status":195,"phases":19543,"primaryCompletion":2067,"completion":2067,"start":2524,"enrollment":2737,"conditions":19544,"interventions":19545},"NCT00702325","Phase4\u002FSymbicort® Versus Pulmicort Flexhaler® in African Americans",[93],[16],[19546,9972],"Budesonide \u002F formoterol fumarate",{"nctId":19548,"briefTitle":19549,"status":195,"phases":19550,"primaryCompletion":12954,"completion":12954,"start":19551,"enrollment":19552,"conditions":19553,"interventions":19554},"NCT00641914","Inhaled Steroid Treatment as Regular Therapy in Early Asthma",[93],"1996-10",6800,[16],[9857],{"nctId":19556,"briefTitle":19557,"status":195,"phases":19558,"primaryCompletion":9909,"completion":9909,"start":12860,"enrollment":19559,"conditions":19560,"interventions":19562},"NCT00641212","Children, Perennial Allergic Rhinitis (PAR), l-t Growth",[93],209,[19561],"Perennial Allergic Rhinitis",[9972],{"trials":19564,"activeCount":102},[],{"intervention":19228,"totalTrials":4497,"cells":19566},{"EARLY_PHASE1":19567,"PHASE1":19569,"PHASE2":19607,"PHASE3":19621,"PHASE4":19635,"NA":19661},{"trials":19568,"activeCount":102},[],{"trials":19570,"activeCount":102},[19571,19579,19589,19596,19600],{"nctId":19572,"briefTitle":19573,"status":195,"phases":19574,"completion":2068,"start":2095,"enrollment":2260,"conditions":19575,"interventions":19577},"NCT00853450","Bleeding Time Study With AZD6482, Clopidogrel and ASA",[90],[19576],"Antiplatelet Effect",[19578,19228,19229],"AZD6482",{"nctId":19580,"briefTitle":19581,"status":195,"phases":19582,"primaryCompletion":2615,"completion":2615,"start":2243,"enrollment":19583,"conditions":19584,"interventions":19585},"NCT01147588","Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel",[90],149,[19],[19586,19587,19588,19273],"lansoprazole","omeprazole","esomeprazole",{"nctId":19590,"briefTitle":19591,"status":195,"phases":19592,"primaryCompletion":2675,"completion":2675,"start":2349,"enrollment":3180,"conditions":19593,"interventions":19594},"NCT01210339","An Interaction Study to Evaluate the Effect of Esomeprazole\u002FAcetylsalicylic Acid on the Metabolism and Effect of Clopidogrel",[90],[36],[19228,19595],"Esomeprazole\u002FASA",{"nctId":19222,"briefTitle":19223,"status":195,"phases":19597,"primaryCompletion":7618,"completion":7618,"start":2616,"enrollment":5947,"conditions":19598,"interventions":19599},[90],[19226],[12616,19228,19229],{"nctId":19601,"briefTitle":19602,"status":195,"phases":19603,"primaryCompletion":6436,"completion":6436,"start":2560,"enrollment":6419,"conditions":19604,"interventions":19606},"NCT02185534","Clopidogrel Bioequivalence Study in Healthy Subjects",[90],[19605],"Bioequivalence, AUC, Cmax, Pharmacokinetics",[19228],{"trials":19608,"activeCount":102},[19609,19613,19617],{"nctId":19233,"briefTitle":19234,"status":195,"phases":19610,"primaryCompletion":2077,"completion":2077,"start":4297,"enrollment":19236,"conditions":19611,"interventions":19612},[91],[12734],[12616,19239,19240],{"nctId":19260,"briefTitle":19261,"status":195,"phases":19614,"primaryCompletion":2077,"completion":2077,"start":2221,"enrollment":8285,"conditions":19615,"interventions":19616},[91],[19264],[12616,19228,19240],{"nctId":19267,"briefTitle":19268,"status":195,"phases":19618,"primaryCompletion":2570,"completion":2570,"start":2113,"enrollment":19270,"conditions":19619,"interventions":19620},[91],[19264],[19190,19273],{"trials":19622,"activeCount":102},[19623,19627,19631],{"nctId":19296,"briefTitle":19297,"status":195,"phases":19624,"primaryCompletion":2481,"completion":2481,"start":2433,"enrollment":19299,"conditions":19625,"interventions":19626},[92],[12948,19301],[12616,19228,19303],{"nctId":19305,"briefTitle":19306,"status":195,"phases":19628,"primaryCompletion":5238,"completion":5238,"start":19308,"enrollment":19309,"conditions":19629,"interventions":19630},[92],[19311],[12616,19228],{"nctId":19314,"briefTitle":19315,"status":195,"phases":19632,"primaryCompletion":2077,"completion":2077,"start":2639,"enrollment":19317,"conditions":19633,"interventions":19634},[92],[12948],[12616,19228],{"trials":19636,"activeCount":102},[19637,19641,19645,19649,19653,19657],{"nctId":19341,"briefTitle":19342,"status":195,"phases":19638,"primaryCompletion":7354,"completion":7354,"start":4496,"enrollment":2161,"conditions":19639,"interventions":19640},[93],[19264],[12616,19228],{"nctId":19347,"briefTitle":19348,"status":443,"phases":19642,"primaryCompletion":16033,"completion":16033,"start":2180,"enrollment":17655,"conditions":19643,"interventions":19644},[93],[19351],[19190,19273],{"nctId":19354,"briefTitle":19355,"status":195,"phases":19646,"primaryCompletion":4006,"completion":4006,"start":7354,"enrollment":477,"conditions":19647,"interventions":19648},[93],[19358],[12616,19228],{"nctId":19361,"briefTitle":19362,"status":195,"phases":19650,"primaryCompletion":19364,"completion":19364,"start":687,"enrollment":4286,"conditions":19651,"interventions":19652},[93],[19264],[12616,19228],{"nctId":19368,"briefTitle":19369,"status":195,"phases":19654,"primaryCompletion":2470,"completion":2470,"start":2481,"enrollment":19371,"conditions":19655,"interventions":19656},[93],[12948],[12616,19228],{"nctId":19384,"briefTitle":19385,"status":624,"phases":19658,"primaryCompletion":19387,"completion":19387,"start":2179,"enrollment":102,"conditions":19659,"interventions":19660},[93],[19311,19389,19390,19391,19392],[12616,19273],{"trials":19662,"activeCount":102},[],{"intervention":2081,"totalTrials":1757,"cells":19664},{"EARLY_PHASE1":19665,"PHASE1":19667,"PHASE2":19683,"PHASE3":19685,"PHASE4":19718,"NA":19737},{"trials":19666,"activeCount":102},[],{"trials":19668,"activeCount":102},[19669,19673,19677],{"nctId":2074,"briefTitle":2075,"status":195,"phases":19670,"primaryCompletion":688,"completion":688,"start":2077,"enrollment":1336,"conditions":19671,"interventions":19672},[90],[22],[2044,2080,2081],{"nctId":2118,"briefTitle":2119,"status":195,"phases":19674,"primaryCompletion":2121,"completion":2121,"start":2122,"enrollment":451,"conditions":19675,"interventions":19676},[90],[2124],[2126,2081,2044],{"nctId":19678,"briefTitle":19679,"status":195,"phases":19680,"primaryCompletion":2243,"completion":2243,"start":2212,"enrollment":1757,"conditions":19681,"interventions":19682},"NCT01095991","Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus",[90],[22],[15883,2081],{"trials":19684,"activeCount":102},[],{"trials":19686,"activeCount":102},[19687,19691,19695,19703,19707,19711],{"nctId":2393,"briefTitle":2394,"status":195,"phases":19688,"primaryCompletion":2396,"completion":2396,"start":2397,"enrollment":2398,"conditions":19689,"interventions":19690},[92],[31],[2108,2044,2081],{"nctId":15928,"briefTitle":15929,"status":195,"phases":19692,"primaryCompletion":2406,"completion":2516,"start":2414,"enrollment":15931,"conditions":19693,"interventions":19694},[92],[22],[15934,2333,15935,15893],{"nctId":19696,"briefTitle":19697,"status":195,"phases":19698,"primaryCompletion":7618,"completion":7618,"start":2405,"enrollment":19070,"conditions":19699,"interventions":19701},"NCT01652729","Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",[92],[19700],"Diabetes Type 2",[19702,2081],"Exenatide once weekly suspension",{"nctId":2586,"briefTitle":2587,"status":195,"phases":19704,"primaryCompletion":2242,"completion":2589,"start":2095,"enrollment":2590,"conditions":19705,"interventions":19706},[92],[22],[2044,2173,2081],{"nctId":15937,"briefTitle":15938,"status":195,"phases":19708,"primaryCompletion":2095,"completion":2068,"start":6710,"enrollment":6573,"conditions":19709,"interventions":19710},[92],[22],[15934,15935,15893],{"nctId":19712,"briefTitle":19713,"status":195,"phases":19714,"primaryCompletion":2077,"completion":2077,"start":2251,"enrollment":19715,"conditions":19716,"interventions":19717},"NCT00666458","18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)",[92],822,[31],[18965,15935],{"trials":19719,"activeCount":102},[19720,19724,19733],{"nctId":18462,"briefTitle":18463,"status":195,"phases":19721,"primaryCompletion":2415,"completion":2415,"start":6718,"enrollment":188,"conditions":19722,"interventions":19723},[93],[22],[18239,15935],{"nctId":19725,"briefTitle":19726,"status":195,"phases":19727,"primaryCompletion":19728,"completion":19728,"start":19729,"enrollment":19730,"conditions":19731,"interventions":19732},"NCT02917031","Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure",[93],"2019-08-23","2017-01-10",348,[22,1520],[2108,2081],{"nctId":18468,"briefTitle":18469,"status":195,"phases":19734,"primaryCompletion":2350,"completion":2350,"start":2220,"enrollment":6597,"conditions":19735,"interventions":19736},[93],[22],[18239,15935],{"trials":19738,"activeCount":102},[],{"intervention":8361,"totalTrials":1757,"cells":19740},{"EARLY_PHASE1":19741,"PHASE1":19743,"PHASE2":19775,"PHASE3":19777,"PHASE4":19817,"NA":19826},{"trials":19742,"activeCount":102},[],{"trials":19744,"activeCount":102},[19745,19749,19753,19757,19761,19767],{"nctId":13905,"briefTitle":13906,"status":195,"phases":19746,"primaryCompletion":13908,"completion":13908,"start":13165,"enrollment":579,"conditions":19747,"interventions":19748},[90],[5851],[12597,8361],{"nctId":19580,"briefTitle":19581,"status":195,"phases":19750,"primaryCompletion":2615,"completion":2615,"start":2243,"enrollment":19583,"conditions":19751,"interventions":19752},[90],[19],[19586,19587,19588,19273],{"nctId":8355,"briefTitle":8356,"status":195,"phases":19754,"primaryCompletion":3197,"completion":3197,"start":8358,"enrollment":3209,"conditions":19755,"interventions":19756},[90],[36],[6431,5870,8361,8362,8363],{"nctId":16306,"briefTitle":16307,"status":443,"phases":19758,"primaryCompletion":16309,"completion":16309,"start":3072,"enrollment":723,"conditions":19759,"interventions":19760},[90],[498],[3914,5911,7055,8361],{"nctId":19762,"briefTitle":19763,"status":195,"phases":19764,"primaryCompletion":1693,"completion":1693,"start":1701,"enrollment":680,"conditions":19765,"interventions":19766},"NCT01921920","Prilosec Bioequivalence Study in Healthy Volunteers",[90],[19605],[8361],{"nctId":19768,"briefTitle":19769,"status":195,"phases":19770,"primaryCompletion":3862,"completion":3862,"start":2406,"enrollment":2069,"conditions":19771,"interventions":19773},"NCT01159145","Study to Assess the Pharmacodynamics\u002FPharmacokinetics After Repeated Dosing of D961H 10 mg and Omeprazole 10 mg in Japanese Healthy Male Subjects",[90],[19772],"Pharmacodynamics Study",[19774,8361],"D961H",{"trials":19776,"activeCount":102},[],{"trials":19778,"activeCount":102},[19779,19786,19795,19802,19811],{"nctId":19780,"briefTitle":19781,"status":195,"phases":19782,"primaryCompletion":9963,"completion":9963,"start":6572,"enrollment":1448,"conditions":19783,"interventions":19785},"NCT00259051","A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population",[92],[19784],"Non-erosive Reflux Disease",[8361],{"nctId":19787,"briefTitle":19788,"status":195,"phases":19789,"completion":4915,"start":4298,"enrollment":19790,"conditions":19791,"interventions":19793},"NCT00633932","Reflux Esophagitis Phase III Study (Initial Treatment)",[92],602,[19792],"Reflux Esophagitis",[19794,19794,8361],"Esomeprazole",{"nctId":19796,"briefTitle":19797,"status":195,"phases":19798,"primaryCompletion":8692,"completion":8692,"start":9075,"enrollment":19799,"conditions":19800,"interventions":19801},"NCT00259077","Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population",[92],270,[19784],[8361],{"nctId":19803,"briefTitle":19804,"status":195,"phases":19805,"primaryCompletion":3809,"completion":3809,"start":19806,"enrollment":19807,"conditions":19808,"interventions":19810},"NCT00256737","Sopran - Omeprazole Treatment Versus Surgery",[92],"1998-01",219,[19809],"GERD",[8361],{"nctId":19812,"briefTitle":19813,"status":195,"phases":19814,"completion":688,"start":6710,"enrollment":8294,"conditions":19815,"interventions":19816},"NCT00634114","Reflux Esophagitis Phase III Study (Maintenance Treatment)",[92],[19792],[19794,19794,8361],{"trials":19818,"activeCount":102},[19819],{"nctId":19820,"briefTitle":19821,"status":195,"phases":19822,"primaryCompletion":4256,"completion":4256,"start":13676,"enrollment":2045,"conditions":19823,"interventions":19825},"NCT00641264","Quality of Life Validation in Laryngitis",[93],[19824],"Laryngopharyngeal Reflux (LPR)",[8361],{"trials":19827,"activeCount":102},[],{"intervention":19829,"totalTrials":4343,"cells":19830},"Budesonide\u002FFormoterol Turbuhaler",{"EARLY_PHASE1":19831,"PHASE1":19842,"PHASE2":19844,"PHASE3":19846,"PHASE4":19884,"NA":19905},{"trials":19832,"activeCount":102},[19833],{"nctId":19834,"briefTitle":19835,"status":195,"phases":19836,"primaryCompletion":2471,"completion":2471,"start":2675,"enrollment":17655,"conditions":19837,"interventions":19840},"NCT01257048","Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler",[89],[19838,19839],"COPD Method Evaluation","Chronic Obstructive Pulmonary Disease Method Evaluation",[19841,19829,19841],"Formoterol Turbuhaler",{"trials":19843,"activeCount":102},[],{"trials":19845,"activeCount":102},[],{"trials":19847,"activeCount":102},[19848,19855,19863,19870,19876],{"nctId":19849,"briefTitle":19850,"status":195,"phases":19851,"completion":4284,"start":4285,"enrollment":9987,"conditions":19852,"interventions":19853},"NCT00259792","SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults",[92],[16],[19854],"Budesonide\u002Fformoterol Turbuhaler",{"nctId":19856,"briefTitle":19857,"status":195,"phases":19858,"completion":3839,"start":7554,"enrollment":221,"conditions":19859,"interventions":19860},"NCT00244608","A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®",[92],[16],[19829,19861,19862],"Budesonide Turbuhaler","Terbutaline Turbuhaler",{"nctId":19864,"briefTitle":19865,"status":195,"phases":19866,"primaryCompletion":3809,"completion":3809,"start":13575,"enrollment":19867,"conditions":19868,"interventions":19869},"NCT00238784","SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults",[92],1300,[16],[19854],{"nctId":19871,"briefTitle":19872,"status":195,"phases":19873,"primaryCompletion":2639,"completion":5742,"start":6780,"enrollment":221,"conditions":19874,"interventions":19875},"NCT00235911","Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting",[92],[16],[10089],{"nctId":19877,"briefTitle":19878,"status":195,"phases":19879,"completion":7494,"start":7554,"enrollment":19880,"conditions":19881,"interventions":19882},"NCT00242775","Comparison of the Efficacy\u002FSafety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50\u002F500 µg & Terbutaline Turbuhaler® 0.4 mg",[92],2100,[16],[19854,19883],"Salmeterol\u002Ffluticasone Diskus",{"trials":19885,"activeCount":102},[19886,19890,19898],{"nctId":10084,"briefTitle":10085,"status":195,"phases":19887,"completion":6517,"start":6370,"enrollment":5876,"conditions":19888,"interventions":19889},[93],[16],[10089,10090,10091],{"nctId":19891,"briefTitle":19892,"status":195,"phases":19893,"primaryCompletion":2639,"completion":2639,"start":4285,"enrollment":19894,"conditions":19895,"interventions":19896},"NCT00242411","MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults",[93],1900,[16],[19829,19897],"Conventional Best Asthma Therapy",{"nctId":19899,"briefTitle":19900,"status":195,"phases":19901,"completion":2252,"start":5563,"enrollment":680,"conditions":19902,"interventions":19903},"NCT00379028","Airway Clearance Study",[93],[28],[19829,19904],"Salmeterol\u002FFluticasone Diskus",{"trials":19906,"activeCount":102},[],{"intervention":2080,"totalTrials":370,"cells":19908},{"EARLY_PHASE1":19909,"PHASE1":19911,"PHASE2":19921,"PHASE3":19923,"PHASE4":19937,"NA":19953},{"trials":19910,"activeCount":102},[],{"trials":19912,"activeCount":102},[19913,19917],{"nctId":2074,"briefTitle":2075,"status":195,"phases":19914,"primaryCompletion":688,"completion":688,"start":2077,"enrollment":1336,"conditions":19915,"interventions":19916},[90],[22],[2044,2080,2081],{"nctId":2217,"briefTitle":2218,"status":195,"phases":19918,"primaryCompletion":2220,"completion":2220,"start":2221,"enrollment":2222,"conditions":19919,"interventions":19920},[90],[2089],[2044,2080,2225],{"trials":19922,"activeCount":102},[],{"trials":19924,"activeCount":102},[19925,19929,19933],{"nctId":2494,"briefTitle":2495,"status":195,"phases":19926,"primaryCompletion":2057,"completion":2243,"start":2251,"enrollment":2497,"conditions":19927,"interventions":19928},[92],[31],[2246,2080,2500,2501,2502],{"nctId":18358,"briefTitle":18359,"status":195,"phases":19930,"primaryCompletion":2570,"completion":2570,"start":5563,"enrollment":18361,"conditions":19931,"interventions":19932},[92],[22],[18239,18364],{"nctId":2644,"briefTitle":2645,"status":195,"phases":19934,"primaryCompletion":2647,"completion":2648,"start":2649,"enrollment":2650,"conditions":19935,"interventions":19936},[92],[2652],[2108,2044,2080],{"trials":19938,"activeCount":102},[19939,19945,19949],{"nctId":19940,"briefTitle":19941,"status":195,"phases":19942,"primaryCompletion":2471,"completion":2471,"start":2350,"enrollment":3440,"conditions":19943,"interventions":19944},"NCT01006603","Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin",[93],[22],[2108,2080],{"nctId":2806,"briefTitle":2807,"status":195,"phases":19946,"primaryCompletion":2809,"completion":2809,"start":2810,"enrollment":2811,"conditions":19947,"interventions":19948},[93],[2089],[2044,2080],{"nctId":2850,"briefTitle":2851,"status":195,"phases":19950,"primaryCompletion":2853,"completion":2853,"start":2854,"enrollment":2855,"conditions":19951,"interventions":19952},[93],[22,2621],[2044,2108,2080],{"trials":19954,"activeCount":102},[],{"intervention":18724,"totalTrials":1855,"cells":19956},{"EARLY_PHASE1":19957,"PHASE1":19959,"PHASE2":19961,"PHASE3":19963,"PHASE4":19984,"NA":20003},{"trials":19958,"activeCount":102},[],{"trials":19960,"activeCount":102},[],{"trials":19962,"activeCount":102},[],{"trials":19964,"activeCount":102},[19965,19969,19973,19977],{"nctId":18718,"briefTitle":18719,"status":195,"phases":19966,"completion":2639,"start":6370,"enrollment":18721,"conditions":19967,"interventions":19968},[92],[18714],[18716,18724,18725],{"nctId":18814,"briefTitle":18815,"status":195,"phases":19970,"completion":6562,"start":9065,"enrollment":3000,"conditions":19971,"interventions":19972},[92],[18818,18732],[18689,18820],{"nctId":18886,"briefTitle":18887,"status":195,"phases":19974,"completion":7439,"start":4284,"enrollment":1529,"conditions":19975,"interventions":19976},[92],[18714,18890],[18676,18724,18725],{"nctId":19978,"briefTitle":19979,"status":195,"phases":19980,"completion":5563,"start":12937,"enrollment":18721,"conditions":19981,"interventions":19982},"NCT00081380","Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder",[92],[18732],[19983,18724,18725],"Seroquel®, quetiapine fumarate",{"trials":19985,"activeCount":102},[19986,19990,19994],{"nctId":18901,"briefTitle":18902,"status":195,"phases":19987,"primaryCompletion":2068,"completion":2068,"start":2251,"enrollment":18904,"conditions":19988,"interventions":19989},[93],[18906],[18689,18820],{"nctId":18938,"briefTitle":18939,"status":443,"phases":19991,"primaryCompletion":2365,"completion":2365,"start":2143,"enrollment":18941,"conditions":19992,"interventions":19993},[93],[18919],[18676,18724],{"nctId":19995,"briefTitle":19996,"status":195,"phases":19997,"primaryCompletion":2349,"completion":2349,"start":2152,"enrollment":19998,"conditions":19999,"interventions":20001},"NCT00931723","Adult Bipolar Mania",[93],356,[20000],"Acute Mania",[20002,18820],"Quetiapine fumarate XR",{"trials":20004,"activeCount":102},[],{"intervention":20006,"totalTrials":1039,"cells":20007},"Quetiapine XR",{"EARLY_PHASE1":20008,"PHASE1":20010,"PHASE2":20012,"PHASE3":20014,"PHASE4":20047,"NA":20062},{"trials":20009,"activeCount":102},[],{"trials":20011,"activeCount":102},[],{"trials":20013,"activeCount":102},[],{"trials":20015,"activeCount":102},[20016,20023,20033,20039],{"nctId":20017,"briefTitle":20018,"status":195,"phases":20019,"primaryCompletion":2251,"completion":2251,"start":5563,"enrollment":170,"conditions":20020,"interventions":20022},"NCT00389064","Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder",[92],[20021],"Anxiety Disorders",[20006],{"nctId":20024,"briefTitle":20025,"status":195,"phases":20026,"primaryCompletion":2151,"completion":2151,"start":2414,"enrollment":20027,"conditions":20028,"interventions":20030},"NCT00789854","Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients",[92],688,[18697,20029],"Treatment Resistant Depression",[20006,20031,20032],"Lithium carbonate","SSRI\u002FVenlafaxine",{"nctId":20034,"briefTitle":20035,"status":195,"phases":20036,"primaryCompletion":2349,"completion":2349,"start":7544,"enrollment":19326,"conditions":20037,"interventions":20038},"NCT00811473","Pediatric Bipolar Depression",[92],[18733],[20006],{"nctId":20040,"briefTitle":20041,"status":195,"phases":20042,"primaryCompletion":2350,"completion":2350,"start":6710,"enrollment":20043,"conditions":20044,"interventions":20046},"NCT00600756","Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone",[92],798,[20045],"Schizophrenic Disorders",[20006,18800],{"trials":20048,"activeCount":102},[20049,20056],{"nctId":20050,"briefTitle":20051,"status":443,"phases":20052,"primaryCompletion":2414,"completion":2414,"start":2507,"enrollment":1855,"conditions":20053,"interventions":20055},"NCT00681629","Schizophrenic Patients in Integrated Care",[93],[33,18934,20054],"Schizophreniform Disorder",[20006],{"nctId":20057,"briefTitle":20058,"status":195,"phases":20059,"primaryCompletion":2212,"completion":2113,"start":2067,"enrollment":1348,"conditions":20060,"interventions":20061},"NCT00954122","Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia",[93],[33],[20006],{"trials":20063,"activeCount":102},[],{"intervention":20065,"totalTrials":1039,"cells":20066},"Lansoprazole",{"EARLY_PHASE1":20067,"PHASE1":20069,"PHASE2":20075,"PHASE3":20077,"PHASE4":20079,"NA":20120},{"trials":20068,"activeCount":102},[],{"trials":20070,"activeCount":102},[20071],{"nctId":19580,"briefTitle":19581,"status":195,"phases":20072,"primaryCompletion":2615,"completion":2615,"start":2243,"enrollment":19583,"conditions":20073,"interventions":20074},[90],[19],[19586,19587,19588,19273],{"trials":20076,"activeCount":102},[],{"trials":20078,"activeCount":102},[],{"trials":20080,"activeCount":102},[20081,20087,20093,20103,20113],{"nctId":20082,"briefTitle":20083,"status":195,"phases":20084,"primaryCompletion":6563,"completion":6563,"start":6499,"enrollment":9987,"conditions":20085,"interventions":20086},"NCT00641602","A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis",[93],[10949],[19794,20065],{"nctId":20088,"briefTitle":20089,"status":195,"phases":20090,"primaryCompletion":6572,"completion":6572,"start":6499,"enrollment":9978,"conditions":20091,"interventions":20092},"NCT00644735","Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed",[93],[10949],[19794,20065],{"nctId":20094,"briefTitle":20095,"status":195,"phases":20096,"primaryCompletion":12954,"completion":12954,"start":7447,"enrollment":20097,"conditions":20098,"interventions":20101},"NCT00637845","Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)",[93],248,[20099,20100],"Heartburn","Gastroesophageal Reflux Disease",[20102,20065],"Esomeprazole Magnesium",{"nctId":20104,"briefTitle":20105,"status":195,"phases":20106,"primaryCompletion":4264,"completion":4264,"start":6445,"enrollment":221,"conditions":20107,"interventions":20111},"NCT00625274","A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients",[93],[20099,20108,20109,20110],"Upper Abdominal Pain","Nausea","Acid Regurgitation",[19794,20065,20112],"Pantoprazole",{"nctId":20114,"briefTitle":20115,"status":195,"phases":20116,"completion":7439,"start":4284,"enrollment":1395,"conditions":20117,"interventions":20119},"NCT00352261","An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients",[93],[20118],"Barrett's Esophagus",[19794,20065],{"trials":20121,"activeCount":102},[],{"intervention":20123,"totalTrials":1039,"cells":20124},"Esomeprazole magnesium",{"EARLY_PHASE1":20125,"PHASE1":20127,"PHASE2":20138,"PHASE3":20140,"PHASE4":20149,"NA":20173},{"trials":20126,"activeCount":102},[],{"trials":20128,"activeCount":102},[20129],{"nctId":20130,"briefTitle":20131,"status":195,"phases":20132,"primaryCompletion":2221,"completion":2221,"start":4916,"enrollment":1448,"conditions":20133,"interventions":20136},"NCT00687245","Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)",[90],[20134,20135],"Endoscopically-Proven GERD","Reflux",[20137],"esomeprazole magnesium",{"trials":20139,"activeCount":102},[],{"trials":20141,"activeCount":102},[20142],{"nctId":20143,"briefTitle":20144,"status":195,"phases":20145,"completion":13583,"start":9901,"enrollment":98,"conditions":20146,"interventions":20148},"NCT00079833","Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome",[92],[20147],"Zollinger-Ellison Syndrome",[20123],{"trials":20150,"activeCount":102},[20151,20157,20163,20167],{"nctId":20152,"briefTitle":20153,"status":195,"phases":20154,"completion":13583,"start":4264,"enrollment":4546,"conditions":20155,"interventions":20156},"NCT00206024","Acid-Associated Heartburn Symptoms and Dose of Esomeprazole",[93],[20099],[20123],{"nctId":20158,"briefTitle":20159,"status":195,"phases":20160,"primaryCompletion":9909,"completion":9909,"start":12938,"enrollment":4286,"conditions":20161,"interventions":20162},"NCT00637559","Barrett's Esophagus - 315 - 3 Way Cross-Over",[93],[20118],[20102],{"nctId":20094,"briefTitle":20095,"status":195,"phases":20164,"primaryCompletion":12954,"completion":12954,"start":7447,"enrollment":20097,"conditions":20165,"interventions":20166},[93],[20099,20100],[20102,20065],{"nctId":20168,"briefTitle":20169,"status":195,"phases":20170,"completion":9065,"start":6445,"enrollment":2187,"conditions":20171,"interventions":20172},"NCT00206180","NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis",[93],[10949,19792,20100],[20137],{"trials":20174,"activeCount":102},[],{"intervention":18800,"totalTrials":1039,"cells":20176},{"EARLY_PHASE1":20177,"PHASE1":20179,"PHASE2":20181,"PHASE3":20190,"PHASE4":20214,"NA":20220},{"trials":20178,"activeCount":102},[],{"trials":20180,"activeCount":102},[],{"trials":20182,"activeCount":102},[20183],{"nctId":20184,"briefTitle":20185,"status":195,"phases":20186,"primaryCompletion":2243,"completion":2243,"start":2152,"enrollment":13802,"conditions":20187,"interventions":20188},"NCT00921804","Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients",[91],[33],[20189,18800],"AZD 8529",{"trials":20191,"activeCount":102},[20192,20199,20203,20207],{"nctId":20193,"briefTitle":20194,"status":195,"phases":20195,"primaryCompletion":2114,"completion":2114,"start":2168,"enrollment":6143,"conditions":20196,"interventions":20197},"NCT00640562","Quetiapine Extended Release Depression Symptoms",[92],[33,18734],[20198,18800],"Quetiapine Extended Release",{"nctId":18795,"briefTitle":18796,"status":195,"phases":20200,"completion":12846,"start":12891,"enrollment":1864,"conditions":20201,"interventions":20202},[92],[33],[18676,18800],{"nctId":20040,"briefTitle":20041,"status":195,"phases":20204,"primaryCompletion":2350,"completion":2350,"start":6710,"enrollment":20043,"conditions":20205,"interventions":20206},[92],[20045],[20006,18800],{"nctId":20208,"briefTitle":20209,"status":443,"phases":20210,"primaryCompletion":4915,"completion":4915,"start":3827,"enrollment":8185,"conditions":20211,"interventions":20212},"NCT00660595","Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose",[92],[20045],[20213,18800],"Quetiapine",{"trials":20215,"activeCount":102},[20216],{"nctId":18929,"briefTitle":18930,"status":195,"phases":20217,"primaryCompletion":2086,"completion":2086,"start":6780,"enrollment":18932,"conditions":20218,"interventions":20219},[93],[33,18934],[18716,18936],{"trials":20221,"activeCount":102},[],{"intervention":10026,"totalTrials":723,"cells":20223},{"EARLY_PHASE1":20224,"PHASE1":20226,"PHASE2":20228,"PHASE3":20244,"PHASE4":20260,"NA":20266},{"trials":20225,"activeCount":102},[],{"trials":20227,"activeCount":102},[],{"trials":20229,"activeCount":102},[20230,20237],{"nctId":20231,"briefTitle":20232,"status":195,"phases":20233,"primaryCompletion":2057,"completion":2057,"start":2152,"enrollment":98,"conditions":20234,"interventions":20235},"NCT00939211","The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease",[91],[28],[20236,10026],"AZD9164",{"nctId":20238,"briefTitle":20239,"status":443,"phases":20240,"primaryCompletion":2616,"completion":2616,"start":2365,"enrollment":3887,"conditions":20241,"interventions":20242},"NCT01708057","A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],[28,10066],[20243,10026],"AZD8683",{"trials":20245,"activeCount":102},[20246,20253],{"nctId":20247,"briefTitle":20248,"status":195,"phases":20249,"primaryCompletion":5725,"completion":5725,"start":2328,"enrollment":3755,"conditions":20250,"interventions":20251},"NCT00435760","Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients",[92],[6083],[20252,10026],"Aclidinium bromide",{"nctId":20254,"briefTitle":20255,"status":195,"phases":20256,"primaryCompletion":687,"completion":10063,"start":4580,"enrollment":20257,"conditions":20258,"interventions":20259},"NCT01462929","Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[92],414,[6083],[20252,10026],{"trials":20261,"activeCount":102},[20262],{"nctId":10020,"briefTitle":10021,"status":195,"phases":20263,"primaryCompletion":2746,"completion":2746,"start":6709,"enrollment":10023,"conditions":20264,"interventions":20265},[93],[6083],[6190,10026],{"trials":20267,"activeCount":102},[],{"intervention":19841,"totalTrials":723,"cells":20269},{"EARLY_PHASE1":20270,"PHASE1":20276,"PHASE2":20278,"PHASE3":20280,"PHASE4":20303,"NA":20309},{"trials":20271,"activeCount":102},[20272],{"nctId":19834,"briefTitle":19835,"status":195,"phases":20273,"primaryCompletion":2471,"completion":2471,"start":2675,"enrollment":17655,"conditions":20274,"interventions":20275},[89],[19838,19839],[19841,19829,19841],{"trials":20277,"activeCount":102},[],{"trials":20279,"activeCount":102},[],{"trials":20281,"activeCount":102},[20282,20289,20297],{"nctId":20283,"briefTitle":20284,"status":195,"phases":20285,"primaryCompletion":2151,"completion":2151,"start":13014,"enrollment":4027,"conditions":20286,"interventions":20287},"NCT00419744","A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD",[92],[28],[20288,19841],"Budesonide\u002Fformoterol (SYMBICORT) pMDI",{"nctId":20290,"briefTitle":20291,"status":195,"phases":20292,"completion":5742,"start":13047,"enrollment":12914,"conditions":20293,"interventions":20294},"NCT00206154","A Comparison of Symbicort® pMDI 2 x 160\u002F4.5 μg Bid and Symbicort® pMDI 2 x 80\u002F4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients",[92],[28],[20295,20296,19841],"Budesonide\u002Fformoterol pMDI","Budesonide pMDI",{"nctId":20298,"briefTitle":20299,"status":195,"phases":20300,"completion":2415,"start":13047,"enrollment":7555,"conditions":20301,"interventions":20302},"NCT00206167","A Comparison of Symbicort® pMDI 2 x 160\u002F4.5 μg Bid and 2 x 80\u002F4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD",[92],[28],[20295,19841],{"trials":20304,"activeCount":102},[20305],{"nctId":10084,"briefTitle":10085,"status":195,"phases":20306,"completion":6517,"start":6370,"enrollment":5876,"conditions":20307,"interventions":20308},[93],[16],[10089,10090,10091],{"trials":20310,"activeCount":102},[],{"intervention":19240,"totalTrials":723,"cells":20312},{"EARLY_PHASE1":20313,"PHASE1":20315,"PHASE2":20323,"PHASE3":20341,"PHASE4":20343,"NA":20352},{"trials":20314,"activeCount":102},[],{"trials":20316,"activeCount":102},[20317],{"nctId":20318,"briefTitle":20319,"status":195,"phases":20320,"primaryCompletion":2349,"completion":2349,"start":3862,"enrollment":17655,"conditions":20321,"interventions":20322},"NCT01199328","Study to Evaluate the Interaction Between Aspirin and Nexium",[90],[36],[19240,19794],{"trials":20324,"activeCount":102},[20325,20329,20337],{"nctId":19233,"briefTitle":19234,"status":195,"phases":20326,"primaryCompletion":2077,"completion":2077,"start":4297,"enrollment":19236,"conditions":20327,"interventions":20328},[91],[12734],[12616,19239,19240],{"nctId":20330,"briefTitle":20331,"status":195,"phases":20332,"primaryCompletion":2086,"completion":2086,"start":4297,"enrollment":589,"conditions":20333,"interventions":20335},"NCT00623779","Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)",[91],[20334],"Persistent or Permanent Non-valvular Atrial Fibrillation",[20336,19240],"AZD0837",{"nctId":19260,"briefTitle":19261,"status":195,"phases":20338,"primaryCompletion":2077,"completion":2077,"start":2221,"enrollment":8285,"conditions":20339,"interventions":20340},[91],[19264],[12616,19228,19240],{"trials":20342,"activeCount":102},[],{"trials":20344,"activeCount":102},[20345],{"nctId":20346,"briefTitle":20347,"status":195,"phases":20348,"primaryCompletion":4256,"completion":4256,"start":15911,"enrollment":579,"conditions":20349,"interventions":20350},"NCT00637988","Barrett's Esophagus - 315 - 3 Way Cross Over",[93],[20118],[19794,19240,20351],"Rofecoxib",{"trials":20353,"activeCount":102},[],{"intervention":2353,"totalTrials":723,"cells":20355},{"EARLY_PHASE1":20356,"PHASE1":20358,"PHASE2":20360,"PHASE3":20366,"PHASE4":20392,"NA":20402},{"trials":20357,"activeCount":102},[],{"trials":20359,"activeCount":102},[],{"trials":20361,"activeCount":102},[20362],{"nctId":2346,"briefTitle":2347,"status":195,"phases":20363,"primaryCompletion":2349,"completion":2349,"start":2350,"enrollment":662,"conditions":20364,"interventions":20365},[91],[22],[2044,2353],{"trials":20367,"activeCount":102},[20368,20376,20384],{"nctId":20369,"briefTitle":20370,"status":195,"phases":20371,"primaryCompletion":5725,"completion":4297,"start":5563,"enrollment":20372,"conditions":20373,"interventions":20374},"NCT00383929","Antihypertensive Efficacy and Safety of Candesartan\u002FHCT 32\u002F12.5 and 32\u002F25 mg in Comparison With Candesartan 32 mg",[92],1979,[2620],[20375,2353,2353],"Candesartan cilexetil",{"nctId":20377,"briefTitle":20378,"status":195,"phases":20379,"primaryCompletion":8692,"completion":8692,"start":4256,"enrollment":19894,"conditions":20380,"interventions":20382},"NCT00642096","Factorial Study of Metoprolol Succinate TOPROL-XL (324A)",[92],[20381],"High Blood Pressure (Hypertension).",[20383,2353],"Metoprolol Succinate",{"nctId":20385,"briefTitle":20386,"status":195,"phases":20387,"primaryCompletion":6710,"completion":6710,"start":13014,"enrollment":20388,"conditions":20389,"interventions":20390},"NCT00434967","Antihypertensive Efficacy and Safety of Candesartan\u002FHCT 32\u002F25 mg in Comparison With Individual Components and Placebo",[92],2207,[2620],[20375,2353,20391],"Candesartan\u002FHCT 32\u002F25 mg",{"trials":20393,"activeCount":102},[20394],{"nctId":20395,"briefTitle":20396,"status":195,"phases":20397,"primaryCompletion":2077,"completion":2077,"start":2168,"enrollment":3524,"conditions":20398,"interventions":20400},"NCT00621153","Candesartan Effect in Second Stage Arterial Hypertension",[93],[20399],"Stage II Hypertension",[20401,2353,20401],"Candesartan Cilexetil",{"trials":20403,"activeCount":102},[],{"intervention":12769,"totalTrials":1979,"cells":20405},{"EARLY_PHASE1":20406,"PHASE1":20408,"PHASE2":20418,"PHASE3":20420,"PHASE4":20430,"NA":20436},{"trials":20407,"activeCount":102},[],{"trials":20409,"activeCount":102},[20410],{"nctId":20411,"briefTitle":20412,"status":195,"phases":20413,"primaryCompletion":12721,"completion":12721,"start":2433,"enrollment":1710,"conditions":20414,"interventions":20416},"NCT01254461","A Drug-Drug Interaction Study Between AZD1981 and Pravastatin to Study the Effect of AZD1981 on the Kinetics of Pravastatin",[90],[20415],"Drug Interaction",[20417,20417,12769],"AZD1981",{"trials":20419,"activeCount":102},[],{"trials":20421,"activeCount":102},[20422,20426],{"nctId":12763,"briefTitle":12764,"status":195,"phases":20423,"primaryCompletion":2328,"completion":2328,"start":9944,"enrollment":1710,"conditions":20424,"interventions":20425},[92],[12767],[5887,12551,12769],{"nctId":12828,"briefTitle":12829,"status":195,"phases":20427,"completion":3990,"start":12831,"enrollment":12832,"conditions":20428,"interventions":20429},[92],[12760],[5887,12587,12835,12588],{"trials":20431,"activeCount":102},[20432],{"nctId":12989,"briefTitle":12990,"status":195,"phases":20433,"primaryCompletion":2086,"completion":2086,"start":4297,"enrollment":12992,"conditions":20434,"interventions":20435},[93],[12994],[5887,12835,12587],{"trials":20437,"activeCount":102},[],{"intervention":12122,"totalTrials":1979,"cells":20439},{"EARLY_PHASE1":20440,"PHASE1":20442,"PHASE2":20450,"PHASE3":20460,"PHASE4":20462,"NA":20468},{"trials":20441,"activeCount":102},[],{"trials":20443,"activeCount":102},[20444],{"nctId":20445,"briefTitle":20446,"status":195,"phases":20447,"completion":2095,"start":2414,"enrollment":1757,"conditions":20448,"interventions":20449},"NCT00790153","To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension",[90],[31],[12122,15883],{"trials":20451,"activeCount":102},[20452,20456],{"nctId":18274,"briefTitle":18275,"status":195,"phases":20453,"primaryCompletion":9065,"completion":9065,"start":4306,"enrollment":507,"conditions":20454,"interventions":20455},[91],[22],[18239,12122],{"nctId":12116,"briefTitle":12117,"status":195,"phases":20457,"primaryCompletion":246,"completion":246,"start":12119,"enrollment":3476,"conditions":20458,"interventions":20459},[91],[12093],[10762,12122,12123,12122,12123],{"trials":20461,"activeCount":102},[],{"trials":20463,"activeCount":102},[20464],{"nctId":19156,"briefTitle":19157,"status":195,"phases":20465,"primaryCompletion":13056,"completion":13056,"start":13756,"enrollment":9428,"conditions":20466,"interventions":20467},[93],[19160],[19162,2173,12122],{"trials":20469,"activeCount":102},[],{"intervention":20002,"totalTrials":1979,"cells":20471},{"EARLY_PHASE1":20472,"PHASE1":20474,"PHASE2":20476,"PHASE3":20478,"PHASE4":20498,"NA":20511},{"trials":20473,"activeCount":102},[],{"trials":20475,"activeCount":102},[],{"trials":20477,"activeCount":102},[],{"trials":20479,"activeCount":102},[20480,20490],{"nctId":20481,"briefTitle":20482,"status":195,"phases":20483,"primaryCompletion":3827,"completion":3827,"start":5725,"enrollment":12,"conditions":20484,"interventions":20488},"NCT00534599","Generalized Anxiety Disorder Adjunct Study",[92],[20485,20021,20486,20487],"Anxiety","Anxiety Neuroses","Anxiety States",[20489],"quetiapine fumarate XR",{"nctId":20491,"briefTitle":20492,"status":195,"phases":20493,"primaryCompletion":2570,"completion":2570,"start":2320,"enrollment":20494,"conditions":20495,"interventions":20497},"NCT00883493","Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression",[92],421,[20496],"Acute Bipolar Depression",[20002,20031],{"trials":20499,"activeCount":102},[20500,20504],{"nctId":19995,"briefTitle":19996,"status":195,"phases":20501,"primaryCompletion":2349,"completion":2349,"start":2152,"enrollment":19998,"conditions":20502,"interventions":20503},[93],[20000],[20002,18820],{"nctId":20505,"briefTitle":20506,"status":195,"phases":20507,"primaryCompletion":2068,"completion":2068,"start":2414,"enrollment":14210,"conditions":20508,"interventions":20509},"NCT00779506","Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)",[93],[33],[20510],"Quetiapine Fumarate XR",{"trials":20512,"activeCount":102},[],{"intervention":20514,"totalTrials":1979,"cells":20515},"metoprolol succinate",{"EARLY_PHASE1":20516,"PHASE1":20518,"PHASE2":20520,"PHASE3":20522,"PHASE4":20540,"NA":20561},{"trials":20517,"activeCount":102},[],{"trials":20519,"activeCount":102},[],{"trials":20521,"activeCount":102},[],{"trials":20523,"activeCount":102},[20524,20528,20534],{"nctId":20377,"briefTitle":20378,"status":195,"phases":20525,"primaryCompletion":8692,"completion":8692,"start":4256,"enrollment":19894,"conditions":20526,"interventions":20527},[92],[20381],[20383,2353],{"nctId":20529,"briefTitle":20530,"status":195,"phases":20531,"start":3810,"enrollment":221,"conditions":20532,"interventions":20533},"NCT00255502","307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects",[92],[2620],[20514],{"nctId":20535,"briefTitle":20536,"status":195,"phases":20537,"start":3810,"enrollment":6419,"conditions":20538,"interventions":20539},"NCT00255528","Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects",[92],[2620],[20514],{"trials":20541,"activeCount":102},[20542],{"nctId":20543,"briefTitle":20544,"status":195,"phases":20545,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":20546,"interventions":20548},"NCT00391846","Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone",[93],[1520,20547],"Ventricular Dysfunction, Left",[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],"Captopril","Enalapril","Ramipril","Trandolapril","Bisoprolol","Carvedilol","Metoprolol succinate","Candesartan","Eplerenone","Spironolactone","Diuretics","HF treatment according to Swedish guidelines",{"trials":20562,"activeCount":102},[],{"intervention":20564,"totalTrials":3887,"cells":20565},"Seroquel",{"EARLY_PHASE1":20566,"PHASE1":20568,"PHASE2":20570,"PHASE3":20572,"PHASE4":20588,"NA":20597},{"trials":20567,"activeCount":102},[],{"trials":20569,"activeCount":102},[],{"trials":20571,"activeCount":102},[],{"trials":20573,"activeCount":102},[20574,20580],{"nctId":20575,"briefTitle":20576,"status":195,"phases":20577,"completion":6369,"start":5796,"enrollment":9131,"conditions":20578,"interventions":20579},"NCT00228462","Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo",[92],[33],[20564],{"nctId":20581,"briefTitle":20582,"status":195,"phases":20583,"primaryCompletion":6780,"completion":6780,"start":6651,"conditions":20584,"interventions":20586},"NCT00060489","Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression",[92],[18732,20585],"Depression, Bipolar",[20587],"SEROQUEL (quetiapine fumarate)",{"trials":20589,"activeCount":102},[20590],{"nctId":20591,"briefTitle":20592,"status":195,"phases":20593,"completion":3809,"start":6370,"enrollment":20594,"conditions":20595,"interventions":20596},"NCT00214578","Seroquel on Glucose Metabolism",[93],572,[33],[20564],{"trials":20598,"activeCount":102},[],{"intervention":20600,"totalTrials":3887,"cells":20601},"Esomeprazole 40 mg",{"EARLY_PHASE1":20602,"PHASE1":20604,"PHASE2":20606,"PHASE3":20608,"PHASE4":20620,"NA":20635},{"trials":20603,"activeCount":102},[],{"trials":20605,"activeCount":102},[],{"trials":20607,"activeCount":102},[],{"trials":20609,"activeCount":102},[20610],{"nctId":20611,"briefTitle":20612,"status":195,"phases":20613,"primaryCompletion":2220,"completion":2220,"start":2328,"enrollment":20614,"conditions":20615,"interventions":20618},"NCT00441727","Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)",[92],2426,[20616,20617],"Gastric Ulcer","Duodenal Ulcer",[20600,20619],"Esomeprazole 20 mg",{"trials":20621,"activeCount":102},[20622,20629],{"nctId":20623,"briefTitle":20624,"status":195,"phases":20625,"primaryCompletion":2542,"completion":2542,"start":2349,"enrollment":3645,"conditions":20626,"interventions":20627},"NCT01249651","To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole",[93],[20099],[20628],"esomeprazole 40 mg",{"nctId":20630,"briefTitle":20631,"status":195,"phases":20632,"primaryCompletion":2086,"completion":2086,"start":2169,"enrollment":1248,"conditions":20633,"interventions":20634},"NCT00734097","A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)",[93],[20100],[20600],{"trials":20636,"activeCount":102},[],{"intervention":20619,"totalTrials":3887,"cells":20638},{"EARLY_PHASE1":20639,"PHASE1":20641,"PHASE2":20643,"PHASE3":20645,"PHASE4":20660,"NA":20670},{"trials":20640,"activeCount":102},[],{"trials":20642,"activeCount":102},[],{"trials":20644,"activeCount":102},[],{"trials":20646,"activeCount":102},[20647,20651],{"nctId":20611,"briefTitle":20612,"status":195,"phases":20648,"primaryCompletion":2220,"completion":2220,"start":2328,"enrollment":20614,"conditions":20649,"interventions":20650},[92],[20616,20617],[20600,20619],{"nctId":20652,"briefTitle":20653,"status":195,"phases":20654,"primaryCompletion":2067,"completion":2067,"start":4297,"enrollment":20655,"conditions":20656,"interventions":20659},"NCT00595517","Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer",[92],395,[20616,20617,7267,20657,20658],"Osteoarthritis","Lumbago",[20619],{"trials":20661,"activeCount":102},[20662],{"nctId":20663,"briefTitle":20664,"status":195,"phases":20665,"primaryCompletion":2747,"completion":2747,"start":2675,"enrollment":20666,"conditions":20667,"interventions":20668},"NCT01397084","To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole",[93],107,[20100,19809,19792],[20669],"esomeprazole 20 mg",{"trials":20671,"activeCount":102},[],{"intervention":12176,"totalTrials":3887,"cells":20673},{"EARLY_PHASE1":20674,"PHASE1":20676,"PHASE2":20682,"PHASE3":20684,"PHASE4":20690,"NA":20696},{"trials":20675,"activeCount":102},[],{"trials":20677,"activeCount":102},[20678],{"nctId":2092,"briefTitle":2093,"status":195,"phases":20679,"primaryCompletion":2077,"completion":2077,"start":2095,"enrollment":1130,"conditions":20680,"interventions":20681},[90],[22],[2098,2044,2098,2099],{"trials":20683,"activeCount":102},[],{"trials":20685,"activeCount":102},[20686],{"nctId":12166,"briefTitle":12167,"status":443,"phases":20687,"primaryCompletion":12169,"completion":12169,"start":12170,"enrollment":12171,"conditions":20688,"interventions":20689},[92],[12173,12093],[10762,12175,12176,12177],{"trials":20691,"activeCount":102},[20692],{"nctId":20543,"briefTitle":20544,"status":195,"phases":20693,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":20694,"interventions":20695},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":20697,"activeCount":102},[],{"intervention":20699,"totalTrials":3887,"cells":20700},"Roxadustat",{"EARLY_PHASE1":20701,"PHASE1":20703,"PHASE2":20705,"PHASE3":20707,"PHASE4":20726,"NA":20737},{"trials":20702,"activeCount":102},[],{"trials":20704,"activeCount":102},[],{"trials":20706,"activeCount":102},[],{"trials":20708,"activeCount":102},[20709,20718],{"nctId":20710,"briefTitle":20711,"status":195,"phases":20712,"primaryCompletion":19325,"completion":19325,"start":20713,"enrollment":1787,"conditions":20714,"interventions":20716},"NCT02174731","Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.",[92],"2014-07-01",[20715],"Anemia",[20699,20717],"Epoetin alfa",{"nctId":20719,"briefTitle":20720,"status":195,"phases":20721,"primaryCompletion":81,"completion":81,"start":20722,"enrollment":20723,"conditions":20724,"interventions":20725},"NCT02174627","Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis",[92],"2014-06-26",2781,[20715],[20699],{"trials":20727,"activeCount":102},[20728],{"nctId":20729,"briefTitle":20730,"status":195,"phases":20731,"primaryCompletion":20732,"completion":20732,"start":4489,"enrollment":98,"conditions":20733,"interventions":20735},"NCT04655027","A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)",[93],"2021-10-12",[20734],"Anemia of Chronic Kidney Disease",[20699,20736],"rHuEPO",{"trials":20738,"activeCount":102},[],{"intervention":9912,"totalTrials":3887,"cells":20740},{"EARLY_PHASE1":20741,"PHASE1":20743,"PHASE2":20745,"PHASE3":20747,"PHASE4":20757,"NA":20763},{"trials":20742,"activeCount":102},[],{"trials":20744,"activeCount":102},[],{"trials":20746,"activeCount":102},[],{"trials":20748,"activeCount":102},[20749,20753],{"nctId":9906,"briefTitle":9907,"status":195,"phases":20750,"completion":6780,"start":9909,"enrollment":5898,"conditions":20751,"interventions":20752},[92],[16],[9842,9904,9912],{"nctId":9927,"briefTitle":9928,"status":195,"phases":20754,"completion":6563,"start":9930,"enrollment":5898,"conditions":20755,"interventions":20756},[92],[16],[9842,9904,9912],{"trials":20758,"activeCount":102},[20759],{"nctId":10112,"briefTitle":10113,"status":195,"phases":20760,"primaryCompletion":6928,"completion":6928,"start":10115,"enrollment":3645,"conditions":20761,"interventions":20762},[93],[10117],[10095,10119],{"trials":20764,"activeCount":102},[],{"intervention":20766,"totalTrials":3887,"cells":20767},"Zolmitriptan",{"EARLY_PHASE1":20768,"PHASE1":20770,"PHASE2":20772,"PHASE3":20774,"PHASE4":20784,"NA":20800},{"trials":20769,"activeCount":102},[],{"trials":20771,"activeCount":102},[],{"trials":20773,"activeCount":102},[],{"trials":20775,"activeCount":102},[20776],{"nctId":20777,"briefTitle":20778,"status":195,"phases":20779,"completion":4256,"start":6651,"enrollment":20780,"conditions":20781,"interventions":20783},"NCT00617747","Efficacy and Tolerability of Zolmitriptan Nasal Spray",[92],2114,[20782],"Migraine",[20766],{"trials":20785,"activeCount":102},[20786,20792],{"nctId":20787,"briefTitle":20788,"status":195,"phases":20789,"completion":7554,"start":8692,"enrollment":2187,"conditions":20790,"interventions":20791},"NCT00637286","ZAP, US. Zomig for Appropriate for Primary Care",[93],[20782],[20766],{"nctId":20793,"briefTitle":20794,"status":195,"phases":20795,"primaryCompletion":4204,"completion":4204,"start":3862,"enrollment":20796,"conditions":20797,"interventions":20799},"NCT01211145","Zomig - Treatment of Acute Migraine Headache in Adolescents",[93],1653,[20798],"Migraine Headache",[20766,20766,20766],{"trials":20801,"activeCount":102},[],{"intervention":19117,"totalTrials":3887,"cells":20803},{"EARLY_PHASE1":20804,"PHASE1":20806,"PHASE2":20808,"PHASE3":20810,"PHASE4":20825,"NA":20834},{"trials":20805,"activeCount":102},[],{"trials":20807,"activeCount":102},[],{"trials":20809,"activeCount":102},[],{"trials":20811,"activeCount":102},[20812,20821],{"nctId":20813,"briefTitle":20814,"status":195,"phases":20815,"primaryCompletion":20816,"completion":20816,"start":20817,"enrollment":20,"conditions":20818,"interventions":20819},"NCT02582814","The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM",[92],"2017-06-15","2015-10-26",[2369],[19117,20820],"Dapagliflozin 10mg",{"nctId":19110,"briefTitle":19111,"status":443,"phases":20822,"primaryCompletion":753,"completion":753,"start":19113,"enrollment":6275,"conditions":20823,"interventions":20824},[92],[22],[19116,19117,19118,19119,19120,2173],{"trials":20826,"activeCount":102},[20827],{"nctId":20828,"briefTitle":20829,"status":195,"phases":20830,"primaryCompletion":2561,"completion":20831,"start":2470,"enrollment":852,"conditions":20832,"interventions":20833},"NCT02157298","Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.",[93],"2015-11",[22],[19117],{"trials":20835,"activeCount":102},[],{"intervention":20558,"totalTrials":447,"cells":20837},{"EARLY_PHASE1":20838,"PHASE1":20840,"PHASE2":20849,"PHASE3":20851,"PHASE4":20853,"NA":20859},{"trials":20839,"activeCount":102},[],{"trials":20841,"activeCount":102},[20842],{"nctId":20843,"briefTitle":20844,"status":443,"phases":20845,"primaryCompletion":8197,"completion":8197,"start":20846,"enrollment":5726,"conditions":20847,"interventions":20848},"NCT03682497","Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium",[90],"2018-11-01",[1520],[2389,20558],{"trials":20850,"activeCount":102},[],{"trials":20852,"activeCount":102},[],{"trials":20854,"activeCount":102},[20855],{"nctId":20543,"briefTitle":20544,"status":195,"phases":20856,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":20857,"interventions":20858},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":20860,"activeCount":102},[],{"intervention":20862,"totalTrials":447,"cells":20863},"SPIRIVA",{"EARLY_PHASE1":20864,"PHASE1":20866,"PHASE2":20877,"PHASE3":20879,"PHASE4":20881,"NA":20891},{"trials":20865,"activeCount":102},[],{"trials":20867,"activeCount":102},[20868],{"nctId":20869,"briefTitle":20870,"status":195,"phases":20871,"primaryCompletion":20872,"completion":20872,"start":20873,"enrollment":3855,"conditions":20874,"interventions":20875},"NCT03097380","PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium",[90],"2017-12-30","2017-04-26",[36],[20876,20862],"AZD2115",{"trials":20878,"activeCount":102},[],{"trials":20880,"activeCount":102},[],{"trials":20882,"activeCount":102},[20883],{"nctId":20884,"briefTitle":20885,"status":195,"phases":20886,"primaryCompletion":2524,"completion":2524,"start":6718,"enrollment":1806,"conditions":20887,"interventions":20889},"NCT00496470","Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.",[93],[20888],"Chronic Obstructive Pulmonary Disease, COPD",[19501,20890],"Spiriva",{"trials":20892,"activeCount":102},[],{"intervention":20198,"totalTrials":447,"cells":20894},{"EARLY_PHASE1":20895,"PHASE1":20897,"PHASE2":20899,"PHASE3":20901,"PHASE4":20907,"NA":20916},{"trials":20896,"activeCount":102},[],{"trials":20898,"activeCount":102},[],{"trials":20900,"activeCount":102},[],{"trials":20902,"activeCount":102},[20903],{"nctId":20193,"briefTitle":20194,"status":195,"phases":20904,"primaryCompletion":2114,"completion":2114,"start":2168,"enrollment":6143,"conditions":20905,"interventions":20906},[92],[33,18734],[20198,18800],{"trials":20908,"activeCount":102},[20909],{"nctId":20910,"briefTitle":20911,"status":195,"phases":20912,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1873,"conditions":20913,"interventions":20914},"NCT00926393","Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression",[93],[18733],[20915,20198],"Quetiapine Immediate Release",{"trials":20917,"activeCount":102},[],{"intervention":20919,"totalTrials":447,"cells":20920},"exenatide and placebo",{"EARLY_PHASE1":20921,"PHASE1":20923,"PHASE2":20932,"PHASE3":20934,"PHASE4":20936,"NA":20946},{"trials":20922,"activeCount":102},[],{"trials":20924,"activeCount":102},[20925],{"nctId":20926,"briefTitle":20927,"status":195,"phases":20928,"primaryCompletion":6650,"completion":6650,"start":4876,"enrollment":4497,"conditions":20929,"interventions":20930},"NCT00517283","A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes",[90],[22],[20919,20931,20931],"Exenatide and placebo",{"trials":20933,"activeCount":102},[],{"trials":20935,"activeCount":102},[],{"trials":20937,"activeCount":102},[20938],{"nctId":20939,"briefTitle":20940,"status":195,"phases":20941,"primaryCompletion":2113,"completion":2113,"start":2077,"enrollment":20942,"conditions":20943,"interventions":20944},"NCT00870194","A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin",[93],255,[22],[20945,20919],"exenatide and sitagliptin",{"trials":20947,"activeCount":102},[],{"intervention":20949,"totalTrials":447,"cells":20950},"Bydureon",{"EARLY_PHASE1":20951,"PHASE1":20953,"PHASE2":20955,"PHASE3":20957,"PHASE4":20959,"NA":20975},{"trials":20952,"activeCount":102},[],{"trials":20954,"activeCount":102},[],{"trials":20956,"activeCount":102},[],{"trials":20958,"activeCount":102},[],{"trials":20960,"activeCount":102},[20961,20968],{"nctId":20962,"briefTitle":20963,"status":195,"phases":20964,"primaryCompletion":20965,"completion":20965,"start":2179,"enrollment":13857,"conditions":20966,"interventions":20967},"NCT02288273","Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.",[93],"2015-08",[31],[20949],{"nctId":20969,"briefTitle":20970,"status":195,"phases":20971,"primaryCompletion":20972,"completion":20972,"start":2667,"enrollment":744,"conditions":20973,"interventions":20974},"NCT02533453","A 12\u002F24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.",[93],"2016-12-07",[22],[20949],{"trials":20976,"activeCount":102},[],{"intervention":19904,"totalTrials":447,"cells":20978},{"EARLY_PHASE1":20979,"PHASE1":20981,"PHASE2":20983,"PHASE3":20985,"PHASE4":20991,"NA":20997},{"trials":20980,"activeCount":102},[],{"trials":20982,"activeCount":102},[],{"trials":20984,"activeCount":102},[],{"trials":20986,"activeCount":102},[20987],{"nctId":19877,"briefTitle":19878,"status":195,"phases":20988,"completion":7494,"start":7554,"enrollment":19880,"conditions":20989,"interventions":20990},[92],[16],[19854,19883],{"trials":20992,"activeCount":102},[20993],{"nctId":19899,"briefTitle":19900,"status":195,"phases":20994,"completion":2252,"start":5563,"enrollment":680,"conditions":20995,"interventions":20996},[93],[28],[19829,19904],{"trials":20998,"activeCount":102},[],{"intervention":2795,"totalTrials":447,"cells":21000},{"EARLY_PHASE1":21001,"PHASE1":21003,"PHASE2":21005,"PHASE3":21007,"PHASE4":21009,"NA":21022},{"trials":21002,"activeCount":102},[],{"trials":21004,"activeCount":102},[],{"trials":21006,"activeCount":102},[],{"trials":21008,"activeCount":102},[],{"trials":21010,"activeCount":102},[21011,21015],{"nctId":2787,"briefTitle":2788,"status":443,"phases":21012,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":2792,"conditions":21013,"interventions":21014},[93],[22],[2044,2795],{"nctId":21016,"briefTitle":21017,"status":195,"phases":21018,"primaryCompletion":21019,"completion":21019,"start":2180,"enrollment":1796,"conditions":21020,"interventions":21021},"NCT02243176","24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy",[93],"2015-09",[22],[2108,2795],{"trials":21023,"activeCount":102},[],{"intervention":12175,"totalTrials":447,"cells":21025},{"EARLY_PHASE1":21026,"PHASE1":21028,"PHASE2":21030,"PHASE3":21032,"PHASE4":21038,"NA":21044},{"trials":21027,"activeCount":102},[],{"trials":21029,"activeCount":102},[],{"trials":21031,"activeCount":102},[],{"trials":21033,"activeCount":102},[21034],{"nctId":12166,"briefTitle":12167,"status":443,"phases":21035,"primaryCompletion":12169,"completion":12169,"start":12170,"enrollment":12171,"conditions":21036,"interventions":21037},[92],[12173,12093],[10762,12175,12176,12177],{"trials":21039,"activeCount":102},[21040],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21041,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21042,"interventions":21043},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21045,"activeCount":102},[],{"intervention":8179,"totalTrials":447,"cells":21047},{"EARLY_PHASE1":21048,"PHASE1":21050,"PHASE2":21052,"PHASE3":21054,"PHASE4":21060,"NA":21071},{"trials":21049,"activeCount":102},[],{"trials":21051,"activeCount":102},[],{"trials":21053,"activeCount":102},[],{"trials":21055,"activeCount":102},[21056],{"nctId":8170,"briefTitle":8171,"status":195,"phases":21057,"primaryCompletion":8173,"completion":8174,"start":8175,"enrollment":6532,"conditions":21058,"interventions":21059},[92],[8177],[82,5243,8179],{"trials":21061,"activeCount":102},[21062],{"nctId":21063,"briefTitle":21064,"status":624,"phases":21065,"primaryCompletion":21066,"completion":21066,"start":21067,"enrollment":102,"conditions":21068,"interventions":21069},"NCT03181880","To Evaluate Effectiveness of Aclidinium Bromide\u002FFormoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease",[93],"2018-12-03","2017-12-04",[28],[21070,8179],"Aclidinium bromide\u002Fformoterol fumarate combination",{"trials":21072,"activeCount":102},[],{"intervention":20112,"totalTrials":447,"cells":21074},{"EARLY_PHASE1":21075,"PHASE1":21077,"PHASE2":21079,"PHASE3":21081,"PHASE4":21083,"NA":21096},{"trials":21076,"activeCount":102},[],{"trials":21078,"activeCount":102},[],{"trials":21080,"activeCount":102},[],{"trials":21082,"activeCount":102},[],{"trials":21084,"activeCount":102},[21085,21089],{"nctId":20104,"briefTitle":20105,"status":195,"phases":21086,"primaryCompletion":4264,"completion":4264,"start":6445,"enrollment":221,"conditions":21087,"interventions":21088},[93],[20099,20108,20109,20110],[19794,20065,20112],{"nctId":21090,"briefTitle":21091,"status":195,"phases":21092,"primaryCompletion":9986,"completion":9986,"start":4285,"enrollment":1448,"conditions":21093,"interventions":21094},"NCT00206050","Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po",[93],[19],[19794,21095],"pantoprazole",{"trials":21097,"activeCount":102},[],{"intervention":21099,"totalTrials":447,"cells":21100},"Pulmicort (budesonide) Turbuhaler",{"EARLY_PHASE1":21101,"PHASE1":21103,"PHASE2":21105,"PHASE3":21107,"PHASE4":21109,"NA":21124},{"trials":21102,"activeCount":102},[],{"trials":21104,"activeCount":102},[],{"trials":21106,"activeCount":102},[],{"trials":21108,"activeCount":102},[],{"trials":21110,"activeCount":102},[21111,21118],{"nctId":21112,"briefTitle":21113,"status":195,"phases":21114,"completion":4306,"start":21115,"enrollment":1173,"conditions":21116,"interventions":21117},"NCT00232674","Efficacy Study of the Effect of Budesonide on Emphysema",[93],"1999-07",[28],[21099],{"nctId":21119,"briefTitle":21120,"status":195,"phases":21121,"completion":3809,"start":4285,"enrollment":370,"conditions":21122,"interventions":21123},"NCT00228475","A Study to Assess the Concentration of Budesonide in Breast Milk From Asthmatic Women",[93],[16],[21099],{"trials":21125,"activeCount":102},[],{"intervention":21127,"totalTrials":122,"cells":21128},"Quetiapine 600mg",{"EARLY_PHASE1":21129,"PHASE1":21131,"PHASE2":21133,"PHASE3":21135,"PHASE4":21137,"NA":21148},{"trials":21130,"activeCount":102},[],{"trials":21132,"activeCount":102},[],{"trials":21134,"activeCount":102},[],{"trials":21136,"activeCount":102},[],{"trials":21138,"activeCount":102},[21139],{"nctId":21140,"briefTitle":21141,"status":195,"phases":21142,"primaryCompletion":2151,"completion":2151,"start":2221,"enrollment":4917,"conditions":21143,"interventions":21147},"NCT00521365","Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.",[93],[18732,21144,18818,21145,21146],"Bipolar Affective Psychosis","Manic Disorder","Manic State",[21127],{"trials":21149,"activeCount":102},[],{"intervention":21151,"totalTrials":122,"cells":21152},"Xolaam®",{"EARLY_PHASE1":21153,"PHASE1":21155,"PHASE2":21157,"PHASE3":21159,"PHASE4":21161,"NA":21170},{"trials":21154,"activeCount":102},[],{"trials":21156,"activeCount":102},[],{"trials":21158,"activeCount":102},[],{"trials":21160,"activeCount":102},[],{"trials":21162,"activeCount":102},[21163],{"nctId":21164,"briefTitle":21165,"status":195,"phases":21166,"primaryCompletion":2086,"completion":2086,"start":3839,"enrollment":21167,"conditions":21168,"interventions":21169},"NCT00444275","Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients",[93],3029,[19809],[19588,21151],{"trials":21171,"activeCount":102},[],{"intervention":21173,"totalTrials":122,"cells":21174},"Polyethylene Glycol 3350",{"EARLY_PHASE1":21175,"PHASE1":21177,"PHASE2":21179,"PHASE3":21181,"PHASE4":21183,"NA":21195},{"trials":21176,"activeCount":102},[],{"trials":21178,"activeCount":102},[],{"trials":21180,"activeCount":102},[],{"trials":21182,"activeCount":102},[],{"trials":21184,"activeCount":102},[21185],{"nctId":21186,"briefTitle":21187,"status":195,"phases":21188,"primaryCompletion":21189,"completion":21189,"start":21190,"enrollment":1903,"conditions":21191,"interventions":21193},"NCT03060512","To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation",[93],"2017-08-23","2017-03-02",[21192],"Opioid Induced Constipation",[21173,21194],"Movantik",{"trials":21196,"activeCount":102},[],{"intervention":21194,"totalTrials":122,"cells":21198},{"EARLY_PHASE1":21199,"PHASE1":21201,"PHASE2":21203,"PHASE3":21205,"PHASE4":21207,"NA":21213},{"trials":21200,"activeCount":102},[],{"trials":21202,"activeCount":102},[],{"trials":21204,"activeCount":102},[],{"trials":21206,"activeCount":102},[],{"trials":21208,"activeCount":102},[21209],{"nctId":21186,"briefTitle":21187,"status":195,"phases":21210,"primaryCompletion":21189,"completion":21189,"start":21190,"enrollment":1903,"conditions":21211,"interventions":21212},[93],[21192],[21173,21194],{"trials":21214,"activeCount":102},[],{"intervention":20351,"totalTrials":122,"cells":21216},{"EARLY_PHASE1":21217,"PHASE1":21219,"PHASE2":21221,"PHASE3":21223,"PHASE4":21225,"NA":21231},{"trials":21218,"activeCount":102},[],{"trials":21220,"activeCount":102},[],{"trials":21222,"activeCount":102},[],{"trials":21224,"activeCount":102},[],{"trials":21226,"activeCount":102},[21227],{"nctId":20346,"briefTitle":20347,"status":195,"phases":21228,"primaryCompletion":4256,"completion":4256,"start":15911,"enrollment":579,"conditions":21229,"interventions":21230},[93],[20118],[19794,19240,20351],{"trials":21232,"activeCount":102},[],{"intervention":20945,"totalTrials":122,"cells":21234},{"EARLY_PHASE1":21235,"PHASE1":21237,"PHASE2":21239,"PHASE3":21241,"PHASE4":21243,"NA":21249},{"trials":21236,"activeCount":102},[],{"trials":21238,"activeCount":102},[],{"trials":21240,"activeCount":102},[],{"trials":21242,"activeCount":102},[],{"trials":21244,"activeCount":102},[21245],{"nctId":20939,"briefTitle":20940,"status":195,"phases":21246,"primaryCompletion":2113,"completion":2113,"start":2077,"enrollment":20942,"conditions":21247,"interventions":21248},[93],[22],[20945,20919],{"trials":21250,"activeCount":102},[],{"intervention":21252,"totalTrials":122,"cells":21253},"Esomeprazole Sodium",{"EARLY_PHASE1":21254,"PHASE1":21256,"PHASE2":21258,"PHASE3":21260,"PHASE4":21262,"NA":21270},{"trials":21255,"activeCount":102},[],{"trials":21257,"activeCount":102},[],{"trials":21259,"activeCount":102},[],{"trials":21261,"activeCount":102},[],{"trials":21263,"activeCount":102},[21264],{"nctId":21265,"briefTitle":21266,"status":195,"phases":21267,"primaryCompletion":7342,"completion":7342,"start":2639,"enrollment":1448,"conditions":21268,"interventions":21269},"NCT00428701","An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium",[93],[20616],[21252],{"trials":21271,"activeCount":102},[],{"intervention":19897,"totalTrials":122,"cells":21273},{"EARLY_PHASE1":21274,"PHASE1":21276,"PHASE2":21278,"PHASE3":21280,"PHASE4":21282,"NA":21288},{"trials":21275,"activeCount":102},[],{"trials":21277,"activeCount":102},[],{"trials":21279,"activeCount":102},[],{"trials":21281,"activeCount":102},[],{"trials":21283,"activeCount":102},[21284],{"nctId":19891,"briefTitle":19892,"status":195,"phases":21285,"primaryCompletion":2639,"completion":2639,"start":4285,"enrollment":19894,"conditions":21286,"interventions":21287},[93],[16],[19829,19897],{"trials":21289,"activeCount":102},[],{"intervention":21291,"totalTrials":122,"cells":21292},"Budesonide-Formoterol treatment",{"EARLY_PHASE1":21293,"PHASE1":21295,"PHASE2":21297,"PHASE3":21299,"PHASE4":21301,"NA":21311},{"trials":21294,"activeCount":102},[],{"trials":21296,"activeCount":102},[],{"trials":21298,"activeCount":102},[],{"trials":21300,"activeCount":102},[],{"trials":21302,"activeCount":102},[21303],{"nctId":21304,"briefTitle":21305,"status":195,"phases":21306,"primaryCompletion":21307,"completion":21307,"start":10240,"enrollment":9987,"conditions":21308,"interventions":21310},"NCT06590740","Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.",[93],"2025-09-03",[21309],"Cough-Variant Asthma",[21291],{"trials":21312,"activeCount":102},[],{"intervention":7539,"totalTrials":122,"cells":21314},{"EARLY_PHASE1":21315,"PHASE1":21317,"PHASE2":21319,"PHASE3":21321,"PHASE4":21323,"NA":21329},{"trials":21316,"activeCount":102},[],{"trials":21318,"activeCount":102},[],{"trials":21320,"activeCount":102},[],{"trials":21322,"activeCount":102},[],{"trials":21324,"activeCount":102},[21325],{"nctId":7533,"briefTitle":7534,"status":195,"phases":21326,"primaryCompletion":4297,"completion":4297,"start":6370,"enrollment":7536,"conditions":21327,"interventions":21328},[93],[25],[120,7539],{"trials":21330,"activeCount":102},[],{"intervention":21332,"totalTrials":122,"cells":21333},"Seroquel XR- quetiapine fumarate extended release",{"EARLY_PHASE1":21334,"PHASE1":21336,"PHASE2":21338,"PHASE3":21340,"PHASE4":21342,"NA":21351},{"trials":21335,"activeCount":102},[],{"trials":21337,"activeCount":102},[],{"trials":21339,"activeCount":102},[],{"trials":21341,"activeCount":102},[],{"trials":21343,"activeCount":102},[21344],{"nctId":21345,"briefTitle":21346,"status":195,"phases":21347,"primaryCompletion":2675,"completion":2675,"start":2349,"enrollment":1883,"conditions":21348,"interventions":21349},"NCT01213836","Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia",[93],[33],[21332,21350],"Seroquel IR - quetiapine fumarate",{"trials":21352,"activeCount":102},[],{"intervention":21350,"totalTrials":122,"cells":21354},{"EARLY_PHASE1":21355,"PHASE1":21357,"PHASE2":21359,"PHASE3":21361,"PHASE4":21363,"NA":21369},{"trials":21356,"activeCount":102},[],{"trials":21358,"activeCount":102},[],{"trials":21360,"activeCount":102},[],{"trials":21362,"activeCount":102},[],{"trials":21364,"activeCount":102},[21365],{"nctId":21345,"briefTitle":21346,"status":195,"phases":21366,"primaryCompletion":2675,"completion":2675,"start":2349,"enrollment":1883,"conditions":21367,"interventions":21368},[93],[33],[21332,21350],{"trials":21370,"activeCount":102},[],{"intervention":21372,"totalTrials":122,"cells":21373},"Aclidinium\u002FFormoterol",{"EARLY_PHASE1":21374,"PHASE1":21376,"PHASE2":21378,"PHASE3":21380,"PHASE4":21382,"NA":21391},{"trials":21375,"activeCount":102},[],{"trials":21377,"activeCount":102},[],{"trials":21379,"activeCount":102},[],{"trials":21381,"activeCount":102},[],{"trials":21383,"activeCount":102},[21384],{"nctId":21385,"briefTitle":21386,"status":195,"phases":21387,"primaryCompletion":21388,"completion":21388,"start":1608,"enrollment":5239,"conditions":21389,"interventions":21390},"NCT02424344","Effect of Aclidinium\u002FFormoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients",[93],"2016-07-25",[18651],[21372],{"trials":21392,"activeCount":102},[],{"intervention":21394,"totalTrials":122,"cells":21395},"Ki-67 protein expression",{"EARLY_PHASE1":21396,"PHASE1":21398,"PHASE2":21400,"PHASE3":21402,"PHASE4":21404,"NA":21413},{"trials":21397,"activeCount":102},[],{"trials":21399,"activeCount":102},[],{"trials":21401,"activeCount":102},[],{"trials":21403,"activeCount":102},[],{"trials":21405,"activeCount":102},[21406],{"nctId":21407,"briefTitle":21408,"status":195,"phases":21409,"primaryCompletion":2113,"completion":2113,"start":2151,"enrollment":3209,"conditions":21410,"interventions":21411},"NCT01000740","A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa",[93],[1049],[21412,21394],"EGFR Mutation Test",{"trials":21414,"activeCount":102},[],{"intervention":21416,"totalTrials":122,"cells":21417},"Rosuvastatin or atorvastatin or simvastatin and clopidogrel",{"EARLY_PHASE1":21418,"PHASE1":21420,"PHASE2":21422,"PHASE3":21424,"PHASE4":21426,"NA":21434},{"trials":21419,"activeCount":102},[],{"trials":21421,"activeCount":102},[],{"trials":21423,"activeCount":102},[],{"trials":21425,"activeCount":102},[],{"trials":21427,"activeCount":102},[21428],{"nctId":21429,"briefTitle":21430,"status":195,"phases":21431,"primaryCompletion":2087,"completion":2087,"start":6572,"enrollment":20942,"conditions":21432,"interventions":21433},"NCT00235950","Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease",[93],[12789],[21416],{"trials":21435,"activeCount":102},[],{"intervention":20736,"totalTrials":122,"cells":21437},{"EARLY_PHASE1":21438,"PHASE1":21440,"PHASE2":21442,"PHASE3":21444,"PHASE4":21446,"NA":21452},{"trials":21439,"activeCount":102},[],{"trials":21441,"activeCount":102},[],{"trials":21443,"activeCount":102},[],{"trials":21445,"activeCount":102},[],{"trials":21447,"activeCount":102},[21448],{"nctId":20729,"briefTitle":20730,"status":195,"phases":21449,"primaryCompletion":20732,"completion":20732,"start":4489,"enrollment":98,"conditions":21450,"interventions":21451},[93],[20734],[20699,20736],{"trials":21453,"activeCount":102},[],{"intervention":18927,"totalTrials":122,"cells":21455},{"EARLY_PHASE1":21456,"PHASE1":21458,"PHASE2":21460,"PHASE3":21462,"PHASE4":21464,"NA":21470},{"trials":21457,"activeCount":102},[],{"trials":21459,"activeCount":102},[],{"trials":21461,"activeCount":102},[],{"trials":21463,"activeCount":102},[],{"trials":21465,"activeCount":102},[21466],{"nctId":18922,"briefTitle":18923,"status":443,"phases":21467,"primaryCompletion":6562,"completion":6562,"start":13583,"enrollment":4497,"conditions":21468,"interventions":21469},[93],[18732],[18676,18927],{"trials":21471,"activeCount":102},[],{"intervention":21473,"totalTrials":122,"cells":21474},"Succinate Metoprolol",{"EARLY_PHASE1":21475,"PHASE1":21477,"PHASE2":21479,"PHASE3":21481,"PHASE4":21483,"NA":21492},{"trials":21476,"activeCount":102},[],{"trials":21478,"activeCount":102},[],{"trials":21480,"activeCount":102},[],{"trials":21482,"activeCount":102},[],{"trials":21484,"activeCount":102},[21485],{"nctId":21486,"briefTitle":21487,"status":195,"phases":21488,"primaryCompletion":2571,"completion":2571,"start":2489,"enrollment":17,"conditions":21489,"interventions":21491},"NCT01213173","Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients",[93],[21490],"Angina Pectoris",[21473,21473],{"trials":21493,"activeCount":102},[],{"intervention":21495,"totalTrials":122,"cells":21496},"Seroquel and Risperidone",{"EARLY_PHASE1":21497,"PHASE1":21499,"PHASE2":21501,"PHASE3":21503,"PHASE4":21505,"NA":21513},{"trials":21498,"activeCount":102},[],{"trials":21500,"activeCount":102},[],{"trials":21502,"activeCount":102},[],{"trials":21504,"activeCount":102},[],{"trials":21506,"activeCount":102},[21507],{"nctId":21508,"briefTitle":21509,"status":195,"phases":21510,"completion":6562,"start":12883,"enrollment":1395,"conditions":21511,"interventions":21512},"NCT00254241","Safety and Efficacy of Seroquel in First Episode Schizophrenia",[93],[33],[21495],{"trials":21514,"activeCount":102},[],{"intervention":21516,"totalTrials":122,"cells":21517},"budesonide\u002Fformoterol Turbuhaler 320\u002F9µg",{"EARLY_PHASE1":21518,"PHASE1":21520,"PHASE2":21522,"PHASE3":21524,"PHASE4":21526,"NA":21535},{"trials":21519,"activeCount":102},[],{"trials":21521,"activeCount":102},[],{"trials":21523,"activeCount":102},[],{"trials":21525,"activeCount":102},[],{"trials":21527,"activeCount":102},[21528],{"nctId":21529,"briefTitle":21530,"status":195,"phases":21531,"primaryCompletion":2220,"completion":2220,"start":2252,"enrollment":8304,"conditions":21532,"interventions":21533},"NCT00489853","Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide\u002FFormoterol) Compared to Placebo and Oxis in Patients With Severe COPD",[93],[28],[21516,21534],"formoterol Turbuhaler 9µg",{"trials":21536,"activeCount":102},[],{"intervention":21534,"totalTrials":122,"cells":21538},{"EARLY_PHASE1":21539,"PHASE1":21541,"PHASE2":21543,"PHASE3":21545,"PHASE4":21547,"NA":21553},{"trials":21540,"activeCount":102},[],{"trials":21542,"activeCount":102},[],{"trials":21544,"activeCount":102},[],{"trials":21546,"activeCount":102},[],{"trials":21548,"activeCount":102},[21549],{"nctId":21529,"briefTitle":21530,"status":195,"phases":21550,"primaryCompletion":2220,"completion":2220,"start":2252,"enrollment":8304,"conditions":21551,"interventions":21552},[93],[28],[21516,21534],{"trials":21554,"activeCount":102},[],{"intervention":21556,"totalTrials":122,"cells":21557},"Nexium",{"EARLY_PHASE1":21558,"PHASE1":21560,"PHASE2":21562,"PHASE3":21564,"PHASE4":21566,"NA":21575},{"trials":21559,"activeCount":102},[],{"trials":21561,"activeCount":102},[],{"trials":21563,"activeCount":102},[],{"trials":21565,"activeCount":102},[],{"trials":21567,"activeCount":102},[21568],{"nctId":21569,"briefTitle":21570,"status":195,"phases":21571,"completion":9213,"start":6719,"enrollment":221,"conditions":21572,"interventions":21573},"NCT00230516","Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects",[93],[19],[21556,21574],"Prevacid",{"trials":21576,"activeCount":102},[],{"intervention":21574,"totalTrials":122,"cells":21578},{"EARLY_PHASE1":21579,"PHASE1":21581,"PHASE2":21583,"PHASE3":21585,"PHASE4":21587,"NA":21593},{"trials":21580,"activeCount":102},[],{"trials":21582,"activeCount":102},[],{"trials":21584,"activeCount":102},[],{"trials":21586,"activeCount":102},[],{"trials":21588,"activeCount":102},[21589],{"nctId":21569,"briefTitle":21570,"status":195,"phases":21590,"completion":9213,"start":6719,"enrollment":221,"conditions":21591,"interventions":21592},[93],[19],[21556,21574],{"trials":21594,"activeCount":102},[],{"intervention":19539,"totalTrials":122,"cells":21596},{"EARLY_PHASE1":21597,"PHASE1":21599,"PHASE2":21601,"PHASE3":21603,"PHASE4":21605,"NA":21611},{"trials":21598,"activeCount":102},[],{"trials":21600,"activeCount":102},[],{"trials":21602,"activeCount":102},[],{"trials":21604,"activeCount":102},[],{"trials":21606,"activeCount":102},[21607],{"nctId":19533,"briefTitle":19534,"status":195,"phases":21608,"primaryCompletion":9075,"completion":9075,"start":19536,"enrollment":10196,"conditions":21609,"interventions":21610},[93],[16],[9857,19539],{"trials":21612,"activeCount":102},[],{"intervention":20915,"totalTrials":122,"cells":21614},{"EARLY_PHASE1":21615,"PHASE1":21617,"PHASE2":21619,"PHASE3":21621,"PHASE4":21623,"NA":21629},{"trials":21616,"activeCount":102},[],{"trials":21618,"activeCount":102},[],{"trials":21620,"activeCount":102},[],{"trials":21622,"activeCount":102},[],{"trials":21624,"activeCount":102},[21625],{"nctId":20910,"briefTitle":20911,"status":195,"phases":21626,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1873,"conditions":21627,"interventions":21628},[93],[18733],[20915,20198],{"trials":21630,"activeCount":102},[],{"intervention":21632,"totalTrials":122,"cells":21633},"quetiapine fumarate vs risperidone",{"EARLY_PHASE1":21634,"PHASE1":21636,"PHASE2":21638,"PHASE3":21640,"PHASE4":21642,"NA":21651},{"trials":21635,"activeCount":102},[],{"trials":21637,"activeCount":102},[],{"trials":21639,"activeCount":102},[],{"trials":21641,"activeCount":102},[],{"trials":21643,"activeCount":102},[21644],{"nctId":21645,"briefTitle":21646,"status":195,"phases":21647,"primaryCompletion":6651,"completion":6651,"start":21648,"conditions":21649,"interventions":21650},"NCT00034905","A Comparison of Seroquel vs. Risperidone in Schizophrenia",[93],"2001-07",[33],[21632],{"trials":21652,"activeCount":102},[],{"intervention":20549,"totalTrials":122,"cells":21654},{"EARLY_PHASE1":21655,"PHASE1":21657,"PHASE2":21659,"PHASE3":21661,"PHASE4":21663,"NA":21669},{"trials":21656,"activeCount":102},[],{"trials":21658,"activeCount":102},[],{"trials":21660,"activeCount":102},[],{"trials":21662,"activeCount":102},[],{"trials":21664,"activeCount":102},[21665],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21666,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21667,"interventions":21668},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21670,"activeCount":102},[],{"intervention":20550,"totalTrials":122,"cells":21672},{"EARLY_PHASE1":21673,"PHASE1":21675,"PHASE2":21677,"PHASE3":21679,"PHASE4":21681,"NA":21687},{"trials":21674,"activeCount":102},[],{"trials":21676,"activeCount":102},[],{"trials":21678,"activeCount":102},[],{"trials":21680,"activeCount":102},[],{"trials":21682,"activeCount":102},[21683],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21684,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21685,"interventions":21686},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21688,"activeCount":102},[],{"intervention":20551,"totalTrials":122,"cells":21690},{"EARLY_PHASE1":21691,"PHASE1":21693,"PHASE2":21695,"PHASE3":21697,"PHASE4":21699,"NA":21705},{"trials":21692,"activeCount":102},[],{"trials":21694,"activeCount":102},[],{"trials":21696,"activeCount":102},[],{"trials":21698,"activeCount":102},[],{"trials":21700,"activeCount":102},[21701],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21702,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21703,"interventions":21704},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21706,"activeCount":102},[],{"intervention":20552,"totalTrials":122,"cells":21708},{"EARLY_PHASE1":21709,"PHASE1":21711,"PHASE2":21713,"PHASE3":21715,"PHASE4":21717,"NA":21723},{"trials":21710,"activeCount":102},[],{"trials":21712,"activeCount":102},[],{"trials":21714,"activeCount":102},[],{"trials":21716,"activeCount":102},[],{"trials":21718,"activeCount":102},[21719],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21720,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21721,"interventions":21722},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21724,"activeCount":102},[],{"intervention":20553,"totalTrials":122,"cells":21726},{"EARLY_PHASE1":21727,"PHASE1":21729,"PHASE2":21731,"PHASE3":21733,"PHASE4":21735,"NA":21741},{"trials":21728,"activeCount":102},[],{"trials":21730,"activeCount":102},[],{"trials":21732,"activeCount":102},[],{"trials":21734,"activeCount":102},[],{"trials":21736,"activeCount":102},[21737],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21738,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21739,"interventions":21740},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21742,"activeCount":102},[],{"intervention":20554,"totalTrials":122,"cells":21744},{"EARLY_PHASE1":21745,"PHASE1":21747,"PHASE2":21749,"PHASE3":21751,"PHASE4":21753,"NA":21759},{"trials":21746,"activeCount":102},[],{"trials":21748,"activeCount":102},[],{"trials":21750,"activeCount":102},[],{"trials":21752,"activeCount":102},[],{"trials":21754,"activeCount":102},[21755],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21756,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21757,"interventions":21758},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21760,"activeCount":102},[],{"intervention":20557,"totalTrials":122,"cells":21762},{"EARLY_PHASE1":21763,"PHASE1":21765,"PHASE2":21767,"PHASE3":21769,"PHASE4":21771,"NA":21777},{"trials":21764,"activeCount":102},[],{"trials":21766,"activeCount":102},[],{"trials":21768,"activeCount":102},[],{"trials":21770,"activeCount":102},[],{"trials":21772,"activeCount":102},[21773],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21774,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21775,"interventions":21776},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21778,"activeCount":102},[],{"intervention":20559,"totalTrials":122,"cells":21780},{"EARLY_PHASE1":21781,"PHASE1":21783,"PHASE2":21785,"PHASE3":21787,"PHASE4":21789,"NA":21795},{"trials":21782,"activeCount":102},[],{"trials":21784,"activeCount":102},[],{"trials":21786,"activeCount":102},[],{"trials":21788,"activeCount":102},[],{"trials":21790,"activeCount":102},[21791],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21792,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21793,"interventions":21794},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21796,"activeCount":102},[],{"intervention":20560,"totalTrials":122,"cells":21798},{"EARLY_PHASE1":21799,"PHASE1":21801,"PHASE2":21803,"PHASE3":21805,"PHASE4":21807,"NA":21813},{"trials":21800,"activeCount":102},[],{"trials":21802,"activeCount":102},[],{"trials":21804,"activeCount":102},[],{"trials":21806,"activeCount":102},[],{"trials":21808,"activeCount":102},[21809],{"nctId":20543,"briefTitle":20544,"status":195,"phases":21810,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":21811,"interventions":21812},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":21814,"activeCount":102},[],{"intervention":21816,"totalTrials":122,"cells":21817},"Gene Profile explore",{"EARLY_PHASE1":21818,"PHASE1":21820,"PHASE2":21822,"PHASE3":21824,"PHASE4":21826,"NA":21836},{"trials":21819,"activeCount":102},[],{"trials":21821,"activeCount":102},[],{"trials":21823,"activeCount":102},[],{"trials":21825,"activeCount":102},[],{"trials":21827,"activeCount":102},[21828],{"nctId":21829,"briefTitle":21830,"status":195,"phases":21831,"primaryCompletion":1068,"completion":1068,"start":21832,"enrollment":2590,"conditions":21833,"interventions":21835},"NCT05219162","Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).",[93],"2022-02-25",[21834],"Advanced NSCLC",[21816],{"trials":21837,"activeCount":102},[],{"intervention":21839,"totalTrials":122,"cells":21840},"Goserelin",{"EARLY_PHASE1":21841,"PHASE1":21843,"PHASE2":21845,"PHASE3":21847,"PHASE4":21849,"NA":21857},{"trials":21842,"activeCount":102},[],{"trials":21844,"activeCount":102},[],{"trials":21846,"activeCount":102},[],{"trials":21848,"activeCount":102},[],{"trials":21850,"activeCount":102},[21851],{"nctId":21852,"briefTitle":21853,"status":624,"phases":21854,"start":9963,"enrollment":520,"conditions":21855,"interventions":21856},"NCT00255268","CMAB vs IMAB in Metastatic Prostate Cancer",[93],[1937],[21839,7385],{"trials":21858,"activeCount":102},[],{"intervention":21860,"totalTrials":122,"cells":21861},"Gelusil-Lac",{"EARLY_PHASE1":21862,"PHASE1":21864,"PHASE2":21866,"PHASE3":21868,"PHASE4":21870,"NA":21879},{"trials":21863,"activeCount":102},[],{"trials":21865,"activeCount":102},[],{"trials":21867,"activeCount":102},[],{"trials":21869,"activeCount":102},[],{"trials":21871,"activeCount":102},[21872],{"nctId":21873,"briefTitle":21874,"status":195,"phases":21875,"primaryCompletion":5725,"completion":5725,"start":4916,"enrollment":21876,"conditions":21877,"interventions":21878},"NCT00343161","Symptom Adapted Therapy in GERD Patients",[93],441,[20100],[19588,21860],{"trials":21880,"activeCount":102},[],{"intervention":19546,"totalTrials":122,"cells":21882},{"EARLY_PHASE1":21883,"PHASE1":21885,"PHASE2":21887,"PHASE3":21889,"PHASE4":21891,"NA":21897},{"trials":21884,"activeCount":102},[],{"trials":21886,"activeCount":102},[],{"trials":21888,"activeCount":102},[],{"trials":21890,"activeCount":102},[],{"trials":21892,"activeCount":102},[21893],{"nctId":19541,"briefTitle":19542,"status":195,"phases":21894,"primaryCompletion":2067,"completion":2067,"start":2524,"enrollment":2737,"conditions":21895,"interventions":21896},[93],[16],[19546,9972],{"trials":21898,"activeCount":102},[],{"intervention":21900,"totalTrials":122,"cells":21901},"Symbicort Turbuhaler (budesonide\u002Fformoterol) 320\u002F9 μg",{"EARLY_PHASE1":21902,"PHASE1":21904,"PHASE2":21906,"PHASE3":21908,"PHASE4":21910,"NA":21919},{"trials":21903,"activeCount":102},[],{"trials":21905,"activeCount":102},[],{"trials":21907,"activeCount":102},[],{"trials":21909,"activeCount":102},[],{"trials":21911,"activeCount":102},[21912],{"nctId":21913,"briefTitle":21914,"status":195,"phases":21915,"primaryCompletion":2220,"completion":2220,"start":2415,"enrollment":1300,"conditions":21916,"interventions":21917},"NCT00542880","Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®",[93],[6083],[21900,21918],"Seretide Diskus (salmeterol\u002Ffluticasone) 50\u002F500 μg",{"trials":21920,"activeCount":102},[],{"intervention":21918,"totalTrials":122,"cells":21922},{"EARLY_PHASE1":21923,"PHASE1":21925,"PHASE2":21927,"PHASE3":21929,"PHASE4":21931,"NA":21937},{"trials":21924,"activeCount":102},[],{"trials":21926,"activeCount":102},[],{"trials":21928,"activeCount":102},[],{"trials":21930,"activeCount":102},[],{"trials":21932,"activeCount":102},[21933],{"nctId":21913,"briefTitle":21914,"status":195,"phases":21934,"primaryCompletion":2220,"completion":2220,"start":2415,"enrollment":1300,"conditions":21935,"interventions":21936},[93],[6083],[21900,21918],{"trials":21938,"activeCount":102},[],{"intervention":21940,"totalTrials":122,"cells":21941},"Drug: Budesonide\u002Fformoterol (Symbicort Turbuhaler",{"EARLY_PHASE1":21942,"PHASE1":21944,"PHASE2":21946,"PHASE3":21948,"PHASE4":21950,"NA":21963},{"trials":21943,"activeCount":102},[],{"trials":21945,"activeCount":102},[],{"trials":21947,"activeCount":102},[],{"trials":21949,"activeCount":102},[],{"trials":21951,"activeCount":102},[21952],{"nctId":21953,"briefTitle":21954,"status":195,"phases":21955,"primaryCompletion":21956,"completion":21956,"start":21957,"enrollment":21958,"conditions":21959,"interventions":21960},"NCT01415518","Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients",[93],"2012-12-01","2011-09-01",581,[6083],[21940,21961,21962],"Drug: ipratropium","theophylline SR",{"trials":21964,"activeCount":102},[],{"intervention":21961,"totalTrials":122,"cells":21966},{"EARLY_PHASE1":21967,"PHASE1":21969,"PHASE2":21971,"PHASE3":21973,"PHASE4":21975,"NA":21981},{"trials":21968,"activeCount":102},[],{"trials":21970,"activeCount":102},[],{"trials":21972,"activeCount":102},[],{"trials":21974,"activeCount":102},[],{"trials":21976,"activeCount":102},[21977],{"nctId":21953,"briefTitle":21954,"status":195,"phases":21978,"primaryCompletion":21956,"completion":21956,"start":21957,"enrollment":21958,"conditions":21979,"interventions":21980},[93],[6083],[21940,21961,21962],{"trials":21982,"activeCount":102},[],{"intervention":21962,"totalTrials":122,"cells":21984},{"EARLY_PHASE1":21985,"PHASE1":21987,"PHASE2":21989,"PHASE3":21991,"PHASE4":21993,"NA":21999},{"trials":21986,"activeCount":102},[],{"trials":21988,"activeCount":102},[],{"trials":21990,"activeCount":102},[],{"trials":21992,"activeCount":102},[],{"trials":21994,"activeCount":102},[21995],{"nctId":21953,"briefTitle":21954,"status":195,"phases":21996,"primaryCompletion":21956,"completion":21956,"start":21957,"enrollment":21958,"conditions":21997,"interventions":21998},[93],[6083],[21940,21961,21962],{"trials":22000,"activeCount":102},[],{"intervention":22002,"totalTrials":122,"cells":22003},"SYMBICORT and salbutamol",{"EARLY_PHASE1":22004,"PHASE1":22006,"PHASE2":22008,"PHASE3":22010,"PHASE4":22012,"NA":22022},{"trials":22005,"activeCount":102},[],{"trials":22007,"activeCount":102},[],{"trials":22009,"activeCount":102},[],{"trials":22011,"activeCount":102},[],{"trials":22013,"activeCount":102},[22014],{"nctId":22015,"briefTitle":22016,"status":195,"phases":22017,"primaryCompletion":8198,"completion":8198,"start":22018,"enrollment":2069,"conditions":22019,"interventions":22021},"NCT03924635","An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients",[93],"2019-08-01",[22020,16],"Airway Inflammation",[22002],{"trials":22023,"activeCount":102},[],{"intervention":22025,"totalTrials":122,"cells":22026},"Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily",{"EARLY_PHASE1":22027,"PHASE1":22029,"PHASE2":22031,"PHASE3":22033,"PHASE4":22035,"NA":22046},{"trials":22028,"activeCount":102},[],{"trials":22030,"activeCount":102},[],{"trials":22032,"activeCount":102},[],{"trials":22034,"activeCount":102},[],{"trials":22036,"activeCount":102},[22037],{"nctId":22038,"briefTitle":22039,"status":195,"phases":22040,"primaryCompletion":22041,"completion":22041,"start":22042,"enrollment":1373,"conditions":22043,"interventions":22045},"NCT02406248","Brilinta Taiwan Post Approval Safety Study",[93],"2017-02-09","2015-04-23",[22044],"Non ST-elevation Myocardial Infarction",[22025],{"trials":22047,"activeCount":102},[],{"intervention":22049,"totalTrials":122,"cells":22050},"Xigduo (Dapagliflozin and Metformin hydrochloride extended-release)",{"EARLY_PHASE1":22051,"PHASE1":22053,"PHASE2":22055,"PHASE3":22057,"PHASE4":22059,"NA":22070},{"trials":22052,"activeCount":102},[],{"trials":22054,"activeCount":102},[],{"trials":22056,"activeCount":102},[],{"trials":22058,"activeCount":102},[],{"trials":22060,"activeCount":102},[22061],{"nctId":22062,"briefTitle":22063,"status":195,"phases":22064,"primaryCompletion":1406,"completion":1406,"start":22065,"enrollment":22066,"conditions":22067,"interventions":22068},"NCT06327815","Efficacy of FDC Regimen of Dapagliflozin\u002FMetformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM",[93],"2024-03-15",633,[2059],[22049,22069],"Dapagliflozin tablets and Metformin HCl extended-release",{"trials":22071,"activeCount":102},[],{"intervention":22069,"totalTrials":122,"cells":22073},{"EARLY_PHASE1":22074,"PHASE1":22076,"PHASE2":22078,"PHASE3":22080,"PHASE4":22082,"NA":22088},{"trials":22075,"activeCount":102},[],{"trials":22077,"activeCount":102},[],{"trials":22079,"activeCount":102},[],{"trials":22081,"activeCount":102},[],{"trials":22083,"activeCount":102},[22084],{"nctId":22062,"briefTitle":22063,"status":195,"phases":22085,"primaryCompletion":1406,"completion":1406,"start":22065,"enrollment":22066,"conditions":22086,"interventions":22087},[93],[2059],[22049,22069],{"trials":22089,"activeCount":102},[],{"intervention":22091,"totalTrials":122,"cells":22092},"Zoladex and Casodex",{"EARLY_PHASE1":22093,"PHASE1":22095,"PHASE2":22097,"PHASE3":22099,"PHASE4":22101,"NA":22111},{"trials":22094,"activeCount":102},[],{"trials":22096,"activeCount":102},[],{"trials":22098,"activeCount":102},[],{"trials":22100,"activeCount":102},[],{"trials":22102,"activeCount":102},[22103],{"nctId":22104,"briefTitle":22105,"status":443,"phases":22106,"primaryCompletion":22107,"completion":22107,"start":7466,"enrollment":4343,"conditions":22108,"interventions":22110},"NCT03971110","A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.",[93],"2022-11-09",[22109],"Advanced Prostate Cancer",[22091],{"trials":22112,"activeCount":102},[],{"intervention":22114,"totalTrials":122,"cells":22115},"Ciclesonide nasal spray + placebo Azelastine",{"EARLY_PHASE1":22116,"PHASE1":22118,"PHASE2":22120,"PHASE3":22122,"PHASE4":22124,"NA":22134},{"trials":22117,"activeCount":102},[],{"trials":22119,"activeCount":102},[],{"trials":22121,"activeCount":102},[],{"trials":22123,"activeCount":102},[],{"trials":22125,"activeCount":102},[22126],{"nctId":22127,"briefTitle":22128,"status":195,"phases":22129,"primaryCompletion":6718,"completion":5725,"start":7342,"enrollment":5269,"conditions":22130,"interventions":22132},"NCT00806754","Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010\u002FM1-490)",[93],[22131],"Rhinitis, Allergic, Perennial",[22114,22133],"Ciclesonide nasal spray + Azelastine",{"trials":22135,"activeCount":102},[],{"intervention":22133,"totalTrials":122,"cells":22137},{"EARLY_PHASE1":22138,"PHASE1":22140,"PHASE2":22142,"PHASE3":22144,"PHASE4":22146,"NA":22152},{"trials":22139,"activeCount":102},[],{"trials":22141,"activeCount":102},[],{"trials":22143,"activeCount":102},[],{"trials":22145,"activeCount":102},[],{"trials":22147,"activeCount":102},[22148],{"nctId":22127,"briefTitle":22128,"status":195,"phases":22149,"primaryCompletion":6718,"completion":5725,"start":7342,"enrollment":5269,"conditions":22150,"interventions":22151},[93],[22131],[22114,22133],{"trials":22153,"activeCount":102},[],{"intervention":22155,"totalTrials":122,"cells":22156},"Budesonide inhalation suspension",{"EARLY_PHASE1":22157,"PHASE1":22159,"PHASE2":22161,"PHASE3":22163,"PHASE4":22165,"NA":22175},{"trials":22158,"activeCount":102},[],{"trials":22160,"activeCount":102},[],{"trials":22162,"activeCount":102},[],{"trials":22164,"activeCount":102},[],{"trials":22166,"activeCount":102},[22167],{"nctId":22168,"briefTitle":22169,"status":195,"phases":22170,"primaryCompletion":9944,"completion":9944,"start":7448,"enrollment":22171,"conditions":22172,"interventions":22173},"NCT00641472","Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children",[93],380,[16],[22155,22174],"Montelukast Sodium",{"trials":22176,"activeCount":102},[],{"intervention":22174,"totalTrials":122,"cells":22178},{"EARLY_PHASE1":22179,"PHASE1":22181,"PHASE2":22183,"PHASE3":22185,"PHASE4":22187,"NA":22193},{"trials":22180,"activeCount":102},[],{"trials":22182,"activeCount":102},[],{"trials":22184,"activeCount":102},[],{"trials":22186,"activeCount":102},[],{"trials":22188,"activeCount":102},[22189],{"nctId":22168,"briefTitle":22169,"status":195,"phases":22190,"primaryCompletion":9944,"completion":9944,"start":7448,"enrollment":22171,"conditions":22191,"interventions":22192},[93],[16],[22155,22174],{"trials":22194,"activeCount":102},[],{"intervention":22196,"totalTrials":122,"cells":22197},"Inhibition of Platelet Aggregation by \"Brilinta\"",{"EARLY_PHASE1":22198,"PHASE1":22200,"PHASE2":22202,"PHASE3":22204,"PHASE4":22206,"NA":22216},{"trials":22199,"activeCount":102},[],{"trials":22201,"activeCount":102},[],{"trials":22203,"activeCount":102},[],{"trials":22205,"activeCount":102},[],{"trials":22207,"activeCount":102},[22208],{"nctId":22209,"briefTitle":22210,"status":195,"phases":22211,"primaryCompletion":16044,"completion":16044,"start":2204,"enrollment":22212,"conditions":22213,"interventions":22215},"NCT02064985","Ticagrelor China Pharmacokinetic\u002FPharmacodynamic Study",[93],61,[22214],"Stable Coronary Heart Disease (CHD)",[22196],{"trials":22217,"activeCount":102},[],{"intervention":12197,"totalTrials":122,"cells":22219},{"EARLY_PHASE1":22220,"PHASE1":22222,"PHASE2":22224,"PHASE3":22226,"PHASE4":22228,"NA":22234},{"trials":22221,"activeCount":102},[],{"trials":22223,"activeCount":102},[],{"trials":22225,"activeCount":102},[],{"trials":22227,"activeCount":102},[],{"trials":22229,"activeCount":102},[22230],{"nctId":12190,"briefTitle":12191,"status":195,"phases":22231,"primaryCompletion":12193,"completion":12193,"start":1746,"enrollment":12194,"conditions":22232,"interventions":22233},[93],[10760,2134],[10762,12197],{"trials":22235,"activeCount":102},[],{"intervention":22237,"totalTrials":122,"cells":22238},"Pulmicort (budesonide) pMDI",{"EARLY_PHASE1":22239,"PHASE1":22241,"PHASE2":22243,"PHASE3":22245,"PHASE4":22247,"NA":22255},{"trials":22240,"activeCount":102},[],{"trials":22242,"activeCount":102},[],{"trials":22244,"activeCount":102},[],{"trials":22246,"activeCount":102},[],{"trials":22248,"activeCount":102},[22249],{"nctId":22250,"briefTitle":22251,"status":195,"phases":22252,"completion":9986,"start":6509,"enrollment":1078,"conditions":22253,"interventions":22254},"NCT00234390","PreAsthmaControl (PAC)",[93],[16],[22237],{"trials":22256,"activeCount":102},[],{"intervention":22258,"totalTrials":122,"cells":22259},"Usual Care Inhaled Glucocorticosteroids",{"EARLY_PHASE1":22260,"PHASE1":22262,"PHASE2":22264,"PHASE3":22266,"PHASE4":22268,"NA":22277},{"trials":22261,"activeCount":102},[],{"trials":22263,"activeCount":102},[],{"trials":22265,"activeCount":102},[],{"trials":22267,"activeCount":102},[],{"trials":22269,"activeCount":102},[22270],{"nctId":22271,"briefTitle":22272,"status":195,"phases":22273,"primaryCompletion":2251,"completion":4915,"start":7342,"enrollment":22274,"conditions":22275,"interventions":22276},"NCT00404547","Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010\u002FCA-102)",[93],1121,[16],[10076,22258],{"trials":22278,"activeCount":102},[],{"intervention":22280,"totalTrials":122,"cells":22281},"dapagliflozin and saxagliptin",{"EARLY_PHASE1":22282,"PHASE1":22284,"PHASE2":22286,"PHASE3":22288,"PHASE4":22290,"NA":22300},{"trials":22283,"activeCount":102},[],{"trials":22285,"activeCount":102},[],{"trials":22287,"activeCount":102},[],{"trials":22289,"activeCount":102},[],{"trials":22291,"activeCount":102},[22292],{"nctId":22293,"briefTitle":22294,"status":195,"phases":22295,"primaryCompletion":22296,"completion":22296,"start":22297,"enrollment":12152,"conditions":22298,"interventions":22299},"NCT04445714","To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients",[93],"2023-03-14","2021-04-07",[22],[22280],{"trials":22301,"activeCount":102},[],{"intervention":22303,"totalTrials":122,"cells":22304},"Budesonide\u002Fglycopyrrolate\u002Fformoterol fumarate (Breztri Aerosphere) 320 μg\u002F18 μg\u002F9.6 μg administered as two inhalations, twice daily.",{"EARLY_PHASE1":22305,"PHASE1":22307,"PHASE2":22309,"PHASE3":22311,"PHASE4":22313,"NA":22321},{"trials":22306,"activeCount":102},[],{"trials":22308,"activeCount":102},[],{"trials":22310,"activeCount":102},[],{"trials":22312,"activeCount":102},[],{"trials":22314,"activeCount":102},[22315],{"nctId":22316,"briefTitle":22317,"status":624,"phases":22318,"primaryCompletion":1317,"completion":1317,"start":6959,"enrollment":102,"conditions":22319,"interventions":22320},"NCT05970263","IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US",[93],[10066],[22303],{"trials":22322,"activeCount":102},[],{"intervention":22324,"totalTrials":122,"cells":22325},"Candesartan Cilexetil 32mg",{"EARLY_PHASE1":22326,"PHASE1":22328,"PHASE2":22330,"PHASE3":22332,"PHASE4":22334,"NA":22343},{"trials":22327,"activeCount":102},[],{"trials":22329,"activeCount":102},[],{"trials":22331,"activeCount":102},[],{"trials":22333,"activeCount":102},[],{"trials":22335,"activeCount":102},[22336],{"nctId":22337,"briefTitle":22338,"status":195,"phases":22339,"primaryCompletion":2151,"completion":2151,"start":4298,"enrollment":589,"conditions":22340,"interventions":22342},"NCT00573430","ARIA (Atacand Renoprotection In NephropAthy Pt.)",[93],[22341],"Non-diabetic Nephropathy With Hypertension",[20401,20401,22324],{"trials":22344,"activeCount":102},[],{"intervention":22346,"totalTrials":122,"cells":22347},"metoprolol succinate prolonged-release tablet and felodipine",{"EARLY_PHASE1":22348,"PHASE1":22350,"PHASE2":22352,"PHASE3":22354,"PHASE4":22356,"NA":22364},{"trials":22349,"activeCount":102},[],{"trials":22351,"activeCount":102},[],{"trials":22353,"activeCount":102},[],{"trials":22355,"activeCount":102},[],{"trials":22357,"activeCount":102},[22358],{"nctId":22359,"briefTitle":22360,"status":195,"phases":22361,"primaryCompletion":6369,"completion":7494,"start":3809,"enrollment":15641,"conditions":22362,"interventions":22363},"NCT00861016","Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension",[93],[2620],[22346],{"trials":22365,"activeCount":102},[],{"intervention":19162,"totalTrials":122,"cells":22367},{"EARLY_PHASE1":22368,"PHASE1":22370,"PHASE2":22372,"PHASE3":22374,"PHASE4":22376,"NA":22382},{"trials":22369,"activeCount":102},[],{"trials":22371,"activeCount":102},[],{"trials":22373,"activeCount":102},[],{"trials":22375,"activeCount":102},[],{"trials":22377,"activeCount":102},[22378],{"nctId":19156,"briefTitle":19157,"status":195,"phases":22379,"primaryCompletion":13056,"completion":13056,"start":13756,"enrollment":9428,"conditions":22380,"interventions":22381},[93],[19160],[19162,2173,12122],{"trials":22383,"activeCount":102},[],{"intervention":22385,"totalTrials":122,"cells":22386},"Casodex 150mg",{"EARLY_PHASE1":22387,"PHASE1":22389,"PHASE2":22391,"PHASE3":22393,"PHASE4":22395,"NA":22403},{"trials":22388,"activeCount":102},[],{"trials":22390,"activeCount":102},[],{"trials":22392,"activeCount":102},[],{"trials":22394,"activeCount":102},[],{"trials":22396,"activeCount":102},[22397],{"nctId":22398,"briefTitle":22399,"status":195,"phases":22400,"start":4256,"enrollment":2811,"conditions":22401,"interventions":22402},"NCT00590213","Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX",[93],[416],[22385],{"trials":22404,"activeCount":102},[],{"intervention":22406,"totalTrials":122,"cells":22407},"Esomeprazole 40mg",{"EARLY_PHASE1":22408,"PHASE1":22410,"PHASE2":22412,"PHASE3":22414,"PHASE4":22416,"NA":22426},{"trials":22409,"activeCount":102},[],{"trials":22411,"activeCount":102},[],{"trials":22413,"activeCount":102},[],{"trials":22415,"activeCount":102},[],{"trials":22417,"activeCount":102},[22418],{"nctId":22419,"briefTitle":22420,"status":195,"phases":22421,"completion":6718,"start":2639,"enrollment":2045,"conditions":22422,"interventions":22423},"NCT00410592","Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD",[93],[20100],[22406,22424,22425],"Pantoprazole 40mg","Lansoprazole 30mg",{"trials":22427,"activeCount":102},[],{"intervention":22424,"totalTrials":122,"cells":22429},{"EARLY_PHASE1":22430,"PHASE1":22432,"PHASE2":22434,"PHASE3":22436,"PHASE4":22438,"NA":22444},{"trials":22431,"activeCount":102},[],{"trials":22433,"activeCount":102},[],{"trials":22435,"activeCount":102},[],{"trials":22437,"activeCount":102},[],{"trials":22439,"activeCount":102},[22440],{"nctId":22419,"briefTitle":22420,"status":195,"phases":22441,"completion":6718,"start":2639,"enrollment":2045,"conditions":22442,"interventions":22443},[93],[20100],[22406,22424,22425],{"trials":22445,"activeCount":102},[],{"intervention":22425,"totalTrials":122,"cells":22447},{"EARLY_PHASE1":22448,"PHASE1":22450,"PHASE2":22452,"PHASE3":22454,"PHASE4":22456,"NA":22462},{"trials":22449,"activeCount":102},[],{"trials":22451,"activeCount":102},[],{"trials":22453,"activeCount":102},[],{"trials":22455,"activeCount":102},[],{"trials":22457,"activeCount":102},[22458],{"nctId":22419,"briefTitle":22420,"status":195,"phases":22459,"completion":6718,"start":2639,"enrollment":2045,"conditions":22460,"interventions":22461},[93],[20100],[22406,22424,22425],{"trials":22463,"activeCount":102},[],{"intervention":22465,"totalTrials":122,"cells":22466},"Symbicort®",{"EARLY_PHASE1":22467,"PHASE1":22469,"PHASE2":22471,"PHASE3":22473,"PHASE4":22475,"NA":22488},{"trials":22468,"activeCount":102},[],{"trials":22470,"activeCount":102},[],{"trials":22472,"activeCount":102},[],{"trials":22474,"activeCount":102},[],{"trials":22476,"activeCount":102},[22477],{"nctId":22478,"briefTitle":22479,"status":195,"phases":22480,"primaryCompletion":22481,"completion":22481,"start":22482,"enrollment":22483,"conditions":22484,"interventions":22485},"NCT04159519","A Study to Assess the Reduction of Daily Maintenance ICS\u002FLABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab",[93],"2023-01-31","2020-07-27",170,[16,1650],[22465,22486,22487],"Fasenra®","Ventolin®",{"trials":22489,"activeCount":102},[],{"intervention":22486,"totalTrials":122,"cells":22491},{"EARLY_PHASE1":22492,"PHASE1":22494,"PHASE2":22496,"PHASE3":22498,"PHASE4":22500,"NA":22506},{"trials":22493,"activeCount":102},[],{"trials":22495,"activeCount":102},[],{"trials":22497,"activeCount":102},[],{"trials":22499,"activeCount":102},[],{"trials":22501,"activeCount":102},[22502],{"nctId":22478,"briefTitle":22479,"status":195,"phases":22503,"primaryCompletion":22481,"completion":22481,"start":22482,"enrollment":22483,"conditions":22504,"interventions":22505},[93],[16,1650],[22465,22486,22487],{"trials":22507,"activeCount":102},[],{"intervention":22487,"totalTrials":122,"cells":22509},{"EARLY_PHASE1":22510,"PHASE1":22512,"PHASE2":22514,"PHASE3":22516,"PHASE4":22518,"NA":22524},{"trials":22511,"activeCount":102},[],{"trials":22513,"activeCount":102},[],{"trials":22515,"activeCount":102},[],{"trials":22517,"activeCount":102},[],{"trials":22519,"activeCount":102},[22520],{"nctId":22478,"briefTitle":22479,"status":195,"phases":22521,"primaryCompletion":22481,"completion":22481,"start":22482,"enrollment":22483,"conditions":22522,"interventions":22523},[93],[16,1650],[22465,22486,22487],{"trials":22525,"activeCount":102},[],{"intervention":22527,"totalTrials":122,"cells":22528},"Other PPI marketed in Sweden",{"EARLY_PHASE1":22529,"PHASE1":22531,"PHASE2":22533,"PHASE3":22535,"PHASE4":22537,"NA":22545},{"trials":22530,"activeCount":102},[],{"trials":22532,"activeCount":102},[],{"trials":22534,"activeCount":102},[],{"trials":22536,"activeCount":102},[],{"trials":22538,"activeCount":102},[22539],{"nctId":22540,"briefTitle":22541,"status":195,"phases":22542,"completion":2328,"start":2329,"enrollment":170,"conditions":22543,"interventions":22544},"NCT00272701","Esomeprazole in PPI Failures - IMPROVE",[93],[20100],[19794,22527],{"trials":22546,"activeCount":102},[],{"intervention":21070,"totalTrials":122,"cells":22548},{"EARLY_PHASE1":22549,"PHASE1":22551,"PHASE2":22553,"PHASE3":22555,"PHASE4":22557,"NA":22563},{"trials":22550,"activeCount":102},[],{"trials":22552,"activeCount":102},[],{"trials":22554,"activeCount":102},[],{"trials":22556,"activeCount":102},[],{"trials":22558,"activeCount":102},[22559],{"nctId":21063,"briefTitle":21064,"status":624,"phases":22560,"primaryCompletion":21066,"completion":21066,"start":21067,"enrollment":102,"conditions":22561,"interventions":22562},[93],[28],[21070,8179],{"trials":22564,"activeCount":102},[],{"intervention":13040,"totalTrials":122,"cells":22566},{"EARLY_PHASE1":22567,"PHASE1":22569,"PHASE2":22571,"PHASE3":22573,"PHASE4":22575,"NA":22581},{"trials":22568,"activeCount":102},[],{"trials":22570,"activeCount":102},[],{"trials":22572,"activeCount":102},[],{"trials":22574,"activeCount":102},[],{"trials":22576,"activeCount":102},[22577],{"nctId":13035,"briefTitle":13036,"status":195,"phases":22578,"primaryCompletion":2086,"completion":2086,"start":3809,"enrollment":3524,"conditions":22579,"interventions":22580},[93],[12818],[5887,13040],{"trials":22582,"activeCount":102},[],{"intervention":18950,"totalTrials":122,"cells":22584},{"EARLY_PHASE1":22585,"PHASE1":22587,"PHASE2":22589,"PHASE3":22591,"PHASE4":22593,"NA":22599},{"trials":22586,"activeCount":102},[],{"trials":22588,"activeCount":102},[],{"trials":22590,"activeCount":102},[],{"trials":22592,"activeCount":102},[],{"trials":22594,"activeCount":102},[22595],{"nctId":18945,"briefTitle":18946,"status":195,"phases":22596,"primaryCompletion":4298,"completion":4298,"start":6719,"enrollment":3007,"conditions":22597,"interventions":22598},[93],[33],[18676,18950],{"trials":22600,"activeCount":102},[],{"intervention":22602,"totalTrials":122,"cells":22603},"rapid acting insulin",{"EARLY_PHASE1":22604,"PHASE1":22606,"PHASE2":22608,"PHASE3":22610,"PHASE4":22612,"NA":22621},{"trials":22605,"activeCount":102},[],{"trials":22607,"activeCount":102},[],{"trials":22609,"activeCount":102},[],{"trials":22611,"activeCount":102},[],{"trials":22613,"activeCount":102},[22614],{"nctId":22615,"briefTitle":22616,"status":195,"phases":22617,"primaryCompletion":2251,"completion":2251,"start":6718,"enrollment":8138,"conditions":22618,"interventions":22619},"NCT00467649","A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes",[93],[22],[22620,22602,18489],"pramlintide acetate",{"trials":22622,"activeCount":102},[],{"intervention":22624,"totalTrials":122,"cells":22625},"Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol",{"EARLY_PHASE1":22626,"PHASE1":22628,"PHASE2":22630,"PHASE3":22632,"PHASE4":22634,"NA":22644},{"trials":22627,"activeCount":102},[],{"trials":22629,"activeCount":102},[],{"trials":22631,"activeCount":102},[],{"trials":22633,"activeCount":102},[],{"trials":22635,"activeCount":102},[22636],{"nctId":22637,"briefTitle":22638,"status":195,"phases":22639,"primaryCompletion":22640,"completion":22640,"start":22641,"enrollment":5425,"conditions":22642,"interventions":22643},"NCT02533505","Phase IV O2 Consumption Study in COPD Patients.",[93],"2016-08-12","2015-08-25",[6083],[22624],{"trials":22645,"activeCount":102},[],{"intervention":22647,"totalTrials":122,"cells":22648},"Rosuvastatin; improvement of lipid profile",{"EARLY_PHASE1":22649,"PHASE1":22651,"PHASE2":22653,"PHASE3":22655,"PHASE4":22657,"NA":22665},{"trials":22650,"activeCount":102},[],{"trials":22652,"activeCount":102},[],{"trials":22654,"activeCount":102},[],{"trials":22656,"activeCount":102},[],{"trials":22658,"activeCount":102},[22659],{"nctId":22660,"briefTitle":22661,"status":195,"phases":22662,"start":3809,"enrollment":221,"conditions":22663,"interventions":22664},"NCT00262548","C-Reactive Protein (CRP) in Obese Diabetic Women",[93],[2089],[22647],{"trials":22666,"activeCount":102},[],{"intervention":22668,"totalTrials":122,"cells":22669},"Symbicort Turbuhaler 160\u002F4.5",{"EARLY_PHASE1":22670,"PHASE1":22672,"PHASE2":22674,"PHASE3":22676,"PHASE4":22678,"NA":22687},{"trials":22671,"activeCount":102},[],{"trials":22673,"activeCount":102},[],{"trials":22675,"activeCount":102},[],{"trials":22677,"activeCount":102},[],{"trials":22679,"activeCount":102},[22680],{"nctId":22681,"briefTitle":22682,"status":195,"phases":22683,"completion":2414,"start":6710,"enrollment":22684,"conditions":22685,"interventions":22686},"NCT00576316","Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia",[93],201,[16],[22668],{"trials":22688,"activeCount":102},[],{"intervention":22690,"totalTrials":122,"cells":22691},"Metoprolol XL 50mg + Amlodipine 5mg",{"EARLY_PHASE1":22692,"PHASE1":22694,"PHASE2":22696,"PHASE3":22698,"PHASE4":22700,"NA":22714},{"trials":22693,"activeCount":102},[],{"trials":22695,"activeCount":102},[],{"trials":22697,"activeCount":102},[],{"trials":22699,"activeCount":102},[],{"trials":22701,"activeCount":102},[22702],{"nctId":22703,"briefTitle":22704,"status":195,"phases":22705,"completion":2151,"start":2414,"enrollment":22706,"conditions":22707,"interventions":22709},"NCT00819104","A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components",[93],402,[22708],"Primary Hypertension",[22690,22710,22711,22712,22713],"Metoprolol XL 25 mg + Amlodipine 2.5mg","Metoprolol XL 50mg","Metoprolol XL 25 mg","Amlodipine 5mg",{"trials":22715,"activeCount":102},[],{"intervention":22710,"totalTrials":122,"cells":22717},{"EARLY_PHASE1":22718,"PHASE1":22720,"PHASE2":22722,"PHASE3":22724,"PHASE4":22726,"NA":22732},{"trials":22719,"activeCount":102},[],{"trials":22721,"activeCount":102},[],{"trials":22723,"activeCount":102},[],{"trials":22725,"activeCount":102},[],{"trials":22727,"activeCount":102},[22728],{"nctId":22703,"briefTitle":22704,"status":195,"phases":22729,"completion":2151,"start":2414,"enrollment":22706,"conditions":22730,"interventions":22731},[93],[22708],[22690,22710,22711,22712,22713],{"trials":22733,"activeCount":102},[],{"intervention":22711,"totalTrials":122,"cells":22735},{"EARLY_PHASE1":22736,"PHASE1":22738,"PHASE2":22740,"PHASE3":22742,"PHASE4":22744,"NA":22750},{"trials":22737,"activeCount":102},[],{"trials":22739,"activeCount":102},[],{"trials":22741,"activeCount":102},[],{"trials":22743,"activeCount":102},[],{"trials":22745,"activeCount":102},[22746],{"nctId":22703,"briefTitle":22704,"status":195,"phases":22747,"completion":2151,"start":2414,"enrollment":22706,"conditions":22748,"interventions":22749},[93],[22708],[22690,22710,22711,22712,22713],{"trials":22751,"activeCount":102},[],{"intervention":22712,"totalTrials":122,"cells":22753},{"EARLY_PHASE1":22754,"PHASE1":22756,"PHASE2":22758,"PHASE3":22760,"PHASE4":22762,"NA":22768},{"trials":22755,"activeCount":102},[],{"trials":22757,"activeCount":102},[],{"trials":22759,"activeCount":102},[],{"trials":22761,"activeCount":102},[],{"trials":22763,"activeCount":102},[22764],{"nctId":22703,"briefTitle":22704,"status":195,"phases":22765,"completion":2151,"start":2414,"enrollment":22706,"conditions":22766,"interventions":22767},[93],[22708],[22690,22710,22711,22712,22713],{"trials":22769,"activeCount":102},[],{"intervention":22713,"totalTrials":122,"cells":22771},{"EARLY_PHASE1":22772,"PHASE1":22774,"PHASE2":22776,"PHASE3":22778,"PHASE4":22780,"NA":22786},{"trials":22773,"activeCount":102},[],{"trials":22775,"activeCount":102},[],{"trials":22777,"activeCount":102},[],{"trials":22779,"activeCount":102},[],{"trials":22781,"activeCount":102},[22782],{"nctId":22703,"briefTitle":22704,"status":195,"phases":22783,"completion":2151,"start":2414,"enrollment":22706,"conditions":22784,"interventions":22785},[93],[22708],[22690,22710,22711,22712,22713],{"trials":22787,"activeCount":102},[],{"intervention":12604,"totalTrials":5876,"cells":22789},{"EARLY_PHASE1":22790,"PHASE1":22792,"PHASE2":22860,"PHASE3":22894,"PHASE4":22923,"NA":22925},{"trials":22791,"activeCount":102},[],{"trials":22793,"activeCount":102},[22794,22800,22804,22810,22816,22820,22827,22836,22840,22847,22853],{"nctId":22795,"briefTitle":22796,"status":195,"phases":22797,"primaryCompletion":2542,"completion":2542,"start":2349,"enrollment":1130,"conditions":22798,"interventions":22799},"NCT01245790","A Study of Fostamatinib in Subjects With Impaired Kidney Function",[90],[7267,2279],[15892],{"nctId":16415,"briefTitle":16416,"status":195,"phases":22801,"primaryCompletion":2571,"completion":2571,"start":2542,"enrollment":544,"conditions":22802,"interventions":22803},[90],[36,7267],[2198,12604],{"nctId":22805,"briefTitle":22806,"status":195,"phases":22807,"primaryCompletion":2105,"completion":2105,"start":10063,"enrollment":1543,"conditions":22808,"interventions":22809},"NCT01598571","Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose",[90],[19],[12604,12604],{"nctId":22811,"briefTitle":22812,"status":195,"phases":22813,"primaryCompletion":2736,"completion":2736,"start":2675,"enrollment":1130,"conditions":22814,"interventions":22815},"NCT01387308","Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets",[90],[19],[12604,12604,12604,12604,12604],{"nctId":12599,"briefTitle":12600,"status":195,"phases":22817,"primaryCompletion":2579,"completion":2579,"start":2104,"enrollment":2069,"conditions":22818,"interventions":22819},[90],[7267],[12604,5887,12588],{"nctId":22821,"briefTitle":22822,"status":195,"phases":22823,"primaryCompletion":2615,"completion":2615,"start":2570,"enrollment":520,"conditions":22824,"interventions":22825},"NCT01311622","Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects",[90],[7267,1556],[22826,15892],"warfarin",{"nctId":22828,"briefTitle":22829,"status":195,"phases":22830,"primaryCompletion":4580,"completion":4580,"start":2570,"enrollment":434,"conditions":22831,"interventions":22834},"NCT01276262","Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects",[90],[22832,22833],"Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction","Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction",[15892,22835],"Microgynon® 30",{"nctId":15885,"briefTitle":15886,"status":195,"phases":22837,"primaryCompletion":2615,"completion":2615,"start":2570,"enrollment":520,"conditions":22838,"interventions":22839},[90],[7267,36,15776,2448,15889,15890],[15892,15893],{"nctId":22841,"briefTitle":22842,"status":195,"phases":22843,"primaryCompletion":2542,"completion":2542,"start":2489,"enrollment":579,"conditions":22844,"interventions":22846},"NCT01222455","A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function",[90],[6914,36,15776,22845],"Amount of R406 in Blood",[12604],{"nctId":22848,"briefTitle":22849,"status":195,"phases":22850,"primaryCompletion":6709,"completion":6709,"start":12721,"enrollment":520,"conditions":22851,"interventions":22852},"NCT01336218","Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.",[90],[7267,36],[15892,7642],{"nctId":22854,"briefTitle":22855,"status":195,"phases":22856,"primaryCompletion":2349,"completion":2349,"start":3862,"enrollment":1130,"conditions":22857,"interventions":22859},"NCT01208155","Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets",[90],[22858,15776],"Bioavailability",[12604,12604,12604,12604],{"trials":22861,"activeCount":102},[22862,22868,22874,22882,22888],{"nctId":22863,"briefTitle":22864,"status":443,"phases":22865,"primaryCompletion":13856,"completion":13856,"start":4496,"enrollment":2640,"conditions":22866,"interventions":22867},"NCT01569074","Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis",[91],[7267],[12604,12604,12604,12604],{"nctId":22869,"briefTitle":22870,"status":195,"phases":22871,"primaryCompletion":2579,"completion":2579,"start":4496,"enrollment":852,"conditions":22872,"interventions":22873},"NCT01563978","Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis",[91],[7267],[15892],{"nctId":22875,"briefTitle":22876,"status":443,"phases":22877,"primaryCompletion":13856,"completion":13856,"start":2433,"enrollment":22878,"conditions":22879,"interventions":22880},"NCT02092961","Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study",[91],198,[7267],[12604,22881],"Adalimumab",{"nctId":22883,"briefTitle":22884,"status":195,"phases":22885,"primaryCompletion":4204,"completion":4204,"start":2589,"enrollment":3645,"conditions":22886,"interventions":22887},"NCT01499303","Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer",[91],[1419],[12604],{"nctId":22889,"briefTitle":22890,"status":443,"phases":22891,"primaryCompletion":13856,"completion":13856,"start":2481,"enrollment":3755,"conditions":22892,"interventions":22893},"NCT01640054","A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis",[91],[7267],[12604],{"trials":22895,"activeCount":102},[22896,22903,22909,22916],{"nctId":22897,"briefTitle":22898,"status":195,"phases":22899,"primaryCompletion":2443,"completion":2443,"start":3862,"enrollment":22900,"conditions":22901,"interventions":22902},"NCT01197534","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.",[92],913,[7267],[15892,15892],{"nctId":22904,"briefTitle":22905,"status":195,"phases":22906,"primaryCompletion":2104,"completion":2104,"start":3862,"enrollment":4651,"conditions":22907,"interventions":22908},"NCT01197521","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.",[92],[7267],[15892,15892],{"nctId":22910,"briefTitle":22911,"status":195,"phases":22912,"primaryCompletion":2405,"completion":2405,"start":3862,"enrollment":22913,"conditions":22914,"interventions":22915},"NCT01197755","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist",[92],323,[7267],[15892,15892],{"nctId":22917,"briefTitle":22918,"status":443,"phases":22919,"primaryCompletion":2299,"completion":2299,"start":2516,"enrollment":22920,"conditions":22921,"interventions":22922},"NCT01242514","Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)",[92],1917,[7267],[12604,12604,12604],{"trials":22924,"activeCount":102},[],{"trials":22926,"activeCount":102},[],{"intervention":22928,"totalTrials":520,"cells":22929},"TC-5214",{"EARLY_PHASE1":22930,"PHASE1":22932,"PHASE2":22996,"PHASE3":23004,"PHASE4":23041,"NA":23043},{"trials":22931,"activeCount":102},[],{"trials":22933,"activeCount":102},[22934,22940,22947,22957,22963,22969,22976,22982,22989],{"nctId":22935,"briefTitle":22936,"status":195,"phases":22937,"primaryCompletion":2747,"completion":2747,"start":4580,"enrollment":1336,"conditions":22938,"interventions":22939},"NCT01458899","Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214",[90],[1556],[22928],{"nctId":22941,"briefTitle":22942,"status":195,"phases":22943,"primaryCompletion":2615,"completion":2615,"start":2516,"enrollment":579,"conditions":22944,"interventions":22946},"NCT01239771","A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects",[90],[22945],"Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.",[22928],{"nctId":22948,"briefTitle":22949,"status":624,"phases":22950,"primaryCompletion":4496,"completion":4496,"start":2747,"enrollment":102,"conditions":22951,"interventions":22953},"NCT01500018","Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214",[90],[22952,19],"Drug Abuse",[22928,22954,22955,22956,22928,22928,22956],"TC-5214 Placebo","Ketamine","Phentermine",{"nctId":22958,"briefTitle":22959,"status":195,"phases":22960,"primaryCompletion":2144,"completion":2144,"start":2242,"enrollment":132,"conditions":22961,"interventions":22962},"NCT01145768","To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days",[90],[19],[22928,22928],{"nctId":22964,"briefTitle":22965,"status":195,"phases":22966,"primaryCompletion":3862,"completion":3862,"start":2406,"enrollment":5898,"conditions":22967,"interventions":22968},"NCT01175564","To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects",[90],[19],[22928],{"nctId":22970,"briefTitle":22971,"status":443,"phases":22972,"primaryCompletion":4496,"completion":4496,"start":2542,"enrollment":486,"conditions":22973,"interventions":22975},"NCT01359618","Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart",[90],[22974],"Healthy Male",[22928,2255],{"nctId":22977,"briefTitle":22978,"status":195,"phases":22979,"primaryCompletion":2736,"completion":2736,"start":6709,"enrollment":5898,"conditions":22980,"interventions":22981},"NCT01392820","A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers",[90],[19],[22928],{"nctId":22983,"briefTitle":22984,"status":443,"phases":22985,"primaryCompletion":2105,"completion":2105,"start":2675,"enrollment":1395,"conditions":22986,"interventions":22988},"NCT01403922","To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension",[90],[22987],"Chronic Hypertension",[22928,22928],{"nctId":22990,"briefTitle":22991,"status":195,"phases":22992,"primaryCompletion":6709,"completion":6709,"start":2349,"enrollment":1448,"conditions":22993,"interventions":22995},"NCT01240967","To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function",[90],[36,22994,15776,2279],"Patients",[22928],{"trials":22997,"activeCount":102},[22998],{"nctId":22999,"briefTitle":23000,"status":443,"phases":23001,"primaryCompletion":2105,"completion":2105,"start":2433,"enrollment":7698,"conditions":23002,"interventions":23003},"NCT01288079","A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.",[91],[18697],[22928,18854],{"trials":23005,"activeCount":102},[23006,23013,23021,23028,23035],{"nctId":23007,"briefTitle":23008,"status":195,"phases":23009,"primaryCompletion":4580,"completion":4580,"start":2242,"enrollment":23010,"conditions":23011,"interventions":23012},"NCT01157078","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)",[92],319,[18697,18734],[22928],{"nctId":23014,"briefTitle":23015,"status":195,"phases":23016,"primaryCompletion":2366,"completion":2366,"start":2242,"enrollment":23017,"conditions":23018,"interventions":23020},"NCT01152554","A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder",[92],813,[18697,23019,18734],"MDD",[22928],{"nctId":23022,"briefTitle":23023,"status":195,"phases":23024,"primaryCompletion":2571,"completion":2571,"start":3862,"enrollment":23025,"conditions":23026,"interventions":23027},"NCT01180400","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder",[92],295,[18697,18734],[22928],{"nctId":23029,"briefTitle":23030,"status":195,"phases":23031,"primaryCompletion":2747,"completion":2747,"start":3862,"enrollment":23032,"conditions":23033,"interventions":23034},"NCT01197508","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.",[92],696,[18697],[22928],{"nctId":23036,"briefTitle":23023,"status":195,"phases":23037,"primaryCompletion":2747,"completion":2747,"start":2242,"enrollment":23038,"conditions":23039,"interventions":23040},"NCT01153347",[92],2409,[18697,18734],[22928],{"trials":23042,"activeCount":102},[],{"trials":23044,"activeCount":102},[],{"intervention":12588,"totalTrials":1638,"cells":23046},{"EARLY_PHASE1":23047,"PHASE1":23049,"PHASE2":23099,"PHASE3":23101,"PHASE4":23131,"NA":23133},{"trials":23048,"activeCount":102},[],{"trials":23050,"activeCount":102},[23051,23055,23059,23067,23071,23079,23086,23093],{"nctId":2092,"briefTitle":2093,"status":195,"phases":23052,"primaryCompletion":2077,"completion":2077,"start":2095,"enrollment":1130,"conditions":23053,"interventions":23054},[90],[22],[2098,2044,2098,2099],{"nctId":12579,"briefTitle":12580,"status":195,"phases":23056,"primaryCompletion":12582,"completion":12582,"start":1007,"enrollment":507,"conditions":23057,"interventions":23058},[90],[5851],[12585,5887,12586,12587,12588,12589],{"nctId":23060,"briefTitle":23061,"status":195,"phases":23062,"primaryCompletion":461,"completion":23063,"start":23064,"enrollment":14693,"conditions":23065,"interventions":23066},"NCT02197234","Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC",[90],"2024-06-03","2014-12-22",[3864],[12588,12577],{"nctId":12599,"briefTitle":12600,"status":195,"phases":23068,"primaryCompletion":2579,"completion":2579,"start":2104,"enrollment":2069,"conditions":23069,"interventions":23070},[90],[7267],[12604,5887,12588],{"nctId":23072,"briefTitle":23073,"status":195,"phases":23074,"primaryCompletion":23075,"completion":23075,"start":461,"enrollment":11272,"conditions":23076,"interventions":23077},"NCT02406261","A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants",[90],"2015-08-31",[19],[12640,12588,5870,5870,23078,12640],"Donepezil",{"nctId":23080,"briefTitle":23081,"status":195,"phases":23082,"primaryCompletion":687,"completion":687,"start":4580,"enrollment":14693,"conditions":23083,"interventions":23084},"NCT01486433","The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects",[90],[13022],[12588,19198,23085],"omefas",{"nctId":23087,"briefTitle":23088,"status":195,"phases":23089,"primaryCompletion":3827,"completion":3827,"start":2220,"enrollment":1757,"conditions":23090,"interventions":23091},"NCT00736606","A Study to Assess Co-Administered AZD9056 (Steady State) and Simvastatin (Single Dose) in Healthy Volunteers",[90],[36],[2098,23092],"AZD9056 + simvastatin",{"nctId":23094,"briefTitle":23095,"status":195,"phases":23096,"primaryCompletion":2144,"completion":2144,"start":2212,"enrollment":3811,"conditions":23097,"interventions":23098},"NCT01096940","Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin",[90],[22],[15883,2098],{"trials":23100,"activeCount":102},[],{"trials":23102,"activeCount":102},[23103,23107,23111,23115,23119,23123],{"nctId":12711,"briefTitle":12712,"status":195,"phases":23104,"completion":6370,"start":6651,"enrollment":1300,"conditions":23105,"interventions":23106},[92],[12715],[5887,12588],{"nctId":12792,"briefTitle":12793,"status":195,"phases":23108,"completion":4285,"start":7447,"enrollment":12795,"conditions":23109,"interventions":23110},[92],[12760],[5887,12588,12587],{"nctId":12828,"briefTitle":12829,"status":195,"phases":23112,"completion":3990,"start":12831,"enrollment":12832,"conditions":23113,"interventions":23114},[92],[12760],[5887,12587,12835,12588],{"nctId":12850,"briefTitle":12851,"status":195,"phases":23116,"primaryCompletion":3827,"completion":3827,"start":5725,"enrollment":12853,"conditions":23117,"interventions":23118},[92],[12760,12789,12540],[5887,6905,12588],{"nctId":12888,"briefTitle":12889,"status":195,"phases":23120,"completion":4285,"start":12891,"enrollment":12892,"conditions":23121,"interventions":23122},[92],[12760],[5887,12587,12588],{"nctId":23124,"briefTitle":23125,"status":195,"phases":23126,"primaryCompletion":2152,"completion":2152,"start":2414,"enrollment":23127,"conditions":23128,"interventions":23130},"NCT00812955","Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (\"Bad Cholesterol\") and Triglycerides",[92],474,[23129],"Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",[12566,2098],{"trials":23132,"activeCount":102},[],{"trials":23134,"activeCount":102},[],{"intervention":15914,"totalTrials":963,"cells":23136},{"EARLY_PHASE1":23137,"PHASE1":23139,"PHASE2":23141,"PHASE3":23161,"PHASE4":23215,"NA":23217},{"trials":23138,"activeCount":102},[],{"trials":23140,"activeCount":102},[],{"trials":23142,"activeCount":102},[23143,23147,23153,23157],{"nctId":15908,"briefTitle":15909,"status":195,"phases":23144,"completion":4256,"start":15911,"enrollment":6346,"conditions":23145,"interventions":23146},[91],[31],[15914,2448],{"nctId":23148,"briefTitle":23149,"status":443,"phases":23150,"completion":3809,"start":13575,"enrollment":10196,"conditions":23151,"interventions":23152},"NCT00261417","Dose Response Study in Japanese Patients",[91],[31],[15914],{"nctId":15916,"briefTitle":15917,"status":443,"phases":23154,"primaryCompletion":6562,"completion":6562,"start":4285,"enrollment":221,"conditions":23155,"interventions":23156},[91],[2089],[15914,15893],{"nctId":19009,"briefTitle":19010,"status":443,"phases":23158,"completion":12905,"start":9065,"enrollment":1428,"conditions":23159,"interventions":23160},[91],[31],[15914,2173],{"trials":23162,"activeCount":102},[23163,23171,23175,23181,23187,23194,23200,23207,23211],{"nctId":23164,"briefTitle":23165,"status":443,"phases":23166,"completion":5742,"start":4285,"enrollment":23167,"conditions":23168,"interventions":23169},"NCT00255541","GALLANT 4 Tesaglitazar vs. Glibenclamide",[92],580,[31],[15914,23170],"Glibenclamide",{"nctId":19021,"briefTitle":19022,"status":443,"phases":23172,"completion":2087,"start":8692,"enrollment":19024,"conditions":23173,"interventions":23174},[92],[31],[15914,2173],{"nctId":23176,"briefTitle":23177,"status":443,"phases":23178,"completion":7342,"start":4285,"enrollment":1395,"conditions":23179,"interventions":23180},"NCT00252772","GALLANT 2 Tesaglitazar vs. Placebo",[92],[31],[15914],{"nctId":23182,"briefTitle":23183,"status":443,"phases":23184,"completion":5742,"start":3809,"enrollment":1078,"conditions":23185,"interventions":23186},"NCT00300105","GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes",[92],[31],[15914],{"nctId":23188,"briefTitle":23189,"status":443,"phases":23190,"completion":13014,"start":5796,"enrollment":18649,"conditions":23191,"interventions":23192},"NCT00252876","GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes",[92],[31],[23193],"tesaglitazar",{"nctId":23195,"briefTitle":23196,"status":443,"phases":23197,"primaryCompletion":5742,"completion":5742,"start":9944,"enrollment":19799,"conditions":23198,"interventions":23199},"NCT00229710","GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes",[92],[2089],[15914],{"nctId":23201,"briefTitle":23202,"status":443,"phases":23203,"completion":5742,"start":13047,"enrollment":23204,"conditions":23205,"interventions":23206},"NCT00252837","GALLANT 22 Tesaglitazar vs. Placebo",[92],475,[31],[15914],{"nctId":19122,"briefTitle":19123,"status":443,"phases":23208,"completion":5742,"start":5796,"enrollment":9987,"conditions":23209,"interventions":23210},[92],[31],[15914,2173,19127],{"nctId":15966,"briefTitle":15967,"status":443,"phases":23212,"primaryCompletion":5742,"completion":5742,"start":5796,"enrollment":3654,"conditions":23213,"interventions":23214},[92],[2089],[15914,2448],{"trials":23216,"activeCount":102},[],{"trials":23218,"activeCount":102},[],{"intervention":9882,"totalTrials":1757,"cells":23220},{"EARLY_PHASE1":23221,"PHASE1":23223,"PHASE2":23225,"PHASE3":23260,"PHASE4":23292,"NA":23294},{"trials":23222,"activeCount":102},[],{"trials":23224,"activeCount":102},[],{"trials":23226,"activeCount":102},[23227,23234,23242,23246,23253],{"nctId":23228,"briefTitle":23229,"status":195,"phases":23230,"primaryCompletion":687,"completion":687,"start":2747,"enrollment":1130,"conditions":23231,"interventions":23232},"NCT01551888","Pharmacokinetic, Safety and Tolerability Study of Aclidinium\u002FFormoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[91],[6083],[23233,9882],"Aclidinium\u002Fformoterol 400\u002F12μg",{"nctId":23235,"briefTitle":23236,"status":195,"phases":23237,"primaryCompletion":2212,"completion":2212,"start":2152,"enrollment":23238,"conditions":23239,"interventions":23240},"NCT00929708","Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],329,[10066],[23241,9866],"AZD3199",{"nctId":9860,"briefTitle":9861,"status":195,"phases":23243,"completion":4299,"start":7448,"enrollment":3125,"conditions":23244,"interventions":23245},[91],[9864],[9842,9866],{"nctId":23247,"briefTitle":23248,"status":195,"phases":23249,"primaryCompletion":4915,"completion":4915,"start":2220,"enrollment":1543,"conditions":23250,"interventions":23252},"NCT00736489","Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199",[91],[16,23251],"Airway Obstruction",[23241,9882],{"nctId":23254,"briefTitle":23255,"status":195,"phases":23256,"primaryCompletion":2243,"completion":2243,"start":2056,"enrollment":18672,"conditions":23257,"interventions":23258},"NCT01048333","Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®",[91],[28],[9882,23259],"Salmeterol",{"trials":23261,"activeCount":102},[23262,23266,23270,23274,23280,23284,23288],{"nctId":9870,"briefTitle":9871,"status":195,"phases":23263,"completion":6572,"start":3810,"enrollment":170,"conditions":23264,"interventions":23265},[92],[16],[9842,9857,9866],{"nctId":9876,"briefTitle":9877,"status":195,"phases":23267,"primaryCompletion":2570,"completion":2570,"start":2056,"enrollment":9879,"conditions":23268,"interventions":23269},[92],[28],[6190,9882],{"nctId":9914,"briefTitle":9915,"status":195,"phases":23271,"completion":6780,"start":5797,"enrollment":170,"conditions":23272,"interventions":23273},[92],[16],[9842,9857,9866],{"nctId":23275,"briefTitle":23276,"status":195,"phases":23277,"primaryCompletion":2516,"completion":6709,"start":2055,"enrollment":17,"conditions":23278,"interventions":23279},"NCT01047553","Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients",[92],[28],[9882],{"nctId":9991,"briefTitle":9992,"status":195,"phases":23281,"completion":9075,"start":3810,"enrollment":9994,"conditions":23282,"interventions":23283},[92],[16],[9842,9857,9866],{"nctId":10006,"briefTitle":10007,"status":195,"phases":23285,"completion":7494,"start":3990,"enrollment":486,"conditions":23286,"interventions":23287},[92],[16],[9866,9842],{"nctId":19515,"briefTitle":19516,"status":195,"phases":23289,"completion":6718,"start":6370,"enrollment":19518,"conditions":23290,"interventions":23291},[92],[16],[9972,9882,19521],{"trials":23293,"activeCount":102},[],{"trials":23295,"activeCount":102},[],{"intervention":23297,"totalTrials":2222,"cells":23298},"NKTR-118",{"EARLY_PHASE1":23299,"PHASE1":23301,"PHASE2":23340,"PHASE3":23350,"PHASE4":23386,"NA":23388},{"trials":23300,"activeCount":102},[],{"trials":23302,"activeCount":102},[23303,23312,23319,23325,23333],{"nctId":23304,"briefTitle":23305,"status":195,"phases":23306,"primaryCompletion":6709,"completion":6709,"start":12721,"enrollment":1864,"conditions":23307,"interventions":23310},"NCT01325415","A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects",[90],[23308,23309],"Amount of NKTR-118 in Blood","Variation in the Heart's Electrical Cycle",[23297,23311],"moxifloxacin",{"nctId":23313,"briefTitle":23314,"status":195,"phases":23315,"primaryCompletion":10063,"completion":10063,"start":687,"enrollment":434,"conditions":23316,"interventions":23318},"NCT01533870","Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118",[90],[23317],"Drug Induced Constipation",[23297,2215],{"nctId":23320,"briefTitle":23321,"status":195,"phases":23322,"primaryCompletion":6709,"completion":6709,"start":2570,"enrollment":4286,"conditions":23323,"interventions":23324},"NCT01318655","Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects",[90],[19],[23297],{"nctId":23326,"briefTitle":23327,"status":195,"phases":23328,"primaryCompletion":4496,"completion":4496,"start":2366,"enrollment":434,"conditions":23329,"interventions":23331},"NCT01520896","Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118",[90],[22858,36,23330],"Drug- Drug Interactions",[23297,23332],"Ketoconazole",{"nctId":23334,"briefTitle":23335,"status":195,"phases":23336,"primaryCompletion":4580,"completion":4580,"start":6709,"enrollment":1130,"conditions":23337,"interventions":23339},"NCT01392807","Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function",[90],[23338],"Hepatic; Functional Disturbance",[23297],{"trials":23341,"activeCount":102},[23342],{"nctId":23343,"briefTitle":23344,"status":195,"phases":23345,"primaryCompletion":2077,"completion":2320,"start":4298,"enrollment":23346,"conditions":23347,"interventions":23349},"NCT00600119","A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)",[91],207,[23348],"Opioid Induced Constipation (OIC)",[23297],{"trials":23351,"activeCount":102},[23352,23359,23368,23374,23380],{"nctId":23353,"briefTitle":23354,"status":443,"phases":23355,"primaryCompletion":2432,"completion":2432,"start":2542,"enrollment":1638,"conditions":23356,"interventions":23358},"NCT01384292","Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain",[92],[23357],"Opioid-Induced Constipation",[23297,23297],{"nctId":23360,"briefTitle":23361,"status":195,"phases":23362,"primaryCompletion":2616,"completion":2616,"start":12721,"enrollment":23363,"conditions":23364,"interventions":23366},"NCT01336205","Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation",[92],844,[23365],"Opioid-Induced Constipation (OIC)",[23297,23367],"Usual care",{"nctId":23369,"briefTitle":23370,"status":195,"phases":23371,"primaryCompletion":2432,"completion":2432,"start":2570,"enrollment":4625,"conditions":23372,"interventions":23373},"NCT01323790","Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation",[92],[23365],[23297,23297],{"nctId":23375,"briefTitle":23376,"status":195,"phases":23377,"primaryCompletion":2432,"completion":2432,"start":6709,"enrollment":817,"conditions":23378,"interventions":23379},"NCT01395524","A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation",[92],[23365],[23297,23297],{"nctId":23381,"briefTitle":23370,"status":195,"phases":23382,"primaryCompletion":2105,"completion":2105,"start":2570,"enrollment":23383,"conditions":23384,"interventions":23385},"NCT01309841",[92],652,[23365],[23297,23297],{"trials":23387,"activeCount":102},[],{"trials":23389,"activeCount":102},[],{"intervention":4931,"totalTrials":2222,"cells":23391},{"EARLY_PHASE1":23392,"PHASE1":23394,"PHASE2":23439,"PHASE3":23445,"PHASE4":23466,"NA":23468},{"trials":23393,"activeCount":102},[],{"trials":23395,"activeCount":102},[23396,23403,23411,23417,23423,23427,23433],{"nctId":23397,"briefTitle":23398,"status":195,"phases":23399,"primaryCompletion":2220,"completion":2220,"start":2507,"enrollment":1757,"conditions":23400,"interventions":23401},"NCT00709553","Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)",[90],[19],[23402,4931],"midazolam",{"nctId":23404,"briefTitle":23405,"status":195,"phases":23406,"completion":2414,"start":2524,"enrollment":1448,"conditions":23407,"interventions":23408},"NCT00713336","Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval",[90],[19],[4931,2255,23409,23410,23409,4931,4931],"ZD4054 Placebo","Moxifloxacin placebo",{"nctId":23412,"briefTitle":23413,"status":195,"phases":23414,"primaryCompletion":3862,"completion":12721,"start":2350,"enrollment":520,"conditions":23415,"interventions":23416},"NCT00997945","10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies",[90],[157],[4931],{"nctId":23418,"briefTitle":23419,"status":195,"phases":23420,"primaryCompletion":2220,"completion":2220,"start":2524,"enrollment":1710,"conditions":23421,"interventions":23422},"NCT00710047","Food Effect Study of a Single Dose of ZD4054 (Zibotentan)",[90],[36],[4931],{"nctId":6639,"briefTitle":6640,"status":195,"phases":23424,"primaryCompletion":2580,"completion":2077,"start":2087,"enrollment":3811,"conditions":23425,"interventions":23426},[90],[416],[4931,369],{"nctId":23428,"briefTitle":23429,"status":195,"phases":23430,"completion":2077,"start":2251,"enrollment":579,"conditions":23431,"interventions":23432},"NCT00672581","Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment",[90],[6914],[4931],{"nctId":23434,"briefTitle":23435,"status":195,"phases":23436,"completion":2220,"start":2524,"enrollment":5876,"conditions":23437,"interventions":23438},"NCT00713791","Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.",[90],[19],[4931,4931,4931,4931],{"trials":23440,"activeCount":102},[23441],{"nctId":4925,"briefTitle":4926,"status":195,"phases":23442,"primaryCompletion":2056,"completion":2056,"start":2220,"enrollment":4928,"conditions":23443,"interventions":23444},[91],[3864,3174],[4931,345],{"trials":23446,"activeCount":102},[23447,23455,23459],{"nctId":23448,"briefTitle":23449,"status":443,"phases":23450,"primaryCompletion":2516,"completion":2615,"start":6710,"enrollment":23451,"conditions":23452,"interventions":23453},"NCT00626548","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer",[92],2577,[416],[4931,23454],"Palcebo",{"nctId":6706,"briefTitle":6707,"status":195,"phases":23456,"primaryCompletion":2615,"completion":6709,"start":6710,"enrollment":6711,"conditions":23457,"interventions":23458},[92],[416],[369,4931],{"nctId":23460,"briefTitle":23461,"status":195,"phases":23462,"primaryCompletion":2406,"completion":2675,"start":2169,"enrollment":23463,"conditions":23464,"interventions":23465},"NCT00554229","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases",[92],896,[416],[4931],{"trials":23467,"activeCount":102},[],{"trials":23469,"activeCount":102},[],{"intervention":2061,"totalTrials":269,"cells":23471},{"EARLY_PHASE1":23472,"PHASE1":23474,"PHASE2":23501,"PHASE3":23503,"PHASE4":23536,"NA":23538},{"trials":23473,"activeCount":102},[],{"trials":23475,"activeCount":102},[23476,23480,23487,23495],{"nctId":2052,"briefTitle":2053,"status":195,"phases":23477,"primaryCompletion":2055,"completion":2056,"start":2057,"enrollment":520,"conditions":23478,"interventions":23479},[90],[2059],[2044,2061,2062],{"nctId":23481,"briefTitle":23482,"status":443,"phases":23483,"primaryCompletion":2746,"completion":2746,"start":2432,"enrollment":1979,"conditions":23484,"interventions":23485},"NCT01525225","Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations\u002FLevels in Pediatric Subjects With T2DM",[90],[22],[2565,2108,2475,23486,2061],"Saxagliptin\u002FMetformin XR FDC",{"nctId":23488,"briefTitle":23489,"status":195,"phases":23490,"primaryCompletion":2055,"completion":2055,"start":2057,"enrollment":1710,"conditions":23491,"interventions":23492},"NCT01192139","Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)",[90],[2631],[18965,23493,23494],"metformin XR","saxagliptin + metformin XR",{"nctId":23496,"briefTitle":23497,"status":624,"phases":23498,"primaryCompletion":2570,"completion":2570,"start":2570,"enrollment":102,"conditions":23499,"interventions":23500},"NCT01305551","BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States",[90],[31],[2108,2061,23486],{"trials":23502,"activeCount":102},[],{"trials":23504,"activeCount":102},[23505,23511,23515,23519,23526,23532],{"nctId":23506,"briefTitle":23507,"status":195,"phases":23508,"primaryCompletion":2243,"completion":2243,"start":2151,"enrollment":19807,"conditions":23509,"interventions":23510},"NCT00918138","Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg",[92],[31],[2108,2061,2061],{"nctId":2477,"briefTitle":2478,"status":195,"phases":23512,"primaryCompletion":2480,"completion":2480,"start":2481,"enrollment":2482,"conditions":23513,"interventions":23514},[92],[31],[2108,2061,2044],{"nctId":2521,"briefTitle":2522,"status":195,"phases":23516,"primaryCompletion":2151,"completion":2151,"start":2524,"enrollment":2525,"conditions":23517,"interventions":23518},[92],[31],[2044,2061],{"nctId":23520,"briefTitle":23521,"status":195,"phases":23522,"primaryCompletion":2489,"completion":2489,"start":2151,"enrollment":23523,"conditions":23524,"interventions":23525},"NCT00960076","An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes",[92],282,[31],[2108,2061,2061],{"nctId":23527,"briefTitle":23528,"status":195,"phases":23529,"primaryCompletion":6468,"completion":6468,"start":10063,"enrollment":579,"conditions":23530,"interventions":23531},"NCT01434186","A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",[92],[2089],[2475,2061,2108],{"nctId":2688,"briefTitle":2689,"status":195,"phases":23533,"primaryCompletion":2243,"completion":2243,"start":2320,"enrollment":2691,"conditions":23534,"interventions":23535},[92],[22],[2044,2061,2061],{"trials":23537,"activeCount":102},[],{"trials":23539,"activeCount":102},[],{"intervention":16338,"totalTrials":269,"cells":23541},{"EARLY_PHASE1":23542,"PHASE1":23544,"PHASE2":23593,"PHASE3":23611,"PHASE4":23621,"NA":23623},{"trials":23543,"activeCount":102},[],{"trials":23545,"activeCount":102},[23546,23552,23560,23567,23571,23579,23586],{"nctId":23547,"briefTitle":23548,"status":195,"phases":23549,"primaryCompletion":1528,"completion":1528,"start":3163,"enrollment":1710,"conditions":23550,"interventions":23551},"NCT05457270","A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.",[90],[36],[16338],{"nctId":23553,"briefTitle":23554,"status":195,"phases":23555,"primaryCompletion":23556,"completion":23556,"start":23557,"enrollment":579,"conditions":23558,"interventions":23559},"NCT04232345","A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers",[90],"2021-03-11","2020-01-16",[2723],[16338],{"nctId":23561,"briefTitle":23562,"status":195,"phases":23563,"primaryCompletion":23564,"completion":23564,"start":1902,"enrollment":1638,"conditions":23565,"interventions":23566},"NCT05052710","Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam",[90],"2021-11-29",[36],[16338,5870],{"nctId":16332,"briefTitle":16333,"status":195,"phases":23568,"primaryCompletion":16335,"completion":16335,"start":3674,"enrollment":544,"conditions":23569,"interventions":23570},[90],[36],[16338,5911],{"nctId":23572,"briefTitle":23573,"status":195,"phases":23574,"primaryCompletion":23575,"completion":23575,"start":23576,"enrollment":3717,"conditions":23577,"interventions":23578},"NCT03136991","A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease",[90],"2017-11-22","2017-05-15",[2619],[16338],{"nctId":23580,"briefTitle":23581,"status":195,"phases":23582,"primaryCompletion":23583,"completion":23583,"start":14811,"enrollment":5876,"conditions":23584,"interventions":23585},"NCT04949438","A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers",[90],"2022-03-04",[2279],[16338],{"nctId":23587,"briefTitle":23588,"status":443,"phases":23589,"primaryCompletion":13102,"completion":13102,"start":13787,"enrollment":4877,"conditions":23590,"interventions":23591},"NCT02712372","A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects",[90],[2619],[16338,23592],"AZD4831 placebo",{"trials":23594,"activeCount":102},[23595,23603],{"nctId":23596,"briefTitle":23597,"status":195,"phases":23598,"primaryCompletion":3263,"completion":3263,"start":23599,"enrollment":8138,"conditions":23600,"interventions":23602},"NCT05638737","A Study in Participants With Non-cirrhotic NASH With Fibrosis",[91],"2022-10-26",[23601],"Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis",[16338],{"nctId":23604,"briefTitle":23605,"status":443,"phases":23606,"primaryCompletion":23607,"completion":23607,"start":23608,"enrollment":6275,"conditions":23609,"interventions":23610},"NCT03756285","Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.",[91],"2020-05-07","2018-12-11",[1520],[16338],{"trials":23612,"activeCount":102},[23613],{"nctId":23614,"briefTitle":23615,"status":195,"phases":23616,"primaryCompletion":23617,"completion":23617,"start":7414,"enrollment":23618,"conditions":23619,"interventions":23620},"NCT04986202","Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%",[91,92],"2024-03-27",711,[2609],[16338],{"trials":23622,"activeCount":102},[],{"trials":23624,"activeCount":102},[],{"intervention":20213,"totalTrials":4343,"cells":23626},{"EARLY_PHASE1":23627,"PHASE1":23629,"PHASE2":23631,"PHASE3":23646,"PHASE4":23700,"NA":23702},{"trials":23628,"activeCount":102},[],{"trials":23630,"activeCount":102},[],{"trials":23632,"activeCount":102},[23633,23639],{"nctId":23634,"briefTitle":23635,"status":195,"phases":23636,"completion":4916,"start":9124,"enrollment":2045,"conditions":23637,"interventions":23638},"NCT00318539","Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study",[91],[18882],[20213],{"nctId":23640,"briefTitle":23641,"status":443,"phases":23642,"primaryCompletion":2086,"completion":2086,"start":5725,"enrollment":723,"conditions":23643,"interventions":23645},"NCT00681668","Quetiapine in Postpartum Depression",[91],[23644],"Postpartum Depressive Disorder",[20213],{"trials":23647,"activeCount":102},[23648,23655,23662,23668,23681,23689,23696],{"nctId":23649,"briefTitle":23650,"status":195,"phases":23651,"completion":6719,"start":3990,"enrollment":3000,"conditions":23652,"interventions":23654},"NCT00254813","Fast Titration Of Quetiapine Versus Currently Approved Titration",[92],[23653],"Psychotic Disorders",[20213],{"nctId":23656,"briefTitle":23657,"status":195,"phases":23658,"completion":6719,"start":9075,"enrollment":4546,"conditions":23659,"interventions":23661},"NCT00328978","Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects",[92],[33,23660],"Schizoaffective Disorders",[20213],{"nctId":23663,"briefTitle":23664,"status":443,"phases":23665,"primaryCompletion":5725,"completion":5725,"start":6718,"conditions":23666,"interventions":23667},"NCT00486798","FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis",[92],[23653,33,18732],[20213],{"nctId":23669,"briefTitle":23670,"status":195,"phases":23671,"completion":7439,"start":7494,"enrollment":23672,"conditions":23673,"interventions":23674},"NCT00351910","Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder",[92],494,[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],"Amitriptyline","Citalopram","Escitalopram","Fluoxetine","Sertraline","Venlafaxine",{"nctId":23682,"briefTitle":23683,"status":443,"phases":23684,"primaryCompletion":5742,"completion":5742,"start":6562,"enrollment":4286,"conditions":23685,"interventions":23687},"NCT00302770","Efficacy of Quetiapine in Generalised Social Anxiety Disorder",[92],[23686],"Social Anxiety Disorder",[23688],"quetiapine",{"nctId":23690,"briefTitle":23691,"status":195,"phases":23692,"primaryCompletion":4298,"completion":4298,"start":5563,"enrollment":23693,"conditions":23694,"interventions":23695},"NCT00388973","Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder",[92],338,[18697],[20213],{"nctId":20208,"briefTitle":20209,"status":443,"phases":23697,"primaryCompletion":4915,"completion":4915,"start":3827,"enrollment":8185,"conditions":23698,"interventions":23699},[92],[20045],[20213,18800],{"trials":23701,"activeCount":102},[],{"trials":23703,"activeCount":102},[],{"intervention":13870,"totalTrials":4343,"cells":23705},{"EARLY_PHASE1":23706,"PHASE1":23708,"PHASE2":23729,"PHASE3":23768,"PHASE4":23774,"NA":23776},{"trials":23707,"activeCount":102},[],{"trials":23709,"activeCount":102},[23710,23716,23722],{"nctId":23711,"briefTitle":23712,"status":195,"phases":23713,"primaryCompletion":2168,"completion":2168,"start":6562,"enrollment":3007,"conditions":23714,"interventions":23715},"NCT00431275","Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody",[90],[410],[13870,13870],{"nctId":23717,"briefTitle":23718,"status":443,"phases":23719,"primaryCompletion":2056,"completion":2056,"start":4298,"enrollment":507,"conditions":23720,"interventions":23721},"NCT00585000","A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma",[90],[410],[13870],{"nctId":23723,"briefTitle":23724,"status":195,"phases":23725,"primaryCompletion":2243,"completion":2243,"start":7342,"enrollment":2260,"conditions":23726,"interventions":23727},"NCT00372853","Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma",[90],[7102],[13870,23728,13870,23728],"SU011248",{"trials":23730,"activeCount":102},[23731,23739,23745,23752,23759],{"nctId":23732,"briefTitle":23733,"status":195,"phases":23734,"primaryCompletion":2251,"completion":2114,"start":7494,"enrollment":2045,"conditions":23735,"interventions":23737},"NCT00312975","Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)",[91],[23736],"Carcinoma, Non-small-cell Lung",[13870,23738],"best supportive care",{"nctId":23740,"briefTitle":23741,"status":195,"phases":23742,"primaryCompletion":2524,"completion":2524,"start":7494,"enrollment":507,"conditions":23743,"interventions":23744},"NCT00313794","Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment",[91],[5368],[13870],{"nctId":23746,"briefTitle":23747,"status":195,"phases":23748,"primaryCompletion":2055,"completion":2055,"start":2329,"enrollment":17,"conditions":23749,"interventions":23751},"NCT00254579","Study of CP-675,206 in Refractory Melanoma",[91],[23750],"Refractory Melanoma",[13870],{"nctId":23753,"briefTitle":23754,"status":195,"phases":23755,"primaryCompletion":6718,"completion":688,"start":6563,"enrollment":23756,"conditions":23757,"interventions":23758},"NCT00086489","CP-675,206 In Patients With Advanced Melanoma",[91],118,[16016],[13870,13870],{"nctId":23760,"briefTitle":23761,"status":195,"phases":23762,"primaryCompletion":3734,"completion":3734,"start":23763,"enrollment":1543,"conditions":23764,"interventions":23767},"NCT00378482","A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.",[91],"2007-03-05",[5368,410,23765,417,3841,23766],"Prostatic Neoplasms","Patients Who Have\u002FHave Had Melanoma and Other Tumors",[13870],{"trials":23769,"activeCount":102},[23770],{"nctId":13863,"briefTitle":13864,"status":195,"phases":23771,"primaryCompletion":2144,"completion":2144,"start":2087,"enrollment":13866,"conditions":23772,"interventions":23773},[92],[410],[13869,13870,13871],{"trials":23775,"activeCount":102},[],{"trials":23777,"activeCount":102},[],{"intervention":12640,"totalTrials":370,"cells":23779},{"EARLY_PHASE1":23780,"PHASE1":23782,"PHASE2":23814,"PHASE3":23816,"PHASE4":23843,"NA":23845},{"trials":23781,"activeCount":102},[],{"trials":23783,"activeCount":102},[23784,23793,23800,23804,23808],{"nctId":23785,"briefTitle":23786,"status":195,"phases":23787,"primaryCompletion":23788,"completion":23788,"start":23789,"enrollment":477,"conditions":23790,"interventions":23791},"NCT02568397","A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants",[90],"2016-01-31","2015-10-31",[19],[12640,23792],"Dabigatran etexilate",{"nctId":23794,"briefTitle":23795,"status":195,"phases":23796,"primaryCompletion":23797,"completion":23797,"start":23788,"enrollment":1336,"conditions":23798,"interventions":23799},"NCT02663128","A Study of Lanabecestat (LY3314814) in Healthy Participants",[90],"2016-03-31",[19],[12640],{"nctId":23072,"briefTitle":23073,"status":195,"phases":23801,"primaryCompletion":23075,"completion":23075,"start":461,"enrollment":11272,"conditions":23802,"interventions":23803},[90],[19],[12640,12588,5870,5870,23078,12640],{"nctId":12633,"briefTitle":12634,"status":195,"phases":23805,"primaryCompletion":12636,"completion":12636,"start":12637,"enrollment":2069,"conditions":23806,"interventions":23807},[90],[19],[12640,5887],{"nctId":23809,"briefTitle":23810,"status":195,"phases":23811,"primaryCompletion":23788,"completion":23788,"start":19335,"enrollment":520,"conditions":23812,"interventions":23813},"NCT02540668","A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants",[90],[19],[12640,2197],{"trials":23815,"activeCount":102},[],{"trials":23817,"activeCount":102},[23818,23826,23835],{"nctId":23819,"briefTitle":23820,"status":443,"phases":23821,"primaryCompletion":23822,"completion":23822,"start":1626,"enrollment":23823,"conditions":23824,"interventions":23825},"NCT02783573","A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia",[92],"2018-09-28",1722,[18867],[12640],{"nctId":23827,"briefTitle":23828,"status":443,"phases":23829,"primaryCompletion":81,"completion":81,"start":23830,"enrollment":23831,"conditions":23832,"interventions":23834},"NCT02245737","An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease",[91,92],"2014-09-30",2218,[23833],"Alzheimer´s Disease",[12640],{"nctId":23836,"briefTitle":23837,"status":443,"phases":23838,"primaryCompletion":23839,"completion":23839,"start":23840,"enrollment":20494,"conditions":23841,"interventions":23842},"NCT02972658","A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia",[92],"2018-10-02","2017-03-15",[18867],[12640],{"trials":23844,"activeCount":102},[],{"trials":23846,"activeCount":102},[],{"intervention":23848,"totalTrials":1855,"cells":23849},"AZD1152",{"EARLY_PHASE1":23850,"PHASE1":23852,"PHASE2":23894,"PHASE3":23896,"PHASE4":23904,"NA":23906},{"trials":23851,"activeCount":102},[],{"trials":23853,"activeCount":102},[23854,23862,23868,23874,23881,23887],{"nctId":23855,"briefTitle":23856,"status":195,"phases":23857,"primaryCompletion":2144,"completion":2615,"start":2152,"enrollment":1979,"conditions":23858,"interventions":23860},"NCT00926731","Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)",[90],[23859],"Acute Myeloid Leukemia",[23848,23861],"LDAC",{"nctId":23863,"briefTitle":23864,"status":443,"phases":23865,"completion":2252,"start":4916,"enrollment":1864,"conditions":23866,"interventions":23867},"NCT00497679","AZD1152 in Patients With Advanced Solid Malignancies-Study 3",[90],[466],[23848],{"nctId":23869,"briefTitle":23870,"status":443,"phases":23871,"primaryCompletion":2524,"completion":2320,"start":7554,"enrollment":3476,"conditions":23872,"interventions":23873},"NCT00497731","AZD1152 in Patients With Advanced Solid Malignancies-Study 1",[90],[3056],[23848],{"nctId":23875,"briefTitle":23876,"status":195,"phases":23877,"primaryCompletion":2350,"completion":2113,"start":7494,"enrollment":5189,"conditions":23878,"interventions":23880},"NCT00497991","Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia",[90],[23879],"Myeloid Leukemia",[23848],{"nctId":23882,"briefTitle":23883,"status":195,"phases":23884,"primaryCompletion":2151,"completion":2151,"start":2169,"enrollment":1710,"conditions":23885,"interventions":23886},"NCT00530699","Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)",[90],[8842],[23848],{"nctId":23888,"briefTitle":23889,"status":195,"phases":23890,"primaryCompletion":2242,"completion":2242,"start":2057,"enrollment":723,"conditions":23891,"interventions":23892},"NCT01019161","An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)",[90],[8842],[23848,23893],"C14 AZD1152",{"trials":23895,"activeCount":102},[],{"trials":23897,"activeCount":102},[23898],{"nctId":23899,"briefTitle":23900,"status":195,"phases":23901,"primaryCompletion":2542,"completion":2542,"start":2068,"enrollment":12547,"conditions":23902,"interventions":23903},"NCT00952588","Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients",[91,92],[23859],[23848,23861],{"trials":23905,"activeCount":102},[],{"trials":23907,"activeCount":102},[],{"intervention":23909,"totalTrials":1855,"cells":23910},"AZD7442",{"EARLY_PHASE1":23911,"PHASE1":23913,"PHASE2":23939,"PHASE3":23949,"PHASE4":23977,"NA":23979},{"trials":23912,"activeCount":102},[],{"trials":23914,"activeCount":102},[23915,23922,23929],{"nctId":23916,"briefTitle":23917,"status":195,"phases":23918,"primaryCompletion":23919,"completion":23919,"start":208,"enrollment":477,"conditions":23920,"interventions":23921},"NCT04507256","AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19",[90],"2021-10-19",[1387],[23909],{"nctId":23923,"briefTitle":23924,"status":195,"phases":23925,"primaryCompletion":1766,"completion":1766,"start":2122,"enrollment":451,"conditions":23926,"interventions":23928},"NCT05281601","AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics",[90],[23927],"SARS-CoV-2",[23909],{"nctId":23930,"briefTitle":23931,"status":195,"phases":23932,"primaryCompletion":23933,"completion":23933,"start":3735,"enrollment":2289,"conditions":23934,"interventions":23936},"NCT05166421","Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants",[90],"2023-07-19",[23935],"Corona Virus Disease",[23909,23937,23938,23937,23938],"AZD8895","AZD1061",{"trials":23940,"activeCount":102},[23941],{"nctId":23942,"briefTitle":23943,"status":443,"phases":23944,"primaryCompletion":23945,"completion":23945,"start":7757,"enrollment":17,"conditions":23946,"interventions":23948},"NCT05375760","A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19",[91],"2023-10-04",[23947],"Coronavirus Disease 2019 (COVID-19)",[23909,23909],{"trials":23950,"activeCount":102},[23951,23960,23969],{"nctId":23952,"briefTitle":23953,"status":195,"phases":23954,"primaryCompletion":23955,"completion":23956,"start":7466,"enrollment":23957,"conditions":23958,"interventions":23959},"NCT04723394","Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults",[92],"2021-08-21","2022-10-19",910,[1387],[23909],{"nctId":23961,"briefTitle":23962,"status":195,"phases":23963,"primaryCompletion":7663,"completion":23964,"start":23965,"enrollment":23966,"conditions":23967,"interventions":23968},"NCT04625725","Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.",[92],"2023-12-08","2020-11-21",5197,[1387],[23909],{"nctId":23970,"briefTitle":23971,"status":195,"phases":23972,"primaryCompletion":22297,"completion":23973,"start":3054,"enrollment":23974,"conditions":23975,"interventions":23976},"NCT04625972","Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults",[92],"2022-07-25",1131,[1387],[23909],{"trials":23978,"activeCount":102},[],{"trials":23980,"activeCount":102},[],{"intervention":12566,"totalTrials":1039,"cells":23982},{"EARLY_PHASE1":23983,"PHASE1":23985,"PHASE2":24013,"PHASE3":24015,"PHASE4":24021,"NA":24023},{"trials":23984,"activeCount":102},[],{"trials":23986,"activeCount":102},[23987,23991,23999,24003,24009],{"nctId":12559,"briefTitle":12560,"status":195,"phases":23988,"primaryCompletion":2220,"start":2221,"enrollment":4307,"conditions":23989,"interventions":23990},[90],[12563,12564],[12566,12567,5887],{"nctId":23992,"briefTitle":23993,"status":195,"phases":23994,"primaryCompletion":3827,"start":2220,"enrollment":579,"conditions":23995,"interventions":23997},"NCT00728780","Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5\u002F45mg Dosage Form.",[90],[12563,23996],"Pharmacokinetic Variables",[12566,23998],"ABT-335 and rosuvastatin",{"nctId":12651,"briefTitle":12652,"status":195,"phases":24000,"primaryCompletion":7544,"start":4915,"enrollment":2045,"conditions":24001,"interventions":24002},[90],[19],[12566,12567,12551],{"nctId":24004,"briefTitle":24005,"status":195,"phases":24006,"primaryCompletion":3827,"start":2507,"enrollment":3755,"conditions":24007,"interventions":24008},"NCT00719693","Assessment of the Effect of Food on ABT-143 Bioavailability",[90],[23996],[12566,12566],{"nctId":12683,"briefTitle":12684,"status":195,"phases":24010,"primaryCompletion":2414,"start":2414,"enrollment":2045,"conditions":24011,"interventions":24012},[90],[19],[12566,12567,12551],{"trials":24014,"activeCount":102},[],{"trials":24016,"activeCount":102},[24017],{"nctId":23124,"briefTitle":23125,"status":195,"phases":24018,"primaryCompletion":2152,"completion":2152,"start":2414,"enrollment":23127,"conditions":24019,"interventions":24020},[92],[23129],[12566,2098],{"trials":24022,"activeCount":102},[],{"trials":24024,"activeCount":102},[],{"intervention":24026,"totalTrials":1039,"cells":24027},"Formoterol Fumarate",{"EARLY_PHASE1":24028,"PHASE1":24030,"PHASE2":24032,"PHASE3":24044,"PHASE4":24086,"NA":24088},{"trials":24029,"activeCount":102},[],{"trials":24031,"activeCount":102},[],{"trials":24033,"activeCount":102},[24034],{"nctId":24035,"briefTitle":24036,"status":195,"phases":24037,"primaryCompletion":20972,"completion":20972,"start":1191,"enrollment":24038,"conditions":24039,"interventions":24041},"NCT02796651","Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)",[91],132,[24040],"Chronic Obstructive Pulmonary Disease - COPD",[24042,24043,24042,24042],"Formoterol fumarate","Formoterol furmarate",{"trials":24045,"activeCount":102},[24046,24054,24062,24069,24076],{"nctId":24047,"briefTitle":24048,"status":195,"phases":24049,"primaryCompletion":3228,"completion":3228,"start":2597,"enrollment":24050,"conditions":24051,"interventions":24052},"NCT03022097","Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide\u002FFormoterol Fumarate in Stabile COPD Patients",[92],1625,[10066],[24053,20252,24026],"Aclidinium bromide\u002Fformoterol Fixed-Dose Combination",{"nctId":24055,"briefTitle":24056,"status":195,"phases":24057,"primaryCompletion":2405,"completion":2405,"start":2571,"enrollment":13767,"conditions":24058,"interventions":24059},"NCT01437397","Efficacy, Safety and Tolerability of Aclidinium Bromide\u002FFormoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[92],[28],[24060,24060,24061,24026],"Aclidinium Bromide\u002FFormoterol Fumarate","Aclidinium Bromide",{"nctId":24063,"briefTitle":24064,"status":195,"phases":24065,"primaryCompletion":2746,"completion":2746,"start":4496,"enrollment":24066,"conditions":24067,"interventions":24068},"NCT01572792","Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide\u002FFormoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",[92],921,[28],[24053,24053,20252,24026],{"nctId":24070,"briefTitle":24071,"status":195,"phases":24072,"primaryCompletion":2579,"completion":2579,"start":2736,"enrollment":24073,"conditions":24074,"interventions":24075},"NCT01462942","Long-term Efficacy and Safety of Aclidinium Bromide\u002FFormoterol Fumarate Fixed-Dose Combination",[92],2443,[6083],[24060,24060,24061,24026],{"nctId":24077,"briefTitle":24078,"status":195,"phases":24079,"primaryCompletion":24080,"completion":24081,"start":24082,"enrollment":24083,"conditions":24084,"interventions":24085},"NCT01437540","Safety and Tolerability of Aclidinium Bromide\u002FFormoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",[92],"2013-03-31","2013-04-30","2011-09-19",590,[28],[24060,24026],{"trials":24087,"activeCount":102},[],{"trials":24089,"activeCount":102},[],{"intervention":15822,"totalTrials":1039,"cells":24091},{"EARLY_PHASE1":24092,"PHASE1":24094,"PHASE2":24105,"PHASE3":24107,"PHASE4":24141,"NA":24143},{"trials":24093,"activeCount":102},[],{"trials":24095,"activeCount":102},[24096],{"nctId":24097,"briefTitle":24098,"status":195,"phases":24099,"completion":2095,"start":3827,"enrollment":4286,"conditions":24100,"interventions":24103},"NCT00766025","Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin",[90],[24101,24102],"CYP2C19 Poor","Extensive Metabolizers",[24104],"Rosuvastatin Calcium",{"trials":24106,"activeCount":102},[],{"trials":24108,"activeCount":102},[24109,24116,24123,24127,24135],{"nctId":24110,"briefTitle":24111,"status":195,"phases":24112,"primaryCompletion":2168,"completion":2168,"start":7439,"enrollment":3695,"conditions":24113,"interventions":24114},"NCT00463606","A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia",[92],[12760,6903],[24115,12567,15822],"ABT-335 and rosuvastatin calcium",{"nctId":24117,"briefTitle":24118,"status":195,"phases":24119,"primaryCompletion":2405,"completion":2405,"start":2114,"enrollment":2472,"conditions":24120,"interventions":24122},"NCT01078675","An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia",[92],[24121],"Familial Hypercholesterolaemia",[15822,15822,15822],{"nctId":15816,"briefTitle":15817,"status":195,"phases":24124,"primaryCompletion":5725,"completion":5725,"start":9124,"enrollment":3613,"conditions":24125,"interventions":24126},[92],[15820],[15822,13002],{"nctId":24128,"briefTitle":24129,"status":195,"phases":24130,"primaryCompletion":6517,"completion":6517,"start":9066,"enrollment":170,"conditions":24131,"interventions":24133},"NCT00240318","A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)",[92],[24132],"Coronary Arteriosclerosis",[24134],"Rosuvastatin calcium",{"nctId":24136,"briefTitle":24137,"status":195,"phases":24138,"primaryCompletion":7494,"completion":7494,"start":5797,"enrollment":291,"conditions":24139,"interventions":24140},"NCT00225589","A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)",[92],[12818],[24134],{"trials":24142,"activeCount":102},[],{"trials":24144,"activeCount":102},[],{"intervention":24146,"totalTrials":1039,"cells":24147},"AC2993",{"EARLY_PHASE1":24148,"PHASE1":24150,"PHASE2":24152,"PHASE3":24161,"PHASE4":24197,"NA":24199},{"trials":24149,"activeCount":102},[],{"trials":24151,"activeCount":102},[],{"trials":24153,"activeCount":102},[24154],{"nctId":24155,"briefTitle":24156,"status":195,"phases":24157,"primaryCompletion":2580,"completion":2580,"start":4331,"enrollment":3172,"conditions":24158,"interventions":24159},"NCT00064714","Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes",[91],[2631],[24146,24160],"daclizumab",{"trials":24162,"activeCount":102},[24163,24170,24177,24184,24190],{"nctId":24164,"briefTitle":24165,"status":195,"phases":24166,"primaryCompletion":6563,"completion":6563,"start":12757,"enrollment":12292,"conditions":24167,"interventions":24169},"NCT00039026","Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea",[92],[24168],"Diabetes Mellitus, Non-Insulin-Dependent",[24146,24146],{"nctId":24171,"briefTitle":24172,"status":195,"phases":24173,"primaryCompletion":4256,"completion":4256,"start":12938,"enrollment":24174,"conditions":24175,"interventions":24176},"NCT00039013","Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin",[92],336,[2089],[24146,24146],{"nctId":24178,"briefTitle":24179,"status":195,"phases":24180,"primaryCompletion":6563,"completion":6563,"start":12883,"enrollment":24181,"conditions":24182,"interventions":24183},"NCT00035984","Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus",[92],734,[24168],[24146,24146],{"nctId":24185,"briefTitle":24186,"status":195,"phases":24187,"primaryCompletion":6719,"completion":6719,"start":5797,"enrollment":975,"conditions":24188,"interventions":24189},"NCT00044668","Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination",[92],[2089],[24146],{"nctId":24191,"briefTitle":24192,"status":195,"phases":24193,"primaryCompletion":6445,"completion":6445,"start":6651,"enrollment":24194,"conditions":24195,"interventions":24196},"NCT01789957","Extension Study for 2993-112",[92],225,[22],[24146],{"trials":24198,"activeCount":102},[],{"trials":24200,"activeCount":102},[],{"intervention":24202,"totalTrials":723,"cells":24203},"Symbicort Turbuhaler",{"EARLY_PHASE1":24204,"PHASE1":24206,"PHASE2":24208,"PHASE3":24210,"PHASE4":24249,"NA":24251},{"trials":24205,"activeCount":102},[],{"trials":24207,"activeCount":102},[],{"trials":24209,"activeCount":102},[],{"trials":24211,"activeCount":102},[24212,24220,24229,24236,24243],{"nctId":24213,"briefTitle":24214,"status":195,"phases":24215,"primaryCompletion":187,"completion":187,"start":24216,"enrollment":1348,"conditions":24217,"interventions":24218},"NCT04078126","Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.",[92],"2019-09-10",[6083],[24219,24202],"BFF",{"nctId":24221,"briefTitle":24222,"status":195,"phases":24223,"primaryCompletion":2251,"completion":2251,"start":2415,"enrollment":24224,"conditions":24225,"interventions":24227},"NCT00536731","Symbicort Rapihaler Therapeutic Equivalence Study",[92],742,[24226],"Bronchial Asthma",[24202,24228,19490],"Symbicort pMDI",{"nctId":24230,"briefTitle":24231,"status":195,"phases":24232,"primaryCompletion":2433,"completion":2433,"start":2095,"enrollment":24233,"conditions":24234,"interventions":24235},"NCT00839800","Study to Investigate the Efficacy of Symbicort® SMART.",[92],2091,[16],[24202,19862],{"nctId":24237,"briefTitle":24238,"status":195,"phases":24239,"primaryCompletion":2736,"completion":2736,"start":2056,"enrollment":3336,"conditions":24240,"interventions":24241},"NCT01070784","A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan",[92],[28],[24202,24242],"Drug: any available COPD treatment; investigator to decide",{"nctId":24244,"briefTitle":24245,"status":195,"phases":24246,"primaryCompletion":2068,"completion":2068,"start":7544,"enrollment":98,"conditions":24247,"interventions":24248},"NCT00837967","Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients",[92],[16],[24202,19862],{"trials":24250,"activeCount":102},[],{"trials":24252,"activeCount":102},[],{"intervention":19116,"totalTrials":723,"cells":24254},{"EARLY_PHASE1":24255,"PHASE1":24257,"PHASE2":24259,"PHASE3":24270,"PHASE4":24304,"NA":24306},{"trials":24256,"activeCount":102},[],{"trials":24258,"activeCount":102},[],{"trials":24260,"activeCount":102},[24261],{"nctId":24262,"briefTitle":24263,"status":443,"phases":24264,"primaryCompletion":1023,"completion":1023,"start":24265,"enrollment":24266,"conditions":24267,"interventions":24268},"NCT04492722","A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease",[91],"2020-10-01",613,[2134],[24269,19116],"AZD5718",{"trials":24271,"activeCount":102},[24272,24281,24290,24300],{"nctId":24273,"briefTitle":24274,"status":195,"phases":24275,"primaryCompletion":24276,"completion":24276,"start":24277,"enrollment":24278,"conditions":24279,"interventions":24280},"NCT02413398","A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes",[92],"2017-11-07","2015-06-15",321,[22],[19116],{"nctId":24282,"briefTitle":24283,"status":195,"phases":24284,"primaryCompletion":7706,"completion":7706,"start":2854,"enrollment":24285,"conditions":24286,"interventions":24288},"NCT02547935","A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",[91,92],459,[24287],"Type 2 Diabetes Mellitus, CKD and Albuminuria",[19116,24289],"Saxagliptin 2.5 mg",{"nctId":24291,"briefTitle":24292,"status":195,"phases":24293,"primaryCompletion":24294,"completion":24294,"start":24295,"enrollment":24296,"conditions":24297,"interventions":24299},"NCT01730534","Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events",[92],"2018-09-11","2013-04-25",17190,[24168,24298],"High Risk for Cardiovascular Event",[19116],{"nctId":19110,"briefTitle":19111,"status":443,"phases":24301,"primaryCompletion":753,"completion":753,"start":19113,"enrollment":6275,"conditions":24302,"interventions":24303},[92],[22],[19116,19117,19118,19119,19120,2173],{"trials":24305,"activeCount":102},[],{"trials":24307,"activeCount":102},[],{"intervention":18305,"totalTrials":723,"cells":24309},{"EARLY_PHASE1":24310,"PHASE1":24312,"PHASE2":24314,"PHASE3":24316,"PHASE4":24346,"NA":24348},{"trials":24311,"activeCount":102},[],{"trials":24313,"activeCount":102},[],{"trials":24315,"activeCount":102},[],{"trials":24317,"activeCount":102},[24318,24322,24331,24335,24342],{"nctId":18300,"briefTitle":18301,"status":195,"phases":24319,"primaryCompletion":2055,"completion":2055,"start":4285,"enrollment":12271,"conditions":24320,"interventions":24321},[92],[22],[18239,18305,2173],{"nctId":24323,"briefTitle":24324,"status":195,"phases":24325,"primaryCompletion":688,"completion":2057,"start":2251,"enrollment":24326,"conditions":24327,"interventions":24328},"NCT00641056","Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)",[92],467,[22],[24329,24330],"Exenatide Once Weekly","Insulin Glargine",{"nctId":18351,"briefTitle":18352,"status":195,"phases":24332,"primaryCompletion":2507,"completion":2507,"start":4256,"enrollment":18354,"conditions":24333,"interventions":24334},[92],[2089],[18258,18305],{"nctId":24336,"briefTitle":24337,"status":195,"phases":24338,"primaryCompletion":3862,"completion":6709,"start":2068,"enrollment":24339,"conditions":24340,"interventions":24341},"NCT00935532","Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus",[92],427,[22],[15934,18458],{"nctId":18452,"briefTitle":18453,"status":195,"phases":24343,"primaryCompletion":2251,"completion":2251,"start":6562,"enrollment":18455,"conditions":24344,"interventions":24345},[92],[31],[18239,18458],{"trials":24347,"activeCount":102},[],{"trials":24349,"activeCount":102},[],{"intervention":12567,"totalTrials":723,"cells":24351},{"EARLY_PHASE1":24352,"PHASE1":24354,"PHASE2":24372,"PHASE3":24374,"PHASE4":24380,"NA":24382},{"trials":24353,"activeCount":102},[],{"trials":24355,"activeCount":102},[24356,24360,24364,24368],{"nctId":12559,"briefTitle":12560,"status":195,"phases":24357,"primaryCompletion":2220,"start":2221,"enrollment":4307,"conditions":24358,"interventions":24359},[90],[12563,12564],[12566,12567,5887],{"nctId":12651,"briefTitle":12652,"status":195,"phases":24361,"primaryCompletion":7544,"start":4915,"enrollment":2045,"conditions":24362,"interventions":24363},[90],[19],[12566,12567,12551],{"nctId":12657,"briefTitle":12658,"status":195,"phases":24365,"primaryCompletion":2086,"completion":2086,"start":6710,"enrollment":1543,"conditions":24366,"interventions":24367},[90],[12661],[12567,5887],{"nctId":12683,"briefTitle":12684,"status":195,"phases":24369,"primaryCompletion":2414,"start":2414,"enrollment":2045,"conditions":24370,"interventions":24371},[90],[19],[12566,12567,12551],{"trials":24373,"activeCount":102},[],{"trials":24375,"activeCount":102},[24376],{"nctId":24110,"briefTitle":24111,"status":195,"phases":24377,"primaryCompletion":2168,"completion":2168,"start":7439,"enrollment":3695,"conditions":24378,"interventions":24379},[92],[12760,6903],[24115,12567,15822],{"trials":24381,"activeCount":102},[],{"trials":24383,"activeCount":102},[],{"intervention":6636,"totalTrials":723,"cells":24385},{"EARLY_PHASE1":24386,"PHASE1":24388,"PHASE2":24401,"PHASE3":24407,"PHASE4":24422,"NA":24424},{"trials":24387,"activeCount":102},[],{"trials":24389,"activeCount":102},[24390,24397],{"nctId":24391,"briefTitle":24392,"status":195,"phases":24393,"primaryCompletion":7544,"completion":7544,"start":13014,"enrollment":1448,"conditions":24394,"interventions":24396},"NCT00516802","A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine",[90],[24395],"Melanoma Neoplasms",[3877,13869],{"nctId":6624,"briefTitle":6625,"status":195,"phases":24398,"primaryCompletion":6627,"completion":6628,"start":6629,"enrollment":1842,"conditions":24399,"interventions":24400},[90],[25,306,6631,6632,6633,3174,410,6634],[43,6636,5317,369,6637],{"trials":24402,"activeCount":102},[24403],{"nctId":16041,"briefTitle":16042,"status":195,"phases":24404,"primaryCompletion":4580,"completion":16044,"start":2068,"enrollment":16045,"conditions":24405,"interventions":24406},[91],[410],[43,6636],{"trials":24408,"activeCount":102},[24409,24418],{"nctId":24410,"briefTitle":24411,"status":195,"phases":24412,"primaryCompletion":13756,"completion":13102,"start":7618,"enrollment":3466,"conditions":24413,"interventions":24416},"NCT01974752","Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)",[92],[24414,24415],"Metastatic","Uveal Melanoma",[24417,6636],"75mg selumetinib",{"nctId":13863,"briefTitle":13864,"status":195,"phases":24419,"primaryCompletion":2144,"completion":2144,"start":2087,"enrollment":13866,"conditions":24420,"interventions":24421},[92],[410],[13869,13870,13871],{"trials":24423,"activeCount":102},[],{"trials":24425,"activeCount":102},[],{"intervention":2475,"totalTrials":723,"cells":24427},{"EARLY_PHASE1":24428,"PHASE1":24430,"PHASE2":24443,"PHASE3":24445,"PHASE4":24459,"NA":24461},{"trials":24429,"activeCount":102},[],{"trials":24431,"activeCount":102},[24432,24436],{"nctId":23481,"briefTitle":23482,"status":443,"phases":24433,"primaryCompletion":2746,"completion":2746,"start":2432,"enrollment":1979,"conditions":24434,"interventions":24435},[90],[22],[2565,2108,2475,23486,2061],{"nctId":24437,"briefTitle":24438,"status":195,"phases":24439,"primaryCompletion":2068,"completion":2068,"start":2152,"enrollment":1130,"conditions":24440,"interventions":24441},"NCT00897390","Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)",[90],[22],[2108,2475,24442],"Saxagliptin + Metformin IR",{"trials":24444,"activeCount":102},[],{"trials":24446,"activeCount":102},[24447,24451,24455],{"nctId":2467,"briefTitle":2468,"status":195,"phases":24448,"primaryCompletion":2470,"completion":2299,"start":2471,"enrollment":2472,"conditions":24449,"interventions":24450},[92],[31],[2108,2044,2475],{"nctId":23527,"briefTitle":23528,"status":195,"phases":24452,"primaryCompletion":6468,"completion":6468,"start":10063,"enrollment":579,"conditions":24453,"interventions":24454},[92],[2089],[2475,2061,2108],{"nctId":19137,"briefTitle":19138,"status":195,"phases":24456,"primaryCompletion":6468,"completion":6468,"start":2542,"enrollment":2827,"conditions":24457,"interventions":24458},[92],[31],[2108,2475,2173],{"trials":24460,"activeCount":102},[],{"trials":24462,"activeCount":102},[],{"intervention":2447,"totalTrials":723,"cells":24464},{"EARLY_PHASE1":24465,"PHASE1":24467,"PHASE2":24469,"PHASE3":24471,"PHASE4":24493,"NA":24495},{"trials":24466,"activeCount":102},[],{"trials":24468,"activeCount":102},[],{"trials":24470,"activeCount":102},[],{"trials":24472,"activeCount":102},[24473,24477,24481,24485,24489],{"nctId":2440,"briefTitle":2441,"status":195,"phases":24474,"primaryCompletion":2443,"completion":2443,"start":2242,"enrollment":2444,"conditions":24475,"interventions":24476},[92],[31],[2044,2044,2173,2447,2448],{"nctId":2664,"briefTitle":2665,"status":195,"phases":24478,"primaryCompletion":2667,"completion":2667,"start":2668,"enrollment":209,"conditions":24479,"interventions":24480},[92],[2652],[2044,2447],{"nctId":2702,"briefTitle":2703,"status":195,"phases":24482,"primaryCompletion":687,"completion":687,"start":2242,"enrollment":2705,"conditions":24483,"interventions":24484},[92],[31],[2044,2044,2173,2447],{"nctId":2752,"briefTitle":2753,"status":195,"phases":24486,"primaryCompletion":2755,"completion":2755,"start":2756,"enrollment":132,"conditions":24487,"interventions":24488},[92],[31],[2044,2759],{"nctId":2769,"briefTitle":2770,"status":195,"phases":24490,"primaryCompletion":2095,"completion":2406,"start":2415,"enrollment":2772,"conditions":24491,"interventions":24492},[92],[31],[2044,2759,2173],{"trials":24494,"activeCount":102},[],{"trials":24496,"activeCount":102},[],{"intervention":8696,"totalTrials":723,"cells":24498},{"EARLY_PHASE1":24499,"PHASE1":24501,"PHASE2":24503,"PHASE3":24530,"PHASE4":24539,"NA":24541},{"trials":24500,"activeCount":102},[],{"trials":24502,"activeCount":102},[],{"trials":24504,"activeCount":102},[24505,24509,24516,24523],{"nctId":8689,"briefTitle":8690,"status":624,"phases":24506,"primaryCompletion":4284,"completion":4284,"start":8692,"enrollment":8693,"conditions":24507,"interventions":24508},[91],[5121],[8696,4615,8697,4843],{"nctId":24510,"briefTitle":24511,"status":195,"phases":24512,"completion":4916,"start":9124,"enrollment":188,"conditions":24513,"interventions":24515},"NCT00319787","Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer",[91],[24514],"Locally Advanced Prostate Cancer",[8696],{"nctId":24517,"briefTitle":24518,"status":443,"phases":24519,"completion":9213,"start":8692,"enrollment":3172,"conditions":24520,"interventions":24522},"NCT00234442","Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer",[91],[24521,3864],"Brain Neoplasms",[8696],{"nctId":24524,"briefTitle":24525,"status":624,"phases":24526,"start":4331,"enrollment":2260,"conditions":24527,"interventions":24529},"NCT00233636","Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck",[91],[408,24528],"Carcinoma, Squamous Cell",[8696],{"trials":24531,"activeCount":102},[24532],{"nctId":24533,"briefTitle":24534,"status":443,"phases":24535,"completion":5725,"start":6572,"enrollment":24536,"conditions":24537,"interventions":24538},"NCT00234468","Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC",[92],490,[3813],[8696],{"trials":24540,"activeCount":102},[],{"trials":24542,"activeCount":102},[],{"intervention":24544,"totalTrials":1979,"cells":24545},"Ranitidine",{"EARLY_PHASE1":24546,"PHASE1":24548,"PHASE2":24560,"PHASE3":24562,"PHASE4":24585,"NA":24587},{"trials":24547,"activeCount":102},[],{"trials":24549,"activeCount":102},[24550],{"nctId":24551,"briefTitle":24552,"status":195,"phases":24553,"primaryCompletion":2616,"completion":2616,"start":2432,"enrollment":2260,"conditions":24554,"interventions":24555},"NCT01682408","Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability",[90],[15776],[24556,24557,24558,24559,24544],"Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded","Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed","Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded","Fostamatinib - 1 x 150mg mannitol based 38% drug loaded",{"trials":24561,"activeCount":102},[],{"trials":24563,"activeCount":102},[24564,24572,24578],{"nctId":24565,"briefTitle":24566,"status":195,"phases":24567,"completion":9930,"start":24568,"enrollment":1078,"conditions":24569,"interventions":24571},"NCT00633412","A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only",[92],"2001-02",[24570],"NSAID Associated Gastric Ulcers",[19794,24544,19794],{"nctId":24573,"briefTitle":24574,"status":195,"phases":24575,"primaryCompletion":9075,"completion":9075,"start":24568,"enrollment":1078,"conditions":24576,"interventions":24577},"NCT00633672","A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued",[92],[24570],[19794,24544,19794],{"nctId":24579,"briefTitle":24580,"status":195,"phases":24581,"completion":2414,"start":2087,"enrollment":24582,"conditions":24583,"interventions":24584},"NCT00401752","Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer",[92],397,[20616],[19794,24544],{"trials":24586,"activeCount":102},[],{"trials":24588,"activeCount":102},[],{"intervention":9939,"totalTrials":1979,"cells":24590},{"EARLY_PHASE1":24591,"PHASE1":24593,"PHASE2":24605,"PHASE3":24623,"PHASE4":24629,"NA":24631},{"trials":24592,"activeCount":102},[],{"trials":24594,"activeCount":102},[24595],{"nctId":24596,"briefTitle":24597,"status":195,"phases":24598,"primaryCompletion":5238,"completion":5238,"start":24599,"enrollment":132,"conditions":24600,"interventions":24603},"NCT02512575","A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.",[90],"2015-11-18",[10052,24601,15776,24602,1556,7267],"Tolerability","Pharmacodynamics",[24604,9939],"AZD9567 Monohydrat",{"trials":24606,"activeCount":102},[24607,24616],{"nctId":24608,"briefTitle":24609,"status":195,"phases":24610,"primaryCompletion":24611,"completion":24611,"start":24612,"enrollment":544,"conditions":24613,"interventions":24614},"NCT03368235","Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis",[91],"2019-11-12","2018-01-18",[7267],[24615,9939],"AZD9567",{"nctId":24617,"briefTitle":24618,"status":195,"phases":24619,"primaryCompletion":24620,"completion":24620,"start":3080,"enrollment":451,"conditions":24621,"interventions":24622},"NCT04556760","Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes",[91],"2021-06-09",[2089],[24615,9939],{"trials":24624,"activeCount":102},[24625],{"nctId":9934,"briefTitle":9935,"status":195,"phases":24626,"completion":2252,"start":6719,"enrollment":2187,"conditions":24627,"interventions":24628},[92],[28],[9842,9939],{"trials":24630,"activeCount":102},[],{"trials":24632,"activeCount":102},[],{"intervention":9134,"totalTrials":1979,"cells":24634},{"EARLY_PHASE1":24635,"PHASE1":24637,"PHASE2":24639,"PHASE3":24653,"PHASE4":24666,"NA":24668},{"trials":24636,"activeCount":102},[],{"trials":24638,"activeCount":102},[],{"trials":24640,"activeCount":102},[24641,24647],{"nctId":24642,"briefTitle":24643,"status":195,"phases":24644,"primaryCompletion":5725,"completion":2095,"start":9213,"enrollment":22483,"conditions":24645,"interventions":24646},"NCT00303524","Comparative Study of Oestradiol Suppression: Zoladex 10.8mg\u002F3 Month vs. 3.6mg\u002FMonth in ER +ve EBC Pre-menopausal Patients",[91],[25],[9134,9134],{"nctId":24648,"briefTitle":24649,"status":195,"phases":24650,"completion":2057,"start":6369,"enrollment":8285,"conditions":24651,"interventions":24652},"NCT00322348","Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women",[91],[6348],[9134,9134],{"trials":24654,"activeCount":102},[24655,24662],{"nctId":24656,"briefTitle":24657,"status":624,"phases":24658,"primaryCompletion":4496,"completion":4496,"enrollment":188,"conditions":24659,"interventions":24661},"NCT00888082","Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy",[92],[25,24660],"Ovarian Function",[9134],{"nctId":9128,"briefTitle":9129,"status":195,"phases":24663,"primaryCompletion":2057,"completion":2143,"start":4297,"enrollment":9131,"conditions":24664,"interventions":24665},[92],[25],[468,6463,9134],{"trials":24667,"activeCount":102},[],{"trials":24669,"activeCount":102},[],{"intervention":18854,"totalTrials":1979,"cells":24671},{"EARLY_PHASE1":24672,"PHASE1":24674,"PHASE2":24676,"PHASE3":24689,"PHASE4":24699,"NA":24701},{"trials":24673,"activeCount":102},[],{"trials":24675,"activeCount":102},[],{"trials":24677,"activeCount":102},[24678,24682],{"nctId":22999,"briefTitle":23000,"status":443,"phases":24679,"primaryCompletion":2105,"completion":2105,"start":2433,"enrollment":7698,"conditions":24680,"interventions":24681},[91],[18697],[22928,18854],{"nctId":24683,"briefTitle":24684,"status":443,"phases":24685,"primaryCompletion":2349,"completion":2349,"start":2243,"enrollment":18941,"conditions":24686,"interventions":24687},"NCT01145755","6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder",[91],[18697],[24688,18854],"AZD2066",{"trials":24690,"activeCount":102},[24691,24695],{"nctId":23669,"briefTitle":23670,"status":195,"phases":24692,"completion":7439,"start":7494,"enrollment":23672,"conditions":24693,"interventions":24694},[92],[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],{"nctId":18849,"briefTitle":18850,"status":195,"phases":24696,"completion":6718,"start":6369,"enrollment":365,"conditions":24697,"interventions":24698},[92],[18697],[18676,18854],{"trials":24700,"activeCount":102},[],{"trials":24702,"activeCount":102},[],{"intervention":24704,"totalTrials":1979,"cells":24705},"Experimental: Tezepelumab",{"EARLY_PHASE1":24706,"PHASE1":24708,"PHASE2":24718,"PHASE3":24720,"PHASE4":24749,"NA":24751},{"trials":24707,"activeCount":102},[],{"trials":24709,"activeCount":102},[24710],{"nctId":24711,"briefTitle":24712,"status":195,"phases":24713,"primaryCompletion":24714,"completion":24714,"start":24715,"enrollment":5898,"conditions":24716,"interventions":24717},"NCT04362410","Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects",[90],"2020-10-09","2020-05-18",[1556],[24704],{"trials":24719,"activeCount":102},[],{"trials":24721,"activeCount":102},[24722,24730,24739],{"nctId":24723,"briefTitle":24724,"status":195,"phases":24725,"primaryCompletion":24726,"completion":1574,"start":12090,"enrollment":24727,"conditions":24728,"interventions":24729},"NCT03347279","Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma",[92],"2020-09-08",1061,[16],[24704],{"nctId":24731,"briefTitle":24732,"status":195,"phases":24733,"primaryCompletion":24734,"completion":24735,"start":24736,"enrollment":9994,"conditions":24737,"interventions":24738},"NCT03927157","Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma",[92],"2024-05-24","2024-08-13","2019-06-14",[16],[24704],{"nctId":24740,"briefTitle":24741,"status":195,"phases":24742,"primaryCompletion":24743,"completion":13274,"start":24744,"enrollment":24745,"conditions":24746,"interventions":24747},"NCT04851964","Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis",[92],"2024-09-23","2021-04-22",416,[6163],[24704,24748],"Mometasone furoate or equivalent intranasal corticosteroid",{"trials":24750,"activeCount":102},[],{"trials":24752,"activeCount":102},[],{"intervention":24754,"totalTrials":1979,"cells":24755},"Epanova",{"EARLY_PHASE1":24756,"PHASE1":24758,"PHASE2":24777,"PHASE3":24785,"PHASE4":24797,"NA":24799},{"trials":24757,"activeCount":102},[],{"trials":24759,"activeCount":102},[24760,24768],{"nctId":24761,"briefTitle":24762,"status":195,"phases":24763,"primaryCompletion":24764,"completion":24764,"start":24765,"enrollment":1638,"conditions":24766,"interventions":24767},"NCT03574142","A Ph 1 Study of Epanova® in Healthy Chineses",[90],"2018-06-27","2018-06-04",[1556],[24754],{"nctId":24769,"briefTitle":24770,"status":195,"phases":24771,"primaryCompletion":24772,"completion":24772,"start":6436,"enrollment":1710,"conditions":24773,"interventions":24775},"NCT02189252","An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis",[90],"2015-07",[24774],"Severe Hypertriglyceridemia",[24754,24776],"Lovaza",{"trials":24778,"activeCount":102},[24779],{"nctId":24780,"briefTitle":24781,"status":195,"phases":24782,"primaryCompletion":2349,"completion":2349,"start":3862,"enrollment":680,"conditions":24783,"interventions":24784},"NCT01208961","Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation",[91],[24774],[24754,24776],{"trials":24786,"activeCount":102},[24787],{"nctId":24788,"briefTitle":24789,"status":195,"phases":24790,"primaryCompletion":24791,"completion":24791,"start":24792,"enrollment":24793,"conditions":24794,"interventions":24795},"NCT02009865","Epanova® for Lowering Very High Triglycerides II (EVOLVE II)",[92],"2014-12-23","2013-12-16",379,[13022],[24754,24796],"Olive Oil",{"trials":24798,"activeCount":102},[],{"trials":24800,"activeCount":102},[],{"intervention":24802,"totalTrials":1979,"cells":24803},"Nirsevimab",{"EARLY_PHASE1":24804,"PHASE1":24806,"PHASE2":24816,"PHASE3":24827,"PHASE4":24846,"NA":24848},{"trials":24805,"activeCount":102},[],{"trials":24807,"activeCount":102},[24808],{"nctId":24809,"briefTitle":24810,"status":195,"phases":24811,"primaryCompletion":10166,"completion":10166,"start":317,"enrollment":1130,"conditions":24812,"interventions":24814},"NCT04840849","Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults",[90],[24813],"Evaluate PK Profile",[24815],"nirsevimab",{"trials":24817,"activeCount":102},[24818],{"nctId":24819,"briefTitle":24820,"status":195,"phases":24821,"primaryCompletion":24822,"completion":24822,"start":24823,"enrollment":221,"conditions":24824,"interventions":24826},"NCT04484935","Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children",[91],"2023-02-17","2020-08-19",[24825],"RSV Infection",[24802],{"trials":24828,"activeCount":102},[24829,24838],{"nctId":24830,"briefTitle":24831,"status":195,"phases":24832,"primaryCompletion":24833,"completion":24833,"start":24834,"enrollment":689,"conditions":24835,"interventions":24837},"NCT06042049","A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab",[92],"2025-07-24","2023-07-27",[24836],"Respiratory Syncytial Virus Infections",[24802],{"nctId":24839,"briefTitle":24840,"status":195,"phases":24841,"primaryCompletion":2932,"completion":2932,"start":24842,"enrollment":5155,"conditions":24843,"interventions":24845},"NCT05110261","Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China",[92],"2021-11-24",[24844],"Lower Respiratory Tract Infection",[24802],{"trials":24847,"activeCount":102},[],{"trials":24849,"activeCount":102},[],{"intervention":20295,"totalTrials":1979,"cells":24851},{"EARLY_PHASE1":24852,"PHASE1":24854,"PHASE2":24856,"PHASE3":24858,"PHASE4":24881,"NA":24883},{"trials":24853,"activeCount":102},[],{"trials":24855,"activeCount":102},[],{"trials":24857,"activeCount":102},[],{"trials":24859,"activeCount":102},[24860,24864,24871,24877],{"nctId":20290,"briefTitle":20291,"status":195,"phases":24861,"completion":5742,"start":13047,"enrollment":12914,"conditions":24862,"interventions":24863},[92],[28],[20295,20296,19841],{"nctId":24865,"briefTitle":24866,"status":195,"phases":24867,"completion":2169,"start":3839,"enrollment":1666,"conditions":24868,"interventions":24869},"NCT00449501","A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects",[92],[16],[20295,24870],"Budesonide HFA pMDI",{"nctId":24872,"briefTitle":24873,"status":195,"phases":24874,"completion":5725,"start":3839,"enrollment":19236,"conditions":24875,"interventions":24876},"NCT00449527","A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects",[92],[16],[20295,24870],{"nctId":20298,"briefTitle":20299,"status":195,"phases":24878,"completion":2415,"start":13047,"enrollment":7555,"conditions":24879,"interventions":24880},[92],[28],[20295,19841],{"trials":24882,"activeCount":102},[],{"trials":24884,"activeCount":102},[],{"intervention":24886,"totalTrials":1979,"cells":24887},"Tralokinumab",{"EARLY_PHASE1":24888,"PHASE1":24890,"PHASE2":24892,"PHASE3":24910,"PHASE4":24930,"NA":24932},{"trials":24889,"activeCount":102},[],{"trials":24891,"activeCount":102},[],{"trials":24893,"activeCount":102},[24894,24902],{"nctId":24895,"briefTitle":24896,"status":195,"phases":24897,"primaryCompletion":2443,"completion":2746,"start":687,"enrollment":1151,"conditions":24898,"interventions":24900},"NCT01482884","Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis",[91],[24899],"Ulcerative Colitis",[24901],"tralokinumab",{"nctId":24903,"briefTitle":24904,"status":195,"phases":24905,"primaryCompletion":24906,"completion":24906,"start":24907,"enrollment":464,"conditions":24908,"interventions":24909},"NCT02449473","Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids",[91],"2017-06-21","2015-09-29",[16],[24886],{"trials":24911,"activeCount":102},[24912,24923],{"nctId":24913,"briefTitle":24914,"status":195,"phases":24915,"primaryCompletion":24916,"completion":24917,"start":24918,"enrollment":24919,"conditions":24920,"interventions":24922},"NCT02161757","A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma",[92],"2017-02-28","2017-07-18","2014-06-13",1207,[24921],"Uncontrolled Asthma",[24886],{"nctId":24924,"briefTitle":24925,"status":195,"phases":24926,"primaryCompletion":1823,"completion":1823,"start":24927,"enrollment":1842,"conditions":24928,"interventions":24929},"NCT02281357","Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma",[92],"2015-02-19",[16],[24886],{"trials":24931,"activeCount":102},[],{"trials":24933,"activeCount":102},[],{"intervention":24870,"totalTrials":1979,"cells":24935},{"EARLY_PHASE1":24936,"PHASE1":24938,"PHASE2":24940,"PHASE3":24942,"PHASE4":24965,"NA":24967},{"trials":24937,"activeCount":102},[],{"trials":24939,"activeCount":102},[],{"trials":24941,"activeCount":102},[],{"trials":24943,"activeCount":102},[24944,24948,24952,24959],{"nctId":24865,"briefTitle":24866,"status":195,"phases":24945,"completion":2169,"start":3839,"enrollment":1666,"conditions":24946,"interventions":24947},[92],[16],[20295,24870],{"nctId":24872,"briefTitle":24873,"status":195,"phases":24949,"completion":5725,"start":3839,"enrollment":19236,"conditions":24950,"interventions":24951},[92],[16],[20295,24870],{"nctId":24953,"briefTitle":24954,"status":195,"phases":24955,"primaryCompletion":2524,"completion":2524,"start":13014,"enrollment":24956,"conditions":24957,"interventions":24958},"NCT00419757","An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma",[92],558,[16],[20288,24870],{"nctId":24960,"briefTitle":24961,"status":195,"phases":24962,"primaryCompletion":2057,"completion":2057,"start":2328,"enrollment":24224,"conditions":24963,"interventions":24964},"NCT00419952","A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.",[92],[16],[20288,24870],{"trials":24966,"activeCount":102},[],{"trials":24968,"activeCount":102},[],{"intervention":24970,"totalTrials":3887,"cells":24971},"NXY-059",{"EARLY_PHASE1":24972,"PHASE1":24974,"PHASE2":24976,"PHASE3":24985,"PHASE4":25003,"NA":25005},{"trials":24973,"activeCount":102},[],{"trials":24975,"activeCount":102},[],{"trials":24977,"activeCount":102},[24978],{"nctId":24979,"briefTitle":24980,"status":195,"phases":24981,"primaryCompletion":4284,"completion":4284,"start":9963,"enrollment":365,"conditions":24982,"interventions":24984},"NCT00075959","Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke",[91],[24983],"Intracerebral Hemorrhage",[24970],{"trials":24986,"activeCount":102},[24987,24998],{"nctId":24988,"briefTitle":24989,"status":195,"phases":24990,"primaryCompletion":5563,"completion":5563,"start":4299,"enrollment":24991,"conditions":24992,"interventions":24997},"NCT00061022","Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke",[92],3200,[24993,24994,24995,24996],"Cerebral Stroke","Stroke, Acute","Cerebrovascular Stroke","Ischemic Attack, Transient",[24970],{"nctId":24999,"briefTitle":24989,"status":195,"phases":25000,"primaryCompletion":9944,"completion":9944,"start":4256,"enrollment":12939,"conditions":25001,"interventions":25002},"NCT00119626",[92],[24993,24996],[24970],{"trials":25004,"activeCount":102},[],{"trials":25006,"activeCount":102},[],{"intervention":25008,"totalTrials":3887,"cells":25009},"AZD3152",{"EARLY_PHASE1":25010,"PHASE1":25012,"PHASE2":25031,"PHASE3":25033,"PHASE4":25047,"NA":25049},{"trials":25011,"activeCount":102},[],{"trials":25013,"activeCount":102},[25014,25023],{"nctId":25015,"briefTitle":25016,"status":195,"phases":25017,"primaryCompletion":25018,"completion":25018,"start":25019,"enrollment":1130,"conditions":25020,"interventions":25022},"NCT05932641","Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants",[90],"2024-12-05","2023-07-31",[25021],"COVID-19, SARS-CoV-2",[25008,25008,25008],{"nctId":25024,"briefTitle":25025,"status":195,"phases":25026,"primaryCompletion":25027,"completion":25027,"start":25028,"enrollment":8285,"conditions":25029,"interventions":25030},"NCT05872958","Dose Exploration Intramuscular\u002FIntravenous Prophylaxis Pharmacokinetic Exposure Response Study",[90],"2024-08-20","2023-05-19",[1387],[25008],{"trials":25032,"activeCount":102},[],{"trials":25034,"activeCount":102},[25035],{"nctId":25036,"briefTitle":25037,"status":195,"phases":25038,"primaryCompletion":8926,"completion":25039,"start":8198,"enrollment":25040,"conditions":25041,"interventions":25042},"NCT05648110","Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study",[91,92],"2025-02-11",3882,[25021],[25043,25044,25008,25008,25045,25046],"AZD5156","EVUSHELD™","AZD7442 - EVUSHELD™","AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152",{"trials":25048,"activeCount":102},[],{"trials":25050,"activeCount":102},[],{"intervention":6463,"totalTrials":3887,"cells":25052},{"EARLY_PHASE1":25053,"PHASE1":25055,"PHASE2":25057,"PHASE3":25067,"PHASE4":25073,"NA":25075},{"trials":25054,"activeCount":102},[],{"trials":25056,"activeCount":102},[],{"trials":25058,"activeCount":102},[25059,25063],{"nctId":13590,"briefTitle":13591,"status":195,"phases":25060,"completion":6517,"start":6572,"enrollment":754,"conditions":25061,"interventions":25062},[91],[25],[6463,1013],{"nctId":6458,"briefTitle":6459,"status":195,"phases":25064,"primaryCompletion":2086,"completion":2086,"start":6370,"enrollment":2187,"conditions":25065,"interventions":25066},[91],[25],[53,6463],{"trials":25068,"activeCount":102},[25069],{"nctId":9128,"briefTitle":9129,"status":195,"phases":25070,"primaryCompletion":2057,"completion":2143,"start":4297,"enrollment":9131,"conditions":25071,"interventions":25072},[92],[25],[468,6463,9134],{"trials":25074,"activeCount":102},[],{"trials":25076,"activeCount":102},[],{"intervention":18725,"totalTrials":3887,"cells":25078},{"EARLY_PHASE1":25079,"PHASE1":25081,"PHASE2":25083,"PHASE3":25085,"PHASE4":25099,"NA":25101},{"trials":25080,"activeCount":102},[],{"trials":25082,"activeCount":102},[],{"trials":25084,"activeCount":102},[],{"trials":25086,"activeCount":102},[25087,25091,25095],{"nctId":18718,"briefTitle":18719,"status":195,"phases":25088,"completion":2639,"start":6370,"enrollment":18721,"conditions":25089,"interventions":25090},[92],[18714],[18716,18724,18725],{"nctId":18886,"briefTitle":18887,"status":195,"phases":25092,"completion":7439,"start":4284,"enrollment":1529,"conditions":25093,"interventions":25094},[92],[18714,18890],[18676,18724,18725],{"nctId":19978,"briefTitle":19979,"status":195,"phases":25096,"completion":5563,"start":12937,"enrollment":18721,"conditions":25097,"interventions":25098},[92],[18732],[19983,18724,18725],{"trials":25100,"activeCount":102},[],{"trials":25102,"activeCount":102},[],{"intervention":24228,"totalTrials":3887,"cells":25104},{"EARLY_PHASE1":25105,"PHASE1":25107,"PHASE2":25109,"PHASE3":25111,"PHASE4":25132,"NA":25134},{"trials":25106,"activeCount":102},[],{"trials":25108,"activeCount":102},[],{"trials":25110,"activeCount":102},[],{"trials":25112,"activeCount":102},[25113,25117,25124],{"nctId":24221,"briefTitle":24222,"status":195,"phases":25114,"primaryCompletion":2251,"completion":2251,"start":2415,"enrollment":24224,"conditions":25115,"interventions":25116},[92],[24226],[24202,24228,19490],{"nctId":25118,"briefTitle":25119,"status":195,"phases":25120,"primaryCompletion":6468,"completion":6468,"start":7618,"enrollment":25121,"conditions":25122,"interventions":25123},"NCT02091986","A 12-Week Study in Asthmatic Children Ages 6 to \u003C12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80\u002F2.25 μg and Symbicort pMDI 80\u002F4.5 μg, Compared With Budesonide pMDI 80 μg",[92],882,[16],[24228,24228],{"nctId":25125,"briefTitle":25126,"status":195,"phases":25127,"primaryCompletion":13056,"completion":13056,"start":2589,"enrollment":25128,"conditions":25129,"interventions":25130},"NCT01444430","A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents",[92],12460,[16],[24228,25131],"budesonide pMDI",{"trials":25133,"activeCount":102},[],{"trials":25135,"activeCount":102},[],{"intervention":18827,"totalTrials":3887,"cells":25137},{"EARLY_PHASE1":25138,"PHASE1":25140,"PHASE2":25142,"PHASE3":25144,"PHASE4":25158,"NA":25160},{"trials":25139,"activeCount":102},[],{"trials":25141,"activeCount":102},[],{"trials":25143,"activeCount":102},[],{"trials":25145,"activeCount":102},[25146,25150,25154],{"nctId":18727,"briefTitle":18728,"status":195,"phases":25147,"completion":6718,"start":7554,"enrollment":18730,"conditions":25148,"interventions":25149},[92],[18732,18733,18734],[18716,18736],{"nctId":18822,"briefTitle":18823,"status":195,"phases":25151,"completion":6718,"start":7494,"enrollment":5155,"conditions":25152,"interventions":25153},[92],[18742],[18676,18827],{"nctId":23669,"briefTitle":23670,"status":195,"phases":25155,"completion":7439,"start":7494,"enrollment":23672,"conditions":25156,"interventions":25157},[92],[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],{"trials":25159,"activeCount":102},[],{"trials":25161,"activeCount":102},[],{"intervention":19120,"totalTrials":3887,"cells":25163},{"EARLY_PHASE1":25164,"PHASE1":25166,"PHASE2":25179,"PHASE3":25181,"PHASE4":25195,"NA":25197},{"trials":25165,"activeCount":102},[],{"trials":25167,"activeCount":102},[25168],{"nctId":25169,"briefTitle":25170,"status":195,"phases":25171,"primaryCompletion":19426,"completion":19426,"start":2405,"enrollment":4307,"conditions":25172,"interventions":25174},"NCT01755494","A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin\u002FMetformin XR Relative to Co-Administration",[90],[25173],"Type 2 Diabetes Mellitus(T2DM)",[19120,25175,25176,25177,25178],"Metformin XR 500 mg","Mertformin XR 2 x 500 mg","Komboglyze XR 5\u002F500 mg","Komboglyze XR 5\u002F1000 mg",{"trials":25180,"activeCount":102},[],{"trials":25182,"activeCount":102},[25183,25191],{"nctId":25184,"briefTitle":25185,"status":195,"phases":25186,"primaryCompletion":13123,"completion":13123,"start":2179,"enrollment":25187,"conditions":25188,"interventions":25189},"NCT02273050","Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control",[92],1136,[22],[19120,25190],"Metformin 500 mg with titration",{"nctId":19110,"briefTitle":19111,"status":443,"phases":25192,"primaryCompletion":753,"completion":753,"start":19113,"enrollment":6275,"conditions":25193,"interventions":25194},[92],[22],[19116,19117,19118,19119,19120,2173],{"trials":25196,"activeCount":102},[],{"trials":25198,"activeCount":102},[],{"intervention":19862,"totalTrials":3887,"cells":25200},{"EARLY_PHASE1":25201,"PHASE1":25203,"PHASE2":25205,"PHASE3":25207,"PHASE4":25221,"NA":25223},{"trials":25202,"activeCount":102},[],{"trials":25204,"activeCount":102},[],{"trials":25206,"activeCount":102},[],{"trials":25208,"activeCount":102},[25209,25213,25217],{"nctId":24230,"briefTitle":24231,"status":195,"phases":25210,"primaryCompletion":2433,"completion":2433,"start":2095,"enrollment":24233,"conditions":25211,"interventions":25212},[92],[16],[24202,19862],{"nctId":19856,"briefTitle":19857,"status":195,"phases":25214,"completion":3839,"start":7554,"enrollment":221,"conditions":25215,"interventions":25216},[92],[16],[19829,19861,19862],{"nctId":24244,"briefTitle":24245,"status":195,"phases":25218,"primaryCompletion":2068,"completion":2068,"start":7544,"enrollment":98,"conditions":25219,"interventions":25220},[92],[16],[24202,19862],{"trials":25222,"activeCount":102},[],{"trials":25224,"activeCount":102},[],{"intervention":24060,"totalTrials":3887,"cells":25226},{"EARLY_PHASE1":25227,"PHASE1":25229,"PHASE2":25231,"PHASE3":25233,"PHASE4":25247,"NA":25249},{"trials":25228,"activeCount":102},[],{"trials":25230,"activeCount":102},[],{"trials":25232,"activeCount":102},[],{"trials":25234,"activeCount":102},[25235,25239,25243],{"nctId":24055,"briefTitle":24056,"status":195,"phases":25236,"primaryCompletion":2405,"completion":2405,"start":2571,"enrollment":13767,"conditions":25237,"interventions":25238},[92],[28],[24060,24060,24061,24026],{"nctId":24070,"briefTitle":24071,"status":195,"phases":25240,"primaryCompletion":2579,"completion":2579,"start":2736,"enrollment":24073,"conditions":25241,"interventions":25242},[92],[6083],[24060,24060,24061,24026],{"nctId":24077,"briefTitle":24078,"status":195,"phases":25244,"primaryCompletion":24080,"completion":24081,"start":24082,"enrollment":24083,"conditions":25245,"interventions":25246},[92],[28],[24060,24026],{"trials":25248,"activeCount":102},[],{"trials":25250,"activeCount":102},[],{"intervention":25252,"totalTrials":3887,"cells":25253},"Epanova®",{"EARLY_PHASE1":25254,"PHASE1":25256,"PHASE2":25272,"PHASE3":25283,"PHASE4":25296,"NA":25298},{"trials":25255,"activeCount":102},[],{"trials":25257,"activeCount":102},[25258],{"nctId":25259,"briefTitle":25260,"status":195,"phases":25261,"primaryCompletion":25262,"completion":25262,"start":25263,"enrollment":8304,"conditions":25264,"interventions":25268},"NCT02359045","Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions",[90],"2015-07-27","2015-02-12",[25265,25266,25267,15776],"Relative Bioavailability","AUC","Cmax",[25269,25270,25271,25252],"D1400147","D14000136","D14000137",{"trials":25273,"activeCount":102},[25274],{"nctId":25275,"briefTitle":25276,"status":195,"phases":25277,"primaryCompletion":20831,"completion":20831,"start":25278,"enrollment":24536,"conditions":25279,"interventions":25281},"NCT02370537","A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI",[91],"2015-03",[2089,25280],"Exocrine Pancreatic Insufficiency",[25252,25282],"Omacor®",{"trials":25284,"activeCount":102},[25285],{"nctId":25286,"briefTitle":25287,"status":195,"phases":25288,"primaryCompletion":25289,"completion":25289,"start":25290,"enrollment":25291,"conditions":25292,"interventions":25294},"NCT02104817","Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia",[92],"2020-05-27","2014-10-30",13078,[25293],"Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)",[25252,25295],"corn oil control",{"trials":25297,"activeCount":102},[],{"trials":25299,"activeCount":102},[],{"intervention":19198,"totalTrials":3887,"cells":25301},{"EARLY_PHASE1":25302,"PHASE1":25304,"PHASE2":25314,"PHASE3":25316,"PHASE4":25322,"NA":25324},{"trials":25303,"activeCount":102},[],{"trials":25305,"activeCount":102},[25306,25310],{"nctId":19192,"briefTitle":19193,"status":195,"phases":25307,"primaryCompletion":5417,"completion":5417,"start":659,"enrollment":1510,"conditions":25308,"interventions":25309},[90],[2619],[19197,12616,19198],{"nctId":23080,"briefTitle":23081,"status":195,"phases":25311,"primaryCompletion":687,"completion":687,"start":4580,"enrollment":14693,"conditions":25312,"interventions":25313},[90],[13022],[12588,19198,23085],{"trials":25315,"activeCount":102},[],{"trials":25317,"activeCount":102},[25318],{"nctId":19286,"briefTitle":19287,"status":195,"phases":25319,"primaryCompletion":19289,"completion":19289,"start":19290,"enrollment":19291,"conditions":25320,"interventions":25321},[92],[19282,19283],[19190,19294],{"trials":25323,"activeCount":102},[],{"trials":25325,"activeCount":102},[],{"intervention":6905,"totalTrials":3887,"cells":25327},{"EARLY_PHASE1":25328,"PHASE1":25330,"PHASE2":25336,"PHASE3":25338,"PHASE4":25348,"NA":25350},{"trials":25329,"activeCount":102},[],{"trials":25331,"activeCount":102},[25332],{"nctId":6897,"briefTitle":6898,"status":195,"phases":25333,"primaryCompletion":6900,"completion":6900,"start":3438,"enrollment":6901,"conditions":25334,"interventions":25335},[90],[6903],[6860,6905,5887,6906],{"trials":25337,"activeCount":102},[],{"trials":25339,"activeCount":102},[25340,25344],{"nctId":12785,"briefTitle":12786,"status":195,"phases":25341,"completion":6650,"start":6445,"conditions":25342,"interventions":25343},[92],[12760,12789,12540],[5887,6905],{"nctId":12850,"briefTitle":12851,"status":195,"phases":25345,"primaryCompletion":3827,"completion":3827,"start":5725,"enrollment":12853,"conditions":25346,"interventions":25347},[92],[12760,12789,12540],[5887,6905,12588],{"trials":25349,"activeCount":102},[],{"trials":25351,"activeCount":102},[],{"intervention":9904,"totalTrials":3887,"cells":25353},{"EARLY_PHASE1":25354,"PHASE1":25356,"PHASE2":25358,"PHASE3":25360,"PHASE4":25374,"NA":25376},{"trials":25355,"activeCount":102},[],{"trials":25357,"activeCount":102},[],{"trials":25359,"activeCount":102},[],{"trials":25361,"activeCount":102},[25362,25366,25370],{"nctId":9898,"briefTitle":9899,"status":195,"phases":25363,"completion":4876,"start":9901,"enrollment":4027,"conditions":25364,"interventions":25365},[92],[16],[9842,9904],{"nctId":9906,"briefTitle":9907,"status":195,"phases":25367,"completion":6780,"start":9909,"enrollment":5898,"conditions":25368,"interventions":25369},[92],[16],[9842,9904,9912],{"nctId":9927,"briefTitle":9928,"status":195,"phases":25371,"completion":6563,"start":9930,"enrollment":5898,"conditions":25372,"interventions":25373},[92],[16],[9842,9904,9912],{"trials":25375,"activeCount":102},[],{"trials":25377,"activeCount":102},[],{"intervention":20288,"totalTrials":3887,"cells":25379},{"EARLY_PHASE1":25380,"PHASE1":25382,"PHASE2":25384,"PHASE3":25386,"PHASE4":25400,"NA":25402},{"trials":25381,"activeCount":102},[],{"trials":25383,"activeCount":102},[],{"trials":25385,"activeCount":102},[],{"trials":25387,"activeCount":102},[25388,25392,25396],{"nctId":20283,"briefTitle":20284,"status":195,"phases":25389,"primaryCompletion":2151,"completion":2151,"start":13014,"enrollment":4027,"conditions":25390,"interventions":25391},[92],[28],[20288,19841],{"nctId":24953,"briefTitle":24954,"status":195,"phases":25393,"primaryCompletion":2524,"completion":2524,"start":13014,"enrollment":24956,"conditions":25394,"interventions":25395},[92],[16],[20288,24870],{"nctId":24960,"briefTitle":24961,"status":195,"phases":25397,"primaryCompletion":2057,"completion":2057,"start":2328,"enrollment":24224,"conditions":25398,"interventions":25399},[92],[16],[20288,24870],{"trials":25401,"activeCount":102},[],{"trials":25403,"activeCount":102},[],{"intervention":15949,"totalTrials":3887,"cells":25405},{"EARLY_PHASE1":25406,"PHASE1":25408,"PHASE2":25410,"PHASE3":25412,"PHASE4":25426,"NA":25428},{"trials":25407,"activeCount":102},[],{"trials":25409,"activeCount":102},[],{"trials":25411,"activeCount":102},[],{"trials":25413,"activeCount":102},[25414,25418,25422],{"nctId":2494,"briefTitle":2495,"status":195,"phases":25415,"primaryCompletion":2057,"completion":2243,"start":2251,"enrollment":2497,"conditions":25416,"interventions":25417},[92],[31],[2246,2080,2500,2501,2502],{"nctId":15943,"briefTitle":15944,"status":195,"phases":25419,"primaryCompletion":4297,"completion":2086,"start":2087,"enrollment":15946,"conditions":25420,"interventions":25421},[92],[2089],[2108,2108,15893,15949,2333],{"nctId":18437,"briefTitle":18438,"status":195,"phases":25423,"primaryCompletion":2507,"completion":2507,"start":3809,"enrollment":8304,"conditions":25424,"interventions":25425},[92],[2089],[18239,15949],{"trials":25427,"activeCount":102},[],{"trials":25429,"activeCount":102},[],{"intervention":23677,"totalTrials":3887,"cells":25431},{"EARLY_PHASE1":25432,"PHASE1":25434,"PHASE2":25436,"PHASE3":25445,"PHASE4":25457,"NA":25459},{"trials":25433,"activeCount":102},[],{"trials":25435,"activeCount":102},[],{"trials":25437,"activeCount":102},[25438],{"nctId":25439,"briefTitle":25440,"status":195,"phases":25441,"primaryCompletion":2113,"completion":2113,"start":2057,"enrollment":1009,"conditions":25442,"interventions":25443},"NCT01020799","AZD7268 Safety and Tolerability Study",[91],[18697],[25444,23677],"AZD7268",{"trials":25446,"activeCount":102},[25447,25451],{"nctId":23669,"briefTitle":23670,"status":195,"phases":25448,"completion":7439,"start":7494,"enrollment":23672,"conditions":25449,"interventions":25450},[92],[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],{"nctId":25452,"briefTitle":23670,"status":195,"phases":25453,"completion":5562,"start":7494,"enrollment":170,"conditions":25454,"interventions":25455},"NCT00351169",[92],[18697],[25456,23677],"Quetiapine SR",{"trials":25458,"activeCount":102},[],{"trials":25460,"activeCount":102},[],{"intervention":10283,"totalTrials":3887,"cells":25462},{"EARLY_PHASE1":25463,"PHASE1":25465,"PHASE2":25467,"PHASE3":25469,"PHASE4":25490,"NA":25492},{"trials":25464,"activeCount":102},[],{"trials":25466,"activeCount":102},[],{"trials":25468,"activeCount":102},[],{"trials":25470,"activeCount":102},[25471,25482,25486],{"nctId":25472,"briefTitle":25473,"status":195,"phases":25474,"primaryCompletion":13166,"completion":13166,"start":25475,"enrollment":25476,"conditions":25477,"interventions":25478},"NCT05202262","A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)",[92],"2022-01-12",645,[16],[10283,25479,25480,25481],"BFF MDI 160\u002F9.6 μg","BD MDI 320 μg","Open-label Symbicort TBH 320\u002F9 μg",{"nctId":10274,"briefTitle":10275,"status":195,"phases":25483,"primaryCompletion":10277,"completion":10277,"start":10278,"enrollment":10279,"conditions":25484,"interventions":25485},[92],[16],[10282,10263,10283,10284],{"nctId":10286,"briefTitle":10287,"status":195,"phases":25487,"primaryCompletion":10289,"completion":10289,"start":504,"enrollment":10290,"conditions":25488,"interventions":25489},[92],[16],[10282,10263,10283,10284],{"trials":25491,"activeCount":102},[],{"trials":25493,"activeCount":102},[],{"intervention":23085,"totalTrials":3887,"cells":25495},{"EARLY_PHASE1":25496,"PHASE1":25498,"PHASE2":25511,"PHASE3":25513,"PHASE4":25522,"NA":25524},{"trials":25497,"activeCount":102},[],{"trials":25499,"activeCount":102},[25500,25504],{"nctId":23080,"briefTitle":23081,"status":195,"phases":25501,"primaryCompletion":687,"completion":687,"start":4580,"enrollment":14693,"conditions":25502,"interventions":25503},[90],[13022],[12588,19198,23085],{"nctId":25505,"briefTitle":25506,"status":195,"phases":25507,"primaryCompletion":2736,"completion":2736,"start":2675,"enrollment":14693,"conditions":25508,"interventions":25509},"NCT01431690","Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals",[90],[13022],[22826,23085,25510],"omega-3-acid ethyl esters",{"trials":25512,"activeCount":102},[],{"trials":25514,"activeCount":102},[25515],{"nctId":25516,"briefTitle":25517,"status":195,"phases":25518,"primaryCompletion":687,"completion":4496,"start":2516,"enrollment":25519,"conditions":25520,"interventions":25521},"NCT01242527","Epanova® for Lowering Very High Triglycerides",[91,92],399,[24774],[23085,23085,23085],{"trials":25523,"activeCount":102},[],{"trials":25525,"activeCount":102},[],{"intervention":25527,"totalTrials":3887,"cells":25528},"Roflumilast placebo",{"EARLY_PHASE1":25529,"PHASE1":25531,"PHASE2":25542,"PHASE3":25551,"PHASE4":25564,"NA":25566},{"trials":25530,"activeCount":102},[],{"trials":25532,"activeCount":102},[25533],{"nctId":25534,"briefTitle":25535,"status":195,"phases":25536,"primaryCompletion":2203,"completion":2203,"start":2480,"enrollment":2003,"conditions":25537,"interventions":25539},"NCT02051335","Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults",[90],[25538,18867],"Memory Impairment",[10068,25527,23078,25540,25541],"Donepezil placebo","Scopolamine",{"trials":25543,"activeCount":102},[25544],{"nctId":25545,"briefTitle":25546,"status":195,"phases":25547,"primaryCompletion":4204,"completion":4204,"start":2405,"enrollment":4307,"conditions":25548,"interventions":25549},"NCT01765192","Roflumilast Plus Montelukast in Adults With Severe Asthma",[91],[16],[10068,25527,25550],"Montelukast",{"trials":25552,"activeCount":102},[25553],{"nctId":25554,"briefTitle":25555,"status":195,"phases":25556,"primaryCompletion":25557,"completion":25557,"start":25558,"enrollment":25559,"conditions":25560,"interventions":25561},"NCT02165826","Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD",[92],"2015-09-01","2014-05-01",1323,[6083],[10068,25562,25563],"Roflumilast Placebo","Standard of Care COPD Treatment",{"trials":25565,"activeCount":102},[],{"trials":25567,"activeCount":102},[],{"intervention":25569,"totalTrials":447,"cells":25570},"budesonide\u002Fformoterol 'as needed' + budesonide placebo bid",{"EARLY_PHASE1":25571,"PHASE1":25573,"PHASE2":25575,"PHASE3":25577,"PHASE4":25600,"NA":25602},{"trials":25572,"activeCount":102},[],{"trials":25574,"activeCount":102},[],{"trials":25576,"activeCount":102},[],{"trials":25578,"activeCount":102},[25579,25590],{"nctId":25580,"briefTitle":25581,"status":195,"phases":25582,"primaryCompletion":25583,"completion":25583,"start":25584,"enrollment":25585,"conditions":25586,"interventions":25587},"NCT02149199","A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.",[92],"2017-08-02","2014-07-07",3850,[16],[25569,25588,25589],"terbutaline 'as needed' + placebo budesonide bid","budesonide bid + terbutaline 'as needed'",{"nctId":25591,"briefTitle":25592,"status":195,"phases":25593,"primaryCompletion":25594,"completion":25594,"start":25595,"enrollment":25596,"conditions":25597,"interventions":25598},"NCT02224157","A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma",[92],"2017-08-16","2014-11-28",4215,[16],[25569,25599],"budesonode bid + terbutaline 'as needed'",{"trials":25601,"activeCount":102},[],{"trials":25603,"activeCount":102},[],{"intervention":19490,"totalTrials":447,"cells":25605},{"EARLY_PHASE1":25606,"PHASE1":25608,"PHASE2":25610,"PHASE3":25612,"PHASE4":25622,"NA":25624},{"trials":25607,"activeCount":102},[],{"trials":25609,"activeCount":102},[],{"trials":25611,"activeCount":102},[],{"trials":25613,"activeCount":102},[25614,25618],{"nctId":24221,"briefTitle":24222,"status":195,"phases":25615,"primaryCompletion":2251,"completion":2251,"start":2415,"enrollment":24224,"conditions":25616,"interventions":25617},[92],[24226],[24202,24228,19490],{"nctId":19485,"briefTitle":19486,"status":195,"phases":25619,"primaryCompletion":2151,"completion":2151,"start":2095,"enrollment":1373,"conditions":25620,"interventions":25621},[92],[16],[9972,19490],{"trials":25623,"activeCount":102},[],{"trials":25625,"activeCount":102},[],{"intervention":25627,"totalTrials":447,"cells":25628},"Aclidinium bromide 200 μg bid",{"EARLY_PHASE1":25629,"PHASE1":25631,"PHASE2":25633,"PHASE3":25644,"PHASE4":25654,"NA":25656},{"trials":25630,"activeCount":102},[],{"trials":25632,"activeCount":102},[],{"trials":25634,"activeCount":102},[25635],{"nctId":25636,"briefTitle":25637,"status":195,"phases":25638,"primaryCompletion":2144,"completion":2144,"start":2243,"enrollment":464,"conditions":25639,"interventions":25640},"NCT01120093","Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.",[91],[6083],[25641,25627,25642,25643],"Aclidinium bromide 100 μg bid","Aclidininum bromide 400 μg bid","Formoterol 12 μg bid",{"trials":25645,"activeCount":102},[25646],{"nctId":25647,"briefTitle":25648,"status":195,"phases":25649,"primaryCompletion":2349,"completion":2349,"start":2350,"enrollment":25650,"conditions":25651,"interventions":25652},"NCT01001494","Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients",[92],828,[6083],[25627,25653],"Aclidinium bromide 400 μg bid",{"trials":25655,"activeCount":102},[],{"trials":25657,"activeCount":102},[],{"intervention":25653,"totalTrials":447,"cells":25659},{"EARLY_PHASE1":25660,"PHASE1":25662,"PHASE2":25664,"PHASE3":25673,"PHASE4":25679,"NA":25681},{"trials":25661,"activeCount":102},[],{"trials":25663,"activeCount":102},[],{"trials":25665,"activeCount":102},[25666],{"nctId":25667,"briefTitle":25668,"status":195,"phases":25669,"primaryCompletion":2068,"completion":2068,"start":2077,"enrollment":1710,"conditions":25670,"interventions":25671},"NCT00868231","Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],[6083],[25653,25672],"Tiotropium 18 μg once-daily",{"trials":25674,"activeCount":102},[25675],{"nctId":25647,"briefTitle":25648,"status":195,"phases":25676,"primaryCompletion":2349,"completion":2349,"start":2350,"enrollment":25650,"conditions":25677,"interventions":25678},[92],[6083],[25627,25653],{"trials":25680,"activeCount":102},[],{"trials":25682,"activeCount":102},[],{"intervention":24053,"totalTrials":447,"cells":25684},{"EARLY_PHASE1":25685,"PHASE1":25687,"PHASE2":25689,"PHASE3":25691,"PHASE4":25701,"NA":25703},{"trials":25686,"activeCount":102},[],{"trials":25688,"activeCount":102},[],{"trials":25690,"activeCount":102},[],{"trials":25692,"activeCount":102},[25693,25697],{"nctId":24047,"briefTitle":24048,"status":195,"phases":25694,"primaryCompletion":3228,"completion":3228,"start":2597,"enrollment":24050,"conditions":25695,"interventions":25696},[92],[10066],[24053,20252,24026],{"nctId":24063,"briefTitle":24064,"status":195,"phases":25698,"primaryCompletion":2746,"completion":2746,"start":4496,"enrollment":24066,"conditions":25699,"interventions":25700},[92],[28],[24053,24053,20252,24026],{"trials":25702,"activeCount":102},[],{"trials":25704,"activeCount":102},[],{"intervention":18966,"totalTrials":447,"cells":25706},{"EARLY_PHASE1":25707,"PHASE1":25709,"PHASE2":25715,"PHASE3":25717,"PHASE4":25723,"NA":25725},{"trials":25708,"activeCount":102},[],{"trials":25710,"activeCount":102},[25711],{"nctId":18960,"briefTitle":18961,"status":195,"phases":25712,"primaryCompletion":2212,"completion":2212,"start":2114,"enrollment":1130,"conditions":25713,"interventions":25714},[90],[22],[18965,2333,18966],{"trials":25716,"activeCount":102},[],{"trials":25718,"activeCount":102},[25719],{"nctId":15951,"briefTitle":15952,"status":195,"phases":25720,"primaryCompletion":2639,"completion":2114,"start":9065,"enrollment":15954,"conditions":25721,"interventions":25722},[92],[2089],[15957,15957,15957,2448],{"trials":25724,"activeCount":102},[],{"trials":25726,"activeCount":102},[],{"intervention":13105,"totalTrials":447,"cells":25728},{"EARLY_PHASE1":25729,"PHASE1":25731,"PHASE2":25733,"PHASE3":25739,"PHASE4":25745,"NA":25747},{"trials":25730,"activeCount":102},[],{"trials":25732,"activeCount":102},[],{"trials":25734,"activeCount":102},[25735],{"nctId":13099,"briefTitle":13100,"status":195,"phases":25736,"primaryCompletion":2580,"completion":13102,"start":13014,"enrollment":1428,"conditions":25737,"interventions":25738},[91],[417],[268,13105],{"trials":25740,"activeCount":102},[25741],{"nctId":13120,"briefTitle":13121,"status":195,"phases":25742,"primaryCompletion":2212,"completion":13123,"start":7342,"enrollment":13124,"conditions":25743,"interventions":25744},[92],[5121],[268,4774,4775,13105],{"trials":25746,"activeCount":102},[],{"trials":25748,"activeCount":102},[],{"intervention":25750,"totalTrials":447,"cells":25751},"MEDI3250",{"EARLY_PHASE1":25752,"PHASE1":25754,"PHASE2":25756,"PHASE3":25758,"PHASE4":25775,"NA":25777},{"trials":25753,"activeCount":102},[],{"trials":25755,"activeCount":102},[],{"trials":25757,"activeCount":102},[],{"trials":25759,"activeCount":102},[25760,25768],{"nctId":25761,"briefTitle":25762,"status":195,"phases":25763,"primaryCompletion":16033,"completion":16033,"start":6436,"enrollment":25764,"conditions":25765,"interventions":25767},"NCT02269475","A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years",[92],1369,[25766],"Healthy Japanese Children Age 7 Years Through 18 Years",[25750],{"nctId":25769,"briefTitle":25770,"status":195,"phases":25771,"primaryCompletion":2561,"completion":2561,"start":16044,"enrollment":221,"conditions":25772,"interventions":25774},"NCT02269488","A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years",[92],[25773],"Healthy Japanese Children Age 2 Years Through 6 Years",[25750],{"trials":25776,"activeCount":102},[],{"trials":25778,"activeCount":102},[],{"intervention":19455,"totalTrials":447,"cells":25780},{"EARLY_PHASE1":25781,"PHASE1":25783,"PHASE2":25785,"PHASE3":25787,"PHASE4":25800,"NA":25802},{"trials":25782,"activeCount":102},[],{"trials":25784,"activeCount":102},[],{"trials":25786,"activeCount":102},[],{"trials":25788,"activeCount":102},[25789,25793],{"nctId":19450,"briefTitle":19451,"status":195,"phases":25790,"completion":4297,"start":2639,"enrollment":1173,"conditions":25791,"interventions":25792},[92],[16],[9857,19455],{"nctId":25794,"briefTitle":25795,"status":195,"phases":25796,"primaryCompletion":2220,"completion":3827,"start":7494,"enrollment":1543,"conditions":25797,"interventions":25798},"NCT00306163","Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010\u002FNL-101)",[92],[16],[10076,25799],"Fluticasone",{"trials":25801,"activeCount":102},[],{"trials":25803,"activeCount":102},[],{"intervention":25805,"totalTrials":447,"cells":25806},"Daptomycin",{"EARLY_PHASE1":25807,"PHASE1":25809,"PHASE2":25817,"PHASE3":25819,"PHASE4":25830,"NA":25832},{"trials":25808,"activeCount":102},[],{"trials":25810,"activeCount":102},[25811],{"nctId":25812,"briefTitle":25813,"status":195,"phases":25814,"completion":2077,"start":2095,"enrollment":1130,"conditions":25815,"interventions":25816},"NCT00858325","Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China",[90],[19],[25805],{"trials":25818,"activeCount":102},[],{"trials":25820,"activeCount":102},[25821],{"nctId":25822,"briefTitle":25823,"status":195,"phases":25824,"primaryCompletion":3862,"completion":3862,"start":3827,"enrollment":4381,"conditions":25825,"interventions":25828},"NCT00772447","China Registration Study in Patients With Skin Infections",[92],[25826,25827],"Skin Diseases","Infectious",[25805,25829],"Vancomycin",{"trials":25831,"activeCount":102},[],{"trials":25833,"activeCount":102},[],{"intervention":2565,"totalTrials":447,"cells":25835},{"EARLY_PHASE1":25836,"PHASE1":25838,"PHASE2":25844,"PHASE3":25846,"PHASE4":25852,"NA":25854},{"trials":25837,"activeCount":102},[],{"trials":25839,"activeCount":102},[25840],{"nctId":23481,"briefTitle":23482,"status":443,"phases":25841,"primaryCompletion":2746,"completion":2746,"start":2432,"enrollment":1979,"conditions":25842,"interventions":25843},[90],[22],[2565,2108,2475,23486,2061],{"trials":25845,"activeCount":102},[],{"trials":25847,"activeCount":102},[25848],{"nctId":2557,"briefTitle":2558,"status":195,"phases":25849,"primaryCompletion":2560,"completion":2561,"start":2432,"enrollment":2562,"conditions":25850,"interventions":25851},[92],[31],[2044,2108,2565],{"trials":25853,"activeCount":102},[],{"trials":25855,"activeCount":102},[],{"intervention":25857,"totalTrials":447,"cells":25858},"Glipizide",{"EARLY_PHASE1":25859,"PHASE1":25861,"PHASE2":25863,"PHASE3":25872,"PHASE4":25878,"NA":25880},{"trials":25860,"activeCount":102},[],{"trials":25862,"activeCount":102},[],{"trials":25864,"activeCount":102},[25865],{"nctId":25866,"briefTitle":25867,"status":195,"phases":25868,"primaryCompletion":2433,"completion":2433,"start":2350,"enrollment":18755,"conditions":25869,"interventions":25871},"NCT01020123","Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients",[91],[25870],"Type II Diabetes Mellitus",[15883,25857],{"trials":25873,"activeCount":102},[25874],{"nctId":2576,"briefTitle":2577,"status":195,"phases":25875,"primaryCompletion":2055,"completion":2579,"start":2580,"enrollment":2581,"conditions":25876,"interventions":25877},[92],[31],[2246,2584,2500],{"trials":25879,"activeCount":102},[],{"trials":25881,"activeCount":102},[],{"intervention":23861,"totalTrials":447,"cells":25883},{"EARLY_PHASE1":25884,"PHASE1":25886,"PHASE2":25892,"PHASE3":25894,"PHASE4":25900,"NA":25902},{"trials":25885,"activeCount":102},[],{"trials":25887,"activeCount":102},[25888],{"nctId":23855,"briefTitle":23856,"status":195,"phases":25889,"primaryCompletion":2144,"completion":2615,"start":2152,"enrollment":1979,"conditions":25890,"interventions":25891},[90],[23859],[23848,23861],{"trials":25893,"activeCount":102},[],{"trials":25895,"activeCount":102},[25896],{"nctId":23899,"briefTitle":23900,"status":195,"phases":25897,"primaryCompletion":2542,"completion":2542,"start":2068,"enrollment":12547,"conditions":25898,"interventions":25899},[91,92],[23859],[23848,23861],{"trials":25901,"activeCount":102},[],{"trials":25903,"activeCount":102},[],{"intervention":25905,"totalTrials":447,"cells":25906},"ICI35,868",{"EARLY_PHASE1":25907,"PHASE1":25909,"PHASE2":25911,"PHASE3":25921,"PHASE4":25931,"NA":25933},{"trials":25908,"activeCount":102},[],{"trials":25910,"activeCount":102},[],{"trials":25912,"activeCount":102},[25913],{"nctId":25914,"briefTitle":25915,"status":195,"phases":25916,"primaryCompletion":2349,"completion":2349,"start":2144,"enrollment":19236,"conditions":25917,"interventions":25920},"NCT01189604","Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests",[91],[25918,25919],"Gastrointestinal Endoscopy","Gastrointestinal Polypectomy",[25905,25905,25905,25905,25905,25905],{"trials":25922,"activeCount":102},[25923],{"nctId":25924,"briefTitle":25925,"status":195,"phases":25926,"primaryCompletion":4006,"completion":4006,"start":4204,"enrollment":831,"conditions":25927,"interventions":25929},"NCT01961349","Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645\u002FA (SDS) on Gastrointestinal Endoscopy",[92],[25928],"Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy",[25930,25905,25905],"Intralipid",{"trials":25932,"activeCount":102},[],{"trials":25934,"activeCount":102},[],{"intervention":9858,"totalTrials":447,"cells":25936},{"EARLY_PHASE1":25937,"PHASE1":25939,"PHASE2":25941,"PHASE3":25947,"PHASE4":25953,"NA":25955},{"trials":25938,"activeCount":102},[],{"trials":25940,"activeCount":102},[],{"trials":25942,"activeCount":102},[25943],{"nctId":9851,"briefTitle":9852,"status":195,"phases":25944,"primaryCompletion":2406,"completion":2406,"start":2067,"enrollment":4928,"conditions":25945,"interventions":25946},[91],[9855],[9857,9858,9842],{"trials":25948,"activeCount":102},[25949],{"nctId":19515,"briefTitle":19516,"status":195,"phases":25950,"completion":6718,"start":6370,"enrollment":19518,"conditions":25951,"interventions":25952},[92],[16],[9972,9882,19521],{"trials":25954,"activeCount":102},[],{"trials":25956,"activeCount":102},[],{"intervention":25958,"totalTrials":447,"cells":25959},"BGF MDI HFA 320\u002F14.4\u002F9.6 μg",{"EARLY_PHASE1":25960,"PHASE1":25962,"PHASE2":25964,"PHASE3":25966,"PHASE4":25985,"NA":25987},{"trials":25961,"activeCount":102},[],{"trials":25963,"activeCount":102},[],{"trials":25965,"activeCount":102},[],{"trials":25967,"activeCount":102},[25968,25975],{"nctId":25969,"briefTitle":25970,"status":195,"phases":25971,"primaryCompletion":445,"completion":445,"start":6061,"enrollment":1192,"conditions":25972,"interventions":25973},"NCT05573464","A Study to Assess the Safety of Budesonide\u002FGlycopyrronium\u002FFormoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",[92],[6083],[25974,25958],"BGF MDI HFO 320\u002F14.4\u002F9.6 μg",{"nctId":25976,"briefTitle":25977,"status":195,"phases":25978,"primaryCompletion":25979,"completion":25979,"start":25980,"enrollment":25981,"conditions":25982,"interventions":25983},"NCT06075095","A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD",[92],"2025-08-12","2024-01-11",297,[10299],[25984,25958],"BGF MDI HFO 320\u002F14.4\u002F9.6μg",{"trials":25986,"activeCount":102},[],{"trials":25988,"activeCount":102},[],{"intervention":25990,"totalTrials":447,"cells":25991},"EXANTA",{"EARLY_PHASE1":25992,"PHASE1":25994,"PHASE2":25996,"PHASE3":26005,"PHASE4":26015,"NA":26017},{"trials":25993,"activeCount":102},[],{"trials":25995,"activeCount":102},[],{"trials":25997,"activeCount":102},[25998],{"nctId":25999,"briefTitle":26000,"status":443,"phases":26001,"primaryCompletion":6445,"completion":6369,"start":12740,"enrollment":1832,"conditions":26002,"interventions":26004},"NCT00206063","Long Term Open Follow-up With H376\u002F95 vs. Warfarin",[91],[26003],"Stroke Prevention in Patients With Atrial Fibrillation",[25990],{"trials":26006,"activeCount":102},[26007],{"nctId":26008,"briefTitle":26009,"status":443,"phases":26010,"primaryCompletion":4916,"completion":4916,"start":6719,"enrollment":26011,"conditions":26012,"interventions":26014},"NCT00206089","Melagatran\u002FXimelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events",[92],3300,[26013],"Thromboembolism",[25990],{"trials":26016,"activeCount":102},[],{"trials":26018,"activeCount":102},[],{"intervention":25456,"totalTrials":447,"cells":26020},{"EARLY_PHASE1":26021,"PHASE1":26023,"PHASE2":26025,"PHASE3":26027,"PHASE4":26040,"NA":26042},{"trials":26022,"activeCount":102},[],{"trials":26024,"activeCount":102},[],{"trials":26026,"activeCount":102},[],{"trials":26028,"activeCount":102},[26029,26036],{"nctId":26030,"briefTitle":26031,"status":195,"phases":26032,"completion":5725,"start":2087,"enrollment":26033,"conditions":26034,"interventions":26035},"NCT00314210","Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.",[92],575,[20021],[25456],{"nctId":25452,"briefTitle":23670,"status":195,"phases":26037,"completion":5562,"start":7494,"enrollment":170,"conditions":26038,"interventions":26039},[92],[18697],[25456,23677],{"trials":26041,"activeCount":102},[],{"trials":26043,"activeCount":102},[],{"intervention":20820,"totalTrials":447,"cells":26045},{"EARLY_PHASE1":26046,"PHASE1":26048,"PHASE2":26057,"PHASE3":26059,"PHASE4":26065,"NA":26067},{"trials":26047,"activeCount":102},[],{"trials":26049,"activeCount":102},[26050],{"nctId":26051,"briefTitle":26052,"status":195,"phases":26053,"primaryCompletion":13787,"completion":13787,"start":13056,"enrollment":2069,"conditions":26054,"interventions":26055},"NCT02582840","The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM",[90],[2369],[26056,20820],"Dapagliflozin 5mg",{"trials":26058,"activeCount":102},[],{"trials":26060,"activeCount":102},[26061],{"nctId":20813,"briefTitle":20814,"status":195,"phases":26062,"primaryCompletion":20816,"completion":20816,"start":20817,"enrollment":20,"conditions":26063,"interventions":26064},[92],[2369],[19117,20820],{"trials":26066,"activeCount":102},[],{"trials":26068,"activeCount":102},[],{"intervention":26070,"totalTrials":447,"cells":26071},"Brazikumab Induction Dose",{"EARLY_PHASE1":26072,"PHASE1":26074,"PHASE2":26076,"PHASE3":26087,"PHASE4":26097,"NA":26099},{"trials":26073,"activeCount":102},[],{"trials":26075,"activeCount":102},[],{"trials":26077,"activeCount":102},[26078],{"nctId":26079,"briefTitle":26080,"status":443,"phases":26081,"primaryCompletion":26082,"completion":26082,"start":26083,"enrollment":4215,"conditions":26084,"interventions":26085},"NCT04277546","Open-label Extension Study of Brazikumab in Ulcerative Colitis",[91],"2023-10-10","2020-03-03",[24899],[26086,26070],"Brazikumab Maintenance Dose",{"trials":26088,"activeCount":102},[26089],{"nctId":26090,"briefTitle":26091,"status":443,"phases":26092,"primaryCompletion":5407,"completion":5407,"start":26093,"enrollment":1336,"conditions":26094,"interventions":26096},"NCT03961815","Open-label Extension Study of Brazikumab in Crohn's Disease",[92],"2020-01-06",[13237,26095],"IBD",[26070,26086],{"trials":26098,"activeCount":102},[],{"trials":26100,"activeCount":102},[],{"intervention":26086,"totalTrials":447,"cells":26102},{"EARLY_PHASE1":26103,"PHASE1":26105,"PHASE2":26107,"PHASE3":26113,"PHASE4":26119,"NA":26121},{"trials":26104,"activeCount":102},[],{"trials":26106,"activeCount":102},[],{"trials":26108,"activeCount":102},[26109],{"nctId":26079,"briefTitle":26080,"status":443,"phases":26110,"primaryCompletion":26082,"completion":26082,"start":26083,"enrollment":4215,"conditions":26111,"interventions":26112},[91],[24899],[26086,26070],{"trials":26114,"activeCount":102},[26115],{"nctId":26090,"briefTitle":26091,"status":443,"phases":26116,"primaryCompletion":5407,"completion":5407,"start":26093,"enrollment":1336,"conditions":26117,"interventions":26118},[92],[13237,26095],[26070,26086],{"trials":26120,"activeCount":102},[],{"trials":26122,"activeCount":102},[],{"intervention":26124,"totalTrials":447,"cells":26125},"AZD0585",{"EARLY_PHASE1":26126,"PHASE1":26128,"PHASE2":26136,"PHASE3":26138,"PHASE4":26149,"NA":26151},{"trials":26127,"activeCount":102},[],{"trials":26129,"activeCount":102},[26130],{"nctId":26131,"briefTitle":26132,"status":195,"phases":26133,"primaryCompletion":13756,"completion":13756,"start":25278,"enrollment":132,"conditions":26134,"interventions":26135},"NCT02372344","A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects",[90],[19],[26124],{"trials":26137,"activeCount":102},[],{"trials":26139,"activeCount":102},[26140],{"nctId":26141,"briefTitle":26142,"status":195,"phases":26143,"primaryCompletion":26144,"completion":26144,"start":495,"enrollment":26145,"conditions":26146,"interventions":26147},"NCT02463071","AZD0585 Phase III Long-term Study in Japan",[92],"2017-03-11",383,[13022],[26124,26148],"AZD0585 placebo",{"trials":26150,"activeCount":102},[],{"trials":26152,"activeCount":102},[],{"intervention":26154,"totalTrials":447,"cells":26155},"Tiotropium 18 μg",{"EARLY_PHASE1":26156,"PHASE1":26158,"PHASE2":26175,"PHASE3":26177,"PHASE4":26191,"NA":26193},{"trials":26157,"activeCount":102},[],{"trials":26159,"activeCount":102},[26160],{"nctId":26161,"briefTitle":26162,"status":195,"phases":26163,"primaryCompletion":26164,"completion":26164,"start":26165,"enrollment":2783,"conditions":26166,"interventions":26167},"NCT02059434","Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD",[90],"2014-10-06","2013-09-01",[6083,16],[26168,26169,26170,26171,26172,26173,26168,26169,26154,26174],"LAS190792 Dose 1","LAS190792 Dose 2","LAS190792 Dose 3","LAS190792 Dose 4","LAS190792 Dose 5","LAS190792 Dose 6","Indacaterol 150 μg",{"trials":26176,"activeCount":102},[],{"trials":26178,"activeCount":102},[26179],{"nctId":26180,"briefTitle":26181,"status":195,"phases":26182,"primaryCompletion":26183,"completion":26183,"start":26184,"enrollment":26185,"conditions":26186,"interventions":26187},"NCT02796677","AMPLIFY - D6571C00001 Duaklir USA Phase III Study",[92],"2017-06-08","2016-07-05",1595,[28],[26188,26189,26190,26154],"Aclidinium bromide 400 μg\u002FFormoterol Fumarate 12 μg","Aclidinium bromide 400 μg","Formoterol fumarate 12 μg",{"trials":26192,"activeCount":102},[],{"trials":26194,"activeCount":102},[],{"intervention":26196,"totalTrials":447,"cells":26197},"Quetiapine fumarate (Seroquel) SR",{"EARLY_PHASE1":26198,"PHASE1":26200,"PHASE2":26202,"PHASE3":26204,"PHASE4":26221,"NA":26223},{"trials":26199,"activeCount":102},[],{"trials":26201,"activeCount":102},[],{"trials":26203,"activeCount":102},[],{"trials":26205,"activeCount":102},[26206,26215],{"nctId":26207,"briefTitle":26208,"status":195,"phases":26209,"completion":5562,"start":5742,"enrollment":1078,"conditions":26210,"interventions":26214},"NCT00422214","Phase III\u002FSeroquel SR Bipolar Depression Monotherapy - US",[92],[26211,20585,26212,26213],"Affective Psychosis, Bipolar","Manic-Depressive Psychosis","Psychoses, Manic-Depressive",[26196],{"nctId":26216,"briefTitle":26217,"status":195,"phases":26218,"completion":2252,"start":13014,"enrollment":1675,"conditions":26219,"interventions":26220},"NCT00422123","Phase 3 \u002FSeroquel SR Acute Mania Monotherapy - US",[92],[26211,21145,26212,18818,21146,26213],[26196],{"trials":26222,"activeCount":102},[],{"trials":26224,"activeCount":102},[],{"intervention":26226,"totalTrials":447,"cells":26227},"Aclidinium Bromide 400 μg",{"EARLY_PHASE1":26228,"PHASE1":26230,"PHASE2":26240,"PHASE3":26242,"PHASE4":26248,"NA":26250},{"trials":26229,"activeCount":102},[],{"trials":26231,"activeCount":102},[26232],{"nctId":26233,"briefTitle":26234,"status":195,"phases":26235,"primaryCompletion":26236,"completion":26236,"start":26237,"enrollment":5876,"conditions":26238,"interventions":26239},"NCT03276052","A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants",[90],"2021-11-26","2021-10-14",[36],[26226],{"trials":26241,"activeCount":102},[],{"trials":26243,"activeCount":102},[26244],{"nctId":26180,"briefTitle":26181,"status":195,"phases":26245,"primaryCompletion":26183,"completion":26183,"start":26184,"enrollment":26185,"conditions":26246,"interventions":26247},[92],[28],[26188,26189,26190,26154],{"trials":26249,"activeCount":102},[],{"trials":26251,"activeCount":102},[],{"intervention":5243,"totalTrials":447,"cells":26253},{"EARLY_PHASE1":26254,"PHASE1":26256,"PHASE2":26258,"PHASE3":26264,"PHASE4":26270,"NA":26272},{"trials":26255,"activeCount":102},[],{"trials":26257,"activeCount":102},[],{"trials":26259,"activeCount":102},[26260],{"nctId":5235,"briefTitle":5236,"status":195,"phases":26261,"primaryCompletion":5238,"completion":4106,"start":4537,"enrollment":5239,"conditions":26262,"interventions":26263},[91],[5241],[82,3137,5243],{"trials":26265,"activeCount":102},[26266],{"nctId":8170,"briefTitle":8171,"status":195,"phases":26267,"primaryCompletion":8173,"completion":8174,"start":8175,"enrollment":6532,"conditions":26268,"interventions":26269},[92],[8177],[82,5243,8179],{"trials":26271,"activeCount":102},[],{"trials":26273,"activeCount":102},[],{"intervention":26275,"totalTrials":447,"cells":26276},"Rosuvastatin 20mg",{"EARLY_PHASE1":26277,"PHASE1":26279,"PHASE2":26281,"PHASE3":26283,"PHASE4":26300,"NA":26302},{"trials":26278,"activeCount":102},[],{"trials":26280,"activeCount":102},[],{"trials":26282,"activeCount":102},[],{"trials":26284,"activeCount":102},[26285,26294],{"nctId":26286,"briefTitle":26287,"status":195,"phases":26288,"primaryCompletion":26289,"completion":26289,"start":26290,"enrollment":4343,"conditions":26291,"interventions":26293},"NCT02434497","A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia",[92],"2016-11-17","2015-06-06",[26292],"Homozygous Familial Hypercholesterolemia (HoFH)",[26275],{"nctId":26295,"briefTitle":26296,"status":195,"phases":26297,"primaryCompletion":24772,"completion":24772,"start":16044,"enrollment":5876,"conditions":26298,"interventions":26299},"NCT02226198","A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia",[92],[26292],[26275],{"trials":26301,"activeCount":102},[],{"trials":26303,"activeCount":102},[],{"intervention":13184,"totalTrials":447,"cells":26305},{"EARLY_PHASE1":26306,"PHASE1":26308,"PHASE2":26314,"PHASE3":26316,"PHASE4":26322,"NA":26324},{"trials":26307,"activeCount":102},[],{"trials":26309,"activeCount":102},[26310],{"nctId":13177,"briefTitle":13178,"status":195,"phases":26311,"primaryCompletion":13155,"completion":13155,"start":13180,"enrollment":486,"conditions":26312,"interventions":26313},[90],[13158,5851],[13145,5870,13183,13184],{"trials":26315,"activeCount":102},[],{"trials":26317,"activeCount":102},[26318],{"nctId":23669,"briefTitle":23670,"status":195,"phases":26319,"completion":7439,"start":7494,"enrollment":23672,"conditions":26320,"interventions":26321},[92],[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],{"trials":26323,"activeCount":102},[],{"trials":26325,"activeCount":102},[],{"intervention":23679,"totalTrials":447,"cells":26327},{"EARLY_PHASE1":26328,"PHASE1":26330,"PHASE2":26332,"PHASE3":26334,"PHASE4":26348,"NA":26350},{"trials":26329,"activeCount":102},[],{"trials":26331,"activeCount":102},[],{"trials":26333,"activeCount":102},[],{"trials":26335,"activeCount":102},[26336,26340],{"nctId":23669,"briefTitle":23670,"status":195,"phases":26337,"completion":7439,"start":7494,"enrollment":23672,"conditions":26338,"interventions":26339},[92],[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],{"nctId":26341,"briefTitle":26342,"status":195,"phases":26343,"primaryCompletion":2433,"completion":2433,"start":688,"enrollment":2003,"conditions":26344,"interventions":26345},"NCT00857584","Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy",[92],[18732,18733],[26346,23679,26347],"Extended release quetiapine","adequate mood stabilizer",{"trials":26349,"activeCount":102},[],{"trials":26351,"activeCount":102},[],{"intervention":26353,"totalTrials":447,"cells":26354},"Benralizumab Arm A",{"EARLY_PHASE1":26355,"PHASE1":26357,"PHASE2":26359,"PHASE3":26361,"PHASE4":26383,"NA":26385},{"trials":26356,"activeCount":102},[],{"trials":26358,"activeCount":102},[],{"trials":26360,"activeCount":102},[],{"trials":26362,"activeCount":102},[26363,26375],{"nctId":26364,"briefTitle":26365,"status":195,"phases":26366,"primaryCompletion":26367,"completion":26367,"start":26368,"enrollment":26369,"conditions":26370,"interventions":26372},"NCT02155660","Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History",[92],"2018-04-09","2014-06-25",2255,[26371],"Moderate to Very Severe Chronic Obstructive Pulmonary Disease",[26353,26373,26374],"Benralizumab Arm B","Benralizumab Arm C",{"nctId":26376,"briefTitle":26377,"status":195,"phases":26378,"primaryCompletion":26379,"completion":26379,"start":24918,"enrollment":26380,"conditions":26381,"interventions":26382},"NCT02138916","Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History",[92],"2018-04-10",1656,[26371],[26353,26373],{"trials":26384,"activeCount":102},[],{"trials":26386,"activeCount":102},[],{"intervention":26373,"totalTrials":447,"cells":26388},{"EARLY_PHASE1":26389,"PHASE1":26391,"PHASE2":26393,"PHASE3":26395,"PHASE4":26405,"NA":26407},{"trials":26390,"activeCount":102},[],{"trials":26392,"activeCount":102},[],{"trials":26394,"activeCount":102},[],{"trials":26396,"activeCount":102},[26397,26401],{"nctId":26364,"briefTitle":26365,"status":195,"phases":26398,"primaryCompletion":26367,"completion":26367,"start":26368,"enrollment":26369,"conditions":26399,"interventions":26400},[92],[26371],[26353,26373,26374],{"nctId":26376,"briefTitle":26377,"status":195,"phases":26402,"primaryCompletion":26379,"completion":26379,"start":24918,"enrollment":26380,"conditions":26403,"interventions":26404},[92],[26371],[26353,26373],{"trials":26406,"activeCount":102},[],{"trials":26408,"activeCount":102},[],{"intervention":26410,"totalTrials":447,"cells":26411},"MEDI8897",{"EARLY_PHASE1":26412,"PHASE1":26414,"PHASE2":26416,"PHASE3":26418,"PHASE4":26439,"NA":26441},{"trials":26413,"activeCount":102},[],{"trials":26415,"activeCount":102},[],{"trials":26417,"activeCount":102},[],{"trials":26419,"activeCount":102},[26420,26429],{"nctId":26421,"briefTitle":26422,"status":195,"phases":26423,"primaryCompletion":23556,"completion":26424,"start":26425,"enrollment":26426,"conditions":26427,"interventions":26428},"NCT03979313","A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)",[92],"2023-03-21","2019-07-23",3012,[24836],[26410],{"nctId":26430,"briefTitle":26431,"status":195,"phases":26432,"primaryCompletion":26433,"completion":26434,"start":6080,"enrollment":26435,"conditions":26436,"interventions":26437},"NCT03959488","A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children",[91,92],"2021-05-03","2023-01-20",925,[24836],[26410,26438],"Palivizumab",{"trials":26440,"activeCount":102},[],{"trials":26442,"activeCount":102},[],{"intervention":20296,"totalTrials":447,"cells":26444},{"EARLY_PHASE1":26445,"PHASE1":26447,"PHASE2":26449,"PHASE3":26451,"PHASE4":26461,"NA":26463},{"trials":26446,"activeCount":102},[],{"trials":26448,"activeCount":102},[],{"trials":26450,"activeCount":102},[],{"trials":26452,"activeCount":102},[26453,26457],{"nctId":20290,"briefTitle":20291,"status":195,"phases":26454,"completion":5742,"start":13047,"enrollment":12914,"conditions":26455,"interventions":26456},[92],[28],[20295,20296,19841],{"nctId":25125,"briefTitle":25126,"status":195,"phases":26458,"primaryCompletion":13056,"completion":13056,"start":2589,"enrollment":25128,"conditions":26459,"interventions":26460},[92],[16],[24228,25131],{"trials":26462,"activeCount":102},[],{"trials":26464,"activeCount":102},[],{"intervention":20031,"totalTrials":447,"cells":26466},{"EARLY_PHASE1":26467,"PHASE1":26469,"PHASE2":26471,"PHASE3":26473,"PHASE4":26483,"NA":26485},{"trials":26468,"activeCount":102},[],{"trials":26470,"activeCount":102},[],{"trials":26472,"activeCount":102},[],{"trials":26474,"activeCount":102},[26475,26479],{"nctId":20024,"briefTitle":20025,"status":195,"phases":26476,"primaryCompletion":2151,"completion":2151,"start":2414,"enrollment":20027,"conditions":26477,"interventions":26478},[92],[18697,20029],[20006,20031,20032],{"nctId":20491,"briefTitle":20492,"status":195,"phases":26480,"primaryCompletion":2570,"completion":2570,"start":2320,"enrollment":20494,"conditions":26481,"interventions":26482},[92],[20496],[20002,20031],{"trials":26484,"activeCount":102},[],{"trials":26486,"activeCount":102},[],{"intervention":10282,"totalTrials":447,"cells":26488},{"EARLY_PHASE1":26489,"PHASE1":26491,"PHASE2":26493,"PHASE3":26495,"PHASE4":26505,"NA":26507},{"trials":26490,"activeCount":102},[],{"trials":26492,"activeCount":102},[],{"trials":26494,"activeCount":102},[],{"trials":26496,"activeCount":102},[26497,26501],{"nctId":10274,"briefTitle":10275,"status":195,"phases":26498,"primaryCompletion":10277,"completion":10277,"start":10278,"enrollment":10279,"conditions":26499,"interventions":26500},[92],[16],[10282,10263,10283,10284],{"nctId":10286,"briefTitle":10287,"status":195,"phases":26502,"primaryCompletion":10289,"completion":10289,"start":504,"enrollment":10290,"conditions":26503,"interventions":26504},[92],[16],[10282,10263,10283,10284],{"trials":26506,"activeCount":102},[],{"trials":26508,"activeCount":102},[],{"intervention":10284,"totalTrials":447,"cells":26510},{"EARLY_PHASE1":26511,"PHASE1":26513,"PHASE2":26515,"PHASE3":26517,"PHASE4":26527,"NA":26529},{"trials":26512,"activeCount":102},[],{"trials":26514,"activeCount":102},[],{"trials":26516,"activeCount":102},[],{"trials":26518,"activeCount":102},[26519,26523],{"nctId":10274,"briefTitle":10275,"status":195,"phases":26520,"primaryCompletion":10277,"completion":10277,"start":10278,"enrollment":10279,"conditions":26521,"interventions":26522},[92],[16],[10282,10263,10283,10284],{"nctId":10286,"briefTitle":10287,"status":195,"phases":26524,"primaryCompletion":10289,"completion":10289,"start":504,"enrollment":10290,"conditions":26525,"interventions":26526},[92],[16],[10282,10263,10283,10284],{"trials":26528,"activeCount":102},[],{"trials":26530,"activeCount":102},[],{"intervention":26532,"totalTrials":447,"cells":26533},"Ticagrelor 60 mg",{"EARLY_PHASE1":26534,"PHASE1":26536,"PHASE2":26538,"PHASE3":26540,"PHASE4":26564,"NA":26566},{"trials":26535,"activeCount":102},[],{"trials":26537,"activeCount":102},[],{"trials":26539,"activeCount":102},[],{"trials":26541,"activeCount":102},[26542,26552],{"nctId":26543,"briefTitle":26544,"status":195,"phases":26545,"primaryCompletion":26546,"completion":26546,"start":26547,"enrollment":26548,"conditions":26549,"interventions":26550},"NCT01991795","A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus",[92],"2019-01-25","2014-02-10",19271,[2089],[26532,26551],"Ticagrelor placebo",{"nctId":26553,"briefTitle":26554,"status":195,"phases":26555,"primaryCompletion":2179,"completion":2179,"start":2489,"enrollment":26556,"conditions":26557,"interventions":26561},"NCT01225562","Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",[92],21379,[19380,26558,26559,26560],"Cardiovascular Death","Atherothrombosis","Stroke",[26562,26532,26563],"Ticagrelor 90 mg","Ticagrelor Placebo",{"trials":26565,"activeCount":102},[],{"trials":26567,"activeCount":102},[],{"intervention":26551,"totalTrials":447,"cells":26569},{"EARLY_PHASE1":26570,"PHASE1":26572,"PHASE2":26574,"PHASE3":26576,"PHASE4":26586,"NA":26588},{"trials":26571,"activeCount":102},[],{"trials":26573,"activeCount":102},[],{"trials":26575,"activeCount":102},[],{"trials":26577,"activeCount":102},[26578,26582],{"nctId":26543,"briefTitle":26544,"status":195,"phases":26579,"primaryCompletion":26546,"completion":26546,"start":26547,"enrollment":26548,"conditions":26580,"interventions":26581},[92],[2089],[26532,26551],{"nctId":26553,"briefTitle":26554,"status":195,"phases":26583,"primaryCompletion":2179,"completion":2179,"start":2489,"enrollment":26556,"conditions":26584,"interventions":26585},[92],[19380,26558,26559,26560],[26562,26532,26563],{"trials":26587,"activeCount":102},[],{"trials":26589,"activeCount":102},[],{"intervention":26591,"totalTrials":447,"cells":26592},"Galida",{"EARLY_PHASE1":26593,"PHASE1":26595,"PHASE2":26597,"PHASE3":26599,"PHASE4":26615,"NA":26617},{"trials":26594,"activeCount":102},[],{"trials":26596,"activeCount":102},[],{"trials":26598,"activeCount":102},[],{"trials":26600,"activeCount":102},[26601,26608],{"nctId":26602,"briefTitle":26603,"status":443,"phases":26604,"primaryCompletion":2639,"completion":2639,"start":9963,"enrollment":26605,"conditions":26606,"interventions":26607},"NCT00214565","GALLANT 6 Tesaglitazar vs. Pioglitazone",[92],1450,[2089],[26591],{"nctId":26609,"briefTitle":26610,"status":443,"phases":26611,"primaryCompletion":5742,"completion":5742,"start":9963,"enrollment":23167,"conditions":26612,"interventions":26613},"NCT00214591","GALLANT 5 Tesaglitazar Versus Metformin",[92],[2089],[26614],"GALIDA",{"trials":26616,"activeCount":102},[],{"trials":26618,"activeCount":102},[],{"intervention":5317,"totalTrials":447,"cells":26620},{"EARLY_PHASE1":26621,"PHASE1":26623,"PHASE2":26629,"PHASE3":26631,"PHASE4":26637,"NA":26639},{"trials":26622,"activeCount":102},[],{"trials":26624,"activeCount":102},[26625],{"nctId":6624,"briefTitle":6625,"status":195,"phases":26626,"primaryCompletion":6627,"completion":6628,"start":6629,"enrollment":1842,"conditions":26627,"interventions":26628},[90],[25,306,6631,6632,6633,3174,410,6634],[43,6636,5317,369,6637],{"trials":26630,"activeCount":102},[],{"trials":26632,"activeCount":102},[26633],{"nctId":5309,"briefTitle":5310,"status":195,"phases":26634,"primaryCompletion":5312,"completion":3071,"start":5313,"enrollment":2497,"conditions":26635,"interventions":26636},[92],[5315],[82,1051,283,5317,82,3038],{"trials":26638,"activeCount":102},[],{"trials":26640,"activeCount":102},[],{"intervention":19702,"totalTrials":447,"cells":26642},{"EARLY_PHASE1":26643,"PHASE1":26645,"PHASE2":26647,"PHASE3":26649,"PHASE4":26662,"NA":26664},{"trials":26644,"activeCount":102},[],{"trials":26646,"activeCount":102},[],{"trials":26648,"activeCount":102},[],{"trials":26650,"activeCount":102},[26651,26655],{"nctId":19696,"briefTitle":19697,"status":195,"phases":26652,"primaryCompletion":7618,"completion":7618,"start":2405,"enrollment":19070,"conditions":26653,"interventions":26654},[92],[19700],[19702,2081],{"nctId":26656,"briefTitle":26657,"status":195,"phases":26658,"primaryCompletion":2560,"completion":2560,"start":2579,"enrollment":12292,"conditions":26659,"interventions":26660},"NCT01652716","Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes",[92],[2089],[19702,26661],"Exenatide twice daily",{"trials":26663,"activeCount":102},[],{"trials":26665,"activeCount":102},[],{"intervention":26667,"totalTrials":447,"cells":26668},"ARIMIDEX",{"EARLY_PHASE1":26669,"PHASE1":26671,"PHASE2":26681,"PHASE3":26683,"PHASE4":26694,"NA":26696},{"trials":26670,"activeCount":102},[],{"trials":26672,"activeCount":102},[26673],{"nctId":26674,"briefTitle":26675,"status":195,"phases":26676,"primaryCompletion":2471,"completion":2471,"start":4496,"enrollment":3180,"conditions":26677,"interventions":26678},"NCT01568281","Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects",[90],[10052,15776],[26679,26680,26679,26680],"Anastrozole ODF","Arimidex",{"trials":26682,"activeCount":102},[],{"trials":26684,"activeCount":102},[26685],{"nctId":26686,"briefTitle":26687,"status":195,"phases":26688,"primaryCompletion":12846,"completion":4298,"start":26689,"enrollment":26690,"conditions":26691,"interventions":26692},"NCT00232661","PROACT - Pre-Operative Arimidex Compared To Tamoxifen",[92],"2000-08",452,[25],[26667,26693],"NOLVADEX",{"trials":26695,"activeCount":102},[],{"trials":26697,"activeCount":102},[],{"intervention":26699,"totalTrials":447,"cells":26700},"Seroquel SR",{"EARLY_PHASE1":26701,"PHASE1":26703,"PHASE2":26705,"PHASE3":26707,"PHASE4":26721,"NA":26723},{"trials":26702,"activeCount":102},[],{"trials":26704,"activeCount":102},[],{"trials":26706,"activeCount":102},[],{"trials":26708,"activeCount":102},[26709,26715],{"nctId":26710,"briefTitle":26711,"status":195,"phases":26712,"primaryCompletion":9213,"completion":9213,"start":4264,"enrollment":340,"conditions":26713,"interventions":26714},"NCT00206128","Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia",[92],[33],[26699],{"nctId":26716,"briefTitle":26717,"status":195,"phases":26718,"completion":7494,"start":4264,"enrollment":9887,"conditions":26719,"interventions":26720},"NCT00234377","Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia",[92],[33],[26699],{"trials":26722,"activeCount":102},[],{"trials":26724,"activeCount":102},[],{"intervention":26726,"totalTrials":447,"cells":26727},"D961H capsule 10mg",{"EARLY_PHASE1":26728,"PHASE1":26730,"PHASE2":26732,"PHASE3":26734,"PHASE4":26758,"NA":26760},{"trials":26729,"activeCount":102},[],{"trials":26731,"activeCount":102},[],{"trials":26733,"activeCount":102},[],{"trials":26735,"activeCount":102},[26736,26749],{"nctId":26737,"briefTitle":26738,"status":195,"phases":26739,"primaryCompletion":6468,"completion":6468,"start":2470,"enrollment":2783,"conditions":26740,"interventions":26746},"NCT02153398","A Phase I\u002FIII Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases",[92],[26741,26742,26743,26744,26745,20147],"Gastric Ulcer (GU)","Duodenal Ulcer (DU)","Anastomotic Ulcer (AU)","Non-erosive Reflux Esophagitis Disease (NERD)","Reflux Esophagitis (RE)",[26747,26726,26748],"D961H sachet 10 mg","D961H capsule 20 mg",{"nctId":26750,"briefTitle":26751,"status":195,"phases":26752,"primaryCompletion":26753,"completion":26753,"start":26754,"enrollment":4286,"conditions":26755,"interventions":26756},"NCT03553563","A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer",[92],"2022-12-27","2018-07-24",[19792,20616,20617],[26726,26757],"D961H sachet 10mg",{"trials":26759,"activeCount":102},[],{"trials":26761,"activeCount":102},[],{"intervention":26763,"totalTrials":447,"cells":26764},"Cimetidine",{"EARLY_PHASE1":26765,"PHASE1":26767,"PHASE2":26769,"PHASE3":26771,"PHASE4":26789,"NA":26791},{"trials":26766,"activeCount":102},[],{"trials":26768,"activeCount":102},[],{"trials":26770,"activeCount":102},[],{"trials":26772,"activeCount":102},[26773,26780],{"nctId":26774,"briefTitle":26775,"status":195,"phases":26776,"primaryCompletion":19387,"completion":19387,"start":1692,"enrollment":19371,"conditions":26777,"interventions":26779},"NCT02157376","Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients",[92],[26778],"Stress Ulcer Prophylaxis",[19794,26763],{"nctId":26781,"briefTitle":26782,"status":195,"phases":26783,"primaryCompletion":2179,"completion":2179,"start":2405,"enrollment":13857,"conditions":26784,"interventions":26786},"NCT01757275","High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer",[92],[26785],"Bleeding Peptic Ulcer",[26787,26763,26788],"Esomeprazole Na","Esomeprazole Mg",{"trials":26790,"activeCount":102},[],{"trials":26792,"activeCount":102},[],{"intervention":18146,"totalTrials":447,"cells":26794},{"EARLY_PHASE1":26795,"PHASE1":26797,"PHASE2":26799,"PHASE3":26801,"PHASE4":26811,"NA":26813},{"trials":26796,"activeCount":102},[],{"trials":26798,"activeCount":102},[],{"trials":26800,"activeCount":102},[],{"trials":26802,"activeCount":102},[26803,26807],{"nctId":18139,"briefTitle":18140,"status":624,"phases":26804,"primaryCompletion":9620,"completion":18142,"start":6882,"enrollment":102,"conditions":26805,"interventions":26806},[92],[18144],[17964,18146],{"nctId":23360,"briefTitle":23361,"status":195,"phases":26808,"primaryCompletion":2616,"completion":2616,"start":12721,"enrollment":23363,"conditions":26809,"interventions":26810},[92],[23365],[23297,23367],{"trials":26812,"activeCount":102},[],{"trials":26814,"activeCount":102},[],{"intervention":26816,"totalTrials":447,"cells":26817},"Sodium Zirconium Cyclosilicate (ZS) 5g",{"EARLY_PHASE1":26818,"PHASE1":26820,"PHASE2":26822,"PHASE3":26824,"PHASE4":26843,"NA":26845},{"trials":26819,"activeCount":102},[],{"trials":26821,"activeCount":102},[],{"trials":26823,"activeCount":102},[],{"trials":26825,"activeCount":102},[26826,26835],{"nctId":26827,"briefTitle":26828,"status":195,"phases":26829,"primaryCompletion":26830,"completion":26830,"start":26831,"enrollment":1510,"conditions":26832,"interventions":26833},"NCT03127644","ZS Ph2\u002F3 Dose-response Study in Japan",[91,92],"2018-02-23","2017-06-14",[12093],[26816,26834],"Sodium Zirconium Cyclosilicate (ZS) 10g",{"nctId":26836,"briefTitle":26837,"status":195,"phases":26838,"primaryCompletion":26839,"completion":26839,"start":26840,"enrollment":5239,"conditions":26841,"interventions":26842},"NCT02875834","A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia",[92],"2018-02-14","2017-03-03",[12093],[26834,26816,26834],{"trials":26844,"activeCount":102},[],{"trials":26846,"activeCount":102},[],{"intervention":26834,"totalTrials":447,"cells":26848},{"EARLY_PHASE1":26849,"PHASE1":26851,"PHASE2":26853,"PHASE3":26855,"PHASE4":26865,"NA":26867},{"trials":26850,"activeCount":102},[],{"trials":26852,"activeCount":102},[],{"trials":26854,"activeCount":102},[],{"trials":26856,"activeCount":102},[26857,26861],{"nctId":26827,"briefTitle":26828,"status":195,"phases":26858,"primaryCompletion":26830,"completion":26830,"start":26831,"enrollment":1510,"conditions":26859,"interventions":26860},[91,92],[12093],[26816,26834],{"nctId":26836,"briefTitle":26837,"status":195,"phases":26862,"primaryCompletion":26839,"completion":26839,"start":26840,"enrollment":5239,"conditions":26863,"interventions":26864},[92],[12093],[26834,26816,26834],{"trials":26866,"activeCount":102},[],{"trials":26868,"activeCount":102},[],{"intervention":26870,"totalTrials":447,"cells":26871},"candsartan cilexetil",{"EARLY_PHASE1":26872,"PHASE1":26874,"PHASE2":26876,"PHASE3":26878,"PHASE4":26894,"NA":26896},{"trials":26873,"activeCount":102},[],{"trials":26875,"activeCount":102},[],{"trials":26877,"activeCount":102},[],{"trials":26879,"activeCount":102},[26880,26888],{"nctId":26881,"briefTitle":26882,"status":195,"phases":26883,"completion":6517,"start":6780,"enrollment":26884,"conditions":26885,"interventions":26887},"NCT00244634","Atacand Dose Range Finding Study in Pediatric Subjects 6 to \u003C17 Years of Age",[92],238,[26886],"Pediatric Hypertension",[26870],{"nctId":26889,"briefTitle":26890,"status":195,"phases":26891,"completion":7342,"start":6780,"enrollment":18455,"conditions":26892,"interventions":26893},"NCT00244595","Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to \u003C 17 Years of Age",[92],[2620],[26870],{"trials":26895,"activeCount":102},[],{"trials":26897,"activeCount":102},[],{"intervention":26899,"totalTrials":447,"cells":26900},"Ciclesonide nasal spray",{"EARLY_PHASE1":26901,"PHASE1":26903,"PHASE2":26905,"PHASE3":26907,"PHASE4":26924,"NA":26926},{"trials":26902,"activeCount":102},[],{"trials":26904,"activeCount":102},[],{"trials":26906,"activeCount":102},[],{"trials":26908,"activeCount":102},[26909,26916],{"nctId":26910,"briefTitle":26911,"status":195,"phases":26912,"primaryCompletion":2639,"completion":2639,"start":2087,"enrollment":1806,"conditions":26913,"interventions":26915},"NCT00305487","Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010\u002FM1-417)",[92],[26914,19420],"Hay Fever",[26899],{"nctId":26917,"briefTitle":26918,"status":195,"phases":26919,"primaryCompletion":13014,"completion":13014,"start":2639,"enrollment":6346,"conditions":26920,"interventions":26922},"NCT00384475","A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010\u002FM1-413)",[92],[26921,26914],"Rhinitis, Allergic, Seasonal",[26923],"Ciclesonide Nasal Spray",{"trials":26925,"activeCount":102},[],{"trials":26927,"activeCount":102},[],{"intervention":26929,"totalTrials":447,"cells":26930},"AZD9291 Dosing",{"EARLY_PHASE1":26931,"PHASE1":26933,"PHASE2":26935,"PHASE3":26937,"PHASE4":26954,"NA":26956},{"trials":26932,"activeCount":102},[],{"trials":26934,"activeCount":102},[],{"trials":26936,"activeCount":102},[],{"trials":26938,"activeCount":102},[26939,26946],{"nctId":26940,"briefTitle":26941,"status":195,"phases":26942,"primaryCompletion":5377,"completion":5377,"start":26943,"enrollment":872,"conditions":26944,"interventions":26945},"NCT02997501","T790M Plasma Testing Methodology Comparison and Clinical Validation",[92],"2016-12-23",[3174],[26929],{"nctId":26947,"briefTitle":26948,"status":195,"phases":26949,"primaryCompletion":5501,"completion":5501,"start":26950,"enrollment":26951,"conditions":26952,"interventions":26953},"NCT02474355","Real World Treatment Study of AZD9291 for Advanced\u002FMetastatic EGFR T790M Mutation NSCLC",[92],"2015-09-18",3017,[3174],[26929],{"trials":26955,"activeCount":102},[],{"trials":26957,"activeCount":102},[],{"intervention":26959,"totalTrials":122,"cells":26960},"GFF",{"EARLY_PHASE1":26961,"PHASE1":26963,"PHASE2":26965,"PHASE3":26967,"PHASE4":26978,"NA":26980},{"trials":26962,"activeCount":102},[],{"trials":26964,"activeCount":102},[],{"trials":26966,"activeCount":102},[],{"trials":26968,"activeCount":102},[26969],{"nctId":26970,"briefTitle":26971,"status":195,"phases":26972,"primaryCompletion":26973,"completion":26973,"start":26974,"enrollment":554,"conditions":26975,"interventions":26976},"NCT03836677","A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD",[92],"2019-11-11","2019-02-26",[6083],[26977,26959],"BGF",{"trials":26979,"activeCount":102},[],{"trials":26981,"activeCount":102},[],{"intervention":26983,"totalTrials":122,"cells":26984},"HFA MDI",{"EARLY_PHASE1":26985,"PHASE1":26987,"PHASE2":26989,"PHASE3":26991,"PHASE4":27001,"NA":27003},{"trials":26986,"activeCount":102},[],{"trials":26988,"activeCount":102},[],{"trials":26990,"activeCount":102},[],{"trials":26992,"activeCount":102},[26993],{"nctId":26994,"briefTitle":26995,"status":195,"phases":26996,"primaryCompletion":26997,"completion":26997,"start":1508,"enrollment":14693,"conditions":26998,"interventions":26999},"NCT05850494","Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well\u002FPartially Controlled Asthma",[92],"2023-08-21",[16],[26983,27000],"HFO MDI",{"trials":27002,"activeCount":102},[],{"trials":27004,"activeCount":102},[],{"intervention":27000,"totalTrials":122,"cells":27006},{"EARLY_PHASE1":27007,"PHASE1":27009,"PHASE2":27011,"PHASE3":27013,"PHASE4":27019,"NA":27021},{"trials":27008,"activeCount":102},[],{"trials":27010,"activeCount":102},[],{"trials":27012,"activeCount":102},[],{"trials":27014,"activeCount":102},[27015],{"nctId":26994,"briefTitle":26995,"status":195,"phases":27016,"primaryCompletion":26997,"completion":26997,"start":1508,"enrollment":14693,"conditions":27017,"interventions":27018},[92],[16],[26983,27000],{"trials":27020,"activeCount":102},[],{"trials":27022,"activeCount":102},[],{"intervention":27024,"totalTrials":122,"cells":27025},"exenatide\u002Finsulin glargine",{"EARLY_PHASE1":27026,"PHASE1":27028,"PHASE2":27030,"PHASE3":27032,"PHASE4":27041,"NA":27043},{"trials":27027,"activeCount":102},[],{"trials":27029,"activeCount":102},[],{"trials":27031,"activeCount":102},[],{"trials":27033,"activeCount":102},[27034],{"nctId":27035,"briefTitle":27036,"status":195,"phases":27037,"primaryCompletion":9065,"completion":9065,"start":4285,"enrollment":113,"conditions":27038,"interventions":27039},"NCT00099619","Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy",[92],[22],[27024,27040],"insulin glargine\u002Fexenatide",{"trials":27042,"activeCount":102},[],{"trials":27044,"activeCount":102},[],{"intervention":27040,"totalTrials":122,"cells":27046},{"EARLY_PHASE1":27047,"PHASE1":27049,"PHASE2":27051,"PHASE3":27053,"PHASE4":27059,"NA":27061},{"trials":27048,"activeCount":102},[],{"trials":27050,"activeCount":102},[],{"trials":27052,"activeCount":102},[],{"trials":27054,"activeCount":102},[27055],{"nctId":27035,"briefTitle":27036,"status":195,"phases":27056,"primaryCompletion":9065,"completion":9065,"start":4285,"enrollment":113,"conditions":27057,"interventions":27058},[92],[22],[27024,27040],{"trials":27060,"activeCount":102},[],{"trials":27062,"activeCount":102},[],{"intervention":24219,"totalTrials":122,"cells":27064},{"EARLY_PHASE1":27065,"PHASE1":27067,"PHASE2":27069,"PHASE3":27071,"PHASE4":27077,"NA":27079},{"trials":27066,"activeCount":102},[],{"trials":27068,"activeCount":102},[],{"trials":27070,"activeCount":102},[],{"trials":27072,"activeCount":102},[27073],{"nctId":24213,"briefTitle":24214,"status":195,"phases":27074,"primaryCompletion":187,"completion":187,"start":24216,"enrollment":1348,"conditions":27075,"interventions":27076},[92],[6083],[24219,24202],{"trials":27078,"activeCount":102},[],{"trials":27080,"activeCount":102},[],{"intervention":27082,"totalTrials":122,"cells":27083},"Ciclesonide Placebo",{"EARLY_PHASE1":27084,"PHASE1":27086,"PHASE2":27088,"PHASE3":27090,"PHASE4":27098,"NA":27100},{"trials":27085,"activeCount":102},[],{"trials":27087,"activeCount":102},[],{"trials":27089,"activeCount":102},[],{"trials":27091,"activeCount":102},[27092],{"nctId":27093,"briefTitle":27094,"status":195,"phases":27095,"primaryCompletion":6436,"completion":16044,"start":2560,"enrollment":1395,"conditions":27096,"interventions":27097},"NCT02155881","Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia",[92],[19420],[10076,27082],{"trials":27099,"activeCount":102},[],{"trials":27101,"activeCount":102},[],{"intervention":9093,"totalTrials":122,"cells":27103},{"EARLY_PHASE1":27104,"PHASE1":27106,"PHASE2":27108,"PHASE3":27110,"PHASE4":27116,"NA":27118},{"trials":27105,"activeCount":102},[],{"trials":27107,"activeCount":102},[],{"trials":27109,"activeCount":102},[],{"trials":27111,"activeCount":102},[27112],{"nctId":9086,"briefTitle":9087,"status":195,"phases":27113,"primaryCompletion":9089,"completion":2113,"start":9090,"enrollment":7432,"conditions":27114,"interventions":27115},[92],[25],[9093,468,9094,9095],{"trials":27117,"activeCount":102},[],{"trials":27119,"activeCount":102},[],{"intervention":9094,"totalTrials":122,"cells":27121},{"EARLY_PHASE1":27122,"PHASE1":27124,"PHASE2":27126,"PHASE3":27128,"PHASE4":27134,"NA":27136},{"trials":27123,"activeCount":102},[],{"trials":27125,"activeCount":102},[],{"trials":27127,"activeCount":102},[],{"trials":27129,"activeCount":102},[27130],{"nctId":9086,"briefTitle":9087,"status":195,"phases":27131,"primaryCompletion":9089,"completion":2113,"start":9090,"enrollment":7432,"conditions":27132,"interventions":27133},[92],[25],[9093,468,9094,9095],{"trials":27135,"activeCount":102},[],{"trials":27137,"activeCount":102},[],{"intervention":9095,"totalTrials":122,"cells":27139},{"EARLY_PHASE1":27140,"PHASE1":27142,"PHASE2":27144,"PHASE3":27146,"PHASE4":27152,"NA":27154},{"trials":27141,"activeCount":102},[],{"trials":27143,"activeCount":102},[],{"trials":27145,"activeCount":102},[],{"trials":27147,"activeCount":102},[27148],{"nctId":9086,"briefTitle":9087,"status":195,"phases":27149,"primaryCompletion":9089,"completion":2113,"start":9090,"enrollment":7432,"conditions":27150,"interventions":27151},[92],[25],[9093,468,9094,9095],{"trials":27153,"activeCount":102},[],{"trials":27155,"activeCount":102},[],{"intervention":25588,"totalTrials":122,"cells":27157},{"EARLY_PHASE1":27158,"PHASE1":27160,"PHASE2":27162,"PHASE3":27164,"PHASE4":27170,"NA":27172},{"trials":27159,"activeCount":102},[],{"trials":27161,"activeCount":102},[],{"trials":27163,"activeCount":102},[],{"trials":27165,"activeCount":102},[27166],{"nctId":25580,"briefTitle":25581,"status":195,"phases":27167,"primaryCompletion":25583,"completion":25583,"start":25584,"enrollment":25585,"conditions":27168,"interventions":27169},[92],[16],[25569,25588,25589],{"trials":27171,"activeCount":102},[],{"trials":27173,"activeCount":102},[],{"intervention":25589,"totalTrials":122,"cells":27175},{"EARLY_PHASE1":27176,"PHASE1":27178,"PHASE2":27180,"PHASE3":27182,"PHASE4":27188,"NA":27190},{"trials":27177,"activeCount":102},[],{"trials":27179,"activeCount":102},[],{"trials":27181,"activeCount":102},[],{"trials":27183,"activeCount":102},[27184],{"nctId":25580,"briefTitle":25581,"status":195,"phases":27185,"primaryCompletion":25583,"completion":25583,"start":25584,"enrollment":25585,"conditions":27186,"interventions":27187},[92],[16],[25569,25588,25589],{"trials":27189,"activeCount":102},[],{"trials":27191,"activeCount":102},[],{"intervention":27193,"totalTrials":122,"cells":27194},"Tralokinumab open-label",{"EARLY_PHASE1":27195,"PHASE1":27197,"PHASE2":27199,"PHASE3":27201,"PHASE4":27212,"NA":27214},{"trials":27196,"activeCount":102},[],{"trials":27198,"activeCount":102},[],{"trials":27200,"activeCount":102},[],{"trials":27202,"activeCount":102},[27203],{"nctId":27204,"briefTitle":27205,"status":443,"phases":27206,"primaryCompletion":27207,"completion":27207,"start":27208,"enrollment":2260,"conditions":27209,"interventions":27211},"NCT02902809","A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma",[92],"2018-01-19","2016-11-11",[27210],"Inadequately Controlled Asthma",[27193],{"trials":27213,"activeCount":102},[],{"trials":27215,"activeCount":102},[],{"intervention":27217,"totalTrials":122,"cells":27218},"Budesonide\u002Falbuterol metered-dose inhaler 160\u002F180 μg",{"EARLY_PHASE1":27219,"PHASE1":27221,"PHASE2":27223,"PHASE3":27225,"PHASE4":27235,"NA":27237},{"trials":27220,"activeCount":102},[],{"trials":27222,"activeCount":102},[],{"trials":27224,"activeCount":102},[],{"trials":27226,"activeCount":102},[27227],{"nctId":27228,"briefTitle":27229,"status":195,"phases":27230,"primaryCompletion":1259,"completion":1259,"start":27231,"enrollment":4307,"conditions":27232,"interventions":27234},"NCT06245551","A Study to Investigate the Effects of PT027 (Budesonide\u002FAlbuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma",[92],"2023-12-22",[27233],"Asthma, Exercise-Induced",[27217],{"trials":27236,"activeCount":102},[],{"trials":27238,"activeCount":102},[],{"intervention":25190,"totalTrials":122,"cells":27240},{"EARLY_PHASE1":27241,"PHASE1":27243,"PHASE2":27245,"PHASE3":27247,"PHASE4":27253,"NA":27255},{"trials":27242,"activeCount":102},[],{"trials":27244,"activeCount":102},[],{"trials":27246,"activeCount":102},[],{"trials":27248,"activeCount":102},[27249],{"nctId":25184,"briefTitle":25185,"status":195,"phases":27250,"primaryCompletion":13123,"completion":13123,"start":2179,"enrollment":25187,"conditions":27251,"interventions":27252},[92],[22],[19120,25190],{"trials":27254,"activeCount":102},[],{"trials":27256,"activeCount":102},[],{"intervention":18744,"totalTrials":122,"cells":27258},{"EARLY_PHASE1":27259,"PHASE1":27261,"PHASE2":27263,"PHASE3":27265,"PHASE4":27271,"NA":27273},{"trials":27260,"activeCount":102},[],{"trials":27262,"activeCount":102},[],{"trials":27264,"activeCount":102},[],{"trials":27266,"activeCount":102},[27267],{"nctId":18738,"briefTitle":18739,"status":195,"phases":27268,"completion":2415,"start":6369,"enrollment":5155,"conditions":27269,"interventions":27270},[92],[18742],[18689,18744],{"trials":27272,"activeCount":102},[],{"trials":27274,"activeCount":102},[],{"intervention":27276,"totalTrials":122,"cells":27277},"Open Label Run In Esomeprazole",{"EARLY_PHASE1":27278,"PHASE1":27280,"PHASE2":27282,"PHASE3":27284,"PHASE4":27295,"NA":27297},{"trials":27279,"activeCount":102},[],{"trials":27281,"activeCount":102},[],{"trials":27283,"activeCount":102},[],{"trials":27285,"activeCount":102},[27286],{"nctId":27287,"briefTitle":27288,"status":195,"phases":27289,"primaryCompletion":2524,"completion":2524,"start":7439,"enrollment":8285,"conditions":27290,"interventions":27292},"NCT00468559","Phase 3\u002FSafety & Efficacy of Esomeprazole in Infants",[92],[27291],"Gastroesophageal Reflux Disease (GERD)",[27276,27293,27294],"Double Blind Esomeprazole","Double Blind Placebo",{"trials":27296,"activeCount":102},[],{"trials":27298,"activeCount":102},[],{"intervention":27293,"totalTrials":122,"cells":27300},{"EARLY_PHASE1":27301,"PHASE1":27303,"PHASE2":27305,"PHASE3":27307,"PHASE4":27313,"NA":27315},{"trials":27302,"activeCount":102},[],{"trials":27304,"activeCount":102},[],{"trials":27306,"activeCount":102},[],{"trials":27308,"activeCount":102},[27309],{"nctId":27287,"briefTitle":27288,"status":195,"phases":27310,"primaryCompletion":2524,"completion":2524,"start":7439,"enrollment":8285,"conditions":27311,"interventions":27312},[92],[27291],[27276,27293,27294],{"trials":27314,"activeCount":102},[],{"trials":27316,"activeCount":102},[],{"intervention":27294,"totalTrials":122,"cells":27318},{"EARLY_PHASE1":27319,"PHASE1":27321,"PHASE2":27323,"PHASE3":27325,"PHASE4":27331,"NA":27333},{"trials":27320,"activeCount":102},[],{"trials":27322,"activeCount":102},[],{"trials":27324,"activeCount":102},[],{"trials":27326,"activeCount":102},[27327],{"nctId":27287,"briefTitle":27288,"status":195,"phases":27328,"primaryCompletion":2524,"completion":2524,"start":7439,"enrollment":8285,"conditions":27329,"interventions":27330},[92],[27291],[27276,27293,27294],{"trials":27332,"activeCount":102},[],{"trials":27334,"activeCount":102},[],{"intervention":27336,"totalTrials":122,"cells":27337},"Olive oil, 4g",{"EARLY_PHASE1":27338,"PHASE1":27340,"PHASE2":27342,"PHASE3":27344,"PHASE4":27355,"NA":27357},{"trials":27339,"activeCount":102},[],{"trials":27341,"activeCount":102},[],{"trials":27343,"activeCount":102},[],{"trials":27345,"activeCount":102},[27346],{"nctId":27347,"briefTitle":27348,"status":195,"phases":27349,"primaryCompletion":2471,"completion":2471,"start":2675,"enrollment":27350,"conditions":27351,"interventions":27352},"NCT01408303","[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL",[92],646,[13022,2619],[27336,27353,27354],"omega-3-carboxylic acids, 2g","omega-3-carboxylic acids, 4g",{"trials":27356,"activeCount":102},[],{"trials":27358,"activeCount":102},[],{"intervention":27353,"totalTrials":122,"cells":27360},{"EARLY_PHASE1":27361,"PHASE1":27363,"PHASE2":27365,"PHASE3":27367,"PHASE4":27373,"NA":27375},{"trials":27362,"activeCount":102},[],{"trials":27364,"activeCount":102},[],{"trials":27366,"activeCount":102},[],{"trials":27368,"activeCount":102},[27369],{"nctId":27347,"briefTitle":27348,"status":195,"phases":27370,"primaryCompletion":2471,"completion":2471,"start":2675,"enrollment":27350,"conditions":27371,"interventions":27372},[92],[13022,2619],[27336,27353,27354],{"trials":27374,"activeCount":102},[],{"trials":27376,"activeCount":102},[],{"intervention":27354,"totalTrials":122,"cells":27378},{"EARLY_PHASE1":27379,"PHASE1":27381,"PHASE2":27383,"PHASE3":27385,"PHASE4":27391,"NA":27393},{"trials":27380,"activeCount":102},[],{"trials":27382,"activeCount":102},[],{"trials":27384,"activeCount":102},[],{"trials":27386,"activeCount":102},[27387],{"nctId":27347,"briefTitle":27348,"status":195,"phases":27388,"primaryCompletion":2471,"completion":2471,"start":2675,"enrollment":27350,"conditions":27389,"interventions":27390},[92],[13022,2619],[27336,27353,27354],{"trials":27392,"activeCount":102},[],{"trials":27394,"activeCount":102},[],{"intervention":24115,"totalTrials":122,"cells":27396},{"EARLY_PHASE1":27397,"PHASE1":27399,"PHASE2":27401,"PHASE3":27403,"PHASE4":27409,"NA":27411},{"trials":27398,"activeCount":102},[],{"trials":27400,"activeCount":102},[],{"trials":27402,"activeCount":102},[],{"trials":27404,"activeCount":102},[27405],{"nctId":24110,"briefTitle":24111,"status":195,"phases":27406,"primaryCompletion":2168,"completion":2168,"start":7439,"enrollment":3695,"conditions":27407,"interventions":27408},[92],[12760,6903],[24115,12567,15822],{"trials":27410,"activeCount":102},[],{"trials":27412,"activeCount":102},[],{"intervention":24417,"totalTrials":122,"cells":27414},{"EARLY_PHASE1":27415,"PHASE1":27417,"PHASE2":27419,"PHASE3":27421,"PHASE4":27427,"NA":27429},{"trials":27416,"activeCount":102},[],{"trials":27418,"activeCount":102},[],{"trials":27420,"activeCount":102},[],{"trials":27422,"activeCount":102},[27423],{"nctId":24410,"briefTitle":24411,"status":195,"phases":27424,"primaryCompletion":13756,"completion":13102,"start":7618,"enrollment":3466,"conditions":27425,"interventions":27426},[92],[24414,24415],[24417,6636],{"trials":27428,"activeCount":102},[],{"trials":27430,"activeCount":102},[],{"intervention":23170,"totalTrials":122,"cells":27432},{"EARLY_PHASE1":27433,"PHASE1":27435,"PHASE2":27437,"PHASE3":27439,"PHASE4":27445,"NA":27447},{"trials":27434,"activeCount":102},[],{"trials":27436,"activeCount":102},[],{"trials":27438,"activeCount":102},[],{"trials":27440,"activeCount":102},[27441],{"nctId":23164,"briefTitle":23165,"status":443,"phases":27442,"completion":5742,"start":4285,"enrollment":23167,"conditions":27443,"interventions":27444},[92],[31],[15914,23170],{"trials":27446,"activeCount":102},[],{"trials":27448,"activeCount":102},[],{"intervention":27450,"totalTrials":122,"cells":27451},"AZD9291 80 mg\u002F40 mg + placebo",{"EARLY_PHASE1":27452,"PHASE1":27454,"PHASE2":27456,"PHASE3":27458,"PHASE4":27473,"NA":27475},{"trials":27453,"activeCount":102},[],{"trials":27455,"activeCount":102},[],{"trials":27457,"activeCount":102},[],{"trials":27459,"activeCount":102},[27460],{"nctId":27461,"briefTitle":27462,"status":195,"phases":27463,"primaryCompletion":27464,"completion":27465,"start":27466,"enrollment":27467,"conditions":27468,"interventions":27470},"NCT02296125","AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer",[92],"2017-06-19","2025-11-20","2014-12-03",674,[27469],"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer",[27450,27471,27472],"Erlotinib 150\u002F100 mg","Gefitinib 250 mg",{"trials":27474,"activeCount":102},[],{"trials":27476,"activeCount":102},[],{"intervention":27471,"totalTrials":122,"cells":27478},{"EARLY_PHASE1":27479,"PHASE1":27481,"PHASE2":27483,"PHASE3":27485,"PHASE4":27491,"NA":27493},{"trials":27480,"activeCount":102},[],{"trials":27482,"activeCount":102},[],{"trials":27484,"activeCount":102},[],{"trials":27486,"activeCount":102},[27487],{"nctId":27461,"briefTitle":27462,"status":195,"phases":27488,"primaryCompletion":27464,"completion":27465,"start":27466,"enrollment":27467,"conditions":27489,"interventions":27490},[92],[27469],[27450,27471,27472],{"trials":27492,"activeCount":102},[],{"trials":27494,"activeCount":102},[],{"intervention":27472,"totalTrials":122,"cells":27496},{"EARLY_PHASE1":27497,"PHASE1":27499,"PHASE2":27501,"PHASE3":27503,"PHASE4":27509,"NA":27511},{"trials":27498,"activeCount":102},[],{"trials":27500,"activeCount":102},[],{"trials":27502,"activeCount":102},[],{"trials":27504,"activeCount":102},[27505],{"nctId":27461,"briefTitle":27462,"status":195,"phases":27506,"primaryCompletion":27464,"completion":27465,"start":27466,"enrollment":27467,"conditions":27507,"interventions":27508},[92],[27469],[27450,27471,27472],{"trials":27510,"activeCount":102},[],{"trials":27512,"activeCount":102},[],{"intervention":27514,"totalTrials":122,"cells":27515},"Zirconium Cyclosilicate",{"EARLY_PHASE1":27516,"PHASE1":27518,"PHASE2":27520,"PHASE3":27522,"PHASE4":27532,"NA":27534},{"trials":27517,"activeCount":102},[],{"trials":27519,"activeCount":102},[],{"trials":27521,"activeCount":102},[],{"trials":27523,"activeCount":102},[27524],{"nctId":27525,"briefTitle":27526,"status":195,"phases":27527,"primaryCompletion":27528,"completion":27528,"start":27529,"enrollment":3000,"conditions":27530,"interventions":27531},"NCT03172702","Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia",[92],"2019-07-06","2017-09-04",[12093],[27514],{"trials":27533,"activeCount":102},[],{"trials":27535,"activeCount":102},[],{"intervention":12726,"totalTrials":122,"cells":27537},{"EARLY_PHASE1":27538,"PHASE1":27540,"PHASE2":27542,"PHASE3":27544,"PHASE4":27550,"NA":27552},{"trials":27539,"activeCount":102},[],{"trials":27541,"activeCount":102},[],{"trials":27543,"activeCount":102},[],{"trials":27545,"activeCount":102},[27546],{"nctId":12718,"briefTitle":12719,"status":195,"phases":27547,"primaryCompletion":12721,"completion":12721,"start":2524,"enrollment":12722,"conditions":27548,"interventions":27549},[92],[6903,12724],[12726,5887],{"trials":27551,"activeCount":102},[],{"trials":27553,"activeCount":102},[],{"intervention":19861,"totalTrials":122,"cells":27555},{"EARLY_PHASE1":27556,"PHASE1":27558,"PHASE2":27560,"PHASE3":27562,"PHASE4":27568,"NA":27570},{"trials":27557,"activeCount":102},[],{"trials":27559,"activeCount":102},[],{"trials":27561,"activeCount":102},[],{"trials":27563,"activeCount":102},[27564],{"nctId":19856,"briefTitle":19857,"status":195,"phases":27565,"completion":3839,"start":7554,"enrollment":221,"conditions":27566,"interventions":27567},[92],[16],[19829,19861,19862],{"trials":27569,"activeCount":102},[],{"trials":27571,"activeCount":102},[],{"intervention":27573,"totalTrials":122,"cells":27574},"Tesaglitazar 0.5",{"EARLY_PHASE1":27575,"PHASE1":27577,"PHASE2":27579,"PHASE3":27581,"PHASE4":27590,"NA":27592},{"trials":27576,"activeCount":102},[],{"trials":27578,"activeCount":102},[],{"trials":27580,"activeCount":102},[],{"trials":27582,"activeCount":102},[27583],{"nctId":27584,"briefTitle":27585,"status":443,"phases":27586,"completion":2087,"start":9963,"enrollment":8955,"conditions":27587,"interventions":27588},"NCT00242372","GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin",[92],[22],[27573,27589],"Insulin at least 30 units\u002Fday",{"trials":27591,"activeCount":102},[],{"trials":27593,"activeCount":102},[],{"intervention":27589,"totalTrials":122,"cells":27595},{"EARLY_PHASE1":27596,"PHASE1":27598,"PHASE2":27600,"PHASE3":27602,"PHASE4":27608,"NA":27610},{"trials":27597,"activeCount":102},[],{"trials":27599,"activeCount":102},[],{"trials":27601,"activeCount":102},[],{"trials":27603,"activeCount":102},[27604],{"nctId":27584,"briefTitle":27585,"status":443,"phases":27605,"completion":2087,"start":9963,"enrollment":8955,"conditions":27606,"interventions":27607},[92],[22],[27573,27589],{"trials":27609,"activeCount":102},[],{"trials":27611,"activeCount":102},[],{"intervention":27613,"totalTrials":122,"cells":27614},"Aclidinium Bromide \u002F Formoterol Fumarate",{"EARLY_PHASE1":27615,"PHASE1":27617,"PHASE2":27619,"PHASE3":27621,"PHASE4":27631,"NA":27633},{"trials":27616,"activeCount":102},[],{"trials":27618,"activeCount":102},[],{"trials":27620,"activeCount":102},[],{"trials":27622,"activeCount":102},[27623],{"nctId":27624,"briefTitle":27625,"status":195,"phases":27626,"primaryCompletion":2560,"completion":2560,"start":19364,"enrollment":27627,"conditions":27628,"interventions":27629},"NCT01908140","Study of Aclidinium Bromide\u002FFormoterol Fumarate Compared With Salmeterol\u002FFluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],933,[6083],[27613,27630],"Salmeterol \u002F Fluticasone",{"trials":27632,"activeCount":102},[],{"trials":27634,"activeCount":102},[],{"intervention":27630,"totalTrials":122,"cells":27636},{"EARLY_PHASE1":27637,"PHASE1":27639,"PHASE2":27641,"PHASE3":27643,"PHASE4":27649,"NA":27651},{"trials":27638,"activeCount":102},[],{"trials":27640,"activeCount":102},[],{"trials":27642,"activeCount":102},[],{"trials":27644,"activeCount":102},[27645],{"nctId":27624,"briefTitle":27625,"status":195,"phases":27646,"primaryCompletion":2560,"completion":2560,"start":19364,"enrollment":27627,"conditions":27647,"interventions":27648},[92],[6083],[27613,27630],{"trials":27650,"activeCount":102},[],{"trials":27652,"activeCount":102},[],{"intervention":18765,"totalTrials":122,"cells":27654},{"EARLY_PHASE1":27655,"PHASE1":27657,"PHASE2":27659,"PHASE3":27661,"PHASE4":27667,"NA":27669},{"trials":27656,"activeCount":102},[],{"trials":27658,"activeCount":102},[],{"trials":27660,"activeCount":102},[],{"trials":27662,"activeCount":102},[27663],{"nctId":18759,"briefTitle":18760,"status":195,"phases":27664,"primaryCompletion":2415,"completion":2220,"start":9986,"enrollment":2045,"conditions":27665,"interventions":27666},[92],[18763],[18689,18765],{"trials":27668,"activeCount":102},[],{"trials":27670,"activeCount":102},[],{"intervention":19038,"totalTrials":122,"cells":27672},{"EARLY_PHASE1":27673,"PHASE1":27675,"PHASE2":27677,"PHASE3":27679,"PHASE4":27685,"NA":27687},{"trials":27674,"activeCount":102},[],{"trials":27676,"activeCount":102},[],{"trials":27678,"activeCount":102},[],{"trials":27680,"activeCount":102},[27681],{"nctId":19032,"briefTitle":19033,"status":195,"phases":27682,"primaryCompletion":2415,"completion":3827,"start":6369,"enrollment":19035,"conditions":27683,"interventions":27684},[92],[2652],[2108,2108,19038,19038,2173],{"trials":27686,"activeCount":102},[],{"trials":27688,"activeCount":102},[],{"intervention":18780,"totalTrials":122,"cells":27690},{"EARLY_PHASE1":27691,"PHASE1":27693,"PHASE2":27695,"PHASE3":27697,"PHASE4":27703,"NA":27705},{"trials":27692,"activeCount":102},[],{"trials":27694,"activeCount":102},[],{"trials":27696,"activeCount":102},[],{"trials":27698,"activeCount":102},[27699],{"nctId":18774,"briefTitle":18775,"status":195,"phases":27700,"primaryCompletion":2406,"completion":2406,"start":2320,"enrollment":18777,"conditions":27701,"interventions":27702},[92],[33],[18689,18780],{"trials":27704,"activeCount":102},[],{"trials":27706,"activeCount":102},[],{"intervention":20717,"totalTrials":122,"cells":27708},{"EARLY_PHASE1":27709,"PHASE1":27711,"PHASE2":27713,"PHASE3":27715,"PHASE4":27721,"NA":27723},{"trials":27710,"activeCount":102},[],{"trials":27712,"activeCount":102},[],{"trials":27714,"activeCount":102},[],{"trials":27716,"activeCount":102},[27717],{"nctId":20710,"briefTitle":20711,"status":195,"phases":27718,"primaryCompletion":19325,"completion":19325,"start":20713,"enrollment":1787,"conditions":27719,"interventions":27720},[92],[20715],[20699,20717],{"trials":27722,"activeCount":102},[],{"trials":27724,"activeCount":102},[],{"intervention":27726,"totalTrials":122,"cells":27727},"Saxagliptin, 5 mg + insulin",{"EARLY_PHASE1":27728,"PHASE1":27730,"PHASE2":27732,"PHASE3":27734,"PHASE4":27743,"NA":27745},{"trials":27729,"activeCount":102},[],{"trials":27731,"activeCount":102},[],{"trials":27733,"activeCount":102},[],{"trials":27735,"activeCount":102},[27736],{"nctId":27737,"briefTitle":27738,"status":195,"phases":27739,"primaryCompletion":2113,"completion":2113,"start":2414,"enrollment":27740,"conditions":27741,"interventions":27742},"NCT00757588","Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin",[92],455,[31],[27726],{"trials":27744,"activeCount":102},[],{"trials":27746,"activeCount":102},[],{"intervention":25829,"totalTrials":122,"cells":27748},{"EARLY_PHASE1":27749,"PHASE1":27751,"PHASE2":27753,"PHASE3":27755,"PHASE4":27761,"NA":27763},{"trials":27750,"activeCount":102},[],{"trials":27752,"activeCount":102},[],{"trials":27754,"activeCount":102},[],{"trials":27756,"activeCount":102},[27757],{"nctId":25822,"briefTitle":25823,"status":195,"phases":27758,"primaryCompletion":3862,"completion":3862,"start":3827,"enrollment":4381,"conditions":27759,"interventions":27760},[92],[25826,25827],[25805,25829],{"trials":27762,"activeCount":102},[],{"trials":27764,"activeCount":102},[],{"intervention":27766,"totalTrials":122,"cells":27767},"Gefitinib, raltitrexed",{"EARLY_PHASE1":27768,"PHASE1":27770,"PHASE2":27772,"PHASE3":27774,"PHASE4":27782,"NA":27784},{"trials":27769,"activeCount":102},[],{"trials":27771,"activeCount":102},[],{"trials":27773,"activeCount":102},[],{"trials":27775,"activeCount":102},[27776],{"nctId":27777,"briefTitle":27778,"status":195,"phases":27779,"completion":6562,"start":9901,"enrollment":12547,"conditions":27780,"interventions":27781},"NCT00234429","A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma",[91,92],[691],[27766],{"trials":27783,"activeCount":102},[],{"trials":27785,"activeCount":102},[],{"intervention":23454,"totalTrials":122,"cells":27787},{"EARLY_PHASE1":27788,"PHASE1":27790,"PHASE2":27792,"PHASE3":27794,"PHASE4":27800,"NA":27802},{"trials":27789,"activeCount":102},[],{"trials":27791,"activeCount":102},[],{"trials":27793,"activeCount":102},[],{"trials":27795,"activeCount":102},[27796],{"nctId":23448,"briefTitle":23449,"status":443,"phases":27797,"primaryCompletion":2516,"completion":2615,"start":6710,"enrollment":23451,"conditions":27798,"interventions":27799},[92],[416],[4931,23454],{"trials":27801,"activeCount":102},[],{"trials":27803,"activeCount":102},[],{"intervention":27805,"totalTrials":122,"cells":27806},"Ciclesonide nasal",{"EARLY_PHASE1":27807,"PHASE1":27809,"PHASE2":27811,"PHASE3":27813,"PHASE4":27821,"NA":27823},{"trials":27808,"activeCount":102},[],{"trials":27810,"activeCount":102},[],{"trials":27812,"activeCount":102},[],{"trials":27814,"activeCount":102},[27815],{"nctId":27816,"briefTitle":27817,"status":195,"phases":27818,"primaryCompletion":13047,"completion":6517,"start":4285,"enrollment":2187,"conditions":27819,"interventions":27820},"NCT00658918","To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010\u002FM1-405)",[92],[22131,26914],[27805],{"trials":27822,"activeCount":102},[],{"trials":27824,"activeCount":102},[],{"intervention":27826,"totalTrials":122,"cells":27827},"D9421-C capsule 3 mg",{"EARLY_PHASE1":27828,"PHASE1":27830,"PHASE2":27832,"PHASE3":27834,"PHASE4":27843,"NA":27845},{"trials":27829,"activeCount":102},[],{"trials":27831,"activeCount":102},[],{"trials":27833,"activeCount":102},[],{"trials":27835,"activeCount":102},[27836],{"nctId":27837,"briefTitle":27838,"status":195,"phases":27839,"primaryCompletion":2180,"completion":2180,"start":2366,"enrollment":19236,"conditions":27840,"interventions":27841},"NCT01514240","Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan",[92],[13237],[27826,27842],"Mesalazine",{"trials":27844,"activeCount":102},[],{"trials":27846,"activeCount":102},[],{"intervention":27842,"totalTrials":122,"cells":27848},{"EARLY_PHASE1":27849,"PHASE1":27851,"PHASE2":27853,"PHASE3":27855,"PHASE4":27861,"NA":27863},{"trials":27850,"activeCount":102},[],{"trials":27852,"activeCount":102},[],{"trials":27854,"activeCount":102},[],{"trials":27856,"activeCount":102},[27857],{"nctId":27837,"briefTitle":27838,"status":195,"phases":27858,"primaryCompletion":2180,"completion":2180,"start":2366,"enrollment":19236,"conditions":27859,"interventions":27860},[92],[13237],[27826,27842],{"trials":27862,"activeCount":102},[],{"trials":27864,"activeCount":102},[],{"intervention":27866,"totalTrials":122,"cells":27867},"Olanzapine, risperidone",{"EARLY_PHASE1":27868,"PHASE1":27870,"PHASE2":27872,"PHASE3":27874,"PHASE4":27884,"NA":27886},{"trials":27869,"activeCount":102},[],{"trials":27871,"activeCount":102},[],{"trials":27873,"activeCount":102},[],{"trials":27875,"activeCount":102},[27876],{"nctId":27877,"briefTitle":27878,"status":195,"phases":27879,"primaryCompletion":5796,"completion":5796,"start":12938,"conditions":27880,"interventions":27883},"NCT00034892","CAFE Comparison of Atypicals in First Episode of Psychosis",[92],[33,23653,27881,27882],"Mental Health","Mental Disorders",[27866],{"trials":27885,"activeCount":102},[],{"trials":27887,"activeCount":102},[],{"intervention":24289,"totalTrials":122,"cells":27889},{"EARLY_PHASE1":27890,"PHASE1":27892,"PHASE2":27894,"PHASE3":27896,"PHASE4":27902,"NA":27904},{"trials":27891,"activeCount":102},[],{"trials":27893,"activeCount":102},[],{"trials":27895,"activeCount":102},[],{"trials":27897,"activeCount":102},[27898],{"nctId":24282,"briefTitle":24283,"status":195,"phases":27899,"primaryCompletion":7706,"completion":7706,"start":2854,"enrollment":24285,"conditions":27900,"interventions":27901},[91,92],[24287],[19116,24289],{"trials":27903,"activeCount":102},[],{"trials":27905,"activeCount":102},[],{"intervention":1629,"totalTrials":122,"cells":27907},{"EARLY_PHASE1":27908,"PHASE1":27910,"PHASE2":27912,"PHASE3":27914,"PHASE4":27920,"NA":27922},{"trials":27909,"activeCount":102},[],{"trials":27911,"activeCount":102},[],{"trials":27913,"activeCount":102},[],{"trials":27915,"activeCount":102},[27916],{"nctId":1622,"briefTitle":1623,"status":195,"phases":27917,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1510,"conditions":27918,"interventions":27919},[92],[16],[1542,1629,1630],{"trials":27921,"activeCount":102},[],{"trials":27923,"activeCount":102},[],{"intervention":1630,"totalTrials":122,"cells":27925},{"EARLY_PHASE1":27926,"PHASE1":27928,"PHASE2":27930,"PHASE3":27932,"PHASE4":27938,"NA":27940},{"trials":27927,"activeCount":102},[],{"trials":27929,"activeCount":102},[],{"trials":27931,"activeCount":102},[],{"trials":27933,"activeCount":102},[27934],{"nctId":1622,"briefTitle":1623,"status":195,"phases":27935,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1510,"conditions":27936,"interventions":27937},[92],[16],[1542,1629,1630],{"trials":27939,"activeCount":102},[],{"trials":27941,"activeCount":102},[],{"intervention":24796,"totalTrials":122,"cells":27943},{"EARLY_PHASE1":27944,"PHASE1":27946,"PHASE2":27948,"PHASE3":27950,"PHASE4":27956,"NA":27958},{"trials":27945,"activeCount":102},[],{"trials":27947,"activeCount":102},[],{"trials":27949,"activeCount":102},[],{"trials":27951,"activeCount":102},[27952],{"nctId":24788,"briefTitle":24789,"status":195,"phases":27953,"primaryCompletion":24791,"completion":24791,"start":24792,"enrollment":24793,"conditions":27954,"interventions":27955},[92],[13022],[24754,24796],{"trials":27957,"activeCount":102},[],{"trials":27959,"activeCount":102},[],{"intervention":27961,"totalTrials":122,"cells":27962},"Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate",{"EARLY_PHASE1":27963,"PHASE1":27965,"PHASE2":27967,"PHASE3":27969,"PHASE4":27980,"NA":27982},{"trials":27964,"activeCount":102},[],{"trials":27966,"activeCount":102},[],{"trials":27968,"activeCount":102},[],{"trials":27970,"activeCount":102},[27971],{"nctId":27972,"briefTitle":27973,"status":195,"phases":27974,"primaryCompletion":27975,"completion":27975,"start":4026,"enrollment":2367,"conditions":27976,"interventions":27977},"NCT06067828","A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).",[92],"2026-01-22",[28],[27961,27978,27979],"Treatment B: Budesonide and Formoterol Fumarate","Treatment C : Placebo",{"trials":27981,"activeCount":102},[],{"trials":27983,"activeCount":102},[],{"intervention":27978,"totalTrials":122,"cells":27985},{"EARLY_PHASE1":27986,"PHASE1":27988,"PHASE2":27990,"PHASE3":27992,"PHASE4":27998,"NA":28000},{"trials":27987,"activeCount":102},[],{"trials":27989,"activeCount":102},[],{"trials":27991,"activeCount":102},[],{"trials":27993,"activeCount":102},[27994],{"nctId":27972,"briefTitle":27973,"status":195,"phases":27995,"primaryCompletion":27975,"completion":27975,"start":4026,"enrollment":2367,"conditions":27996,"interventions":27997},[92],[28],[27961,27978,27979],{"trials":27999,"activeCount":102},[],{"trials":28001,"activeCount":102},[],{"intervention":27979,"totalTrials":122,"cells":28003},{"EARLY_PHASE1":28004,"PHASE1":28006,"PHASE2":28008,"PHASE3":28010,"PHASE4":28016,"NA":28018},{"trials":28005,"activeCount":102},[],{"trials":28007,"activeCount":102},[],{"trials":28009,"activeCount":102},[],{"trials":28011,"activeCount":102},[28012],{"nctId":27972,"briefTitle":27973,"status":195,"phases":28013,"primaryCompletion":27975,"completion":27975,"start":4026,"enrollment":2367,"conditions":28014,"interventions":28015},[92],[28],[27961,27978,27979],{"trials":28017,"activeCount":102},[],{"trials":28019,"activeCount":102},[],{"intervention":28021,"totalTrials":122,"cells":28022},"ZOLADEX 10.8 mg",{"EARLY_PHASE1":28023,"PHASE1":28025,"PHASE2":28027,"PHASE3":28029,"PHASE4":28039,"NA":28041},{"trials":28024,"activeCount":102},[],{"trials":28026,"activeCount":102},[],{"trials":28028,"activeCount":102},[],{"trials":28030,"activeCount":102},[28031],{"nctId":28032,"briefTitle":28033,"status":624,"phases":28034,"primaryCompletion":28035,"completion":28035,"start":8197,"enrollment":102,"conditions":28036,"interventions":28037},"NCT03658213","To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.",[92],"2021-11-04",[25],[28021,28038],"ZOLADEX 3.6mg",{"trials":28040,"activeCount":102},[],{"trials":28042,"activeCount":102},[],{"intervention":28038,"totalTrials":122,"cells":28044},{"EARLY_PHASE1":28045,"PHASE1":28047,"PHASE2":28049,"PHASE3":28051,"PHASE4":28057,"NA":28059},{"trials":28046,"activeCount":102},[],{"trials":28048,"activeCount":102},[],{"trials":28050,"activeCount":102},[],{"trials":28052,"activeCount":102},[28053],{"nctId":28032,"briefTitle":28033,"status":624,"phases":28054,"primaryCompletion":28035,"completion":28035,"start":8197,"enrollment":102,"conditions":28055,"interventions":28056},[92],[25],[28021,28038],{"trials":28058,"activeCount":102},[],{"trials":28060,"activeCount":102},[],{"intervention":25974,"totalTrials":122,"cells":28062},{"EARLY_PHASE1":28063,"PHASE1":28065,"PHASE2":28067,"PHASE3":28069,"PHASE4":28075,"NA":28077},{"trials":28064,"activeCount":102},[],{"trials":28066,"activeCount":102},[],{"trials":28068,"activeCount":102},[],{"trials":28070,"activeCount":102},[28071],{"nctId":25969,"briefTitle":25970,"status":195,"phases":28072,"primaryCompletion":445,"completion":445,"start":6061,"enrollment":1192,"conditions":28073,"interventions":28074},[92],[6083],[25974,25958],{"trials":28076,"activeCount":102},[],{"trials":28078,"activeCount":102},[],{"intervention":19053,"totalTrials":122,"cells":28080},{"EARLY_PHASE1":28081,"PHASE1":28083,"PHASE2":28085,"PHASE3":28087,"PHASE4":28093,"NA":28095},{"trials":28082,"activeCount":102},[],{"trials":28084,"activeCount":102},[],{"trials":28086,"activeCount":102},[],{"trials":28088,"activeCount":102},[28089],{"nctId":19044,"briefTitle":19045,"status":195,"phases":28090,"primaryCompletion":19047,"completion":19048,"start":19049,"enrollment":19050,"conditions":28091,"interventions":28092},[92],[22],[19053,19054,19055,2173],{"trials":28094,"activeCount":102},[],{"trials":28096,"activeCount":102},[],{"intervention":19054,"totalTrials":122,"cells":28098},{"EARLY_PHASE1":28099,"PHASE1":28101,"PHASE2":28103,"PHASE3":28105,"PHASE4":28111,"NA":28113},{"trials":28100,"activeCount":102},[],{"trials":28102,"activeCount":102},[],{"trials":28104,"activeCount":102},[],{"trials":28106,"activeCount":102},[28107],{"nctId":19044,"briefTitle":19045,"status":195,"phases":28108,"primaryCompletion":19047,"completion":19048,"start":19049,"enrollment":19050,"conditions":28109,"interventions":28110},[92],[22],[19053,19054,19055,2173],{"trials":28112,"activeCount":102},[],{"trials":28114,"activeCount":102},[],{"intervention":19055,"totalTrials":122,"cells":28116},{"EARLY_PHASE1":28117,"PHASE1":28119,"PHASE2":28121,"PHASE3":28123,"PHASE4":28129,"NA":28131},{"trials":28118,"activeCount":102},[],{"trials":28120,"activeCount":102},[],{"trials":28122,"activeCount":102},[],{"trials":28124,"activeCount":102},[28125],{"nctId":19044,"briefTitle":19045,"status":195,"phases":28126,"primaryCompletion":19047,"completion":19048,"start":19049,"enrollment":19050,"conditions":28127,"interventions":28128},[92],[22],[19053,19054,19055,2173],{"trials":28130,"activeCount":102},[],{"trials":28132,"activeCount":102},[],{"intervention":26148,"totalTrials":122,"cells":28134},{"EARLY_PHASE1":28135,"PHASE1":28137,"PHASE2":28139,"PHASE3":28141,"PHASE4":28147,"NA":28149},{"trials":28136,"activeCount":102},[],{"trials":28138,"activeCount":102},[],{"trials":28140,"activeCount":102},[],{"trials":28142,"activeCount":102},[28143],{"nctId":26141,"briefTitle":26142,"status":195,"phases":28144,"primaryCompletion":26144,"completion":26144,"start":495,"enrollment":26145,"conditions":28145,"interventions":28146},[92],[13022],[26124,26148],{"trials":28148,"activeCount":102},[],{"trials":28150,"activeCount":102},[],{"intervention":28152,"totalTrials":122,"cells":28153},"Brilinta",{"EARLY_PHASE1":28154,"PHASE1":28156,"PHASE2":28158,"PHASE3":28160,"PHASE4":28170,"NA":28172},{"trials":28155,"activeCount":102},[],{"trials":28157,"activeCount":102},[],{"trials":28159,"activeCount":102},[],{"trials":28161,"activeCount":102},[28162],{"nctId":28163,"briefTitle":28164,"status":624,"phases":28165,"primaryCompletion":28166,"completion":28166,"start":28167,"enrollment":102,"conditions":28168,"interventions":28169},"NCT04293172","Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.",[92],"2022-10-10","2020-06-30",[19206],[28152],{"trials":28171,"activeCount":102},[],{"trials":28173,"activeCount":102},[],{"intervention":13135,"totalTrials":122,"cells":28175},{"EARLY_PHASE1":28176,"PHASE1":28178,"PHASE2":28180,"PHASE3":28182,"PHASE4":28188,"NA":28190},{"trials":28177,"activeCount":102},[],{"trials":28179,"activeCount":102},[],{"trials":28181,"activeCount":102},[],{"trials":28183,"activeCount":102},[28184],{"nctId":13128,"briefTitle":13129,"status":195,"phases":28185,"primaryCompletion":2113,"completion":13131,"start":2086,"enrollment":13132,"conditions":28186,"interventions":28187},[92],[13092],[268,268,13135],{"trials":28189,"activeCount":102},[],{"trials":28191,"activeCount":102},[],{"intervention":28193,"totalTrials":122,"cells":28194},"Tesaglitazar 0.5 or 1 mg",{"EARLY_PHASE1":28195,"PHASE1":28197,"PHASE2":28199,"PHASE3":28201,"PHASE4":28210,"NA":28212},{"trials":28196,"activeCount":102},[],{"trials":28198,"activeCount":102},[],{"trials":28200,"activeCount":102},[],{"trials":28202,"activeCount":102},[28203],{"nctId":28204,"briefTitle":28205,"status":443,"phases":28206,"completion":2087,"start":8692,"enrollment":19024,"conditions":28207,"interventions":28208},"NCT00251940","GALLANT 7 Tesaglitazar Add-on to Sulphonylurea",[92],[31],[28193,28209],"Glibenclamide 2.5, 5, 10 or 15 mg",{"trials":28211,"activeCount":102},[],{"trials":28213,"activeCount":102},[],{"intervention":28209,"totalTrials":122,"cells":28215},{"EARLY_PHASE1":28216,"PHASE1":28218,"PHASE2":28220,"PHASE3":28222,"PHASE4":28228,"NA":28230},{"trials":28217,"activeCount":102},[],{"trials":28219,"activeCount":102},[],{"trials":28221,"activeCount":102},[],{"trials":28223,"activeCount":102},[28224],{"nctId":28204,"briefTitle":28205,"status":443,"phases":28225,"completion":2087,"start":8692,"enrollment":19024,"conditions":28226,"interventions":28227},[92],[31],[28193,28209],{"trials":28229,"activeCount":102},[],{"trials":28231,"activeCount":102},[],{"intervention":25984,"totalTrials":122,"cells":28233},{"EARLY_PHASE1":28234,"PHASE1":28236,"PHASE2":28238,"PHASE3":28240,"PHASE4":28246,"NA":28248},{"trials":28235,"activeCount":102},[],{"trials":28237,"activeCount":102},[],{"trials":28239,"activeCount":102},[],{"trials":28241,"activeCount":102},[28242],{"nctId":25976,"briefTitle":25977,"status":195,"phases":28243,"primaryCompletion":25979,"completion":25979,"start":25980,"enrollment":25981,"conditions":28244,"interventions":28245},[92],[10299],[25984,25958],{"trials":28247,"activeCount":102},[],{"trials":28249,"activeCount":102},[],{"intervention":28251,"totalTrials":122,"cells":28252},"insulin detemir",{"EARLY_PHASE1":28253,"PHASE1":28255,"PHASE2":28257,"PHASE3":28259,"PHASE4":28268,"NA":28270},{"trials":28254,"activeCount":102},[],{"trials":28256,"activeCount":102},[],{"trials":28258,"activeCount":102},[],{"trials":28260,"activeCount":102},[28261],{"nctId":28262,"briefTitle":28263,"status":195,"phases":28264,"primaryCompletion":6709,"completion":2589,"start":2350,"enrollment":28265,"conditions":28266,"interventions":28267},"NCT01003184","Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes",[92],222,[22],[15934,28251],{"trials":28269,"activeCount":102},[],{"trials":28271,"activeCount":102},[],{"intervention":2501,"totalTrials":122,"cells":28273},{"EARLY_PHASE1":28274,"PHASE1":28276,"PHASE2":28278,"PHASE3":28280,"PHASE4":28286,"NA":28288},{"trials":28275,"activeCount":102},[],{"trials":28277,"activeCount":102},[],{"trials":28279,"activeCount":102},[],{"trials":28281,"activeCount":102},[28282],{"nctId":2494,"briefTitle":2495,"status":195,"phases":28283,"primaryCompletion":2057,"completion":2243,"start":2251,"enrollment":2497,"conditions":28284,"interventions":28285},[92],[31],[2246,2080,2500,2501,2502],{"trials":28287,"activeCount":102},[],{"trials":28289,"activeCount":102},[],{"intervention":28291,"totalTrials":122,"cells":28292},"faslodex 500mg",{"EARLY_PHASE1":28293,"PHASE1":28295,"PHASE2":28297,"PHASE3":28299,"PHASE4":28314,"NA":28316},{"trials":28294,"activeCount":102},[],{"trials":28296,"activeCount":102},[],{"trials":28298,"activeCount":102},[],{"trials":28300,"activeCount":102},[28301],{"nctId":28302,"briefTitle":28303,"status":195,"phases":28304,"primaryCompletion":28305,"completion":1271,"start":28306,"enrollment":28307,"conditions":28308,"interventions":28310},"NCT01602380","A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.",[92],"2016-04-11","2012-10-17",462,[28309],"Hormone Receptor Positive Breast Cancer",[28291,28311,28312,28313],"arimidex 1mg","faslodex dummy","arimidex dummy",{"trials":28315,"activeCount":102},[],{"trials":28317,"activeCount":102},[],{"intervention":28311,"totalTrials":122,"cells":28319},{"EARLY_PHASE1":28320,"PHASE1":28322,"PHASE2":28324,"PHASE3":28326,"PHASE4":28332,"NA":28334},{"trials":28321,"activeCount":102},[],{"trials":28323,"activeCount":102},[],{"trials":28325,"activeCount":102},[],{"trials":28327,"activeCount":102},[28328],{"nctId":28302,"briefTitle":28303,"status":195,"phases":28329,"primaryCompletion":28305,"completion":1271,"start":28306,"enrollment":28307,"conditions":28330,"interventions":28331},[92],[28309],[28291,28311,28312,28313],{"trials":28333,"activeCount":102},[],{"trials":28335,"activeCount":102},[],{"intervention":28312,"totalTrials":122,"cells":28337},{"EARLY_PHASE1":28338,"PHASE1":28340,"PHASE2":28342,"PHASE3":28344,"PHASE4":28350,"NA":28352},{"trials":28339,"activeCount":102},[],{"trials":28341,"activeCount":102},[],{"trials":28343,"activeCount":102},[],{"trials":28345,"activeCount":102},[28346],{"nctId":28302,"briefTitle":28303,"status":195,"phases":28347,"primaryCompletion":28305,"completion":1271,"start":28306,"enrollment":28307,"conditions":28348,"interventions":28349},[92],[28309],[28291,28311,28312,28313],{"trials":28351,"activeCount":102},[],{"trials":28353,"activeCount":102},[],{"intervention":28313,"totalTrials":122,"cells":28355},{"EARLY_PHASE1":28356,"PHASE1":28358,"PHASE2":28360,"PHASE3":28362,"PHASE4":28368,"NA":28370},{"trials":28357,"activeCount":102},[],{"trials":28359,"activeCount":102},[],{"trials":28361,"activeCount":102},[],{"trials":28363,"activeCount":102},[28364],{"nctId":28302,"briefTitle":28303,"status":195,"phases":28365,"primaryCompletion":28305,"completion":1271,"start":28306,"enrollment":28307,"conditions":28366,"interventions":28367},[92],[28309],[28291,28311,28312,28313],{"trials":28369,"activeCount":102},[],{"trials":28371,"activeCount":102},[],{"intervention":23675,"totalTrials":122,"cells":28373},{"EARLY_PHASE1":28374,"PHASE1":28376,"PHASE2":28378,"PHASE3":28380,"PHASE4":28386,"NA":28388},{"trials":28375,"activeCount":102},[],{"trials":28377,"activeCount":102},[],{"trials":28379,"activeCount":102},[],{"trials":28381,"activeCount":102},[28382],{"nctId":23669,"briefTitle":23670,"status":195,"phases":28383,"completion":7439,"start":7494,"enrollment":23672,"conditions":28384,"interventions":28385},[92],[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],{"trials":28387,"activeCount":102},[],{"trials":28389,"activeCount":102},[],{"intervention":23676,"totalTrials":122,"cells":28391},{"EARLY_PHASE1":28392,"PHASE1":28394,"PHASE2":28396,"PHASE3":28398,"PHASE4":28404,"NA":28406},{"trials":28393,"activeCount":102},[],{"trials":28395,"activeCount":102},[],{"trials":28397,"activeCount":102},[],{"trials":28399,"activeCount":102},[28400],{"nctId":23669,"briefTitle":23670,"status":195,"phases":28401,"completion":7439,"start":7494,"enrollment":23672,"conditions":28402,"interventions":28403},[92],[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],{"trials":28405,"activeCount":102},[],{"trials":28407,"activeCount":102},[],{"intervention":23678,"totalTrials":122,"cells":28409},{"EARLY_PHASE1":28410,"PHASE1":28412,"PHASE2":28414,"PHASE3":28416,"PHASE4":28422,"NA":28424},{"trials":28411,"activeCount":102},[],{"trials":28413,"activeCount":102},[],{"trials":28415,"activeCount":102},[],{"trials":28417,"activeCount":102},[28418],{"nctId":23669,"briefTitle":23670,"status":195,"phases":28419,"completion":7439,"start":7494,"enrollment":23672,"conditions":28420,"interventions":28421},[92],[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],{"trials":28423,"activeCount":102},[],{"trials":28425,"activeCount":102},[],{"intervention":23680,"totalTrials":122,"cells":28427},{"EARLY_PHASE1":28428,"PHASE1":28430,"PHASE2":28432,"PHASE3":28434,"PHASE4":28440,"NA":28442},{"trials":28429,"activeCount":102},[],{"trials":28431,"activeCount":102},[],{"trials":28433,"activeCount":102},[],{"trials":28435,"activeCount":102},[28436],{"nctId":23669,"briefTitle":23670,"status":195,"phases":28437,"completion":7439,"start":7494,"enrollment":23672,"conditions":28438,"interventions":28439},[92],[18697],[20213,23675,13184,23676,18854,23677,23678,18827,23679,23680],{"trials":28441,"activeCount":102},[],{"trials":28443,"activeCount":102},[],{"intervention":26374,"totalTrials":122,"cells":28445},{"EARLY_PHASE1":28446,"PHASE1":28448,"PHASE2":28450,"PHASE3":28452,"PHASE4":28458,"NA":28460},{"trials":28447,"activeCount":102},[],{"trials":28449,"activeCount":102},[],{"trials":28451,"activeCount":102},[],{"trials":28453,"activeCount":102},[28454],{"nctId":26364,"briefTitle":26365,"status":195,"phases":28455,"primaryCompletion":26367,"completion":26367,"start":26368,"enrollment":26369,"conditions":28456,"interventions":28457},[92],[26371],[26353,26373,26374],{"trials":28459,"activeCount":102},[],{"trials":28461,"activeCount":102},[],{"intervention":4394,"totalTrials":122,"cells":28463},{"EARLY_PHASE1":28464,"PHASE1":28466,"PHASE2":28468,"PHASE3":28470,"PHASE4":28476,"NA":28478},{"trials":28465,"activeCount":102},[],{"trials":28467,"activeCount":102},[],{"trials":28469,"activeCount":102},[],{"trials":28471,"activeCount":102},[28472],{"nctId":4389,"briefTitle":4390,"status":4034,"phases":28473,"start":4036,"conditions":28474,"interventions":28475},[92],[3174],[3803,4039,4394],{"trials":28477,"activeCount":102},[],{"trials":28479,"activeCount":102},[],{"intervention":2511,"totalTrials":122,"cells":28481},{"EARLY_PHASE1":28482,"PHASE1":28484,"PHASE2":28486,"PHASE3":28488,"PHASE4":28494,"NA":28496},{"trials":28483,"activeCount":102},[],{"trials":28485,"activeCount":102},[],{"trials":28487,"activeCount":102},[],{"trials":28489,"activeCount":102},[28490],{"nctId":2504,"briefTitle":2505,"status":195,"phases":28491,"primaryCompletion":2056,"completion":2242,"start":2507,"enrollment":2508,"conditions":28492,"interventions":28493},[92],[31],[2044,2044,2511],{"trials":28495,"activeCount":102},[],{"trials":28497,"activeCount":102},[],{"intervention":28499,"totalTrials":122,"cells":28500},"Terbutaline Turbuhaler®",{"EARLY_PHASE1":28501,"PHASE1":28503,"PHASE2":28505,"PHASE3":28507,"PHASE4":28516,"NA":28518},{"trials":28502,"activeCount":102},[],{"trials":28504,"activeCount":102},[],{"trials":28506,"activeCount":102},[],{"trials":28508,"activeCount":102},[28509],{"nctId":28510,"briefTitle":28511,"status":195,"phases":28512,"primaryCompletion":2113,"completion":2113,"start":2212,"enrollment":1130,"conditions":28513,"interventions":28514},"NCT01096017","To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study",[92],[16],[28499,28515],"Salbutamol pMDI",{"trials":28517,"activeCount":102},[],{"trials":28519,"activeCount":102},[],{"intervention":28515,"totalTrials":122,"cells":28521},{"EARLY_PHASE1":28522,"PHASE1":28524,"PHASE2":28526,"PHASE3":28528,"PHASE4":28534,"NA":28536},{"trials":28523,"activeCount":102},[],{"trials":28525,"activeCount":102},[],{"trials":28527,"activeCount":102},[],{"trials":28529,"activeCount":102},[28530],{"nctId":28510,"briefTitle":28511,"status":195,"phases":28531,"primaryCompletion":2113,"completion":2113,"start":2212,"enrollment":1130,"conditions":28532,"interventions":28533},[92],[16],[28499,28515],{"trials":28535,"activeCount":102},[],{"trials":28537,"activeCount":102},[],{"intervention":28539,"totalTrials":122,"cells":28540},"PT027",{"EARLY_PHASE1":28541,"PHASE1":28543,"PHASE2":28545,"PHASE3":28547,"PHASE4":28556,"NA":28558},{"trials":28542,"activeCount":102},[],{"trials":28544,"activeCount":102},[],{"trials":28546,"activeCount":102},[],{"trials":28548,"activeCount":102},[28549],{"nctId":28550,"briefTitle":28551,"status":195,"phases":28552,"primaryCompletion":4098,"completion":4098,"start":3754,"enrollment":8693,"conditions":28553,"interventions":28554},"NCT05555290","PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction",[92],[16],[28539,28555],"PT007",{"trials":28557,"activeCount":102},[],{"trials":28559,"activeCount":102},[],{"intervention":28555,"totalTrials":122,"cells":28561},{"EARLY_PHASE1":28562,"PHASE1":28564,"PHASE2":28566,"PHASE3":28568,"PHASE4":28574,"NA":28576},{"trials":28563,"activeCount":102},[],{"trials":28565,"activeCount":102},[],{"trials":28567,"activeCount":102},[],{"trials":28569,"activeCount":102},[28570],{"nctId":28550,"briefTitle":28551,"status":195,"phases":28571,"primaryCompletion":4098,"completion":4098,"start":3754,"enrollment":8693,"conditions":28572,"interventions":28573},[92],[16],[28539,28555],{"trials":28575,"activeCount":102},[],{"trials":28577,"activeCount":102},[],{"intervention":28579,"totalTrials":122,"cells":28580},"Budesonide\u002Fformoterol Turbuhaler vs Conventional Best Asthma Therapy",{"EARLY_PHASE1":28581,"PHASE1":28583,"PHASE2":28585,"PHASE3":28587,"PHASE4":28595,"NA":28597},{"trials":28582,"activeCount":102},[],{"trials":28584,"activeCount":102},[],{"trials":28586,"activeCount":102},[],{"trials":28588,"activeCount":102},[28589],{"nctId":28590,"briefTitle":28591,"status":195,"phases":28592,"completion":5742,"start":13583,"enrollment":9987,"conditions":28593,"interventions":28594},"NCT00252824","STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma",[92],[16],[28579],{"trials":28596,"activeCount":102},[],{"trials":28598,"activeCount":102},[],{"intervention":25930,"totalTrials":122,"cells":28600},{"EARLY_PHASE1":28601,"PHASE1":28603,"PHASE2":28605,"PHASE3":28607,"PHASE4":28613,"NA":28615},{"trials":28602,"activeCount":102},[],{"trials":28604,"activeCount":102},[],{"trials":28606,"activeCount":102},[],{"trials":28608,"activeCount":102},[28609],{"nctId":25924,"briefTitle":25925,"status":195,"phases":28610,"primaryCompletion":4006,"completion":4006,"start":4204,"enrollment":831,"conditions":28611,"interventions":28612},[92],[25928],[25930,25905,25905],{"trials":28614,"activeCount":102},[],{"trials":28616,"activeCount":102},[],{"intervention":28618,"totalTrials":122,"cells":28619},"90 mg Ticagrelor",{"EARLY_PHASE1":28620,"PHASE1":28622,"PHASE2":28624,"PHASE3":28626,"PHASE4":28635,"NA":28637},{"trials":28621,"activeCount":102},[],{"trials":28623,"activeCount":102},[],{"trials":28625,"activeCount":102},[],{"trials":28627,"activeCount":102},[28628],{"nctId":28629,"briefTitle":28630,"status":624,"phases":28631,"primaryCompletion":19426,"completion":19426,"start":2579,"enrollment":102,"conditions":28632,"interventions":28633},"NCT01757262","A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient",[92],[12789],[28618,28634],"75mg Clopidogrel",{"trials":28636,"activeCount":102},[],{"trials":28638,"activeCount":102},[],{"intervention":28634,"totalTrials":122,"cells":28640},{"EARLY_PHASE1":28641,"PHASE1":28643,"PHASE2":28645,"PHASE3":28647,"PHASE4":28653,"NA":28655},{"trials":28642,"activeCount":102},[],{"trials":28644,"activeCount":102},[],{"trials":28646,"activeCount":102},[],{"trials":28648,"activeCount":102},[28649],{"nctId":28629,"briefTitle":28630,"status":624,"phases":28650,"primaryCompletion":19426,"completion":19426,"start":2579,"enrollment":102,"conditions":28651,"interventions":28652},[92],[12789],[28618,28634],{"trials":28654,"activeCount":102},[],{"trials":28656,"activeCount":102},[],{"intervention":20032,"totalTrials":122,"cells":28658},{"EARLY_PHASE1":28659,"PHASE1":28661,"PHASE2":28663,"PHASE3":28665,"PHASE4":28671,"NA":28673},{"trials":28660,"activeCount":102},[],{"trials":28662,"activeCount":102},[],{"trials":28664,"activeCount":102},[],{"trials":28666,"activeCount":102},[28667],{"nctId":20024,"briefTitle":20025,"status":195,"phases":28668,"primaryCompletion":2151,"completion":2151,"start":2414,"enrollment":20027,"conditions":28669,"interventions":28670},[92],[18697,20029],[20006,20031,20032],{"trials":28672,"activeCount":102},[],{"trials":28674,"activeCount":102},[],{"intervention":25479,"totalTrials":122,"cells":28676},{"EARLY_PHASE1":28677,"PHASE1":28679,"PHASE2":28681,"PHASE3":28683,"PHASE4":28689,"NA":28691},{"trials":28678,"activeCount":102},[],{"trials":28680,"activeCount":102},[],{"trials":28682,"activeCount":102},[],{"trials":28684,"activeCount":102},[28685],{"nctId":25472,"briefTitle":25473,"status":195,"phases":28686,"primaryCompletion":13166,"completion":13166,"start":25475,"enrollment":25476,"conditions":28687,"interventions":28688},[92],[16],[10283,25479,25480,25481],{"trials":28690,"activeCount":102},[],{"trials":28692,"activeCount":102},[],{"intervention":25480,"totalTrials":122,"cells":28694},{"EARLY_PHASE1":28695,"PHASE1":28697,"PHASE2":28699,"PHASE3":28701,"PHASE4":28707,"NA":28709},{"trials":28696,"activeCount":102},[],{"trials":28698,"activeCount":102},[],{"trials":28700,"activeCount":102},[],{"trials":28702,"activeCount":102},[28703],{"nctId":25472,"briefTitle":25473,"status":195,"phases":28704,"primaryCompletion":13166,"completion":13166,"start":25475,"enrollment":25476,"conditions":28705,"interventions":28706},[92],[16],[10283,25479,25480,25481],{"trials":28708,"activeCount":102},[],{"trials":28710,"activeCount":102},[],{"intervention":25481,"totalTrials":122,"cells":28712},{"EARLY_PHASE1":28713,"PHASE1":28715,"PHASE2":28717,"PHASE3":28719,"PHASE4":28725,"NA":28727},{"trials":28714,"activeCount":102},[],{"trials":28716,"activeCount":102},[],{"trials":28718,"activeCount":102},[],{"trials":28720,"activeCount":102},[28721],{"nctId":25472,"briefTitle":25473,"status":195,"phases":28722,"primaryCompletion":13166,"completion":13166,"start":25475,"enrollment":25476,"conditions":28723,"interventions":28724},[92],[16],[10283,25479,25480,25481],{"trials":28726,"activeCount":102},[],{"trials":28728,"activeCount":102},[],{"intervention":28730,"totalTrials":122,"cells":28731},"AZD2816",{"EARLY_PHASE1":28732,"PHASE1":28734,"PHASE2":28736,"PHASE3":28738,"PHASE4":28751,"NA":28753},{"trials":28733,"activeCount":102},[],{"trials":28735,"activeCount":102},[],{"trials":28737,"activeCount":102},[],{"trials":28739,"activeCount":102},[28740],{"nctId":28741,"briefTitle":28742,"status":195,"phases":28743,"primaryCompletion":28744,"completion":28745,"start":28746,"enrollment":28747,"conditions":28748,"interventions":28749},"NCT04973449","Phase II\u002FIII Study of AZD2816, for the Prevention of COVID-19 in Adults",[91,92],"2022-02-04","2022-08-02","2021-06-27",2843,[1387,23927],[28750,28730],"AZD1222",{"trials":28752,"activeCount":102},[],{"trials":28754,"activeCount":102},[],{"intervention":19303,"totalTrials":122,"cells":28756},{"EARLY_PHASE1":28757,"PHASE1":28759,"PHASE2":28761,"PHASE3":28763,"PHASE4":28769,"NA":28771},{"trials":28758,"activeCount":102},[],{"trials":28760,"activeCount":102},[],{"trials":28762,"activeCount":102},[],{"trials":28764,"activeCount":102},[28765],{"nctId":19296,"briefTitle":19297,"status":195,"phases":28766,"primaryCompletion":2481,"completion":2481,"start":2433,"enrollment":19299,"conditions":28767,"interventions":28768},[92],[12948,19301],[12616,19228,19303],{"trials":28770,"activeCount":102},[],{"trials":28772,"activeCount":102},[],{"intervention":28774,"totalTrials":122,"cells":28775},"quetiapine fumarate or valproate",{"EARLY_PHASE1":28776,"PHASE1":28778,"PHASE2":28780,"PHASE3":28782,"PHASE4":28791,"NA":28793},{"trials":28777,"activeCount":102},[],{"trials":28779,"activeCount":102},[],{"trials":28781,"activeCount":102},[],{"trials":28783,"activeCount":102},[28784],{"nctId":28785,"briefTitle":28786,"status":195,"phases":28787,"completion":2087,"start":28788,"enrollment":3811,"conditions":28789,"interventions":28790},"NCT00254774","Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling",[92],"2002-01",[18732],[28774],{"trials":28792,"activeCount":102},[],{"trials":28794,"activeCount":102},[],{"intervention":823,"totalTrials":122,"cells":28796},{"EARLY_PHASE1":28797,"PHASE1":28799,"PHASE2":28801,"PHASE3":28803,"PHASE4":28809,"NA":28811},{"trials":28798,"activeCount":102},[],{"trials":28800,"activeCount":102},[],{"trials":28802,"activeCount":102},[],{"trials":28804,"activeCount":102},[28805],{"nctId":811,"briefTitle":812,"status":195,"phases":28806,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":28807,"interventions":28808},[92],[819,820,821],[267,823],{"trials":28810,"activeCount":102},[],{"trials":28812,"activeCount":102},[],{"intervention":26188,"totalTrials":122,"cells":28814},{"EARLY_PHASE1":28815,"PHASE1":28817,"PHASE2":28819,"PHASE3":28821,"PHASE4":28827,"NA":28829},{"trials":28816,"activeCount":102},[],{"trials":28818,"activeCount":102},[],{"trials":28820,"activeCount":102},[],{"trials":28822,"activeCount":102},[28823],{"nctId":26180,"briefTitle":26181,"status":195,"phases":28824,"primaryCompletion":26183,"completion":26183,"start":26184,"enrollment":26185,"conditions":28825,"interventions":28826},[92],[28],[26188,26189,26190,26154],{"trials":28828,"activeCount":102},[],{"trials":28830,"activeCount":102},[],{"intervention":26190,"totalTrials":122,"cells":28832},{"EARLY_PHASE1":28833,"PHASE1":28835,"PHASE2":28837,"PHASE3":28839,"PHASE4":28845,"NA":28847},{"trials":28834,"activeCount":102},[],{"trials":28836,"activeCount":102},[],{"trials":28838,"activeCount":102},[],{"trials":28840,"activeCount":102},[28841],{"nctId":26180,"briefTitle":26181,"status":195,"phases":28842,"primaryCompletion":26183,"completion":26183,"start":26184,"enrollment":26185,"conditions":28843,"interventions":28844},[92],[28],[26188,26189,26190,26154],{"trials":28846,"activeCount":102},[],{"trials":28848,"activeCount":102},[],{"intervention":28850,"totalTrials":122,"cells":28851},"ZD9393 (Zoladex) 10.8 mg",{"EARLY_PHASE1":28852,"PHASE1":28854,"PHASE2":28856,"PHASE3":28858,"PHASE4":28870,"NA":28872},{"trials":28853,"activeCount":102},[],{"trials":28855,"activeCount":102},[],{"trials":28857,"activeCount":102},[],{"trials":28859,"activeCount":102},[28860],{"nctId":28861,"briefTitle":28862,"status":195,"phases":28863,"primaryCompletion":28864,"completion":28865,"start":28866,"enrollment":28265,"conditions":28867,"interventions":28868},"NCT01073865","Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer",[92],"2012-09-19","2017-11-20","2010-02-26",[25],[28850,28869],"ZD9393 (Zoladex) 3.6 mg",{"trials":28871,"activeCount":102},[],{"trials":28873,"activeCount":102},[],{"intervention":28869,"totalTrials":122,"cells":28875},{"EARLY_PHASE1":28876,"PHASE1":28878,"PHASE2":28880,"PHASE3":28882,"PHASE4":28888,"NA":28890},{"trials":28877,"activeCount":102},[],{"trials":28879,"activeCount":102},[],{"trials":28881,"activeCount":102},[],{"trials":28883,"activeCount":102},[28884],{"nctId":28861,"briefTitle":28862,"status":195,"phases":28885,"primaryCompletion":28864,"completion":28865,"start":28866,"enrollment":28265,"conditions":28886,"interventions":28887},[92],[25],[28850,28869],{"trials":28889,"activeCount":102},[],{"trials":28891,"activeCount":102},[],{"intervention":28893,"totalTrials":122,"cells":28894},"Esomeprazole (D961H) twice daily",{"EARLY_PHASE1":28895,"PHASE1":28897,"PHASE2":28899,"PHASE3":28901,"PHASE4":28912,"NA":28914},{"trials":28896,"activeCount":102},[],{"trials":28898,"activeCount":102},[],{"trials":28900,"activeCount":102},[],{"trials":28902,"activeCount":102},[28903],{"nctId":28904,"briefTitle":28905,"status":195,"phases":28906,"primaryCompletion":2203,"completion":2203,"start":2105,"enrollment":28907,"conditions":28908,"interventions":28910},"NCT01669811","Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)",[92],1398,[28909],"Refractory Reflux Esophagitis",[28893,28911],"Esomeprazole (D961H) once daily",{"trials":28913,"activeCount":102},[],{"trials":28915,"activeCount":102},[],{"intervention":28911,"totalTrials":122,"cells":28917},{"EARLY_PHASE1":28918,"PHASE1":28920,"PHASE2":28922,"PHASE3":28924,"PHASE4":28930,"NA":28932},{"trials":28919,"activeCount":102},[],{"trials":28921,"activeCount":102},[],{"trials":28923,"activeCount":102},[],{"trials":28925,"activeCount":102},[28926],{"nctId":28904,"briefTitle":28905,"status":195,"phases":28927,"primaryCompletion":2203,"completion":2203,"start":2105,"enrollment":28907,"conditions":28928,"interventions":28929},[92],[28909],[28893,28911],{"trials":28931,"activeCount":102},[],{"trials":28933,"activeCount":102},[],{"intervention":28935,"totalTrials":122,"cells":28936},"CRESTOR",{"EARLY_PHASE1":28937,"PHASE1":28939,"PHASE2":28941,"PHASE3":28943,"PHASE4":28952,"NA":28954},{"trials":28938,"activeCount":102},[],{"trials":28940,"activeCount":102},[],{"trials":28942,"activeCount":102},[],{"trials":28944,"activeCount":102},[28945],{"nctId":28946,"briefTitle":28947,"status":195,"phases":28948,"primaryCompletion":2252,"completion":2252,"start":6780,"enrollment":28949,"conditions":28950,"interventions":28951},"NCT00206310","Crestor Versus Placebo in Subjects With Heart Failure",[92],5013,[1520],[28935],{"trials":28953,"activeCount":102},[],{"trials":28955,"activeCount":102},[],{"intervention":9925,"totalTrials":122,"cells":28957},{"EARLY_PHASE1":28958,"PHASE1":28960,"PHASE2":28962,"PHASE3":28964,"PHASE4":28970,"NA":28972},{"trials":28959,"activeCount":102},[],{"trials":28961,"activeCount":102},[],{"trials":28963,"activeCount":102},[],{"trials":28965,"activeCount":102},[28966],{"nctId":9920,"briefTitle":9921,"status":195,"phases":28967,"completion":2169,"start":5563,"enrollment":2472,"conditions":28968,"interventions":28969},[92],[28],[9842,9857,9925],{"trials":28971,"activeCount":102},[],{"trials":28973,"activeCount":102},[],{"intervention":26693,"totalTrials":122,"cells":28975},{"EARLY_PHASE1":28976,"PHASE1":28978,"PHASE2":28980,"PHASE3":28982,"PHASE4":28988,"NA":28990},{"trials":28977,"activeCount":102},[],{"trials":28979,"activeCount":102},[],{"trials":28981,"activeCount":102},[],{"trials":28983,"activeCount":102},[28984],{"nctId":26686,"briefTitle":26687,"status":195,"phases":28985,"primaryCompletion":12846,"completion":4298,"start":26689,"enrollment":26690,"conditions":28986,"interventions":28987},[92],[25],[26667,26693],{"trials":28989,"activeCount":102},[],{"trials":28991,"activeCount":102},[],{"intervention":26747,"totalTrials":122,"cells":28993},{"EARLY_PHASE1":28994,"PHASE1":28996,"PHASE2":28998,"PHASE3":29000,"PHASE4":29006,"NA":29008},{"trials":28995,"activeCount":102},[],{"trials":28997,"activeCount":102},[],{"trials":28999,"activeCount":102},[],{"trials":29001,"activeCount":102},[29002],{"nctId":26737,"briefTitle":26738,"status":195,"phases":29003,"primaryCompletion":6468,"completion":6468,"start":2470,"enrollment":2783,"conditions":29004,"interventions":29005},[92],[26741,26742,26743,26744,26745,20147],[26747,26726,26748],{"trials":29007,"activeCount":102},[],{"trials":29009,"activeCount":102},[],{"intervention":26748,"totalTrials":122,"cells":29011},{"EARLY_PHASE1":29012,"PHASE1":29014,"PHASE2":29016,"PHASE3":29018,"PHASE4":29024,"NA":29026},{"trials":29013,"activeCount":102},[],{"trials":29015,"activeCount":102},[],{"trials":29017,"activeCount":102},[],{"trials":29019,"activeCount":102},[29020],{"nctId":26737,"briefTitle":26738,"status":195,"phases":29021,"primaryCompletion":6468,"completion":6468,"start":2470,"enrollment":2783,"conditions":29022,"interventions":29023},[92],[26741,26742,26743,26744,26745,20147],[26747,26726,26748],{"trials":29025,"activeCount":102},[],{"trials":29027,"activeCount":102},[],{"intervention":29029,"totalTrials":122,"cells":29030},"Symbicort TBH - Turbuhaler",{"EARLY_PHASE1":29031,"PHASE1":29033,"PHASE2":29035,"PHASE3":29037,"PHASE4":29046,"NA":29048},{"trials":29032,"activeCount":102},[],{"trials":29034,"activeCount":102},[],{"trials":29036,"activeCount":102},[],{"trials":29038,"activeCount":102},[29039],{"nctId":29040,"briefTitle":29041,"status":195,"phases":29042,"primaryCompletion":3827,"completion":3827,"start":2329,"enrollment":19474,"conditions":29043,"interventions":29044},"NCT00628758","A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma",[92],[16],[29029,29045],"beta-II-agonist, inhale steroid",{"trials":29047,"activeCount":102},[],{"trials":29049,"activeCount":102},[],{"intervention":29045,"totalTrials":122,"cells":29051},{"EARLY_PHASE1":29052,"PHASE1":29054,"PHASE2":29056,"PHASE3":29058,"PHASE4":29064,"NA":29066},{"trials":29053,"activeCount":102},[],{"trials":29055,"activeCount":102},[],{"trials":29057,"activeCount":102},[],{"trials":29059,"activeCount":102},[29060],{"nctId":29040,"briefTitle":29041,"status":195,"phases":29061,"primaryCompletion":3827,"completion":3827,"start":2329,"enrollment":19474,"conditions":29062,"interventions":29063},[92],[16],[29029,29045],{"trials":29065,"activeCount":102},[],{"trials":29067,"activeCount":102},[],{"intervention":855,"totalTrials":122,"cells":29069},{"EARLY_PHASE1":29070,"PHASE1":29072,"PHASE2":29074,"PHASE3":29076,"PHASE4":29082,"NA":29084},{"trials":29071,"activeCount":102},[],{"trials":29073,"activeCount":102},[],{"trials":29075,"activeCount":102},[],{"trials":29077,"activeCount":102},[29078],{"nctId":846,"briefTitle":847,"status":195,"phases":29079,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":29080,"interventions":29081},[92],[720],[722,855],{"trials":29083,"activeCount":102},[],{"trials":29085,"activeCount":102},[],{"intervention":29087,"totalTrials":122,"cells":29088},"Benralizumab 30 mg",{"EARLY_PHASE1":29089,"PHASE1":29091,"PHASE2":29093,"PHASE3":29095,"PHASE4":29108,"NA":29110},{"trials":29090,"activeCount":102},[],{"trials":29092,"activeCount":102},[],{"trials":29094,"activeCount":102},[],{"trials":29096,"activeCount":102},[29097],{"nctId":29098,"briefTitle":29099,"status":443,"phases":29100,"primaryCompletion":29101,"completion":1226,"start":29102,"enrollment":23025,"conditions":29103,"interventions":29106},"NCT04157335","Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)",[92],"2024-08-06","2019-11-25",[29104,29105],"Nasal Polyposis","Eosinophilic Chronic Rhinosinusitis",[29087,29107],"Matched placebo",{"trials":29109,"activeCount":102},[],{"trials":29111,"activeCount":102},[],{"intervention":29107,"totalTrials":122,"cells":29113},{"EARLY_PHASE1":29114,"PHASE1":29116,"PHASE2":29118,"PHASE3":29120,"PHASE4":29126,"NA":29128},{"trials":29115,"activeCount":102},[],{"trials":29117,"activeCount":102},[],{"trials":29119,"activeCount":102},[],{"trials":29121,"activeCount":102},[29122],{"nctId":29098,"briefTitle":29099,"status":443,"phases":29123,"primaryCompletion":29101,"completion":1226,"start":29102,"enrollment":23025,"conditions":29124,"interventions":29125},[92],[29104,29105],[29087,29107],{"trials":29127,"activeCount":102},[],{"trials":29129,"activeCount":102},[],{"intervention":29131,"totalTrials":122,"cells":29132},"Aclidinium Bromide 200 µg",{"EARLY_PHASE1":29133,"PHASE1":29135,"PHASE2":29137,"PHASE3":29139,"PHASE4":29149,"NA":29151},{"trials":29134,"activeCount":102},[],{"trials":29136,"activeCount":102},[],{"trials":29138,"activeCount":102},[],{"trials":29140,"activeCount":102},[29141],{"nctId":29142,"briefTitle":29143,"status":195,"phases":29144,"primaryCompletion":12721,"completion":12721,"start":2057,"enrollment":29145,"conditions":29146,"interventions":29147},"NCT01044459","Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)",[92],605,[28],[29131,29148],"Aclidinium Bromide 400 µg",{"trials":29150,"activeCount":102},[],{"trials":29152,"activeCount":102},[],{"intervention":29148,"totalTrials":122,"cells":29154},{"EARLY_PHASE1":29155,"PHASE1":29157,"PHASE2":29159,"PHASE3":29161,"PHASE4":29167,"NA":29169},{"trials":29156,"activeCount":102},[],{"trials":29158,"activeCount":102},[],{"trials":29160,"activeCount":102},[],{"trials":29162,"activeCount":102},[29163],{"nctId":29142,"briefTitle":29143,"status":195,"phases":29164,"primaryCompletion":12721,"completion":12721,"start":2057,"enrollment":29145,"conditions":29165,"interventions":29166},[92],[28],[29131,29148],{"trials":29168,"activeCount":102},[],{"trials":29170,"activeCount":102},[],{"intervention":29172,"totalTrials":122,"cells":29173},"Brazikumab low dose",{"EARLY_PHASE1":29174,"PHASE1":29176,"PHASE2":29178,"PHASE3":29180,"PHASE4":29193,"NA":29195},{"trials":29175,"activeCount":102},[],{"trials":29177,"activeCount":102},[],{"trials":29179,"activeCount":102},[],{"trials":29181,"activeCount":102},[29182],{"nctId":29183,"briefTitle":29184,"status":443,"phases":29185,"primaryCompletion":29186,"completion":29186,"start":29187,"enrollment":29188,"conditions":29189,"interventions":29190},"NCT03759288","An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease",[91,92],"2023-10-18","2018-12-07",89,[13237,26095],[29172,29191,29192],"Brazikumab high dose","Humira®",{"trials":29194,"activeCount":102},[],{"trials":29196,"activeCount":102},[],{"intervention":29191,"totalTrials":122,"cells":29198},{"EARLY_PHASE1":29199,"PHASE1":29201,"PHASE2":29203,"PHASE3":29205,"PHASE4":29211,"NA":29213},{"trials":29200,"activeCount":102},[],{"trials":29202,"activeCount":102},[],{"trials":29204,"activeCount":102},[],{"trials":29206,"activeCount":102},[29207],{"nctId":29183,"briefTitle":29184,"status":443,"phases":29208,"primaryCompletion":29186,"completion":29186,"start":29187,"enrollment":29188,"conditions":29209,"interventions":29210},[91,92],[13237,26095],[29172,29191,29192],{"trials":29212,"activeCount":102},[],{"trials":29214,"activeCount":102},[],{"intervention":29192,"totalTrials":122,"cells":29216},{"EARLY_PHASE1":29217,"PHASE1":29219,"PHASE2":29221,"PHASE3":29223,"PHASE4":29229,"NA":29231},{"trials":29218,"activeCount":102},[],{"trials":29220,"activeCount":102},[],{"trials":29222,"activeCount":102},[],{"trials":29224,"activeCount":102},[29225],{"nctId":29183,"briefTitle":29184,"status":443,"phases":29226,"primaryCompletion":29186,"completion":29186,"start":29187,"enrollment":29188,"conditions":29227,"interventions":29228},[91,92],[13237,26095],[29172,29191,29192],{"trials":29230,"activeCount":102},[],{"trials":29232,"activeCount":102},[],{"intervention":29234,"totalTrials":122,"cells":29235},"Biological: Experimental: Tezepelumab",{"EARLY_PHASE1":29236,"PHASE1":29238,"PHASE2":29240,"PHASE3":29242,"PHASE4":29252,"NA":29254},{"trials":29237,"activeCount":102},[],{"trials":29239,"activeCount":102},[],{"trials":29241,"activeCount":102},[],{"trials":29243,"activeCount":102},[29244],{"nctId":29245,"briefTitle":29246,"status":195,"phases":29247,"primaryCompletion":29248,"completion":29248,"start":29249,"enrollment":5189,"conditions":29250,"interventions":29251},"NCT04048343","Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma",[92],"2021-03-18","2019-06-10",[6117],[29234],{"trials":29253,"activeCount":102},[],{"trials":29255,"activeCount":102},[],{"intervention":26346,"totalTrials":122,"cells":29257},{"EARLY_PHASE1":29258,"PHASE1":29260,"PHASE2":29262,"PHASE3":29264,"PHASE4":29270,"NA":29272},{"trials":29259,"activeCount":102},[],{"trials":29261,"activeCount":102},[],{"trials":29263,"activeCount":102},[],{"trials":29265,"activeCount":102},[29266],{"nctId":26341,"briefTitle":26342,"status":195,"phases":29267,"primaryCompletion":2433,"completion":2433,"start":688,"enrollment":2003,"conditions":29268,"interventions":29269},[92],[18732,18733],[26346,23679,26347],{"trials":29271,"activeCount":102},[],{"trials":29273,"activeCount":102},[],{"intervention":26347,"totalTrials":122,"cells":29275},{"EARLY_PHASE1":29276,"PHASE1":29278,"PHASE2":29280,"PHASE3":29282,"PHASE4":29288,"NA":29290},{"trials":29277,"activeCount":102},[],{"trials":29279,"activeCount":102},[],{"trials":29281,"activeCount":102},[],{"trials":29283,"activeCount":102},[29284],{"nctId":26341,"briefTitle":26342,"status":195,"phases":29285,"primaryCompletion":2433,"completion":2433,"start":688,"enrollment":2003,"conditions":29286,"interventions":29287},[92],[18732,18733],[26346,23679,26347],{"trials":29289,"activeCount":102},[],{"trials":29291,"activeCount":102},[],{"intervention":24242,"totalTrials":122,"cells":29293},{"EARLY_PHASE1":29294,"PHASE1":29296,"PHASE2":29298,"PHASE3":29300,"PHASE4":29306,"NA":29308},{"trials":29295,"activeCount":102},[],{"trials":29297,"activeCount":102},[],{"trials":29299,"activeCount":102},[],{"trials":29301,"activeCount":102},[29302],{"nctId":24237,"briefTitle":24238,"status":195,"phases":29303,"primaryCompletion":2736,"completion":2736,"start":2056,"enrollment":3336,"conditions":29304,"interventions":29305},[92],[28],[24202,24242],{"trials":29307,"activeCount":102},[],{"trials":29309,"activeCount":102},[],{"intervention":26438,"totalTrials":122,"cells":29311},{"EARLY_PHASE1":29312,"PHASE1":29314,"PHASE2":29316,"PHASE3":29318,"PHASE4":29324,"NA":29326},{"trials":29313,"activeCount":102},[],{"trials":29315,"activeCount":102},[],{"trials":29317,"activeCount":102},[],{"trials":29319,"activeCount":102},[29320],{"nctId":26430,"briefTitle":26431,"status":195,"phases":29321,"primaryCompletion":26433,"completion":26434,"start":6080,"enrollment":26435,"conditions":29322,"interventions":29323},[91,92],[24836],[26410,26438],{"trials":29325,"activeCount":102},[],{"trials":29327,"activeCount":102},[],{"intervention":29329,"totalTrials":122,"cells":29330},"Saxagliptin 5mg",{"EARLY_PHASE1":29331,"PHASE1":29333,"PHASE2":29335,"PHASE3":29337,"PHASE4":29345,"NA":29347},{"trials":29332,"activeCount":102},[],{"trials":29334,"activeCount":102},[],{"trials":29336,"activeCount":102},[],{"trials":29338,"activeCount":102},[29339],{"nctId":29340,"briefTitle":29341,"status":195,"phases":29342,"primaryCompletion":2683,"completion":2683,"start":8157,"enrollment":7824,"conditions":29343,"interventions":29344},"NCT02104804","Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control",[92],[22],[29329],{"trials":29346,"activeCount":102},[],{"trials":29348,"activeCount":102},[],{"intervention":26757,"totalTrials":122,"cells":29350},{"EARLY_PHASE1":29351,"PHASE1":29353,"PHASE2":29355,"PHASE3":29357,"PHASE4":29363,"NA":29365},{"trials":29352,"activeCount":102},[],{"trials":29354,"activeCount":102},[],{"trials":29356,"activeCount":102},[],{"trials":29358,"activeCount":102},[29359],{"nctId":26750,"briefTitle":26751,"status":195,"phases":29360,"primaryCompletion":26753,"completion":26753,"start":26754,"enrollment":4286,"conditions":29361,"interventions":29362},[92],[19792,20616,20617],[26726,26757],{"trials":29364,"activeCount":102},[],{"trials":29366,"activeCount":102},[],{"intervention":29368,"totalTrials":122,"cells":29369},"Linaclotide",{"EARLY_PHASE1":29370,"PHASE1":29372,"PHASE2":29374,"PHASE3":29376,"PHASE4":29385,"NA":29387},{"trials":29371,"activeCount":102},[],{"trials":29373,"activeCount":102},[],{"trials":29375,"activeCount":102},[],{"trials":29377,"activeCount":102},[29378],{"nctId":29379,"briefTitle":29380,"status":195,"phases":29381,"primaryCompletion":13756,"completion":13756,"start":13856,"enrollment":23823,"conditions":29382,"interventions":29384},"NCT01880424","A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",[92],[29383],"Irritable Bowel Syndrome With Constipation (IBS-C)",[29368],{"trials":29386,"activeCount":102},[],{"trials":29388,"activeCount":102},[],{"intervention":4113,"totalTrials":122,"cells":29390},{"EARLY_PHASE1":29391,"PHASE1":29393,"PHASE2":29395,"PHASE3":29397,"PHASE4":29403,"NA":29405},{"trials":29392,"activeCount":102},[],{"trials":29394,"activeCount":102},[],{"trials":29396,"activeCount":102},[],{"trials":29398,"activeCount":102},[29399],{"nctId":4103,"briefTitle":4104,"status":195,"phases":29400,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":29401,"interventions":29402},[92],[4111],[82,3137,4113,4114,296,177,344],{"trials":29404,"activeCount":102},[],{"trials":29406,"activeCount":102},[],{"intervention":19088,"totalTrials":122,"cells":29408},{"EARLY_PHASE1":29409,"PHASE1":29411,"PHASE2":29413,"PHASE3":29415,"PHASE4":29421,"NA":29423},{"trials":29410,"activeCount":102},[],{"trials":29412,"activeCount":102},[],{"trials":29414,"activeCount":102},[],{"trials":29416,"activeCount":102},[29417],{"nctId":19082,"briefTitle":19083,"status":195,"phases":29418,"primaryCompletion":2151,"completion":2144,"start":4298,"enrollment":19085,"conditions":29419,"interventions":29420},[92],[31],[2173,19088,2108],{"trials":29422,"activeCount":102},[],{"trials":29424,"activeCount":102},[],{"intervention":18384,"totalTrials":122,"cells":29426},{"EARLY_PHASE1":29427,"PHASE1":29429,"PHASE2":29431,"PHASE3":29433,"PHASE4":29439,"NA":29441},{"trials":29428,"activeCount":102},[],{"trials":29430,"activeCount":102},[],{"trials":29432,"activeCount":102},[],{"trials":29434,"activeCount":102},[29435],{"nctId":18378,"briefTitle":18379,"status":195,"phases":29436,"primaryCompletion":2105,"completion":2105,"start":2067,"enrollment":18381,"conditions":29437,"interventions":29438},[92],[22],[18239,18384,2173,18385],{"trials":29440,"activeCount":102},[],{"trials":29442,"activeCount":102},[],{"intervention":18385,"totalTrials":122,"cells":29444},{"EARLY_PHASE1":29445,"PHASE1":29447,"PHASE2":29449,"PHASE3":29451,"PHASE4":29457,"NA":29459},{"trials":29446,"activeCount":102},[],{"trials":29448,"activeCount":102},[],{"trials":29450,"activeCount":102},[],{"trials":29452,"activeCount":102},[29453],{"nctId":18378,"briefTitle":18379,"status":195,"phases":29454,"primaryCompletion":2105,"completion":2105,"start":2067,"enrollment":18381,"conditions":29455,"interventions":29456},[92],[22],[18239,18384,2173,18385],{"trials":29458,"activeCount":102},[],{"trials":29460,"activeCount":102},[],{"intervention":2633,"totalTrials":122,"cells":29462},{"EARLY_PHASE1":29463,"PHASE1":29465,"PHASE2":29467,"PHASE3":29469,"PHASE4":29475,"NA":29477},{"trials":29464,"activeCount":102},[],{"trials":29466,"activeCount":102},[],{"trials":29468,"activeCount":102},[],{"trials":29470,"activeCount":102},[29471],{"nctId":2624,"briefTitle":2625,"status":195,"phases":29472,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":155,"conditions":29473,"interventions":29474},[92],[2631],[2633,2634,2044],{"trials":29476,"activeCount":102},[],{"trials":29478,"activeCount":102},[],{"intervention":2634,"totalTrials":122,"cells":29480},{"EARLY_PHASE1":29481,"PHASE1":29483,"PHASE2":29485,"PHASE3":29487,"PHASE4":29493,"NA":29495},{"trials":29482,"activeCount":102},[],{"trials":29484,"activeCount":102},[],{"trials":29486,"activeCount":102},[],{"trials":29488,"activeCount":102},[29489],{"nctId":2624,"briefTitle":2625,"status":195,"phases":29490,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":155,"conditions":29491,"interventions":29492},[92],[2631],[2633,2634,2044],{"trials":29494,"activeCount":102},[],{"trials":29496,"activeCount":102},[],{"intervention":29498,"totalTrials":122,"cells":29499},"Terbutaline sulphate",{"EARLY_PHASE1":29500,"PHASE1":29502,"PHASE2":29504,"PHASE3":29506,"PHASE4":29514,"NA":29516},{"trials":29501,"activeCount":102},[],{"trials":29503,"activeCount":102},[],{"trials":29505,"activeCount":102},[],{"trials":29507,"activeCount":102},[29508],{"nctId":29509,"briefTitle":29510,"status":195,"phases":29511,"primaryCompletion":20831,"completion":20831,"start":25278,"enrollment":29,"conditions":29512,"interventions":29513},"NCT02322788","Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3",[92],[16],[29498,29498],{"trials":29515,"activeCount":102},[],{"trials":29517,"activeCount":102},[],{"intervention":19483,"totalTrials":122,"cells":29519},{"EARLY_PHASE1":29520,"PHASE1":29522,"PHASE2":29524,"PHASE3":29526,"PHASE4":29532,"NA":29534},{"trials":29521,"activeCount":102},[],{"trials":29523,"activeCount":102},[],{"trials":29525,"activeCount":102},[],{"trials":29527,"activeCount":102},[29528],{"nctId":19478,"briefTitle":19479,"status":195,"phases":29529,"primaryCompletion":4331,"completion":4331,"start":9909,"enrollment":9978,"conditions":29530,"interventions":29531},[92],[19420],[9972,19483],{"trials":29533,"activeCount":102},[],{"trials":29535,"activeCount":102},[],{"intervention":29537,"totalTrials":122,"cells":29538},"Active Comparator: Olaparib",{"EARLY_PHASE1":29539,"PHASE1":29541,"PHASE2":29543,"PHASE3":29545,"PHASE4":29555,"NA":29557},{"trials":29540,"activeCount":102},[],{"trials":29542,"activeCount":102},[],{"trials":29544,"activeCount":102},[],{"trials":29546,"activeCount":102},[29547],{"nctId":29548,"briefTitle":29549,"status":195,"phases":29550,"primaryCompletion":29551,"completion":29552,"start":26183,"enrollment":1832,"conditions":29553,"interventions":29554},"NCT03106987","A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.",[92],"2021-02-15","2022-02-17",[3865],[29537],{"trials":29556,"activeCount":102},[],{"trials":29558,"activeCount":102},[],{"intervention":29560,"totalTrials":122,"cells":29561},"premixed insulin aspart twice daily",{"EARLY_PHASE1":29562,"PHASE1":29564,"PHASE2":29566,"PHASE3":29568,"PHASE4":29577,"NA":29579},{"trials":29563,"activeCount":102},[],{"trials":29565,"activeCount":102},[],{"trials":29567,"activeCount":102},[],{"trials":29569,"activeCount":102},[29570],{"nctId":29571,"briefTitle":29572,"status":195,"phases":29573,"primaryCompletion":2152,"completion":2152,"start":2328,"enrollment":23672,"conditions":29574,"interventions":29575},"NCT00434954","Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes",[92],[22],[29576,29560],"exenatide twice daily",{"trials":29578,"activeCount":102},[],{"trials":29580,"activeCount":102},[],{"intervention":19118,"totalTrials":122,"cells":29582},{"EARLY_PHASE1":29583,"PHASE1":29585,"PHASE2":29587,"PHASE3":29589,"PHASE4":29595,"NA":29597},{"trials":29584,"activeCount":102},[],{"trials":29586,"activeCount":102},[],{"trials":29588,"activeCount":102},[],{"trials":29590,"activeCount":102},[29591],{"nctId":19110,"briefTitle":19111,"status":443,"phases":29592,"primaryCompletion":753,"completion":753,"start":19113,"enrollment":6275,"conditions":29593,"interventions":29594},[92],[22],[19116,19117,19118,19119,19120,2173],{"trials":29596,"activeCount":102},[],{"trials":29598,"activeCount":102},[],{"intervention":19119,"totalTrials":122,"cells":29600},{"EARLY_PHASE1":29601,"PHASE1":29603,"PHASE2":29605,"PHASE3":29607,"PHASE4":29613,"NA":29615},{"trials":29602,"activeCount":102},[],{"trials":29604,"activeCount":102},[],{"trials":29606,"activeCount":102},[],{"trials":29608,"activeCount":102},[29609],{"nctId":19110,"briefTitle":19111,"status":443,"phases":29610,"primaryCompletion":753,"completion":753,"start":19113,"enrollment":6275,"conditions":29611,"interventions":29612},[92],[22],[19116,19117,19118,19119,19120,2173],{"trials":29614,"activeCount":102},[],{"trials":29616,"activeCount":102},[],{"intervention":18400,"totalTrials":122,"cells":29618},{"EARLY_PHASE1":29619,"PHASE1":29621,"PHASE2":29623,"PHASE3":29625,"PHASE4":29631,"NA":29633},{"trials":29620,"activeCount":102},[],{"trials":29622,"activeCount":102},[],{"trials":29624,"activeCount":102},[],{"trials":29626,"activeCount":102},[29627],{"nctId":18394,"briefTitle":18395,"status":195,"phases":29628,"primaryCompletion":2507,"completion":2560,"start":6369,"enrollment":18397,"conditions":29629,"interventions":29630},[92],[22],[18400,18239],{"trials":29632,"activeCount":102},[],{"trials":29634,"activeCount":102},[],{"intervention":29636,"totalTrials":122,"cells":29637},"Formoterol Turbuhaler® 4.5mg",{"EARLY_PHASE1":29638,"PHASE1":29640,"PHASE2":29642,"PHASE3":29644,"PHASE4":29654,"NA":29656},{"trials":29639,"activeCount":102},[],{"trials":29641,"activeCount":102},[],{"trials":29643,"activeCount":102},[],{"trials":29645,"activeCount":102},[29646],{"nctId":29647,"briefTitle":29648,"status":195,"phases":29649,"primaryCompletion":2320,"completion":2320,"start":4298,"enrollment":24266,"conditions":29650,"interventions":29651},"NCT00628862","Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU",[92],[28],[29636,29652,29653],"Formoterol Turbuhaler® 9 mg","Turbuhaler® placebo",{"trials":29655,"activeCount":102},[],{"trials":29657,"activeCount":102},[],{"intervention":29652,"totalTrials":122,"cells":29659},{"EARLY_PHASE1":29660,"PHASE1":29662,"PHASE2":29664,"PHASE3":29666,"PHASE4":29672,"NA":29674},{"trials":29661,"activeCount":102},[],{"trials":29663,"activeCount":102},[],{"trials":29665,"activeCount":102},[],{"trials":29667,"activeCount":102},[29668],{"nctId":29647,"briefTitle":29648,"status":195,"phases":29669,"primaryCompletion":2320,"completion":2320,"start":4298,"enrollment":24266,"conditions":29670,"interventions":29671},[92],[28],[29636,29652,29653],{"trials":29673,"activeCount":102},[],{"trials":29675,"activeCount":102},[],{"intervention":29653,"totalTrials":122,"cells":29677},{"EARLY_PHASE1":29678,"PHASE1":29680,"PHASE2":29682,"PHASE3":29684,"PHASE4":29690,"NA":29692},{"trials":29679,"activeCount":102},[],{"trials":29681,"activeCount":102},[],{"trials":29683,"activeCount":102},[],{"trials":29685,"activeCount":102},[29686],{"nctId":29647,"briefTitle":29648,"status":195,"phases":29687,"primaryCompletion":2320,"completion":2320,"start":4298,"enrollment":24266,"conditions":29688,"interventions":29689},[92],[28],[29636,29652,29653],{"trials":29691,"activeCount":102},[],{"trials":29693,"activeCount":102},[],{"intervention":29695,"totalTrials":122,"cells":29696},"10mg Rosuvastatin",{"EARLY_PHASE1":29697,"PHASE1":29699,"PHASE2":29701,"PHASE3":29703,"PHASE4":29713,"NA":29715},{"trials":29698,"activeCount":102},[],{"trials":29700,"activeCount":102},[],{"trials":29702,"activeCount":102},[],{"trials":29704,"activeCount":102},[29705],{"nctId":29706,"briefTitle":29707,"status":195,"phases":29708,"primaryCompletion":2086,"completion":2086,"start":12846,"enrollment":29709,"conditions":29710,"interventions":29712},"NCT00240331","AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)",[92],2776,[29711],"Renal Failure",[29695],{"trials":29714,"activeCount":102},[],{"trials":29716,"activeCount":102},[],{"intervention":29718,"totalTrials":122,"cells":29719},"Quetiapine Fumarate Extended- Release",{"EARLY_PHASE1":29720,"PHASE1":29722,"PHASE2":29724,"PHASE3":29726,"PHASE4":29735,"NA":29737},{"trials":29721,"activeCount":102},[],{"trials":29723,"activeCount":102},[],{"trials":29725,"activeCount":102},[],{"trials":29727,"activeCount":102},[29728],{"nctId":29729,"briefTitle":29730,"status":195,"phases":29731,"primaryCompletion":2406,"completion":2406,"start":2580,"enrollment":29732,"conditions":29733,"interventions":29734},"NCT00640601","Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia",[92],331,[33],[29718],{"trials":29736,"activeCount":102},[],{"trials":29738,"activeCount":102},[],{"intervention":29740,"totalTrials":122,"cells":29741},"Esomeprazole IV",{"EARLY_PHASE1":29742,"PHASE1":29744,"PHASE2":29746,"PHASE3":29748,"PHASE4":29758,"NA":29760},{"trials":29743,"activeCount":102},[],{"trials":29745,"activeCount":102},[],{"trials":29747,"activeCount":102},[],{"trials":29749,"activeCount":102},[29750],{"nctId":29751,"briefTitle":29752,"status":195,"phases":29753,"completion":4297,"start":4916,"enrollment":10435,"conditions":29754,"interventions":29756},"NCT00402259","Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding",[92],[29755],"Gastrointestinal Hemorrhage",[29740,29757],"Omeprazole IV",{"trials":29759,"activeCount":102},[],{"trials":29761,"activeCount":102},[],{"intervention":29757,"totalTrials":122,"cells":29763},{"EARLY_PHASE1":29764,"PHASE1":29766,"PHASE2":29768,"PHASE3":29770,"PHASE4":29776,"NA":29778},{"trials":29765,"activeCount":102},[],{"trials":29767,"activeCount":102},[],{"trials":29769,"activeCount":102},[],{"trials":29771,"activeCount":102},[29772],{"nctId":29751,"briefTitle":29752,"status":195,"phases":29773,"completion":4297,"start":4916,"enrollment":10435,"conditions":29774,"interventions":29775},[92],[29755],[29740,29757],{"trials":29777,"activeCount":102},[],{"trials":29779,"activeCount":102},[],{"intervention":29781,"totalTrials":122,"cells":29782},"Durvalumab plus chemotherapy",{"EARLY_PHASE1":29783,"PHASE1":29785,"PHASE2":29787,"PHASE3":29789,"PHASE4":29799,"NA":29801},{"trials":29784,"activeCount":102},[],{"trials":29786,"activeCount":102},[],{"trials":29788,"activeCount":102},[],{"trials":29790,"activeCount":102},[29791],{"nctId":29792,"briefTitle":29793,"status":195,"phases":29794,"primaryCompletion":3270,"completion":3270,"start":29795,"enrollment":29796,"conditions":29797,"interventions":29798},"NCT04449861","Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)",[92],"2020-12-07",166,[3432],[29781],{"trials":29800,"activeCount":102},[],{"trials":29802,"activeCount":102},[],{"intervention":8203,"totalTrials":122,"cells":29804},{"EARLY_PHASE1":29805,"PHASE1":29807,"PHASE2":29809,"PHASE3":29811,"PHASE4":29817,"NA":29819},{"trials":29806,"activeCount":102},[],{"trials":29808,"activeCount":102},[],{"trials":29810,"activeCount":102},[],{"trials":29812,"activeCount":102},[29813],{"nctId":8194,"briefTitle":8195,"status":195,"phases":29814,"primaryCompletion":8197,"completion":8198,"start":8199,"enrollment":8200,"conditions":29815,"interventions":29816},[92],[157],[82,8203],{"trials":29818,"activeCount":102},[],{"trials":29820,"activeCount":102},[],{"intervention":20391,"totalTrials":122,"cells":29822},{"EARLY_PHASE1":29823,"PHASE1":29825,"PHASE2":29827,"PHASE3":29829,"PHASE4":29835,"NA":29837},{"trials":29824,"activeCount":102},[],{"trials":29826,"activeCount":102},[],{"trials":29828,"activeCount":102},[],{"trials":29830,"activeCount":102},[29831],{"nctId":20385,"briefTitle":20386,"status":195,"phases":29832,"primaryCompletion":6710,"completion":6710,"start":13014,"enrollment":20388,"conditions":29833,"interventions":29834},[92],[2620],[20375,2353,20391],{"trials":29836,"activeCount":102},[],{"trials":29838,"activeCount":102},[],{"intervention":19127,"totalTrials":122,"cells":29840},{"EARLY_PHASE1":29841,"PHASE1":29843,"PHASE2":29845,"PHASE3":29847,"PHASE4":29853,"NA":29855},{"trials":29842,"activeCount":102},[],{"trials":29844,"activeCount":102},[],{"trials":29846,"activeCount":102},[],{"trials":29848,"activeCount":102},[29849],{"nctId":19122,"briefTitle":19123,"status":443,"phases":29850,"completion":5742,"start":5796,"enrollment":9987,"conditions":29851,"interventions":29852},[92],[31],[15914,2173,19127],{"trials":29854,"activeCount":102},[],{"trials":29856,"activeCount":102},[],{"intervention":29858,"totalTrials":122,"cells":29859},"Budesonide\u002Fformoterol pMDI 40\u002F2.25ug + spacer",{"EARLY_PHASE1":29860,"PHASE1":29862,"PHASE2":29864,"PHASE3":29866,"PHASE4":29875,"NA":29877},{"trials":29861,"activeCount":102},[],{"trials":29863,"activeCount":102},[],{"trials":29865,"activeCount":102},[],{"trials":29867,"activeCount":102},[29868],{"nctId":29869,"briefTitle":29870,"status":195,"phases":29871,"primaryCompletion":2168,"completion":2168,"start":2415,"enrollment":20666,"conditions":29872,"interventions":29873},"NCT00536913","Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma",[92],[16],[29858,29874],"Budesonide\u002Fformoterol pMDI 40\u002F2.25 ug",{"trials":29876,"activeCount":102},[],{"trials":29878,"activeCount":102},[],{"intervention":29874,"totalTrials":122,"cells":29880},{"EARLY_PHASE1":29881,"PHASE1":29883,"PHASE2":29885,"PHASE3":29887,"PHASE4":29893,"NA":29895},{"trials":29882,"activeCount":102},[],{"trials":29884,"activeCount":102},[],{"trials":29886,"activeCount":102},[],{"trials":29888,"activeCount":102},[29889],{"nctId":29869,"briefTitle":29870,"status":195,"phases":29890,"primaryCompletion":2168,"completion":2168,"start":2415,"enrollment":20666,"conditions":29891,"interventions":29892},[92],[16],[29858,29874],{"trials":29894,"activeCount":102},[],{"trials":29896,"activeCount":102},[],{"intervention":18428,"totalTrials":122,"cells":29898},{"EARLY_PHASE1":29899,"PHASE1":29901,"PHASE2":29903,"PHASE3":29905,"PHASE4":29911,"NA":29913},{"trials":29900,"activeCount":102},[],{"trials":29902,"activeCount":102},[],{"trials":29904,"activeCount":102},[],{"trials":29906,"activeCount":102},[29907],{"nctId":18422,"briefTitle":18423,"status":195,"phases":29908,"primaryCompletion":2507,"completion":2507,"start":9901,"enrollment":18425,"conditions":29909,"interventions":29910},[92],[2089],[18239,18428],{"trials":29912,"activeCount":102},[],{"trials":29914,"activeCount":102},[],{"intervention":7711,"totalTrials":122,"cells":29916},{"EARLY_PHASE1":29917,"PHASE1":29919,"PHASE2":29921,"PHASE3":29923,"PHASE4":29929,"NA":29931},{"trials":29918,"activeCount":102},[],{"trials":29920,"activeCount":102},[],{"trials":29922,"activeCount":102},[],{"trials":29924,"activeCount":102},[29925],{"nctId":7703,"briefTitle":7704,"status":443,"phases":29926,"primaryCompletion":7706,"completion":3714,"start":7707,"enrollment":1852,"conditions":29927,"interventions":29928},[92],[7709],[68,7711],{"trials":29930,"activeCount":102},[],{"trials":29932,"activeCount":102},[],{"intervention":25563,"totalTrials":122,"cells":29934},{"EARLY_PHASE1":29935,"PHASE1":29937,"PHASE2":29939,"PHASE3":29941,"PHASE4":29947,"NA":29949},{"trials":29936,"activeCount":102},[],{"trials":29938,"activeCount":102},[],{"trials":29940,"activeCount":102},[],{"trials":29942,"activeCount":102},[29943],{"nctId":25554,"briefTitle":25555,"status":195,"phases":29944,"primaryCompletion":25557,"completion":25557,"start":25558,"enrollment":25559,"conditions":29945,"interventions":29946},[92],[6083],[10068,25562,25563],{"trials":29948,"activeCount":102},[],{"trials":29950,"activeCount":102},[],{"intervention":29952,"totalTrials":122,"cells":29953},"Symbicort, used twice daily",{"EARLY_PHASE1":29954,"PHASE1":29956,"PHASE2":29958,"PHASE3":29960,"PHASE4":29980,"NA":29982},{"trials":29955,"activeCount":102},[],{"trials":29957,"activeCount":102},[],{"trials":29959,"activeCount":102},[],{"trials":29961,"activeCount":102},[29962],{"nctId":29963,"briefTitle":29964,"status":195,"phases":29965,"completion":7494,"start":9986,"enrollment":7555,"conditions":29966,"interventions":29967},"NCT00252863","DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults",[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],"Budesonide Turbuhaler 200 µg","Fluticasone Discus 250 µg","Formoterol Turbuhaler 4.5 µg","Terbutaline Turbuhaler 0.5 mg","Salbutamol pressurized metered dose inhaler (pMDI) 100 µg","Salmeterol Discus 50 µg","Budesonide\u002FFormoterol Turbuhaler 160\u002F4.5 µg","Fluticasone\u002FSalmeterol Discus 250\u002F50 µg","Fluticasone\u002FSalmeterol Discus 500\u002F50 µg","Theophylline 200 mg","Theophylline 300 mg","Singulair 10 mg",{"trials":29981,"activeCount":102},[],{"trials":29983,"activeCount":102},[],{"intervention":29968,"totalTrials":122,"cells":29985},{"EARLY_PHASE1":29986,"PHASE1":29988,"PHASE2":29990,"PHASE3":29992,"PHASE4":29998,"NA":30000},{"trials":29987,"activeCount":102},[],{"trials":29989,"activeCount":102},[],{"trials":29991,"activeCount":102},[],{"trials":29993,"activeCount":102},[29994],{"nctId":29963,"briefTitle":29964,"status":195,"phases":29995,"completion":7494,"start":9986,"enrollment":7555,"conditions":29996,"interventions":29997},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":29999,"activeCount":102},[],{"trials":30001,"activeCount":102},[],{"intervention":29969,"totalTrials":122,"cells":30003},{"EARLY_PHASE1":30004,"PHASE1":30006,"PHASE2":30008,"PHASE3":30010,"PHASE4":30016,"NA":30018},{"trials":30005,"activeCount":102},[],{"trials":30007,"activeCount":102},[],{"trials":30009,"activeCount":102},[],{"trials":30011,"activeCount":102},[30012],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30013,"completion":7494,"start":9986,"enrollment":7555,"conditions":30014,"interventions":30015},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30017,"activeCount":102},[],{"trials":30019,"activeCount":102},[],{"intervention":29970,"totalTrials":122,"cells":30021},{"EARLY_PHASE1":30022,"PHASE1":30024,"PHASE2":30026,"PHASE3":30028,"PHASE4":30034,"NA":30036},{"trials":30023,"activeCount":102},[],{"trials":30025,"activeCount":102},[],{"trials":30027,"activeCount":102},[],{"trials":30029,"activeCount":102},[30030],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30031,"completion":7494,"start":9986,"enrollment":7555,"conditions":30032,"interventions":30033},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30035,"activeCount":102},[],{"trials":30037,"activeCount":102},[],{"intervention":29971,"totalTrials":122,"cells":30039},{"EARLY_PHASE1":30040,"PHASE1":30042,"PHASE2":30044,"PHASE3":30046,"PHASE4":30052,"NA":30054},{"trials":30041,"activeCount":102},[],{"trials":30043,"activeCount":102},[],{"trials":30045,"activeCount":102},[],{"trials":30047,"activeCount":102},[30048],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30049,"completion":7494,"start":9986,"enrollment":7555,"conditions":30050,"interventions":30051},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30053,"activeCount":102},[],{"trials":30055,"activeCount":102},[],{"intervention":29972,"totalTrials":122,"cells":30057},{"EARLY_PHASE1":30058,"PHASE1":30060,"PHASE2":30062,"PHASE3":30064,"PHASE4":30070,"NA":30072},{"trials":30059,"activeCount":102},[],{"trials":30061,"activeCount":102},[],{"trials":30063,"activeCount":102},[],{"trials":30065,"activeCount":102},[30066],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30067,"completion":7494,"start":9986,"enrollment":7555,"conditions":30068,"interventions":30069},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30071,"activeCount":102},[],{"trials":30073,"activeCount":102},[],{"intervention":29973,"totalTrials":122,"cells":30075},{"EARLY_PHASE1":30076,"PHASE1":30078,"PHASE2":30080,"PHASE3":30082,"PHASE4":30088,"NA":30090},{"trials":30077,"activeCount":102},[],{"trials":30079,"activeCount":102},[],{"trials":30081,"activeCount":102},[],{"trials":30083,"activeCount":102},[30084],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30085,"completion":7494,"start":9986,"enrollment":7555,"conditions":30086,"interventions":30087},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30089,"activeCount":102},[],{"trials":30091,"activeCount":102},[],{"intervention":29974,"totalTrials":122,"cells":30093},{"EARLY_PHASE1":30094,"PHASE1":30096,"PHASE2":30098,"PHASE3":30100,"PHASE4":30106,"NA":30108},{"trials":30095,"activeCount":102},[],{"trials":30097,"activeCount":102},[],{"trials":30099,"activeCount":102},[],{"trials":30101,"activeCount":102},[30102],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30103,"completion":7494,"start":9986,"enrollment":7555,"conditions":30104,"interventions":30105},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30107,"activeCount":102},[],{"trials":30109,"activeCount":102},[],{"intervention":29975,"totalTrials":122,"cells":30111},{"EARLY_PHASE1":30112,"PHASE1":30114,"PHASE2":30116,"PHASE3":30118,"PHASE4":30124,"NA":30126},{"trials":30113,"activeCount":102},[],{"trials":30115,"activeCount":102},[],{"trials":30117,"activeCount":102},[],{"trials":30119,"activeCount":102},[30120],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30121,"completion":7494,"start":9986,"enrollment":7555,"conditions":30122,"interventions":30123},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30125,"activeCount":102},[],{"trials":30127,"activeCount":102},[],{"intervention":29976,"totalTrials":122,"cells":30129},{"EARLY_PHASE1":30130,"PHASE1":30132,"PHASE2":30134,"PHASE3":30136,"PHASE4":30142,"NA":30144},{"trials":30131,"activeCount":102},[],{"trials":30133,"activeCount":102},[],{"trials":30135,"activeCount":102},[],{"trials":30137,"activeCount":102},[30138],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30139,"completion":7494,"start":9986,"enrollment":7555,"conditions":30140,"interventions":30141},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30143,"activeCount":102},[],{"trials":30145,"activeCount":102},[],{"intervention":29977,"totalTrials":122,"cells":30147},{"EARLY_PHASE1":30148,"PHASE1":30150,"PHASE2":30152,"PHASE3":30154,"PHASE4":30160,"NA":30162},{"trials":30149,"activeCount":102},[],{"trials":30151,"activeCount":102},[],{"trials":30153,"activeCount":102},[],{"trials":30155,"activeCount":102},[30156],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30157,"completion":7494,"start":9986,"enrollment":7555,"conditions":30158,"interventions":30159},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30161,"activeCount":102},[],{"trials":30163,"activeCount":102},[],{"intervention":29978,"totalTrials":122,"cells":30165},{"EARLY_PHASE1":30166,"PHASE1":30168,"PHASE2":30170,"PHASE3":30172,"PHASE4":30178,"NA":30180},{"trials":30167,"activeCount":102},[],{"trials":30169,"activeCount":102},[],{"trials":30171,"activeCount":102},[],{"trials":30173,"activeCount":102},[30174],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30175,"completion":7494,"start":9986,"enrollment":7555,"conditions":30176,"interventions":30177},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30179,"activeCount":102},[],{"trials":30181,"activeCount":102},[],{"intervention":29979,"totalTrials":122,"cells":30183},{"EARLY_PHASE1":30184,"PHASE1":30186,"PHASE2":30188,"PHASE3":30190,"PHASE4":30196,"NA":30198},{"trials":30185,"activeCount":102},[],{"trials":30187,"activeCount":102},[],{"trials":30189,"activeCount":102},[],{"trials":30191,"activeCount":102},[30192],{"nctId":29963,"briefTitle":29964,"status":195,"phases":30193,"completion":7494,"start":9986,"enrollment":7555,"conditions":30194,"interventions":30195},[92],[16],[29952,29968,29969,29970,29971,29972,29973,29974,29975,29976,29977,29978,29979],{"trials":30197,"activeCount":102},[],{"trials":30199,"activeCount":102},[],{"intervention":9973,"totalTrials":122,"cells":30201},{"EARLY_PHASE1":30202,"PHASE1":30204,"PHASE2":30206,"PHASE3":30208,"PHASE4":30214,"NA":30216},{"trials":30203,"activeCount":102},[],{"trials":30205,"activeCount":102},[],{"trials":30207,"activeCount":102},[],{"trials":30209,"activeCount":102},[30210],{"nctId":9967,"briefTitle":9968,"status":195,"phases":30211,"completion":7342,"start":3809,"enrollment":5269,"conditions":30212,"interventions":30213},[92],[16],[9896,9972,9973],{"trials":30215,"activeCount":102},[],{"trials":30217,"activeCount":102},[],{"intervention":30219,"totalTrials":122,"cells":30220},"Glycopyrronium\u002FFormoterol Fumarate",{"EARLY_PHASE1":30221,"PHASE1":30223,"PHASE2":30225,"PHASE3":30227,"PHASE4":30240,"NA":30242},{"trials":30222,"activeCount":102},[],{"trials":30224,"activeCount":102},[],{"trials":30226,"activeCount":102},[],{"trials":30228,"activeCount":102},[30229],{"nctId":30230,"briefTitle":30231,"status":195,"phases":30232,"primaryCompletion":30233,"completion":30233,"start":30234,"enrollment":30235,"conditions":30236,"interventions":30238},"NCT03162055","Efficacy and Safety of Glycopyrronium\u002FFormoterol Fumarate Fixed-dose Combination Relative to Umeclidinium\u002FVilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",[92],"2018-05-04","2017-05-25",1119,[30237],"Chronic Obstructive Pulmonary Disease COPD",[30219,30239],"umeclidinium\u002Fvilanterol",{"trials":30241,"activeCount":102},[],{"trials":30243,"activeCount":102},[],{"intervention":30239,"totalTrials":122,"cells":30245},{"EARLY_PHASE1":30246,"PHASE1":30248,"PHASE2":30250,"PHASE3":30252,"PHASE4":30258,"NA":30260},{"trials":30247,"activeCount":102},[],{"trials":30249,"activeCount":102},[],{"trials":30251,"activeCount":102},[],{"trials":30253,"activeCount":102},[30254],{"nctId":30230,"briefTitle":30231,"status":195,"phases":30255,"primaryCompletion":30233,"completion":30233,"start":30234,"enrollment":30235,"conditions":30256,"interventions":30257},[92],[30237],[30219,30239],{"trials":30259,"activeCount":102},[],{"trials":30261,"activeCount":102},[],{"intervention":25295,"totalTrials":122,"cells":30263},{"EARLY_PHASE1":30264,"PHASE1":30266,"PHASE2":30268,"PHASE3":30270,"PHASE4":30276,"NA":30278},{"trials":30265,"activeCount":102},[],{"trials":30267,"activeCount":102},[],{"trials":30269,"activeCount":102},[],{"trials":30271,"activeCount":102},[30272],{"nctId":25286,"briefTitle":25287,"status":195,"phases":30273,"primaryCompletion":25289,"completion":25289,"start":25290,"enrollment":25291,"conditions":30274,"interventions":30275},[92],[25293],[25252,25295],{"trials":30277,"activeCount":102},[],{"trials":30279,"activeCount":102},[],{"intervention":9981,"totalTrials":122,"cells":30281},{"EARLY_PHASE1":30282,"PHASE1":30284,"PHASE2":30286,"PHASE3":30288,"PHASE4":30294,"NA":30296},{"trials":30283,"activeCount":102},[],{"trials":30285,"activeCount":102},[],{"trials":30287,"activeCount":102},[],{"trials":30289,"activeCount":102},[30290],{"nctId":9975,"briefTitle":9976,"status":195,"phases":30291,"completion":6445,"start":9909,"enrollment":9978,"conditions":30292,"interventions":30293},[92],[16],[9842,9981],{"trials":30295,"activeCount":102},[],{"trials":30297,"activeCount":102},[],{"intervention":30299,"totalTrials":122,"cells":30300},"5 mg rosuvastatin calcium with a Web App",{"EARLY_PHASE1":30301,"PHASE1":30303,"PHASE2":30305,"PHASE3":30307,"PHASE4":30319,"NA":30321},{"trials":30302,"activeCount":102},[],{"trials":30304,"activeCount":102},[],{"trials":30306,"activeCount":102},[],{"trials":30308,"activeCount":102},[30309],{"nctId":30310,"briefTitle":30311,"status":195,"phases":30312,"primaryCompletion":30313,"completion":30313,"start":30314,"enrollment":30315,"conditions":30316,"interventions":30318},"NCT04964544","Technology-Assisted Cholesterol Trial in Consumers (TACTiC)",[92],"2023-03-01","2021-07-08",1196,[30317],"High Cholesterol",[30299],{"trials":30320,"activeCount":102},[],{"trials":30322,"activeCount":102},[],{"intervention":30324,"totalTrials":122,"cells":30325},"HFO-1234ze",{"EARLY_PHASE1":30326,"PHASE1":30328,"PHASE2":30330,"PHASE3":30332,"PHASE4":30343,"NA":30345},{"trials":30327,"activeCount":102},[],{"trials":30329,"activeCount":102},[],{"trials":30331,"activeCount":102},[],{"trials":30333,"activeCount":102},[30334],{"nctId":30335,"briefTitle":30336,"status":195,"phases":30337,"primaryCompletion":11332,"completion":11332,"start":30338,"enrollment":1348,"conditions":30339,"interventions":30341},"NCT05755932","Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants",[92],"2023-06-14",[30340],"Mucociliary Clearance",[30324,30342],"HFA-134a",{"trials":30344,"activeCount":102},[],{"trials":30346,"activeCount":102},[],{"intervention":30342,"totalTrials":122,"cells":30348},{"EARLY_PHASE1":30349,"PHASE1":30351,"PHASE2":30353,"PHASE3":30355,"PHASE4":30361,"NA":30363},{"trials":30350,"activeCount":102},[],{"trials":30352,"activeCount":102},[],{"trials":30354,"activeCount":102},[],{"trials":30356,"activeCount":102},[30357],{"nctId":30335,"briefTitle":30336,"status":195,"phases":30358,"primaryCompletion":11332,"completion":11332,"start":30338,"enrollment":1348,"conditions":30359,"interventions":30360},[92],[30340],[30324,30342],{"trials":30362,"activeCount":102},[],{"trials":30364,"activeCount":102},[],{"intervention":30366,"totalTrials":122,"cells":30367},"Experimental: Tralokinumab",{"EARLY_PHASE1":30368,"PHASE1":30370,"PHASE2":30372,"PHASE3":30374,"PHASE4":30383,"NA":30385},{"trials":30369,"activeCount":102},[],{"trials":30371,"activeCount":102},[],{"trials":30373,"activeCount":102},[],{"trials":30375,"activeCount":102},[30376],{"nctId":30377,"briefTitle":24914,"status":195,"phases":30378,"primaryCompletion":30379,"completion":30380,"start":25290,"enrollment":7476,"conditions":30381,"interventions":30382},"NCT02194699",[92],"2017-05-10","2017-09-21",[24921],[30366],{"trials":30384,"activeCount":102},[],{"trials":30386,"activeCount":102},[],{"intervention":30388,"totalTrials":122,"cells":30389},"Formoterol turbohaler",{"EARLY_PHASE1":30390,"PHASE1":30392,"PHASE2":30394,"PHASE3":30396,"PHASE4":30407,"NA":30409},{"trials":30391,"activeCount":102},[],{"trials":30393,"activeCount":102},[],{"trials":30395,"activeCount":102},[],{"trials":30397,"activeCount":102},[30398],{"nctId":30399,"briefTitle":30400,"status":195,"phases":30401,"primaryCompletion":10048,"completion":10048,"start":30402,"enrollment":30403,"conditions":30404,"interventions":30406},"NCT02157935","Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease",[92],"2014-06-27",2026,[30405],"COPD Patients",[19501,30388],{"trials":30408,"activeCount":102},[],{"trials":30410,"activeCount":102},[],{"intervention":30412,"totalTrials":122,"cells":30413},"Durvalumab + SoC chemotherapy",{"EARLY_PHASE1":30414,"PHASE1":30416,"PHASE2":30418,"PHASE3":30420,"PHASE4":30429,"NA":30431},{"trials":30415,"activeCount":102},[],{"trials":30417,"activeCount":102},[],{"trials":30419,"activeCount":102},[],{"trials":30421,"activeCount":102},[30422],{"nctId":30423,"briefTitle":30424,"status":195,"phases":30425,"primaryCompletion":7681,"completion":7681,"start":30426,"enrollment":29188,"conditions":30427,"interventions":30428},"NCT04385368","Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)",[92],"2020-07-17",[992],[30412],{"trials":30430,"activeCount":102},[],{"trials":30432,"activeCount":102},[],{"intervention":30434,"totalTrials":122,"cells":30435},"Gefitinib or Docetaxel",{"EARLY_PHASE1":30436,"PHASE1":30438,"PHASE2":30440,"PHASE3":30442,"PHASE4":30451,"NA":30453},{"trials":30437,"activeCount":102},[],{"trials":30439,"activeCount":102},[],{"trials":30441,"activeCount":102},[],{"trials":30443,"activeCount":102},[30444],{"nctId":30445,"briefTitle":30446,"status":195,"phases":30447,"completion":7342,"start":6780,"enrollment":30448,"conditions":30449,"interventions":30450},"NCT00252707","Iressa 2nd Line Phase III Study in Japan",[92],484,[262],[30434],{"trials":30452,"activeCount":102},[],{"trials":30454,"activeCount":102},[],{"intervention":30456,"totalTrials":122,"cells":30457},"Benralizumab 30 mg SC + Mometasone Furoate",{"EARLY_PHASE1":30458,"PHASE1":30460,"PHASE2":30462,"PHASE3":30464,"PHASE4":30474,"NA":30476},{"trials":30459,"activeCount":102},[],{"trials":30461,"activeCount":102},[],{"trials":30463,"activeCount":102},[],{"trials":30465,"activeCount":102},[30466],{"nctId":30467,"briefTitle":30468,"status":195,"phases":30469,"primaryCompletion":30470,"completion":30470,"start":2809,"enrollment":30471,"conditions":30472,"interventions":30473},"NCT03401229","Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis",[92],"2020-07-31",413,[29104],[30456],{"trials":30475,"activeCount":102},[],{"trials":30477,"activeCount":102},[],{"intervention":30479,"totalTrials":122,"cells":30480},"Quetiapine Fumarate (SEROQUEL) Extended Release",{"EARLY_PHASE1":30481,"PHASE1":30483,"PHASE2":30485,"PHASE3":30487,"PHASE4":30496,"NA":30498},{"trials":30482,"activeCount":102},[],{"trials":30484,"activeCount":102},[],{"trials":30486,"activeCount":102},[],{"trials":30488,"activeCount":102},[30489],{"nctId":30490,"briefTitle":30491,"status":195,"phases":30492,"primaryCompletion":2104,"completion":2104,"start":2143,"enrollment":30493,"conditions":30494,"interventions":30495},"NCT01256177","Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression",[92],361,[18733],[30479],{"trials":30497,"activeCount":102},[],{"trials":30499,"activeCount":102},[],{"intervention":30501,"totalTrials":122,"cells":30502},"Chemotherapy",{"EARLY_PHASE1":30503,"PHASE1":30505,"PHASE2":30507,"PHASE3":30509,"PHASE4":30522,"NA":30524},{"trials":30504,"activeCount":102},[],{"trials":30506,"activeCount":102},[],{"trials":30508,"activeCount":102},[],{"trials":30510,"activeCount":102},[30511],{"nctId":30512,"briefTitle":30513,"status":195,"phases":30514,"primaryCompletion":30515,"completion":30516,"start":30517,"enrollment":20494,"conditions":30518,"interventions":30520},"NCT02151981","AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[92],"2016-04-15","2023-12-15","2014-08-04",[30519],"Anticancer Treatment",[30501,30521],"Cross-over to Osimertinib",{"trials":30523,"activeCount":102},[],{"trials":30525,"activeCount":102},[],{"intervention":30521,"totalTrials":122,"cells":30527},{"EARLY_PHASE1":30528,"PHASE1":30530,"PHASE2":30532,"PHASE3":30534,"PHASE4":30540,"NA":30542},{"trials":30529,"activeCount":102},[],{"trials":30531,"activeCount":102},[],{"trials":30533,"activeCount":102},[],{"trials":30535,"activeCount":102},[30536],{"nctId":30512,"briefTitle":30513,"status":195,"phases":30537,"primaryCompletion":30515,"completion":30516,"start":30517,"enrollment":20494,"conditions":30538,"interventions":30539},[92],[30519],[30501,30521],{"trials":30541,"activeCount":102},[],{"trials":30543,"activeCount":102},[],{"intervention":10004,"totalTrials":122,"cells":30545},{"EARLY_PHASE1":30546,"PHASE1":30548,"PHASE2":30550,"PHASE3":30552,"PHASE4":30558,"NA":30560},{"trials":30547,"activeCount":102},[],{"trials":30549,"activeCount":102},[],{"trials":30551,"activeCount":102},[],{"trials":30553,"activeCount":102},[30554],{"nctId":9998,"briefTitle":9999,"status":195,"phases":30555,"completion":4876,"start":6563,"enrollment":10001,"conditions":30556,"interventions":30557},[92],[16],[9842,10004],{"trials":30559,"activeCount":102},[],{"trials":30561,"activeCount":102},[],{"intervention":30563,"totalTrials":122,"cells":30564},"Quetiapine Fumarate Sustained Release",{"EARLY_PHASE1":30565,"PHASE1":30567,"PHASE2":30569,"PHASE3":30571,"PHASE4":30579,"NA":30581},{"trials":30566,"activeCount":102},[],{"trials":30568,"activeCount":102},[],{"trials":30570,"activeCount":102},[],{"trials":30572,"activeCount":102},[30573],{"nctId":30574,"briefTitle":30575,"status":195,"phases":30576,"completion":5725,"start":2329,"enrollment":12921,"conditions":30577,"interventions":30578},"NCT00278941","Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder",[92],[18697],[30563],{"trials":30580,"activeCount":102},[],{"trials":30582,"activeCount":102},[],{"intervention":25043,"totalTrials":122,"cells":30584},{"EARLY_PHASE1":30585,"PHASE1":30587,"PHASE2":30589,"PHASE3":30591,"PHASE4":30597,"NA":30599},{"trials":30586,"activeCount":102},[],{"trials":30588,"activeCount":102},[],{"trials":30590,"activeCount":102},[],{"trials":30592,"activeCount":102},[30593],{"nctId":25036,"briefTitle":25037,"status":195,"phases":30594,"primaryCompletion":8926,"completion":25039,"start":8198,"enrollment":25040,"conditions":30595,"interventions":30596},[91,92],[25021],[25043,25044,25008,25008,25045,25046],{"trials":30598,"activeCount":102},[],{"trials":30600,"activeCount":102},[],{"intervention":25044,"totalTrials":122,"cells":30602},{"EARLY_PHASE1":30603,"PHASE1":30605,"PHASE2":30607,"PHASE3":30609,"PHASE4":30615,"NA":30617},{"trials":30604,"activeCount":102},[],{"trials":30606,"activeCount":102},[],{"trials":30608,"activeCount":102},[],{"trials":30610,"activeCount":102},[30611],{"nctId":25036,"briefTitle":25037,"status":195,"phases":30612,"primaryCompletion":8926,"completion":25039,"start":8198,"enrollment":25040,"conditions":30613,"interventions":30614},[91,92],[25021],[25043,25044,25008,25008,25045,25046],{"trials":30616,"activeCount":102},[],{"trials":30618,"activeCount":102},[],{"intervention":25045,"totalTrials":122,"cells":30620},{"EARLY_PHASE1":30621,"PHASE1":30623,"PHASE2":30625,"PHASE3":30627,"PHASE4":30633,"NA":30635},{"trials":30622,"activeCount":102},[],{"trials":30624,"activeCount":102},[],{"trials":30626,"activeCount":102},[],{"trials":30628,"activeCount":102},[30629],{"nctId":25036,"briefTitle":25037,"status":195,"phases":30630,"primaryCompletion":8926,"completion":25039,"start":8198,"enrollment":25040,"conditions":30631,"interventions":30632},[91,92],[25021],[25043,25044,25008,25008,25045,25046],{"trials":30634,"activeCount":102},[],{"trials":30636,"activeCount":102},[],{"intervention":25046,"totalTrials":122,"cells":30638},{"EARLY_PHASE1":30639,"PHASE1":30641,"PHASE2":30643,"PHASE3":30645,"PHASE4":30651,"NA":30653},{"trials":30640,"activeCount":102},[],{"trials":30642,"activeCount":102},[],{"trials":30644,"activeCount":102},[],{"trials":30646,"activeCount":102},[30647],{"nctId":25036,"briefTitle":25037,"status":195,"phases":30648,"primaryCompletion":8926,"completion":25039,"start":8198,"enrollment":25040,"conditions":30649,"interventions":30650},[91,92],[25021],[25043,25044,25008,25008,25045,25046],{"trials":30652,"activeCount":102},[],{"trials":30654,"activeCount":102},[],{"intervention":30656,"totalTrials":122,"cells":30657},"ATACAND",{"EARLY_PHASE1":30658,"PHASE1":30660,"PHASE2":30662,"PHASE3":30664,"PHASE4":30673,"NA":30675},{"trials":30659,"activeCount":102},[],{"trials":30661,"activeCount":102},[],{"trials":30663,"activeCount":102},[],{"trials":30665,"activeCount":102},[30666],{"nctId":30667,"briefTitle":30668,"status":195,"phases":30669,"primaryCompletion":3809,"completion":3809,"start":30670,"enrollment":9987,"conditions":30671,"interventions":30672},"NCT00227318","TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial",[92],"1998-07",[2620],[30656],{"trials":30674,"activeCount":102},[],{"trials":30676,"activeCount":102},[],{"intervention":30678,"totalTrials":122,"cells":30679},"Quetiapine IR",{"EARLY_PHASE1":30680,"PHASE1":30682,"PHASE2":30684,"PHASE3":30686,"PHASE4":30694,"NA":30696},{"trials":30681,"activeCount":102},[],{"trials":30683,"activeCount":102},[],{"trials":30685,"activeCount":102},[],{"trials":30687,"activeCount":102},[30688],{"nctId":30689,"briefTitle":30690,"status":443,"phases":30691,"completion":2415,"start":2252,"enrollment":6518,"conditions":30692,"interventions":30693},"NCT00457899","Rapid Versus Conventional Titration of Quetiapine in Schizophrenia\u002FSchizoaffective Disorder",[92],[33,23660,23653],[30678],{"trials":30695,"activeCount":102},[],{"trials":30697,"activeCount":102},[],{"intervention":26787,"totalTrials":122,"cells":30699},{"EARLY_PHASE1":30700,"PHASE1":30702,"PHASE2":30704,"PHASE3":30706,"PHASE4":30712,"NA":30714},{"trials":30701,"activeCount":102},[],{"trials":30703,"activeCount":102},[],{"trials":30705,"activeCount":102},[],{"trials":30707,"activeCount":102},[30708],{"nctId":26781,"briefTitle":26782,"status":195,"phases":30709,"primaryCompletion":2179,"completion":2179,"start":2405,"enrollment":13857,"conditions":30710,"interventions":30711},[92],[26785],[26787,26763,26788],{"trials":30713,"activeCount":102},[],{"trials":30715,"activeCount":102},[],{"intervention":26788,"totalTrials":122,"cells":30717},{"EARLY_PHASE1":30718,"PHASE1":30720,"PHASE2":30722,"PHASE3":30724,"PHASE4":30730,"NA":30732},{"trials":30719,"activeCount":102},[],{"trials":30721,"activeCount":102},[],{"trials":30723,"activeCount":102},[],{"trials":30725,"activeCount":102},[30726],{"nctId":26781,"briefTitle":26782,"status":195,"phases":30727,"primaryCompletion":2179,"completion":2179,"start":2405,"enrollment":13857,"conditions":30728,"interventions":30729},[92],[26785],[26787,26763,26788],{"trials":30731,"activeCount":102},[],{"trials":30733,"activeCount":102},[],{"intervention":12164,"totalTrials":122,"cells":30735},{"EARLY_PHASE1":30736,"PHASE1":30738,"PHASE2":30740,"PHASE3":30742,"PHASE4":30748,"NA":30750},{"trials":30737,"activeCount":102},[],{"trials":30739,"activeCount":102},[],{"trials":30741,"activeCount":102},[],{"trials":30743,"activeCount":102},[30744],{"nctId":12156,"briefTitle":12157,"status":443,"phases":30745,"primaryCompletion":12159,"completion":12159,"start":12160,"enrollment":12161,"conditions":30746,"interventions":30747},[92],[12093],[10762,12164],{"trials":30749,"activeCount":102},[],{"trials":30751,"activeCount":102},[],{"intervention":30753,"totalTrials":122,"cells":30754},"Saxagliptin plus metformin IR",{"EARLY_PHASE1":30755,"PHASE1":30757,"PHASE2":30759,"PHASE3":30761,"PHASE4":30769,"NA":30771},{"trials":30756,"activeCount":102},[],{"trials":30758,"activeCount":102},[],{"trials":30760,"activeCount":102},[],{"trials":30762,"activeCount":102},[30763],{"nctId":30764,"briefTitle":30765,"status":195,"phases":30766,"primaryCompletion":2114,"completion":2114,"start":688,"enrollment":29796,"conditions":30767,"interventions":30768},"NCT00885378","Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus",[92],[22],[30753],{"trials":30770,"activeCount":102},[],{"trials":30772,"activeCount":102},[],{"intervention":18884,"totalTrials":122,"cells":30774},{"EARLY_PHASE1":30775,"PHASE1":30777,"PHASE2":30779,"PHASE3":30781,"PHASE4":30787,"NA":30789},{"trials":30776,"activeCount":102},[],{"trials":30778,"activeCount":102},[],{"trials":30780,"activeCount":102},[],{"trials":30782,"activeCount":102},[30783],{"nctId":18878,"briefTitle":18879,"status":195,"phases":30784,"completion":2087,"start":15911,"enrollment":3811,"conditions":30785,"interventions":30786},[92],[18882],[18716,18884],{"trials":30788,"activeCount":102},[],{"trials":30790,"activeCount":102},[],{"intervention":30792,"totalTrials":122,"cells":30793},"Pulmicort (budesonide) Respules",{"EARLY_PHASE1":30794,"PHASE1":30796,"PHASE2":30798,"PHASE3":30800,"PHASE4":30808,"NA":30810},{"trials":30795,"activeCount":102},[],{"trials":30797,"activeCount":102},[],{"trials":30799,"activeCount":102},[],{"trials":30801,"activeCount":102},[30802],{"nctId":30803,"briefTitle":30804,"status":195,"phases":30805,"primaryCompletion":7342,"completion":7342,"start":6572,"enrollment":680,"conditions":30806,"interventions":30807},"NCT00232648","Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma",[92],[16],[30792],{"trials":30809,"activeCount":102},[],{"trials":30811,"activeCount":102},[],{"intervention":30813,"totalTrials":122,"cells":30814},"Sodium Zirconium Cyclosilicate 5g",{"EARLY_PHASE1":30815,"PHASE1":30817,"PHASE2":30819,"PHASE3":30821,"PHASE4":30831,"NA":30833},{"trials":30816,"activeCount":102},[],{"trials":30818,"activeCount":102},[],{"trials":30820,"activeCount":102},[],{"trials":30822,"activeCount":102},[30823],{"nctId":30824,"briefTitle":30825,"status":195,"phases":30826,"primaryCompletion":3363,"completion":3363,"start":30827,"enrollment":19799,"conditions":30828,"interventions":30829},"NCT03528681","A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.",[92],"2021-05-06",[12093],[30813,30830],"Sodium Zirconium Cyclosilicate 10g",{"trials":30832,"activeCount":102},[],{"trials":30834,"activeCount":102},[],{"intervention":30830,"totalTrials":122,"cells":30836},{"EARLY_PHASE1":30837,"PHASE1":30839,"PHASE2":30841,"PHASE3":30843,"PHASE4":30849,"NA":30851},{"trials":30838,"activeCount":102},[],{"trials":30840,"activeCount":102},[],{"trials":30842,"activeCount":102},[],{"trials":30844,"activeCount":102},[30845],{"nctId":30824,"briefTitle":30825,"status":195,"phases":30846,"primaryCompletion":3363,"completion":3363,"start":30827,"enrollment":19799,"conditions":30847,"interventions":30848},[92],[12093],[30813,30830],{"trials":30850,"activeCount":102},[],{"trials":30852,"activeCount":102},[],{"intervention":25599,"totalTrials":122,"cells":30854},{"EARLY_PHASE1":30855,"PHASE1":30857,"PHASE2":30859,"PHASE3":30861,"PHASE4":30867,"NA":30869},{"trials":30856,"activeCount":102},[],{"trials":30858,"activeCount":102},[],{"trials":30860,"activeCount":102},[],{"trials":30862,"activeCount":102},[30863],{"nctId":25591,"briefTitle":25592,"status":195,"phases":30864,"primaryCompletion":25594,"completion":25594,"start":25595,"enrollment":25596,"conditions":30865,"interventions":30866},[92],[16],[25569,25599],{"trials":30868,"activeCount":102},[],{"trials":30870,"activeCount":102},[],{"intervention":30872,"totalTrials":122,"cells":30873},"BFF MDI 160\u002F9.6 μg BID",{"EARLY_PHASE1":30874,"PHASE1":30876,"PHASE2":30878,"PHASE3":30880,"PHASE4":30892,"NA":30894},{"trials":30875,"activeCount":102},[],{"trials":30877,"activeCount":102},[],{"trials":30879,"activeCount":102},[],{"trials":30881,"activeCount":102},[30882],{"nctId":30883,"briefTitle":30884,"status":195,"phases":30885,"primaryCompletion":30886,"completion":30886,"start":30887,"enrollment":30888,"conditions":30889,"interventions":30890},"NCT05755906","A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)",[92],"2024-11-19","2023-02-27",374,[16],[30872,30891],"BD MDI 160 μg BID",{"trials":30893,"activeCount":102},[],{"trials":30895,"activeCount":102},[],{"intervention":30891,"totalTrials":122,"cells":30897},{"EARLY_PHASE1":30898,"PHASE1":30900,"PHASE2":30902,"PHASE3":30904,"PHASE4":30910,"NA":30912},{"trials":30899,"activeCount":102},[],{"trials":30901,"activeCount":102},[],{"trials":30903,"activeCount":102},[],{"trials":30905,"activeCount":102},[30906],{"nctId":30883,"briefTitle":30884,"status":195,"phases":30907,"primaryCompletion":30886,"completion":30886,"start":30887,"enrollment":30888,"conditions":30908,"interventions":30909},[92],[16],[30872,30891],{"trials":30911,"activeCount":102},[],{"trials":30913,"activeCount":102},[],{"intervention":30915,"totalTrials":122,"cells":30916},"Seroquel Sustained Release",{"EARLY_PHASE1":30917,"PHASE1":30919,"PHASE2":30921,"PHASE3":30923,"PHASE4":30933,"NA":30935},{"trials":30918,"activeCount":102},[],{"trials":30920,"activeCount":102},[],{"trials":30922,"activeCount":102},[],{"trials":30924,"activeCount":102},[30925],{"nctId":30926,"briefTitle":30927,"status":195,"phases":30928,"completion":2329,"start":4264,"enrollment":18791,"conditions":30929,"interventions":30931},"NCT00206115","SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia",[92],[30930],"Schizophrenic Disorder",[30915,30932],"Seroquel Immediate Release",{"trials":30934,"activeCount":102},[],{"trials":30936,"activeCount":102},[],{"intervention":30932,"totalTrials":122,"cells":30938},{"EARLY_PHASE1":30939,"PHASE1":30941,"PHASE2":30943,"PHASE3":30945,"PHASE4":30951,"NA":30953},{"trials":30940,"activeCount":102},[],{"trials":30942,"activeCount":102},[],{"trials":30944,"activeCount":102},[],{"trials":30946,"activeCount":102},[30947],{"nctId":30926,"briefTitle":30927,"status":195,"phases":30948,"completion":2329,"start":4264,"enrollment":18791,"conditions":30949,"interventions":30950},[92],[30930],[30915,30932],{"trials":30952,"activeCount":102},[],{"trials":30954,"activeCount":102},[],{"intervention":30956,"totalTrials":122,"cells":30957},"Symbicort (budesonide\u002Fformoterol) Turbuhaler",{"EARLY_PHASE1":30958,"PHASE1":30960,"PHASE2":30962,"PHASE3":30964,"PHASE4":30975,"NA":30977},{"trials":30959,"activeCount":102},[],{"trials":30961,"activeCount":102},[],{"trials":30963,"activeCount":102},[],{"trials":30965,"activeCount":102},[30966],{"nctId":30967,"briefTitle":30968,"status":443,"phases":30969,"completion":2086,"start":5563,"enrollment":30970,"conditions":30971,"interventions":30973},"NCT00385593","Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults",[92],654,[30972],"Asthma, Bronchial",[30956,30974],"Conventional treatment",{"trials":30976,"activeCount":102},[],{"trials":30978,"activeCount":102},[],{"intervention":30974,"totalTrials":122,"cells":30980},{"EARLY_PHASE1":30981,"PHASE1":30983,"PHASE2":30985,"PHASE3":30987,"PHASE4":30993,"NA":30995},{"trials":30982,"activeCount":102},[],{"trials":30984,"activeCount":102},[],{"trials":30986,"activeCount":102},[],{"trials":30988,"activeCount":102},[30989],{"nctId":30967,"briefTitle":30968,"status":443,"phases":30990,"completion":2086,"start":5563,"enrollment":30970,"conditions":30991,"interventions":30992},[92],[30972],[30956,30974],{"trials":30994,"activeCount":102},[],{"trials":30996,"activeCount":102},[],{"intervention":30998,"totalTrials":122,"cells":30999},"Ropivacaine",{"EARLY_PHASE1":31000,"PHASE1":31002,"PHASE2":31004,"PHASE3":31006,"PHASE4":31016,"NA":31018},{"trials":31001,"activeCount":102},[],{"trials":31003,"activeCount":102},[],{"trials":31005,"activeCount":102},[],{"trials":31007,"activeCount":102},[31008],{"nctId":31009,"briefTitle":31010,"status":195,"phases":31011,"completion":5563,"start":6369,"enrollment":1832,"conditions":31012,"interventions":31014},"NCT00358280","Ropivacaine Versus Bupivacaine for Spinal Anaesthesia in Patients Undergoing Unilateral Lower Limb Surgery",[92],[31013],"Anesthesia,Spinal",[30998,31015],"Bupivacaine",{"trials":31017,"activeCount":102},[],{"trials":31019,"activeCount":102},[],{"intervention":31015,"totalTrials":122,"cells":31021},{"EARLY_PHASE1":31022,"PHASE1":31024,"PHASE2":31026,"PHASE3":31028,"PHASE4":31034,"NA":31036},{"trials":31023,"activeCount":102},[],{"trials":31025,"activeCount":102},[],{"trials":31027,"activeCount":102},[],{"trials":31029,"activeCount":102},[31030],{"nctId":31009,"briefTitle":31010,"status":195,"phases":31031,"completion":5563,"start":6369,"enrollment":1832,"conditions":31032,"interventions":31033},[92],[31013],[30998,31015],{"trials":31035,"activeCount":102},[],{"trials":31037,"activeCount":102},[],{"intervention":31039,"totalTrials":122,"cells":31040},"Budesonide HFA",{"EARLY_PHASE1":31041,"PHASE1":31043,"PHASE2":31045,"PHASE3":31047,"PHASE4":31056,"NA":31058},{"trials":31042,"activeCount":102},[],{"trials":31044,"activeCount":102},[],{"trials":31046,"activeCount":102},[],{"trials":31048,"activeCount":102},[31049],{"nctId":31050,"briefTitle":31051,"status":195,"phases":31052,"primaryCompletion":688,"completion":688,"start":2251,"enrollment":6390,"conditions":31053,"interventions":31054},"NCT00667992","Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma",[92],[16],[31039,31055],"Budesonide CFC",{"trials":31057,"activeCount":102},[],{"trials":31059,"activeCount":102},[],{"intervention":31055,"totalTrials":122,"cells":31061},{"EARLY_PHASE1":31062,"PHASE1":31064,"PHASE2":31066,"PHASE3":31068,"PHASE4":31074,"NA":31076},{"trials":31063,"activeCount":102},[],{"trials":31065,"activeCount":102},[],{"trials":31067,"activeCount":102},[],{"trials":31069,"activeCount":102},[31070],{"nctId":31050,"briefTitle":31051,"status":195,"phases":31071,"primaryCompletion":688,"completion":688,"start":2251,"enrollment":6390,"conditions":31072,"interventions":31073},[92],[16],[31039,31055],{"trials":31075,"activeCount":102},[],{"trials":31077,"activeCount":102},[],{"intervention":19529,"totalTrials":122,"cells":31079},{"EARLY_PHASE1":31080,"PHASE1":31082,"PHASE2":31084,"PHASE3":31086,"PHASE4":31092,"NA":31094},{"trials":31081,"activeCount":102},[],{"trials":31083,"activeCount":102},[],{"trials":31085,"activeCount":102},[],{"trials":31087,"activeCount":102},[31088],{"nctId":19523,"briefTitle":19524,"status":195,"phases":31089,"primaryCompletion":2086,"completion":2086,"start":5742,"enrollment":19526,"conditions":31090,"interventions":31091},[92],[16],[9972,19529],{"trials":31093,"activeCount":102},[],{"trials":31095,"activeCount":102},[],{"intervention":31097,"totalTrials":122,"cells":31098},"Seloken ZOK\u002FToprol-XL",{"EARLY_PHASE1":31099,"PHASE1":31101,"PHASE2":31103,"PHASE3":31105,"PHASE4":31114,"NA":31116},{"trials":31100,"activeCount":102},[],{"trials":31102,"activeCount":102},[],{"trials":31104,"activeCount":102},[],{"trials":31106,"activeCount":102},[31107],{"nctId":31108,"briefTitle":31109,"status":195,"phases":31110,"primaryCompletion":6780,"completion":6780,"start":31111,"enrollment":12425,"conditions":31112,"interventions":31113},"NCT00038077","Reversal of Ventricular Remodeling With Toprol-XL",[92],"2001-08",[12964],[31097,31097],{"trials":31115,"activeCount":102},[],{"trials":31117,"activeCount":102},[],{"intervention":24748,"totalTrials":122,"cells":31119},{"EARLY_PHASE1":31120,"PHASE1":31122,"PHASE2":31124,"PHASE3":31126,"PHASE4":31132,"NA":31134},{"trials":31121,"activeCount":102},[],{"trials":31123,"activeCount":102},[],{"trials":31125,"activeCount":102},[],{"trials":31127,"activeCount":102},[31128],{"nctId":24740,"briefTitle":24741,"status":195,"phases":31129,"primaryCompletion":24743,"completion":13274,"start":24744,"enrollment":24745,"conditions":31130,"interventions":31131},[92],[6163],[24704,24748],{"trials":31133,"activeCount":102},[],{"trials":31135,"activeCount":102},[],{"intervention":19983,"totalTrials":122,"cells":31137},{"EARLY_PHASE1":31138,"PHASE1":31140,"PHASE2":31142,"PHASE3":31144,"PHASE4":31150,"NA":31152},{"trials":31139,"activeCount":102},[],{"trials":31141,"activeCount":102},[],{"trials":31143,"activeCount":102},[],{"trials":31145,"activeCount":102},[31146],{"nctId":19978,"briefTitle":19979,"status":195,"phases":31147,"completion":5563,"start":12937,"enrollment":18721,"conditions":31148,"interventions":31149},[92],[18732],[19983,18724,18725],{"trials":31151,"activeCount":102},[],{"trials":31153,"activeCount":102},[],{"intervention":7515,"totalTrials":122,"cells":31155},{"EARLY_PHASE1":31156,"PHASE1":31158,"PHASE2":31160,"PHASE3":31162,"PHASE4":31168,"NA":31170},{"trials":31157,"activeCount":102},[],{"trials":31159,"activeCount":102},[],{"trials":31161,"activeCount":102},[],{"trials":31163,"activeCount":102},[31164],{"nctId":7508,"briefTitle":7509,"status":195,"phases":31165,"completion":2329,"start":7511,"enrollment":7512,"conditions":31166,"interventions":31167},[92],[25],[120,468,7515,7516],{"trials":31169,"activeCount":102},[],{"trials":31171,"activeCount":102},[],{"intervention":7516,"totalTrials":122,"cells":31173},{"EARLY_PHASE1":31174,"PHASE1":31176,"PHASE2":31178,"PHASE3":31180,"PHASE4":31186,"NA":31188},{"trials":31175,"activeCount":102},[],{"trials":31177,"activeCount":102},[],{"trials":31179,"activeCount":102},[],{"trials":31181,"activeCount":102},[31182],{"nctId":7508,"briefTitle":7509,"status":195,"phases":31183,"completion":2329,"start":7511,"enrollment":7512,"conditions":31184,"interventions":31185},[92],[25],[120,468,7515,7516],{"trials":31187,"activeCount":102},[],{"trials":31189,"activeCount":102},[],{"intervention":12177,"totalTrials":122,"cells":31191},{"EARLY_PHASE1":31192,"PHASE1":31194,"PHASE2":31196,"PHASE3":31198,"PHASE4":31204,"NA":31206},{"trials":31193,"activeCount":102},[],{"trials":31195,"activeCount":102},[],{"trials":31197,"activeCount":102},[],{"trials":31199,"activeCount":102},[31200],{"nctId":12166,"briefTitle":12167,"status":443,"phases":31201,"primaryCompletion":12169,"completion":12169,"start":12170,"enrollment":12171,"conditions":31202,"interventions":31203},[92],[12173,12093],[10762,12175,12176,12177],{"trials":31205,"activeCount":102},[],{"trials":31207,"activeCount":102},[],{"intervention":15883,"totalTrials":1130,"cells":31209},{"EARLY_PHASE1":31210,"PHASE1":31212,"PHASE2":31328,"PHASE3":31352,"PHASE4":31354,"NA":31356},{"trials":31211,"activeCount":102},[],{"trials":31213,"activeCount":102},[31214,31218,31225,31229,31233,31239,31245,31252,31258,31262,31268,31274,31280,31286,31292,31299,31305,31311,31317,31324],{"nctId":15878,"briefTitle":15879,"status":195,"phases":31215,"primaryCompletion":2243,"completion":2243,"start":2114,"enrollment":2260,"conditions":31216,"interventions":31217},[90],[22],[15883,2448],{"nctId":31219,"briefTitle":31220,"status":195,"phases":31221,"primaryCompletion":2489,"completion":2489,"start":2212,"enrollment":544,"conditions":31222,"interventions":31224},"NCT01069926","To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients",[90],[31223],"Glucose Lowering",[15883],{"nctId":16421,"briefTitle":16422,"status":195,"phases":31226,"primaryCompletion":2143,"completion":2143,"start":2242,"enrollment":5876,"conditions":31227,"interventions":31228},[90],[22],[15883,2198],{"nctId":20445,"briefTitle":20446,"status":195,"phases":31230,"completion":2095,"start":2414,"enrollment":1757,"conditions":31231,"interventions":31232},[90],[31],[12122,15883],{"nctId":31234,"briefTitle":31235,"status":195,"phases":31236,"primaryCompletion":2516,"completion":2516,"start":3862,"enrollment":5876,"conditions":31237,"interventions":31238},"NCT01221519","A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients",[90],[22,2437],[15883],{"nctId":31240,"briefTitle":31241,"status":195,"phases":31242,"primaryCompletion":688,"completion":688,"start":7544,"enrollment":496,"conditions":31243,"interventions":31244},"NCT00819884","To Evaluate 24-hr Glucose After OD vs BD AZD1656",[90],[19160],[15883],{"nctId":31246,"briefTitle":31247,"status":195,"phases":31248,"primaryCompletion":2320,"completion":2320,"start":2095,"enrollment":370,"conditions":31249,"interventions":31250},"NCT00817271","To Evaluate the Response to Glucagon During Hypoglycemia",[90],[31],[15883,31251],"Glucagon",{"nctId":31253,"briefTitle":31254,"status":195,"phases":31255,"primaryCompletion":3827,"completion":3827,"start":2507,"enrollment":579,"conditions":31256,"interventions":31257},"NCT00726427","A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers",[90],[19],[15883,15883],{"nctId":19678,"briefTitle":19679,"status":195,"phases":31259,"primaryCompletion":2243,"completion":2243,"start":2212,"enrollment":1757,"conditions":31260,"interventions":31261},[90],[22],[15883,2081],{"nctId":31263,"briefTitle":31264,"status":195,"phases":31265,"primaryCompletion":2516,"completion":2516,"start":2489,"enrollment":1130,"conditions":31266,"interventions":31267},"NCT01221545","A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients",[90],[22],[15883],{"nctId":31269,"briefTitle":31270,"status":195,"phases":31271,"primaryCompletion":2320,"completion":2320,"start":2220,"enrollment":14693,"conditions":31272,"interventions":31273},"NCT00747175","A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes",[90],[31],[15883,15883],{"nctId":31275,"briefTitle":31276,"status":195,"phases":31277,"primaryCompletion":4915,"completion":4915,"start":2220,"enrollment":496,"conditions":31278,"interventions":31279},"NCT00741689","A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers",[90],[36],[15883],{"nctId":31281,"briefTitle":31282,"status":195,"phases":31283,"completion":2056,"start":2086,"enrollment":3476,"conditions":31284,"interventions":31285},"NCT00774553","To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin",[90],[31],[15883],{"nctId":31287,"briefTitle":31288,"status":195,"phases":31289,"completion":2350,"start":688,"enrollment":1130,"conditions":31290,"interventions":31291},"NCT00916604","To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients",[90],[31],[15883],{"nctId":31293,"briefTitle":31294,"status":195,"phases":31295,"primaryCompletion":2077,"completion":2067,"start":4915,"enrollment":2222,"conditions":31296,"interventions":31298},"NCT00817505","To Evaluate the Bioavailability of a Tablet of AZD1656",[90],[31297],"Type 1 Diabetes",[15883,15883],{"nctId":31300,"briefTitle":31301,"status":195,"phases":31302,"primaryCompletion":2114,"completion":2114,"start":2350,"enrollment":1883,"conditions":31303,"interventions":31304},"NCT00995787","Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea",[90],[25870],[15883],{"nctId":31306,"briefTitle":31307,"status":195,"phases":31308,"primaryCompletion":2144,"completion":2144,"start":2113,"enrollment":486,"conditions":31309,"interventions":31310},"NCT01103609","Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients",[90],[22],[2197,15883],{"nctId":31312,"briefTitle":31313,"status":195,"phases":31314,"primaryCompletion":2077,"completion":2077,"start":3827,"enrollment":1130,"conditions":31315,"interventions":31316},"NCT00768105","To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin",[90],[31],[15883],{"nctId":31318,"briefTitle":31319,"status":195,"phases":31320,"primaryCompletion":2242,"completion":2242,"start":2212,"enrollment":3855,"conditions":31321,"interventions":31322},"NCT01083212","To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656",[90],[22],[15883,31323],"Gemfibrozil",{"nctId":23094,"briefTitle":23095,"status":195,"phases":31325,"primaryCompletion":2144,"completion":2144,"start":2212,"enrollment":3811,"conditions":31326,"interventions":31327},[90],[22],[15883,2098],{"trials":31329,"activeCount":102},[31330,31334,31340,31346],{"nctId":25866,"briefTitle":25867,"status":195,"phases":31331,"primaryCompletion":2433,"completion":2433,"start":2350,"enrollment":18755,"conditions":31332,"interventions":31333},[91],[25870],[15883,25857],{"nctId":31335,"briefTitle":31336,"status":195,"phases":31337,"primaryCompletion":2068,"completion":2068,"start":7544,"enrollment":2003,"conditions":31338,"interventions":31339},"NCT00817778","Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin",[91],[31],[15883],{"nctId":31341,"briefTitle":31342,"status":195,"phases":31343,"primaryCompletion":2151,"completion":2151,"start":2095,"enrollment":5876,"conditions":31344,"interventions":31345},"NCT00856908","Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes",[91],[19160],[15883],{"nctId":31347,"briefTitle":31348,"status":195,"phases":31349,"primaryCompletion":2615,"completion":2615,"start":2243,"enrollment":2289,"conditions":31350,"interventions":31351},"NCT01152385","Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients",[91],[22],[15883],{"trials":31353,"activeCount":102},[],{"trials":31355,"activeCount":102},[],{"trials":31357,"activeCount":102},[],{"intervention":3830,"totalTrials":4497,"cells":31359},{"EARLY_PHASE1":31360,"PHASE1":31362,"PHASE2":31438,"PHASE3":31466,"PHASE4":31468,"NA":31470},{"trials":31361,"activeCount":102},[],{"trials":31363,"activeCount":102},[31364,31368,31374,31378,31385,31389,31395,31402,31409,31416,31423,31429],{"nctId":4191,"briefTitle":4192,"status":195,"phases":31365,"primaryCompletion":2151,"completion":2366,"start":2168,"enrollment":37,"conditions":31366,"interventions":31367},[90],[3174],[3830,1017,177],{"nctId":31369,"briefTitle":31370,"status":195,"phases":31371,"primaryCompletion":2086,"completion":2350,"start":6718,"enrollment":1448,"conditions":31372,"interventions":31373},"NCT00475956","Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours",[90],[3841],[3830,3843],{"nctId":4873,"briefTitle":4874,"status":195,"phases":31375,"primaryCompletion":2169,"completion":2542,"start":4876,"enrollment":4877,"conditions":31376,"interventions":31377},[90],[4879],[3830,4774,345,4615,369],{"nctId":31379,"briefTitle":31380,"status":195,"phases":31381,"primaryCompletion":2406,"completion":2480,"start":6710,"enrollment":496,"conditions":31382,"interventions":31384},"NCT00621725","Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours",[90],[31383,6914],"Advanced Cancer",[3830],{"nctId":3824,"briefTitle":3825,"status":443,"phases":31386,"primaryCompletion":3827,"completion":3827,"start":2415,"enrollment":1039,"conditions":31387,"interventions":31388},[90],[992],[3830,118,344],{"nctId":31390,"briefTitle":31391,"status":195,"phases":31392,"primaryCompletion":2221,"completion":2068,"start":2329,"enrollment":3855,"conditions":31393,"interventions":31394},"NCT00243347","The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer",[90],[4058,6695,4258],[3830],{"nctId":31396,"briefTitle":31397,"status":195,"phases":31398,"primaryCompletion":6562,"completion":6562,"start":9963,"enrollment":5189,"conditions":31399,"interventions":31401},"NCT00502060","Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer",[90],[31400],"Advanced Tumor",[3830,4334],{"nctId":31403,"briefTitle":31404,"status":195,"phases":31405,"start":12937,"enrollment":1448,"conditions":31406,"interventions":31408},"NCT00502164","Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer",[90],[31407],"Advanced Prostate Adenocarcinoma",[3830],{"nctId":31410,"briefTitle":31411,"status":195,"phases":31412,"completion":7494,"start":6517,"enrollment":1039,"conditions":31413,"interventions":31415},"NCT00503412","Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors",[90],[31414],"Advanced Solid Metastatic Tumor",[3830],{"nctId":31417,"briefTitle":31418,"status":195,"phases":31419,"primaryCompletion":13047,"completion":9213,"start":12954,"enrollment":1395,"conditions":31420,"interventions":31422},"NCT00501605","Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases",[90],[4879,31421],"Liver Metastases",[3830],{"nctId":31424,"briefTitle":31425,"status":195,"phases":31426,"primaryCompletion":2252,"completion":7544,"start":3809,"enrollment":1448,"conditions":31427,"interventions":31428},"NCT00503477","A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan",[90],[4879],[3830],{"nctId":31430,"briefTitle":31431,"status":195,"phases":31432,"start":6370,"enrollment":680,"conditions":31433,"interventions":31437},"NCT00502385","Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML",[90],[31434,31435,31436],"Leukaemia","Myelocytic","Acute",[3830],{"trials":31439,"activeCount":102},[31440,31444,31448,31452,31460],{"nctId":13820,"briefTitle":13821,"status":195,"phases":31441,"primaryCompletion":2350,"completion":2105,"start":5562,"enrollment":13823,"conditions":31442,"interventions":31443},[90,91],[5121],[3830,4774],{"nctId":5649,"briefTitle":5650,"status":195,"phases":31445,"primaryCompletion":2169,"completion":2350,"start":4284,"enrollment":5652,"conditions":31446,"interventions":31447},[91],[691],[3830,296,4843,175,239],{"nctId":6465,"briefTitle":6466,"status":195,"phases":31449,"primaryCompletion":4915,"completion":6468,"start":3839,"enrollment":1883,"conditions":31450,"interventions":31451},[91],[6348],[3830,53],{"nctId":31453,"briefTitle":31454,"status":195,"phases":31455,"primaryCompletion":2524,"completion":2055,"start":5563,"enrollment":1348,"conditions":31456,"interventions":31459},"NCT00385203","The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).",[91],[31457,31458],"Gastrointestinal Stromal Tumors","Soft Tissue Sarcomas",[3830],{"nctId":31461,"briefTitle":31462,"status":195,"phases":31463,"primaryCompletion":13014,"completion":12721,"start":6517,"enrollment":990,"conditions":31464,"interventions":31465},"NCT00264004","Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours",[91],[13585],[3830],{"trials":31467,"activeCount":102},[],{"trials":31469,"activeCount":102},[],{"trials":31471,"activeCount":102},[],{"intervention":16451,"totalTrials":963,"cells":31473},{"EARLY_PHASE1":31474,"PHASE1":31476,"PHASE2":31530,"PHASE3":31559,"PHASE4":31561,"NA":31563},{"trials":31475,"activeCount":102},[],{"trials":31477,"activeCount":102},[31478,31484,31490,31496,31500,31506,31512,31518,31524],{"nctId":31479,"briefTitle":31480,"status":195,"phases":31481,"primaryCompletion":2221,"completion":2221,"start":6710,"enrollment":496,"conditions":31482,"interventions":31483},"NCT00688831","Single Ascending Dose Study (SAD) iv Formulation",[90],[19],[16451],{"nctId":31485,"briefTitle":31486,"status":195,"phases":31487,"primaryCompletion":2507,"completion":2507,"start":7439,"enrollment":13516,"conditions":31488,"interventions":31489},"NCT00689039","Study of an Extended Release (ER) Tablet, Single and Repeated Dosing",[90],[19],[16451],{"nctId":31491,"briefTitle":31492,"status":195,"phases":31493,"primaryCompletion":2507,"completion":2507,"start":2168,"enrollment":4286,"conditions":31494,"interventions":31495},"NCT00689403","Evaluate Different Extended-release (ER) Tablets\u002FCapsules of AZD1305",[90],[19],[16451,16451],{"nctId":16445,"briefTitle":16446,"status":195,"phases":31497,"primaryCompletion":2414,"completion":2414,"start":2220,"enrollment":1336,"conditions":31498,"interventions":31499},[90],[16449],[16451,2198],{"nctId":31501,"briefTitle":31502,"status":195,"phases":31503,"primaryCompletion":2414,"completion":2414,"start":2507,"enrollment":2003,"conditions":31504,"interventions":31505},"NCT00707551","An Interaction Study of Ketoconazole\u002FVerapamil Versus AZD1305",[90],[19],[23332,16379,16451],{"nctId":31507,"briefTitle":31508,"status":443,"phases":31509,"primaryCompletion":2057,"completion":2057,"start":2068,"enrollment":1864,"conditions":31510,"interventions":31511},"NCT00935025","AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects",[90],[19],[16451],{"nctId":31513,"briefTitle":31514,"status":195,"phases":31515,"primaryCompletion":2221,"completion":2221,"start":2251,"enrollment":269,"conditions":31516,"interventions":31517},"NCT00689247","To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305",[90],[19],[16451,16451],{"nctId":31519,"briefTitle":31520,"status":195,"phases":31521,"completion":2086,"start":2507,"enrollment":496,"conditions":31522,"interventions":31523},"NCT00738322","To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects",[90],[19],[16451],{"nctId":31525,"briefTitle":31526,"status":195,"phases":31527,"completion":2057,"start":2151,"enrollment":1130,"conditions":31528,"interventions":31529},"NCT00957437","Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305",[90],[19],[16451,16451,16451],{"trials":31531,"activeCount":102},[31532,31538,31545,31552],{"nctId":31533,"briefTitle":31534,"status":195,"phases":31535,"primaryCompletion":2220,"completion":2220,"start":2580,"enrollment":5189,"conditions":31536,"interventions":31537},"NCT00643448","Explorative Study of AZD1305 in Atrial Fibrillation Patients",[91],[16449],[16451,16451],{"nctId":31539,"briefTitle":31540,"status":195,"phases":31541,"primaryCompletion":2524,"completion":2524,"start":6710,"enrollment":2783,"conditions":31542,"interventions":31544},"NCT00616629","Cardiac Electrophysiological Study",[91],[31543],"Atrial Flutter",[16451],{"nctId":31546,"briefTitle":31547,"status":195,"phases":31548,"primaryCompletion":2055,"completion":2055,"start":688,"enrollment":31549,"conditions":31550,"interventions":31551},"NCT00915356","Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305",[91],228,[16449],[16451],{"nctId":31553,"briefTitle":31554,"status":195,"phases":31555,"primaryCompletion":2068,"completion":2068,"start":2220,"enrollment":486,"conditions":31556,"interventions":31558},"NCT00748982","Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction",[91],[31557],"Left Ventricle Function",[16451],{"trials":31560,"activeCount":102},[],{"trials":31562,"activeCount":102},[],{"trials":31564,"activeCount":102},[],{"intervention":20417,"totalTrials":2222,"cells":31566},{"EARLY_PHASE1":31567,"PHASE1":31569,"PHASE2":31617,"PHASE3":31645,"PHASE4":31647,"NA":31649},{"trials":31568,"activeCount":102},[],{"trials":31570,"activeCount":102},[31571,31575,31581,31589,31596,31604,31611],{"nctId":20411,"briefTitle":20412,"status":195,"phases":31572,"primaryCompletion":12721,"completion":12721,"start":2433,"enrollment":1710,"conditions":31573,"interventions":31574},[90],[20415],[20417,20417,12769],{"nctId":31576,"briefTitle":31577,"status":195,"phases":31578,"primaryCompletion":2212,"completion":2212,"start":2114,"enrollment":1979,"conditions":31579,"interventions":31580},"NCT01058447","Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers",[90],[19],[20417],{"nctId":31582,"briefTitle":31583,"status":195,"phases":31584,"primaryCompletion":2489,"completion":2489,"start":2243,"enrollment":2260,"conditions":31585,"interventions":31587},"NCT01110525","A Drug-drug Interaction Study to Investigate the Effects of AZD1981 on the Metabolism and Pharmacodynamics of Oral Contraceptives",[90],[31586],"Oral Contraceptives",[20417,31588],"Neovletta 21\u002F28",{"nctId":31590,"briefTitle":31591,"status":195,"phases":31592,"completion":2320,"start":2077,"enrollment":2260,"conditions":31593,"interventions":31595},"NCT00859352","AZD1981 Midazolam CYP4503A Induction Study",[90],[31594],"Healthy Male Volunteer",[20417,5870],{"nctId":31597,"briefTitle":31598,"status":195,"phases":31599,"completion":2068,"start":2152,"enrollment":1638,"conditions":31600,"interventions":31603},"NCT00918398","AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations",[90],[19,31601,31602],"Postmenopausal","Surgically Sterile Women",[20417,20417,20417,20417],{"nctId":31605,"briefTitle":31606,"status":195,"phases":31607,"primaryCompletion":2143,"completion":2143,"start":2489,"enrollment":2260,"conditions":31608,"interventions":31610},"NCT01199341","A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin",[90],[31609],"Pharmakokinetic",[20417,2197,20417],{"nctId":31612,"briefTitle":31613,"status":195,"phases":31614,"primaryCompletion":2086,"completion":2086,"start":2220,"enrollment":3172,"conditions":31615,"interventions":31616},"NCT00698282","Single and Multiple Ascending Doses of AZD1981 in Japan",[90],[19],[20417,20417],{"trials":31618,"activeCount":102},[31619,31627,31633,31639],{"nctId":31620,"briefTitle":31621,"status":195,"phases":31622,"primaryCompletion":2366,"completion":2366,"start":2489,"enrollment":31623,"conditions":31624,"interventions":31626},"NCT01197794","Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients",[91],1144,[31625],"Asthma Patients",[20417,20417],{"nctId":31628,"briefTitle":31629,"status":195,"phases":31630,"completion":2068,"start":3827,"enrollment":6106,"conditions":31631,"interventions":31632},"NCT00758589","One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids",[91],[16],[20417,20417,20417],{"nctId":31634,"briefTitle":31635,"status":195,"phases":31636,"completion":2152,"start":2414,"enrollment":14693,"conditions":31637,"interventions":31638},"NCT00766415","14729-D9831C00002- 1 Month Biopsy Study",[91],[28],[20417],{"nctId":31640,"briefTitle":31641,"status":195,"phases":31642,"primaryCompletion":4915,"completion":4915,"start":2221,"enrollment":23756,"conditions":31643,"interventions":31644},"NCT00690482","Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[91],[3002],[20417],{"trials":31646,"activeCount":102},[],{"trials":31648,"activeCount":102},[],{"trials":31650,"activeCount":102},[],{"intervention":31652,"totalTrials":2222,"cells":31653},"AZD1446",{"EARLY_PHASE1":31654,"PHASE1":31656,"PHASE2":31708,"PHASE3":31730,"PHASE4":31732,"NA":31734},{"trials":31655,"activeCount":102},[],{"trials":31657,"activeCount":102},[31658,31664,31670,31676,31682,31690,31696,31702],{"nctId":31659,"briefTitle":31660,"status":195,"phases":31661,"primaryCompletion":2320,"completion":2320,"start":4915,"enrollment":744,"conditions":31662,"interventions":31663},"NCT00803855","Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers",[90],[19],[31652],{"nctId":31665,"briefTitle":31666,"status":195,"phases":31667,"primaryCompletion":2242,"completion":2242,"start":2055,"enrollment":13007,"conditions":31668,"interventions":31669},"NCT01021189","Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject",[90],[19],[31652],{"nctId":31671,"briefTitle":31672,"status":195,"phases":31673,"completion":2067,"start":2320,"enrollment":1395,"conditions":31674,"interventions":31675},"NCT00902993","Study to Investigate Safety, Tolerability and Pharmacokinetics With Single and Multiple Ascending Doses of AZD1446",[90],[19],[31652],{"nctId":31677,"briefTitle":31678,"status":195,"phases":31679,"primaryCompletion":2406,"completion":2406,"start":2114,"enrollment":37,"conditions":31680,"interventions":31681},"NCT01092299","A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions",[90],[19],[31652,31652,31652,31652,31652],{"nctId":31683,"briefTitle":31684,"status":195,"phases":31685,"primaryCompletion":2113,"completion":2113,"start":2055,"enrollment":5876,"conditions":31686,"interventions":31688},"NCT01044342","A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition",[90],[31687],"Cognition",[31652,31652,31689],"donepezil",{"nctId":31691,"briefTitle":31692,"status":195,"phases":31693,"primaryCompletion":2151,"completion":2151,"start":2320,"enrollment":2222,"conditions":31694,"interventions":31695},"NCT00886067","Positron Emission Tomography (PET) Study",[90],[19],[31652],{"nctId":31697,"briefTitle":31698,"status":195,"phases":31699,"primaryCompletion":2143,"completion":2143,"start":3862,"enrollment":1130,"conditions":31700,"interventions":31701},"NCT01199315","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses",[90],[19],[31652],{"nctId":31703,"briefTitle":31704,"status":195,"phases":31705,"primaryCompletion":2055,"completion":2055,"start":2350,"enrollment":13007,"conditions":31706,"interventions":31707},"NCT00997308","A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers",[90],[19],[31652],{"trials":31709,"activeCount":102},[31710,31716,31723],{"nctId":31711,"briefTitle":31712,"status":443,"phases":31713,"primaryCompletion":2570,"completion":2570,"start":2242,"enrollment":1448,"conditions":31714,"interventions":31715},"NCT01125683","To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease",[91],[23833],[31652,23078],{"nctId":31717,"briefTitle":31718,"status":195,"phases":31719,"primaryCompletion":2144,"completion":2144,"start":2057,"enrollment":390,"conditions":31720,"interventions":31722},"NCT01012375","Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.",[91],[31721],"Adult ADHD",[31652,31652,31652],{"nctId":31724,"briefTitle":31725,"status":195,"phases":31726,"primaryCompletion":2406,"completion":2406,"start":2055,"enrollment":6390,"conditions":31727,"interventions":31729},"NCT01039701","4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease",[91],[31728],"Mild to Moderate Alzheimer's Disease",[31652],{"trials":31731,"activeCount":102},[],{"trials":31733,"activeCount":102},[],{"trials":31735,"activeCount":102},[],{"intervention":31737,"totalTrials":2222,"cells":31738},"AZD1386",{"EARLY_PHASE1":31739,"PHASE1":31741,"PHASE2":31791,"PHASE3":31819,"PHASE4":31821,"NA":31823},{"trials":31740,"activeCount":102},[],{"trials":31742,"activeCount":102},[31743,31750,31757,31763,31770,31778,31785],{"nctId":31744,"briefTitle":31745,"status":195,"phases":31746,"primaryCompletion":2086,"completion":2086,"start":2168,"enrollment":12271,"conditions":31747,"interventions":31749},"NCT00690079","Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386",[90],[31748],"Chronic Pain",[31737],{"nctId":31751,"briefTitle":31752,"status":195,"phases":31753,"completion":2095,"start":7544,"enrollment":1039,"conditions":31754,"interventions":31756},"NCT00832169","Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386",[90],[31755],"Pain",[31737],{"nctId":31758,"briefTitle":31759,"status":195,"phases":31760,"completion":3827,"start":2524,"enrollment":579,"conditions":31761,"interventions":31762},"NCT00736658","AZD1386 Japanese Multiple Ascending Dosing Study",[90],[31748],[31737],{"nctId":31764,"briefTitle":31765,"status":195,"phases":31766,"completion":2068,"start":2524,"enrollment":1864,"conditions":31767,"interventions":31769},"NCT00711048","Esophageal Hypersensitivity Study in Healthy Volunteers",[90],[31755,31768],"Esophageal Sensitivity",[31737],{"nctId":31771,"briefTitle":31772,"status":195,"phases":31773,"primaryCompletion":2221,"completion":2221,"start":6710,"enrollment":496,"conditions":31774,"interventions":31777},"NCT00692146","Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)",[90],[31775,31776],"Capsaicin Evoked Pain","Heat Sensitivity",[31737],{"nctId":31779,"briefTitle":31780,"status":443,"phases":31781,"primaryCompletion":2067,"completion":2067,"start":2151,"enrollment":2222,"conditions":31782,"interventions":31783},"NCT00945178","Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers",[90],[36],[31737,31784],"Naproxen",{"nctId":31786,"briefTitle":31787,"status":195,"phases":31788,"primaryCompletion":2220,"completion":2220,"start":2524,"enrollment":1757,"conditions":31789,"interventions":31790},"NCT00714337","Formulation and Food Effect Study of AZD1386 in Healthy Volunteers",[90],[15776],[31737,31737,31737],{"trials":31792,"activeCount":102},[31793,31800,31806,31813],{"nctId":31794,"briefTitle":31795,"status":443,"phases":31796,"completion":2114,"start":2067,"enrollment":2045,"conditions":31797,"interventions":31799},"NCT00976534","Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain",[91],[31755,31798],"Neuropathic Pain",[31737],{"nctId":31801,"briefTitle":31802,"status":443,"phases":31803,"primaryCompletion":2068,"completion":2068,"start":2077,"enrollment":19526,"conditions":31804,"interventions":31805},"NCT00878501","Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee",[91],[31755],[31737,31737],{"nctId":31807,"briefTitle":31808,"status":195,"phases":31809,"primaryCompletion":2516,"completion":2516,"start":2057,"enrollment":1638,"conditions":31810,"interventions":31812},"NCT01019928","Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)",[91],[31811],"Sensitivity in Esophagus",[31737],{"nctId":31814,"briefTitle":31815,"status":195,"phases":31816,"primaryCompletion":2524,"completion":2524,"start":2251,"enrollment":1510,"conditions":31817,"interventions":31818},"NCT00672646","Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386",[91],[31755],[31737,31784],{"trials":31820,"activeCount":102},[],{"trials":31822,"activeCount":102},[],{"trials":31824,"activeCount":102},[],{"intervention":31826,"totalTrials":2222,"cells":31827},"AZD7325",{"EARLY_PHASE1":31828,"PHASE1":31830,"PHASE2":31895,"PHASE3":31911,"PHASE4":31913,"NA":31915},{"trials":31829,"activeCount":102},[],{"trials":31831,"activeCount":102},[31832,31840,31846,31852,31858,31865,31872,31879,31885],{"nctId":31833,"briefTitle":31834,"status":195,"phases":31835,"primaryCompletion":2220,"completion":2220,"start":2524,"enrollment":486,"conditions":31836,"interventions":31838},"NCT00720421","A Sedation\u002FCognition\u002FElectroencephalogram (EEG) Study Using AZD7325 and Comparator.",[90],[31837],"Healthy Volunteer",[31826,31826,31826,31839,31839],"Lorazepam",{"nctId":31841,"briefTitle":31842,"status":443,"phases":31843,"completion":2057,"start":2068,"enrollment":5898,"conditions":31844,"interventions":31845},"NCT00945425","AZD7325 Japan Multiple Ascending Dose (MAD) Study",[90],[19],[31826],{"nctId":31847,"briefTitle":31848,"status":195,"phases":31849,"primaryCompletion":2507,"completion":2507,"start":2580,"enrollment":5898,"conditions":31850,"interventions":31851},"NCT00681915","AZD7325 Multiple Ascending Dose Study",[90],[31837],[31826],{"nctId":31853,"briefTitle":31854,"status":195,"phases":31855,"primaryCompletion":2077,"completion":2077,"start":2086,"enrollment":5898,"conditions":31856,"interventions":31857},"NCT00769899","AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects",[90],[31837],[31826],{"nctId":31859,"briefTitle":31860,"status":195,"phases":31861,"completion":2067,"start":688,"enrollment":221,"conditions":31862,"interventions":31864},"NCT00902772","Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users",[90],[31863],"Recreational CNS Depressant Use",[31839,31826],{"nctId":31866,"briefTitle":31867,"status":2744,"phases":31868,"primaryCompletion":2067,"completion":2067,"start":688,"enrollment":2933,"conditions":31869,"interventions":31870},"NCT00901290","Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects",[90],[15776],[31871,31826],"monophasic oral contraceptive",{"nctId":31873,"briefTitle":31874,"status":195,"phases":31875,"primaryCompletion":2507,"completion":2507,"start":2168,"enrollment":1979,"conditions":31876,"interventions":31877},"NCT00681720","Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325",[90],[20485],[31826,31878],"Radioligand (11C) flumazenil",{"nctId":31880,"briefTitle":31881,"status":195,"phases":31882,"primaryCompletion":3827,"completion":3827,"start":2507,"enrollment":1130,"conditions":31883,"interventions":31884},"NCT00790114","Determine the Effect of Multiple Doses of AZD7325, CYP Study",[90],[31837],[31826,5870,13183],{"nctId":31886,"briefTitle":31887,"status":2744,"phases":31888,"primaryCompletion":2350,"completion":2350,"start":2151,"enrollment":370,"conditions":31889,"interventions":31894},"NCT00940641","Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration",[90],[31890,31891,31892,31893],"Absorption","Distribution","Metabolism","Excretion",[31826,31826],{"trials":31896,"activeCount":102},[31897,31904],{"nctId":31898,"briefTitle":31899,"status":195,"phases":31900,"primaryCompletion":688,"completion":688,"start":4915,"enrollment":31901,"conditions":31902,"interventions":31903},"NCT00808249","AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)",[91],725,[20021],[31826,31826,31826],{"nctId":31905,"briefTitle":31906,"status":195,"phases":31907,"primaryCompletion":688,"completion":688,"start":4915,"enrollment":31908,"conditions":31909,"interventions":31910},"NCT00807937","Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325",[91],369,[20021],[31826,31826,31839],{"trials":31912,"activeCount":102},[],{"trials":31914,"activeCount":102},[],{"trials":31916,"activeCount":102},[],{"intervention":5273,"totalTrials":269,"cells":31918},{"EARLY_PHASE1":31919,"PHASE1":31921,"PHASE2":31976,"PHASE3":31998,"PHASE4":32000,"NA":32002},{"trials":31920,"activeCount":102},[],{"trials":31922,"activeCount":102},[31923,31929,31936,31944,31950,31956,31962],{"nctId":31924,"briefTitle":31925,"status":195,"phases":31926,"primaryCompletion":2433,"completion":2433,"start":2243,"enrollment":18686,"conditions":31927,"interventions":31928},"NCT01100047","Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069",[90],[19],[5273],{"nctId":31930,"briefTitle":31931,"status":195,"phases":31932,"primaryCompletion":2055,"completion":2055,"start":2068,"enrollment":31933,"conditions":31934,"interventions":31935},"NCT00953888","Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and\u002For Female Subjects",[90],203,[19],[5273],{"nctId":31937,"briefTitle":31938,"status":195,"phases":31939,"primaryCompletion":2470,"completion":2470,"start":1693,"enrollment":532,"conditions":31940,"interventions":31942},"NCT01962935","Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and\u002For With AZD 5069",[90],[31941],"Chronic Obstructive Pulmonary Disease (COPD).",[31943,5273],"AZD4721",{"nctId":31945,"briefTitle":31946,"status":195,"phases":31947,"primaryCompletion":2560,"completion":2560,"start":4006,"enrollment":963,"conditions":31948,"interventions":31949},"NCT01890148","Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069",[90],[16],[5273],{"nctId":31951,"briefTitle":31952,"status":195,"phases":31953,"primaryCompletion":2406,"completion":2406,"start":2114,"enrollment":1130,"conditions":31954,"interventions":31955},"NCT01083238","This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose",[90],[28],[5273],{"nctId":31957,"briefTitle":31958,"status":195,"phases":31959,"primaryCompletion":2113,"completion":2113,"start":2056,"enrollment":370,"conditions":31960,"interventions":31961},"NCT01051505","A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers",[90],[19],[5273],{"nctId":31963,"briefTitle":31964,"status":195,"phases":31965,"primaryCompletion":2405,"completion":2405,"start":2616,"enrollment":520,"conditions":31966,"interventions":31975},"NCT01735240","Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.",[90],[31967,31968,31969,31970,31971,31972,31973,31974],"Asthma,","Pharmacokinetics,","Cmax,","Tmax,","λz,","AUC,","Ketoconazole,","Metabolite",[5273,23332],{"trials":31977,"activeCount":102},[31978,31987,31994],{"nctId":31979,"briefTitle":31980,"status":195,"phases":31981,"primaryCompletion":2366,"completion":2366,"start":2433,"enrollment":6597,"conditions":31982,"interventions":31986},"NCT01255592","Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis",[91],[31983,31984,31985],"Bronchiectasis","Lung Disease","Respiratory Diseases",[5273],{"nctId":31988,"briefTitle":31989,"status":195,"phases":31990,"primaryCompletion":2560,"completion":2560,"start":2104,"enrollment":31991,"conditions":31992,"interventions":31993},"NCT01704495","A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.",[91],1147,[16],[5273],{"nctId":5264,"briefTitle":5265,"status":195,"phases":31995,"primaryCompletion":5267,"completion":5268,"start":588,"enrollment":5269,"conditions":31996,"interventions":31997},[90,91],[5271],[571,82,5273,3038],{"trials":31999,"activeCount":102},[],{"trials":32001,"activeCount":102},[],{"trials":32003,"activeCount":102},[],{"intervention":32005,"totalTrials":269,"cells":32006},"AZD3480",{"EARLY_PHASE1":32007,"PHASE1":32009,"PHASE2":32055,"PHASE3":32078,"PHASE4":32080,"NA":32082},{"trials":32008,"activeCount":102},[],{"trials":32010,"activeCount":102},[32011,32018,32024,32031,32037,32043,32049],{"nctId":32012,"briefTitle":32013,"status":195,"phases":32014,"completion":2320,"start":2580,"enrollment":14693,"conditions":32015,"interventions":32016},"NCT00689559","Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects",[90],[18867],[32005,32017],"Aripiprazole",{"nctId":32019,"briefTitle":32020,"status":443,"phases":32021,"primaryCompletion":2350,"completion":2350,"start":2086,"enrollment":4343,"conditions":32022,"interventions":32023},"NCT00777361","Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers",[90],[18867],[32005,32005],{"nctId":32025,"briefTitle":32026,"status":195,"phases":32027,"primaryCompletion":3827,"completion":3827,"start":2169,"enrollment":1336,"conditions":32028,"interventions":32029},"NCT00692510","Drug Interaction Study Between AZD3480 and Cytochrome P450",[90],[31892,18867],[32005,32030],"Cocktail mix",{"nctId":32032,"briefTitle":32033,"status":195,"phases":32034,"completion":2095,"start":2415,"enrollment":2827,"conditions":32035,"interventions":32036},"NCT00689637","Drug Interaction Study Between AZD3480 and Warfarin",[90],[18867],[32005,2197],{"nctId":32038,"briefTitle":32039,"status":195,"phases":32040,"primaryCompletion":2220,"completion":2220,"start":6710,"enrollment":1883,"conditions":32041,"interventions":32042},"NCT00686179","Investigate the Effect on the QT\u002FQTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days",[90],[19],[32005,2255],{"nctId":32044,"briefTitle":32045,"status":195,"phases":32046,"primaryCompletion":2220,"completion":2220,"start":6710,"enrollment":4343,"conditions":32047,"interventions":32048},"NCT00686413","Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects",[90],[19],[32005],{"nctId":32050,"briefTitle":32051,"status":443,"phases":32052,"primaryCompletion":4915,"completion":4915,"start":4915,"enrollment":689,"conditions":32053,"interventions":32054},"NCT00713765","Pharmacokinetic Interaction Between AZD3480 and Donepezil",[90],[18867],[32005,23078],{"trials":32056,"activeCount":102},[32057,32065,32072],{"nctId":32058,"briefTitle":32059,"status":195,"phases":32060,"primaryCompletion":2220,"completion":2220,"start":2252,"enrollment":32061,"conditions":32062,"interventions":32064},"NCT00501111","Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease",[91],659,[32063],"Alzheimer Disease",[32005,23078],{"nctId":32066,"briefTitle":32067,"status":195,"phases":32068,"completion":2068,"start":2221,"enrollment":1130,"conditions":32069,"interventions":32071},"NCT00683462","An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[91],[32070],"ADHD",[32005,32005],{"nctId":32073,"briefTitle":32074,"status":195,"phases":32075,"primaryCompletion":2086,"completion":2414,"start":5725,"enrollment":1078,"conditions":32076,"interventions":32077},"NCT00528905","Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia",[91],[33],[32005],{"trials":32079,"activeCount":102},[],{"trials":32081,"activeCount":102},[],{"trials":32083,"activeCount":102},[],{"intervention":32085,"totalTrials":269,"cells":32086},"AZD9668",{"EARLY_PHASE1":32087,"PHASE1":32089,"PHASE2":32114,"PHASE3":32156,"PHASE4":32158,"NA":32160},{"trials":32088,"activeCount":102},[],{"trials":32090,"activeCount":102},[32091,32097,32103,32109],{"nctId":32092,"briefTitle":32093,"status":624,"phases":32094,"primaryCompletion":2143,"completion":2143,"start":2349,"enrollment":102,"conditions":32095,"interventions":32096},"NCT01214122","A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin",[90],[15776,24602],[32085,2197],{"nctId":32098,"briefTitle":32099,"status":195,"phases":32100,"primaryCompletion":2242,"completion":2242,"start":2242,"enrollment":1039,"conditions":32101,"interventions":32102},"NCT01161355","Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject",[90],[19],[32085],{"nctId":32104,"briefTitle":32105,"status":195,"phases":32106,"primaryCompletion":2055,"completion":2055,"start":2057,"enrollment":520,"conditions":32107,"interventions":32108},"NCT01035411","AZD9668 Relative Bioavailability",[90],[28],[32085,32085,32085],{"nctId":32110,"briefTitle":32105,"status":195,"phases":32111,"primaryCompletion":2055,"completion":2055,"start":2057,"enrollment":2260,"conditions":32112,"interventions":32113},"NCT01034982",[90],[28],[32085,32085],{"trials":32115,"activeCount":102},[32116,32122,32128,32136,32144,32150],{"nctId":32117,"briefTitle":32118,"status":195,"phases":32119,"primaryCompletion":2144,"completion":2144,"start":2057,"enrollment":9945,"conditions":32120,"interventions":32121},"NCT01023516","Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide\u002FFormoterol",[91],[6083],[32085],{"nctId":32123,"briefTitle":32124,"status":195,"phases":32125,"primaryCompletion":3827,"completion":3827,"start":2524,"enrollment":1336,"conditions":32126,"interventions":32127},"NCT00703391","A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],[6083],[32085],{"nctId":32129,"briefTitle":32130,"status":195,"phases":32131,"primaryCompletion":2151,"completion":2151,"start":2086,"enrollment":2933,"conditions":32132,"interventions":32134},"NCT00757848","A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis",[91],[32133],"Cystic Fibrosis",[32085,32135],"AZD9668 Placebo equivalent",{"nctId":32137,"briefTitle":32138,"status":195,"phases":32139,"primaryCompletion":2144,"completion":2144,"start":2068,"enrollment":32140,"conditions":32141,"interventions":32142},"NCT00949975","A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium",[91],838,[28],[32085,32085,32085,32143],"AZD9668 Placebo",{"nctId":32145,"briefTitle":32146,"status":195,"phases":32147,"primaryCompletion":2349,"completion":2349,"start":2056,"enrollment":14693,"conditions":32148,"interventions":32149},"NCT01054170","Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],[6083],[32085],{"nctId":32151,"briefTitle":32152,"status":195,"phases":32153,"primaryCompletion":2320,"completion":2320,"start":3827,"enrollment":3717,"conditions":32154,"interventions":32155},"NCT00769119","A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis",[91],[31983],[32085],{"trials":32157,"activeCount":102},[],{"trials":32159,"activeCount":102},[],{"trials":32161,"activeCount":102},[],{"intervention":24688,"totalTrials":269,"cells":32163},{"EARLY_PHASE1":32164,"PHASE1":32166,"PHASE2":32208,"PHASE3":32235,"PHASE4":32237,"NA":32239},{"trials":32165,"activeCount":102},[],{"trials":32167,"activeCount":102},[32168,32174,32183,32189,32195,32201],{"nctId":32169,"briefTitle":32170,"status":195,"phases":32171,"primaryCompletion":2524,"completion":2524,"start":2251,"enrollment":5876,"conditions":32172,"interventions":32173},"NCT00690404","AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers",[90],[19],[24688],{"nctId":32175,"briefTitle":32176,"status":195,"phases":32177,"completion":2067,"start":2152,"enrollment":520,"conditions":32178,"interventions":32179},"NCT00930306","AZD2066 Cocktail Study",[90],[31748],[24688,13183,32180,32181,32182],"Tolbutamide","Omeprazole Tablet, 20 mg","Midazolam Tablet, 7.5 mg",{"nctId":32184,"briefTitle":32185,"status":195,"phases":32186,"completion":2095,"start":7544,"enrollment":1039,"conditions":32187,"interventions":32188},"NCT00829088","Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066",[90],[31755],[24688],{"nctId":32190,"briefTitle":32191,"status":195,"phases":32192,"primaryCompletion":2414,"completion":2414,"start":6710,"enrollment":744,"conditions":32193,"interventions":32194},"NCT00684502","Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects",[90],[31755],[24688],{"nctId":32196,"briefTitle":32197,"status":195,"phases":32198,"completion":2068,"start":3827,"enrollment":24038,"conditions":32199,"interventions":32200},"NCT00766012","Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects",[90],[19],[24688],{"nctId":32202,"briefTitle":32203,"status":195,"phases":32204,"primaryCompletion":2524,"completion":2524,"start":2251,"enrollment":1039,"conditions":32205,"interventions":32206},"NCT00686504","Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066",[90],[19],[24688,32207],"radioligand [11C] AZ12713580",{"trials":32209,"activeCount":102},[32210,32214,32221,32228],{"nctId":24683,"briefTitle":24684,"status":443,"phases":32211,"primaryCompletion":2349,"completion":2349,"start":2243,"enrollment":18941,"conditions":32212,"interventions":32213},[91],[18697],[24688,18854],{"nctId":32215,"briefTitle":32216,"status":195,"phases":32217,"completion":2057,"start":4915,"enrollment":1448,"conditions":32218,"interventions":32220},"NCT00813306","14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations",[90,91],[32219],"Reflux Episodes",[24688,24688,24688],{"nctId":32222,"briefTitle":32223,"status":195,"phases":32224,"primaryCompletion":2151,"completion":2151,"start":2095,"enrollment":235,"conditions":32225,"interventions":32227},"NCT00857623","Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy",[91],[31755,32226],"Diabetic Neuropathy",[24688],{"nctId":32229,"briefTitle":32230,"status":443,"phases":32231,"primaryCompletion":2349,"completion":2349,"start":2151,"enrollment":19246,"conditions":32232,"interventions":32234},"NCT00939094","AZD2066 Neuropathic Pain - Mechanical Hypersensitivity",[91],[31798,32233],"Mechanical Hypersensitivity",[24688],{"trials":32236,"activeCount":102},[],{"trials":32238,"activeCount":102},[],{"trials":32240,"activeCount":102},[],{"intervention":32242,"totalTrials":370,"cells":32243},"AZD6765",{"EARLY_PHASE1":32244,"PHASE1":32246,"PHASE2":32278,"PHASE3":32299,"PHASE4":32301,"NA":32303},{"trials":32245,"activeCount":102},[],{"trials":32247,"activeCount":102},[32248,32254,32260,32266,32272],{"nctId":32249,"briefTitle":32250,"status":624,"phases":32251,"primaryCompletion":2095,"completion":2212,"start":2414,"enrollment":102,"conditions":32252,"interventions":32253},"NCT00963365","AZD6765 Oral Single Ascending Dose\u002FMultiple Ascending Dose (SAD\u002FMAD)",[90],[19],[32242,32242],{"nctId":32255,"briefTitle":32256,"status":195,"phases":32257,"primaryCompletion":2243,"completion":2243,"start":2114,"enrollment":451,"conditions":32258,"interventions":32259},"NCT01069822","A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels",[90],[19],[32242,23402],{"nctId":32261,"briefTitle":32262,"status":195,"phases":32263,"primaryCompletion":2570,"completion":2570,"start":2055,"enrollment":589,"conditions":32264,"interventions":32265},"NCT01046630","Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects",[90],[18734],[32242,22955],{"nctId":32267,"briefTitle":32268,"status":443,"phases":32269,"primaryCompletion":2516,"completion":2516,"start":2243,"enrollment":496,"conditions":32270,"interventions":32271},"NCT01130909","A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765",[90],[19],[32242,32242,22955],{"nctId":32273,"briefTitle":32274,"status":195,"phases":32275,"primaryCompletion":2077,"completion":2077,"start":2414,"enrollment":1448,"conditions":32276,"interventions":32277},"NCT00785915","AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects",[90],[19],[32242],{"trials":32279,"activeCount":102},[32280,32287,32293],{"nctId":32281,"briefTitle":32282,"status":195,"phases":32283,"primaryCompletion":2589,"completion":2589,"start":2055,"enrollment":434,"conditions":32284,"interventions":32286},"NCT00986479","This is a Study to Determine the Antidepressant Effects of AZD6765",[91],[32285],"Treatment Resistant Major Depressive Disorder",[32242],{"nctId":32288,"briefTitle":32289,"status":195,"phases":32290,"primaryCompletion":2169,"completion":2169,"start":2252,"enrollment":17655,"conditions":32291,"interventions":32292},"NCT00491686","AZD6765 for Treatment Resistant Depression",[91],[18734],[32242],{"nctId":32294,"briefTitle":32295,"status":195,"phases":32296,"primaryCompletion":2212,"completion":2212,"start":2086,"enrollment":3466,"conditions":32297,"interventions":32298},"NCT00781742","AZD6765 Severe Major Depressive Disorder (MDD) IV",[91],[18697],[32242],{"trials":32300,"activeCount":102},[],{"trials":32302,"activeCount":102},[],{"trials":32304,"activeCount":102},[],{"intervention":32306,"totalTrials":370,"cells":32307},"AZD8848",{"EARLY_PHASE1":32308,"PHASE1":32310,"PHASE2":32352,"PHASE3":32368,"PHASE4":32370,"NA":32372},{"trials":32309,"activeCount":102},[],{"trials":32311,"activeCount":102},[32312,32319,32325,32332,32338,32344],{"nctId":32313,"briefTitle":32314,"status":195,"phases":32315,"primaryCompletion":2433,"completion":2747,"start":3862,"enrollment":434,"conditions":32316,"interventions":32318},"NCT01205867","Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects",[90],[32317],"Butyrylcholinesterase Deficiency",[32306],{"nctId":32320,"briefTitle":32321,"status":195,"phases":32322,"primaryCompletion":2077,"completion":2114,"start":3827,"enrollment":1510,"conditions":32323,"interventions":32324},"NCT00770003","Tolerability\u002FPoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848",[90],[19413],[32306],{"nctId":32326,"briefTitle":32327,"status":195,"phases":32328,"primaryCompletion":2221,"completion":2320,"start":6710,"enrollment":32329,"conditions":32330,"interventions":32331},"NCT00688779","Tolerability\u002FSafety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season",[90],130,[19,19413],[32306],{"nctId":32333,"briefTitle":32334,"status":195,"phases":32335,"primaryCompletion":1692,"completion":1692,"start":10063,"enrollment":3172,"conditions":32336,"interventions":32337},"NCT01560234","AZD8848 Single Ascending Dose Study",[90],[19],[32306],{"nctId":32339,"briefTitle":32340,"status":195,"phases":32341,"primaryCompletion":2570,"completion":2366,"start":2349,"enrollment":2783,"conditions":32342,"interventions":32343},"NCT01203124","A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers",[90],[36],[32306],{"nctId":32345,"briefTitle":32346,"status":195,"phases":32347,"primaryCompletion":2204,"completion":2204,"start":2480,"enrollment":370,"conditions":32348,"interventions":32351},"NCT01818869","To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects",[90],[32349,32350,1556],"Safety,","Tolerability,",[32306],{"trials":32353,"activeCount":102},[32354,32361],{"nctId":32355,"briefTitle":32356,"status":195,"phases":32357,"primaryCompletion":2433,"completion":2589,"start":2350,"enrollment":477,"conditions":32358,"interventions":32360},"NCT00999466","The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen",[91],[32359],"Allergic Asthma",[32306],{"nctId":32362,"briefTitle":32363,"status":195,"phases":32364,"primaryCompletion":2143,"completion":2747,"start":3862,"enrollment":6454,"conditions":32365,"interventions":32366},"NCT01185080","Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848",[91],[19413],[32306,32367],"AZD8848 and placebo",{"trials":32369,"activeCount":102},[],{"trials":32371,"activeCount":102},[],{"trials":32373,"activeCount":102},[],{"intervention":32375,"totalTrials":370,"cells":32376},"AZD3355",{"EARLY_PHASE1":32377,"PHASE1":32379,"PHASE2":32407,"PHASE3":32438,"PHASE4":32440,"NA":32442},{"trials":32378,"activeCount":102},[],{"trials":32380,"activeCount":102},[32381,32387,32394,32401],{"nctId":32382,"briefTitle":32383,"status":195,"phases":32384,"primaryCompletion":2524,"completion":2524,"start":2580,"enrollment":1710,"conditions":32385,"interventions":32386},"NCT00684190","Drug Interaction Study Between AZD3355 and Nexium",[90],[20100],[32375,19794],{"nctId":32388,"briefTitle":32389,"status":195,"phases":32390,"primaryCompletion":4915,"completion":4915,"start":3827,"enrollment":680,"conditions":32391,"interventions":32393},"NCT00757419","AZD3355 Dose-escalation Study in Healthy Males",[90],[32392],"Reflux Disease",[32375],{"nctId":32395,"briefTitle":32396,"status":195,"phases":32397,"primaryCompletion":2114,"completion":2114,"start":2077,"enrollment":554,"conditions":32398,"interventions":32400},"NCT00863161","Renal Impairment Study",[90],[20135,32399],"Renal Excretion",[32375],{"nctId":32402,"briefTitle":32403,"status":195,"phases":32404,"primaryCompletion":2524,"completion":2524,"start":2251,"enrollment":5898,"conditions":32405,"interventions":32406},"NCT00688402","Study to Compare Different Formulations of AZD3355",[90],[20100],[32375],{"trials":32408,"activeCount":102},[32409,32416,32422,32432],{"nctId":32410,"briefTitle":32411,"status":195,"phases":32412,"primaryCompletion":5562,"completion":5562,"start":7342,"enrollment":32413,"conditions":32414,"interventions":32415},"NCT00394472","Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients",[91],244,[27291],[32375],{"nctId":32417,"briefTitle":32418,"status":195,"phases":32419,"primaryCompletion":2243,"completion":2243,"start":2055,"enrollment":2003,"conditions":32420,"interventions":32421},"NCT01043185","A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience",[91],[20100],[32375,32375,32375,32375],{"nctId":32423,"briefTitle":32424,"status":195,"phases":32425,"primaryCompletion":7544,"completion":7544,"start":2221,"enrollment":32426,"conditions":32427,"interventions":32430},"NCT00703534","Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms",[91],478,[19809,32428,20099,32429],"Acid Reflux Disease","Regurgitation",[32375,32431],"Gelusil®",{"nctId":32433,"briefTitle":32434,"status":195,"phases":32435,"primaryCompletion":2168,"completion":2168,"start":2328,"enrollment":2003,"conditions":32436,"interventions":32437},"NCT00743444","TLESR-impedance Study in Patients",[91],[32219],[32375],{"trials":32439,"activeCount":102},[],{"trials":32441,"activeCount":102},[],{"trials":32443,"activeCount":102},[],{"intervention":15778,"totalTrials":370,"cells":32445},{"EARLY_PHASE1":32446,"PHASE1":32448,"PHASE2":32488,"PHASE3":32497,"PHASE4":32499,"NA":32501},{"trials":32447,"activeCount":102},[],{"trials":32449,"activeCount":102},[32450,32456,32462,32466,32472,32476,32482],{"nctId":32451,"briefTitle":32452,"status":195,"phases":32453,"completion":2507,"start":2524,"enrollment":1979,"conditions":32454,"interventions":32455},"NCT00711074","Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers",[90],[7267],[15778],{"nctId":32457,"briefTitle":32458,"status":195,"phases":32459,"completion":688,"start":2077,"enrollment":1130,"conditions":32460,"interventions":32461},"NCT00871767","AZD5672 Bioavailability Study in Healthy Male and Female Subjects",[90],[7267],[15778,15778,15778,15778],{"nctId":15772,"briefTitle":15773,"status":195,"phases":32463,"primaryCompletion":2220,"completion":2220,"start":2507,"enrollment":1757,"conditions":32464,"interventions":32465},[90],[36,15776],[15778,13002],{"nctId":32467,"briefTitle":32468,"status":195,"phases":32469,"primaryCompletion":7544,"completion":7544,"start":2220,"enrollment":2827,"conditions":32470,"interventions":32471},"NCT00746837","AZD5672 Absolute Bioavailability Study",[90],[36],[15778,15778,15778],{"nctId":16439,"briefTitle":16440,"status":195,"phases":32473,"primaryCompletion":4915,"completion":4915,"start":2507,"enrollment":1130,"conditions":32474,"interventions":32475},[90],[36,15776],[15778,2198],{"nctId":32477,"briefTitle":32478,"status":195,"phases":32479,"completion":2068,"start":2320,"enrollment":4307,"conditions":32480,"interventions":32481},"NCT00887770","A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart",[90],[7267],[15778,2255,15778],{"nctId":32483,"briefTitle":32484,"status":195,"phases":32485,"primaryCompletion":2095,"completion":2095,"start":2507,"enrollment":1448,"conditions":32486,"interventions":32487},"NCT00715702","Safety Study of AZD5672 in Renally Impaired Subjects",[90],[2279],[15778],{"trials":32489,"activeCount":102},[32490],{"nctId":32491,"briefTitle":32492,"status":195,"phases":32493,"primaryCompletion":2320,"completion":2320,"start":2507,"enrollment":1219,"conditions":32494,"interventions":32495},"NCT00713544","A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis",[91],[7267],[15778,32496,15778,15778,15778],"Etanercept",{"trials":32498,"activeCount":102},[],{"trials":32500,"activeCount":102},[],{"trials":32502,"activeCount":102},[],{"intervention":32504,"totalTrials":1855,"cells":32505},"Allopurinol",{"EARLY_PHASE1":32506,"PHASE1":32508,"PHASE2":32546,"PHASE3":32574,"PHASE4":32576,"NA":32578},{"trials":32507,"activeCount":102},[],{"trials":32509,"activeCount":102},[32510,32521,32529,32537],{"nctId":32511,"briefTitle":32512,"status":195,"phases":32513,"primaryCompletion":32514,"completion":32514,"start":32515,"enrollment":98,"conditions":32516,"interventions":32517},"NCT04550234","A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol",[90],"2021-07-15","2021-04-13",[2134],[32518,32504,32519,32520],"Verinurad prolonged release HPMC","Verinurad\u002FAllopurinol FDC","Verinurad prolonged release gelatin",{"nctId":32522,"briefTitle":32523,"status":195,"phases":32524,"primaryCompletion":32525,"completion":32525,"start":26083,"enrollment":1130,"conditions":32526,"interventions":32528},"NCT04256629","A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart",[90],"2020-08-21",[32527],"Healthy Volunteers (Intended Indication: Chronic Kidney Disease)",[2314,32504],{"nctId":32530,"briefTitle":32531,"status":195,"phases":32532,"primaryCompletion":32533,"completion":32533,"start":32534,"enrollment":1039,"conditions":32535,"interventions":32536},"NCT03836599","A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects",[90],"2019-04-26","2019-01-16",[2134],[2314,32504],{"nctId":32538,"briefTitle":32539,"status":195,"phases":32540,"primaryCompletion":32541,"completion":32541,"start":32542,"enrollment":1638,"conditions":32543,"interventions":32544},"NCT04532918","Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers",[90],"2020-11-23","2020-09-10",[2134],[2314,32504,32545,7055],"Cyclosporine",{"trials":32547,"activeCount":102},[32548,32556,32567],{"nctId":32549,"briefTitle":32550,"status":195,"phases":32551,"primaryCompletion":32552,"completion":32552,"start":26425,"enrollment":32553,"conditions":32554,"interventions":32555},"NCT03990363","A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia",[91],"2021-11-22",861,[2134],[2314,32504],{"nctId":32557,"briefTitle":32558,"status":195,"phases":32559,"primaryCompletion":32560,"completion":32560,"start":32561,"enrollment":32562,"conditions":32563,"interventions":32565},"NCT02078219","Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia",[91],"2015-03-13","2014-01-05",204,[32564],"Gout and Hyperuricemia",[32566,32504],"RDEA3170",{"nctId":32568,"briefTitle":32569,"status":195,"phases":32570,"primaryCompletion":6234,"completion":6234,"start":32571,"enrollment":1586,"conditions":32572,"interventions":32573},"NCT04327024","Study of Verinurad in Heart Failure With Preserved Ejection Fraction",[91],"2020-05-19",[2723],[2314,32504],{"trials":32575,"activeCount":102},[],{"trials":32577,"activeCount":102},[],{"trials":32579,"activeCount":102},[],{"intervention":23078,"totalTrials":1855,"cells":32581},{"EARLY_PHASE1":32582,"PHASE1":32590,"PHASE2":32608,"PHASE3":32618,"PHASE4":32620,"NA":32622},{"trials":32583,"activeCount":102},[32584],{"nctId":32585,"briefTitle":32586,"status":195,"phases":32587,"primaryCompletion":2516,"completion":2516,"start":2055,"enrollment":975,"conditions":32588,"interventions":32589},"NCT01024660","The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil",[89],[18867],[23078,23078],{"trials":32591,"activeCount":102},[32592,32596,32600,32604],{"nctId":31683,"briefTitle":31684,"status":195,"phases":32593,"primaryCompletion":2113,"completion":2113,"start":2055,"enrollment":5876,"conditions":32594,"interventions":32595},[90],[31687],[31652,31652,31689],{"nctId":23072,"briefTitle":23073,"status":195,"phases":32597,"primaryCompletion":23075,"completion":23075,"start":461,"enrollment":11272,"conditions":32598,"interventions":32599},[90],[19],[12640,12588,5870,5870,23078,12640],{"nctId":25534,"briefTitle":25535,"status":195,"phases":32601,"primaryCompletion":2203,"completion":2203,"start":2480,"enrollment":2003,"conditions":32602,"interventions":32603},[90],[25538,18867],[10068,25527,23078,25540,25541],{"nctId":32050,"briefTitle":32051,"status":443,"phases":32605,"primaryCompletion":4915,"completion":4915,"start":4915,"enrollment":689,"conditions":32606,"interventions":32607},[90],[18867],[32005,23078],{"trials":32609,"activeCount":102},[32610,32614],{"nctId":32058,"briefTitle":32059,"status":195,"phases":32611,"primaryCompletion":2220,"completion":2220,"start":2252,"enrollment":32061,"conditions":32612,"interventions":32613},[91],[32063],[32005,23078],{"nctId":31711,"briefTitle":31712,"status":443,"phases":32615,"primaryCompletion":2570,"completion":2570,"start":2242,"enrollment":1448,"conditions":32616,"interventions":32617},[91],[23833],[31652,23078],{"trials":32619,"activeCount":102},[],{"trials":32621,"activeCount":102},[],{"trials":32623,"activeCount":102},[],{"intervention":4501,"totalTrials":1855,"cells":32625},{"EARLY_PHASE1":32626,"PHASE1":32628,"PHASE2":32652,"PHASE3":32666,"PHASE4":32668,"NA":32670},{"trials":32627,"activeCount":102},[],{"trials":32629,"activeCount":102},[32630,32636,32642,32646],{"nctId":32631,"briefTitle":32632,"status":195,"phases":32633,"completion":2068,"start":2077,"enrollment":1130,"conditions":32634,"interventions":32635},"NCT00879346","A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets",[90],[19],[4501],{"nctId":32637,"briefTitle":32638,"status":195,"phases":32639,"primaryCompletion":2615,"completion":2615,"start":12721,"enrollment":2827,"conditions":32640,"interventions":32641},"NCT01330758","A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females",[90],[19],[4501,4501],{"nctId":4493,"briefTitle":4494,"status":195,"phases":32643,"primaryCompletion":4496,"completion":4496,"start":2350,"enrollment":4497,"conditions":32644,"interventions":32645},[90],[3841,4499,25],[4501,118],{"nctId":32647,"briefTitle":32648,"status":195,"phases":32649,"primaryCompletion":2152,"completion":2616,"start":2168,"enrollment":6275,"conditions":32650,"interventions":32651},"NCT00637039","Study of AZD8931 in Patients With Advanced Solid Malignancies",[90],[157],[4501],{"trials":32653,"activeCount":102},[32654,32658,32662],{"nctId":4543,"briefTitle":4544,"status":195,"phases":32655,"primaryCompletion":4496,"completion":2561,"start":2152,"enrollment":4546,"conditions":32656,"interventions":32657},[90,91],[3841,306,25],[4501,118],{"nctId":7358,"briefTitle":7359,"status":443,"phases":32659,"primaryCompletion":2579,"completion":2579,"start":2242,"enrollment":7361,"conditions":32660,"interventions":32661},[91],[3841,306,25],[4501,6411],{"nctId":4562,"briefTitle":4563,"status":443,"phases":32663,"primaryCompletion":2443,"completion":2443,"start":4496,"enrollment":3190,"conditions":32664,"interventions":32665},[91],[4566],[4501,118],{"trials":32667,"activeCount":102},[],{"trials":32669,"activeCount":102},[],{"trials":32671,"activeCount":102},[],{"intervention":19435,"totalTrials":1855,"cells":32673},{"EARLY_PHASE1":32674,"PHASE1":32676,"PHASE2":32709,"PHASE3":32722,"PHASE4":32724,"NA":32726},{"trials":32675,"activeCount":102},[],{"trials":32677,"activeCount":102},[32678,32684,32690,32697,32703],{"nctId":32679,"briefTitle":32680,"status":195,"phases":32681,"primaryCompletion":2736,"completion":2736,"start":12721,"enrollment":1757,"conditions":32682,"interventions":32683},"NCT01310322","A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways",[90],[19,16],[19435,19435,19435,19435],{"nctId":32685,"briefTitle":32686,"status":195,"phases":32687,"primaryCompletion":2113,"completion":2113,"start":2056,"enrollment":2003,"conditions":32688,"interventions":32689},"NCT01037504","AZD5423 Multiple Ascending Dose Study",[90],[19],[19435],{"nctId":32691,"briefTitle":32692,"status":195,"phases":32693,"primaryCompletion":2616,"completion":2616,"start":2105,"enrollment":1336,"conditions":32694,"interventions":32696},"NCT01635985","A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways",[90],[32695],"Bioavailability and AUC",[19435,19435,19435,19435,19435,19435],{"nctId":32698,"briefTitle":32699,"status":195,"phases":32700,"primaryCompletion":2057,"completion":2057,"start":2151,"enrollment":132,"conditions":32701,"interventions":32702},"NCT00963183","AZD5423 Single Ascending Dose Study",[90],[36],[19435],{"nctId":32704,"briefTitle":32705,"status":195,"phases":32706,"primaryCompletion":2589,"completion":2589,"start":2542,"enrollment":14210,"conditions":32707,"interventions":32708},"NCT01338350","Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects",[90],[19],[19435],{"trials":32710,"activeCount":102},[32711,32718],{"nctId":32712,"briefTitle":32713,"status":195,"phases":32714,"primaryCompletion":2589,"completion":2589,"start":2349,"enrollment":2003,"conditions":32715,"interventions":32716},"NCT01225549","The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen",[91],[16],[19435,32717],"Budesonide 200 microgram",{"nctId":19430,"briefTitle":19431,"status":195,"phases":32719,"primaryCompletion":19426,"completion":19426,"start":4496,"enrollment":12705,"conditions":32720,"interventions":32721},[91],[6083],[19435,9972],{"trials":32723,"activeCount":102},[],{"trials":32725,"activeCount":102},[],{"trials":32727,"activeCount":102},[],{"intervention":2389,"totalTrials":1855,"cells":32729},{"EARLY_PHASE1":32730,"PHASE1":32732,"PHASE2":32774,"PHASE3":32780,"PHASE4":32782,"NA":32784},{"trials":32731,"activeCount":102},[],{"trials":32733,"activeCount":102},[32734,32738,32747,32754,32758,32766],{"nctId":20843,"briefTitle":20844,"status":443,"phases":32735,"primaryCompletion":8197,"completion":8197,"start":20846,"enrollment":5726,"conditions":32736,"interventions":32737},[90],[1520],[2389,20558],{"nctId":32739,"briefTitle":32740,"status":195,"phases":32741,"primaryCompletion":32742,"completion":32742,"start":19204,"enrollment":963,"conditions":32743,"interventions":32744},"NCT03450759","A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects",[90],"2018-06-06",[36],[32745,2389,32746,32746],"AZD9977 Oral suspension","AZD9977 ER",{"nctId":32748,"briefTitle":32749,"status":195,"phases":32750,"primaryCompletion":339,"completion":339,"start":32751,"enrollment":1336,"conditions":32752,"interventions":32753},"NCT04469907","Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment",[90],"2020-06-22",[2279],[2389],{"nctId":16359,"briefTitle":16360,"status":195,"phases":32755,"primaryCompletion":16362,"completion":16362,"start":16363,"enrollment":1638,"conditions":32756,"interventions":32757},[90],[2723],[2389,5911],{"nctId":32759,"briefTitle":32760,"status":195,"phases":32761,"primaryCompletion":32762,"completion":32762,"start":32763,"enrollment":2260,"conditions":32764,"interventions":32765},"NCT03801967","A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration",[90],"2019-05-02","2019-01-24",[1520],[2389],{"nctId":32767,"briefTitle":32768,"status":195,"phases":32769,"primaryCompletion":32770,"completion":32770,"start":32771,"enrollment":2003,"conditions":32772,"interventions":32773},"NCT03435276","Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects",[90],"2018-06-13","2018-02-27",[36],[2389],{"trials":32775,"activeCount":102},[32776],{"nctId":2381,"briefTitle":2382,"status":195,"phases":32777,"primaryCompletion":2384,"completion":2384,"start":2385,"enrollment":2386,"conditions":32778,"interventions":32779},[91],[1520,2134],[2389,2044],{"trials":32781,"activeCount":102},[],{"trials":32783,"activeCount":102},[],{"trials":32785,"activeCount":102},[],{"intervention":20336,"totalTrials":1855,"cells":32787},{"EARLY_PHASE1":32788,"PHASE1":32790,"PHASE2":32817,"PHASE3":32841,"PHASE4":32843,"NA":32845},{"trials":32789,"activeCount":102},[],{"trials":32791,"activeCount":102},[32792,32798,32804,32811],{"nctId":32793,"briefTitle":32794,"status":195,"phases":32795,"completion":688,"start":2320,"enrollment":496,"conditions":32796,"interventions":32797},"NCT00878618","Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837",[90],[19],[20336,20336],{"nctId":32799,"briefTitle":32800,"status":195,"phases":32801,"completion":2152,"start":688,"enrollment":496,"conditions":32802,"interventions":32803},"NCT00904800","AZD0837 Extended Release (ER) Japan Study",[90],[19],[20336],{"nctId":32805,"briefTitle":32806,"status":195,"phases":32807,"primaryCompletion":2077,"completion":2077,"start":4915,"enrollment":5876,"conditions":32808,"interventions":32809},"NCT00812344","Effect of Ketoconazole on Biliary Excretion of AZD0837",[90],[19],[20336,23332,32810],"ketoconazole",{"nctId":32812,"briefTitle":32813,"status":195,"phases":32814,"completion":2095,"start":7544,"enrollment":370,"conditions":32815,"interventions":32816},"NCT00812643","Excretion of Radiolabelled AZD0837",[90],[19],[20336],{"trials":32818,"activeCount":102},[32819,32828,32832],{"nctId":32820,"briefTitle":32821,"status":195,"phases":32822,"primaryCompletion":2524,"completion":2524,"start":2328,"enrollment":32823,"conditions":32824,"interventions":32826},"NCT00684307","Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation",[91],1084,[32825],"Nonvalvular Atrial Fibrillation",[20336,32827,20336],"Vitamin-K antagonist at INR 2-3",{"nctId":20330,"briefTitle":20331,"status":195,"phases":32829,"primaryCompletion":2086,"completion":2086,"start":4297,"enrollment":589,"conditions":32830,"interventions":32831},[91],[20334],[20336,19240],{"nctId":32833,"briefTitle":32834,"status":195,"phases":32835,"primaryCompletion":688,"completion":688,"start":4297,"enrollment":32836,"conditions":32837,"interventions":32839},"NCT00645853","Long-term Safety in Atrial Fibrillation Patients",[91],523,[32838],"Persistent or Permanent Nonvalvular Atrial Fibrillation",[20336,32840],"VKA INR 2-3",{"trials":32842,"activeCount":102},[],{"trials":32844,"activeCount":102},[],{"trials":32846,"activeCount":102},[],{"intervention":3877,"totalTrials":1855,"cells":32848},{"EARLY_PHASE1":32849,"PHASE1":32851,"PHASE2":32886,"PHASE3":32898,"PHASE4":32900,"NA":32902},{"trials":32850,"activeCount":102},[],{"trials":32852,"activeCount":102},[32853,32857,32861,32872,32876,32880],{"nctId":5722,"briefTitle":5723,"status":195,"phases":32854,"primaryCompletion":2736,"completion":2481,"start":5725,"enrollment":5726,"conditions":32855,"interventions":32856},[90],[5728],[3877,283],{"nctId":10393,"briefTitle":10394,"status":195,"phases":32858,"primaryCompletion":2077,"completion":2057,"start":2252,"enrollment":5898,"conditions":32859,"interventions":32860},[90],[509],[3877,4685],{"nctId":32862,"briefTitle":32863,"status":195,"phases":32864,"primaryCompletion":32865,"completion":32866,"start":32867,"enrollment":8285,"conditions":32868,"interventions":32871},"NCT00516373","A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)",[90],"2008-12-17","2023-04-26","2005-07-11",[3026,32869,32870],"BRCA1 Protein","BRCA2 Protein",[3877],{"nctId":24391,"briefTitle":24392,"status":195,"phases":32873,"primaryCompletion":7544,"completion":7544,"start":13014,"enrollment":1448,"conditions":32874,"interventions":32875},[90],[24395],[3877,13869],{"nctId":3868,"briefTitle":3869,"status":195,"phases":32877,"primaryCompletion":3871,"completion":1058,"start":3872,"enrollment":3873,"conditions":32878,"interventions":32879},[90],[3875,784,344,118],[3877,344,3877,118,3877,3878],{"nctId":32881,"briefTitle":32882,"status":195,"phases":32883,"primaryCompletion":2077,"completion":2152,"start":2169,"enrollment":1336,"conditions":32884,"interventions":32885},"NCT00572364","Open Label, Dose Escalation Phase I Study of AZD2281",[90],[157],[3877],{"trials":32887,"activeCount":102},[32888],{"nctId":32889,"briefTitle":32890,"status":195,"phases":32891,"primaryCompletion":32892,"completion":32893,"start":32894,"enrollment":3180,"conditions":32895,"interventions":32897},"NCT00494442","Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer",[91],"2009-03-17","2017-07-20","2007-06-11",[32896],"Ovarian Neoplasm",[3877,3877],{"trials":32899,"activeCount":102},[],{"trials":32901,"activeCount":102},[],{"trials":32903,"activeCount":102},[],{"intervention":3843,"totalTrials":1855,"cells":32905},{"EARLY_PHASE1":32906,"PHASE1":32908,"PHASE2":32934,"PHASE3":32948,"PHASE4":32950,"NA":32952},{"trials":32907,"activeCount":102},[],{"trials":32909,"activeCount":102},[32910,32914,32920,32924,32928],{"nctId":31369,"briefTitle":31370,"status":195,"phases":32911,"primaryCompletion":2086,"completion":2350,"start":6718,"enrollment":1448,"conditions":32912,"interventions":32913},[90],[3841],[3830,3843],{"nctId":32915,"briefTitle":32916,"status":195,"phases":32917,"completion":2077,"start":2414,"enrollment":1336,"conditions":32918,"interventions":32919},"NCT00771979","Relative Bioavailability of Phase II and Phase III Formulations of AZD0530",[90],[19],[3843,3843],{"nctId":3836,"briefTitle":3837,"status":195,"phases":32921,"primaryCompletion":2056,"completion":2212,"start":3839,"enrollment":3484,"conditions":32922,"interventions":32923},[90],[3841],[3843,344,118],{"nctId":3859,"briefTitle":3860,"status":624,"phases":32925,"primaryCompletion":3862,"completion":2570,"start":2056,"enrollment":2003,"conditions":32926,"interventions":32927},[90],[556,3864,3865],[3843,344,620],{"nctId":32929,"briefTitle":32930,"status":195,"phases":32931,"primaryCompletion":2516,"completion":2615,"start":2524,"enrollment":1336,"conditions":32932,"interventions":32933},"NCT00704366","AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours",[90],[3728],[3843],{"trials":32935,"activeCount":102},[32936,32940],{"nctId":3899,"briefTitle":3900,"status":195,"phases":32937,"primaryCompletion":2151,"completion":2747,"start":2251,"enrollment":1599,"conditions":32938,"interventions":32939},[91],[3026,414],[3843,344,118],{"nctId":32941,"briefTitle":32942,"status":195,"phases":32943,"primaryCompletion":2056,"completion":2105,"start":2168,"enrollment":1873,"conditions":32944,"interventions":32946},"NCT00558272","Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease",[91],[25,416,32945],"Bone Neoplasms",[3843,32947],"Zoledronic Acid",{"trials":32949,"activeCount":102},[],{"trials":32951,"activeCount":102},[],{"trials":32953,"activeCount":102},[],{"intervention":32955,"totalTrials":1039,"cells":32956},"AZD4877",{"EARLY_PHASE1":32957,"PHASE1":32959,"PHASE2":32993,"PHASE3":33005,"PHASE4":33007,"NA":33009},{"trials":32958,"activeCount":102},[],{"trials":32960,"activeCount":102},[32961,32967,32974,32980,32986],{"nctId":32962,"briefTitle":32963,"status":195,"phases":32964,"primaryCompletion":2220,"completion":2086,"start":5563,"enrollment":1883,"conditions":32965,"interventions":32966},"NCT00389389","Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors",[90],[3841],[32955],{"nctId":32968,"briefTitle":32969,"status":443,"phases":32970,"completion":2068,"start":2252,"enrollment":3172,"conditions":32971,"interventions":32973},"NCT00486265","Phase I\u002FII, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)",[90],[32972],"Acute Myelogenous Leukemia",[32955],{"nctId":32975,"briefTitle":32976,"status":443,"phases":32977,"completion":5725,"start":3839,"enrollment":1883,"conditions":32978,"interventions":32979},"NCT00460460","Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies",[90],[510],[32955],{"nctId":32981,"briefTitle":32982,"status":195,"phases":32983,"primaryCompletion":2152,"completion":2152,"start":6710,"enrollment":1710,"conditions":32984,"interventions":32985},"NCT00613652","A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients",[90],[556,13585,4058],[32955],{"nctId":32987,"briefTitle":32988,"status":443,"phases":32989,"completion":4915,"start":7439,"enrollment":3811,"conditions":32990,"interventions":32992},"NCT00471367","Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877",[90],[510,32991,5006],"NHL",[32955],{"trials":32994,"activeCount":102},[32995],{"nctId":32996,"briefTitle":32997,"status":195,"phases":32998,"primaryCompletion":688,"completion":2055,"start":2221,"enrollment":680,"conditions":32999,"interventions":33004},"NCT00661609","A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer",[91],[403,33000,33001,33002,33003],"Transitional Cell Bladder Cancer","Urethra Cancer","Ureter Cancer","Renal Pelvis Cancer",[32955],{"trials":33006,"activeCount":102},[],{"trials":33008,"activeCount":102},[],{"trials":33010,"activeCount":102},[],{"intervention":2314,"totalTrials":1039,"cells":33012},{"EARLY_PHASE1":33013,"PHASE1":33015,"PHASE2":33029,"PHASE3":33043,"PHASE4":33045,"NA":33047},{"trials":33014,"activeCount":102},[],{"trials":33016,"activeCount":102},[33017,33021,33025],{"nctId":32522,"briefTitle":32523,"status":195,"phases":33018,"primaryCompletion":32525,"completion":32525,"start":26083,"enrollment":1130,"conditions":33019,"interventions":33020},[90],[32527],[2314,32504],{"nctId":32530,"briefTitle":32531,"status":195,"phases":33022,"primaryCompletion":32533,"completion":32533,"start":32534,"enrollment":1039,"conditions":33023,"interventions":33024},[90],[2134],[2314,32504],{"nctId":32538,"briefTitle":32539,"status":195,"phases":33026,"primaryCompletion":32541,"completion":32541,"start":32542,"enrollment":1638,"conditions":33027,"interventions":33028},[90],[2134],[2314,32504,32545,7055],{"trials":33030,"activeCount":102},[33031,33035,33039],{"nctId":32549,"briefTitle":32550,"status":195,"phases":33032,"primaryCompletion":32552,"completion":32552,"start":26425,"enrollment":32553,"conditions":33033,"interventions":33034},[91],[2134],[2314,32504],{"nctId":2306,"briefTitle":2307,"status":195,"phases":33036,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":496,"conditions":33037,"interventions":33038},[91],[2312],[2314,2315,2044],{"nctId":32568,"briefTitle":32569,"status":195,"phases":33040,"primaryCompletion":6234,"completion":6234,"start":32571,"enrollment":1586,"conditions":33041,"interventions":33042},[91],[2723],[2314,32504],{"trials":33044,"activeCount":102},[],{"trials":33046,"activeCount":102},[],{"trials":33048,"activeCount":102},[],{"intervention":31784,"totalTrials":1039,"cells":33050},{"EARLY_PHASE1":33051,"PHASE1":33053,"PHASE2":33080,"PHASE3":33093,"PHASE4":33095,"NA":33097},{"trials":33052,"activeCount":102},[],{"trials":33054,"activeCount":102},[33055,33062,33070,33076],{"nctId":33056,"briefTitle":33057,"status":195,"phases":33058,"primaryCompletion":4915,"completion":4915,"start":3827,"enrollment":3717,"conditions":33059,"interventions":33060},"NCT00761501","Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E",[90],[31837],[33061,31784,31784],"PN400",{"nctId":33063,"briefTitle":33064,"status":195,"phases":33065,"primaryCompletion":2542,"completion":2542,"start":2615,"enrollment":2260,"conditions":33066,"interventions":33068},"NCT01358383","Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers",[90],[33067],"Juvenile Idiopathic Arthritis",[33069,19588],"naproxen",{"nctId":33071,"briefTitle":33072,"status":195,"phases":33073,"primaryCompletion":2067,"completion":2067,"start":688,"enrollment":5898,"conditions":33074,"interventions":33075},"NCT00907400","Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E",[90],[19],[33061,31784],{"nctId":31779,"briefTitle":31780,"status":443,"phases":33077,"primaryCompletion":2067,"completion":2067,"start":2151,"enrollment":2222,"conditions":33078,"interventions":33079},[90],[36],[31737,31784],{"trials":33081,"activeCount":102},[33082,33086],{"nctId":31814,"briefTitle":31815,"status":195,"phases":33083,"primaryCompletion":2524,"completion":2524,"start":2251,"enrollment":1510,"conditions":33084,"interventions":33085},[91],[31755],[31737,31784],{"nctId":33087,"briefTitle":33088,"status":195,"phases":33089,"primaryCompletion":2221,"completion":2221,"start":2168,"enrollment":20,"conditions":33090,"interventions":33091},"NCT00659490","Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940",[91],[31755],[33092,31784],"AZD1940",{"trials":33094,"activeCount":102},[],{"trials":33096,"activeCount":102},[],{"trials":33098,"activeCount":102},[],{"intervention":2281,"totalTrials":1039,"cells":33100},{"EARLY_PHASE1":33101,"PHASE1":33103,"PHASE2":33132,"PHASE3":33142,"PHASE4":33144,"NA":33146},{"trials":33102,"activeCount":102},[],{"trials":33104,"activeCount":102},[33105,33111,33117,33121,33128],{"nctId":33106,"briefTitle":33107,"status":195,"phases":33108,"primaryCompletion":10157,"completion":10157,"start":1138,"enrollment":8285,"conditions":33109,"interventions":33110},"NCT04994106","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers",[90],[5851],[2281],{"nctId":33112,"briefTitle":33113,"status":195,"phases":33114,"primaryCompletion":13976,"completion":13976,"start":4098,"enrollment":486,"conditions":33115,"interventions":33116},"NCT06661733","A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment",[90],[2279],[2281],{"nctId":12622,"briefTitle":12623,"status":195,"phases":33118,"primaryCompletion":1497,"completion":1497,"start":12625,"enrollment":579,"conditions":33119,"interventions":33120},[90],[5851],[2281,5870,5887,2198],{"nctId":33122,"briefTitle":33123,"status":195,"phases":33124,"primaryCompletion":12407,"completion":12407,"start":33125,"enrollment":486,"conditions":33126,"interventions":33127},"NCT05512806","A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers",[90],"2022-08-24",[5851],[2281],{"nctId":2274,"briefTitle":2275,"status":443,"phases":33129,"primaryCompletion":2277,"completion":2277,"start":941,"enrollment":370,"conditions":33130,"interventions":33131},[90],[2279,1520],[2281,2044],{"trials":33133,"activeCount":102},[33134],{"nctId":33135,"briefTitle":33136,"status":195,"phases":33137,"primaryCompletion":13945,"completion":13945,"start":33138,"enrollment":2748,"conditions":33139,"interventions":33141},"NCT06299826","A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure",[91],"2024-06-04",[33140],"Chronic Heart Failure",[2281],{"trials":33143,"activeCount":102},[],{"trials":33145,"activeCount":102},[],{"trials":33147,"activeCount":102},[],{"intervention":1925,"totalTrials":723,"cells":33149},{"EARLY_PHASE1":33150,"PHASE1":33152,"PHASE2":33175,"PHASE3":33185,"PHASE4":33187,"NA":33189},{"trials":33151,"activeCount":102},[],{"trials":33153,"activeCount":102},[33154,33158,33167],{"nctId":1913,"briefTitle":1914,"status":195,"phases":33155,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":33156,"interventions":33157},[90],[157,1921,1922,1923],[1925,117,1926,1927,251,369],{"nctId":33159,"briefTitle":33160,"status":195,"phases":33161,"primaryCompletion":33162,"completion":33162,"start":33163,"enrollment":2260,"conditions":33164,"interventions":33166},"NCT04478513","A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers",[90],"2020-12-23","2020-07-21",[33165],"Healthy Volunteer\u002FDDI Study",[1925,7073],{"nctId":33168,"briefTitle":33169,"status":195,"phases":33170,"primaryCompletion":33171,"completion":33171,"start":33172,"enrollment":269,"conditions":33173,"interventions":33174},"NCT03980821","A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies",[90],"2020-09-07","2019-07-04",[157],[1925],{"trials":33176,"activeCount":102},[33177,33181],{"nctId":3141,"briefTitle":3142,"status":195,"phases":33178,"primaryCompletion":3144,"completion":3145,"start":753,"enrollment":1710,"conditions":33179,"interventions":33180},[91],[3147],[1925,117,2032],{"nctId":3203,"briefTitle":3204,"status":195,"phases":33182,"primaryCompletion":3206,"completion":3207,"start":3208,"enrollment":3209,"conditions":33183,"interventions":33184},[91],[416,3211],[1925,251,117],{"trials":33186,"activeCount":102},[],{"trials":33188,"activeCount":102},[],{"trials":33190,"activeCount":102},[],{"intervention":25444,"totalTrials":723,"cells":33192},{"EARLY_PHASE1":33193,"PHASE1":33195,"PHASE2":33221,"PHASE3":33227,"PHASE4":33229,"NA":33231},{"trials":33194,"activeCount":102},[],{"trials":33196,"activeCount":102},[33197,33203,33209,33215],{"nctId":33198,"briefTitle":33199,"status":195,"phases":33200,"primaryCompletion":2406,"completion":2406,"start":2113,"enrollment":1710,"conditions":33201,"interventions":33202},"NCT01116011","Multiple Ascending Dose Study for AZD 7268 in Japanese Healthy Male Volunteers",[90],[19],[25444],{"nctId":33204,"briefTitle":33205,"status":195,"phases":33206,"completion":2077,"start":4915,"enrollment":5898,"conditions":33207,"interventions":33208},"NCT00796965","Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects",[90],[31837],[25444],{"nctId":33210,"briefTitle":33211,"status":195,"phases":33212,"primaryCompletion":2350,"completion":2350,"start":688,"enrollment":2933,"conditions":33213,"interventions":33214},"NCT00912353","AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects",[90],[19],[25444],{"nctId":33216,"briefTitle":33217,"status":195,"phases":33218,"completion":2350,"start":2320,"enrollment":1448,"conditions":33219,"interventions":33220},"NCT00861718","Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers",[90],[19],[25444,25444],{"trials":33222,"activeCount":102},[33223],{"nctId":25439,"briefTitle":25440,"status":195,"phases":33224,"primaryCompletion":2113,"completion":2113,"start":2057,"enrollment":1009,"conditions":33225,"interventions":33226},[91],[18697],[25444,23677],{"trials":33228,"activeCount":102},[],{"trials":33230,"activeCount":102},[],{"trials":33232,"activeCount":102},[],{"intervention":2136,"totalTrials":723,"cells":33234},{"EARLY_PHASE1":33235,"PHASE1":33237,"PHASE2":33266,"PHASE3":33272,"PHASE4":33274,"NA":33276},{"trials":33236,"activeCount":102},[],{"trials":33238,"activeCount":102},[33239,33247,33251,33259],{"nctId":33240,"briefTitle":33241,"status":195,"phases":33242,"primaryCompletion":33243,"completion":33243,"start":33244,"enrollment":1757,"conditions":33245,"interventions":33246},"NCT05112419","A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment",[90],"2021-12-15","2021-11-10",[6914,2279],[2136],{"nctId":2128,"briefTitle":2129,"status":195,"phases":33248,"primaryCompletion":2131,"completion":2131,"start":2132,"enrollment":2003,"conditions":33249,"interventions":33250},[90],[2134],[2136,2044,2137,2138],{"nctId":33252,"briefTitle":33253,"status":195,"phases":33254,"primaryCompletion":33255,"completion":33255,"start":33125,"enrollment":1130,"conditions":33256,"interventions":33258},"NCT05505162","Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.",[90],"2023-01-10",[33257],"Healthy Female Participants",[2136,10177],{"nctId":33260,"briefTitle":33261,"status":195,"phases":33262,"primaryCompletion":1281,"completion":1281,"start":25018,"enrollment":1710,"conditions":33263,"interventions":33265},"NCT06715670","A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants",[90],[33264],"Liver Cirrhosis",[2136],{"trials":33267,"activeCount":102},[33268],{"nctId":2372,"briefTitle":2373,"status":195,"phases":33269,"primaryCompletion":2375,"completion":2375,"start":2376,"enrollment":2377,"conditions":33270,"interventions":33271},[91],[2134],[2136,2044],{"trials":33273,"activeCount":102},[],{"trials":33275,"activeCount":102},[],{"trials":33277,"activeCount":102},[],{"intervention":20243,"totalTrials":723,"cells":33279},{"EARLY_PHASE1":33280,"PHASE1":33282,"PHASE2":33308,"PHASE3":33314,"PHASE4":33316,"NA":33318},{"trials":33281,"activeCount":102},[],{"trials":33283,"activeCount":102},[33284,33290,33296,33302],{"nctId":33285,"briefTitle":33286,"status":195,"phases":33287,"primaryCompletion":2056,"completion":2056,"start":2350,"enrollment":32329,"conditions":33288,"interventions":33289},"NCT00979849","AZD8683 Single Ascending Dose Study",[90],[36],[20243],{"nctId":33291,"briefTitle":33292,"status":624,"phases":33293,"primaryCompletion":2443,"completion":2443,"start":2104,"enrollment":102,"conditions":33294,"interventions":33295},"NCT01666613","A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways",[90],[19],[20243,20243,20243,20243],{"nctId":33297,"briefTitle":33298,"status":443,"phases":33299,"primaryCompletion":2104,"completion":2104,"start":2471,"enrollment":1710,"conditions":33300,"interventions":33301},"NCT01584739","AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients",[90],[10066],[20243],{"nctId":33303,"briefTitle":33304,"status":195,"phases":33305,"primaryCompletion":10063,"completion":10063,"start":2736,"enrollment":3717,"conditions":33306,"interventions":33307},"NCT01419600","To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683",[90],[19],[20243],{"trials":33309,"activeCount":102},[33310],{"nctId":20238,"briefTitle":20239,"status":443,"phases":33311,"primaryCompletion":2616,"completion":2616,"start":2365,"enrollment":3887,"conditions":33312,"interventions":33313},[91],[28,10066],[20243,10026],{"trials":33315,"activeCount":102},[],{"trials":33317,"activeCount":102},[],{"trials":33319,"activeCount":102},[],{"intervention":33321,"totalTrials":723,"cells":33322},"AZD5213",{"EARLY_PHASE1":33323,"PHASE1":33325,"PHASE2":33353,"PHASE3":33364,"PHASE4":33366,"NA":33368},{"trials":33324,"activeCount":102},[],{"trials":33326,"activeCount":102},[33327,33333,33340,33347],{"nctId":33328,"briefTitle":33329,"status":195,"phases":33330,"primaryCompletion":2736,"completion":2736,"start":12721,"enrollment":5898,"conditions":33331,"interventions":33332},"NCT01335451","Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects",[90],[19],[33321],{"nctId":33334,"briefTitle":33335,"status":195,"phases":33336,"primaryCompletion":2542,"completion":2542,"start":2349,"enrollment":963,"conditions":33337,"interventions":33339},"NCT01194986","Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration",[90],[33338],"Brain Distribution of [11C]AZ12807110 and AZD5213",[33321],{"nctId":33341,"briefTitle":33342,"status":195,"phases":33343,"primaryCompletion":2615,"completion":2615,"start":2406,"enrollment":33344,"conditions":33345,"interventions":33346},"NCT01171105","Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects",[90],73,[19],[33321],{"nctId":33348,"briefTitle":33349,"status":195,"phases":33350,"primaryCompletion":2143,"completion":2143,"start":2243,"enrollment":4917,"conditions":33351,"interventions":33352},"NCT01121302","Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects",[90],[24601],[33321],{"trials":33354,"activeCount":102},[33355],{"nctId":33356,"briefTitle":33357,"status":195,"phases":33358,"primaryCompletion":2579,"completion":2579,"start":4496,"enrollment":33359,"conditions":33360,"interventions":33363},"NCT01548287","A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's\u002FCognitive Impairment",[91],164,[33361,33362],"Mild Cognitive Impairment","Mild Alzheimer's Disease",[33321,33321,33321],{"trials":33365,"activeCount":102},[],{"trials":33367,"activeCount":102},[],{"trials":33369,"activeCount":102},[],{"intervention":33371,"totalTrials":723,"cells":33372},"AZD2693",{"EARLY_PHASE1":33373,"PHASE1":33375,"PHASE2":33407,"PHASE3":33418,"PHASE4":33420,"NA":33422},{"trials":33374,"activeCount":102},[],{"trials":33376,"activeCount":102},[33377,33386,33392,33400],{"nctId":33378,"briefTitle":33379,"status":195,"phases":33380,"primaryCompletion":33381,"completion":33381,"start":33382,"enrollment":12547,"conditions":33383,"interventions":33385},"NCT04483947","A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients",[90],"2023-12-18","2020-11-06",[33384],"Non-alcoholic Steatohepatitis (NASH)",[33371],{"nctId":33387,"briefTitle":33388,"status":195,"phases":33389,"primaryCompletion":8378,"completion":8378,"start":197,"enrollment":1348,"conditions":33390,"interventions":33391},"NCT05919069","A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693",[90],[6914],[33371],{"nctId":33393,"briefTitle":33394,"status":195,"phases":33395,"primaryCompletion":8368,"completion":8368,"start":33396,"enrollment":33344,"conditions":33397,"interventions":33399},"NCT04142424","A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects",[90],"2019-10-28",[33398,12328],"Metabolic Disorders",[33371],{"nctId":33401,"briefTitle":33402,"status":195,"phases":33403,"primaryCompletion":26424,"completion":26424,"start":33404,"enrollment":3811,"conditions":33405,"interventions":33406},"NCT05107336","Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants",[90],"2021-11-25",[5851],[33371],{"trials":33408,"activeCount":102},[33409],{"nctId":33410,"briefTitle":33411,"status":195,"phases":33412,"primaryCompletion":33413,"completion":13934,"start":33414,"enrollment":1832,"conditions":33415,"interventions":33417},"NCT05809934","A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis",[91],"2025-07-14","2023-03-15",[33416],"Nonalcoholic Steatohepatitis",[33371],{"trials":33419,"activeCount":102},[],{"trials":33421,"activeCount":102},[],{"trials":33423,"activeCount":102},[],{"intervention":23241,"totalTrials":723,"cells":33425},{"EARLY_PHASE1":33426,"PHASE1":33428,"PHASE2":33442,"PHASE3":33458,"PHASE4":33460,"NA":33462},{"trials":33427,"activeCount":102},[],{"trials":33429,"activeCount":102},[33430,33436],{"nctId":33431,"briefTitle":33432,"status":195,"phases":33433,"primaryCompletion":2414,"completion":2414,"start":2220,"enrollment":2003,"conditions":33434,"interventions":33435},"NCT00713271","Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men",[90],[36],[23241,23241,23241],{"nctId":33437,"briefTitle":33438,"status":195,"phases":33439,"primaryCompletion":2433,"completion":2433,"start":2349,"enrollment":1448,"conditions":33440,"interventions":33441},"NCT01222442","To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart",[90],[28,31984],[23241,2255],{"trials":33443,"activeCount":102},[33444,33448,33454],{"nctId":23235,"briefTitle":23236,"status":195,"phases":33445,"primaryCompletion":2212,"completion":2212,"start":2152,"enrollment":23238,"conditions":33446,"interventions":33447},[91],[10066],[23241,9866],{"nctId":33449,"briefTitle":33450,"status":195,"phases":33451,"primaryCompletion":2366,"completion":2366,"start":2615,"enrollment":3190,"conditions":33452,"interventions":33453},"NCT01348139","Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma",[91],[16],[23241,23241],{"nctId":23247,"briefTitle":23248,"status":195,"phases":33455,"primaryCompletion":4915,"completion":4915,"start":2220,"enrollment":1543,"conditions":33456,"interventions":33457},[91],[16,23251],[23241,9882],{"trials":33459,"activeCount":102},[],{"trials":33461,"activeCount":102},[],{"trials":33463,"activeCount":102},[],{"intervention":3914,"totalTrials":723,"cells":33465},{"EARLY_PHASE1":33466,"PHASE1":33468,"PHASE2":33489,"PHASE3":33504,"PHASE4":33506,"NA":33508},{"trials":33467,"activeCount":102},[],{"trials":33469,"activeCount":102},[33470,33474,33481],{"nctId":16306,"briefTitle":16307,"status":443,"phases":33471,"primaryCompletion":16309,"completion":16309,"start":3072,"enrollment":723,"conditions":33472,"interventions":33473},[90],[498],[3914,5911,7055,8361],{"nctId":33475,"briefTitle":33476,"status":443,"phases":33477,"primaryCompletion":33478,"completion":33478,"start":1228,"enrollment":3887,"conditions":33479,"interventions":33480},"NCT04949425","A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours",[90],"2022-04-21",[498],[3914],{"nctId":33482,"briefTitle":33483,"status":195,"phases":33484,"primaryCompletion":33485,"completion":33485,"start":33486,"enrollment":1039,"conditions":33487,"interventions":33488},"NCT04462952","Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours",[90],"2021-09-22","2020-06-24",[498],[3914],{"trials":33490,"activeCount":102},[33491,33495],{"nctId":3905,"briefTitle":3906,"status":195,"phases":33492,"primaryCompletion":3908,"completion":3909,"start":3910,"enrollment":29,"conditions":33493,"interventions":33494},[91],[3912],[3914,118,344,283,3915],{"nctId":33496,"briefTitle":33497,"status":195,"phases":33498,"primaryCompletion":33499,"completion":33500,"start":3383,"enrollment":18672,"conditions":33501,"interventions":33503},"NCT04590248","A Study of Adavosertib as Treatment for Uterine Serous Carcinoma",[91],"2022-05-23","2023-02-07",[33502],"Uterine Serous Carcinoma",[3914],{"trials":33505,"activeCount":102},[],{"trials":33507,"activeCount":102},[],{"trials":33509,"activeCount":102},[],{"intervention":19001,"totalTrials":723,"cells":33511},{"EARLY_PHASE1":33512,"PHASE1":33514,"PHASE2":33534,"PHASE3":33551,"PHASE4":33553,"NA":33555},{"trials":33513,"activeCount":102},[],{"trials":33515,"activeCount":102},[33516,33523,33530],{"nctId":33517,"briefTitle":33518,"status":195,"phases":33519,"primaryCompletion":12160,"completion":12160,"start":33520,"enrollment":689,"conditions":33521,"interventions":33522},"NCT05470725","Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function",[90],"2021-01-12",[2620],[19001],{"nctId":33524,"briefTitle":33525,"status":195,"phases":33526,"primaryCompletion":14061,"completion":14061,"start":33527,"enrollment":2933,"conditions":33528,"interventions":33529},"NCT05500820","Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects",[90],"2019-12-19",[2620],[19001],{"nctId":18995,"briefTitle":18996,"status":195,"phases":33531,"primaryCompletion":18998,"completion":18998,"start":5529,"enrollment":2003,"conditions":33532,"interventions":33533},[90],[2620],[2173,19001],{"trials":33535,"activeCount":102},[33536,33545],{"nctId":33537,"briefTitle":33538,"status":195,"phases":33539,"primaryCompletion":33540,"completion":33540,"start":6234,"enrollment":33541,"conditions":33542,"interventions":33544},"NCT05432167","A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease",[91],"2024-05-02",195,[10187,33543],"Chronic Kidney Diseases",[19001],{"nctId":33546,"briefTitle":33547,"status":195,"phases":33548,"primaryCompletion":988,"completion":988,"start":7647,"enrollment":3125,"conditions":33549,"interventions":33550},"NCT05459688","Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124",[91],[2620],[19001],{"trials":33552,"activeCount":102},[],{"trials":33554,"activeCount":102},[],{"trials":33556,"activeCount":102},[],{"intervention":33558,"totalTrials":723,"cells":33559},"AZD4017",{"EARLY_PHASE1":33560,"PHASE1":33562,"PHASE2":33588,"PHASE3":33597,"PHASE4":33599,"NA":33601},{"trials":33561,"activeCount":102},[],{"trials":33563,"activeCount":102},[33564,33570,33576,33582],{"nctId":33565,"briefTitle":33566,"status":195,"phases":33567,"completion":2077,"start":2414,"enrollment":1448,"conditions":33568,"interventions":33569},"NCT00791752","Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017",[90],[19],[33558],{"nctId":33571,"briefTitle":33572,"status":195,"phases":33573,"completion":2320,"start":4915,"enrollment":2933,"conditions":33574,"interventions":33575},"NCT00799747","Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.",[90],[19],[33558],{"nctId":33577,"briefTitle":33578,"status":195,"phases":33579,"completion":688,"start":2095,"enrollment":20666,"conditions":33580,"interventions":33581},"NCT00841048","Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses",[90],[2803],[33558],{"nctId":33583,"briefTitle":33584,"status":195,"phases":33585,"primaryCompletion":2243,"completion":2243,"start":2212,"enrollment":520,"conditions":33586,"interventions":33587},"NCT01096004","Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue",[90],[12275],[33558],{"trials":33589,"activeCount":102},[33590],{"nctId":33591,"briefTitle":33592,"status":195,"phases":33593,"primaryCompletion":2104,"completion":2104,"start":2143,"enrollment":4286,"conditions":33594,"interventions":33596},"NCT01173471","A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure",[91],[33595],"Raised Intraocular Pressure",[33558,33558],{"trials":33598,"activeCount":102},[],{"trials":33600,"activeCount":102},[],{"trials":33602,"activeCount":102},[],{"intervention":33604,"totalTrials":1979,"cells":33605},"AZD8233",{"EARLY_PHASE1":33606,"PHASE1":33608,"PHASE2":33627,"PHASE3":33646,"PHASE4":33648,"NA":33650},{"trials":33607,"activeCount":102},[],{"trials":33609,"activeCount":102},[33610,33618],{"nctId":33611,"briefTitle":33612,"status":195,"phases":33613,"primaryCompletion":33614,"completion":33614,"start":33615,"enrollment":33344,"conditions":33616,"interventions":33617},"NCT03593785","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.",[90],"2020-12-19","2018-08-03",[12760],[33604],{"nctId":33619,"briefTitle":33620,"status":443,"phases":33621,"primaryCompletion":33622,"completion":33622,"start":33623,"enrollment":3887,"conditions":33624,"interventions":33626},"NCT05065463","To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.",[90],"2022-11-23","2022-08-10",[33625],"End Stage Renal Disease",[33604],{"trials":33628,"activeCount":102},[33629,33639],{"nctId":33630,"briefTitle":33631,"status":195,"phases":33632,"primaryCompletion":33633,"completion":33633,"start":33634,"enrollment":33635,"conditions":33636,"interventions":33638},"NCT04964557","A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia",[91],"2022-07-15","2021-07-07",411,[33637],"Hyperlipidaemia",[33604],{"nctId":33640,"briefTitle":33641,"status":195,"phases":33642,"primaryCompletion":33643,"completion":33643,"start":5529,"enrollment":990,"conditions":33644,"interventions":33645},"NCT04641299","A Study of AZD8233 in Participants With Dyslipidemia",[91],"2021-07-20",[6873],[33604],{"trials":33647,"activeCount":102},[],{"trials":33649,"activeCount":102},[],{"trials":33651,"activeCount":102},[],{"intervention":33653,"totalTrials":1979,"cells":33654},"AZD1236",{"EARLY_PHASE1":33655,"PHASE1":33657,"PHASE2":33665,"PHASE3":33685,"PHASE4":33687,"NA":33689},{"trials":33656,"activeCount":102},[],{"trials":33658,"activeCount":102},[33659],{"nctId":33660,"briefTitle":33661,"status":195,"phases":33662,"completion":4915,"start":3827,"enrollment":5898,"conditions":33663,"interventions":33664},"NCT00767052","Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236",[90],[31837],[33653,33653,33653],{"trials":33666,"activeCount":102},[33667,33673,33679],{"nctId":33668,"briefTitle":33669,"status":195,"phases":33670,"primaryCompletion":688,"completion":688,"start":3827,"enrollment":2783,"conditions":33671,"interventions":33672},"NCT00758706","A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],[28],[33653],{"nctId":33674,"briefTitle":33675,"status":624,"phases":33676,"completion":2144,"start":2055,"enrollment":3811,"conditions":33677,"interventions":33678},"NCT00812045","Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis",[91],[32133],[33653],{"nctId":33680,"briefTitle":33681,"status":195,"phases":33682,"completion":2077,"start":3827,"enrollment":12547,"conditions":33683,"interventions":33684},"NCT00758459","Safety\u002FTolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],[28],[33653],{"trials":33686,"activeCount":102},[],{"trials":33688,"activeCount":102},[],{"trials":33690,"activeCount":102},[],{"intervention":20876,"totalTrials":1979,"cells":33692},{"EARLY_PHASE1":33693,"PHASE1":33695,"PHASE2":33714,"PHASE3":33724,"PHASE4":33726,"NA":33728},{"trials":33694,"activeCount":102},[],{"trials":33696,"activeCount":102},[33697,33701,33707],{"nctId":20869,"briefTitle":20870,"status":195,"phases":33698,"primaryCompletion":20872,"completion":20872,"start":20873,"enrollment":3855,"conditions":33699,"interventions":33700},[90],[36],[20876,20862],{"nctId":33702,"briefTitle":33703,"status":195,"phases":33704,"primaryCompletion":2481,"completion":2481,"start":2736,"enrollment":579,"conditions":33705,"interventions":33706},"NCT01445782","AZD2115 Multiple Ascending Dose Study",[90],[19],[20876],{"nctId":33708,"briefTitle":33709,"status":195,"phases":33710,"primaryCompletion":2675,"completion":2675,"start":2516,"enrollment":14210,"conditions":33711,"interventions":33713},"NCT01283984","AZD2115 Single Ascending Dose Study",[90],[28,33712],"Lung Disease Causing Persistent Narrowing of the Airways",[20876],{"trials":33715,"activeCount":102},[33716],{"nctId":33717,"briefTitle":33718,"status":195,"phases":33719,"primaryCompletion":2365,"completion":2365,"start":687,"enrollment":3190,"conditions":33720,"interventions":33721},"NCT01498081","A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients",[91],[10066],[20876,33722,33723],"Indacaterol","Indacaterol + Tiotropium",{"trials":33725,"activeCount":102},[],{"trials":33727,"activeCount":102},[],{"trials":33729,"activeCount":102},[],{"intervention":24269,"totalTrials":1979,"cells":33731},{"EARLY_PHASE1":33732,"PHASE1":33734,"PHASE2":33749,"PHASE3":33764,"PHASE4":33766,"NA":33768},{"trials":33733,"activeCount":102},[],{"trials":33735,"activeCount":102},[33736,33742],{"nctId":33737,"briefTitle":33738,"status":195,"phases":33739,"primaryCompletion":5906,"completion":5906,"start":5907,"enrollment":486,"conditions":33740,"interventions":33741},"NCT04734275","Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers",[90],[2134],[24269],{"nctId":33743,"briefTitle":33744,"status":195,"phases":33745,"primaryCompletion":3634,"completion":3634,"start":33746,"enrollment":1638,"conditions":33747,"interventions":33748},"NCT04492709","A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects",[90],"2020-07-30",[2619],[5870,24269],{"trials":33750,"activeCount":102},[33751,33760],{"nctId":33752,"briefTitle":33753,"status":195,"phases":33754,"primaryCompletion":33755,"completion":33755,"start":33756,"enrollment":33757,"conditions":33758,"interventions":33759},"NCT03317002","AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).",[91],"2020-04-08","2017-10-30",129,[12734],[24269,24269],{"nctId":24262,"briefTitle":24263,"status":443,"phases":33761,"primaryCompletion":1023,"completion":1023,"start":24265,"enrollment":24266,"conditions":33762,"interventions":33763},[91],[2134],[24269,19116],{"trials":33765,"activeCount":102},[],{"trials":33767,"activeCount":102},[],{"trials":33769,"activeCount":102},[],{"intervention":33771,"totalTrials":1979,"cells":33772},"Cotadutide",{"EARLY_PHASE1":33773,"PHASE1":33775,"PHASE2":33801,"PHASE3":33812,"PHASE4":33814,"NA":33816},{"trials":33774,"activeCount":102},[],{"trials":33776,"activeCount":102},[33777,33787,33793],{"nctId":33778,"briefTitle":33779,"status":443,"phases":33780,"primaryCompletion":33781,"completion":33781,"start":33782,"enrollment":3248,"conditions":33783,"interventions":33784},"NCT05668936","A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants",[90],"2023-03-10","2023-01-03",[12328],[33771,33785,2255,33786],"Cotadutide-placebo","Moxifloxacin-placebo",{"nctId":33788,"briefTitle":33789,"status":443,"phases":33790,"primaryCompletion":30887,"completion":30887,"start":1023,"enrollment":1130,"conditions":33791,"interventions":33792},"NCT05517226","Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment",[90],[6914],[33771],{"nctId":33794,"briefTitle":33795,"status":195,"phases":33796,"primaryCompletion":33797,"completion":33797,"start":33798,"enrollment":486,"conditions":33799,"interventions":33800},"NCT04208620","Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus",[90],"2020-07-08","2020-01-21",[31],[33771],{"trials":33802,"activeCount":102},[33803],{"nctId":33804,"briefTitle":33805,"status":195,"phases":33806,"primaryCompletion":33807,"completion":33807,"start":33808,"enrollment":680,"conditions":33809,"interventions":33811},"NCT05364931","A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis",[91],"2024-04-19","2022-07-14",[33810],"Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis",[33771],{"trials":33813,"activeCount":102},[],{"trials":33815,"activeCount":102},[],{"trials":33817,"activeCount":102},[],{"intervention":33819,"totalTrials":1979,"cells":33820},"AZD4604",{"EARLY_PHASE1":33821,"PHASE1":33823,"PHASE2":33838,"PHASE3":33855,"PHASE4":33857,"NA":33859},{"trials":33822,"activeCount":102},[],{"trials":33824,"activeCount":102},[33825,33832],{"nctId":33826,"briefTitle":33827,"status":195,"phases":33828,"primaryCompletion":33829,"completion":33829,"start":12184,"enrollment":2933,"conditions":33830,"interventions":33831},"NCT06519968","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.",[90],"2024-12-27",[5851],[33819],{"nctId":33833,"briefTitle":33834,"status":195,"phases":33835,"primaryCompletion":2277,"completion":2277,"start":1446,"enrollment":2260,"conditions":33836,"interventions":33837},"NCT06732882","Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.",[90],[16],[33819],{"trials":33839,"activeCount":102},[33840,33846],{"nctId":33841,"briefTitle":33842,"status":195,"phases":33843,"primaryCompletion":7737,"completion":7737,"start":7696,"enrollment":496,"conditions":33844,"interventions":33845},"NCT06435273","Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma",[91],[16],[33819],{"nctId":33847,"briefTitle":33848,"status":195,"phases":33849,"primaryCompletion":33850,"completion":33850,"start":33851,"enrollment":33852,"conditions":33853,"interventions":33854},"NCT06020014","Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA",[91],"2025-10-28","2023-11-16",339,[16],[33819],{"trials":33856,"activeCount":102},[],{"trials":33858,"activeCount":102},[],{"trials":33860,"activeCount":102},[],{"intervention":33862,"totalTrials":1979,"cells":33863},"AZD8630",{"EARLY_PHASE1":33864,"PHASE1":33866,"PHASE2":33891,"PHASE3":33902,"PHASE4":33904,"NA":33906},{"trials":33865,"activeCount":102},[],{"trials":33867,"activeCount":102},[33868,33876,33884],{"nctId":33869,"briefTitle":33870,"status":195,"phases":33871,"primaryCompletion":33872,"completion":33872,"start":33873,"enrollment":269,"conditions":33874,"interventions":33875},"NCT07065331","A Study of Inhaled AZD8630 in Adolescents With Asthma",[90],"2025-09-19","2025-06-11",[16],[33862],{"nctId":33877,"briefTitle":33878,"status":195,"phases":33879,"primaryCompletion":33880,"completion":33880,"start":33881,"enrollment":22483,"conditions":33882,"interventions":33883},"NCT05110976","A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists",[90],"2023-08-02","2021-12-16",[16],[33862],{"nctId":33885,"briefTitle":33886,"status":195,"phases":33887,"primaryCompletion":13908,"completion":13908,"start":33888,"enrollment":1130,"conditions":33889,"interventions":33890},"NCT06795906","A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma",[90],"2025-01-28",[16],[33862],{"trials":33892,"activeCount":102},[33893],{"nctId":33894,"briefTitle":33895,"status":195,"phases":33896,"primaryCompletion":33897,"completion":33897,"start":33898,"enrollment":33899,"conditions":33900,"interventions":33901},"NCT06529419","A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations",[91],"2026-02-04","2024-08-30",537,[16],[33862],{"trials":33903,"activeCount":102},[],{"trials":33905,"activeCount":102},[],{"trials":33907,"activeCount":102},[],{"intervention":33909,"totalTrials":1979,"cells":33910},"AZD0328",{"EARLY_PHASE1":33911,"PHASE1":33913,"PHASE2":33933,"PHASE3":33941,"PHASE4":33943,"NA":33945},{"trials":33912,"activeCount":102},[],{"trials":33914,"activeCount":102},[33915,33921,33927],{"nctId":33916,"briefTitle":33917,"status":195,"phases":33918,"primaryCompletion":2086,"completion":2086,"start":3827,"enrollment":1638,"conditions":33919,"interventions":33920},"NCT00752830","To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328",[90],[19],[33909],{"nctId":33922,"briefTitle":33923,"status":195,"phases":33924,"primaryCompletion":2086,"completion":2086,"start":2524,"enrollment":4307,"conditions":33925,"interventions":33926},"NCT00738959","Safety, Tolerability & PK of AZD0328 in Caucasian & Japanese",[90],[36],[33909],{"nctId":33928,"briefTitle":33929,"status":195,"phases":33930,"primaryCompletion":2524,"completion":2524,"start":2169,"enrollment":8138,"conditions":33931,"interventions":33932},"NCT00687141","Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects",[90],[18867],[33909],{"trials":33934,"activeCount":102},[33935],{"nctId":33936,"briefTitle":33937,"status":443,"phases":33938,"primaryCompletion":2414,"completion":2414,"start":2251,"enrollment":221,"conditions":33939,"interventions":33940},"NCT00669903","Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia",[91],[33],[33909],{"trials":33942,"activeCount":102},[],{"trials":33944,"activeCount":102},[],{"trials":33946,"activeCount":102},[],{"intervention":2344,"totalTrials":1979,"cells":33948},{"EARLY_PHASE1":33949,"PHASE1":33951,"PHASE2":33959,"PHASE3":33981,"PHASE4":33983,"NA":33985},{"trials":33950,"activeCount":102},[],{"trials":33952,"activeCount":102},[33953],{"nctId":33954,"briefTitle":33955,"status":195,"phases":33956,"primaryCompletion":3392,"completion":3392,"start":6151,"enrollment":3190,"conditions":33957,"interventions":33958},"NCT05070312","Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants",[90],[31837],[2344],{"trials":33960,"activeCount":102},[33961,33969,33973],{"nctId":33962,"briefTitle":33963,"status":195,"phases":33964,"primaryCompletion":33965,"completion":10157,"start":33966,"enrollment":3484,"conditions":33967,"interventions":33968},"NCT04212169","Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis",[91],"2022-07-21","2019-12-09",[1577],[2344],{"nctId":2335,"briefTitle":2336,"status":195,"phases":33970,"primaryCompletion":2338,"completion":2338,"start":2339,"enrollment":2340,"conditions":33971,"interventions":33972},[91],[2342],[2344,2044],{"nctId":33974,"briefTitle":33975,"status":195,"phases":33976,"primaryCompletion":33977,"completion":1597,"start":33978,"enrollment":10196,"conditions":33979,"interventions":33980},"NCT04570657","Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma",[91],"2022-12-12","2020-09-17",[16],[2344],{"trials":33982,"activeCount":102},[],{"trials":33984,"activeCount":102},[],{"trials":33986,"activeCount":102},[],{"intervention":31839,"totalTrials":1979,"cells":33988},{"EARLY_PHASE1":33989,"PHASE1":33991,"PHASE2":34008,"PHASE3":34014,"PHASE4":34016,"NA":34018},{"trials":33990,"activeCount":102},[],{"trials":33992,"activeCount":102},[33993,34000,34004],{"nctId":33994,"briefTitle":33995,"status":195,"phases":33996,"completion":4915,"start":3827,"enrollment":4497,"conditions":33997,"interventions":33998},"NCT00750802","A Sedation\u002FCognition\u002FEEG Study Using AZD6280 and Comparator",[90],[31837],[33999,33999,31839],"AZD6280",{"nctId":31833,"briefTitle":31834,"status":195,"phases":34001,"primaryCompletion":2220,"completion":2220,"start":2524,"enrollment":486,"conditions":34002,"interventions":34003},[90],[31837],[31826,31826,31826,31839,31839],{"nctId":31859,"briefTitle":31860,"status":195,"phases":34005,"completion":2067,"start":688,"enrollment":221,"conditions":34006,"interventions":34007},[90],[31863],[31839,31826],{"trials":34009,"activeCount":102},[34010],{"nctId":31905,"briefTitle":31906,"status":195,"phases":34011,"primaryCompletion":688,"completion":688,"start":4915,"enrollment":31908,"conditions":34012,"interventions":34013},[91],[20021],[31826,31826,31839],{"trials":34015,"activeCount":102},[],{"trials":34017,"activeCount":102},[],{"trials":34019,"activeCount":102},[],{"intervention":34021,"totalTrials":1979,"cells":34022},"AZD3427",{"EARLY_PHASE1":34023,"PHASE1":34025,"PHASE2":34048,"PHASE3":34058,"PHASE4":34060,"NA":34062},{"trials":34024,"activeCount":102},[],{"trials":34026,"activeCount":102},[34027,34035,34042],{"nctId":34028,"briefTitle":34029,"status":443,"phases":34030,"primaryCompletion":34031,"completion":34031,"start":1047,"enrollment":269,"conditions":34032,"interventions":34033},"NCT06611423","AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment",[90],"2025-08-21",[2661,2279],[34021,34034],"Dopamine",{"nctId":34036,"briefTitle":34037,"status":624,"phases":34038,"primaryCompletion":28745,"completion":28745,"start":34039,"enrollment":102,"conditions":34040,"interventions":34041},"NCT04890548","Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure",[90],"2021-11-23",[1520],[34021],{"nctId":34043,"briefTitle":34044,"status":195,"phases":34045,"primaryCompletion":12140,"completion":12140,"start":1383,"enrollment":1428,"conditions":34046,"interventions":34047},"NCT04630067","Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427",[90],[1520],[34021],{"trials":34049,"activeCount":102},[34050],{"nctId":34051,"briefTitle":34052,"status":195,"phases":34053,"primaryCompletion":15604,"completion":4139,"start":4319,"enrollment":34054,"conditions":34055,"interventions":34057},"NCT05737940","A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2",[91],260,[34056,1520],"Pulmonary Hypertension (World Health Organization Group 2)",[34021],{"trials":34059,"activeCount":102},[],{"trials":34061,"activeCount":102},[],{"trials":34063,"activeCount":102},[],{"intervention":20236,"totalTrials":3887,"cells":34065},{"EARLY_PHASE1":34066,"PHASE1":34068,"PHASE2":34082,"PHASE3":34088,"PHASE4":34090,"NA":34092},{"trials":34067,"activeCount":102},[],{"trials":34069,"activeCount":102},[34070,34076],{"nctId":34071,"briefTitle":34072,"status":195,"phases":34073,"completion":2320,"start":2095,"enrollment":5189,"conditions":34074,"interventions":34075},"NCT00847249","AZD9164 Single Ascending Dose Study in Healthy Male Subjects",[90],[19],[20236],{"nctId":34077,"briefTitle":34078,"status":443,"phases":34079,"primaryCompletion":2242,"completion":2242,"start":2212,"enrollment":2003,"conditions":34080,"interventions":34081},"NCT01096563","A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects",[90],[19],[20236],{"trials":34083,"activeCount":102},[34084],{"nctId":20231,"briefTitle":20232,"status":195,"phases":34085,"primaryCompletion":2057,"completion":2057,"start":2152,"enrollment":98,"conditions":34086,"interventions":34087},[91],[28],[20236,10026],{"trials":34089,"activeCount":102},[],{"trials":34091,"activeCount":102},[],{"trials":34093,"activeCount":102},[],{"intervention":1452,"totalTrials":3887,"cells":34095},{"EARLY_PHASE1":34096,"PHASE1":34098,"PHASE2":34112,"PHASE3":34128,"PHASE4":34130,"NA":34132},{"trials":34097,"activeCount":102},[],{"trials":34099,"activeCount":102},[34100],{"nctId":34101,"briefTitle":34102,"status":195,"phases":34103,"primaryCompletion":12170,"completion":12170,"start":12091,"enrollment":3811,"conditions":34104,"interventions":34111},"NCT03263637","Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed\u002FRefractory Haematological Malignancies",[90],[34105,23859,34106,1408,34107,34108,34109,1465,34110,1409,7892],"Relapsed or Refractory Haematological Malignancies Including","Acute Lymphocytic Leukemia","High Risk Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia","Richter's Syndrome","T-cell Non-Hodgkin Lymphoma",[1452],{"trials":34113,"activeCount":102},[34114,34124],{"nctId":34115,"briefTitle":34116,"status":195,"phases":34117,"primaryCompletion":34118,"completion":34119,"start":33243,"enrollment":14693,"conditions":34120,"interventions":34123},"NCT05140382","AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r\u002Fr PTCL or r\u002Fr cHL",[91],"2023-08-25","2024-02-16",[34121,34122],"Relapsed\u002FRefractory Peripheral T-cell Lymphoma","Relapsed\u002FRefractory Classical Hodgkins Lymphoma",[1452],{"nctId":1442,"briefTitle":1443,"status":195,"phases":34125,"primaryCompletion":1445,"completion":1446,"start":1447,"enrollment":1448,"conditions":34126,"interventions":34127},[90,91],[1450],[1452,1335],{"trials":34129,"activeCount":102},[],{"trials":34131,"activeCount":102},[],{"trials":34133,"activeCount":102},[],{"intervention":34135,"totalTrials":3887,"cells":34136},"AZD8871",{"EARLY_PHASE1":34137,"PHASE1":34139,"PHASE2":34155,"PHASE3":34165,"PHASE4":34167,"NA":34169},{"trials":34138,"activeCount":102},[],{"trials":34140,"activeCount":102},[34141,34148],{"nctId":34142,"briefTitle":34143,"status":195,"phases":34144,"primaryCompletion":34145,"completion":34145,"start":2756,"enrollment":1130,"conditions":34146,"interventions":34147},"NCT02814656","Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects",[90],"2016-11-28",[28],[34135],{"nctId":34149,"briefTitle":34150,"status":195,"phases":34151,"primaryCompletion":34152,"completion":34152,"start":27464,"enrollment":98,"conditions":34153,"interventions":34154},"NCT03159442","Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects",[90],"2017-10-13",[24040],[34135],{"trials":34156,"activeCount":102},[34157],{"nctId":34158,"briefTitle":34159,"status":195,"phases":34160,"primaryCompletion":34161,"completion":34161,"start":849,"enrollment":33344,"conditions":34162,"interventions":34163},"NCT03645434","A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.",[91],"2019-08-07",[28],[34135,34164],"Anoro® Ellipta®",{"trials":34166,"activeCount":102},[],{"trials":34168,"activeCount":102},[],{"trials":34170,"activeCount":102},[],{"intervention":34172,"totalTrials":3887,"cells":34173},"AZD9773",{"EARLY_PHASE1":34174,"PHASE1":34176,"PHASE2":34178,"PHASE3":34200,"PHASE4":34202,"NA":34204},{"trials":34175,"activeCount":102},[],{"trials":34177,"activeCount":102},[],{"trials":34179,"activeCount":102},[34180,34187,34194],{"nctId":34181,"briefTitle":34182,"status":195,"phases":34183,"primaryCompletion":2068,"completion":2068,"start":6710,"enrollment":3476,"conditions":34184,"interventions":34186},"NCT00615017","AZD9773 Dose Escalation Study",[91],[34185],"Severe Sepsis",[34172],{"nctId":34188,"briefTitle":34189,"status":195,"phases":34190,"primaryCompletion":2675,"completion":2675,"start":2406,"enrollment":5876,"conditions":34191,"interventions":34193},"NCT01144624","A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis\u002FSeptic Shock",[91],[34185,34192],"Septic Shock",[34172],{"nctId":34195,"briefTitle":34196,"status":195,"phases":34197,"primaryCompletion":10063,"completion":10063,"start":2489,"enrollment":12425,"conditions":34198,"interventions":34199},"NCT01145560","A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and\u002For Septic Shock",[91],[34185,34192],[34172],{"trials":34201,"activeCount":102},[],{"trials":34203,"activeCount":102},[],{"trials":34205,"activeCount":102},[],{"intervention":34207,"totalTrials":3887,"cells":34208},"AZD3241",{"EARLY_PHASE1":34209,"PHASE1":34211,"PHASE2":34225,"PHASE3":34234,"PHASE4":34236,"NA":34238},{"trials":34210,"activeCount":102},[],{"trials":34212,"activeCount":102},[34213,34219],{"nctId":34214,"briefTitle":34215,"status":195,"phases":34216,"primaryCompletion":2212,"completion":2212,"start":2152,"enrollment":6652,"conditions":34217,"interventions":34218},"NCT00914303","Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241",[90],[19],[34207],{"nctId":34220,"briefTitle":34221,"status":195,"phases":34222,"primaryCompletion":2414,"completion":2414,"start":2507,"enrollment":4307,"conditions":34223,"interventions":34224},"NCT00729443","Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers",[90],[36],[34207],{"trials":34226,"activeCount":102},[34227],{"nctId":34228,"briefTitle":34229,"status":195,"phases":34230,"primaryCompletion":72,"completion":72,"start":1608,"enrollment":3209,"conditions":34231,"interventions":34233},"NCT02388295","AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients",[91],[34232],"Multiple System Atrophy, MSA",[34207],{"trials":34235,"activeCount":102},[],{"trials":34237,"activeCount":102},[],{"trials":34239,"activeCount":102},[],{"intervention":10318,"totalTrials":3887,"cells":34241},{"EARLY_PHASE1":34242,"PHASE1":34244,"PHASE2":34256,"PHASE3":34264,"PHASE4":34266,"NA":34268},{"trials":34243,"activeCount":102},[],{"trials":34245,"activeCount":102},[34246,34250],{"nctId":10313,"briefTitle":10314,"status":624,"phases":34247,"completion":2067,"start":688,"enrollment":1757,"conditions":34248,"interventions":34249},[90],[7267],[10318,3584],{"nctId":34251,"briefTitle":34252,"status":195,"phases":34253,"primaryCompletion":2220,"completion":2220,"start":2524,"enrollment":1757,"conditions":34254,"interventions":34255},"NCT00700986","Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056",[90],[7267],[10318],{"trials":34257,"activeCount":102},[34258],{"nctId":34259,"briefTitle":34260,"status":195,"phases":34261,"completion":2077,"start":5725,"enrollment":16045,"conditions":34262,"interventions":34263},"NCT00520572","A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)",[91],[7267],[10318,32496],{"trials":34265,"activeCount":102},[],{"trials":34267,"activeCount":102},[],{"trials":34269,"activeCount":102},[],{"intervention":34271,"totalTrials":3887,"cells":34272},"AZD2624",{"EARLY_PHASE1":34273,"PHASE1":34275,"PHASE2":34289,"PHASE3":34299,"PHASE4":34301,"NA":34303},{"trials":34274,"activeCount":102},[],{"trials":34276,"activeCount":102},[34277,34283],{"nctId":34278,"briefTitle":34279,"status":195,"phases":34280,"completion":2220,"start":2221,"enrollment":1710,"conditions":34281,"interventions":34282},"NCT00696865","AZD2624 Multiple Ascending Dose Study in Japan",[90],[19,10052],[34271],{"nctId":34284,"briefTitle":34285,"status":195,"phases":34286,"completion":2320,"start":2077,"enrollment":486,"conditions":34287,"interventions":34288},"NCT00867685","Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation",[90],[19],[34271,34271],{"trials":34290,"activeCount":102},[34291],{"nctId":34292,"briefTitle":34293,"status":195,"phases":34294,"primaryCompletion":2077,"completion":2077,"start":2221,"enrollment":34295,"conditions":34296,"interventions":34297},"NCT00686998","Phase IIA Study in Patients With Schizophrenia",[91],106,[33],[34271,34298],"Olanzapine",{"trials":34300,"activeCount":102},[],{"trials":34302,"activeCount":102},[],{"trials":34304,"activeCount":102},[],{"intervention":34306,"totalTrials":3887,"cells":34307},"MEDI7352",{"EARLY_PHASE1":34308,"PHASE1":34310,"PHASE2":34321,"PHASE3":34337,"PHASE4":34339,"NA":34341},{"trials":34309,"activeCount":102},[],{"trials":34311,"activeCount":102},[34312],{"nctId":34313,"briefTitle":34314,"status":195,"phases":34315,"primaryCompletion":34316,"completion":34316,"start":34317,"enrollment":1130,"conditions":34318,"interventions":34320},"NCT04770428","Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers",[90],"2021-12-02","2021-04-20",[34319],"Painful Osteoarthritis of the Knee",[34306],{"trials":34322,"activeCount":102},[34323,34331],{"nctId":34324,"briefTitle":34325,"status":443,"phases":34326,"primaryCompletion":615,"completion":615,"start":34327,"enrollment":8138,"conditions":34328,"interventions":34330},"NCT03755934","Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy",[91],"2018-11-19",[34329],"Painful Diabetic Neuropathy",[34306],{"nctId":34332,"briefTitle":34333,"status":195,"phases":34334,"primaryCompletion":110,"completion":110,"start":3054,"enrollment":4056,"conditions":34335,"interventions":34336},"NCT04675034","A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee",[91],[34319],[34306],{"trials":34338,"activeCount":102},[],{"trials":34340,"activeCount":102},[],{"trials":34342,"activeCount":102},[],{"intervention":24615,"totalTrials":447,"cells":34344},{"EARLY_PHASE1":34345,"PHASE1":34347,"PHASE2":34349,"PHASE3":34359,"PHASE4":34361,"NA":34363},{"trials":34346,"activeCount":102},[],{"trials":34348,"activeCount":102},[],{"trials":34350,"activeCount":102},[34351,34355],{"nctId":24608,"briefTitle":24609,"status":195,"phases":34352,"primaryCompletion":24611,"completion":24611,"start":24612,"enrollment":544,"conditions":34353,"interventions":34354},[91],[7267],[24615,9939],{"nctId":24617,"briefTitle":24618,"status":195,"phases":34356,"primaryCompletion":24620,"completion":24620,"start":3080,"enrollment":451,"conditions":34357,"interventions":34358},[91],[2089],[24615,9939],{"trials":34360,"activeCount":102},[],{"trials":34362,"activeCount":102},[],{"trials":34364,"activeCount":102},[],{"intervention":34366,"totalTrials":447,"cells":34367},"ZD4054 10 mg",{"EARLY_PHASE1":34368,"PHASE1":34370,"PHASE2":34372,"PHASE3":34388,"PHASE4":34390,"NA":34392},{"trials":34369,"activeCount":102},[],{"trials":34371,"activeCount":102},[],{"trials":34373,"activeCount":102},[34374,34382],{"nctId":34375,"briefTitle":34376,"status":195,"phases":34377,"primaryCompletion":3809,"completion":3809,"start":4256,"enrollment":434,"conditions":34378,"interventions":34379},"NCT00055471","A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer",[91],[23765,6782],[34366,34380,34381],"ZD4054 15 mg","ZD4054 22.5 mg",{"nctId":34383,"briefTitle":34384,"status":195,"phases":34385,"primaryCompletion":4915,"completion":2675,"start":8692,"enrollment":1675,"conditions":34386,"interventions":34387},"NCT00090363","ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)",[91],[416],[34380,34366],{"trials":34389,"activeCount":102},[],{"trials":34391,"activeCount":102},[],{"trials":34393,"activeCount":102},[],{"intervention":34380,"totalTrials":447,"cells":34395},{"EARLY_PHASE1":34396,"PHASE1":34398,"PHASE2":34400,"PHASE3":34410,"PHASE4":34412,"NA":34414},{"trials":34397,"activeCount":102},[],{"trials":34399,"activeCount":102},[],{"trials":34401,"activeCount":102},[34402,34406],{"nctId":34375,"briefTitle":34376,"status":195,"phases":34403,"primaryCompletion":3809,"completion":3809,"start":4256,"enrollment":434,"conditions":34404,"interventions":34405},[91],[23765,6782],[34366,34380,34381],{"nctId":34383,"briefTitle":34384,"status":195,"phases":34407,"primaryCompletion":4915,"completion":2675,"start":8692,"enrollment":1675,"conditions":34408,"interventions":34409},[91],[416],[34380,34366],{"trials":34411,"activeCount":102},[],{"trials":34413,"activeCount":102},[],{"trials":34415,"activeCount":102},[],{"intervention":34417,"totalTrials":447,"cells":34418},"AZD1402",{"EARLY_PHASE1":34419,"PHASE1":34421,"PHASE2":34431,"PHASE3":34441,"PHASE4":34443,"NA":34445},{"trials":34420,"activeCount":102},[],{"trials":34422,"activeCount":102},[34423],{"nctId":34424,"briefTitle":34425,"status":195,"phases":34426,"primaryCompletion":34427,"completion":34427,"start":34428,"enrollment":1336,"conditions":34429,"interventions":34430},"NCT03921268","Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402",[90],"2019-06-13","2019-03-25",[16],[34417],{"trials":34432,"activeCount":102},[34433],{"nctId":34434,"briefTitle":34435,"status":443,"phases":34436,"primaryCompletion":6483,"completion":6483,"start":3702,"enrollment":132,"conditions":34437,"interventions":34438},"NCT04643158","Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids",[91],[16],[34417,34439,34440],"Short acting beta agonist","Run-in medications",{"trials":34442,"activeCount":102},[],{"trials":34444,"activeCount":102},[],{"trials":34446,"activeCount":102},[],{"intervention":33092,"totalTrials":447,"cells":34448},{"EARLY_PHASE1":34449,"PHASE1":34451,"PHASE2":34460,"PHASE3":34466,"PHASE4":34468,"NA":34470},{"trials":34450,"activeCount":102},[],{"trials":34452,"activeCount":102},[34453],{"nctId":34454,"briefTitle":34455,"status":195,"phases":34456,"primaryCompletion":2414,"completion":2414,"start":2580,"enrollment":477,"conditions":34457,"interventions":34459},"NCT00689780","Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940",[90],[34458],"Low Back Pain",[33092,5870],{"trials":34461,"activeCount":102},[34462],{"nctId":33087,"briefTitle":33088,"status":195,"phases":34463,"primaryCompletion":2221,"completion":2221,"start":2168,"enrollment":20,"conditions":34464,"interventions":34465},[91],[31755],[33092,31784],{"trials":34467,"activeCount":102},[],{"trials":34469,"activeCount":102},[],{"trials":34471,"activeCount":102},[],{"intervention":34473,"totalTrials":447,"cells":34474},"AZD2927",{"EARLY_PHASE1":34475,"PHASE1":34477,"PHASE2":34485,"PHASE3":34494,"PHASE4":34496,"NA":34498},{"trials":34476,"activeCount":102},[],{"trials":34478,"activeCount":102},[34479],{"nctId":34480,"briefTitle":34481,"status":195,"phases":34482,"primaryCompletion":2615,"completion":2615,"start":2516,"enrollment":5898,"conditions":34483,"interventions":34484},"NCT01264250","A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers",[90],[19],[34473],{"trials":34486,"activeCount":102},[34487],{"nctId":34488,"briefTitle":34489,"status":195,"phases":34490,"primaryCompletion":2747,"completion":2747,"start":2571,"enrollment":5876,"conditions":34491,"interventions":34493},"NCT01396226","A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients",[91],[34492],"Arrhythmia",[34473],{"trials":34495,"activeCount":102},[],{"trials":34497,"activeCount":102},[],{"trials":34499,"activeCount":102},[],{"intervention":32566,"totalTrials":447,"cells":34501},{"EARLY_PHASE1":34502,"PHASE1":34504,"PHASE2":34506,"PHASE3":34520,"PHASE4":34522,"NA":34524},{"trials":34503,"activeCount":102},[],{"trials":34505,"activeCount":102},[],{"trials":34507,"activeCount":102},[34508,34512],{"nctId":32557,"briefTitle":32558,"status":195,"phases":34509,"primaryCompletion":32560,"completion":32560,"start":32561,"enrollment":32562,"conditions":34510,"interventions":34511},[91],[32564],[32566,32504],{"nctId":34513,"briefTitle":34514,"status":195,"phases":34515,"primaryCompletion":4005,"completion":4005,"start":2179,"enrollment":744,"conditions":34516,"interventions":34518},"NCT02317861","A PD\u002FSafety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients",[90,91],[34517],"Gout and Asymptomatic Hyperuricemia",[32566,2315,34519],"Benzbromarone",{"trials":34521,"activeCount":102},[],{"trials":34523,"activeCount":102},[],{"trials":34525,"activeCount":102},[],{"intervention":34527,"totalTrials":447,"cells":34528},"AZD0865",{"EARLY_PHASE1":34529,"PHASE1":34531,"PHASE2":34533,"PHASE3":34550,"PHASE4":34552,"NA":34554},{"trials":34530,"activeCount":102},[],{"trials":34532,"activeCount":102},[],{"trials":34534,"activeCount":102},[34535,34543],{"nctId":34536,"briefTitle":34537,"status":195,"phases":34538,"completion":13047,"start":13575,"enrollment":34539,"conditions":34540,"interventions":34542},"NCT00206284","A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.",[91],1400,[34541],"GERD Without Erosive Esophagitis",[34527],{"nctId":34544,"briefTitle":34545,"status":195,"phases":34546,"completion":5796,"start":13575,"enrollment":34539,"conditions":34547,"interventions":34549},"NCT00206245","A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.",[91],[34548],"GERD With Erosive Esophagitis",[34527],{"trials":34551,"activeCount":102},[],{"trials":34553,"activeCount":102},[],{"trials":34555,"activeCount":102},[],{"intervention":34557,"totalTrials":447,"cells":34558},"Brazikumab",{"EARLY_PHASE1":34559,"PHASE1":34561,"PHASE2":34571,"PHASE3":34582,"PHASE4":34584,"NA":34586},{"trials":34560,"activeCount":102},[],{"trials":34562,"activeCount":102},[34563],{"nctId":34564,"briefTitle":34565,"status":195,"phases":34566,"primaryCompletion":34567,"completion":34567,"start":34568,"enrollment":5898,"conditions":34569,"interventions":34570},"NCT05033431","Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants",[90],"2022-10-12","2021-10-11",[5851],[34557],{"trials":34572,"activeCount":102},[34573],{"nctId":34574,"briefTitle":34575,"status":443,"phases":34576,"primaryCompletion":34577,"completion":34577,"start":34578,"enrollment":34579,"conditions":34580,"interventions":34581},"NCT03616821","Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis",[91],"2023-10-23","2018-08-07",242,[24899,26095],[34557],{"trials":34583,"activeCount":102},[],{"trials":34585,"activeCount":102},[],{"trials":34587,"activeCount":102},[],{"intervention":34589,"totalTrials":447,"cells":34590},"Formoterol 12 μg",{"EARLY_PHASE1":34591,"PHASE1":34593,"PHASE2":34595,"PHASE3":34615,"PHASE4":34617,"NA":34619},{"trials":34592,"activeCount":102},[],{"trials":34594,"activeCount":102},[],{"trials":34596,"activeCount":102},[34597,34606],{"nctId":34598,"briefTitle":34599,"status":195,"phases":34600,"primaryCompletion":2144,"completion":2144,"start":2055,"enrollment":589,"conditions":34601,"interventions":34602},"NCT01049360","Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo",[91],[28],[34603,34604,34605,34589],"Aclidinium 400 μg \u002F Formoterol 12 μg","Aclidinium 400 μg \u002F Formoterol 6 μg","Aclidinium 400 μg",{"nctId":34607,"briefTitle":34608,"status":195,"phases":34609,"primaryCompletion":3862,"completion":3862,"start":2114,"enrollment":16948,"conditions":34610,"interventions":34611},"NCT01078623","Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate",[91],[28],[34612,34589,34613,34614],"Aclidinium 200 μg \u002F formoterol 12 μg","Aclidinium 200 μg","Aclidinium 200 μg \u002F Formoterol 6 μg",{"trials":34616,"activeCount":102},[],{"trials":34618,"activeCount":102},[],{"trials":34620,"activeCount":102},[],{"intervention":6784,"totalTrials":447,"cells":34622},{"EARLY_PHASE1":34623,"PHASE1":34625,"PHASE2":34627,"PHASE3":34639,"PHASE4":34641,"NA":34643},{"trials":34624,"activeCount":102},[],{"trials":34626,"activeCount":102},[],{"trials":34628,"activeCount":102},[34629,34635],{"nctId":34630,"briefTitle":34631,"status":2744,"phases":34632,"primaryCompletion":4306,"completion":4306,"start":6563,"conditions":34633,"interventions":34634},"NCT00065572","Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)",[91],[7102,7103],[6784],{"nctId":6777,"briefTitle":6778,"status":443,"phases":34636,"primaryCompletion":4306,"completion":4306,"start":6780,"enrollment":1120,"conditions":34637,"interventions":34638},[91],[5368,6782],[6784,296,6785,6786],{"trials":34640,"activeCount":102},[],{"trials":34642,"activeCount":102},[],{"trials":34644,"activeCount":102},[],{"intervention":34646,"totalTrials":447,"cells":34647},"Mitiperstat",{"EARLY_PHASE1":34648,"PHASE1":34650,"PHASE2":34660,"PHASE3":34668,"PHASE4":34670,"NA":34672},{"trials":34649,"activeCount":102},[],{"trials":34651,"activeCount":102},[34652],{"nctId":34653,"briefTitle":34654,"status":195,"phases":34655,"primaryCompletion":34656,"completion":34656,"start":34657,"enrollment":3248,"conditions":34658,"interventions":34659},"NCT05751759","Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment",[90],"2024-11-21","2023-03-20",[6914],[34646],{"trials":34661,"activeCount":102},[34662],{"nctId":34663,"briefTitle":34664,"status":195,"phases":34665,"primaryCompletion":278,"completion":278,"start":3746,"enrollment":18712,"conditions":34666,"interventions":34667},"NCT05492877","An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.",[91],[6083],[34646],{"trials":34669,"activeCount":102},[],{"trials":34671,"activeCount":102},[],{"trials":34673,"activeCount":102},[],{"intervention":3915,"totalTrials":447,"cells":34675},{"EARLY_PHASE1":34676,"PHASE1":34678,"PHASE2":34680,"PHASE3":34696,"PHASE4":34698,"NA":34700},{"trials":34677,"activeCount":102},[],{"trials":34679,"activeCount":102},[],{"trials":34681,"activeCount":102},[34682,34686],{"nctId":3905,"briefTitle":3906,"status":195,"phases":34683,"primaryCompletion":3908,"completion":3909,"start":3910,"enrollment":29,"conditions":34684,"interventions":34685},[91],[3912],[3914,118,344,283,3915],{"nctId":34687,"briefTitle":34688,"status":195,"phases":34689,"primaryCompletion":34690,"completion":34690,"start":34691,"enrollment":1710,"conditions":34692,"interventions":34694},"NCT03907969","A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.",[90,91],"2022-12-07","2019-10-09",[34693],"Advanced Malignancies",[34695,3915],"AZD7648",{"trials":34697,"activeCount":102},[],{"trials":34699,"activeCount":102},[],{"trials":34701,"activeCount":102},[],{"intervention":34703,"totalTrials":447,"cells":34704},"metreleptin",{"EARLY_PHASE1":34705,"PHASE1":34707,"PHASE2":34709,"PHASE3":34727,"PHASE4":34729,"NA":34731},{"trials":34706,"activeCount":102},[],{"trials":34708,"activeCount":102},[],{"trials":34710,"activeCount":102},[34711,34720],{"nctId":34712,"briefTitle":34713,"status":195,"phases":34714,"primaryCompletion":2415,"completion":2415,"start":2639,"enrollment":1385,"conditions":34715,"interventions":34717},"NCT00392925","A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects",[91],[34716,12275],"Overweight",[34718,34703,34719],"pramlintide acetate 360 mcg","Pramlintide acetate 180 mcg",{"nctId":34721,"briefTitle":34722,"status":195,"phases":34723,"primaryCompletion":2320,"completion":2350,"start":2251,"enrollment":34724,"conditions":34725,"interventions":34726},"NCT00673387","Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects",[91],636,[34716,12275],[22620,34703],{"trials":34728,"activeCount":102},[],{"trials":34730,"activeCount":102},[],{"trials":34732,"activeCount":102},[],{"intervention":15635,"totalTrials":447,"cells":34734},{"EARLY_PHASE1":34735,"PHASE1":34737,"PHASE2":34739,"PHASE3":34755,"PHASE4":34757,"NA":34759},{"trials":34736,"activeCount":102},[],{"trials":34738,"activeCount":102},[],{"trials":34740,"activeCount":102},[34741,34751],{"nctId":34742,"briefTitle":34743,"status":195,"phases":34744,"primaryCompletion":34745,"completion":34745,"start":7606,"enrollment":20097,"conditions":34746,"interventions":34747},"NCT04515849","A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus",[91],"2022-03-08",[22,33543],[34748,34749,34750,15635],"Cotadutide 100 micrograms","Cotadutide 300 micrograms","Cotadutide 600 micrograms",{"nctId":15629,"briefTitle":15630,"status":195,"phases":34752,"primaryCompletion":2999,"completion":2999,"start":12613,"enrollment":15632,"conditions":34753,"interventions":34754},[91],[2089],[12585,15635],{"trials":34756,"activeCount":102},[],{"trials":34758,"activeCount":102},[],{"trials":34760,"activeCount":102},[],{"intervention":2315,"totalTrials":447,"cells":34762},{"EARLY_PHASE1":34763,"PHASE1":34765,"PHASE2":34767,"PHASE3":34777,"PHASE4":34779,"NA":34781},{"trials":34764,"activeCount":102},[],{"trials":34766,"activeCount":102},[],{"trials":34768,"activeCount":102},[34769,34773],{"nctId":2306,"briefTitle":2307,"status":195,"phases":34770,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":496,"conditions":34771,"interventions":34772},[91],[2312],[2314,2315,2044],{"nctId":34513,"briefTitle":34514,"status":195,"phases":34774,"primaryCompletion":4005,"completion":4005,"start":2179,"enrollment":744,"conditions":34775,"interventions":34776},[90,91],[34517],[32566,2315,34519],{"trials":34778,"activeCount":102},[],{"trials":34780,"activeCount":102},[],{"trials":34782,"activeCount":102},[],{"intervention":34784,"totalTrials":447,"cells":34785},"AZD4818",{"EARLY_PHASE1":34786,"PHASE1":34788,"PHASE2":34796,"PHASE3":34804,"PHASE4":34806,"NA":34808},{"trials":34787,"activeCount":102},[],{"trials":34789,"activeCount":102},[34790],{"nctId":34791,"briefTitle":34792,"status":195,"phases":34793,"primaryCompletion":2221,"completion":2221,"start":6710,"enrollment":1710,"conditions":34794,"interventions":34795},"NCT00687232","Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers",[90],[19],[34784],{"trials":34797,"activeCount":102},[34798],{"nctId":34799,"briefTitle":34800,"status":195,"phases":34801,"primaryCompletion":2524,"completion":2220,"start":6710,"enrollment":5189,"conditions":34802,"interventions":34803},"NCT00629239","Tolerability\u002FSafety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[91],[6083],[34784],{"trials":34805,"activeCount":102},[],{"trials":34807,"activeCount":102},[],{"trials":34809,"activeCount":102},[],{"intervention":34811,"totalTrials":447,"cells":34812},"MEDI4736 monotherapy",{"EARLY_PHASE1":34813,"PHASE1":34815,"PHASE2":34817,"PHASE3":34839,"PHASE4":34841,"NA":34843},{"trials":34814,"activeCount":102},[],{"trials":34816,"activeCount":102},[],{"trials":34818,"activeCount":102},[34819,34830],{"nctId":34820,"briefTitle":34821,"status":195,"phases":34822,"primaryCompletion":34823,"completion":1584,"start":4016,"enrollment":4307,"conditions":34824,"interventions":34827},"NCT02527434","Study of Tremelimumab in Patients With Advanced Solid Tumors",[91],"2018-02-17",[34825,34826,5772],"Urothelial Bladder Cancer","Triple-negative Breast Cancer",[34828,34811,34829],"Tremelimumab monotherapy","MEDI4736 + tremelimumab combination therapy",{"nctId":34831,"briefTitle":34832,"status":195,"phases":34833,"primaryCompletion":20816,"completion":20816,"start":34834,"enrollment":5189,"conditions":34835,"interventions":34837},"NCT02558894","Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma",[91],"2015-11-16",[34836],"Metastatic Pancreatic Ductal Adenocarcinoma",[34811,34838],"tremelimumab+MEDI4736",{"trials":34840,"activeCount":102},[],{"trials":34842,"activeCount":102},[],{"trials":34844,"activeCount":102},[],{"intervention":22956,"totalTrials":447,"cells":34846},{"EARLY_PHASE1":34847,"PHASE1":34849,"PHASE2":34855,"PHASE3":34865,"PHASE4":34867,"NA":34869},{"trials":34848,"activeCount":102},[],{"trials":34850,"activeCount":102},[34851],{"nctId":22948,"briefTitle":22949,"status":624,"phases":34852,"primaryCompletion":4496,"completion":4496,"start":2747,"enrollment":102,"conditions":34853,"interventions":34854},[90],[22952,19],[22928,22954,22955,22956,22928,22928,22956],{"trials":34856,"activeCount":102},[34857],{"nctId":34858,"briefTitle":34859,"status":195,"phases":34860,"primaryCompletion":5725,"completion":5725,"start":7342,"enrollment":5947,"conditions":34861,"interventions":34862},"NCT00402077","A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects",[91],[34716,12275],[22620,34863,34864],"sibutramine","phentermine",{"trials":34866,"activeCount":102},[],{"trials":34868,"activeCount":102},[],{"trials":34870,"activeCount":102},[],{"intervention":16137,"totalTrials":447,"cells":34872},{"EARLY_PHASE1":34873,"PHASE1":34875,"PHASE2":34881,"PHASE3":34887,"PHASE4":34889,"NA":34891},{"trials":34874,"activeCount":102},[],{"trials":34876,"activeCount":102},[34877],{"nctId":16103,"briefTitle":16104,"status":443,"phases":34878,"primaryCompletion":16106,"completion":16107,"start":16108,"enrollment":3811,"conditions":34879,"interventions":34880},[90],[3056],[48,16111],{"trials":34882,"activeCount":102},[34883],{"nctId":16129,"briefTitle":16130,"status":195,"phases":34884,"primaryCompletion":16132,"completion":16133,"start":16134,"enrollment":13007,"conditions":34885,"interventions":34886},[91],[3026],[48,16137,48],{"trials":34888,"activeCount":102},[],{"trials":34890,"activeCount":102},[],{"trials":34892,"activeCount":102},[],{"intervention":34894,"totalTrials":447,"cells":34895},"Roflumilast cream",{"EARLY_PHASE1":34896,"PHASE1":34898,"PHASE2":34900,"PHASE3":34916,"PHASE4":34918,"NA":34920},{"trials":34897,"activeCount":102},[],{"trials":34899,"activeCount":102},[],{"trials":34901,"activeCount":102},[34902,34909],{"nctId":34903,"briefTitle":34904,"status":624,"phases":34905,"primaryCompletion":2152,"completion":2067,"start":2414,"enrollment":102,"conditions":34906,"interventions":34908},"NCT00746382","A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)",[91],[34907],"Dermatitis",[34894],{"nctId":34910,"briefTitle":34911,"status":624,"phases":34912,"primaryCompletion":2152,"completion":2067,"start":2414,"enrollment":102,"conditions":34913,"interventions":34915},"NCT00746434","A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis",[91],[34914],"Plaque Psoriasis",[34894],{"trials":34917,"activeCount":102},[],{"trials":34919,"activeCount":102},[],{"trials":34921,"activeCount":102},[],{"intervention":24776,"totalTrials":447,"cells":34923},{"EARLY_PHASE1":34924,"PHASE1":34926,"PHASE2":34932,"PHASE3":34938,"PHASE4":34940,"NA":34942},{"trials":34925,"activeCount":102},[],{"trials":34927,"activeCount":102},[34928],{"nctId":24769,"briefTitle":24770,"status":195,"phases":34929,"primaryCompletion":24772,"completion":24772,"start":6436,"enrollment":1710,"conditions":34930,"interventions":34931},[90],[24774],[24754,24776],{"trials":34933,"activeCount":102},[34934],{"nctId":24780,"briefTitle":24781,"status":195,"phases":34935,"primaryCompletion":2349,"completion":2349,"start":3862,"enrollment":680,"conditions":34936,"interventions":34937},[91],[24774],[24754,24776],{"trials":34939,"activeCount":102},[],{"trials":34941,"activeCount":102},[],{"trials":34943,"activeCount":102},[],{"intervention":32496,"totalTrials":447,"cells":34945},{"EARLY_PHASE1":34946,"PHASE1":34948,"PHASE2":34950,"PHASE3":34960,"PHASE4":34962,"NA":34964},{"trials":34947,"activeCount":102},[],{"trials":34949,"activeCount":102},[],{"trials":34951,"activeCount":102},[34952,34956],{"nctId":34259,"briefTitle":34260,"status":195,"phases":34953,"completion":2077,"start":5725,"enrollment":16045,"conditions":34954,"interventions":34955},[91],[7267],[10318,32496],{"nctId":32491,"briefTitle":32492,"status":195,"phases":34957,"primaryCompletion":2320,"completion":2320,"start":2507,"enrollment":1219,"conditions":34958,"interventions":34959},[91],[7267],[15778,32496,15778,15778,15778],{"trials":34961,"activeCount":102},[],{"trials":34963,"activeCount":102},[],{"trials":34965,"activeCount":102},[],{"intervention":3096,"totalTrials":447,"cells":34967},{"EARLY_PHASE1":34968,"PHASE1":34970,"PHASE2":34976,"PHASE3":34982,"PHASE4":34984,"NA":34986},{"trials":34969,"activeCount":102},[],{"trials":34971,"activeCount":102},[34972],{"nctId":3087,"briefTitle":3088,"status":195,"phases":34973,"primaryCompletion":3090,"completion":3091,"start":3092,"enrollment":3093,"conditions":34974,"interventions":34975},[90],[498],[571,117,177,3096,344,283,3097],{"trials":34977,"activeCount":102},[34978],{"nctId":4303,"briefTitle":4304,"status":195,"phases":34979,"completion":2252,"start":4306,"enrollment":4307,"conditions":34980,"interventions":34981},[91],[4309,4310],[4039,3803,4312],{"trials":34983,"activeCount":102},[],{"trials":34985,"activeCount":102},[],{"trials":34987,"activeCount":102},[],{"intervention":23233,"totalTrials":122,"cells":34989},{"EARLY_PHASE1":34990,"PHASE1":34992,"PHASE2":34994,"PHASE3":35000,"PHASE4":35002,"NA":35004},{"trials":34991,"activeCount":102},[],{"trials":34993,"activeCount":102},[],{"trials":34995,"activeCount":102},[34996],{"nctId":23228,"briefTitle":23229,"status":195,"phases":34997,"primaryCompletion":687,"completion":687,"start":2747,"enrollment":1130,"conditions":34998,"interventions":34999},[91],[6083],[23233,9882],{"trials":35001,"activeCount":102},[],{"trials":35003,"activeCount":102},[],{"trials":35005,"activeCount":102},[],{"intervention":35007,"totalTrials":122,"cells":35008},"budesonide\u002Fformoterol, 2x 200\u002F6 microgram. 4 times daily",{"EARLY_PHASE1":35009,"PHASE1":35011,"PHASE2":35013,"PHASE3":35022,"PHASE4":35024,"NA":35026},{"trials":35010,"activeCount":102},[],{"trials":35012,"activeCount":102},[],{"trials":35014,"activeCount":102},[35015],{"nctId":35016,"briefTitle":35017,"status":195,"phases":35018,"completion":4876,"start":7449,"enrollment":2187,"conditions":35019,"interventions":35020},"NCT00239278","Budesonide \u002F Formoterol in Treatment of Exacerbations of COPD",[91],[28],[35007,35021],"prednisolone, 30 mg once daily and placebo",{"trials":35023,"activeCount":102},[],{"trials":35025,"activeCount":102},[],{"trials":35027,"activeCount":102},[],{"intervention":35021,"totalTrials":122,"cells":35029},{"EARLY_PHASE1":35030,"PHASE1":35032,"PHASE2":35034,"PHASE3":35040,"PHASE4":35042,"NA":35044},{"trials":35031,"activeCount":102},[],{"trials":35033,"activeCount":102},[],{"trials":35035,"activeCount":102},[35036],{"nctId":35016,"briefTitle":35017,"status":195,"phases":35037,"completion":4876,"start":7449,"enrollment":2187,"conditions":35038,"interventions":35039},[91],[28],[35007,35021],{"trials":35041,"activeCount":102},[],{"trials":35043,"activeCount":102},[],{"trials":35045,"activeCount":102},[],{"intervention":35047,"totalTrials":122,"cells":35048},"AZD4901",{"EARLY_PHASE1":35049,"PHASE1":35051,"PHASE2":35053,"PHASE3":35062,"PHASE4":35064,"NA":35066},{"trials":35050,"activeCount":102},[],{"trials":35052,"activeCount":102},[],{"trials":35054,"activeCount":102},[35055],{"nctId":35056,"briefTitle":35057,"status":195,"phases":35058,"primaryCompletion":1692,"completion":1692,"start":2746,"enrollment":1617,"conditions":35059,"interventions":35061},"NCT01872078","A Study of AZD4901 in Females With Polycystic Ovary Syndrome",[91],[35060],"Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder",[35047],{"trials":35063,"activeCount":102},[],{"trials":35065,"activeCount":102},[],{"trials":35067,"activeCount":102},[],{"intervention":34381,"totalTrials":122,"cells":35069},{"EARLY_PHASE1":35070,"PHASE1":35072,"PHASE2":35074,"PHASE3":35080,"PHASE4":35082,"NA":35084},{"trials":35071,"activeCount":102},[],{"trials":35073,"activeCount":102},[],{"trials":35075,"activeCount":102},[35076],{"nctId":34375,"briefTitle":34376,"status":195,"phases":35077,"primaryCompletion":3809,"completion":3809,"start":4256,"enrollment":434,"conditions":35078,"interventions":35079},[91],[23765,6782],[34366,34380,34381],{"trials":35081,"activeCount":102},[],{"trials":35083,"activeCount":102},[],{"trials":35085,"activeCount":102},[],{"intervention":35087,"totalTrials":122,"cells":35088},"600 mg AZD7442 IV",{"EARLY_PHASE1":35089,"PHASE1":35091,"PHASE2":35093,"PHASE3":35105,"PHASE4":35107,"NA":35109},{"trials":35090,"activeCount":102},[],{"trials":35092,"activeCount":102},[],{"trials":35094,"activeCount":102},[35095],{"nctId":35096,"briefTitle":35097,"status":195,"phases":35098,"primaryCompletion":35099,"completion":35100,"start":35101,"enrollment":718,"conditions":35102,"interventions":35103},"NCT05184062","A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults",[91],"2022-08-15","2023-05-06","2021-12-03",[23947],[35087,35104],"600mg placebo IV",{"trials":35106,"activeCount":102},[],{"trials":35108,"activeCount":102},[],{"trials":35110,"activeCount":102},[],{"intervention":35104,"totalTrials":122,"cells":35112},{"EARLY_PHASE1":35113,"PHASE1":35115,"PHASE2":35117,"PHASE3":35123,"PHASE4":35125,"NA":35127},{"trials":35114,"activeCount":102},[],{"trials":35116,"activeCount":102},[],{"trials":35118,"activeCount":102},[35119],{"nctId":35096,"briefTitle":35097,"status":195,"phases":35120,"primaryCompletion":35099,"completion":35100,"start":35101,"enrollment":718,"conditions":35121,"interventions":35122},[91],[23947],[35087,35104],{"trials":35124,"activeCount":102},[],{"trials":35126,"activeCount":102},[],{"trials":35128,"activeCount":102},[],{"intervention":35130,"totalTrials":122,"cells":35131},"Ciclesonide HFA",{"EARLY_PHASE1":35132,"PHASE1":35134,"PHASE2":35136,"PHASE3":35145,"PHASE4":35147,"NA":35149},{"trials":35133,"activeCount":102},[],{"trials":35135,"activeCount":102},[],{"trials":35137,"activeCount":102},[35138],{"nctId":35139,"briefTitle":35140,"status":195,"phases":35141,"primaryCompletion":5562,"completion":2252,"start":7439,"enrollment":35142,"conditions":35143,"interventions":35144},"NCT00807053","Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010\u002FM1-602)",[91],480,[26921],[35130,35130,35130],{"trials":35146,"activeCount":102},[],{"trials":35148,"activeCount":102},[],{"trials":35150,"activeCount":102},[],{"intervention":35152,"totalTrials":122,"cells":35153},"Gefitinib, radiotherapy",{"EARLY_PHASE1":35154,"PHASE1":35156,"PHASE2":35158,"PHASE3":35167,"PHASE4":35169,"NA":35171},{"trials":35155,"activeCount":102},[],{"trials":35157,"activeCount":102},[],{"trials":35159,"activeCount":102},[35160],{"nctId":35161,"briefTitle":35162,"status":195,"phases":35163,"completion":7494,"start":12846,"enrollment":2069,"conditions":35164,"interventions":35166},"NCT00239291","Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer",[90,91],[35165],"Non-Metastatic Prostate Cancer",[35152],{"trials":35168,"activeCount":102},[],{"trials":35170,"activeCount":102},[],{"trials":35172,"activeCount":102},[],{"intervention":3897,"totalTrials":122,"cells":35174},{"EARLY_PHASE1":35175,"PHASE1":35177,"PHASE2":35179,"PHASE3":35185,"PHASE4":35187,"NA":35189},{"trials":35176,"activeCount":102},[],{"trials":35178,"activeCount":102},[],{"trials":35180,"activeCount":102},[35181],{"nctId":3891,"briefTitle":3892,"status":443,"phases":35182,"primaryCompletion":2542,"completion":2542,"start":2152,"enrollment":2187,"conditions":35183,"interventions":35184},[91],[3895],[3897,118,344],{"trials":35186,"activeCount":102},[],{"trials":35188,"activeCount":102},[],{"trials":35190,"activeCount":102},[],{"intervention":4541,"totalTrials":122,"cells":35192},{"EARLY_PHASE1":35193,"PHASE1":35195,"PHASE2":35197,"PHASE3":35203,"PHASE4":35205,"NA":35207},{"trials":35194,"activeCount":102},[],{"trials":35196,"activeCount":102},[],{"trials":35198,"activeCount":102},[35199],{"nctId":4533,"briefTitle":4534,"status":443,"phases":35200,"primaryCompletion":4536,"completion":4536,"start":4537,"enrollment":2222,"conditions":35201,"interventions":35202},[91],[4539],[4541,620],{"trials":35204,"activeCount":102},[],{"trials":35206,"activeCount":102},[],{"trials":35208,"activeCount":102},[],{"intervention":35210,"totalTrials":122,"cells":35211},"Verinurad 9 mg+Febuxostat 80 mg",{"EARLY_PHASE1":35212,"PHASE1":35214,"PHASE2":35216,"PHASE3":35228,"PHASE4":35230,"NA":35232},{"trials":35213,"activeCount":102},[],{"trials":35215,"activeCount":102},[],{"trials":35217,"activeCount":102},[35218],{"nctId":35219,"briefTitle":35220,"status":195,"phases":35221,"primaryCompletion":35222,"completion":35222,"start":35223,"enrollment":477,"conditions":35224,"interventions":35227},"NCT03118739","Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria",[91],"2018-08-13","2017-05-18",[35225,35226,31],"Hyperuricemia","Albuminuria",[35210],{"trials":35229,"activeCount":102},[],{"trials":35231,"activeCount":102},[],{"trials":35233,"activeCount":102},[],{"intervention":35235,"totalTrials":122,"cells":35236},"Biological: AZD3152",{"EARLY_PHASE1":35237,"PHASE1":35239,"PHASE2":35241,"PHASE3":35250,"PHASE4":35252,"NA":35254},{"trials":35238,"activeCount":102},[],{"trials":35240,"activeCount":102},[],{"trials":35242,"activeCount":102},[35243],{"nctId":35244,"briefTitle":35245,"status":195,"phases":35246,"primaryCompletion":12406,"completion":12406,"start":12341,"enrollment":2321,"conditions":35247,"interventions":35248},"NCT06057064","Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19",[91],[25021],[35235,35249],"Biological: Placebo",{"trials":35251,"activeCount":102},[],{"trials":35253,"activeCount":102},[],{"trials":35255,"activeCount":102},[],{"intervention":35249,"totalTrials":122,"cells":35257},{"EARLY_PHASE1":35258,"PHASE1":35260,"PHASE2":35262,"PHASE3":35268,"PHASE4":35270,"NA":35272},{"trials":35259,"activeCount":102},[],{"trials":35261,"activeCount":102},[],{"trials":35263,"activeCount":102},[35264],{"nctId":35244,"briefTitle":35245,"status":195,"phases":35265,"primaryCompletion":12406,"completion":12406,"start":12341,"enrollment":2321,"conditions":35266,"interventions":35267},[91],[25021],[35235,35249],{"trials":35269,"activeCount":102},[],{"trials":35271,"activeCount":102},[],{"trials":35273,"activeCount":102},[],{"intervention":24160,"totalTrials":122,"cells":35275},{"EARLY_PHASE1":35276,"PHASE1":35278,"PHASE2":35280,"PHASE3":35286,"PHASE4":35288,"NA":35290},{"trials":35277,"activeCount":102},[],{"trials":35279,"activeCount":102},[],{"trials":35281,"activeCount":102},[35282],{"nctId":24155,"briefTitle":24156,"status":195,"phases":35283,"primaryCompletion":2580,"completion":2580,"start":4331,"enrollment":3172,"conditions":35284,"interventions":35285},[91],[2631],[24146,24160],{"trials":35287,"activeCount":102},[],{"trials":35289,"activeCount":102},[],{"trials":35291,"activeCount":102},[],{"intervention":34439,"totalTrials":122,"cells":35293},{"EARLY_PHASE1":35294,"PHASE1":35296,"PHASE2":35298,"PHASE3":35304,"PHASE4":35306,"NA":35308},{"trials":35295,"activeCount":102},[],{"trials":35297,"activeCount":102},[],{"trials":35299,"activeCount":102},[35300],{"nctId":34434,"briefTitle":34435,"status":443,"phases":35301,"primaryCompletion":6483,"completion":6483,"start":3702,"enrollment":132,"conditions":35302,"interventions":35303},[91],[16],[34417,34439,34440],{"trials":35305,"activeCount":102},[],{"trials":35307,"activeCount":102},[],{"trials":35309,"activeCount":102},[],{"intervention":34440,"totalTrials":122,"cells":35311},{"EARLY_PHASE1":35312,"PHASE1":35314,"PHASE2":35316,"PHASE3":35322,"PHASE4":35324,"NA":35326},{"trials":35313,"activeCount":102},[],{"trials":35315,"activeCount":102},[],{"trials":35317,"activeCount":102},[35318],{"nctId":34434,"briefTitle":34435,"status":443,"phases":35319,"primaryCompletion":6483,"completion":6483,"start":3702,"enrollment":132,"conditions":35320,"interventions":35321},[91],[16],[34417,34439,34440],{"trials":35323,"activeCount":102},[],{"trials":35325,"activeCount":102},[],{"trials":35327,"activeCount":102},[],{"intervention":9070,"totalTrials":122,"cells":35329},{"EARLY_PHASE1":35330,"PHASE1":35332,"PHASE2":35334,"PHASE3":35340,"PHASE4":35342,"NA":35344},{"trials":35331,"activeCount":102},[],{"trials":35333,"activeCount":102},[],{"trials":35335,"activeCount":102},[35336],{"nctId":9062,"briefTitle":9063,"status":195,"phases":35337,"primaryCompletion":6650,"completion":9065,"start":9066,"conditions":35338,"interventions":35339},[91],[9068,416],[9070,468],{"trials":35341,"activeCount":102},[],{"trials":35343,"activeCount":102},[],{"trials":35345,"activeCount":102},[],{"intervention":35347,"totalTrials":122,"cells":35348},"AZD5069 50mg",{"EARLY_PHASE1":35349,"PHASE1":35351,"PHASE2":35353,"PHASE3":35364,"PHASE4":35366,"NA":35368},{"trials":35350,"activeCount":102},[],{"trials":35352,"activeCount":102},[],{"trials":35354,"activeCount":102},[35355],{"nctId":35356,"briefTitle":35357,"status":195,"phases":35358,"primaryCompletion":2570,"completion":2570,"start":2349,"enrollment":18672,"conditions":35359,"interventions":35362},"NCT01233232","A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[91],[35360,35361],"Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)","Laymen Terminology Chronic Bronchitis and Emphysema",[35347,35363],"AZD5069 80mg",{"trials":35365,"activeCount":102},[],{"trials":35367,"activeCount":102},[],{"trials":35369,"activeCount":102},[],{"intervention":35363,"totalTrials":122,"cells":35371},{"EARLY_PHASE1":35372,"PHASE1":35374,"PHASE2":35376,"PHASE3":35382,"PHASE4":35384,"NA":35386},{"trials":35373,"activeCount":102},[],{"trials":35375,"activeCount":102},[],{"trials":35377,"activeCount":102},[35378],{"nctId":35356,"briefTitle":35357,"status":195,"phases":35379,"primaryCompletion":2570,"completion":2570,"start":2349,"enrollment":18672,"conditions":35380,"interventions":35381},[91],[35360,35361],[35347,35363],{"trials":35383,"activeCount":102},[],{"trials":35385,"activeCount":102},[],{"trials":35387,"activeCount":102},[],{"intervention":32827,"totalTrials":122,"cells":35389},{"EARLY_PHASE1":35390,"PHASE1":35392,"PHASE2":35394,"PHASE3":35400,"PHASE4":35402,"NA":35404},{"trials":35391,"activeCount":102},[],{"trials":35393,"activeCount":102},[],{"trials":35395,"activeCount":102},[35396],{"nctId":32820,"briefTitle":32821,"status":195,"phases":35397,"primaryCompletion":2524,"completion":2524,"start":2328,"enrollment":32823,"conditions":35398,"interventions":35399},[91],[32825],[20336,32827,20336],{"trials":35401,"activeCount":102},[],{"trials":35403,"activeCount":102},[],{"trials":35405,"activeCount":102},[],{"intervention":35407,"totalTrials":122,"cells":35408},"MEDI-545",{"EARLY_PHASE1":35409,"PHASE1":35411,"PHASE2":35413,"PHASE3":35425,"PHASE4":35427,"NA":35429},{"trials":35410,"activeCount":102},[],{"trials":35412,"activeCount":102},[],{"trials":35414,"activeCount":102},[35415],{"nctId":35416,"briefTitle":35417,"status":195,"phases":35418,"primaryCompletion":35419,"completion":35420,"start":35421,"enrollment":1710,"conditions":35422,"interventions":35423},"NCT01031836","A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.",[91],"2012-11-07","2016-07-11","2009-11-25",[1140],[35407,35407,35407,35407,35407,35424],"MEDI-545 600",{"trials":35426,"activeCount":102},[],{"trials":35428,"activeCount":102},[],{"trials":35430,"activeCount":102},[],{"intervention":35424,"totalTrials":122,"cells":35432},{"EARLY_PHASE1":35433,"PHASE1":35435,"PHASE2":35437,"PHASE3":35443,"PHASE4":35445,"NA":35447},{"trials":35434,"activeCount":102},[],{"trials":35436,"activeCount":102},[],{"trials":35438,"activeCount":102},[35439],{"nctId":35416,"briefTitle":35417,"status":195,"phases":35440,"primaryCompletion":35419,"completion":35420,"start":35421,"enrollment":1710,"conditions":35441,"interventions":35442},[91],[1140],[35407,35407,35407,35407,35407,35424],{"trials":35444,"activeCount":102},[],{"trials":35446,"activeCount":102},[],{"trials":35448,"activeCount":102},[],{"intervention":32431,"totalTrials":122,"cells":35450},{"EARLY_PHASE1":35451,"PHASE1":35453,"PHASE2":35455,"PHASE3":35461,"PHASE4":35463,"NA":35465},{"trials":35452,"activeCount":102},[],{"trials":35454,"activeCount":102},[],{"trials":35456,"activeCount":102},[35457],{"nctId":32423,"briefTitle":32424,"status":195,"phases":35458,"primaryCompletion":7544,"completion":7544,"start":2221,"enrollment":32426,"conditions":35459,"interventions":35460},[91],[19809,32428,20099,32429],[32375,32431],{"trials":35462,"activeCount":102},[],{"trials":35464,"activeCount":102},[],{"trials":35466,"activeCount":102},[],{"intervention":35468,"totalTrials":122,"cells":35469},"tralokinumab cohort 1",{"EARLY_PHASE1":35470,"PHASE1":35472,"PHASE2":35474,"PHASE3":35484,"PHASE4":35486,"NA":35488},{"trials":35471,"activeCount":102},[],{"trials":35473,"activeCount":102},[],{"trials":35475,"activeCount":102},[35476],{"nctId":35477,"briefTitle":35478,"status":195,"phases":35479,"primaryCompletion":20831,"completion":20831,"start":2480,"enrollment":1543,"conditions":35480,"interventions":35482},"NCT02036580","D2212C00002 J-Phase II Study",[91],[35481],"Idiopathic Pulmonary Fibrosis",[35468,35483],"tralokinumab cohort 2",{"trials":35485,"activeCount":102},[],{"trials":35487,"activeCount":102},[],{"trials":35489,"activeCount":102},[],{"intervention":35483,"totalTrials":122,"cells":35491},{"EARLY_PHASE1":35492,"PHASE1":35494,"PHASE2":35496,"PHASE3":35502,"PHASE4":35504,"NA":35506},{"trials":35493,"activeCount":102},[],{"trials":35495,"activeCount":102},[],{"trials":35497,"activeCount":102},[35498],{"nctId":35477,"briefTitle":35478,"status":195,"phases":35499,"primaryCompletion":20831,"completion":20831,"start":2480,"enrollment":1543,"conditions":35500,"interventions":35501},[91],[35481],[35468,35483],{"trials":35503,"activeCount":102},[],{"trials":35505,"activeCount":102},[],{"trials":35507,"activeCount":102},[],{"intervention":35509,"totalTrials":122,"cells":35510},"AZD2327",{"EARLY_PHASE1":35511,"PHASE1":35513,"PHASE2":35515,"PHASE3":35524,"PHASE4":35526,"NA":35528},{"trials":35512,"activeCount":102},[],{"trials":35514,"activeCount":102},[],{"trials":35516,"activeCount":102},[35517],{"nctId":35518,"briefTitle":35519,"status":195,"phases":35520,"primaryCompletion":2736,"completion":2736,"start":7544,"enrollment":434,"conditions":35521,"interventions":35523},"NCT00759395","Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)",[91],[35522],"Anxious Major Depressive Disorder",[35509],{"trials":35525,"activeCount":102},[],{"trials":35527,"activeCount":102},[],{"trials":35529,"activeCount":102},[],{"intervention":35531,"totalTrials":122,"cells":35532},"Formoterol Fumarate in the Pressair DPI, Low Dose",{"EARLY_PHASE1":35533,"PHASE1":35535,"PHASE2":35537,"PHASE3":35548,"PHASE4":35550,"NA":35552},{"trials":35534,"activeCount":102},[],{"trials":35536,"activeCount":102},[],{"trials":35538,"activeCount":102},[35539],{"nctId":35540,"briefTitle":35541,"status":195,"phases":35542,"primaryCompletion":2405,"completion":2405,"start":2471,"enrollment":1935,"conditions":35543,"interventions":35544},"NCT01641081","Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma",[91],[16],[35531,35545,35546,35547],"Formoterol Fumarate in the Pressair DPI, High Dose","Foradil Aerolizer, Low Dose","Foradil Aerolizer, High Dose",{"trials":35549,"activeCount":102},[],{"trials":35551,"activeCount":102},[],{"trials":35553,"activeCount":102},[],{"intervention":35545,"totalTrials":122,"cells":35555},{"EARLY_PHASE1":35556,"PHASE1":35558,"PHASE2":35560,"PHASE3":35566,"PHASE4":35568,"NA":35570},{"trials":35557,"activeCount":102},[],{"trials":35559,"activeCount":102},[],{"trials":35561,"activeCount":102},[35562],{"nctId":35540,"briefTitle":35541,"status":195,"phases":35563,"primaryCompletion":2405,"completion":2405,"start":2471,"enrollment":1935,"conditions":35564,"interventions":35565},[91],[16],[35531,35545,35546,35547],{"trials":35567,"activeCount":102},[],{"trials":35569,"activeCount":102},[],{"trials":35571,"activeCount":102},[],{"intervention":35546,"totalTrials":122,"cells":35573},{"EARLY_PHASE1":35574,"PHASE1":35576,"PHASE2":35578,"PHASE3":35584,"PHASE4":35586,"NA":35588},{"trials":35575,"activeCount":102},[],{"trials":35577,"activeCount":102},[],{"trials":35579,"activeCount":102},[35580],{"nctId":35540,"briefTitle":35541,"status":195,"phases":35581,"primaryCompletion":2405,"completion":2405,"start":2471,"enrollment":1935,"conditions":35582,"interventions":35583},[91],[16],[35531,35545,35546,35547],{"trials":35585,"activeCount":102},[],{"trials":35587,"activeCount":102},[],{"trials":35589,"activeCount":102},[],{"intervention":35547,"totalTrials":122,"cells":35591},{"EARLY_PHASE1":35592,"PHASE1":35594,"PHASE2":35596,"PHASE3":35602,"PHASE4":35604,"NA":35606},{"trials":35593,"activeCount":102},[],{"trials":35595,"activeCount":102},[],{"trials":35597,"activeCount":102},[35598],{"nctId":35540,"briefTitle":35541,"status":195,"phases":35599,"primaryCompletion":2405,"completion":2405,"start":2471,"enrollment":1935,"conditions":35600,"interventions":35601},[91],[16],[35531,35545,35546,35547],{"trials":35603,"activeCount":102},[],{"trials":35605,"activeCount":102},[],{"trials":35607,"activeCount":102},[],{"intervention":34603,"totalTrials":122,"cells":35609},{"EARLY_PHASE1":35610,"PHASE1":35612,"PHASE2":35614,"PHASE3":35620,"PHASE4":35622,"NA":35624},{"trials":35611,"activeCount":102},[],{"trials":35613,"activeCount":102},[],{"trials":35615,"activeCount":102},[35616],{"nctId":34598,"briefTitle":34599,"status":195,"phases":35617,"primaryCompletion":2144,"completion":2144,"start":2055,"enrollment":589,"conditions":35618,"interventions":35619},[91],[28],[34603,34604,34605,34589],{"trials":35621,"activeCount":102},[],{"trials":35623,"activeCount":102},[],{"trials":35625,"activeCount":102},[],{"intervention":34604,"totalTrials":122,"cells":35627},{"EARLY_PHASE1":35628,"PHASE1":35630,"PHASE2":35632,"PHASE3":35638,"PHASE4":35640,"NA":35642},{"trials":35629,"activeCount":102},[],{"trials":35631,"activeCount":102},[],{"trials":35633,"activeCount":102},[35634],{"nctId":34598,"briefTitle":34599,"status":195,"phases":35635,"primaryCompletion":2144,"completion":2144,"start":2055,"enrollment":589,"conditions":35636,"interventions":35637},[91],[28],[34603,34604,34605,34589],{"trials":35639,"activeCount":102},[],{"trials":35641,"activeCount":102},[],{"trials":35643,"activeCount":102},[],{"intervention":34605,"totalTrials":122,"cells":35645},{"EARLY_PHASE1":35646,"PHASE1":35648,"PHASE2":35650,"PHASE3":35656,"PHASE4":35658,"NA":35660},{"trials":35647,"activeCount":102},[],{"trials":35649,"activeCount":102},[],{"trials":35651,"activeCount":102},[35652],{"nctId":34598,"briefTitle":34599,"status":195,"phases":35653,"primaryCompletion":2144,"completion":2144,"start":2055,"enrollment":589,"conditions":35654,"interventions":35655},[91],[28],[34603,34604,34605,34589],{"trials":35657,"activeCount":102},[],{"trials":35659,"activeCount":102},[],{"trials":35661,"activeCount":102},[],{"intervention":25672,"totalTrials":122,"cells":35663},{"EARLY_PHASE1":35664,"PHASE1":35666,"PHASE2":35668,"PHASE3":35674,"PHASE4":35676,"NA":35678},{"trials":35665,"activeCount":102},[],{"trials":35667,"activeCount":102},[],{"trials":35669,"activeCount":102},[35670],{"nctId":25667,"briefTitle":25668,"status":195,"phases":35671,"primaryCompletion":2068,"completion":2068,"start":2077,"enrollment":1710,"conditions":35672,"interventions":35673},[91],[6083],[25653,25672],{"trials":35675,"activeCount":102},[],{"trials":35677,"activeCount":102},[],{"trials":35679,"activeCount":102},[],{"intervention":35681,"totalTrials":122,"cells":35682},"Brazikumab IV",{"EARLY_PHASE1":35683,"PHASE1":35685,"PHASE2":35687,"PHASE3":35698,"PHASE4":35700,"NA":35702},{"trials":35684,"activeCount":102},[],{"trials":35686,"activeCount":102},[],{"trials":35688,"activeCount":102},[35689],{"nctId":35690,"briefTitle":35691,"status":443,"phases":35692,"primaryCompletion":35693,"completion":35694,"start":2810,"enrollment":8185,"conditions":35695,"interventions":35696},"NCT02574637","Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease",[91],"2017-07-28","2018-01-29",[13237],[35681,35697],"Brazikumab SC",{"trials":35699,"activeCount":102},[],{"trials":35701,"activeCount":102},[],{"trials":35703,"activeCount":102},[],{"intervention":35697,"totalTrials":122,"cells":35705},{"EARLY_PHASE1":35706,"PHASE1":35708,"PHASE2":35710,"PHASE3":35716,"PHASE4":35718,"NA":35720},{"trials":35707,"activeCount":102},[],{"trials":35709,"activeCount":102},[],{"trials":35711,"activeCount":102},[35712],{"nctId":35690,"briefTitle":35691,"status":443,"phases":35713,"primaryCompletion":35693,"completion":35694,"start":2810,"enrollment":8185,"conditions":35714,"interventions":35715},[91],[13237],[35681,35697],{"trials":35717,"activeCount":102},[],{"trials":35719,"activeCount":102},[],{"trials":35721,"activeCount":102},[],{"intervention":35723,"totalTrials":122,"cells":35724},"AZD5213 + pregabalin",{"EARLY_PHASE1":35725,"PHASE1":35727,"PHASE2":35729,"PHASE3":35739,"PHASE4":35741,"NA":35743},{"trials":35726,"activeCount":102},[],{"trials":35728,"activeCount":102},[],{"trials":35730,"activeCount":102},[35731],{"nctId":35732,"briefTitle":35733,"status":195,"phases":35734,"primaryCompletion":13756,"completion":13756,"start":1693,"enrollment":3000,"conditions":35735,"interventions":35737},"NCT01928381","Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability",[91],[35736],"Diabetic Neuropathy, Painful; Diabetic Neuropathies",[35723,35738],"pregabalin",{"trials":35740,"activeCount":102},[],{"trials":35742,"activeCount":102},[],{"trials":35744,"activeCount":102},[],{"intervention":35738,"totalTrials":122,"cells":35746},{"EARLY_PHASE1":35747,"PHASE1":35749,"PHASE2":35751,"PHASE3":35757,"PHASE4":35759,"NA":35761},{"trials":35748,"activeCount":102},[],{"trials":35750,"activeCount":102},[],{"trials":35752,"activeCount":102},[35753],{"nctId":35732,"briefTitle":35733,"status":195,"phases":35754,"primaryCompletion":13756,"completion":13756,"start":1693,"enrollment":3000,"conditions":35755,"interventions":35756},[91],[35736],[35723,35738],{"trials":35758,"activeCount":102},[],{"trials":35760,"activeCount":102},[],{"trials":35762,"activeCount":102},[],{"intervention":23738,"totalTrials":122,"cells":35764},{"EARLY_PHASE1":35765,"PHASE1":35767,"PHASE2":35769,"PHASE3":35775,"PHASE4":35777,"NA":35779},{"trials":35766,"activeCount":102},[],{"trials":35768,"activeCount":102},[],{"trials":35770,"activeCount":102},[35771],{"nctId":23732,"briefTitle":23733,"status":195,"phases":35772,"primaryCompletion":2251,"completion":2114,"start":7494,"enrollment":2045,"conditions":35773,"interventions":35774},[91],[23736],[13870,23738],{"trials":35776,"activeCount":102},[],{"trials":35778,"activeCount":102},[],{"trials":35780,"activeCount":102},[],{"intervention":32717,"totalTrials":122,"cells":35782},{"EARLY_PHASE1":35783,"PHASE1":35785,"PHASE2":35787,"PHASE3":35793,"PHASE4":35795,"NA":35797},{"trials":35784,"activeCount":102},[],{"trials":35786,"activeCount":102},[],{"trials":35788,"activeCount":102},[35789],{"nctId":32712,"briefTitle":32713,"status":195,"phases":35790,"primaryCompletion":2589,"completion":2589,"start":2349,"enrollment":2003,"conditions":35791,"interventions":35792},[91],[16],[19435,32717],{"trials":35794,"activeCount":102},[],{"trials":35796,"activeCount":102},[],{"trials":35798,"activeCount":102},[],{"intervention":35800,"totalTrials":122,"cells":35801},"AZD7624 1.0 mg",{"EARLY_PHASE1":35802,"PHASE1":35804,"PHASE2":35806,"PHASE3":35816,"PHASE4":35818,"NA":35820},{"trials":35803,"activeCount":102},[],{"trials":35805,"activeCount":102},[],{"trials":35807,"activeCount":102},[35808],{"nctId":35809,"briefTitle":35810,"status":195,"phases":35811,"primaryCompletion":839,"completion":839,"start":35812,"enrollment":35813,"conditions":35814,"interventions":35815},"NCT02238483","A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy",[91],"2014-10-28",213,[30237],[35800],{"trials":35817,"activeCount":102},[],{"trials":35819,"activeCount":102},[],{"trials":35821,"activeCount":102},[],{"intervention":1411,"totalTrials":122,"cells":35823},{"EARLY_PHASE1":35824,"PHASE1":35826,"PHASE2":35828,"PHASE3":35834,"PHASE4":35836,"NA":35838},{"trials":35825,"activeCount":102},[],{"trials":35827,"activeCount":102},[],{"trials":35829,"activeCount":102},[35830],{"nctId":1401,"briefTitle":1402,"status":624,"phases":35831,"primaryCompletion":1404,"completion":1405,"start":1406,"enrollment":102,"conditions":35832,"interventions":35833},[91],[1408,1409],[1411,1335],{"trials":35835,"activeCount":102},[],{"trials":35837,"activeCount":102},[],{"trials":35839,"activeCount":102},[],{"intervention":2304,"totalTrials":122,"cells":35841},{"EARLY_PHASE1":35842,"PHASE1":35844,"PHASE2":35846,"PHASE3":35852,"PHASE4":35854,"NA":35856},{"trials":35843,"activeCount":102},[],{"trials":35845,"activeCount":102},[],{"trials":35847,"activeCount":102},[35848],{"nctId":2295,"briefTitle":2296,"status":195,"phases":35849,"primaryCompletion":2298,"completion":2298,"start":2299,"enrollment":2300,"conditions":35850,"interventions":35851},[91],[2302],[2304,2044],{"trials":35853,"activeCount":102},[],{"trials":35855,"activeCount":102},[],{"trials":35857,"activeCount":102},[],{"intervention":35859,"totalTrials":122,"cells":35860},"CP-675,206 and leuprolide acetate and bicalutamide",{"EARLY_PHASE1":35861,"PHASE1":35863,"PHASE2":35865,"PHASE3":35874,"PHASE4":35876,"NA":35878},{"trials":35862,"activeCount":102},[],{"trials":35864,"activeCount":102},[],{"trials":35866,"activeCount":102},[35867],{"nctId":35868,"briefTitle":35869,"status":195,"phases":35870,"completion":2087,"start":12937,"enrollment":370,"conditions":35871,"interventions":35872},"NCT00075192","CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer",[90,91],[23765],[35859,35873],"leuprolide acetate and bicalutamide",{"trials":35875,"activeCount":102},[],{"trials":35877,"activeCount":102},[],{"trials":35879,"activeCount":102},[],{"intervention":35873,"totalTrials":122,"cells":35881},{"EARLY_PHASE1":35882,"PHASE1":35884,"PHASE2":35886,"PHASE3":35892,"PHASE4":35894,"NA":35896},{"trials":35883,"activeCount":102},[],{"trials":35885,"activeCount":102},[],{"trials":35887,"activeCount":102},[35888],{"nctId":35868,"briefTitle":35869,"status":195,"phases":35889,"completion":2087,"start":12937,"enrollment":370,"conditions":35890,"interventions":35891},[90,91],[23765],[35859,35873],{"trials":35893,"activeCount":102},[],{"trials":35895,"activeCount":102},[],{"trials":35897,"activeCount":102},[],{"intervention":34164,"totalTrials":122,"cells":35899},{"EARLY_PHASE1":35900,"PHASE1":35902,"PHASE2":35904,"PHASE3":35910,"PHASE4":35912,"NA":35914},{"trials":35901,"activeCount":102},[],{"trials":35903,"activeCount":102},[],{"trials":35905,"activeCount":102},[35906],{"nctId":34158,"briefTitle":34159,"status":195,"phases":35907,"primaryCompletion":34161,"completion":34161,"start":849,"enrollment":33344,"conditions":35908,"interventions":35909},[91],[28],[34135,34164],{"trials":35911,"activeCount":102},[],{"trials":35913,"activeCount":102},[],{"trials":35915,"activeCount":102},[],{"intervention":19258,"totalTrials":122,"cells":35917},{"EARLY_PHASE1":35918,"PHASE1":35920,"PHASE2":35922,"PHASE3":35928,"PHASE4":35930,"NA":35932},{"trials":35919,"activeCount":102},[],{"trials":35921,"activeCount":102},[],{"trials":35923,"activeCount":102},[35924],{"nctId":19250,"briefTitle":19251,"status":443,"phases":35925,"primaryCompletion":19253,"completion":19253,"start":19254,"enrollment":1448,"conditions":35926,"interventions":35927},[91],[19256],[12616,19258],{"trials":35929,"activeCount":102},[],{"trials":35931,"activeCount":102},[],{"trials":35933,"activeCount":102},[],{"intervention":35935,"totalTrials":122,"cells":35936},"AZD8853",{"EARLY_PHASE1":35937,"PHASE1":35939,"PHASE2":35941,"PHASE3":35951,"PHASE4":35953,"NA":35955},{"trials":35938,"activeCount":102},[],{"trials":35940,"activeCount":102},[],{"trials":35942,"activeCount":102},[35943],{"nctId":35944,"briefTitle":35945,"status":443,"phases":35946,"primaryCompletion":6889,"completion":6889,"start":35947,"enrollment":4497,"conditions":35948,"interventions":35949},"NCT05397171","A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced\u002FMetastatic Solid Tumours",[90,91],"2022-06-07",[664,691,992],[35935,35950],"Zirconium-89 crefmirlimab berdoxam",{"trials":35952,"activeCount":102},[],{"trials":35954,"activeCount":102},[],{"trials":35956,"activeCount":102},[],{"intervention":35950,"totalTrials":122,"cells":35958},{"EARLY_PHASE1":35959,"PHASE1":35961,"PHASE2":35963,"PHASE3":35969,"PHASE4":35971,"NA":35973},{"trials":35960,"activeCount":102},[],{"trials":35962,"activeCount":102},[],{"trials":35964,"activeCount":102},[35965],{"nctId":35944,"briefTitle":35945,"status":443,"phases":35966,"primaryCompletion":6889,"completion":6889,"start":35947,"enrollment":4497,"conditions":35967,"interventions":35968},[90,91],[664,691,992],[35935,35950],{"trials":35970,"activeCount":102},[],{"trials":35972,"activeCount":102},[],{"trials":35974,"activeCount":102},[],{"intervention":35976,"totalTrials":122,"cells":35977},"LAS100977",{"EARLY_PHASE1":35978,"PHASE1":35980,"PHASE2":35982,"PHASE3":35991,"PHASE4":35993,"NA":35995},{"trials":35979,"activeCount":102},[],{"trials":35981,"activeCount":102},[],{"trials":35983,"activeCount":102},[35984],{"nctId":35985,"briefTitle":35986,"status":195,"phases":35987,"primaryCompletion":687,"completion":687,"start":2675,"enrollment":19246,"conditions":35988,"interventions":35989},"NCT01425814","Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population",[91],[6083],[35976,35976,35976,35976,35990],"Reference",{"trials":35992,"activeCount":102},[],{"trials":35994,"activeCount":102},[],{"trials":35996,"activeCount":102},[],{"intervention":35990,"totalTrials":122,"cells":35998},{"EARLY_PHASE1":35999,"PHASE1":36001,"PHASE2":36003,"PHASE3":36009,"PHASE4":36011,"NA":36013},{"trials":36000,"activeCount":102},[],{"trials":36002,"activeCount":102},[],{"trials":36004,"activeCount":102},[36005],{"nctId":35985,"briefTitle":35986,"status":195,"phases":36006,"primaryCompletion":687,"completion":687,"start":2675,"enrollment":19246,"conditions":36007,"interventions":36008},[91],[6083],[35976,35976,35976,35976,35990],{"trials":36010,"activeCount":102},[],{"trials":36012,"activeCount":102},[],{"trials":36014,"activeCount":102},[],{"intervention":16195,"totalTrials":122,"cells":36016},{"EARLY_PHASE1":36017,"PHASE1":36019,"PHASE2":36021,"PHASE3":36027,"PHASE4":36029,"NA":36031},{"trials":36018,"activeCount":102},[],{"trials":36020,"activeCount":102},[],{"trials":36022,"activeCount":102},[36023],{"nctId":16189,"briefTitle":16190,"status":443,"phases":36024,"primaryCompletion":13756,"completion":13756,"start":4006,"enrollment":5898,"conditions":36025,"interventions":36026},[91],[16193],[570,16195,16196,16197],{"trials":36028,"activeCount":102},[],{"trials":36030,"activeCount":102},[],{"trials":36032,"activeCount":102},[],{"intervention":16196,"totalTrials":122,"cells":36034},{"EARLY_PHASE1":36035,"PHASE1":36037,"PHASE2":36039,"PHASE3":36045,"PHASE4":36047,"NA":36049},{"trials":36036,"activeCount":102},[],{"trials":36038,"activeCount":102},[],{"trials":36040,"activeCount":102},[36041],{"nctId":16189,"briefTitle":16190,"status":443,"phases":36042,"primaryCompletion":13756,"completion":13756,"start":4006,"enrollment":5898,"conditions":36043,"interventions":36044},[91],[16193],[570,16195,16196,16197],{"trials":36046,"activeCount":102},[],{"trials":36048,"activeCount":102},[],{"trials":36050,"activeCount":102},[],{"intervention":16197,"totalTrials":122,"cells":36052},{"EARLY_PHASE1":36053,"PHASE1":36055,"PHASE2":36057,"PHASE3":36063,"PHASE4":36065,"NA":36067},{"trials":36054,"activeCount":102},[],{"trials":36056,"activeCount":102},[],{"trials":36058,"activeCount":102},[36059],{"nctId":16189,"briefTitle":16190,"status":443,"phases":36060,"primaryCompletion":13756,"completion":13756,"start":4006,"enrollment":5898,"conditions":36061,"interventions":36062},[91],[16193],[570,16195,16196,16197],{"trials":36064,"activeCount":102},[],{"trials":36066,"activeCount":102},[],{"trials":36068,"activeCount":102},[],{"intervention":13112,"totalTrials":122,"cells":36070},{"EARLY_PHASE1":36071,"PHASE1":36073,"PHASE2":36075,"PHASE3":36081,"PHASE4":36083,"NA":36085},{"trials":36072,"activeCount":102},[],{"trials":36074,"activeCount":102},[],{"trials":36076,"activeCount":102},[36077],{"nctId":13107,"briefTitle":13108,"status":195,"phases":36078,"primaryCompletion":6710,"completion":3827,"start":6562,"enrollment":477,"conditions":36079,"interventions":36080},[91],[556],[268,13112],{"trials":36082,"activeCount":102},[],{"trials":36084,"activeCount":102},[],{"trials":36086,"activeCount":102},[],{"intervention":36088,"totalTrials":122,"cells":36089},"AZD6094",{"EARLY_PHASE1":36090,"PHASE1":36092,"PHASE2":36094,"PHASE3":36106,"PHASE4":36108,"NA":36110},{"trials":36091,"activeCount":102},[],{"trials":36093,"activeCount":102},[],{"trials":36095,"activeCount":102},[36096],{"nctId":36097,"briefTitle":36098,"status":195,"phases":36099,"primaryCompletion":36100,"completion":36101,"start":36102,"enrollment":3325,"conditions":36103,"interventions":36105},"NCT02127710","A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)",[91],"2016-04-14","2020-04-20","2014-04-30",[36104],"Papillary Renal Cell Cancer",[36088],{"trials":36107,"activeCount":102},[],{"trials":36109,"activeCount":102},[],{"trials":36111,"activeCount":102},[],{"intervention":34718,"totalTrials":122,"cells":36113},{"EARLY_PHASE1":36114,"PHASE1":36116,"PHASE2":36118,"PHASE3":36124,"PHASE4":36126,"NA":36128},{"trials":36115,"activeCount":102},[],{"trials":36117,"activeCount":102},[],{"trials":36119,"activeCount":102},[36120],{"nctId":34712,"briefTitle":34713,"status":195,"phases":36121,"primaryCompletion":2415,"completion":2415,"start":2639,"enrollment":1385,"conditions":36122,"interventions":36123},[91],[34716,12275],[34718,34703,34719],{"trials":36125,"activeCount":102},[],{"trials":36127,"activeCount":102},[],{"trials":36129,"activeCount":102},[],{"intervention":34719,"totalTrials":122,"cells":36131},{"EARLY_PHASE1":36132,"PHASE1":36134,"PHASE2":36136,"PHASE3":36142,"PHASE4":36144,"NA":36146},{"trials":36133,"activeCount":102},[],{"trials":36135,"activeCount":102},[],{"trials":36137,"activeCount":102},[36138],{"nctId":34712,"briefTitle":34713,"status":195,"phases":36139,"primaryCompletion":2415,"completion":2415,"start":2639,"enrollment":1385,"conditions":36140,"interventions":36141},[91],[34716,12275],[34718,34703,34719],{"trials":36143,"activeCount":102},[],{"trials":36145,"activeCount":102},[],{"trials":36147,"activeCount":102},[],{"intervention":36149,"totalTrials":122,"cells":36150},"AZD8601",{"EARLY_PHASE1":36151,"PHASE1":36153,"PHASE2":36155,"PHASE3":36164,"PHASE4":36166,"NA":36168},{"trials":36152,"activeCount":102},[],{"trials":36154,"activeCount":102},[],{"trials":36156,"activeCount":102},[36157],{"nctId":36158,"briefTitle":36159,"status":195,"phases":36160,"primaryCompletion":7414,"completion":7414,"start":36161,"enrollment":2222,"conditions":36162,"interventions":36163},"NCT03370887","AZD8601 Study in CABG Patients",[91],"2018-02-05",[1520],[36149],{"trials":36165,"activeCount":102},[],{"trials":36167,"activeCount":102},[],{"trials":36169,"activeCount":102},[],{"intervention":36171,"totalTrials":122,"cells":36172},"80\u002F2.25 μg Symbicort pMDI",{"EARLY_PHASE1":36173,"PHASE1":36175,"PHASE2":36177,"PHASE3":36188,"PHASE4":36190,"NA":36192},{"trials":36174,"activeCount":102},[],{"trials":36176,"activeCount":102},[],{"trials":36178,"activeCount":102},[36179],{"nctId":36180,"briefTitle":36181,"status":195,"phases":36182,"primaryCompletion":2589,"completion":2589,"start":3862,"enrollment":680,"conditions":36183,"interventions":36184},"NCT01136655","A Study in Asthmatic Children (6 to \u003C12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy",[91],[16],[36171,36185,36186,36187],"80\u002F4.5 μg Symbicort pMDI","Foradil Aerolizer 12 μg","40 μg budesonide HFA pMDI",{"trials":36189,"activeCount":102},[],{"trials":36191,"activeCount":102},[],{"trials":36193,"activeCount":102},[],{"intervention":36185,"totalTrials":122,"cells":36195},{"EARLY_PHASE1":36196,"PHASE1":36198,"PHASE2":36200,"PHASE3":36206,"PHASE4":36208,"NA":36210},{"trials":36197,"activeCount":102},[],{"trials":36199,"activeCount":102},[],{"trials":36201,"activeCount":102},[36202],{"nctId":36180,"briefTitle":36181,"status":195,"phases":36203,"primaryCompletion":2589,"completion":2589,"start":3862,"enrollment":680,"conditions":36204,"interventions":36205},[91],[16],[36171,36185,36186,36187],{"trials":36207,"activeCount":102},[],{"trials":36209,"activeCount":102},[],{"trials":36211,"activeCount":102},[],{"intervention":36186,"totalTrials":122,"cells":36213},{"EARLY_PHASE1":36214,"PHASE1":36216,"PHASE2":36218,"PHASE3":36224,"PHASE4":36226,"NA":36228},{"trials":36215,"activeCount":102},[],{"trials":36217,"activeCount":102},[],{"trials":36219,"activeCount":102},[36220],{"nctId":36180,"briefTitle":36181,"status":195,"phases":36221,"primaryCompletion":2589,"completion":2589,"start":3862,"enrollment":680,"conditions":36222,"interventions":36223},[91],[16],[36171,36185,36186,36187],{"trials":36225,"activeCount":102},[],{"trials":36227,"activeCount":102},[],{"trials":36229,"activeCount":102},[],{"intervention":36187,"totalTrials":122,"cells":36231},{"EARLY_PHASE1":36232,"PHASE1":36234,"PHASE2":36236,"PHASE3":36242,"PHASE4":36244,"NA":36246},{"trials":36233,"activeCount":102},[],{"trials":36235,"activeCount":102},[],{"trials":36237,"activeCount":102},[36238],{"nctId":36180,"briefTitle":36181,"status":195,"phases":36239,"primaryCompletion":2589,"completion":2589,"start":3862,"enrollment":680,"conditions":36240,"interventions":36241},[91],[16],[36171,36185,36186,36187],{"trials":36243,"activeCount":102},[],{"trials":36245,"activeCount":102},[],{"trials":36247,"activeCount":102},[],{"intervention":34748,"totalTrials":122,"cells":36249},{"EARLY_PHASE1":36250,"PHASE1":36252,"PHASE2":36254,"PHASE3":36260,"PHASE4":36262,"NA":36264},{"trials":36251,"activeCount":102},[],{"trials":36253,"activeCount":102},[],{"trials":36255,"activeCount":102},[36256],{"nctId":34742,"briefTitle":34743,"status":195,"phases":36257,"primaryCompletion":34745,"completion":34745,"start":7606,"enrollment":20097,"conditions":36258,"interventions":36259},[91],[22,33543],[34748,34749,34750,15635],{"trials":36261,"activeCount":102},[],{"trials":36263,"activeCount":102},[],{"trials":36265,"activeCount":102},[],{"intervention":34749,"totalTrials":122,"cells":36267},{"EARLY_PHASE1":36268,"PHASE1":36270,"PHASE2":36272,"PHASE3":36278,"PHASE4":36280,"NA":36282},{"trials":36269,"activeCount":102},[],{"trials":36271,"activeCount":102},[],{"trials":36273,"activeCount":102},[36274],{"nctId":34742,"briefTitle":34743,"status":195,"phases":36275,"primaryCompletion":34745,"completion":34745,"start":7606,"enrollment":20097,"conditions":36276,"interventions":36277},[91],[22,33543],[34748,34749,34750,15635],{"trials":36279,"activeCount":102},[],{"trials":36281,"activeCount":102},[],{"trials":36283,"activeCount":102},[],{"intervention":34750,"totalTrials":122,"cells":36285},{"EARLY_PHASE1":36286,"PHASE1":36288,"PHASE2":36290,"PHASE3":36296,"PHASE4":36298,"NA":36300},{"trials":36287,"activeCount":102},[],{"trials":36289,"activeCount":102},[],{"trials":36291,"activeCount":102},[36292],{"nctId":34742,"briefTitle":34743,"status":195,"phases":36293,"primaryCompletion":34745,"completion":34745,"start":7606,"enrollment":20097,"conditions":36294,"interventions":36295},[91],[22,33543],[34748,34749,34750,15635],{"trials":36297,"activeCount":102},[],{"trials":36299,"activeCount":102},[],{"trials":36301,"activeCount":102},[],{"intervention":36303,"totalTrials":122,"cells":36304},"0.9% (w\u002Fv) saline",{"EARLY_PHASE1":36305,"PHASE1":36307,"PHASE2":36309,"PHASE3":36318,"PHASE4":36320,"NA":36322},{"trials":36306,"activeCount":102},[],{"trials":36308,"activeCount":102},[],{"trials":36310,"activeCount":102},[36311],{"nctId":36312,"briefTitle":36313,"status":195,"phases":36314,"primaryCompletion":32552,"completion":32552,"start":36315,"enrollment":872,"conditions":36316,"interventions":36317},"NCT04568031","Study of AZD1222 for the Prevention of COVID-19 in Japan",[90,91],"2020-08-23",[1387],[28750,36303],{"trials":36319,"activeCount":102},[],{"trials":36321,"activeCount":102},[],{"trials":36323,"activeCount":102},[],{"intervention":34695,"totalTrials":122,"cells":36325},{"EARLY_PHASE1":36326,"PHASE1":36328,"PHASE2":36330,"PHASE3":36336,"PHASE4":36338,"NA":36340},{"trials":36327,"activeCount":102},[],{"trials":36329,"activeCount":102},[],{"trials":36331,"activeCount":102},[36332],{"nctId":34687,"briefTitle":34688,"status":195,"phases":36333,"primaryCompletion":34690,"completion":34690,"start":34691,"enrollment":1710,"conditions":36334,"interventions":36335},[90,91],[34693],[34695,3915],{"trials":36337,"activeCount":102},[],{"trials":36339,"activeCount":102},[],{"trials":36341,"activeCount":102},[],{"intervention":36343,"totalTrials":122,"cells":36344},"AS MDI 90 μg",{"EARLY_PHASE1":36345,"PHASE1":36347,"PHASE2":36349,"PHASE3":36361,"PHASE4":36363,"NA":36365},{"trials":36346,"activeCount":102},[],{"trials":36348,"activeCount":102},[],{"trials":36350,"activeCount":102},[36351],{"nctId":36352,"briefTitle":36353,"status":195,"phases":36354,"primaryCompletion":6377,"completion":6377,"start":2791,"enrollment":36355,"conditions":36356,"interventions":36357},"NCT03364608","Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma",[91],86,[16],[36343,36358,36359,36360],"AS MDI 180 µg","Proventil 90 μg","Proventil 180 μg",{"trials":36362,"activeCount":102},[],{"trials":36364,"activeCount":102},[],{"trials":36366,"activeCount":102},[],{"intervention":36358,"totalTrials":122,"cells":36368},{"EARLY_PHASE1":36369,"PHASE1":36371,"PHASE2":36373,"PHASE3":36379,"PHASE4":36381,"NA":36383},{"trials":36370,"activeCount":102},[],{"trials":36372,"activeCount":102},[],{"trials":36374,"activeCount":102},[36375],{"nctId":36352,"briefTitle":36353,"status":195,"phases":36376,"primaryCompletion":6377,"completion":6377,"start":2791,"enrollment":36355,"conditions":36377,"interventions":36378},[91],[16],[36343,36358,36359,36360],{"trials":36380,"activeCount":102},[],{"trials":36382,"activeCount":102},[],{"trials":36384,"activeCount":102},[],{"intervention":36359,"totalTrials":122,"cells":36386},{"EARLY_PHASE1":36387,"PHASE1":36389,"PHASE2":36391,"PHASE3":36397,"PHASE4":36399,"NA":36401},{"trials":36388,"activeCount":102},[],{"trials":36390,"activeCount":102},[],{"trials":36392,"activeCount":102},[36393],{"nctId":36352,"briefTitle":36353,"status":195,"phases":36394,"primaryCompletion":6377,"completion":6377,"start":2791,"enrollment":36355,"conditions":36395,"interventions":36396},[91],[16],[36343,36358,36359,36360],{"trials":36398,"activeCount":102},[],{"trials":36400,"activeCount":102},[],{"trials":36402,"activeCount":102},[],{"intervention":36360,"totalTrials":122,"cells":36404},{"EARLY_PHASE1":36405,"PHASE1":36407,"PHASE2":36409,"PHASE3":36415,"PHASE4":36417,"NA":36419},{"trials":36406,"activeCount":102},[],{"trials":36408,"activeCount":102},[],{"trials":36410,"activeCount":102},[36411],{"nctId":36352,"briefTitle":36353,"status":195,"phases":36412,"primaryCompletion":6377,"completion":6377,"start":2791,"enrollment":36355,"conditions":36413,"interventions":36414},[91],[16],[36343,36358,36359,36360],{"trials":36416,"activeCount":102},[],{"trials":36418,"activeCount":102},[],{"trials":36420,"activeCount":102},[],{"intervention":36422,"totalTrials":122,"cells":36423},"Fostamatinib and placebo injections",{"EARLY_PHASE1":36424,"PHASE1":36426,"PHASE2":36428,"PHASE3":36437,"PHASE4":36439,"NA":36441},{"trials":36425,"activeCount":102},[],{"trials":36427,"activeCount":102},[],{"trials":36429,"activeCount":102},[36430],{"nctId":36431,"briefTitle":36432,"status":443,"phases":36433,"primaryCompletion":2365,"completion":1701,"start":2516,"enrollment":4141,"conditions":36434,"interventions":36435},"NCT01264770","Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)",[91],[7267],[36422,36422,36422,36436],"Adalimumab and placebo of fostamatinib",{"trials":36438,"activeCount":102},[],{"trials":36440,"activeCount":102},[],{"trials":36442,"activeCount":102},[],{"intervention":36436,"totalTrials":122,"cells":36444},{"EARLY_PHASE1":36445,"PHASE1":36447,"PHASE2":36449,"PHASE3":36455,"PHASE4":36457,"NA":36459},{"trials":36446,"activeCount":102},[],{"trials":36448,"activeCount":102},[],{"trials":36450,"activeCount":102},[36451],{"nctId":36431,"briefTitle":36432,"status":443,"phases":36452,"primaryCompletion":2365,"completion":1701,"start":2516,"enrollment":4141,"conditions":36453,"interventions":36454},[91],[7267],[36422,36422,36422,36436],{"trials":36456,"activeCount":102},[],{"trials":36458,"activeCount":102},[],{"trials":36460,"activeCount":102},[],{"intervention":36462,"totalTrials":122,"cells":36463},"Atuliflapon",{"EARLY_PHASE1":36464,"PHASE1":36466,"PHASE2":36468,"PHASE3":36478,"PHASE4":36480,"NA":36482},{"trials":36465,"activeCount":102},[],{"trials":36467,"activeCount":102},[],{"trials":36469,"activeCount":102},[36470],{"nctId":36471,"briefTitle":36472,"status":195,"phases":36473,"primaryCompletion":36474,"completion":36474,"start":36475,"enrollment":2028,"conditions":36476,"interventions":36477},"NCT05251259","Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma",[91],"2026-01-07","2022-01-27",[16],[36462],{"trials":36479,"activeCount":102},[],{"trials":36481,"activeCount":102},[],{"trials":36483,"activeCount":102},[],{"intervention":36485,"totalTrials":122,"cells":36486},"Aclidinium bromide and formoterol",{"EARLY_PHASE1":36487,"PHASE1":36489,"PHASE2":36491,"PHASE3":36501,"PHASE4":36503,"NA":36505},{"trials":36488,"activeCount":102},[],{"trials":36490,"activeCount":102},[],{"trials":36492,"activeCount":102},[36493],{"nctId":36494,"briefTitle":36495,"status":195,"phases":36496,"primaryCompletion":2414,"completion":2414,"start":2168,"enrollment":36497,"conditions":36498,"interventions":36499},"NCT00626522","Aclidinium\u002FFormoterol Fixed Combination Dose Finding Study",[91],808,[6083],[36485,36500],"Aclidinium bromide and formoterol placebo",{"trials":36502,"activeCount":102},[],{"trials":36504,"activeCount":102},[],{"trials":36506,"activeCount":102},[],{"intervention":36500,"totalTrials":122,"cells":36508},{"EARLY_PHASE1":36509,"PHASE1":36511,"PHASE2":36513,"PHASE3":36519,"PHASE4":36521,"NA":36523},{"trials":36510,"activeCount":102},[],{"trials":36512,"activeCount":102},[],{"trials":36514,"activeCount":102},[36515],{"nctId":36494,"briefTitle":36495,"status":195,"phases":36516,"primaryCompletion":2414,"completion":2414,"start":2168,"enrollment":36497,"conditions":36517,"interventions":36518},[91],[6083],[36485,36500],{"trials":36520,"activeCount":102},[],{"trials":36522,"activeCount":102},[],{"trials":36524,"activeCount":102},[],{"intervention":8697,"totalTrials":122,"cells":36526},{"EARLY_PHASE1":36527,"PHASE1":36529,"PHASE2":36531,"PHASE3":36537,"PHASE4":36539,"NA":36541},{"trials":36528,"activeCount":102},[],{"trials":36530,"activeCount":102},[],{"trials":36532,"activeCount":102},[36533],{"nctId":8689,"briefTitle":8690,"status":624,"phases":36534,"primaryCompletion":4284,"completion":4284,"start":8692,"enrollment":8693,"conditions":36535,"interventions":36536},[91],[5121],[8696,4615,8697,4843],{"trials":36538,"activeCount":102},[],{"trials":36540,"activeCount":102},[],{"trials":36542,"activeCount":102},[],{"intervention":36544,"totalTrials":122,"cells":36545},"Part A: Placebo",{"EARLY_PHASE1":36546,"PHASE1":36548,"PHASE2":36550,"PHASE3":36564,"PHASE4":36566,"NA":36568},{"trials":36547,"activeCount":102},[],{"trials":36549,"activeCount":102},[],{"trials":36551,"activeCount":102},[36552],{"nctId":36553,"briefTitle":36554,"status":443,"phases":36555,"primaryCompletion":15606,"completion":220,"start":3724,"enrollment":6407,"conditions":36556,"interventions":36557},"NCT05516498","Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)",[91],[33264],[36544,36558,36559,36560,36561,36562,36563],"Part A: zibotentan (dose B) + dapagliflozin","Part B: Placebo","Part B: placebo (matching zibotentan capsule) + dapagliflozin","Part B: zibotentan (dose A) + dapagliflozin","Part B: zibotentan (dose B) + dapagliflozin","Part B: zibotentan (dose C) + dapagliflozin",{"trials":36565,"activeCount":102},[],{"trials":36567,"activeCount":102},[],{"trials":36569,"activeCount":102},[],{"intervention":36558,"totalTrials":122,"cells":36571},{"EARLY_PHASE1":36572,"PHASE1":36574,"PHASE2":36576,"PHASE3":36582,"PHASE4":36584,"NA":36586},{"trials":36573,"activeCount":102},[],{"trials":36575,"activeCount":102},[],{"trials":36577,"activeCount":102},[36578],{"nctId":36553,"briefTitle":36554,"status":443,"phases":36579,"primaryCompletion":15606,"completion":220,"start":3724,"enrollment":6407,"conditions":36580,"interventions":36581},[91],[33264],[36544,36558,36559,36560,36561,36562,36563],{"trials":36583,"activeCount":102},[],{"trials":36585,"activeCount":102},[],{"trials":36587,"activeCount":102},[],{"intervention":36559,"totalTrials":122,"cells":36589},{"EARLY_PHASE1":36590,"PHASE1":36592,"PHASE2":36594,"PHASE3":36600,"PHASE4":36602,"NA":36604},{"trials":36591,"activeCount":102},[],{"trials":36593,"activeCount":102},[],{"trials":36595,"activeCount":102},[36596],{"nctId":36553,"briefTitle":36554,"status":443,"phases":36597,"primaryCompletion":15606,"completion":220,"start":3724,"enrollment":6407,"conditions":36598,"interventions":36599},[91],[33264],[36544,36558,36559,36560,36561,36562,36563],{"trials":36601,"activeCount":102},[],{"trials":36603,"activeCount":102},[],{"trials":36605,"activeCount":102},[],{"intervention":36560,"totalTrials":122,"cells":36607},{"EARLY_PHASE1":36608,"PHASE1":36610,"PHASE2":36612,"PHASE3":36618,"PHASE4":36620,"NA":36622},{"trials":36609,"activeCount":102},[],{"trials":36611,"activeCount":102},[],{"trials":36613,"activeCount":102},[36614],{"nctId":36553,"briefTitle":36554,"status":443,"phases":36615,"primaryCompletion":15606,"completion":220,"start":3724,"enrollment":6407,"conditions":36616,"interventions":36617},[91],[33264],[36544,36558,36559,36560,36561,36562,36563],{"trials":36619,"activeCount":102},[],{"trials":36621,"activeCount":102},[],{"trials":36623,"activeCount":102},[],{"intervention":36561,"totalTrials":122,"cells":36625},{"EARLY_PHASE1":36626,"PHASE1":36628,"PHASE2":36630,"PHASE3":36636,"PHASE4":36638,"NA":36640},{"trials":36627,"activeCount":102},[],{"trials":36629,"activeCount":102},[],{"trials":36631,"activeCount":102},[36632],{"nctId":36553,"briefTitle":36554,"status":443,"phases":36633,"primaryCompletion":15606,"completion":220,"start":3724,"enrollment":6407,"conditions":36634,"interventions":36635},[91],[33264],[36544,36558,36559,36560,36561,36562,36563],{"trials":36637,"activeCount":102},[],{"trials":36639,"activeCount":102},[],{"trials":36641,"activeCount":102},[],{"intervention":36562,"totalTrials":122,"cells":36643},{"EARLY_PHASE1":36644,"PHASE1":36646,"PHASE2":36648,"PHASE3":36654,"PHASE4":36656,"NA":36658},{"trials":36645,"activeCount":102},[],{"trials":36647,"activeCount":102},[],{"trials":36649,"activeCount":102},[36650],{"nctId":36553,"briefTitle":36554,"status":443,"phases":36651,"primaryCompletion":15606,"completion":220,"start":3724,"enrollment":6407,"conditions":36652,"interventions":36653},[91],[33264],[36544,36558,36559,36560,36561,36562,36563],{"trials":36655,"activeCount":102},[],{"trials":36657,"activeCount":102},[],{"trials":36659,"activeCount":102},[],{"intervention":36563,"totalTrials":122,"cells":36661},{"EARLY_PHASE1":36662,"PHASE1":36664,"PHASE2":36666,"PHASE3":36672,"PHASE4":36674,"NA":36676},{"trials":36663,"activeCount":102},[],{"trials":36665,"activeCount":102},[],{"trials":36667,"activeCount":102},[36668],{"nctId":36553,"briefTitle":36554,"status":443,"phases":36669,"primaryCompletion":15606,"completion":220,"start":3724,"enrollment":6407,"conditions":36670,"interventions":36671},[91],[33264],[36544,36558,36559,36560,36561,36562,36563],{"trials":36673,"activeCount":102},[],{"trials":36675,"activeCount":102},[],{"trials":36677,"activeCount":102},[],{"intervention":34828,"totalTrials":122,"cells":36679},{"EARLY_PHASE1":36680,"PHASE1":36682,"PHASE2":36684,"PHASE3":36690,"PHASE4":36692,"NA":36694},{"trials":36681,"activeCount":102},[],{"trials":36683,"activeCount":102},[],{"trials":36685,"activeCount":102},[36686],{"nctId":34820,"briefTitle":34821,"status":195,"phases":36687,"primaryCompletion":34823,"completion":1584,"start":4016,"enrollment":4307,"conditions":36688,"interventions":36689},[91],[34825,34826,5772],[34828,34811,34829],{"trials":36691,"activeCount":102},[],{"trials":36693,"activeCount":102},[],{"trials":36695,"activeCount":102},[],{"intervention":34829,"totalTrials":122,"cells":36697},{"EARLY_PHASE1":36698,"PHASE1":36700,"PHASE2":36702,"PHASE3":36708,"PHASE4":36710,"NA":36712},{"trials":36699,"activeCount":102},[],{"trials":36701,"activeCount":102},[],{"trials":36703,"activeCount":102},[36704],{"nctId":34820,"briefTitle":34821,"status":195,"phases":36705,"primaryCompletion":34823,"completion":1584,"start":4016,"enrollment":4307,"conditions":36706,"interventions":36707},[91],[34825,34826,5772],[34828,34811,34829],{"trials":36709,"activeCount":102},[],{"trials":36711,"activeCount":102},[],{"trials":36713,"activeCount":102},[],{"intervention":36715,"totalTrials":122,"cells":36716},"AZD5363 when combined with weekly paclitaxel.",{"EARLY_PHASE1":36717,"PHASE1":36719,"PHASE2":36721,"PHASE3":36735,"PHASE4":36737,"NA":36739},{"trials":36718,"activeCount":102},[],{"trials":36720,"activeCount":102},[],{"trials":36722,"activeCount":102},[36723],{"nctId":36724,"briefTitle":36725,"status":195,"phases":36726,"primaryCompletion":36727,"completion":36728,"start":36729,"enrollment":3484,"conditions":36730,"interventions":36732},"NCT01625286","Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",[90,91],"2017-01-28","2022-10-03","2012-10-03",[330,36731],"ER+ve Advanced or Metastatic Breast Cancer",[36715,36715,36733,36734],"AZD5363when combined with weekly paclitaxel.","A placebo in combination with weekly paclitaxel.",{"trials":36736,"activeCount":102},[],{"trials":36738,"activeCount":102},[],{"trials":36740,"activeCount":102},[],{"intervention":36733,"totalTrials":122,"cells":36742},{"EARLY_PHASE1":36743,"PHASE1":36745,"PHASE2":36747,"PHASE3":36753,"PHASE4":36755,"NA":36757},{"trials":36744,"activeCount":102},[],{"trials":36746,"activeCount":102},[],{"trials":36748,"activeCount":102},[36749],{"nctId":36724,"briefTitle":36725,"status":195,"phases":36750,"primaryCompletion":36727,"completion":36728,"start":36729,"enrollment":3484,"conditions":36751,"interventions":36752},[90,91],[330,36731],[36715,36715,36733,36734],{"trials":36754,"activeCount":102},[],{"trials":36756,"activeCount":102},[],{"trials":36758,"activeCount":102},[],{"intervention":36734,"totalTrials":122,"cells":36760},{"EARLY_PHASE1":36761,"PHASE1":36763,"PHASE2":36765,"PHASE3":36771,"PHASE4":36773,"NA":36775},{"trials":36762,"activeCount":102},[],{"trials":36764,"activeCount":102},[],{"trials":36766,"activeCount":102},[36767],{"nctId":36724,"briefTitle":36725,"status":195,"phases":36768,"primaryCompletion":36727,"completion":36728,"start":36729,"enrollment":3484,"conditions":36769,"interventions":36770},[90,91],[330,36731],[36715,36715,36733,36734],{"trials":36772,"activeCount":102},[],{"trials":36774,"activeCount":102},[],{"trials":36776,"activeCount":102},[],{"intervention":36778,"totalTrials":122,"cells":36779},"Exenatide - Exenatide - Placebo",{"EARLY_PHASE1":36780,"PHASE1":36782,"PHASE2":36784,"PHASE3":36793,"PHASE4":36795,"NA":36797},{"trials":36781,"activeCount":102},[],{"trials":36783,"activeCount":102},[],{"trials":36785,"activeCount":102},[36786],{"nctId":36787,"briefTitle":36788,"status":195,"phases":36789,"primaryCompletion":2328,"completion":2328,"start":9213,"enrollment":963,"conditions":36790,"interventions":36791},"NCT00254254","A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus",[91],[22],[36778,36792],"Exenatide - Placebo - Exenatide",{"trials":36794,"activeCount":102},[],{"trials":36796,"activeCount":102},[],{"trials":36798,"activeCount":102},[],{"intervention":36792,"totalTrials":122,"cells":36800},{"EARLY_PHASE1":36801,"PHASE1":36803,"PHASE2":36805,"PHASE3":36811,"PHASE4":36813,"NA":36815},{"trials":36802,"activeCount":102},[],{"trials":36804,"activeCount":102},[],{"trials":36806,"activeCount":102},[36807],{"nctId":36787,"briefTitle":36788,"status":195,"phases":36808,"primaryCompletion":2328,"completion":2328,"start":9213,"enrollment":963,"conditions":36809,"interventions":36810},[91],[22],[36778,36792],{"trials":36812,"activeCount":102},[],{"trials":36814,"activeCount":102},[],{"trials":36816,"activeCount":102},[],{"intervention":36818,"totalTrials":122,"cells":36819},"ER tablet 25 mg AZD3241",{"EARLY_PHASE1":36820,"PHASE1":36822,"PHASE2":36824,"PHASE3":36834,"PHASE4":36836,"NA":36838},{"trials":36821,"activeCount":102},[],{"trials":36823,"activeCount":102},[],{"trials":36825,"activeCount":102},[36826],{"nctId":36827,"briefTitle":36828,"status":195,"phases":36829,"primaryCompletion":2616,"completion":2579,"start":4496,"enrollment":1130,"conditions":36830,"interventions":36832},"NCT01527695","PET Study in Parkinson's Disease Patients",[91],[36831],"Parkinson's Disease",[36818,36833],"ER tablet 100 mg AZD3241",{"trials":36835,"activeCount":102},[],{"trials":36837,"activeCount":102},[],{"trials":36839,"activeCount":102},[],{"intervention":36833,"totalTrials":122,"cells":36841},{"EARLY_PHASE1":36842,"PHASE1":36844,"PHASE2":36846,"PHASE3":36852,"PHASE4":36854,"NA":36856},{"trials":36843,"activeCount":102},[],{"trials":36845,"activeCount":102},[],{"trials":36847,"activeCount":102},[36848],{"nctId":36827,"briefTitle":36828,"status":195,"phases":36849,"primaryCompletion":2616,"completion":2579,"start":4496,"enrollment":1130,"conditions":36850,"interventions":36851},[91],[36831],[36818,36833],{"trials":36853,"activeCount":102},[],{"trials":36855,"activeCount":102},[],{"trials":36857,"activeCount":102},[],{"intervention":36859,"totalTrials":122,"cells":36860},"AZD7594 DPI 55μg\u002F50μg.",{"EARLY_PHASE1":36861,"PHASE1":36863,"PHASE2":36865,"PHASE3":36880,"PHASE4":36882,"NA":36884},{"trials":36862,"activeCount":102},[],{"trials":36864,"activeCount":102},[],{"trials":36866,"activeCount":102},[36867],{"nctId":36868,"briefTitle":36869,"status":195,"phases":36870,"primaryCompletion":36871,"completion":36871,"start":36872,"enrollment":36497,"conditions":36873,"interventions":36874},"NCT03622112","A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects",[91],"2019-09-30","2019-01-02",[16],[36859,36875,36876,36877,36878,36879],"AZD7594 DPI 99 µg\u002F90 µg","AZD7594 DPI 198 µg\u002F180 µg","AZD7594 DPI 396 µg\u002F360 µg once daily.","AZD7594 DPI 792 µg\u002F720 µg","FF 100 µg once daily",{"trials":36881,"activeCount":102},[],{"trials":36883,"activeCount":102},[],{"trials":36885,"activeCount":102},[],{"intervention":36875,"totalTrials":122,"cells":36887},{"EARLY_PHASE1":36888,"PHASE1":36890,"PHASE2":36892,"PHASE3":36898,"PHASE4":36900,"NA":36902},{"trials":36889,"activeCount":102},[],{"trials":36891,"activeCount":102},[],{"trials":36893,"activeCount":102},[36894],{"nctId":36868,"briefTitle":36869,"status":195,"phases":36895,"primaryCompletion":36871,"completion":36871,"start":36872,"enrollment":36497,"conditions":36896,"interventions":36897},[91],[16],[36859,36875,36876,36877,36878,36879],{"trials":36899,"activeCount":102},[],{"trials":36901,"activeCount":102},[],{"trials":36903,"activeCount":102},[],{"intervention":36876,"totalTrials":122,"cells":36905},{"EARLY_PHASE1":36906,"PHASE1":36908,"PHASE2":36910,"PHASE3":36916,"PHASE4":36918,"NA":36920},{"trials":36907,"activeCount":102},[],{"trials":36909,"activeCount":102},[],{"trials":36911,"activeCount":102},[36912],{"nctId":36868,"briefTitle":36869,"status":195,"phases":36913,"primaryCompletion":36871,"completion":36871,"start":36872,"enrollment":36497,"conditions":36914,"interventions":36915},[91],[16],[36859,36875,36876,36877,36878,36879],{"trials":36917,"activeCount":102},[],{"trials":36919,"activeCount":102},[],{"trials":36921,"activeCount":102},[],{"intervention":36877,"totalTrials":122,"cells":36923},{"EARLY_PHASE1":36924,"PHASE1":36926,"PHASE2":36928,"PHASE3":36934,"PHASE4":36936,"NA":36938},{"trials":36925,"activeCount":102},[],{"trials":36927,"activeCount":102},[],{"trials":36929,"activeCount":102},[36930],{"nctId":36868,"briefTitle":36869,"status":195,"phases":36931,"primaryCompletion":36871,"completion":36871,"start":36872,"enrollment":36497,"conditions":36932,"interventions":36933},[91],[16],[36859,36875,36876,36877,36878,36879],{"trials":36935,"activeCount":102},[],{"trials":36937,"activeCount":102},[],{"trials":36939,"activeCount":102},[],{"intervention":36878,"totalTrials":122,"cells":36941},{"EARLY_PHASE1":36942,"PHASE1":36944,"PHASE2":36946,"PHASE3":36952,"PHASE4":36954,"NA":36956},{"trials":36943,"activeCount":102},[],{"trials":36945,"activeCount":102},[],{"trials":36947,"activeCount":102},[36948],{"nctId":36868,"briefTitle":36869,"status":195,"phases":36949,"primaryCompletion":36871,"completion":36871,"start":36872,"enrollment":36497,"conditions":36950,"interventions":36951},[91],[16],[36859,36875,36876,36877,36878,36879],{"trials":36953,"activeCount":102},[],{"trials":36955,"activeCount":102},[],{"trials":36957,"activeCount":102},[],{"intervention":36879,"totalTrials":122,"cells":36959},{"EARLY_PHASE1":36960,"PHASE1":36962,"PHASE2":36964,"PHASE3":36970,"PHASE4":36972,"NA":36974},{"trials":36961,"activeCount":102},[],{"trials":36963,"activeCount":102},[],{"trials":36965,"activeCount":102},[36966],{"nctId":36868,"briefTitle":36869,"status":195,"phases":36967,"primaryCompletion":36871,"completion":36871,"start":36872,"enrollment":36497,"conditions":36968,"interventions":36969},[91],[16],[36859,36875,36876,36877,36878,36879],{"trials":36971,"activeCount":102},[],{"trials":36973,"activeCount":102},[],{"trials":36975,"activeCount":102},[],{"intervention":36977,"totalTrials":122,"cells":36978},"AC2307",{"EARLY_PHASE1":36979,"PHASE1":36981,"PHASE2":36983,"PHASE3":36991,"PHASE4":36993,"NA":36995},{"trials":36980,"activeCount":102},[],{"trials":36982,"activeCount":102},[],{"trials":36984,"activeCount":102},[36985],{"nctId":36986,"briefTitle":36987,"status":195,"phases":36988,"primaryCompletion":2067,"completion":2067,"start":4915,"enrollment":15283,"conditions":36989,"interventions":36990},"NCT00785408","Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects",[91],[12275,34716],[36977,36977,36977],{"trials":36992,"activeCount":102},[],{"trials":36994,"activeCount":102},[],{"trials":36996,"activeCount":102},[],{"intervention":34612,"totalTrials":122,"cells":36998},{"EARLY_PHASE1":36999,"PHASE1":37001,"PHASE2":37003,"PHASE3":37009,"PHASE4":37011,"NA":37013},{"trials":37000,"activeCount":102},[],{"trials":37002,"activeCount":102},[],{"trials":37004,"activeCount":102},[37005],{"nctId":34607,"briefTitle":34608,"status":195,"phases":37006,"primaryCompletion":3862,"completion":3862,"start":2114,"enrollment":16948,"conditions":37007,"interventions":37008},[91],[28],[34612,34589,34613,34614],{"trials":37010,"activeCount":102},[],{"trials":37012,"activeCount":102},[],{"trials":37014,"activeCount":102},[],{"intervention":34613,"totalTrials":122,"cells":37016},{"EARLY_PHASE1":37017,"PHASE1":37019,"PHASE2":37021,"PHASE3":37027,"PHASE4":37029,"NA":37031},{"trials":37018,"activeCount":102},[],{"trials":37020,"activeCount":102},[],{"trials":37022,"activeCount":102},[37023],{"nctId":34607,"briefTitle":34608,"status":195,"phases":37024,"primaryCompletion":3862,"completion":3862,"start":2114,"enrollment":16948,"conditions":37025,"interventions":37026},[91],[28],[34612,34589,34613,34614],{"trials":37028,"activeCount":102},[],{"trials":37030,"activeCount":102},[],{"trials":37032,"activeCount":102},[],{"intervention":34614,"totalTrials":122,"cells":37034},{"EARLY_PHASE1":37035,"PHASE1":37037,"PHASE2":37039,"PHASE3":37045,"PHASE4":37047,"NA":37049},{"trials":37036,"activeCount":102},[],{"trials":37038,"activeCount":102},[],{"trials":37040,"activeCount":102},[37041],{"nctId":34607,"briefTitle":34608,"status":195,"phases":37042,"primaryCompletion":3862,"completion":3862,"start":2114,"enrollment":16948,"conditions":37043,"interventions":37044},[91],[28],[34612,34589,34613,34614],{"trials":37046,"activeCount":102},[],{"trials":37048,"activeCount":102},[],{"trials":37050,"activeCount":102},[],{"intervention":25282,"totalTrials":122,"cells":37052},{"EARLY_PHASE1":37053,"PHASE1":37055,"PHASE2":37057,"PHASE3":37063,"PHASE4":37065,"NA":37067},{"trials":37054,"activeCount":102},[],{"trials":37056,"activeCount":102},[],{"trials":37058,"activeCount":102},[37059],{"nctId":25275,"briefTitle":25276,"status":195,"phases":37060,"primaryCompletion":20831,"completion":20831,"start":25278,"enrollment":24536,"conditions":37061,"interventions":37062},[91],[2089,25280],[25252,25282],{"trials":37064,"activeCount":102},[],{"trials":37066,"activeCount":102},[],{"trials":37068,"activeCount":102},[],{"intervention":37070,"totalTrials":122,"cells":37071},"BMS-512148",{"EARLY_PHASE1":37072,"PHASE1":37074,"PHASE2":37076,"PHASE3":37084,"PHASE4":37086,"NA":37088},{"trials":37073,"activeCount":102},[],{"trials":37075,"activeCount":102},[],{"trials":37077,"activeCount":102},[37078],{"nctId":37079,"briefTitle":37080,"status":195,"phases":37081,"primaryCompletion":9065,"completion":9065,"start":13047,"enrollment":3172,"conditions":37082,"interventions":37083},"NCT00162305","A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects",[91],[2089],[37070,37070,37070],{"trials":37085,"activeCount":102},[],{"trials":37087,"activeCount":102},[],{"trials":37089,"activeCount":102},[],{"intervention":37091,"totalTrials":122,"cells":37092},"MEDI8968",{"EARLY_PHASE1":37093,"PHASE1":37095,"PHASE2":37097,"PHASE3":37107,"PHASE4":37109,"NA":37111},{"trials":37094,"activeCount":102},[],{"trials":37096,"activeCount":102},[],{"trials":37098,"activeCount":102},[37099],{"nctId":37100,"briefTitle":37101,"status":443,"phases":37102,"primaryCompletion":6436,"completion":6436,"start":7354,"enrollment":2289,"conditions":37103,"interventions":37105},"NCT01838499","Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa",[91],[37104],"Hidradenitis Suppurativa",[37091,37106],"Saline",{"trials":37108,"activeCount":102},[],{"trials":37110,"activeCount":102},[],{"trials":37112,"activeCount":102},[],{"intervention":37106,"totalTrials":122,"cells":37114},{"EARLY_PHASE1":37115,"PHASE1":37117,"PHASE2":37119,"PHASE3":37125,"PHASE4":37127,"NA":37129},{"trials":37116,"activeCount":102},[],{"trials":37118,"activeCount":102},[],{"trials":37120,"activeCount":102},[37121],{"nctId":37100,"briefTitle":37101,"status":443,"phases":37122,"primaryCompletion":6436,"completion":6436,"start":7354,"enrollment":2289,"conditions":37123,"interventions":37124},[91],[37104],[37091,37106],{"trials":37126,"activeCount":102},[],{"trials":37128,"activeCount":102},[],{"trials":37130,"activeCount":102},[],{"intervention":37132,"totalTrials":122,"cells":37133},"Arimidex 1 mg",{"EARLY_PHASE1":37134,"PHASE1":37136,"PHASE2":37138,"PHASE3":37146,"PHASE4":37148,"NA":37150},{"trials":37135,"activeCount":102},[],{"trials":37137,"activeCount":102},[],{"trials":37139,"activeCount":102},[37140],{"nctId":37141,"briefTitle":37142,"status":195,"phases":37143,"primaryCompletion":9213,"completion":20965,"start":5797,"enrollment":1448,"conditions":37144,"interventions":37145},"NCT00055302","Arimidex in McCune Albright Syndrome",[91],[6487],[37132],{"trials":37147,"activeCount":102},[],{"trials":37149,"activeCount":102},[],{"trials":37151,"activeCount":102},[],{"intervention":37153,"totalTrials":122,"cells":37154},"Exenatide LAR",{"EARLY_PHASE1":37155,"PHASE1":37157,"PHASE2":37159,"PHASE3":37167,"PHASE4":37169,"NA":37171},{"trials":37156,"activeCount":102},[],{"trials":37158,"activeCount":102},[],{"trials":37160,"activeCount":102},[37161],{"nctId":37162,"briefTitle":37163,"status":195,"phases":37164,"primaryCompletion":3809,"completion":3809,"start":9944,"enrollment":1864,"conditions":37165,"interventions":37166},"NCT00103935","Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes",[91],[22],[37153,37153],{"trials":37168,"activeCount":102},[],{"trials":37170,"activeCount":102},[],{"trials":37172,"activeCount":102},[],{"intervention":37174,"totalTrials":122,"cells":37175},"Durvalumab and Tremelimumab",{"EARLY_PHASE1":37176,"PHASE1":37178,"PHASE2":37180,"PHASE3":37192,"PHASE4":37194,"NA":37196},{"trials":37177,"activeCount":102},[],{"trials":37179,"activeCount":102},[],{"trials":37181,"activeCount":102},[37182],{"nctId":37183,"briefTitle":37184,"status":195,"phases":37185,"primaryCompletion":32751,"completion":37186,"start":34145,"enrollment":132,"conditions":37187,"interventions":37189},"NCT02937818","A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer",[91],"2023-11-27",[37188],"Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma",[37174,37190,37191],"AZD1775 and carboplatin","AZD6738 and olaparib",{"trials":37193,"activeCount":102},[],{"trials":37195,"activeCount":102},[],{"trials":37197,"activeCount":102},[],{"intervention":37190,"totalTrials":122,"cells":37199},{"EARLY_PHASE1":37200,"PHASE1":37202,"PHASE2":37204,"PHASE3":37210,"PHASE4":37212,"NA":37214},{"trials":37201,"activeCount":102},[],{"trials":37203,"activeCount":102},[],{"trials":37205,"activeCount":102},[37206],{"nctId":37183,"briefTitle":37184,"status":195,"phases":37207,"primaryCompletion":32751,"completion":37186,"start":34145,"enrollment":132,"conditions":37208,"interventions":37209},[91],[37188],[37174,37190,37191],{"trials":37211,"activeCount":102},[],{"trials":37213,"activeCount":102},[],{"trials":37215,"activeCount":102},[],{"intervention":37191,"totalTrials":122,"cells":37217},{"EARLY_PHASE1":37218,"PHASE1":37220,"PHASE2":37222,"PHASE3":37228,"PHASE4":37230,"NA":37232},{"trials":37219,"activeCount":102},[],{"trials":37221,"activeCount":102},[],{"trials":37223,"activeCount":102},[37224],{"nctId":37183,"briefTitle":37184,"status":195,"phases":37225,"primaryCompletion":32751,"completion":37186,"start":34145,"enrollment":132,"conditions":37226,"interventions":37227},[91],[37188],[37174,37190,37191],{"trials":37229,"activeCount":102},[],{"trials":37231,"activeCount":102},[],{"trials":37233,"activeCount":102},[],{"intervention":32367,"totalTrials":122,"cells":37235},{"EARLY_PHASE1":37236,"PHASE1":37238,"PHASE2":37240,"PHASE3":37246,"PHASE4":37248,"NA":37250},{"trials":37237,"activeCount":102},[],{"trials":37239,"activeCount":102},[],{"trials":37241,"activeCount":102},[37242],{"nctId":32362,"briefTitle":32363,"status":195,"phases":37243,"primaryCompletion":2143,"completion":2747,"start":3862,"enrollment":6454,"conditions":37244,"interventions":37245},[91],[19413],[32306,32367],{"trials":37247,"activeCount":102},[],{"trials":37249,"activeCount":102},[],{"trials":37251,"activeCount":102},[],{"intervention":37253,"totalTrials":122,"cells":37254},"MEDI7183 low dose",{"EARLY_PHASE1":37255,"PHASE1":37257,"PHASE2":37259,"PHASE3":37271,"PHASE4":37273,"NA":37275},{"trials":37256,"activeCount":102},[],{"trials":37258,"activeCount":102},[],{"trials":37260,"activeCount":102},[37261],{"nctId":37262,"briefTitle":37263,"status":195,"phases":37264,"primaryCompletion":37265,"completion":26379,"start":37266,"enrollment":3811,"conditions":37267,"interventions":37268},"NCT01959165","MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients",[91],"2015-08-11","2013-11-21",[24899],[37253,37269,37270],"MEDI7183 medium dose","MEDI7183 high dose",{"trials":37272,"activeCount":102},[],{"trials":37274,"activeCount":102},[],{"trials":37276,"activeCount":102},[],{"intervention":37269,"totalTrials":122,"cells":37278},{"EARLY_PHASE1":37279,"PHASE1":37281,"PHASE2":37283,"PHASE3":37289,"PHASE4":37291,"NA":37293},{"trials":37280,"activeCount":102},[],{"trials":37282,"activeCount":102},[],{"trials":37284,"activeCount":102},[37285],{"nctId":37262,"briefTitle":37263,"status":195,"phases":37286,"primaryCompletion":37265,"completion":26379,"start":37266,"enrollment":3811,"conditions":37287,"interventions":37288},[91],[24899],[37253,37269,37270],{"trials":37290,"activeCount":102},[],{"trials":37292,"activeCount":102},[],{"trials":37294,"activeCount":102},[],{"intervention":37270,"totalTrials":122,"cells":37296},{"EARLY_PHASE1":37297,"PHASE1":37299,"PHASE2":37301,"PHASE3":37307,"PHASE4":37309,"NA":37311},{"trials":37298,"activeCount":102},[],{"trials":37300,"activeCount":102},[],{"trials":37302,"activeCount":102},[37303],{"nctId":37262,"briefTitle":37263,"status":195,"phases":37304,"primaryCompletion":37265,"completion":26379,"start":37266,"enrollment":3811,"conditions":37305,"interventions":37306},[91],[24899],[37253,37269,37270],{"trials":37308,"activeCount":102},[],{"trials":37310,"activeCount":102},[],{"trials":37312,"activeCount":102},[],{"intervention":37314,"totalTrials":122,"cells":37315},"plevitrexed",{"EARLY_PHASE1":37316,"PHASE1":37318,"PHASE2":37320,"PHASE3":37331,"PHASE4":37333,"NA":37335},{"trials":37317,"activeCount":102},[],{"trials":37319,"activeCount":102},[],{"trials":37321,"activeCount":102},[37322],{"nctId":37323,"briefTitle":37324,"status":195,"phases":37325,"completion":4306,"start":37326,"conditions":37327,"interventions":37329},"NCT00014690","ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",[91],"2001-03",[9004,414,37328],"Primary Peritoneal Cavity Cancer",[37314,37330],"topotecan hydrochloride",{"trials":37332,"activeCount":102},[],{"trials":37334,"activeCount":102},[],{"trials":37336,"activeCount":102},[],{"intervention":37330,"totalTrials":122,"cells":37338},{"EARLY_PHASE1":37339,"PHASE1":37341,"PHASE2":37343,"PHASE3":37349,"PHASE4":37351,"NA":37353},{"trials":37340,"activeCount":102},[],{"trials":37342,"activeCount":102},[],{"trials":37344,"activeCount":102},[37345],{"nctId":37323,"briefTitle":37324,"status":195,"phases":37346,"completion":4306,"start":37326,"conditions":37347,"interventions":37348},[91],[9004,414,37328],[37314,37330],{"trials":37350,"activeCount":102},[],{"trials":37352,"activeCount":102},[],{"trials":37354,"activeCount":102},[],{"intervention":37356,"totalTrials":122,"cells":37357},"AZD8154 nebulizer suspension, 20 mg\u002FmL",{"EARLY_PHASE1":37358,"PHASE1":37360,"PHASE2":37362,"PHASE3":37371,"PHASE4":37373,"NA":37375},{"trials":37359,"activeCount":102},[],{"trials":37361,"activeCount":102},[],{"trials":37363,"activeCount":102},[37364],{"nctId":37365,"briefTitle":37366,"status":624,"phases":37367,"primaryCompletion":33244,"completion":33244,"start":37368,"enrollment":102,"conditions":37369,"interventions":37370},"NCT04187508","A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen",[91],"2020-02-06",[16],[37356],{"trials":37372,"activeCount":102},[],{"trials":37374,"activeCount":102},[],{"trials":37376,"activeCount":102},[],{"intervention":37378,"totalTrials":122,"cells":37379},"AC2592",{"EARLY_PHASE1":37380,"PHASE1":37382,"PHASE2":37384,"PHASE3":37393,"PHASE4":37395,"NA":37397},{"trials":37381,"activeCount":102},[],{"trials":37383,"activeCount":102},[],{"trials":37385,"activeCount":102},[37386],{"nctId":37387,"briefTitle":37388,"status":195,"phases":37389,"primaryCompletion":5563,"completion":5563,"start":5796,"enrollment":22212,"conditions":37390,"interventions":37392},"NCT00099580","PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure",[91],[37391],"Congestive Heart Failure",[37378],{"trials":37394,"activeCount":102},[],{"trials":37396,"activeCount":102},[],{"trials":37398,"activeCount":102},[],{"intervention":37400,"totalTrials":122,"cells":37401},"Once-daily aclidinium\u002Fformoterol",{"EARLY_PHASE1":37402,"PHASE1":37404,"PHASE2":37406,"PHASE3":37418,"PHASE4":37420,"NA":37422},{"trials":37403,"activeCount":102},[],{"trials":37405,"activeCount":102},[],{"trials":37407,"activeCount":102},[37408],{"nctId":37409,"briefTitle":37410,"status":443,"phases":37411,"primaryCompletion":37412,"completion":37412,"start":37413,"enrollment":5531,"conditions":37414,"interventions":37415},"NCT00706914","Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[91],"2008-11-11","2008-06-30",[18651],[37400,37416,37417],"Twice-daily formoterol fumarate","Once-daily formoterol fumarate",{"trials":37419,"activeCount":102},[],{"trials":37421,"activeCount":102},[],{"trials":37423,"activeCount":102},[],{"intervention":37416,"totalTrials":122,"cells":37425},{"EARLY_PHASE1":37426,"PHASE1":37428,"PHASE2":37430,"PHASE3":37436,"PHASE4":37438,"NA":37440},{"trials":37427,"activeCount":102},[],{"trials":37429,"activeCount":102},[],{"trials":37431,"activeCount":102},[37432],{"nctId":37409,"briefTitle":37410,"status":443,"phases":37433,"primaryCompletion":37412,"completion":37412,"start":37413,"enrollment":5531,"conditions":37434,"interventions":37435},[91],[18651],[37400,37416,37417],{"trials":37437,"activeCount":102},[],{"trials":37439,"activeCount":102},[],{"trials":37441,"activeCount":102},[],{"intervention":37417,"totalTrials":122,"cells":37443},{"EARLY_PHASE1":37444,"PHASE1":37446,"PHASE2":37448,"PHASE3":37454,"PHASE4":37456,"NA":37458},{"trials":37445,"activeCount":102},[],{"trials":37447,"activeCount":102},[],{"trials":37449,"activeCount":102},[37450],{"nctId":37409,"briefTitle":37410,"status":443,"phases":37451,"primaryCompletion":37412,"completion":37412,"start":37413,"enrollment":5531,"conditions":37452,"interventions":37453},[91],[18651],[37400,37416,37417],{"trials":37455,"activeCount":102},[],{"trials":37457,"activeCount":102},[],{"trials":37459,"activeCount":102},[],{"intervention":37461,"totalTrials":122,"cells":37462},"Gefitinib, Cisplatin and Radiotherapy",{"EARLY_PHASE1":37463,"PHASE1":37465,"PHASE2":37467,"PHASE3":37475,"PHASE4":37477,"NA":37479},{"trials":37464,"activeCount":102},[],{"trials":37466,"activeCount":102},[],{"trials":37468,"activeCount":102},[37469],{"nctId":37470,"briefTitle":37471,"status":195,"phases":37472,"completion":2252,"start":6499,"enrollment":3172,"conditions":37473,"interventions":37474},"NCT00242749","IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma",[91],[4310],[37461],{"trials":37476,"activeCount":102},[],{"trials":37478,"activeCount":102},[],{"trials":37480,"activeCount":102},[],{"intervention":20189,"totalTrials":122,"cells":37482},{"EARLY_PHASE1":37483,"PHASE1":37485,"PHASE2":37487,"PHASE3":37493,"PHASE4":37495,"NA":37497},{"trials":37484,"activeCount":102},[],{"trials":37486,"activeCount":102},[],{"trials":37488,"activeCount":102},[37489],{"nctId":20184,"briefTitle":20185,"status":195,"phases":37490,"primaryCompletion":2243,"completion":2243,"start":2152,"enrollment":13802,"conditions":37491,"interventions":37492},[91],[33],[20189,18800],{"trials":37494,"activeCount":102},[],{"trials":37496,"activeCount":102},[],{"trials":37498,"activeCount":102},[],{"intervention":32947,"totalTrials":122,"cells":37500},{"EARLY_PHASE1":37501,"PHASE1":37503,"PHASE2":37505,"PHASE3":37511,"PHASE4":37513,"NA":37515},{"trials":37502,"activeCount":102},[],{"trials":37504,"activeCount":102},[],{"trials":37506,"activeCount":102},[37507],{"nctId":32941,"briefTitle":32942,"status":195,"phases":37508,"primaryCompletion":2056,"completion":2105,"start":2168,"enrollment":1873,"conditions":37509,"interventions":37510},[91],[25,416,32945],[3843,32947],{"trials":37512,"activeCount":102},[],{"trials":37514,"activeCount":102},[],{"trials":37516,"activeCount":102},[],{"intervention":37518,"totalTrials":122,"cells":37519},"AZD5213 and placebo",{"EARLY_PHASE1":37520,"PHASE1":37522,"PHASE2":37524,"PHASE3":37533,"PHASE4":37535,"NA":37537},{"trials":37521,"activeCount":102},[],{"trials":37523,"activeCount":102},[],{"trials":37525,"activeCount":102},[37526],{"nctId":37527,"briefTitle":37528,"status":195,"phases":37529,"primaryCompletion":2561,"completion":2561,"start":1701,"enrollment":8185,"conditions":37530,"interventions":37532},"NCT01904773","Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder",[91],[37531],"Tourette Syndrome",[37518],{"trials":37534,"activeCount":102},[],{"trials":37536,"activeCount":102},[],{"trials":37538,"activeCount":102},[],{"intervention":37540,"totalTrials":122,"cells":37541},"Pramlintide+Metreleptin",{"EARLY_PHASE1":37542,"PHASE1":37544,"PHASE2":37546,"PHASE3":37554,"PHASE4":37556,"NA":37558},{"trials":37543,"activeCount":102},[],{"trials":37545,"activeCount":102},[],{"trials":37547,"activeCount":102},[37548],{"nctId":37549,"briefTitle":37550,"status":443,"phases":37551,"primaryCompletion":2571,"completion":2571,"start":2516,"enrollment":35813,"conditions":37552,"interventions":37553},"NCT01235741","A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects",[91],[12275],[37540],{"trials":37555,"activeCount":102},[],{"trials":37557,"activeCount":102},[],{"trials":37559,"activeCount":102},[],{"intervention":37561,"totalTrials":122,"cells":37562},"AZD3241 300 mg BID",{"EARLY_PHASE1":37563,"PHASE1":37565,"PHASE2":37567,"PHASE3":37576,"PHASE4":37578,"NA":37580},{"trials":37564,"activeCount":102},[],{"trials":37566,"activeCount":102},[],{"trials":37568,"activeCount":102},[37569],{"nctId":37570,"briefTitle":37571,"status":195,"phases":37572,"primaryCompletion":2746,"completion":2746,"start":2365,"enrollment":5425,"conditions":37573,"interventions":37574},"NCT01603069","A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease",[91],[36831],[37561,37575],"AZD3241 600 mg BID",{"trials":37577,"activeCount":102},[],{"trials":37579,"activeCount":102},[],{"trials":37581,"activeCount":102},[],{"intervention":37575,"totalTrials":122,"cells":37583},{"EARLY_PHASE1":37584,"PHASE1":37586,"PHASE2":37588,"PHASE3":37594,"PHASE4":37596,"NA":37598},{"trials":37585,"activeCount":102},[],{"trials":37587,"activeCount":102},[],{"trials":37589,"activeCount":102},[37590],{"nctId":37570,"briefTitle":37571,"status":195,"phases":37591,"primaryCompletion":2746,"completion":2746,"start":2365,"enrollment":5425,"conditions":37592,"interventions":37593},[91],[36831],[37561,37575],{"trials":37595,"activeCount":102},[],{"trials":37597,"activeCount":102},[],{"trials":37599,"activeCount":102},[],{"intervention":37601,"totalTrials":122,"cells":37602},"lesogaberan",{"EARLY_PHASE1":37603,"PHASE1":37605,"PHASE2":37607,"PHASE3":37616,"PHASE4":37618,"NA":37620},{"trials":37604,"activeCount":102},[],{"trials":37606,"activeCount":102},[],{"trials":37608,"activeCount":102},[37609],{"nctId":37610,"briefTitle":37611,"status":195,"phases":37612,"primaryCompletion":2406,"completion":2406,"start":2350,"enrollment":37613,"conditions":37614,"interventions":37615},"NCT01005251","Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI",[91],661,[20100,20099,32429],[37601,37601,37601,37601],{"trials":37617,"activeCount":102},[],{"trials":37619,"activeCount":102},[],{"trials":37621,"activeCount":102},[],{"intervention":37623,"totalTrials":122,"cells":37624},"MEDI2070",{"EARLY_PHASE1":37625,"PHASE1":37627,"PHASE2":37629,"PHASE3":37639,"PHASE4":37641,"NA":37643},{"trials":37626,"activeCount":102},[],{"trials":37628,"activeCount":102},[],{"trials":37630,"activeCount":102},[37631],{"nctId":37632,"briefTitle":37633,"status":195,"phases":37634,"primaryCompletion":37635,"completion":3852,"start":37636,"enrollment":1777,"conditions":37637,"interventions":37638},"NCT01714726","Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.",[91],"2014-05-20","2013-02-01",[13237],[37623],{"trials":37640,"activeCount":102},[],{"trials":37642,"activeCount":102},[],{"trials":37644,"activeCount":102},[],{"intervention":37646,"totalTrials":122,"cells":37647},"Selumetinib 75 mg",{"EARLY_PHASE1":37648,"PHASE1":37650,"PHASE2":37652,"PHASE3":37664,"PHASE4":37666,"NA":37668},{"trials":37649,"activeCount":102},[],{"trials":37651,"activeCount":102},[],{"trials":37653,"activeCount":102},[37654],{"nctId":37655,"briefTitle":37656,"status":195,"phases":37657,"primaryCompletion":37658,"completion":3724,"start":37659,"enrollment":12458,"conditions":37660,"interventions":37661},"NCT01750281","Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.",[91],"2016-01-27","2012-12-18",[6735],[37646,37662,37663],"Docetaxel 75 mg\u002Fm2","Docetaxel 60 mg\u002Fm2",{"trials":37665,"activeCount":102},[],{"trials":37667,"activeCount":102},[],{"trials":37669,"activeCount":102},[],{"intervention":37662,"totalTrials":122,"cells":37671},{"EARLY_PHASE1":37672,"PHASE1":37674,"PHASE2":37676,"PHASE3":37682,"PHASE4":37684,"NA":37686},{"trials":37673,"activeCount":102},[],{"trials":37675,"activeCount":102},[],{"trials":37677,"activeCount":102},[37678],{"nctId":37655,"briefTitle":37656,"status":195,"phases":37679,"primaryCompletion":37658,"completion":3724,"start":37659,"enrollment":12458,"conditions":37680,"interventions":37681},[91],[6735],[37646,37662,37663],{"trials":37683,"activeCount":102},[],{"trials":37685,"activeCount":102},[],{"trials":37687,"activeCount":102},[],{"intervention":37663,"totalTrials":122,"cells":37689},{"EARLY_PHASE1":37690,"PHASE1":37692,"PHASE2":37694,"PHASE3":37700,"PHASE4":37702,"NA":37704},{"trials":37691,"activeCount":102},[],{"trials":37693,"activeCount":102},[],{"trials":37695,"activeCount":102},[37696],{"nctId":37655,"briefTitle":37656,"status":195,"phases":37697,"primaryCompletion":37658,"completion":3724,"start":37659,"enrollment":12458,"conditions":37698,"interventions":37699},[91],[6735],[37646,37662,37663],{"trials":37701,"activeCount":102},[],{"trials":37703,"activeCount":102},[],{"trials":37705,"activeCount":102},[],{"intervention":37707,"totalTrials":122,"cells":37708},"Interferon beta-1a Nebuliser solution 48 μg\u002FmL",{"EARLY_PHASE1":37709,"PHASE1":37711,"PHASE2":37713,"PHASE3":37722,"PHASE4":37724,"NA":37726},{"trials":37710,"activeCount":102},[],{"trials":37712,"activeCount":102},[],{"trials":37714,"activeCount":102},[37715],{"nctId":37716,"briefTitle":37717,"status":195,"phases":37718,"primaryCompletion":37719,"completion":37719,"start":5298,"enrollment":1777,"conditions":37720,"interventions":37721},"NCT02491684","A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection",[91],"2016-11-24",[16],[37707],{"trials":37723,"activeCount":102},[],{"trials":37725,"activeCount":102},[],{"trials":37727,"activeCount":102},[],{"intervention":32135,"totalTrials":122,"cells":37729},{"EARLY_PHASE1":37730,"PHASE1":37732,"PHASE2":37734,"PHASE3":37740,"PHASE4":37742,"NA":37744},{"trials":37731,"activeCount":102},[],{"trials":37733,"activeCount":102},[],{"trials":37735,"activeCount":102},[37736],{"nctId":32129,"briefTitle":32130,"status":195,"phases":37737,"primaryCompletion":2151,"completion":2151,"start":2086,"enrollment":2933,"conditions":37738,"interventions":37739},[91],[32133],[32085,32135],{"trials":37741,"activeCount":102},[],{"trials":37743,"activeCount":102},[],{"trials":37745,"activeCount":102},[],{"intervention":34298,"totalTrials":122,"cells":37747},{"EARLY_PHASE1":37748,"PHASE1":37750,"PHASE2":37752,"PHASE3":37758,"PHASE4":37760,"NA":37762},{"trials":37749,"activeCount":102},[],{"trials":37751,"activeCount":102},[],{"trials":37753,"activeCount":102},[37754],{"nctId":34292,"briefTitle":34293,"status":195,"phases":37755,"primaryCompletion":2077,"completion":2077,"start":2221,"enrollment":34295,"conditions":37756,"interventions":37757},[91],[33],[34271,34298],{"trials":37759,"activeCount":102},[],{"trials":37761,"activeCount":102},[],{"trials":37763,"activeCount":102},[],{"intervention":10427,"totalTrials":122,"cells":37765},{"EARLY_PHASE1":37766,"PHASE1":37768,"PHASE2":37770,"PHASE3":37776,"PHASE4":37778,"NA":37780},{"trials":37767,"activeCount":102},[],{"trials":37769,"activeCount":102},[],{"trials":37771,"activeCount":102},[37772],{"nctId":10420,"briefTitle":10421,"status":195,"phases":37773,"primaryCompletion":10423,"completion":10423,"start":10424,"enrollment":451,"conditions":37774,"interventions":37775},[91],[16],[10411,10427],{"trials":37777,"activeCount":102},[],{"trials":37779,"activeCount":102},[],{"trials":37781,"activeCount":102},[],{"intervention":37783,"totalTrials":122,"cells":37784},"Intervention: AS MDI",{"EARLY_PHASE1":37785,"PHASE1":37787,"PHASE2":37789,"PHASE3":37800,"PHASE4":37802,"NA":37804},{"trials":37786,"activeCount":102},[],{"trials":37788,"activeCount":102},[],{"trials":37790,"activeCount":102},[37791],{"nctId":37792,"briefTitle":37793,"status":195,"phases":37794,"primaryCompletion":7008,"completion":7008,"start":37795,"enrollment":23756,"conditions":37796,"interventions":37797},"NCT06644924","A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma",[91],"2025-02-10",[16],[37783,37798,37799],"Intervention: Ventolin Evohaler","Intervention: Placebo matching AS MDI",{"trials":37801,"activeCount":102},[],{"trials":37803,"activeCount":102},[],{"trials":37805,"activeCount":102},[],{"intervention":37798,"totalTrials":122,"cells":37807},{"EARLY_PHASE1":37808,"PHASE1":37810,"PHASE2":37812,"PHASE3":37818,"PHASE4":37820,"NA":37822},{"trials":37809,"activeCount":102},[],{"trials":37811,"activeCount":102},[],{"trials":37813,"activeCount":102},[37814],{"nctId":37792,"briefTitle":37793,"status":195,"phases":37815,"primaryCompletion":7008,"completion":7008,"start":37795,"enrollment":23756,"conditions":37816,"interventions":37817},[91],[16],[37783,37798,37799],{"trials":37819,"activeCount":102},[],{"trials":37821,"activeCount":102},[],{"trials":37823,"activeCount":102},[],{"intervention":37799,"totalTrials":122,"cells":37825},{"EARLY_PHASE1":37826,"PHASE1":37828,"PHASE2":37830,"PHASE3":37836,"PHASE4":37838,"NA":37840},{"trials":37827,"activeCount":102},[],{"trials":37829,"activeCount":102},[],{"trials":37831,"activeCount":102},[37832],{"nctId":37792,"briefTitle":37793,"status":195,"phases":37833,"primaryCompletion":7008,"completion":7008,"start":37795,"enrollment":23756,"conditions":37834,"interventions":37835},[91],[16],[37783,37798,37799],{"trials":37837,"activeCount":102},[],{"trials":37839,"activeCount":102},[],{"trials":37841,"activeCount":102},[],{"intervention":22881,"totalTrials":122,"cells":37843},{"EARLY_PHASE1":37844,"PHASE1":37846,"PHASE2":37848,"PHASE3":37854,"PHASE4":37856,"NA":37858},{"trials":37845,"activeCount":102},[],{"trials":37847,"activeCount":102},[],{"trials":37849,"activeCount":102},[37850],{"nctId":22875,"briefTitle":22876,"status":443,"phases":37851,"primaryCompletion":13856,"completion":13856,"start":2433,"enrollment":22878,"conditions":37852,"interventions":37853},[91],[7267],[12604,22881],{"trials":37855,"activeCount":102},[],{"trials":37857,"activeCount":102},[],{"trials":37859,"activeCount":102},[],{"intervention":37861,"totalTrials":122,"cells":37862},"D9421-C, 9mg",{"EARLY_PHASE1":37863,"PHASE1":37865,"PHASE2":37867,"PHASE3":37876,"PHASE4":37878,"NA":37880},{"trials":37864,"activeCount":102},[],{"trials":37866,"activeCount":102},[],{"trials":37868,"activeCount":102},[37869],{"nctId":37870,"briefTitle":37871,"status":195,"phases":37872,"primaryCompletion":2580,"completion":2580,"start":2639,"enrollment":1883,"conditions":37873,"interventions":37874},"NCT00573469","Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease",[91],[13237],[37861,37875],"D9421-C, 15mg",{"trials":37877,"activeCount":102},[],{"trials":37879,"activeCount":102},[],{"trials":37881,"activeCount":102},[],{"intervention":37875,"totalTrials":122,"cells":37883},{"EARLY_PHASE1":37884,"PHASE1":37886,"PHASE2":37888,"PHASE3":37894,"PHASE4":37896,"NA":37898},{"trials":37885,"activeCount":102},[],{"trials":37887,"activeCount":102},[],{"trials":37889,"activeCount":102},[37890],{"nctId":37870,"briefTitle":37871,"status":195,"phases":37891,"primaryCompletion":2580,"completion":2580,"start":2639,"enrollment":1883,"conditions":37892,"interventions":37893},[91],[13237],[37861,37875],{"trials":37895,"activeCount":102},[],{"trials":37897,"activeCount":102},[],{"trials":37899,"activeCount":102},[],{"intervention":37901,"totalTrials":122,"cells":37902},"Fostamatinib Disodium",{"EARLY_PHASE1":37903,"PHASE1":37905,"PHASE2":37907,"PHASE3":37916,"PHASE4":37918,"NA":37920},{"trials":37904,"activeCount":102},[],{"trials":37906,"activeCount":102},[],{"trials":37908,"activeCount":102},[37909],{"nctId":37910,"briefTitle":37911,"status":443,"phases":37912,"primaryCompletion":1701,"completion":1701,"start":2220,"enrollment":37913,"conditions":37914,"interventions":37915},"NCT00805467","Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies",[91],624,[7267],[37901],{"trials":37917,"activeCount":102},[],{"trials":37919,"activeCount":102},[],{"trials":37921,"activeCount":102},[],{"intervention":37923,"totalTrials":122,"cells":37924},"Anastrozole and goserelin",{"EARLY_PHASE1":37925,"PHASE1":37927,"PHASE2":37929,"PHASE3":37937,"PHASE4":37939,"NA":37941},{"trials":37926,"activeCount":102},[],{"trials":37928,"activeCount":102},[],{"trials":37930,"activeCount":102},[37931],{"nctId":37932,"briefTitle":37933,"status":195,"phases":37934,"completion":5742,"start":12731,"enrollment":1864,"conditions":37935,"interventions":37936},"NCT00235937","Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex",[91],[25],[37923],{"trials":37938,"activeCount":102},[],{"trials":37940,"activeCount":102},[],{"trials":37942,"activeCount":102},[],{"intervention":32143,"totalTrials":122,"cells":37944},{"EARLY_PHASE1":37945,"PHASE1":37947,"PHASE2":37949,"PHASE3":37955,"PHASE4":37957,"NA":37959},{"trials":37946,"activeCount":102},[],{"trials":37948,"activeCount":102},[],{"trials":37950,"activeCount":102},[37951],{"nctId":32137,"briefTitle":32138,"status":195,"phases":37952,"primaryCompletion":2144,"completion":2144,"start":2068,"enrollment":32140,"conditions":37953,"interventions":37954},[91],[28],[32085,32085,32085,32143],{"trials":37956,"activeCount":102},[],{"trials":37958,"activeCount":102},[],{"trials":37960,"activeCount":102},[],{"intervention":37962,"totalTrials":122,"cells":37963},"AZD6765 iv",{"EARLY_PHASE1":37964,"PHASE1":37966,"PHASE2":37968,"PHASE3":37977,"PHASE4":37979,"NA":37981},{"trials":37965,"activeCount":102},[],{"trials":37967,"activeCount":102},[],{"trials":37969,"activeCount":102},[37970],{"nctId":37971,"briefTitle":37972,"status":195,"phases":37973,"primaryCompletion":9252,"completion":9252,"start":37974,"enrollment":2377,"conditions":37975,"interventions":37976},"NCT01482221","A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder",[91],"2011-12-16",[18697],[37962,37962],{"trials":37978,"activeCount":102},[],{"trials":37980,"activeCount":102},[],{"trials":37982,"activeCount":102},[],{"intervention":37984,"totalTrials":122,"cells":37985},"Part A:Placebo",{"EARLY_PHASE1":37986,"PHASE1":37988,"PHASE2":37990,"PHASE3":38004,"PHASE4":38006,"NA":38008},{"trials":37987,"activeCount":102},[],{"trials":37989,"activeCount":102},[],{"trials":37991,"activeCount":102},[37992],{"nctId":37993,"briefTitle":37994,"status":195,"phases":37995,"primaryCompletion":37996,"completion":37996,"start":542,"enrollment":19246,"conditions":37997,"interventions":37998},"NCT04823611","A Study of AZD8233 in Participants With Dyslipidemia.",[90,91],"2022-09-10",[6903],[37984,37999,38000,38001,38002,38003],"Part A:AZD8233","Part B:Placebo","Part B:AZD8233","Part C: Placebo","Part C: AZD8233",{"trials":38005,"activeCount":102},[],{"trials":38007,"activeCount":102},[],{"trials":38009,"activeCount":102},[],{"intervention":37999,"totalTrials":122,"cells":38011},{"EARLY_PHASE1":38012,"PHASE1":38014,"PHASE2":38016,"PHASE3":38022,"PHASE4":38024,"NA":38026},{"trials":38013,"activeCount":102},[],{"trials":38015,"activeCount":102},[],{"trials":38017,"activeCount":102},[38018],{"nctId":37993,"briefTitle":37994,"status":195,"phases":38019,"primaryCompletion":37996,"completion":37996,"start":542,"enrollment":19246,"conditions":38020,"interventions":38021},[90,91],[6903],[37984,37999,38000,38001,38002,38003],{"trials":38023,"activeCount":102},[],{"trials":38025,"activeCount":102},[],{"trials":38027,"activeCount":102},[],{"intervention":38000,"totalTrials":122,"cells":38029},{"EARLY_PHASE1":38030,"PHASE1":38032,"PHASE2":38034,"PHASE3":38040,"PHASE4":38042,"NA":38044},{"trials":38031,"activeCount":102},[],{"trials":38033,"activeCount":102},[],{"trials":38035,"activeCount":102},[38036],{"nctId":37993,"briefTitle":37994,"status":195,"phases":38037,"primaryCompletion":37996,"completion":37996,"start":542,"enrollment":19246,"conditions":38038,"interventions":38039},[90,91],[6903],[37984,37999,38000,38001,38002,38003],{"trials":38041,"activeCount":102},[],{"trials":38043,"activeCount":102},[],{"trials":38045,"activeCount":102},[],{"intervention":38001,"totalTrials":122,"cells":38047},{"EARLY_PHASE1":38048,"PHASE1":38050,"PHASE2":38052,"PHASE3":38058,"PHASE4":38060,"NA":38062},{"trials":38049,"activeCount":102},[],{"trials":38051,"activeCount":102},[],{"trials":38053,"activeCount":102},[38054],{"nctId":37993,"briefTitle":37994,"status":195,"phases":38055,"primaryCompletion":37996,"completion":37996,"start":542,"enrollment":19246,"conditions":38056,"interventions":38057},[90,91],[6903],[37984,37999,38000,38001,38002,38003],{"trials":38059,"activeCount":102},[],{"trials":38061,"activeCount":102},[],{"trials":38063,"activeCount":102},[],{"intervention":38002,"totalTrials":122,"cells":38065},{"EARLY_PHASE1":38066,"PHASE1":38068,"PHASE2":38070,"PHASE3":38076,"PHASE4":38078,"NA":38080},{"trials":38067,"activeCount":102},[],{"trials":38069,"activeCount":102},[],{"trials":38071,"activeCount":102},[38072],{"nctId":37993,"briefTitle":37994,"status":195,"phases":38073,"primaryCompletion":37996,"completion":37996,"start":542,"enrollment":19246,"conditions":38074,"interventions":38075},[90,91],[6903],[37984,37999,38000,38001,38002,38003],{"trials":38077,"activeCount":102},[],{"trials":38079,"activeCount":102},[],{"trials":38081,"activeCount":102},[],{"intervention":38003,"totalTrials":122,"cells":38083},{"EARLY_PHASE1":38084,"PHASE1":38086,"PHASE2":38088,"PHASE3":38094,"PHASE4":38096,"NA":38098},{"trials":38085,"activeCount":102},[],{"trials":38087,"activeCount":102},[],{"trials":38089,"activeCount":102},[38090],{"nctId":37993,"briefTitle":37994,"status":195,"phases":38091,"primaryCompletion":37996,"completion":37996,"start":542,"enrollment":19246,"conditions":38092,"interventions":38093},[90,91],[6903],[37984,37999,38000,38001,38002,38003],{"trials":38095,"activeCount":102},[],{"trials":38097,"activeCount":102},[],{"trials":38099,"activeCount":102},[],{"intervention":654,"totalTrials":122,"cells":38101},{"EARLY_PHASE1":38102,"PHASE1":38104,"PHASE2":38106,"PHASE3":38112,"PHASE4":38114,"NA":38116},{"trials":38103,"activeCount":102},[],{"trials":38105,"activeCount":102},[],{"trials":38107,"activeCount":102},[38108],{"nctId":643,"briefTitle":644,"status":195,"phases":38109,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":38110,"interventions":38111},[91],[651],[267,653,654],{"trials":38113,"activeCount":102},[],{"trials":38115,"activeCount":102},[],{"trials":38117,"activeCount":102},[],{"intervention":5258,"totalTrials":122,"cells":38119},{"EARLY_PHASE1":38120,"PHASE1":38122,"PHASE2":38124,"PHASE3":38130,"PHASE4":38132,"NA":38134},{"trials":38121,"activeCount":102},[],{"trials":38123,"activeCount":102},[],{"trials":38125,"activeCount":102},[38126],{"nctId":5249,"briefTitle":5250,"status":195,"phases":38127,"primaryCompletion":5252,"completion":5252,"start":5253,"enrollment":579,"conditions":38128,"interventions":38129},[91],[5255],[1013,5257,5258,3137],{"trials":38131,"activeCount":102},[],{"trials":38133,"activeCount":102},[],{"trials":38135,"activeCount":102},[],{"intervention":38137,"totalTrials":122,"cells":38138},"AZD1419",{"EARLY_PHASE1":38139,"PHASE1":38141,"PHASE2":38143,"PHASE3":38153,"PHASE4":38155,"NA":38157},{"trials":38140,"activeCount":102},[],{"trials":38142,"activeCount":102},[],{"trials":38144,"activeCount":102},[38145],{"nctId":38146,"briefTitle":38147,"status":195,"phases":38148,"primaryCompletion":38149,"completion":38149,"start":38150,"enrollment":6901,"conditions":38151,"interventions":38152},"NCT02898662","AZD1419 Ph2a Study",[91],"2018-09-25","2016-10-12",[16],[38137],{"trials":38154,"activeCount":102},[],{"trials":38156,"activeCount":102},[],{"trials":38158,"activeCount":102},[],{"intervention":38160,"totalTrials":122,"cells":38161},"Tomudex",{"EARLY_PHASE1":38162,"PHASE1":38164,"PHASE2":38166,"PHASE3":38175,"PHASE4":38177,"NA":38179},{"trials":38163,"activeCount":102},[],{"trials":38165,"activeCount":102},[],{"trials":38167,"activeCount":102},[38168],{"nctId":38169,"briefTitle":38170,"status":195,"phases":38171,"start":5797,"enrollment":507,"conditions":38172,"interventions":38174},"NCT00590278","A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer",[91],[38173],"Inoperable or Recurrent Rectal Cancer",[38160],{"trials":38176,"activeCount":102},[],{"trials":38178,"activeCount":102},[],{"trials":38180,"activeCount":102},[],{"intervention":38182,"totalTrials":122,"cells":38183},"Ciclesonide\u002FFormoterol Combination",{"EARLY_PHASE1":38184,"PHASE1":38186,"PHASE2":38188,"PHASE3":38196,"PHASE4":38198,"NA":38200},{"trials":38185,"activeCount":102},[],{"trials":38187,"activeCount":102},[],{"trials":38189,"activeCount":102},[38190],{"nctId":38191,"briefTitle":38192,"status":195,"phases":38193,"primaryCompletion":4284,"completion":4284,"start":13583,"enrollment":1173,"conditions":38194,"interventions":38195},"NCT00314509","Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010\u002FM1-506)",[91],[16],[38182],{"trials":38197,"activeCount":102},[],{"trials":38199,"activeCount":102},[],{"trials":38201,"activeCount":102},[],{"intervention":33722,"totalTrials":122,"cells":38203},{"EARLY_PHASE1":38204,"PHASE1":38206,"PHASE2":38208,"PHASE3":38214,"PHASE4":38216,"NA":38218},{"trials":38205,"activeCount":102},[],{"trials":38207,"activeCount":102},[],{"trials":38209,"activeCount":102},[38210],{"nctId":33717,"briefTitle":33718,"status":195,"phases":38211,"primaryCompletion":2365,"completion":2365,"start":687,"enrollment":3190,"conditions":38212,"interventions":38213},[91],[10066],[20876,33722,33723],{"trials":38215,"activeCount":102},[],{"trials":38217,"activeCount":102},[],{"trials":38219,"activeCount":102},[],{"intervention":33723,"totalTrials":122,"cells":38221},{"EARLY_PHASE1":38222,"PHASE1":38224,"PHASE2":38226,"PHASE3":38232,"PHASE4":38234,"NA":38236},{"trials":38223,"activeCount":102},[],{"trials":38225,"activeCount":102},[],{"trials":38227,"activeCount":102},[38228],{"nctId":33717,"briefTitle":33718,"status":195,"phases":38229,"primaryCompletion":2365,"completion":2365,"start":687,"enrollment":3190,"conditions":38230,"interventions":38231},[91],[10066],[20876,33722,33723],{"trials":38233,"activeCount":102},[],{"trials":38235,"activeCount":102},[],{"trials":38237,"activeCount":102},[],{"intervention":25641,"totalTrials":122,"cells":38239},{"EARLY_PHASE1":38240,"PHASE1":38242,"PHASE2":38244,"PHASE3":38250,"PHASE4":38252,"NA":38254},{"trials":38241,"activeCount":102},[],{"trials":38243,"activeCount":102},[],{"trials":38245,"activeCount":102},[38246],{"nctId":25636,"briefTitle":25637,"status":195,"phases":38247,"primaryCompletion":2144,"completion":2144,"start":2243,"enrollment":464,"conditions":38248,"interventions":38249},[91],[6083],[25641,25627,25642,25643],{"trials":38251,"activeCount":102},[],{"trials":38253,"activeCount":102},[],{"trials":38255,"activeCount":102},[],{"intervention":25642,"totalTrials":122,"cells":38257},{"EARLY_PHASE1":38258,"PHASE1":38260,"PHASE2":38262,"PHASE3":38268,"PHASE4":38270,"NA":38272},{"trials":38259,"activeCount":102},[],{"trials":38261,"activeCount":102},[],{"trials":38263,"activeCount":102},[38264],{"nctId":25636,"briefTitle":25637,"status":195,"phases":38265,"primaryCompletion":2144,"completion":2144,"start":2243,"enrollment":464,"conditions":38266,"interventions":38267},[91],[6083],[25641,25627,25642,25643],{"trials":38269,"activeCount":102},[],{"trials":38271,"activeCount":102},[],{"trials":38273,"activeCount":102},[],{"intervention":25643,"totalTrials":122,"cells":38275},{"EARLY_PHASE1":38276,"PHASE1":38278,"PHASE2":38280,"PHASE3":38286,"PHASE4":38288,"NA":38290},{"trials":38277,"activeCount":102},[],{"trials":38279,"activeCount":102},[],{"trials":38281,"activeCount":102},[38282],{"nctId":25636,"briefTitle":25637,"status":195,"phases":38283,"primaryCompletion":2144,"completion":2144,"start":2243,"enrollment":464,"conditions":38284,"interventions":38285},[91],[6083],[25641,25627,25642,25643],{"trials":38287,"activeCount":102},[],{"trials":38289,"activeCount":102},[],{"trials":38291,"activeCount":102},[],{"intervention":38293,"totalTrials":122,"cells":38294},"AZD2516, 5 mg",{"EARLY_PHASE1":38295,"PHASE1":38297,"PHASE2":38299,"PHASE3":38309,"PHASE4":38311,"NA":38313},{"trials":38296,"activeCount":102},[],{"trials":38298,"activeCount":102},[],{"trials":38300,"activeCount":102},[38301],{"nctId":38302,"briefTitle":38303,"status":195,"phases":38304,"primaryCompletion":3862,"completion":3862,"start":2243,"enrollment":5876,"conditions":38305,"interventions":38306},"NCT01154634","Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects",[91],[20135],[38293,38307,38308],"AZD2516, 16 mg","AZD2516, 40 mg",{"trials":38310,"activeCount":102},[],{"trials":38312,"activeCount":102},[],{"trials":38314,"activeCount":102},[],{"intervention":38307,"totalTrials":122,"cells":38316},{"EARLY_PHASE1":38317,"PHASE1":38319,"PHASE2":38321,"PHASE3":38327,"PHASE4":38329,"NA":38331},{"trials":38318,"activeCount":102},[],{"trials":38320,"activeCount":102},[],{"trials":38322,"activeCount":102},[38323],{"nctId":38302,"briefTitle":38303,"status":195,"phases":38324,"primaryCompletion":3862,"completion":3862,"start":2243,"enrollment":5876,"conditions":38325,"interventions":38326},[91],[20135],[38293,38307,38308],{"trials":38328,"activeCount":102},[],{"trials":38330,"activeCount":102},[],{"trials":38332,"activeCount":102},[],{"intervention":38308,"totalTrials":122,"cells":38334},{"EARLY_PHASE1":38335,"PHASE1":38337,"PHASE2":38339,"PHASE3":38345,"PHASE4":38347,"NA":38349},{"trials":38336,"activeCount":102},[],{"trials":38338,"activeCount":102},[],{"trials":38340,"activeCount":102},[38341],{"nctId":38302,"briefTitle":38303,"status":195,"phases":38342,"primaryCompletion":3862,"completion":3862,"start":2243,"enrollment":5876,"conditions":38343,"interventions":38344},[91],[20135],[38293,38307,38308],{"trials":38346,"activeCount":102},[],{"trials":38348,"activeCount":102},[],{"trials":38350,"activeCount":102},[],{"intervention":23259,"totalTrials":122,"cells":38352},{"EARLY_PHASE1":38353,"PHASE1":38355,"PHASE2":38357,"PHASE3":38363,"PHASE4":38365,"NA":38367},{"trials":38354,"activeCount":102},[],{"trials":38356,"activeCount":102},[],{"trials":38358,"activeCount":102},[38359],{"nctId":23254,"briefTitle":23255,"status":195,"phases":38360,"primaryCompletion":2243,"completion":2243,"start":2056,"enrollment":18672,"conditions":38361,"interventions":38362},[91],[28],[9882,23259],{"trials":38364,"activeCount":102},[],{"trials":38366,"activeCount":102},[],{"trials":38368,"activeCount":102},[],{"intervention":38370,"totalTrials":122,"cells":38371},"Aclidinium Bromide\u002FFormoterol Fumarate 400\u002F12μg BID",{"EARLY_PHASE1":38372,"PHASE1":38374,"PHASE2":38376,"PHASE3":38385,"PHASE4":38387,"NA":38389},{"trials":38373,"activeCount":102},[],{"trials":38375,"activeCount":102},[],{"trials":38377,"activeCount":102},[38378],{"nctId":38379,"briefTitle":38380,"status":195,"phases":38381,"primaryCompletion":38382,"completion":38382,"start":12090,"enrollment":5876,"conditions":38383,"interventions":38384},"NCT03276078","Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide\u002FFormoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",[91],"2018-06-12",[18651],[38370],{"trials":38386,"activeCount":102},[],{"trials":38388,"activeCount":102},[],{"trials":38390,"activeCount":102},[],{"intervention":38392,"totalTrials":122,"cells":38393},"gefitinib and fulvestrant",{"EARLY_PHASE1":38394,"PHASE1":38396,"PHASE2":38398,"PHASE3":38406,"PHASE4":38408,"NA":38410},{"trials":38395,"activeCount":102},[],{"trials":38397,"activeCount":102},[],{"trials":38399,"activeCount":102},[38400],{"nctId":38401,"briefTitle":38402,"status":195,"phases":38403,"completion":4297,"start":13575,"enrollment":477,"conditions":38404,"interventions":38405},"NCT00234403","A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer",[91],[25],[38392],{"trials":38407,"activeCount":102},[],{"trials":38409,"activeCount":102},[],{"trials":38411,"activeCount":102},[],{"intervention":38413,"totalTrials":122,"cells":38414},"AZD8871 100 µg",{"EARLY_PHASE1":38415,"PHASE1":38417,"PHASE2":38419,"PHASE3":38430,"PHASE4":38432,"NA":38434},{"trials":38416,"activeCount":102},[],{"trials":38418,"activeCount":102},[],{"trials":38420,"activeCount":102},[38421],{"nctId":38422,"briefTitle":38423,"status":195,"phases":38424,"primaryCompletion":38425,"completion":38425,"start":38426,"enrollment":2069,"conditions":38427,"interventions":38428},"NCT02971293","Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871",[91],"2017-08-18","2016-12-15",[30237],[38413,38429],"AZD8871 600 µg",{"trials":38431,"activeCount":102},[],{"trials":38433,"activeCount":102},[],{"trials":38435,"activeCount":102},[],{"intervention":38429,"totalTrials":122,"cells":38437},{"EARLY_PHASE1":38438,"PHASE1":38440,"PHASE2":38442,"PHASE3":38448,"PHASE4":38450,"NA":38452},{"trials":38439,"activeCount":102},[],{"trials":38441,"activeCount":102},[],{"trials":38443,"activeCount":102},[38444],{"nctId":38422,"briefTitle":38423,"status":195,"phases":38445,"primaryCompletion":38425,"completion":38425,"start":38426,"enrollment":2069,"conditions":38446,"interventions":38447},[91],[30237],[38413,38429],{"trials":38449,"activeCount":102},[],{"trials":38451,"activeCount":102},[],{"trials":38453,"activeCount":102},[],{"intervention":38455,"totalTrials":122,"cells":38456},"MEDI6570",{"EARLY_PHASE1":38457,"PHASE1":38459,"PHASE2":38461,"PHASE3":38471,"PHASE4":38473,"NA":38475},{"trials":38458,"activeCount":102},[],{"trials":38460,"activeCount":102},[],{"trials":38462,"activeCount":102},[38463],{"nctId":38464,"briefTitle":38465,"status":195,"phases":38466,"primaryCompletion":1247,"completion":1247,"start":38467,"enrollment":13132,"conditions":38468,"interventions":38470},"NCT04610892","Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction",[91],"2020-11-04",[38469],"Coronary Heart Disease (CHD)",[38455],{"trials":38472,"activeCount":102},[],{"trials":38474,"activeCount":102},[],{"trials":38476,"activeCount":102},[],{"intervention":38478,"totalTrials":122,"cells":38479},"Pramlintide and Metreleptin",{"EARLY_PHASE1":38480,"PHASE1":38482,"PHASE2":38484,"PHASE3":38492,"PHASE4":38494,"NA":38496},{"trials":38481,"activeCount":102},[],{"trials":38483,"activeCount":102},[],{"trials":38485,"activeCount":102},[38486],{"nctId":38487,"briefTitle":38488,"status":195,"phases":38489,"primaryCompletion":2350,"completion":2057,"start":2414,"enrollment":5522,"conditions":38490,"interventions":38491},"NCT00819234","Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin",[91],[12275],[38478],{"trials":38493,"activeCount":102},[],{"trials":38495,"activeCount":102},[],{"trials":38497,"activeCount":102},[],{"intervention":38499,"totalTrials":122,"cells":38500},"IR",{"EARLY_PHASE1":38501,"PHASE1":38503,"PHASE2":38505,"PHASE3":38513,"PHASE4":38515,"NA":38517},{"trials":38502,"activeCount":102},[],{"trials":38504,"activeCount":102},[],{"trials":38506,"activeCount":102},[38507],{"nctId":38508,"briefTitle":38509,"status":195,"phases":38510,"completion":4284,"start":6650,"enrollment":1710,"conditions":38511,"interventions":38512},"NCT00254787","Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients",[91],[33],[38499],{"trials":38514,"activeCount":102},[],{"trials":38516,"activeCount":102},[],{"trials":38518,"activeCount":102},[],{"intervention":25550,"totalTrials":122,"cells":38520},{"EARLY_PHASE1":38521,"PHASE1":38523,"PHASE2":38525,"PHASE3":38531,"PHASE4":38533,"NA":38535},{"trials":38522,"activeCount":102},[],{"trials":38524,"activeCount":102},[],{"trials":38526,"activeCount":102},[38527],{"nctId":25545,"briefTitle":25546,"status":195,"phases":38528,"primaryCompletion":4204,"completion":4204,"start":2405,"enrollment":4307,"conditions":38529,"interventions":38530},[91],[16],[10068,25527,25550],{"trials":38532,"activeCount":102},[],{"trials":38534,"activeCount":102},[],{"trials":38536,"activeCount":102},[],{"intervention":32840,"totalTrials":122,"cells":38538},{"EARLY_PHASE1":38539,"PHASE1":38541,"PHASE2":38543,"PHASE3":38549,"PHASE4":38551,"NA":38553},{"trials":38540,"activeCount":102},[],{"trials":38542,"activeCount":102},[],{"trials":38544,"activeCount":102},[38545],{"nctId":32833,"briefTitle":32834,"status":195,"phases":38546,"primaryCompletion":688,"completion":688,"start":4297,"enrollment":32836,"conditions":38547,"interventions":38548},[91],[32838],[20336,32840],{"trials":38550,"activeCount":102},[],{"trials":38552,"activeCount":102},[],{"trials":38554,"activeCount":102},[],{"intervention":38556,"totalTrials":122,"cells":38557},"AZD2423 Placebo",{"EARLY_PHASE1":38558,"PHASE1":38560,"PHASE2":38562,"PHASE3":38571,"PHASE4":38573,"NA":38575},{"trials":38559,"activeCount":102},[],{"trials":38561,"activeCount":102},[],{"trials":38563,"activeCount":102},[38564],{"nctId":38565,"briefTitle":38566,"status":195,"phases":38567,"primaryCompletion":6709,"completion":6709,"start":2489,"enrollment":34,"conditions":38568,"interventions":38569},"NCT01153321","Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)",[91],[28,31984],[38570,38556],"AZD2423",{"trials":38572,"activeCount":102},[],{"trials":38574,"activeCount":102},[],{"trials":38576,"activeCount":102},[],{"intervention":38578,"totalTrials":122,"cells":38579},"AZD8683, 50 mcg",{"EARLY_PHASE1":38580,"PHASE1":38582,"PHASE2":38584,"PHASE3":38593,"PHASE4":38595,"NA":38597},{"trials":38581,"activeCount":102},[],{"trials":38583,"activeCount":102},[],{"trials":38585,"activeCount":102},[38586],{"nctId":38587,"briefTitle":38588,"status":195,"phases":38589,"primaryCompletion":2143,"completion":2143,"start":2489,"enrollment":2260,"conditions":38590,"interventions":38591},"NCT01205269","The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[6083],[38578,38592],"AZD8683, 200 mcg",{"trials":38594,"activeCount":102},[],{"trials":38596,"activeCount":102},[],{"trials":38598,"activeCount":102},[],{"intervention":38592,"totalTrials":122,"cells":38600},{"EARLY_PHASE1":38601,"PHASE1":38603,"PHASE2":38605,"PHASE3":38611,"PHASE4":38613,"NA":38615},{"trials":38602,"activeCount":102},[],{"trials":38604,"activeCount":102},[],{"trials":38606,"activeCount":102},[38607],{"nctId":38587,"briefTitle":38588,"status":195,"phases":38608,"primaryCompletion":2143,"completion":2143,"start":2489,"enrollment":2260,"conditions":38609,"interventions":38610},[91],[6083],[38578,38592],{"trials":38612,"activeCount":102},[],{"trials":38614,"activeCount":102},[],{"trials":38616,"activeCount":102},[],{"intervention":38618,"totalTrials":122,"cells":38619},"Omega-3 carboxylic acid",{"EARLY_PHASE1":38620,"PHASE1":38622,"PHASE2":38624,"PHASE3":38636,"PHASE4":38638,"NA":38640},{"trials":38621,"activeCount":102},[],{"trials":38623,"activeCount":102},[],{"trials":38625,"activeCount":102},[38626],{"nctId":38627,"briefTitle":38628,"status":195,"phases":38629,"primaryCompletion":38630,"completion":38630,"start":25557,"enrollment":38631,"conditions":38632,"interventions":38634},"NCT02354976","A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.",[91],"2016-05-26",78,[38633,13022],"Non-alcoholic Fatty Liver Disease (NAFLD",[38618,38635],"Fenofibrate 200mg",{"trials":38637,"activeCount":102},[],{"trials":38639,"activeCount":102},[],{"trials":38641,"activeCount":102},[],{"intervention":38635,"totalTrials":122,"cells":38643},{"EARLY_PHASE1":38644,"PHASE1":38646,"PHASE2":38648,"PHASE3":38654,"PHASE4":38656,"NA":38658},{"trials":38645,"activeCount":102},[],{"trials":38647,"activeCount":102},[],{"trials":38649,"activeCount":102},[38650],{"nctId":38627,"briefTitle":38628,"status":195,"phases":38651,"primaryCompletion":38630,"completion":38630,"start":25557,"enrollment":38631,"conditions":38652,"interventions":38653},[91],[38633,13022],[38618,38635],{"trials":38655,"activeCount":102},[],{"trials":38657,"activeCount":102},[],{"trials":38659,"activeCount":102},[],{"intervention":38661,"totalTrials":122,"cells":38662},"cediranib and olaparib",{"EARLY_PHASE1":38663,"PHASE1":38665,"PHASE2":38667,"PHASE3":38679,"PHASE4":38681,"NA":38683},{"trials":38664,"activeCount":102},[],{"trials":38666,"activeCount":102},[],{"trials":38668,"activeCount":102},[38669],{"nctId":38670,"briefTitle":38671,"status":195,"phases":38672,"primaryCompletion":38673,"completion":38674,"start":38675,"enrollment":37,"conditions":38676,"interventions":38678},"NCT02889900","Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer",[91],"2019-08-27","2021-03-16","2017-01-17",[38677],"Recurrent Platinum Resistant Ovarian Cancer",[38661],{"trials":38680,"activeCount":102},[],{"trials":38682,"activeCount":102},[],{"trials":38684,"activeCount":102},[],{"intervention":34863,"totalTrials":122,"cells":38686},{"EARLY_PHASE1":38687,"PHASE1":38689,"PHASE2":38691,"PHASE3":38697,"PHASE4":38699,"NA":38701},{"trials":38688,"activeCount":102},[],{"trials":38690,"activeCount":102},[],{"trials":38692,"activeCount":102},[38693],{"nctId":34858,"briefTitle":34859,"status":195,"phases":38694,"primaryCompletion":5725,"completion":5725,"start":7342,"enrollment":5947,"conditions":38695,"interventions":38696},[91],[34716,12275],[22620,34863,34864],{"trials":38698,"activeCount":102},[],{"trials":38700,"activeCount":102},[],{"trials":38702,"activeCount":102},[],{"intervention":12123,"totalTrials":122,"cells":38704},{"EARLY_PHASE1":38705,"PHASE1":38707,"PHASE2":38709,"PHASE3":38715,"PHASE4":38717,"NA":38719},{"trials":38706,"activeCount":102},[],{"trials":38708,"activeCount":102},[],{"trials":38710,"activeCount":102},[38711],{"nctId":12116,"briefTitle":12117,"status":195,"phases":38712,"primaryCompletion":246,"completion":246,"start":12119,"enrollment":3476,"conditions":38713,"interventions":38714},[91],[12093],[10762,12122,12123,12122,12123],{"trials":38716,"activeCount":102},[],{"trials":38718,"activeCount":102},[],{"trials":38720,"activeCount":102},[],{"intervention":38722,"totalTrials":122,"cells":38723},"exenatide once monthly suspension",{"EARLY_PHASE1":38724,"PHASE1":38726,"PHASE2":38728,"PHASE3":38736,"PHASE4":38738,"NA":38740},{"trials":38725,"activeCount":102},[],{"trials":38727,"activeCount":102},[],{"trials":38729,"activeCount":102},[38730],{"nctId":38731,"briefTitle":38732,"status":195,"phases":38733,"primaryCompletion":2143,"completion":2143,"start":2243,"enrollment":1777,"conditions":38734,"interventions":38735},"NCT01104701","A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension",[91],[31],[15934,38722,38722,38722],{"trials":38737,"activeCount":102},[],{"trials":38739,"activeCount":102},[],{"trials":38741,"activeCount":102},[],{"intervention":38743,"totalTrials":122,"cells":38744},"0.5% Roflumilast Cream",{"EARLY_PHASE1":38745,"PHASE1":38747,"PHASE2":38749,"PHASE3":38758,"PHASE4":38760,"NA":38762},{"trials":38746,"activeCount":102},[],{"trials":38748,"activeCount":102},[],{"trials":38750,"activeCount":102},[38751],{"nctId":38752,"briefTitle":38753,"status":195,"phases":38754,"primaryCompletion":4006,"completion":4006,"start":2746,"enrollment":1448,"conditions":38755,"interventions":38756},"NCT01856764","Topical Roflumilast in Adults With Atopic Dermatitis",[91],[1577],[38743,38757],"Vehicle Cream",{"trials":38759,"activeCount":102},[],{"trials":38761,"activeCount":102},[],{"trials":38763,"activeCount":102},[],{"intervention":38757,"totalTrials":122,"cells":38765},{"EARLY_PHASE1":38766,"PHASE1":38768,"PHASE2":38770,"PHASE3":38776,"PHASE4":38778,"NA":38780},{"trials":38767,"activeCount":102},[],{"trials":38769,"activeCount":102},[],{"trials":38771,"activeCount":102},[38772],{"nctId":38752,"briefTitle":38753,"status":195,"phases":38773,"primaryCompletion":4006,"completion":4006,"start":2746,"enrollment":1448,"conditions":38774,"interventions":38775},[91],[1577],[38743,38757],{"trials":38777,"activeCount":102},[],{"trials":38779,"activeCount":102},[],{"trials":38781,"activeCount":102},[],{"intervention":38783,"totalTrials":122,"cells":38784},"Zibotentan + placebo",{"EARLY_PHASE1":38785,"PHASE1":38787,"PHASE2":38789,"PHASE3":38799,"PHASE4":38801,"NA":38803},{"trials":38786,"activeCount":102},[],{"trials":38788,"activeCount":102},[],{"trials":38790,"activeCount":102},[38791],{"nctId":38792,"briefTitle":38793,"status":195,"phases":38794,"primaryCompletion":13274,"completion":13274,"start":38795,"enrollment":33344,"conditions":38796,"interventions":38797},"NCT06269484","A Phase IIb Study to Evaluate the Safety of Zibotentan\u002FDapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK",[91],"2024-02-15",[33264],[38783,38798],"Zibotentan + dapagliflozin",{"trials":38800,"activeCount":102},[],{"trials":38802,"activeCount":102},[],{"trials":38804,"activeCount":102},[],{"intervention":38798,"totalTrials":122,"cells":38806},{"EARLY_PHASE1":38807,"PHASE1":38809,"PHASE2":38811,"PHASE3":38817,"PHASE4":38819,"NA":38821},{"trials":38808,"activeCount":102},[],{"trials":38810,"activeCount":102},[],{"trials":38812,"activeCount":102},[38813],{"nctId":38792,"briefTitle":38793,"status":195,"phases":38814,"primaryCompletion":13274,"completion":13274,"start":38795,"enrollment":33344,"conditions":38815,"interventions":38816},[91],[33264],[38783,38798],{"trials":38818,"activeCount":102},[],{"trials":38820,"activeCount":102},[],{"trials":38822,"activeCount":102},[],{"intervention":38824,"totalTrials":122,"cells":38825},"CIN-107 2 mg dosing",{"EARLY_PHASE1":38826,"PHASE1":38828,"PHASE2":38830,"PHASE3":38842,"PHASE4":38844,"NA":38846},{"trials":38827,"activeCount":102},[],{"trials":38829,"activeCount":102},[],{"trials":38831,"activeCount":102},[38832],{"nctId":38833,"briefTitle":38834,"status":195,"phases":38835,"primaryCompletion":11175,"completion":11175,"start":12185,"enrollment":520,"conditions":38836,"interventions":38839},"NCT04605549","A Study of CIN-107 in Adults With Primary Aldosteronism",[91],[38837,38838],"Primary Aldosteronism","Hyperaldosteronism",[38824,38840,38841],"CIN-107 4 mg dosing","CIN-107 8 mg dosing",{"trials":38843,"activeCount":102},[],{"trials":38845,"activeCount":102},[],{"trials":38847,"activeCount":102},[],{"intervention":38840,"totalTrials":122,"cells":38849},{"EARLY_PHASE1":38850,"PHASE1":38852,"PHASE2":38854,"PHASE3":38860,"PHASE4":38862,"NA":38864},{"trials":38851,"activeCount":102},[],{"trials":38853,"activeCount":102},[],{"trials":38855,"activeCount":102},[38856],{"nctId":38833,"briefTitle":38834,"status":195,"phases":38857,"primaryCompletion":11175,"completion":11175,"start":12185,"enrollment":520,"conditions":38858,"interventions":38859},[91],[38837,38838],[38824,38840,38841],{"trials":38861,"activeCount":102},[],{"trials":38863,"activeCount":102},[],{"trials":38865,"activeCount":102},[],{"intervention":38841,"totalTrials":122,"cells":38867},{"EARLY_PHASE1":38868,"PHASE1":38870,"PHASE2":38872,"PHASE3":38878,"PHASE4":38880,"NA":38882},{"trials":38869,"activeCount":102},[],{"trials":38871,"activeCount":102},[],{"trials":38873,"activeCount":102},[38874],{"nctId":38833,"briefTitle":38834,"status":195,"phases":38875,"primaryCompletion":11175,"completion":11175,"start":12185,"enrollment":520,"conditions":38876,"interventions":38877},[91],[38837,38838],[38824,38840,38841],{"trials":38879,"activeCount":102},[],{"trials":38881,"activeCount":102},[],{"trials":38883,"activeCount":102},[],{"intervention":38885,"totalTrials":122,"cells":38886},"LAS100977 0.313 μg",{"EARLY_PHASE1":38887,"PHASE1":38889,"PHASE2":38891,"PHASE3":38906,"PHASE4":38908,"NA":38910},{"trials":38888,"activeCount":102},[],{"trials":38890,"activeCount":102},[],{"trials":38892,"activeCount":102},[38893],{"nctId":38894,"briefTitle":38895,"status":195,"phases":38896,"primaryCompletion":4212,"completion":4212,"start":38897,"enrollment":37,"conditions":38898,"interventions":38899},"NCT01425801","Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.",[91],"2011-08-01",[16],[38885,38900,38901,38902,38903,38904,38905],"LAS100977 0.625 μg","LAS100977 1.25 μg","LAS100977 2.5 μg","Salbutamol 400 μg","Salbutamol placebo","LAS100977 placebo",{"trials":38907,"activeCount":102},[],{"trials":38909,"activeCount":102},[],{"trials":38911,"activeCount":102},[],{"intervention":38900,"totalTrials":122,"cells":38913},{"EARLY_PHASE1":38914,"PHASE1":38916,"PHASE2":38918,"PHASE3":38924,"PHASE4":38926,"NA":38928},{"trials":38915,"activeCount":102},[],{"trials":38917,"activeCount":102},[],{"trials":38919,"activeCount":102},[38920],{"nctId":38894,"briefTitle":38895,"status":195,"phases":38921,"primaryCompletion":4212,"completion":4212,"start":38897,"enrollment":37,"conditions":38922,"interventions":38923},[91],[16],[38885,38900,38901,38902,38903,38904,38905],{"trials":38925,"activeCount":102},[],{"trials":38927,"activeCount":102},[],{"trials":38929,"activeCount":102},[],{"intervention":38901,"totalTrials":122,"cells":38931},{"EARLY_PHASE1":38932,"PHASE1":38934,"PHASE2":38936,"PHASE3":38942,"PHASE4":38944,"NA":38946},{"trials":38933,"activeCount":102},[],{"trials":38935,"activeCount":102},[],{"trials":38937,"activeCount":102},[38938],{"nctId":38894,"briefTitle":38895,"status":195,"phases":38939,"primaryCompletion":4212,"completion":4212,"start":38897,"enrollment":37,"conditions":38940,"interventions":38941},[91],[16],[38885,38900,38901,38902,38903,38904,38905],{"trials":38943,"activeCount":102},[],{"trials":38945,"activeCount":102},[],{"trials":38947,"activeCount":102},[],{"intervention":38902,"totalTrials":122,"cells":38949},{"EARLY_PHASE1":38950,"PHASE1":38952,"PHASE2":38954,"PHASE3":38960,"PHASE4":38962,"NA":38964},{"trials":38951,"activeCount":102},[],{"trials":38953,"activeCount":102},[],{"trials":38955,"activeCount":102},[38956],{"nctId":38894,"briefTitle":38895,"status":195,"phases":38957,"primaryCompletion":4212,"completion":4212,"start":38897,"enrollment":37,"conditions":38958,"interventions":38959},[91],[16],[38885,38900,38901,38902,38903,38904,38905],{"trials":38961,"activeCount":102},[],{"trials":38963,"activeCount":102},[],{"trials":38965,"activeCount":102},[],{"intervention":38903,"totalTrials":122,"cells":38967},{"EARLY_PHASE1":38968,"PHASE1":38970,"PHASE2":38972,"PHASE3":38978,"PHASE4":38980,"NA":38982},{"trials":38969,"activeCount":102},[],{"trials":38971,"activeCount":102},[],{"trials":38973,"activeCount":102},[38974],{"nctId":38894,"briefTitle":38895,"status":195,"phases":38975,"primaryCompletion":4212,"completion":4212,"start":38897,"enrollment":37,"conditions":38976,"interventions":38977},[91],[16],[38885,38900,38901,38902,38903,38904,38905],{"trials":38979,"activeCount":102},[],{"trials":38981,"activeCount":102},[],{"trials":38983,"activeCount":102},[],{"intervention":38904,"totalTrials":122,"cells":38985},{"EARLY_PHASE1":38986,"PHASE1":38988,"PHASE2":38990,"PHASE3":38996,"PHASE4":38998,"NA":39000},{"trials":38987,"activeCount":102},[],{"trials":38989,"activeCount":102},[],{"trials":38991,"activeCount":102},[38992],{"nctId":38894,"briefTitle":38895,"status":195,"phases":38993,"primaryCompletion":4212,"completion":4212,"start":38897,"enrollment":37,"conditions":38994,"interventions":38995},[91],[16],[38885,38900,38901,38902,38903,38904,38905],{"trials":38997,"activeCount":102},[],{"trials":38999,"activeCount":102},[],{"trials":39001,"activeCount":102},[],{"intervention":38905,"totalTrials":122,"cells":39003},{"EARLY_PHASE1":39004,"PHASE1":39006,"PHASE2":39008,"PHASE3":39014,"PHASE4":39016,"NA":39018},{"trials":39005,"activeCount":102},[],{"trials":39007,"activeCount":102},[],{"trials":39009,"activeCount":102},[39010],{"nctId":38894,"briefTitle":38895,"status":195,"phases":39011,"primaryCompletion":4212,"completion":4212,"start":38897,"enrollment":37,"conditions":39012,"interventions":39013},[91],[16],[38885,38900,38901,38902,38903,38904,38905],{"trials":39015,"activeCount":102},[],{"trials":39017,"activeCount":102},[],{"trials":39019,"activeCount":102},[],{"intervention":39021,"totalTrials":122,"cells":39022},"[18F]AZD4694",{"EARLY_PHASE1":39023,"PHASE1":39025,"PHASE2":39027,"PHASE3":39035,"PHASE4":39037,"NA":39039},{"trials":39024,"activeCount":102},[],{"trials":39026,"activeCount":102},[],{"trials":39028,"activeCount":102},[39029],{"nctId":39030,"briefTitle":39031,"status":195,"phases":39032,"primaryCompletion":2675,"completion":2675,"start":2114,"enrollment":98,"conditions":39033,"interventions":39034},"NCT00991419","To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden",[91],[18867],[39021],{"trials":39036,"activeCount":102},[],{"trials":39038,"activeCount":102},[],{"trials":39040,"activeCount":102},[],{"intervention":10054,"totalTrials":122,"cells":39042},{"EARLY_PHASE1":39043,"PHASE1":39045,"PHASE2":39047,"PHASE3":39053,"PHASE4":39055,"NA":39057},{"trials":39044,"activeCount":102},[],{"trials":39046,"activeCount":102},[],{"trials":39048,"activeCount":102},[39049],{"nctId":10045,"briefTitle":10046,"status":195,"phases":39050,"primaryCompletion":10048,"completion":10048,"start":10049,"enrollment":680,"conditions":39051,"interventions":39052},[91],[16,10051,10052],[10054,10055,10056,6193],{"trials":39054,"activeCount":102},[],{"trials":39056,"activeCount":102},[],{"trials":39058,"activeCount":102},[],{"intervention":10055,"totalTrials":122,"cells":39060},{"EARLY_PHASE1":39061,"PHASE1":39063,"PHASE2":39065,"PHASE3":39071,"PHASE4":39073,"NA":39075},{"trials":39062,"activeCount":102},[],{"trials":39064,"activeCount":102},[],{"trials":39066,"activeCount":102},[39067],{"nctId":10045,"briefTitle":10046,"status":195,"phases":39068,"primaryCompletion":10048,"completion":10048,"start":10049,"enrollment":680,"conditions":39069,"interventions":39070},[91],[16,10051,10052],[10054,10055,10056,6193],{"trials":39072,"activeCount":102},[],{"trials":39074,"activeCount":102},[],{"trials":39076,"activeCount":102},[],{"intervention":10056,"totalTrials":122,"cells":39078},{"EARLY_PHASE1":39079,"PHASE1":39081,"PHASE2":39083,"PHASE3":39089,"PHASE4":39091,"NA":39093},{"trials":39080,"activeCount":102},[],{"trials":39082,"activeCount":102},[],{"trials":39084,"activeCount":102},[39085],{"nctId":10045,"briefTitle":10046,"status":195,"phases":39086,"primaryCompletion":10048,"completion":10048,"start":10049,"enrollment":680,"conditions":39087,"interventions":39088},[91],[16,10051,10052],[10054,10055,10056,6193],{"trials":39090,"activeCount":102},[],{"trials":39092,"activeCount":102},[],{"trials":39094,"activeCount":102},[],{"intervention":34838,"totalTrials":122,"cells":39096},{"EARLY_PHASE1":39097,"PHASE1":39099,"PHASE2":39101,"PHASE3":39107,"PHASE4":39109,"NA":39111},{"trials":39098,"activeCount":102},[],{"trials":39100,"activeCount":102},[],{"trials":39102,"activeCount":102},[39103],{"nctId":34831,"briefTitle":34832,"status":195,"phases":39104,"primaryCompletion":20816,"completion":20816,"start":34834,"enrollment":5189,"conditions":39105,"interventions":39106},[91],[34836],[34811,34838],{"trials":39108,"activeCount":102},[],{"trials":39110,"activeCount":102},[],{"trials":39112,"activeCount":102},[],{"intervention":24043,"totalTrials":122,"cells":39114},{"EARLY_PHASE1":39115,"PHASE1":39117,"PHASE2":39119,"PHASE3":39125,"PHASE4":39127,"NA":39129},{"trials":39116,"activeCount":102},[],{"trials":39118,"activeCount":102},[],{"trials":39120,"activeCount":102},[39121],{"nctId":24035,"briefTitle":24036,"status":195,"phases":39122,"primaryCompletion":20972,"completion":20972,"start":1191,"enrollment":24038,"conditions":39123,"interventions":39124},[91],[24040],[24042,24043,24042,24042],{"trials":39126,"activeCount":102},[],{"trials":39128,"activeCount":102},[],{"trials":39130,"activeCount":102},[],{"intervention":39132,"totalTrials":122,"cells":39133},"AZD7009, no generic name available",{"EARLY_PHASE1":39134,"PHASE1":39136,"PHASE2":39138,"PHASE3":39146,"PHASE4":39148,"NA":39150},{"trials":39135,"activeCount":102},[],{"trials":39137,"activeCount":102},[],{"trials":39139,"activeCount":102},[39140],{"nctId":39141,"briefTitle":39142,"status":195,"phases":39143,"completion":7494,"start":6719,"enrollment":12342,"conditions":39144,"interventions":39145},"NCT00255281","Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation",[91],[16449],[39132],{"trials":39147,"activeCount":102},[],{"trials":39149,"activeCount":102},[],{"trials":39151,"activeCount":102},[],{"intervention":39153,"totalTrials":122,"cells":39154},"MEDI0382 100 μg",{"EARLY_PHASE1":39155,"PHASE1":39157,"PHASE2":39159,"PHASE3":39174,"PHASE4":39176,"NA":39178},{"trials":39156,"activeCount":102},[],{"trials":39158,"activeCount":102},[],{"trials":39160,"activeCount":102},[39161],{"nctId":39162,"briefTitle":39163,"status":195,"phases":39164,"primaryCompletion":39165,"completion":39165,"start":39166,"enrollment":22212,"conditions":39167,"interventions":39168},"NCT03645421","Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes",[91],"2019-01-17","2018-08-10",[31],[39153,39169,39170,39171,39172,39173],"MEDI0382 200 μg","MEDI0382 300 μg","PlaceboA","MEDI0382 50 ug","PlaceboB",{"trials":39175,"activeCount":102},[],{"trials":39177,"activeCount":102},[],{"trials":39179,"activeCount":102},[],{"intervention":39169,"totalTrials":122,"cells":39181},{"EARLY_PHASE1":39182,"PHASE1":39184,"PHASE2":39186,"PHASE3":39192,"PHASE4":39194,"NA":39196},{"trials":39183,"activeCount":102},[],{"trials":39185,"activeCount":102},[],{"trials":39187,"activeCount":102},[39188],{"nctId":39162,"briefTitle":39163,"status":195,"phases":39189,"primaryCompletion":39165,"completion":39165,"start":39166,"enrollment":22212,"conditions":39190,"interventions":39191},[91],[31],[39153,39169,39170,39171,39172,39173],{"trials":39193,"activeCount":102},[],{"trials":39195,"activeCount":102},[],{"trials":39197,"activeCount":102},[],{"intervention":39170,"totalTrials":122,"cells":39199},{"EARLY_PHASE1":39200,"PHASE1":39202,"PHASE2":39204,"PHASE3":39210,"PHASE4":39212,"NA":39214},{"trials":39201,"activeCount":102},[],{"trials":39203,"activeCount":102},[],{"trials":39205,"activeCount":102},[39206],{"nctId":39162,"briefTitle":39163,"status":195,"phases":39207,"primaryCompletion":39165,"completion":39165,"start":39166,"enrollment":22212,"conditions":39208,"interventions":39209},[91],[31],[39153,39169,39170,39171,39172,39173],{"trials":39211,"activeCount":102},[],{"trials":39213,"activeCount":102},[],{"trials":39215,"activeCount":102},[],{"intervention":39171,"totalTrials":122,"cells":39217},{"EARLY_PHASE1":39218,"PHASE1":39220,"PHASE2":39222,"PHASE3":39228,"PHASE4":39230,"NA":39232},{"trials":39219,"activeCount":102},[],{"trials":39221,"activeCount":102},[],{"trials":39223,"activeCount":102},[39224],{"nctId":39162,"briefTitle":39163,"status":195,"phases":39225,"primaryCompletion":39165,"completion":39165,"start":39166,"enrollment":22212,"conditions":39226,"interventions":39227},[91],[31],[39153,39169,39170,39171,39172,39173],{"trials":39229,"activeCount":102},[],{"trials":39231,"activeCount":102},[],{"trials":39233,"activeCount":102},[],{"intervention":39172,"totalTrials":122,"cells":39235},{"EARLY_PHASE1":39236,"PHASE1":39238,"PHASE2":39240,"PHASE3":39246,"PHASE4":39248,"NA":39250},{"trials":39237,"activeCount":102},[],{"trials":39239,"activeCount":102},[],{"trials":39241,"activeCount":102},[39242],{"nctId":39162,"briefTitle":39163,"status":195,"phases":39243,"primaryCompletion":39165,"completion":39165,"start":39166,"enrollment":22212,"conditions":39244,"interventions":39245},[91],[31],[39153,39169,39170,39171,39172,39173],{"trials":39247,"activeCount":102},[],{"trials":39249,"activeCount":102},[],{"trials":39251,"activeCount":102},[],{"intervention":39173,"totalTrials":122,"cells":39253},{"EARLY_PHASE1":39254,"PHASE1":39256,"PHASE2":39258,"PHASE3":39264,"PHASE4":39266,"NA":39268},{"trials":39255,"activeCount":102},[],{"trials":39257,"activeCount":102},[],{"trials":39259,"activeCount":102},[39260],{"nctId":39162,"briefTitle":39163,"status":195,"phases":39261,"primaryCompletion":39165,"completion":39165,"start":39166,"enrollment":22212,"conditions":39262,"interventions":39263},[91],[31],[39153,39169,39170,39171,39172,39173],{"trials":39265,"activeCount":102},[],{"trials":39267,"activeCount":102},[],{"trials":39269,"activeCount":102},[],{"intervention":39271,"totalTrials":122,"cells":39272},"Gefitinib 250mg",{"EARLY_PHASE1":39273,"PHASE1":39275,"PHASE2":39277,"PHASE3":39285,"PHASE4":39287,"NA":39289},{"trials":39274,"activeCount":102},[],{"trials":39276,"activeCount":102},[],{"trials":39278,"activeCount":102},[39279],{"nctId":39280,"briefTitle":39281,"status":195,"phases":39282,"primaryCompletion":1692,"completion":1692,"start":2481,"enrollment":22212,"conditions":39283,"interventions":39284},"NCT01530334","Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment",[91],[3174],[39271],{"trials":39286,"activeCount":102},[],{"trials":39288,"activeCount":102},[],{"trials":39290,"activeCount":102},[],{"intervention":39292,"totalTrials":122,"cells":39293},"B - Exenatide 10 mcg twice daily",{"EARLY_PHASE1":39294,"PHASE1":39296,"PHASE2":39298,"PHASE3":39308,"PHASE4":39310,"NA":39312},{"trials":39295,"activeCount":102},[],{"trials":39297,"activeCount":102},[],{"trials":39299,"activeCount":102},[39300],{"nctId":39301,"briefTitle":39302,"status":195,"phases":39303,"primaryCompletion":6572,"completion":6572,"start":6780,"enrollment":6390,"conditions":39304,"interventions":39305},"NCT00085969","Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus",[91],[2089],[39292,39306,39307],"C - Exenatide 10 mcg once daily","Exenatide 20 mcg once daily",{"trials":39309,"activeCount":102},[],{"trials":39311,"activeCount":102},[],{"trials":39313,"activeCount":102},[],{"intervention":39306,"totalTrials":122,"cells":39315},{"EARLY_PHASE1":39316,"PHASE1":39318,"PHASE2":39320,"PHASE3":39326,"PHASE4":39328,"NA":39330},{"trials":39317,"activeCount":102},[],{"trials":39319,"activeCount":102},[],{"trials":39321,"activeCount":102},[39322],{"nctId":39301,"briefTitle":39302,"status":195,"phases":39323,"primaryCompletion":6572,"completion":6572,"start":6780,"enrollment":6390,"conditions":39324,"interventions":39325},[91],[2089],[39292,39306,39307],{"trials":39327,"activeCount":102},[],{"trials":39329,"activeCount":102},[],{"trials":39331,"activeCount":102},[],{"intervention":39307,"totalTrials":122,"cells":39333},{"EARLY_PHASE1":39334,"PHASE1":39336,"PHASE2":39338,"PHASE3":39344,"PHASE4":39346,"NA":39348},{"trials":39335,"activeCount":102},[],{"trials":39337,"activeCount":102},[],{"trials":39339,"activeCount":102},[39340],{"nctId":39301,"briefTitle":39302,"status":195,"phases":39341,"primaryCompletion":6572,"completion":6572,"start":6780,"enrollment":6390,"conditions":39342,"interventions":39343},[91],[2089],[39292,39306,39307],{"trials":39345,"activeCount":102},[],{"trials":39347,"activeCount":102},[],{"trials":39349,"activeCount":102},[],{"intervention":39351,"totalTrials":122,"cells":39352},"MEDI0382 low dose",{"EARLY_PHASE1":39353,"PHASE1":39355,"PHASE2":39357,"PHASE3":39370,"PHASE4":39372,"NA":39374},{"trials":39354,"activeCount":102},[],{"trials":39356,"activeCount":102},[],{"trials":39358,"activeCount":102},[39359],{"nctId":39360,"briefTitle":39361,"status":195,"phases":39362,"primaryCompletion":39363,"completion":24736,"start":25583,"enrollment":39364,"conditions":39365,"interventions":39366},"NCT03235050","A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes",[91],"2018-05-03",834,[2089],[39351,39367,39368,39369],"MEDI0382 mid dose","MEDI0382 high dose","Liraglutide",{"trials":39371,"activeCount":102},[],{"trials":39373,"activeCount":102},[],{"trials":39375,"activeCount":102},[],{"intervention":39367,"totalTrials":122,"cells":39377},{"EARLY_PHASE1":39378,"PHASE1":39380,"PHASE2":39382,"PHASE3":39388,"PHASE4":39390,"NA":39392},{"trials":39379,"activeCount":102},[],{"trials":39381,"activeCount":102},[],{"trials":39383,"activeCount":102},[39384],{"nctId":39360,"briefTitle":39361,"status":195,"phases":39385,"primaryCompletion":39363,"completion":24736,"start":25583,"enrollment":39364,"conditions":39386,"interventions":39387},[91],[2089],[39351,39367,39368,39369],{"trials":39389,"activeCount":102},[],{"trials":39391,"activeCount":102},[],{"trials":39393,"activeCount":102},[],{"intervention":39368,"totalTrials":122,"cells":39395},{"EARLY_PHASE1":39396,"PHASE1":39398,"PHASE2":39400,"PHASE3":39406,"PHASE4":39408,"NA":39410},{"trials":39397,"activeCount":102},[],{"trials":39399,"activeCount":102},[],{"trials":39401,"activeCount":102},[39402],{"nctId":39360,"briefTitle":39361,"status":195,"phases":39403,"primaryCompletion":39363,"completion":24736,"start":25583,"enrollment":39364,"conditions":39404,"interventions":39405},[91],[2089],[39351,39367,39368,39369],{"trials":39407,"activeCount":102},[],{"trials":39409,"activeCount":102},[],{"trials":39411,"activeCount":102},[],{"intervention":39413,"totalTrials":122,"cells":39414},"Ticagrelor Dose 1a + Dose 2a",{"EARLY_PHASE1":39415,"PHASE1":39417,"PHASE2":39419,"PHASE3":39431,"PHASE4":39433,"NA":39435},{"trials":39416,"activeCount":102},[],{"trials":39418,"activeCount":102},[],{"trials":39420,"activeCount":102},[39421],{"nctId":39422,"briefTitle":39423,"status":195,"phases":39424,"primaryCompletion":39425,"completion":39425,"start":39426,"enrollment":451,"conditions":39427,"interventions":39429},"NCT02214121","A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease",[91],"2017-02-27","2014-09-11",[39428],"Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease",[39413,39430],"Ticagrelor Dose 1b + Dose 2b",{"trials":39432,"activeCount":102},[],{"trials":39434,"activeCount":102},[],{"trials":39436,"activeCount":102},[],{"intervention":39430,"totalTrials":122,"cells":39438},{"EARLY_PHASE1":39439,"PHASE1":39441,"PHASE2":39443,"PHASE3":39449,"PHASE4":39451,"NA":39453},{"trials":39440,"activeCount":102},[],{"trials":39442,"activeCount":102},[],{"trials":39444,"activeCount":102},[39445],{"nctId":39422,"briefTitle":39423,"status":195,"phases":39446,"primaryCompletion":39425,"completion":39425,"start":39426,"enrollment":451,"conditions":39447,"interventions":39448},[91],[39428],[39413,39430],{"trials":39450,"activeCount":102},[],{"trials":39452,"activeCount":102},[],{"trials":39454,"activeCount":102},[],{"intervention":39456,"totalTrials":122,"cells":39457},"MEDI4736 in combination with nab-paclitaxel and gemcitabine",{"EARLY_PHASE1":39458,"PHASE1":39460,"PHASE2":39462,"PHASE3":39472,"PHASE4":39474,"NA":39476},{"trials":39459,"activeCount":102},[],{"trials":39461,"activeCount":102},[],{"trials":39463,"activeCount":102},[39464],{"nctId":39465,"briefTitle":39466,"status":195,"phases":39467,"primaryCompletion":3853,"completion":3853,"start":39468,"enrollment":554,"conditions":39469,"interventions":39470},"NCT02583477","Phase Ib\u002FII Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma",[90,91],"2016-03-25",[34836],[39456,39471],"MEDI4736 in combination with AZD5069",{"trials":39473,"activeCount":102},[],{"trials":39475,"activeCount":102},[],{"trials":39477,"activeCount":102},[],{"intervention":39471,"totalTrials":122,"cells":39479},{"EARLY_PHASE1":39480,"PHASE1":39482,"PHASE2":39484,"PHASE3":39490,"PHASE4":39492,"NA":39494},{"trials":39481,"activeCount":102},[],{"trials":39483,"activeCount":102},[],{"trials":39485,"activeCount":102},[39486],{"nctId":39465,"briefTitle":39466,"status":195,"phases":39487,"primaryCompletion":3853,"completion":3853,"start":39468,"enrollment":554,"conditions":39488,"interventions":39489},[90,91],[34836],[39456,39471],{"trials":39491,"activeCount":102},[],{"trials":39493,"activeCount":102},[],{"trials":39495,"activeCount":102},[],{"intervention":39497,"totalTrials":122,"cells":39498},"Gefitinib and capecitabine",{"EARLY_PHASE1":39499,"PHASE1":39501,"PHASE2":39503,"PHASE3":39511,"PHASE4":39513,"NA":39515},{"trials":39500,"activeCount":102},[],{"trials":39502,"activeCount":102},[],{"trials":39504,"activeCount":102},[39505],{"nctId":39506,"briefTitle":39507,"status":195,"phases":39508,"completion":6517,"start":4306,"enrollment":1448,"conditions":39509,"interventions":39510},"NCT00242788","IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure",[90,91],[691],[39497],{"trials":39512,"activeCount":102},[],{"trials":39514,"activeCount":102},[],{"trials":39516,"activeCount":102},[],{"intervention":39518,"totalTrials":122,"cells":39519},"Gefitinib, 5-fluorouracil, leucovorin and radiotherapy",{"EARLY_PHASE1":39520,"PHASE1":39522,"PHASE2":39524,"PHASE3":39533,"PHASE4":39535,"NA":39537},{"trials":39521,"activeCount":102},[],{"trials":39523,"activeCount":102},[],{"trials":39525,"activeCount":102},[39526],{"nctId":39527,"briefTitle":39528,"status":443,"phases":39529,"completion":4306,"start":4331,"enrollment":17655,"conditions":39530,"interventions":39532},"NCT00237900","Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer",[90,91],[39531],"Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC",[39518],{"trials":39534,"activeCount":102},[],{"trials":39536,"activeCount":102},[],{"trials":39538,"activeCount":102},[],{"intervention":34519,"totalTrials":122,"cells":39540},{"EARLY_PHASE1":39541,"PHASE1":39543,"PHASE2":39545,"PHASE3":39551,"PHASE4":39553,"NA":39555},{"trials":39542,"activeCount":102},[],{"trials":39544,"activeCount":102},[],{"trials":39546,"activeCount":102},[39547],{"nctId":34513,"briefTitle":34514,"status":195,"phases":39548,"primaryCompletion":4005,"completion":4005,"start":2179,"enrollment":744,"conditions":39549,"interventions":39550},[90,91],[34517],[32566,2315,34519],{"trials":39552,"activeCount":102},[],{"trials":39554,"activeCount":102},[],{"trials":39556,"activeCount":102},[],{"intervention":39558,"totalTrials":122,"cells":39559},"AC2993 2.5 mcg",{"EARLY_PHASE1":39560,"PHASE1":39562,"PHASE2":39564,"PHASE3":39575,"PHASE4":39577,"NA":39579},{"trials":39561,"activeCount":102},[],{"trials":39563,"activeCount":102},[],{"trials":39565,"activeCount":102},[39566],{"nctId":39567,"briefTitle":39568,"status":195,"phases":39569,"primaryCompletion":4299,"completion":4299,"start":5797,"enrollment":5531,"conditions":39570,"interventions":39571},"NCT00044694","Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus",[91],[24168],[39558,39572,39573,39574],"AC2993 5.0 mcg","AC2993 7.5 mcg","AC2993 10.0 mcg",{"trials":39576,"activeCount":102},[],{"trials":39578,"activeCount":102},[],{"trials":39580,"activeCount":102},[],{"intervention":39572,"totalTrials":122,"cells":39582},{"EARLY_PHASE1":39583,"PHASE1":39585,"PHASE2":39587,"PHASE3":39593,"PHASE4":39595,"NA":39597},{"trials":39584,"activeCount":102},[],{"trials":39586,"activeCount":102},[],{"trials":39588,"activeCount":102},[39589],{"nctId":39567,"briefTitle":39568,"status":195,"phases":39590,"primaryCompletion":4299,"completion":4299,"start":5797,"enrollment":5531,"conditions":39591,"interventions":39592},[91],[24168],[39558,39572,39573,39574],{"trials":39594,"activeCount":102},[],{"trials":39596,"activeCount":102},[],{"trials":39598,"activeCount":102},[],{"intervention":39573,"totalTrials":122,"cells":39600},{"EARLY_PHASE1":39601,"PHASE1":39603,"PHASE2":39605,"PHASE3":39611,"PHASE4":39613,"NA":39615},{"trials":39602,"activeCount":102},[],{"trials":39604,"activeCount":102},[],{"trials":39606,"activeCount":102},[39607],{"nctId":39567,"briefTitle":39568,"status":195,"phases":39608,"primaryCompletion":4299,"completion":4299,"start":5797,"enrollment":5531,"conditions":39609,"interventions":39610},[91],[24168],[39558,39572,39573,39574],{"trials":39612,"activeCount":102},[],{"trials":39614,"activeCount":102},[],{"trials":39616,"activeCount":102},[],{"intervention":39574,"totalTrials":122,"cells":39618},{"EARLY_PHASE1":39619,"PHASE1":39621,"PHASE2":39623,"PHASE3":39629,"PHASE4":39631,"NA":39633},{"trials":39620,"activeCount":102},[],{"trials":39622,"activeCount":102},[],{"trials":39624,"activeCount":102},[39625],{"nctId":39567,"briefTitle":39568,"status":195,"phases":39626,"primaryCompletion":4299,"completion":4299,"start":5797,"enrollment":5531,"conditions":39627,"interventions":39628},[91],[24168],[39558,39572,39573,39574],{"trials":39630,"activeCount":102},[],{"trials":39632,"activeCount":102},[],{"trials":39634,"activeCount":102},[],{"intervention":5870,"totalTrials":486,"cells":39636},{"EARLY_PHASE1":39637,"PHASE1":39639,"PHASE2":39707,"PHASE3":39709,"PHASE4":39711,"NA":39713},{"trials":39638,"activeCount":102},[],{"trials":39640,"activeCount":102},[39641,39645,39649,39653,39657,39661,39665,39669,39673,39677,39681,39685,39691,39695,39699,39703],{"nctId":32255,"briefTitle":32256,"status":195,"phases":39642,"primaryCompletion":2243,"completion":2243,"start":2114,"enrollment":451,"conditions":39643,"interventions":39644},[90],[19],[32242,23402],{"nctId":34454,"briefTitle":34455,"status":195,"phases":39646,"primaryCompletion":2414,"completion":2414,"start":2580,"enrollment":477,"conditions":39647,"interventions":39648},[90],[34458],[33092,5870],{"nctId":33743,"briefTitle":33744,"status":195,"phases":39650,"primaryCompletion":3634,"completion":3634,"start":33746,"enrollment":1638,"conditions":39651,"interventions":39652},[90],[2619],[5870,24269],{"nctId":8355,"briefTitle":8356,"status":195,"phases":39654,"primaryCompletion":3197,"completion":3197,"start":8358,"enrollment":3209,"conditions":39655,"interventions":39656},[90],[36],[6431,5870,8361,8362,8363],{"nctId":23397,"briefTitle":23398,"status":195,"phases":39658,"primaryCompletion":2220,"completion":2220,"start":2507,"enrollment":1757,"conditions":39659,"interventions":39660},[90],[19],[23402,4931],{"nctId":6867,"briefTitle":6868,"status":195,"phases":39662,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":3209,"conditions":39663,"interventions":39664},[90],[6873],[6860,5911,6875,5870,6876],{"nctId":31590,"briefTitle":31591,"status":195,"phases":39666,"completion":2320,"start":2077,"enrollment":2260,"conditions":39667,"interventions":39668},[90],[31594],[20417,5870],{"nctId":12622,"briefTitle":12623,"status":195,"phases":39670,"primaryCompletion":1497,"completion":1497,"start":12625,"enrollment":579,"conditions":39671,"interventions":39672},[90],[5851],[2281,5870,5887,2198],{"nctId":23072,"briefTitle":23073,"status":195,"phases":39674,"primaryCompletion":23075,"completion":23075,"start":461,"enrollment":11272,"conditions":39675,"interventions":39676},[90],[19],[12640,12588,5870,5870,23078,12640],{"nctId":23561,"briefTitle":23562,"status":195,"phases":39678,"primaryCompletion":23564,"completion":23564,"start":1902,"enrollment":1638,"conditions":39679,"interventions":39680},[90],[36],[16338,5870],{"nctId":5863,"briefTitle":5864,"status":195,"phases":39682,"primaryCompletion":1597,"completion":883,"start":5866,"enrollment":544,"conditions":39683,"interventions":39684},[90],[5868],[119,5870],{"nctId":39686,"briefTitle":39687,"status":195,"phases":39688,"completion":2077,"start":7544,"enrollment":1130,"conditions":39689,"interventions":39690},"NCT00824057","Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)",[90],[19],[33999,5870,13183],{"nctId":13177,"briefTitle":13178,"status":195,"phases":39692,"primaryCompletion":13155,"completion":13155,"start":13180,"enrollment":486,"conditions":39693,"interventions":39694},[90],[13158,5851],[13145,5870,13183,13184],{"nctId":31880,"briefTitle":31881,"status":195,"phases":39696,"primaryCompletion":3827,"completion":3827,"start":2507,"enrollment":1130,"conditions":39697,"interventions":39698},[90],[31837],[31826,5870,13183],{"nctId":7145,"briefTitle":7146,"status":195,"phases":39700,"primaryCompletion":7148,"completion":7148,"start":3983,"enrollment":1448,"conditions":39701,"interventions":39702},[90],[5851],[5870,3966,6875],{"nctId":7075,"briefTitle":7076,"status":195,"phases":39704,"primaryCompletion":7078,"completion":7078,"start":7079,"enrollment":1638,"conditions":39705,"interventions":39706},[90],[3056],[87,5870],{"trials":39708,"activeCount":102},[],{"trials":39710,"activeCount":102},[],{"trials":39712,"activeCount":102},[],{"trials":39714,"activeCount":102},[],{"intervention":2255,"totalTrials":1638,"cells":39716},{"EARLY_PHASE1":39717,"PHASE1":39719,"PHASE2":39785,"PHASE3":39787,"PHASE4":39789,"NA":39791},{"trials":39718,"activeCount":102},[],{"trials":39720,"activeCount":102},[39721,39725,39729,39733,39740,39744,39748,39752,39756,39760,39764,39768,39777,39781],{"nctId":10137,"briefTitle":10138,"status":195,"phases":39722,"primaryCompletion":10140,"completion":10140,"start":10141,"enrollment":2260,"conditions":39723,"interventions":39724},[90],[5851],[10123,2255],{"nctId":33778,"briefTitle":33779,"status":443,"phases":39726,"primaryCompletion":33781,"completion":33781,"start":33782,"enrollment":3248,"conditions":39727,"interventions":39728},[90],[12328],[33771,33785,2255,33786],{"nctId":18246,"briefTitle":18247,"status":195,"phases":39730,"primaryCompletion":2507,"completion":2507,"start":2251,"enrollment":3476,"conditions":39731,"interventions":39732},[90],[1556],[18239,2255],{"nctId":39734,"briefTitle":39735,"status":195,"phases":39736,"primaryCompletion":2203,"completion":2203,"start":2480,"enrollment":14693,"conditions":39737,"interventions":39738},"NCT02040987","AZD3293 Thorough QT Study in Healthy Male Volunteers",[90],[18867],[39739,39739,2255],"AZD3293",{"nctId":32477,"briefTitle":32478,"status":195,"phases":39741,"completion":2068,"start":2320,"enrollment":4307,"conditions":39742,"interventions":39743},[90],[7267],[15778,2255,15778],{"nctId":23304,"briefTitle":23305,"status":195,"phases":39745,"primaryCompletion":6709,"completion":6709,"start":12721,"enrollment":1864,"conditions":39746,"interventions":39747},[90],[23308,23309],[23297,23311],{"nctId":23404,"briefTitle":23405,"status":195,"phases":39749,"completion":2414,"start":2524,"enrollment":1448,"conditions":39750,"interventions":39751},[90],[19],[4931,2255,23409,23410,23409,4931,4931],{"nctId":33437,"briefTitle":33438,"status":195,"phases":39753,"primaryCompletion":2433,"completion":2433,"start":2349,"enrollment":1448,"conditions":39754,"interventions":39755},[90],[28,31984],[23241,2255],{"nctId":18260,"briefTitle":18261,"status":195,"phases":39757,"primaryCompletion":12721,"completion":2615,"start":2433,"enrollment":13516,"conditions":39758,"interventions":39759},[90],[1556],[18258,2255],{"nctId":2248,"briefTitle":2249,"status":195,"phases":39761,"completion":2251,"start":2252,"enrollment":496,"conditions":39762,"interventions":39763},[90],[19],[2044,2044,2255],{"nctId":22970,"briefTitle":22971,"status":443,"phases":39765,"primaryCompletion":4496,"completion":4496,"start":2542,"enrollment":486,"conditions":39766,"interventions":39767},[90],[22974],[22928,2255],{"nctId":39769,"briefTitle":39770,"status":195,"phases":39771,"primaryCompletion":39772,"completion":39772,"start":39773,"enrollment":1864,"conditions":39774,"interventions":39775},"NCT03258515","A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers",[90],"2018-03-24","2017-09-06",[3056],[39776,2255],"AZD6094 200 mg",{"nctId":32038,"briefTitle":32039,"status":195,"phases":39778,"primaryCompletion":2220,"completion":2220,"start":6710,"enrollment":1883,"conditions":39779,"interventions":39780},[90],[19],[32005,2255],{"nctId":7669,"briefTitle":7670,"status":195,"phases":39782,"primaryCompletion":2560,"completion":2560,"start":4006,"enrollment":680,"conditions":39783,"interventions":39784},[90],[466],[68,2255,7674],{"trials":39786,"activeCount":102},[],{"trials":39788,"activeCount":102},[],{"trials":39790,"activeCount":102},[],{"trials":39792,"activeCount":102},[],{"intervention":2197,"totalTrials":4343,"cells":39794},{"EARLY_PHASE1":39795,"PHASE1":39797,"PHASE2":39839,"PHASE3":39841,"PHASE4":39843,"NA":39845},{"trials":39796,"activeCount":102},[],{"trials":39798,"activeCount":102},[39799,39803,39807,39811,39815,39819,39823,39831,39835],{"nctId":32092,"briefTitle":32093,"status":624,"phases":39800,"primaryCompletion":2143,"completion":2143,"start":2349,"enrollment":102,"conditions":39801,"interventions":39802},[90],[15776,24602],[32085,2197],{"nctId":2192,"briefTitle":2193,"status":195,"phases":39804,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1710,"conditions":39805,"interventions":39806},[90],[22],[2044,2197,2198],{"nctId":22821,"briefTitle":22822,"status":195,"phases":39808,"primaryCompletion":2615,"completion":2615,"start":2570,"enrollment":520,"conditions":39809,"interventions":39810},[90],[7267,1556],[22826,15892],{"nctId":23809,"briefTitle":23810,"status":195,"phases":39812,"primaryCompletion":23788,"completion":23788,"start":19335,"enrollment":520,"conditions":39813,"interventions":39814},[90],[19],[12640,2197],{"nctId":31605,"briefTitle":31606,"status":195,"phases":39816,"primaryCompletion":2143,"completion":2143,"start":2489,"enrollment":2260,"conditions":39817,"interventions":39818},[90],[31609],[20417,2197,20417],{"nctId":32032,"briefTitle":32033,"status":195,"phases":39820,"completion":2095,"start":2415,"enrollment":2827,"conditions":39821,"interventions":39822},[90],[18867],[32005,2197],{"nctId":39824,"briefTitle":39825,"status":195,"phases":39826,"primaryCompletion":2252,"completion":2252,"start":5562,"enrollment":1864,"conditions":39827,"interventions":39828},"NCT00487136","Interaction Between ABT-335, Rosuvastatin and Warfarin",[90],[19],[2197,39829,39830],"warfarin plus ABT-335 plus rosuvastatin 5 mg","warfarin plus ABT-335 plus rosuvastatin 20 mg",{"nctId":31306,"briefTitle":31307,"status":195,"phases":39832,"primaryCompletion":2144,"completion":2144,"start":2113,"enrollment":486,"conditions":39833,"interventions":39834},[90],[22],[2197,15883],{"nctId":25505,"briefTitle":25506,"status":195,"phases":39836,"primaryCompletion":2736,"completion":2736,"start":2675,"enrollment":14693,"conditions":39837,"interventions":39838},[90],[13022],[22826,23085,25510],{"trials":39840,"activeCount":102},[],{"trials":39842,"activeCount":102},[],{"trials":39844,"activeCount":102},[],{"trials":39846,"activeCount":102},[],{"intervention":16475,"totalTrials":370,"cells":39848},{"EARLY_PHASE1":39849,"PHASE1":39851,"PHASE2":39912,"PHASE3":39914,"PHASE4":39916,"NA":39918},{"trials":39850,"activeCount":102},[],{"trials":39852,"activeCount":102},[39853,39859,39863,39870,39878,39890,39898,39905],{"nctId":39854,"briefTitle":39855,"status":195,"phases":39856,"primaryCompletion":3207,"completion":3207,"start":910,"enrollment":1373,"conditions":39857,"interventions":39858},"NCT05477108","Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant",[90],[28],[16475,16476],{"nctId":16467,"briefTitle":16468,"status":195,"phases":39860,"primaryCompletion":16470,"completion":16470,"start":16471,"enrollment":1130,"conditions":39861,"interventions":39862},[90],[16473,5851],[16475,16476,16477,16478,12255],{"nctId":39864,"briefTitle":39865,"status":195,"phases":39866,"primaryCompletion":39867,"completion":39867,"start":3634,"enrollment":3172,"conditions":39868,"interventions":39869},"NCT04600505","A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol",[90],"2021-05-17",[6083],[16475,16476,16477],{"nctId":39871,"briefTitle":39872,"status":195,"phases":39873,"primaryCompletion":39874,"completion":39874,"start":39875,"enrollment":14379,"conditions":39876,"interventions":39877},"NCT03772223","A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.",[90],"2019-05-10","2019-01-21",[36],[16475,16476,16477],{"nctId":39879,"briefTitle":39880,"status":195,"phases":39881,"primaryCompletion":39882,"completion":39882,"start":39883,"enrollment":5876,"conditions":39884,"interventions":39885},"NCT04798222","Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers",[90],"2021-09-03","2021-06-29",[1520],[16475,16476,16477,16478,39886,39887,39888,39889],"Treatment E","Treatment F","Treatment G","Treatment H",{"nctId":39891,"briefTitle":39892,"status":195,"phases":39893,"primaryCompletion":39894,"completion":39894,"start":33851,"enrollment":4928,"conditions":39895,"interventions":39897},"NCT06139991","Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.",[90],"2024-05-04",[39896],"Heathy Participants",[16475,16476],{"nctId":39899,"briefTitle":39900,"status":195,"phases":39901,"primaryCompletion":3199,"completion":3199,"start":39902,"enrollment":1757,"conditions":39903,"interventions":39904},"NCT03804645","A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects",[90],"2019-02-05",[1520],[16475,16476,16477,16478],{"nctId":39906,"briefTitle":39907,"status":195,"phases":39908,"primaryCompletion":39909,"completion":39909,"start":5222,"enrollment":1638,"conditions":39910,"interventions":39911},"NCT04087187","A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718",[90],"2019-10-31",[12734],[16475,16476,16477],{"trials":39913,"activeCount":102},[],{"trials":39915,"activeCount":102},[],{"trials":39917,"activeCount":102},[],{"trials":39919,"activeCount":102},[],{"intervention":16476,"totalTrials":370,"cells":39921},{"EARLY_PHASE1":39922,"PHASE1":39924,"PHASE2":39958,"PHASE3":39960,"PHASE4":39962,"NA":39964},{"trials":39923,"activeCount":102},[],{"trials":39925,"activeCount":102},[39926,39930,39934,39938,39942,39946,39950,39954],{"nctId":39854,"briefTitle":39855,"status":195,"phases":39927,"primaryCompletion":3207,"completion":3207,"start":910,"enrollment":1373,"conditions":39928,"interventions":39929},[90],[28],[16475,16476],{"nctId":16467,"briefTitle":16468,"status":195,"phases":39931,"primaryCompletion":16470,"completion":16470,"start":16471,"enrollment":1130,"conditions":39932,"interventions":39933},[90],[16473,5851],[16475,16476,16477,16478,12255],{"nctId":39864,"briefTitle":39865,"status":195,"phases":39935,"primaryCompletion":39867,"completion":39867,"start":3634,"enrollment":3172,"conditions":39936,"interventions":39937},[90],[6083],[16475,16476,16477],{"nctId":39871,"briefTitle":39872,"status":195,"phases":39939,"primaryCompletion":39874,"completion":39874,"start":39875,"enrollment":14379,"conditions":39940,"interventions":39941},[90],[36],[16475,16476,16477],{"nctId":39879,"briefTitle":39880,"status":195,"phases":39943,"primaryCompletion":39882,"completion":39882,"start":39883,"enrollment":5876,"conditions":39944,"interventions":39945},[90],[1520],[16475,16476,16477,16478,39886,39887,39888,39889],{"nctId":39891,"briefTitle":39892,"status":195,"phases":39947,"primaryCompletion":39894,"completion":39894,"start":33851,"enrollment":4928,"conditions":39948,"interventions":39949},[90],[39896],[16475,16476],{"nctId":39899,"briefTitle":39900,"status":195,"phases":39951,"primaryCompletion":3199,"completion":3199,"start":39902,"enrollment":1757,"conditions":39952,"interventions":39953},[90],[1520],[16475,16476,16477,16478],{"nctId":39906,"briefTitle":39907,"status":195,"phases":39955,"primaryCompletion":39909,"completion":39909,"start":5222,"enrollment":1638,"conditions":39956,"interventions":39957},[90],[12734],[16475,16476,16477],{"trials":39959,"activeCount":102},[],{"trials":39961,"activeCount":102},[],{"trials":39963,"activeCount":102},[],{"trials":39965,"activeCount":102},[],{"intervention":7055,"totalTrials":1855,"cells":39967},{"EARLY_PHASE1":39968,"PHASE1":39970,"PHASE2":40008,"PHASE3":40010,"PHASE4":40012,"NA":40014},{"trials":39969,"activeCount":102},[],{"trials":39971,"activeCount":102},[39972,39980,39984,39988,39992,39996,40004],{"nctId":39973,"briefTitle":39974,"status":195,"phases":39975,"primaryCompletion":2203,"completion":39976,"start":39977,"enrollment":579,"conditions":39978,"interventions":39979},"NCT01929603","Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours",[90],"2016-11","2013-12",[466],[7055,16326],{"nctId":16306,"briefTitle":16307,"status":443,"phases":39981,"primaryCompletion":16309,"completion":16309,"start":3072,"enrollment":723,"conditions":39982,"interventions":39983},[90],[498],[3914,5911,7055,8361],{"nctId":32538,"briefTitle":32539,"status":195,"phases":39985,"primaryCompletion":32541,"completion":32541,"start":32542,"enrollment":1638,"conditions":39986,"interventions":39987},[90],[2134],[2314,32504,32545,7055],{"nctId":7048,"briefTitle":7049,"status":195,"phases":39989,"primaryCompletion":7051,"completion":7051,"start":7052,"enrollment":1448,"conditions":39990,"interventions":39991},[90],[3056],[87,7055],{"nctId":7637,"briefTitle":7638,"status":195,"phases":39993,"primaryCompletion":7618,"completion":7618,"start":2204,"enrollment":1130,"conditions":39994,"interventions":39995},[90],[466],[3801,7642,3801,7642],{"nctId":39997,"briefTitle":39998,"status":195,"phases":39999,"primaryCompletion":1218,"completion":40000,"start":40001,"enrollment":6275,"conditions":40002,"interventions":40003},"NCT02197247","Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",[90],"2021-05-26","2014-12-04",[3864],[7055,12577],{"nctId":22848,"briefTitle":22849,"status":195,"phases":40005,"primaryCompletion":6709,"completion":6709,"start":12721,"enrollment":520,"conditions":40006,"interventions":40007},[90],[7267,36],[15892,7642],{"trials":40009,"activeCount":102},[],{"trials":40011,"activeCount":102},[],{"trials":40013,"activeCount":102},[],{"trials":40015,"activeCount":102},[],{"intervention":40017,"totalTrials":1039,"cells":40018},"AZD6140",{"EARLY_PHASE1":40019,"PHASE1":40021,"PHASE2":40063,"PHASE3":40065,"PHASE4":40067,"NA":40069},{"trials":40020,"activeCount":102},[],{"trials":40022,"activeCount":102},[40023,40029,40036,40043,40049,40057],{"nctId":40024,"briefTitle":40025,"status":195,"phases":40026,"primaryCompletion":2220,"completion":2220,"start":2524,"enrollment":1130,"conditions":40027,"interventions":40028},"NCT00721448","An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers",[90],[15776],[40017,40017],{"nctId":40030,"briefTitle":40031,"status":195,"phases":40032,"primaryCompletion":2507,"completion":2507,"start":2221,"enrollment":1130,"conditions":40033,"interventions":40035},"NCT00738842","Uric Acid Study in Healthy Male Volunteers",[90],[40034,12734],"Gout",[40017],{"nctId":40037,"briefTitle":40038,"status":195,"phases":40039,"primaryCompletion":2086,"completion":2086,"start":2251,"enrollment":1130,"conditions":40040,"interventions":40041},"NCT00685906","AZD6140 Oral Contraceptive Interaction Study",[90],[19],[40017,40042],"Levonorgestrel and Ethinyl Estradiol",{"nctId":40044,"briefTitle":40045,"status":195,"phases":40046,"primaryCompletion":2471,"completion":2471,"start":10063,"enrollment":1757,"conditions":40047,"interventions":40048},"NCT01588626","Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers",[90],[19],[40017],{"nctId":40050,"briefTitle":40051,"status":195,"phases":40052,"primaryCompletion":12721,"completion":12721,"start":2143,"enrollment":3190,"conditions":40053,"interventions":40056},"NCT01226602","Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.",[90],[40054,40055],"Blood Flow Speed","Coronary Flow Velocity",[40017],{"nctId":40058,"briefTitle":40059,"status":195,"phases":40060,"primaryCompletion":3827,"completion":3827,"start":2328,"enrollment":1130,"conditions":40061,"interventions":40062},"NCT00733265","Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers",[90],[2279],[40017],{"trials":40064,"activeCount":102},[],{"trials":40066,"activeCount":102},[],{"trials":40068,"activeCount":102},[],{"trials":40070,"activeCount":102},[],{"intervention":19229,"totalTrials":1039,"cells":40072},{"EARLY_PHASE1":40073,"PHASE1":40075,"PHASE2":40116,"PHASE3":40118,"PHASE4":40120,"NA":40122},{"trials":40074,"activeCount":102},[],{"trials":40076,"activeCount":102},[40077,40081,40088,40097,40103,40107],{"nctId":19572,"briefTitle":19573,"status":195,"phases":40078,"completion":2068,"start":2095,"enrollment":2260,"conditions":40079,"interventions":40080},[90],[19576],[19578,19228,19229],{"nctId":40082,"briefTitle":40083,"status":195,"phases":40084,"primaryCompletion":2243,"completion":2243,"start":2212,"enrollment":1448,"conditions":40085,"interventions":40087},"NCT01094483","A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin",[90],[40086],"Platelet Inhibition",[33061,19229],{"nctId":40089,"briefTitle":40090,"status":195,"phases":40091,"primaryCompletion":2055,"completion":2055,"start":2067,"enrollment":113,"conditions":40092,"interventions":40094},"NCT00998075","Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately",[90],[40093],"Peptic Ulcer Disease",[40095,40096,19229],"Esomeprazole\u002FASA Fixed Combination","Esomeprazole - Nexium",{"nctId":40098,"briefTitle":40099,"status":443,"phases":40100,"completion":2212,"start":2057,"enrollment":1710,"conditions":40101,"interventions":40102},"NCT01015729","Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately",[90],[40093],[40095,19794,19229],{"nctId":19222,"briefTitle":19223,"status":195,"phases":40104,"primaryCompletion":7618,"completion":7618,"start":2616,"enrollment":5947,"conditions":40105,"interventions":40106},[90],[19226],[12616,19228,19229],{"nctId":40108,"briefTitle":40109,"status":195,"phases":40110,"primaryCompletion":2251,"completion":2251,"start":2251,"enrollment":532,"conditions":40111,"interventions":40114},"NCT00688428","Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination",[90],[40112,40113],"Ulcers","Upper GI Symptoms",[40115,19794,19229],"Esomeprazole 40mg\u002FASA 325mg",{"trials":40117,"activeCount":102},[],{"trials":40119,"activeCount":102},[],{"trials":40121,"activeCount":102},[],{"trials":40123,"activeCount":102},[],{"intervention":16477,"totalTrials":1039,"cells":40125},{"EARLY_PHASE1":40126,"PHASE1":40128,"PHASE2":40154,"PHASE3":40156,"PHASE4":40158,"NA":40160},{"trials":40127,"activeCount":102},[],{"trials":40129,"activeCount":102},[40130,40134,40138,40142,40146,40150],{"nctId":16467,"briefTitle":16468,"status":195,"phases":40131,"primaryCompletion":16470,"completion":16470,"start":16471,"enrollment":1130,"conditions":40132,"interventions":40133},[90],[16473,5851],[16475,16476,16477,16478,12255],{"nctId":39864,"briefTitle":39865,"status":195,"phases":40135,"primaryCompletion":39867,"completion":39867,"start":3634,"enrollment":3172,"conditions":40136,"interventions":40137},[90],[6083],[16475,16476,16477],{"nctId":39871,"briefTitle":39872,"status":195,"phases":40139,"primaryCompletion":39874,"completion":39874,"start":39875,"enrollment":14379,"conditions":40140,"interventions":40141},[90],[36],[16475,16476,16477],{"nctId":39879,"briefTitle":39880,"status":195,"phases":40143,"primaryCompletion":39882,"completion":39882,"start":39883,"enrollment":5876,"conditions":40144,"interventions":40145},[90],[1520],[16475,16476,16477,16478,39886,39887,39888,39889],{"nctId":39899,"briefTitle":39900,"status":195,"phases":40147,"primaryCompletion":3199,"completion":3199,"start":39902,"enrollment":1757,"conditions":40148,"interventions":40149},[90],[1520],[16475,16476,16477,16478],{"nctId":39906,"briefTitle":39907,"status":195,"phases":40151,"primaryCompletion":39909,"completion":39909,"start":5222,"enrollment":1638,"conditions":40152,"interventions":40153},[90],[12734],[16475,16476,16477],{"trials":40155,"activeCount":102},[],{"trials":40157,"activeCount":102},[],{"trials":40159,"activeCount":102},[],{"trials":40161,"activeCount":102},[],{"intervention":6382,"totalTrials":723,"cells":40163},{"EARLY_PHASE1":40164,"PHASE1":40166,"PHASE2":40199,"PHASE3":40201,"PHASE4":40203,"NA":40205},{"trials":40165,"activeCount":102},[],{"trials":40167,"activeCount":102},[40168,40178,40184,40191,40195],{"nctId":40169,"briefTitle":40170,"status":624,"phases":40171,"primaryCompletion":40172,"completion":40172,"start":13787,"enrollment":102,"conditions":40173,"interventions":40176},"NCT02780830","AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[90],"2019-04",[40174,40175],"Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma","Module 1: Non-GCB Diffuse Large B-Cell Lymphoma",[6382,40177],"Ibrutinib",{"nctId":40179,"briefTitle":40180,"status":195,"phases":40181,"primaryCompletion":2560,"completion":2560,"start":2055,"enrollment":13823,"conditions":40182,"interventions":40183},"NCT01026402","Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014",[90],[157],[6382],{"nctId":40185,"briefTitle":40186,"status":195,"phases":40187,"primaryCompletion":3161,"completion":3161,"start":40188,"enrollment":2260,"conditions":40189,"interventions":40190},"NCT02398747","Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies",[90],"2015-03-17",[157],[6382],{"nctId":6374,"briefTitle":6375,"status":195,"phases":40192,"primaryCompletion":6377,"completion":3685,"start":6378,"enrollment":680,"conditions":40193,"interventions":40194},[90],[6380],[6382,5977,53],{"nctId":6384,"briefTitle":6385,"status":195,"phases":40196,"primaryCompletion":6387,"completion":6388,"start":6389,"enrollment":6390,"conditions":40197,"interventions":40198},[90],[6392],[6382,53],{"trials":40200,"activeCount":102},[],{"trials":40202,"activeCount":102},[],{"trials":40204,"activeCount":102},[],{"trials":40206,"activeCount":102},[],{"intervention":12577,"totalTrials":723,"cells":40208},{"EARLY_PHASE1":40209,"PHASE1":40211,"PHASE2":40240,"PHASE3":40242,"PHASE4":40244,"NA":40246},{"trials":40210,"activeCount":102},[],{"trials":40212,"activeCount":102},[40213,40217,40221,40228,40232],{"nctId":12569,"briefTitle":12570,"status":195,"phases":40214,"primaryCompletion":12572,"completion":12573,"start":12574,"enrollment":3811,"conditions":40215,"interventions":40216},[90],[3864],[12577,5887],{"nctId":23060,"briefTitle":23061,"status":195,"phases":40218,"primaryCompletion":461,"completion":23063,"start":23064,"enrollment":14693,"conditions":40219,"interventions":40220},[90],[3864],[12588,12577],{"nctId":40222,"briefTitle":40223,"status":195,"phases":40224,"primaryCompletion":2299,"completion":2299,"start":2180,"enrollment":12505,"conditions":40225,"interventions":40226},"NCT02224053","Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers",[90],[31837],[12577,40227],"Omeprazole tablet dosing",{"nctId":39997,"briefTitle":39998,"status":195,"phases":40229,"primaryCompletion":1218,"completion":40000,"start":40001,"enrollment":6275,"conditions":40230,"interventions":40231},[90],[3864],[7055,12577],{"nctId":40233,"briefTitle":40234,"status":195,"phases":40235,"primaryCompletion":40236,"completion":40237,"start":23064,"enrollment":1710,"conditions":40238,"interventions":40239},"NCT02161770","Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment",[90],"2017-05-16","2017-08-22",[466],[12577],{"trials":40241,"activeCount":102},[],{"trials":40243,"activeCount":102},[],{"trials":40245,"activeCount":102},[],{"trials":40247,"activeCount":102},[],{"intervention":40249,"totalTrials":723,"cells":40250},"AZD8529",{"EARLY_PHASE1":40251,"PHASE1":40259,"PHASE2":40285,"PHASE3":40287,"PHASE4":40289,"NA":40291},{"trials":40252,"activeCount":102},[40253],{"nctId":40254,"briefTitle":40255,"status":195,"phases":40256,"primaryCompletion":12721,"completion":12721,"start":2114,"enrollment":5876,"conditions":40257,"interventions":40258},"NCT00985933","The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers",[89],[19,25538],[40249],{"trials":40260,"activeCount":102},[40261,40267,40273,40279],{"nctId":40262,"briefTitle":40263,"status":195,"phases":40264,"primaryCompletion":2736,"completion":2736,"start":2057,"enrollment":3209,"conditions":40265,"interventions":40266},"NCT00986531","The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics",[90],[33],[40249],{"nctId":40268,"briefTitle":40269,"status":195,"phases":40270,"completion":2068,"start":2320,"enrollment":5898,"conditions":40271,"interventions":40272},"NCT00886756","AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects",[90],[19],[40249],{"nctId":40274,"briefTitle":40275,"status":195,"phases":40276,"completion":2077,"start":3827,"enrollment":3180,"conditions":40277,"interventions":40278},"NCT00755378","AZD8529 Single Ascending Dose Study",[90],[31837],[40249],{"nctId":40280,"briefTitle":40281,"status":195,"phases":40282,"completion":2077,"start":2086,"enrollment":3172,"conditions":40283,"interventions":40284},"NCT00765492","AZD8529 Multiple Ascending Dose Study in Healthy Subjects",[90],[31837],[40249],{"trials":40286,"activeCount":102},[],{"trials":40288,"activeCount":102},[],{"trials":40290,"activeCount":102},[],{"trials":40292,"activeCount":102},[],{"intervention":40294,"totalTrials":723,"cells":40295},"AZD9742",{"EARLY_PHASE1":40296,"PHASE1":40298,"PHASE2":40331,"PHASE3":40333,"PHASE4":40335,"NA":40337},{"trials":40297,"activeCount":102},[],{"trials":40299,"activeCount":102},[40300,40306,40312,40318,40325],{"nctId":40301,"briefTitle":40302,"status":195,"phases":40303,"primaryCompletion":2406,"completion":2406,"start":2243,"enrollment":2260,"conditions":40304,"interventions":40305},"NCT01124760","Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers",[90],[15776],[40294,16380,32810],{"nctId":40307,"briefTitle":40308,"status":195,"phases":40309,"primaryCompletion":2144,"completion":2144,"start":2114,"enrollment":496,"conditions":40310,"interventions":40311},"NCT01064388","A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days",[90],[19],[40294],{"nctId":40313,"briefTitle":40314,"status":195,"phases":40315,"primaryCompletion":2212,"completion":2212,"start":2057,"enrollment":5898,"conditions":40316,"interventions":40317},"NCT01030224","This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects",[90],[19],[40294],{"nctId":40319,"briefTitle":40320,"status":195,"phases":40321,"primaryCompletion":2406,"completion":2406,"start":2242,"enrollment":1757,"conditions":40322,"interventions":40324},"NCT01154621","Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects",[90],[24601,19,40323],"Elderly",[40294],{"nctId":40326,"briefTitle":40327,"status":195,"phases":40328,"primaryCompletion":2406,"completion":2406,"start":2113,"enrollment":1348,"conditions":40329,"interventions":40330},"NCT01114152","AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects",[90],[19],[40294],{"trials":40332,"activeCount":102},[],{"trials":40334,"activeCount":102},[],{"trials":40336,"activeCount":102},[],{"trials":40338,"activeCount":102},[],{"intervention":23332,"totalTrials":723,"cells":40340},{"EARLY_PHASE1":40341,"PHASE1":40343,"PHASE2":40365,"PHASE3":40367,"PHASE4":40369,"NA":40371},{"trials":40342,"activeCount":102},[],{"trials":40344,"activeCount":102},[40345,40349,40353,40357,40361],{"nctId":40301,"briefTitle":40302,"status":195,"phases":40346,"primaryCompletion":2406,"completion":2406,"start":2243,"enrollment":2260,"conditions":40347,"interventions":40348},[90],[15776],[40294,16380,32810],{"nctId":32805,"briefTitle":32806,"status":195,"phases":40350,"primaryCompletion":2077,"completion":2077,"start":4915,"enrollment":5876,"conditions":40351,"interventions":40352},[90],[19],[20336,23332,32810],{"nctId":31501,"briefTitle":31502,"status":195,"phases":40354,"primaryCompletion":2414,"completion":2414,"start":2507,"enrollment":2003,"conditions":40355,"interventions":40356},[90],[19],[23332,16379,16451],{"nctId":31963,"briefTitle":31964,"status":195,"phases":40358,"primaryCompletion":2405,"completion":2405,"start":2616,"enrollment":520,"conditions":40359,"interventions":40360},[90],[31967,31968,31969,31970,31971,31972,31973,31974],[5273,23332],{"nctId":23326,"briefTitle":23327,"status":195,"phases":40362,"primaryCompletion":4496,"completion":4496,"start":2366,"enrollment":434,"conditions":40363,"interventions":40364},[90],[22858,36,23330],[23297,23332],{"trials":40366,"activeCount":102},[],{"trials":40368,"activeCount":102},[],{"trials":40370,"activeCount":102},[],{"trials":40372,"activeCount":102},[],{"intervention":39739,"totalTrials":723,"cells":40374},{"EARLY_PHASE1":40375,"PHASE1":40377,"PHASE2":40412,"PHASE3":40414,"PHASE4":40416,"NA":40418},{"trials":40376,"activeCount":102},[],{"trials":40378,"activeCount":102},[40379,40386,40393,40397,40405],{"nctId":40380,"briefTitle":40381,"status":195,"phases":40382,"primaryCompletion":2203,"completion":2203,"start":2203,"enrollment":1757,"conditions":40383,"interventions":40385},"NCT02126514","A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293",[90],[36,40384],"Mass Balance Study",[39739],{"nctId":40387,"briefTitle":40388,"status":195,"phases":40389,"primaryCompletion":1692,"completion":1692,"start":39977,"enrollment":3218,"conditions":40390,"interventions":40392},"NCT02005211","A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers",[90],[40391],"Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers",[39739],{"nctId":39734,"briefTitle":39735,"status":195,"phases":40394,"primaryCompletion":2203,"completion":2203,"start":2480,"enrollment":14693,"conditions":40395,"interventions":40396},[90],[18867],[39739,39739,2255],{"nctId":40398,"briefTitle":40399,"status":195,"phases":40400,"primaryCompletion":7354,"completion":7354,"start":2616,"enrollment":132,"conditions":40401,"interventions":40404},"NCT01739647","A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects",[90],[40402,40403],"Healthy Young Volunteers","Healthy Elderly Volunteers",[39739],{"nctId":40406,"briefTitle":40407,"status":195,"phases":40408,"primaryCompletion":4006,"completion":4006,"start":2443,"enrollment":3172,"conditions":40409,"interventions":40411},"NCT01795339","A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients",[90],[40403,40410],"Mild-to-moderate Alzheimer's Disease Patients",[39739],{"trials":40413,"activeCount":102},[],{"trials":40415,"activeCount":102},[],{"trials":40417,"activeCount":102},[],{"trials":40419,"activeCount":102},[],{"intervention":40421,"totalTrials":1979,"cells":40422},"ICI176,334-1",{"EARLY_PHASE1":40423,"PHASE1":40425,"PHASE2":40452,"PHASE3":40454,"PHASE4":40456,"NA":40458},{"trials":40424,"activeCount":102},[],{"trials":40426,"activeCount":102},[40427,40434,40440,40446],{"nctId":40428,"briefTitle":40429,"status":443,"phases":40430,"primaryCompletion":2349,"completion":2349,"start":2406,"enrollment":188,"conditions":40431,"interventions":40432},"NCT01416870","Bioequivalence of Bicalutamide New Formulation in Japan",[90],[19],[40421,40433],"Casodex 80 mg",{"nctId":40435,"briefTitle":40436,"status":443,"phases":40437,"primaryCompletion":2144,"completion":2144,"start":2406,"enrollment":370,"conditions":40438,"interventions":40439},"NCT01416883","Oral Mucosal Absorption Study of Bicalutamide New Formulation",[90],[19],[40421],{"nctId":40441,"briefTitle":40442,"status":195,"phases":40443,"primaryCompletion":4580,"completion":2589,"start":2675,"enrollment":5898,"conditions":40444,"interventions":40445},"NCT01415778","Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects",[90],[19],[40421,40433],{"nctId":40447,"briefTitle":40448,"status":195,"phases":40449,"primaryCompletion":2571,"completion":2571,"start":2675,"enrollment":370,"conditions":40450,"interventions":40451},"NCT01415791","Oral Mucosal Absorption of ICI176,334-1",[90],[19],[40421],{"trials":40453,"activeCount":102},[],{"trials":40455,"activeCount":102},[],{"trials":40457,"activeCount":102},[],{"trials":40459,"activeCount":102},[],{"intervention":40461,"totalTrials":1979,"cells":40462},"AZD8055",{"EARLY_PHASE1":40463,"PHASE1":40465,"PHASE2":40492,"PHASE3":40494,"PHASE4":40496,"NA":40498},{"trials":40464,"activeCount":102},[],{"trials":40466,"activeCount":102},[40467,40473,40479,40485],{"nctId":40468,"briefTitle":40469,"status":195,"phases":40470,"primaryCompletion":2349,"completion":2349,"start":2507,"enrollment":4307,"conditions":40471,"interventions":40472},"NCT00731263","A Study of Tor Kinase Inhibitor in Advanced Tumors",[90],[3056],[40461],{"nctId":40474,"briefTitle":40475,"status":195,"phases":40476,"primaryCompletion":2589,"completion":2589,"start":2350,"enrollment":2827,"conditions":40477,"interventions":40478},"NCT00999882","Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients",[90],[556,3327],[40461],{"nctId":40480,"briefTitle":40481,"status":195,"phases":40482,"primaryCompletion":2143,"completion":2143,"start":2151,"enrollment":3855,"conditions":40483,"interventions":40484},"NCT00973076","Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055",[90],[556,3056,157],[40461],{"nctId":40486,"briefTitle":40487,"status":624,"phases":40488,"enrollment":18686,"conditions":40489,"interventions":40491},"NCT01194193","Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours",[90],[556,498,40490],"Lymphomas",[40461],{"trials":40493,"activeCount":102},[],{"trials":40495,"activeCount":102},[],{"trials":40497,"activeCount":102},[],{"trials":40499,"activeCount":102},[],{"intervention":33061,"totalTrials":1979,"cells":40501},{"EARLY_PHASE1":40502,"PHASE1":40504,"PHASE2":40525,"PHASE3":40527,"PHASE4":40529,"NA":40531},{"trials":40503,"activeCount":102},[],{"trials":40505,"activeCount":102},[40506,40510,40514,40518],{"nctId":40082,"briefTitle":40083,"status":195,"phases":40507,"primaryCompletion":2243,"completion":2243,"start":2212,"enrollment":1448,"conditions":40508,"interventions":40509},[90],[40086],[33061,19229],{"nctId":33056,"briefTitle":33057,"status":195,"phases":40511,"primaryCompletion":4915,"completion":4915,"start":3827,"enrollment":3717,"conditions":40512,"interventions":40513},[90],[31837],[33061,31784,31784],{"nctId":33071,"briefTitle":33072,"status":195,"phases":40515,"primaryCompletion":2067,"completion":2067,"start":688,"enrollment":5898,"conditions":40516,"interventions":40517},[90],[19],[33061,31784],{"nctId":40519,"briefTitle":40520,"status":195,"phases":40521,"completion":2350,"start":2067,"enrollment":1130,"conditions":40522,"interventions":40523},"NCT00992381","Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone",[90],[19],[33061,40524],"Naprosyn",{"trials":40526,"activeCount":102},[],{"trials":40528,"activeCount":102},[],{"trials":40530,"activeCount":102},[],{"trials":40532,"activeCount":102},[],{"intervention":16392,"totalTrials":1979,"cells":40534},{"EARLY_PHASE1":40535,"PHASE1":40537,"PHASE2":40567,"PHASE3":40569,"PHASE4":40571,"NA":40573},{"trials":40536,"activeCount":102},[],{"trials":40538,"activeCount":102},[40539,40547,40556,40560],{"nctId":40540,"briefTitle":40541,"status":195,"phases":40542,"primaryCompletion":40543,"completion":40543,"start":3763,"enrollment":1864,"conditions":40544,"interventions":40545},"NCT05587998","A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.",[90],"2023-05-25",[16390],[40546,16392],"Morphine",{"nctId":40548,"briefTitle":40549,"status":195,"phases":40550,"primaryCompletion":40551,"completion":40551,"start":40552,"enrollment":5898,"conditions":40553,"interventions":40555},"NCT04076540","A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers",[90],"2022-01-02","2019-10-03",[40554],"Smoking Cessation",[16392],{"nctId":16386,"briefTitle":16387,"status":443,"phases":40557,"primaryCompletion":15717,"completion":15717,"start":10140,"enrollment":520,"conditions":40558,"interventions":40559},[90],[16390],[16392,5911,16393,16394,16395],{"nctId":40561,"briefTitle":40562,"status":195,"phases":40563,"primaryCompletion":35947,"completion":35947,"start":920,"enrollment":496,"conditions":40564,"interventions":40566},"NCT05233085","A Safety Study of AZD4041 in Healthy Participants",[90],[40565],"Opioid Use Disorder (OUD)",[16392],{"trials":40568,"activeCount":102},[],{"trials":40570,"activeCount":102},[],{"trials":40572,"activeCount":102},[],{"trials":40574,"activeCount":102},[],{"intervention":40576,"totalTrials":1979,"cells":40577},"AZD7594",{"EARLY_PHASE1":40578,"PHASE1":40580,"PHASE2":40614,"PHASE3":40616,"PHASE4":40618,"NA":40620},{"trials":40579,"activeCount":102},[],{"trials":40581,"activeCount":102},[40582,40590,40600,40607],{"nctId":40583,"briefTitle":40584,"status":195,"phases":40585,"primaryCompletion":40586,"completion":40586,"start":40587,"enrollment":1130,"conditions":40588,"interventions":40589},"NCT04072562","A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.",[90],"2019-11-28","2019-09-19",[16],[40576],{"nctId":40591,"briefTitle":40592,"status":195,"phases":40593,"primaryCompletion":40594,"completion":40594,"start":37719,"enrollment":1638,"conditions":40595,"interventions":40596},"NCT02967159","A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants",[90],"2017-04-06",[6083,16],[40597,40576,40598,40599],"Abediterol","AZD7594\u002Fabediterol","AZD7594 and abediterol",{"nctId":40601,"briefTitle":40602,"status":195,"phases":40603,"primaryCompletion":2720,"completion":2720,"start":40604,"enrollment":496,"conditions":40605,"interventions":40606},"NCT03976869","A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma",[90],"2019-07-24",[16],[40576],{"nctId":40608,"briefTitle":40609,"status":195,"phases":40610,"primaryCompletion":2746,"completion":2746,"start":2432,"enrollment":33344,"conditions":40611,"interventions":40613},"NCT01636024","To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594",[90],[10052,15776,40612],"Pharmacodynamics of AZD7594",[40576],{"trials":40615,"activeCount":102},[],{"trials":40617,"activeCount":102},[],{"trials":40619,"activeCount":102},[],{"trials":40621,"activeCount":102},[],{"intervention":16326,"totalTrials":1979,"cells":40623},{"EARLY_PHASE1":40624,"PHASE1":40626,"PHASE2":40651,"PHASE3":40653,"PHASE4":40655,"NA":40657},{"trials":40625,"activeCount":102},[],{"trials":40627,"activeCount":102},[40628,40632,40636,40642],{"nctId":39973,"briefTitle":39974,"status":195,"phases":40629,"primaryCompletion":2203,"completion":39976,"start":39977,"enrollment":579,"conditions":40630,"interventions":40631},[90],[466],[7055,16326],{"nctId":16321,"briefTitle":16322,"status":195,"phases":40633,"primaryCompletion":7618,"completion":13131,"start":4204,"enrollment":3007,"conditions":40634,"interventions":40635},[90],[466],[16326,5911],{"nctId":40637,"briefTitle":40638,"status":195,"phases":40639,"primaryCompletion":25278,"completion":19387,"start":1693,"enrollment":2933,"conditions":40640,"interventions":40641},"NCT01894256","Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function",[90],[466],[16326],{"nctId":40643,"briefTitle":40644,"status":195,"phases":40645,"primaryCompletion":40646,"completion":40647,"start":40648,"enrollment":3248,"conditions":40649,"interventions":40650},"NCT01894243","Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment",[90],"2016-11-29","2017-03-30","2014-03-13",[466],[16326],{"trials":40652,"activeCount":102},[],{"trials":40654,"activeCount":102},[],{"trials":40656,"activeCount":102},[],{"trials":40658,"activeCount":102},[],{"intervention":33999,"totalTrials":1979,"cells":40660},{"EARLY_PHASE1":40661,"PHASE1":40663,"PHASE2":40686,"PHASE3":40688,"PHASE4":40690,"NA":40692},{"trials":40662,"activeCount":102},[],{"trials":40664,"activeCount":102},[40665,40671,40675,40679],{"nctId":40666,"briefTitle":40667,"status":195,"phases":40668,"primaryCompletion":2507,"completion":2507,"start":2580,"enrollment":5898,"conditions":40669,"interventions":40670},"NCT00681317","AZD6280 Multiple Ascending Dose Study",[90],[31837],[33999],{"nctId":33994,"briefTitle":33995,"status":195,"phases":40672,"completion":4915,"start":3827,"enrollment":4497,"conditions":40673,"interventions":40674},[90],[31837],[33999,33999,31839],{"nctId":39686,"briefTitle":39687,"status":195,"phases":40676,"completion":2077,"start":7544,"enrollment":1130,"conditions":40677,"interventions":40678},[90],[19],[33999,5870,13183],{"nctId":40680,"briefTitle":40681,"status":195,"phases":40682,"primaryCompletion":3827,"completion":3827,"start":2168,"enrollment":370,"conditions":40683,"interventions":40684},"NCT00681746","Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280",[90],[20485],[33999,40685],"(11C) flumazenil",{"trials":40687,"activeCount":102},[],{"trials":40689,"activeCount":102},[],{"trials":40691,"activeCount":102},[],{"trials":40693,"activeCount":102},[],{"intervention":13183,"totalTrials":1979,"cells":40695},{"EARLY_PHASE1":40696,"PHASE1":40698,"PHASE2":40716,"PHASE3":40718,"PHASE4":40720,"NA":40722},{"trials":40697,"activeCount":102},[],{"trials":40699,"activeCount":102},[40700,40704,40708,40712],{"nctId":32175,"briefTitle":32176,"status":195,"phases":40701,"completion":2067,"start":2152,"enrollment":520,"conditions":40702,"interventions":40703},[90],[31748],[24688,13183,32180,32181,32182],{"nctId":39686,"briefTitle":39687,"status":195,"phases":40705,"completion":2077,"start":7544,"enrollment":1130,"conditions":40706,"interventions":40707},[90],[19],[33999,5870,13183],{"nctId":13177,"briefTitle":13178,"status":195,"phases":40709,"primaryCompletion":13155,"completion":13155,"start":13180,"enrollment":486,"conditions":40710,"interventions":40711},[90],[13158,5851],[13145,5870,13183,13184],{"nctId":31880,"briefTitle":31881,"status":195,"phases":40713,"primaryCompletion":3827,"completion":3827,"start":2507,"enrollment":1130,"conditions":40714,"interventions":40715},[90],[31837],[31826,5870,13183],{"trials":40717,"activeCount":102},[],{"trials":40719,"activeCount":102},[],{"trials":40721,"activeCount":102},[],{"trials":40723,"activeCount":102},[],{"intervention":40725,"totalTrials":1979,"cells":40726},"AZD2516",{"EARLY_PHASE1":40727,"PHASE1":40729,"PHASE2":40757,"PHASE3":40759,"PHASE4":40761,"NA":40763},{"trials":40728,"activeCount":102},[],{"trials":40730,"activeCount":102},[40731,40739,40745,40751],{"nctId":40732,"briefTitle":40733,"status":195,"phases":40734,"primaryCompletion":2406,"completion":2406,"start":2242,"enrollment":1039,"conditions":40735,"interventions":40738},"NCT01148095","To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers",[90],[40736,40737],"Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.","Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80",[40725],{"nctId":40740,"briefTitle":40741,"status":195,"phases":40742,"primaryCompletion":2414,"completion":4915,"start":3827,"enrollment":132,"conditions":40743,"interventions":40744},"NCT00754715","Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers",[90],[19],[40725],{"nctId":40746,"briefTitle":40747,"status":195,"phases":40748,"completion":2350,"start":2320,"enrollment":1039,"conditions":40749,"interventions":40750},"NCT00892944","An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516",[90],[19],[40725],{"nctId":40752,"briefTitle":40753,"status":195,"phases":40754,"primaryCompletion":2055,"completion":2055,"start":2067,"enrollment":1448,"conditions":40755,"interventions":40756},"NCT00972049","Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects",[90],[19],[40725],{"trials":40758,"activeCount":102},[],{"trials":40760,"activeCount":102},[],{"trials":40762,"activeCount":102},[],{"trials":40764,"activeCount":102},[],{"intervention":40766,"totalTrials":1979,"cells":40767},"AZD3043",{"EARLY_PHASE1":40768,"PHASE1":40770,"PHASE2":40797,"PHASE3":40799,"PHASE4":40801,"NA":40803},{"trials":40769,"activeCount":102},[],{"trials":40771,"activeCount":102},[40772,40778,40784,40790],{"nctId":40773,"briefTitle":40774,"status":195,"phases":40775,"completion":2055,"start":2067,"enrollment":132,"conditions":40776,"interventions":40777},"NCT00984880","Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043",[90],[19],[40766],{"nctId":40779,"briefTitle":40780,"status":195,"phases":40781,"primaryCompletion":2144,"completion":2144,"start":2055,"enrollment":132,"conditions":40782,"interventions":40783},"NCT01028040","AZD Single Ascending Dose Study In Healthy Japanese Subjects",[90],[19],[40766,40766],{"nctId":40785,"briefTitle":40786,"status":195,"phases":40787,"completion":2151,"start":688,"enrollment":2161,"conditions":40788,"interventions":40789},"NCT00918515","Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD3043",[90],[19],[40766],{"nctId":40791,"briefTitle":40792,"status":624,"phases":40793,"primaryCompletion":2113,"completion":2113,"start":2212,"enrollment":102,"conditions":40794,"interventions":40796},"NCT01086813","Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043",[90],[10052,24601,15776,40795],"Sedation",[40766],{"trials":40798,"activeCount":102},[],{"trials":40800,"activeCount":102},[],{"trials":40802,"activeCount":102},[],{"trials":40804,"activeCount":102},[],{"intervention":16478,"totalTrials":3887,"cells":40806},{"EARLY_PHASE1":40807,"PHASE1":40809,"PHASE2":40823,"PHASE3":40825,"PHASE4":40827,"NA":40829},{"trials":40808,"activeCount":102},[],{"trials":40810,"activeCount":102},[40811,40815,40819],{"nctId":16467,"briefTitle":16468,"status":195,"phases":40812,"primaryCompletion":16470,"completion":16470,"start":16471,"enrollment":1130,"conditions":40813,"interventions":40814},[90],[16473,5851],[16475,16476,16477,16478,12255],{"nctId":39879,"briefTitle":39880,"status":195,"phases":40816,"primaryCompletion":39882,"completion":39882,"start":39883,"enrollment":5876,"conditions":40817,"interventions":40818},[90],[1520],[16475,16476,16477,16478,39886,39887,39888,39889],{"nctId":39899,"briefTitle":39900,"status":195,"phases":40820,"primaryCompletion":3199,"completion":3199,"start":39902,"enrollment":1757,"conditions":40821,"interventions":40822},[90],[1520],[16475,16476,16477,16478],{"trials":40824,"activeCount":102},[],{"trials":40826,"activeCount":102},[],{"trials":40828,"activeCount":102},[],{"trials":40830,"activeCount":102},[],{"intervention":10177,"totalTrials":3887,"cells":40832},{"EARLY_PHASE1":40833,"PHASE1":40835,"PHASE2":40849,"PHASE3":40851,"PHASE4":40853,"NA":40855},{"trials":40834,"activeCount":102},[],{"trials":40836,"activeCount":102},[40837,40841,40845],{"nctId":15560,"briefTitle":15561,"status":195,"phases":40838,"primaryCompletion":6115,"completion":6115,"start":6999,"enrollment":5425,"conditions":40839,"interventions":40840},[90],[5851],[12585,5911,10177],{"nctId":33252,"briefTitle":33253,"status":195,"phases":40842,"primaryCompletion":33255,"completion":33255,"start":33125,"enrollment":1130,"conditions":40843,"interventions":40844},[90],[33257],[2136,10177],{"nctId":10170,"briefTitle":10171,"status":195,"phases":40846,"primaryCompletion":10173,"completion":10173,"start":10174,"enrollment":434,"conditions":40847,"interventions":40848},[90],[5851],[10177,10123],{"trials":40850,"activeCount":102},[],{"trials":40852,"activeCount":102},[],{"trials":40854,"activeCount":102},[],{"trials":40856,"activeCount":102},[],{"intervention":22955,"totalTrials":3887,"cells":40858},{"EARLY_PHASE1":40859,"PHASE1":40861,"PHASE2":40875,"PHASE3":40877,"PHASE4":40879,"NA":40881},{"trials":40860,"activeCount":102},[],{"trials":40862,"activeCount":102},[40863,40867,40871],{"nctId":32261,"briefTitle":32262,"status":195,"phases":40864,"primaryCompletion":2570,"completion":2570,"start":2055,"enrollment":589,"conditions":40865,"interventions":40866},[90],[18734],[32242,22955],{"nctId":22948,"briefTitle":22949,"status":624,"phases":40868,"primaryCompletion":4496,"completion":4496,"start":2747,"enrollment":102,"conditions":40869,"interventions":40870},[90],[22952,19],[22928,22954,22955,22956,22928,22928,22956],{"nctId":32267,"briefTitle":32268,"status":443,"phases":40872,"primaryCompletion":2516,"completion":2516,"start":2243,"enrollment":496,"conditions":40873,"interventions":40874},[90],[19],[32242,32242,22955],{"trials":40876,"activeCount":102},[],{"trials":40878,"activeCount":102},[],{"trials":40880,"activeCount":102},[],{"trials":40882,"activeCount":102},[],{"intervention":13160,"totalTrials":3887,"cells":40884},{"EARLY_PHASE1":40885,"PHASE1":40887,"PHASE2":40910,"PHASE3":40912,"PHASE4":40914,"NA":40916},{"trials":40886,"activeCount":102},[],{"trials":40888,"activeCount":102},[40889,40897,40901],{"nctId":40890,"briefTitle":40891,"status":195,"phases":40892,"primaryCompletion":2432,"completion":2432,"start":687,"enrollment":3524,"conditions":40893,"interventions":40894},"NCT01533155","Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118",[90],[23317],[40895,13160,40896,40546],"Nektar 118","Quinidine placebo",{"nctId":13152,"briefTitle":13153,"status":195,"phases":40898,"primaryCompletion":13155,"completion":13155,"start":13156,"enrollment":486,"conditions":40899,"interventions":40900},[90],[13158,5851],[13145,13160],{"nctId":40902,"briefTitle":40903,"status":195,"phases":40904,"primaryCompletion":40905,"completion":40905,"start":12300,"enrollment":1638,"conditions":40906,"interventions":40907},"NCT06979388","A Study to Investigate the Effect of Food on Balcinrenone\u002FDapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.",[90],"2025-07-12",[5851],[40908,40909],"balcinrenone\u002F dapagliflozin","quinidine",{"trials":40911,"activeCount":102},[],{"trials":40913,"activeCount":102},[],{"trials":40915,"activeCount":102},[],{"trials":40917,"activeCount":102},[],{"intervention":40919,"totalTrials":3887,"cells":40920},"AZD7624",{"EARLY_PHASE1":40921,"PHASE1":40923,"PHASE2":40944,"PHASE3":40946,"PHASE4":40948,"NA":40950},{"trials":40922,"activeCount":102},[],{"trials":40924,"activeCount":102},[40925,40931,40938],{"nctId":40926,"briefTitle":40927,"status":195,"phases":40928,"primaryCompletion":1701,"completion":1701,"start":2579,"enrollment":4215,"conditions":40929,"interventions":40930},"NCT01754844","A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects",[90],[6083],[40919],{"nctId":40932,"briefTitle":40933,"status":195,"phases":40934,"primaryCompletion":7618,"completion":7618,"start":4204,"enrollment":477,"conditions":40935,"interventions":40937},"NCT01937338","Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge",[90],[40936],"LPS Challenge, Neutrophils",[40919],{"nctId":40939,"briefTitle":40940,"status":195,"phases":40941,"primaryCompletion":6436,"completion":6436,"start":19364,"enrollment":14693,"conditions":40942,"interventions":40943},"NCT01817855","To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients",[90],[10066,1556],[40919],{"trials":40945,"activeCount":102},[],{"trials":40947,"activeCount":102},[],{"trials":40949,"activeCount":102},[],{"trials":40951,"activeCount":102},[],{"intervention":40953,"totalTrials":3887,"cells":40954},"AZD8566",{"EARLY_PHASE1":40955,"PHASE1":40957,"PHASE2":40979,"PHASE3":40981,"PHASE4":40983,"NA":40985},{"trials":40956,"activeCount":102},[],{"trials":40958,"activeCount":102},[40959,40965,40973],{"nctId":40960,"briefTitle":40961,"status":195,"phases":40962,"primaryCompletion":2095,"completion":2095,"start":2220,"enrollment":1373,"conditions":40963,"interventions":40964},"NCT00749333","Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.",[90],[31837],[40953],{"nctId":40966,"briefTitle":40967,"status":195,"phases":40968,"primaryCompletion":2077,"completion":2320,"start":2077,"enrollment":544,"conditions":40969,"interventions":40971},"NCT00866385","AZD8566 Food Effect\u002FMicrotracer Study",[90],[40970],"Healthy Volunteer Study",[40953,40972],"AZD8566 IV carbon labelled",{"nctId":40974,"briefTitle":40975,"status":195,"phases":40976,"primaryCompletion":2320,"completion":2320,"start":7544,"enrollment":496,"conditions":40977,"interventions":40978},"NCT00844103","Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.",[90],[15776],[40953],{"trials":40980,"activeCount":102},[],{"trials":40982,"activeCount":102},[],{"trials":40984,"activeCount":102},[],{"trials":40986,"activeCount":102},[],{"intervention":40988,"totalTrials":3887,"cells":40989},"AZD9496",{"EARLY_PHASE1":40990,"PHASE1":40992,"PHASE2":41024,"PHASE3":41026,"PHASE4":41028,"NA":41030},{"trials":40991,"activeCount":102},[],{"trials":40993,"activeCount":102},[40994,41003,41013],{"nctId":40995,"briefTitle":40996,"status":195,"phases":40997,"primaryCompletion":40998,"completion":40999,"start":41000,"enrollment":1864,"conditions":41001,"interventions":41002},"NCT02248090","AZD9496 First Time in Patients Ascending Dose Study",[90],"2017-01-31","2019-04-03","2014-10-22",[7161],[40988,40988],{"nctId":41004,"briefTitle":41005,"status":195,"phases":41006,"primaryCompletion":41007,"completion":41007,"start":41008,"enrollment":507,"conditions":41009,"interventions":41011},"NCT03236974","Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.",[90],"2019-02-12","2017-10-05",[41010],"Postmenopausal Women With ER+ HER2- Primary Breast Cancer",[41012,40988],"Standard Arm - Fulvestrant",{"nctId":41014,"briefTitle":41015,"status":195,"phases":41016,"primaryCompletion":2396,"completion":2396,"start":41017,"enrollment":1638,"conditions":41018,"interventions":41019},"NCT02780713","A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects",[90],"2016-06-02",[25],[40988,41020,41021,41022,41023],"AZD9496 Variant A","AZD9496 Variant B","AZD9496 Variant C","AZD9496 Variant D",{"trials":41025,"activeCount":102},[],{"trials":41027,"activeCount":102},[],{"trials":41029,"activeCount":102},[],{"trials":41031,"activeCount":102},[],{"intervention":40597,"totalTrials":3887,"cells":41033},{"EARLY_PHASE1":41034,"PHASE1":41036,"PHASE2":41056,"PHASE3":41058,"PHASE4":41060,"NA":41062},{"trials":41035,"activeCount":102},[],{"trials":41037,"activeCount":102},[41038,41042,41049],{"nctId":40591,"briefTitle":40592,"status":195,"phases":41039,"primaryCompletion":40594,"completion":40594,"start":37719,"enrollment":1638,"conditions":41040,"interventions":41041},[90],[6083,16],[40597,40576,40598,40599],{"nctId":41043,"briefTitle":41044,"status":195,"phases":41045,"primaryCompletion":41046,"completion":41046,"start":30380,"enrollment":1757,"conditions":41047,"interventions":41048},"NCT03273127","To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids",[90],"2017-11-09",[16],[40597],{"nctId":41050,"briefTitle":41051,"status":443,"phases":41052,"primaryCompletion":14061,"completion":14061,"start":41053,"enrollment":98,"conditions":41054,"interventions":41055},"NCT04199598","Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.",[90],"2020-01-28",[28],[40597,40597,40597,40597],{"trials":41057,"activeCount":102},[],{"trials":41059,"activeCount":102},[],{"trials":41061,"activeCount":102},[],{"trials":41063,"activeCount":102},[],{"intervention":41065,"totalTrials":3887,"cells":41066},"AZD0466",{"EARLY_PHASE1":41067,"PHASE1":41069,"PHASE2":41095,"PHASE3":41097,"PHASE4":41099,"NA":41101},{"trials":41068,"activeCount":102},[],{"trials":41070,"activeCount":102},[41071,41077,41086],{"nctId":41072,"briefTitle":41073,"status":443,"phases":41074,"primaryCompletion":7069,"completion":7069,"start":10158,"enrollment":1855,"conditions":41075,"interventions":41076},"NCT05205161","A Phase I\u002FII Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma",[90],[5006],[41065],{"nctId":41078,"briefTitle":41079,"status":443,"phases":41080,"primaryCompletion":41081,"completion":41081,"start":41082,"enrollment":4343,"conditions":41083,"interventions":41085},"NCT04214093","A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors",[90],"2021-06-18","2019-12-16",[4217,510,7892,41084],"Hematologic Malignancies",[41065],{"nctId":41087,"briefTitle":41088,"status":443,"phases":41089,"primaryCompletion":1537,"completion":1537,"start":41090,"enrollment":451,"conditions":41091,"interventions":41093},"NCT04865419","Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies",[90],"2021-06-11",[41092],"Haematological Malignancies",[41065,41094],"Voriconazole",{"trials":41096,"activeCount":102},[],{"trials":41098,"activeCount":102},[],{"trials":41100,"activeCount":102},[],{"trials":41102,"activeCount":102},[],{"intervention":16379,"totalTrials":3887,"cells":41104},{"EARLY_PHASE1":41105,"PHASE1":41107,"PHASE2":41125,"PHASE3":41127,"PHASE4":41129,"NA":41131},{"trials":41106,"activeCount":102},[],{"trials":41108,"activeCount":102},[41109,41117,41121],{"nctId":41110,"briefTitle":41111,"status":195,"phases":41112,"primaryCompletion":2489,"completion":2489,"start":3862,"enrollment":520,"conditions":41113,"interventions":41115},"NCT01197781","Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers",[90],[41114,36],"Drug Drug Interactions",[41116,16379],"FOSTAMATIN",{"nctId":31501,"briefTitle":31502,"status":195,"phases":41118,"primaryCompletion":2414,"completion":2414,"start":2507,"enrollment":2003,"conditions":41119,"interventions":41120},[90],[19],[23332,16379,16451],{"nctId":16371,"briefTitle":16372,"status":195,"phases":41122,"primaryCompletion":16374,"completion":16374,"start":16375,"enrollment":520,"conditions":41123,"interventions":41124},[90],[1556],[16378,16379,5911,16380],{"trials":41126,"activeCount":102},[],{"trials":41128,"activeCount":102},[],{"trials":41130,"activeCount":102},[],{"trials":41132,"activeCount":102},[],{"intervention":5745,"totalTrials":3887,"cells":41134},{"EARLY_PHASE1":41135,"PHASE1":41137,"PHASE2":41151,"PHASE3":41153,"PHASE4":41155,"NA":41157},{"trials":41136,"activeCount":102},[],{"trials":41138,"activeCount":102},[41139,41143,41147],{"nctId":5739,"briefTitle":5740,"status":195,"phases":41140,"primaryCompletion":2243,"completion":2243,"start":5742,"enrollment":2069,"conditions":41141,"interventions":41142},[90],[3056],[5745,283],{"nctId":9166,"briefTitle":9167,"status":443,"phases":41144,"primaryCompletion":2516,"completion":2516,"start":6718,"enrollment":477,"conditions":41145,"interventions":41146},[90],[4217,556,157],[5745,4615],{"nctId":5751,"briefTitle":5752,"status":443,"phases":41148,"primaryCompletion":2433,"completion":2433,"start":2068,"enrollment":1130,"conditions":41149,"interventions":41150},[90],[556,3056,157],[5745,3802],{"trials":41152,"activeCount":102},[],{"trials":41154,"activeCount":102},[],{"trials":41156,"activeCount":102},[],{"trials":41158,"activeCount":102},[],{"intervention":13239,"totalTrials":3887,"cells":41160},{"EARLY_PHASE1":41161,"PHASE1":41170,"PHASE2":41180,"PHASE3":41182,"PHASE4":41184,"NA":41186},{"trials":41162,"activeCount":102},[41163],{"nctId":41164,"briefTitle":41165,"status":195,"phases":41166,"primaryCompletion":14354,"completion":14354,"start":41167,"enrollment":370,"conditions":41168,"interventions":41169},"NCT05818514","A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy Participants",[89],"2023-04-27",[36],[13239],{"trials":41171,"activeCount":102},[41172,41176],{"nctId":13232,"briefTitle":13233,"status":195,"phases":41173,"primaryCompletion":12613,"completion":12613,"start":13235,"enrollment":963,"conditions":41174,"interventions":41175},[90],[13237],[13225,13239],{"nctId":13250,"briefTitle":13251,"status":195,"phases":41177,"primaryCompletion":13253,"completion":13253,"start":13254,"enrollment":4343,"conditions":41178,"interventions":41179},[90],[13256],[13225,13239],{"trials":41181,"activeCount":102},[],{"trials":41183,"activeCount":102},[],{"trials":41185,"activeCount":102},[],{"trials":41187,"activeCount":102},[],{"intervention":41189,"totalTrials":3887,"cells":41190},"AZD7687",{"EARLY_PHASE1":41191,"PHASE1":41193,"PHASE2":41214,"PHASE3":41216,"PHASE4":41218,"NA":41220},{"trials":41192,"activeCount":102},[],{"trials":41194,"activeCount":102},[41195,41201,41207],{"nctId":41196,"briefTitle":41197,"status":195,"phases":41198,"primaryCompletion":2242,"completion":2242,"start":2057,"enrollment":4307,"conditions":41199,"interventions":41200},"NCT01046357","A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687",[90],[19],[41189],{"nctId":41202,"briefTitle":41203,"status":195,"phases":41204,"primaryCompletion":6709,"completion":6709,"start":2349,"enrollment":496,"conditions":41205,"interventions":41206},"NCT01217905","Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687",[90],[31,12275],[41189],{"nctId":41208,"briefTitle":41209,"status":195,"phases":41210,"primaryCompletion":2570,"completion":2570,"start":2113,"enrollment":1864,"conditions":41211,"interventions":41213},"NCT01119352","AZD7687 Multiple Ascending Dose Study",[90],[34716,41212],"Obese",[41189],{"trials":41215,"activeCount":102},[],{"trials":41217,"activeCount":102},[],{"trials":41219,"activeCount":102},[],{"trials":41221,"activeCount":102},[],{"intervention":41223,"totalTrials":3887,"cells":41224},"AZD5055",{"EARLY_PHASE1":41225,"PHASE1":41227,"PHASE2":41250,"PHASE3":41252,"PHASE4":41254,"NA":41256},{"trials":41226,"activeCount":102},[],{"trials":41228,"activeCount":102},[41229,41235,41244],{"nctId":41230,"briefTitle":41231,"status":195,"phases":41232,"primaryCompletion":446,"completion":446,"start":24834,"enrollment":3717,"conditions":41233,"interventions":41234},"NCT05955183","Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..",[90],[5851],[41223],{"nctId":41236,"briefTitle":41237,"status":443,"phases":41238,"primaryCompletion":41239,"completion":41239,"start":41240,"enrollment":1336,"conditions":41241,"interventions":41242},"NCT05644600","A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.",[90],"2023-07-17","2023-05-26",[1556],[41243,41223],"Nintedanib",{"nctId":41245,"briefTitle":41246,"status":195,"phases":41247,"primaryCompletion":1917,"completion":1917,"start":10166,"enrollment":18686,"conditions":41248,"interventions":41249},"NCT05134727","Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants",[90],[35481],[41223],{"trials":41251,"activeCount":102},[],{"trials":41253,"activeCount":102},[],{"trials":41255,"activeCount":102},[],{"trials":41257,"activeCount":102},[],{"intervention":41259,"totalTrials":3887,"cells":41260},"AZD5363",{"EARLY_PHASE1":41261,"PHASE1":41263,"PHASE2":41296,"PHASE3":41298,"PHASE4":41300,"NA":41302},{"trials":41262,"activeCount":102},[],{"trials":41264,"activeCount":102},[41265,41275,41282],{"nctId":41266,"briefTitle":41267,"status":195,"phases":41268,"primaryCompletion":2561,"completion":24772,"start":39977,"enrollment":689,"conditions":41269,"interventions":41274},"NCT01895946","Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability",[90],[41270,41271,41272,41273],"Advanced Solid Malignancy,","Safety and Tolerability,","Pharmacokinetics, Pharmacodynamics,","Tumour Response,",[41259,41259],{"nctId":41276,"briefTitle":41277,"status":195,"phases":41278,"primaryCompletion":1692,"completion":1692,"start":2542,"enrollment":3190,"conditions":41279,"interventions":41281},"NCT01353781","Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies",[90],[41280,4879],"Advanced Solid Malignancy",[41259],{"nctId":41283,"briefTitle":41284,"status":195,"phases":41285,"primaryCompletion":32533,"completion":6217,"start":41286,"enrollment":7512,"conditions":41287,"interventions":41295},"NCT01226316","Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",[90],"2010-12-01",[41280,41288,15776,24602,41289,330,414,404,367,41290,41291,41292,41293,41294],"Safety and Tolerability","Tumour Response","PIK3CA","AKT1","PTEN","ER Positive","HER2 Positive",[41259,41259,41259,41259],{"trials":41297,"activeCount":102},[],{"trials":41299,"activeCount":102},[],{"trials":41301,"activeCount":102},[],{"trials":41303,"activeCount":102},[],{"intervention":41305,"totalTrials":3887,"cells":41306},"AZD8329",{"EARLY_PHASE1":41307,"PHASE1":41309,"PHASE2":41331,"PHASE3":41333,"PHASE4":41335,"NA":41337},{"trials":41308,"activeCount":102},[],{"trials":41310,"activeCount":102},[41311,41318,41325],{"nctId":41312,"briefTitle":41313,"status":195,"phases":41314,"primaryCompletion":2143,"completion":2143,"start":3862,"enrollment":1864,"conditions":41315,"interventions":41317},"NCT01207089","To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329",[90],[34716,19,41316],"Male",[41305],{"nctId":41319,"briefTitle":41320,"status":195,"phases":41321,"primaryCompletion":2144,"completion":2144,"start":2068,"enrollment":990,"conditions":41322,"interventions":41324},"NCT00935662","A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses",[90],[41323],"Healthy Men",[41305],{"nctId":41326,"briefTitle":41327,"status":195,"phases":41328,"primaryCompletion":2143,"completion":2143,"start":2349,"enrollment":1336,"conditions":41329,"interventions":41330},"NCT01225939","A Study Conducted Over 3 Periods to Look at the Drug in the Body",[90],[22],[41305,41305],{"trials":41332,"activeCount":102},[],{"trials":41334,"activeCount":102},[],{"trials":41336,"activeCount":102},[],{"trials":41338,"activeCount":102},[],{"intervention":41340,"totalTrials":447,"cells":41341},"AZD1704",{"EARLY_PHASE1":41342,"PHASE1":41344,"PHASE2":41358,"PHASE3":41360,"PHASE4":41362,"NA":41364},{"trials":41343,"activeCount":102},[],{"trials":41345,"activeCount":102},[41346,41352],{"nctId":41347,"briefTitle":41348,"status":195,"phases":41349,"primaryCompletion":2524,"completion":2524,"start":2580,"enrollment":1395,"conditions":41350,"interventions":41351},"NCT00692042","Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704",[90],[31755],[41340],{"nctId":41353,"briefTitle":41354,"status":443,"phases":41355,"primaryCompletion":3827,"completion":3827,"start":2220,"enrollment":486,"conditions":41356,"interventions":41357},"NCT00736788","Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers",[90],[36],[41340],{"trials":41359,"activeCount":102},[],{"trials":41361,"activeCount":102},[],{"trials":41363,"activeCount":102},[],{"trials":41365,"activeCount":102},[],{"intervention":41367,"totalTrials":447,"cells":41368},"AZD5847",{"EARLY_PHASE1":41369,"PHASE1":41371,"PHASE2":41385,"PHASE3":41387,"PHASE4":41389,"NA":41391},{"trials":41370,"activeCount":102},[],{"trials":41372,"activeCount":102},[41373,41379],{"nctId":41374,"briefTitle":41375,"status":195,"phases":41376,"primaryCompletion":2489,"completion":2489,"start":2113,"enrollment":477,"conditions":41377,"interventions":41378},"NCT01116258","A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days",[90],[19],[41367],{"nctId":41380,"briefTitle":41381,"status":195,"phases":41382,"completion":2113,"start":2055,"enrollment":4307,"conditions":41383,"interventions":41384},"NCT01037725","Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers",[90],[19],[41367],{"trials":41386,"activeCount":102},[],{"trials":41388,"activeCount":102},[],{"trials":41390,"activeCount":102},[],{"trials":41392,"activeCount":102},[],{"intervention":19578,"totalTrials":447,"cells":41394},{"EARLY_PHASE1":41395,"PHASE1":41397,"PHASE2":41409,"PHASE3":41411,"PHASE4":41413,"NA":41415},{"trials":41396,"activeCount":102},[],{"trials":41398,"activeCount":102},[41399,41403],{"nctId":19572,"briefTitle":19573,"status":195,"phases":41400,"completion":2068,"start":2095,"enrollment":2260,"conditions":41401,"interventions":41402},[90],[19576],[19578,19228,19229],{"nctId":41404,"briefTitle":41405,"status":195,"phases":41406,"primaryCompletion":2221,"completion":2221,"start":6710,"enrollment":507,"conditions":41407,"interventions":41408},"NCT00688714","Study to Investigate Safety and Tolerability of a Single Dose of AZD6482",[90],[19576],[19578],{"trials":41410,"activeCount":102},[],{"trials":41412,"activeCount":102},[],{"trials":41414,"activeCount":102},[],{"trials":41416,"activeCount":102},[],{"intervention":2190,"totalTrials":447,"cells":41418},{"EARLY_PHASE1":41419,"PHASE1":41421,"PHASE2":41433,"PHASE3":41435,"PHASE4":41437,"NA":41439},{"trials":41420,"activeCount":102},[],{"trials":41422,"activeCount":102},[41423,41429],{"nctId":41424,"briefTitle":41425,"status":195,"phases":41426,"primaryCompletion":2144,"completion":2144,"start":2242,"enrollment":1336,"conditions":41427,"interventions":41428},"NCT01156246","Study to Assess the Effect of Food on Combination Dapagliflozin\u002FMetformin Tablet in Healthy Volunteers",[90],[19],[2190],{"nctId":2184,"briefTitle":2185,"status":195,"phases":41430,"primaryCompletion":2113,"completion":2113,"start":2056,"enrollment":2187,"conditions":41431,"interventions":41432},[90],[36],[2190,2044,2173,2190,2044,2173],{"trials":41434,"activeCount":102},[],{"trials":41436,"activeCount":102},[],{"trials":41438,"activeCount":102},[],{"trials":41440,"activeCount":102},[],{"intervention":40433,"totalTrials":447,"cells":41442},{"EARLY_PHASE1":41443,"PHASE1":41445,"PHASE2":41455,"PHASE3":41457,"PHASE4":41459,"NA":41461},{"trials":41444,"activeCount":102},[],{"trials":41446,"activeCount":102},[41447,41451],{"nctId":40428,"briefTitle":40429,"status":443,"phases":41448,"primaryCompletion":2349,"completion":2349,"start":2406,"enrollment":188,"conditions":41449,"interventions":41450},[90],[19],[40421,40433],{"nctId":40441,"briefTitle":40442,"status":195,"phases":41452,"primaryCompletion":4580,"completion":2589,"start":2675,"enrollment":5898,"conditions":41453,"interventions":41454},[90],[19],[40421,40433],{"trials":41456,"activeCount":102},[],{"trials":41458,"activeCount":102},[],{"trials":41460,"activeCount":102},[],{"trials":41462,"activeCount":102},[],{"intervention":41464,"totalTrials":447,"cells":41465},"AZD0284",{"EARLY_PHASE1":41466,"PHASE1":41468,"PHASE2":41486,"PHASE3":41488,"PHASE4":41490,"NA":41492},{"trials":41467,"activeCount":102},[],{"trials":41469,"activeCount":102},[41470,41478],{"nctId":41471,"briefTitle":41472,"status":195,"phases":41473,"primaryCompletion":41474,"completion":41474,"start":814,"enrollment":6597,"conditions":41475,"interventions":41477},"NCT02976831","Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects",[90],"2017-05-30",[41476],"Plaque Psoriasis Vulgaris",[41464],{"nctId":41479,"briefTitle":41480,"status":195,"phases":41481,"primaryCompletion":41482,"completion":41482,"start":10457,"enrollment":1039,"conditions":41483,"interventions":41484},"NCT03029741","Bioavailability of AZD0284 and IV Microtracer Study",[90],"2017-03-23",[41476],[41464,41485],"[14C]AZD0284",{"trials":41487,"activeCount":102},[],{"trials":41489,"activeCount":102},[],{"trials":41491,"activeCount":102},[],{"trials":41493,"activeCount":102},[],{"intervention":41495,"totalTrials":447,"cells":41496},"Wee-1 kinase inhibitor AZD1775",{"EARLY_PHASE1":41497,"PHASE1":41499,"PHASE2":41521,"PHASE3":41523,"PHASE4":41525,"NA":41527},{"trials":41498,"activeCount":102},[],{"trials":41500,"activeCount":102},[41501,41509],{"nctId":41502,"briefTitle":41503,"status":195,"phases":41504,"primaryCompletion":41505,"completion":41505,"start":41506,"enrollment":5898,"conditions":41507,"interventions":41508},"NCT03313557","AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies",[90],"2019-05-17","2017-10-27",[3056],[41495],{"nctId":41510,"briefTitle":41511,"status":195,"phases":41512,"primaryCompletion":41513,"completion":41513,"start":41514,"enrollment":689,"conditions":41515,"interventions":41516},"NCT03333824","Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer",[90],"2019-01-22","2017-12-01",[466],[41517,41518,41519,41520,41495],"CYP1A2","CYP2C19","CYP3A","Kytril",{"trials":41522,"activeCount":102},[],{"trials":41524,"activeCount":102},[],{"trials":41526,"activeCount":102},[],{"trials":41528,"activeCount":102},[],{"intervention":41530,"totalTrials":447,"cells":41531},"AZD5985",{"EARLY_PHASE1":41532,"PHASE1":41534,"PHASE2":41548,"PHASE3":41550,"PHASE4":41552,"NA":41554},{"trials":41533,"activeCount":102},[],{"trials":41535,"activeCount":102},[41536,41542],{"nctId":41537,"briefTitle":41538,"status":195,"phases":41539,"primaryCompletion":2095,"completion":2095,"start":2414,"enrollment":579,"conditions":41540,"interventions":41541},"NCT00799331","Exploratory Study to Assess the Pharmacokinetics of AZD5985",[90],[19],[41530],{"nctId":41543,"briefTitle":41544,"status":443,"phases":41545,"completion":2057,"start":2151,"enrollment":132,"conditions":41546,"interventions":41547},"NCT00967356","AZD5985 Single Ascending Dose Study",[90],[19],[41530],{"trials":41549,"activeCount":102},[],{"trials":41551,"activeCount":102},[],{"trials":41553,"activeCount":102},[],{"trials":41555,"activeCount":102},[],{"intervention":40546,"totalTrials":447,"cells":41557},{"EARLY_PHASE1":41558,"PHASE1":41560,"PHASE2":41570,"PHASE3":41572,"PHASE4":41574,"NA":41576},{"trials":41559,"activeCount":102},[],{"trials":41561,"activeCount":102},[41562,41566],{"nctId":40540,"briefTitle":40541,"status":195,"phases":41563,"primaryCompletion":40543,"completion":40543,"start":3763,"enrollment":1864,"conditions":41564,"interventions":41565},[90],[16390],[40546,16392],{"nctId":40890,"briefTitle":40891,"status":195,"phases":41567,"primaryCompletion":2432,"completion":2432,"start":687,"enrollment":3524,"conditions":41568,"interventions":41569},[90],[23317],[40895,13160,40896,40546],{"trials":41571,"activeCount":102},[],{"trials":41573,"activeCount":102},[],{"trials":41575,"activeCount":102},[],{"trials":41577,"activeCount":102},[],{"intervention":41579,"totalTrials":447,"cells":41580},"AZD8075",{"EARLY_PHASE1":41581,"PHASE1":41583,"PHASE2":41597,"PHASE3":41599,"PHASE4":41601,"NA":41603},{"trials":41582,"activeCount":102},[],{"trials":41584,"activeCount":102},[41585,41591],{"nctId":41586,"briefTitle":41587,"status":443,"phases":41588,"primaryCompletion":7544,"completion":7544,"start":2086,"enrollment":132,"conditions":41589,"interventions":41590},"NCT00787072","AZD8075 Single Ascending Dose Study",[90],[36],[41579],{"nctId":41592,"briefTitle":41593,"status":624,"phases":41594,"primaryCompletion":7544,"completion":7544,"start":7544,"enrollment":2003,"conditions":41595,"interventions":41596},"NCT00829127","AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers",[90],[19],[41579],{"trials":41598,"activeCount":102},[],{"trials":41600,"activeCount":102},[],{"trials":41602,"activeCount":102},[],{"trials":41604,"activeCount":102},[],{"intervention":8362,"totalTrials":447,"cells":41606},{"EARLY_PHASE1":41607,"PHASE1":41609,"PHASE2":41619,"PHASE3":41621,"PHASE4":41623,"NA":41625},{"trials":41608,"activeCount":102},[],{"trials":41610,"activeCount":102},[41611,41615],{"nctId":8355,"briefTitle":8356,"status":195,"phases":41612,"primaryCompletion":3197,"completion":3197,"start":8358,"enrollment":3209,"conditions":41613,"interventions":41614},[90],[36],[6431,5870,8361,8362,8363],{"nctId":23785,"briefTitle":23786,"status":195,"phases":41616,"primaryCompletion":23788,"completion":23788,"start":23789,"enrollment":477,"conditions":41617,"interventions":41618},[90],[19],[12640,23792],{"trials":41620,"activeCount":102},[],{"trials":41622,"activeCount":102},[],{"trials":41624,"activeCount":102},[],{"trials":41626,"activeCount":102},[],{"intervention":40095,"totalTrials":447,"cells":41628},{"EARLY_PHASE1":41629,"PHASE1":41631,"PHASE2":41641,"PHASE3":41643,"PHASE4":41645,"NA":41647},{"trials":41630,"activeCount":102},[],{"trials":41632,"activeCount":102},[41633,41637],{"nctId":40089,"briefTitle":40090,"status":195,"phases":41634,"primaryCompletion":2055,"completion":2055,"start":2067,"enrollment":113,"conditions":41635,"interventions":41636},[90],[40093],[40095,40096,19229],{"nctId":40098,"briefTitle":40099,"status":443,"phases":41638,"completion":2212,"start":2057,"enrollment":1710,"conditions":41639,"interventions":41640},[90],[40093],[40095,19794,19229],{"trials":41642,"activeCount":102},[],{"trials":41644,"activeCount":102},[],{"trials":41646,"activeCount":102},[],{"trials":41648,"activeCount":102},[],{"intervention":23486,"totalTrials":447,"cells":41650},{"EARLY_PHASE1":41651,"PHASE1":41653,"PHASE2":41663,"PHASE3":41665,"PHASE4":41667,"NA":41669},{"trials":41652,"activeCount":102},[],{"trials":41654,"activeCount":102},[41655,41659],{"nctId":23481,"briefTitle":23482,"status":443,"phases":41656,"primaryCompletion":2746,"completion":2746,"start":2432,"enrollment":1979,"conditions":41657,"interventions":41658},[90],[22],[2565,2108,2475,23486,2061],{"nctId":23496,"briefTitle":23497,"status":624,"phases":41660,"primaryCompletion":2570,"completion":2570,"start":2570,"enrollment":102,"conditions":41661,"interventions":41662},[90],[31],[2108,2061,23486],{"trials":41664,"activeCount":102},[],{"trials":41666,"activeCount":102},[],{"trials":41668,"activeCount":102},[],{"trials":41670,"activeCount":102},[],{"intervention":6875,"totalTrials":447,"cells":41672},{"EARLY_PHASE1":41673,"PHASE1":41675,"PHASE2":41685,"PHASE3":41687,"PHASE4":41689,"NA":41691},{"trials":41674,"activeCount":102},[],{"trials":41676,"activeCount":102},[41677,41681],{"nctId":6867,"briefTitle":6868,"status":195,"phases":41678,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":3209,"conditions":41679,"interventions":41680},[90],[6873],[6860,5911,6875,5870,6876],{"nctId":7145,"briefTitle":7146,"status":195,"phases":41682,"primaryCompletion":7148,"completion":7148,"start":3983,"enrollment":1448,"conditions":41683,"interventions":41684},[90],[5851],[5870,3966,6875],{"trials":41686,"activeCount":102},[],{"trials":41688,"activeCount":102},[],{"trials":41690,"activeCount":102},[],{"trials":41692,"activeCount":102},[],{"intervention":41694,"totalTrials":447,"cells":41695},"AZD1208",{"EARLY_PHASE1":41696,"PHASE1":41698,"PHASE2":41713,"PHASE3":41715,"PHASE4":41717,"NA":41719},{"trials":41697,"activeCount":102},[],{"trials":41699,"activeCount":102},[41700,41707],{"nctId":41701,"briefTitle":41702,"status":195,"phases":41703,"primaryCompletion":1692,"completion":1692,"start":2481,"enrollment":911,"conditions":41704,"interventions":41706},"NCT01588548","Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma",[90],[157,41705],"Malignant Lymphoma",[41694],{"nctId":41708,"briefTitle":41709,"status":443,"phases":41710,"primaryCompletion":2203,"completion":2203,"start":2366,"enrollment":2783,"conditions":41711,"interventions":41712},"NCT01489722","Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients",[90],[23859],[41694],{"trials":41714,"activeCount":102},[],{"trials":41716,"activeCount":102},[],{"trials":41718,"activeCount":102},[],{"trials":41720,"activeCount":102},[],{"intervention":19189,"totalTrials":447,"cells":41722},{"EARLY_PHASE1":41723,"PHASE1":41725,"PHASE2":41735,"PHASE3":41737,"PHASE4":41739,"NA":41741},{"trials":41724,"activeCount":102},[],{"trials":41726,"activeCount":102},[41727,41731],{"nctId":19184,"briefTitle":19185,"status":195,"phases":41728,"primaryCompletion":2471,"completion":2471,"start":2747,"enrollment":5876,"conditions":41729,"interventions":41730},[90],[19],[19189,19190],{"nctId":32538,"briefTitle":32539,"status":195,"phases":41732,"primaryCompletion":32541,"completion":32541,"start":32542,"enrollment":1638,"conditions":41733,"interventions":41734},[90],[2134],[2314,32504,32545,7055],{"trials":41736,"activeCount":102},[],{"trials":41738,"activeCount":102},[],{"trials":41740,"activeCount":102},[],{"trials":41742,"activeCount":102},[],{"intervention":16380,"totalTrials":447,"cells":41744},{"EARLY_PHASE1":41745,"PHASE1":41747,"PHASE2":41757,"PHASE3":41759,"PHASE4":41761,"NA":41763},{"trials":41746,"activeCount":102},[],{"trials":41748,"activeCount":102},[41749,41753],{"nctId":40301,"briefTitle":40302,"status":195,"phases":41750,"primaryCompletion":2406,"completion":2406,"start":2243,"enrollment":2260,"conditions":41751,"interventions":41752},[90],[15776],[40294,16380,32810],{"nctId":16371,"briefTitle":16372,"status":195,"phases":41754,"primaryCompletion":16374,"completion":16374,"start":16375,"enrollment":520,"conditions":41755,"interventions":41756},[90],[1556],[16378,16379,5911,16380],{"trials":41758,"activeCount":102},[],{"trials":41760,"activeCount":102},[],{"trials":41762,"activeCount":102},[],{"trials":41764,"activeCount":102},[],{"intervention":41766,"totalTrials":447,"cells":41767},"AZD9977 oral suspension",{"EARLY_PHASE1":41768,"PHASE1":41770,"PHASE2":41785,"PHASE3":41787,"PHASE4":41789,"NA":41791},{"trials":41769,"activeCount":102},[],{"trials":41771,"activeCount":102},[41772,41781],{"nctId":41773,"briefTitle":41774,"status":195,"phases":41775,"primaryCompletion":2298,"completion":2298,"start":21019,"enrollment":1448,"conditions":41776,"interventions":41777},"NCT02532998","A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects",[90],[24602,1556],[41766,41778,41779,41780],"AZD9977 placebo oral suspension","Fludrocortisone,","Eplerenone,",{"nctId":32739,"briefTitle":32740,"status":195,"phases":41782,"primaryCompletion":32742,"completion":32742,"start":19204,"enrollment":963,"conditions":41783,"interventions":41784},[90],[36],[32745,2389,32746,32746],{"trials":41786,"activeCount":102},[],{"trials":41788,"activeCount":102},[],{"trials":41790,"activeCount":102},[],{"trials":41792,"activeCount":102},[],{"intervention":41794,"totalTrials":447,"cells":41795},"AZD2820",{"EARLY_PHASE1":41796,"PHASE1":41798,"PHASE2":41812,"PHASE3":41814,"PHASE4":41816,"NA":41818},{"trials":41797,"activeCount":102},[],{"trials":41799,"activeCount":102},[41800,41806],{"nctId":41801,"briefTitle":41802,"status":195,"phases":41803,"primaryCompletion":4580,"completion":4580,"start":2615,"enrollment":2045,"conditions":41804,"interventions":41805},"NCT01332214","To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses",[90],[19],[41794],{"nctId":41807,"briefTitle":41808,"status":443,"phases":41809,"primaryCompletion":2616,"completion":2616,"start":687,"enrollment":1336,"conditions":41810,"interventions":41811},"NCT01469923","To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses",[90],[12275],[41794],{"trials":41813,"activeCount":102},[],{"trials":41815,"activeCount":102},[],{"trials":41817,"activeCount":102},[],{"trials":41819,"activeCount":102},[],{"intervention":41821,"totalTrials":447,"cells":41822},"AZD4076",{"EARLY_PHASE1":41823,"PHASE1":41825,"PHASE2":41844,"PHASE3":41846,"PHASE4":41848,"NA":41850},{"trials":41824,"activeCount":102},[],{"trials":41826,"activeCount":102},[41827,41835],{"nctId":41828,"briefTitle":41829,"status":195,"phases":41830,"primaryCompletion":41831,"completion":13915,"start":41832,"enrollment":1448,"conditions":41833,"interventions":41834},"NCT02612662","A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects",[90],"2017-11-04","2015-11-24",[33384],[41821],{"nctId":41836,"briefTitle":41837,"status":195,"phases":41838,"primaryCompletion":41839,"completion":41839,"start":41840,"enrollment":1638,"conditions":41841,"interventions":41843},"NCT02826525","AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.",[90],"2019-10-11","2016-07-18",[41842],"T2DM With NAFLD",[41821],{"trials":41845,"activeCount":102},[],{"trials":41847,"activeCount":102},[],{"trials":41849,"activeCount":102},[],{"trials":41851,"activeCount":102},[],{"intervention":41853,"totalTrials":447,"cells":41854},"AZD7594 inhalation powder",{"EARLY_PHASE1":41855,"PHASE1":41857,"PHASE2":41881,"PHASE3":41883,"PHASE4":41885,"NA":41887},{"trials":41856,"activeCount":102},[],{"trials":41858,"activeCount":102},[41859,41870],{"nctId":41860,"briefTitle":41861,"status":195,"phases":41862,"primaryCompletion":41863,"completion":41863,"start":41864,"enrollment":2003,"conditions":41865,"interventions":41866},"NCT02645253","A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men",[90],"2016-04-17","2016-01-12",[16,30237],[41853,41853,41867,41868,41869],"AZD7594 pressurized inhalation suspension","AZD7594 placebo inhalation powder","AZD7594 placebo pressurized inhalation suspension",{"nctId":41871,"briefTitle":41872,"status":195,"phases":41873,"primaryCompletion":41874,"completion":41874,"start":41864,"enrollment":1710,"conditions":41875,"interventions":41876},"NCT02648438","A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects",[90],"2016-06-01",[16,6083],[41877,41878,41879,41879,41880],"AZD7594 Solution for","AZD7594 Oral suspension","AZD7594 Inhalation powder","AZD7594 Pressurized inhalation suspension (400 μg) by pMDI",{"trials":41882,"activeCount":102},[],{"trials":41884,"activeCount":102},[],{"trials":41886,"activeCount":102},[],{"trials":41888,"activeCount":102},[],{"intervention":41890,"totalTrials":447,"cells":41891},"Acalabrutinib Treatment A",{"EARLY_PHASE1":41892,"PHASE1":41894,"PHASE2":41915,"PHASE3":41917,"PHASE4":41919,"NA":41921},{"trials":41893,"activeCount":102},[],{"trials":41895,"activeCount":102},[41896,41908],{"nctId":41897,"briefTitle":41898,"status":195,"phases":41899,"primaryCompletion":41900,"completion":41900,"start":41901,"enrollment":5876,"conditions":41902,"interventions":41904},"NCT04564040","A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole",[90],"2020-12-11","2020-10-12",[41903,1387],"Mantle Cell Lymphoma",[41890,41905,41906,41907],"Acalabrutinib Treatment B","Acalabrutinib Treatment C","Acalabrutinib Treatment D",{"nctId":41909,"briefTitle":41910,"status":195,"phases":41911,"primaryCompletion":41912,"completion":41912,"start":12111,"enrollment":3190,"conditions":41913,"interventions":41914},"NCT04435483","A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers",[90],"2020-06-26",[15776,22858],[41890,41905,41906],{"trials":41916,"activeCount":102},[],{"trials":41918,"activeCount":102},[],{"trials":41920,"activeCount":102},[],{"trials":41922,"activeCount":102},[],{"intervention":41905,"totalTrials":447,"cells":41924},{"EARLY_PHASE1":41925,"PHASE1":41927,"PHASE2":41937,"PHASE3":41939,"PHASE4":41941,"NA":41943},{"trials":41926,"activeCount":102},[],{"trials":41928,"activeCount":102},[41929,41933],{"nctId":41897,"briefTitle":41898,"status":195,"phases":41930,"primaryCompletion":41900,"completion":41900,"start":41901,"enrollment":5876,"conditions":41931,"interventions":41932},[90],[41903,1387],[41890,41905,41906,41907],{"nctId":41909,"briefTitle":41910,"status":195,"phases":41934,"primaryCompletion":41912,"completion":41912,"start":12111,"enrollment":3190,"conditions":41935,"interventions":41936},[90],[15776,22858],[41890,41905,41906],{"trials":41938,"activeCount":102},[],{"trials":41940,"activeCount":102},[],{"trials":41942,"activeCount":102},[],{"trials":41944,"activeCount":102},[],{"intervention":41906,"totalTrials":447,"cells":41946},{"EARLY_PHASE1":41947,"PHASE1":41949,"PHASE2":41959,"PHASE3":41961,"PHASE4":41963,"NA":41965},{"trials":41948,"activeCount":102},[],{"trials":41950,"activeCount":102},[41951,41955],{"nctId":41897,"briefTitle":41898,"status":195,"phases":41952,"primaryCompletion":41900,"completion":41900,"start":41901,"enrollment":5876,"conditions":41953,"interventions":41954},[90],[41903,1387],[41890,41905,41906,41907],{"nctId":41909,"briefTitle":41910,"status":195,"phases":41956,"primaryCompletion":41912,"completion":41912,"start":12111,"enrollment":3190,"conditions":41957,"interventions":41958},[90],[15776,22858],[41890,41905,41906],{"trials":41960,"activeCount":102},[],{"trials":41962,"activeCount":102},[],{"trials":41964,"activeCount":102},[],{"trials":41966,"activeCount":102},[],{"intervention":41968,"totalTrials":447,"cells":41969},"MEDI1341",{"EARLY_PHASE1":41970,"PHASE1":41972,"PHASE2":41988,"PHASE3":41990,"PHASE4":41992,"NA":41994},{"trials":41971,"activeCount":102},[],{"trials":41973,"activeCount":102},[41974,41981],{"nctId":41975,"briefTitle":41976,"status":195,"phases":41977,"primaryCompletion":1616,"completion":1616,"start":41978,"enrollment":4286,"conditions":41979,"interventions":41980},"NCT03272165","Single Ascending Dose Study of MEDI1341 in Healthy Volunteers",[90],"2017-10-17",[36831],[41968],{"nctId":41982,"briefTitle":41983,"status":195,"phases":41984,"primaryCompletion":41985,"completion":41985,"start":753,"enrollment":98,"conditions":41986,"interventions":41987},"NCT04449484","Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease",[90],"2022-01-05",[36831],[41968],{"trials":41989,"activeCount":102},[],{"trials":41991,"activeCount":102},[],{"trials":41993,"activeCount":102},[],{"trials":41995,"activeCount":102},[],{"intervention":41997,"totalTrials":447,"cells":41998},"AZD3514",{"EARLY_PHASE1":41999,"PHASE1":42001,"PHASE2":42015,"PHASE3":42017,"PHASE4":42019,"NA":42021},{"trials":42000,"activeCount":102},[],{"trials":42002,"activeCount":102},[42003,42009],{"nctId":42004,"briefTitle":42005,"status":195,"phases":42006,"primaryCompletion":2443,"completion":7354,"start":2675,"enrollment":963,"conditions":42007,"interventions":42008},"NCT01351688","An Open Label Prostate Cancer Study in Japanese Patients",[90],[416],[41997],{"nctId":42010,"briefTitle":42011,"status":195,"phases":42012,"primaryCompletion":2443,"completion":13056,"start":2144,"enrollment":4307,"conditions":42013,"interventions":42014},"NCT01162395","Open Label Prostate Cancer Study",[90],[416],[41997],{"trials":42016,"activeCount":102},[],{"trials":42018,"activeCount":102},[],{"trials":42020,"activeCount":102},[],{"trials":42022,"activeCount":102},[],{"intervention":23494,"totalTrials":447,"cells":42024},{"EARLY_PHASE1":42025,"PHASE1":42027,"PHASE2":42040,"PHASE3":42042,"PHASE4":42044,"NA":42046},{"trials":42026,"activeCount":102},[],{"trials":42028,"activeCount":102},[42029,42033],{"nctId":23488,"briefTitle":23489,"status":195,"phases":42030,"primaryCompletion":2055,"completion":2055,"start":2057,"enrollment":1710,"conditions":42031,"interventions":42032},[90],[2631],[18965,23493,23494],{"nctId":42034,"briefTitle":42035,"status":195,"phases":42036,"primaryCompletion":2055,"completion":2055,"start":2057,"enrollment":1710,"conditions":42037,"interventions":42038},"NCT01192152","Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin\u002F1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR",[90],[2631],[18965,42039,23494],"Glucophage XR",{"trials":42041,"activeCount":102},[],{"trials":42043,"activeCount":102},[],{"trials":42045,"activeCount":102},[],{"trials":42047,"activeCount":102},[],{"intervention":42049,"totalTrials":447,"cells":42050},"Treatment A: BGF MDI HFO",{"EARLY_PHASE1":42051,"PHASE1":42053,"PHASE2":42070,"PHASE3":42072,"PHASE4":42074,"NA":42076},{"trials":42052,"activeCount":102},[],{"trials":42054,"activeCount":102},[42055,42063],{"nctId":42056,"briefTitle":42057,"status":195,"phases":42058,"primaryCompletion":42059,"completion":42059,"start":1863,"enrollment":1373,"conditions":42060,"interventions":42061},"NCT05569421","A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant",[90],"2023-04-14",[28],[42049,42062],"Treatment B: BGF MDI HFA",{"nctId":42064,"briefTitle":42065,"status":195,"phases":42066,"primaryCompletion":42067,"completion":42067,"start":3771,"enrollment":1428,"conditions":42068,"interventions":42069},"NCT06723756","A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults",[90],"2025-06-01",[5851],[42049,42062],{"trials":42071,"activeCount":102},[],{"trials":42073,"activeCount":102},[],{"trials":42075,"activeCount":102},[],{"trials":42077,"activeCount":102},[],{"intervention":42062,"totalTrials":447,"cells":42079},{"EARLY_PHASE1":42080,"PHASE1":42082,"PHASE2":42092,"PHASE3":42094,"PHASE4":42096,"NA":42098},{"trials":42081,"activeCount":102},[],{"trials":42083,"activeCount":102},[42084,42088],{"nctId":42056,"briefTitle":42057,"status":195,"phases":42085,"primaryCompletion":42059,"completion":42059,"start":1863,"enrollment":1373,"conditions":42086,"interventions":42087},[90],[28],[42049,42062],{"nctId":42064,"briefTitle":42065,"status":195,"phases":42089,"primaryCompletion":42067,"completion":42067,"start":3771,"enrollment":1428,"conditions":42090,"interventions":42091},[90],[5851],[42049,42062],{"trials":42093,"activeCount":102},[],{"trials":42095,"activeCount":102},[],{"trials":42097,"activeCount":102},[],{"trials":42099,"activeCount":102},[],{"intervention":42101,"totalTrials":447,"cells":42102},"AZD1480",{"EARLY_PHASE1":42103,"PHASE1":42105,"PHASE2":42122,"PHASE3":42124,"PHASE4":42126,"NA":42128},{"trials":42104,"activeCount":102},[],{"trials":42106,"activeCount":102},[42107,42113],{"nctId":42108,"briefTitle":42109,"status":443,"phases":42110,"primaryCompletion":2432,"completion":2432,"start":2113,"enrollment":132,"conditions":42111,"interventions":42112},"NCT01112397","Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours",[90],[4456],[42101],{"nctId":42114,"briefTitle":42115,"status":195,"phases":42116,"primaryCompletion":687,"completion":2560,"start":688,"enrollment":5189,"conditions":42117,"interventions":42121},"NCT00910728","Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases",[90],[42118,42119,42120],"Primary Myelofibrosis (PMF)","Post-Polycythaemia Vera","Essential Thrombocythaemia Myelofibrosis",[42101],{"trials":42123,"activeCount":102},[],{"trials":42125,"activeCount":102},[],{"trials":42127,"activeCount":102},[],{"trials":42129,"activeCount":102},[],{"intervention":42131,"totalTrials":447,"cells":42132},"AZD2373 subcutaneous",{"EARLY_PHASE1":42133,"PHASE1":42135,"PHASE2":42153,"PHASE3":42155,"PHASE4":42157,"NA":42159},{"trials":42134,"activeCount":102},[],{"trials":42136,"activeCount":102},[42137,42145],{"nctId":42138,"briefTitle":42139,"status":195,"phases":42140,"primaryCompletion":42141,"completion":42141,"start":42142,"enrollment":1710,"conditions":42143,"interventions":42144},"NCT04269031","A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.",[90],"2021-08-31","2020-02-13",[36],[42131],{"nctId":42146,"briefTitle":42147,"status":195,"phases":42148,"primaryCompletion":42149,"completion":42149,"start":42150,"enrollment":1130,"conditions":42151,"interventions":42152},"NCT05351047","A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry",[90],"2023-07-06","2022-04-04",[36],[42131],{"trials":42154,"activeCount":102},[],{"trials":42156,"activeCount":102},[],{"trials":42158,"activeCount":102},[],{"trials":42160,"activeCount":102},[],{"intervention":42162,"totalTrials":447,"cells":42163},"D961H Sachet 20 mg",{"EARLY_PHASE1":42164,"PHASE1":42166,"PHASE2":42185,"PHASE3":42187,"PHASE4":42189,"NA":42191},{"trials":42165,"activeCount":102},[],{"trials":42167,"activeCount":102},[42168,42176],{"nctId":42169,"briefTitle":42170,"status":195,"phases":42171,"primaryCompletion":2471,"completion":2471,"start":10063,"enrollment":34,"conditions":42172,"interventions":42174},"NCT01595425","Bioequivalence Study Comparing D961H Sachet and D961H Capsule in Japanese Healthy Male Subjects",[90],[42173],"Bioequivalence Study",[42162,42175],"D961H HPMC capsule 20 mg",{"nctId":42177,"briefTitle":42178,"status":195,"phases":42179,"primaryCompletion":39977,"completion":39977,"start":4204,"enrollment":17655,"conditions":42180,"interventions":42183},"NCT01964131","BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects",[90],[20616,20617,42181,19792,42182],"Anastomotic Ulcer","Etc.",[42184,42175],"D961H sachet 20 mg",{"trials":42186,"activeCount":102},[],{"trials":42188,"activeCount":102},[],{"trials":42190,"activeCount":102},[],{"trials":42192,"activeCount":102},[],{"intervention":42175,"totalTrials":447,"cells":42194},{"EARLY_PHASE1":42195,"PHASE1":42197,"PHASE2":42207,"PHASE3":42209,"PHASE4":42211,"NA":42213},{"trials":42196,"activeCount":102},[],{"trials":42198,"activeCount":102},[42199,42203],{"nctId":42169,"briefTitle":42170,"status":195,"phases":42200,"primaryCompletion":2471,"completion":2471,"start":10063,"enrollment":34,"conditions":42201,"interventions":42202},[90],[42173],[42162,42175],{"nctId":42177,"briefTitle":42178,"status":195,"phases":42204,"primaryCompletion":39977,"completion":39977,"start":4204,"enrollment":17655,"conditions":42205,"interventions":42206},[90],[20616,20617,42181,19792,42182],[42184,42175],{"trials":42208,"activeCount":102},[],{"trials":42210,"activeCount":102},[],{"trials":42212,"activeCount":102},[],{"trials":42214,"activeCount":102},[],{"intervention":42216,"totalTrials":447,"cells":42217},"AZD7503",{"EARLY_PHASE1":42218,"PHASE1":42220,"PHASE2":42237,"PHASE3":42239,"PHASE4":42241,"NA":42243},{"trials":42219,"activeCount":102},[],{"trials":42221,"activeCount":102},[42222,42230],{"nctId":42223,"briefTitle":42224,"status":443,"phases":42225,"primaryCompletion":42226,"completion":42226,"start":1917,"enrollment":1448,"conditions":42227,"interventions":42229},"NCT05864391","A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.",[90],"2024-03-20",[42228],"Steatohepatitis",[42216],{"nctId":42231,"briefTitle":42232,"status":195,"phases":42233,"primaryCompletion":22107,"completion":22107,"start":42234,"enrollment":2933,"conditions":42235,"interventions":42236},"NCT05143905","A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants",[90],"2021-12-06",[10052,24601,15776,5851],[42216],{"trials":42238,"activeCount":102},[],{"trials":42240,"activeCount":102},[],{"trials":42242,"activeCount":102},[],{"trials":42244,"activeCount":102},[],{"intervention":2215,"totalTrials":447,"cells":42246},{"EARLY_PHASE1":42247,"PHASE1":42249,"PHASE2":42259,"PHASE3":42261,"PHASE4":42263,"NA":42265},{"trials":42248,"activeCount":102},[],{"trials":42250,"activeCount":102},[42251,42255],{"nctId":2209,"briefTitle":2210,"status":443,"phases":42252,"primaryCompletion":2113,"completion":2113,"start":2212,"enrollment":1638,"conditions":42253,"interventions":42254},[90],[22],[2044,2215],{"nctId":23313,"briefTitle":23314,"status":195,"phases":42256,"primaryCompletion":10063,"completion":10063,"start":687,"enrollment":434,"conditions":42257,"interventions":42258},[90],[23317],[23297,2215],{"trials":42260,"activeCount":102},[],{"trials":42262,"activeCount":102},[],{"trials":42264,"activeCount":102},[],{"trials":42266,"activeCount":102},[],{"intervention":42268,"totalTrials":447,"cells":42269},"Naloxegol",{"EARLY_PHASE1":42270,"PHASE1":42272,"PHASE2":42287,"PHASE3":42289,"PHASE4":42291,"NA":42293},{"trials":42271,"activeCount":102},[],{"trials":42273,"activeCount":102},[42274,42280],{"nctId":42275,"briefTitle":42276,"status":195,"phases":42277,"primaryCompletion":2432,"completion":2432,"start":2481,"enrollment":2069,"conditions":42278,"interventions":42279},"NCT01623609","Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol",[90],[21192],[42268,42268],{"nctId":42281,"briefTitle":42282,"status":195,"phases":42283,"primaryCompletion":2105,"completion":2105,"start":10063,"enrollment":3811,"conditions":42284,"interventions":42285},"NCT01594619","Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol",[90],[23317],[42268,42286],"Diltiazem XR",{"trials":42288,"activeCount":102},[],{"trials":42290,"activeCount":102},[],{"trials":42292,"activeCount":102},[],{"trials":42294,"activeCount":102},[],{"intervention":7073,"totalTrials":447,"cells":42296},{"EARLY_PHASE1":42297,"PHASE1":42299,"PHASE2":42309,"PHASE3":42311,"PHASE4":42313,"NA":42315},{"trials":42298,"activeCount":102},[],{"trials":42300,"activeCount":102},[42301,42305],{"nctId":33159,"briefTitle":33160,"status":195,"phases":42302,"primaryCompletion":33162,"completion":33162,"start":33163,"enrollment":2260,"conditions":42303,"interventions":42304},[90],[33165],[1925,7073],{"nctId":7066,"briefTitle":7067,"status":195,"phases":42306,"primaryCompletion":7069,"completion":7069,"start":7070,"enrollment":486,"conditions":42307,"interventions":42308},[90],[7029],[87,7073],{"trials":42310,"activeCount":102},[],{"trials":42312,"activeCount":102},[],{"trials":42314,"activeCount":102},[],{"trials":42316,"activeCount":102},[],{"intervention":42318,"totalTrials":447,"cells":42319},"Treatment A: BGF MDI HFA",{"EARLY_PHASE1":42320,"PHASE1":42322,"PHASE2":42340,"PHASE3":42342,"PHASE4":42344,"NA":42346},{"trials":42321,"activeCount":102},[],{"trials":42323,"activeCount":102},[42324,42333],{"nctId":42325,"briefTitle":42326,"status":624,"phases":42327,"primaryCompletion":1446,"completion":1446,"start":42328,"enrollment":102,"conditions":42329,"interventions":42330},"NCT06340581","A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer",[90],"2024-10-17",[19],[42318,42331,42332],"Treatment B: BGF MDI HFO","Treatment C: BGF MDI HFO",{"nctId":42334,"briefTitle":42335,"status":195,"phases":42336,"primaryCompletion":42337,"completion":42337,"start":1068,"enrollment":2069,"conditions":42338,"interventions":42339},"NCT06297668","A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer",[90],"2024-06-11",[28],[42318,42331,42332],{"trials":42341,"activeCount":102},[],{"trials":42343,"activeCount":102},[],{"trials":42345,"activeCount":102},[],{"trials":42347,"activeCount":102},[],{"intervention":42331,"totalTrials":447,"cells":42349},{"EARLY_PHASE1":42350,"PHASE1":42352,"PHASE2":42362,"PHASE3":42364,"PHASE4":42366,"NA":42368},{"trials":42351,"activeCount":102},[],{"trials":42353,"activeCount":102},[42354,42358],{"nctId":42325,"briefTitle":42326,"status":624,"phases":42355,"primaryCompletion":1446,"completion":1446,"start":42328,"enrollment":102,"conditions":42356,"interventions":42357},[90],[19],[42318,42331,42332],{"nctId":42334,"briefTitle":42335,"status":195,"phases":42359,"primaryCompletion":42337,"completion":42337,"start":1068,"enrollment":2069,"conditions":42360,"interventions":42361},[90],[28],[42318,42331,42332],{"trials":42363,"activeCount":102},[],{"trials":42365,"activeCount":102},[],{"trials":42367,"activeCount":102},[],{"trials":42369,"activeCount":102},[],{"intervention":42332,"totalTrials":447,"cells":42371},{"EARLY_PHASE1":42372,"PHASE1":42374,"PHASE2":42384,"PHASE3":42386,"PHASE4":42388,"NA":42390},{"trials":42373,"activeCount":102},[],{"trials":42375,"activeCount":102},[42376,42380],{"nctId":42325,"briefTitle":42326,"status":624,"phases":42377,"primaryCompletion":1446,"completion":1446,"start":42328,"enrollment":102,"conditions":42378,"interventions":42379},[90],[19],[42318,42331,42332],{"nctId":42334,"briefTitle":42335,"status":195,"phases":42381,"primaryCompletion":42337,"completion":42337,"start":1068,"enrollment":2069,"conditions":42382,"interventions":42383},[90],[28],[42318,42331,42332],{"trials":42385,"activeCount":102},[],{"trials":42387,"activeCount":102},[],{"trials":42389,"activeCount":102},[],{"trials":42391,"activeCount":102},[],{"intervention":42393,"totalTrials":447,"cells":42394},"selumetinib 75mg single dose",{"EARLY_PHASE1":42395,"PHASE1":42397,"PHASE2":42413,"PHASE3":42415,"PHASE4":42417,"NA":42419},{"trials":42396,"activeCount":102},[],{"trials":42398,"activeCount":102},[42399,42406],{"nctId":42400,"briefTitle":42401,"status":195,"phases":42402,"primaryCompletion":16044,"completion":16044,"start":6436,"enrollment":544,"conditions":42403,"interventions":42405},"NCT02238782","A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.",[90],[42404],"Healthy Volunteers Bioavailability Study",[42393],{"nctId":42407,"briefTitle":42408,"status":195,"phases":42409,"primaryCompletion":16033,"completion":16033,"start":2561,"enrollment":5898,"conditions":42410,"interventions":42412},"NCT02322749","A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers",[90],[42411],"Healthy Volunteers Bioequivalence or Bioavailability Study",[42393,42393,42393],{"trials":42414,"activeCount":102},[],{"trials":42416,"activeCount":102},[],{"trials":42418,"activeCount":102},[],{"trials":42420,"activeCount":102},[],{"intervention":42422,"totalTrials":447,"cells":42423},"AMG 139",{"EARLY_PHASE1":42424,"PHASE1":42426,"PHASE2":42445,"PHASE3":42447,"PHASE4":42449,"NA":42451},{"trials":42425,"activeCount":102},[],{"trials":42427,"activeCount":102},[42428,42437],{"nctId":42429,"briefTitle":42430,"status":195,"phases":42431,"primaryCompletion":42432,"completion":42432,"start":42433,"enrollment":33344,"conditions":42434,"interventions":42436},"NCT01094093","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis",[90],"2011-07-26","2010-04-11",[42435],"Psoriasis",[42422],{"nctId":42438,"briefTitle":42439,"status":195,"phases":42440,"primaryCompletion":42441,"completion":42441,"start":42442,"enrollment":5898,"conditions":42443,"interventions":42444},"NCT01258205","Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects",[90],"2015-02-18","2011-02-28",[13237],[42422],{"trials":42446,"activeCount":102},[],{"trials":42448,"activeCount":102},[],{"trials":42450,"activeCount":102},[],{"trials":42452,"activeCount":102},[],{"intervention":19774,"totalTrials":447,"cells":42454},{"EARLY_PHASE1":42455,"PHASE1":42457,"PHASE2":42469,"PHASE3":42471,"PHASE4":42473,"NA":42475},{"trials":42456,"activeCount":102},[],{"trials":42458,"activeCount":102},[42459,42465],{"nctId":42460,"briefTitle":42461,"status":195,"phases":42462,"completion":2151,"start":2152,"enrollment":5898,"conditions":42463,"interventions":42464},"NCT00930215","Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males",[90],[19],[19774,19774],{"nctId":19768,"briefTitle":19769,"status":195,"phases":42466,"primaryCompletion":3862,"completion":3862,"start":2406,"enrollment":2069,"conditions":42467,"interventions":42468},[90],[19772],[19774,8361],{"trials":42470,"activeCount":102},[],{"trials":42472,"activeCount":102},[],{"trials":42474,"activeCount":102},[],{"trials":42476,"activeCount":102},[],{"intervention":42478,"totalTrials":447,"cells":42479},"MEDI0618",{"EARLY_PHASE1":42480,"PHASE1":42482,"PHASE2":42499,"PHASE3":42501,"PHASE4":42503,"NA":42505},{"trials":42481,"activeCount":102},[],{"trials":42483,"activeCount":102},[42484,42491],{"nctId":42485,"briefTitle":42486,"status":195,"phases":42487,"primaryCompletion":42488,"completion":42488,"start":33977,"enrollment":496,"conditions":42489,"interventions":42490},"NCT05714254","Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers",[90],"2023-12-12",[31748],[42478],{"nctId":42492,"briefTitle":42493,"status":195,"phases":42494,"primaryCompletion":42495,"completion":42495,"start":42496,"enrollment":4307,"conditions":42497,"interventions":42498},"NCT04198558","A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers",[90],"2022-02-23","2019-11-29",[31748],[42478],{"trials":42500,"activeCount":102},[],{"trials":42502,"activeCount":102},[],{"trials":42504,"activeCount":102},[],{"trials":42506,"activeCount":102},[],{"intervention":42508,"totalTrials":447,"cells":42509},"Ticagrelor OD tablet (90 mg single dose) administered without water",{"EARLY_PHASE1":42510,"PHASE1":42512,"PHASE2":42533,"PHASE3":42535,"PHASE4":42537,"NA":42539},{"trials":42511,"activeCount":102},[],{"trials":42513,"activeCount":102},[42514,42524],{"nctId":42515,"briefTitle":42516,"status":195,"phases":42517,"primaryCompletion":20965,"completion":20965,"start":4005,"enrollment":5425,"conditions":42518,"interventions":42521},"NCT02436577","Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects",[90],[42519,42520,15776],"Bioequivalence","Healthy Japanese Subjects",[42522,42508,42523],"Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water","Ticagrelor IR tablet (90 mg) administered with 150 mL of water",{"nctId":42525,"briefTitle":42526,"status":195,"phases":42527,"primaryCompletion":24772,"completion":24772,"start":4005,"enrollment":221,"conditions":42528,"interventions":42529},"NCT02400333","Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet",[90],[22858,1556],[42530,42508,42531,42532],"Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water","Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube","Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water",{"trials":42534,"activeCount":102},[],{"trials":42536,"activeCount":102},[],{"trials":42538,"activeCount":102},[],{"trials":42540,"activeCount":102},[],{"intervention":12681,"totalTrials":447,"cells":42542},{"EARLY_PHASE1":42543,"PHASE1":42545,"PHASE2":42558,"PHASE3":42560,"PHASE4":42562,"NA":42564},{"trials":42544,"activeCount":102},[],{"trials":42546,"activeCount":102},[42547,42554],{"nctId":42548,"briefTitle":42549,"status":195,"phases":42550,"primaryCompletion":38382,"completion":38382,"start":42551,"enrollment":579,"conditions":42552,"interventions":42553},"NCT03400488","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men",[90],"2018-01-16",[12734],[12681],{"nctId":12672,"briefTitle":12673,"status":195,"phases":42555,"primaryCompletion":12675,"completion":12675,"start":12676,"enrollment":1757,"conditions":42556,"interventions":42557},[90],[12678],[12680,12681,5887],{"trials":42559,"activeCount":102},[],{"trials":42561,"activeCount":102},[],{"trials":42563,"activeCount":102},[],{"trials":42565,"activeCount":102},[],{"intervention":40177,"totalTrials":122,"cells":42567},{"EARLY_PHASE1":42568,"PHASE1":42570,"PHASE2":42576,"PHASE3":42578,"PHASE4":42580,"NA":42582},{"trials":42569,"activeCount":102},[],{"trials":42571,"activeCount":102},[42572],{"nctId":40169,"briefTitle":40170,"status":624,"phases":42573,"primaryCompletion":40172,"completion":40172,"start":13787,"enrollment":102,"conditions":42574,"interventions":42575},[90],[40174,40175],[6382,40177],{"trials":42577,"activeCount":102},[],{"trials":42579,"activeCount":102},[],{"trials":42581,"activeCount":102},[],{"trials":42583,"activeCount":102},[],{"intervention":2062,"totalTrials":122,"cells":42585},{"EARLY_PHASE1":42586,"PHASE1":42588,"PHASE2":42594,"PHASE3":42596,"PHASE4":42598,"NA":42600},{"trials":42587,"activeCount":102},[],{"trials":42589,"activeCount":102},[42590],{"nctId":2052,"briefTitle":2053,"status":195,"phases":42591,"primaryCompletion":2055,"completion":2056,"start":2057,"enrollment":520,"conditions":42592,"interventions":42593},[90],[2059],[2044,2061,2062],{"trials":42595,"activeCount":102},[],{"trials":42597,"activeCount":102},[],{"trials":42599,"activeCount":102},[],{"trials":42601,"activeCount":102},[],{"intervention":42603,"totalTrials":122,"cells":42604},"Part 1 - AZD2423 or Placebo",{"EARLY_PHASE1":42605,"PHASE1":42607,"PHASE2":42617,"PHASE3":42619,"PHASE4":42621,"NA":42623},{"trials":42606,"activeCount":102},[],{"trials":42608,"activeCount":102},[42609],{"nctId":42610,"briefTitle":42611,"status":195,"phases":42612,"primaryCompletion":2243,"completion":2243,"start":2350,"enrollment":12547,"conditions":42613,"interventions":42614},"NCT00977626","Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers",[90],[19],[42603,42615,42616],"Part 2 - AZD2423","Part 3 - AZD2423",{"trials":42618,"activeCount":102},[],{"trials":42620,"activeCount":102},[],{"trials":42622,"activeCount":102},[],{"trials":42624,"activeCount":102},[],{"intervention":42615,"totalTrials":122,"cells":42626},{"EARLY_PHASE1":42627,"PHASE1":42629,"PHASE2":42635,"PHASE3":42637,"PHASE4":42639,"NA":42641},{"trials":42628,"activeCount":102},[],{"trials":42630,"activeCount":102},[42631],{"nctId":42610,"briefTitle":42611,"status":195,"phases":42632,"primaryCompletion":2243,"completion":2243,"start":2350,"enrollment":12547,"conditions":42633,"interventions":42634},[90],[19],[42603,42615,42616],{"trials":42636,"activeCount":102},[],{"trials":42638,"activeCount":102},[],{"trials":42640,"activeCount":102},[],{"trials":42642,"activeCount":102},[],{"intervention":42616,"totalTrials":122,"cells":42644},{"EARLY_PHASE1":42645,"PHASE1":42647,"PHASE2":42653,"PHASE3":42655,"PHASE4":42657,"NA":42659},{"trials":42646,"activeCount":102},[],{"trials":42648,"activeCount":102},[42649],{"nctId":42610,"briefTitle":42611,"status":195,"phases":42650,"primaryCompletion":2243,"completion":2243,"start":2350,"enrollment":12547,"conditions":42651,"interventions":42652},[90],[19],[42603,42615,42616],{"trials":42654,"activeCount":102},[],{"trials":42656,"activeCount":102},[],{"trials":42658,"activeCount":102},[],{"trials":42660,"activeCount":102},[],{"intervention":4458,"totalTrials":122,"cells":42662},{"EARLY_PHASE1":42663,"PHASE1":42665,"PHASE2":42671,"PHASE3":42673,"PHASE4":42675,"NA":42677},{"trials":42664,"activeCount":102},[],{"trials":42666,"activeCount":102},[42667],{"nctId":4450,"briefTitle":4451,"status":195,"phases":42668,"primaryCompletion":4453,"completion":4454,"start":2667,"enrollment":1979,"conditions":42669,"interventions":42670},[90],[4456],[4458,4459,53,118],{"trials":42672,"activeCount":102},[],{"trials":42674,"activeCount":102},[],{"trials":42676,"activeCount":102},[],{"trials":42678,"activeCount":102},[],{"intervention":4459,"totalTrials":122,"cells":42680},{"EARLY_PHASE1":42681,"PHASE1":42683,"PHASE2":42689,"PHASE3":42691,"PHASE4":42693,"NA":42695},{"trials":42682,"activeCount":102},[],{"trials":42684,"activeCount":102},[42685],{"nctId":4450,"briefTitle":4451,"status":195,"phases":42686,"primaryCompletion":4453,"completion":4454,"start":2667,"enrollment":1979,"conditions":42687,"interventions":42688},[90],[4456],[4458,4459,53,118],{"trials":42690,"activeCount":102},[],{"trials":42692,"activeCount":102},[],{"trials":42694,"activeCount":102},[],{"trials":42696,"activeCount":102},[],{"intervention":32518,"totalTrials":122,"cells":42698},{"EARLY_PHASE1":42699,"PHASE1":42701,"PHASE2":42707,"PHASE3":42709,"PHASE4":42711,"NA":42713},{"trials":42700,"activeCount":102},[],{"trials":42702,"activeCount":102},[42703],{"nctId":32511,"briefTitle":32512,"status":195,"phases":42704,"primaryCompletion":32514,"completion":32514,"start":32515,"enrollment":98,"conditions":42705,"interventions":42706},[90],[2134],[32518,32504,32519,32520],{"trials":42708,"activeCount":102},[],{"trials":42710,"activeCount":102},[],{"trials":42712,"activeCount":102},[],{"trials":42714,"activeCount":102},[],{"intervention":32519,"totalTrials":122,"cells":42716},{"EARLY_PHASE1":42717,"PHASE1":42719,"PHASE2":42725,"PHASE3":42727,"PHASE4":42729,"NA":42731},{"trials":42718,"activeCount":102},[],{"trials":42720,"activeCount":102},[42721],{"nctId":32511,"briefTitle":32512,"status":195,"phases":42722,"primaryCompletion":32514,"completion":32514,"start":32515,"enrollment":98,"conditions":42723,"interventions":42724},[90],[2134],[32518,32504,32519,32520],{"trials":42726,"activeCount":102},[],{"trials":42728,"activeCount":102},[],{"trials":42730,"activeCount":102},[],{"trials":42732,"activeCount":102},[],{"intervention":32520,"totalTrials":122,"cells":42734},{"EARLY_PHASE1":42735,"PHASE1":42737,"PHASE2":42743,"PHASE3":42745,"PHASE4":42747,"NA":42749},{"trials":42736,"activeCount":102},[],{"trials":42738,"activeCount":102},[42739],{"nctId":32511,"briefTitle":32512,"status":195,"phases":42740,"primaryCompletion":32514,"completion":32514,"start":32515,"enrollment":98,"conditions":42741,"interventions":42742},[90],[2134],[32518,32504,32519,32520],{"trials":42744,"activeCount":102},[],{"trials":42746,"activeCount":102},[],{"trials":42748,"activeCount":102},[],{"trials":42750,"activeCount":102},[],{"intervention":42752,"totalTrials":122,"cells":42753},"AZD5718 oral suspension crystalline form",{"EARLY_PHASE1":42754,"PHASE1":42756,"PHASE2":42768,"PHASE3":42770,"PHASE4":42772,"NA":42774},{"trials":42755,"activeCount":102},[],{"trials":42757,"activeCount":102},[42758],{"nctId":42759,"briefTitle":42760,"status":195,"phases":42761,"primaryCompletion":42762,"completion":42762,"start":42763,"enrollment":14210,"conditions":42764,"interventions":42765},"NCT02632526","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects",[90],"2016-08-26","2016-02-10",[7029,2619],[42752,42766,42767,42766],"AZD5718 oral suspension amorphous","AZD5718 placebo oral suspension",{"trials":42769,"activeCount":102},[],{"trials":42771,"activeCount":102},[],{"trials":42773,"activeCount":102},[],{"trials":42775,"activeCount":102},[],{"intervention":42766,"totalTrials":122,"cells":42777},{"EARLY_PHASE1":42778,"PHASE1":42780,"PHASE2":42786,"PHASE3":42788,"PHASE4":42790,"NA":42792},{"trials":42779,"activeCount":102},[],{"trials":42781,"activeCount":102},[42782],{"nctId":42759,"briefTitle":42760,"status":195,"phases":42783,"primaryCompletion":42762,"completion":42762,"start":42763,"enrollment":14210,"conditions":42784,"interventions":42785},[90],[7029,2619],[42752,42766,42767,42766],{"trials":42787,"activeCount":102},[],{"trials":42789,"activeCount":102},[],{"trials":42791,"activeCount":102},[],{"trials":42793,"activeCount":102},[],{"intervention":42767,"totalTrials":122,"cells":42795},{"EARLY_PHASE1":42796,"PHASE1":42798,"PHASE2":42804,"PHASE3":42806,"PHASE4":42808,"NA":42810},{"trials":42797,"activeCount":102},[],{"trials":42799,"activeCount":102},[42800],{"nctId":42759,"briefTitle":42760,"status":195,"phases":42801,"primaryCompletion":42762,"completion":42762,"start":42763,"enrollment":14210,"conditions":42802,"interventions":42803},[90],[7029,2619],[42752,42766,42767,42766],{"trials":42805,"activeCount":102},[],{"trials":42807,"activeCount":102},[],{"trials":42809,"activeCount":102},[],{"trials":42811,"activeCount":102},[],{"intervention":42813,"totalTrials":122,"cells":42814},"radioligand [18F]AZD4694",{"EARLY_PHASE1":42815,"PHASE1":42817,"PHASE2":42826,"PHASE3":42828,"PHASE4":42830,"NA":42832},{"trials":42816,"activeCount":102},[],{"trials":42818,"activeCount":102},[42819],{"nctId":42820,"briefTitle":42821,"status":195,"phases":42822,"completion":2350,"start":7544,"enrollment":2827,"conditions":42823,"interventions":42824},"NCT00838877","Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid",[90],[18867],[42813,42825],"radioligand [11C]AZD2184",{"trials":42827,"activeCount":102},[],{"trials":42829,"activeCount":102},[],{"trials":42831,"activeCount":102},[],{"trials":42833,"activeCount":102},[],{"intervention":42825,"totalTrials":122,"cells":42835},{"EARLY_PHASE1":42836,"PHASE1":42838,"PHASE2":42844,"PHASE3":42846,"PHASE4":42848,"NA":42850},{"trials":42837,"activeCount":102},[],{"trials":42839,"activeCount":102},[42840],{"nctId":42820,"briefTitle":42821,"status":195,"phases":42841,"completion":2350,"start":7544,"enrollment":2827,"conditions":42842,"interventions":42843},[90],[18867],[42813,42825],{"trials":42845,"activeCount":102},[],{"trials":42847,"activeCount":102},[],{"trials":42849,"activeCount":102},[],{"trials":42851,"activeCount":102},[],{"intervention":42853,"totalTrials":122,"cells":42854},"AZD5634",{"EARLY_PHASE1":42855,"PHASE1":42857,"PHASE2":42867,"PHASE3":42869,"PHASE4":42871,"NA":42873},{"trials":42856,"activeCount":102},[],{"trials":42858,"activeCount":102},[42859],{"nctId":42860,"briefTitle":42861,"status":195,"phases":42862,"primaryCompletion":42863,"completion":42863,"start":41474,"enrollment":4343,"conditions":42864,"interventions":42866},"NCT02950805","A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis",[90],"2018-04-12",[42865],"Pulmonary\u002FRespiratory Diseases",[42853],{"trials":42868,"activeCount":102},[],{"trials":42870,"activeCount":102},[],{"trials":42872,"activeCount":102},[],{"trials":42874,"activeCount":102},[],{"intervention":2072,"totalTrials":122,"cells":42876},{"EARLY_PHASE1":42877,"PHASE1":42879,"PHASE2":42885,"PHASE3":42887,"PHASE4":42889,"NA":42891},{"trials":42878,"activeCount":102},[],{"trials":42880,"activeCount":102},[42881],{"nctId":2064,"briefTitle":2065,"status":195,"phases":42882,"primaryCompletion":2067,"completion":2067,"start":2068,"enrollment":2069,"conditions":42883,"interventions":42884},[90],[22],[2072,2044],{"trials":42886,"activeCount":102},[],{"trials":42888,"activeCount":102},[],{"trials":42890,"activeCount":102},[],{"trials":42892,"activeCount":102},[],{"intervention":19182,"totalTrials":122,"cells":42894},{"EARLY_PHASE1":42895,"PHASE1":42897,"PHASE2":42903,"PHASE3":42905,"PHASE4":42907,"NA":42909},{"trials":42896,"activeCount":102},[],{"trials":42898,"activeCount":102},[42899],{"nctId":19176,"briefTitle":19177,"status":195,"phases":42900,"primaryCompletion":687,"completion":687,"start":2615,"enrollment":434,"conditions":42901,"interventions":42902},[90],[19180],[12616,19182],{"trials":42904,"activeCount":102},[],{"trials":42906,"activeCount":102},[],{"trials":42908,"activeCount":102},[],{"trials":42910,"activeCount":102},[],{"intervention":42912,"totalTrials":122,"cells":42913},"[14C] NKTR-118",{"EARLY_PHASE1":42914,"PHASE1":42916,"PHASE2":42924,"PHASE3":42926,"PHASE4":42928,"NA":42930},{"trials":42915,"activeCount":102},[],{"trials":42917,"activeCount":102},[42918],{"nctId":42919,"briefTitle":42920,"status":195,"phases":42921,"primaryCompletion":2571,"completion":2571,"start":2542,"enrollment":1039,"conditions":42922,"interventions":42923},"NCT01348724","Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118",[90],[36],[42912],{"trials":42925,"activeCount":102},[],{"trials":42927,"activeCount":102},[],{"trials":42929,"activeCount":102},[],{"trials":42931,"activeCount":102},[],{"intervention":42933,"totalTrials":122,"cells":42934},"ethinyl estradiol and levonorgestrel; exenatide",{"EARLY_PHASE1":42935,"PHASE1":42937,"PHASE2":42945,"PHASE3":42947,"PHASE4":42949,"NA":42951},{"trials":42936,"activeCount":102},[],{"trials":42938,"activeCount":102},[42939],{"nctId":42940,"briefTitle":42941,"status":195,"phases":42942,"primaryCompletion":4916,"completion":4916,"start":6517,"enrollment":3717,"conditions":42943,"interventions":42944},"NCT00254800","The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females",[90],[22],[42933,42933,42933],{"trials":42946,"activeCount":102},[],{"trials":42948,"activeCount":102},[],{"trials":42950,"activeCount":102},[],{"trials":42952,"activeCount":102},[],{"intervention":42954,"totalTrials":122,"cells":42955},"Symbicort pMDI with spacer device",{"EARLY_PHASE1":42956,"PHASE1":42958,"PHASE2":42969,"PHASE3":42971,"PHASE4":42973,"NA":42975},{"trials":42957,"activeCount":102},[],{"trials":42959,"activeCount":102},[42960],{"nctId":42961,"briefTitle":42962,"status":195,"phases":42963,"primaryCompletion":3429,"completion":3429,"start":42964,"enrollment":4286,"conditions":42965,"interventions":42967},"NCT02934607","A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers",[90],"2016-11-04",[42966],"Study is Being Conducted in Healthy Volunteers",[42954,42968],"Symbicort pMDI without spacer device",{"trials":42970,"activeCount":102},[],{"trials":42972,"activeCount":102},[],{"trials":42974,"activeCount":102},[],{"trials":42976,"activeCount":102},[],{"intervention":42968,"totalTrials":122,"cells":42978},{"EARLY_PHASE1":42979,"PHASE1":42981,"PHASE2":42987,"PHASE3":42989,"PHASE4":42991,"NA":42993},{"trials":42980,"activeCount":102},[],{"trials":42982,"activeCount":102},[42983],{"nctId":42961,"briefTitle":42962,"status":195,"phases":42984,"primaryCompletion":3429,"completion":3429,"start":42964,"enrollment":4286,"conditions":42985,"interventions":42986},[90],[42966],[42954,42968],{"trials":42988,"activeCount":102},[],{"trials":42990,"activeCount":102},[],{"trials":42992,"activeCount":102},[],{"trials":42994,"activeCount":102},[],{"intervention":42996,"totalTrials":122,"cells":42997},"AZD9819",{"EARLY_PHASE1":42998,"PHASE1":43000,"PHASE2":43008,"PHASE3":43010,"PHASE4":43012,"NA":43014},{"trials":42999,"activeCount":102},[],{"trials":43001,"activeCount":102},[43002],{"nctId":43003,"briefTitle":43004,"status":195,"phases":43005,"primaryCompletion":2516,"completion":2516,"start":2144,"enrollment":221,"conditions":43006,"interventions":43007},"NCT01166698","Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects",[90],[36,10052,24601],[42996,42996],{"trials":43009,"activeCount":102},[],{"trials":43011,"activeCount":102},[],{"trials":43013,"activeCount":102},[],{"trials":43015,"activeCount":102},[],{"intervention":43017,"totalTrials":122,"cells":43018},"AZD9977 capsule 50 mg",{"EARLY_PHASE1":43019,"PHASE1":43021,"PHASE2":43033,"PHASE3":43035,"PHASE4":43037,"NA":43039},{"trials":43020,"activeCount":102},[],{"trials":43022,"activeCount":102},[43023],{"nctId":43024,"briefTitle":43025,"status":195,"phases":43026,"primaryCompletion":43027,"completion":43027,"start":43028,"enrollment":370,"conditions":43029,"interventions":43030},"NCT04686591","Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects",[90],"2021-02-04","2020-12-21",[2619],[43017,43031,43032],"[14C]AZD9977 Solution for Infusion, 20 µg\u002FmL","[14C]AZD9977 Oral Suspension, 100 mg",{"trials":43034,"activeCount":102},[],{"trials":43036,"activeCount":102},[],{"trials":43038,"activeCount":102},[],{"trials":43040,"activeCount":102},[],{"intervention":43031,"totalTrials":122,"cells":43042},{"EARLY_PHASE1":43043,"PHASE1":43045,"PHASE2":43051,"PHASE3":43053,"PHASE4":43055,"NA":43057},{"trials":43044,"activeCount":102},[],{"trials":43046,"activeCount":102},[43047],{"nctId":43024,"briefTitle":43025,"status":195,"phases":43048,"primaryCompletion":43027,"completion":43027,"start":43028,"enrollment":370,"conditions":43049,"interventions":43050},[90],[2619],[43017,43031,43032],{"trials":43052,"activeCount":102},[],{"trials":43054,"activeCount":102},[],{"trials":43056,"activeCount":102},[],{"trials":43058,"activeCount":102},[],{"intervention":43032,"totalTrials":122,"cells":43060},{"EARLY_PHASE1":43061,"PHASE1":43063,"PHASE2":43069,"PHASE3":43071,"PHASE4":43073,"NA":43075},{"trials":43062,"activeCount":102},[],{"trials":43064,"activeCount":102},[43065],{"nctId":43024,"briefTitle":43025,"status":195,"phases":43066,"primaryCompletion":43027,"completion":43027,"start":43028,"enrollment":370,"conditions":43067,"interventions":43068},[90],[2619],[43017,43031,43032],{"trials":43070,"activeCount":102},[],{"trials":43072,"activeCount":102},[],{"trials":43074,"activeCount":102},[],{"trials":43076,"activeCount":102},[],{"intervention":43078,"totalTrials":122,"cells":43079},"Group 1 AZD3293",{"EARLY_PHASE1":43080,"PHASE1":43082,"PHASE2":43096,"PHASE3":43098,"PHASE4":43100,"NA":43102},{"trials":43081,"activeCount":102},[],{"trials":43083,"activeCount":102},[43084],{"nctId":43085,"briefTitle":43086,"status":195,"phases":43087,"primaryCompletion":2204,"completion":2204,"start":39977,"enrollment":2933,"conditions":43088,"interventions":43090},"NCT02010970","A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4\u002FCYP3A5) Substrate",[90],[36,43089],"Pharmacologic Action",[43078,43091,43092,43093,43094,43095],"Group 2 AZD3293","Group 3 AZD3293","Group 1 Itraconazole","Group 2 Diltiazem","Group 3 Midazolam",{"trials":43097,"activeCount":102},[],{"trials":43099,"activeCount":102},[],{"trials":43101,"activeCount":102},[],{"trials":43103,"activeCount":102},[],{"intervention":43091,"totalTrials":122,"cells":43105},{"EARLY_PHASE1":43106,"PHASE1":43108,"PHASE2":43114,"PHASE3":43116,"PHASE4":43118,"NA":43120},{"trials":43107,"activeCount":102},[],{"trials":43109,"activeCount":102},[43110],{"nctId":43085,"briefTitle":43086,"status":195,"phases":43111,"primaryCompletion":2204,"completion":2204,"start":39977,"enrollment":2933,"conditions":43112,"interventions":43113},[90],[36,43089],[43078,43091,43092,43093,43094,43095],{"trials":43115,"activeCount":102},[],{"trials":43117,"activeCount":102},[],{"trials":43119,"activeCount":102},[],{"trials":43121,"activeCount":102},[],{"intervention":43092,"totalTrials":122,"cells":43123},{"EARLY_PHASE1":43124,"PHASE1":43126,"PHASE2":43132,"PHASE3":43134,"PHASE4":43136,"NA":43138},{"trials":43125,"activeCount":102},[],{"trials":43127,"activeCount":102},[43128],{"nctId":43085,"briefTitle":43086,"status":195,"phases":43129,"primaryCompletion":2204,"completion":2204,"start":39977,"enrollment":2933,"conditions":43130,"interventions":43131},[90],[36,43089],[43078,43091,43092,43093,43094,43095],{"trials":43133,"activeCount":102},[],{"trials":43135,"activeCount":102},[],{"trials":43137,"activeCount":102},[],{"trials":43139,"activeCount":102},[],{"intervention":43093,"totalTrials":122,"cells":43141},{"EARLY_PHASE1":43142,"PHASE1":43144,"PHASE2":43150,"PHASE3":43152,"PHASE4":43154,"NA":43156},{"trials":43143,"activeCount":102},[],{"trials":43145,"activeCount":102},[43146],{"nctId":43085,"briefTitle":43086,"status":195,"phases":43147,"primaryCompletion":2204,"completion":2204,"start":39977,"enrollment":2933,"conditions":43148,"interventions":43149},[90],[36,43089],[43078,43091,43092,43093,43094,43095],{"trials":43151,"activeCount":102},[],{"trials":43153,"activeCount":102},[],{"trials":43155,"activeCount":102},[],{"trials":43157,"activeCount":102},[],{"intervention":43094,"totalTrials":122,"cells":43159},{"EARLY_PHASE1":43160,"PHASE1":43162,"PHASE2":43168,"PHASE3":43170,"PHASE4":43172,"NA":43174},{"trials":43161,"activeCount":102},[],{"trials":43163,"activeCount":102},[43164],{"nctId":43085,"briefTitle":43086,"status":195,"phases":43165,"primaryCompletion":2204,"completion":2204,"start":39977,"enrollment":2933,"conditions":43166,"interventions":43167},[90],[36,43089],[43078,43091,43092,43093,43094,43095],{"trials":43169,"activeCount":102},[],{"trials":43171,"activeCount":102},[],{"trials":43173,"activeCount":102},[],{"trials":43175,"activeCount":102},[],{"intervention":43095,"totalTrials":122,"cells":43177},{"EARLY_PHASE1":43178,"PHASE1":43180,"PHASE2":43186,"PHASE3":43188,"PHASE4":43190,"NA":43192},{"trials":43179,"activeCount":102},[],{"trials":43181,"activeCount":102},[43182],{"nctId":43085,"briefTitle":43086,"status":195,"phases":43183,"primaryCompletion":2204,"completion":2204,"start":39977,"enrollment":2933,"conditions":43184,"interventions":43185},[90],[36,43089],[43078,43091,43092,43093,43094,43095],{"trials":43187,"activeCount":102},[],{"trials":43189,"activeCount":102},[],{"trials":43191,"activeCount":102},[],{"trials":43193,"activeCount":102},[],{"intervention":43195,"totalTrials":122,"cells":43196},"Anifrolumab SC",{"EARLY_PHASE1":43197,"PHASE1":43199,"PHASE2":43211,"PHASE3":43213,"PHASE4":43215,"NA":43217},{"trials":43198,"activeCount":102},[],{"trials":43200,"activeCount":102},[43201],{"nctId":43202,"briefTitle":43203,"status":195,"phases":43204,"primaryCompletion":43205,"completion":43205,"start":34834,"enrollment":1710,"conditions":43206,"interventions":43207},"NCT02601625","A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects",[90],"2016-05-25",[10052,15776,1556],[43195,43208,43195,43209,43210,43209],"Anifrolumab IV","Anifrolumab placebo SC","Anifrolumab placebo IV",{"trials":43212,"activeCount":102},[],{"trials":43214,"activeCount":102},[],{"trials":43216,"activeCount":102},[],{"trials":43218,"activeCount":102},[],{"intervention":43208,"totalTrials":122,"cells":43220},{"EARLY_PHASE1":43221,"PHASE1":43223,"PHASE2":43229,"PHASE3":43231,"PHASE4":43233,"NA":43235},{"trials":43222,"activeCount":102},[],{"trials":43224,"activeCount":102},[43225],{"nctId":43202,"briefTitle":43203,"status":195,"phases":43226,"primaryCompletion":43205,"completion":43205,"start":34834,"enrollment":1710,"conditions":43227,"interventions":43228},[90],[10052,15776,1556],[43195,43208,43195,43209,43210,43209],{"trials":43230,"activeCount":102},[],{"trials":43232,"activeCount":102},[],{"trials":43234,"activeCount":102},[],{"trials":43236,"activeCount":102},[],{"intervention":43209,"totalTrials":122,"cells":43238},{"EARLY_PHASE1":43239,"PHASE1":43241,"PHASE2":43247,"PHASE3":43249,"PHASE4":43251,"NA":43253},{"trials":43240,"activeCount":102},[],{"trials":43242,"activeCount":102},[43243],{"nctId":43202,"briefTitle":43203,"status":195,"phases":43244,"primaryCompletion":43205,"completion":43205,"start":34834,"enrollment":1710,"conditions":43245,"interventions":43246},[90],[10052,15776,1556],[43195,43208,43195,43209,43210,43209],{"trials":43248,"activeCount":102},[],{"trials":43250,"activeCount":102},[],{"trials":43252,"activeCount":102},[],{"trials":43254,"activeCount":102},[],{"intervention":43210,"totalTrials":122,"cells":43256},{"EARLY_PHASE1":43257,"PHASE1":43259,"PHASE2":43265,"PHASE3":43267,"PHASE4":43269,"NA":43271},{"trials":43258,"activeCount":102},[],{"trials":43260,"activeCount":102},[43261],{"nctId":43202,"briefTitle":43203,"status":195,"phases":43262,"primaryCompletion":43205,"completion":43205,"start":34834,"enrollment":1710,"conditions":43263,"interventions":43264},[90],[10052,15776,1556],[43195,43208,43195,43209,43210,43209],{"trials":43266,"activeCount":102},[],{"trials":43268,"activeCount":102},[],{"trials":43270,"activeCount":102},[],{"trials":43272,"activeCount":102},[],{"intervention":7741,"totalTrials":122,"cells":43274},{"EARLY_PHASE1":43275,"PHASE1":43277,"PHASE2":43283,"PHASE3":43285,"PHASE4":43287,"NA":43289},{"trials":43276,"activeCount":102},[],{"trials":43278,"activeCount":102},[43279],{"nctId":7734,"briefTitle":7735,"status":443,"phases":43280,"primaryCompletion":7737,"completion":6628,"start":7738,"enrollment":122,"conditions":43281,"interventions":43282},[90],[498],[265,7741,7742,7743],{"trials":43284,"activeCount":102},[],{"trials":43286,"activeCount":102},[],{"trials":43288,"activeCount":102},[],{"trials":43290,"activeCount":102},[],{"intervention":7742,"totalTrials":122,"cells":43292},{"EARLY_PHASE1":43293,"PHASE1":43295,"PHASE2":43301,"PHASE3":43303,"PHASE4":43305,"NA":43307},{"trials":43294,"activeCount":102},[],{"trials":43296,"activeCount":102},[43297],{"nctId":7734,"briefTitle":7735,"status":443,"phases":43298,"primaryCompletion":7737,"completion":6628,"start":7738,"enrollment":122,"conditions":43299,"interventions":43300},[90],[498],[265,7741,7742,7743],{"trials":43302,"activeCount":102},[],{"trials":43304,"activeCount":102},[],{"trials":43306,"activeCount":102},[],{"trials":43308,"activeCount":102},[],{"intervention":7743,"totalTrials":122,"cells":43310},{"EARLY_PHASE1":43311,"PHASE1":43313,"PHASE2":43319,"PHASE3":43321,"PHASE4":43323,"NA":43325},{"trials":43312,"activeCount":102},[],{"trials":43314,"activeCount":102},[43315],{"nctId":7734,"briefTitle":7735,"status":443,"phases":43316,"primaryCompletion":7737,"completion":6628,"start":7738,"enrollment":122,"conditions":43317,"interventions":43318},[90],[498],[265,7741,7742,7743],{"trials":43320,"activeCount":102},[],{"trials":43322,"activeCount":102},[],{"trials":43324,"activeCount":102},[],{"trials":43326,"activeCount":102},[],{"intervention":43328,"totalTrials":122,"cells":43329},"AZD6615",{"EARLY_PHASE1":43330,"PHASE1":43332,"PHASE2":43341,"PHASE3":43343,"PHASE4":43345,"NA":43347},{"trials":43331,"activeCount":102},[],{"trials":43333,"activeCount":102},[43334],{"nctId":43335,"briefTitle":43336,"status":443,"phases":43337,"primaryCompletion":43338,"completion":43338,"start":40604,"enrollment":1130,"conditions":43339,"interventions":43340},"NCT04055168","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects",[90],"2020-02-10",[6903],[43328],{"trials":43342,"activeCount":102},[],{"trials":43344,"activeCount":102},[],{"trials":43346,"activeCount":102},[],{"trials":43348,"activeCount":102},[],{"intervention":43350,"totalTrials":122,"cells":43351},"AZD8165",{"EARLY_PHASE1":43352,"PHASE1":43354,"PHASE2":43363,"PHASE3":43365,"PHASE4":43367,"NA":43369},{"trials":43353,"activeCount":102},[],{"trials":43355,"activeCount":102},[43356],{"nctId":43357,"briefTitle":43358,"status":443,"phases":43359,"primaryCompletion":2144,"completion":2144,"start":2242,"enrollment":4343,"conditions":43360,"interventions":43362},"NCT01150812","Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects",[90],[43361],"Thrombin Inhibition",[43350],{"trials":43364,"activeCount":102},[],{"trials":43366,"activeCount":102},[],{"trials":43368,"activeCount":102},[],{"trials":43370,"activeCount":102},[],{"intervention":33785,"totalTrials":122,"cells":43372},{"EARLY_PHASE1":43373,"PHASE1":43375,"PHASE2":43381,"PHASE3":43383,"PHASE4":43385,"NA":43387},{"trials":43374,"activeCount":102},[],{"trials":43376,"activeCount":102},[43377],{"nctId":33778,"briefTitle":33779,"status":443,"phases":43378,"primaryCompletion":33781,"completion":33781,"start":33782,"enrollment":3248,"conditions":43379,"interventions":43380},[90],[12328],[33771,33785,2255,33786],{"trials":43382,"activeCount":102},[],{"trials":43384,"activeCount":102},[],{"trials":43386,"activeCount":102},[],{"trials":43388,"activeCount":102},[],{"intervention":33786,"totalTrials":122,"cells":43390},{"EARLY_PHASE1":43391,"PHASE1":43393,"PHASE2":43399,"PHASE3":43401,"PHASE4":43403,"NA":43405},{"trials":43392,"activeCount":102},[],{"trials":43394,"activeCount":102},[43395],{"nctId":33778,"briefTitle":33779,"status":443,"phases":43396,"primaryCompletion":33781,"completion":33781,"start":33782,"enrollment":3248,"conditions":43397,"interventions":43398},[90],[12328],[33771,33785,2255,33786],{"trials":43400,"activeCount":102},[],{"trials":43402,"activeCount":102},[],{"trials":43404,"activeCount":102},[],{"trials":43406,"activeCount":102},[],{"intervention":43408,"totalTrials":122,"cells":43409},"Onglyza",{"EARLY_PHASE1":43410,"PHASE1":43412,"PHASE2":43424,"PHASE3":43426,"PHASE4":43428,"NA":43430},{"trials":43411,"activeCount":102},[],{"trials":43413,"activeCount":102},[43414],{"nctId":43415,"briefTitle":43416,"status":195,"phases":43417,"primaryCompletion":2589,"completion":2589,"start":2736,"enrollment":2260,"conditions":43418,"interventions":43420},"NCT01441869","Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin \u002F Metformin Produc",[90],[43419],"Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin",[43408,43421,43422,43421,43423],"Diabex","5-mg saxagliptin\u002F1000 mg metformin","5-mg saxagliptin\u002F500 mg metformin",{"trials":43425,"activeCount":102},[],{"trials":43427,"activeCount":102},[],{"trials":43429,"activeCount":102},[],{"trials":43431,"activeCount":102},[],{"intervention":43421,"totalTrials":122,"cells":43433},{"EARLY_PHASE1":43434,"PHASE1":43436,"PHASE2":43442,"PHASE3":43444,"PHASE4":43446,"NA":43448},{"trials":43435,"activeCount":102},[],{"trials":43437,"activeCount":102},[43438],{"nctId":43415,"briefTitle":43416,"status":195,"phases":43439,"primaryCompletion":2589,"completion":2589,"start":2736,"enrollment":2260,"conditions":43440,"interventions":43441},[90],[43419],[43408,43421,43422,43421,43423],{"trials":43443,"activeCount":102},[],{"trials":43445,"activeCount":102},[],{"trials":43447,"activeCount":102},[],{"trials":43449,"activeCount":102},[],{"intervention":43422,"totalTrials":122,"cells":43451},{"EARLY_PHASE1":43452,"PHASE1":43454,"PHASE2":43460,"PHASE3":43462,"PHASE4":43464,"NA":43466},{"trials":43453,"activeCount":102},[],{"trials":43455,"activeCount":102},[43456],{"nctId":43415,"briefTitle":43416,"status":195,"phases":43457,"primaryCompletion":2589,"completion":2589,"start":2736,"enrollment":2260,"conditions":43458,"interventions":43459},[90],[43419],[43408,43421,43422,43421,43423],{"trials":43461,"activeCount":102},[],{"trials":43463,"activeCount":102},[],{"trials":43465,"activeCount":102},[],{"trials":43467,"activeCount":102},[],{"intervention":43423,"totalTrials":122,"cells":43469},{"EARLY_PHASE1":43470,"PHASE1":43472,"PHASE2":43478,"PHASE3":43480,"PHASE4":43482,"NA":43484},{"trials":43471,"activeCount":102},[],{"trials":43473,"activeCount":102},[43474],{"nctId":43415,"briefTitle":43416,"status":195,"phases":43475,"primaryCompletion":2589,"completion":2589,"start":2736,"enrollment":2260,"conditions":43476,"interventions":43477},[90],[43419],[43408,43421,43422,43421,43423],{"trials":43479,"activeCount":102},[],{"trials":43481,"activeCount":102},[],{"trials":43483,"activeCount":102},[],{"trials":43485,"activeCount":102},[],{"intervention":43487,"totalTrials":122,"cells":43488},"Fostamatinib 100mg",{"EARLY_PHASE1":43489,"PHASE1":43491,"PHASE2":43501,"PHASE3":43503,"PHASE4":43505,"NA":43507},{"trials":43490,"activeCount":102},[],{"trials":43492,"activeCount":102},[43493],{"nctId":43494,"briefTitle":43495,"status":195,"phases":43496,"primaryCompletion":2105,"completion":2105,"start":2471,"enrollment":1130,"conditions":43497,"interventions":43499},"NCT01608542","A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects",[90],[43498],"Healthy Japanese Volunteers",[43487,43500],"Fostamatinib 200mg",{"trials":43502,"activeCount":102},[],{"trials":43504,"activeCount":102},[],{"trials":43506,"activeCount":102},[],{"trials":43508,"activeCount":102},[],{"intervention":43500,"totalTrials":122,"cells":43510},{"EARLY_PHASE1":43511,"PHASE1":43513,"PHASE2":43519,"PHASE3":43521,"PHASE4":43523,"NA":43525},{"trials":43512,"activeCount":102},[],{"trials":43514,"activeCount":102},[43515],{"nctId":43494,"briefTitle":43495,"status":195,"phases":43516,"primaryCompletion":2105,"completion":2105,"start":2471,"enrollment":1130,"conditions":43517,"interventions":43518},[90],[43498],[43487,43500],{"trials":43520,"activeCount":102},[],{"trials":43522,"activeCount":102},[],{"trials":43524,"activeCount":102},[],{"trials":43526,"activeCount":102},[],{"intervention":31588,"totalTrials":122,"cells":43528},{"EARLY_PHASE1":43529,"PHASE1":43531,"PHASE2":43537,"PHASE3":43539,"PHASE4":43541,"NA":43543},{"trials":43530,"activeCount":102},[],{"trials":43532,"activeCount":102},[43533],{"nctId":31582,"briefTitle":31583,"status":195,"phases":43534,"primaryCompletion":2489,"completion":2489,"start":2243,"enrollment":2260,"conditions":43535,"interventions":43536},[90],[31586],[20417,31588],{"trials":43538,"activeCount":102},[],{"trials":43540,"activeCount":102},[],{"trials":43542,"activeCount":102},[],{"trials":43544,"activeCount":102},[],{"intervention":43546,"totalTrials":122,"cells":43547},"AZD1981, current small-particle",{"EARLY_PHASE1":43548,"PHASE1":43550,"PHASE2":43560,"PHASE3":43562,"PHASE4":43564,"NA":43566},{"trials":43549,"activeCount":102},[],{"trials":43551,"activeCount":102},[43552],{"nctId":43553,"briefTitle":43554,"status":195,"phases":43555,"primaryCompletion":2615,"completion":2542,"start":12721,"enrollment":486,"conditions":43556,"interventions":43557},"NCT01311635","A Bioavailability Study Comparing 3 Different AZD1981 Tablets",[90],[19],[43546,43558,43559],"AZD1981, new small-particle","AZD1981, new large-particle table",{"trials":43561,"activeCount":102},[],{"trials":43563,"activeCount":102},[],{"trials":43565,"activeCount":102},[],{"trials":43567,"activeCount":102},[],{"intervention":43558,"totalTrials":122,"cells":43569},{"EARLY_PHASE1":43570,"PHASE1":43572,"PHASE2":43578,"PHASE3":43580,"PHASE4":43582,"NA":43584},{"trials":43571,"activeCount":102},[],{"trials":43573,"activeCount":102},[43574],{"nctId":43553,"briefTitle":43554,"status":195,"phases":43575,"primaryCompletion":2615,"completion":2542,"start":12721,"enrollment":486,"conditions":43576,"interventions":43577},[90],[19],[43546,43558,43559],{"trials":43579,"activeCount":102},[],{"trials":43581,"activeCount":102},[],{"trials":43583,"activeCount":102},[],{"trials":43585,"activeCount":102},[],{"intervention":43559,"totalTrials":122,"cells":43587},{"EARLY_PHASE1":43588,"PHASE1":43590,"PHASE2":43596,"PHASE3":43598,"PHASE4":43600,"NA":43602},{"trials":43589,"activeCount":102},[],{"trials":43591,"activeCount":102},[43592],{"nctId":43553,"briefTitle":43554,"status":195,"phases":43593,"primaryCompletion":2615,"completion":2542,"start":12721,"enrollment":486,"conditions":43594,"interventions":43595},[90],[19],[43546,43558,43559],{"trials":43597,"activeCount":102},[],{"trials":43599,"activeCount":102},[],{"trials":43601,"activeCount":102},[],{"trials":43603,"activeCount":102},[],{"intervention":2126,"totalTrials":122,"cells":43605},{"EARLY_PHASE1":43606,"PHASE1":43608,"PHASE2":43614,"PHASE3":43616,"PHASE4":43618,"NA":43620},{"trials":43607,"activeCount":102},[],{"trials":43609,"activeCount":102},[43610],{"nctId":2118,"briefTitle":2119,"status":195,"phases":43611,"primaryCompletion":2121,"completion":2121,"start":2122,"enrollment":451,"conditions":43612,"interventions":43613},[90],[2124],[2126,2081,2044],{"trials":43615,"activeCount":102},[],{"trials":43617,"activeCount":102},[],{"trials":43619,"activeCount":102},[],{"trials":43621,"activeCount":102},[],{"intervention":43623,"totalTrials":122,"cells":43624},"AZD5718 tablet, Formulation A",{"EARLY_PHASE1":43625,"PHASE1":43627,"PHASE2":43641,"PHASE3":43643,"PHASE4":43645,"NA":43647},{"trials":43626,"activeCount":102},[],{"trials":43628,"activeCount":102},[43629],{"nctId":43630,"briefTitle":43631,"status":195,"phases":43632,"primaryCompletion":43633,"completion":43633,"start":485,"enrollment":1757,"conditions":43634,"interventions":43636},"NCT04210388","A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers",[90],"2020-03-09",[43635],"Coronary Artery Disease (CAD)",[43623,43637,43638,43639,43640],"AZD5718 tablet, Formulation B","AZD5718 tablet, Formulation C","AZD5718 tablet, Formulation D","AZD5718 film-coated tablet, Reference treatment",{"trials":43642,"activeCount":102},[],{"trials":43644,"activeCount":102},[],{"trials":43646,"activeCount":102},[],{"trials":43648,"activeCount":102},[],{"intervention":43637,"totalTrials":122,"cells":43650},{"EARLY_PHASE1":43651,"PHASE1":43653,"PHASE2":43659,"PHASE3":43661,"PHASE4":43663,"NA":43665},{"trials":43652,"activeCount":102},[],{"trials":43654,"activeCount":102},[43655],{"nctId":43630,"briefTitle":43631,"status":195,"phases":43656,"primaryCompletion":43633,"completion":43633,"start":485,"enrollment":1757,"conditions":43657,"interventions":43658},[90],[43635],[43623,43637,43638,43639,43640],{"trials":43660,"activeCount":102},[],{"trials":43662,"activeCount":102},[],{"trials":43664,"activeCount":102},[],{"trials":43666,"activeCount":102},[],{"intervention":43638,"totalTrials":122,"cells":43668},{"EARLY_PHASE1":43669,"PHASE1":43671,"PHASE2":43677,"PHASE3":43679,"PHASE4":43681,"NA":43683},{"trials":43670,"activeCount":102},[],{"trials":43672,"activeCount":102},[43673],{"nctId":43630,"briefTitle":43631,"status":195,"phases":43674,"primaryCompletion":43633,"completion":43633,"start":485,"enrollment":1757,"conditions":43675,"interventions":43676},[90],[43635],[43623,43637,43638,43639,43640],{"trials":43678,"activeCount":102},[],{"trials":43680,"activeCount":102},[],{"trials":43682,"activeCount":102},[],{"trials":43684,"activeCount":102},[],{"intervention":43639,"totalTrials":122,"cells":43686},{"EARLY_PHASE1":43687,"PHASE1":43689,"PHASE2":43695,"PHASE3":43697,"PHASE4":43699,"NA":43701},{"trials":43688,"activeCount":102},[],{"trials":43690,"activeCount":102},[43691],{"nctId":43630,"briefTitle":43631,"status":195,"phases":43692,"primaryCompletion":43633,"completion":43633,"start":485,"enrollment":1757,"conditions":43693,"interventions":43694},[90],[43635],[43623,43637,43638,43639,43640],{"trials":43696,"activeCount":102},[],{"trials":43698,"activeCount":102},[],{"trials":43700,"activeCount":102},[],{"trials":43702,"activeCount":102},[],{"intervention":43640,"totalTrials":122,"cells":43704},{"EARLY_PHASE1":43705,"PHASE1":43707,"PHASE2":43713,"PHASE3":43715,"PHASE4":43717,"NA":43719},{"trials":43706,"activeCount":102},[],{"trials":43708,"activeCount":102},[43709],{"nctId":43630,"briefTitle":43631,"status":195,"phases":43710,"primaryCompletion":43633,"completion":43633,"start":485,"enrollment":1757,"conditions":43711,"interventions":43712},[90],[43635],[43623,43637,43638,43639,43640],{"trials":43714,"activeCount":102},[],{"trials":43716,"activeCount":102},[],{"trials":43718,"activeCount":102},[],{"trials":43720,"activeCount":102},[],{"intervention":43722,"totalTrials":122,"cells":43723},"baxdrostat (formerly CIN-107) oral solution",{"EARLY_PHASE1":43724,"PHASE1":43726,"PHASE2":43734,"PHASE3":43736,"PHASE4":43738,"NA":43740},{"trials":43725,"activeCount":102},[],{"trials":43727,"activeCount":102},[43728],{"nctId":43729,"briefTitle":43730,"status":195,"phases":43731,"primaryCompletion":1427,"completion":1427,"start":7060,"enrollment":1638,"conditions":43732,"interventions":43733},"NCT05963009","Baxdrostat Bioavailability and Bioequivalence Study",[90],[2620],[43722],{"trials":43735,"activeCount":102},[],{"trials":43737,"activeCount":102},[],{"trials":43739,"activeCount":102},[],{"trials":43741,"activeCount":102},[],{"intervention":2137,"totalTrials":122,"cells":43743},{"EARLY_PHASE1":43744,"PHASE1":43746,"PHASE2":43752,"PHASE3":43754,"PHASE4":43756,"NA":43758},{"trials":43745,"activeCount":102},[],{"trials":43747,"activeCount":102},[43748],{"nctId":2128,"briefTitle":2129,"status":195,"phases":43749,"primaryCompletion":2131,"completion":2131,"start":2132,"enrollment":2003,"conditions":43750,"interventions":43751},[90],[2134],[2136,2044,2137,2138],{"trials":43753,"activeCount":102},[],{"trials":43755,"activeCount":102},[],{"trials":43757,"activeCount":102},[],{"trials":43759,"activeCount":102},[],{"intervention":2138,"totalTrials":122,"cells":43761},{"EARLY_PHASE1":43762,"PHASE1":43764,"PHASE2":43770,"PHASE3":43772,"PHASE4":43774,"NA":43776},{"trials":43763,"activeCount":102},[],{"trials":43765,"activeCount":102},[43766],{"nctId":2128,"briefTitle":2129,"status":195,"phases":43767,"primaryCompletion":2131,"completion":2131,"start":2132,"enrollment":2003,"conditions":43768,"interventions":43769},[90],[2134],[2136,2044,2137,2138],{"trials":43771,"activeCount":102},[],{"trials":43773,"activeCount":102},[],{"trials":43775,"activeCount":102},[],{"trials":43777,"activeCount":102},[],{"intervention":43779,"totalTrials":122,"cells":43780},"Elarekibep",{"EARLY_PHASE1":43781,"PHASE1":43783,"PHASE2":43793,"PHASE3":43795,"PHASE4":43797,"NA":43799},{"trials":43782,"activeCount":102},[],{"trials":43784,"activeCount":102},[43785],{"nctId":43786,"briefTitle":43787,"status":443,"phases":43788,"primaryCompletion":43789,"completion":43789,"start":3207,"enrollment":1710,"conditions":43790,"interventions":43792},"NCT05794672","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects",[90],"2023-07-08",[43791],"Healthy Subjects (Indication: Asthma)",[43779],{"trials":43794,"activeCount":102},[],{"trials":43796,"activeCount":102},[],{"trials":43798,"activeCount":102},[],{"trials":43800,"activeCount":102},[],{"intervention":43802,"totalTrials":122,"cells":43803},"AZD6244 Dosing Period 1",{"EARLY_PHASE1":43804,"PHASE1":43806,"PHASE2":43817,"PHASE3":43819,"PHASE4":43821,"NA":43823},{"trials":43805,"activeCount":102},[],{"trials":43807,"activeCount":102},[43808],{"nctId":43809,"briefTitle":43810,"status":195,"phases":43811,"primaryCompletion":2365,"completion":2365,"start":2481,"enrollment":2003,"conditions":43812,"interventions":43813},"NCT01635023","A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244",[90],[36],[43802,43814,43815,43816],"AZD6244 Dosing Period 2","AZD6244 Dosing Period 3","AZD6244 Dosing Period 4",{"trials":43818,"activeCount":102},[],{"trials":43820,"activeCount":102},[],{"trials":43822,"activeCount":102},[],{"trials":43824,"activeCount":102},[],{"intervention":43814,"totalTrials":122,"cells":43826},{"EARLY_PHASE1":43827,"PHASE1":43829,"PHASE2":43835,"PHASE3":43837,"PHASE4":43839,"NA":43841},{"trials":43828,"activeCount":102},[],{"trials":43830,"activeCount":102},[43831],{"nctId":43809,"briefTitle":43810,"status":195,"phases":43832,"primaryCompletion":2365,"completion":2365,"start":2481,"enrollment":2003,"conditions":43833,"interventions":43834},[90],[36],[43802,43814,43815,43816],{"trials":43836,"activeCount":102},[],{"trials":43838,"activeCount":102},[],{"trials":43840,"activeCount":102},[],{"trials":43842,"activeCount":102},[],{"intervention":43815,"totalTrials":122,"cells":43844},{"EARLY_PHASE1":43845,"PHASE1":43847,"PHASE2":43853,"PHASE3":43855,"PHASE4":43857,"NA":43859},{"trials":43846,"activeCount":102},[],{"trials":43848,"activeCount":102},[43849],{"nctId":43809,"briefTitle":43810,"status":195,"phases":43850,"primaryCompletion":2365,"completion":2365,"start":2481,"enrollment":2003,"conditions":43851,"interventions":43852},[90],[36],[43802,43814,43815,43816],{"trials":43854,"activeCount":102},[],{"trials":43856,"activeCount":102},[],{"trials":43858,"activeCount":102},[],{"trials":43860,"activeCount":102},[],{"intervention":43816,"totalTrials":122,"cells":43862},{"EARLY_PHASE1":43863,"PHASE1":43865,"PHASE2":43871,"PHASE3":43873,"PHASE4":43875,"NA":43877},{"trials":43864,"activeCount":102},[],{"trials":43866,"activeCount":102},[43867],{"nctId":43809,"briefTitle":43810,"status":195,"phases":43868,"primaryCompletion":2365,"completion":2365,"start":2481,"enrollment":2003,"conditions":43869,"interventions":43870},[90],[36],[43802,43814,43815,43816],{"trials":43872,"activeCount":102},[],{"trials":43874,"activeCount":102},[],{"trials":43876,"activeCount":102},[],{"trials":43878,"activeCount":102},[],{"intervention":12586,"totalTrials":122,"cells":43880},{"EARLY_PHASE1":43881,"PHASE1":43883,"PHASE2":43889,"PHASE3":43891,"PHASE4":43893,"NA":43895},{"trials":43882,"activeCount":102},[],{"trials":43884,"activeCount":102},[43885],{"nctId":12579,"briefTitle":12580,"status":195,"phases":43886,"primaryCompletion":12582,"completion":12582,"start":1007,"enrollment":507,"conditions":43887,"interventions":43888},[90],[5851],[12585,5887,12586,12587,12588,12589],{"trials":43890,"activeCount":102},[],{"trials":43892,"activeCount":102},[],{"trials":43894,"activeCount":102},[],{"trials":43896,"activeCount":102},[],{"intervention":12589,"totalTrials":122,"cells":43898},{"EARLY_PHASE1":43899,"PHASE1":43901,"PHASE2":43907,"PHASE3":43909,"PHASE4":43911,"NA":43913},{"trials":43900,"activeCount":102},[],{"trials":43902,"activeCount":102},[43903],{"nctId":12579,"briefTitle":12580,"status":195,"phases":43904,"primaryCompletion":12582,"completion":12582,"start":1007,"enrollment":507,"conditions":43905,"interventions":43906},[90],[5851],[12585,5887,12586,12587,12588,12589],{"trials":43908,"activeCount":102},[],{"trials":43910,"activeCount":102},[],{"trials":43912,"activeCount":102},[],{"trials":43914,"activeCount":102},[],{"intervention":25269,"totalTrials":122,"cells":43916},{"EARLY_PHASE1":43917,"PHASE1":43919,"PHASE2":43925,"PHASE3":43927,"PHASE4":43929,"NA":43931},{"trials":43918,"activeCount":102},[],{"trials":43920,"activeCount":102},[43921],{"nctId":25259,"briefTitle":25260,"status":195,"phases":43922,"primaryCompletion":25262,"completion":25262,"start":25263,"enrollment":8304,"conditions":43923,"interventions":43924},[90],[25265,25266,25267,15776],[25269,25270,25271,25252],{"trials":43926,"activeCount":102},[],{"trials":43928,"activeCount":102},[],{"trials":43930,"activeCount":102},[],{"trials":43932,"activeCount":102},[],{"intervention":25270,"totalTrials":122,"cells":43934},{"EARLY_PHASE1":43935,"PHASE1":43937,"PHASE2":43943,"PHASE3":43945,"PHASE4":43947,"NA":43949},{"trials":43936,"activeCount":102},[],{"trials":43938,"activeCount":102},[43939],{"nctId":25259,"briefTitle":25260,"status":195,"phases":43940,"primaryCompletion":25262,"completion":25262,"start":25263,"enrollment":8304,"conditions":43941,"interventions":43942},[90],[25265,25266,25267,15776],[25269,25270,25271,25252],{"trials":43944,"activeCount":102},[],{"trials":43946,"activeCount":102},[],{"trials":43948,"activeCount":102},[],{"trials":43950,"activeCount":102},[],{"intervention":25271,"totalTrials":122,"cells":43952},{"EARLY_PHASE1":43953,"PHASE1":43955,"PHASE2":43961,"PHASE3":43963,"PHASE4":43965,"NA":43967},{"trials":43954,"activeCount":102},[],{"trials":43956,"activeCount":102},[43957],{"nctId":25259,"briefTitle":25260,"status":195,"phases":43958,"primaryCompletion":25262,"completion":25262,"start":25263,"enrollment":8304,"conditions":43959,"interventions":43960},[90],[25265,25266,25267,15776],[25269,25270,25271,25252],{"trials":43962,"activeCount":102},[],{"trials":43964,"activeCount":102},[],{"trials":43966,"activeCount":102},[],{"trials":43968,"activeCount":102},[],{"intervention":8363,"totalTrials":122,"cells":43970},{"EARLY_PHASE1":43971,"PHASE1":43973,"PHASE2":43979,"PHASE3":43981,"PHASE4":43983,"NA":43985},{"trials":43972,"activeCount":102},[],{"trials":43974,"activeCount":102},[43975],{"nctId":8355,"briefTitle":8356,"status":195,"phases":43976,"primaryCompletion":3197,"completion":3197,"start":8358,"enrollment":3209,"conditions":43977,"interventions":43978},[90],[36],[6431,5870,8361,8362,8363],{"trials":43980,"activeCount":102},[],{"trials":43982,"activeCount":102},[],{"trials":43984,"activeCount":102},[],{"trials":43986,"activeCount":102},[],{"intervention":43988,"totalTrials":122,"cells":43989},"AZD6088",{"EARLY_PHASE1":43990,"PHASE1":43992,"PHASE2":44000,"PHASE3":44002,"PHASE4":44004,"NA":44006},{"trials":43991,"activeCount":102},[],{"trials":43993,"activeCount":102},[43994],{"nctId":43995,"briefTitle":43996,"status":195,"phases":43997,"completion":2151,"start":2152,"enrollment":1348,"conditions":43998,"interventions":43999},"NCT00931541","AZD6088 Single Ascending Dose Study",[90],[36],[43988],{"trials":44001,"activeCount":102},[],{"trials":44003,"activeCount":102},[],{"trials":44005,"activeCount":102},[],{"trials":44007,"activeCount":102},[],{"intervention":44009,"totalTrials":122,"cells":44010},"AZD5099",{"EARLY_PHASE1":44011,"PHASE1":44013,"PHASE2":44021,"PHASE3":44023,"PHASE4":44025,"NA":44027},{"trials":44012,"activeCount":102},[],{"trials":44014,"activeCount":102},[44015],{"nctId":44016,"briefTitle":44017,"status":2744,"phases":44018,"primaryCompletion":2589,"completion":2589,"start":2615,"enrollment":1395,"conditions":44019,"interventions":44020},"NCT01340183","Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects",[90],[19],[44009],{"trials":44022,"activeCount":102},[],{"trials":44024,"activeCount":102},[],{"trials":44026,"activeCount":102},[],{"trials":44028,"activeCount":102},[],{"intervention":40096,"totalTrials":122,"cells":44030},{"EARLY_PHASE1":44031,"PHASE1":44033,"PHASE2":44039,"PHASE3":44041,"PHASE4":44043,"NA":44045},{"trials":44032,"activeCount":102},[],{"trials":44034,"activeCount":102},[44035],{"nctId":40089,"briefTitle":40090,"status":195,"phases":44036,"primaryCompletion":2055,"completion":2055,"start":2067,"enrollment":113,"conditions":44037,"interventions":44038},[90],[40093],[40095,40096,19229],{"trials":44040,"activeCount":102},[],{"trials":44042,"activeCount":102},[],{"trials":44044,"activeCount":102},[],{"trials":44046,"activeCount":102},[],{"intervention":44048,"totalTrials":122,"cells":44049},"D1000078",{"EARLY_PHASE1":44050,"PHASE1":44052,"PHASE2":44069,"PHASE3":44071,"PHASE4":44073,"NA":44075},{"trials":44051,"activeCount":102},[],{"trials":44053,"activeCount":102},[44054],{"nctId":44055,"briefTitle":44056,"status":195,"phases":44057,"primaryCompletion":2349,"completion":2349,"start":2489,"enrollment":723,"conditions":44058,"interventions":44065},"NCT01224587","Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions",[90],[44059,44060,44061,44062,44063,44064],"Magnetic Marker Monitoring","Gastrointestinal-transport","Gastric Emptying Time","Small Intestinal Transit Time","Time for Colon Arrival","Food Effect",[44048,44066,44067,44068],"D1000082","D1000083","D1000085",{"trials":44070,"activeCount":102},[],{"trials":44072,"activeCount":102},[],{"trials":44074,"activeCount":102},[],{"trials":44076,"activeCount":102},[],{"intervention":44066,"totalTrials":122,"cells":44078},{"EARLY_PHASE1":44079,"PHASE1":44081,"PHASE2":44087,"PHASE3":44089,"PHASE4":44091,"NA":44093},{"trials":44080,"activeCount":102},[],{"trials":44082,"activeCount":102},[44083],{"nctId":44055,"briefTitle":44056,"status":195,"phases":44084,"primaryCompletion":2349,"completion":2349,"start":2489,"enrollment":723,"conditions":44085,"interventions":44086},[90],[44059,44060,44061,44062,44063,44064],[44048,44066,44067,44068],{"trials":44088,"activeCount":102},[],{"trials":44090,"activeCount":102},[],{"trials":44092,"activeCount":102},[],{"trials":44094,"activeCount":102},[],{"intervention":44067,"totalTrials":122,"cells":44096},{"EARLY_PHASE1":44097,"PHASE1":44099,"PHASE2":44105,"PHASE3":44107,"PHASE4":44109,"NA":44111},{"trials":44098,"activeCount":102},[],{"trials":44100,"activeCount":102},[44101],{"nctId":44055,"briefTitle":44056,"status":195,"phases":44102,"primaryCompletion":2349,"completion":2349,"start":2489,"enrollment":723,"conditions":44103,"interventions":44104},[90],[44059,44060,44061,44062,44063,44064],[44048,44066,44067,44068],{"trials":44106,"activeCount":102},[],{"trials":44108,"activeCount":102},[],{"trials":44110,"activeCount":102},[],{"trials":44112,"activeCount":102},[],{"intervention":44068,"totalTrials":122,"cells":44114},{"EARLY_PHASE1":44115,"PHASE1":44117,"PHASE2":44123,"PHASE3":44125,"PHASE4":44127,"NA":44129},{"trials":44116,"activeCount":102},[],{"trials":44118,"activeCount":102},[44119],{"nctId":44055,"briefTitle":44056,"status":195,"phases":44120,"primaryCompletion":2349,"completion":2349,"start":2489,"enrollment":723,"conditions":44121,"interventions":44122},[90],[44059,44060,44061,44062,44063,44064],[44048,44066,44067,44068],{"trials":44124,"activeCount":102},[],{"trials":44126,"activeCount":102},[],{"trials":44128,"activeCount":102},[],{"trials":44130,"activeCount":102},[],{"intervention":44132,"totalTrials":122,"cells":44133},"MEDI9447",{"EARLY_PHASE1":44134,"PHASE1":44136,"PHASE2":44144,"PHASE3":44146,"PHASE4":44148,"NA":44150},{"trials":44135,"activeCount":102},[],{"trials":44137,"activeCount":102},[44138],{"nctId":44139,"briefTitle":44140,"status":195,"phases":44141,"primaryCompletion":6069,"completion":6069,"start":12150,"enrollment":1039,"conditions":44142,"interventions":44143},"NCT03736473","A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients",[90],[157],[44132],{"trials":44145,"activeCount":102},[],{"trials":44147,"activeCount":102},[],{"trials":44149,"activeCount":102},[],{"trials":44151,"activeCount":102},[],{"intervention":44153,"totalTrials":122,"cells":44154},"AZD7442 IM",{"EARLY_PHASE1":44155,"PHASE1":44157,"PHASE2":44168,"PHASE3":44170,"PHASE4":44172,"NA":44174},{"trials":44156,"activeCount":102},[],{"trials":44158,"activeCount":102},[44159],{"nctId":44160,"briefTitle":44161,"status":195,"phases":44162,"primaryCompletion":44163,"completion":4771,"start":44164,"enrollment":22212,"conditions":44165,"interventions":44166},"NCT05437289","A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults",[90],"2021-11-27","2021-10-09",[23947,31837],[44153,44153,44167,44167],"AZD7442 IV",{"trials":44169,"activeCount":102},[],{"trials":44171,"activeCount":102},[],{"trials":44173,"activeCount":102},[],{"trials":44175,"activeCount":102},[],{"intervention":44167,"totalTrials":122,"cells":44177},{"EARLY_PHASE1":44178,"PHASE1":44180,"PHASE2":44186,"PHASE3":44188,"PHASE4":44190,"NA":44192},{"trials":44179,"activeCount":102},[],{"trials":44181,"activeCount":102},[44182],{"nctId":44160,"briefTitle":44161,"status":195,"phases":44183,"primaryCompletion":44163,"completion":4771,"start":44164,"enrollment":22212,"conditions":44184,"interventions":44185},[90],[23947,31837],[44153,44153,44167,44167],{"trials":44187,"activeCount":102},[],{"trials":44189,"activeCount":102},[],{"trials":44191,"activeCount":102},[],{"trials":44193,"activeCount":102},[],{"intervention":44195,"totalTrials":122,"cells":44196},"AZD4785",{"EARLY_PHASE1":44197,"PHASE1":44199,"PHASE2":44208,"PHASE3":44210,"PHASE4":44212,"NA":44214},{"trials":44198,"activeCount":102},[],{"trials":44200,"activeCount":102},[44201],{"nctId":44202,"briefTitle":44203,"status":195,"phases":44204,"primaryCompletion":44205,"completion":44205,"start":23576,"enrollment":2260,"conditions":44206,"interventions":44207},"NCT03101839","Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours",[90],"2019-01-08",[262,498],[44195],{"trials":44209,"activeCount":102},[],{"trials":44211,"activeCount":102},[],{"trials":44213,"activeCount":102},[],{"trials":44215,"activeCount":102},[],{"intervention":19595,"totalTrials":122,"cells":44217},{"EARLY_PHASE1":44218,"PHASE1":44220,"PHASE2":44226,"PHASE3":44228,"PHASE4":44230,"NA":44232},{"trials":44219,"activeCount":102},[],{"trials":44221,"activeCount":102},[44222],{"nctId":19590,"briefTitle":19591,"status":195,"phases":44223,"primaryCompletion":2675,"completion":2675,"start":2349,"enrollment":3180,"conditions":44224,"interventions":44225},[90],[36],[19228,19595],{"trials":44227,"activeCount":102},[],{"trials":44229,"activeCount":102},[],{"trials":44231,"activeCount":102},[],{"trials":44233,"activeCount":102},[],{"intervention":44235,"totalTrials":122,"cells":44236},"Auto-injector with exenatide suspension",{"EARLY_PHASE1":44237,"PHASE1":44239,"PHASE2":44249,"PHASE3":44251,"PHASE4":44253,"NA":44255},{"trials":44238,"activeCount":102},[],{"trials":44240,"activeCount":102},[44241],{"nctId":44242,"briefTitle":44243,"status":195,"phases":44244,"primaryCompletion":39977,"completion":39977,"start":2405,"enrollment":44245,"conditions":44246,"interventions":44247},"NCT02349802","Autoinjector Device Assessment Study",[90],3052,[1556],[44235,44248],"Syringe with exenatide suspension",{"trials":44250,"activeCount":102},[],{"trials":44252,"activeCount":102},[],{"trials":44254,"activeCount":102},[],{"trials":44256,"activeCount":102},[],{"intervention":44248,"totalTrials":122,"cells":44258},{"EARLY_PHASE1":44259,"PHASE1":44261,"PHASE2":44267,"PHASE3":44269,"PHASE4":44271,"NA":44273},{"trials":44260,"activeCount":102},[],{"trials":44262,"activeCount":102},[44263],{"nctId":44242,"briefTitle":44243,"status":195,"phases":44264,"primaryCompletion":39977,"completion":39977,"start":2405,"enrollment":44245,"conditions":44265,"interventions":44266},[90],[1556],[44235,44248],{"trials":44268,"activeCount":102},[],{"trials":44270,"activeCount":102},[],{"trials":44272,"activeCount":102},[],{"trials":44274,"activeCount":102},[],{"intervention":44276,"totalTrials":122,"cells":44277},"cotadutide solution for",{"EARLY_PHASE1":44278,"PHASE1":44280,"PHASE2":44288,"PHASE3":44290,"PHASE4":44292,"NA":44294},{"trials":44279,"activeCount":102},[],{"trials":44281,"activeCount":102},[44282],{"nctId":44283,"briefTitle":44284,"status":195,"phases":44285,"primaryCompletion":1497,"completion":1497,"start":3694,"enrollment":269,"conditions":44286,"interventions":44287},"NCT05294458","A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects",[90],[12328,2059,2134],[44276],{"trials":44289,"activeCount":102},[],{"trials":44291,"activeCount":102},[],{"trials":44293,"activeCount":102},[],{"trials":44295,"activeCount":102},[],{"intervention":40895,"totalTrials":122,"cells":44297},{"EARLY_PHASE1":44298,"PHASE1":44300,"PHASE2":44306,"PHASE3":44308,"PHASE4":44310,"NA":44312},{"trials":44299,"activeCount":102},[],{"trials":44301,"activeCount":102},[44302],{"nctId":40890,"briefTitle":40891,"status":195,"phases":44303,"primaryCompletion":2432,"completion":2432,"start":687,"enrollment":3524,"conditions":44304,"interventions":44305},[90],[23317],[40895,13160,40896,40546],{"trials":44307,"activeCount":102},[],{"trials":44309,"activeCount":102},[],{"trials":44311,"activeCount":102},[],{"trials":44313,"activeCount":102},[],{"intervention":40896,"totalTrials":122,"cells":44315},{"EARLY_PHASE1":44316,"PHASE1":44318,"PHASE2":44324,"PHASE3":44326,"PHASE4":44328,"NA":44330},{"trials":44317,"activeCount":102},[],{"trials":44319,"activeCount":102},[44320],{"nctId":40890,"briefTitle":40891,"status":195,"phases":44321,"primaryCompletion":2432,"completion":2432,"start":687,"enrollment":3524,"conditions":44322,"interventions":44323},[90],[23317],[40895,13160,40896,40546],{"trials":44325,"activeCount":102},[],{"trials":44327,"activeCount":102},[],{"trials":44329,"activeCount":102},[],{"trials":44331,"activeCount":102},[],{"intervention":44333,"totalTrials":122,"cells":44334},"budesonide\u002Falbuterol sulfate metered dose inhaleor",{"EARLY_PHASE1":44335,"PHASE1":44337,"PHASE2":44346,"PHASE3":44348,"PHASE4":44350,"NA":44352},{"trials":44336,"activeCount":102},[],{"trials":44338,"activeCount":102},[44339],{"nctId":44340,"briefTitle":44341,"status":195,"phases":44342,"primaryCompletion":6132,"completion":6132,"start":44343,"enrollment":1638,"conditions":44344,"interventions":44345},"NCT06514157","Phase I PK Study of Budesonide\u002FAlbuterol Delivered From PT027 in Healthy Chinese Participants.",[90],"2024-08-19",[31837],[44333],{"trials":44347,"activeCount":102},[],{"trials":44349,"activeCount":102},[],{"trials":44351,"activeCount":102},[],{"trials":44353,"activeCount":102},[],{"intervention":44355,"totalTrials":122,"cells":44356},"Part A: AZD8186 monotherapy",{"EARLY_PHASE1":44357,"PHASE1":44359,"PHASE2":44377,"PHASE3":44379,"PHASE4":44381,"NA":44383},{"trials":44358,"activeCount":102},[],{"trials":44360,"activeCount":102},[44361],{"nctId":44362,"briefTitle":44363,"status":195,"phases":44364,"primaryCompletion":44365,"completion":14060,"start":44366,"enrollment":1151,"conditions":44367,"interventions":44371},"NCT01884285","AZD8186 First Time In Patient Ascending Dose Study",[90],"2019-03-31","2013-07-09",[44368,44369,44370],"Advanced Castrate-resistant Prostate Cancer CRPC","Squamous Non-Small Cell Lung Cancer sqNSCLC","Triple Negative Breast Cancer TNBC",[44355,44372,44373,44374,44375,44376],"Part B: AZD8186 monotherapy","Part C1: Abiraterone acetate combination with AZD8186","Part D1: AZD2014 combination with AZD8186","Part D2 AZD2014 combination with AZD8186","Part C2: Abiraterone acetate combination with AZD8186",{"trials":44378,"activeCount":102},[],{"trials":44380,"activeCount":102},[],{"trials":44382,"activeCount":102},[],{"trials":44384,"activeCount":102},[],{"intervention":44372,"totalTrials":122,"cells":44386},{"EARLY_PHASE1":44387,"PHASE1":44389,"PHASE2":44395,"PHASE3":44397,"PHASE4":44399,"NA":44401},{"trials":44388,"activeCount":102},[],{"trials":44390,"activeCount":102},[44391],{"nctId":44362,"briefTitle":44363,"status":195,"phases":44392,"primaryCompletion":44365,"completion":14060,"start":44366,"enrollment":1151,"conditions":44393,"interventions":44394},[90],[44368,44369,44370],[44355,44372,44373,44374,44375,44376],{"trials":44396,"activeCount":102},[],{"trials":44398,"activeCount":102},[],{"trials":44400,"activeCount":102},[],{"trials":44402,"activeCount":102},[],{"intervention":44373,"totalTrials":122,"cells":44404},{"EARLY_PHASE1":44405,"PHASE1":44407,"PHASE2":44413,"PHASE3":44415,"PHASE4":44417,"NA":44419},{"trials":44406,"activeCount":102},[],{"trials":44408,"activeCount":102},[44409],{"nctId":44362,"briefTitle":44363,"status":195,"phases":44410,"primaryCompletion":44365,"completion":14060,"start":44366,"enrollment":1151,"conditions":44411,"interventions":44412},[90],[44368,44369,44370],[44355,44372,44373,44374,44375,44376],{"trials":44414,"activeCount":102},[],{"trials":44416,"activeCount":102},[],{"trials":44418,"activeCount":102},[],{"trials":44420,"activeCount":102},[],{"intervention":44374,"totalTrials":122,"cells":44422},{"EARLY_PHASE1":44423,"PHASE1":44425,"PHASE2":44431,"PHASE3":44433,"PHASE4":44435,"NA":44437},{"trials":44424,"activeCount":102},[],{"trials":44426,"activeCount":102},[44427],{"nctId":44362,"briefTitle":44363,"status":195,"phases":44428,"primaryCompletion":44365,"completion":14060,"start":44366,"enrollment":1151,"conditions":44429,"interventions":44430},[90],[44368,44369,44370],[44355,44372,44373,44374,44375,44376],{"trials":44432,"activeCount":102},[],{"trials":44434,"activeCount":102},[],{"trials":44436,"activeCount":102},[],{"trials":44438,"activeCount":102},[],{"intervention":44375,"totalTrials":122,"cells":44440},{"EARLY_PHASE1":44441,"PHASE1":44443,"PHASE2":44449,"PHASE3":44451,"PHASE4":44453,"NA":44455},{"trials":44442,"activeCount":102},[],{"trials":44444,"activeCount":102},[44445],{"nctId":44362,"briefTitle":44363,"status":195,"phases":44446,"primaryCompletion":44365,"completion":14060,"start":44366,"enrollment":1151,"conditions":44447,"interventions":44448},[90],[44368,44369,44370],[44355,44372,44373,44374,44375,44376],{"trials":44450,"activeCount":102},[],{"trials":44452,"activeCount":102},[],{"trials":44454,"activeCount":102},[],{"trials":44456,"activeCount":102},[],{"intervention":44376,"totalTrials":122,"cells":44458},{"EARLY_PHASE1":44459,"PHASE1":44461,"PHASE2":44467,"PHASE3":44469,"PHASE4":44471,"NA":44473},{"trials":44460,"activeCount":102},[],{"trials":44462,"activeCount":102},[44463],{"nctId":44362,"briefTitle":44363,"status":195,"phases":44464,"primaryCompletion":44365,"completion":14060,"start":44366,"enrollment":1151,"conditions":44465,"interventions":44466},[90],[44368,44369,44370],[44355,44372,44373,44374,44375,44376],{"trials":44468,"activeCount":102},[],{"trials":44470,"activeCount":102},[],{"trials":44472,"activeCount":102},[],{"trials":44474,"activeCount":102},[],{"intervention":44476,"totalTrials":122,"cells":44477},"NKTR118 Group1",{"EARLY_PHASE1":44478,"PHASE1":44480,"PHASE2":44491,"PHASE3":44493,"PHASE4":44495,"NA":44497},{"trials":44479,"activeCount":102},[],{"trials":44481,"activeCount":102},[44482],{"nctId":44483,"briefTitle":44484,"status":195,"phases":44485,"primaryCompletion":2736,"completion":4580,"start":2542,"enrollment":579,"conditions":44486,"interventions":44487},"NCT01372826","Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function",[90],[2279],[44476,44488,44489,44490],"NKTR118 Group 2","NKTR118 Group3","NKTR118",{"trials":44492,"activeCount":102},[],{"trials":44494,"activeCount":102},[],{"trials":44496,"activeCount":102},[],{"trials":44498,"activeCount":102},[],{"intervention":44488,"totalTrials":122,"cells":44500},{"EARLY_PHASE1":44501,"PHASE1":44503,"PHASE2":44509,"PHASE3":44511,"PHASE4":44513,"NA":44515},{"trials":44502,"activeCount":102},[],{"trials":44504,"activeCount":102},[44505],{"nctId":44483,"briefTitle":44484,"status":195,"phases":44506,"primaryCompletion":2736,"completion":4580,"start":2542,"enrollment":579,"conditions":44507,"interventions":44508},[90],[2279],[44476,44488,44489,44490],{"trials":44510,"activeCount":102},[],{"trials":44512,"activeCount":102},[],{"trials":44514,"activeCount":102},[],{"trials":44516,"activeCount":102},[],{"intervention":44489,"totalTrials":122,"cells":44518},{"EARLY_PHASE1":44519,"PHASE1":44521,"PHASE2":44527,"PHASE3":44529,"PHASE4":44531,"NA":44533},{"trials":44520,"activeCount":102},[],{"trials":44522,"activeCount":102},[44523],{"nctId":44483,"briefTitle":44484,"status":195,"phases":44524,"primaryCompletion":2736,"completion":4580,"start":2542,"enrollment":579,"conditions":44525,"interventions":44526},[90],[2279],[44476,44488,44489,44490],{"trials":44528,"activeCount":102},[],{"trials":44530,"activeCount":102},[],{"trials":44532,"activeCount":102},[],{"trials":44534,"activeCount":102},[],{"intervention":44490,"totalTrials":122,"cells":44536},{"EARLY_PHASE1":44537,"PHASE1":44539,"PHASE2":44545,"PHASE3":44547,"PHASE4":44549,"NA":44551},{"trials":44538,"activeCount":102},[],{"trials":44540,"activeCount":102},[44541],{"nctId":44483,"briefTitle":44484,"status":195,"phases":44542,"primaryCompletion":2736,"completion":4580,"start":2542,"enrollment":579,"conditions":44543,"interventions":44544},[90],[2279],[44476,44488,44489,44490],{"trials":44546,"activeCount":102},[],{"trials":44548,"activeCount":102},[],{"trials":44550,"activeCount":102},[],{"trials":44552,"activeCount":102},[],{"intervention":44554,"totalTrials":122,"cells":44555},"MEDI-573",{"EARLY_PHASE1":44556,"PHASE1":44558,"PHASE2":44566,"PHASE3":44568,"PHASE4":44570,"NA":44572},{"trials":44557,"activeCount":102},[],{"trials":44559,"activeCount":102},[44560],{"nctId":44561,"briefTitle":44562,"status":195,"phases":44563,"primaryCompletion":4496,"completion":10063,"start":6709,"enrollment":269,"conditions":44564,"interventions":44565},"NCT01340040","Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects",[90],[556,157],[44554],{"trials":44567,"activeCount":102},[],{"trials":44569,"activeCount":102},[],{"trials":44571,"activeCount":102},[],{"trials":44573,"activeCount":102},[],{"intervention":44575,"totalTrials":122,"cells":44576},"[C14] selumetinib",{"EARLY_PHASE1":44577,"PHASE1":44579,"PHASE2":44587,"PHASE3":44589,"PHASE4":44591,"NA":44593},{"trials":44578,"activeCount":102},[],{"trials":44580,"activeCount":102},[44581],{"nctId":44582,"briefTitle":44583,"status":195,"phases":44584,"primaryCompletion":1693,"completion":1693,"start":4204,"enrollment":1039,"conditions":44585,"interventions":44586},"NCT01931761","Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers",[90],[466],[44575],{"trials":44588,"activeCount":102},[],{"trials":44590,"activeCount":102},[],{"trials":44592,"activeCount":102},[],{"trials":44594,"activeCount":102},[],{"intervention":19197,"totalTrials":122,"cells":44596},{"EARLY_PHASE1":44597,"PHASE1":44599,"PHASE2":44605,"PHASE3":44607,"PHASE4":44609,"NA":44611},{"trials":44598,"activeCount":102},[],{"trials":44600,"activeCount":102},[44601],{"nctId":19192,"briefTitle":19193,"status":195,"phases":44602,"primaryCompletion":5417,"completion":5417,"start":659,"enrollment":1510,"conditions":44603,"interventions":44604},[90],[2619],[19197,12616,19198],{"trials":44606,"activeCount":102},[],{"trials":44608,"activeCount":102},[],{"trials":44610,"activeCount":102},[],{"trials":44612,"activeCount":102},[],{"intervention":18973,"totalTrials":122,"cells":44614},{"EARLY_PHASE1":44615,"PHASE1":44617,"PHASE2":44623,"PHASE3":44625,"PHASE4":44627,"NA":44629},{"trials":44616,"activeCount":102},[],{"trials":44618,"activeCount":102},[44619],{"nctId":18968,"briefTitle":18969,"status":195,"phases":44620,"primaryCompletion":4580,"completion":4580,"start":2542,"enrollment":8138,"conditions":44621,"interventions":44622},[90],[22],[18973,2108,18974,18975,2173],{"trials":44624,"activeCount":102},[],{"trials":44626,"activeCount":102},[],{"trials":44628,"activeCount":102},[],{"trials":44630,"activeCount":102},[],{"intervention":18974,"totalTrials":122,"cells":44632},{"EARLY_PHASE1":44633,"PHASE1":44635,"PHASE2":44641,"PHASE3":44643,"PHASE4":44645,"NA":44647},{"trials":44634,"activeCount":102},[],{"trials":44636,"activeCount":102},[44637],{"nctId":18968,"briefTitle":18969,"status":195,"phases":44638,"primaryCompletion":4580,"completion":4580,"start":2542,"enrollment":8138,"conditions":44639,"interventions":44640},[90],[22],[18973,2108,18974,18975,2173],{"trials":44642,"activeCount":102},[],{"trials":44644,"activeCount":102},[],{"trials":44646,"activeCount":102},[],{"trials":44648,"activeCount":102},[],{"intervention":18975,"totalTrials":122,"cells":44650},{"EARLY_PHASE1":44651,"PHASE1":44653,"PHASE2":44659,"PHASE3":44661,"PHASE4":44663,"NA":44665},{"trials":44652,"activeCount":102},[],{"trials":44654,"activeCount":102},[44655],{"nctId":18968,"briefTitle":18969,"status":195,"phases":44656,"primaryCompletion":4580,"completion":4580,"start":2542,"enrollment":8138,"conditions":44657,"interventions":44658},[90],[22],[18973,2108,18974,18975,2173],{"trials":44660,"activeCount":102},[],{"trials":44662,"activeCount":102},[],{"trials":44664,"activeCount":102},[],{"trials":44666,"activeCount":102},[],{"intervention":40598,"totalTrials":122,"cells":44668},{"EARLY_PHASE1":44669,"PHASE1":44671,"PHASE2":44677,"PHASE3":44679,"PHASE4":44681,"NA":44683},{"trials":44670,"activeCount":102},[],{"trials":44672,"activeCount":102},[44673],{"nctId":40591,"briefTitle":40592,"status":195,"phases":44674,"primaryCompletion":40594,"completion":40594,"start":37719,"enrollment":1638,"conditions":44675,"interventions":44676},[90],[6083,16],[40597,40576,40598,40599],{"trials":44678,"activeCount":102},[],{"trials":44680,"activeCount":102},[],{"trials":44682,"activeCount":102},[],{"trials":44684,"activeCount":102},[],{"intervention":40599,"totalTrials":122,"cells":44686},{"EARLY_PHASE1":44687,"PHASE1":44689,"PHASE2":44695,"PHASE3":44697,"PHASE4":44699,"NA":44701},{"trials":44688,"activeCount":102},[],{"trials":44690,"activeCount":102},[44691],{"nctId":40591,"briefTitle":40592,"status":195,"phases":44692,"primaryCompletion":40594,"completion":40594,"start":37719,"enrollment":1638,"conditions":44693,"interventions":44694},[90],[6083,16],[40597,40576,40598,40599],{"trials":44696,"activeCount":102},[],{"trials":44698,"activeCount":102},[],{"trials":44700,"activeCount":102},[],{"trials":44702,"activeCount":102},[],{"intervention":44704,"totalTrials":122,"cells":44705},"Dapagliflozin + Glucophage tablet fasted",{"EARLY_PHASE1":44706,"PHASE1":44708,"PHASE2":44719,"PHASE3":44721,"PHASE4":44723,"NA":44725},{"trials":44707,"activeCount":102},[],{"trials":44709,"activeCount":102},[44710],{"nctId":44711,"briefTitle":44712,"status":195,"phases":44713,"primaryCompletion":13856,"completion":13856,"start":19426,"enrollment":34,"conditions":44714,"interventions":44715},"NCT01535677","To Compare the Similarity of a Combination Dapagliflozin\u002FMetformin Tablet With the Two Drugs Administered Separately",[90],[22],[44704,44716,44717,44718],"Dapagliflozin\u002Fmetformin IR FDC tablet fasted","Dapagliflozin + Glucophage tablet fed","Dapagliflozin\u002Fmetformin IR FDC tablet fed",{"trials":44720,"activeCount":102},[],{"trials":44722,"activeCount":102},[],{"trials":44724,"activeCount":102},[],{"trials":44726,"activeCount":102},[],{"intervention":44716,"totalTrials":122,"cells":44728},{"EARLY_PHASE1":44729,"PHASE1":44731,"PHASE2":44737,"PHASE3":44739,"PHASE4":44741,"NA":44743},{"trials":44730,"activeCount":102},[],{"trials":44732,"activeCount":102},[44733],{"nctId":44711,"briefTitle":44712,"status":195,"phases":44734,"primaryCompletion":13856,"completion":13856,"start":19426,"enrollment":34,"conditions":44735,"interventions":44736},[90],[22],[44704,44716,44717,44718],{"trials":44738,"activeCount":102},[],{"trials":44740,"activeCount":102},[],{"trials":44742,"activeCount":102},[],{"trials":44744,"activeCount":102},[],{"intervention":44717,"totalTrials":122,"cells":44746},{"EARLY_PHASE1":44747,"PHASE1":44749,"PHASE2":44755,"PHASE3":44757,"PHASE4":44759,"NA":44761},{"trials":44748,"activeCount":102},[],{"trials":44750,"activeCount":102},[44751],{"nctId":44711,"briefTitle":44712,"status":195,"phases":44752,"primaryCompletion":13856,"completion":13856,"start":19426,"enrollment":34,"conditions":44753,"interventions":44754},[90],[22],[44704,44716,44717,44718],{"trials":44756,"activeCount":102},[],{"trials":44758,"activeCount":102},[],{"trials":44760,"activeCount":102},[],{"trials":44762,"activeCount":102},[],{"intervention":44718,"totalTrials":122,"cells":44764},{"EARLY_PHASE1":44765,"PHASE1":44767,"PHASE2":44773,"PHASE3":44775,"PHASE4":44777,"NA":44779},{"trials":44766,"activeCount":102},[],{"trials":44768,"activeCount":102},[44769],{"nctId":44711,"briefTitle":44712,"status":195,"phases":44770,"primaryCompletion":13856,"completion":13856,"start":19426,"enrollment":34,"conditions":44771,"interventions":44772},[90],[22],[44704,44716,44717,44718],{"trials":44774,"activeCount":102},[],{"trials":44776,"activeCount":102},[],{"trials":44778,"activeCount":102},[],{"trials":44780,"activeCount":102},[],{"intervention":44782,"totalTrials":122,"cells":44783},"AZD3241 ER formulation 1",{"EARLY_PHASE1":44784,"PHASE1":44786,"PHASE2":44795,"PHASE3":44797,"PHASE4":44799,"NA":44801},{"trials":44785,"activeCount":102},[],{"trials":44787,"activeCount":102},[44788],{"nctId":44789,"briefTitle":44790,"status":195,"phases":44791,"primaryCompletion":2589,"completion":2589,"start":4580,"enrollment":1130,"conditions":44792,"interventions":44793},"NCT01457807","To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers",[90],[36831],[44782,44794],"AZD3241 Alternative titration scheme with formulation 1 or 2",{"trials":44796,"activeCount":102},[],{"trials":44798,"activeCount":102},[],{"trials":44800,"activeCount":102},[],{"trials":44802,"activeCount":102},[],{"intervention":44794,"totalTrials":122,"cells":44804},{"EARLY_PHASE1":44805,"PHASE1":44807,"PHASE2":44813,"PHASE3":44815,"PHASE4":44817,"NA":44819},{"trials":44806,"activeCount":102},[],{"trials":44808,"activeCount":102},[44809],{"nctId":44789,"briefTitle":44790,"status":195,"phases":44810,"primaryCompletion":2589,"completion":2589,"start":4580,"enrollment":1130,"conditions":44811,"interventions":44812},[90],[36831],[44782,44794],{"trials":44814,"activeCount":102},[],{"trials":44816,"activeCount":102},[],{"trials":44818,"activeCount":102},[],{"trials":44820,"activeCount":102},[],{"intervention":41778,"totalTrials":122,"cells":44822},{"EARLY_PHASE1":44823,"PHASE1":44825,"PHASE2":44831,"PHASE3":44833,"PHASE4":44835,"NA":44837},{"trials":44824,"activeCount":102},[],{"trials":44826,"activeCount":102},[44827],{"nctId":41773,"briefTitle":41774,"status":195,"phases":44828,"primaryCompletion":2298,"completion":2298,"start":21019,"enrollment":1448,"conditions":44829,"interventions":44830},[90],[24602,1556],[41766,41778,41779,41780],{"trials":44832,"activeCount":102},[],{"trials":44834,"activeCount":102},[],{"trials":44836,"activeCount":102},[],{"trials":44838,"activeCount":102},[],{"intervention":41779,"totalTrials":122,"cells":44840},{"EARLY_PHASE1":44841,"PHASE1":44843,"PHASE2":44849,"PHASE3":44851,"PHASE4":44853,"NA":44855},{"trials":44842,"activeCount":102},[],{"trials":44844,"activeCount":102},[44845],{"nctId":41773,"briefTitle":41774,"status":195,"phases":44846,"primaryCompletion":2298,"completion":2298,"start":21019,"enrollment":1448,"conditions":44847,"interventions":44848},[90],[24602,1556],[41766,41778,41779,41780],{"trials":44850,"activeCount":102},[],{"trials":44852,"activeCount":102},[],{"trials":44854,"activeCount":102},[],{"trials":44856,"activeCount":102},[],{"intervention":41780,"totalTrials":122,"cells":44858},{"EARLY_PHASE1":44859,"PHASE1":44861,"PHASE2":44867,"PHASE3":44869,"PHASE4":44871,"NA":44873},{"trials":44860,"activeCount":102},[],{"trials":44862,"activeCount":102},[44863],{"nctId":41773,"briefTitle":41774,"status":195,"phases":44864,"primaryCompletion":2298,"completion":2298,"start":21019,"enrollment":1448,"conditions":44865,"interventions":44866},[90],[24602,1556],[41766,41778,41779,41780],{"trials":44868,"activeCount":102},[],{"trials":44870,"activeCount":102},[],{"trials":44872,"activeCount":102},[],{"trials":44874,"activeCount":102},[],{"intervention":44876,"totalTrials":122,"cells":44877},"AZD8601+Placebo",{"EARLY_PHASE1":44878,"PHASE1":44880,"PHASE2":44892,"PHASE3":44894,"PHASE4":44896,"NA":44898},{"trials":44879,"activeCount":102},[],{"trials":44881,"activeCount":102},[44882],{"nctId":44883,"briefTitle":44884,"status":195,"phases":44885,"primaryCompletion":44886,"completion":44887,"start":44888,"enrollment":3811,"conditions":44889,"interventions":44891},"NCT02935712","Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)",[90],"2017-08-04","2018-01-08","2016-12-16",[44890],"Male Subjects With Type II Diabetes (T2DM)",[44876,44876],{"trials":44893,"activeCount":102},[],{"trials":44895,"activeCount":102},[],{"trials":44897,"activeCount":102},[],{"trials":44899,"activeCount":102},[],{"intervention":39886,"totalTrials":122,"cells":44901},{"EARLY_PHASE1":44902,"PHASE1":44904,"PHASE2":44910,"PHASE3":44912,"PHASE4":44914,"NA":44916},{"trials":44903,"activeCount":102},[],{"trials":44905,"activeCount":102},[44906],{"nctId":39879,"briefTitle":39880,"status":195,"phases":44907,"primaryCompletion":39882,"completion":39882,"start":39883,"enrollment":5876,"conditions":44908,"interventions":44909},[90],[1520],[16475,16476,16477,16478,39886,39887,39888,39889],{"trials":44911,"activeCount":102},[],{"trials":44913,"activeCount":102},[],{"trials":44915,"activeCount":102},[],{"trials":44917,"activeCount":102},[],{"intervention":39887,"totalTrials":122,"cells":44919},{"EARLY_PHASE1":44920,"PHASE1":44922,"PHASE2":44928,"PHASE3":44930,"PHASE4":44932,"NA":44934},{"trials":44921,"activeCount":102},[],{"trials":44923,"activeCount":102},[44924],{"nctId":39879,"briefTitle":39880,"status":195,"phases":44925,"primaryCompletion":39882,"completion":39882,"start":39883,"enrollment":5876,"conditions":44926,"interventions":44927},[90],[1520],[16475,16476,16477,16478,39886,39887,39888,39889],{"trials":44929,"activeCount":102},[],{"trials":44931,"activeCount":102},[],{"trials":44933,"activeCount":102},[],{"trials":44935,"activeCount":102},[],{"intervention":39888,"totalTrials":122,"cells":44937},{"EARLY_PHASE1":44938,"PHASE1":44940,"PHASE2":44946,"PHASE3":44948,"PHASE4":44950,"NA":44952},{"trials":44939,"activeCount":102},[],{"trials":44941,"activeCount":102},[44942],{"nctId":39879,"briefTitle":39880,"status":195,"phases":44943,"primaryCompletion":39882,"completion":39882,"start":39883,"enrollment":5876,"conditions":44944,"interventions":44945},[90],[1520],[16475,16476,16477,16478,39886,39887,39888,39889],{"trials":44947,"activeCount":102},[],{"trials":44949,"activeCount":102},[],{"trials":44951,"activeCount":102},[],{"trials":44953,"activeCount":102},[],{"intervention":39889,"totalTrials":122,"cells":44955},{"EARLY_PHASE1":44956,"PHASE1":44958,"PHASE2":44964,"PHASE3":44966,"PHASE4":44968,"NA":44970},{"trials":44957,"activeCount":102},[],{"trials":44959,"activeCount":102},[44960],{"nctId":39879,"briefTitle":39880,"status":195,"phases":44961,"primaryCompletion":39882,"completion":39882,"start":39883,"enrollment":5876,"conditions":44962,"interventions":44963},[90],[1520],[16475,16476,16477,16478,39886,39887,39888,39889],{"trials":44965,"activeCount":102},[],{"trials":44967,"activeCount":102},[],{"trials":44969,"activeCount":102},[],{"trials":44971,"activeCount":102},[],{"intervention":44973,"totalTrials":122,"cells":44974},"AZD5658",{"EARLY_PHASE1":44975,"PHASE1":44977,"PHASE2":44985,"PHASE3":44987,"PHASE4":44989,"NA":44991},{"trials":44976,"activeCount":102},[],{"trials":44978,"activeCount":102},[44979],{"nctId":44980,"briefTitle":44981,"status":195,"phases":44982,"primaryCompletion":2433,"completion":2433,"start":2406,"enrollment":1130,"conditions":44983,"interventions":44984},"NCT01176097","To Assess Safety, Tolerability, Pharmacokinetics\u002FPharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes",[90],[31],[44973],{"trials":44986,"activeCount":102},[],{"trials":44988,"activeCount":102},[],{"trials":44990,"activeCount":102},[],{"trials":44992,"activeCount":102},[],{"intervention":3034,"totalTrials":122,"cells":44994},{"EARLY_PHASE1":44995,"PHASE1":44997,"PHASE2":45003,"PHASE3":45005,"PHASE4":45007,"NA":45009},{"trials":44996,"activeCount":102},[],{"trials":44998,"activeCount":102},[44999],{"nctId":3018,"briefTitle":3019,"status":195,"phases":45000,"primaryCompletion":3021,"completion":3021,"start":2781,"enrollment":579,"conditions":45001,"interventions":45002},[90],[3023,3024,3025,249,3026,3027,3028,3029,3030,3031],[3033,3034,3035,3036,3037,900,3038,3039,3040],{"trials":45004,"activeCount":102},[],{"trials":45006,"activeCount":102},[],{"trials":45008,"activeCount":102},[],{"trials":45010,"activeCount":102},[],{"intervention":3036,"totalTrials":122,"cells":45012},{"EARLY_PHASE1":45013,"PHASE1":45015,"PHASE2":45021,"PHASE3":45023,"PHASE4":45025,"NA":45027},{"trials":45014,"activeCount":102},[],{"trials":45016,"activeCount":102},[45017],{"nctId":3018,"briefTitle":3019,"status":195,"phases":45018,"primaryCompletion":3021,"completion":3021,"start":2781,"enrollment":579,"conditions":45019,"interventions":45020},[90],[3023,3024,3025,249,3026,3027,3028,3029,3030,3031],[3033,3034,3035,3036,3037,900,3038,3039,3040],{"trials":45022,"activeCount":102},[],{"trials":45024,"activeCount":102},[],{"trials":45026,"activeCount":102},[],{"trials":45028,"activeCount":102},[],{"intervention":3037,"totalTrials":122,"cells":45030},{"EARLY_PHASE1":45031,"PHASE1":45033,"PHASE2":45039,"PHASE3":45041,"PHASE4":45043,"NA":45045},{"trials":45032,"activeCount":102},[],{"trials":45034,"activeCount":102},[45035],{"nctId":3018,"briefTitle":3019,"status":195,"phases":45036,"primaryCompletion":3021,"completion":3021,"start":2781,"enrollment":579,"conditions":45037,"interventions":45038},[90],[3023,3024,3025,249,3026,3027,3028,3029,3030,3031],[3033,3034,3035,3036,3037,900,3038,3039,3040],{"trials":45040,"activeCount":102},[],{"trials":45042,"activeCount":102},[],{"trials":45044,"activeCount":102},[],{"trials":45046,"activeCount":102},[],{"intervention":3039,"totalTrials":122,"cells":45048},{"EARLY_PHASE1":45049,"PHASE1":45051,"PHASE2":45057,"PHASE3":45059,"PHASE4":45061,"NA":45063},{"trials":45050,"activeCount":102},[],{"trials":45052,"activeCount":102},[45053],{"nctId":3018,"briefTitle":3019,"status":195,"phases":45054,"primaryCompletion":3021,"completion":3021,"start":2781,"enrollment":579,"conditions":45055,"interventions":45056},[90],[3023,3024,3025,249,3026,3027,3028,3029,3030,3031],[3033,3034,3035,3036,3037,900,3038,3039,3040],{"trials":45058,"activeCount":102},[],{"trials":45060,"activeCount":102},[],{"trials":45062,"activeCount":102},[],{"trials":45064,"activeCount":102},[],{"intervention":3040,"totalTrials":122,"cells":45066},{"EARLY_PHASE1":45067,"PHASE1":45069,"PHASE2":45075,"PHASE3":45077,"PHASE4":45079,"NA":45081},{"trials":45068,"activeCount":102},[],{"trials":45070,"activeCount":102},[45071],{"nctId":3018,"briefTitle":3019,"status":195,"phases":45072,"primaryCompletion":3021,"completion":3021,"start":2781,"enrollment":579,"conditions":45073,"interventions":45074},[90],[3023,3024,3025,249,3026,3027,3028,3029,3030,3031],[3033,3034,3035,3036,3037,900,3038,3039,3040],{"trials":45076,"activeCount":102},[],{"trials":45078,"activeCount":102},[],{"trials":45080,"activeCount":102},[],{"trials":45082,"activeCount":102},[],{"intervention":2174,"totalTrials":122,"cells":45084},{"EARLY_PHASE1":45085,"PHASE1":45087,"PHASE2":45093,"PHASE3":45095,"PHASE4":45097,"NA":45099},{"trials":45086,"activeCount":102},[],{"trials":45088,"activeCount":102},[45089],{"nctId":2165,"briefTitle":2166,"status":195,"phases":45090,"primaryCompletion":2168,"completion":2168,"start":2169,"enrollment":1336,"conditions":45091,"interventions":45092},[90],[2171],[2044,2173,2174],{"trials":45094,"activeCount":102},[],{"trials":45096,"activeCount":102},[],{"trials":45098,"activeCount":102},[],{"trials":45100,"activeCount":102},[],{"intervention":45102,"totalTrials":122,"cells":45103},"AZD9977, oral suspension",{"EARLY_PHASE1":45104,"PHASE1":45106,"PHASE2":45115,"PHASE3":45117,"PHASE4":45119,"NA":45121},{"trials":45105,"activeCount":102},[],{"trials":45107,"activeCount":102},[45108],{"nctId":45109,"briefTitle":45110,"status":195,"phases":45111,"primaryCompletion":20831,"completion":20831,"start":24772,"enrollment":12152,"conditions":45112,"interventions":45113},"NCT02484729","A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males",[90],[10052,24601,15776,1556],[45102,45114],"AZD9977, oral solution",{"trials":45116,"activeCount":102},[],{"trials":45118,"activeCount":102},[],{"trials":45120,"activeCount":102},[],{"trials":45122,"activeCount":102},[],{"intervention":45114,"totalTrials":122,"cells":45124},{"EARLY_PHASE1":45125,"PHASE1":45127,"PHASE2":45133,"PHASE3":45135,"PHASE4":45137,"NA":45139},{"trials":45126,"activeCount":102},[],{"trials":45128,"activeCount":102},[45129],{"nctId":45109,"briefTitle":45110,"status":195,"phases":45130,"primaryCompletion":20831,"completion":20831,"start":24772,"enrollment":12152,"conditions":45131,"interventions":45132},[90],[10052,24601,15776,1556],[45102,45114],{"trials":45134,"activeCount":102},[],{"trials":45136,"activeCount":102},[],{"trials":45138,"activeCount":102},[],{"trials":45140,"activeCount":102},[],{"intervention":40042,"totalTrials":122,"cells":45142},{"EARLY_PHASE1":45143,"PHASE1":45145,"PHASE2":45151,"PHASE3":45153,"PHASE4":45155,"NA":45157},{"trials":45144,"activeCount":102},[],{"trials":45146,"activeCount":102},[45147],{"nctId":40037,"briefTitle":40038,"status":195,"phases":45148,"primaryCompletion":2086,"completion":2086,"start":2251,"enrollment":1130,"conditions":45149,"interventions":45150},[90],[19],[40017,40042],{"trials":45152,"activeCount":102},[],{"trials":45154,"activeCount":102},[],{"trials":45156,"activeCount":102},[],{"trials":45158,"activeCount":102},[],{"intervention":45160,"totalTrials":122,"cells":45161},"AZD2461",{"EARLY_PHASE1":45162,"PHASE1":45164,"PHASE2":45174,"PHASE3":45176,"PHASE4":45178,"NA":45180},{"trials":45163,"activeCount":102},[],{"trials":45165,"activeCount":102},[45166],{"nctId":45167,"briefTitle":45168,"status":195,"phases":45169,"primaryCompletion":2615,"completion":2615,"start":2349,"enrollment":1883,"conditions":45170,"interventions":45173},"NCT01247168","An Open-Label, Dose-Escalation Study of AZD2461",[90],[45171,45172],"Refractory Solid Tumors","Cancer Tumor",[45160],{"trials":45175,"activeCount":102},[],{"trials":45177,"activeCount":102},[],{"trials":45179,"activeCount":102},[],{"trials":45181,"activeCount":102},[],{"intervention":45183,"totalTrials":122,"cells":45184},"AZD9977 immediate release (IR) oral suspension",{"EARLY_PHASE1":45185,"PHASE1":45187,"PHASE2":45199,"PHASE3":45201,"PHASE4":45203,"NA":45205},{"trials":45186,"activeCount":102},[],{"trials":45188,"activeCount":102},[45189],{"nctId":45190,"briefTitle":45191,"status":624,"phases":45192,"primaryCompletion":45193,"completion":45193,"start":20831,"enrollment":102,"conditions":45194,"interventions":45195},"NCT02560363","A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects",[90],"2016-01",[15776,7029,10052,44064],[45183,45196,45197,45198],"AZD9977 extended release (ER) capsules [fast]","AZD9977 extended release (ER) capsules [intermediate]","AZD9977 extended release (ER) capsules [slow]",{"trials":45200,"activeCount":102},[],{"trials":45202,"activeCount":102},[],{"trials":45204,"activeCount":102},[],{"trials":45206,"activeCount":102},[],{"intervention":45196,"totalTrials":122,"cells":45208},{"EARLY_PHASE1":45209,"PHASE1":45211,"PHASE2":45217,"PHASE3":45219,"PHASE4":45221,"NA":45223},{"trials":45210,"activeCount":102},[],{"trials":45212,"activeCount":102},[45213],{"nctId":45190,"briefTitle":45191,"status":624,"phases":45214,"primaryCompletion":45193,"completion":45193,"start":20831,"enrollment":102,"conditions":45215,"interventions":45216},[90],[15776,7029,10052,44064],[45183,45196,45197,45198],{"trials":45218,"activeCount":102},[],{"trials":45220,"activeCount":102},[],{"trials":45222,"activeCount":102},[],{"trials":45224,"activeCount":102},[],{"intervention":45197,"totalTrials":122,"cells":45226},{"EARLY_PHASE1":45227,"PHASE1":45229,"PHASE2":45235,"PHASE3":45237,"PHASE4":45239,"NA":45241},{"trials":45228,"activeCount":102},[],{"trials":45230,"activeCount":102},[45231],{"nctId":45190,"briefTitle":45191,"status":624,"phases":45232,"primaryCompletion":45193,"completion":45193,"start":20831,"enrollment":102,"conditions":45233,"interventions":45234},[90],[15776,7029,10052,44064],[45183,45196,45197,45198],{"trials":45236,"activeCount":102},[],{"trials":45238,"activeCount":102},[],{"trials":45240,"activeCount":102},[],{"trials":45242,"activeCount":102},[],{"intervention":45198,"totalTrials":122,"cells":45244},{"EARLY_PHASE1":45245,"PHASE1":45247,"PHASE2":45253,"PHASE3":45255,"PHASE4":45257,"NA":45259},{"trials":45246,"activeCount":102},[],{"trials":45248,"activeCount":102},[45249],{"nctId":45190,"briefTitle":45191,"status":624,"phases":45250,"primaryCompletion":45193,"completion":45193,"start":20831,"enrollment":102,"conditions":45251,"interventions":45252},[90],[15776,7029,10052,44064],[45183,45196,45197,45198],{"trials":45254,"activeCount":102},[],{"trials":45256,"activeCount":102},[],{"trials":45258,"activeCount":102},[],{"trials":45260,"activeCount":102},[],{"intervention":45262,"totalTrials":122,"cells":45263},"VIMOVO",{"EARLY_PHASE1":45264,"PHASE1":45266,"PHASE2":45275,"PHASE3":45277,"PHASE4":45279,"NA":45281},{"trials":45265,"activeCount":102},[],{"trials":45267,"activeCount":102},[45268],{"nctId":45269,"briefTitle":45270,"status":195,"phases":45271,"primaryCompletion":2736,"completion":2736,"start":2571,"enrollment":496,"conditions":45272,"interventions":45273},"NCT01331993","A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation",[90],[36,42519],[45262,45262,45274],"Marketed enteric-coated naproxen formulation",{"trials":45276,"activeCount":102},[],{"trials":45278,"activeCount":102},[],{"trials":45280,"activeCount":102},[],{"trials":45282,"activeCount":102},[],{"intervention":45274,"totalTrials":122,"cells":45284},{"EARLY_PHASE1":45285,"PHASE1":45287,"PHASE2":45293,"PHASE3":45295,"PHASE4":45297,"NA":45299},{"trials":45286,"activeCount":102},[],{"trials":45288,"activeCount":102},[45289],{"nctId":45269,"briefTitle":45270,"status":195,"phases":45290,"primaryCompletion":2736,"completion":2736,"start":2571,"enrollment":496,"conditions":45291,"interventions":45292},[90],[36,42519],[45262,45262,45274],{"trials":45294,"activeCount":102},[],{"trials":45296,"activeCount":102},[],{"trials":45298,"activeCount":102},[],{"trials":45300,"activeCount":102},[],{"intervention":45302,"totalTrials":122,"cells":45303},"SEROQUEL XR",{"EARLY_PHASE1":45304,"PHASE1":45306,"PHASE2":45316,"PHASE3":45318,"PHASE4":45320,"NA":45322},{"trials":45305,"activeCount":102},[],{"trials":45307,"activeCount":102},[45308],{"nctId":45309,"briefTitle":45310,"status":195,"phases":45311,"completion":2067,"start":7544,"enrollment":269,"conditions":45312,"interventions":45313},"NCT00832221","Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL",[90],[18734],[45302,45314,45315],"SEROQUEL IR","radioligand [11C]raclopride",{"trials":45317,"activeCount":102},[],{"trials":45319,"activeCount":102},[],{"trials":45321,"activeCount":102},[],{"trials":45323,"activeCount":102},[],{"intervention":45314,"totalTrials":122,"cells":45325},{"EARLY_PHASE1":45326,"PHASE1":45328,"PHASE2":45334,"PHASE3":45336,"PHASE4":45338,"NA":45340},{"trials":45327,"activeCount":102},[],{"trials":45329,"activeCount":102},[45330],{"nctId":45309,"briefTitle":45310,"status":195,"phases":45331,"completion":2067,"start":7544,"enrollment":269,"conditions":45332,"interventions":45333},[90],[18734],[45302,45314,45315],{"trials":45335,"activeCount":102},[],{"trials":45337,"activeCount":102},[],{"trials":45339,"activeCount":102},[],{"trials":45341,"activeCount":102},[],{"intervention":45315,"totalTrials":122,"cells":45343},{"EARLY_PHASE1":45344,"PHASE1":45346,"PHASE2":45352,"PHASE3":45354,"PHASE4":45356,"NA":45358},{"trials":45345,"activeCount":102},[],{"trials":45347,"activeCount":102},[45348],{"nctId":45309,"briefTitle":45310,"status":195,"phases":45349,"completion":2067,"start":7544,"enrollment":269,"conditions":45350,"interventions":45351},[90],[18734],[45302,45314,45315],{"trials":45353,"activeCount":102},[],{"trials":45355,"activeCount":102},[],{"trials":45357,"activeCount":102},[],{"trials":45359,"activeCount":102},[],{"intervention":41867,"totalTrials":122,"cells":45361},{"EARLY_PHASE1":45362,"PHASE1":45364,"PHASE2":45370,"PHASE3":45372,"PHASE4":45374,"NA":45376},{"trials":45363,"activeCount":102},[],{"trials":45365,"activeCount":102},[45366],{"nctId":41860,"briefTitle":41861,"status":195,"phases":45367,"primaryCompletion":41863,"completion":41863,"start":41864,"enrollment":2003,"conditions":45368,"interventions":45369},[90],[16,30237],[41853,41853,41867,41868,41869],{"trials":45371,"activeCount":102},[],{"trials":45373,"activeCount":102},[],{"trials":45375,"activeCount":102},[],{"trials":45377,"activeCount":102},[],{"intervention":41868,"totalTrials":122,"cells":45379},{"EARLY_PHASE1":45380,"PHASE1":45382,"PHASE2":45388,"PHASE3":45390,"PHASE4":45392,"NA":45394},{"trials":45381,"activeCount":102},[],{"trials":45383,"activeCount":102},[45384],{"nctId":41860,"briefTitle":41861,"status":195,"phases":45385,"primaryCompletion":41863,"completion":41863,"start":41864,"enrollment":2003,"conditions":45386,"interventions":45387},[90],[16,30237],[41853,41853,41867,41868,41869],{"trials":45389,"activeCount":102},[],{"trials":45391,"activeCount":102},[],{"trials":45393,"activeCount":102},[],{"trials":45395,"activeCount":102},[],{"intervention":41869,"totalTrials":122,"cells":45397},{"EARLY_PHASE1":45398,"PHASE1":45400,"PHASE2":45406,"PHASE3":45408,"PHASE4":45410,"NA":45412},{"trials":45399,"activeCount":102},[],{"trials":45401,"activeCount":102},[45402],{"nctId":41860,"briefTitle":41861,"status":195,"phases":45403,"primaryCompletion":41863,"completion":41863,"start":41864,"enrollment":2003,"conditions":45404,"interventions":45405},[90],[16,30237],[41853,41853,41867,41868,41869],{"trials":45407,"activeCount":102},[],{"trials":45409,"activeCount":102},[],{"trials":45411,"activeCount":102},[],{"trials":45413,"activeCount":102},[],{"intervention":45415,"totalTrials":122,"cells":45416},"Zibotentan\u002FDapagliflozin FDC",{"EARLY_PHASE1":45417,"PHASE1":45419,"PHASE2":45429,"PHASE3":45431,"PHASE4":45433,"NA":45435},{"trials":45418,"activeCount":102},[],{"trials":45420,"activeCount":102},[45421],{"nctId":45422,"briefTitle":45423,"status":195,"phases":45424,"primaryCompletion":45425,"completion":45425,"start":45426,"enrollment":2827,"conditions":45427,"interventions":45428},"NCT07404137","A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food",[90],"2026-04-02","2026-02-16",[5851],[45415],{"trials":45430,"activeCount":102},[],{"trials":45432,"activeCount":102},[],{"trials":45434,"activeCount":102},[],{"trials":45436,"activeCount":102},[],{"intervention":45438,"totalTrials":122,"cells":45439},"AZD5991",{"EARLY_PHASE1":45440,"PHASE1":45442,"PHASE2":45452,"PHASE3":45454,"PHASE4":45456,"NA":45458},{"trials":45441,"activeCount":102},[],{"trials":45443,"activeCount":102},[45444],{"nctId":45445,"briefTitle":45446,"status":443,"phases":45447,"primaryCompletion":870,"completion":870,"start":25583,"enrollment":3476,"conditions":45448,"interventions":45450},"NCT03218683","Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.",[90],[45449],"Relapsed or Refractory Acute Myeloid Leukemia (AML)",[45438,45451],"AZD5991 + Venetoclax",{"trials":45453,"activeCount":102},[],{"trials":45455,"activeCount":102},[],{"trials":45457,"activeCount":102},[],{"trials":45459,"activeCount":102},[],{"intervention":45451,"totalTrials":122,"cells":45461},{"EARLY_PHASE1":45462,"PHASE1":45464,"PHASE2":45470,"PHASE3":45472,"PHASE4":45474,"NA":45476},{"trials":45463,"activeCount":102},[],{"trials":45465,"activeCount":102},[45466],{"nctId":45445,"briefTitle":45446,"status":443,"phases":45467,"primaryCompletion":870,"completion":870,"start":25583,"enrollment":3476,"conditions":45468,"interventions":45469},[90],[45449],[45438,45451],{"trials":45471,"activeCount":102},[],{"trials":45473,"activeCount":102},[],{"trials":45475,"activeCount":102},[],{"trials":45477,"activeCount":102},[],{"intervention":7622,"totalTrials":122,"cells":45479},{"EARLY_PHASE1":45480,"PHASE1":45482,"PHASE2":45488,"PHASE3":45490,"PHASE4":45492,"NA":45494},{"trials":45481,"activeCount":102},[],{"trials":45483,"activeCount":102},[45484],{"nctId":7615,"briefTitle":7616,"status":195,"phases":45485,"primaryCompletion":2470,"completion":2470,"start":7618,"enrollment":2827,"conditions":45486,"interventions":45487},[90],[466],[3801,7621,7621,3801,3801,7622,7622,3801],{"trials":45489,"activeCount":102},[],{"trials":45491,"activeCount":102},[],{"trials":45493,"activeCount":102},[],{"trials":45495,"activeCount":102},[],{"intervention":45497,"totalTrials":122,"cells":45498},"MEDI9929",{"EARLY_PHASE1":45499,"PHASE1":45501,"PHASE2":45509,"PHASE3":45511,"PHASE4":45513,"NA":45515},{"trials":45500,"activeCount":102},[],{"trials":45502,"activeCount":102},[45503],{"nctId":45504,"briefTitle":45505,"status":195,"phases":45506,"primaryCompletion":2480,"completion":2480,"start":1701,"enrollment":4307,"conditions":45507,"interventions":45508},"NCT01913028","A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects",[90],[19],[45497],{"trials":45510,"activeCount":102},[],{"trials":45512,"activeCount":102},[],{"trials":45514,"activeCount":102},[],{"trials":45516,"activeCount":102},[],{"intervention":45518,"totalTrials":122,"cells":45519},"[14C] AZD8931",{"EARLY_PHASE1":45520,"PHASE1":45522,"PHASE2":45530,"PHASE3":45532,"PHASE4":45534,"NA":45536},{"trials":45521,"activeCount":102},[],{"trials":45523,"activeCount":102},[45524],{"nctId":45525,"briefTitle":45526,"status":195,"phases":45527,"primaryCompletion":2615,"completion":2615,"start":2570,"enrollment":1039,"conditions":45528,"interventions":45529},"NCT01284595","Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931",[90],[19],[45518],{"trials":45531,"activeCount":102},[],{"trials":45533,"activeCount":102},[],{"trials":45535,"activeCount":102},[],{"trials":45537,"activeCount":102},[],{"intervention":32017,"totalTrials":122,"cells":45539},{"EARLY_PHASE1":45540,"PHASE1":45542,"PHASE2":45548,"PHASE3":45550,"PHASE4":45552,"NA":45554},{"trials":45541,"activeCount":102},[],{"trials":45543,"activeCount":102},[45544],{"nctId":32012,"briefTitle":32013,"status":195,"phases":45545,"completion":2320,"start":2580,"enrollment":14693,"conditions":45546,"interventions":45547},[90],[18867],[32005,32017],{"trials":45549,"activeCount":102},[],{"trials":45551,"activeCount":102},[],{"trials":45553,"activeCount":102},[],{"trials":45555,"activeCount":102},[],{"intervention":45557,"totalTrials":122,"cells":45558},"AZD0449",{"EARLY_PHASE1":45559,"PHASE1":45561,"PHASE2":45569,"PHASE3":45571,"PHASE4":45573,"NA":45575},{"trials":45560,"activeCount":102},[],{"trials":45562,"activeCount":102},[45563],{"nctId":45564,"briefTitle":45565,"status":195,"phases":45566,"primaryCompletion":743,"completion":743,"start":3561,"enrollment":18941,"conditions":45567,"interventions":45568},"NCT03766399","A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449",[90],[16],[45557],{"trials":45570,"activeCount":102},[],{"trials":45572,"activeCount":102},[],{"trials":45574,"activeCount":102},[],{"trials":45576,"activeCount":102},[],{"intervention":32180,"totalTrials":122,"cells":45578},{"EARLY_PHASE1":45579,"PHASE1":45581,"PHASE2":45587,"PHASE3":45589,"PHASE4":45591,"NA":45593},{"trials":45580,"activeCount":102},[],{"trials":45582,"activeCount":102},[45583],{"nctId":32175,"briefTitle":32176,"status":195,"phases":45584,"completion":2067,"start":2152,"enrollment":520,"conditions":45585,"interventions":45586},[90],[31748],[24688,13183,32180,32181,32182],{"trials":45588,"activeCount":102},[],{"trials":45590,"activeCount":102},[],{"trials":45592,"activeCount":102},[],{"trials":45594,"activeCount":102},[],{"intervention":32181,"totalTrials":122,"cells":45596},{"EARLY_PHASE1":45597,"PHASE1":45599,"PHASE2":45605,"PHASE3":45607,"PHASE4":45609,"NA":45611},{"trials":45598,"activeCount":102},[],{"trials":45600,"activeCount":102},[45601],{"nctId":32175,"briefTitle":32176,"status":195,"phases":45602,"completion":2067,"start":2152,"enrollment":520,"conditions":45603,"interventions":45604},[90],[31748],[24688,13183,32180,32181,32182],{"trials":45606,"activeCount":102},[],{"trials":45608,"activeCount":102},[],{"trials":45610,"activeCount":102},[],{"trials":45612,"activeCount":102},[],{"intervention":32182,"totalTrials":122,"cells":45614},{"EARLY_PHASE1":45615,"PHASE1":45617,"PHASE2":45623,"PHASE3":45625,"PHASE4":45627,"NA":45629},{"trials":45616,"activeCount":102},[],{"trials":45618,"activeCount":102},[45619],{"nctId":32175,"briefTitle":32176,"status":195,"phases":45620,"completion":2067,"start":2152,"enrollment":520,"conditions":45621,"interventions":45622},[90],[31748],[24688,13183,32180,32181,32182],{"trials":45624,"activeCount":102},[],{"trials":45626,"activeCount":102},[],{"trials":45628,"activeCount":102},[],{"trials":45630,"activeCount":102},[],{"intervention":45632,"totalTrials":122,"cells":45633},"Ticagrelor 90 mg whole",{"EARLY_PHASE1":45634,"PHASE1":45636,"PHASE2":45647,"PHASE3":45649,"PHASE4":45651,"NA":45653},{"trials":45635,"activeCount":102},[],{"trials":45637,"activeCount":102},[45638],{"nctId":45639,"briefTitle":45640,"status":195,"phases":45641,"primaryCompletion":19364,"completion":19364,"start":13856,"enrollment":496,"conditions":45642,"interventions":45644},"NCT01887626","Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.",[90],[45643],"Bioavailability Heathy Volunteers",[45632,45645,45646],"Ticagrelor 90 mg tablet crushed","Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube",{"trials":45648,"activeCount":102},[],{"trials":45650,"activeCount":102},[],{"trials":45652,"activeCount":102},[],{"trials":45654,"activeCount":102},[],{"intervention":45645,"totalTrials":122,"cells":45656},{"EARLY_PHASE1":45657,"PHASE1":45659,"PHASE2":45665,"PHASE3":45667,"PHASE4":45669,"NA":45671},{"trials":45658,"activeCount":102},[],{"trials":45660,"activeCount":102},[45661],{"nctId":45639,"briefTitle":45640,"status":195,"phases":45662,"primaryCompletion":19364,"completion":19364,"start":13856,"enrollment":496,"conditions":45663,"interventions":45664},[90],[45643],[45632,45645,45646],{"trials":45666,"activeCount":102},[],{"trials":45668,"activeCount":102},[],{"trials":45670,"activeCount":102},[],{"trials":45672,"activeCount":102},[],{"intervention":45646,"totalTrials":122,"cells":45674},{"EARLY_PHASE1":45675,"PHASE1":45677,"PHASE2":45683,"PHASE3":45685,"PHASE4":45687,"NA":45689},{"trials":45676,"activeCount":102},[],{"trials":45678,"activeCount":102},[45679],{"nctId":45639,"briefTitle":45640,"status":195,"phases":45680,"primaryCompletion":19364,"completion":19364,"start":13856,"enrollment":496,"conditions":45681,"interventions":45682},[90],[45643],[45632,45645,45646],{"trials":45684,"activeCount":102},[],{"trials":45686,"activeCount":102},[],{"trials":45688,"activeCount":102},[],{"trials":45690,"activeCount":102},[],{"intervention":32746,"totalTrials":122,"cells":45692},{"EARLY_PHASE1":45693,"PHASE1":45695,"PHASE2":45701,"PHASE3":45703,"PHASE4":45705,"NA":45707},{"trials":45694,"activeCount":102},[],{"trials":45696,"activeCount":102},[45697],{"nctId":32739,"briefTitle":32740,"status":195,"phases":45698,"primaryCompletion":32742,"completion":32742,"start":19204,"enrollment":963,"conditions":45699,"interventions":45700},[90],[36],[32745,2389,32746,32746],{"trials":45702,"activeCount":102},[],{"trials":45704,"activeCount":102},[],{"trials":45706,"activeCount":102},[],{"trials":45708,"activeCount":102},[],{"intervention":45710,"totalTrials":122,"cells":45711},"Intravenous",{"EARLY_PHASE1":45712,"PHASE1":45714,"PHASE2":45725,"PHASE3":45727,"PHASE4":45729,"NA":45731},{"trials":45713,"activeCount":102},[],{"trials":45715,"activeCount":102},[45716],{"nctId":45717,"briefTitle":45718,"status":195,"phases":45719,"primaryCompletion":45720,"completion":45720,"start":45721,"enrollment":1039,"conditions":45722,"interventions":45723},"NCT04002427","Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594",[90],"2019-07-05","2019-06-11",[16],[45710,45724],"Inhaled dose",{"trials":45726,"activeCount":102},[],{"trials":45728,"activeCount":102},[],{"trials":45730,"activeCount":102},[],{"trials":45732,"activeCount":102},[],{"intervention":45724,"totalTrials":122,"cells":45734},{"EARLY_PHASE1":45735,"PHASE1":45737,"PHASE2":45743,"PHASE3":45745,"PHASE4":45747,"NA":45749},{"trials":45736,"activeCount":102},[],{"trials":45738,"activeCount":102},[45739],{"nctId":45717,"briefTitle":45718,"status":195,"phases":45740,"primaryCompletion":45720,"completion":45720,"start":45721,"enrollment":1039,"conditions":45741,"interventions":45742},[90],[16],[45710,45724],{"trials":45744,"activeCount":102},[],{"trials":45746,"activeCount":102},[],{"trials":45748,"activeCount":102},[],{"trials":45750,"activeCount":102},[],{"intervention":24556,"totalTrials":122,"cells":45752},{"EARLY_PHASE1":45753,"PHASE1":45755,"PHASE2":45761,"PHASE3":45763,"PHASE4":45765,"NA":45767},{"trials":45754,"activeCount":102},[],{"trials":45756,"activeCount":102},[45757],{"nctId":24551,"briefTitle":24552,"status":195,"phases":45758,"primaryCompletion":2616,"completion":2616,"start":2432,"enrollment":2260,"conditions":45759,"interventions":45760},[90],[15776],[24556,24557,24558,24559,24544],{"trials":45762,"activeCount":102},[],{"trials":45764,"activeCount":102},[],{"trials":45766,"activeCount":102},[],{"trials":45768,"activeCount":102},[],{"intervention":24557,"totalTrials":122,"cells":45770},{"EARLY_PHASE1":45771,"PHASE1":45773,"PHASE2":45779,"PHASE3":45781,"PHASE4":45783,"NA":45785},{"trials":45772,"activeCount":102},[],{"trials":45774,"activeCount":102},[45775],{"nctId":24551,"briefTitle":24552,"status":195,"phases":45776,"primaryCompletion":2616,"completion":2616,"start":2432,"enrollment":2260,"conditions":45777,"interventions":45778},[90],[15776],[24556,24557,24558,24559,24544],{"trials":45780,"activeCount":102},[],{"trials":45782,"activeCount":102},[],{"trials":45784,"activeCount":102},[],{"trials":45786,"activeCount":102},[],{"intervention":24558,"totalTrials":122,"cells":45788},{"EARLY_PHASE1":45789,"PHASE1":45791,"PHASE2":45797,"PHASE3":45799,"PHASE4":45801,"NA":45803},{"trials":45790,"activeCount":102},[],{"trials":45792,"activeCount":102},[45793],{"nctId":24551,"briefTitle":24552,"status":195,"phases":45794,"primaryCompletion":2616,"completion":2616,"start":2432,"enrollment":2260,"conditions":45795,"interventions":45796},[90],[15776],[24556,24557,24558,24559,24544],{"trials":45798,"activeCount":102},[],{"trials":45800,"activeCount":102},[],{"trials":45802,"activeCount":102},[],{"trials":45804,"activeCount":102},[],{"intervention":24559,"totalTrials":122,"cells":45806},{"EARLY_PHASE1":45807,"PHASE1":45809,"PHASE2":45815,"PHASE3":45817,"PHASE4":45819,"NA":45821},{"trials":45808,"activeCount":102},[],{"trials":45810,"activeCount":102},[45811],{"nctId":24551,"briefTitle":24552,"status":195,"phases":45812,"primaryCompletion":2616,"completion":2616,"start":2432,"enrollment":2260,"conditions":45813,"interventions":45814},[90],[15776],[24556,24557,24558,24559,24544],{"trials":45816,"activeCount":102},[],{"trials":45818,"activeCount":102},[],{"trials":45820,"activeCount":102},[],{"trials":45822,"activeCount":102},[],{"intervention":26056,"totalTrials":122,"cells":45824},{"EARLY_PHASE1":45825,"PHASE1":45827,"PHASE2":45833,"PHASE3":45835,"PHASE4":45837,"NA":45839},{"trials":45826,"activeCount":102},[],{"trials":45828,"activeCount":102},[45829],{"nctId":26051,"briefTitle":26052,"status":195,"phases":45830,"primaryCompletion":13787,"completion":13787,"start":13056,"enrollment":2069,"conditions":45831,"interventions":45832},[90],[2369],[26056,20820],{"trials":45834,"activeCount":102},[],{"trials":45836,"activeCount":102},[],{"trials":45838,"activeCount":102},[],{"trials":45840,"activeCount":102},[],{"intervention":512,"totalTrials":122,"cells":45842},{"EARLY_PHASE1":45843,"PHASE1":45845,"PHASE2":45851,"PHASE3":45853,"PHASE4":45855,"NA":45857},{"trials":45844,"activeCount":102},[],{"trials":45846,"activeCount":102},[45847],{"nctId":501,"briefTitle":502,"status":195,"phases":45848,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":45849,"interventions":45850},[90],[509,510,414,25,415,416],[512,267],{"trials":45852,"activeCount":102},[],{"trials":45854,"activeCount":102},[],{"trials":45856,"activeCount":102},[],{"trials":45858,"activeCount":102},[],{"intervention":45860,"totalTrials":122,"cells":45861},"Olaparib Treatment A",{"EARLY_PHASE1":45862,"PHASE1":45864,"PHASE2":45879,"PHASE3":45881,"PHASE4":45883,"NA":45885},{"trials":45863,"activeCount":102},[],{"trials":45865,"activeCount":102},[45866],{"nctId":45867,"briefTitle":45868,"status":195,"phases":45869,"primaryCompletion":45870,"completion":45871,"start":45872,"enrollment":1336,"conditions":45873,"interventions":45875},"NCT03553108","A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.",[90],"2019-03-12","2020-07-01","2018-05-16",[45874],"Malignant Solid Tumor",[45860,45876,45877,45878],"Olaparib Treatment B","Olaparib Treatment C","Olaparib Treatment D",{"trials":45880,"activeCount":102},[],{"trials":45882,"activeCount":102},[],{"trials":45884,"activeCount":102},[],{"trials":45886,"activeCount":102},[],{"intervention":45876,"totalTrials":122,"cells":45888},{"EARLY_PHASE1":45889,"PHASE1":45891,"PHASE2":45897,"PHASE3":45899,"PHASE4":45901,"NA":45903},{"trials":45890,"activeCount":102},[],{"trials":45892,"activeCount":102},[45893],{"nctId":45867,"briefTitle":45868,"status":195,"phases":45894,"primaryCompletion":45870,"completion":45871,"start":45872,"enrollment":1336,"conditions":45895,"interventions":45896},[90],[45874],[45860,45876,45877,45878],{"trials":45898,"activeCount":102},[],{"trials":45900,"activeCount":102},[],{"trials":45902,"activeCount":102},[],{"trials":45904,"activeCount":102},[],{"intervention":45877,"totalTrials":122,"cells":45906},{"EARLY_PHASE1":45907,"PHASE1":45909,"PHASE2":45915,"PHASE3":45917,"PHASE4":45919,"NA":45921},{"trials":45908,"activeCount":102},[],{"trials":45910,"activeCount":102},[45911],{"nctId":45867,"briefTitle":45868,"status":195,"phases":45912,"primaryCompletion":45870,"completion":45871,"start":45872,"enrollment":1336,"conditions":45913,"interventions":45914},[90],[45874],[45860,45876,45877,45878],{"trials":45916,"activeCount":102},[],{"trials":45918,"activeCount":102},[],{"trials":45920,"activeCount":102},[],{"trials":45922,"activeCount":102},[],{"intervention":45878,"totalTrials":122,"cells":45924},{"EARLY_PHASE1":45925,"PHASE1":45927,"PHASE2":45933,"PHASE3":45935,"PHASE4":45937,"NA":45939},{"trials":45926,"activeCount":102},[],{"trials":45928,"activeCount":102},[45929],{"nctId":45867,"briefTitle":45868,"status":195,"phases":45930,"primaryCompletion":45870,"completion":45871,"start":45872,"enrollment":1336,"conditions":45931,"interventions":45932},[90],[45874],[45860,45876,45877,45878],{"trials":45934,"activeCount":102},[],{"trials":45936,"activeCount":102},[],{"trials":45938,"activeCount":102},[],{"trials":45940,"activeCount":102},[],{"intervention":31943,"totalTrials":122,"cells":45942},{"EARLY_PHASE1":45943,"PHASE1":45945,"PHASE2":45951,"PHASE3":45953,"PHASE4":45955,"NA":45957},{"trials":45944,"activeCount":102},[],{"trials":45946,"activeCount":102},[45947],{"nctId":31937,"briefTitle":31938,"status":195,"phases":45948,"primaryCompletion":2470,"completion":2470,"start":1693,"enrollment":532,"conditions":45949,"interventions":45950},[90],[31941],[31943,5273],{"trials":45952,"activeCount":102},[],{"trials":45954,"activeCount":102},[],{"trials":45956,"activeCount":102},[],{"trials":45958,"activeCount":102},[],{"intervention":45960,"totalTrials":122,"cells":45961},"AZD8330",{"EARLY_PHASE1":45962,"PHASE1":45964,"PHASE2":45972,"PHASE3":45974,"PHASE4":45976,"NA":45978},{"trials":45963,"activeCount":102},[],{"trials":45965,"activeCount":102},[45966],{"nctId":45967,"briefTitle":45968,"status":195,"phases":45969,"primaryCompletion":2489,"completion":2570,"start":3839,"enrollment":6597,"conditions":45970,"interventions":45971},"NCT00454090","AZD8330 First Time in Man in Patients With Advanced Malignancies",[90],[556],[45960],{"trials":45973,"activeCount":102},[],{"trials":45975,"activeCount":102},[],{"trials":45977,"activeCount":102},[],{"trials":45979,"activeCount":102},[],{"intervention":10245,"totalTrials":122,"cells":45981},{"EARLY_PHASE1":45982,"PHASE1":45984,"PHASE2":45990,"PHASE3":45992,"PHASE4":45994,"NA":45996},{"trials":45983,"activeCount":102},[],{"trials":45985,"activeCount":102},[45986],{"nctId":10235,"briefTitle":10236,"status":443,"phases":45987,"primaryCompletion":10238,"completion":10239,"start":10240,"enrollment":4497,"conditions":45988,"interventions":45989},[90],[498,1921,10242,10243],[10245,4114],{"trials":45991,"activeCount":102},[],{"trials":45993,"activeCount":102},[],{"trials":45995,"activeCount":102},[],{"trials":45997,"activeCount":102},[],{"intervention":45999,"totalTrials":122,"cells":46000},"MEDI-578",{"EARLY_PHASE1":46001,"PHASE1":46003,"PHASE2":46011,"PHASE3":46013,"PHASE4":46015,"NA":46017},{"trials":46002,"activeCount":102},[],{"trials":46004,"activeCount":102},[46005],{"nctId":46006,"briefTitle":46007,"status":443,"phases":46008,"primaryCompletion":3862,"completion":3862,"start":2114,"enrollment":1373,"conditions":46009,"interventions":46010},"NCT01072591","Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee",[90],[20657,31755],[45999],{"trials":46012,"activeCount":102},[],{"trials":46014,"activeCount":102},[],{"trials":46016,"activeCount":102},[],{"trials":46018,"activeCount":102},[],{"intervention":7046,"totalTrials":122,"cells":46020},{"EARLY_PHASE1":46021,"PHASE1":46023,"PHASE2":46029,"PHASE3":46031,"PHASE4":46033,"NA":46035},{"trials":46022,"activeCount":102},[],{"trials":46024,"activeCount":102},[46025],{"nctId":7040,"briefTitle":7041,"status":195,"phases":46026,"primaryCompletion":7043,"completion":7043,"start":3161,"enrollment":1855,"conditions":46027,"interventions":46028},[90],[36],[7046,87],{"trials":46030,"activeCount":102},[],{"trials":46032,"activeCount":102},[],{"trials":46034,"activeCount":102},[],{"trials":46036,"activeCount":102},[],{"intervention":46038,"totalTrials":122,"cells":46039},"AZD3161",{"EARLY_PHASE1":46040,"PHASE1":46042,"PHASE2":46054,"PHASE3":46056,"PHASE4":46058,"NA":46060},{"trials":46041,"activeCount":102},[],{"trials":46043,"activeCount":102},[46044],{"nctId":46045,"briefTitle":46046,"status":195,"phases":46047,"primaryCompletion":2570,"completion":2570,"start":2143,"enrollment":2827,"conditions":46048,"interventions":46051},"NCT01240148","Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers",[90],[46049,46050],"Peripheral Neuropathic Pain","Nociceptive Pain",[46038,46052,46053],"Lidocaine","AZD3161 Placebo",{"trials":46055,"activeCount":102},[],{"trials":46057,"activeCount":102},[],{"trials":46059,"activeCount":102},[],{"trials":46061,"activeCount":102},[],{"intervention":46052,"totalTrials":122,"cells":46063},{"EARLY_PHASE1":46064,"PHASE1":46066,"PHASE2":46072,"PHASE3":46074,"PHASE4":46076,"NA":46078},{"trials":46065,"activeCount":102},[],{"trials":46067,"activeCount":102},[46068],{"nctId":46045,"briefTitle":46046,"status":195,"phases":46069,"primaryCompletion":2570,"completion":2570,"start":2143,"enrollment":2827,"conditions":46070,"interventions":46071},[90],[46049,46050],[46038,46052,46053],{"trials":46073,"activeCount":102},[],{"trials":46075,"activeCount":102},[],{"trials":46077,"activeCount":102},[],{"trials":46079,"activeCount":102},[],{"intervention":46053,"totalTrials":122,"cells":46081},{"EARLY_PHASE1":46082,"PHASE1":46084,"PHASE2":46090,"PHASE3":46092,"PHASE4":46094,"NA":46096},{"trials":46083,"activeCount":102},[],{"trials":46085,"activeCount":102},[46086],{"nctId":46045,"briefTitle":46046,"status":195,"phases":46087,"primaryCompletion":2570,"completion":2570,"start":2143,"enrollment":2827,"conditions":46088,"interventions":46089},[90],[46049,46050],[46038,46052,46053],{"trials":46091,"activeCount":102},[],{"trials":46093,"activeCount":102},[],{"trials":46095,"activeCount":102},[],{"trials":46097,"activeCount":102},[],{"intervention":41907,"totalTrials":122,"cells":46099},{"EARLY_PHASE1":46100,"PHASE1":46102,"PHASE2":46108,"PHASE3":46110,"PHASE4":46112,"NA":46114},{"trials":46101,"activeCount":102},[],{"trials":46103,"activeCount":102},[46104],{"nctId":41897,"briefTitle":41898,"status":195,"phases":46105,"primaryCompletion":41900,"completion":41900,"start":41901,"enrollment":5876,"conditions":46106,"interventions":46107},[90],[41903,1387],[41890,41905,41906,41907],{"trials":46109,"activeCount":102},[],{"trials":46111,"activeCount":102},[],{"trials":46113,"activeCount":102},[],{"trials":46115,"activeCount":102},[],{"intervention":46117,"totalTrials":122,"cells":46118},"AZD4635 50 mg nano-suspension",{"EARLY_PHASE1":46119,"PHASE1":46121,"PHASE2":46135,"PHASE3":46137,"PHASE4":46139,"NA":46141},{"trials":46120,"activeCount":102},[],{"trials":46122,"activeCount":102},[46123],{"nctId":46124,"briefTitle":46125,"status":195,"phases":46126,"primaryCompletion":1554,"completion":1554,"start":20846,"enrollment":544,"conditions":46127,"interventions":46128},"NCT03710434","AZD4635 Relative Bioavailability Study",[90],[36],[46117,46129,46130,46131,46132,46133,46134],"AZD4635 solid oral formulation - fasted","AZD4635 solid oral formulation - fed","Lansoprazole and AZD4635 50 mg solid oral formulation","AZD4635 solid oral formulation variant 1 - fasted","AZD4635 solid oral formulation variant 2 - fasted","[14C] AZD4635 IV microtracer - fasted",{"trials":46136,"activeCount":102},[],{"trials":46138,"activeCount":102},[],{"trials":46140,"activeCount":102},[],{"trials":46142,"activeCount":102},[],{"intervention":46129,"totalTrials":122,"cells":46144},{"EARLY_PHASE1":46145,"PHASE1":46147,"PHASE2":46153,"PHASE3":46155,"PHASE4":46157,"NA":46159},{"trials":46146,"activeCount":102},[],{"trials":46148,"activeCount":102},[46149],{"nctId":46124,"briefTitle":46125,"status":195,"phases":46150,"primaryCompletion":1554,"completion":1554,"start":20846,"enrollment":544,"conditions":46151,"interventions":46152},[90],[36],[46117,46129,46130,46131,46132,46133,46134],{"trials":46154,"activeCount":102},[],{"trials":46156,"activeCount":102},[],{"trials":46158,"activeCount":102},[],{"trials":46160,"activeCount":102},[],{"intervention":46130,"totalTrials":122,"cells":46162},{"EARLY_PHASE1":46163,"PHASE1":46165,"PHASE2":46171,"PHASE3":46173,"PHASE4":46175,"NA":46177},{"trials":46164,"activeCount":102},[],{"trials":46166,"activeCount":102},[46167],{"nctId":46124,"briefTitle":46125,"status":195,"phases":46168,"primaryCompletion":1554,"completion":1554,"start":20846,"enrollment":544,"conditions":46169,"interventions":46170},[90],[36],[46117,46129,46130,46131,46132,46133,46134],{"trials":46172,"activeCount":102},[],{"trials":46174,"activeCount":102},[],{"trials":46176,"activeCount":102},[],{"trials":46178,"activeCount":102},[],{"intervention":46131,"totalTrials":122,"cells":46180},{"EARLY_PHASE1":46181,"PHASE1":46183,"PHASE2":46189,"PHASE3":46191,"PHASE4":46193,"NA":46195},{"trials":46182,"activeCount":102},[],{"trials":46184,"activeCount":102},[46185],{"nctId":46124,"briefTitle":46125,"status":195,"phases":46186,"primaryCompletion":1554,"completion":1554,"start":20846,"enrollment":544,"conditions":46187,"interventions":46188},[90],[36],[46117,46129,46130,46131,46132,46133,46134],{"trials":46190,"activeCount":102},[],{"trials":46192,"activeCount":102},[],{"trials":46194,"activeCount":102},[],{"trials":46196,"activeCount":102},[],{"intervention":46132,"totalTrials":122,"cells":46198},{"EARLY_PHASE1":46199,"PHASE1":46201,"PHASE2":46207,"PHASE3":46209,"PHASE4":46211,"NA":46213},{"trials":46200,"activeCount":102},[],{"trials":46202,"activeCount":102},[46203],{"nctId":46124,"briefTitle":46125,"status":195,"phases":46204,"primaryCompletion":1554,"completion":1554,"start":20846,"enrollment":544,"conditions":46205,"interventions":46206},[90],[36],[46117,46129,46130,46131,46132,46133,46134],{"trials":46208,"activeCount":102},[],{"trials":46210,"activeCount":102},[],{"trials":46212,"activeCount":102},[],{"trials":46214,"activeCount":102},[],{"intervention":46133,"totalTrials":122,"cells":46216},{"EARLY_PHASE1":46217,"PHASE1":46219,"PHASE2":46225,"PHASE3":46227,"PHASE4":46229,"NA":46231},{"trials":46218,"activeCount":102},[],{"trials":46220,"activeCount":102},[46221],{"nctId":46124,"briefTitle":46125,"status":195,"phases":46222,"primaryCompletion":1554,"completion":1554,"start":20846,"enrollment":544,"conditions":46223,"interventions":46224},[90],[36],[46117,46129,46130,46131,46132,46133,46134],{"trials":46226,"activeCount":102},[],{"trials":46228,"activeCount":102},[],{"trials":46230,"activeCount":102},[],{"trials":46232,"activeCount":102},[],{"intervention":46134,"totalTrials":122,"cells":46234},{"EARLY_PHASE1":46235,"PHASE1":46237,"PHASE2":46243,"PHASE3":46245,"PHASE4":46247,"NA":46249},{"trials":46236,"activeCount":102},[],{"trials":46238,"activeCount":102},[46239],{"nctId":46124,"briefTitle":46125,"status":195,"phases":46240,"primaryCompletion":1554,"completion":1554,"start":20846,"enrollment":544,"conditions":46241,"interventions":46242},[90],[36],[46117,46129,46130,46131,46132,46133,46134],{"trials":46244,"activeCount":102},[],{"trials":46246,"activeCount":102},[],{"trials":46248,"activeCount":102},[],{"trials":46250,"activeCount":102},[],{"intervention":46252,"totalTrials":122,"cells":46253},"MEDI7352 for IV",{"EARLY_PHASE1":46254,"PHASE1":46256,"PHASE2":46266,"PHASE3":46268,"PHASE4":46270,"NA":46272},{"trials":46255,"activeCount":102},[],{"trials":46257,"activeCount":102},[46258],{"nctId":46259,"briefTitle":46260,"status":195,"phases":46261,"primaryCompletion":33162,"completion":33162,"start":46262,"enrollment":24038,"conditions":46263,"interventions":46264},"NCT02508155","A Study of MEDI7352 in Painful Osteoarthritis of the Knee",[90],"2015-11-17",[31748],[46252,46265],"MEDI7352 for Subcutaneous",{"trials":46267,"activeCount":102},[],{"trials":46269,"activeCount":102},[],{"trials":46271,"activeCount":102},[],{"trials":46273,"activeCount":102},[],{"intervention":46265,"totalTrials":122,"cells":46275},{"EARLY_PHASE1":46276,"PHASE1":46278,"PHASE2":46284,"PHASE3":46286,"PHASE4":46288,"NA":46290},{"trials":46277,"activeCount":102},[],{"trials":46279,"activeCount":102},[46280],{"nctId":46259,"briefTitle":46260,"status":195,"phases":46281,"primaryCompletion":33162,"completion":33162,"start":46262,"enrollment":24038,"conditions":46282,"interventions":46283},[90],[31748],[46252,46265],{"trials":46285,"activeCount":102},[],{"trials":46287,"activeCount":102},[],{"trials":46289,"activeCount":102},[],{"trials":46291,"activeCount":102},[],{"intervention":41877,"totalTrials":122,"cells":46293},{"EARLY_PHASE1":46294,"PHASE1":46296,"PHASE2":46302,"PHASE3":46304,"PHASE4":46306,"NA":46308},{"trials":46295,"activeCount":102},[],{"trials":46297,"activeCount":102},[46298],{"nctId":41871,"briefTitle":41872,"status":195,"phases":46299,"primaryCompletion":41874,"completion":41874,"start":41864,"enrollment":1710,"conditions":46300,"interventions":46301},[90],[16,6083],[41877,41878,41879,41879,41880],{"trials":46303,"activeCount":102},[],{"trials":46305,"activeCount":102},[],{"trials":46307,"activeCount":102},[],{"trials":46309,"activeCount":102},[],{"intervention":41878,"totalTrials":122,"cells":46311},{"EARLY_PHASE1":46312,"PHASE1":46314,"PHASE2":46320,"PHASE3":46322,"PHASE4":46324,"NA":46326},{"trials":46313,"activeCount":102},[],{"trials":46315,"activeCount":102},[46316],{"nctId":41871,"briefTitle":41872,"status":195,"phases":46317,"primaryCompletion":41874,"completion":41874,"start":41864,"enrollment":1710,"conditions":46318,"interventions":46319},[90],[16,6083],[41877,41878,41879,41879,41880],{"trials":46321,"activeCount":102},[],{"trials":46323,"activeCount":102},[],{"trials":46325,"activeCount":102},[],{"trials":46327,"activeCount":102},[],{"intervention":41880,"totalTrials":122,"cells":46329},{"EARLY_PHASE1":46330,"PHASE1":46332,"PHASE2":46338,"PHASE3":46340,"PHASE4":46342,"NA":46344},{"trials":46331,"activeCount":102},[],{"trials":46333,"activeCount":102},[46334],{"nctId":41871,"briefTitle":41872,"status":195,"phases":46335,"primaryCompletion":41874,"completion":41874,"start":41864,"enrollment":1710,"conditions":46336,"interventions":46337},[90],[16,6083],[41877,41878,41879,41879,41880],{"trials":46339,"activeCount":102},[],{"trials":46341,"activeCount":102},[],{"trials":46343,"activeCount":102},[],{"trials":46345,"activeCount":102},[],{"intervention":26168,"totalTrials":122,"cells":46347},{"EARLY_PHASE1":46348,"PHASE1":46350,"PHASE2":46356,"PHASE3":46358,"PHASE4":46360,"NA":46362},{"trials":46349,"activeCount":102},[],{"trials":46351,"activeCount":102},[46352],{"nctId":26161,"briefTitle":26162,"status":195,"phases":46353,"primaryCompletion":26164,"completion":26164,"start":26165,"enrollment":2783,"conditions":46354,"interventions":46355},[90],[6083,16],[26168,26169,26170,26171,26172,26173,26168,26169,26154,26174],{"trials":46357,"activeCount":102},[],{"trials":46359,"activeCount":102},[],{"trials":46361,"activeCount":102},[],{"trials":46363,"activeCount":102},[],{"intervention":26169,"totalTrials":122,"cells":46365},{"EARLY_PHASE1":46366,"PHASE1":46368,"PHASE2":46374,"PHASE3":46376,"PHASE4":46378,"NA":46380},{"trials":46367,"activeCount":102},[],{"trials":46369,"activeCount":102},[46370],{"nctId":26161,"briefTitle":26162,"status":195,"phases":46371,"primaryCompletion":26164,"completion":26164,"start":26165,"enrollment":2783,"conditions":46372,"interventions":46373},[90],[6083,16],[26168,26169,26170,26171,26172,26173,26168,26169,26154,26174],{"trials":46375,"activeCount":102},[],{"trials":46377,"activeCount":102},[],{"trials":46379,"activeCount":102},[],{"trials":46381,"activeCount":102},[],{"intervention":26170,"totalTrials":122,"cells":46383},{"EARLY_PHASE1":46384,"PHASE1":46386,"PHASE2":46392,"PHASE3":46394,"PHASE4":46396,"NA":46398},{"trials":46385,"activeCount":102},[],{"trials":46387,"activeCount":102},[46388],{"nctId":26161,"briefTitle":26162,"status":195,"phases":46389,"primaryCompletion":26164,"completion":26164,"start":26165,"enrollment":2783,"conditions":46390,"interventions":46391},[90],[6083,16],[26168,26169,26170,26171,26172,26173,26168,26169,26154,26174],{"trials":46393,"activeCount":102},[],{"trials":46395,"activeCount":102},[],{"trials":46397,"activeCount":102},[],{"trials":46399,"activeCount":102},[],{"intervention":26171,"totalTrials":122,"cells":46401},{"EARLY_PHASE1":46402,"PHASE1":46404,"PHASE2":46410,"PHASE3":46412,"PHASE4":46414,"NA":46416},{"trials":46403,"activeCount":102},[],{"trials":46405,"activeCount":102},[46406],{"nctId":26161,"briefTitle":26162,"status":195,"phases":46407,"primaryCompletion":26164,"completion":26164,"start":26165,"enrollment":2783,"conditions":46408,"interventions":46409},[90],[6083,16],[26168,26169,26170,26171,26172,26173,26168,26169,26154,26174],{"trials":46411,"activeCount":102},[],{"trials":46413,"activeCount":102},[],{"trials":46415,"activeCount":102},[],{"trials":46417,"activeCount":102},[],{"intervention":26172,"totalTrials":122,"cells":46419},{"EARLY_PHASE1":46420,"PHASE1":46422,"PHASE2":46428,"PHASE3":46430,"PHASE4":46432,"NA":46434},{"trials":46421,"activeCount":102},[],{"trials":46423,"activeCount":102},[46424],{"nctId":26161,"briefTitle":26162,"status":195,"phases":46425,"primaryCompletion":26164,"completion":26164,"start":26165,"enrollment":2783,"conditions":46426,"interventions":46427},[90],[6083,16],[26168,26169,26170,26171,26172,26173,26168,26169,26154,26174],{"trials":46429,"activeCount":102},[],{"trials":46431,"activeCount":102},[],{"trials":46433,"activeCount":102},[],{"trials":46435,"activeCount":102},[],{"intervention":26173,"totalTrials":122,"cells":46437},{"EARLY_PHASE1":46438,"PHASE1":46440,"PHASE2":46446,"PHASE3":46448,"PHASE4":46450,"NA":46452},{"trials":46439,"activeCount":102},[],{"trials":46441,"activeCount":102},[46442],{"nctId":26161,"briefTitle":26162,"status":195,"phases":46443,"primaryCompletion":26164,"completion":26164,"start":26165,"enrollment":2783,"conditions":46444,"interventions":46445},[90],[6083,16],[26168,26169,26170,26171,26172,26173,26168,26169,26154,26174],{"trials":46447,"activeCount":102},[],{"trials":46449,"activeCount":102},[],{"trials":46451,"activeCount":102},[],{"trials":46453,"activeCount":102},[],{"intervention":26174,"totalTrials":122,"cells":46455},{"EARLY_PHASE1":46456,"PHASE1":46458,"PHASE2":46464,"PHASE3":46466,"PHASE4":46468,"NA":46470},{"trials":46457,"activeCount":102},[],{"trials":46459,"activeCount":102},[46460],{"nctId":26161,"briefTitle":26162,"status":195,"phases":46461,"primaryCompletion":26164,"completion":26164,"start":26165,"enrollment":2783,"conditions":46462,"interventions":46463},[90],[6083,16],[26168,26169,26170,26171,26172,26173,26168,26169,26154,26174],{"trials":46465,"activeCount":102},[],{"trials":46467,"activeCount":102},[],{"trials":46469,"activeCount":102},[],{"trials":46471,"activeCount":102},[],{"intervention":4892,"totalTrials":122,"cells":46473},{"EARLY_PHASE1":46474,"PHASE1":46476,"PHASE2":46482,"PHASE3":46484,"PHASE4":46486,"NA":46488},{"trials":46475,"activeCount":102},[],{"trials":46477,"activeCount":102},[46478],{"nctId":4886,"briefTitle":4887,"status":443,"phases":46479,"primaryCompletion":2077,"completion":2077,"start":2220,"enrollment":1883,"conditions":46480,"interventions":46481},[90],[4890,3056,157],[4892,3802,3804],{"trials":46483,"activeCount":102},[],{"trials":46485,"activeCount":102},[],{"trials":46487,"activeCount":102},[],{"trials":46489,"activeCount":102},[],{"intervention":46491,"totalTrials":122,"cells":46492},"AZD6553",{"EARLY_PHASE1":46493,"PHASE1":46495,"PHASE2":46503,"PHASE3":46505,"PHASE4":46507,"NA":46509},{"trials":46494,"activeCount":102},[],{"trials":46496,"activeCount":102},[46497],{"nctId":46498,"briefTitle":46499,"status":443,"phases":46500,"primaryCompletion":2243,"completion":2243,"start":2114,"enrollment":18672,"conditions":46501,"interventions":46502},"NCT01068184","A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)",[90],[28],[46491],{"trials":46504,"activeCount":102},[],{"trials":46506,"activeCount":102},[],{"trials":46508,"activeCount":102},[],{"trials":46510,"activeCount":102},[],{"intervention":46512,"totalTrials":122,"cells":46513},"Verinurad ER8 capsule formulation",{"EARLY_PHASE1":46514,"PHASE1":46516,"PHASE2":46527,"PHASE3":46529,"PHASE4":46531,"NA":46533},{"trials":46515,"activeCount":102},[],{"trials":46517,"activeCount":102},[46518],{"nctId":46519,"briefTitle":46520,"status":195,"phases":46521,"primaryCompletion":2648,"completion":2648,"start":46522,"enrollment":98,"conditions":46523,"interventions":46524},"NCT04024501","A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition",[90],"2019-07-20",[2134],[46512,46525,46525,46526,46526],"Verinurad A-capsule formulation","Verinurad B-capsule formulation",{"trials":46528,"activeCount":102},[],{"trials":46530,"activeCount":102},[],{"trials":46532,"activeCount":102},[],{"trials":46534,"activeCount":102},[],{"intervention":46525,"totalTrials":122,"cells":46536},{"EARLY_PHASE1":46537,"PHASE1":46539,"PHASE2":46545,"PHASE3":46547,"PHASE4":46549,"NA":46551},{"trials":46538,"activeCount":102},[],{"trials":46540,"activeCount":102},[46541],{"nctId":46519,"briefTitle":46520,"status":195,"phases":46542,"primaryCompletion":2648,"completion":2648,"start":46522,"enrollment":98,"conditions":46543,"interventions":46544},[90],[2134],[46512,46525,46525,46526,46526],{"trials":46546,"activeCount":102},[],{"trials":46548,"activeCount":102},[],{"trials":46550,"activeCount":102},[],{"trials":46552,"activeCount":102},[],{"intervention":46526,"totalTrials":122,"cells":46554},{"EARLY_PHASE1":46555,"PHASE1":46557,"PHASE2":46563,"PHASE3":46565,"PHASE4":46567,"NA":46569},{"trials":46556,"activeCount":102},[],{"trials":46558,"activeCount":102},[46559],{"nctId":46519,"briefTitle":46520,"status":195,"phases":46560,"primaryCompletion":2648,"completion":2648,"start":46522,"enrollment":98,"conditions":46561,"interventions":46562},[90],[2134],[46512,46525,46525,46526,46526],{"trials":46564,"activeCount":102},[],{"trials":46566,"activeCount":102},[],{"trials":46568,"activeCount":102},[],{"trials":46570,"activeCount":102},[],{"intervention":40972,"totalTrials":122,"cells":46572},{"EARLY_PHASE1":46573,"PHASE1":46575,"PHASE2":46581,"PHASE3":46583,"PHASE4":46585,"NA":46587},{"trials":46574,"activeCount":102},[],{"trials":46576,"activeCount":102},[46577],{"nctId":40966,"briefTitle":40967,"status":195,"phases":46578,"primaryCompletion":2077,"completion":2320,"start":2077,"enrollment":544,"conditions":46579,"interventions":46580},[90],[40970],[40953,40972],{"trials":46582,"activeCount":102},[],{"trials":46584,"activeCount":102},[],{"trials":46586,"activeCount":102},[],{"trials":46588,"activeCount":102},[],{"intervention":23998,"totalTrials":122,"cells":46590},{"EARLY_PHASE1":46591,"PHASE1":46593,"PHASE2":46599,"PHASE3":46601,"PHASE4":46603,"NA":46605},{"trials":46592,"activeCount":102},[],{"trials":46594,"activeCount":102},[46595],{"nctId":23992,"briefTitle":23993,"status":195,"phases":46596,"primaryCompletion":3827,"start":2220,"enrollment":579,"conditions":46597,"interventions":46598},[90],[12563,23996],[12566,23998],{"trials":46600,"activeCount":102},[],{"trials":46602,"activeCount":102},[],{"trials":46604,"activeCount":102},[],{"trials":46606,"activeCount":102},[],{"intervention":46608,"totalTrials":122,"cells":46609},"AZD8154 nebuliser",{"EARLY_PHASE1":46610,"PHASE1":46612,"PHASE2":46623,"PHASE3":46625,"PHASE4":46627,"NA":46629},{"trials":46611,"activeCount":102},[],{"trials":46613,"activeCount":102},[46614],{"nctId":46615,"briefTitle":46616,"status":443,"phases":46617,"primaryCompletion":46618,"completion":46618,"start":30426,"enrollment":269,"conditions":46619,"interventions":46620},"NCT04480879","Evaluation of AZD8154 Concentrations in Blood",[90],"2020-09-02",[16],[46608,46621,46622],"AZD8154 Monodose DPI presented in","AZD8154 Placebo Monodose DPI presented in",{"trials":46624,"activeCount":102},[],{"trials":46626,"activeCount":102},[],{"trials":46628,"activeCount":102},[],{"trials":46630,"activeCount":102},[],{"intervention":46621,"totalTrials":122,"cells":46632},{"EARLY_PHASE1":46633,"PHASE1":46635,"PHASE2":46641,"PHASE3":46643,"PHASE4":46645,"NA":46647},{"trials":46634,"activeCount":102},[],{"trials":46636,"activeCount":102},[46637],{"nctId":46615,"briefTitle":46616,"status":443,"phases":46638,"primaryCompletion":46618,"completion":46618,"start":30426,"enrollment":269,"conditions":46639,"interventions":46640},[90],[16],[46608,46621,46622],{"trials":46642,"activeCount":102},[],{"trials":46644,"activeCount":102},[],{"trials":46646,"activeCount":102},[],{"trials":46648,"activeCount":102},[],{"intervention":46622,"totalTrials":122,"cells":46650},{"EARLY_PHASE1":46651,"PHASE1":46653,"PHASE2":46659,"PHASE3":46661,"PHASE4":46663,"NA":46665},{"trials":46652,"activeCount":102},[],{"trials":46654,"activeCount":102},[46655],{"nctId":46615,"briefTitle":46616,"status":443,"phases":46656,"primaryCompletion":46618,"completion":46618,"start":30426,"enrollment":269,"conditions":46657,"interventions":46658},[90],[16],[46608,46621,46622],{"trials":46660,"activeCount":102},[],{"trials":46662,"activeCount":102},[],{"trials":46664,"activeCount":102},[],{"trials":46666,"activeCount":102},[],{"intervention":46668,"totalTrials":122,"cells":46669},"AZD8965",{"EARLY_PHASE1":46670,"PHASE1":46672,"PHASE2":46681,"PHASE3":46683,"PHASE4":46685,"NA":46687},{"trials":46671,"activeCount":102},[],{"trials":46673,"activeCount":102},[46674],{"nctId":46675,"briefTitle":46676,"status":195,"phases":46677,"primaryCompletion":42067,"completion":46678,"start":6882,"enrollment":1151,"conditions":46679,"interventions":46680},"NCT06502379","A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants",[90],"2025-11-15",[5851],[46668],{"trials":46682,"activeCount":102},[],{"trials":46684,"activeCount":102},[],{"trials":46686,"activeCount":102},[],{"trials":46688,"activeCount":102},[],{"intervention":46690,"totalTrials":122,"cells":46691},"Radioligand (11C)AZD2995",{"EARLY_PHASE1":46692,"PHASE1":46694,"PHASE2":46703,"PHASE3":46705,"PHASE4":46707,"NA":46709},{"trials":46693,"activeCount":102},[],{"trials":46695,"activeCount":102},[46696],{"nctId":46697,"briefTitle":46698,"status":195,"phases":46699,"primaryCompletion":4915,"completion":4915,"start":6710,"enrollment":963,"conditions":46700,"interventions":46701},"NCT00692705","Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid",[90],[23833],[46690,46702],"Radioligand (11C)AZD2184",{"trials":46704,"activeCount":102},[],{"trials":46706,"activeCount":102},[],{"trials":46708,"activeCount":102},[],{"trials":46710,"activeCount":102},[],{"intervention":46702,"totalTrials":122,"cells":46712},{"EARLY_PHASE1":46713,"PHASE1":46715,"PHASE2":46721,"PHASE3":46723,"PHASE4":46725,"NA":46727},{"trials":46714,"activeCount":102},[],{"trials":46716,"activeCount":102},[46717],{"nctId":46697,"briefTitle":46698,"status":195,"phases":46718,"primaryCompletion":4915,"completion":4915,"start":6710,"enrollment":963,"conditions":46719,"interventions":46720},[90],[23833],[46690,46702],{"trials":46722,"activeCount":102},[],{"trials":46724,"activeCount":102},[],{"trials":46726,"activeCount":102},[],{"trials":46728,"activeCount":102},[],{"intervention":46730,"totalTrials":122,"cells":46731},"dapagliflozin\u002Fmetformin XR 5\u002F500 mg test drug",{"EARLY_PHASE1":46732,"PHASE1":46734,"PHASE2":46748,"PHASE3":46750,"PHASE4":46752,"NA":46754},{"trials":46733,"activeCount":102},[],{"trials":46735,"activeCount":102},[46736],{"nctId":46737,"briefTitle":46738,"status":195,"phases":46739,"primaryCompletion":46740,"completion":46740,"start":46741,"enrollment":1395,"conditions":46742,"interventions":46744},"NCT02637037","A Study to Assess the Bioequivalence of Dapagliflozin\u002FMetformin XR Fixed-dose Combination Tablets in Healthy Subjects",[90],"2016-04-07","2015-12-21",[42519,46743,2171],"Fixed Dose Combination Tablets",[46730,46745,46746,46747],"dapagliflozin\u002Fmetformin XR 5\u002F500 mg reference drug","dapagliflozin\u002Fmetformin XR 10\u002F1000 mg test drug","dapagliflozin\u002Fmetformin XR 10\u002F1000 mg reference drug",{"trials":46749,"activeCount":102},[],{"trials":46751,"activeCount":102},[],{"trials":46753,"activeCount":102},[],{"trials":46755,"activeCount":102},[],{"intervention":46745,"totalTrials":122,"cells":46757},{"EARLY_PHASE1":46758,"PHASE1":46760,"PHASE2":46766,"PHASE3":46768,"PHASE4":46770,"NA":46772},{"trials":46759,"activeCount":102},[],{"trials":46761,"activeCount":102},[46762],{"nctId":46737,"briefTitle":46738,"status":195,"phases":46763,"primaryCompletion":46740,"completion":46740,"start":46741,"enrollment":1395,"conditions":46764,"interventions":46765},[90],[42519,46743,2171],[46730,46745,46746,46747],{"trials":46767,"activeCount":102},[],{"trials":46769,"activeCount":102},[],{"trials":46771,"activeCount":102},[],{"trials":46773,"activeCount":102},[],{"intervention":46746,"totalTrials":122,"cells":46775},{"EARLY_PHASE1":46776,"PHASE1":46778,"PHASE2":46784,"PHASE3":46786,"PHASE4":46788,"NA":46790},{"trials":46777,"activeCount":102},[],{"trials":46779,"activeCount":102},[46780],{"nctId":46737,"briefTitle":46738,"status":195,"phases":46781,"primaryCompletion":46740,"completion":46740,"start":46741,"enrollment":1395,"conditions":46782,"interventions":46783},[90],[42519,46743,2171],[46730,46745,46746,46747],{"trials":46785,"activeCount":102},[],{"trials":46787,"activeCount":102},[],{"trials":46789,"activeCount":102},[],{"trials":46791,"activeCount":102},[],{"intervention":46747,"totalTrials":122,"cells":46793},{"EARLY_PHASE1":46794,"PHASE1":46796,"PHASE2":46802,"PHASE3":46804,"PHASE4":46806,"NA":46808},{"trials":46795,"activeCount":102},[],{"trials":46797,"activeCount":102},[46798],{"nctId":46737,"briefTitle":46738,"status":195,"phases":46799,"primaryCompletion":46740,"completion":46740,"start":46741,"enrollment":1395,"conditions":46800,"interventions":46801},[90],[42519,46743,2171],[46730,46745,46746,46747],{"trials":46803,"activeCount":102},[],{"trials":46805,"activeCount":102},[],{"trials":46807,"activeCount":102},[],{"trials":46809,"activeCount":102},[],{"intervention":46811,"totalTrials":122,"cells":46812},"AZD5004 film-coated",{"EARLY_PHASE1":46813,"PHASE1":46815,"PHASE2":46826,"PHASE3":46828,"PHASE4":46830,"NA":46832},{"trials":46814,"activeCount":102},[],{"trials":46816,"activeCount":102},[46817],{"nctId":46818,"briefTitle":46819,"status":195,"phases":46820,"primaryCompletion":46821,"completion":46821,"start":15573,"enrollment":370,"conditions":46822,"interventions":46823},"NCT06857695","A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004",[90],"2025-05-05",[5851],[46811,46824,46825],"[14C]AZD5004 Solution for","[14C]AZD5004 Oral Solution",{"trials":46827,"activeCount":102},[],{"trials":46829,"activeCount":102},[],{"trials":46831,"activeCount":102},[],{"trials":46833,"activeCount":102},[],{"intervention":46824,"totalTrials":122,"cells":46835},{"EARLY_PHASE1":46836,"PHASE1":46838,"PHASE2":46844,"PHASE3":46846,"PHASE4":46848,"NA":46850},{"trials":46837,"activeCount":102},[],{"trials":46839,"activeCount":102},[46840],{"nctId":46818,"briefTitle":46819,"status":195,"phases":46841,"primaryCompletion":46821,"completion":46821,"start":15573,"enrollment":370,"conditions":46842,"interventions":46843},[90],[5851],[46811,46824,46825],{"trials":46845,"activeCount":102},[],{"trials":46847,"activeCount":102},[],{"trials":46849,"activeCount":102},[],{"trials":46851,"activeCount":102},[],{"intervention":46825,"totalTrials":122,"cells":46853},{"EARLY_PHASE1":46854,"PHASE1":46856,"PHASE2":46862,"PHASE3":46864,"PHASE4":46866,"NA":46868},{"trials":46855,"activeCount":102},[],{"trials":46857,"activeCount":102},[46858],{"nctId":46818,"briefTitle":46819,"status":195,"phases":46859,"primaryCompletion":46821,"completion":46821,"start":15573,"enrollment":370,"conditions":46860,"interventions":46861},[90],[5851],[46811,46824,46825],{"trials":46863,"activeCount":102},[],{"trials":46865,"activeCount":102},[],{"trials":46867,"activeCount":102},[],{"trials":46869,"activeCount":102},[],{"intervention":46871,"totalTrials":122,"cells":46872},"100 mg (50 mg x 2) AZD5069",{"EARLY_PHASE1":46873,"PHASE1":46875,"PHASE2":46885,"PHASE3":46887,"PHASE4":46889,"NA":46891},{"trials":46874,"activeCount":102},[],{"trials":46876,"activeCount":102},[46877],{"nctId":46878,"briefTitle":46879,"status":195,"phases":46880,"primaryCompletion":2481,"completion":2481,"start":2589,"enrollment":1710,"conditions":46881,"interventions":46883},"NCT01480739","AZD5069 Neutrophil Function Study",[90],[46882],"Chemokine Receptor 2 (CXCR2) Antagonist",[46871,46884],"100 mg Placebo",{"trials":46886,"activeCount":102},[],{"trials":46888,"activeCount":102},[],{"trials":46890,"activeCount":102},[],{"trials":46892,"activeCount":102},[],{"intervention":46884,"totalTrials":122,"cells":46894},{"EARLY_PHASE1":46895,"PHASE1":46897,"PHASE2":46903,"PHASE3":46905,"PHASE4":46907,"NA":46909},{"trials":46896,"activeCount":102},[],{"trials":46898,"activeCount":102},[46899],{"nctId":46878,"briefTitle":46879,"status":195,"phases":46900,"primaryCompletion":2481,"completion":2481,"start":2589,"enrollment":1710,"conditions":46901,"interventions":46902},[90],[46882],[46871,46884],{"trials":46904,"activeCount":102},[],{"trials":46906,"activeCount":102},[],{"trials":46908,"activeCount":102},[],{"trials":46910,"activeCount":102},[],{"intervention":46912,"totalTrials":122,"cells":46913},"[14C] AZD5069",{"EARLY_PHASE1":46914,"PHASE1":46916,"PHASE2":46924,"PHASE3":46926,"PHASE4":46928,"NA":46930},{"trials":46915,"activeCount":102},[],{"trials":46917,"activeCount":102},[46918],{"nctId":46919,"briefTitle":46920,"status":195,"phases":46921,"primaryCompletion":6709,"completion":6709,"start":2615,"enrollment":1039,"conditions":46922,"interventions":46923},"NCT01332903","Open Label, Healthy Volunteers, ADME Study With Single Oral Administration of [14C] AZD5069",[90],[19],[46912],{"trials":46925,"activeCount":102},[],{"trials":46927,"activeCount":102},[],{"trials":46929,"activeCount":102},[],{"trials":46931,"activeCount":102},[],{"intervention":41485,"totalTrials":122,"cells":46933},{"EARLY_PHASE1":46934,"PHASE1":46936,"PHASE2":46942,"PHASE3":46944,"PHASE4":46946,"NA":46948},{"trials":46935,"activeCount":102},[],{"trials":46937,"activeCount":102},[46938],{"nctId":41479,"briefTitle":41480,"status":195,"phases":46939,"primaryCompletion":41482,"completion":41482,"start":10457,"enrollment":1039,"conditions":46940,"interventions":46941},[90],[41476],[41464,41485],{"trials":46943,"activeCount":102},[],{"trials":46945,"activeCount":102},[],{"trials":46947,"activeCount":102},[],{"trials":46949,"activeCount":102},[],{"intervention":41517,"totalTrials":122,"cells":46951},{"EARLY_PHASE1":46952,"PHASE1":46954,"PHASE2":46960,"PHASE3":46962,"PHASE4":46964,"NA":46966},{"trials":46953,"activeCount":102},[],{"trials":46955,"activeCount":102},[46956],{"nctId":41510,"briefTitle":41511,"status":195,"phases":46957,"primaryCompletion":41513,"completion":41513,"start":41514,"enrollment":689,"conditions":46958,"interventions":46959},[90],[466],[41517,41518,41519,41520,41495],{"trials":46961,"activeCount":102},[],{"trials":46963,"activeCount":102},[],{"trials":46965,"activeCount":102},[],{"trials":46967,"activeCount":102},[],{"intervention":41518,"totalTrials":122,"cells":46969},{"EARLY_PHASE1":46970,"PHASE1":46972,"PHASE2":46978,"PHASE3":46980,"PHASE4":46982,"NA":46984},{"trials":46971,"activeCount":102},[],{"trials":46973,"activeCount":102},[46974],{"nctId":41510,"briefTitle":41511,"status":195,"phases":46975,"primaryCompletion":41513,"completion":41513,"start":41514,"enrollment":689,"conditions":46976,"interventions":46977},[90],[466],[41517,41518,41519,41520,41495],{"trials":46979,"activeCount":102},[],{"trials":46981,"activeCount":102},[],{"trials":46983,"activeCount":102},[],{"trials":46985,"activeCount":102},[],{"intervention":41519,"totalTrials":122,"cells":46987},{"EARLY_PHASE1":46988,"PHASE1":46990,"PHASE2":46996,"PHASE3":46998,"PHASE4":47000,"NA":47002},{"trials":46989,"activeCount":102},[],{"trials":46991,"activeCount":102},[46992],{"nctId":41510,"briefTitle":41511,"status":195,"phases":46993,"primaryCompletion":41513,"completion":41513,"start":41514,"enrollment":689,"conditions":46994,"interventions":46995},[90],[466],[41517,41518,41519,41520,41495],{"trials":46997,"activeCount":102},[],{"trials":46999,"activeCount":102},[],{"trials":47001,"activeCount":102},[],{"trials":47003,"activeCount":102},[],{"intervention":41520,"totalTrials":122,"cells":47005},{"EARLY_PHASE1":47006,"PHASE1":47008,"PHASE2":47014,"PHASE3":47016,"PHASE4":47018,"NA":47020},{"trials":47007,"activeCount":102},[],{"trials":47009,"activeCount":102},[47010],{"nctId":41510,"briefTitle":41511,"status":195,"phases":47011,"primaryCompletion":41513,"completion":41513,"start":41514,"enrollment":689,"conditions":47012,"interventions":47013},[90],[466],[41517,41518,41519,41520,41495],{"trials":47015,"activeCount":102},[],{"trials":47017,"activeCount":102},[],{"trials":47019,"activeCount":102},[],{"trials":47021,"activeCount":102},[],{"intervention":47023,"totalTrials":122,"cells":47024},"AZD5462 film-coated",{"EARLY_PHASE1":47025,"PHASE1":47027,"PHASE2":47037,"PHASE3":47039,"PHASE4":47041,"NA":47043},{"trials":47026,"activeCount":102},[],{"trials":47028,"activeCount":102},[47029],{"nctId":47030,"briefTitle":47031,"status":195,"phases":47032,"primaryCompletion":6245,"completion":6245,"start":12300,"enrollment":370,"conditions":47033,"interventions":47034},"NCT06989983","A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462",[90],[1520],[47023,47035,47036],"[14C]AZD5462 Solution for","[14C]AZD5462 Oral Solution",{"trials":47038,"activeCount":102},[],{"trials":47040,"activeCount":102},[],{"trials":47042,"activeCount":102},[],{"trials":47044,"activeCount":102},[],{"intervention":47035,"totalTrials":122,"cells":47046},{"EARLY_PHASE1":47047,"PHASE1":47049,"PHASE2":47055,"PHASE3":47057,"PHASE4":47059,"NA":47061},{"trials":47048,"activeCount":102},[],{"trials":47050,"activeCount":102},[47051],{"nctId":47030,"briefTitle":47031,"status":195,"phases":47052,"primaryCompletion":6245,"completion":6245,"start":12300,"enrollment":370,"conditions":47053,"interventions":47054},[90],[1520],[47023,47035,47036],{"trials":47056,"activeCount":102},[],{"trials":47058,"activeCount":102},[],{"trials":47060,"activeCount":102},[],{"trials":47062,"activeCount":102},[],{"intervention":47036,"totalTrials":122,"cells":47064},{"EARLY_PHASE1":47065,"PHASE1":47067,"PHASE2":47073,"PHASE3":47075,"PHASE4":47077,"NA":47079},{"trials":47066,"activeCount":102},[],{"trials":47068,"activeCount":102},[47069],{"nctId":47030,"briefTitle":47031,"status":195,"phases":47070,"primaryCompletion":6245,"completion":6245,"start":12300,"enrollment":370,"conditions":47071,"interventions":47072},[90],[1520],[47023,47035,47036],{"trials":47074,"activeCount":102},[],{"trials":47076,"activeCount":102},[],{"trials":47078,"activeCount":102},[],{"trials":47080,"activeCount":102},[],{"intervention":47082,"totalTrials":122,"cells":47083},"MSC-1",{"EARLY_PHASE1":47084,"PHASE1":47086,"PHASE2":47096,"PHASE3":47098,"PHASE4":47100,"NA":47102},{"trials":47085,"activeCount":102},[],{"trials":47087,"activeCount":102},[47088],{"nctId":47089,"briefTitle":47090,"status":195,"phases":47091,"primaryCompletion":47092,"completion":47092,"start":47093,"enrollment":6275,"conditions":47094,"interventions":47095},"NCT03490669","Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors",[90],"2019-09-23","2018-05-21",[4217,415,3864,414],[47082],{"trials":47097,"activeCount":102},[],{"trials":47099,"activeCount":102},[],{"trials":47101,"activeCount":102},[],{"trials":47103,"activeCount":102},[],{"intervention":34034,"totalTrials":122,"cells":47105},{"EARLY_PHASE1":47106,"PHASE1":47108,"PHASE2":47114,"PHASE3":47116,"PHASE4":47118,"NA":47120},{"trials":47107,"activeCount":102},[],{"trials":47109,"activeCount":102},[47110],{"nctId":34028,"briefTitle":34029,"status":443,"phases":47111,"primaryCompletion":34031,"completion":34031,"start":1047,"enrollment":269,"conditions":47112,"interventions":47113},[90],[2661,2279],[34021,34034],{"trials":47115,"activeCount":102},[],{"trials":47117,"activeCount":102},[],{"trials":47119,"activeCount":102},[],{"trials":47121,"activeCount":102},[],{"intervention":41012,"totalTrials":122,"cells":47123},{"EARLY_PHASE1":47124,"PHASE1":47126,"PHASE2":47132,"PHASE3":47134,"PHASE4":47136,"NA":47138},{"trials":47125,"activeCount":102},[],{"trials":47127,"activeCount":102},[47128],{"nctId":41004,"briefTitle":41005,"status":195,"phases":47129,"primaryCompletion":41007,"completion":41007,"start":41008,"enrollment":507,"conditions":47130,"interventions":47131},[90],[41010],[41012,40988],{"trials":47133,"activeCount":102},[],{"trials":47135,"activeCount":102},[],{"trials":47137,"activeCount":102},[],{"trials":47139,"activeCount":102},[],{"intervention":47141,"totalTrials":122,"cells":47142},"AZD8835",{"EARLY_PHASE1":47143,"PHASE1":47145,"PHASE2":47156,"PHASE3":47158,"PHASE4":47160,"NA":47162},{"trials":47144,"activeCount":102},[],{"trials":47146,"activeCount":102},[47147],{"nctId":47148,"briefTitle":47149,"status":195,"phases":47150,"primaryCompletion":772,"completion":772,"start":16044,"enrollment":5876,"conditions":47151,"interventions":47154},"NCT02260661","Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",[90],[157,47152,47153],"Breast Cancer - ER+, HER2 -","Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation",[47141,47141,47155,47155],"AZD8835 in combination with fulvestrant",{"trials":47157,"activeCount":102},[],{"trials":47159,"activeCount":102},[],{"trials":47161,"activeCount":102},[],{"trials":47163,"activeCount":102},[],{"intervention":47155,"totalTrials":122,"cells":47165},{"EARLY_PHASE1":47166,"PHASE1":47168,"PHASE2":47174,"PHASE3":47176,"PHASE4":47178,"NA":47180},{"trials":47167,"activeCount":102},[],{"trials":47169,"activeCount":102},[47170],{"nctId":47148,"briefTitle":47149,"status":195,"phases":47171,"primaryCompletion":772,"completion":772,"start":16044,"enrollment":5876,"conditions":47172,"interventions":47173},[90],[157,47152,47153],[47141,47141,47155,47155],{"trials":47175,"activeCount":102},[],{"trials":47177,"activeCount":102},[],{"trials":47179,"activeCount":102},[],{"trials":47181,"activeCount":102},[],{"intervention":47183,"totalTrials":122,"cells":47184},"terbutaline sulphate delivered dose",{"EARLY_PHASE1":47185,"PHASE1":47187,"PHASE2":47196,"PHASE3":47198,"PHASE4":47200,"NA":47202},{"trials":47186,"activeCount":102},[],{"trials":47188,"activeCount":102},[47189],{"nctId":47190,"briefTitle":47191,"status":195,"phases":47192,"primaryCompletion":16044,"completion":16044,"start":2560,"enrollment":17655,"conditions":47193,"interventions":47194},"NCT02178059","Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2",[90],[36],[47183,47195],"terbutaline sulphate metered dose",{"trials":47197,"activeCount":102},[],{"trials":47199,"activeCount":102},[],{"trials":47201,"activeCount":102},[],{"trials":47203,"activeCount":102},[],{"intervention":47195,"totalTrials":122,"cells":47205},{"EARLY_PHASE1":47206,"PHASE1":47208,"PHASE2":47214,"PHASE3":47216,"PHASE4":47218,"NA":47220},{"trials":47207,"activeCount":102},[],{"trials":47209,"activeCount":102},[47210],{"nctId":47190,"briefTitle":47191,"status":195,"phases":47211,"primaryCompletion":16044,"completion":16044,"start":2560,"enrollment":17655,"conditions":47212,"interventions":47213},[90],[36],[47183,47195],{"trials":47215,"activeCount":102},[],{"trials":47217,"activeCount":102},[],{"trials":47219,"activeCount":102},[],{"trials":47221,"activeCount":102},[],{"intervention":47223,"totalTrials":122,"cells":47224},"AR-C165395XX",{"EARLY_PHASE1":47225,"PHASE1":47227,"PHASE2":47235,"PHASE3":47237,"PHASE4":47239,"NA":47241},{"trials":47226,"activeCount":102},[],{"trials":47228,"activeCount":102},[47229],{"nctId":47230,"briefTitle":47231,"status":195,"phases":47232,"primaryCompletion":13756,"completion":13756,"start":25278,"enrollment":1710,"conditions":47233,"interventions":47234},"NCT02367066","A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)",[90],[22],[47223],{"trials":47236,"activeCount":102},[],{"trials":47238,"activeCount":102},[],{"trials":47240,"activeCount":102},[],{"trials":47242,"activeCount":102},[],{"intervention":47244,"totalTrials":122,"cells":47245},"AZD8233 subcutaneous",{"EARLY_PHASE1":47246,"PHASE1":47248,"PHASE2":47257,"PHASE3":47259,"PHASE4":47261,"NA":47263},{"trials":47247,"activeCount":102},[],{"trials":47249,"activeCount":102},[47250],{"nctId":47251,"briefTitle":47252,"status":195,"phases":47253,"primaryCompletion":47254,"completion":47254,"start":1709,"enrollment":17655,"conditions":47255,"interventions":47256},"NCT04155645","To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia",[90],"2021-06-07",[6903],[47244],{"trials":47258,"activeCount":102},[],{"trials":47260,"activeCount":102},[],{"trials":47262,"activeCount":102},[],{"trials":47264,"activeCount":102},[],{"intervention":47266,"totalTrials":122,"cells":47267},"Dose 1, AZD8871 50 μg",{"EARLY_PHASE1":47268,"PHASE1":47270,"PHASE2":47289,"PHASE3":47291,"PHASE4":47293,"NA":47295},{"trials":47269,"activeCount":102},[],{"trials":47271,"activeCount":102},[47272],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47275,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47276,"interventions":47279},"NCT02573155","Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects",[90],[47277,47278],"Asthma (Part 1)","COPD (Part 2)",[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],"Dose 2, AZD8871 100 μg","Dose 3, AZD8871 300 μg","Dose 4, AZD8871 600 µg","Dose 5, AZD8871 1200 µg","Dose 6, AZD8871 1800 μg","Treatment A, AZD8871 dose A","Treatment B, AZD8871 dose B","Treatment C, Indacaterol 150 μg","Treatment D, Tiotropium 18 μg",{"trials":47290,"activeCount":102},[],{"trials":47292,"activeCount":102},[],{"trials":47294,"activeCount":102},[],{"trials":47296,"activeCount":102},[],{"intervention":47280,"totalTrials":122,"cells":47298},{"EARLY_PHASE1":47299,"PHASE1":47301,"PHASE2":47307,"PHASE3":47309,"PHASE4":47311,"NA":47313},{"trials":47300,"activeCount":102},[],{"trials":47302,"activeCount":102},[47303],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47304,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47305,"interventions":47306},[90],[47277,47278],[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],{"trials":47308,"activeCount":102},[],{"trials":47310,"activeCount":102},[],{"trials":47312,"activeCount":102},[],{"trials":47314,"activeCount":102},[],{"intervention":47281,"totalTrials":122,"cells":47316},{"EARLY_PHASE1":47317,"PHASE1":47319,"PHASE2":47325,"PHASE3":47327,"PHASE4":47329,"NA":47331},{"trials":47318,"activeCount":102},[],{"trials":47320,"activeCount":102},[47321],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47322,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47323,"interventions":47324},[90],[47277,47278],[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],{"trials":47326,"activeCount":102},[],{"trials":47328,"activeCount":102},[],{"trials":47330,"activeCount":102},[],{"trials":47332,"activeCount":102},[],{"intervention":47282,"totalTrials":122,"cells":47334},{"EARLY_PHASE1":47335,"PHASE1":47337,"PHASE2":47343,"PHASE3":47345,"PHASE4":47347,"NA":47349},{"trials":47336,"activeCount":102},[],{"trials":47338,"activeCount":102},[47339],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47340,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47341,"interventions":47342},[90],[47277,47278],[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],{"trials":47344,"activeCount":102},[],{"trials":47346,"activeCount":102},[],{"trials":47348,"activeCount":102},[],{"trials":47350,"activeCount":102},[],{"intervention":47283,"totalTrials":122,"cells":47352},{"EARLY_PHASE1":47353,"PHASE1":47355,"PHASE2":47361,"PHASE3":47363,"PHASE4":47365,"NA":47367},{"trials":47354,"activeCount":102},[],{"trials":47356,"activeCount":102},[47357],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47358,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47359,"interventions":47360},[90],[47277,47278],[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],{"trials":47362,"activeCount":102},[],{"trials":47364,"activeCount":102},[],{"trials":47366,"activeCount":102},[],{"trials":47368,"activeCount":102},[],{"intervention":47284,"totalTrials":122,"cells":47370},{"EARLY_PHASE1":47371,"PHASE1":47373,"PHASE2":47379,"PHASE3":47381,"PHASE4":47383,"NA":47385},{"trials":47372,"activeCount":102},[],{"trials":47374,"activeCount":102},[47375],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47376,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47377,"interventions":47378},[90],[47277,47278],[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],{"trials":47380,"activeCount":102},[],{"trials":47382,"activeCount":102},[],{"trials":47384,"activeCount":102},[],{"trials":47386,"activeCount":102},[],{"intervention":47285,"totalTrials":122,"cells":47388},{"EARLY_PHASE1":47389,"PHASE1":47391,"PHASE2":47397,"PHASE3":47399,"PHASE4":47401,"NA":47403},{"trials":47390,"activeCount":102},[],{"trials":47392,"activeCount":102},[47393],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47394,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47395,"interventions":47396},[90],[47277,47278],[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],{"trials":47398,"activeCount":102},[],{"trials":47400,"activeCount":102},[],{"trials":47402,"activeCount":102},[],{"trials":47404,"activeCount":102},[],{"intervention":47286,"totalTrials":122,"cells":47406},{"EARLY_PHASE1":47407,"PHASE1":47409,"PHASE2":47415,"PHASE3":47417,"PHASE4":47419,"NA":47421},{"trials":47408,"activeCount":102},[],{"trials":47410,"activeCount":102},[47411],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47412,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47413,"interventions":47414},[90],[47277,47278],[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],{"trials":47416,"activeCount":102},[],{"trials":47418,"activeCount":102},[],{"trials":47420,"activeCount":102},[],{"trials":47422,"activeCount":102},[],{"intervention":47287,"totalTrials":122,"cells":47424},{"EARLY_PHASE1":47425,"PHASE1":47427,"PHASE2":47433,"PHASE3":47435,"PHASE4":47437,"NA":47439},{"trials":47426,"activeCount":102},[],{"trials":47428,"activeCount":102},[47429],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47430,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47431,"interventions":47432},[90],[47277,47278],[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],{"trials":47434,"activeCount":102},[],{"trials":47436,"activeCount":102},[],{"trials":47438,"activeCount":102},[],{"trials":47440,"activeCount":102},[],{"intervention":47288,"totalTrials":122,"cells":47442},{"EARLY_PHASE1":47443,"PHASE1":47445,"PHASE2":47451,"PHASE3":47453,"PHASE4":47455,"NA":47457},{"trials":47444,"activeCount":102},[],{"trials":47446,"activeCount":102},[47447],{"nctId":47273,"briefTitle":47274,"status":195,"phases":47448,"primaryCompletion":13123,"completion":13123,"start":13056,"enrollment":1666,"conditions":47449,"interventions":47450},[90],[47277,47278],[47266,47280,47281,47282,47283,47284,47285,47286,47287,47288],{"trials":47452,"activeCount":102},[],{"trials":47454,"activeCount":102},[],{"trials":47456,"activeCount":102},[],{"trials":47458,"activeCount":102},[],{"intervention":47460,"totalTrials":122,"cells":47461},"Dapagliflozin\u002Fmetformin XR 5\u002F500mg",{"EARLY_PHASE1":47462,"PHASE1":47464,"PHASE2":47477,"PHASE3":47479,"PHASE4":47481,"NA":47483},{"trials":47463,"activeCount":102},[],{"trials":47465,"activeCount":102},[47466],{"nctId":47467,"briefTitle":47468,"status":195,"phases":47469,"primaryCompletion":12573,"completion":12573,"start":47470,"enrollment":47471,"conditions":47472,"interventions":47474},"NCT03216278","The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin\u002FMetformin XR in Healthy Subjects Under Fasting and Fed Conditions",[90],"2017-09-26",284,[47473],"Healthy Subjects in Fasted and Fed State",[47460,47475,47460,47460,47476,47476,47476,47476],"Dapagliflozin\u002Fmetformin XR 5\u002F500 mg","Dapagliflozin\u002Fmetformin XR 10\u002F1000mg",{"trials":47478,"activeCount":102},[],{"trials":47480,"activeCount":102},[],{"trials":47482,"activeCount":102},[],{"trials":47484,"activeCount":102},[],{"intervention":47475,"totalTrials":122,"cells":47486},{"EARLY_PHASE1":47487,"PHASE1":47489,"PHASE2":47495,"PHASE3":47497,"PHASE4":47499,"NA":47501},{"trials":47488,"activeCount":102},[],{"trials":47490,"activeCount":102},[47491],{"nctId":47467,"briefTitle":47468,"status":195,"phases":47492,"primaryCompletion":12573,"completion":12573,"start":47470,"enrollment":47471,"conditions":47493,"interventions":47494},[90],[47473],[47460,47475,47460,47460,47476,47476,47476,47476],{"trials":47496,"activeCount":102},[],{"trials":47498,"activeCount":102},[],{"trials":47500,"activeCount":102},[],{"trials":47502,"activeCount":102},[],{"intervention":47476,"totalTrials":122,"cells":47504},{"EARLY_PHASE1":47505,"PHASE1":47507,"PHASE2":47513,"PHASE3":47515,"PHASE4":47517,"NA":47519},{"trials":47506,"activeCount":102},[],{"trials":47508,"activeCount":102},[47509],{"nctId":47467,"briefTitle":47468,"status":195,"phases":47510,"primaryCompletion":12573,"completion":12573,"start":47470,"enrollment":47471,"conditions":47511,"interventions":47512},[90],[47473],[47460,47475,47460,47460,47476,47476,47476,47476],{"trials":47514,"activeCount":102},[],{"trials":47516,"activeCount":102},[],{"trials":47518,"activeCount":102},[],{"trials":47520,"activeCount":102},[],{"intervention":47522,"totalTrials":122,"cells":47523},"AZD9833 film-coated tablet A Dose 1",{"EARLY_PHASE1":47524,"PHASE1":47526,"PHASE2":47538,"PHASE3":47540,"PHASE4":47542,"NA":47544},{"trials":47525,"activeCount":102},[],{"trials":47527,"activeCount":102},[47528],{"nctId":47529,"briefTitle":47530,"status":195,"phases":47531,"primaryCompletion":942,"completion":942,"start":33978,"enrollment":579,"conditions":47532,"interventions":47533},"NCT04546347","A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833",[90],[36],[47522,47534,47535,47536,47537],"AZD9833 Oral Solution","AZD9833 film-coated tablet B Dose 1","AZD9833 film-coated tablet A Dose 2","AZD9833 film-coated tablet B Dose 2",{"trials":47539,"activeCount":102},[],{"trials":47541,"activeCount":102},[],{"trials":47543,"activeCount":102},[],{"trials":47545,"activeCount":102},[],{"intervention":47534,"totalTrials":122,"cells":47547},{"EARLY_PHASE1":47548,"PHASE1":47550,"PHASE2":47556,"PHASE3":47558,"PHASE4":47560,"NA":47562},{"trials":47549,"activeCount":102},[],{"trials":47551,"activeCount":102},[47552],{"nctId":47529,"briefTitle":47530,"status":195,"phases":47553,"primaryCompletion":942,"completion":942,"start":33978,"enrollment":579,"conditions":47554,"interventions":47555},[90],[36],[47522,47534,47535,47536,47537],{"trials":47557,"activeCount":102},[],{"trials":47559,"activeCount":102},[],{"trials":47561,"activeCount":102},[],{"trials":47563,"activeCount":102},[],{"intervention":47535,"totalTrials":122,"cells":47565},{"EARLY_PHASE1":47566,"PHASE1":47568,"PHASE2":47574,"PHASE3":47576,"PHASE4":47578,"NA":47580},{"trials":47567,"activeCount":102},[],{"trials":47569,"activeCount":102},[47570],{"nctId":47529,"briefTitle":47530,"status":195,"phases":47571,"primaryCompletion":942,"completion":942,"start":33978,"enrollment":579,"conditions":47572,"interventions":47573},[90],[36],[47522,47534,47535,47536,47537],{"trials":47575,"activeCount":102},[],{"trials":47577,"activeCount":102},[],{"trials":47579,"activeCount":102},[],{"trials":47581,"activeCount":102},[],{"intervention":47536,"totalTrials":122,"cells":47583},{"EARLY_PHASE1":47584,"PHASE1":47586,"PHASE2":47592,"PHASE3":47594,"PHASE4":47596,"NA":47598},{"trials":47585,"activeCount":102},[],{"trials":47587,"activeCount":102},[47588],{"nctId":47529,"briefTitle":47530,"status":195,"phases":47589,"primaryCompletion":942,"completion":942,"start":33978,"enrollment":579,"conditions":47590,"interventions":47591},[90],[36],[47522,47534,47535,47536,47537],{"trials":47593,"activeCount":102},[],{"trials":47595,"activeCount":102},[],{"trials":47597,"activeCount":102},[],{"trials":47599,"activeCount":102},[],{"intervention":47537,"totalTrials":122,"cells":47601},{"EARLY_PHASE1":47602,"PHASE1":47604,"PHASE2":47610,"PHASE3":47612,"PHASE4":47614,"NA":47616},{"trials":47603,"activeCount":102},[],{"trials":47605,"activeCount":102},[47606],{"nctId":47529,"briefTitle":47530,"status":195,"phases":47607,"primaryCompletion":942,"completion":942,"start":33978,"enrollment":579,"conditions":47608,"interventions":47609},[90],[36],[47522,47534,47535,47536,47537],{"trials":47611,"activeCount":102},[],{"trials":47613,"activeCount":102},[],{"trials":47615,"activeCount":102},[],{"trials":47617,"activeCount":102},[],{"intervention":47619,"totalTrials":122,"cells":47620},"Loxoprofen",{"EARLY_PHASE1":47621,"PHASE1":47623,"PHASE2":47631,"PHASE3":47633,"PHASE4":47635,"NA":47637},{"trials":47622,"activeCount":102},[],{"trials":47624,"activeCount":102},[47625],{"nctId":47626,"briefTitle":47627,"status":195,"phases":47628,"primaryCompletion":2507,"completion":2507,"start":2251,"enrollment":1710,"conditions":47629,"interventions":47630},"NCT00676117","Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males",[90],[19],[19794,47619],{"trials":47632,"activeCount":102},[],{"trials":47634,"activeCount":102},[],{"trials":47636,"activeCount":102},[],{"trials":47638,"activeCount":102},[],{"intervention":47640,"totalTrials":122,"cells":47641},"MEDI-551",{"EARLY_PHASE1":47642,"PHASE1":47644,"PHASE2":47656,"PHASE3":47658,"PHASE4":47660,"NA":47662},{"trials":47643,"activeCount":102},[],{"trials":47645,"activeCount":102},[47646],{"nctId":47647,"briefTitle":47648,"status":195,"phases":47649,"primaryCompletion":47650,"completion":47650,"start":47651,"enrollment":579,"conditions":47652,"interventions":47655},"NCT01957579","A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies",[90],"2015-09-15","2011-05-25",[47653,47654],"Blood Cancer","Advanced B Cell Malignancies",[47640],{"trials":47657,"activeCount":102},[],{"trials":47659,"activeCount":102},[],{"trials":47661,"activeCount":102},[],{"trials":47663,"activeCount":102},[],{"intervention":41116,"totalTrials":122,"cells":47665},{"EARLY_PHASE1":47666,"PHASE1":47668,"PHASE2":47674,"PHASE3":47676,"PHASE4":47678,"NA":47680},{"trials":47667,"activeCount":102},[],{"trials":47669,"activeCount":102},[47670],{"nctId":41110,"briefTitle":41111,"status":195,"phases":47671,"primaryCompletion":2489,"completion":2489,"start":3862,"enrollment":520,"conditions":47672,"interventions":47673},[90],[41114,36],[41116,16379],{"trials":47675,"activeCount":102},[],{"trials":47677,"activeCount":102},[],{"trials":47679,"activeCount":102},[],{"trials":47681,"activeCount":102},[],{"intervention":47683,"totalTrials":122,"cells":47684},"BDA MDI 160\u002F180 mcg",{"EARLY_PHASE1":47685,"PHASE1":47687,"PHASE2":47697,"PHASE3":47699,"PHASE4":47701,"NA":47703},{"trials":47686,"activeCount":102},[],{"trials":47688,"activeCount":102},[47689],{"nctId":47690,"briefTitle":47691,"status":195,"phases":47692,"primaryCompletion":24216,"completion":24216,"start":47693,"enrollment":2222,"conditions":47694,"interventions":47695},"NCT03934333","A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)",[90],"2019-05-16",[25265],[47683,47696],"Pulmicort Flexhaler 180 mcg",{"trials":47698,"activeCount":102},[],{"trials":47700,"activeCount":102},[],{"trials":47702,"activeCount":102},[],{"trials":47704,"activeCount":102},[],{"intervention":47696,"totalTrials":122,"cells":47706},{"EARLY_PHASE1":47707,"PHASE1":47709,"PHASE2":47715,"PHASE3":47717,"PHASE4":47719,"NA":47721},{"trials":47708,"activeCount":102},[],{"trials":47710,"activeCount":102},[47711],{"nctId":47690,"briefTitle":47691,"status":195,"phases":47712,"primaryCompletion":24216,"completion":24216,"start":47693,"enrollment":2222,"conditions":47713,"interventions":47714},[90],[25265],[47683,47696],{"trials":47716,"activeCount":102},[],{"trials":47718,"activeCount":102},[],{"trials":47720,"activeCount":102},[],{"trials":47722,"activeCount":102},[],{"intervention":47724,"totalTrials":122,"cells":47725},"AZD3293 oral solution",{"EARLY_PHASE1":47726,"PHASE1":47728,"PHASE2":47738,"PHASE3":47740,"PHASE4":47742,"NA":47744},{"trials":47727,"activeCount":102},[],{"trials":47729,"activeCount":102},[47730],{"nctId":47731,"briefTitle":47732,"status":195,"phases":47733,"primaryCompletion":4006,"completion":4006,"start":2204,"enrollment":122,"conditions":47734,"interventions":47735},"NCT02039180","Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects",[90],[36,43089],[47724,47736,47737],"AZD3293 tablet formulation A","AZD3293 tablet formulation B",{"trials":47739,"activeCount":102},[],{"trials":47741,"activeCount":102},[],{"trials":47743,"activeCount":102},[],{"trials":47745,"activeCount":102},[],{"intervention":47736,"totalTrials":122,"cells":47747},{"EARLY_PHASE1":47748,"PHASE1":47750,"PHASE2":47756,"PHASE3":47758,"PHASE4":47760,"NA":47762},{"trials":47749,"activeCount":102},[],{"trials":47751,"activeCount":102},[47752],{"nctId":47731,"briefTitle":47732,"status":195,"phases":47753,"primaryCompletion":4006,"completion":4006,"start":2204,"enrollment":122,"conditions":47754,"interventions":47755},[90],[36,43089],[47724,47736,47737],{"trials":47757,"activeCount":102},[],{"trials":47759,"activeCount":102},[],{"trials":47761,"activeCount":102},[],{"trials":47763,"activeCount":102},[],{"intervention":47737,"totalTrials":122,"cells":47765},{"EARLY_PHASE1":47766,"PHASE1":47768,"PHASE2":47774,"PHASE3":47776,"PHASE4":47778,"NA":47780},{"trials":47767,"activeCount":102},[],{"trials":47769,"activeCount":102},[47770],{"nctId":47731,"briefTitle":47732,"status":195,"phases":47771,"primaryCompletion":4006,"completion":4006,"start":2204,"enrollment":122,"conditions":47772,"interventions":47773},[90],[36,43089],[47724,47736,47737],{"trials":47775,"activeCount":102},[],{"trials":47777,"activeCount":102},[],{"trials":47779,"activeCount":102},[],{"trials":47781,"activeCount":102},[],{"intervention":47783,"totalTrials":122,"cells":47784},"AZD5634 for inhalation",{"EARLY_PHASE1":47785,"PHASE1":47787,"PHASE2":47798,"PHASE3":47800,"PHASE4":47802,"NA":47804},{"trials":47786,"activeCount":102},[],{"trials":47788,"activeCount":102},[47789],{"nctId":47790,"briefTitle":47791,"status":195,"phases":47792,"primaryCompletion":47793,"completion":47793,"start":47794,"enrollment":18686,"conditions":47795,"interventions":47796},"NCT02679729","To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration",[90],"2016-10-24","2016-02-11",[32133],[47783,47797],"AZD5634 for",{"trials":47799,"activeCount":102},[],{"trials":47801,"activeCount":102},[],{"trials":47803,"activeCount":102},[],{"trials":47805,"activeCount":102},[],{"intervention":47797,"totalTrials":122,"cells":47807},{"EARLY_PHASE1":47808,"PHASE1":47810,"PHASE2":47816,"PHASE3":47818,"PHASE4":47820,"NA":47822},{"trials":47809,"activeCount":102},[],{"trials":47811,"activeCount":102},[47812],{"nctId":47790,"briefTitle":47791,"status":195,"phases":47813,"primaryCompletion":47793,"completion":47793,"start":47794,"enrollment":18686,"conditions":47814,"interventions":47815},[90],[32133],[47783,47797],{"trials":47817,"activeCount":102},[],{"trials":47819,"activeCount":102},[],{"trials":47821,"activeCount":102},[],{"trials":47823,"activeCount":102},[],{"intervention":47825,"totalTrials":122,"cells":47826},"Ticagrelor granule",{"EARLY_PHASE1":47827,"PHASE1":47829,"PHASE2":47842,"PHASE3":47844,"PHASE4":47846,"NA":47848},{"trials":47828,"activeCount":102},[],{"trials":47830,"activeCount":102},[47831],{"nctId":47832,"briefTitle":47833,"status":195,"phases":47834,"primaryCompletion":47835,"completion":47835,"start":47836,"enrollment":3811,"conditions":47837,"interventions":47838},"NCT03126695","A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered",[90],"2017-07-24","2017-05-12",[19206],[47825,47839,47840,47841],"Ticagrelor pediatric","Ticagrelor pediatric tablets suspended in water","Ticagrelor immediate release",{"trials":47843,"activeCount":102},[],{"trials":47845,"activeCount":102},[],{"trials":47847,"activeCount":102},[],{"trials":47849,"activeCount":102},[],{"intervention":47839,"totalTrials":122,"cells":47851},{"EARLY_PHASE1":47852,"PHASE1":47854,"PHASE2":47860,"PHASE3":47862,"PHASE4":47864,"NA":47866},{"trials":47853,"activeCount":102},[],{"trials":47855,"activeCount":102},[47856],{"nctId":47832,"briefTitle":47833,"status":195,"phases":47857,"primaryCompletion":47835,"completion":47835,"start":47836,"enrollment":3811,"conditions":47858,"interventions":47859},[90],[19206],[47825,47839,47840,47841],{"trials":47861,"activeCount":102},[],{"trials":47863,"activeCount":102},[],{"trials":47865,"activeCount":102},[],{"trials":47867,"activeCount":102},[],{"intervention":47840,"totalTrials":122,"cells":47869},{"EARLY_PHASE1":47870,"PHASE1":47872,"PHASE2":47878,"PHASE3":47880,"PHASE4":47882,"NA":47884},{"trials":47871,"activeCount":102},[],{"trials":47873,"activeCount":102},[47874],{"nctId":47832,"briefTitle":47833,"status":195,"phases":47875,"primaryCompletion":47835,"completion":47835,"start":47836,"enrollment":3811,"conditions":47876,"interventions":47877},[90],[19206],[47825,47839,47840,47841],{"trials":47879,"activeCount":102},[],{"trials":47881,"activeCount":102},[],{"trials":47883,"activeCount":102},[],{"trials":47885,"activeCount":102},[],{"intervention":47841,"totalTrials":122,"cells":47887},{"EARLY_PHASE1":47888,"PHASE1":47890,"PHASE2":47896,"PHASE3":47898,"PHASE4":47900,"NA":47902},{"trials":47889,"activeCount":102},[],{"trials":47891,"activeCount":102},[47892],{"nctId":47832,"briefTitle":47833,"status":195,"phases":47893,"primaryCompletion":47835,"completion":47835,"start":47836,"enrollment":3811,"conditions":47894,"interventions":47895},[90],[19206],[47825,47839,47840,47841],{"trials":47897,"activeCount":102},[],{"trials":47899,"activeCount":102},[],{"trials":47901,"activeCount":102},[],{"trials":47903,"activeCount":102},[],{"intervention":31251,"totalTrials":122,"cells":47905},{"EARLY_PHASE1":47906,"PHASE1":47908,"PHASE2":47914,"PHASE3":47916,"PHASE4":47918,"NA":47920},{"trials":47907,"activeCount":102},[],{"trials":47909,"activeCount":102},[47910],{"nctId":31246,"briefTitle":31247,"status":195,"phases":47911,"primaryCompletion":2320,"completion":2320,"start":2095,"enrollment":370,"conditions":47912,"interventions":47913},[90],[31],[15883,31251],{"trials":47915,"activeCount":102},[],{"trials":47917,"activeCount":102},[],{"trials":47919,"activeCount":102},[],{"trials":47921,"activeCount":102},[],{"intervention":523,"totalTrials":122,"cells":47923},{"EARLY_PHASE1":47924,"PHASE1":47926,"PHASE2":47932,"PHASE3":47934,"PHASE4":47936,"NA":47938},{"trials":47925,"activeCount":102},[],{"trials":47927,"activeCount":102},[47928],{"nctId":514,"briefTitle":515,"status":443,"phases":47929,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":47930,"interventions":47931},[90],[25],[267,344,523,524],{"trials":47933,"activeCount":102},[],{"trials":47935,"activeCount":102},[],{"trials":47937,"activeCount":102},[],{"trials":47939,"activeCount":102},[],{"intervention":3058,"totalTrials":122,"cells":47941},{"EARLY_PHASE1":47942,"PHASE1":47944,"PHASE2":47950,"PHASE3":47952,"PHASE4":47954,"NA":47956},{"trials":47943,"activeCount":102},[],{"trials":47945,"activeCount":102},[47946],{"nctId":3050,"briefTitle":3051,"status":443,"phases":47947,"primaryCompletion":3053,"completion":3053,"start":3054,"enrollment":1448,"conditions":47948,"interventions":47949},[90],[3056],[3058,117],{"trials":47951,"activeCount":102},[],{"trials":47953,"activeCount":102},[],{"trials":47955,"activeCount":102},[],{"trials":47957,"activeCount":102},[],{"intervention":6894,"totalTrials":122,"cells":47959},{"EARLY_PHASE1":47960,"PHASE1":47962,"PHASE2":47968,"PHASE3":47970,"PHASE4":47972,"NA":47974},{"trials":47961,"activeCount":102},[],{"trials":47963,"activeCount":102},[47964],{"nctId":6886,"briefTitle":6887,"status":195,"phases":47965,"primaryCompletion":6889,"completion":6889,"start":6890,"enrollment":370,"conditions":47966,"interventions":47967},[90],[6892],[6860,6894,6895],{"trials":47969,"activeCount":102},[],{"trials":47971,"activeCount":102},[],{"trials":47973,"activeCount":102},[],{"trials":47975,"activeCount":102},[],{"intervention":6895,"totalTrials":122,"cells":47977},{"EARLY_PHASE1":47978,"PHASE1":47980,"PHASE2":47986,"PHASE3":47988,"PHASE4":47990,"NA":47992},{"trials":47979,"activeCount":102},[],{"trials":47981,"activeCount":102},[47982],{"nctId":6886,"briefTitle":6887,"status":195,"phases":47983,"primaryCompletion":6889,"completion":6889,"start":6890,"enrollment":370,"conditions":47984,"interventions":47985},[90],[6892],[6860,6894,6895],{"trials":47987,"activeCount":102},[],{"trials":47989,"activeCount":102},[],{"trials":47991,"activeCount":102},[],{"trials":47993,"activeCount":102},[],{"intervention":47995,"totalTrials":122,"cells":47996},"Sabestomig",{"EARLY_PHASE1":47997,"PHASE1":47999,"PHASE2":48009,"PHASE3":48011,"PHASE4":48013,"NA":48015},{"trials":47998,"activeCount":102},[],{"trials":48000,"activeCount":102},[48001],{"nctId":48002,"briefTitle":48003,"status":195,"phases":48004,"primaryCompletion":33898,"completion":13173,"start":48005,"enrollment":1864,"conditions":48006,"interventions":48008},"NCT05216835","Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma",[90],"2022-03-18",[48007],"Relapsed or Refractory Classical Hodgkin Lymphoma",[47995],{"trials":48010,"activeCount":102},[],{"trials":48012,"activeCount":102},[],{"trials":48014,"activeCount":102},[],{"trials":48016,"activeCount":102},[],{"intervention":6906,"totalTrials":122,"cells":48018},{"EARLY_PHASE1":48019,"PHASE1":48021,"PHASE2":48027,"PHASE3":48029,"PHASE4":48031,"NA":48033},{"trials":48020,"activeCount":102},[],{"trials":48022,"activeCount":102},[48023],{"nctId":6897,"briefTitle":6898,"status":195,"phases":48024,"primaryCompletion":6900,"completion":6900,"start":3438,"enrollment":6901,"conditions":48025,"interventions":48026},[90],[6903],[6860,6905,5887,6906],{"trials":48028,"activeCount":102},[],{"trials":48030,"activeCount":102},[],{"trials":48032,"activeCount":102},[],{"trials":48034,"activeCount":102},[],{"intervention":42039,"totalTrials":122,"cells":48036},{"EARLY_PHASE1":48037,"PHASE1":48039,"PHASE2":48045,"PHASE3":48047,"PHASE4":48049,"NA":48051},{"trials":48038,"activeCount":102},[],{"trials":48040,"activeCount":102},[48041],{"nctId":42034,"briefTitle":42035,"status":195,"phases":48042,"primaryCompletion":2055,"completion":2055,"start":2057,"enrollment":1710,"conditions":48043,"interventions":48044},[90],[2631],[18965,42039,23494],{"trials":48046,"activeCount":102},[],{"trials":48048,"activeCount":102},[],{"trials":48050,"activeCount":102},[],{"trials":48052,"activeCount":102},[],{"intervention":7064,"totalTrials":122,"cells":48054},{"EARLY_PHASE1":48055,"PHASE1":48057,"PHASE2":48063,"PHASE3":48065,"PHASE4":48067,"NA":48069},{"trials":48056,"activeCount":102},[],{"trials":48058,"activeCount":102},[48059],{"nctId":7057,"briefTitle":7058,"status":195,"phases":48060,"primaryCompletion":7060,"completion":7060,"start":7061,"enrollment":486,"conditions":48061,"interventions":48062},[90],[466],[87,7064],{"trials":48064,"activeCount":102},[],{"trials":48066,"activeCount":102},[],{"trials":48068,"activeCount":102},[],{"trials":48070,"activeCount":102},[],{"intervention":48072,"totalTrials":122,"cells":48073},"Eplontersen Solution for",{"EARLY_PHASE1":48074,"PHASE1":48076,"PHASE2":48086,"PHASE3":48088,"PHASE4":48090,"NA":48092},{"trials":48075,"activeCount":102},[],{"trials":48077,"activeCount":102},[48078],{"nctId":48079,"briefTitle":48080,"status":195,"phases":48081,"primaryCompletion":10115,"completion":48082,"start":29101,"enrollment":1757,"conditions":48083,"interventions":48085},"NCT06527755","A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers",[90],"2024-11-15",[48084],"Transthyretin-mediated Amyloidosis",[48072],{"trials":48087,"activeCount":102},[],{"trials":48089,"activeCount":102},[],{"trials":48091,"activeCount":102},[],{"trials":48093,"activeCount":102},[],{"intervention":48095,"totalTrials":122,"cells":48096},"Administration of AZD6738",{"EARLY_PHASE1":48097,"PHASE1":48099,"PHASE2":48110,"PHASE3":48112,"PHASE4":48114,"NA":48116},{"trials":48098,"activeCount":102},[],{"trials":48100,"activeCount":102},[48101],{"nctId":48102,"briefTitle":48103,"status":195,"phases":48104,"primaryCompletion":39977,"completion":39977,"start":1693,"enrollment":447,"conditions":48105,"interventions":48109},"NCT01955668","AZD6738 First Time in Patient Multiple Ascending Dose Study",[90],[48106,48107,48108],"11q-deleted Relapsed\u002FRefractory Chronic Lymphocytic Leukaemia (CLL),","Prolymphocytic Leukaemia (PLL)","B Cell Lymphomas",[48095],{"trials":48111,"activeCount":102},[],{"trials":48113,"activeCount":102},[],{"trials":48115,"activeCount":102},[],{"trials":48117,"activeCount":102},[],{"intervention":48119,"totalTrials":122,"cells":48120},"Intermittent dosing of AZD5363",{"EARLY_PHASE1":48121,"PHASE1":48123,"PHASE2":48135,"PHASE3":48137,"PHASE4":48139,"NA":48141},{"trials":48122,"activeCount":102},[],{"trials":48124,"activeCount":102},[48125],{"nctId":48126,"briefTitle":48127,"status":195,"phases":48128,"primaryCompletion":2470,"completion":2470,"start":2104,"enrollment":3209,"conditions":48129,"interventions":48134},"NCT01692262","Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.",[90],[48130,48131,41271,31968,48132,48133],"Metastatic Castrate-Resistant Prostate Cancer (mCRPC),","Efficacy,","Pharmacodynamics,","Tumour Response.",[48119,48119,48119],{"trials":48136,"activeCount":102},[],{"trials":48138,"activeCount":102},[],{"trials":48140,"activeCount":102},[],{"trials":48142,"activeCount":102},[],{"intervention":22954,"totalTrials":122,"cells":48144},{"EARLY_PHASE1":48145,"PHASE1":48147,"PHASE2":48153,"PHASE3":48155,"PHASE4":48157,"NA":48159},{"trials":48146,"activeCount":102},[],{"trials":48148,"activeCount":102},[48149],{"nctId":22948,"briefTitle":22949,"status":624,"phases":48150,"primaryCompletion":4496,"completion":4496,"start":2747,"enrollment":102,"conditions":48151,"interventions":48152},[90],[22952,19],[22928,22954,22955,22956,22928,22928,22956],{"trials":48154,"activeCount":102},[],{"trials":48156,"activeCount":102},[],{"trials":48158,"activeCount":102},[],{"trials":48160,"activeCount":102},[],{"intervention":48162,"totalTrials":122,"cells":48163},"Saxagliptin, 2.5 mg + Metformin, 500 mg",{"EARLY_PHASE1":48164,"PHASE1":48166,"PHASE2":48175,"PHASE3":48177,"PHASE4":48179,"NA":48181},{"trials":48165,"activeCount":102},[],{"trials":48167,"activeCount":102},[48168],{"nctId":48169,"briefTitle":48170,"status":195,"phases":48171,"primaryCompletion":2212,"completion":2212,"start":2212,"enrollment":2003,"conditions":48172,"interventions":48173},"NCT01068717","Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants",[90],[22],[48162,48174,48162,48174],"Saxagliptin, 2.5 mg \u002FMetformin, 500 mg FDC",{"trials":48176,"activeCount":102},[],{"trials":48178,"activeCount":102},[],{"trials":48180,"activeCount":102},[],{"trials":48182,"activeCount":102},[],{"intervention":48174,"totalTrials":122,"cells":48184},{"EARLY_PHASE1":48185,"PHASE1":48187,"PHASE2":48193,"PHASE3":48195,"PHASE4":48197,"NA":48199},{"trials":48186,"activeCount":102},[],{"trials":48188,"activeCount":102},[48189],{"nctId":48169,"briefTitle":48170,"status":195,"phases":48190,"primaryCompletion":2212,"completion":2212,"start":2212,"enrollment":2003,"conditions":48191,"interventions":48192},[90],[22],[48162,48174,48162,48174],{"trials":48194,"activeCount":102},[],{"trials":48196,"activeCount":102},[],{"trials":48198,"activeCount":102},[],{"trials":48200,"activeCount":102},[],{"intervention":48202,"totalTrials":122,"cells":48203},"[14C]Adavosertib",{"EARLY_PHASE1":48204,"PHASE1":48206,"PHASE2":48216,"PHASE3":48218,"PHASE4":48220,"NA":48222},{"trials":48205,"activeCount":102},[],{"trials":48207,"activeCount":102},[48208],{"nctId":48209,"briefTitle":48210,"status":443,"phases":48211,"primaryCompletion":48212,"completion":48212,"start":48213,"enrollment":447,"conditions":48214,"interventions":48215},"NCT05008913","Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib",[90],"2021-11-16","2021-10-01",[4217],[48202],{"trials":48217,"activeCount":102},[],{"trials":48219,"activeCount":102},[],{"trials":48221,"activeCount":102},[],{"trials":48223,"activeCount":102},[],{"intervention":48225,"totalTrials":122,"cells":48226},"Treatment A - AZD1775 administered under fasted conditions",{"EARLY_PHASE1":48227,"PHASE1":48229,"PHASE2":48240,"PHASE3":48242,"PHASE4":48244,"NA":48246},{"trials":48228,"activeCount":102},[],{"trials":48230,"activeCount":102},[48231],{"nctId":48232,"briefTitle":48233,"status":195,"phases":48234,"primaryCompletion":48235,"completion":48235,"start":48236,"enrollment":3248,"conditions":48237,"interventions":48238},"NCT03315091","Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours",[90],"2018-04-05","2017-09-29",[466],[48225,48239],"Treatment B - AZD1775 administered under fed conditions.",{"trials":48241,"activeCount":102},[],{"trials":48243,"activeCount":102},[],{"trials":48245,"activeCount":102},[],{"trials":48247,"activeCount":102},[],{"intervention":48239,"totalTrials":122,"cells":48249},{"EARLY_PHASE1":48250,"PHASE1":48252,"PHASE2":48258,"PHASE3":48260,"PHASE4":48262,"NA":48264},{"trials":48251,"activeCount":102},[],{"trials":48253,"activeCount":102},[48254],{"nctId":48232,"briefTitle":48233,"status":195,"phases":48255,"primaryCompletion":48235,"completion":48235,"start":48236,"enrollment":3248,"conditions":48256,"interventions":48257},[90],[466],[48225,48239],{"trials":48259,"activeCount":102},[],{"trials":48261,"activeCount":102},[],{"trials":48263,"activeCount":102},[],{"trials":48265,"activeCount":102},[],{"intervention":48267,"totalTrials":122,"cells":48268},"AZD1981, 2000mg",{"EARLY_PHASE1":48269,"PHASE1":48271,"PHASE2":48281,"PHASE3":48283,"PHASE4":48285,"NA":48287},{"trials":48270,"activeCount":102},[],{"trials":48272,"activeCount":102},[48273],{"nctId":48274,"briefTitle":48275,"status":195,"phases":48276,"primaryCompletion":12721,"completion":12721,"start":2516,"enrollment":3811,"conditions":48277,"interventions":48278},"NCT01265641","To Investigate the Effects of AZD1981 on the QT Interval",[90],[16],[48267,48279,48280],"AZD1981, 200mg","Moxifloxacin, 400mg",{"trials":48282,"activeCount":102},[],{"trials":48284,"activeCount":102},[],{"trials":48286,"activeCount":102},[],{"trials":48288,"activeCount":102},[],{"intervention":48279,"totalTrials":122,"cells":48290},{"EARLY_PHASE1":48291,"PHASE1":48293,"PHASE2":48299,"PHASE3":48301,"PHASE4":48303,"NA":48305},{"trials":48292,"activeCount":102},[],{"trials":48294,"activeCount":102},[48295],{"nctId":48274,"briefTitle":48275,"status":195,"phases":48296,"primaryCompletion":12721,"completion":12721,"start":2516,"enrollment":3811,"conditions":48297,"interventions":48298},[90],[16],[48267,48279,48280],{"trials":48300,"activeCount":102},[],{"trials":48302,"activeCount":102},[],{"trials":48304,"activeCount":102},[],{"trials":48306,"activeCount":102},[],{"intervention":48280,"totalTrials":122,"cells":48308},{"EARLY_PHASE1":48309,"PHASE1":48311,"PHASE2":48317,"PHASE3":48319,"PHASE4":48321,"NA":48323},{"trials":48310,"activeCount":102},[],{"trials":48312,"activeCount":102},[48313],{"nctId":48274,"briefTitle":48275,"status":195,"phases":48314,"primaryCompletion":12721,"completion":12721,"start":2516,"enrollment":3811,"conditions":48315,"interventions":48316},[90],[16],[48267,48279,48280],{"trials":48318,"activeCount":102},[],{"trials":48320,"activeCount":102},[],{"trials":48322,"activeCount":102},[],{"trials":48324,"activeCount":102},[],{"intervention":48326,"totalTrials":122,"cells":48327},"D5884",{"EARLY_PHASE1":48328,"PHASE1":48330,"PHASE2":48338,"PHASE3":48340,"PHASE4":48342,"NA":48344},{"trials":48329,"activeCount":102},[],{"trials":48331,"activeCount":102},[48332],{"nctId":48333,"briefTitle":48334,"status":195,"phases":48335,"primaryCompletion":16044,"completion":16044,"start":2560,"enrollment":36355,"conditions":48336,"interventions":48337},"NCT02209766","A Ph1 Study in Healthy Male Japanese and Caucasian After Single and Multiple Doses of D5884(Omega-3-carboxylic Acids)",[90],[19],[48326],{"trials":48339,"activeCount":102},[],{"trials":48341,"activeCount":102},[],{"trials":48343,"activeCount":102},[],{"trials":48345,"activeCount":102},[],{"intervention":48347,"totalTrials":122,"cells":48348},"Naloxegol 25 mg tablet, crushed, suspended in water, given orally",{"EARLY_PHASE1":48349,"PHASE1":48351,"PHASE2":48362,"PHASE3":48364,"PHASE4":48366,"NA":48368},{"trials":48350,"activeCount":102},[],{"trials":48352,"activeCount":102},[48353],{"nctId":48354,"briefTitle":48355,"status":195,"phases":48356,"primaryCompletion":24772,"completion":24772,"start":13756,"enrollment":3811,"conditions":48357,"interventions":48358},"NCT02446171","A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution",[90],[22858,1556],[48347,48359,48360,48361],"Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube","Naloxegol 25 mg","Naloxegol 25 mg tablet, given orally",{"trials":48363,"activeCount":102},[],{"trials":48365,"activeCount":102},[],{"trials":48367,"activeCount":102},[],{"trials":48369,"activeCount":102},[],{"intervention":48359,"totalTrials":122,"cells":48371},{"EARLY_PHASE1":48372,"PHASE1":48374,"PHASE2":48380,"PHASE3":48382,"PHASE4":48384,"NA":48386},{"trials":48373,"activeCount":102},[],{"trials":48375,"activeCount":102},[48376],{"nctId":48354,"briefTitle":48355,"status":195,"phases":48377,"primaryCompletion":24772,"completion":24772,"start":13756,"enrollment":3811,"conditions":48378,"interventions":48379},[90],[22858,1556],[48347,48359,48360,48361],{"trials":48381,"activeCount":102},[],{"trials":48383,"activeCount":102},[],{"trials":48385,"activeCount":102},[],{"trials":48387,"activeCount":102},[],{"intervention":48360,"totalTrials":122,"cells":48389},{"EARLY_PHASE1":48390,"PHASE1":48392,"PHASE2":48398,"PHASE3":48400,"PHASE4":48402,"NA":48404},{"trials":48391,"activeCount":102},[],{"trials":48393,"activeCount":102},[48394],{"nctId":48354,"briefTitle":48355,"status":195,"phases":48395,"primaryCompletion":24772,"completion":24772,"start":13756,"enrollment":3811,"conditions":48396,"interventions":48397},[90],[22858,1556],[48347,48359,48360,48361],{"trials":48399,"activeCount":102},[],{"trials":48401,"activeCount":102},[],{"trials":48403,"activeCount":102},[],{"trials":48405,"activeCount":102},[],{"intervention":48361,"totalTrials":122,"cells":48407},{"EARLY_PHASE1":48408,"PHASE1":48410,"PHASE2":48416,"PHASE3":48418,"PHASE4":48420,"NA":48422},{"trials":48409,"activeCount":102},[],{"trials":48411,"activeCount":102},[48412],{"nctId":48354,"briefTitle":48355,"status":195,"phases":48413,"primaryCompletion":24772,"completion":24772,"start":13756,"enrollment":3811,"conditions":48414,"interventions":48415},[90],[22858,1556],[48347,48359,48360,48361],{"trials":48417,"activeCount":102},[],{"trials":48419,"activeCount":102},[],{"trials":48421,"activeCount":102},[],{"trials":48423,"activeCount":102},[],{"intervention":48425,"totalTrials":122,"cells":48426},"AZD8630 (test formulation) via test inhaler",{"EARLY_PHASE1":48427,"PHASE1":48429,"PHASE2":48439,"PHASE3":48441,"PHASE4":48443,"NA":48445},{"trials":48428,"activeCount":102},[],{"trials":48430,"activeCount":102},[48431],{"nctId":48432,"briefTitle":48433,"status":195,"phases":48434,"primaryCompletion":48435,"completion":48435,"start":29101,"enrollment":579,"conditions":48436,"interventions":48437},"NCT06531811","A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.",[90],"2024-10-03",[5851],[48425,48438],"AZD8630 (reference formulation) via Monodose inhaler",{"trials":48440,"activeCount":102},[],{"trials":48442,"activeCount":102},[],{"trials":48444,"activeCount":102},[],{"trials":48446,"activeCount":102},[],{"intervention":48438,"totalTrials":122,"cells":48448},{"EARLY_PHASE1":48449,"PHASE1":48451,"PHASE2":48457,"PHASE3":48459,"PHASE4":48461,"NA":48463},{"trials":48450,"activeCount":102},[],{"trials":48452,"activeCount":102},[48453],{"nctId":48432,"briefTitle":48433,"status":195,"phases":48454,"primaryCompletion":48435,"completion":48435,"start":29101,"enrollment":579,"conditions":48455,"interventions":48456},[90],[5851],[48425,48438],{"trials":48458,"activeCount":102},[],{"trials":48460,"activeCount":102},[],{"trials":48462,"activeCount":102},[],{"trials":48464,"activeCount":102},[],{"intervention":40227,"totalTrials":122,"cells":48466},{"EARLY_PHASE1":48467,"PHASE1":48469,"PHASE2":48475,"PHASE3":48477,"PHASE4":48479,"NA":48481},{"trials":48468,"activeCount":102},[],{"trials":48470,"activeCount":102},[48471],{"nctId":40222,"briefTitle":40223,"status":195,"phases":48472,"primaryCompletion":2299,"completion":2299,"start":2180,"enrollment":12505,"conditions":48473,"interventions":48474},[90],[31837],[12577,40227],{"trials":48476,"activeCount":102},[],{"trials":48478,"activeCount":102},[],{"trials":48480,"activeCount":102},[],{"trials":48482,"activeCount":102},[],{"intervention":48484,"totalTrials":122,"cells":48485},"Form 1 of AZD5718",{"EARLY_PHASE1":48486,"PHASE1":48488,"PHASE2":48501,"PHASE3":48503,"PHASE4":48505,"NA":48507},{"trials":48487,"activeCount":102},[],{"trials":48489,"activeCount":102},[48490],{"nctId":48491,"briefTitle":48492,"status":195,"phases":48493,"primaryCompletion":2454,"completion":2454,"start":36161,"enrollment":1638,"conditions":48494,"interventions":48495},"NCT03420092","A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers",[90],[12734],[48484,48496,48497,48498,48499,48500],"Form 2 of AZD5718","Form 3 of AZD5718","Form 4 of AZD5718","Form 5 of AZD5718","Selected form (Form 2 - 5) of AZD5718",{"trials":48502,"activeCount":102},[],{"trials":48504,"activeCount":102},[],{"trials":48506,"activeCount":102},[],{"trials":48508,"activeCount":102},[],{"intervention":48496,"totalTrials":122,"cells":48510},{"EARLY_PHASE1":48511,"PHASE1":48513,"PHASE2":48519,"PHASE3":48521,"PHASE4":48523,"NA":48525},{"trials":48512,"activeCount":102},[],{"trials":48514,"activeCount":102},[48515],{"nctId":48491,"briefTitle":48492,"status":195,"phases":48516,"primaryCompletion":2454,"completion":2454,"start":36161,"enrollment":1638,"conditions":48517,"interventions":48518},[90],[12734],[48484,48496,48497,48498,48499,48500],{"trials":48520,"activeCount":102},[],{"trials":48522,"activeCount":102},[],{"trials":48524,"activeCount":102},[],{"trials":48526,"activeCount":102},[],{"intervention":48497,"totalTrials":122,"cells":48528},{"EARLY_PHASE1":48529,"PHASE1":48531,"PHASE2":48537,"PHASE3":48539,"PHASE4":48541,"NA":48543},{"trials":48530,"activeCount":102},[],{"trials":48532,"activeCount":102},[48533],{"nctId":48491,"briefTitle":48492,"status":195,"phases":48534,"primaryCompletion":2454,"completion":2454,"start":36161,"enrollment":1638,"conditions":48535,"interventions":48536},[90],[12734],[48484,48496,48497,48498,48499,48500],{"trials":48538,"activeCount":102},[],{"trials":48540,"activeCount":102},[],{"trials":48542,"activeCount":102},[],{"trials":48544,"activeCount":102},[],{"intervention":48498,"totalTrials":122,"cells":48546},{"EARLY_PHASE1":48547,"PHASE1":48549,"PHASE2":48555,"PHASE3":48557,"PHASE4":48559,"NA":48561},{"trials":48548,"activeCount":102},[],{"trials":48550,"activeCount":102},[48551],{"nctId":48491,"briefTitle":48492,"status":195,"phases":48552,"primaryCompletion":2454,"completion":2454,"start":36161,"enrollment":1638,"conditions":48553,"interventions":48554},[90],[12734],[48484,48496,48497,48498,48499,48500],{"trials":48556,"activeCount":102},[],{"trials":48558,"activeCount":102},[],{"trials":48560,"activeCount":102},[],{"trials":48562,"activeCount":102},[],{"intervention":48499,"totalTrials":122,"cells":48564},{"EARLY_PHASE1":48565,"PHASE1":48567,"PHASE2":48573,"PHASE3":48575,"PHASE4":48577,"NA":48579},{"trials":48566,"activeCount":102},[],{"trials":48568,"activeCount":102},[48569],{"nctId":48491,"briefTitle":48492,"status":195,"phases":48570,"primaryCompletion":2454,"completion":2454,"start":36161,"enrollment":1638,"conditions":48571,"interventions":48572},[90],[12734],[48484,48496,48497,48498,48499,48500],{"trials":48574,"activeCount":102},[],{"trials":48576,"activeCount":102},[],{"trials":48578,"activeCount":102},[],{"trials":48580,"activeCount":102},[],{"intervention":48500,"totalTrials":122,"cells":48582},{"EARLY_PHASE1":48583,"PHASE1":48585,"PHASE2":48591,"PHASE3":48593,"PHASE4":48595,"NA":48597},{"trials":48584,"activeCount":102},[],{"trials":48586,"activeCount":102},[48587],{"nctId":48491,"briefTitle":48492,"status":195,"phases":48588,"primaryCompletion":2454,"completion":2454,"start":36161,"enrollment":1638,"conditions":48589,"interventions":48590},[90],[12734],[48484,48496,48497,48498,48499,48500],{"trials":48592,"activeCount":102},[],{"trials":48594,"activeCount":102},[],{"trials":48596,"activeCount":102},[],{"trials":48598,"activeCount":102},[],{"intervention":48600,"totalTrials":122,"cells":48601},"AZD9150, Durvalumab",{"EARLY_PHASE1":48602,"PHASE1":48604,"PHASE2":48613,"PHASE3":48615,"PHASE4":48617,"NA":48619},{"trials":48603,"activeCount":102},[],{"trials":48605,"activeCount":102},[48606],{"nctId":48607,"briefTitle":48608,"status":195,"phases":48609,"primaryCompletion":48610,"completion":48610,"start":830,"enrollment":2222,"conditions":48611,"interventions":48612},"NCT03394144","Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies",[90],"2019-04-12",[157],[48600],{"trials":48614,"activeCount":102},[],{"trials":48616,"activeCount":102},[],{"trials":48618,"activeCount":102},[],{"trials":48620,"activeCount":102},[],{"intervention":18257,"totalTrials":122,"cells":48622},{"EARLY_PHASE1":48623,"PHASE1":48625,"PHASE2":48631,"PHASE3":48633,"PHASE4":48635,"NA":48637},{"trials":48624,"activeCount":102},[],{"trials":48626,"activeCount":102},[48627],{"nctId":18252,"briefTitle":18253,"status":195,"phases":48628,"primaryCompletion":2104,"completion":2104,"start":2481,"enrollment":1448,"conditions":48629,"interventions":48630},[90],[31],[10068,18257,18258],{"trials":48632,"activeCount":102},[],{"trials":48634,"activeCount":102},[],{"trials":48636,"activeCount":102},[],{"trials":48638,"activeCount":102},[],{"intervention":48640,"totalTrials":122,"cells":48641},"AZD5055 solution for",{"EARLY_PHASE1":48642,"PHASE1":48644,"PHASE2":48656,"PHASE3":48658,"PHASE4":48660,"NA":48662},{"trials":48643,"activeCount":102},[],{"trials":48645,"activeCount":102},[48646],{"nctId":48647,"briefTitle":48648,"status":195,"phases":48649,"primaryCompletion":5424,"completion":5424,"start":48650,"enrollment":544,"conditions":48651,"interventions":48652},"NCT05630677","A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.",[90],"2022-11-04",[36],[48640,48653,48654,48654,48655,48655],"AZD5055 oral suspension","AZD5055 film-coated","Rabeprazole, Delayed-release",{"trials":48657,"activeCount":102},[],{"trials":48659,"activeCount":102},[],{"trials":48661,"activeCount":102},[],{"trials":48663,"activeCount":102},[],{"intervention":48653,"totalTrials":122,"cells":48665},{"EARLY_PHASE1":48666,"PHASE1":48668,"PHASE2":48674,"PHASE3":48676,"PHASE4":48678,"NA":48680},{"trials":48667,"activeCount":102},[],{"trials":48669,"activeCount":102},[48670],{"nctId":48647,"briefTitle":48648,"status":195,"phases":48671,"primaryCompletion":5424,"completion":5424,"start":48650,"enrollment":544,"conditions":48672,"interventions":48673},[90],[36],[48640,48653,48654,48654,48655,48655],{"trials":48675,"activeCount":102},[],{"trials":48677,"activeCount":102},[],{"trials":48679,"activeCount":102},[],{"trials":48681,"activeCount":102},[],{"intervention":48654,"totalTrials":122,"cells":48683},{"EARLY_PHASE1":48684,"PHASE1":48686,"PHASE2":48692,"PHASE3":48694,"PHASE4":48696,"NA":48698},{"trials":48685,"activeCount":102},[],{"trials":48687,"activeCount":102},[48688],{"nctId":48647,"briefTitle":48648,"status":195,"phases":48689,"primaryCompletion":5424,"completion":5424,"start":48650,"enrollment":544,"conditions":48690,"interventions":48691},[90],[36],[48640,48653,48654,48654,48655,48655],{"trials":48693,"activeCount":102},[],{"trials":48695,"activeCount":102},[],{"trials":48697,"activeCount":102},[],{"trials":48699,"activeCount":102},[],{"intervention":48655,"totalTrials":122,"cells":48701},{"EARLY_PHASE1":48702,"PHASE1":48704,"PHASE2":48710,"PHASE3":48712,"PHASE4":48714,"NA":48716},{"trials":48703,"activeCount":102},[],{"trials":48705,"activeCount":102},[48706],{"nctId":48647,"briefTitle":48648,"status":195,"phases":48707,"primaryCompletion":5424,"completion":5424,"start":48650,"enrollment":544,"conditions":48708,"interventions":48709},[90],[36],[48640,48653,48654,48654,48655,48655],{"trials":48711,"activeCount":102},[],{"trials":48713,"activeCount":102},[],{"trials":48715,"activeCount":102},[],{"trials":48717,"activeCount":102},[],{"intervention":48719,"totalTrials":122,"cells":48720},"Treatment A - AZD7594",{"EARLY_PHASE1":48721,"PHASE1":48723,"PHASE2":48736,"PHASE3":48738,"PHASE4":48740,"NA":48742},{"trials":48722,"activeCount":102},[],{"trials":48724,"activeCount":102},[48725],{"nctId":48726,"briefTitle":48727,"status":195,"phases":48728,"primaryCompletion":48729,"completion":48729,"start":48730,"enrollment":1757,"conditions":48731,"interventions":48733},"NCT02928354","A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers",[90],"2017-03-21","2016-11-25",[48732],"Asthma, Chronic Obstructive Pulmonary Disease (COPD)",[48719,48734,48735],"Treatment B - AZD7594","Treatment C - AZD7594",{"trials":48737,"activeCount":102},[],{"trials":48739,"activeCount":102},[],{"trials":48741,"activeCount":102},[],{"trials":48743,"activeCount":102},[],{"intervention":48734,"totalTrials":122,"cells":48745},{"EARLY_PHASE1":48746,"PHASE1":48748,"PHASE2":48754,"PHASE3":48756,"PHASE4":48758,"NA":48760},{"trials":48747,"activeCount":102},[],{"trials":48749,"activeCount":102},[48750],{"nctId":48726,"briefTitle":48727,"status":195,"phases":48751,"primaryCompletion":48729,"completion":48729,"start":48730,"enrollment":1757,"conditions":48752,"interventions":48753},[90],[48732],[48719,48734,48735],{"trials":48755,"activeCount":102},[],{"trials":48757,"activeCount":102},[],{"trials":48759,"activeCount":102},[],{"trials":48761,"activeCount":102},[],{"intervention":48735,"totalTrials":122,"cells":48763},{"EARLY_PHASE1":48764,"PHASE1":48766,"PHASE2":48772,"PHASE3":48774,"PHASE4":48776,"NA":48778},{"trials":48765,"activeCount":102},[],{"trials":48767,"activeCount":102},[48768],{"nctId":48726,"briefTitle":48727,"status":195,"phases":48769,"primaryCompletion":48729,"completion":48729,"start":48730,"enrollment":1757,"conditions":48770,"interventions":48771},[90],[48732],[48719,48734,48735],{"trials":48773,"activeCount":102},[],{"trials":48775,"activeCount":102},[],{"trials":48777,"activeCount":102},[],{"trials":48779,"activeCount":102},[],{"intervention":48781,"totalTrials":122,"cells":48782},"14C]AZD4831 Oral Solution",{"EARLY_PHASE1":48783,"PHASE1":48785,"PHASE2":48794,"PHASE3":48796,"PHASE4":48798,"NA":48800},{"trials":48784,"activeCount":102},[],{"trials":48786,"activeCount":102},[48787],{"nctId":48788,"briefTitle":48789,"status":195,"phases":48790,"primaryCompletion":48791,"completion":48791,"start":28167,"enrollment":370,"conditions":48792,"interventions":48793},"NCT04407091","A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831",[90],"2020-08-06",[2619],[48781],{"trials":48795,"activeCount":102},[],{"trials":48797,"activeCount":102},[],{"trials":48799,"activeCount":102},[],{"trials":48801,"activeCount":102},[],{"intervention":48803,"totalTrials":122,"cells":48804},"AZD0284 oral solution 2.5 mg\u002FmL",{"EARLY_PHASE1":48805,"PHASE1":48807,"PHASE2":48816,"PHASE3":48818,"PHASE4":48820,"NA":48822},{"trials":48806,"activeCount":102},[],{"trials":48808,"activeCount":102},[48809],{"nctId":48810,"briefTitle":48811,"status":443,"phases":48812,"primaryCompletion":2454,"completion":2454,"start":48813,"enrollment":4343,"conditions":48814,"interventions":48815},"NCT03310320","Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis",[90],"2017-11-29",[41476],[48803],{"trials":48817,"activeCount":102},[],{"trials":48819,"activeCount":102},[],{"trials":48821,"activeCount":102},[],{"trials":48823,"activeCount":102},[],{"intervention":48825,"totalTrials":122,"cells":48826},"AZD1152 part A",{"EARLY_PHASE1":48827,"PHASE1":48829,"PHASE2":48840,"PHASE3":48842,"PHASE4":48844,"NA":48846},{"trials":48828,"activeCount":102},[],{"trials":48830,"activeCount":102},[48831],{"nctId":48832,"briefTitle":48833,"status":195,"phases":48834,"primaryCompletion":48835,"completion":12675,"start":48836,"enrollment":911,"conditions":48837,"interventions":48838},"NCT00338182","AZD1152 in Patients With Advanced Solid Malignancies",[90],"2008-06-06","2006-05-23",[13585],[48825,48839],"AZD1152 part B",{"trials":48841,"activeCount":102},[],{"trials":48843,"activeCount":102},[],{"trials":48845,"activeCount":102},[],{"trials":48847,"activeCount":102},[],{"intervention":48839,"totalTrials":122,"cells":48849},{"EARLY_PHASE1":48850,"PHASE1":48852,"PHASE2":48858,"PHASE3":48860,"PHASE4":48862,"NA":48864},{"trials":48851,"activeCount":102},[],{"trials":48853,"activeCount":102},[48854],{"nctId":48832,"briefTitle":48833,"status":195,"phases":48855,"primaryCompletion":48835,"completion":12675,"start":48836,"enrollment":911,"conditions":48856,"interventions":48857},[90],[13585],[48825,48839],{"trials":48859,"activeCount":102},[],{"trials":48861,"activeCount":102},[],{"trials":48863,"activeCount":102},[],{"trials":48865,"activeCount":102},[],{"intervention":48867,"totalTrials":122,"cells":48868},"AZD8108",{"EARLY_PHASE1":48869,"PHASE1":48871,"PHASE2":48879,"PHASE3":48881,"PHASE4":48883,"NA":48885},{"trials":48870,"activeCount":102},[],{"trials":48872,"activeCount":102},[48873],{"nctId":48874,"briefTitle":48875,"status":195,"phases":48876,"primaryCompletion":21019,"completion":21019,"start":16044,"enrollment":5947,"conditions":48877,"interventions":48878},"NCT02248818","AZD8108 SAD\u002FMAD in Healthy Volunteers",[90],[36],[48867],{"trials":48880,"activeCount":102},[],{"trials":48882,"activeCount":102},[],{"trials":48884,"activeCount":102},[],{"trials":48886,"activeCount":102},[],{"intervention":22835,"totalTrials":122,"cells":48888},{"EARLY_PHASE1":48889,"PHASE1":48891,"PHASE2":48897,"PHASE3":48899,"PHASE4":48901,"NA":48903},{"trials":48890,"activeCount":102},[],{"trials":48892,"activeCount":102},[48893],{"nctId":22828,"briefTitle":22829,"status":195,"phases":48894,"primaryCompletion":4580,"completion":4580,"start":2570,"enrollment":434,"conditions":48895,"interventions":48896},[90],[22832,22833],[15892,22835],{"trials":48898,"activeCount":102},[],{"trials":48900,"activeCount":102},[],{"trials":48902,"activeCount":102},[],{"trials":48904,"activeCount":102},[],{"intervention":48906,"totalTrials":122,"cells":48907},"LY3314814",{"EARLY_PHASE1":48908,"PHASE1":48910,"PHASE2":48920,"PHASE3":48922,"PHASE4":48924,"NA":48926},{"trials":48909,"activeCount":102},[],{"trials":48911,"activeCount":102},[48912],{"nctId":48913,"briefTitle":48914,"status":195,"phases":48915,"primaryCompletion":48916,"completion":48916,"start":2809,"enrollment":370,"conditions":48917,"interventions":48918},"NCT03222427","A Study of LY3314814 in Healthy Participants",[90],"2018-02-16",[19],[48906,48919],"[13C415N3] LY3314814",{"trials":48921,"activeCount":102},[],{"trials":48923,"activeCount":102},[],{"trials":48925,"activeCount":102},[],{"trials":48927,"activeCount":102},[],{"intervention":48919,"totalTrials":122,"cells":48929},{"EARLY_PHASE1":48930,"PHASE1":48932,"PHASE2":48938,"PHASE3":48940,"PHASE4":48942,"NA":48944},{"trials":48931,"activeCount":102},[],{"trials":48933,"activeCount":102},[48934],{"nctId":48913,"briefTitle":48914,"status":195,"phases":48935,"primaryCompletion":48916,"completion":48916,"start":2809,"enrollment":370,"conditions":48936,"interventions":48937},[90],[19],[48906,48919],{"trials":48939,"activeCount":102},[],{"trials":48941,"activeCount":102},[],{"trials":48943,"activeCount":102},[],{"trials":48945,"activeCount":102},[],{"intervention":48947,"totalTrials":122,"cells":48948},"AZD8154",{"EARLY_PHASE1":48949,"PHASE1":48951,"PHASE2":48961,"PHASE3":48963,"PHASE4":48965,"NA":48967},{"trials":48950,"activeCount":102},[],{"trials":48952,"activeCount":102},[48953],{"nctId":48954,"briefTitle":48955,"status":195,"phases":48956,"primaryCompletion":48957,"completion":48957,"start":48958,"enrollment":38631,"conditions":48959,"interventions":48960},"NCT03436316","A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.",[90],"2019-07-29","2018-07-26",[16],[48947],{"trials":48962,"activeCount":102},[],{"trials":48964,"activeCount":102},[],{"trials":48966,"activeCount":102},[],{"trials":48968,"activeCount":102},[],{"intervention":48970,"totalTrials":122,"cells":48971},"AZD5122",{"EARLY_PHASE1":48972,"PHASE1":48974,"PHASE2":48982,"PHASE3":48984,"PHASE4":48986,"NA":48988},{"trials":48973,"activeCount":102},[],{"trials":48975,"activeCount":102},[48976],{"nctId":48977,"briefTitle":48978,"status":195,"phases":48979,"completion":2057,"start":2067,"enrollment":221,"conditions":48980,"interventions":48981},"NCT00984477","Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects",[90],[19],[48970,48970],{"trials":48983,"activeCount":102},[],{"trials":48985,"activeCount":102},[],{"trials":48987,"activeCount":102},[],{"trials":48989,"activeCount":102},[],{"intervention":2207,"totalTrials":122,"cells":48991},{"EARLY_PHASE1":48992,"PHASE1":48994,"PHASE2":49000,"PHASE3":49002,"PHASE4":49004,"NA":49006},{"trials":48993,"activeCount":102},[],{"trials":48995,"activeCount":102},[48996],{"nctId":2200,"briefTitle":2201,"status":195,"phases":48997,"primaryCompletion":2203,"completion":2203,"start":2204,"enrollment":132,"conditions":48998,"interventions":48999},[90],[22],[2108,2044,2207],{"trials":49001,"activeCount":102},[],{"trials":49003,"activeCount":102},[],{"trials":49005,"activeCount":102},[],{"trials":49007,"activeCount":102},[],{"intervention":49009,"totalTrials":122,"cells":49010},"[C14]AZD9668",{"EARLY_PHASE1":49011,"PHASE1":49013,"PHASE2":49021,"PHASE3":49023,"PHASE4":49025,"NA":49027},{"trials":49012,"activeCount":102},[],{"trials":49014,"activeCount":102},[49015],{"nctId":49016,"briefTitle":49017,"status":195,"phases":49018,"primaryCompletion":2406,"completion":2406,"start":2242,"enrollment":1979,"conditions":49019,"interventions":49020},"NCT01147549","Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers",[90],[19],[49009],{"trials":49022,"activeCount":102},[],{"trials":49024,"activeCount":102},[],{"trials":49026,"activeCount":102},[],{"trials":49028,"activeCount":102},[],{"intervention":535,"totalTrials":122,"cells":49030},{"EARLY_PHASE1":49031,"PHASE1":49033,"PHASE2":49039,"PHASE3":49041,"PHASE4":49043,"NA":49045},{"trials":49032,"activeCount":102},[],{"trials":49034,"activeCount":102},[49035],{"nctId":526,"briefTitle":527,"status":195,"phases":49036,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":49037,"interventions":49038},[90],[498],[535,267,536,174,537],{"trials":49040,"activeCount":102},[],{"trials":49042,"activeCount":102},[],{"trials":49044,"activeCount":102},[],{"trials":49046,"activeCount":102},[],{"intervention":537,"totalTrials":122,"cells":49048},{"EARLY_PHASE1":49049,"PHASE1":49051,"PHASE2":49057,"PHASE3":49059,"PHASE4":49061,"NA":49063},{"trials":49050,"activeCount":102},[],{"trials":49052,"activeCount":102},[49053],{"nctId":526,"briefTitle":527,"status":195,"phases":49054,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":49055,"interventions":49056},[90],[498],[535,267,536,174,537],{"trials":49058,"activeCount":102},[],{"trials":49060,"activeCount":102},[],{"trials":49062,"activeCount":102},[],{"trials":49064,"activeCount":102},[],{"intervention":49066,"totalTrials":122,"cells":49067},"Phase IIb formulation",{"EARLY_PHASE1":49068,"PHASE1":49070,"PHASE2":49083,"PHASE3":49085,"PHASE4":49087,"NA":49089},{"trials":49069,"activeCount":102},[],{"trials":49071,"activeCount":102},[49072],{"nctId":49073,"briefTitle":49074,"status":195,"phases":49075,"primaryCompletion":7618,"completion":7618,"start":2480,"enrollment":496,"conditions":49076,"interventions":49078},"NCT01989520","Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069",[90],[49077],"Uncontrolled and Persistent Asthma",[49066,49079,49080,49081,49082],"Putative phase III formulation","Slow dissolution variant 1","Slow dissolution variant 2","Test treatment E",{"trials":49084,"activeCount":102},[],{"trials":49086,"activeCount":102},[],{"trials":49088,"activeCount":102},[],{"trials":49090,"activeCount":102},[],{"intervention":49079,"totalTrials":122,"cells":49092},{"EARLY_PHASE1":49093,"PHASE1":49095,"PHASE2":49101,"PHASE3":49103,"PHASE4":49105,"NA":49107},{"trials":49094,"activeCount":102},[],{"trials":49096,"activeCount":102},[49097],{"nctId":49073,"briefTitle":49074,"status":195,"phases":49098,"primaryCompletion":7618,"completion":7618,"start":2480,"enrollment":496,"conditions":49099,"interventions":49100},[90],[49077],[49066,49079,49080,49081,49082],{"trials":49102,"activeCount":102},[],{"trials":49104,"activeCount":102},[],{"trials":49106,"activeCount":102},[],{"trials":49108,"activeCount":102},[],{"intervention":49080,"totalTrials":122,"cells":49110},{"EARLY_PHASE1":49111,"PHASE1":49113,"PHASE2":49119,"PHASE3":49121,"PHASE4":49123,"NA":49125},{"trials":49112,"activeCount":102},[],{"trials":49114,"activeCount":102},[49115],{"nctId":49073,"briefTitle":49074,"status":195,"phases":49116,"primaryCompletion":7618,"completion":7618,"start":2480,"enrollment":496,"conditions":49117,"interventions":49118},[90],[49077],[49066,49079,49080,49081,49082],{"trials":49120,"activeCount":102},[],{"trials":49122,"activeCount":102},[],{"trials":49124,"activeCount":102},[],{"trials":49126,"activeCount":102},[],{"intervention":49081,"totalTrials":122,"cells":49128},{"EARLY_PHASE1":49129,"PHASE1":49131,"PHASE2":49137,"PHASE3":49139,"PHASE4":49141,"NA":49143},{"trials":49130,"activeCount":102},[],{"trials":49132,"activeCount":102},[49133],{"nctId":49073,"briefTitle":49074,"status":195,"phases":49134,"primaryCompletion":7618,"completion":7618,"start":2480,"enrollment":496,"conditions":49135,"interventions":49136},[90],[49077],[49066,49079,49080,49081,49082],{"trials":49138,"activeCount":102},[],{"trials":49140,"activeCount":102},[],{"trials":49142,"activeCount":102},[],{"trials":49144,"activeCount":102},[],{"intervention":49082,"totalTrials":122,"cells":49146},{"EARLY_PHASE1":49147,"PHASE1":49149,"PHASE2":49155,"PHASE3":49157,"PHASE4":49159,"NA":49161},{"trials":49148,"activeCount":102},[],{"trials":49150,"activeCount":102},[49151],{"nctId":49073,"briefTitle":49074,"status":195,"phases":49152,"primaryCompletion":7618,"completion":7618,"start":2480,"enrollment":496,"conditions":49153,"interventions":49154},[90],[49077],[49066,49079,49080,49081,49082],{"trials":49156,"activeCount":102},[],{"trials":49158,"activeCount":102},[],{"trials":49160,"activeCount":102},[],{"trials":49162,"activeCount":102},[],{"intervention":24442,"totalTrials":122,"cells":49164},{"EARLY_PHASE1":49165,"PHASE1":49167,"PHASE2":49173,"PHASE3":49175,"PHASE4":49177,"NA":49179},{"trials":49166,"activeCount":102},[],{"trials":49168,"activeCount":102},[49169],{"nctId":24437,"briefTitle":24438,"status":195,"phases":49170,"primaryCompletion":2068,"completion":2068,"start":2152,"enrollment":1130,"conditions":49171,"interventions":49172},[90],[22],[2108,2475,24442],{"trials":49174,"activeCount":102},[],{"trials":49176,"activeCount":102},[],{"trials":49178,"activeCount":102},[],{"trials":49180,"activeCount":102},[],{"intervention":49182,"totalTrials":122,"cells":49183},"Experimental: Cotadutide",{"EARLY_PHASE1":49184,"PHASE1":49186,"PHASE2":49194,"PHASE3":49196,"PHASE4":49198,"NA":49200},{"trials":49185,"activeCount":102},[],{"trials":49187,"activeCount":102},[49188],{"nctId":49189,"briefTitle":49190,"status":195,"phases":49191,"primaryCompletion":33977,"completion":33977,"start":21832,"enrollment":486,"conditions":49192,"interventions":49193},"NCT05437848","Chinese Multiple Dose Escalation (MDE) High Dose Study",[90],[2652],[49182],{"trials":49195,"activeCount":102},[],{"trials":49197,"activeCount":102},[],{"trials":49199,"activeCount":102},[],{"trials":49201,"activeCount":102},[],{"intervention":8844,"totalTrials":122,"cells":49203},{"EARLY_PHASE1":49204,"PHASE1":49206,"PHASE2":49212,"PHASE3":49214,"PHASE4":49216,"NA":49218},{"trials":49205,"activeCount":102},[],{"trials":49207,"activeCount":102},[49208],{"nctId":8837,"briefTitle":8838,"status":443,"phases":49209,"primaryCompletion":5906,"completion":5906,"start":8840,"enrollment":4286,"conditions":49210,"interventions":49211},[90],[8842],[3252,8844,1377],{"trials":49213,"activeCount":102},[],{"trials":49215,"activeCount":102},[],{"trials":49217,"activeCount":102},[],{"trials":49219,"activeCount":102},[],{"intervention":23409,"totalTrials":122,"cells":49221},{"EARLY_PHASE1":49222,"PHASE1":49224,"PHASE2":49230,"PHASE3":49232,"PHASE4":49234,"NA":49236},{"trials":49223,"activeCount":102},[],{"trials":49225,"activeCount":102},[49226],{"nctId":23404,"briefTitle":23405,"status":195,"phases":49227,"completion":2414,"start":2524,"enrollment":1448,"conditions":49228,"interventions":49229},[90],[19],[4931,2255,23409,23410,23409,4931,4931],{"trials":49231,"activeCount":102},[],{"trials":49233,"activeCount":102},[],{"trials":49235,"activeCount":102},[],{"trials":49237,"activeCount":102},[],{"intervention":23410,"totalTrials":122,"cells":49239},{"EARLY_PHASE1":49240,"PHASE1":49242,"PHASE2":49248,"PHASE3":49250,"PHASE4":49252,"NA":49254},{"trials":49241,"activeCount":102},[],{"trials":49243,"activeCount":102},[49244],{"nctId":23404,"briefTitle":23405,"status":195,"phases":49245,"completion":2414,"start":2524,"enrollment":1448,"conditions":49246,"interventions":49247},[90],[19],[4931,2255,23409,23410,23409,4931,4931],{"trials":49249,"activeCount":102},[],{"trials":49251,"activeCount":102},[],{"trials":49253,"activeCount":102},[],{"trials":49255,"activeCount":102},[],{"intervention":3085,"totalTrials":122,"cells":49257},{"EARLY_PHASE1":49258,"PHASE1":49260,"PHASE2":49266,"PHASE3":49268,"PHASE4":49270,"NA":49272},{"trials":49259,"activeCount":102},[],{"trials":49261,"activeCount":102},[49262],{"nctId":3076,"briefTitle":3077,"status":195,"phases":49263,"primaryCompletion":3079,"completion":3080,"start":3081,"enrollment":2827,"conditions":49264,"interventions":49265},[90],[3083],[900,3085],{"trials":49267,"activeCount":102},[],{"trials":49269,"activeCount":102},[],{"trials":49271,"activeCount":102},[],{"trials":49273,"activeCount":102},[],{"intervention":49275,"totalTrials":122,"cells":49276},"AZD5438",{"EARLY_PHASE1":49277,"PHASE1":49279,"PHASE2":49287,"PHASE3":49289,"PHASE4":49291,"NA":49293},{"trials":49278,"activeCount":102},[],{"trials":49280,"activeCount":102},[49281],{"nctId":49282,"briefTitle":49283,"status":195,"phases":49284,"primaryCompletion":2329,"completion":2329,"start":8692,"conditions":49285,"interventions":49286},"NCT00088790","AZD5438 in Patients With Advanced Solid Malignancies",[90],[3841],[49275],{"trials":49288,"activeCount":102},[],{"trials":49290,"activeCount":102},[],{"trials":49292,"activeCount":102},[],{"trials":49294,"activeCount":102},[],{"intervention":49296,"totalTrials":122,"cells":49297},"Saxagliptin\u002FMetformin",{"EARLY_PHASE1":49298,"PHASE1":49300,"PHASE2":49307,"PHASE3":49309,"PHASE4":49311,"NA":49313},{"trials":49299,"activeCount":102},[],{"trials":49301,"activeCount":102},[49302],{"nctId":49303,"briefTitle":42173,"status":195,"phases":49304,"primaryCompletion":13856,"completion":13856,"start":2746,"enrollment":2933,"conditions":49305,"interventions":49306},"NCT01874080",[90],[2652],[49296],{"trials":49308,"activeCount":102},[],{"trials":49310,"activeCount":102},[],{"trials":49312,"activeCount":102},[],{"trials":49314,"activeCount":102},[],{"intervention":4233,"totalTrials":122,"cells":49316},{"EARLY_PHASE1":49317,"PHASE1":49319,"PHASE2":49325,"PHASE3":49327,"PHASE4":49329,"NA":49331},{"trials":49318,"activeCount":102},[],{"trials":49320,"activeCount":102},[49321],{"nctId":4228,"briefTitle":4229,"status":195,"phases":49322,"primaryCompletion":2056,"completion":2570,"start":2151,"enrollment":1638,"conditions":49323,"interventions":49324},[90],[172],[268,177,4233,177,121],{"trials":49326,"activeCount":102},[],{"trials":49328,"activeCount":102},[],{"trials":49330,"activeCount":102},[],{"trials":49332,"activeCount":102},[],{"intervention":49334,"totalTrials":122,"cells":49335},"AZD3199 Turbuhaler®",{"EARLY_PHASE1":49336,"PHASE1":49338,"PHASE2":49346,"PHASE3":49348,"PHASE4":49350,"NA":49352},{"trials":49337,"activeCount":102},[],{"trials":49339,"activeCount":102},[49340],{"nctId":49341,"briefTitle":49342,"status":195,"phases":49343,"completion":2095,"start":2086,"enrollment":2003,"conditions":49344,"interventions":49345},"NCT00772759","Assess Safety, Tolerability and PK of AZD3199 in Japanese",[90],[19],[49334],{"trials":49347,"activeCount":102},[],{"trials":49349,"activeCount":102},[],{"trials":49351,"activeCount":102},[],{"trials":49353,"activeCount":102},[],{"intervention":49355,"totalTrials":122,"cells":49356},"Co-administration of Saxagliptin and Metformin IR, Fasted",{"EARLY_PHASE1":49357,"PHASE1":49359,"PHASE2":49370,"PHASE3":49372,"PHASE4":49374,"NA":49376},{"trials":49358,"activeCount":102},[],{"trials":49360,"activeCount":102},[49361],{"nctId":49362,"briefTitle":49363,"status":195,"phases":49364,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1130,"conditions":49365,"interventions":49366},"NCT00899470","Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)",[90],[22],[49355,49367,49368,49369],"Saxagliptin\u002FMetformin, Fasting","Co-administration of Saxagliptin and Metformin IR, Fed","Saxagliptin\u002FMetformin, Fed",{"trials":49371,"activeCount":102},[],{"trials":49373,"activeCount":102},[],{"trials":49375,"activeCount":102},[],{"trials":49377,"activeCount":102},[],{"intervention":49367,"totalTrials":122,"cells":49379},{"EARLY_PHASE1":49380,"PHASE1":49382,"PHASE2":49388,"PHASE3":49390,"PHASE4":49392,"NA":49394},{"trials":49381,"activeCount":102},[],{"trials":49383,"activeCount":102},[49384],{"nctId":49362,"briefTitle":49363,"status":195,"phases":49385,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1130,"conditions":49386,"interventions":49387},[90],[22],[49355,49367,49368,49369],{"trials":49389,"activeCount":102},[],{"trials":49391,"activeCount":102},[],{"trials":49393,"activeCount":102},[],{"trials":49395,"activeCount":102},[],{"intervention":49368,"totalTrials":122,"cells":49397},{"EARLY_PHASE1":49398,"PHASE1":49400,"PHASE2":49406,"PHASE3":49408,"PHASE4":49410,"NA":49412},{"trials":49399,"activeCount":102},[],{"trials":49401,"activeCount":102},[49402],{"nctId":49362,"briefTitle":49363,"status":195,"phases":49403,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1130,"conditions":49404,"interventions":49405},[90],[22],[49355,49367,49368,49369],{"trials":49407,"activeCount":102},[],{"trials":49409,"activeCount":102},[],{"trials":49411,"activeCount":102},[],{"trials":49413,"activeCount":102},[],{"intervention":49369,"totalTrials":122,"cells":49415},{"EARLY_PHASE1":49416,"PHASE1":49418,"PHASE2":49424,"PHASE3":49426,"PHASE4":49428,"NA":49430},{"trials":49417,"activeCount":102},[],{"trials":49419,"activeCount":102},[49420],{"nctId":49362,"briefTitle":49363,"status":195,"phases":49421,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":1130,"conditions":49422,"interventions":49423},[90],[22],[49355,49367,49368,49369],{"trials":49425,"activeCount":102},[],{"trials":49427,"activeCount":102},[],{"trials":49429,"activeCount":102},[],{"trials":49431,"activeCount":102},[],{"intervention":49433,"totalTrials":122,"cells":49434},"AZD4604 for inhalation via DPI",{"EARLY_PHASE1":49435,"PHASE1":49437,"PHASE2":49449,"PHASE3":49451,"PHASE4":49453,"NA":49455},{"trials":49436,"activeCount":102},[],{"trials":49438,"activeCount":102},[49439],{"nctId":49440,"briefTitle":49441,"status":195,"phases":49442,"primaryCompletion":49443,"completion":49443,"start":49444,"enrollment":744,"conditions":49445,"interventions":49446},"NCT04769869","A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma",[90],"2023-01-24","2022-07-08",[16],[49433,49447,49448,49433],"AZD4604 for IV administration","AZD4604 for oral administration",{"trials":49450,"activeCount":102},[],{"trials":49452,"activeCount":102},[],{"trials":49454,"activeCount":102},[],{"trials":49456,"activeCount":102},[],{"intervention":49447,"totalTrials":122,"cells":49458},{"EARLY_PHASE1":49459,"PHASE1":49461,"PHASE2":49467,"PHASE3":49469,"PHASE4":49471,"NA":49473},{"trials":49460,"activeCount":102},[],{"trials":49462,"activeCount":102},[49463],{"nctId":49440,"briefTitle":49441,"status":195,"phases":49464,"primaryCompletion":49443,"completion":49443,"start":49444,"enrollment":744,"conditions":49465,"interventions":49466},[90],[16],[49433,49447,49448,49433],{"trials":49468,"activeCount":102},[],{"trials":49470,"activeCount":102},[],{"trials":49472,"activeCount":102},[],{"trials":49474,"activeCount":102},[],{"intervention":49448,"totalTrials":122,"cells":49476},{"EARLY_PHASE1":49477,"PHASE1":49479,"PHASE2":49485,"PHASE3":49487,"PHASE4":49489,"NA":49491},{"trials":49478,"activeCount":102},[],{"trials":49480,"activeCount":102},[49481],{"nctId":49440,"briefTitle":49441,"status":195,"phases":49482,"primaryCompletion":49443,"completion":49443,"start":49444,"enrollment":744,"conditions":49483,"interventions":49484},[90],[16],[49433,49447,49448,49433],{"trials":49486,"activeCount":102},[],{"trials":49488,"activeCount":102},[],{"trials":49490,"activeCount":102},[],{"trials":49492,"activeCount":102},[],{"intervention":12103,"totalTrials":122,"cells":49494},{"EARLY_PHASE1":49495,"PHASE1":49497,"PHASE2":49503,"PHASE3":49505,"PHASE4":49507,"NA":49509},{"trials":49496,"activeCount":102},[],{"trials":49498,"activeCount":102},[49499],{"nctId":12096,"briefTitle":12097,"status":195,"phases":49500,"primaryCompletion":12099,"completion":12099,"start":12100,"enrollment":37,"conditions":49501,"interventions":49502},[90],[10760],[12103,12104,10762],{"trials":49504,"activeCount":102},[],{"trials":49506,"activeCount":102},[],{"trials":49508,"activeCount":102},[],{"trials":49510,"activeCount":102},[],{"intervention":12104,"totalTrials":122,"cells":49512},{"EARLY_PHASE1":49513,"PHASE1":49515,"PHASE2":49521,"PHASE3":49523,"PHASE4":49525,"NA":49527},{"trials":49514,"activeCount":102},[],{"trials":49516,"activeCount":102},[49517],{"nctId":12096,"briefTitle":12097,"status":195,"phases":49518,"primaryCompletion":12099,"completion":12099,"start":12100,"enrollment":37,"conditions":49519,"interventions":49520},[90],[10760],[12103,12104,10762],{"trials":49522,"activeCount":102},[],{"trials":49524,"activeCount":102},[],{"trials":49526,"activeCount":102},[],{"trials":49528,"activeCount":102},[],{"intervention":49530,"totalTrials":122,"cells":49531},"Dapagliflozin\u002Fmetformin XR FDC 5\u002F500 mg",{"EARLY_PHASE1":49532,"PHASE1":49534,"PHASE2":49547,"PHASE3":49549,"PHASE4":49551,"NA":49553},{"trials":49533,"activeCount":102},[],{"trials":49535,"activeCount":102},[49536],{"nctId":49537,"briefTitle":49538,"status":195,"phases":49539,"primaryCompletion":49540,"completion":49540,"start":49541,"enrollment":1395,"conditions":49542,"interventions":49543},"NCT04856007","A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin\u002FMetformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.",[90],"2021-06-14","2021-04-12",[31837],[49530,49544,49545,49546],"Dapagliflozin\u002Fmetformin XR FDC 10\u002F1000 mg","Dapagliflozin 5 mg + Metformin 500 mg XR","Dapagliflozin 10 mg + Metformin 1000 mg XR",{"trials":49548,"activeCount":102},[],{"trials":49550,"activeCount":102},[],{"trials":49552,"activeCount":102},[],{"trials":49554,"activeCount":102},[],{"intervention":49544,"totalTrials":122,"cells":49556},{"EARLY_PHASE1":49557,"PHASE1":49559,"PHASE2":49565,"PHASE3":49567,"PHASE4":49569,"NA":49571},{"trials":49558,"activeCount":102},[],{"trials":49560,"activeCount":102},[49561],{"nctId":49537,"briefTitle":49538,"status":195,"phases":49562,"primaryCompletion":49540,"completion":49540,"start":49541,"enrollment":1395,"conditions":49563,"interventions":49564},[90],[31837],[49530,49544,49545,49546],{"trials":49566,"activeCount":102},[],{"trials":49568,"activeCount":102},[],{"trials":49570,"activeCount":102},[],{"trials":49572,"activeCount":102},[],{"intervention":49545,"totalTrials":122,"cells":49574},{"EARLY_PHASE1":49575,"PHASE1":49577,"PHASE2":49583,"PHASE3":49585,"PHASE4":49587,"NA":49589},{"trials":49576,"activeCount":102},[],{"trials":49578,"activeCount":102},[49579],{"nctId":49537,"briefTitle":49538,"status":195,"phases":49580,"primaryCompletion":49540,"completion":49540,"start":49541,"enrollment":1395,"conditions":49581,"interventions":49582},[90],[31837],[49530,49544,49545,49546],{"trials":49584,"activeCount":102},[],{"trials":49586,"activeCount":102},[],{"trials":49588,"activeCount":102},[],{"trials":49590,"activeCount":102},[],{"intervention":49546,"totalTrials":122,"cells":49592},{"EARLY_PHASE1":49593,"PHASE1":49595,"PHASE2":49601,"PHASE3":49603,"PHASE4":49605,"NA":49607},{"trials":49594,"activeCount":102},[],{"trials":49596,"activeCount":102},[49597],{"nctId":49537,"briefTitle":49538,"status":195,"phases":49598,"primaryCompletion":49540,"completion":49540,"start":49541,"enrollment":1395,"conditions":49599,"interventions":49600},[90],[31837],[49530,49544,49545,49546],{"trials":49602,"activeCount":102},[],{"trials":49604,"activeCount":102},[],{"trials":49606,"activeCount":102},[],{"trials":49608,"activeCount":102},[],{"intervention":49610,"totalTrials":122,"cells":49611},"AZD5312",{"EARLY_PHASE1":49612,"PHASE1":49614,"PHASE2":49623,"PHASE3":49625,"PHASE4":49627,"NA":49629},{"trials":49613,"activeCount":102},[],{"trials":49615,"activeCount":102},[49616],{"nctId":49617,"briefTitle":49618,"status":195,"phases":49619,"primaryCompletion":1700,"completion":1700,"start":2203,"enrollment":579,"conditions":49620,"interventions":49622},"NCT02144051","Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors",[90],[49621],"Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor",[49610],{"trials":49624,"activeCount":102},[],{"trials":49626,"activeCount":102},[],{"trials":49628,"activeCount":102},[],{"trials":49630,"activeCount":102},[],{"intervention":25540,"totalTrials":122,"cells":49632},{"EARLY_PHASE1":49633,"PHASE1":49635,"PHASE2":49641,"PHASE3":49643,"PHASE4":49645,"NA":49647},{"trials":49634,"activeCount":102},[],{"trials":49636,"activeCount":102},[49637],{"nctId":25534,"briefTitle":25535,"status":195,"phases":49638,"primaryCompletion":2203,"completion":2203,"start":2480,"enrollment":2003,"conditions":49639,"interventions":49640},[90],[25538,18867],[10068,25527,23078,25540,25541],{"trials":49642,"activeCount":102},[],{"trials":49644,"activeCount":102},[],{"trials":49646,"activeCount":102},[],{"trials":49648,"activeCount":102},[],{"intervention":25541,"totalTrials":122,"cells":49650},{"EARLY_PHASE1":49651,"PHASE1":49653,"PHASE2":49659,"PHASE3":49661,"PHASE4":49663,"NA":49665},{"trials":49652,"activeCount":102},[],{"trials":49654,"activeCount":102},[49655],{"nctId":25534,"briefTitle":25535,"status":195,"phases":49656,"primaryCompletion":2203,"completion":2203,"start":2480,"enrollment":2003,"conditions":49657,"interventions":49658},[90],[25538,18867],[10068,25527,23078,25540,25541],{"trials":49660,"activeCount":102},[],{"trials":49662,"activeCount":102},[],{"trials":49664,"activeCount":102},[],{"trials":49666,"activeCount":102},[],{"intervention":2225,"totalTrials":122,"cells":49668},{"EARLY_PHASE1":49669,"PHASE1":49671,"PHASE2":49677,"PHASE3":49679,"PHASE4":49681,"NA":49683},{"trials":49670,"activeCount":102},[],{"trials":49672,"activeCount":102},[49673],{"nctId":2217,"briefTitle":2218,"status":195,"phases":49674,"primaryCompletion":2220,"completion":2220,"start":2221,"enrollment":2222,"conditions":49675,"interventions":49676},[90],[2089],[2044,2080,2225],{"trials":49678,"activeCount":102},[],{"trials":49680,"activeCount":102},[],{"trials":49682,"activeCount":102},[],{"trials":49684,"activeCount":102},[],{"intervention":49686,"totalTrials":122,"cells":49687},"BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold",{"EARLY_PHASE1":49688,"PHASE1":49690,"PHASE2":49700,"PHASE3":49702,"PHASE4":49704,"NA":49706},{"trials":49689,"activeCount":102},[],{"trials":49691,"activeCount":102},[49692],{"nctId":49693,"briefTitle":49694,"status":195,"phases":49695,"primaryCompletion":8379,"completion":8379,"start":49696,"enrollment":269,"conditions":49697,"interventions":49698},"NCT03740373","A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate",[90],"2018-09-04",[18651],[49686,49699],"BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold",{"trials":49701,"activeCount":102},[],{"trials":49703,"activeCount":102},[],{"trials":49705,"activeCount":102},[],{"trials":49707,"activeCount":102},[],{"intervention":49699,"totalTrials":122,"cells":49709},{"EARLY_PHASE1":49710,"PHASE1":49712,"PHASE2":49718,"PHASE3":49720,"PHASE4":49722,"NA":49724},{"trials":49711,"activeCount":102},[],{"trials":49713,"activeCount":102},[49714],{"nctId":49693,"briefTitle":49694,"status":195,"phases":49715,"primaryCompletion":8379,"completion":8379,"start":49696,"enrollment":269,"conditions":49716,"interventions":49717},[90],[18651],[49686,49699],{"trials":49719,"activeCount":102},[],{"trials":49721,"activeCount":102},[],{"trials":49723,"activeCount":102},[],{"trials":49725,"activeCount":102},[],{"intervention":49727,"totalTrials":122,"cells":49728},"CP-675,206 and gemcitabine",{"EARLY_PHASE1":49729,"PHASE1":49731,"PHASE2":49739,"PHASE3":49741,"PHASE4":49743,"NA":49745},{"trials":49730,"activeCount":102},[],{"trials":49732,"activeCount":102},[49733],{"nctId":49734,"briefTitle":49735,"status":195,"phases":49736,"primaryCompletion":2675,"completion":2675,"start":2524,"enrollment":1543,"conditions":49737,"interventions":49738},"NCT00556023","A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer",[90],[415],[49727],{"trials":49740,"activeCount":102},[],{"trials":49742,"activeCount":102},[],{"trials":49744,"activeCount":102},[],{"trials":49746,"activeCount":102},[],{"intervention":32030,"totalTrials":122,"cells":49748},{"EARLY_PHASE1":49749,"PHASE1":49751,"PHASE2":49757,"PHASE3":49759,"PHASE4":49761,"NA":49763},{"trials":49750,"activeCount":102},[],{"trials":49752,"activeCount":102},[49753],{"nctId":32025,"briefTitle":32026,"status":195,"phases":49754,"primaryCompletion":3827,"completion":3827,"start":2169,"enrollment":1336,"conditions":49755,"interventions":49756},[90],[31892,18867],[32005,32030],{"trials":49758,"activeCount":102},[],{"trials":49760,"activeCount":102},[],{"trials":49762,"activeCount":102},[],{"trials":49764,"activeCount":102},[],{"intervention":49766,"totalTrials":122,"cells":49767},"Lispro insulin U-100",{"EARLY_PHASE1":49768,"PHASE1":49770,"PHASE2":49782,"PHASE3":49784,"PHASE4":49786,"NA":49788},{"trials":49769,"activeCount":102},[],{"trials":49771,"activeCount":102},[49772],{"nctId":49773,"briefTitle":49774,"status":195,"phases":49775,"primaryCompletion":49776,"completion":49776,"start":49777,"enrollment":17655,"conditions":49778,"interventions":49779},"NCT02500979","Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus",[90],"2016-08-05","2015-08-17",[2369],[49780,49766,49781],"Pramlintide acetate","Regular insulin U-100",{"trials":49783,"activeCount":102},[],{"trials":49785,"activeCount":102},[],{"trials":49787,"activeCount":102},[],{"trials":49789,"activeCount":102},[],{"intervention":49781,"totalTrials":122,"cells":49791},{"EARLY_PHASE1":49792,"PHASE1":49794,"PHASE2":49800,"PHASE3":49802,"PHASE4":49804,"NA":49806},{"trials":49793,"activeCount":102},[],{"trials":49795,"activeCount":102},[49796],{"nctId":49773,"briefTitle":49774,"status":195,"phases":49797,"primaryCompletion":49776,"completion":49776,"start":49777,"enrollment":17655,"conditions":49798,"interventions":49799},[90],[2369],[49780,49766,49781],{"trials":49801,"activeCount":102},[],{"trials":49803,"activeCount":102},[],{"trials":49805,"activeCount":102},[],{"trials":49807,"activeCount":102},[],{"intervention":31871,"totalTrials":122,"cells":49809},{"EARLY_PHASE1":49810,"PHASE1":49812,"PHASE2":49818,"PHASE3":49820,"PHASE4":49822,"NA":49824},{"trials":49811,"activeCount":102},[],{"trials":49813,"activeCount":102},[49814],{"nctId":31866,"briefTitle":31867,"status":2744,"phases":49815,"primaryCompletion":2067,"completion":2067,"start":688,"enrollment":2933,"conditions":49816,"interventions":49817},[90],[15776],[31871,31826],{"trials":49819,"activeCount":102},[],{"trials":49821,"activeCount":102},[],{"trials":49823,"activeCount":102},[],{"trials":49825,"activeCount":102},[],{"intervention":42286,"totalTrials":122,"cells":49827},{"EARLY_PHASE1":49828,"PHASE1":49830,"PHASE2":49836,"PHASE3":49838,"PHASE4":49840,"NA":49842},{"trials":49829,"activeCount":102},[],{"trials":49831,"activeCount":102},[49832],{"nctId":42281,"briefTitle":42282,"status":195,"phases":49833,"primaryCompletion":2105,"completion":2105,"start":10063,"enrollment":3811,"conditions":49834,"interventions":49835},[90],[23317],[42268,42286],{"trials":49837,"activeCount":102},[],{"trials":49839,"activeCount":102},[],{"trials":49841,"activeCount":102},[],{"trials":49843,"activeCount":102},[],{"intervention":49845,"totalTrials":122,"cells":49846},"AZD7503 Intervention",{"EARLY_PHASE1":49847,"PHASE1":49849,"PHASE2":49863,"PHASE3":49865,"PHASE4":49867,"NA":49869},{"trials":49848,"activeCount":102},[],{"trials":49850,"activeCount":102},[49851],{"nctId":49852,"briefTitle":49853,"status":195,"phases":49854,"primaryCompletion":13190,"completion":49855,"start":16335,"enrollment":3855,"conditions":49856,"interventions":49862},"NCT05560607","Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease",[90],"2024-02-27",[49857,49858,49859,49860,33416,49861],"Non-alcoholic Fatty Liver Disease","Fatty Liver, Nonalcoholic","NAFLD","Nonalcoholic Fatty Liver Disease","NASH",[49845],{"trials":49864,"activeCount":102},[],{"trials":49866,"activeCount":102},[],{"trials":49868,"activeCount":102},[],{"trials":49870,"activeCount":102},[],{"intervention":49872,"totalTrials":122,"cells":49873},"Recentin",{"EARLY_PHASE1":49874,"PHASE1":49876,"PHASE2":49884,"PHASE3":49886,"PHASE4":49888,"NA":49890},{"trials":49875,"activeCount":102},[],{"trials":49877,"activeCount":102},[49878],{"nctId":49879,"briefTitle":49880,"status":195,"phases":49881,"primaryCompletion":2114,"completion":2349,"start":2220,"enrollment":1348,"conditions":49882,"interventions":49883},"NCT00748891","DCE CT\u002FMRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)",[90],[556],[49872],{"trials":49885,"activeCount":102},[],{"trials":49887,"activeCount":102},[],{"trials":49889,"activeCount":102},[],{"trials":49891,"activeCount":102},[],{"intervention":41020,"totalTrials":122,"cells":49893},{"EARLY_PHASE1":49894,"PHASE1":49896,"PHASE2":49902,"PHASE3":49904,"PHASE4":49906,"NA":49908},{"trials":49895,"activeCount":102},[],{"trials":49897,"activeCount":102},[49898],{"nctId":41014,"briefTitle":41015,"status":195,"phases":49899,"primaryCompletion":2396,"completion":2396,"start":41017,"enrollment":1638,"conditions":49900,"interventions":49901},[90],[25],[40988,41020,41021,41022,41023],{"trials":49903,"activeCount":102},[],{"trials":49905,"activeCount":102},[],{"trials":49907,"activeCount":102},[],{"trials":49909,"activeCount":102},[],{"intervention":41021,"totalTrials":122,"cells":49911},{"EARLY_PHASE1":49912,"PHASE1":49914,"PHASE2":49920,"PHASE3":49922,"PHASE4":49924,"NA":49926},{"trials":49913,"activeCount":102},[],{"trials":49915,"activeCount":102},[49916],{"nctId":41014,"briefTitle":41015,"status":195,"phases":49917,"primaryCompletion":2396,"completion":2396,"start":41017,"enrollment":1638,"conditions":49918,"interventions":49919},[90],[25],[40988,41020,41021,41022,41023],{"trials":49921,"activeCount":102},[],{"trials":49923,"activeCount":102},[],{"trials":49925,"activeCount":102},[],{"trials":49927,"activeCount":102},[],{"intervention":41022,"totalTrials":122,"cells":49929},{"EARLY_PHASE1":49930,"PHASE1":49932,"PHASE2":49938,"PHASE3":49940,"PHASE4":49942,"NA":49944},{"trials":49931,"activeCount":102},[],{"trials":49933,"activeCount":102},[49934],{"nctId":41014,"briefTitle":41015,"status":195,"phases":49935,"primaryCompletion":2396,"completion":2396,"start":41017,"enrollment":1638,"conditions":49936,"interventions":49937},[90],[25],[40988,41020,41021,41022,41023],{"trials":49939,"activeCount":102},[],{"trials":49941,"activeCount":102},[],{"trials":49943,"activeCount":102},[],{"trials":49945,"activeCount":102},[],{"intervention":41023,"totalTrials":122,"cells":49947},{"EARLY_PHASE1":49948,"PHASE1":49950,"PHASE2":49956,"PHASE3":49958,"PHASE4":49960,"NA":49962},{"trials":49949,"activeCount":102},[],{"trials":49951,"activeCount":102},[49952],{"nctId":41014,"briefTitle":41015,"status":195,"phases":49953,"primaryCompletion":2396,"completion":2396,"start":41017,"enrollment":1638,"conditions":49954,"interventions":49955},[90],[25],[40988,41020,41021,41022,41023],{"trials":49957,"activeCount":102},[],{"trials":49959,"activeCount":102},[],{"trials":49961,"activeCount":102},[],{"trials":49963,"activeCount":102},[],{"intervention":49965,"totalTrials":122,"cells":49966},"esomeprazole\u002FASA Fixed Dose Combination",{"EARLY_PHASE1":49967,"PHASE1":49969,"PHASE2":49978,"PHASE3":49980,"PHASE4":49982,"NA":49984},{"trials":49968,"activeCount":102},[],{"trials":49970,"activeCount":102},[49971],{"nctId":49972,"briefTitle":49973,"status":195,"phases":49974,"primaryCompletion":3862,"completion":3862,"start":2242,"enrollment":1130,"conditions":49975,"interventions":49977},"NCT01163630","Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg\u002FAcetylsalicylic Acid 81 mg",[90],[49976,15776],"Effect of Food",[49965],{"trials":49979,"activeCount":102},[],{"trials":49981,"activeCount":102},[],{"trials":49983,"activeCount":102},[],{"trials":49985,"activeCount":102},[],{"intervention":49987,"totalTrials":122,"cells":49988},"Selumetinib 50mg",{"EARLY_PHASE1":49989,"PHASE1":49991,"PHASE2":50000,"PHASE3":50002,"PHASE4":50004,"NA":50006},{"trials":49990,"activeCount":102},[],{"trials":49992,"activeCount":102},[49993],{"nctId":49994,"briefTitle":49995,"status":195,"phases":49996,"primaryCompletion":16044,"completion":16044,"start":4006,"enrollment":579,"conditions":49997,"interventions":49998},"NCT02063230","To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects",[90],[3056],[49987,49999],"Selumetinib 25mg",{"trials":50001,"activeCount":102},[],{"trials":50003,"activeCount":102},[],{"trials":50005,"activeCount":102},[],{"trials":50007,"activeCount":102},[],{"intervention":49999,"totalTrials":122,"cells":50009},{"EARLY_PHASE1":50010,"PHASE1":50012,"PHASE2":50018,"PHASE3":50020,"PHASE4":50022,"NA":50024},{"trials":50011,"activeCount":102},[],{"trials":50013,"activeCount":102},[50014],{"nctId":49994,"briefTitle":49995,"status":195,"phases":50015,"primaryCompletion":16044,"completion":16044,"start":4006,"enrollment":579,"conditions":50016,"interventions":50017},[90],[3056],[49987,49999],{"trials":50019,"activeCount":102},[],{"trials":50021,"activeCount":102},[],{"trials":50023,"activeCount":102},[],{"trials":50025,"activeCount":102},[],{"intervention":5380,"totalTrials":122,"cells":50027},{"EARLY_PHASE1":50028,"PHASE1":50030,"PHASE2":50036,"PHASE3":50038,"PHASE4":50040,"NA":50042},{"trials":50029,"activeCount":102},[],{"trials":50031,"activeCount":102},[50032],{"nctId":5372,"briefTitle":5373,"status":195,"phases":50033,"primaryCompletion":5375,"completion":5376,"start":5377,"enrollment":1979,"conditions":50034,"interventions":50035},[90],[1049],[1012,5380],{"trials":50037,"activeCount":102},[],{"trials":50039,"activeCount":102},[],{"trials":50041,"activeCount":102},[],{"trials":50043,"activeCount":102},[],{"intervention":50045,"totalTrials":122,"cells":50046},"AZD6423",{"EARLY_PHASE1":50047,"PHASE1":50049,"PHASE2":50058,"PHASE3":50060,"PHASE4":50062,"NA":50064},{"trials":50048,"activeCount":102},[],{"trials":50050,"activeCount":102},[50051],{"nctId":50052,"briefTitle":50053,"status":195,"phases":50054,"primaryCompletion":4006,"completion":4006,"start":19364,"enrollment":3125,"conditions":50055,"interventions":50057},"NCT01926366","AZD6423 SAD\u002FMAD Study in Healthy Volunteers",[90],[50056],"Healthy Volunteers.",[50045],{"trials":50059,"activeCount":102},[],{"trials":50061,"activeCount":102},[],{"trials":50063,"activeCount":102},[],{"trials":50065,"activeCount":102},[],{"intervention":50067,"totalTrials":122,"cells":50068},"AZD7053",{"EARLY_PHASE1":50069,"PHASE1":50071,"PHASE2":50080,"PHASE3":50082,"PHASE4":50084,"NA":50086},{"trials":50070,"activeCount":102},[],{"trials":50072,"activeCount":102},[50073],{"nctId":50074,"briefTitle":50075,"status":195,"phases":50076,"primaryCompletion":42226,"completion":42226,"start":50077,"enrollment":1757,"conditions":50078,"interventions":50079},"NCT06093542","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.",[90],"2023-10-25",[39896],[50067],{"trials":50081,"activeCount":102},[],{"trials":50083,"activeCount":102},[],{"trials":50085,"activeCount":102},[],{"trials":50087,"activeCount":102},[],{"intervention":50089,"totalTrials":122,"cells":50090},"[14C] AZD0530",{"EARLY_PHASE1":50091,"PHASE1":50093,"PHASE2":50101,"PHASE3":50103,"PHASE4":50105,"NA":50107},{"trials":50092,"activeCount":102},[],{"trials":50094,"activeCount":102},[50095],{"nctId":50096,"briefTitle":50097,"status":195,"phases":50098,"completion":2320,"start":2077,"enrollment":1039,"conditions":50099,"interventions":50100},"NCT00853983","Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers",[90],[19],[50089],{"trials":50102,"activeCount":102},[],{"trials":50104,"activeCount":102},[],{"trials":50106,"activeCount":102},[],{"trials":50108,"activeCount":102},[],{"intervention":13987,"totalTrials":122,"cells":50110},{"EARLY_PHASE1":50111,"PHASE1":50113,"PHASE2":50119,"PHASE3":50121,"PHASE4":50123,"NA":50125},{"trials":50112,"activeCount":102},[],{"trials":50114,"activeCount":102},[50115],{"nctId":13981,"briefTitle":13982,"status":2744,"phases":50116,"primaryCompletion":4053,"completion":4053,"start":13984,"enrollment":2260,"conditions":50117,"interventions":50118},[90],[22],[13957,13987],{"trials":50120,"activeCount":102},[],{"trials":50122,"activeCount":102},[],{"trials":50124,"activeCount":102},[],{"trials":50126,"activeCount":102},[],{"intervention":42522,"totalTrials":122,"cells":50128},{"EARLY_PHASE1":50129,"PHASE1":50131,"PHASE2":50137,"PHASE3":50139,"PHASE4":50141,"NA":50143},{"trials":50130,"activeCount":102},[],{"trials":50132,"activeCount":102},[50133],{"nctId":42515,"briefTitle":42516,"status":195,"phases":50134,"primaryCompletion":20965,"completion":20965,"start":4005,"enrollment":5425,"conditions":50135,"interventions":50136},[90],[42519,42520,15776],[42522,42508,42523],{"trials":50138,"activeCount":102},[],{"trials":50140,"activeCount":102},[],{"trials":50142,"activeCount":102},[],{"trials":50144,"activeCount":102},[],{"intervention":42523,"totalTrials":122,"cells":50146},{"EARLY_PHASE1":50147,"PHASE1":50149,"PHASE2":50155,"PHASE3":50157,"PHASE4":50159,"NA":50161},{"trials":50148,"activeCount":102},[],{"trials":50150,"activeCount":102},[50151],{"nctId":42515,"briefTitle":42516,"status":195,"phases":50152,"primaryCompletion":20965,"completion":20965,"start":4005,"enrollment":5425,"conditions":50153,"interventions":50154},[90],[42519,42520,15776],[42522,42508,42523],{"trials":50156,"activeCount":102},[],{"trials":50158,"activeCount":102},[],{"trials":50160,"activeCount":102},[],{"trials":50162,"activeCount":102},[],{"intervention":50164,"totalTrials":122,"cells":50165},"Balcinrenone",{"EARLY_PHASE1":50166,"PHASE1":50168,"PHASE2":50177,"PHASE3":50179,"PHASE4":50181,"NA":50183},{"trials":50167,"activeCount":102},[],{"trials":50169,"activeCount":102},[50170],{"nctId":50171,"briefTitle":50172,"status":195,"phases":50173,"primaryCompletion":50174,"completion":50174,"start":33540,"enrollment":1710,"conditions":50175,"interventions":50176},"NCT06388616","Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone",[90],"2024-09-05",[6914],[50164],{"trials":50178,"activeCount":102},[],{"trials":50180,"activeCount":102},[],{"trials":50182,"activeCount":102},[],{"trials":50184,"activeCount":102},[],{"intervention":50186,"totalTrials":122,"cells":50187},"AZD6370",{"EARLY_PHASE1":50188,"PHASE1":50190,"PHASE2":50198,"PHASE3":50200,"PHASE4":50202,"NA":50204},{"trials":50189,"activeCount":102},[],{"trials":50191,"activeCount":102},[50192],{"nctId":50193,"briefTitle":50194,"status":195,"phases":50195,"primaryCompletion":2524,"completion":2524,"start":2168,"enrollment":1130,"conditions":50196,"interventions":50197},"NCT00690287","A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients",[90],[31],[50186,50186],{"trials":50199,"activeCount":102},[],{"trials":50201,"activeCount":102},[],{"trials":50203,"activeCount":102},[],{"trials":50205,"activeCount":102},[],{"intervention":50207,"totalTrials":122,"cells":50208},"[14C]AZD9291",{"EARLY_PHASE1":50209,"PHASE1":50211,"PHASE2":50220,"PHASE3":50222,"PHASE4":50224,"NA":50226},{"trials":50210,"activeCount":102},[],{"trials":50212,"activeCount":102},[50213],{"nctId":50214,"briefTitle":50215,"status":195,"phases":50216,"primaryCompletion":20965,"completion":20965,"start":24772,"enrollment":2003,"conditions":50217,"interventions":50219},"NCT02491944","A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291",[90],[50218],"Oncology",[5257,50207],{"trials":50221,"activeCount":102},[],{"trials":50223,"activeCount":102},[],{"trials":50225,"activeCount":102},[],{"trials":50227,"activeCount":102},[],{"intervention":50229,"totalTrials":122,"cells":50230},"Fexofenadine tablet dosing",{"EARLY_PHASE1":50231,"PHASE1":50233,"PHASE2":50242,"PHASE3":50244,"PHASE4":50246,"NA":50248},{"trials":50232,"activeCount":102},[],{"trials":50234,"activeCount":102},[50235],{"nctId":50236,"briefTitle":50237,"status":195,"phases":50238,"primaryCompletion":8840,"completion":1863,"start":21190,"enrollment":1130,"conditions":50239,"interventions":50240},"NCT02908750","Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC",[90],[3864],[50229,50241],"Osimertininb tablet dosing",{"trials":50243,"activeCount":102},[],{"trials":50245,"activeCount":102},[],{"trials":50247,"activeCount":102},[],{"trials":50249,"activeCount":102},[],{"intervention":50241,"totalTrials":122,"cells":50251},{"EARLY_PHASE1":50252,"PHASE1":50254,"PHASE2":50260,"PHASE3":50262,"PHASE4":50264,"NA":50266},{"trials":50253,"activeCount":102},[],{"trials":50255,"activeCount":102},[50256],{"nctId":50236,"briefTitle":50237,"status":195,"phases":50257,"primaryCompletion":8840,"completion":1863,"start":21190,"enrollment":1130,"conditions":50258,"interventions":50259},[90],[3864],[50229,50241],{"trials":50261,"activeCount":102},[],{"trials":50263,"activeCount":102},[],{"trials":50265,"activeCount":102},[],{"trials":50267,"activeCount":102},[],{"intervention":13095,"totalTrials":122,"cells":50269},{"EARLY_PHASE1":50270,"PHASE1":50272,"PHASE2":50278,"PHASE3":50280,"PHASE4":50282,"NA":50284},{"trials":50271,"activeCount":102},[],{"trials":50273,"activeCount":102},[50274],{"nctId":13088,"briefTitle":13089,"status":195,"phases":50275,"primaryCompletion":4915,"completion":4915,"start":2415,"enrollment":5876,"conditions":50276,"interventions":50277},[90],[13092,13093],[268,13095],{"trials":50279,"activeCount":102},[],{"trials":50281,"activeCount":102},[],{"trials":50283,"activeCount":102},[],{"trials":50285,"activeCount":102},[],{"intervention":50287,"totalTrials":122,"cells":50288},"EMLA test patch",{"EARLY_PHASE1":50289,"PHASE1":50291,"PHASE2":50300,"PHASE3":50302,"PHASE4":50304,"NA":50306},{"trials":50290,"activeCount":102},[],{"trials":50292,"activeCount":102},[50293],{"nctId":50294,"briefTitle":50295,"status":195,"phases":50296,"primaryCompletion":41046,"completion":41046,"start":33756,"enrollment":579,"conditions":50297,"interventions":50298},"NCT03313336","A Study to Assess Therapeutic Equivalence Between Test EMLA Patch With Marketed EMLA Patch in Healthy Subjects.",[90],[31755],[50287,50299],"EMLA current reference patch",{"trials":50301,"activeCount":102},[],{"trials":50303,"activeCount":102},[],{"trials":50305,"activeCount":102},[],{"trials":50307,"activeCount":102},[],{"intervention":50299,"totalTrials":122,"cells":50309},{"EARLY_PHASE1":50310,"PHASE1":50312,"PHASE2":50318,"PHASE3":50320,"PHASE4":50322,"NA":50324},{"trials":50311,"activeCount":102},[],{"trials":50313,"activeCount":102},[50314],{"nctId":50294,"briefTitle":50295,"status":195,"phases":50315,"primaryCompletion":41046,"completion":41046,"start":33756,"enrollment":579,"conditions":50316,"interventions":50317},[90],[31755],[50287,50299],{"trials":50319,"activeCount":102},[],{"trials":50321,"activeCount":102},[],{"trials":50323,"activeCount":102},[],{"trials":50325,"activeCount":102},[],{"intervention":50327,"totalTrials":122,"cells":50328},"AZD8418",{"EARLY_PHASE1":50329,"PHASE1":50331,"PHASE2":50339,"PHASE3":50341,"PHASE4":50343,"NA":50345},{"trials":50330,"activeCount":102},[],{"trials":50332,"activeCount":102},[50333],{"nctId":50334,"briefTitle":50335,"status":443,"phases":50336,"primaryCompletion":2212,"completion":2212,"start":2057,"enrollment":1448,"conditions":50337,"interventions":50338},"NCT01027234","This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses",[90],[19],[50327],{"trials":50340,"activeCount":102},[],{"trials":50342,"activeCount":102},[],{"trials":50344,"activeCount":102},[],{"trials":50346,"activeCount":102},[],{"intervention":50348,"totalTrials":122,"cells":50349},"AZD9056 formulation Phase III 50 mg",{"EARLY_PHASE1":50350,"PHASE1":50352,"PHASE2":50363,"PHASE3":50365,"PHASE4":50367,"NA":50369},{"trials":50351,"activeCount":102},[],{"trials":50353,"activeCount":102},[50354],{"nctId":50355,"briefTitle":50356,"status":195,"phases":50357,"completion":2068,"start":688,"enrollment":1130,"conditions":50358,"interventions":50359},"NCT00908934","AZD9056 Relative Bioavailability Study",[90],[19],[50348,50360,50361,50362],"AZD9056 formulation Phase IIb 50 mg","AZD9056 formulation Phase III 200 mg","AZD9056 formulation Phase IIb 200mg",{"trials":50364,"activeCount":102},[],{"trials":50366,"activeCount":102},[],{"trials":50368,"activeCount":102},[],{"trials":50370,"activeCount":102},[],{"intervention":50360,"totalTrials":122,"cells":50372},{"EARLY_PHASE1":50373,"PHASE1":50375,"PHASE2":50381,"PHASE3":50383,"PHASE4":50385,"NA":50387},{"trials":50374,"activeCount":102},[],{"trials":50376,"activeCount":102},[50377],{"nctId":50355,"briefTitle":50356,"status":195,"phases":50378,"completion":2068,"start":688,"enrollment":1130,"conditions":50379,"interventions":50380},[90],[19],[50348,50360,50361,50362],{"trials":50382,"activeCount":102},[],{"trials":50384,"activeCount":102},[],{"trials":50386,"activeCount":102},[],{"trials":50388,"activeCount":102},[],{"intervention":50361,"totalTrials":122,"cells":50390},{"EARLY_PHASE1":50391,"PHASE1":50393,"PHASE2":50399,"PHASE3":50401,"PHASE4":50403,"NA":50405},{"trials":50392,"activeCount":102},[],{"trials":50394,"activeCount":102},[50395],{"nctId":50355,"briefTitle":50356,"status":195,"phases":50396,"completion":2068,"start":688,"enrollment":1130,"conditions":50397,"interventions":50398},[90],[19],[50348,50360,50361,50362],{"trials":50400,"activeCount":102},[],{"trials":50402,"activeCount":102},[],{"trials":50404,"activeCount":102},[],{"trials":50406,"activeCount":102},[],{"intervention":50362,"totalTrials":122,"cells":50408},{"EARLY_PHASE1":50409,"PHASE1":50411,"PHASE2":50417,"PHASE3":50419,"PHASE4":50421,"NA":50423},{"trials":50410,"activeCount":102},[],{"trials":50412,"activeCount":102},[50413],{"nctId":50355,"briefTitle":50356,"status":195,"phases":50414,"completion":2068,"start":688,"enrollment":1130,"conditions":50415,"interventions":50416},[90],[19],[50348,50360,50361,50362],{"trials":50418,"activeCount":102},[],{"trials":50420,"activeCount":102},[],{"trials":50422,"activeCount":102},[],{"trials":50424,"activeCount":102},[],{"intervention":6637,"totalTrials":122,"cells":50426},{"EARLY_PHASE1":50427,"PHASE1":50429,"PHASE2":50435,"PHASE3":50437,"PHASE4":50439,"NA":50441},{"trials":50428,"activeCount":102},[],{"trials":50430,"activeCount":102},[50431],{"nctId":6624,"briefTitle":6625,"status":195,"phases":50432,"primaryCompletion":6627,"completion":6628,"start":6629,"enrollment":1842,"conditions":50433,"interventions":50434},[90],[25,306,6631,6632,6633,3174,410,6634],[43,6636,5317,369,6637],{"trials":50436,"activeCount":102},[],{"trials":50438,"activeCount":102},[],{"trials":50440,"activeCount":102},[],{"trials":50442,"activeCount":102},[],{"intervention":42530,"totalTrials":122,"cells":50444},{"EARLY_PHASE1":50445,"PHASE1":50447,"PHASE2":50453,"PHASE3":50455,"PHASE4":50457,"NA":50459},{"trials":50446,"activeCount":102},[],{"trials":50448,"activeCount":102},[50449],{"nctId":42525,"briefTitle":42526,"status":195,"phases":50450,"primaryCompletion":24772,"completion":24772,"start":4005,"enrollment":221,"conditions":50451,"interventions":50452},[90],[22858,1556],[42530,42508,42531,42532],{"trials":50454,"activeCount":102},[],{"trials":50456,"activeCount":102},[],{"trials":50458,"activeCount":102},[],{"trials":50460,"activeCount":102},[],{"intervention":42531,"totalTrials":122,"cells":50462},{"EARLY_PHASE1":50463,"PHASE1":50465,"PHASE2":50471,"PHASE3":50473,"PHASE4":50475,"NA":50477},{"trials":50464,"activeCount":102},[],{"trials":50466,"activeCount":102},[50467],{"nctId":42525,"briefTitle":42526,"status":195,"phases":50468,"primaryCompletion":24772,"completion":24772,"start":4005,"enrollment":221,"conditions":50469,"interventions":50470},[90],[22858,1556],[42530,42508,42531,42532],{"trials":50472,"activeCount":102},[],{"trials":50474,"activeCount":102},[],{"trials":50476,"activeCount":102},[],{"trials":50478,"activeCount":102},[],{"intervention":42532,"totalTrials":122,"cells":50480},{"EARLY_PHASE1":50481,"PHASE1":50483,"PHASE2":50489,"PHASE3":50491,"PHASE4":50493,"NA":50495},{"trials":50482,"activeCount":102},[],{"trials":50484,"activeCount":102},[50485],{"nctId":42525,"briefTitle":42526,"status":195,"phases":50486,"primaryCompletion":24772,"completion":24772,"start":4005,"enrollment":221,"conditions":50487,"interventions":50488},[90],[22858,1556],[42530,42508,42531,42532],{"trials":50490,"activeCount":102},[],{"trials":50492,"activeCount":102},[],{"trials":50494,"activeCount":102},[],{"trials":50496,"activeCount":102},[],{"intervention":26679,"totalTrials":122,"cells":50498},{"EARLY_PHASE1":50499,"PHASE1":50501,"PHASE2":50507,"PHASE3":50509,"PHASE4":50511,"NA":50513},{"trials":50500,"activeCount":102},[],{"trials":50502,"activeCount":102},[50503],{"nctId":26674,"briefTitle":26675,"status":195,"phases":50504,"primaryCompletion":2471,"completion":2471,"start":4496,"enrollment":3180,"conditions":50505,"interventions":50506},[90],[10052,15776],[26679,26680,26679,26680],{"trials":50508,"activeCount":102},[],{"trials":50510,"activeCount":102},[],{"trials":50512,"activeCount":102},[],{"trials":50514,"activeCount":102},[],{"intervention":13996,"totalTrials":122,"cells":50516},{"EARLY_PHASE1":50517,"PHASE1":50519,"PHASE2":50525,"PHASE3":50527,"PHASE4":50529,"NA":50531},{"trials":50518,"activeCount":102},[],{"trials":50520,"activeCount":102},[50521],{"nctId":13989,"briefTitle":13990,"status":195,"phases":50522,"primaryCompletion":13992,"completion":13992,"start":13993,"enrollment":4497,"conditions":50523,"interventions":50524},[90],[5851],[13957,5911,13996],{"trials":50526,"activeCount":102},[],{"trials":50528,"activeCount":102},[],{"trials":50530,"activeCount":102},[],{"trials":50532,"activeCount":102},[],{"intervention":50534,"totalTrials":122,"cells":50535},"AZD7986, oral solution, 1 to 50 mg\u002FmL",{"EARLY_PHASE1":50536,"PHASE1":50538,"PHASE2":50548,"PHASE3":50550,"PHASE4":50552,"NA":50554},{"trials":50537,"activeCount":102},[],{"trials":50539,"activeCount":102},[50540],{"nctId":50541,"briefTitle":50542,"status":195,"phases":50543,"primaryCompletion":50544,"completion":50544,"start":27466,"enrollment":29188,"conditions":50545,"interventions":50547},"NCT02303574","Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study",[90],"2016-08-03",[50546],"Safety, Pharmacokinetics, Pharmacodynamics, Food Effect",[50534],{"trials":50549,"activeCount":102},[],{"trials":50551,"activeCount":102},[],{"trials":50553,"activeCount":102},[],{"trials":50555,"activeCount":102},[],{"intervention":40524,"totalTrials":122,"cells":50557},{"EARLY_PHASE1":50558,"PHASE1":50560,"PHASE2":50566,"PHASE3":50568,"PHASE4":50570,"NA":50572},{"trials":50559,"activeCount":102},[],{"trials":50561,"activeCount":102},[50562],{"nctId":40519,"briefTitle":40520,"status":195,"phases":50563,"completion":2350,"start":2067,"enrollment":1130,"conditions":50564,"interventions":50565},[90],[19],[33061,40524],{"trials":50567,"activeCount":102},[],{"trials":50569,"activeCount":102},[],{"trials":50571,"activeCount":102},[],{"trials":50573,"activeCount":102},[],{"intervention":50575,"totalTrials":122,"cells":50576},"2.5 mg saxagliptin \u002F 5 mg dapagliflozin \u002F 850 mg metformin XR FDC",{"EARLY_PHASE1":50577,"PHASE1":50579,"PHASE2":50594,"PHASE3":50596,"PHASE4":50598,"NA":50600},{"trials":50578,"activeCount":102},[],{"trials":50580,"activeCount":102},[50581],{"nctId":50582,"briefTitle":50583,"status":195,"phases":50584,"primaryCompletion":50585,"completion":50585,"start":30234,"enrollment":3279,"conditions":50586,"interventions":50587},"NCT03138356","Bioequivalence Study of Combination Tablets of Saxagliptin \u002F Dapagliflozin \u002F Metformin XR (Extended-release) and Dapagliflozin \u002F Metformin XR Relative to Individual Components in Healthy Subjects",[90],"2017-11-28",[22],[50575,50588,50589,50590,50591,50592,50593],"2.5 mg saxagliptin \u002F 5 mg dapagliflozin \u002F 1000 mg metformin XR FDC","5 mg dapagliflozin \u002F 850 mg metformin XR FDC","5 mg dapagliflozin \u002F 1000 mg metformin XR FDC","2.5 mg ONGLYZA® (saxagliptin)","5 mg Forxiga® (dapagliflozin)","500 mg Glucophage XR®",{"trials":50595,"activeCount":102},[],{"trials":50597,"activeCount":102},[],{"trials":50599,"activeCount":102},[],{"trials":50601,"activeCount":102},[],{"intervention":50588,"totalTrials":122,"cells":50603},{"EARLY_PHASE1":50604,"PHASE1":50606,"PHASE2":50612,"PHASE3":50614,"PHASE4":50616,"NA":50618},{"trials":50605,"activeCount":102},[],{"trials":50607,"activeCount":102},[50608],{"nctId":50582,"briefTitle":50583,"status":195,"phases":50609,"primaryCompletion":50585,"completion":50585,"start":30234,"enrollment":3279,"conditions":50610,"interventions":50611},[90],[22],[50575,50588,50589,50590,50591,50592,50593],{"trials":50613,"activeCount":102},[],{"trials":50615,"activeCount":102},[],{"trials":50617,"activeCount":102},[],{"trials":50619,"activeCount":102},[],{"intervention":50589,"totalTrials":122,"cells":50621},{"EARLY_PHASE1":50622,"PHASE1":50624,"PHASE2":50630,"PHASE3":50632,"PHASE4":50634,"NA":50636},{"trials":50623,"activeCount":102},[],{"trials":50625,"activeCount":102},[50626],{"nctId":50582,"briefTitle":50583,"status":195,"phases":50627,"primaryCompletion":50585,"completion":50585,"start":30234,"enrollment":3279,"conditions":50628,"interventions":50629},[90],[22],[50575,50588,50589,50590,50591,50592,50593],{"trials":50631,"activeCount":102},[],{"trials":50633,"activeCount":102},[],{"trials":50635,"activeCount":102},[],{"trials":50637,"activeCount":102},[],{"intervention":50590,"totalTrials":122,"cells":50639},{"EARLY_PHASE1":50640,"PHASE1":50642,"PHASE2":50648,"PHASE3":50650,"PHASE4":50652,"NA":50654},{"trials":50641,"activeCount":102},[],{"trials":50643,"activeCount":102},[50644],{"nctId":50582,"briefTitle":50583,"status":195,"phases":50645,"primaryCompletion":50585,"completion":50585,"start":30234,"enrollment":3279,"conditions":50646,"interventions":50647},[90],[22],[50575,50588,50589,50590,50591,50592,50593],{"trials":50649,"activeCount":102},[],{"trials":50651,"activeCount":102},[],{"trials":50653,"activeCount":102},[],{"trials":50655,"activeCount":102},[],{"intervention":50591,"totalTrials":122,"cells":50657},{"EARLY_PHASE1":50658,"PHASE1":50660,"PHASE2":50666,"PHASE3":50668,"PHASE4":50670,"NA":50672},{"trials":50659,"activeCount":102},[],{"trials":50661,"activeCount":102},[50662],{"nctId":50582,"briefTitle":50583,"status":195,"phases":50663,"primaryCompletion":50585,"completion":50585,"start":30234,"enrollment":3279,"conditions":50664,"interventions":50665},[90],[22],[50575,50588,50589,50590,50591,50592,50593],{"trials":50667,"activeCount":102},[],{"trials":50669,"activeCount":102},[],{"trials":50671,"activeCount":102},[],{"trials":50673,"activeCount":102},[],{"intervention":50592,"totalTrials":122,"cells":50675},{"EARLY_PHASE1":50676,"PHASE1":50678,"PHASE2":50684,"PHASE3":50686,"PHASE4":50688,"NA":50690},{"trials":50677,"activeCount":102},[],{"trials":50679,"activeCount":102},[50680],{"nctId":50582,"briefTitle":50583,"status":195,"phases":50681,"primaryCompletion":50585,"completion":50585,"start":30234,"enrollment":3279,"conditions":50682,"interventions":50683},[90],[22],[50575,50588,50589,50590,50591,50592,50593],{"trials":50685,"activeCount":102},[],{"trials":50687,"activeCount":102},[],{"trials":50689,"activeCount":102},[],{"trials":50691,"activeCount":102},[],{"intervention":50593,"totalTrials":122,"cells":50693},{"EARLY_PHASE1":50694,"PHASE1":50696,"PHASE2":50702,"PHASE3":50704,"PHASE4":50706,"NA":50708},{"trials":50695,"activeCount":102},[],{"trials":50697,"activeCount":102},[50698],{"nctId":50582,"briefTitle":50583,"status":195,"phases":50699,"primaryCompletion":50585,"completion":50585,"start":30234,"enrollment":3279,"conditions":50700,"interventions":50701},[90],[22],[50575,50588,50589,50590,50591,50592,50593],{"trials":50703,"activeCount":102},[],{"trials":50705,"activeCount":102},[],{"trials":50707,"activeCount":102},[],{"trials":50709,"activeCount":102},[],{"intervention":50711,"totalTrials":122,"cells":50712},"rosuvastatin 40 mg",{"EARLY_PHASE1":50713,"PHASE1":50715,"PHASE2":50726,"PHASE3":50728,"PHASE4":50730,"NA":50732},{"trials":50714,"activeCount":102},[],{"trials":50716,"activeCount":102},[50717],{"nctId":50718,"briefTitle":50719,"status":195,"phases":50720,"primaryCompletion":1693,"completion":1693,"start":19364,"enrollment":3218,"conditions":50721,"interventions":50722},"NCT02859129","Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)",[90],[13022],[50711,50723,50724,50725],"Epanova™ QD","Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose","Multiple (20) oral doses of 2 g Vascepa® every 12 hours",{"trials":50727,"activeCount":102},[],{"trials":50729,"activeCount":102},[],{"trials":50731,"activeCount":102},[],{"trials":50733,"activeCount":102},[],{"intervention":50723,"totalTrials":122,"cells":50735},{"EARLY_PHASE1":50736,"PHASE1":50738,"PHASE2":50744,"PHASE3":50746,"PHASE4":50748,"NA":50750},{"trials":50737,"activeCount":102},[],{"trials":50739,"activeCount":102},[50740],{"nctId":50718,"briefTitle":50719,"status":195,"phases":50741,"primaryCompletion":1693,"completion":1693,"start":19364,"enrollment":3218,"conditions":50742,"interventions":50743},[90],[13022],[50711,50723,50724,50725],{"trials":50745,"activeCount":102},[],{"trials":50747,"activeCount":102},[],{"trials":50749,"activeCount":102},[],{"trials":50751,"activeCount":102},[],{"intervention":50724,"totalTrials":122,"cells":50753},{"EARLY_PHASE1":50754,"PHASE1":50756,"PHASE2":50762,"PHASE3":50764,"PHASE4":50766,"NA":50768},{"trials":50755,"activeCount":102},[],{"trials":50757,"activeCount":102},[50758],{"nctId":50718,"briefTitle":50719,"status":195,"phases":50759,"primaryCompletion":1693,"completion":1693,"start":19364,"enrollment":3218,"conditions":50760,"interventions":50761},[90],[13022],[50711,50723,50724,50725],{"trials":50763,"activeCount":102},[],{"trials":50765,"activeCount":102},[],{"trials":50767,"activeCount":102},[],{"trials":50769,"activeCount":102},[],{"intervention":50725,"totalTrials":122,"cells":50771},{"EARLY_PHASE1":50772,"PHASE1":50774,"PHASE2":50780,"PHASE3":50782,"PHASE4":50784,"NA":50786},{"trials":50773,"activeCount":102},[],{"trials":50775,"activeCount":102},[50776],{"nctId":50718,"briefTitle":50719,"status":195,"phases":50777,"primaryCompletion":1693,"completion":1693,"start":19364,"enrollment":3218,"conditions":50778,"interventions":50779},[90],[13022],[50711,50723,50724,50725],{"trials":50781,"activeCount":102},[],{"trials":50783,"activeCount":102},[],{"trials":50785,"activeCount":102},[],{"trials":50787,"activeCount":102},[],{"intervention":50789,"totalTrials":122,"cells":50790},"AZD6094 (Savolitinib) film coated tablets 600 mg",{"EARLY_PHASE1":50791,"PHASE1":50793,"PHASE2":50803,"PHASE3":50805,"PHASE4":50807,"NA":50809},{"trials":50792,"activeCount":102},[],{"trials":50794,"activeCount":102},[50795],{"nctId":50796,"briefTitle":50797,"status":195,"phases":50798,"primaryCompletion":701,"completion":701,"start":8174,"enrollment":370,"conditions":50799,"interventions":50800},"NCT04675021","Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects",[90],[556],[50789,50801,50802],"[14C]-AZD6094","[14C] AZD6094",{"trials":50804,"activeCount":102},[],{"trials":50806,"activeCount":102},[],{"trials":50808,"activeCount":102},[],{"trials":50810,"activeCount":102},[],{"intervention":50801,"totalTrials":122,"cells":50812},{"EARLY_PHASE1":50813,"PHASE1":50815,"PHASE2":50821,"PHASE3":50823,"PHASE4":50825,"NA":50827},{"trials":50814,"activeCount":102},[],{"trials":50816,"activeCount":102},[50817],{"nctId":50796,"briefTitle":50797,"status":195,"phases":50818,"primaryCompletion":701,"completion":701,"start":8174,"enrollment":370,"conditions":50819,"interventions":50820},[90],[556],[50789,50801,50802],{"trials":50822,"activeCount":102},[],{"trials":50824,"activeCount":102},[],{"trials":50826,"activeCount":102},[],{"trials":50828,"activeCount":102},[],{"intervention":50802,"totalTrials":122,"cells":50830},{"EARLY_PHASE1":50831,"PHASE1":50833,"PHASE2":50839,"PHASE3":50841,"PHASE4":50843,"NA":50845},{"trials":50832,"activeCount":102},[],{"trials":50834,"activeCount":102},[50835],{"nctId":50796,"briefTitle":50797,"status":195,"phases":50836,"primaryCompletion":701,"completion":701,"start":8174,"enrollment":370,"conditions":50837,"interventions":50838},[90],[556],[50789,50801,50802],{"trials":50840,"activeCount":102},[],{"trials":50842,"activeCount":102},[],{"trials":50844,"activeCount":102},[],{"trials":50846,"activeCount":102},[],{"intervention":39829,"totalTrials":122,"cells":50848},{"EARLY_PHASE1":50849,"PHASE1":50851,"PHASE2":50857,"PHASE3":50859,"PHASE4":50861,"NA":50863},{"trials":50850,"activeCount":102},[],{"trials":50852,"activeCount":102},[50853],{"nctId":39824,"briefTitle":39825,"status":195,"phases":50854,"primaryCompletion":2252,"completion":2252,"start":5562,"enrollment":1864,"conditions":50855,"interventions":50856},[90],[19],[2197,39829,39830],{"trials":50858,"activeCount":102},[],{"trials":50860,"activeCount":102},[],{"trials":50862,"activeCount":102},[],{"trials":50864,"activeCount":102},[],{"intervention":39830,"totalTrials":122,"cells":50866},{"EARLY_PHASE1":50867,"PHASE1":50869,"PHASE2":50875,"PHASE3":50877,"PHASE4":50879,"NA":50881},{"trials":50868,"activeCount":102},[],{"trials":50870,"activeCount":102},[50871],{"nctId":39824,"briefTitle":39825,"status":195,"phases":50872,"primaryCompletion":2252,"completion":2252,"start":5562,"enrollment":1864,"conditions":50873,"interventions":50874},[90],[19],[2197,39829,39830],{"trials":50876,"activeCount":102},[],{"trials":50878,"activeCount":102},[],{"trials":50880,"activeCount":102},[],{"trials":50882,"activeCount":102},[],{"intervention":50884,"totalTrials":122,"cells":50885},"AZD3839",{"EARLY_PHASE1":50886,"PHASE1":50888,"PHASE2":50898,"PHASE3":50900,"PHASE4":50902,"NA":50904},{"trials":50887,"activeCount":102},[],{"trials":50889,"activeCount":102},[50890],{"nctId":50891,"briefTitle":50892,"status":195,"phases":50893,"primaryCompletion":4580,"completion":4580,"start":2542,"enrollment":132,"conditions":50894,"interventions":50896},"NCT01348737","Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers",[90],[18867,10052,24601,50895,36],"Blood Concentration",[50884,50897],"AZD3839 Placebo",{"trials":50899,"activeCount":102},[],{"trials":50901,"activeCount":102},[],{"trials":50903,"activeCount":102},[],{"trials":50905,"activeCount":102},[],{"intervention":50897,"totalTrials":122,"cells":50907},{"EARLY_PHASE1":50908,"PHASE1":50910,"PHASE2":50916,"PHASE3":50918,"PHASE4":50920,"NA":50922},{"trials":50909,"activeCount":102},[],{"trials":50911,"activeCount":102},[50912],{"nctId":50891,"briefTitle":50892,"status":195,"phases":50913,"primaryCompletion":4580,"completion":4580,"start":2542,"enrollment":132,"conditions":50914,"interventions":50915},[90],[18867,10052,24601,50895,36],[50884,50897],{"trials":50917,"activeCount":102},[],{"trials":50919,"activeCount":102},[],{"trials":50921,"activeCount":102},[],{"trials":50923,"activeCount":102},[],{"intervention":16378,"totalTrials":122,"cells":50925},{"EARLY_PHASE1":50926,"PHASE1":50928,"PHASE2":50934,"PHASE3":50936,"PHASE4":50938,"NA":50940},{"trials":50927,"activeCount":102},[],{"trials":50929,"activeCount":102},[50930],{"nctId":16371,"briefTitle":16372,"status":195,"phases":50931,"primaryCompletion":16374,"completion":16374,"start":16375,"enrollment":520,"conditions":50932,"interventions":50933},[90],[1556],[16378,16379,5911,16380],{"trials":50935,"activeCount":102},[],{"trials":50937,"activeCount":102},[],{"trials":50939,"activeCount":102},[],{"trials":50941,"activeCount":102},[],{"intervention":50943,"totalTrials":122,"cells":50944},"MEDI1814 for IV",{"EARLY_PHASE1":50945,"PHASE1":50947,"PHASE2":50961,"PHASE3":50963,"PHASE4":50965,"NA":50967},{"trials":50946,"activeCount":102},[],{"trials":50948,"activeCount":102},[50949],{"nctId":50950,"briefTitle":50951,"status":195,"phases":50952,"primaryCompletion":50953,"completion":50953,"start":50954,"enrollment":6652,"conditions":50955,"interventions":50958},"NCT02036645","SAD\u002FMAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.",[90],"2016-09-15","2014-02-04",[50956,50957],"Mild-Moderate Alzheimer's Disease","Healthy Elderly",[50943,50959,50960],"MEDI1814 for Subcutaneous","IV Placebo",{"trials":50962,"activeCount":102},[],{"trials":50964,"activeCount":102},[],{"trials":50966,"activeCount":102},[],{"trials":50968,"activeCount":102},[],{"intervention":50959,"totalTrials":122,"cells":50970},{"EARLY_PHASE1":50971,"PHASE1":50973,"PHASE2":50979,"PHASE3":50981,"PHASE4":50983,"NA":50985},{"trials":50972,"activeCount":102},[],{"trials":50974,"activeCount":102},[50975],{"nctId":50950,"briefTitle":50951,"status":195,"phases":50976,"primaryCompletion":50953,"completion":50953,"start":50954,"enrollment":6652,"conditions":50977,"interventions":50978},[90],[50956,50957],[50943,50959,50960],{"trials":50980,"activeCount":102},[],{"trials":50982,"activeCount":102},[],{"trials":50984,"activeCount":102},[],{"trials":50986,"activeCount":102},[],{"intervention":50960,"totalTrials":122,"cells":50988},{"EARLY_PHASE1":50989,"PHASE1":50991,"PHASE2":50997,"PHASE3":50999,"PHASE4":51001,"NA":51003},{"trials":50990,"activeCount":102},[],{"trials":50992,"activeCount":102},[50993],{"nctId":50950,"briefTitle":50951,"status":195,"phases":50994,"primaryCompletion":50953,"completion":50953,"start":50954,"enrollment":6652,"conditions":50995,"interventions":50996},[90],[50956,50957],[50943,50959,50960],{"trials":50998,"activeCount":102},[],{"trials":51000,"activeCount":102},[],{"trials":51002,"activeCount":102},[],{"trials":51004,"activeCount":102},[],{"intervention":51006,"totalTrials":122,"cells":51007},"D961S",{"EARLY_PHASE1":51008,"PHASE1":51010,"PHASE2":51019,"PHASE3":51021,"PHASE4":51023,"NA":51025},{"trials":51009,"activeCount":102},[],{"trials":51011,"activeCount":102},[51012],{"nctId":51013,"briefTitle":51014,"status":195,"phases":51015,"primaryCompletion":687,"completion":687,"start":2747,"enrollment":6652,"conditions":51016,"interventions":51017},"NCT01494402","Study to Assess the Bioequivalence Between D961S and Esomeprazole\u002FBuffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects",[90],[42173],[51006,19794,51018],"Buffered acetylsalicylic acid",{"trials":51020,"activeCount":102},[],{"trials":51022,"activeCount":102},[],{"trials":51024,"activeCount":102},[],{"trials":51026,"activeCount":102},[],{"intervention":51018,"totalTrials":122,"cells":51028},{"EARLY_PHASE1":51029,"PHASE1":51031,"PHASE2":51037,"PHASE3":51039,"PHASE4":51041,"NA":51043},{"trials":51030,"activeCount":102},[],{"trials":51032,"activeCount":102},[51033],{"nctId":51013,"briefTitle":51014,"status":195,"phases":51034,"primaryCompletion":687,"completion":687,"start":2747,"enrollment":6652,"conditions":51035,"interventions":51036},[90],[42173],[51006,19794,51018],{"trials":51038,"activeCount":102},[],{"trials":51040,"activeCount":102},[],{"trials":51042,"activeCount":102},[],{"trials":51044,"activeCount":102},[],{"intervention":51046,"totalTrials":122,"cells":51047},"MEDI-575",{"EARLY_PHASE1":51048,"PHASE1":51050,"PHASE2":51058,"PHASE3":51060,"PHASE4":51062,"NA":51064},{"trials":51049,"activeCount":102},[],{"trials":51051,"activeCount":102},[51052],{"nctId":51053,"briefTitle":51054,"status":195,"phases":51055,"primaryCompletion":2104,"completion":2104,"start":2212,"enrollment":434,"conditions":51056,"interventions":51057},"NCT01102400","A Study of MEDI-575 in Patients With Advanced Solid Malignancies",[90],[157],[51046],{"trials":51059,"activeCount":102},[],{"trials":51061,"activeCount":102},[],{"trials":51063,"activeCount":102},[],{"trials":51065,"activeCount":102},[],{"intervention":51067,"totalTrials":122,"cells":51068},"AZD 1775",{"EARLY_PHASE1":51069,"PHASE1":51071,"PHASE2":51084,"PHASE3":51086,"PHASE4":51088,"NA":51090},{"trials":51070,"activeCount":102},[],{"trials":51072,"activeCount":102},[51073],{"nctId":51074,"briefTitle":51075,"status":195,"phases":51076,"primaryCompletion":51077,"completion":51078,"start":51079,"enrollment":51080,"conditions":51081,"interventions":51083},"NCT02482311","Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours",[90],"2018-01-25","2019-08-22","2015-07-01",92,[51082],"Ovarian Cancer, TNBC, SCLC, Other Solid Tumours",[51067],{"trials":51085,"activeCount":102},[],{"trials":51087,"activeCount":102},[],{"trials":51089,"activeCount":102},[],{"trials":51091,"activeCount":102},[],{"intervention":41243,"totalTrials":122,"cells":51093},{"EARLY_PHASE1":51094,"PHASE1":51096,"PHASE2":51102,"PHASE3":51104,"PHASE4":51106,"NA":51108},{"trials":51095,"activeCount":102},[],{"trials":51097,"activeCount":102},[51098],{"nctId":41236,"briefTitle":41237,"status":443,"phases":51099,"primaryCompletion":41239,"completion":41239,"start":41240,"enrollment":1336,"conditions":51100,"interventions":51101},[90],[1556],[41243,41223],{"trials":51103,"activeCount":102},[],{"trials":51105,"activeCount":102},[],{"trials":51107,"activeCount":102},[],{"trials":51109,"activeCount":102},[],{"intervention":51111,"totalTrials":122,"cells":51112},"Osimertinib; AZD9291",{"EARLY_PHASE1":51113,"PHASE1":51115,"PHASE2":51126,"PHASE3":51128,"PHASE4":51130,"NA":51132},{"trials":51114,"activeCount":102},[],{"trials":51116,"activeCount":102},[51117],{"nctId":51118,"briefTitle":51119,"status":195,"phases":51120,"primaryCompletion":51121,"completion":51122,"start":51123,"enrollment":486,"conditions":51124,"interventions":51125},"NCT02923947","Study to Assess Osimertinib in Patients w\u002F Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment",[90],"2018-09-20","2022-10-28","2017-05-04",[466],[51111],{"trials":51127,"activeCount":102},[],{"trials":51129,"activeCount":102},[],{"trials":51131,"activeCount":102},[],{"trials":51133,"activeCount":102},[],{"intervention":51135,"totalTrials":122,"cells":51136},"balcinrenone\u002Fdapagliflozin",{"EARLY_PHASE1":51137,"PHASE1":51139,"PHASE2":51147,"PHASE3":51149,"PHASE4":51151,"NA":51153},{"trials":51138,"activeCount":102},[],{"trials":51140,"activeCount":102},[51141],{"nctId":51142,"briefTitle":51143,"status":195,"phases":51144,"primaryCompletion":11175,"completion":11175,"start":1129,"enrollment":269,"conditions":51145,"interventions":51146},"NCT06651021","A Phase I PK Study of Balcinrenone\u002FDapagliflozin in Healthy Chinese Participants",[90],[31837],[51135],{"trials":51148,"activeCount":102},[],{"trials":51150,"activeCount":102},[],{"trials":51152,"activeCount":102},[],{"trials":51154,"activeCount":102},[],{"intervention":51156,"totalTrials":122,"cells":51157},"AZD4144- Part A",{"EARLY_PHASE1":51158,"PHASE1":51160,"PHASE2":51171,"PHASE3":51173,"PHASE4":51175,"NA":51177},{"trials":51159,"activeCount":102},[],{"trials":51161,"activeCount":102},[51162],{"nctId":51163,"briefTitle":51164,"status":195,"phases":51165,"primaryCompletion":33873,"completion":33873,"start":12184,"enrollment":14379,"conditions":51166,"interventions":51167},"NCT06491550","A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants",[90],[5851],[51156,51168,51169,51170],"AZD4144- Part B","Rosuvastatin and Furosemide- Part C","Rosuvastatin, Furosemide, and AZD4144 Part C",{"trials":51172,"activeCount":102},[],{"trials":51174,"activeCount":102},[],{"trials":51176,"activeCount":102},[],{"trials":51178,"activeCount":102},[],{"intervention":51168,"totalTrials":122,"cells":51180},{"EARLY_PHASE1":51181,"PHASE1":51183,"PHASE2":51189,"PHASE3":51191,"PHASE4":51193,"NA":51195},{"trials":51182,"activeCount":102},[],{"trials":51184,"activeCount":102},[51185],{"nctId":51163,"briefTitle":51164,"status":195,"phases":51186,"primaryCompletion":33873,"completion":33873,"start":12184,"enrollment":14379,"conditions":51187,"interventions":51188},[90],[5851],[51156,51168,51169,51170],{"trials":51190,"activeCount":102},[],{"trials":51192,"activeCount":102},[],{"trials":51194,"activeCount":102},[],{"trials":51196,"activeCount":102},[],{"intervention":51169,"totalTrials":122,"cells":51198},{"EARLY_PHASE1":51199,"PHASE1":51201,"PHASE2":51207,"PHASE3":51209,"PHASE4":51211,"NA":51213},{"trials":51200,"activeCount":102},[],{"trials":51202,"activeCount":102},[51203],{"nctId":51163,"briefTitle":51164,"status":195,"phases":51204,"primaryCompletion":33873,"completion":33873,"start":12184,"enrollment":14379,"conditions":51205,"interventions":51206},[90],[5851],[51156,51168,51169,51170],{"trials":51208,"activeCount":102},[],{"trials":51210,"activeCount":102},[],{"trials":51212,"activeCount":102},[],{"trials":51214,"activeCount":102},[],{"intervention":51170,"totalTrials":122,"cells":51216},{"EARLY_PHASE1":51217,"PHASE1":51219,"PHASE2":51225,"PHASE3":51227,"PHASE4":51229,"NA":51231},{"trials":51218,"activeCount":102},[],{"trials":51220,"activeCount":102},[51221],{"nctId":51163,"briefTitle":51164,"status":195,"phases":51222,"primaryCompletion":33873,"completion":33873,"start":12184,"enrollment":14379,"conditions":51223,"interventions":51224},[90],[5851],[51156,51168,51169,51170],{"trials":51226,"activeCount":102},[],{"trials":51228,"activeCount":102},[],{"trials":51230,"activeCount":102},[],{"trials":51232,"activeCount":102},[],{"intervention":51234,"totalTrials":122,"cells":51235},"AZD7442 300 mg IM",{"EARLY_PHASE1":51236,"PHASE1":51238,"PHASE2":51250,"PHASE3":51252,"PHASE4":51254,"NA":51256},{"trials":51237,"activeCount":102},[],{"trials":51239,"activeCount":102},[51240],{"nctId":51241,"briefTitle":51242,"status":195,"phases":51243,"primaryCompletion":51244,"completion":51244,"start":38674,"enrollment":1448,"conditions":51245,"interventions":51246},"NCT04896541","Phase I Double-blind, Placebo-controlled Study of AZD7442",[90],"2022-06-14",[1387],[51234,51247,51248,51249],"AZD7442 600 mg IM","AZD7442 300 mg IV","AZD7442 1000 mg IV",{"trials":51251,"activeCount":102},[],{"trials":51253,"activeCount":102},[],{"trials":51255,"activeCount":102},[],{"trials":51257,"activeCount":102},[],{"intervention":51247,"totalTrials":122,"cells":51259},{"EARLY_PHASE1":51260,"PHASE1":51262,"PHASE2":51268,"PHASE3":51270,"PHASE4":51272,"NA":51274},{"trials":51261,"activeCount":102},[],{"trials":51263,"activeCount":102},[51264],{"nctId":51241,"briefTitle":51242,"status":195,"phases":51265,"primaryCompletion":51244,"completion":51244,"start":38674,"enrollment":1448,"conditions":51266,"interventions":51267},[90],[1387],[51234,51247,51248,51249],{"trials":51269,"activeCount":102},[],{"trials":51271,"activeCount":102},[],{"trials":51273,"activeCount":102},[],{"trials":51275,"activeCount":102},[],{"intervention":51248,"totalTrials":122,"cells":51277},{"EARLY_PHASE1":51278,"PHASE1":51280,"PHASE2":51286,"PHASE3":51288,"PHASE4":51290,"NA":51292},{"trials":51279,"activeCount":102},[],{"trials":51281,"activeCount":102},[51282],{"nctId":51241,"briefTitle":51242,"status":195,"phases":51283,"primaryCompletion":51244,"completion":51244,"start":38674,"enrollment":1448,"conditions":51284,"interventions":51285},[90],[1387],[51234,51247,51248,51249],{"trials":51287,"activeCount":102},[],{"trials":51289,"activeCount":102},[],{"trials":51291,"activeCount":102},[],{"trials":51293,"activeCount":102},[],{"intervention":51249,"totalTrials":122,"cells":51295},{"EARLY_PHASE1":51296,"PHASE1":51298,"PHASE2":51304,"PHASE3":51306,"PHASE4":51308,"NA":51310},{"trials":51297,"activeCount":102},[],{"trials":51299,"activeCount":102},[51300],{"nctId":51241,"briefTitle":51242,"status":195,"phases":51301,"primaryCompletion":51244,"completion":51244,"start":38674,"enrollment":1448,"conditions":51302,"interventions":51303},[90],[1387],[51234,51247,51248,51249],{"trials":51305,"activeCount":102},[],{"trials":51307,"activeCount":102},[],{"trials":51309,"activeCount":102},[],{"trials":51311,"activeCount":102},[],{"intervention":51313,"totalTrials":122,"cells":51314},"AZD1981 100 mg twice daily for 61\u002F2 days",{"EARLY_PHASE1":51315,"PHASE1":51317,"PHASE2":51325,"PHASE3":51327,"PHASE4":51329,"NA":51331},{"trials":51316,"activeCount":102},[],{"trials":51318,"activeCount":102},[51319],{"nctId":51320,"briefTitle":51321,"status":195,"phases":51322,"primaryCompletion":2433,"completion":2433,"start":2489,"enrollment":544,"conditions":51323,"interventions":51324},"NCT01196689","Pharmacokinetics in Adolescents",[90],[16],[51313],{"trials":51326,"activeCount":102},[],{"trials":51328,"activeCount":102},[],{"trials":51330,"activeCount":102},[],{"trials":51332,"activeCount":102},[],{"intervention":51334,"totalTrials":122,"cells":51335},"AZD4451",{"EARLY_PHASE1":51336,"PHASE1":51338,"PHASE2":51346,"PHASE3":51348,"PHASE4":51350,"NA":51352},{"trials":51337,"activeCount":102},[],{"trials":51339,"activeCount":102},[51340],{"nctId":51341,"briefTitle":51342,"status":195,"phases":51343,"primaryCompletion":12721,"completion":12721,"start":2144,"enrollment":18686,"conditions":51344,"interventions":51345},"NCT01196676","Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451",[90],[18732],[51334],{"trials":51347,"activeCount":102},[],{"trials":51349,"activeCount":102},[],{"trials":51351,"activeCount":102},[],{"trials":51353,"activeCount":102},[],{"intervention":51355,"totalTrials":122,"cells":51356},"Drug-AZD8931",{"EARLY_PHASE1":51357,"PHASE1":51359,"PHASE2":51369,"PHASE3":51371,"PHASE4":51373,"NA":51375},{"trials":51358,"activeCount":102},[],{"trials":51360,"activeCount":102},[51361],{"nctId":51362,"briefTitle":51363,"status":443,"phases":51364,"primaryCompletion":2443,"completion":7354,"start":2471,"enrollment":3887,"conditions":51365,"interventions":51367},"NCT01596530","Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment",[90],[51366],"Breast Neoplasm",[51355,51368],"Drug-Placebo",{"trials":51370,"activeCount":102},[],{"trials":51372,"activeCount":102},[],{"trials":51374,"activeCount":102},[],{"trials":51376,"activeCount":102},[],{"intervention":51368,"totalTrials":122,"cells":51378},{"EARLY_PHASE1":51379,"PHASE1":51381,"PHASE2":51387,"PHASE3":51389,"PHASE4":51391,"NA":51393},{"trials":51380,"activeCount":102},[],{"trials":51382,"activeCount":102},[51383],{"nctId":51362,"briefTitle":51363,"status":443,"phases":51384,"primaryCompletion":2443,"completion":7354,"start":2471,"enrollment":3887,"conditions":51385,"interventions":51386},[90],[51366],[51355,51368],{"trials":51388,"activeCount":102},[],{"trials":51390,"activeCount":102},[],{"trials":51392,"activeCount":102},[],{"trials":51394,"activeCount":102},[],{"intervention":51396,"totalTrials":122,"cells":51397},"FosD",{"EARLY_PHASE1":51398,"PHASE1":51400,"PHASE2":51408,"PHASE3":51410,"PHASE4":51412,"NA":51414},{"trials":51399,"activeCount":102},[],{"trials":51401,"activeCount":102},[51402],{"nctId":51403,"briefTitle":51404,"status":195,"phases":51405,"primaryCompletion":2615,"completion":2615,"start":2406,"enrollment":2933,"conditions":51406,"interventions":51407},"NCT01167868","A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects",[90],[19],[51396],{"trials":51409,"activeCount":102},[],{"trials":51411,"activeCount":102},[],{"trials":51413,"activeCount":102},[],{"trials":51415,"activeCount":102},[],{"intervention":39776,"totalTrials":122,"cells":51417},{"EARLY_PHASE1":51418,"PHASE1":51420,"PHASE2":51426,"PHASE3":51428,"PHASE4":51430,"NA":51432},{"trials":51419,"activeCount":102},[],{"trials":51421,"activeCount":102},[51422],{"nctId":39769,"briefTitle":39770,"status":195,"phases":51423,"primaryCompletion":39772,"completion":39772,"start":39773,"enrollment":1864,"conditions":51424,"interventions":51425},[90],[3056],[39776,2255],{"trials":51427,"activeCount":102},[],{"trials":51429,"activeCount":102},[],{"trials":51431,"activeCount":102},[],{"trials":51433,"activeCount":102},[],{"intervention":3108,"totalTrials":122,"cells":51435},{"EARLY_PHASE1":51436,"PHASE1":51438,"PHASE2":51444,"PHASE3":51446,"PHASE4":51448,"NA":51450},{"trials":51437,"activeCount":102},[],{"trials":51439,"activeCount":102},[51440],{"nctId":3099,"briefTitle":3100,"status":195,"phases":51441,"primaryCompletion":1964,"completion":1964,"start":208,"enrollment":477,"conditions":51442,"interventions":51443},[90],[3103,3104,249,3105,420,3106,410,404,498],[3108,117],{"trials":51445,"activeCount":102},[],{"trials":51447,"activeCount":102},[],{"trials":51449,"activeCount":102},[],{"trials":51451,"activeCount":102},[],{"intervention":24604,"totalTrials":122,"cells":51453},{"EARLY_PHASE1":51454,"PHASE1":51456,"PHASE2":51462,"PHASE3":51464,"PHASE4":51466,"NA":51468},{"trials":51455,"activeCount":102},[],{"trials":51457,"activeCount":102},[51458],{"nctId":24596,"briefTitle":24597,"status":195,"phases":51459,"primaryCompletion":5238,"completion":5238,"start":24599,"enrollment":132,"conditions":51460,"interventions":51461},[90],[10052,24601,15776,24602,1556,7267],[24604,9939],{"trials":51463,"activeCount":102},[],{"trials":51465,"activeCount":102},[],{"trials":51467,"activeCount":102},[],{"trials":51469,"activeCount":102},[],{"intervention":23728,"totalTrials":122,"cells":51471},{"EARLY_PHASE1":51472,"PHASE1":51474,"PHASE2":51480,"PHASE3":51482,"PHASE4":51484,"NA":51486},{"trials":51473,"activeCount":102},[],{"trials":51475,"activeCount":102},[51476],{"nctId":23723,"briefTitle":23724,"status":195,"phases":51477,"primaryCompletion":2243,"completion":2243,"start":7342,"enrollment":2260,"conditions":51478,"interventions":51479},[90],[7102],[13870,23728,13870,23728],{"trials":51481,"activeCount":102},[],{"trials":51483,"activeCount":102},[],{"trials":51485,"activeCount":102},[],{"trials":51487,"activeCount":102},[],{"intervention":51489,"totalTrials":122,"cells":51490},"AZD6912",{"EARLY_PHASE1":51491,"PHASE1":51493,"PHASE2":51503,"PHASE3":51505,"PHASE4":51507,"NA":51509},{"trials":51492,"activeCount":102},[],{"trials":51494,"activeCount":102},[51495],{"nctId":51496,"briefTitle":51497,"status":195,"phases":51498,"primaryCompletion":51499,"completion":51499,"start":51500,"enrollment":1448,"conditions":51501,"interventions":51502},"NCT06115967","A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants",[90],"2025-10-16","2023-11-15",[7267],[51489],{"trials":51504,"activeCount":102},[],{"trials":51506,"activeCount":102},[],{"trials":51508,"activeCount":102},[],{"trials":51510,"activeCount":102},[],{"intervention":51512,"totalTrials":122,"cells":51513},"AZD0186",{"EARLY_PHASE1":51514,"PHASE1":51516,"PHASE2":51525,"PHASE3":51527,"PHASE4":51529,"NA":51531},{"trials":51515,"activeCount":102},[],{"trials":51517,"activeCount":102},[51518],{"nctId":51519,"briefTitle":51520,"status":443,"phases":51521,"primaryCompletion":51522,"completion":51522,"start":18155,"enrollment":3248,"conditions":51523,"interventions":51524},"NCT05694741","A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186",[90],"2023-05-10",[31],[51512],{"trials":51526,"activeCount":102},[],{"trials":51528,"activeCount":102},[],{"trials":51530,"activeCount":102},[],{"trials":51532,"activeCount":102},[],{"intervention":40685,"totalTrials":122,"cells":51534},{"EARLY_PHASE1":51535,"PHASE1":51537,"PHASE2":51543,"PHASE3":51545,"PHASE4":51547,"NA":51549},{"trials":51536,"activeCount":102},[],{"trials":51538,"activeCount":102},[51539],{"nctId":40680,"briefTitle":40681,"status":195,"phases":51540,"primaryCompletion":3827,"completion":3827,"start":2168,"enrollment":370,"conditions":51541,"interventions":51542},[90],[20485],[33999,40685],{"trials":51544,"activeCount":102},[],{"trials":51546,"activeCount":102},[],{"trials":51548,"activeCount":102},[],{"trials":51550,"activeCount":102},[],{"intervention":31878,"totalTrials":122,"cells":51552},{"EARLY_PHASE1":51553,"PHASE1":51555,"PHASE2":51561,"PHASE3":51563,"PHASE4":51565,"NA":51567},{"trials":51554,"activeCount":102},[],{"trials":51556,"activeCount":102},[51557],{"nctId":31873,"briefTitle":31874,"status":195,"phases":51558,"primaryCompletion":2507,"completion":2507,"start":2168,"enrollment":1979,"conditions":51559,"interventions":51560},[90],[20485],[31826,31878],{"trials":51562,"activeCount":102},[],{"trials":51564,"activeCount":102},[],{"trials":51566,"activeCount":102},[],{"trials":51568,"activeCount":102},[],{"intervention":51570,"totalTrials":122,"cells":51571},"MEDI8367",{"EARLY_PHASE1":51572,"PHASE1":51574,"PHASE2":51584,"PHASE3":51586,"PHASE4":51588,"NA":51590},{"trials":51573,"activeCount":102},[],{"trials":51575,"activeCount":102},[51576],{"nctId":51577,"briefTitle":51578,"status":195,"phases":51579,"primaryCompletion":51580,"completion":51580,"start":51581,"enrollment":1757,"conditions":51582,"interventions":51583},"NCT04365218","A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease",[90],"2021-01-03","2020-07-22",[2134],[51570],{"trials":51585,"activeCount":102},[],{"trials":51587,"activeCount":102},[],{"trials":51589,"activeCount":102},[],{"trials":51591,"activeCount":102},[],{"intervention":51593,"totalTrials":122,"cells":51594},"AZD4604 Inhalation Powder, 1 mg",{"EARLY_PHASE1":51595,"PHASE1":51597,"PHASE2":51607,"PHASE3":51609,"PHASE4":51611,"NA":51613},{"trials":51596,"activeCount":102},[],{"trials":51598,"activeCount":102},[51599],{"nctId":51600,"briefTitle":51601,"status":195,"phases":51602,"primaryCompletion":10434,"completion":10434,"start":34119,"enrollment":370,"conditions":51603,"interventions":51604},"NCT06157255","An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604",[90],[16],[51593,51605,51606],"[14C]AZD4604 Solution for Infusion 6 μg\u002FmL","[14C]AZD4604 Oral Solution, 4 mg",{"trials":51608,"activeCount":102},[],{"trials":51610,"activeCount":102},[],{"trials":51612,"activeCount":102},[],{"trials":51614,"activeCount":102},[],{"intervention":51605,"totalTrials":122,"cells":51616},{"EARLY_PHASE1":51617,"PHASE1":51619,"PHASE2":51625,"PHASE3":51627,"PHASE4":51629,"NA":51631},{"trials":51618,"activeCount":102},[],{"trials":51620,"activeCount":102},[51621],{"nctId":51600,"briefTitle":51601,"status":195,"phases":51622,"primaryCompletion":10434,"completion":10434,"start":34119,"enrollment":370,"conditions":51623,"interventions":51624},[90],[16],[51593,51605,51606],{"trials":51626,"activeCount":102},[],{"trials":51628,"activeCount":102},[],{"trials":51630,"activeCount":102},[],{"trials":51632,"activeCount":102},[],{"intervention":51606,"totalTrials":122,"cells":51634},{"EARLY_PHASE1":51635,"PHASE1":51637,"PHASE2":51643,"PHASE3":51645,"PHASE4":51647,"NA":51649},{"trials":51636,"activeCount":102},[],{"trials":51638,"activeCount":102},[51639],{"nctId":51600,"briefTitle":51601,"status":195,"phases":51640,"primaryCompletion":10434,"completion":10434,"start":34119,"enrollment":370,"conditions":51641,"interventions":51642},[90],[16],[51593,51605,51606],{"trials":51644,"activeCount":102},[],{"trials":51646,"activeCount":102},[],{"trials":51648,"activeCount":102},[],{"trials":51650,"activeCount":102},[],{"intervention":51652,"totalTrials":122,"cells":51653},"AZD9898",{"EARLY_PHASE1":51654,"PHASE1":51656,"PHASE2":51664,"PHASE3":51666,"PHASE4":51668,"NA":51670},{"trials":51655,"activeCount":102},[],{"trials":51657,"activeCount":102},[51658],{"nctId":51659,"briefTitle":51660,"status":443,"phases":51661,"primaryCompletion":21189,"completion":21189,"start":30379,"enrollment":17655,"conditions":51662,"interventions":51663},"NCT03140072","A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898",[90],[16],[51652],{"trials":51665,"activeCount":102},[],{"trials":51667,"activeCount":102},[],{"trials":51669,"activeCount":102},[],{"trials":51671,"activeCount":102},[],{"intervention":51673,"totalTrials":122,"cells":51674},"AZD4721 Solution",{"EARLY_PHASE1":51675,"PHASE1":51677,"PHASE2":51688,"PHASE3":51690,"PHASE4":51692,"NA":51694},{"trials":51676,"activeCount":102},[],{"trials":51678,"activeCount":102},[51679],{"nctId":51680,"briefTitle":51681,"status":195,"phases":51682,"primaryCompletion":39977,"completion":39977,"start":13856,"enrollment":3811,"conditions":51683,"interventions":51685},"NCT01889160","Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels",[90],[51684],"Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1\u002F2λz, and Tmax",[51673,51686,51687],"AZD4721 Placebo","AZD4721 Suspension",{"trials":51689,"activeCount":102},[],{"trials":51691,"activeCount":102},[],{"trials":51693,"activeCount":102},[],{"trials":51695,"activeCount":102},[],{"intervention":51686,"totalTrials":122,"cells":51697},{"EARLY_PHASE1":51698,"PHASE1":51700,"PHASE2":51706,"PHASE3":51708,"PHASE4":51710,"NA":51712},{"trials":51699,"activeCount":102},[],{"trials":51701,"activeCount":102},[51702],{"nctId":51680,"briefTitle":51681,"status":195,"phases":51703,"primaryCompletion":39977,"completion":39977,"start":13856,"enrollment":3811,"conditions":51704,"interventions":51705},[90],[51684],[51673,51686,51687],{"trials":51707,"activeCount":102},[],{"trials":51709,"activeCount":102},[],{"trials":51711,"activeCount":102},[],{"trials":51713,"activeCount":102},[],{"intervention":51687,"totalTrials":122,"cells":51715},{"EARLY_PHASE1":51716,"PHASE1":51718,"PHASE2":51724,"PHASE3":51726,"PHASE4":51728,"NA":51730},{"trials":51717,"activeCount":102},[],{"trials":51719,"activeCount":102},[51720],{"nctId":51680,"briefTitle":51681,"status":195,"phases":51721,"primaryCompletion":39977,"completion":39977,"start":13856,"enrollment":3811,"conditions":51722,"interventions":51723},[90],[51684],[51673,51686,51687],{"trials":51725,"activeCount":102},[],{"trials":51727,"activeCount":102},[],{"trials":51729,"activeCount":102},[],{"trials":51731,"activeCount":102},[],{"intervention":40115,"totalTrials":122,"cells":51733},{"EARLY_PHASE1":51734,"PHASE1":51736,"PHASE2":51742,"PHASE3":51744,"PHASE4":51746,"NA":51748},{"trials":51735,"activeCount":102},[],{"trials":51737,"activeCount":102},[51738],{"nctId":40108,"briefTitle":40109,"status":195,"phases":51739,"primaryCompletion":2251,"completion":2251,"start":2251,"enrollment":532,"conditions":51740,"interventions":51741},[90],[40112,40113],[40115,19794,19229],{"trials":51743,"activeCount":102},[],{"trials":51745,"activeCount":102},[],{"trials":51747,"activeCount":102},[],{"trials":51749,"activeCount":102},[],{"intervention":51751,"totalTrials":122,"cells":51752},"Rapimelt",{"EARLY_PHASE1":51753,"PHASE1":51755,"PHASE2":51764,"PHASE3":51766,"PHASE4":51768,"NA":51770},{"trials":51754,"activeCount":102},[],{"trials":51756,"activeCount":102},[51757],{"nctId":51758,"briefTitle":51759,"status":195,"phases":51760,"primaryCompletion":2489,"completion":2489,"start":2243,"enrollment":269,"conditions":51761,"interventions":51762},"NCT01085123","Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers",[90],[20782],[51751,51763],"[11C]AZ10419369",{"trials":51765,"activeCount":102},[],{"trials":51767,"activeCount":102},[],{"trials":51769,"activeCount":102},[],{"trials":51771,"activeCount":102},[],{"intervention":51763,"totalTrials":122,"cells":51773},{"EARLY_PHASE1":51774,"PHASE1":51776,"PHASE2":51782,"PHASE3":51784,"PHASE4":51786,"NA":51788},{"trials":51775,"activeCount":102},[],{"trials":51777,"activeCount":102},[51778],{"nctId":51758,"briefTitle":51759,"status":195,"phases":51779,"primaryCompletion":2489,"completion":2489,"start":2243,"enrollment":269,"conditions":51780,"interventions":51781},[90],[20782],[51751,51763],{"trials":51783,"activeCount":102},[],{"trials":51785,"activeCount":102},[],{"trials":51787,"activeCount":102},[],{"trials":51789,"activeCount":102},[],{"intervention":23592,"totalTrials":122,"cells":51791},{"EARLY_PHASE1":51792,"PHASE1":51794,"PHASE2":51800,"PHASE3":51802,"PHASE4":51804,"NA":51806},{"trials":51793,"activeCount":102},[],{"trials":51795,"activeCount":102},[51796],{"nctId":23587,"briefTitle":23588,"status":443,"phases":51797,"primaryCompletion":13102,"completion":13102,"start":13787,"enrollment":4877,"conditions":51798,"interventions":51799},[90],[2619],[16338,23592],{"trials":51801,"activeCount":102},[],{"trials":51803,"activeCount":102},[],{"trials":51805,"activeCount":102},[],{"trials":51807,"activeCount":102},[],{"intervention":51809,"totalTrials":122,"cells":51810},"AZD4144 Part A",{"EARLY_PHASE1":51811,"PHASE1":51813,"PHASE2":51822,"PHASE3":51824,"PHASE4":51826,"NA":51828},{"trials":51812,"activeCount":102},[],{"trials":51814,"activeCount":102},[51815],{"nctId":51816,"briefTitle":51817,"status":195,"phases":51818,"primaryCompletion":10184,"completion":10184,"start":988,"enrollment":29,"conditions":51819,"interventions":51820},"NCT06122714","A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants",[90],[5851],[51809,51821],"AZD4144 Part B",{"trials":51823,"activeCount":102},[],{"trials":51825,"activeCount":102},[],{"trials":51827,"activeCount":102},[],{"trials":51829,"activeCount":102},[],{"intervention":51821,"totalTrials":122,"cells":51831},{"EARLY_PHASE1":51832,"PHASE1":51834,"PHASE2":51840,"PHASE3":51842,"PHASE4":51844,"NA":51846},{"trials":51833,"activeCount":102},[],{"trials":51835,"activeCount":102},[51836],{"nctId":51816,"briefTitle":51817,"status":195,"phases":51837,"primaryCompletion":10184,"completion":10184,"start":988,"enrollment":29,"conditions":51838,"interventions":51839},[90],[5851],[51809,51821],{"trials":51841,"activeCount":102},[],{"trials":51843,"activeCount":102},[],{"trials":51845,"activeCount":102},[],{"trials":51847,"activeCount":102},[],{"intervention":51849,"totalTrials":122,"cells":51850},"AZD1979",{"EARLY_PHASE1":51851,"PHASE1":51853,"PHASE2":51861,"PHASE3":51863,"PHASE4":51865,"NA":51867},{"trials":51852,"activeCount":102},[],{"trials":51854,"activeCount":102},[51855],{"nctId":51856,"briefTitle":51857,"status":443,"phases":51858,"primaryCompletion":1692,"completion":1692,"start":4006,"enrollment":2321,"conditions":51859,"interventions":51860},"NCT02072993","A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males",[90],[1556],[51849],{"trials":51862,"activeCount":102},[],{"trials":51864,"activeCount":102},[],{"trials":51866,"activeCount":102},[],{"trials":51868,"activeCount":102},[],{"intervention":51870,"totalTrials":122,"cells":51871},"AZD7295",{"EARLY_PHASE1":51872,"PHASE1":51874,"PHASE2":51882,"PHASE3":51884,"PHASE4":51886,"NA":51888},{"trials":51873,"activeCount":102},[],{"trials":51875,"activeCount":102},[51876],{"nctId":51877,"briefTitle":51878,"status":195,"phases":51879,"completion":688,"start":4915,"enrollment":37,"conditions":51880,"interventions":51881},"NCT00818129","Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese",[90],[1556],[51870],{"trials":51883,"activeCount":102},[],{"trials":51885,"activeCount":102},[],{"trials":51887,"activeCount":102},[],{"trials":51889,"activeCount":102},[],{"intervention":31323,"totalTrials":122,"cells":51891},{"EARLY_PHASE1":51892,"PHASE1":51894,"PHASE2":51900,"PHASE3":51902,"PHASE4":51904,"NA":51906},{"trials":51893,"activeCount":102},[],{"trials":51895,"activeCount":102},[51896],{"nctId":31318,"briefTitle":31319,"status":195,"phases":51897,"primaryCompletion":2242,"completion":2242,"start":2212,"enrollment":3855,"conditions":51898,"interventions":51899},[90],[22],[15883,31323],{"trials":51901,"activeCount":102},[],{"trials":51903,"activeCount":102},[],{"trials":51905,"activeCount":102},[],{"trials":51907,"activeCount":102},[],{"intervention":16393,"totalTrials":122,"cells":51909},{"EARLY_PHASE1":51910,"PHASE1":51912,"PHASE2":51918,"PHASE3":51920,"PHASE4":51922,"NA":51924},{"trials":51911,"activeCount":102},[],{"trials":51913,"activeCount":102},[51914],{"nctId":16386,"briefTitle":16387,"status":443,"phases":51915,"primaryCompletion":15717,"completion":15717,"start":10140,"enrollment":520,"conditions":51916,"interventions":51917},[90],[16390],[16392,5911,16393,16394,16395],{"trials":51919,"activeCount":102},[],{"trials":51921,"activeCount":102},[],{"trials":51923,"activeCount":102},[],{"trials":51925,"activeCount":102},[],{"intervention":16394,"totalTrials":122,"cells":51927},{"EARLY_PHASE1":51928,"PHASE1":51930,"PHASE2":51936,"PHASE3":51938,"PHASE4":51940,"NA":51942},{"trials":51929,"activeCount":102},[],{"trials":51931,"activeCount":102},[51932],{"nctId":16386,"briefTitle":16387,"status":443,"phases":51933,"primaryCompletion":15717,"completion":15717,"start":10140,"enrollment":520,"conditions":51934,"interventions":51935},[90],[16390],[16392,5911,16393,16394,16395],{"trials":51937,"activeCount":102},[],{"trials":51939,"activeCount":102},[],{"trials":51941,"activeCount":102},[],{"trials":51943,"activeCount":102},[],{"intervention":16395,"totalTrials":122,"cells":51945},{"EARLY_PHASE1":51946,"PHASE1":51948,"PHASE2":51954,"PHASE3":51956,"PHASE4":51958,"NA":51960},{"trials":51947,"activeCount":102},[],{"trials":51949,"activeCount":102},[51950],{"nctId":16386,"briefTitle":16387,"status":443,"phases":51951,"primaryCompletion":15717,"completion":15717,"start":10140,"enrollment":520,"conditions":51952,"interventions":51953},[90],[16390],[16392,5911,16393,16394,16395],{"trials":51955,"activeCount":102},[],{"trials":51957,"activeCount":102},[],{"trials":51959,"activeCount":102},[],{"trials":51961,"activeCount":102},[],{"intervention":23092,"totalTrials":122,"cells":51963},{"EARLY_PHASE1":51964,"PHASE1":51966,"PHASE2":51972,"PHASE3":51974,"PHASE4":51976,"NA":51978},{"trials":51965,"activeCount":102},[],{"trials":51967,"activeCount":102},[51968],{"nctId":23087,"briefTitle":23088,"status":195,"phases":51969,"primaryCompletion":3827,"completion":3827,"start":2220,"enrollment":1757,"conditions":51970,"interventions":51971},[90],[36],[2098,23092],{"trials":51973,"activeCount":102},[],{"trials":51975,"activeCount":102},[],{"trials":51977,"activeCount":102},[],{"trials":51979,"activeCount":102},[],{"intervention":2271,"totalTrials":122,"cells":51981},{"EARLY_PHASE1":51982,"PHASE1":51984,"PHASE2":51990,"PHASE3":51992,"PHASE4":51994,"NA":51996},{"trials":51983,"activeCount":102},[],{"trials":51985,"activeCount":102},[51986],{"nctId":2264,"briefTitle":2265,"status":195,"phases":51987,"primaryCompletion":2267,"completion":2267,"start":2268,"enrollment":1448,"conditions":51988,"interventions":51989},[90],[2089],[2271,2272,2044],{"trials":51991,"activeCount":102},[],{"trials":51993,"activeCount":102},[],{"trials":51995,"activeCount":102},[],{"trials":51997,"activeCount":102},[],{"intervention":2272,"totalTrials":122,"cells":51999},{"EARLY_PHASE1":52000,"PHASE1":52002,"PHASE2":52008,"PHASE3":52010,"PHASE4":52012,"NA":52014},{"trials":52001,"activeCount":102},[],{"trials":52003,"activeCount":102},[52004],{"nctId":2264,"briefTitle":2265,"status":195,"phases":52005,"primaryCompletion":2267,"completion":2267,"start":2268,"enrollment":1448,"conditions":52006,"interventions":52007},[90],[2089],[2271,2272,2044],{"trials":52009,"activeCount":102},[],{"trials":52011,"activeCount":102},[],{"trials":52013,"activeCount":102},[],{"trials":52015,"activeCount":102},[],{"intervention":32207,"totalTrials":122,"cells":52017},{"EARLY_PHASE1":52018,"PHASE1":52020,"PHASE2":52026,"PHASE3":52028,"PHASE4":52030,"NA":52032},{"trials":52019,"activeCount":102},[],{"trials":52021,"activeCount":102},[52022],{"nctId":32202,"briefTitle":32203,"status":195,"phases":52023,"primaryCompletion":2524,"completion":2524,"start":2251,"enrollment":1039,"conditions":52024,"interventions":52025},[90],[19],[24688,32207],{"trials":52027,"activeCount":102},[],{"trials":52029,"activeCount":102},[],{"trials":52031,"activeCount":102},[],{"trials":52033,"activeCount":102},[],{"intervention":25510,"totalTrials":122,"cells":52035},{"EARLY_PHASE1":52036,"PHASE1":52038,"PHASE2":52044,"PHASE3":52046,"PHASE4":52048,"NA":52050},{"trials":52037,"activeCount":102},[],{"trials":52039,"activeCount":102},[52040],{"nctId":25505,"briefTitle":25506,"status":195,"phases":52041,"primaryCompletion":2736,"completion":2736,"start":2675,"enrollment":14693,"conditions":52042,"interventions":52043},[90],[13022],[22826,23085,25510],{"trials":52045,"activeCount":102},[],{"trials":52047,"activeCount":102},[],{"trials":52049,"activeCount":102},[],{"trials":52051,"activeCount":102},[],{"intervention":52053,"totalTrials":122,"cells":52054},"Metoprolol- Toprol XL",{"EARLY_PHASE1":52055,"PHASE1":52057,"PHASE2":52066,"PHASE3":52068,"PHASE4":52070,"NA":52072},{"trials":52056,"activeCount":102},[],{"trials":52058,"activeCount":102},[52059],{"nctId":52060,"briefTitle":52061,"status":195,"phases":52062,"primaryCompletion":15911,"completion":15911,"start":13774,"enrollment":2003,"conditions":52063,"interventions":52064},"NCT01523054","Metoprolol in Acute Myocardial Infarction. A PK\u002FPD Study",[90],[2536],[52053,52065],"Metoprolol- Lopressor",{"trials":52067,"activeCount":102},[],{"trials":52069,"activeCount":102},[],{"trials":52071,"activeCount":102},[],{"trials":52073,"activeCount":102},[],{"intervention":52065,"totalTrials":122,"cells":52075},{"EARLY_PHASE1":52076,"PHASE1":52078,"PHASE2":52084,"PHASE3":52086,"PHASE4":52088,"NA":52090},{"trials":52077,"activeCount":102},[],{"trials":52079,"activeCount":102},[52080],{"nctId":52060,"briefTitle":52061,"status":195,"phases":52081,"primaryCompletion":15911,"completion":15911,"start":13774,"enrollment":2003,"conditions":52082,"interventions":52083},[90],[2536],[52053,52065],{"trials":52085,"activeCount":102},[],{"trials":52087,"activeCount":102},[],{"trials":52089,"activeCount":102},[],{"trials":52091,"activeCount":102},[],{"intervention":52093,"totalTrials":122,"cells":52094},"Exenatide Once-Weekly Suspension",{"EARLY_PHASE1":52095,"PHASE1":52097,"PHASE2":52106,"PHASE3":52108,"PHASE4":52110,"NA":52112},{"trials":52096,"activeCount":102},[],{"trials":52098,"activeCount":102},[52099],{"nctId":52100,"briefTitle":52101,"status":624,"phases":52102,"primaryCompletion":52103,"completion":52103,"start":28167,"enrollment":102,"conditions":52104,"interventions":52105},"NCT04001231","Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus",[90],"2021-07-02",[31],[52093],{"trials":52107,"activeCount":102},[],{"trials":52109,"activeCount":102},[],{"trials":52111,"activeCount":102},[],{"trials":52113,"activeCount":102},[],{"intervention":52115,"totalTrials":122,"cells":52116},"AZD9291 40 mg",{"EARLY_PHASE1":52117,"PHASE1":52119,"PHASE2":52131,"PHASE3":52133,"PHASE4":52135,"NA":52137},{"trials":52118,"activeCount":102},[],{"trials":52120,"activeCount":102},[52121],{"nctId":52122,"briefTitle":52123,"status":195,"phases":52124,"primaryCompletion":2667,"completion":52125,"start":52126,"enrollment":3248,"conditions":52127,"interventions":52129},"NCT02529995","Phase I, Study in Chinese NSCLC Patients",[90],"2019-09-27","2015-08-24",[52128],"Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive",[52115,52130],"AZD9291 80 mg",{"trials":52132,"activeCount":102},[],{"trials":52134,"activeCount":102},[],{"trials":52136,"activeCount":102},[],{"trials":52138,"activeCount":102},[],{"intervention":52130,"totalTrials":122,"cells":52140},{"EARLY_PHASE1":52141,"PHASE1":52143,"PHASE2":52149,"PHASE3":52151,"PHASE4":52153,"NA":52155},{"trials":52142,"activeCount":102},[],{"trials":52144,"activeCount":102},[52145],{"nctId":52122,"briefTitle":52123,"status":195,"phases":52146,"primaryCompletion":2667,"completion":52125,"start":52126,"enrollment":3248,"conditions":52147,"interventions":52148},[90],[52128],[52115,52130],{"trials":52150,"activeCount":102},[],{"trials":52152,"activeCount":102},[],{"trials":52154,"activeCount":102},[],{"trials":52156,"activeCount":102},[],{"intervention":52158,"totalTrials":122,"cells":52159},"AZD0233",{"EARLY_PHASE1":52160,"PHASE1":52162,"PHASE2":52172,"PHASE3":52174,"PHASE4":52176,"NA":52178},{"trials":52161,"activeCount":102},[],{"trials":52163,"activeCount":102},[52164],{"nctId":52165,"briefTitle":52166,"status":443,"phases":52167,"primaryCompletion":6920,"completion":6920,"start":52168,"enrollment":532,"conditions":52169,"interventions":52170},"NCT06381466","A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.",[90],"2024-04-01",[16780],[52158,52171],"AZD0233 Placebo",{"trials":52173,"activeCount":102},[],{"trials":52175,"activeCount":102},[],{"trials":52177,"activeCount":102},[],{"trials":52179,"activeCount":102},[],{"intervention":52171,"totalTrials":122,"cells":52181},{"EARLY_PHASE1":52182,"PHASE1":52184,"PHASE2":52190,"PHASE3":52192,"PHASE4":52194,"NA":52196},{"trials":52183,"activeCount":102},[],{"trials":52185,"activeCount":102},[52186],{"nctId":52165,"briefTitle":52166,"status":443,"phases":52187,"primaryCompletion":6920,"completion":6920,"start":52168,"enrollment":532,"conditions":52188,"interventions":52189},[90],[16780],[52158,52171],{"trials":52191,"activeCount":102},[],{"trials":52193,"activeCount":102},[],{"trials":52195,"activeCount":102},[],{"trials":52197,"activeCount":102},[],{"intervention":52199,"totalTrials":122,"cells":52200},"AZD9164 Turbuhaler®",{"EARLY_PHASE1":52201,"PHASE1":52203,"PHASE2":52211,"PHASE3":52213,"PHASE4":52215,"NA":52217},{"trials":52202,"activeCount":102},[],{"trials":52204,"activeCount":102},[52205],{"nctId":52206,"briefTitle":52207,"status":443,"phases":52208,"primaryCompletion":2242,"completion":2242,"start":2055,"enrollment":496,"conditions":52209,"interventions":52210},"NCT01016951","A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease",[90],[19,10066],[52199],{"trials":52212,"activeCount":102},[],{"trials":52214,"activeCount":102},[],{"trials":52216,"activeCount":102},[],{"trials":52218,"activeCount":102},[],{"intervention":52220,"totalTrials":122,"cells":52221},"AZD1480 Daily",{"EARLY_PHASE1":52222,"PHASE1":52224,"PHASE2":52236,"PHASE3":52238,"PHASE4":52240,"NA":52242},{"trials":52223,"activeCount":102},[],{"trials":52225,"activeCount":102},[52226],{"nctId":52227,"briefTitle":52228,"status":443,"phases":52229,"primaryCompletion":2616,"completion":2616,"start":2349,"enrollment":3172,"conditions":52230,"interventions":52234},"NCT01219543","A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.",[90],[5868,157,52231,52232,52233,172],"Child-Pugh A to B7 Advanced Hepatocellular Carcinoma","EGFR and\u002For ROS Mutant NSCLC","Lung Metastasis Carcinoma",[52220,52235],"AZD1480 BID",{"trials":52237,"activeCount":102},[],{"trials":52239,"activeCount":102},[],{"trials":52241,"activeCount":102},[],{"trials":52243,"activeCount":102},[],{"intervention":52235,"totalTrials":122,"cells":52245},{"EARLY_PHASE1":52246,"PHASE1":52248,"PHASE2":52254,"PHASE3":52256,"PHASE4":52258,"NA":52260},{"trials":52247,"activeCount":102},[],{"trials":52249,"activeCount":102},[52250],{"nctId":52227,"briefTitle":52228,"status":443,"phases":52251,"primaryCompletion":2616,"completion":2616,"start":2349,"enrollment":3172,"conditions":52252,"interventions":52253},[90],[5868,157,52231,52232,52233,172],[52220,52235],{"trials":52255,"activeCount":102},[],{"trials":52257,"activeCount":102},[],{"trials":52259,"activeCount":102},[],{"trials":52261,"activeCount":102},[],{"intervention":52263,"totalTrials":122,"cells":52264},"2.5 mg Saxagliptin",{"EARLY_PHASE1":52265,"PHASE1":52267,"PHASE2":52282,"PHASE3":52284,"PHASE4":52286,"NA":52288},{"trials":52266,"activeCount":102},[],{"trials":52268,"activeCount":102},[52269],{"nctId":52270,"briefTitle":52271,"status":195,"phases":52272,"primaryCompletion":52273,"completion":52273,"start":52274,"enrollment":3007,"conditions":52275,"interventions":52276},"NCT03169959","A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin\u002FDapagliflozin\u002FMetformin Extended-release (XR) Against Individual Component Co-administration.",[90],"2017-08-03","2017-05-29",[22],[52263,52277,52278,52279,52280,52281],"5 mg dapagliflozin \u002F 1000 mg metformin XR","Triple FCDP - 2.5 mg saxagliptin \u002F 5 mg dapagliflozin \u002F 1000 mg metformin XR","5 mg saxagliptin","10 mg dapagliflozin \u002F 1000 mg metformin XR","Triple FCDP - 5 mg saxagliptin \u002F 10 mg dapagliflozin \u002F 1000 mg metformin XR",{"trials":52283,"activeCount":102},[],{"trials":52285,"activeCount":102},[],{"trials":52287,"activeCount":102},[],{"trials":52289,"activeCount":102},[],{"intervention":52277,"totalTrials":122,"cells":52291},{"EARLY_PHASE1":52292,"PHASE1":52294,"PHASE2":52300,"PHASE3":52302,"PHASE4":52304,"NA":52306},{"trials":52293,"activeCount":102},[],{"trials":52295,"activeCount":102},[52296],{"nctId":52270,"briefTitle":52271,"status":195,"phases":52297,"primaryCompletion":52273,"completion":52273,"start":52274,"enrollment":3007,"conditions":52298,"interventions":52299},[90],[22],[52263,52277,52278,52279,52280,52281],{"trials":52301,"activeCount":102},[],{"trials":52303,"activeCount":102},[],{"trials":52305,"activeCount":102},[],{"trials":52307,"activeCount":102},[],{"intervention":52278,"totalTrials":122,"cells":52309},{"EARLY_PHASE1":52310,"PHASE1":52312,"PHASE2":52318,"PHASE3":52320,"PHASE4":52322,"NA":52324},{"trials":52311,"activeCount":102},[],{"trials":52313,"activeCount":102},[52314],{"nctId":52270,"briefTitle":52271,"status":195,"phases":52315,"primaryCompletion":52273,"completion":52273,"start":52274,"enrollment":3007,"conditions":52316,"interventions":52317},[90],[22],[52263,52277,52278,52279,52280,52281],{"trials":52319,"activeCount":102},[],{"trials":52321,"activeCount":102},[],{"trials":52323,"activeCount":102},[],{"trials":52325,"activeCount":102},[],{"intervention":52279,"totalTrials":122,"cells":52327},{"EARLY_PHASE1":52328,"PHASE1":52330,"PHASE2":52336,"PHASE3":52338,"PHASE4":52340,"NA":52342},{"trials":52329,"activeCount":102},[],{"trials":52331,"activeCount":102},[52332],{"nctId":52270,"briefTitle":52271,"status":195,"phases":52333,"primaryCompletion":52273,"completion":52273,"start":52274,"enrollment":3007,"conditions":52334,"interventions":52335},[90],[22],[52263,52277,52278,52279,52280,52281],{"trials":52337,"activeCount":102},[],{"trials":52339,"activeCount":102},[],{"trials":52341,"activeCount":102},[],{"trials":52343,"activeCount":102},[],{"intervention":52280,"totalTrials":122,"cells":52345},{"EARLY_PHASE1":52346,"PHASE1":52348,"PHASE2":52354,"PHASE3":52356,"PHASE4":52358,"NA":52360},{"trials":52347,"activeCount":102},[],{"trials":52349,"activeCount":102},[52350],{"nctId":52270,"briefTitle":52271,"status":195,"phases":52351,"primaryCompletion":52273,"completion":52273,"start":52274,"enrollment":3007,"conditions":52352,"interventions":52353},[90],[22],[52263,52277,52278,52279,52280,52281],{"trials":52355,"activeCount":102},[],{"trials":52357,"activeCount":102},[],{"trials":52359,"activeCount":102},[],{"trials":52361,"activeCount":102},[],{"intervention":52281,"totalTrials":122,"cells":52363},{"EARLY_PHASE1":52364,"PHASE1":52366,"PHASE2":52372,"PHASE3":52374,"PHASE4":52376,"NA":52378},{"trials":52365,"activeCount":102},[],{"trials":52367,"activeCount":102},[52368],{"nctId":52270,"briefTitle":52271,"status":195,"phases":52369,"primaryCompletion":52273,"completion":52273,"start":52274,"enrollment":3007,"conditions":52370,"interventions":52371},[90],[22],[52263,52277,52278,52279,52280,52281],{"trials":52373,"activeCount":102},[],{"trials":52375,"activeCount":102},[],{"trials":52377,"activeCount":102},[],{"trials":52379,"activeCount":102},[],{"intervention":52381,"totalTrials":122,"cells":52382},"AZD4316",{"EARLY_PHASE1":52383,"PHASE1":52385,"PHASE2":52393,"PHASE3":52395,"PHASE4":52397,"NA":52399},{"trials":52384,"activeCount":102},[],{"trials":52386,"activeCount":102},[52387],{"nctId":52388,"briefTitle":52389,"status":624,"phases":52390,"primaryCompletion":2542,"completion":2542,"start":2143,"enrollment":589,"conditions":52391,"interventions":52392},"NCT01247103","Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects",[90],[36],[52381,52381],{"trials":52394,"activeCount":102},[],{"trials":52396,"activeCount":102},[],{"trials":52398,"activeCount":102},[],{"trials":52400,"activeCount":102},[],{"intervention":52402,"totalTrials":122,"cells":52403},"AZD9838",{"EARLY_PHASE1":52404,"PHASE1":52406,"PHASE2":52418,"PHASE3":52420,"PHASE4":52422,"NA":52424},{"trials":52405,"activeCount":102},[],{"trials":52407,"activeCount":102},[52408],{"nctId":52409,"briefTitle":52410,"status":195,"phases":52411,"primaryCompletion":52412,"completion":364,"start":37186,"enrollment":247,"conditions":52413,"interventions":52415},"NCT06147063","A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19",[90],"2024-04-30",[1387,52414],"SARS-CoV-2 Infection",[52402,52416,52417],"Licensed mRNA vaccine","AZD6563",{"trials":52419,"activeCount":102},[],{"trials":52421,"activeCount":102},[],{"trials":52423,"activeCount":102},[],{"trials":52425,"activeCount":102},[],{"intervention":52416,"totalTrials":122,"cells":52427},{"EARLY_PHASE1":52428,"PHASE1":52430,"PHASE2":52436,"PHASE3":52438,"PHASE4":52440,"NA":52442},{"trials":52429,"activeCount":102},[],{"trials":52431,"activeCount":102},[52432],{"nctId":52409,"briefTitle":52410,"status":195,"phases":52433,"primaryCompletion":52412,"completion":364,"start":37186,"enrollment":247,"conditions":52434,"interventions":52435},[90],[1387,52414],[52402,52416,52417],{"trials":52437,"activeCount":102},[],{"trials":52439,"activeCount":102},[],{"trials":52441,"activeCount":102},[],{"trials":52443,"activeCount":102},[],{"intervention":52417,"totalTrials":122,"cells":52445},{"EARLY_PHASE1":52446,"PHASE1":52448,"PHASE2":52454,"PHASE3":52456,"PHASE4":52458,"NA":52460},{"trials":52447,"activeCount":102},[],{"trials":52449,"activeCount":102},[52450],{"nctId":52409,"briefTitle":52410,"status":195,"phases":52451,"primaryCompletion":52412,"completion":364,"start":37186,"enrollment":247,"conditions":52452,"interventions":52453},[90],[1387,52414],[52402,52416,52417],{"trials":52455,"activeCount":102},[],{"trials":52457,"activeCount":102},[],{"trials":52459,"activeCount":102},[],{"trials":52461,"activeCount":102},[],{"intervention":52463,"totalTrials":122,"cells":52464},"BGF-MDI",{"EARLY_PHASE1":52465,"PHASE1":52467,"PHASE2":52476,"PHASE3":52478,"PHASE4":52480,"NA":52482},{"trials":52466,"activeCount":102},[],{"trials":52468,"activeCount":102},[52469],{"nctId":52470,"briefTitle":52471,"status":195,"phases":52472,"primaryCompletion":52473,"completion":52473,"start":2721,"enrollment":1336,"conditions":52474,"interventions":52475},"NCT03906045","A Scintigraphy Study of PT010 in COPD Patients",[90],"2020-03-05",[28],[52463],{"trials":52477,"activeCount":102},[],{"trials":52479,"activeCount":102},[],{"trials":52481,"activeCount":102},[],{"trials":52483,"activeCount":102},[],{"intervention":52485,"totalTrials":122,"cells":52486},"Capsule ASA 81mg\u002Fesomeprazole 20mg",{"EARLY_PHASE1":52487,"PHASE1":52489,"PHASE2":52498,"PHASE3":52500,"PHASE4":52502,"NA":52504},{"trials":52488,"activeCount":102},[],{"trials":52490,"activeCount":102},[52491],{"nctId":52492,"briefTitle":52493,"status":195,"phases":52494,"primaryCompletion":4496,"completion":4496,"start":4580,"enrollment":680,"conditions":52495,"interventions":52496},"NCT01448031","A Healthy Female and Male Volunteers Aspirin Study",[90],[19],[52485,52497],"Acetylsalicylzuur Apotex Cardio",{"trials":52499,"activeCount":102},[],{"trials":52501,"activeCount":102},[],{"trials":52503,"activeCount":102},[],{"trials":52505,"activeCount":102},[],{"intervention":52497,"totalTrials":122,"cells":52507},{"EARLY_PHASE1":52508,"PHASE1":52510,"PHASE2":52516,"PHASE3":52518,"PHASE4":52520,"NA":52522},{"trials":52509,"activeCount":102},[],{"trials":52511,"activeCount":102},[52512],{"nctId":52492,"briefTitle":52493,"status":195,"phases":52513,"primaryCompletion":4496,"completion":4496,"start":4580,"enrollment":680,"conditions":52514,"interventions":52515},[90],[19],[52485,52497],{"trials":52517,"activeCount":102},[],{"trials":52519,"activeCount":102},[],{"trials":52521,"activeCount":102},[],{"trials":52523,"activeCount":102},[],{"intervention":52525,"totalTrials":122,"cells":52526},"Part A",{"EARLY_PHASE1":52527,"PHASE1":52529,"PHASE2":52539,"PHASE3":52541,"PHASE4":52543,"NA":52545},{"trials":52528,"activeCount":102},[],{"trials":52530,"activeCount":102},[52531],{"nctId":52532,"briefTitle":52533,"status":195,"phases":52534,"primaryCompletion":4006,"completion":4006,"start":19364,"enrollment":221,"conditions":52535,"interventions":52537},"NCT01929629","A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914",[90],[52536],"Gonococcal (GC) Infection",[52525,52538],"Part B",{"trials":52540,"activeCount":102},[],{"trials":52542,"activeCount":102},[],{"trials":52544,"activeCount":102},[],{"trials":52546,"activeCount":102},[],{"intervention":52538,"totalTrials":122,"cells":52548},{"EARLY_PHASE1":52549,"PHASE1":52551,"PHASE2":52557,"PHASE3":52559,"PHASE4":52561,"NA":52563},{"trials":52550,"activeCount":102},[],{"trials":52552,"activeCount":102},[52553],{"nctId":52532,"briefTitle":52533,"status":195,"phases":52554,"primaryCompletion":4006,"completion":4006,"start":19364,"enrollment":221,"conditions":52555,"interventions":52556},[90],[52536],[52525,52538],{"trials":52558,"activeCount":102},[],{"trials":52560,"activeCount":102},[],{"trials":52562,"activeCount":102},[],{"trials":52564,"activeCount":102},[],{"intervention":52566,"totalTrials":122,"cells":52567},"[14C]-AZD9742",{"EARLY_PHASE1":52568,"PHASE1":52570,"PHASE2":52578,"PHASE3":52580,"PHASE4":52582,"NA":52584},{"trials":52569,"activeCount":102},[],{"trials":52571,"activeCount":102},[52572],{"nctId":52573,"briefTitle":52574,"status":624,"phases":52575,"primaryCompletion":2433,"completion":2433,"start":2516,"enrollment":102,"conditions":52576,"interventions":52577},"NCT01275781","Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion",[90],[19],[52566],{"trials":52579,"activeCount":102},[],{"trials":52581,"activeCount":102},[],{"trials":52583,"activeCount":102},[],{"trials":52585,"activeCount":102},[],{"intervention":12680,"totalTrials":122,"cells":52587},{"EARLY_PHASE1":52588,"PHASE1":52590,"PHASE2":52596,"PHASE3":52598,"PHASE4":52600,"NA":52602},{"trials":52589,"activeCount":102},[],{"trials":52591,"activeCount":102},[52592],{"nctId":12672,"briefTitle":12673,"status":195,"phases":52593,"primaryCompletion":12675,"completion":12675,"start":12676,"enrollment":1757,"conditions":52594,"interventions":52595},[90],[12678],[12680,12681,5887],{"trials":52597,"activeCount":102},[],{"trials":52599,"activeCount":102},[],{"trials":52601,"activeCount":102},[],{"trials":52603,"activeCount":102},[],{"intervention":52605,"totalTrials":122,"cells":52606},"Treatment A- Part 1",{"EARLY_PHASE1":52607,"PHASE1":52609,"PHASE2":52625,"PHASE3":52627,"PHASE4":52629,"NA":52631},{"trials":52608,"activeCount":102},[],{"trials":52610,"activeCount":102},[52611],{"nctId":52612,"briefTitle":52613,"status":195,"phases":52614,"primaryCompletion":542,"completion":542,"start":33486,"enrollment":680,"conditions":52615,"interventions":52617},"NCT04488016","A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects",[90],[22858,52616],"B-cell Lymphoid Cancer",[52605,52618,52619,52620,52621,52622,52623,52624],"Treatment B- Part 1","Treatment C - Part 1","Treatment D- Part 1","Treatment A-Part 2","Treatment B - Part 2","Treatment C - Part 2","Treatment D - Part 2",{"trials":52626,"activeCount":102},[],{"trials":52628,"activeCount":102},[],{"trials":52630,"activeCount":102},[],{"trials":52632,"activeCount":102},[],{"intervention":52618,"totalTrials":122,"cells":52634},{"EARLY_PHASE1":52635,"PHASE1":52637,"PHASE2":52643,"PHASE3":52645,"PHASE4":52647,"NA":52649},{"trials":52636,"activeCount":102},[],{"trials":52638,"activeCount":102},[52639],{"nctId":52612,"briefTitle":52613,"status":195,"phases":52640,"primaryCompletion":542,"completion":542,"start":33486,"enrollment":680,"conditions":52641,"interventions":52642},[90],[22858,52616],[52605,52618,52619,52620,52621,52622,52623,52624],{"trials":52644,"activeCount":102},[],{"trials":52646,"activeCount":102},[],{"trials":52648,"activeCount":102},[],{"trials":52650,"activeCount":102},[],{"intervention":52619,"totalTrials":122,"cells":52652},{"EARLY_PHASE1":52653,"PHASE1":52655,"PHASE2":52661,"PHASE3":52663,"PHASE4":52665,"NA":52667},{"trials":52654,"activeCount":102},[],{"trials":52656,"activeCount":102},[52657],{"nctId":52612,"briefTitle":52613,"status":195,"phases":52658,"primaryCompletion":542,"completion":542,"start":33486,"enrollment":680,"conditions":52659,"interventions":52660},[90],[22858,52616],[52605,52618,52619,52620,52621,52622,52623,52624],{"trials":52662,"activeCount":102},[],{"trials":52664,"activeCount":102},[],{"trials":52666,"activeCount":102},[],{"trials":52668,"activeCount":102},[],{"intervention":52620,"totalTrials":122,"cells":52670},{"EARLY_PHASE1":52671,"PHASE1":52673,"PHASE2":52679,"PHASE3":52681,"PHASE4":52683,"NA":52685},{"trials":52672,"activeCount":102},[],{"trials":52674,"activeCount":102},[52675],{"nctId":52612,"briefTitle":52613,"status":195,"phases":52676,"primaryCompletion":542,"completion":542,"start":33486,"enrollment":680,"conditions":52677,"interventions":52678},[90],[22858,52616],[52605,52618,52619,52620,52621,52622,52623,52624],{"trials":52680,"activeCount":102},[],{"trials":52682,"activeCount":102},[],{"trials":52684,"activeCount":102},[],{"trials":52686,"activeCount":102},[],{"intervention":52621,"totalTrials":122,"cells":52688},{"EARLY_PHASE1":52689,"PHASE1":52691,"PHASE2":52697,"PHASE3":52699,"PHASE4":52701,"NA":52703},{"trials":52690,"activeCount":102},[],{"trials":52692,"activeCount":102},[52693],{"nctId":52612,"briefTitle":52613,"status":195,"phases":52694,"primaryCompletion":542,"completion":542,"start":33486,"enrollment":680,"conditions":52695,"interventions":52696},[90],[22858,52616],[52605,52618,52619,52620,52621,52622,52623,52624],{"trials":52698,"activeCount":102},[],{"trials":52700,"activeCount":102},[],{"trials":52702,"activeCount":102},[],{"trials":52704,"activeCount":102},[],{"intervention":52622,"totalTrials":122,"cells":52706},{"EARLY_PHASE1":52707,"PHASE1":52709,"PHASE2":52715,"PHASE3":52717,"PHASE4":52719,"NA":52721},{"trials":52708,"activeCount":102},[],{"trials":52710,"activeCount":102},[52711],{"nctId":52612,"briefTitle":52613,"status":195,"phases":52712,"primaryCompletion":542,"completion":542,"start":33486,"enrollment":680,"conditions":52713,"interventions":52714},[90],[22858,52616],[52605,52618,52619,52620,52621,52622,52623,52624],{"trials":52716,"activeCount":102},[],{"trials":52718,"activeCount":102},[],{"trials":52720,"activeCount":102},[],{"trials":52722,"activeCount":102},[],{"intervention":52623,"totalTrials":122,"cells":52724},{"EARLY_PHASE1":52725,"PHASE1":52727,"PHASE2":52733,"PHASE3":52735,"PHASE4":52737,"NA":52739},{"trials":52726,"activeCount":102},[],{"trials":52728,"activeCount":102},[52729],{"nctId":52612,"briefTitle":52613,"status":195,"phases":52730,"primaryCompletion":542,"completion":542,"start":33486,"enrollment":680,"conditions":52731,"interventions":52732},[90],[22858,52616],[52605,52618,52619,52620,52621,52622,52623,52624],{"trials":52734,"activeCount":102},[],{"trials":52736,"activeCount":102},[],{"trials":52738,"activeCount":102},[],{"trials":52740,"activeCount":102},[],{"intervention":52624,"totalTrials":122,"cells":52742},{"EARLY_PHASE1":52743,"PHASE1":52745,"PHASE2":52751,"PHASE3":52753,"PHASE4":52755,"NA":52757},{"trials":52744,"activeCount":102},[],{"trials":52746,"activeCount":102},[52747],{"nctId":52612,"briefTitle":52613,"status":195,"phases":52748,"primaryCompletion":542,"completion":542,"start":33486,"enrollment":680,"conditions":52749,"interventions":52750},[90],[22858,52616],[52605,52618,52619,52620,52621,52622,52623,52624],{"trials":52752,"activeCount":102},[],{"trials":52754,"activeCount":102},[],{"trials":52756,"activeCount":102},[],{"trials":52758,"activeCount":102},[],{"intervention":52760,"totalTrials":122,"cells":52761},"MCC-based 13% drug loaded",{"EARLY_PHASE1":52762,"PHASE1":52764,"PHASE2":52773,"PHASE3":52775,"PHASE4":52777,"NA":52779},{"trials":52763,"activeCount":102},[],{"trials":52765,"activeCount":102},[52766],{"nctId":52767,"briefTitle":52768,"status":195,"phases":52769,"primaryCompletion":2443,"completion":2443,"start":2481,"enrollment":4917,"conditions":52770,"interventions":52771},"NCT01645085","A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib",[90],[36],[52760,52772,52760,52772],"Mannitol-based 38% drug-loaded",{"trials":52774,"activeCount":102},[],{"trials":52776,"activeCount":102},[],{"trials":52778,"activeCount":102},[],{"trials":52780,"activeCount":102},[],{"intervention":52772,"totalTrials":122,"cells":52782},{"EARLY_PHASE1":52783,"PHASE1":52785,"PHASE2":52791,"PHASE3":52793,"PHASE4":52795,"NA":52797},{"trials":52784,"activeCount":102},[],{"trials":52786,"activeCount":102},[52787],{"nctId":52767,"briefTitle":52768,"status":195,"phases":52788,"primaryCompletion":2443,"completion":2443,"start":2481,"enrollment":4917,"conditions":52789,"interventions":52790},[90],[36],[52760,52772,52760,52772],{"trials":52792,"activeCount":102},[],{"trials":52794,"activeCount":102},[],{"trials":52796,"activeCount":102},[],{"trials":52798,"activeCount":102},[],{"intervention":52800,"totalTrials":122,"cells":52801},"[14C]AZD9833 Oral Solution, 75 mg",{"EARLY_PHASE1":52802,"PHASE1":52804,"PHASE2":52815,"PHASE3":52817,"PHASE4":52819,"NA":52821},{"trials":52803,"activeCount":102},[],{"trials":52805,"activeCount":102},[52806],{"nctId":52807,"briefTitle":52808,"status":195,"phases":52809,"primaryCompletion":52810,"completion":52810,"start":52811,"enrollment":1039,"conditions":52812,"interventions":52814},"NCT05364255","A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833",[90],"2022-06-20","2022-05-10",[52813],"ER-positive, HER2-negative Breast Cancer",[52800],{"trials":52816,"activeCount":102},[],{"trials":52818,"activeCount":102},[],{"trials":52820,"activeCount":102},[],{"trials":52822,"activeCount":102},[],{"intervention":41094,"totalTrials":122,"cells":52824},{"EARLY_PHASE1":52825,"PHASE1":52827,"PHASE2":52833,"PHASE3":52835,"PHASE4":52837,"NA":52839},{"trials":52826,"activeCount":102},[],{"trials":52828,"activeCount":102},[52829],{"nctId":41087,"briefTitle":41088,"status":443,"phases":52830,"primaryCompletion":1537,"completion":1537,"start":41090,"enrollment":451,"conditions":52831,"interventions":52832},[90],[41092],[41065,41094],{"trials":52834,"activeCount":102},[],{"trials":52836,"activeCount":102},[],{"trials":52838,"activeCount":102},[],{"trials":52840,"activeCount":102},[],{"intervention":52842,"totalTrials":122,"cells":52843},"[11C]AZD1390",{"EARLY_PHASE1":52844,"PHASE1":52846,"PHASE2":52856,"PHASE3":52858,"PHASE4":52860,"NA":52862},{"trials":52845,"activeCount":102},[],{"trials":52847,"activeCount":102},[52848],{"nctId":52849,"briefTitle":52850,"status":195,"phases":52851,"primaryCompletion":4465,"completion":4465,"start":52852,"enrollment":370,"conditions":52853,"interventions":52855},"NCT03215381","AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers",[90],"2017-10-10",[52854],"Healthy Volunteer Male Subjects",[52842],{"trials":52857,"activeCount":102},[],{"trials":52859,"activeCount":102},[],{"trials":52861,"activeCount":102},[],{"trials":52863,"activeCount":102},[],{"intervention":52865,"totalTrials":122,"cells":52866},"AZD9567 10 mg",{"EARLY_PHASE1":52867,"PHASE1":52869,"PHASE2":52887,"PHASE3":52889,"PHASE4":52891,"NA":52893},{"trials":52868,"activeCount":102},[],{"trials":52870,"activeCount":102},[52871],{"nctId":52872,"briefTitle":52873,"status":195,"phases":52874,"primaryCompletion":52875,"completion":52875,"start":52876,"enrollment":4307,"conditions":52877,"interventions":52878},"NCT02760316","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.",[90],"2017-09-11","2016-05-02",[7267],[52865,52879,52880,52881,52882,52883,52884,52885,52886],"AZD9567 20 mg","AZD9567 40 mg","AZD9567 80 mg","Prednisolone 20 mg","AZD9567 125 mg","AZD9567 155 mg","Prednisolone 5 mg","Prednisolone 40 mg",{"trials":52888,"activeCount":102},[],{"trials":52890,"activeCount":102},[],{"trials":52892,"activeCount":102},[],{"trials":52894,"activeCount":102},[],{"intervention":52879,"totalTrials":122,"cells":52896},{"EARLY_PHASE1":52897,"PHASE1":52899,"PHASE2":52905,"PHASE3":52907,"PHASE4":52909,"NA":52911},{"trials":52898,"activeCount":102},[],{"trials":52900,"activeCount":102},[52901],{"nctId":52872,"briefTitle":52873,"status":195,"phases":52902,"primaryCompletion":52875,"completion":52875,"start":52876,"enrollment":4307,"conditions":52903,"interventions":52904},[90],[7267],[52865,52879,52880,52881,52882,52883,52884,52885,52886],{"trials":52906,"activeCount":102},[],{"trials":52908,"activeCount":102},[],{"trials":52910,"activeCount":102},[],{"trials":52912,"activeCount":102},[],{"intervention":52880,"totalTrials":122,"cells":52914},{"EARLY_PHASE1":52915,"PHASE1":52917,"PHASE2":52923,"PHASE3":52925,"PHASE4":52927,"NA":52929},{"trials":52916,"activeCount":102},[],{"trials":52918,"activeCount":102},[52919],{"nctId":52872,"briefTitle":52873,"status":195,"phases":52920,"primaryCompletion":52875,"completion":52875,"start":52876,"enrollment":4307,"conditions":52921,"interventions":52922},[90],[7267],[52865,52879,52880,52881,52882,52883,52884,52885,52886],{"trials":52924,"activeCount":102},[],{"trials":52926,"activeCount":102},[],{"trials":52928,"activeCount":102},[],{"trials":52930,"activeCount":102},[],{"intervention":52881,"totalTrials":122,"cells":52932},{"EARLY_PHASE1":52933,"PHASE1":52935,"PHASE2":52941,"PHASE3":52943,"PHASE4":52945,"NA":52947},{"trials":52934,"activeCount":102},[],{"trials":52936,"activeCount":102},[52937],{"nctId":52872,"briefTitle":52873,"status":195,"phases":52938,"primaryCompletion":52875,"completion":52875,"start":52876,"enrollment":4307,"conditions":52939,"interventions":52940},[90],[7267],[52865,52879,52880,52881,52882,52883,52884,52885,52886],{"trials":52942,"activeCount":102},[],{"trials":52944,"activeCount":102},[],{"trials":52946,"activeCount":102},[],{"trials":52948,"activeCount":102},[],{"intervention":52882,"totalTrials":122,"cells":52950},{"EARLY_PHASE1":52951,"PHASE1":52953,"PHASE2":52959,"PHASE3":52961,"PHASE4":52963,"NA":52965},{"trials":52952,"activeCount":102},[],{"trials":52954,"activeCount":102},[52955],{"nctId":52872,"briefTitle":52873,"status":195,"phases":52956,"primaryCompletion":52875,"completion":52875,"start":52876,"enrollment":4307,"conditions":52957,"interventions":52958},[90],[7267],[52865,52879,52880,52881,52882,52883,52884,52885,52886],{"trials":52960,"activeCount":102},[],{"trials":52962,"activeCount":102},[],{"trials":52964,"activeCount":102},[],{"trials":52966,"activeCount":102},[],{"intervention":52883,"totalTrials":122,"cells":52968},{"EARLY_PHASE1":52969,"PHASE1":52971,"PHASE2":52977,"PHASE3":52979,"PHASE4":52981,"NA":52983},{"trials":52970,"activeCount":102},[],{"trials":52972,"activeCount":102},[52973],{"nctId":52872,"briefTitle":52873,"status":195,"phases":52974,"primaryCompletion":52875,"completion":52875,"start":52876,"enrollment":4307,"conditions":52975,"interventions":52976},[90],[7267],[52865,52879,52880,52881,52882,52883,52884,52885,52886],{"trials":52978,"activeCount":102},[],{"trials":52980,"activeCount":102},[],{"trials":52982,"activeCount":102},[],{"trials":52984,"activeCount":102},[],{"intervention":52884,"totalTrials":122,"cells":52986},{"EARLY_PHASE1":52987,"PHASE1":52989,"PHASE2":52995,"PHASE3":52997,"PHASE4":52999,"NA":53001},{"trials":52988,"activeCount":102},[],{"trials":52990,"activeCount":102},[52991],{"nctId":52872,"briefTitle":52873,"status":195,"phases":52992,"primaryCompletion":52875,"completion":52875,"start":52876,"enrollment":4307,"conditions":52993,"interventions":52994},[90],[7267],[52865,52879,52880,52881,52882,52883,52884,52885,52886],{"trials":52996,"activeCount":102},[],{"trials":52998,"activeCount":102},[],{"trials":53000,"activeCount":102},[],{"trials":53002,"activeCount":102},[],{"intervention":52885,"totalTrials":122,"cells":53004},{"EARLY_PHASE1":53005,"PHASE1":53007,"PHASE2":53013,"PHASE3":53015,"PHASE4":53017,"NA":53019},{"trials":53006,"activeCount":102},[],{"trials":53008,"activeCount":102},[53009],{"nctId":52872,"briefTitle":52873,"status":195,"phases":53010,"primaryCompletion":52875,"completion":52875,"start":52876,"enrollment":4307,"conditions":53011,"interventions":53012},[90],[7267],[52865,52879,52880,52881,52882,52883,52884,52885,52886],{"trials":53014,"activeCount":102},[],{"trials":53016,"activeCount":102},[],{"trials":53018,"activeCount":102},[],{"trials":53020,"activeCount":102},[],{"intervention":52886,"totalTrials":122,"cells":53022},{"EARLY_PHASE1":53023,"PHASE1":53025,"PHASE2":53031,"PHASE3":53033,"PHASE4":53035,"NA":53037},{"trials":53024,"activeCount":102},[],{"trials":53026,"activeCount":102},[53027],{"nctId":52872,"briefTitle":52873,"status":195,"phases":53028,"primaryCompletion":52875,"completion":52875,"start":52876,"enrollment":4307,"conditions":53029,"interventions":53030},[90],[7267],[52865,52879,52880,52881,52882,52883,52884,52885,52886],{"trials":53032,"activeCount":102},[],{"trials":53034,"activeCount":102},[],{"trials":53036,"activeCount":102},[],{"trials":53038,"activeCount":102},[],{"intervention":53040,"totalTrials":122,"cells":53041},"Treatment A: Acalabrutinib",{"EARLY_PHASE1":53042,"PHASE1":53044,"PHASE2":53054,"PHASE3":53056,"PHASE4":53058,"NA":53060},{"trials":53043,"activeCount":102},[],{"trials":53045,"activeCount":102},[53046],{"nctId":53047,"briefTitle":53048,"status":195,"phases":53049,"primaryCompletion":5974,"completion":5974,"start":53050,"enrollment":4928,"conditions":53051,"interventions":53052},"NCT04768985","Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule",[90],"2021-02-25",[42519],[53040,53053],"Treatment B: Acalabrutinib",{"trials":53055,"activeCount":102},[],{"trials":53057,"activeCount":102},[],{"trials":53059,"activeCount":102},[],{"trials":53061,"activeCount":102},[],{"intervention":53053,"totalTrials":122,"cells":53063},{"EARLY_PHASE1":53064,"PHASE1":53066,"PHASE2":53072,"PHASE3":53074,"PHASE4":53076,"NA":53078},{"trials":53065,"activeCount":102},[],{"trials":53067,"activeCount":102},[53068],{"nctId":53047,"briefTitle":53048,"status":195,"phases":53069,"primaryCompletion":5974,"completion":5974,"start":53050,"enrollment":4928,"conditions":53070,"interventions":53071},[90],[42519],[53040,53053],{"trials":53073,"activeCount":102},[],{"trials":53075,"activeCount":102},[],{"trials":53077,"activeCount":102},[],{"trials":53079,"activeCount":102},[],{"intervention":53081,"totalTrials":122,"cells":53082},"AZD3759",{"EARLY_PHASE1":53083,"PHASE1":53085,"PHASE2":53096,"PHASE3":53098,"PHASE4":53100,"NA":53102},{"trials":53084,"activeCount":102},[],{"trials":53086,"activeCount":102},[53087],{"nctId":53088,"briefTitle":53089,"status":195,"phases":53090,"primaryCompletion":53091,"completion":5529,"start":53092,"enrollment":1373,"conditions":53093,"interventions":53095},"NCT02228369","Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",[90],"2017-08-19","2014-11-05",[53094],"EGFR Mutation Positive Advanced Non Small Cell Lung Cancer",[53081,5257],{"trials":53097,"activeCount":102},[],{"trials":53099,"activeCount":102},[],{"trials":53101,"activeCount":102},[],{"trials":53103,"activeCount":102},[],{"intervention":53105,"totalTrials":122,"cells":53106},"AZD6714",{"EARLY_PHASE1":53107,"PHASE1":53109,"PHASE2":53117,"PHASE3":53119,"PHASE4":53121,"NA":53123},{"trials":53108,"activeCount":102},[],{"trials":53110,"activeCount":102},[53111],{"nctId":53112,"briefTitle":53113,"status":443,"phases":53114,"primaryCompletion":2067,"completion":2067,"start":2320,"enrollment":2827,"conditions":53115,"interventions":53116},"NCT00886366","Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients",[90],[31],[53105,53105,53105],{"trials":53118,"activeCount":102},[],{"trials":53120,"activeCount":102},[],{"trials":53122,"activeCount":102},[],{"trials":53124,"activeCount":102},[],{"intervention":23893,"totalTrials":122,"cells":53126},{"EARLY_PHASE1":53127,"PHASE1":53129,"PHASE2":53135,"PHASE3":53137,"PHASE4":53139,"NA":53141},{"trials":53128,"activeCount":102},[],{"trials":53130,"activeCount":102},[53131],{"nctId":23888,"briefTitle":23889,"status":195,"phases":53132,"primaryCompletion":2242,"completion":2242,"start":2057,"enrollment":723,"conditions":53133,"interventions":53134},[90],[8842],[23848,23893],{"trials":53136,"activeCount":102},[],{"trials":53138,"activeCount":102},[],{"trials":53140,"activeCount":102},[],{"trials":53142,"activeCount":102},[],{"intervention":40908,"totalTrials":122,"cells":53144},{"EARLY_PHASE1":53145,"PHASE1":53147,"PHASE2":53153,"PHASE3":53155,"PHASE4":53157,"NA":53159},{"trials":53146,"activeCount":102},[],{"trials":53148,"activeCount":102},[53149],{"nctId":40902,"briefTitle":40903,"status":195,"phases":53150,"primaryCompletion":40905,"completion":40905,"start":12300,"enrollment":1638,"conditions":53151,"interventions":53152},[90],[5851],[40908,40909],{"trials":53154,"activeCount":102},[],{"trials":53156,"activeCount":102},[],{"trials":53158,"activeCount":102},[],{"trials":53160,"activeCount":102},[],{"intervention":7674,"totalTrials":122,"cells":53162},{"EARLY_PHASE1":53163,"PHASE1":53165,"PHASE2":53171,"PHASE3":53173,"PHASE4":53175,"NA":53177},{"trials":53164,"activeCount":102},[],{"trials":53166,"activeCount":102},[53167],{"nctId":7669,"briefTitle":7670,"status":195,"phases":53168,"primaryCompletion":2560,"completion":2560,"start":4006,"enrollment":680,"conditions":53169,"interventions":53170},[90],[466],[68,2255,7674],{"trials":53172,"activeCount":102},[],{"trials":53174,"activeCount":102},[],{"trials":53176,"activeCount":102},[],{"trials":53178,"activeCount":102},[],{"intervention":53180,"totalTrials":122,"cells":53181},"Capivasertib film-coated tablet, 200 mg",{"EARLY_PHASE1":53182,"PHASE1":53184,"PHASE2":53193,"PHASE3":53195,"PHASE4":53197,"NA":53199},{"trials":53183,"activeCount":102},[],{"trials":53185,"activeCount":102},[53186],{"nctId":53187,"briefTitle":53188,"status":195,"phases":53189,"primaryCompletion":13245,"completion":13245,"start":10492,"enrollment":1855,"conditions":53190,"interventions":53191},"NCT05419401","A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)",[90],[31837],[53180,53192],"[14C]AZD5363",{"trials":53194,"activeCount":102},[],{"trials":53196,"activeCount":102},[],{"trials":53198,"activeCount":102},[],{"trials":53200,"activeCount":102},[],{"intervention":53192,"totalTrials":122,"cells":53202},{"EARLY_PHASE1":53203,"PHASE1":53205,"PHASE2":53211,"PHASE3":53213,"PHASE4":53215,"NA":53217},{"trials":53204,"activeCount":102},[],{"trials":53206,"activeCount":102},[53207],{"nctId":53187,"briefTitle":53188,"status":195,"phases":53208,"primaryCompletion":13245,"completion":13245,"start":10492,"enrollment":1855,"conditions":53209,"interventions":53210},[90],[31837],[53180,53192],{"trials":53212,"activeCount":102},[],{"trials":53214,"activeCount":102},[],{"trials":53216,"activeCount":102},[],{"trials":53218,"activeCount":102},[],{"intervention":53220,"totalTrials":122,"cells":53221},"quetiapine fumarate extended-release",{"EARLY_PHASE1":53222,"PHASE1":53224,"PHASE2":53232,"PHASE3":53234,"PHASE4":53236,"NA":53238},{"trials":53223,"activeCount":102},[],{"trials":53225,"activeCount":102},[53226],{"nctId":53227,"briefTitle":53228,"status":195,"phases":53229,"primaryCompletion":2212,"completion":2212,"start":2152,"enrollment":3248,"conditions":53230,"interventions":53231},"NCT00919607","Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients",[90],[33],[53220,53220],{"trials":53233,"activeCount":102},[],{"trials":53235,"activeCount":102},[],{"trials":53237,"activeCount":102},[],{"trials":53239,"activeCount":102},[],{"intervention":23937,"totalTrials":122,"cells":53241},{"EARLY_PHASE1":53242,"PHASE1":53244,"PHASE2":53250,"PHASE3":53252,"PHASE4":53254,"NA":53256},{"trials":53243,"activeCount":102},[],{"trials":53245,"activeCount":102},[53246],{"nctId":23930,"briefTitle":23931,"status":195,"phases":53247,"primaryCompletion":23933,"completion":23933,"start":3735,"enrollment":2289,"conditions":53248,"interventions":53249},[90],[23935],[23909,23937,23938,23937,23938],{"trials":53251,"activeCount":102},[],{"trials":53253,"activeCount":102},[],{"trials":53255,"activeCount":102},[],{"trials":53257,"activeCount":102},[],{"intervention":23938,"totalTrials":122,"cells":53259},{"EARLY_PHASE1":53260,"PHASE1":53262,"PHASE2":53268,"PHASE3":53270,"PHASE4":53272,"NA":53274},{"trials":53261,"activeCount":102},[],{"trials":53263,"activeCount":102},[53264],{"nctId":23930,"briefTitle":23931,"status":195,"phases":53265,"primaryCompletion":23933,"completion":23933,"start":3735,"enrollment":2289,"conditions":53266,"interventions":53267},[90],[23935],[23909,23937,23938,23937,23938],{"trials":53269,"activeCount":102},[],{"trials":53271,"activeCount":102},[],{"trials":53273,"activeCount":102},[],{"trials":53275,"activeCount":102},[],{"intervention":53277,"totalTrials":122,"cells":53278},"Pulmicort pMDI HFA",{"EARLY_PHASE1":53279,"PHASE1":53281,"PHASE2":53292,"PHASE3":53294,"PHASE4":53296,"NA":53298},{"trials":53280,"activeCount":102},[],{"trials":53282,"activeCount":102},[53283],{"nctId":53284,"briefTitle":53285,"status":195,"phases":53286,"completion":2057,"start":2067,"enrollment":486,"conditions":53287,"interventions":53288},"NCT00975754","Lung Deposition Via Different Inhalation Devices",[90],[36],[53277,53289,53290,53291],"Budesonide pMDI HFA","Pulmicort Repulses","Pulmicort Turbohaler",{"trials":53293,"activeCount":102},[],{"trials":53295,"activeCount":102},[],{"trials":53297,"activeCount":102},[],{"trials":53299,"activeCount":102},[],{"intervention":53289,"totalTrials":122,"cells":53301},{"EARLY_PHASE1":53302,"PHASE1":53304,"PHASE2":53310,"PHASE3":53312,"PHASE4":53314,"NA":53316},{"trials":53303,"activeCount":102},[],{"trials":53305,"activeCount":102},[53306],{"nctId":53284,"briefTitle":53285,"status":195,"phases":53307,"completion":2057,"start":2067,"enrollment":486,"conditions":53308,"interventions":53309},[90],[36],[53277,53289,53290,53291],{"trials":53311,"activeCount":102},[],{"trials":53313,"activeCount":102},[],{"trials":53315,"activeCount":102},[],{"trials":53317,"activeCount":102},[],{"intervention":53290,"totalTrials":122,"cells":53319},{"EARLY_PHASE1":53320,"PHASE1":53322,"PHASE2":53328,"PHASE3":53330,"PHASE4":53332,"NA":53334},{"trials":53321,"activeCount":102},[],{"trials":53323,"activeCount":102},[53324],{"nctId":53284,"briefTitle":53285,"status":195,"phases":53325,"completion":2057,"start":2067,"enrollment":486,"conditions":53326,"interventions":53327},[90],[36],[53277,53289,53290,53291],{"trials":53329,"activeCount":102},[],{"trials":53331,"activeCount":102},[],{"trials":53333,"activeCount":102},[],{"trials":53335,"activeCount":102},[],{"intervention":53291,"totalTrials":122,"cells":53337},{"EARLY_PHASE1":53338,"PHASE1":53340,"PHASE2":53346,"PHASE3":53348,"PHASE4":53350,"NA":53352},{"trials":53339,"activeCount":102},[],{"trials":53341,"activeCount":102},[53342],{"nctId":53284,"briefTitle":53285,"status":195,"phases":53343,"completion":2057,"start":2067,"enrollment":486,"conditions":53344,"interventions":53345},[90],[36],[53277,53289,53290,53291],{"trials":53347,"activeCount":102},[],{"trials":53349,"activeCount":102},[],{"trials":53351,"activeCount":102},[],{"trials":53353,"activeCount":102},[],{"intervention":25175,"totalTrials":122,"cells":53355},{"EARLY_PHASE1":53356,"PHASE1":53358,"PHASE2":53364,"PHASE3":53366,"PHASE4":53368,"NA":53370},{"trials":53357,"activeCount":102},[],{"trials":53359,"activeCount":102},[53360],{"nctId":25169,"briefTitle":25170,"status":195,"phases":53361,"primaryCompletion":19426,"completion":19426,"start":2405,"enrollment":4307,"conditions":53362,"interventions":53363},[90],[25173],[19120,25175,25176,25177,25178],{"trials":53365,"activeCount":102},[],{"trials":53367,"activeCount":102},[],{"trials":53369,"activeCount":102},[],{"trials":53371,"activeCount":102},[],{"intervention":25176,"totalTrials":122,"cells":53373},{"EARLY_PHASE1":53374,"PHASE1":53376,"PHASE2":53382,"PHASE3":53384,"PHASE4":53386,"NA":53388},{"trials":53375,"activeCount":102},[],{"trials":53377,"activeCount":102},[53378],{"nctId":25169,"briefTitle":25170,"status":195,"phases":53379,"primaryCompletion":19426,"completion":19426,"start":2405,"enrollment":4307,"conditions":53380,"interventions":53381},[90],[25173],[19120,25175,25176,25177,25178],{"trials":53383,"activeCount":102},[],{"trials":53385,"activeCount":102},[],{"trials":53387,"activeCount":102},[],{"trials":53389,"activeCount":102},[],{"intervention":25177,"totalTrials":122,"cells":53391},{"EARLY_PHASE1":53392,"PHASE1":53394,"PHASE2":53400,"PHASE3":53402,"PHASE4":53404,"NA":53406},{"trials":53393,"activeCount":102},[],{"trials":53395,"activeCount":102},[53396],{"nctId":25169,"briefTitle":25170,"status":195,"phases":53397,"primaryCompletion":19426,"completion":19426,"start":2405,"enrollment":4307,"conditions":53398,"interventions":53399},[90],[25173],[19120,25175,25176,25177,25178],{"trials":53401,"activeCount":102},[],{"trials":53403,"activeCount":102},[],{"trials":53405,"activeCount":102},[],{"trials":53407,"activeCount":102},[],{"intervention":25178,"totalTrials":122,"cells":53409},{"EARLY_PHASE1":53410,"PHASE1":53412,"PHASE2":53418,"PHASE3":53420,"PHASE4":53422,"NA":53424},{"trials":53411,"activeCount":102},[],{"trials":53413,"activeCount":102},[53414],{"nctId":25169,"briefTitle":25170,"status":195,"phases":53415,"primaryCompletion":19426,"completion":19426,"start":2405,"enrollment":4307,"conditions":53416,"interventions":53417},[90],[25173],[19120,25175,25176,25177,25178],{"trials":53419,"activeCount":102},[],{"trials":53421,"activeCount":102},[],{"trials":53423,"activeCount":102},[],{"trials":53425,"activeCount":102},[],{"intervention":53427,"totalTrials":122,"cells":53428},"NKTR118 Formulation 1",{"EARLY_PHASE1":53429,"PHASE1":53431,"PHASE2":53443,"PHASE3":53445,"PHASE4":53447,"NA":53449},{"trials":53430,"activeCount":102},[],{"trials":53432,"activeCount":102},[53433],{"nctId":53434,"briefTitle":53435,"status":195,"phases":53436,"primaryCompletion":2675,"completion":2675,"start":2542,"enrollment":544,"conditions":53437,"interventions":53438},"NCT01365000","Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects",[90],[19],[53427,53439,53440,53441,53442],"NKTR118 Formulation 2","NKTR118 Formulation 3","NKTR118 Formulation 1a","NKTR118 Formulation 3a",{"trials":53444,"activeCount":102},[],{"trials":53446,"activeCount":102},[],{"trials":53448,"activeCount":102},[],{"trials":53450,"activeCount":102},[],{"intervention":53439,"totalTrials":122,"cells":53452},{"EARLY_PHASE1":53453,"PHASE1":53455,"PHASE2":53461,"PHASE3":53463,"PHASE4":53465,"NA":53467},{"trials":53454,"activeCount":102},[],{"trials":53456,"activeCount":102},[53457],{"nctId":53434,"briefTitle":53435,"status":195,"phases":53458,"primaryCompletion":2675,"completion":2675,"start":2542,"enrollment":544,"conditions":53459,"interventions":53460},[90],[19],[53427,53439,53440,53441,53442],{"trials":53462,"activeCount":102},[],{"trials":53464,"activeCount":102},[],{"trials":53466,"activeCount":102},[],{"trials":53468,"activeCount":102},[],{"intervention":53440,"totalTrials":122,"cells":53470},{"EARLY_PHASE1":53471,"PHASE1":53473,"PHASE2":53479,"PHASE3":53481,"PHASE4":53483,"NA":53485},{"trials":53472,"activeCount":102},[],{"trials":53474,"activeCount":102},[53475],{"nctId":53434,"briefTitle":53435,"status":195,"phases":53476,"primaryCompletion":2675,"completion":2675,"start":2542,"enrollment":544,"conditions":53477,"interventions":53478},[90],[19],[53427,53439,53440,53441,53442],{"trials":53480,"activeCount":102},[],{"trials":53482,"activeCount":102},[],{"trials":53484,"activeCount":102},[],{"trials":53486,"activeCount":102},[],{"intervention":53441,"totalTrials":122,"cells":53488},{"EARLY_PHASE1":53489,"PHASE1":53491,"PHASE2":53497,"PHASE3":53499,"PHASE4":53501,"NA":53503},{"trials":53490,"activeCount":102},[],{"trials":53492,"activeCount":102},[53493],{"nctId":53434,"briefTitle":53435,"status":195,"phases":53494,"primaryCompletion":2675,"completion":2675,"start":2542,"enrollment":544,"conditions":53495,"interventions":53496},[90],[19],[53427,53439,53440,53441,53442],{"trials":53498,"activeCount":102},[],{"trials":53500,"activeCount":102},[],{"trials":53502,"activeCount":102},[],{"trials":53504,"activeCount":102},[],{"intervention":53442,"totalTrials":122,"cells":53506},{"EARLY_PHASE1":53507,"PHASE1":53509,"PHASE2":53515,"PHASE3":53517,"PHASE4":53519,"NA":53521},{"trials":53508,"activeCount":102},[],{"trials":53510,"activeCount":102},[53511],{"nctId":53434,"briefTitle":53435,"status":195,"phases":53512,"primaryCompletion":2675,"completion":2675,"start":2542,"enrollment":544,"conditions":53513,"interventions":53514},[90],[19],[53427,53439,53440,53441,53442],{"trials":53516,"activeCount":102},[],{"trials":53518,"activeCount":102},[],{"trials":53520,"activeCount":102},[],{"trials":53522,"activeCount":102},[],{"intervention":53524,"totalTrials":122,"cells":53525},"MEDI8111",{"EARLY_PHASE1":53526,"PHASE1":53528,"PHASE2":53537,"PHASE3":53539,"PHASE4":53541,"NA":53543},{"trials":53527,"activeCount":102},[],{"trials":53529,"activeCount":102},[53530],{"nctId":53531,"briefTitle":53532,"status":195,"phases":53533,"primaryCompletion":6436,"completion":6436,"start":1693,"enrollment":53534,"conditions":53535,"interventions":53536},"NCT01958645","To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.",[90],157,[1556],[53524],{"trials":53538,"activeCount":102},[],{"trials":53540,"activeCount":102},[],{"trials":53542,"activeCount":102},[],{"trials":53544,"activeCount":102},[],{"intervention":53546,"totalTrials":122,"cells":53547},"[14C]AZD5718 Oral Suspension",{"EARLY_PHASE1":53548,"PHASE1":53550,"PHASE2":53559,"PHASE3":53561,"PHASE4":53563,"NA":53565},{"trials":53549,"activeCount":102},[],{"trials":53551,"activeCount":102},[53552],{"nctId":53553,"briefTitle":53554,"status":195,"phases":53555,"primaryCompletion":5468,"completion":5468,"start":53556,"enrollment":1039,"conditions":53557,"interventions":53558},"NCT03948451","Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers",[90],"2019-04-30",[2619],[53546],{"trials":53560,"activeCount":102},[],{"trials":53562,"activeCount":102},[],{"trials":53564,"activeCount":102},[],{"trials":53566,"activeCount":102},[],{"intervention":53568,"totalTrials":122,"cells":53569},"Abediterol 0.156 μg",{"EARLY_PHASE1":53570,"PHASE1":53572,"PHASE2":53583,"PHASE3":53585,"PHASE4":53587,"NA":53589},{"trials":53571,"activeCount":102},[],{"trials":53573,"activeCount":102},[53574],{"nctId":53575,"briefTitle":53576,"status":195,"phases":53577,"primaryCompletion":40646,"completion":40646,"start":53578,"enrollment":1710,"conditions":53579,"interventions":53580},"NCT02777827","A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma",[90],"2016-06-21",[16],[53568,53581,53582,53568,53581],"Abediterol 2.5 μg","Abediterol 0.05 μg",{"trials":53584,"activeCount":102},[],{"trials":53586,"activeCount":102},[],{"trials":53588,"activeCount":102},[],{"trials":53590,"activeCount":102},[],{"intervention":53581,"totalTrials":122,"cells":53592},{"EARLY_PHASE1":53593,"PHASE1":53595,"PHASE2":53601,"PHASE3":53603,"PHASE4":53605,"NA":53607},{"trials":53594,"activeCount":102},[],{"trials":53596,"activeCount":102},[53597],{"nctId":53575,"briefTitle":53576,"status":195,"phases":53598,"primaryCompletion":40646,"completion":40646,"start":53578,"enrollment":1710,"conditions":53599,"interventions":53600},[90],[16],[53568,53581,53582,53568,53581],{"trials":53602,"activeCount":102},[],{"trials":53604,"activeCount":102},[],{"trials":53606,"activeCount":102},[],{"trials":53608,"activeCount":102},[],{"intervention":53582,"totalTrials":122,"cells":53610},{"EARLY_PHASE1":53611,"PHASE1":53613,"PHASE2":53619,"PHASE3":53621,"PHASE4":53623,"NA":53625},{"trials":53612,"activeCount":102},[],{"trials":53614,"activeCount":102},[53615],{"nctId":53575,"briefTitle":53576,"status":195,"phases":53616,"primaryCompletion":40646,"completion":40646,"start":53578,"enrollment":1710,"conditions":53617,"interventions":53618},[90],[16],[53568,53581,53582,53568,53581],{"trials":53620,"activeCount":102},[],{"trials":53622,"activeCount":102},[],{"trials":53624,"activeCount":102},[],{"trials":53626,"activeCount":102},[],{"intervention":53628,"totalTrials":122,"cells":53629},"14C-AZD1236",{"EARLY_PHASE1":53630,"PHASE1":53632,"PHASE2":53640,"PHASE3":53642,"PHASE4":53644,"NA":53646},{"trials":53631,"activeCount":102},[],{"trials":53633,"activeCount":102},[53634],{"nctId":53635,"briefTitle":53636,"status":443,"phases":53637,"completion":2057,"start":2350,"enrollment":1979,"conditions":53638,"interventions":53639},"NCT01007929","Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects",[90],[19],[53628],{"trials":53641,"activeCount":102},[],{"trials":53643,"activeCount":102},[],{"trials":53645,"activeCount":102},[],{"trials":53647,"activeCount":102},[],{"intervention":53649,"totalTrials":122,"cells":53650},"AZD2551",{"EARLY_PHASE1":53651,"PHASE1":53653,"PHASE2":53661,"PHASE3":53663,"PHASE4":53665,"NA":53667},{"trials":53652,"activeCount":102},[],{"trials":53654,"activeCount":102},[53655],{"nctId":53656,"briefTitle":53657,"status":443,"phases":53658,"completion":688,"start":2095,"enrollment":2045,"conditions":53659,"interventions":53660},"NCT00860353","Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551",[90],[19],[53649],{"trials":53662,"activeCount":102},[],{"trials":53664,"activeCount":102},[],{"trials":53666,"activeCount":102},[],{"trials":53668,"activeCount":102},[],{"intervention":53670,"totalTrials":122,"cells":53671},"Atropine",{"EARLY_PHASE1":53672,"PHASE1":53682,"PHASE2":53684,"PHASE3":53686,"PHASE4":53688,"NA":53690},{"trials":53673,"activeCount":102},[53674],{"nctId":53675,"briefTitle":53676,"status":195,"phases":53677,"primaryCompletion":2086,"completion":2414,"start":6718,"enrollment":1757,"conditions":53678,"interventions":53680},"NCT00689208","Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity",[89],[53679],"Insulin Resistance",[53670,53681],"Physostigmine",{"trials":53683,"activeCount":102},[],{"trials":53685,"activeCount":102},[],{"trials":53687,"activeCount":102},[],{"trials":53689,"activeCount":102},[],{"trials":53691,"activeCount":102},[],{"intervention":53681,"totalTrials":122,"cells":53693},{"EARLY_PHASE1":53694,"PHASE1":53700,"PHASE2":53702,"PHASE3":53704,"PHASE4":53706,"NA":53708},{"trials":53695,"activeCount":102},[53696],{"nctId":53675,"briefTitle":53676,"status":195,"phases":53697,"primaryCompletion":2086,"completion":2414,"start":6718,"enrollment":1757,"conditions":53698,"interventions":53699},[89],[53679],[53670,53681],{"trials":53701,"activeCount":102},[],{"trials":53703,"activeCount":102},[],{"trials":53705,"activeCount":102},[],{"trials":53707,"activeCount":102},[],{"trials":53709,"activeCount":102},[],{"intervention":53711,"totalTrials":122,"cells":53712},"Xylocaine",{"EARLY_PHASE1":53713,"PHASE1":53722,"PHASE2":53724,"PHASE3":53726,"PHASE4":53728,"NA":53730},{"trials":53714,"activeCount":102},[53715],{"nctId":53716,"briefTitle":53717,"status":195,"phases":53718,"primaryCompletion":10063,"completion":10063,"start":2433,"enrollment":2003,"conditions":53719,"interventions":53721},"NCT01298310","A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)",[89],[53720],"Morton's Neuroma",[53711,53711],{"trials":53723,"activeCount":102},[],{"trials":53725,"activeCount":102},[],{"trials":53727,"activeCount":102},[],{"trials":53729,"activeCount":102},[],{"trials":53731,"activeCount":102},[],{"intervention":53733,"totalTrials":122,"cells":53734},"IntelliCap",{"EARLY_PHASE1":53735,"PHASE1":53745,"PHASE2":53747,"PHASE3":53749,"PHASE4":53751,"NA":53753},{"trials":53736,"activeCount":102},[53737],{"nctId":53738,"briefTitle":53739,"status":195,"phases":53740,"primaryCompletion":4006,"completion":4006,"start":2480,"enrollment":5876,"conditions":53741,"interventions":53744},"NCT02025348","Explore the Performance of IntelliCap.",[89],[53742,53743],"Plasma Concentration","Pharmacokinetic Profile",[53733],{"trials":53746,"activeCount":102},[],{"trials":53748,"activeCount":102},[],{"trials":53750,"activeCount":102},[],{"trials":53752,"activeCount":102},[],{"trials":53754,"activeCount":102},[],{"intervention":19794,"totalTrials":4307,"cells":53756},{"EARLY_PHASE1":53757,"PHASE1":53759,"PHASE2":53799,"PHASE3":53814,"PHASE4":53975,"NA":54115},{"trials":53758,"activeCount":102},[],{"trials":53760,"activeCount":102},[53761,53765,53769,53775,53779,53783,53787,53791,53795],{"nctId":19580,"briefTitle":19581,"status":195,"phases":53762,"primaryCompletion":2615,"completion":2615,"start":2243,"enrollment":19583,"conditions":53763,"interventions":53764},[90],[19],[19586,19587,19588,19273],{"nctId":32382,"briefTitle":32383,"status":195,"phases":53766,"primaryCompletion":2524,"completion":2524,"start":2580,"enrollment":1710,"conditions":53767,"interventions":53768},[90],[20100],[32375,19794],{"nctId":53770,"briefTitle":53771,"status":195,"phases":53772,"completion":2350,"start":4297,"enrollment":2069,"conditions":53773,"interventions":53774},"NCT00474019","Phase 1 Pharmacokinetics of Intravenous Nexium in Children",[90],[15776],[19588],{"nctId":33063,"briefTitle":33064,"status":195,"phases":53776,"primaryCompletion":2542,"completion":2542,"start":2615,"enrollment":2260,"conditions":53777,"interventions":53778},[90],[33067],[33069,19588],{"nctId":47626,"briefTitle":47627,"status":195,"phases":53780,"primaryCompletion":2507,"completion":2507,"start":2251,"enrollment":1710,"conditions":53781,"interventions":53782},[90],[19],[19794,47619],{"nctId":40098,"briefTitle":40099,"status":443,"phases":53784,"completion":2212,"start":2057,"enrollment":1710,"conditions":53785,"interventions":53786},[90],[40093],[40095,19794,19229],{"nctId":20318,"briefTitle":20319,"status":195,"phases":53788,"primaryCompletion":2349,"completion":2349,"start":3862,"enrollment":17655,"conditions":53789,"interventions":53790},[90],[36],[19240,19794],{"nctId":51013,"briefTitle":51014,"status":195,"phases":53792,"primaryCompletion":687,"completion":687,"start":2747,"enrollment":6652,"conditions":53793,"interventions":53794},[90],[42173],[51006,19794,51018],{"nctId":40108,"briefTitle":40109,"status":195,"phases":53796,"primaryCompletion":2251,"completion":2251,"start":2251,"enrollment":532,"conditions":53797,"interventions":53798},[90],[40112,40113],[40115,19794,19229],{"trials":53800,"activeCount":102},[53801,53808],{"nctId":53802,"briefTitle":53803,"status":195,"phases":53804,"primaryCompletion":2507,"completion":2507,"start":6369,"enrollment":53805,"conditions":53806,"interventions":53807},"NCT00317044","Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma",[91],961,[16,19809],[19794,19794],{"nctId":53809,"briefTitle":53810,"status":195,"phases":53811,"primaryCompletion":6370,"completion":6370,"start":7448,"enrollment":34539,"conditions":53812,"interventions":53813},"NCT00628953","Adult Asthmatics and Acid Reflux",[91],[16],[19794],{"trials":53815,"activeCount":102},[53816,53820,53826,53833,53841,53845,53851,53855,53862,53869,53875,53882,53889,53896,53905,53911,53917,53923,53927,53932,53938,53943,53951,53955,53961,53966,53970],{"nctId":24565,"briefTitle":24566,"status":195,"phases":53817,"completion":9930,"start":24568,"enrollment":1078,"conditions":53818,"interventions":53819},[92],[24570],[19794,24544,19794],{"nctId":53821,"briefTitle":53822,"status":195,"phases":53823,"primaryCompletion":6499,"completion":6499,"start":37326,"enrollment":1648,"conditions":53824,"interventions":53825},"NCT00629512","Prevention of Gastric Ulcers",[92],[24570],[19794,19794],{"nctId":53827,"briefTitle":53828,"status":195,"phases":53829,"primaryCompletion":4580,"completion":4580,"start":2114,"enrollment":24339,"conditions":53830,"interventions":53832},"NCT01069939","Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin",[92],[53831],"Prevention",[19794],{"nctId":53834,"briefTitle":53835,"status":195,"phases":53836,"primaryCompletion":13583,"completion":13583,"start":13575,"enrollment":365,"conditions":53837,"interventions":53840},"NCT00251901","Chest Pain Pilot Study",[92],[53838,53839],"Chest Pain","Gastroesophageal Reflux",[19794],{"nctId":24573,"briefTitle":24574,"status":195,"phases":53842,"primaryCompletion":9075,"completion":9075,"start":24568,"enrollment":1078,"conditions":53843,"interventions":53844},[92],[24570],[19794,24544,19794],{"nctId":53846,"briefTitle":53847,"status":195,"phases":53848,"completion":2320,"start":2639,"enrollment":579,"conditions":53849,"interventions":53850},"NCT00427635","Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients",[92],[19809],[19794],{"nctId":19787,"briefTitle":19788,"status":195,"phases":53852,"completion":4915,"start":4298,"enrollment":19790,"conditions":53853,"interventions":53854},[92],[19792],[19794,19794,8361],{"nctId":53856,"briefTitle":53857,"status":195,"phases":53858,"primaryCompletion":4306,"completion":4306,"start":9930,"enrollment":6346,"conditions":53859,"interventions":53861},"NCT00626535","A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)",[92],[53860],"Symptomatic Gastroesophageal Reflux Disease (sGERD)",[19794],{"nctId":53863,"briefTitle":53864,"status":195,"phases":53865,"primaryCompletion":2736,"completion":2736,"start":2675,"enrollment":53866,"conditions":53867,"interventions":53868},"NCT01370538","Efficacy of Esomeprazole in Patients With Frequent Heartburn",[92],341,[20099],[19794],{"nctId":53870,"briefTitle":53871,"status":195,"phases":53872,"completion":6719,"start":13575,"enrollment":4581,"conditions":53873,"interventions":53874},"NCT00251966","ASTERIX: Low Dose ASA and Nexium",[92],[53839],[19794],{"nctId":53876,"briefTitle":53877,"status":195,"phases":53878,"primaryCompletion":9066,"completion":9066,"start":31111,"enrollment":53879,"conditions":53880,"interventions":53881},"NCT02670642","Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD",[92],877,[53839],[19794],{"nctId":53883,"briefTitle":53884,"status":195,"phases":53885,"primaryCompletion":5562,"completion":5562,"start":13047,"enrollment":1529,"conditions":53886,"interventions":53888},"NCT00243724","HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease",[92],[53839,20099,53887],"Dyspepsia",[19794],{"nctId":53890,"briefTitle":53891,"status":195,"phases":53892,"primaryCompletion":4298,"completion":4298,"start":3809,"enrollment":53893,"conditions":53894,"interventions":53895},"NCT00251979","A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer",[92],1312,[29755],[19794],{"nctId":53897,"briefTitle":53898,"status":195,"phases":53899,"primaryCompletion":6651,"completion":6651,"start":53900,"enrollment":53901,"conditions":53902,"interventions":53904},"NCT00241527","Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs",[92],"2000-12",556,[53903,40113],"NSAIDs",[19794],{"nctId":53906,"briefTitle":53907,"status":195,"phases":53908,"completion":2095,"start":5725,"enrollment":19371,"conditions":53909,"interventions":53910},"NCT00542789","Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID",[92],[20616,20617,7267,20657,20658],[19794],{"nctId":53912,"briefTitle":53913,"status":195,"phases":53914,"primaryCompletion":12954,"completion":12954,"start":24568,"enrollment":1034,"conditions":53915,"interventions":53916},"NCT00241514","Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs",[92],[19809],[19794],{"nctId":53918,"briefTitle":53919,"status":195,"phases":53920,"primaryCompletion":2320,"completion":2320,"start":19536,"enrollment":10064,"conditions":53921,"interventions":53922},"NCT00251927","Esomeprazole (NEXIUM) vs. Surgery",[92],[53839],[19588],{"nctId":26774,"briefTitle":26775,"status":195,"phases":53924,"primaryCompletion":19387,"completion":19387,"start":1692,"enrollment":19371,"conditions":53925,"interventions":53926},[92],[26778],[19794,26763],{"nctId":53928,"briefTitle":53864,"status":195,"phases":53929,"primaryCompletion":2736,"completion":2736,"start":2675,"enrollment":5269,"conditions":53930,"interventions":53931},"NCT01370525",[92],[20099],[19794],{"nctId":53933,"briefTitle":53934,"status":195,"phases":53935,"primaryCompletion":9930,"completion":9930,"start":24568,"enrollment":5155,"conditions":53936,"interventions":53937},"NCT00629928","Ulcer Prevention II",[92],[24570],[19794,19794],{"nctId":53939,"briefTitle":53913,"status":195,"phases":53940,"primaryCompletion":12954,"completion":12954,"start":12831,"enrollment":1903,"conditions":53941,"interventions":53942},"NCT00241553",[92],[53903,40113],[19794],{"nctId":53944,"briefTitle":53945,"status":195,"phases":53946,"primaryCompletion":4876,"completion":4876,"start":6499,"enrollment":4027,"conditions":53947,"interventions":53950},"NCT00251992","Nexium Dyspepsia\u002FAST",[92],[53948,53949,53887],"Gastrointestinal Disease","Signs and Symptoms, Digestive",[19794],{"nctId":24579,"briefTitle":24580,"status":195,"phases":53952,"completion":2414,"start":2087,"enrollment":24582,"conditions":53953,"interventions":53954},[92],[20616],[19794,24544],{"nctId":53956,"briefTitle":53957,"status":195,"phases":53958,"completion":13047,"start":4306,"enrollment":1842,"conditions":53959,"interventions":53960},"NCT00241501","Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients",[92],[27291],[19794],{"nctId":53962,"briefTitle":53898,"status":195,"phases":53963,"primaryCompletion":5797,"completion":5797,"start":7449,"enrollment":36497,"conditions":53964,"interventions":53965},"NCT00241540",[92],[19809],[19794],{"nctId":19812,"briefTitle":19813,"status":195,"phases":53967,"completion":688,"start":6710,"enrollment":8294,"conditions":53968,"interventions":53969},[92],[19792],[19794,19794,8361],{"nctId":53971,"briefTitle":53945,"status":195,"phases":53972,"primaryCompletion":4876,"completion":4876,"start":6499,"enrollment":12914,"conditions":53973,"interventions":53974},"NCT00251914",[92],[53948,53949,53887],[19794],{"trials":53976,"activeCount":102},[53977,53981,53985,53989,53996,54002,54008,54014,54018,54025,54031,54037,54041,54047,54053,54059,54063,54067,54073,54080,54084,54090,54096,54104,54108],{"nctId":21164,"briefTitle":21165,"status":195,"phases":53978,"primaryCompletion":2086,"completion":2086,"start":3839,"enrollment":21167,"conditions":53979,"interventions":53980},[93],[19809],[19588,21151],{"nctId":20082,"briefTitle":20083,"status":195,"phases":53982,"primaryCompletion":6563,"completion":6563,"start":6499,"enrollment":9987,"conditions":53983,"interventions":53984},[93],[10949],[19794,20065],{"nctId":20346,"briefTitle":20347,"status":195,"phases":53986,"primaryCompletion":4256,"completion":4256,"start":15911,"enrollment":579,"conditions":53987,"interventions":53988},[93],[20118],[19794,19240,20351],{"nctId":53990,"briefTitle":53991,"status":195,"phases":53992,"primaryCompletion":6718,"completion":6718,"start":5563,"enrollment":221,"conditions":53993,"interventions":53995},"NCT00384592","PPI Sequencing Study",[93],[53994],"Gastro-Oesophageal Reflux Disease",[19794],{"nctId":53997,"briefTitle":53998,"status":195,"phases":53999,"primaryCompletion":2507,"completion":2507,"start":2251,"enrollment":1903,"conditions":54000,"interventions":54001},"NCT00660660","Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US",[93],[20100],[19794],{"nctId":54003,"briefTitle":54004,"status":195,"phases":54005,"primaryCompletion":7448,"completion":7448,"start":5797,"enrollment":477,"conditions":54006,"interventions":54007},"NCT00635414","Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously",[93],[19809],[19794,19794],{"nctId":54009,"briefTitle":54010,"status":195,"phases":54011,"primaryCompletion":6563,"completion":6563,"start":9909,"enrollment":365,"conditions":54012,"interventions":54013},"NCT00628342","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)",[93],[27291],[19794,19794],{"nctId":20088,"briefTitle":20089,"status":195,"phases":54015,"primaryCompletion":6572,"completion":6572,"start":6499,"enrollment":9978,"conditions":54016,"interventions":54017},[93],[10949],[19794,20065],{"nctId":54019,"briefTitle":54020,"status":195,"phases":54021,"completion":3809,"start":3990,"enrollment":221,"conditions":54022,"interventions":54024},"NCT00228527","Esomeprazole for Treatment of GERD in Pediatric Patients",[93],[27291,10949,54023],"Non-erosive Esophagitis",[19794],{"nctId":54026,"briefTitle":54027,"status":195,"phases":54028,"primaryCompletion":7448,"completion":7448,"start":6651,"enrollment":477,"conditions":54029,"interventions":54030},"NCT00629564","An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)",[93],[19809],[19794,19794],{"nctId":54032,"briefTitle":54033,"status":195,"phases":54034,"completion":6718,"start":3809,"enrollment":18649,"conditions":54035,"interventions":54036},"NCT00392002","Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response",[93],[53839],[19794],{"nctId":21873,"briefTitle":21874,"status":195,"phases":54038,"primaryCompletion":5725,"completion":5725,"start":4916,"enrollment":21876,"conditions":54039,"interventions":54040},[93],[20100],[19588,21860],{"nctId":54042,"briefTitle":54043,"status":195,"phases":54044,"start":12846,"enrollment":221,"conditions":54045,"interventions":54046},"NCT00318084","PPI Test in GP Patients",[93],[19809],[19794],{"nctId":54048,"briefTitle":54049,"status":195,"phases":54050,"primaryCompletion":7448,"completion":7448,"start":3810,"enrollment":477,"conditions":54051,"interventions":54052},"NCT00626262","Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv",[93],[20100],[19794],{"nctId":54054,"briefTitle":54055,"status":195,"phases":54056,"completion":2169,"start":7494,"enrollment":9987,"conditions":54057,"interventions":54058},"NCT00318968","Nexium RESPONSE Trial",[93],[19809],[19794],{"nctId":20104,"briefTitle":20105,"status":195,"phases":54060,"primaryCompletion":4264,"completion":4264,"start":6445,"enrollment":221,"conditions":54061,"interventions":54062},[93],[20099,20108,20109,20110],[19794,20065,20112],{"nctId":21090,"briefTitle":21091,"status":195,"phases":54064,"primaryCompletion":9986,"completion":9986,"start":4285,"enrollment":1448,"conditions":54065,"interventions":54066},[93],[19],[19794,21095],{"nctId":54068,"briefTitle":54069,"status":195,"phases":54070,"completion":4284,"start":3809,"enrollment":1529,"conditions":54071,"interventions":54072},"NCT00242736","An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)",[93],[19809],[19794],{"nctId":54074,"briefTitle":54075,"status":195,"phases":54076,"primaryCompletion":4916,"completion":4916,"start":6517,"enrollment":1842,"conditions":54077,"interventions":54079},"NCT00608712","Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)",[93],[54078],"Postoperative Bariatric Surgery",[19794],{"nctId":22540,"briefTitle":22541,"status":195,"phases":54081,"completion":2328,"start":2329,"enrollment":170,"conditions":54082,"interventions":54083},[93],[20100],[19794,22527],{"nctId":54085,"briefTitle":54086,"status":195,"phases":54087,"completion":7342,"start":6719,"enrollment":1529,"conditions":54088,"interventions":54089},"NCT00291746","Validation of RDQ Questionnaire",[93],[53839],[19794],{"nctId":54091,"briefTitle":54092,"status":195,"phases":54093,"primaryCompletion":9066,"completion":9066,"start":6651,"enrollment":477,"conditions":54094,"interventions":54095},"NCT00625495","Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)",[93],[20100],[19794,19794],{"nctId":54097,"briefTitle":54098,"status":195,"phases":54099,"primaryCompletion":2542,"completion":2542,"start":2113,"enrollment":6134,"conditions":54100,"interventions":54103},"NCT01119768","Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients",[93],[54101,54102],"Non Erosive Reflux Disease","Chronic Gastritis",[19794,19794],{"nctId":20114,"briefTitle":20115,"status":195,"phases":54105,"completion":7439,"start":4284,"enrollment":1395,"conditions":54106,"interventions":54107},[93],[20118],[19794,20065],{"nctId":54109,"briefTitle":54110,"status":195,"phases":54111,"primaryCompletion":9930,"completion":9930,"start":12757,"enrollment":2187,"conditions":54112,"interventions":54114},"NCT00628667","Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux",[93],[54113],"Chronic Posterior Laryngitis (CPL)",[19794],{"trials":54116,"activeCount":102},[54117],{"nctId":54118,"briefTitle":54119,"status":195,"phases":54120,"completion":2580,"start":6445,"enrollment":6125,"conditions":54121,"interventions":54122},"NCT00524251","The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients",[],[19809,7395],[19588],{"intervention":2108,"totalTrials":3172,"cells":54124},{"EARLY_PHASE1":54125,"PHASE1":54127,"PHASE2":54181,"PHASE3":54189,"PHASE4":54302,"NA":54338},{"trials":54126,"activeCount":102},[],{"trials":54128,"activeCount":102},[54129,54135,54139,54143,54147,54151,54155,54159,54163,54167,54171,54177],{"nctId":54130,"briefTitle":54131,"status":195,"phases":54132,"primaryCompletion":2151,"completion":2151,"start":2068,"enrollment":1757,"conditions":54133,"interventions":54134},"NCT00935467","Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects",[90],[22],[2108],{"nctId":18960,"briefTitle":18961,"status":195,"phases":54136,"primaryCompletion":2212,"completion":2212,"start":2114,"enrollment":1130,"conditions":54137,"interventions":54138},[90],[22],[18965,2333,18966],{"nctId":2101,"briefTitle":2102,"status":195,"phases":54140,"primaryCompletion":2104,"completion":2104,"start":2105,"enrollment":2069,"conditions":54141,"interventions":54142},[90],[22],[2108,2044],{"nctId":23481,"briefTitle":23482,"status":443,"phases":54144,"primaryCompletion":2746,"completion":2746,"start":2432,"enrollment":1979,"conditions":54145,"interventions":54146},[90],[22],[2565,2108,2475,23486,2061],{"nctId":18968,"briefTitle":18969,"status":195,"phases":54148,"primaryCompletion":4580,"completion":4580,"start":2542,"enrollment":8138,"conditions":54149,"interventions":54150},[90],[22],[18973,2108,18974,18975,2173],{"nctId":2176,"briefTitle":2177,"status":195,"phases":54152,"primaryCompletion":2179,"completion":2179,"start":2180,"enrollment":496,"conditions":54153,"interventions":54154},[90],[22],[2108,2044],{"nctId":23488,"briefTitle":23489,"status":195,"phases":54156,"primaryCompletion":2055,"completion":2055,"start":2057,"enrollment":1710,"conditions":54157,"interventions":54158},[90],[2631],[18965,23493,23494],{"nctId":42034,"briefTitle":42035,"status":195,"phases":54160,"primaryCompletion":2055,"completion":2055,"start":2057,"enrollment":1710,"conditions":54161,"interventions":54162},[90],[2631],[18965,42039,23494],{"nctId":2200,"briefTitle":2201,"status":195,"phases":54164,"primaryCompletion":2203,"completion":2203,"start":2204,"enrollment":132,"conditions":54165,"interventions":54166},[90],[22],[2108,2044,2207],{"nctId":24437,"briefTitle":24438,"status":195,"phases":54168,"primaryCompletion":2068,"completion":2068,"start":2152,"enrollment":1130,"conditions":54169,"interventions":54170},[90],[22],[2108,2475,24442],{"nctId":54172,"briefTitle":54173,"status":195,"phases":54174,"primaryCompletion":2086,"completion":2086,"start":2086,"enrollment":17655,"conditions":54175,"interventions":54176},"NCT00770302","Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin",[90],[31],[2108],{"nctId":23496,"briefTitle":23497,"status":624,"phases":54178,"primaryCompletion":2570,"completion":2570,"start":2570,"enrollment":102,"conditions":54179,"interventions":54180},[90],[31],[2108,2061,23486],{"trials":54182,"activeCount":102},[54183],{"nctId":54184,"briefTitle":54185,"status":195,"phases":54186,"primaryCompletion":13575,"completion":13575,"start":4299,"enrollment":13132,"conditions":54187,"interventions":54188},"NCT00950599","Study of Multiple Doses of Saxagliptin (BMS-477118)",[91],[22],[2108,2108,2108,2108,2108,2108],{"trials":54190,"activeCount":102},[54191,54195,54199,54203,54209,54213,54217,54223,54229,54233,54237,54241,54245,54249,54253,54257,54261,54265,54269,54273,54277,54284,54288,54292,54296],{"nctId":2393,"briefTitle":2394,"status":195,"phases":54192,"primaryCompletion":2396,"completion":2396,"start":2397,"enrollment":2398,"conditions":54193,"interventions":54194},[92],[31],[2108,2044,2081],{"nctId":23506,"briefTitle":23507,"status":195,"phases":54196,"primaryCompletion":2243,"completion":2243,"start":2151,"enrollment":19807,"conditions":54197,"interventions":54198},[92],[31],[2108,2061,2061],{"nctId":19032,"briefTitle":19033,"status":195,"phases":54200,"primaryCompletion":2415,"completion":3827,"start":6369,"enrollment":19035,"conditions":54201,"interventions":54202},[92],[2652],[2108,2108,19038,19038,2173],{"nctId":54204,"briefTitle":54205,"status":195,"phases":54206,"primaryCompletion":2542,"completion":2542,"start":2242,"enrollment":3941,"conditions":54207,"interventions":54208},"NCT01128153","Saxagliptin Triple Oral Therapy",[92],[31],[2108],{"nctId":2467,"briefTitle":2468,"status":195,"phases":54210,"primaryCompletion":2470,"completion":2299,"start":2471,"enrollment":2472,"conditions":54211,"interventions":54212},[92],[31],[2108,2044,2475],{"nctId":2477,"briefTitle":2478,"status":195,"phases":54214,"primaryCompletion":2480,"completion":2480,"start":2481,"enrollment":2482,"conditions":54215,"interventions":54216},[92],[31],[2108,2061,2044],{"nctId":54218,"briefTitle":54219,"status":195,"phases":54220,"primaryCompletion":2152,"completion":2212,"start":6710,"enrollment":20594,"conditions":54221,"interventions":54222},"NCT00614939","Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment",[92],[31],[2108],{"nctId":54224,"briefTitle":54225,"status":195,"phases":54226,"primaryCompletion":2406,"completion":2406,"start":688,"enrollment":35813,"conditions":54227,"interventions":54228},"NCT00918879","Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control",[92],[31],[2108],{"nctId":19061,"briefTitle":19062,"status":195,"phases":54230,"primaryCompletion":2067,"completion":2067,"start":2524,"enrollment":10001,"conditions":54231,"interventions":54232},[92],[31],[2108,2173],{"nctId":23520,"briefTitle":23521,"status":195,"phases":54234,"primaryCompletion":2489,"completion":2489,"start":2151,"enrollment":23523,"conditions":54235,"interventions":54236},[92],[31],[2108,2061,2061],{"nctId":2557,"briefTitle":2558,"status":195,"phases":54238,"primaryCompletion":2560,"completion":2561,"start":2432,"enrollment":2562,"conditions":54239,"interventions":54240},[92],[31],[2044,2108,2565],{"nctId":19067,"briefTitle":19068,"status":195,"phases":54242,"primaryCompletion":2169,"completion":2414,"start":6562,"enrollment":19070,"conditions":54243,"interventions":54244},[92],[2652],[2108,2108,2108,2108,2333],{"nctId":23527,"briefTitle":23528,"status":195,"phases":54246,"primaryCompletion":6468,"completion":6468,"start":10063,"enrollment":579,"conditions":54247,"interventions":54248},[92],[2089],[2475,2061,2108],{"nctId":15943,"briefTitle":15944,"status":195,"phases":54250,"primaryCompletion":4297,"completion":2086,"start":2087,"enrollment":15946,"conditions":54251,"interventions":54252},[92],[2089],[2108,2108,15893,15949,2333],{"nctId":19712,"briefTitle":19713,"status":195,"phases":54254,"primaryCompletion":2077,"completion":2077,"start":2251,"enrollment":19715,"conditions":54255,"interventions":54256},[92],[31],[18965,15935],{"nctId":19082,"briefTitle":19083,"status":195,"phases":54258,"primaryCompletion":2151,"completion":2144,"start":4298,"enrollment":19085,"conditions":54259,"interventions":54260},[92],[31],[2173,19088,2108],{"nctId":19094,"briefTitle":19095,"status":195,"phases":54262,"primaryCompletion":4916,"completion":2114,"start":13583,"enrollment":5936,"conditions":54263,"interventions":54264},[92],[2089],[2108,2108,2108,2173,2108,2173],{"nctId":19100,"briefTitle":19101,"status":195,"phases":54266,"primaryCompletion":6710,"completion":2055,"start":5563,"enrollment":5531,"conditions":54267,"interventions":54268},[92],[31],[2108,2173,2173],{"nctId":2644,"briefTitle":2645,"status":195,"phases":54270,"primaryCompletion":2647,"completion":2648,"start":2649,"enrollment":2650,"conditions":54271,"interventions":54272},[92],[2652],[2108,2044,2080],{"nctId":2679,"briefTitle":2680,"status":195,"phases":54274,"primaryCompletion":2682,"completion":2682,"start":2683,"enrollment":2684,"conditions":54275,"interventions":54276},[92],[22,2621],[2044,2108],{"nctId":54278,"briefTitle":54279,"status":195,"phases":54280,"primaryCompletion":2350,"completion":2350,"start":2524,"enrollment":54281,"conditions":54282,"interventions":54283},"NCT00698932","Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control",[92],568,[31],[2108],{"nctId":15959,"briefTitle":15960,"status":195,"phases":54285,"primaryCompletion":2169,"completion":4915,"start":7494,"enrollment":15962,"conditions":54286,"interventions":54287},[92],[2652],[2108,2108,2173,15893],{"nctId":2709,"briefTitle":2710,"status":195,"phases":54289,"primaryCompletion":2712,"completion":1484,"start":2713,"enrollment":872,"conditions":54290,"interventions":54291},[92],[2089],[2044,2108],{"nctId":19137,"briefTitle":19138,"status":195,"phases":54293,"primaryCompletion":6468,"completion":6468,"start":2542,"enrollment":2827,"conditions":54294,"interventions":54295},[92],[31],[2108,2475,2173],{"nctId":54297,"briefTitle":54298,"status":195,"phases":54299,"primaryCompletion":2095,"completion":2095,"start":2507,"enrollment":6454,"conditions":54300,"interventions":54301},"NCT00683657","Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone",[92],[31],[2108],{"trials":54303,"activeCount":102},[54304,54308,54315,54322,54326,54330,54334],{"nctId":19725,"briefTitle":19726,"status":195,"phases":54305,"primaryCompletion":19728,"completion":19728,"start":19729,"enrollment":19730,"conditions":54306,"interventions":54307},[93],[22,1520],[2108,2081],{"nctId":54309,"briefTitle":54310,"status":195,"phases":54311,"primaryCompletion":2203,"completion":2203,"start":2104,"enrollment":54312,"conditions":54313,"interventions":54314},"NCT01608724","The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus",[93],2165,[24168],[2108],{"nctId":54316,"briefTitle":54317,"status":195,"phases":54318,"primaryCompletion":7354,"completion":7354,"start":2243,"enrollment":54319,"conditions":54320,"interventions":54321},"NCT01107886","Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications",[93],18206,[22],[2108],{"nctId":19940,"briefTitle":19941,"status":195,"phases":54323,"primaryCompletion":2471,"completion":2471,"start":2350,"enrollment":3440,"conditions":54324,"interventions":54325},[93],[22],[2108,2080],{"nctId":21016,"briefTitle":21017,"status":195,"phases":54327,"primaryCompletion":21019,"completion":21019,"start":2180,"enrollment":1796,"conditions":54328,"interventions":54329},[93],[22],[2108,2795],{"nctId":19149,"briefTitle":19150,"status":195,"phases":54331,"completion":2143,"start":2350,"enrollment":19152,"conditions":54332,"interventions":54333},[93],[22],[2108,2173],{"nctId":2850,"briefTitle":2851,"status":195,"phases":54335,"primaryCompletion":2853,"completion":2853,"start":2854,"enrollment":2855,"conditions":54336,"interventions":54337},[93],[22,2621],[2044,2108,2080],{"trials":54339,"activeCount":102},[54340,54347],{"nctId":54341,"briefTitle":54342,"status":195,"phases":54343,"primaryCompletion":4005,"completion":4005,"start":10063,"enrollment":9987,"conditions":54344,"interventions":54346},"NCT01552005","Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France",[],[54345],"Type 2 Diabetes Mellitus (T2D)",[2108],{"nctId":54348,"briefTitle":54349,"status":195,"phases":54350,"primaryCompletion":7681,"completion":7681,"start":54351,"enrollment":54352,"conditions":54353,"interventions":54354},"NCT06099067","Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)",[],"2020-05-15",239990,[22],[54355,54356,39369,2108,54357],"Canagliflozin","DPP4 inhibitor","2nd generation Sulfonylurea",{"intervention":10068,"totalTrials":689,"cells":54359},{"EARLY_PHASE1":54360,"PHASE1":54362,"PHASE2":54384,"PHASE3":54414,"PHASE4":54545,"NA":54568},{"trials":54361,"activeCount":102},[],{"trials":54363,"activeCount":102},[54364,54370,54376,54380],{"nctId":54365,"briefTitle":54366,"status":195,"phases":54367,"primaryCompletion":8692,"completion":9986,"start":6370,"enrollment":2003,"conditions":54368,"interventions":54369},"NCT00940329","Pharmacodynamic\u002FPharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol",[90],[19],[10068,10068],{"nctId":54371,"briefTitle":54372,"status":195,"phases":54373,"primaryCompletion":2542,"completion":2571,"start":2615,"enrollment":579,"conditions":54374,"interventions":54375},"NCT01354782","Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects",[90],[28],[10068],{"nctId":18252,"briefTitle":18253,"status":195,"phases":54377,"primaryCompletion":2104,"completion":2104,"start":2481,"enrollment":1448,"conditions":54378,"interventions":54379},[90],[31],[10068,18257,18258],{"nctId":25534,"briefTitle":25535,"status":195,"phases":54381,"primaryCompletion":2203,"completion":2203,"start":2480,"enrollment":2003,"conditions":54382,"interventions":54383},[90],[25538,18867],[10068,25527,23078,25540,25541],{"trials":54385,"activeCount":102},[54386,54390,54396,54403,54407],{"nctId":15901,"briefTitle":15902,"status":443,"phases":54387,"primaryCompletion":2180,"completion":2180,"start":2746,"enrollment":5876,"conditions":54388,"interventions":54389},[91],[15905],[10068,2448],{"nctId":54391,"briefTitle":54392,"status":195,"phases":54393,"primaryCompletion":13583,"completion":13583,"start":9986,"enrollment":5898,"conditions":54394,"interventions":54395},"NCT01365533","A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma",[91],[32359],[10068],{"nctId":54397,"briefTitle":54398,"status":443,"phases":54399,"primaryCompletion":4006,"completion":4006,"start":2366,"enrollment":6901,"conditions":54400,"interventions":54402},"NCT01473758","Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease",[91],[54401],"Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation",[10068],{"nctId":25545,"briefTitle":25546,"status":195,"phases":54404,"primaryCompletion":4204,"completion":4204,"start":2405,"enrollment":4307,"conditions":54405,"interventions":54406},[91],[16],[10068,25527,25550],{"nctId":54408,"briefTitle":54409,"status":195,"phases":54410,"primaryCompletion":2169,"completion":2580,"start":4916,"enrollment":54411,"conditions":54412,"interventions":54413},"NCT01140542","Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study",[91],487,[2803],[10068],{"trials":54415,"activeCount":102},[54416,54420,54426,54433,54440,54449,54455,54461,54468,54474,54481,54487,54496,54503,54509,54515,54522,54528,54535,54539],{"nctId":10060,"briefTitle":10061,"status":195,"phases":54417,"primaryCompletion":10063,"completion":10063,"start":2570,"enrollment":10064,"conditions":54418,"interventions":54419},[92],[10066],[10068,6193],{"nctId":54421,"briefTitle":54422,"status":195,"phases":54423,"primaryCompletion":5563,"completion":3839,"start":4264,"enrollment":10001,"conditions":54424,"interventions":54425},"NCT00242294","Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)",[91,92],[6083],[10068],{"nctId":54427,"briefTitle":54428,"status":195,"phases":54429,"primaryCompletion":2251,"completion":2220,"start":2087,"enrollment":54430,"conditions":54431,"interventions":54432},"NCT00297115","Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217\u002FM2-125)",[92],1568,[6083],[10068],{"nctId":54434,"briefTitle":54435,"status":195,"phases":54436,"primaryCompletion":2507,"completion":3827,"start":9213,"enrollment":54437,"conditions":54438,"interventions":54439},"NCT00297102","Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217\u002FM2-124)",[92],1523,[6083],[10068],{"nctId":54441,"briefTitle":54442,"status":195,"phases":54443,"primaryCompletion":54444,"completion":54445,"start":54446,"enrollment":170,"conditions":54447,"interventions":54448},"NCT00242307","Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)",[91,92],"2006-09-01","2007-06-01","2004-05-01",[24226],[10068],{"nctId":54450,"briefTitle":54451,"status":195,"phases":54452,"primaryCompletion":2329,"completion":2329,"start":9124,"enrollment":3654,"conditions":54453,"interventions":54454},"NCT00076089","OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217\u002FM2-111)",[92],[28,10066],[10068],{"nctId":54456,"briefTitle":54457,"status":195,"phases":54458,"completion":6650,"start":9124,"enrollment":19715,"conditions":54459,"interventions":54460},"NCT00076076","The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217\u002FM2-023)",[92],[16],[10068],{"nctId":54462,"briefTitle":54463,"status":195,"phases":54464,"primaryCompletion":6517,"completion":6517,"start":9909,"enrollment":54465,"conditions":54466,"interventions":54467},"NCT00163527","Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217\u002FM2-013)",[92],2054,[16],[10068],{"nctId":54469,"briefTitle":54470,"status":195,"phases":54471,"primaryCompletion":2252,"completion":2168,"start":6369,"enrollment":27627,"conditions":54472,"interventions":54473},"NCT00313209","Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217\u002FM2-127)",[92],[6083],[10068],{"nctId":54475,"briefTitle":54476,"status":195,"phases":54477,"primaryCompletion":54478,"completion":54478,"start":4212,"enrollment":649,"conditions":54479,"interventions":54480},"NCT01509677","Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease",[92],"2016-02-01",[10066,28],[10068],{"nctId":54482,"briefTitle":54483,"status":195,"phases":54484,"primaryCompletion":13014,"completion":4297,"start":7554,"enrollment":3000,"conditions":54485,"interventions":54486},"NCT00246935","Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)",[92],[6083],[10068],{"nctId":54488,"briefTitle":54489,"status":195,"phases":54490,"primaryCompletion":54491,"completion":54492,"start":54493,"enrollment":3000,"conditions":54494,"interventions":54495},"NCT00246922","Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)",[92],"2007-01-01","2007-10-01","2004-12-01",[24226],[10068],{"nctId":54497,"briefTitle":54498,"status":195,"phases":54499,"primaryCompletion":9065,"completion":9065,"start":13575,"enrollment":54500,"conditions":54501,"interventions":54502},"NCT00163475","Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217\u002FM2-015)",[92],511,[16],[10068],{"nctId":54504,"briefTitle":54505,"status":195,"phases":54506,"start":12846,"enrollment":3654,"conditions":54507,"interventions":54508},"NCT00430729","Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217\u002FM2-112)",[92],[28,10066],[10068],{"nctId":54510,"briefTitle":54511,"status":195,"phases":54512,"primaryCompletion":6718,"completion":5725,"start":9065,"enrollment":18354,"conditions":54513,"interventions":54514},"NCT00242320","Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217\u002FM2-119)",[92],[10066],[10068],{"nctId":54516,"briefTitle":54517,"status":195,"phases":54518,"start":9901,"enrollment":54519,"conditions":54520,"interventions":54521},"NCT00073177","Efficacy and Safety of Roflumilast in Patients With Asthma (BY217\u002FM2-012)",[92],819,[16],[10068],{"nctId":54523,"briefTitle":54524,"status":195,"phases":54525,"start":3990,"enrollment":9887,"conditions":54526,"interventions":54527},"NCT00108823","The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217\u002FM2-121)",[92],[20888],[10068],{"nctId":54529,"briefTitle":54530,"status":195,"phases":54531,"primaryCompletion":6710,"completion":2507,"start":13014,"enrollment":54532,"conditions":54533,"interventions":54534},"NCT00424268","Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217\u002FM2-128)",[92],743,[28],[10068],{"nctId":25554,"briefTitle":25555,"status":195,"phases":54536,"primaryCompletion":25557,"completion":25557,"start":25558,"enrollment":25559,"conditions":54537,"interventions":54538},[92],[6083],[10068,25562,25563],{"nctId":54540,"briefTitle":54541,"status":195,"phases":54542,"start":4256,"enrollment":9987,"conditions":54543,"interventions":54544},"NCT00062582","Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217\u002FM2-110)",[92],[28,10066],[10068],{"trials":54546,"activeCount":102},[54547,54554],{"nctId":54548,"briefTitle":54549,"status":195,"phases":54550,"primaryCompletion":4006,"completion":2203,"start":2615,"enrollment":54551,"conditions":54552,"interventions":54553},"NCT01329029","Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)",[93],1945,[28],[10068],{"nctId":54555,"briefTitle":54556,"status":195,"phases":54557,"primaryCompletion":54558,"completion":23788,"start":54559,"enrollment":54560,"conditions":54561,"interventions":54567},"NCT01443845","Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)",[93],"2015-11-30","2011-09-30",2354,[10066,54562,6094,54563,54564,54565,54566],"COPD Exacerbation","Respiratory Disorders","Pulmonary Disease","Chronic Obstructive Lung Diseases","Chronic Obstructive Airway Disease",[10068],{"trials":54569,"activeCount":102},[54570,54579],{"nctId":54571,"briefTitle":54572,"status":195,"phases":54573,"primaryCompletion":54574,"completion":54574,"start":54575,"enrollment":54576,"conditions":54577,"interventions":54578},"NCT03381573","Long-term Observational Study of the Safety of Roflumilast",[],"2022-09-16","2013-12-15",135856,[10066],[10068],{"nctId":54580,"briefTitle":54581,"status":195,"phases":54582,"primaryCompletion":20873,"completion":20873,"start":54583,"enrollment":795,"conditions":54584,"interventions":54585},"NCT02068456","Post Marketing Surveillance of Roflumilast in Korea",[],"2012-09-18",[28],[10068],{"intervention":10076,"totalTrials":579,"cells":54587},{"EARLY_PHASE1":54588,"PHASE1":54590,"PHASE2":54592,"PHASE3":54594,"PHASE4":54769,"NA":54781},{"trials":54589,"activeCount":102},[],{"trials":54591,"activeCount":102},[],{"trials":54593,"activeCount":102},[],{"trials":54595,"activeCount":102},[54596,54600,54606,54613,54619,54625,54631,54637,54643,54649,54653,54659,54665,54671,54677,54683,54690,54696,54702,54708,54714,54723,54729,54735,54741,54747,54753,54757,54763],{"nctId":27093,"briefTitle":27094,"status":195,"phases":54597,"primaryCompletion":6436,"completion":16044,"start":2560,"enrollment":1395,"conditions":54598,"interventions":54599},[92],[19420],[10076,27082],{"nctId":54601,"briefTitle":54602,"status":195,"phases":54603,"primaryCompletion":6517,"completion":6517,"start":3990,"enrollment":9978,"conditions":54604,"interventions":54605},"NCT00163462","Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010\u002FM1-206)",[92],[16],[10076],{"nctId":54607,"briefTitle":54608,"status":195,"phases":54609,"primaryCompletion":13575,"completion":13047,"start":9124,"enrollment":54610,"conditions":54611,"interventions":54612},"NCT00659750","To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010\u002FM1-402)",[92],418,[22131],[10076],{"nctId":54614,"briefTitle":54615,"status":195,"phases":54616,"primaryCompletion":9986,"completion":9986,"start":9909,"enrollment":6346,"conditions":54617,"interventions":54618},"NCT00163410","Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010\u002FM1-205)",[92],[16],[10076],{"nctId":54620,"briefTitle":54621,"status":195,"phases":54622,"primaryCompletion":9944,"completion":6719,"start":4264,"enrollment":6346,"conditions":54623,"interventions":54624},"NCT00659594","Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010\u002FM1-406)",[92],[26921,26914],[10076],{"nctId":54626,"briefTitle":54627,"status":195,"phases":54628,"primaryCompletion":4284,"completion":4284,"start":6719,"enrollment":170,"conditions":54629,"interventions":54630},"NCT00163436","Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010\u002FM1-145)",[92],[16],[10076],{"nctId":54632,"briefTitle":54633,"status":195,"phases":54634,"primaryCompletion":2168,"completion":2168,"start":5563,"enrollment":260,"conditions":54635,"interventions":54636},"NCT00392288","Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.",[92],[16],[10076,10076],{"nctId":54638,"briefTitle":54639,"status":195,"phases":54640,"completion":6517,"start":4264,"enrollment":6346,"conditions":54641,"interventions":54642},"NCT00163319","Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010\u002FIT-101)",[92],[16],[10076],{"nctId":54644,"briefTitle":54645,"status":195,"phases":54646,"primaryCompletion":13047,"completion":13047,"start":9124,"enrollment":365,"conditions":54647,"interventions":54648},"NCT00163501","Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010\u002FM1-404)",[92],[19561,19413,26914],[10076],{"nctId":10070,"briefTitle":10071,"status":195,"phases":54650,"primaryCompletion":5725,"completion":2220,"start":5563,"enrollment":10073,"conditions":54651,"interventions":54652},[92],[16],[10076,6193],{"nctId":54654,"briefTitle":54655,"status":195,"phases":54656,"primaryCompletion":9986,"completion":9944,"start":9124,"enrollment":817,"conditions":54657,"interventions":54658},"NCT00659841","To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010\u002FM1-401)",[92],[26921,26914],[10076],{"nctId":54660,"briefTitle":54661,"status":195,"phases":54662,"primaryCompletion":13047,"completion":2329,"start":9986,"enrollment":34295,"conditions":54663,"interventions":54664},"NCT00659048","Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010\u002FM1-408)",[92],[22131],[10076],{"nctId":54666,"briefTitle":54667,"status":195,"phases":54668,"primaryCompletion":7447,"completion":7447,"start":15911,"enrollment":544,"conditions":54669,"interventions":54670},"NCT00546520","Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010\u002FM1-125)",[92],[16],[10076],{"nctId":54672,"briefTitle":54673,"status":195,"phases":54674,"primaryCompletion":3809,"completion":3809,"start":6780,"enrollment":3229,"conditions":54675,"interventions":54676},"NCT00163358","Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate\u002FSalmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010\u002FM1-132)",[92],[16],[10076],{"nctId":54678,"briefTitle":54679,"status":195,"phases":54680,"primaryCompletion":7494,"completion":7494,"start":6780,"enrollment":5876,"conditions":54681,"interventions":54682},"NCT00163345","Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010\u002FM1-131)",[92],[16],[10076],{"nctId":54684,"briefTitle":54685,"status":195,"phases":54686,"primaryCompletion":2560,"completion":2560,"start":4580,"enrollment":54687,"conditions":54688,"interventions":54689},"NCT01455194","Effect of High Dose Ciclesonide on Asthma Control",[92],520,[24226],[10076],{"nctId":54691,"briefTitle":54692,"status":195,"phases":54693,"primaryCompletion":3839,"completion":2168,"start":9213,"enrollment":3645,"conditions":54694,"interventions":54695},"NCT00305461","Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010\u002FAR-101)",[92],[16],[10076],{"nctId":54697,"briefTitle":54698,"status":195,"phases":54699,"primaryCompletion":9065,"completion":9065,"start":4876,"enrollment":34295,"conditions":54700,"interventions":54701},"NCT00163488","Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate\u002FSalmeterol in Adults With Perennial Allergic Rhinitis (BY9010\u002FM1-409)",[92],[19561,19413,26914],[10076],{"nctId":54703,"briefTitle":54704,"status":195,"phases":54705,"primaryCompletion":2329,"completion":2329,"start":6719,"enrollment":2260,"conditions":54706,"interventions":54707},"NCT00163371","Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010\u002FM1-208)",[92],[16],[10076],{"nctId":54709,"briefTitle":54710,"status":195,"phases":54711,"primaryCompletion":4284,"completion":4284,"start":4264,"enrollment":35142,"conditions":54712,"interventions":54713},"NCT00163423","Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010\u002FM1-142)",[92],[16],[10076],{"nctId":54715,"briefTitle":54716,"status":195,"phases":54717,"primaryCompletion":54718,"completion":54719,"start":54720,"enrollment":1173,"conditions":54721,"interventions":54722},"NCT00163293","Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010\u002FCA-101)",[92],"2009-06-01","2010-04-01","2005-01-01",[16],[10076],{"nctId":54724,"briefTitle":54725,"status":195,"phases":54726,"primaryCompletion":13047,"completion":6517,"start":9944,"enrollment":7302,"conditions":54727,"interventions":54728},"NCT00659503","Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010\u002FM1-407)",[92],[26921,26914],[10076],{"nctId":54730,"briefTitle":54731,"status":195,"phases":54732,"primaryCompletion":6562,"completion":6562,"start":6517,"enrollment":188,"conditions":54733,"interventions":54734},"NCT00261287","Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010\u002FM1-416)",[92],[26914,19561],[10076],{"nctId":54736,"briefTitle":54737,"status":195,"phases":54738,"primaryCompletion":13583,"completion":13583,"start":13575,"enrollment":34724,"conditions":54739,"interventions":54740},"NCT00163514","Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010\u002FM1-403)",[92],[19561,19413,26914],[10076],{"nctId":54742,"briefTitle":54743,"status":195,"phases":54744,"start":9930,"enrollment":1710,"conditions":54745,"interventions":54746},"NCT00163332","Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010\u002FM1-129)",[92],[16],[10076],{"nctId":54748,"briefTitle":54749,"status":195,"phases":54750,"primaryCompletion":7342,"completion":6718,"start":6517,"enrollment":9987,"conditions":54751,"interventions":54752},"NCT00163449","Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010\u002FM1-207)",[92],[16],[10076],{"nctId":25794,"briefTitle":25795,"status":195,"phases":54754,"primaryCompletion":2220,"completion":3827,"start":7494,"enrollment":1543,"conditions":54755,"interventions":54756},[92],[16],[10076,25799],{"nctId":54758,"briefTitle":54759,"status":195,"phases":54760,"primaryCompletion":13583,"completion":13583,"start":6572,"enrollment":2187,"conditions":54761,"interventions":54762},"NCT00163397","Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010\u002FM1-137)",[92],[16],[10076],{"nctId":54764,"briefTitle":54765,"status":195,"phases":54766,"primaryCompletion":7554,"completion":7554,"start":6572,"enrollment":1173,"conditions":54767,"interventions":54768},"NCT00163384","Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010\u002FM1-136)",[92],[16],[10076],{"trials":54770,"activeCount":102},[54771,54777],{"nctId":54772,"briefTitle":54773,"status":195,"phases":54774,"primaryCompletion":2406,"completion":2736,"start":3827,"enrollment":4307,"conditions":54775,"interventions":54776},"NCT00826969","Ciclesonide for the Treatment of Airway Hyperresponsiveness",[93],[16],[10076],{"nctId":22271,"briefTitle":22272,"status":195,"phases":54778,"primaryCompletion":2251,"completion":4915,"start":7342,"enrollment":22274,"conditions":54779,"interventions":54780},[93],[16],[10076,22258],{"trials":54782,"activeCount":102},[54783],{"nctId":54784,"briefTitle":54785,"status":195,"phases":54786,"primaryCompletion":2220,"completion":2220,"start":6710,"enrollment":19880,"conditions":54787,"interventions":54788},"NCT00608218","Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma",[],[16],[10076],{"intervention":20252,"totalTrials":1336,"cells":54790},{"EARLY_PHASE1":54791,"PHASE1":54793,"PHASE2":54795,"PHASE3":54797,"PHASE4":54870,"NA":54893},{"trials":54792,"activeCount":102},[],{"trials":54794,"activeCount":102},[],{"trials":54796,"activeCount":102},[],{"trials":54798,"activeCount":102},[54799,54803,54807,54813,54817,54821,54825,54832,54839,54846,54853,54860,54866],{"nctId":24047,"briefTitle":24048,"status":195,"phases":54800,"primaryCompletion":3228,"completion":3228,"start":2597,"enrollment":24050,"conditions":54801,"interventions":54802},[92],[10066],[24053,20252,24026],{"nctId":24055,"briefTitle":24056,"status":195,"phases":54804,"primaryCompletion":2405,"completion":2405,"start":2571,"enrollment":13767,"conditions":54805,"interventions":54806},[92],[28],[24060,24060,24061,24026],{"nctId":54808,"briefTitle":54809,"status":195,"phases":54810,"primaryCompletion":4915,"completion":3862,"start":2252,"enrollment":922,"conditions":54811,"interventions":54812},"NCT00500318","A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[92],[18651],[24061],{"nctId":24063,"briefTitle":24064,"status":195,"phases":54814,"primaryCompletion":2746,"completion":2746,"start":4496,"enrollment":24066,"conditions":54815,"interventions":54816},[92],[28],[24053,24053,20252,24026],{"nctId":24070,"briefTitle":24071,"status":195,"phases":54818,"primaryCompletion":2579,"completion":2579,"start":2736,"enrollment":24073,"conditions":54819,"interventions":54820},[92],[6083],[24060,24060,24061,24026],{"nctId":20247,"briefTitle":20248,"status":195,"phases":54822,"primaryCompletion":5725,"completion":5725,"start":2328,"enrollment":3755,"conditions":54823,"interventions":54824},[92],[6083],[20252,10026],{"nctId":54826,"briefTitle":54827,"status":195,"phases":54828,"primaryCompletion":2057,"completion":2057,"start":2320,"enrollment":54829,"conditions":54830,"interventions":54831},"NCT00891462","Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)",[92],561,[28],[20252,20252],{"nctId":54833,"briefTitle":54834,"status":195,"phases":54835,"primaryCompletion":2524,"completion":2524,"start":4916,"enrollment":54836,"conditions":54837,"interventions":54838},"NCT00358436","Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)",[92],804,[6083],[20252],{"nctId":54840,"briefTitle":54841,"status":195,"phases":54842,"primaryCompletion":2542,"completion":2542,"start":2077,"enrollment":54843,"conditions":54844,"interventions":54845},"NCT01045161","Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)",[92],544,[28],[20252],{"nctId":54847,"briefTitle":54848,"status":195,"phases":54849,"primaryCompletion":2489,"completion":2489,"start":2151,"enrollment":54850,"conditions":54851,"interventions":54852},"NCT00970268","Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)",[92],291,[28],[20252,20252],{"nctId":54854,"briefTitle":54855,"status":195,"phases":54856,"primaryCompletion":2221,"completion":2221,"start":12905,"enrollment":54857,"conditions":54858,"interventions":54859},"NCT00363896","A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)",[92],843,[6083],[20252],{"nctId":54861,"briefTitle":54862,"status":195,"phases":54863,"primaryCompletion":2471,"completion":2471,"start":4580,"enrollment":8138,"conditions":54864,"interventions":54865},"NCT01471171","Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[92],[6083],[24061],{"nctId":20254,"briefTitle":20255,"status":195,"phases":54867,"primaryCompletion":687,"completion":10063,"start":4580,"enrollment":20257,"conditions":54868,"interventions":54869},[92],[6083],[20252,10026],{"trials":54871,"activeCount":102},[54872,54878,54887],{"nctId":54873,"briefTitle":54874,"status":195,"phases":54875,"primaryCompletion":4005,"completion":4005,"start":7618,"enrollment":1710,"conditions":54876,"interventions":54877},"NCT02153489","A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",[93],[6083],[20252],{"nctId":54879,"briefTitle":54880,"status":195,"phases":54881,"primaryCompletion":30380,"completion":30380,"start":54882,"enrollment":54883,"conditions":54884,"interventions":54886},"NCT01966107","Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.",[93],"2013-10-16",3635,[10066,28,54885],"Moderate to Very Severe COPD",[24061],{"nctId":54888,"briefTitle":54889,"status":195,"phases":54890,"primaryCompletion":20831,"completion":20831,"start":25278,"enrollment":12425,"conditions":54891,"interventions":54892},"NCT02375724","BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH",[93],[18651],[24061],{"trials":54894,"activeCount":102},[54895,54903],{"nctId":54896,"briefTitle":54897,"status":195,"phases":54898,"primaryCompletion":12625,"completion":12625,"start":12675,"enrollment":54899,"conditions":54900,"interventions":54901},"NCT03290287","Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints",[],26839,[18651],[20252,54902],"Other COPD medication",{"nctId":54904,"briefTitle":54905,"status":195,"phases":54906,"primaryCompletion":24916,"completion":24916,"start":54907,"enrollment":54908,"conditions":54909,"interventions":54910},"NCT03333018","A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)",[],"2015-07-06",22155,[18651],[20252,54911,54902],"Aclidinium bromide\u002Fformoterol",{"intervention":22620,"totalTrials":4497,"cells":54913},{"EARLY_PHASE1":54914,"PHASE1":54916,"PHASE2":54928,"PHASE3":54982,"PHASE4":55002,"NA":55014},{"trials":54915,"activeCount":102},[],{"trials":54917,"activeCount":102},[54918,54922],{"nctId":49773,"briefTitle":49774,"status":195,"phases":54919,"primaryCompletion":49776,"completion":49776,"start":49777,"enrollment":17655,"conditions":54920,"interventions":54921},[90],[2369],[49780,49766,49781],{"nctId":54923,"briefTitle":54924,"status":195,"phases":54925,"primaryCompletion":19364,"completion":19364,"start":2104,"enrollment":579,"conditions":54926,"interventions":54927},"NCT01708044","Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM",[90],[31297],[49780],{"trials":54929,"activeCount":102},[54930,54936,54942,54949,54955,54959,54963,54970,54976],{"nctId":54931,"briefTitle":54932,"status":195,"phases":54933,"primaryCompletion":5725,"completion":5725,"start":6369,"enrollment":1757,"conditions":54934,"interventions":54935},"NCT00313183","A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus",[91],[2369],[22620],{"nctId":54937,"briefTitle":54938,"status":195,"phases":54939,"primaryCompletion":5562,"completion":5562,"start":6719,"enrollment":3374,"conditions":54940,"interventions":54941},"NCT00189514","A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects",[91],[12275],[22620],{"nctId":54943,"briefTitle":54944,"status":195,"phases":54945,"primaryCompletion":6499,"completion":6499,"start":7447,"enrollment":1883,"conditions":54946,"interventions":54948},"NCT00042471","Evaluation of the Bioavailability of Pramlintide",[91],[54947,2089],"Diabetes Mellitus, Type 1",[49780],{"nctId":54950,"briefTitle":54951,"status":195,"phases":54952,"primaryCompletion":6517,"completion":6517,"start":7554,"enrollment":1078,"conditions":54953,"interventions":54954},"NCT00112021","A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects",[91],[12275],[22620],{"nctId":34721,"briefTitle":34722,"status":195,"phases":54956,"primaryCompletion":2320,"completion":2350,"start":2251,"enrollment":34724,"conditions":54957,"interventions":54958},[91],[34716,12275],[22620,34703],{"nctId":34858,"briefTitle":34859,"status":195,"phases":54960,"primaryCompletion":5725,"completion":5725,"start":7342,"enrollment":5947,"conditions":54961,"interventions":54962},[91],[34716,12275],[22620,34863,34864],{"nctId":54964,"briefTitle":54965,"status":195,"phases":54966,"primaryCompletion":7554,"completion":7554,"start":9963,"enrollment":54967,"conditions":54968,"interventions":54969},"NCT00444561","Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects",[91],184,[34716,12275],[22620],{"nctId":54971,"briefTitle":54972,"status":195,"phases":54973,"primaryCompletion":6651,"completion":6651,"start":5797,"enrollment":1130,"conditions":54974,"interventions":54975},"NCT00044707","Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide",[91],[24168],[49780],{"nctId":54977,"briefTitle":54978,"status":195,"phases":54979,"primaryCompletion":9075,"completion":9075,"start":3810,"enrollment":5425,"conditions":54980,"interventions":54981},"NCT00042601","Evaluation of the Effect of Pramlintide on Satiety and Food Intake",[91],[54947,2089],[49780],{"trials":54983,"activeCount":102},[54984,54990,54996],{"nctId":54985,"briefTitle":54986,"status":195,"phases":54987,"primaryCompletion":6650,"completion":6650,"start":9909,"enrollment":1078,"conditions":54988,"interventions":54989},"NCT00108004","Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus",[92],[2369,22],[22620],{"nctId":54991,"briefTitle":54992,"status":195,"phases":54993,"primaryCompletion":6650,"completion":6650,"start":9066,"enrollment":8693,"conditions":54994,"interventions":54995},"NCT00107107","Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus",[92],[54947],[22620],{"nctId":54997,"briefTitle":54998,"status":195,"phases":54999,"primaryCompletion":9930,"completion":9930,"start":15911,"enrollment":13802,"conditions":55000,"interventions":55001},"NCT00042458","Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control",[92],[54947],[49780],{"trials":55003,"activeCount":102},[55004,55010],{"nctId":55005,"briefTitle":55006,"status":195,"phases":55007,"primaryCompletion":6562,"completion":6562,"start":3809,"enrollment":1685,"conditions":55008,"interventions":55009},"NCT00240253","A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes",[93],[22],[22620],{"nctId":22615,"briefTitle":22616,"status":195,"phases":55011,"primaryCompletion":2251,"completion":2251,"start":6718,"enrollment":8138,"conditions":55012,"interventions":55013},[93],[22],[22620,22602,18489],{"trials":55015,"activeCount":102},[55016],{"nctId":55017,"briefTitle":55018,"status":195,"phases":55019,"primaryCompletion":2221,"completion":2221,"start":6719,"enrollment":55020,"conditions":55021,"interventions":55022},"NCT00229658","An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes",[],1297,[2369,22],[22620],{"intervention":15934,"totalTrials":486,"cells":55024},{"EARLY_PHASE1":55025,"PHASE1":55027,"PHASE2":55035,"PHASE3":55047,"PHASE4":55110,"NA":55112},{"trials":55026,"activeCount":102},[],{"trials":55028,"activeCount":102},[55029],{"nctId":55030,"briefTitle":55031,"status":195,"phases":55032,"primaryCompletion":2221,"completion":2221,"start":2415,"enrollment":1710,"conditions":55033,"interventions":55034},"NCT00612794","A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes",[90],[31],[15934],{"trials":55036,"activeCount":102},[55037,55043],{"nctId":55038,"briefTitle":55039,"status":195,"phases":55040,"primaryCompletion":2151,"completion":2151,"start":2320,"enrollment":5189,"conditions":55041,"interventions":55042},"NCT00894322","A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension",[90,91],[22],[15934,15934],{"nctId":38731,"briefTitle":38732,"status":195,"phases":55044,"primaryCompletion":2143,"completion":2143,"start":2243,"enrollment":1777,"conditions":55045,"interventions":55046},[91],[31],[15934,38722,38722,38722],{"trials":55048,"activeCount":102},[55049,55056,55062,55066,55076,55080,55084,55088,55096,55106],{"nctId":55050,"briefTitle":55051,"status":195,"phases":55052,"primaryCompletion":3862,"completion":12721,"start":2068,"enrollment":55053,"conditions":55054,"interventions":55055},"NCT00917267","A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects",[92],691,[22],[15934,29576],{"nctId":55057,"briefTitle":55058,"status":195,"phases":55059,"primaryCompletion":2350,"completion":2056,"start":2077,"enrollment":3747,"conditions":55060,"interventions":55061},"NCT00877890","A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",[92],[22],[15934,29576],{"nctId":28262,"briefTitle":28263,"status":195,"phases":55063,"primaryCompletion":6709,"completion":2589,"start":2350,"enrollment":28265,"conditions":55064,"interventions":55065},[92],[22],[15934,28251],{"nctId":55067,"briefTitle":55068,"status":195,"phases":55069,"primaryCompletion":55070,"completion":55071,"start":55072,"enrollment":532,"conditions":55073,"interventions":55075},"NCT01554618","Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes",[92],"2020-05-06","2021-05-05","2011-12-02",[55074],"Children and Adolescent With Type 2 Diabetes",[24329],{"nctId":24323,"briefTitle":24324,"status":195,"phases":55077,"primaryCompletion":688,"completion":2057,"start":2251,"enrollment":24326,"conditions":55078,"interventions":55079},[92],[22],[24329,24330],{"nctId":15928,"briefTitle":15929,"status":195,"phases":55081,"primaryCompletion":2406,"completion":2516,"start":2414,"enrollment":15931,"conditions":55082,"interventions":55083},[92],[22],[15934,2333,15935,15893],{"nctId":15937,"briefTitle":15938,"status":195,"phases":55085,"primaryCompletion":2095,"completion":2068,"start":6710,"enrollment":6573,"conditions":55086,"interventions":55087},[92],[22],[15934,15935,15893],{"nctId":55089,"briefTitle":55090,"status":195,"phases":55091,"primaryCompletion":2516,"completion":12721,"start":2056,"enrollment":55092,"conditions":55093,"interventions":55094},"NCT01029886","Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes",[92],912,[22],[15934,55095],"liraglutide",{"nctId":55097,"briefTitle":55098,"status":195,"phases":55099,"primaryCompletion":55100,"completion":55101,"start":55102,"enrollment":55103,"conditions":55104,"interventions":55105},"NCT01144338","Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus",[92],"2017-04-21","2017-04-24","2010-06-18",14752,[22],[24329],{"nctId":24336,"briefTitle":24337,"status":195,"phases":55107,"primaryCompletion":3862,"completion":6709,"start":2068,"enrollment":24339,"conditions":55108,"interventions":55109},[92],[22],[15934,18458],{"trials":55111,"activeCount":102},[],{"trials":55113,"activeCount":102},[55114,55121,55129],{"nctId":55115,"briefTitle":55116,"status":195,"phases":55117,"primaryCompletion":35812,"completion":35812,"start":35812,"enrollment":55118,"conditions":55119,"interventions":55120},"NCT02974244","Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins",[],7000,[31],[15934,18489],{"nctId":55122,"briefTitle":55123,"status":195,"phases":55124,"primaryCompletion":55125,"completion":55125,"start":55125,"enrollment":55126,"conditions":55127,"interventions":55128},"NCT02987348","Clinical Outcomes of Exenatide Versus Basal Insulin",[],"2015-06-30",18000,[31],[15934,29576,18489],{"nctId":55130,"briefTitle":55131,"status":195,"phases":55132,"primaryCompletion":55133,"completion":55133,"start":55133,"enrollment":55134,"conditions":55135,"interventions":55136},"NCT02917057","Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment",[],"2015-08-01",6024,[31],[15934,18489],{"intervention":5257,"totalTrials":1757,"cells":55138},{"EARLY_PHASE1":55139,"PHASE1":55141,"PHASE2":55177,"PHASE3":55207,"PHASE4":55213,"NA":55215},{"trials":55140,"activeCount":102},[],{"trials":55142,"activeCount":102},[55143,55151,55159,55163,55167,55173],{"nctId":55144,"briefTitle":55145,"status":195,"phases":55146,"primaryCompletion":55147,"completion":55147,"start":55148,"enrollment":1348,"conditions":55149,"interventions":55150},"NCT01951599","To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.",[90],"2014-06-04","2013-10-09",[36],[5257,5257,5257,5257,5257],{"nctId":55152,"briefTitle":55153,"status":195,"phases":55154,"primaryCompletion":55155,"completion":49443,"start":55156,"enrollment":3717,"conditions":55157,"interventions":55158},"NCT02163733","Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer",[90],"2015-03-24","2014-11-14",[16355,16356],[5257],{"nctId":16348,"briefTitle":16349,"status":195,"phases":55160,"primaryCompletion":16351,"completion":16352,"start":16353,"enrollment":3190,"conditions":55161,"interventions":55162},[90],[16355,16356],[5257,5911],{"nctId":50214,"briefTitle":50215,"status":195,"phases":55164,"primaryCompletion":20965,"completion":20965,"start":24772,"enrollment":2003,"conditions":55165,"interventions":55166},[90],[50218],[5257,50207],{"nctId":55168,"briefTitle":55169,"status":195,"phases":55170,"primaryCompletion":2560,"completion":2560,"start":2203,"enrollment":370,"conditions":55171,"interventions":55172},"NCT02096679","Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers",[90],[36],[5257],{"nctId":53088,"briefTitle":53089,"status":195,"phases":55174,"primaryCompletion":53091,"completion":5529,"start":53092,"enrollment":1373,"conditions":55175,"interventions":55176},[90],[53094],[53081,5257],{"trials":55178,"activeCount":102},[55179,55187,55194,55198],{"nctId":55180,"briefTitle":55181,"status":195,"phases":55182,"primaryCompletion":55183,"completion":232,"start":55184,"enrollment":2367,"conditions":55185,"interventions":55186},"NCT02442349","Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific",[91],"2016-03-04","2015-06-22",[262],[5257],{"nctId":55188,"briefTitle":55189,"status":195,"phases":55190,"primaryCompletion":55191,"completion":988,"start":37635,"enrollment":3374,"conditions":55192,"interventions":55193},"NCT02094261","Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours",[91],"2015-05-01",[3864],[5257],{"nctId":5249,"briefTitle":5250,"status":195,"phases":55195,"primaryCompletion":5252,"completion":5252,"start":5253,"enrollment":579,"conditions":55196,"interventions":55197},[91],[5255],[1013,5257,5258,3137],{"nctId":55199,"briefTitle":55200,"status":195,"phases":55201,"primaryCompletion":55191,"completion":55202,"start":55203,"enrollment":55204,"conditions":55205,"interventions":55206},"NCT01802632","AZD9291 First Time In Patients Ascending Dose Study",[90,91],"2023-12-11","2013-03-04",603,[16355,16356],[5257],{"trials":55208,"activeCount":102},[55209],{"nctId":8181,"briefTitle":8182,"status":195,"phases":55210,"primaryCompletion":1775,"completion":3189,"start":8184,"enrollment":8185,"conditions":55211,"interventions":55212},[92],[8187],[5257,82],{"trials":55214,"activeCount":102},[],{"trials":55216,"activeCount":102},[55217],{"nctId":55218,"briefTitle":55219,"status":950,"phases":55220,"conditions":55221,"interventions":55223},"NCT02451852","AZD9291 US Expanded Access Program",[],[55222],"EGFR T790M Mutation Positive NSCLC",[5257],{"intervention":20401,"totalTrials":2222,"cells":55225},{"EARLY_PHASE1":55226,"PHASE1":55228,"PHASE2":55243,"PHASE3":55245,"PHASE4":55282,"NA":55292},{"trials":55227,"activeCount":102},[],{"trials":55229,"activeCount":102},[55230,55236],{"nctId":55231,"briefTitle":55232,"status":195,"phases":55233,"primaryCompletion":2152,"completion":2152,"start":2077,"enrollment":496,"conditions":55234,"interventions":55235},"NCT00844324","Bioequivalence Study in Healthy Subjects",[90],[2620],[20375,20375],{"nctId":55237,"briefTitle":55238,"status":195,"phases":55239,"primaryCompletion":2414,"completion":2414,"start":2086,"enrollment":496,"conditions":55240,"interventions":55241},"NCT00905333","Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal",[90],[19],[20556,55242,20401,55242],"Felodipine",{"trials":55244,"activeCount":102},[],{"trials":55246,"activeCount":102},[55247,55251,55259,55266,55272,55276],{"nctId":20369,"briefTitle":20370,"status":195,"phases":55248,"primaryCompletion":5725,"completion":4297,"start":5563,"enrollment":20372,"conditions":55249,"interventions":55250},[92],[2620],[20375,2353,2353],{"nctId":55252,"briefTitle":55253,"status":195,"phases":55254,"completion":5742,"start":9909,"enrollment":19799,"conditions":55255,"interventions":55257},"NCT00242346","High Doses of Candesartan Cilexetil on the Reduction of Proteinuria",[92],[55256],"Proteinuria",[55258],"candesartan cilexetil",{"nctId":55260,"briefTitle":55261,"status":195,"phases":55262,"primaryCompletion":2251,"completion":2251,"start":9089,"enrollment":55263,"conditions":55264,"interventions":55265},"NCT00252733","Diabetic Retinopathy Candesartan Trials",[92],5238,[31297],[55258],{"nctId":55267,"briefTitle":55268,"status":195,"phases":55269,"primaryCompletion":2220,"completion":2220,"start":4264,"enrollment":29,"conditions":55270,"interventions":55271},"NCT00244621","Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age",[92],[2620],[55258,55258,55258],{"nctId":20385,"briefTitle":20386,"status":195,"phases":55273,"primaryCompletion":6710,"completion":6710,"start":13014,"enrollment":20388,"conditions":55274,"interventions":55275},[92],[2620],[20375,2353,20391],{"nctId":55277,"briefTitle":55278,"status":195,"phases":55279,"primaryCompletion":2067,"completion":2067,"start":2415,"enrollment":1348,"conditions":55280,"interventions":55281},"NCT00690612","Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to\u003C11 Years (Hypertension in Pediatrics)",[92],[2620],[55258],{"trials":55283,"activeCount":102},[55284,55288],{"nctId":22337,"briefTitle":22338,"status":195,"phases":55285,"primaryCompletion":2151,"completion":2151,"start":4298,"enrollment":589,"conditions":55286,"interventions":55287},[93],[22341],[20401,20401,22324],{"nctId":20395,"briefTitle":20396,"status":195,"phases":55289,"primaryCompletion":2077,"completion":2077,"start":2168,"enrollment":3524,"conditions":55290,"interventions":55291},[93],[20399],[20401,2353,20401],{"trials":55293,"activeCount":102},[55294],{"nctId":55295,"briefTitle":55296,"status":195,"phases":55297,"primaryCompletion":2095,"completion":2095,"start":2580,"enrollment":55298,"conditions":55299,"interventions":55300},"NCT00620178","Atacand (Candesartan) Real Life Study",[],14000,[2620],[20401,55301],"Losartan",{"intervention":20556,"totalTrials":4343,"cells":55303},{"EARLY_PHASE1":55304,"PHASE1":55306,"PHASE2":55312,"PHASE3":55314,"PHASE4":55350,"NA":55363},{"trials":55305,"activeCount":102},[],{"trials":55307,"activeCount":102},[55308],{"nctId":55237,"briefTitle":55238,"status":195,"phases":55309,"primaryCompletion":2414,"completion":2414,"start":2086,"enrollment":496,"conditions":55310,"interventions":55311},[90],[19],[20556,55242,20401,55242],{"trials":55313,"activeCount":102},[],{"trials":55315,"activeCount":102},[55316,55323,55331,55337,55344],{"nctId":55317,"briefTitle":55318,"status":195,"phases":55319,"primaryCompletion":4299,"completion":4299,"start":7430,"enrollment":55320,"conditions":55321,"interventions":55322},"NCT00634400","Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)",[92],6268,[37391],[20556],{"nctId":55324,"briefTitle":55325,"status":195,"phases":55326,"primaryCompletion":2168,"completion":2251,"start":31111,"enrollment":55327,"conditions":55328,"interventions":55329},"NCT00252694","DIabetic Retinopathy Candesartan Trials",[92],4717,[31],[55330],"candesartan",{"nctId":55332,"briefTitle":55333,"status":195,"phases":55334,"primaryCompletion":2168,"completion":2251,"start":31111,"enrollment":18537,"conditions":55335,"interventions":55336},"NCT00252720","DIabetic Retinopathy Candesartan Trials.",[92],[31297],[55330],{"nctId":55338,"briefTitle":55339,"status":195,"phases":55340,"primaryCompletion":4299,"completion":4299,"start":55341,"enrollment":2497,"conditions":55342,"interventions":55343},"NCT00634309","Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)",[92],"1999-06",[37391],[20556],{"nctId":55345,"briefTitle":55346,"status":195,"phases":55347,"primaryCompletion":4299,"completion":4299,"start":55341,"enrollment":24181,"conditions":55348,"interventions":55349},"NCT00634712","Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)",[92],[37391],[20556],{"trials":55351,"activeCount":102},[55352,55359],{"nctId":55353,"briefTitle":55354,"status":195,"phases":55355,"primaryCompletion":2524,"completion":2524,"start":6562,"enrollment":2472,"conditions":55356,"interventions":55358},"NCT00348686","Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)",[93],[2620,55357],"Left Ventricular Hypertrophy",[20556,20556,55242,55242],{"nctId":20543,"briefTitle":20544,"status":195,"phases":55360,"primaryCompletion":7544,"completion":7544,"start":2639,"enrollment":2866,"conditions":55361,"interventions":55362},[93],[1520,20547],[20549,20550,12175,20551,20552,20553,20554,20555,20556,12176,20557,20558,20559,20560],{"trials":55364,"activeCount":102},[55365],{"nctId":55366,"briefTitle":55367,"status":195,"phases":55368,"primaryCompletion":2242,"completion":2406,"start":6710,"enrollment":170,"conditions":55369,"interventions":55371},"NCT00679640","Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France",[],[1520,55370],"Cohort Study",[20556],{"intervention":38570,"totalTrials":370,"cells":55373},{"EARLY_PHASE1":55374,"PHASE1":55376,"PHASE2":55396,"PHASE3":55422,"PHASE4":55424,"NA":55426},{"trials":55375,"activeCount":102},[],{"trials":55377,"activeCount":102},[55378,55384,55390],{"nctId":55379,"briefTitle":55380,"status":195,"phases":55381,"primaryCompletion":2055,"completion":2055,"start":2151,"enrollment":579,"conditions":55382,"interventions":55383},"NCT00970775","AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects",[90],[31837],[38570],{"nctId":55385,"briefTitle":55386,"status":195,"phases":55387,"primaryCompletion":2570,"completion":2570,"start":2349,"enrollment":3855,"conditions":55388,"interventions":55389},"NCT01233830","Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Japanese Volunteers",[90],[19],[38570],{"nctId":55391,"briefTitle":55392,"status":195,"phases":55393,"primaryCompletion":2057,"completion":2057,"start":2068,"enrollment":1395,"conditions":55394,"interventions":55395},"NCT00940212","Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers",[90],[36],[38570],{"trials":55397,"activeCount":102},[55398,55404,55410,55414],{"nctId":55399,"briefTitle":55400,"status":195,"phases":55401,"primaryCompletion":2570,"completion":2570,"start":2489,"enrollment":18686,"conditions":55402,"interventions":55403},"NCT01215279","AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)",[91],[28,31984],[38570],{"nctId":55405,"briefTitle":55406,"status":195,"phases":55407,"primaryCompletion":2542,"completion":2542,"start":3862,"enrollment":1666,"conditions":55408,"interventions":55409},"NCT01201317","A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy",[91],[31798],[38570,38570],{"nctId":38565,"briefTitle":38566,"status":195,"phases":55411,"primaryCompletion":6709,"completion":6709,"start":2489,"enrollment":34,"conditions":55412,"interventions":55413},[91],[28,31984],[38570,38556],{"nctId":55415,"briefTitle":55416,"status":195,"phases":55417,"primaryCompletion":4496,"completion":4496,"start":2489,"enrollment":55418,"conditions":55419,"interventions":55421},"NCT01200524","A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..",[91],133,[55420],"Nerve Pain",[38570,38570],{"trials":55423,"activeCount":102},[],{"trials":55425,"activeCount":102},[],{"trials":55427,"activeCount":102},[55428],{"nctId":55429,"briefTitle":55430,"status":195,"phases":55431,"primaryCompletion":2143,"completion":2143,"start":2349,"enrollment":1039,"conditions":55432,"interventions":55434},"NCT01223014","Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers",[],[55433],"Neuroscience",[38570],{"intervention":7385,"totalTrials":370,"cells":55436},{"EARLY_PHASE1":55437,"PHASE1":55439,"PHASE2":55441,"PHASE3":55447,"PHASE4":55485,"NA":55491},{"trials":55438,"activeCount":102},[],{"trials":55440,"activeCount":102},[],{"trials":55442,"activeCount":102},[55443],{"nctId":7377,"briefTitle":7378,"status":195,"phases":55444,"primaryCompletion":7380,"completion":7381,"start":7382,"enrollment":1638,"conditions":55445,"interventions":55446},[91],[6486],[7385,120],{"trials":55448,"activeCount":102},[55449,55457,55461,55468,55477],{"nctId":55450,"briefTitle":55451,"status":195,"phases":55452,"completion":2220,"start":55453,"enrollment":55454,"conditions":55455,"interventions":55456},"NCT00672282","Casodex vs Placebo in Non-Metastatic Early Prostate Cancer",[92],"1995-10",1218,[35165],[7385],{"nctId":9121,"briefTitle":9122,"status":195,"phases":55458,"primaryCompletion":4297,"completion":4297,"start":9124,"enrollment":1120,"conditions":55459,"interventions":55460},[92],[416],[7385,468],{"nctId":55462,"briefTitle":55463,"status":195,"phases":55464,"primaryCompletion":2746,"completion":2746,"start":55465,"enrollment":3645,"conditions":55466,"interventions":55467},"NCT00846976","Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer",[92],"1994-12",[416],[7385],{"nctId":55469,"briefTitle":55470,"status":195,"phases":55471,"primaryCompletion":2507,"completion":2220,"start":55472,"enrollment":55473,"conditions":55474,"interventions":55476},"NCT00657904","Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer",[92],"1995-08",3618,[55475],"Non-metastatic Prostate Cancer",[7385],{"nctId":55478,"briefTitle":55479,"status":195,"phases":55480,"primaryCompletion":2220,"completion":2220,"start":55481,"enrollment":55482,"conditions":55483,"interventions":55484},"NCT00673205","(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer",[92],"1995-09",3588,[35165],[7385],{"trials":55486,"activeCount":102},[55487],{"nctId":21852,"briefTitle":21853,"status":624,"phases":55488,"start":9963,"enrollment":520,"conditions":55489,"interventions":55490},[93],[1937],[21839,7385],{"trials":55492,"activeCount":102},[55493],{"nctId":55494,"briefTitle":55495,"status":950,"phases":55496,"conditions":55497,"interventions":55499},"NCT00636259","Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer",[],[55498],"Adenocarcinoma of the Prostate",[7385],{"intervention":4334,"totalTrials":1855,"cells":55501},{"EARLY_PHASE1":55502,"PHASE1":55504,"PHASE2":55510,"PHASE3":55523,"PHASE4":55539,"NA":55541},{"trials":55503,"activeCount":102},[],{"trials":55505,"activeCount":102},[55506],{"nctId":31396,"briefTitle":31397,"status":195,"phases":55507,"primaryCompletion":6562,"completion":6562,"start":9963,"enrollment":5189,"conditions":55508,"interventions":55509},[90],[31400],[3830,4334],{"trials":55511,"activeCount":102},[55512,55519],{"nctId":55513,"briefTitle":55514,"status":195,"phases":55515,"primaryCompletion":2251,"completion":2251,"start":6780,"enrollment":554,"conditions":55516,"interventions":55518},"NCT00787410","An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma",[91],[55517],"Mesothelioma",[4334],{"nctId":4328,"briefTitle":4329,"status":195,"phases":55520,"primaryCompletion":2087,"completion":2087,"start":4331,"enrollment":496,"conditions":55521,"interventions":55522},[91],[408],[4334,369,177],{"trials":55524,"activeCount":102},[55525,55531],{"nctId":55526,"briefTitle":55527,"status":624,"phases":55528,"primaryCompletion":2169,"completion":2169,"start":4284,"enrollment":102,"conditions":55529,"interventions":55530},"NCT00090675","Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer",[92],[6695],[4334],{"nctId":55532,"briefTitle":55533,"status":195,"phases":55534,"primaryCompletion":9075,"completion":9075,"start":26689,"conditions":55535,"interventions":55538},"NCT00034879","Iressa Expanded Access Program (EAP)",[92],[4058,55536,55537,17614],"Non-small-cell Lung","Metastases",[4334],{"trials":55540,"activeCount":102},[],{"trials":55542,"activeCount":102},[55543,55550],{"nctId":55544,"briefTitle":55545,"status":958,"phases":55546,"conditions":55547,"interventions":55549},"NCT00684385","An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck",[],[3864,55548],"Cancer of the Head and Neck",[4334],{"nctId":55551,"briefTitle":55552,"status":958,"phases":55553,"conditions":55554,"interventions":55555},"NCT00683306","Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment",[],[5503],[4334],{"intervention":26977,"totalTrials":1039,"cells":55557},{"EARLY_PHASE1":55558,"PHASE1":55560,"PHASE2":55562,"PHASE3":55564,"PHASE4":55570,"NA":55572},{"trials":55559,"activeCount":102},[],{"trials":55561,"activeCount":102},[],{"trials":55563,"activeCount":102},[],{"trials":55565,"activeCount":102},[55566],{"nctId":26970,"briefTitle":26971,"status":195,"phases":55567,"primaryCompletion":26973,"completion":26973,"start":26974,"enrollment":554,"conditions":55568,"interventions":55569},[92],[6083],[26977,26959],{"trials":55571,"activeCount":102},[],{"trials":55573,"activeCount":102},[55574,55581,55588,55598,55607],{"nctId":55575,"briefTitle":55576,"status":195,"phases":55577,"primaryCompletion":55578,"completion":55578,"start":2375,"enrollment":10196,"conditions":55579,"interventions":55580},"NCT05862545","Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide \u002F Glycopyrronium \u002F Formoterol)",[],"2025-05-31",[28],[26977],{"nctId":55582,"briefTitle":55583,"status":195,"phases":55584,"primaryCompletion":6186,"completion":6186,"start":3053,"enrollment":55585,"conditions":55586,"interventions":55587},"NCT06742736","EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)",[],13000,[18651],[26977],{"nctId":55589,"briefTitle":55590,"status":195,"phases":55591,"primaryCompletion":55592,"completion":55592,"start":55593,"enrollment":23038,"conditions":55594,"interventions":55597},"NCT06514144","Exacerbations Among Patients Receiving Breztri (EROS Study)",[],"2023-03-07","2022-10-01",[54564,55595,55596],"Chronic Obstructive","Retrospective Studies",[26977],{"nctId":55599,"briefTitle":55600,"status":195,"phases":55601,"primaryCompletion":55602,"completion":55602,"start":10141,"enrollment":55603,"conditions":55604,"interventions":55605},"NCT06744374","A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)",[],"2024-03-30",22369,[18651],[26977,55606],"MITT",{"nctId":55608,"briefTitle":55609,"status":195,"phases":55610,"primaryCompletion":10240,"completion":10240,"start":15574,"enrollment":55611,"conditions":55612,"interventions":55613},"NCT07103642","EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)",[],3402,[18651],[26977],{"intervention":28750,"totalTrials":1039,"cells":55615},{"EARLY_PHASE1":55616,"PHASE1":55618,"PHASE2":55620,"PHASE3":55626,"PHASE4":55648,"NA":55657},{"trials":55617,"activeCount":102},[],{"trials":55619,"activeCount":102},[],{"trials":55621,"activeCount":102},[55622],{"nctId":36312,"briefTitle":36313,"status":195,"phases":55623,"primaryCompletion":32552,"completion":32552,"start":36315,"enrollment":872,"conditions":55624,"interventions":55625},[90,91],[1387],[28750,36303],{"trials":55627,"activeCount":102},[55628,55637,55644],{"nctId":55629,"briefTitle":55630,"status":195,"phases":55631,"primaryCompletion":55632,"completion":55633,"start":1346,"enrollment":55634,"conditions":55635,"interventions":55636},"NCT04516746","Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",[92],"2021-03-05","2023-02-10",32450,[1387,23927],[28750],{"nctId":55638,"briefTitle":55639,"status":624,"phases":55640,"primaryCompletion":55641,"completion":8953,"start":46618,"enrollment":102,"conditions":55642,"interventions":55643},"NCT04540393","AZD1222 Vaccine for the Prevention of COVID-19",[92],"2020-12-04",[1387],[28750],{"nctId":28741,"briefTitle":28742,"status":195,"phases":55645,"primaryCompletion":28744,"completion":28745,"start":28746,"enrollment":28747,"conditions":55646,"interventions":55647},[91,92],[1387,23927],[28750,28730],{"trials":55649,"activeCount":102},[55650],{"nctId":55651,"briefTitle":55652,"status":443,"phases":55653,"primaryCompletion":6890,"completion":6890,"start":55654,"enrollment":17655,"conditions":55655,"interventions":55656},"NCT05057897","A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults",[93],"2022-01-31",[25021],[28750],{"trials":55658,"activeCount":102},[55659],{"nctId":55660,"briefTitle":55661,"status":195,"phases":55662,"primaryCompletion":55663,"completion":55663,"start":3674,"enrollment":55664,"conditions":55665,"interventions":55667},"NCT05126992","EU Secondary Data Post-Authorisation Safety Study of AZD1222",[],"2024-01-24",5321930,[55666],"COVID-19, Vaccine Adverse Events of Special Interest",[28750],{"intervention":19501,"totalTrials":1039,"cells":55669},{"EARLY_PHASE1":55670,"PHASE1":55672,"PHASE2":55674,"PHASE3":55676,"PHASE4":55686,"NA":55699},{"trials":55671,"activeCount":102},[],{"trials":55673,"activeCount":102},[],{"trials":55675,"activeCount":102},[],{"trials":55677,"activeCount":102},[55678,55682],{"nctId":19496,"briefTitle":19497,"status":195,"phases":55679,"primaryCompletion":2105,"completion":2105,"start":4580,"enrollment":3524,"conditions":55680,"interventions":55681},[92],[16],[19501,19501,9972],{"nctId":30399,"briefTitle":30400,"status":195,"phases":55683,"primaryCompletion":10048,"completion":10048,"start":30402,"enrollment":30403,"conditions":55684,"interventions":55685},[92],[30405],[19501,30388],{"trials":55687,"activeCount":102},[55688,55692],{"nctId":20884,"briefTitle":20885,"status":195,"phases":55689,"primaryCompletion":2524,"completion":2524,"start":6718,"enrollment":1806,"conditions":55690,"interventions":55691},[93],[20888],[19501,20890],{"nctId":55693,"briefTitle":55694,"status":195,"phases":55695,"primaryCompletion":2144,"completion":2144,"start":2068,"enrollment":55696,"conditions":55697,"interventions":55698},"NCT00939341","Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia",[93],862,[16],[19501],{"trials":55700,"activeCount":102},[55701,55707],{"nctId":55702,"briefTitle":55703,"status":195,"phases":55704,"primaryCompletion":2221,"completion":2221,"start":2169,"enrollment":4546,"conditions":55705,"interventions":55706},"NCT00573222","Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma",[],[16],[19501],{"nctId":55708,"briefTitle":55709,"status":195,"phases":55710,"completion":5725,"start":5563,"enrollment":18166,"conditions":55711,"interventions":55713},"NCT00812682","Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler",[],[55712],"Perception of Physicians & Patients of AMD",[19501],{"intervention":29576,"totalTrials":723,"cells":55715},{"EARLY_PHASE1":55716,"PHASE1":55718,"PHASE2":55720,"PHASE3":55722,"PHASE4":55740,"NA":55742},{"trials":55717,"activeCount":102},[],{"trials":55719,"activeCount":102},[],{"trials":55721,"activeCount":102},[],{"trials":55723,"activeCount":102},[55724,55728,55732,55736],{"nctId":55050,"briefTitle":55051,"status":195,"phases":55725,"primaryCompletion":3862,"completion":12721,"start":2068,"enrollment":55053,"conditions":55726,"interventions":55727},[92],[22],[15934,29576],{"nctId":55057,"briefTitle":55058,"status":195,"phases":55729,"primaryCompletion":2350,"completion":2056,"start":2077,"enrollment":3747,"conditions":55730,"interventions":55731},[92],[22],[15934,29576],{"nctId":29571,"briefTitle":29572,"status":195,"phases":55733,"primaryCompletion":2152,"completion":2152,"start":2328,"enrollment":23672,"conditions":55734,"interventions":55735},[92],[22],[29576,29560],{"nctId":26656,"briefTitle":26657,"status":195,"phases":55737,"primaryCompletion":2560,"completion":2560,"start":2579,"enrollment":12292,"conditions":55738,"interventions":55739},[92],[2089],[19702,26661],{"trials":55741,"activeCount":102},[],{"trials":55743,"activeCount":102},[55744],{"nctId":55122,"briefTitle":55123,"status":195,"phases":55745,"primaryCompletion":55125,"completion":55125,"start":55125,"enrollment":55126,"conditions":55746,"interventions":55747},[],[31],[15934,29576,18489],{"intervention":55749,"totalTrials":723,"cells":55750},"EVUSHELD",{"EARLY_PHASE1":55751,"PHASE1":55753,"PHASE2":55755,"PHASE3":55757,"PHASE4":55759,"NA":55761},{"trials":55752,"activeCount":102},[],{"trials":55754,"activeCount":102},[],{"trials":55756,"activeCount":102},[],{"trials":55758,"activeCount":102},[],{"trials":55760,"activeCount":102},[],{"trials":55762,"activeCount":102},[55763,55773,55783,55790,55798],{"nctId":55764,"briefTitle":55765,"status":195,"phases":55766,"primaryCompletion":55767,"completion":55767,"start":55768,"enrollment":55769,"conditions":55770,"interventions":55772},"NCT05667116","eVusheld Assessment reaL wORld Effectiveness at UPMC",[],"2023-07-24","2023-01-09",4232,[55771],"SARS-CoV-2, COVID-19",[55749],{"nctId":55774,"briefTitle":55775,"status":195,"phases":55776,"primaryCompletion":55777,"completion":55777,"start":55778,"enrollment":55779,"conditions":55780,"interventions":55781},"NCT05663957","eVusheld Assessment reaL wORld Effectiveness in the VA Health System",[],"2023-09-01","2023-01-04",5814,[55771],[55782],"Evusheld",{"nctId":55784,"briefTitle":55785,"status":195,"phases":55786,"primaryCompletion":8301,"completion":8301,"start":5416,"enrollment":55787,"conditions":55788,"interventions":55789},"NCT05712096","eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services",[],4000,[23927,1387],[55749],{"nctId":55791,"briefTitle":55792,"status":195,"phases":55793,"primaryCompletion":27231,"completion":27231,"start":1839,"enrollment":55794,"conditions":55795,"interventions":55797},"NCT05569408","eVusheld Assessment reaL wORld Effectiveness in DoD Health System",[],4724,[55796],"COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease",[55749],{"nctId":55799,"briefTitle":55800,"status":195,"phases":55801,"primaryCompletion":55802,"completion":55802,"start":55803,"enrollment":24582,"conditions":55804,"interventions":55805},"NCT06156982","An Observational Study to Describe EVUSHELD™ (Tixagevimab\u002FCilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan",[],"2024-01-09","2023-12-06",[1387],[55782],{"intervention":18489,"totalTrials":723,"cells":55807},{"EARLY_PHASE1":55808,"PHASE1":55810,"PHASE2":55812,"PHASE3":55814,"PHASE4":55816,"NA":55822},{"trials":55809,"activeCount":102},[],{"trials":55811,"activeCount":102},[],{"trials":55813,"activeCount":102},[],{"trials":55815,"activeCount":102},[],{"trials":55817,"activeCount":102},[55818],{"nctId":22615,"briefTitle":22616,"status":195,"phases":55819,"primaryCompletion":2251,"completion":2251,"start":6718,"enrollment":8138,"conditions":55820,"interventions":55821},[93],[22],[22620,22602,18489],{"trials":55823,"activeCount":102},[55824,55828,55832,55836],{"nctId":55115,"briefTitle":55116,"status":195,"phases":55825,"primaryCompletion":35812,"completion":35812,"start":35812,"enrollment":55118,"conditions":55826,"interventions":55827},[],[31],[15934,18489],{"nctId":55122,"briefTitle":55123,"status":195,"phases":55829,"primaryCompletion":55125,"completion":55125,"start":55125,"enrollment":55126,"conditions":55830,"interventions":55831},[],[31],[15934,29576,18489],{"nctId":18483,"briefTitle":18484,"status":195,"phases":55833,"primaryCompletion":10063,"completion":10063,"start":2113,"enrollment":18486,"conditions":55834,"interventions":55835},[],[22],[18239,18489],{"nctId":55130,"briefTitle":55131,"status":195,"phases":55837,"primaryCompletion":55133,"completion":55133,"start":55133,"enrollment":55134,"conditions":55838,"interventions":55839},[],[31],[15934,18489],{"intervention":55242,"totalTrials":3887,"cells":55841},{"EARLY_PHASE1":55842,"PHASE1":55844,"PHASE2":55850,"PHASE3":55852,"PHASE4":55854,"NA":55860},{"trials":55843,"activeCount":102},[],{"trials":55845,"activeCount":102},[55846],{"nctId":55237,"briefTitle":55238,"status":195,"phases":55847,"primaryCompletion":2414,"completion":2414,"start":2086,"enrollment":496,"conditions":55848,"interventions":55849},[90],[19],[20556,55242,20401,55242],{"trials":55851,"activeCount":102},[],{"trials":55853,"activeCount":102},[],{"trials":55855,"activeCount":102},[55856],{"nctId":55353,"briefTitle":55354,"status":195,"phases":55857,"primaryCompletion":2524,"completion":2524,"start":6562,"enrollment":2472,"conditions":55858,"interventions":55859},[93],[2620,55357],[20556,20556,55242,55242],{"trials":55861,"activeCount":102},[55862],{"nctId":55863,"briefTitle":55864,"status":195,"phases":55865,"primaryCompletion":6562,"completion":4916,"start":2329,"enrollment":55866,"conditions":55867,"interventions":55868},"NCT02336607","The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.",[94],529,[2620],[55869,55870,55242,55242],"Felodipine tablet (Plendil) alone","Felodipine tablet (Plendil)+Hydrochlorothiazide",{"intervention":39369,"totalTrials":3887,"cells":55872},{"EARLY_PHASE1":55873,"PHASE1":55875,"PHASE2":55877,"PHASE3":55883,"PHASE4":55889,"NA":55891},{"trials":55874,"activeCount":102},[],{"trials":55876,"activeCount":102},[],{"trials":55878,"activeCount":102},[55879],{"nctId":39360,"briefTitle":39361,"status":195,"phases":55880,"primaryCompletion":39363,"completion":24736,"start":25583,"enrollment":39364,"conditions":55881,"interventions":55882},[91],[2089],[39351,39367,39368,39369],{"trials":55884,"activeCount":102},[55885],{"nctId":55089,"briefTitle":55090,"status":195,"phases":55886,"primaryCompletion":2516,"completion":12721,"start":2056,"enrollment":55092,"conditions":55887,"interventions":55888},[92],[22],[15934,55095],{"trials":55890,"activeCount":102},[],{"trials":55892,"activeCount":102},[55893],{"nctId":54348,"briefTitle":54349,"status":195,"phases":55894,"primaryCompletion":7681,"completion":7681,"start":54351,"enrollment":54352,"conditions":55895,"interventions":55896},[],[22],[54355,54356,39369,2108,54357],{"intervention":54902,"totalTrials":447,"cells":55898},{"EARLY_PHASE1":55899,"PHASE1":55901,"PHASE2":55903,"PHASE3":55905,"PHASE4":55907,"NA":55909},{"trials":55900,"activeCount":102},[],{"trials":55902,"activeCount":102},[],{"trials":55904,"activeCount":102},[],{"trials":55906,"activeCount":102},[],{"trials":55908,"activeCount":102},[],{"trials":55910,"activeCount":102},[55911,55915],{"nctId":54896,"briefTitle":54897,"status":195,"phases":55912,"primaryCompletion":12625,"completion":12625,"start":12675,"enrollment":54899,"conditions":55913,"interventions":55914},[],[18651],[20252,54902],{"nctId":54904,"briefTitle":54905,"status":195,"phases":55916,"primaryCompletion":24916,"completion":24916,"start":54907,"enrollment":54908,"conditions":55917,"interventions":55918},[],[18651],[20252,54911,54902],{"intervention":55920,"totalTrials":447,"cells":55921},"EGFR mutation test",{"EARLY_PHASE1":55922,"PHASE1":55924,"PHASE2":55926,"PHASE3":55928,"PHASE4":55930,"NA":55936},{"trials":55923,"activeCount":102},[],{"trials":55925,"activeCount":102},[],{"trials":55927,"activeCount":102},[],{"trials":55929,"activeCount":102},[],{"trials":55931,"activeCount":102},[55932],{"nctId":21407,"briefTitle":21408,"status":195,"phases":55933,"primaryCompletion":2113,"completion":2113,"start":2151,"enrollment":3209,"conditions":55934,"interventions":55935},[93],[1049],[21412,21394],{"trials":55937,"activeCount":102},[55938],{"nctId":55939,"briefTitle":55940,"status":195,"phases":55941,"primaryCompletion":55942,"completion":55943,"start":55944,"enrollment":12741,"conditions":55945,"interventions":55947},"NCT01788163","Asia Pacific and Russia Diagnostic Study for EGFR Testing",[94],"2014-08-25","2016-06-20","2013-02-27",[55946],"EGFR Mutation Status in aNSCLC Patients",[55920],{"intervention":55949,"totalTrials":447,"cells":55950},"Daxas",{"EARLY_PHASE1":55951,"PHASE1":55953,"PHASE2":55955,"PHASE3":55957,"PHASE4":55959,"NA":55961},{"trials":55952,"activeCount":102},[],{"trials":55954,"activeCount":102},[],{"trials":55956,"activeCount":102},[],{"trials":55958,"activeCount":102},[],{"trials":55960,"activeCount":102},[],{"trials":55962,"activeCount":102},[55963,55971],{"nctId":55964,"briefTitle":55965,"status":195,"phases":55966,"primaryCompletion":2105,"completion":2105,"start":2144,"enrollment":55967,"conditions":55968,"interventions":55970},"NCT01285180","Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD",[],5472,[55969],"Severe COPD",[55949],{"nctId":55972,"briefTitle":55973,"status":195,"phases":55974,"primaryCompletion":2366,"completion":2366,"start":2144,"enrollment":55975,"conditions":55976,"interventions":55977},"NCT01285167","Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)",[],3645,[28],[55949],{"intervention":55979,"totalTrials":447,"cells":55980},"Forxiga",{"EARLY_PHASE1":55981,"PHASE1":55983,"PHASE2":55985,"PHASE3":55987,"PHASE4":55989,"NA":55991},{"trials":55982,"activeCount":102},[],{"trials":55984,"activeCount":102},[],{"trials":55986,"activeCount":102},[],{"trials":55988,"activeCount":102},[],{"trials":55990,"activeCount":102},[],{"trials":55992,"activeCount":102},[55993,55999],{"nctId":55994,"briefTitle":55995,"status":443,"phases":55996,"primaryCompletion":13056,"completion":13056,"start":4204,"enrollment":8918,"conditions":55997,"interventions":55998},"NCT01944618","forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)",[],[31],[55979],{"nctId":56000,"briefTitle":56001,"status":195,"phases":56002,"primaryCompletion":56003,"completion":2801,"start":56004,"enrollment":56005,"conditions":56006,"interventions":56007},"NCT03407196","Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey",[],"2017-12-31","2017-05-24",1683,[22],[55979],{"intervention":26562,"totalTrials":447,"cells":56009},{"EARLY_PHASE1":56010,"PHASE1":56012,"PHASE2":56014,"PHASE3":56016,"PHASE4":56022,"NA":56024},{"trials":56011,"activeCount":102},[],{"trials":56013,"activeCount":102},[],{"trials":56015,"activeCount":102},[],{"trials":56017,"activeCount":102},[56018],{"nctId":26553,"briefTitle":26554,"status":195,"phases":56019,"primaryCompletion":2179,"completion":2179,"start":2489,"enrollment":26556,"conditions":56020,"interventions":56021},[92],[19380,26558,26559,26560],[26562,26532,26563],{"trials":56023,"activeCount":102},[],{"trials":56025,"activeCount":102},[56026],{"nctId":56027,"briefTitle":56028,"status":195,"phases":56029,"primaryCompletion":56030,"completion":56030,"start":2826,"enrollment":5214,"conditions":56031,"interventions":56033},"NCT03444012","ADHERE-S (NIS Brilique)",[],"2019-08-13",[56032],"ACS (Acute Coronary Syndrome)",[56034],"ticagrelor 90 mg",{"intervention":56036,"totalTrials":122,"cells":56037},"Biologic treatment",{"EARLY_PHASE1":56038,"PHASE1":56040,"PHASE2":56042,"PHASE3":56044,"PHASE4":56046,"NA":56048},{"trials":56039,"activeCount":102},[],{"trials":56041,"activeCount":102},[],{"trials":56043,"activeCount":102},[],{"trials":56045,"activeCount":102},[],{"trials":56047,"activeCount":102},[],{"trials":56049,"activeCount":102},[56050],{"nctId":56051,"briefTitle":56052,"status":195,"phases":56053,"primaryCompletion":25027,"completion":25027,"start":49855,"enrollment":56054,"conditions":56055,"interventions":56056},"NCT06261567","A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service",[],415,[16],[56036],{"intervention":56058,"totalTrials":122,"cells":56059},"No Intervention",{"EARLY_PHASE1":56060,"PHASE1":56062,"PHASE2":56064,"PHASE3":56066,"PHASE4":56068,"NA":56070},{"trials":56061,"activeCount":102},[],{"trials":56063,"activeCount":102},[],{"trials":56065,"activeCount":102},[],{"trials":56067,"activeCount":102},[],{"trials":56069,"activeCount":102},[],{"trials":56071,"activeCount":102},[56072],{"nctId":56073,"briefTitle":56074,"status":195,"phases":56075,"primaryCompletion":56076,"completion":56076,"start":56077,"enrollment":56078,"conditions":56079,"interventions":56080},"NCT01575483","Korean Post-marketing Surveillance for Onglyza®",[],"2016-09-07","2012-03-01",3433,[2089],[56058],{"intervention":56082,"totalTrials":122,"cells":56083},"Risk of asthma in offspring",{"EARLY_PHASE1":56084,"PHASE1":56086,"PHASE2":56088,"PHASE3":56090,"PHASE4":56092,"NA":56094},{"trials":56085,"activeCount":102},[],{"trials":56087,"activeCount":102},[],{"trials":56089,"activeCount":102},[],{"trials":56091,"activeCount":102},[],{"trials":56093,"activeCount":102},[],{"trials":56095,"activeCount":102},[56096],{"nctId":56097,"briefTitle":56098,"status":195,"phases":56099,"primaryCompletion":2179,"completion":2179,"start":2471,"enrollment":56100,"conditions":56101,"interventions":56103},"NCT01787435","Acid-suppressing Drugs Pregnancy Asthma Offspring Study",[],10116,[56102],"Asthma in Offspring",[56082],{"intervention":56105,"totalTrials":122,"cells":56106},"Risk of seizure",{"EARLY_PHASE1":56107,"PHASE1":56109,"PHASE2":56111,"PHASE3":56113,"PHASE4":56115,"NA":56117},{"trials":56108,"activeCount":102},[],{"trials":56110,"activeCount":102},[],{"trials":56112,"activeCount":102},[],{"trials":56114,"activeCount":102},[],{"trials":56116,"activeCount":102},[],{"trials":56118,"activeCount":102},[56119],{"nctId":56120,"briefTitle":56121,"status":195,"phases":56122,"primaryCompletion":2179,"completion":2179,"start":2443,"enrollment":56123,"conditions":56124,"interventions":56126},"NCT01744301","Acid Suppressing Drug Seizure Epidemiology Study",[],8605,[56125],"Seizure",[56105],{"intervention":56128,"totalTrials":122,"cells":56129},"Moxetumomab Pasudotox",{"EARLY_PHASE1":56130,"PHASE1":56132,"PHASE2":56134,"PHASE3":56136,"PHASE4":56138,"NA":56140},{"trials":56131,"activeCount":102},[],{"trials":56133,"activeCount":102},[],{"trials":56135,"activeCount":102},[],{"trials":56137,"activeCount":102},[],{"trials":56139,"activeCount":102},[],{"trials":56141,"activeCount":102},[56142],{"nctId":56143,"briefTitle":56144,"status":958,"phases":56145,"conditions":56146,"interventions":56148},"NCT03501615","An Early Access Programme for Moxetumomab Pasudotox in Relapsed\u002FRefractory Hairy Cell Leukemia",[],[56147],"Relapsed\u002FRefractory Hairy Cell Leukemia",[56128],{"intervention":56150,"totalTrials":122,"cells":56151},"AZD8309",{"EARLY_PHASE1":56152,"PHASE1":56154,"PHASE2":56156,"PHASE3":56158,"PHASE4":56160,"NA":56162},{"trials":56153,"activeCount":102},[],{"trials":56155,"activeCount":102},[],{"trials":56157,"activeCount":102},[],{"trials":56159,"activeCount":102},[],{"trials":56161,"activeCount":102},[],{"trials":56163,"activeCount":102},[56164],{"nctId":56165,"briefTitle":56166,"status":195,"phases":56167,"completion":2350,"start":2077,"enrollment":5876,"conditions":56168,"interventions":56169},"NCT00860821","A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)",[94],[19],[56150,56150],{"intervention":56171,"totalTrials":122,"cells":56172},"ACS patients treated with OAP",{"EARLY_PHASE1":56173,"PHASE1":56175,"PHASE2":56177,"PHASE3":56179,"PHASE4":56181,"NA":56183},{"trials":56174,"activeCount":102},[],{"trials":56176,"activeCount":102},[],{"trials":56178,"activeCount":102},[],{"trials":56180,"activeCount":102},[],{"trials":56182,"activeCount":102},[],{"trials":56184,"activeCount":102},[56185],{"nctId":56186,"briefTitle":56187,"status":195,"phases":56188,"primaryCompletion":2299,"completion":2299,"start":2180,"enrollment":19474,"conditions":56189,"interventions":56191},"NCT02190123","REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be\u002FLux.",[],[56190],"Treatment of Acute Coronary Syndrome (ACS).",[56171],{"intervention":56193,"totalTrials":122,"cells":56194},"Germline BRCA Test",{"EARLY_PHASE1":56195,"PHASE1":56197,"PHASE2":56199,"PHASE3":56201,"PHASE4":56203,"NA":56205},{"trials":56196,"activeCount":102},[],{"trials":56198,"activeCount":102},[],{"trials":56200,"activeCount":102},[],{"trials":56202,"activeCount":102},[],{"trials":56204,"activeCount":102},[],{"trials":56206,"activeCount":102},[56207],{"nctId":56208,"briefTitle":56209,"status":195,"phases":56210,"primaryCompletion":56211,"completion":56211,"start":2853,"enrollment":56212,"conditions":56213,"interventions":56214},"NCT03078036","International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study",[],"2019-05-20",873,[25],[56193,56215],"FoundationOne Dx Genomic Profile",{"intervention":56215,"totalTrials":122,"cells":56217},{"EARLY_PHASE1":56218,"PHASE1":56220,"PHASE2":56222,"PHASE3":56224,"PHASE4":56226,"NA":56228},{"trials":56219,"activeCount":102},[],{"trials":56221,"activeCount":102},[],{"trials":56223,"activeCount":102},[],{"trials":56225,"activeCount":102},[],{"trials":56227,"activeCount":102},[],{"trials":56229,"activeCount":102},[56230],{"nctId":56208,"briefTitle":56209,"status":195,"phases":56231,"primaryCompletion":56211,"completion":56211,"start":2853,"enrollment":56212,"conditions":56232,"interventions":56233},[],[25],[56193,56215],{"intervention":56235,"totalTrials":122,"cells":56236},"Blood sample testing for hs-CRP",{"EARLY_PHASE1":56237,"PHASE1":56239,"PHASE2":56241,"PHASE3":56243,"PHASE4":56245,"NA":56247},{"trials":56238,"activeCount":102},[],{"trials":56240,"activeCount":102},[],{"trials":56242,"activeCount":102},[],{"trials":56244,"activeCount":102},[],{"trials":56246,"activeCount":102},[],{"trials":56248,"activeCount":102},[56249],{"nctId":56250,"briefTitle":56251,"status":195,"phases":56252,"primaryCompletion":2144,"completion":2144,"start":2350,"enrollment":56253,"conditions":56254,"interventions":56255},"NCT00970918","Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs",[94],2609,[2619],[56235],{"intervention":56257,"totalTrials":122,"cells":56258},"budesonide \u002F glycopyrronium \u002F formoterol",{"EARLY_PHASE1":56259,"PHASE1":56261,"PHASE2":56263,"PHASE3":56265,"PHASE4":56267,"NA":56269},{"trials":56260,"activeCount":102},[],{"trials":56262,"activeCount":102},[],{"trials":56264,"activeCount":102},[],{"trials":56266,"activeCount":102},[],{"trials":56268,"activeCount":102},[],{"trials":56270,"activeCount":102},[56271],{"nctId":56272,"briefTitle":56273,"status":195,"phases":56274,"primaryCompletion":56275,"completion":56275,"start":52412,"enrollment":269,"conditions":56276,"interventions":56277},"NCT06368427","Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD",[],"2025-11-17",[6083],[56257],{"intervention":54355,"totalTrials":122,"cells":56279},{"EARLY_PHASE1":56280,"PHASE1":56282,"PHASE2":56284,"PHASE3":56286,"PHASE4":56288,"NA":56290},{"trials":56281,"activeCount":102},[],{"trials":56283,"activeCount":102},[],{"trials":56285,"activeCount":102},[],{"trials":56287,"activeCount":102},[],{"trials":56289,"activeCount":102},[],{"trials":56291,"activeCount":102},[56292],{"nctId":54348,"briefTitle":54349,"status":195,"phases":56293,"primaryCompletion":7681,"completion":7681,"start":54351,"enrollment":54352,"conditions":56294,"interventions":56295},[],[22],[54355,54356,39369,2108,54357],{"intervention":54356,"totalTrials":122,"cells":56297},{"EARLY_PHASE1":56298,"PHASE1":56300,"PHASE2":56302,"PHASE3":56304,"PHASE4":56306,"NA":56308},{"trials":56299,"activeCount":102},[],{"trials":56301,"activeCount":102},[],{"trials":56303,"activeCount":102},[],{"trials":56305,"activeCount":102},[],{"trials":56307,"activeCount":102},[],{"trials":56309,"activeCount":102},[56310],{"nctId":54348,"briefTitle":54349,"status":195,"phases":56311,"primaryCompletion":7681,"completion":7681,"start":54351,"enrollment":54352,"conditions":56312,"interventions":56313},[],[22],[54355,54356,39369,2108,54357],{"intervention":54357,"totalTrials":122,"cells":56315},{"EARLY_PHASE1":56316,"PHASE1":56318,"PHASE2":56320,"PHASE3":56322,"PHASE4":56324,"NA":56326},{"trials":56317,"activeCount":102},[],{"trials":56319,"activeCount":102},[],{"trials":56321,"activeCount":102},[],{"trials":56323,"activeCount":102},[],{"trials":56325,"activeCount":102},[],{"trials":56327,"activeCount":102},[56328],{"nctId":54348,"briefTitle":54349,"status":195,"phases":56329,"primaryCompletion":7681,"completion":7681,"start":54351,"enrollment":54352,"conditions":56330,"interventions":56331},[],[22],[54355,54356,39369,2108,54357],{"intervention":56333,"totalTrials":122,"cells":56334},"1L treatment",{"EARLY_PHASE1":56335,"PHASE1":56337,"PHASE2":56339,"PHASE3":56341,"PHASE4":56343,"NA":56345},{"trials":56336,"activeCount":102},[],{"trials":56338,"activeCount":102},[],{"trials":56340,"activeCount":102},[],{"trials":56342,"activeCount":102},[],{"trials":56344,"activeCount":102},[],{"trials":56346,"activeCount":102},[56347],{"nctId":56348,"briefTitle":56349,"status":195,"phases":56350,"primaryCompletion":6069,"completion":6069,"start":56351,"enrollment":56352,"conditions":56353,"interventions":56354},"NCT03761901","Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium",[],"2018-09-21",141,[992],[56333,56355,56356],"2L Treatment","3L treatment",{"intervention":56355,"totalTrials":122,"cells":56358},{"EARLY_PHASE1":56359,"PHASE1":56361,"PHASE2":56363,"PHASE3":56365,"PHASE4":56367,"NA":56369},{"trials":56360,"activeCount":102},[],{"trials":56362,"activeCount":102},[],{"trials":56364,"activeCount":102},[],{"trials":56366,"activeCount":102},[],{"trials":56368,"activeCount":102},[],{"trials":56370,"activeCount":102},[56371],{"nctId":56348,"briefTitle":56349,"status":195,"phases":56372,"primaryCompletion":6069,"completion":6069,"start":56351,"enrollment":56352,"conditions":56373,"interventions":56374},[],[992],[56333,56355,56356],{"intervention":56356,"totalTrials":122,"cells":56376},{"EARLY_PHASE1":56377,"PHASE1":56379,"PHASE2":56381,"PHASE3":56383,"PHASE4":56385,"NA":56387},{"trials":56378,"activeCount":102},[],{"trials":56380,"activeCount":102},[],{"trials":56382,"activeCount":102},[],{"trials":56384,"activeCount":102},[],{"trials":56386,"activeCount":102},[],{"trials":56388,"activeCount":102},[56389],{"nctId":56348,"briefTitle":56349,"status":195,"phases":56390,"primaryCompletion":6069,"completion":6069,"start":56351,"enrollment":56352,"conditions":56391,"interventions":56392},[],[992],[56333,56355,56356],{"intervention":56394,"totalTrials":122,"cells":56395},"Benralizumab-exposure",{"EARLY_PHASE1":56396,"PHASE1":56398,"PHASE2":56400,"PHASE3":56402,"PHASE4":56404,"NA":56406},{"trials":56397,"activeCount":102},[],{"trials":56399,"activeCount":102},[],{"trials":56401,"activeCount":102},[],{"trials":56403,"activeCount":102},[],{"trials":56405,"activeCount":102},[],{"trials":56407,"activeCount":102},[56408],{"nctId":56409,"briefTitle":56410,"status":443,"phases":56411,"primaryCompletion":9732,"completion":9732,"start":56412,"enrollment":56413,"conditions":56414,"interventions":56415},"NCT03794999","Benralizumab Pregnancy Exposure Study",[],"2019-03-20",299,[16],[56394,56416],"Exposure to other asthma medications",{"intervention":56416,"totalTrials":122,"cells":56418},{"EARLY_PHASE1":56419,"PHASE1":56421,"PHASE2":56423,"PHASE3":56425,"PHASE4":56427,"NA":56429},{"trials":56420,"activeCount":102},[],{"trials":56422,"activeCount":102},[],{"trials":56424,"activeCount":102},[],{"trials":56426,"activeCount":102},[],{"trials":56428,"activeCount":102},[],{"trials":56430,"activeCount":102},[56431],{"nctId":56409,"briefTitle":56410,"status":443,"phases":56432,"primaryCompletion":9732,"completion":9732,"start":56412,"enrollment":56413,"conditions":56433,"interventions":56434},[],[16],[56394,56416],{"intervention":56436,"totalTrials":122,"cells":56437},"BGF- BUDESONIDE\u002FGLYCOPYRRONIUM\u002FFORMOTEROL",{"EARLY_PHASE1":56438,"PHASE1":56440,"PHASE2":56442,"PHASE3":56444,"PHASE4":56446,"NA":56448},{"trials":56439,"activeCount":102},[],{"trials":56441,"activeCount":102},[],{"trials":56443,"activeCount":102},[],{"trials":56445,"activeCount":102},[],{"trials":56447,"activeCount":102},[],{"trials":56449,"activeCount":102},[56450],{"nctId":56451,"briefTitle":56452,"status":195,"phases":56453,"primaryCompletion":232,"completion":232,"start":1077,"enrollment":56454,"conditions":56455,"interventions":56456},"NCT07414134","Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation",[],3598,[28],[56436],{"intervention":56458,"totalTrials":122,"cells":56459},"Candesartan Cilexeotil 16mg",{"EARLY_PHASE1":56460,"PHASE1":56462,"PHASE2":56464,"PHASE3":56466,"PHASE4":56468,"NA":56470},{"trials":56461,"activeCount":102},[],{"trials":56463,"activeCount":102},[],{"trials":56465,"activeCount":102},[],{"trials":56467,"activeCount":102},[],{"trials":56469,"activeCount":102},[],{"trials":56471,"activeCount":102},[56472],{"nctId":56473,"briefTitle":56474,"status":195,"phases":56475,"primaryCompletion":2168,"completion":2168,"start":2415,"enrollment":56476,"conditions":56477,"interventions":56478},"NCT00573742","Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients",[],1940,[22708],[56458],{"intervention":55301,"totalTrials":122,"cells":56480},{"EARLY_PHASE1":56481,"PHASE1":56483,"PHASE2":56485,"PHASE3":56487,"PHASE4":56489,"NA":56491},{"trials":56482,"activeCount":102},[],{"trials":56484,"activeCount":102},[],{"trials":56486,"activeCount":102},[],{"trials":56488,"activeCount":102},[],{"trials":56490,"activeCount":102},[],{"trials":56492,"activeCount":102},[56493],{"nctId":55295,"briefTitle":55296,"status":195,"phases":56494,"primaryCompletion":2095,"completion":2095,"start":2580,"enrollment":55298,"conditions":56495,"interventions":56496},[],[2620],[20401,55301],{"intervention":18507,"totalTrials":122,"cells":56498},{"EARLY_PHASE1":56499,"PHASE1":56501,"PHASE2":56503,"PHASE3":56505,"PHASE4":56507,"NA":56509},{"trials":56500,"activeCount":102},[],{"trials":56502,"activeCount":102},[],{"trials":56504,"activeCount":102},[],{"trials":56506,"activeCount":102},[],{"trials":56508,"activeCount":102},[],{"trials":56510,"activeCount":102},[56511],{"nctId":18499,"briefTitle":18500,"status":195,"phases":56512,"primaryCompletion":2580,"completion":2580,"start":4285,"enrollment":18502,"conditions":56513,"interventions":56514},[],[18504,18505],[18239,18507],{"intervention":54911,"totalTrials":122,"cells":56516},{"EARLY_PHASE1":56517,"PHASE1":56519,"PHASE2":56521,"PHASE3":56523,"PHASE4":56525,"NA":56527},{"trials":56518,"activeCount":102},[],{"trials":56520,"activeCount":102},[],{"trials":56522,"activeCount":102},[],{"trials":56524,"activeCount":102},[],{"trials":56526,"activeCount":102},[],{"trials":56528,"activeCount":102},[56529],{"nctId":54904,"briefTitle":54905,"status":195,"phases":56530,"primaryCompletion":24916,"completion":24916,"start":54907,"enrollment":54908,"conditions":56531,"interventions":56532},[],[18651],[20252,54911,54902],{"intervention":56534,"totalTrials":122,"cells":56535},"Risk of low dose aspirin discontinuation",{"EARLY_PHASE1":56536,"PHASE1":56538,"PHASE2":56540,"PHASE3":56542,"PHASE4":56544,"NA":56546},{"trials":56537,"activeCount":102},[],{"trials":56539,"activeCount":102},[],{"trials":56541,"activeCount":102},[],{"trials":56543,"activeCount":102},[],{"trials":56545,"activeCount":102},[],{"trials":56547,"activeCount":102},[56548],{"nctId":56549,"briefTitle":56550,"status":195,"phases":56551,"primaryCompletion":2746,"completion":2746,"start":2432,"enrollment":56552,"conditions":56553,"interventions":56555},"NCT01888575","Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy",[],35604,[56554],"Cardiovascular Prevention",[56534],{"intervention":55606,"totalTrials":122,"cells":56557},{"EARLY_PHASE1":56558,"PHASE1":56560,"PHASE2":56562,"PHASE3":56564,"PHASE4":56566,"NA":56568},{"trials":56559,"activeCount":102},[],{"trials":56561,"activeCount":102},[],{"trials":56563,"activeCount":102},[],{"trials":56565,"activeCount":102},[],{"trials":56567,"activeCount":102},[],{"trials":56569,"activeCount":102},[56570],{"nctId":55599,"briefTitle":55600,"status":195,"phases":56571,"primaryCompletion":55602,"completion":55602,"start":10141,"enrollment":55603,"conditions":56572,"interventions":56573},[],[18651],[26977,55606],{"intervention":56575,"totalTrials":122,"cells":56576},"Calcium Polystyrene Sulphonate 15g\u002F60 mL water",{"EARLY_PHASE1":56577,"PHASE1":56579,"PHASE2":56581,"PHASE3":56583,"PHASE4":56585,"NA":56587},{"trials":56578,"activeCount":102},[],{"trials":56580,"activeCount":102},[],{"trials":56582,"activeCount":102},[],{"trials":56584,"activeCount":102},[],{"trials":56586,"activeCount":102},[],{"trials":56588,"activeCount":102},[56589],{"nctId":56590,"briefTitle":56591,"status":195,"phases":56592,"primaryCompletion":25475,"completion":25475,"start":56593,"enrollment":1151,"conditions":56594,"interventions":56596},"NCT04566653","Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia",[],"2020-10-23",[56595],"Chronic Kidney Disease + Hyperkalaemia +\u002F- Heart Failure",[56575,56597,56598,56599,56600],"Lokelma® 5 g\u002F45mL water","Lokelma® 10 g\u002F45 mL water","Veltassa® 8,4 g\u002F80mL water","Sodium Polystyrene Sulphonate 15g\u002F60 mL water",{"intervention":56597,"totalTrials":122,"cells":56602},{"EARLY_PHASE1":56603,"PHASE1":56605,"PHASE2":56607,"PHASE3":56609,"PHASE4":56611,"NA":56613},{"trials":56604,"activeCount":102},[],{"trials":56606,"activeCount":102},[],{"trials":56608,"activeCount":102},[],{"trials":56610,"activeCount":102},[],{"trials":56612,"activeCount":102},[],{"trials":56614,"activeCount":102},[56615],{"nctId":56590,"briefTitle":56591,"status":195,"phases":56616,"primaryCompletion":25475,"completion":25475,"start":56593,"enrollment":1151,"conditions":56617,"interventions":56618},[],[56595],[56575,56597,56598,56599,56600],{"intervention":56598,"totalTrials":122,"cells":56620},{"EARLY_PHASE1":56621,"PHASE1":56623,"PHASE2":56625,"PHASE3":56627,"PHASE4":56629,"NA":56631},{"trials":56622,"activeCount":102},[],{"trials":56624,"activeCount":102},[],{"trials":56626,"activeCount":102},[],{"trials":56628,"activeCount":102},[],{"trials":56630,"activeCount":102},[],{"trials":56632,"activeCount":102},[56633],{"nctId":56590,"briefTitle":56591,"status":195,"phases":56634,"primaryCompletion":25475,"completion":25475,"start":56593,"enrollment":1151,"conditions":56635,"interventions":56636},[],[56595],[56575,56597,56598,56599,56600],{"intervention":56599,"totalTrials":122,"cells":56638},{"EARLY_PHASE1":56639,"PHASE1":56641,"PHASE2":56643,"PHASE3":56645,"PHASE4":56647,"NA":56649},{"trials":56640,"activeCount":102},[],{"trials":56642,"activeCount":102},[],{"trials":56644,"activeCount":102},[],{"trials":56646,"activeCount":102},[],{"trials":56648,"activeCount":102},[],{"trials":56650,"activeCount":102},[56651],{"nctId":56590,"briefTitle":56591,"status":195,"phases":56652,"primaryCompletion":25475,"completion":25475,"start":56593,"enrollment":1151,"conditions":56653,"interventions":56654},[],[56595],[56575,56597,56598,56599,56600],{"intervention":56600,"totalTrials":122,"cells":56656},{"EARLY_PHASE1":56657,"PHASE1":56659,"PHASE2":56661,"PHASE3":56663,"PHASE4":56665,"NA":56667},{"trials":56658,"activeCount":102},[],{"trials":56660,"activeCount":102},[],{"trials":56662,"activeCount":102},[],{"trials":56664,"activeCount":102},[],{"trials":56666,"activeCount":102},[],{"trials":56668,"activeCount":102},[56669],{"nctId":56590,"briefTitle":56591,"status":195,"phases":56670,"primaryCompletion":25475,"completion":25475,"start":56593,"enrollment":1151,"conditions":56671,"interventions":56672},[],[56595],[56575,56597,56598,56599,56600],{"intervention":55869,"totalTrials":122,"cells":56674},{"EARLY_PHASE1":56675,"PHASE1":56677,"PHASE2":56679,"PHASE3":56681,"PHASE4":56683,"NA":56685},{"trials":56676,"activeCount":102},[],{"trials":56678,"activeCount":102},[],{"trials":56680,"activeCount":102},[],{"trials":56682,"activeCount":102},[],{"trials":56684,"activeCount":102},[],{"trials":56686,"activeCount":102},[56687],{"nctId":55863,"briefTitle":55864,"status":195,"phases":56688,"primaryCompletion":6562,"completion":4916,"start":2329,"enrollment":55866,"conditions":56689,"interventions":56690},[94],[2620],[55869,55870,55242,55242],{"intervention":55870,"totalTrials":122,"cells":56692},{"EARLY_PHASE1":56693,"PHASE1":56695,"PHASE2":56697,"PHASE3":56699,"PHASE4":56701,"NA":56703},{"trials":56694,"activeCount":102},[],{"trials":56696,"activeCount":102},[],{"trials":56698,"activeCount":102},[],{"trials":56700,"activeCount":102},[],{"trials":56702,"activeCount":102},[],{"trials":56704,"activeCount":102},[56705],{"nctId":55863,"briefTitle":55864,"status":195,"phases":56706,"primaryCompletion":6562,"completion":4916,"start":2329,"enrollment":55866,"conditions":56707,"interventions":56708},[94],[2620],[55869,55870,55242,55242],{"intervention":18515,"totalTrials":122,"cells":56710},{"EARLY_PHASE1":56711,"PHASE1":56713,"PHASE2":56715,"PHASE3":56717,"PHASE4":56719,"NA":56721},{"trials":56712,"activeCount":102},[],{"trials":56714,"activeCount":102},[],{"trials":56716,"activeCount":102},[],{"trials":56718,"activeCount":102},[],{"trials":56720,"activeCount":102},[],{"trials":56722,"activeCount":102},[56723],{"nctId":18509,"briefTitle":18510,"status":195,"phases":56724,"primaryCompletion":2589,"completion":2589,"start":6710,"enrollment":18512,"conditions":56725,"interventions":56726},[],[22],[18239,18515],{"intervention":18160,"totalTrials":122,"cells":56728},{"EARLY_PHASE1":56729,"PHASE1":56731,"PHASE2":56733,"PHASE3":56735,"PHASE4":56737,"NA":56739},{"trials":56730,"activeCount":102},[],{"trials":56732,"activeCount":102},[],{"trials":56734,"activeCount":102},[],{"trials":56736,"activeCount":102},[],{"trials":56738,"activeCount":102},[],{"trials":56740,"activeCount":102},[56741],{"nctId":18152,"briefTitle":18153,"status":195,"phases":56742,"primaryCompletion":18155,"completion":18155,"start":3363,"enrollment":18156,"conditions":56743,"interventions":56744},[],[18158],[17964,18160],{"intervention":56746,"totalTrials":122,"cells":56747},"Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler",{"EARLY_PHASE1":56748,"PHASE1":56750,"PHASE2":56752,"PHASE3":56754,"PHASE4":56756,"NA":56758},{"trials":56749,"activeCount":102},[],{"trials":56751,"activeCount":102},[],{"trials":56753,"activeCount":102},[],{"trials":56755,"activeCount":102},[],{"trials":56757,"activeCount":102},[],{"trials":56759,"activeCount":102},[56760],{"nctId":56761,"briefTitle":56762,"status":195,"phases":56763,"primaryCompletion":780,"completion":780,"start":3515,"enrollment":12458,"conditions":56764,"interventions":56766},"NCT05915182","Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece",[],[56765],"Pulmonary Disease, Chronic Obstructive (COPD)",[56746],{"intervention":56768,"totalTrials":122,"cells":56769},"Risk of symptomatic peptic ulcer",{"EARLY_PHASE1":56770,"PHASE1":56772,"PHASE2":56774,"PHASE3":56776,"PHASE4":56778,"NA":56780},{"trials":56771,"activeCount":102},[],{"trials":56773,"activeCount":102},[],{"trials":56775,"activeCount":102},[],{"trials":56777,"activeCount":102},[],{"trials":56779,"activeCount":102},[],{"trials":56781,"activeCount":102},[56782],{"nctId":56783,"briefTitle":56784,"status":195,"phases":56785,"primaryCompletion":7354,"completion":7354,"start":2432,"enrollment":55787,"conditions":56786,"interventions":56788},"NCT01888588","Risk of Uncomplicated Peptic Ulcer in the General Population",[],[56787],"Peptic Ulcer [Iowa Type (107680.0010)]",[56768],{"intervention":56790,"totalTrials":122,"cells":56791},"Risk of selected safety events",{"EARLY_PHASE1":56792,"PHASE1":56794,"PHASE2":56796,"PHASE3":56798,"PHASE4":56800,"NA":56802},{"trials":56793,"activeCount":102},[],{"trials":56795,"activeCount":102},[],{"trials":56797,"activeCount":102},[],{"trials":56799,"activeCount":102},[],{"trials":56801,"activeCount":102},[],{"trials":56803,"activeCount":102},[56804],{"nctId":56805,"briefTitle":56806,"status":195,"phases":56807,"primaryCompletion":16033,"completion":16033,"start":2480,"enrollment":56808,"conditions":56809,"interventions":56811},"NCT01276275","Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel",[],7200,[56810],"Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout",[56790],{"intervention":56813,"totalTrials":122,"cells":56814},"Zurampic®",{"EARLY_PHASE1":56815,"PHASE1":56817,"PHASE2":56819,"PHASE3":56821,"PHASE4":56823,"NA":56825},{"trials":56816,"activeCount":102},[],{"trials":56818,"activeCount":102},[],{"trials":56820,"activeCount":102},[],{"trials":56822,"activeCount":102},[],{"trials":56824,"activeCount":102},[],{"trials":56826,"activeCount":102},[56827],{"nctId":56828,"briefTitle":56829,"status":624,"phases":56830,"primaryCompletion":56831,"completion":56831,"start":56832,"enrollment":102,"conditions":56833,"interventions":56834},"NCT04072471","Post-Authorisation Safety Study of Lesinurad",[],"2023-06-30","2021-01-29",[40034,35225],[56813,56835],"Control group: xanthine oxidase inhibitor monotherapy",{"intervention":56835,"totalTrials":122,"cells":56837},{"EARLY_PHASE1":56838,"PHASE1":56840,"PHASE2":56842,"PHASE3":56844,"PHASE4":56846,"NA":56848},{"trials":56839,"activeCount":102},[],{"trials":56841,"activeCount":102},[],{"trials":56843,"activeCount":102},[],{"trials":56845,"activeCount":102},[],{"trials":56847,"activeCount":102},[],{"trials":56849,"activeCount":102},[56850],{"nctId":56828,"briefTitle":56829,"status":624,"phases":56851,"primaryCompletion":56831,"completion":56831,"start":56832,"enrollment":102,"conditions":56852,"interventions":56853},[],[40034,35225],[56813,56835],{"intervention":56855,"totalTrials":122,"cells":56856},"Alvesco",{"EARLY_PHASE1":56857,"PHASE1":56859,"PHASE2":56861,"PHASE3":56863,"PHASE4":56865,"NA":56867},{"trials":56858,"activeCount":102},[],{"trials":56860,"activeCount":102},[],{"trials":56862,"activeCount":102},[],{"trials":56864,"activeCount":102},[],{"trials":56866,"activeCount":102},[],{"trials":56868,"activeCount":102},[56869],{"nctId":56870,"briefTitle":56871,"status":195,"phases":56872,"primaryCompletion":2615,"completion":2675,"start":2212,"enrollment":1078,"conditions":56873,"interventions":56875},"NCT01147224","ATEM (Alvesco Non-interventional Study)",[],[16,56874],"Allergy",[56855],{"intervention":56877,"totalTrials":122,"cells":56878},"Other",{"EARLY_PHASE1":56879,"PHASE1":56881,"PHASE2":56883,"PHASE3":56885,"PHASE4":56887,"NA":56889},{"trials":56880,"activeCount":102},[],{"trials":56882,"activeCount":102},[],{"trials":56884,"activeCount":102},[],{"trials":56886,"activeCount":102},[],{"trials":56888,"activeCount":102},[],{"trials":56890,"activeCount":102},[56891],{"nctId":56892,"briefTitle":56893,"status":195,"phases":56894,"primaryCompletion":56895,"completion":56895,"start":12091,"enrollment":3811,"conditions":56896,"interventions":56897},"NCT03137264","Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients",[],"2018-11-10",[1049],[56877],{"intervention":56899,"totalTrials":122,"cells":56900},"Cohort",{"EARLY_PHASE1":56901,"PHASE1":56903,"PHASE2":56905,"PHASE3":56907,"PHASE4":56909,"NA":56911},{"trials":56902,"activeCount":102},[],{"trials":56904,"activeCount":102},[],{"trials":56906,"activeCount":102},[],{"trials":56908,"activeCount":102},[],{"trials":56910,"activeCount":102},[],{"trials":56912,"activeCount":102},[56913],{"nctId":56914,"briefTitle":56915,"status":195,"phases":56916,"primaryCompletion":56917,"completion":56917,"start":56918,"enrollment":3466,"conditions":56919,"interventions":56920},"NCT05440656","A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.",[],"2025-04-13","2022-06-29",[1650],[56899]]